Torsade	NN	O	B
de	NN	O	I
pointes	NN	O	I
ventricular	NN	O	B
tachycardia	NN	O	I
during	NN	O	O
low	NN	O	O
dose	NN	O	O
intermittent	NN	O	O
dobutamine	NN	O	O
treatment	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
dilated	NN	O	B
cardiomyopathy	NN	O	I
and	NN	O	O
congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
.	NN	O	O

The	NN	O	O
authors	NN	O	O
describe	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
56	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
chronic	NN	O	O
,	NN	O	O
severe	NN	O	O
heart	NN	O	B
failure	NN	O	I
secondary	NN	O	O
to	NN	O	O
dilated	NN	O	B
cardiomyopathy	NN	O	I
and	NN	O	O
absence	NN	O	O
of	NN	O	O
significant	NN	O	O
ventricular	NN	O	B
arrhythmias	NN	O	I
who	NN	O	O
developed	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
and	NN	O	O
torsade	NN	O	B
de	NN	O	I
pointes	NN	O	I
ventricular	NN	O	B
tachycardia	NN	O	I
during	NN	O	O
one	NN	O	O
cycle	NN	O	O
of	NN	O	O
intermittent	NN	O	O
low	NN	O	O
dose	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mcg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
min	NN	O	O
)	NN	O	O
dobutamine	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
of	NN	O	O
torsade	NN	O	B
de	NN	O	I
pointes	NN	O	I
ventricular	NN	O	B
tachycardia	NN	O	I
during	NN	O	O
intermittent	NN	O	O
dobutamine	NN	O	O
supports	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
unpredictable	NN	O	O
fatal	NN	O	O
arrhythmias	NN	O	B
may	NN	O	O
occur	NN	O	O
even	NN	O	O
with	NN	O	O
low	NN	O	O
doses	NN	O	O
and	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
no	NN	O	O
history	NN	O	O
of	NN	O	O
significant	NN	O	O
rhythm	NN	O	O
disturbances	NN	O	O
.	NN	O	O

The	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
proarrhythmic	NN	O	O
effects	NN	O	O
of	NN	O	O
Dubutamine	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Positive	NN	O	O
skin	NN	O	O
tests	NN	O	O
in	NN	O	O
late	NN	O	O
reactions	NN	O	O
to	NN	O	O
radiographic	NN	O	O
contrast	NN	O	O
media	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
last	NN	O	O
few	NN	O	O
years	NN	O	O
delayed	NN	O	O
reactions	NN	O	O
several	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
radiographic	NN	O	O
and	NN	O	O
contrast	NN	O	O
materials	NN	O	O
(	NN	O	O
PRC	NN	O	O
)	NN	O	O
have	NN	O	O
been	NN	O	O
described	NN	O	O
with	NN	O	O
increasing	NN	O	O
frequency	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
report	NN	O	O
two	NN	O	O
observations	NN	O	O
on	NN	O	O
patients	NN	O	O
with	NN	O	O
delayed	NN	O	O
reactions	NN	O	O
in	NN	O	O
whom	NN	O	O
intradermoreactions	NN	O	O
(	NN	O	O
IDR	NN	O	O
)	NN	O	O
and	NN	O	O
patch	NN	O	O
tests	NN	O	O
to	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
ionic	NN	O	O
and	NN	O	O
non	NN	O	O
ionic	NN	O	O
PRC	NN	O	O
were	NN	O	O
studied	NN	O	O
.	NN	O	O

After	NN	O	O
angiography	NN	O	O
by	NN	O	O
the	NN	O	O
venous	NN	O	O
route	NN	O	O
in	NN	O	O
patient	NN	O	O
n	NN	O	O
degree	NN	O	O
1	NN	O	O
a	NN	O	O
biphasic	NN	O	O
reaction	NN	O	O
with	NN	O	O
an	NN	O	O
immediate	NN	O	O
reaction	NN	O	O
(	NN	O	O
dyspnea	NN	O	B
,	NN	O	O
loss	NN	O	B
of	NN	O	I
consciousness	NN	O	I
)	NN	O	O
and	NN	O	O
delayed	NN	O	O
macro	NN	O	B
-	NN	O	I
papular	NN	O	I
rash	NN	O	I
appeared	NN	O	O
,	NN	O	O
whilst	NN	O	O
patient	NN	O	O
n	NN	O	O
degree	NN	O	O
2	NN	O	O
developed	NN	O	O
a	NN	O	O
generalised	NN	O	O
sensation	NN	O	O
of	NN	O	O
heat	NN	O	O
,	NN	O	O
persistent	NN	O	O
pain	NN	O	B
at	NN	O	O
the	NN	O	O
site	NN	O	O
of	NN	O	O
injection	NN	O	O
immediately	NN	O	O
and	NN	O	O
a	NN	O	O
generalised	NN	O	O
macro	NN	O	O
-	NN	O	O
papular	NN	O	O
reaction	NN	O	O
after	NN	O	O
24	NN	O	O
hours	NN	O	O
.	NN	O	O

The	NN	O	O
skin	NN	O	O
tests	NN	O	O
revealed	NN	O	O
positive	NN	O	O
delayed	NN	O	O
reactions	NN	O	O
of	NN	O	O
24	NN	O	O
hours	NN	O	O
and	NN	O	O
48	NN	O	O
hours	NN	O	O
by	NN	O	O
IDR	NN	O	O
and	NN	O	O
patch	NN	O	O
tests	NN	O	O
to	NN	O	O
only	NN	O	O
some	NN	O	O
PRC	NN	O	O
with	NN	O	O
common	NN	O	O
chains	NN	O	O
in	NN	O	O
their	NN	O	O
structures	NN	O	O
.	NN	O	O

The	NN	O	O
positive	NN	O	O
skin	NN	O	O
tests	NN	O	O
are	NN	O	O
in	NN	O	O
favour	NN	O	O
of	NN	O	O
immunological	NN	O	O
reactions	NN	O	O
and	NN	O	O
may	NN	O	O
help	NN	O	O
in	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
allergy	NN	O	B
in	NN	O	O
the	NN	O	O
patients	NN	O	O
.	NN	O	O

Risk	NN	O	O
of	NN	O	O
transient	NN	O	O
hyperammonemic	NN	O	B
encephalopathy	NN	O	I
in	NN	O	O
cancer	NN	O	B
patients	NN	O	O
who	NN	O	O
received	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
with	NN	O	O
the	NN	O	O
complication	NN	O	O
of	NN	O	O
dehydration	NN	O	B
and	NN	O	O
infection	NN	O	B
.	NN	O	O

From	NN	O	O
1986	NN	O	O
to	NN	O	O
1998	NN	O	O
,	NN	O	O
29	NN	O	O
cancer	NN	O	B
patients	NN	O	O
who	NN	O	O
had	NN	O	O
32	NN	O	O
episodes	NN	O	O
of	NN	O	O
transient	NN	O	O
hyperammonemic	NN	O	B
encephalopathy	NN	O	I
related	NN	O	O
to	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
)	NN	O	O
were	NN	O	O
identified	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
had	NN	O	O
decompensated	NN	O	O
liver	NN	O	B
disease	NN	O	I
.	NN	O	O

Onset	NN	O	O
of	NN	O	O
hyperammonemic	NN	O	B
encephalopathy	NN	O	I
varied	NN	O	O
from	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
to	NN	O	O
5	NN	O	O
days	NN	O	O
(	NN	O	O
mean	NN	O	O
:	NN	O	O
2	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
days	NN	O	O
)	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Plasma	NN	O	O
ammonium	NN	O	O
level	NN	O	O
ranged	NN	O	O
from	NN	O	O
248	NN	O	O
to	NN	O	O
2387	NN	O	O
microg	NN	O	O
%	NN	O	O
(	NN	O	O
mean	NN	O	O
:	NN	O	O
626	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
431	NN	O	O
microg	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
32	NN	O	O
episodes	NN	O	O
,	NN	O	O
26	NN	O	O
(	NN	O	O
81	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
various	NN	O	O
degrees	NN	O	O
of	NN	O	O
azotemia	NN	O	B
,	NN	O	O
18	NN	O	O
(	NN	O	O
56	NN	O	O
%	NN	O	O
)	NN	O	O
occurred	NN	O	O
during	NN	O	O
bacterial	NN	O	B
infections	NN	O	I
and	NN	O	O
14	NN	O	O
(	NN	O	O
44	NN	O	O
%	NN	O	O
)	NN	O	O
without	NN	O	O
infection	NN	O	B
occurred	NN	O	O
during	NN	O	O
periods	NN	O	O
of	NN	O	O
dehydration	NN	O	B
.	NN	O	O

Higher	NN	O	O
plasma	NN	O	O
ammonium	NN	O	O
levels	NN	O	O
and	NN	O	O
more	NN	O	O
rapid	NN	O	O
onset	NN	O	O
of	NN	O	O
hyperammonemia	NN	O	B
were	NN	O	O
seen	NN	O	O
in	NN	O	O
18	NN	O	O
patients	NN	O	O
with	NN	O	O
bacterial	NN	O	B
infections	NN	O	I
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
003	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
0006	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
nine	NN	O	O
patients	NN	O	O
receiving	NN	O	O
high	NN	O	O
daily	NN	O	O
doses	NN	O	O
(	NN	O	O
2600	NN	O	O
or	NN	O	O
1800	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
)	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
and	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
25	NN	O	O
out	NN	O	O
of	NN	O	O
32	NN	O	O
episodes	NN	O	O
(	NN	O	O
78	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
plasma	NN	O	O
ammonium	NN	O	O
levels	NN	O	O
and	NN	O	O
mental	NN	O	O
status	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
within	NN	O	O
2	NN	O	O
days	NN	O	O
after	NN	O	O
adequate	NN	O	O
management	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
hyperammonemic	NN	O	B
encephalopathy	NN	O	I
can	NN	O	O
occur	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
.	NN	O	O

Azotemia	NN	O	B
,	NN	O	O
body	NN	O	O
fluid	NN	O	O
insufficiency	NN	O	O
and	NN	O	O
bacterial	NN	O	B
infections	NN	O	I
were	NN	O	O
frequently	NN	O	O
found	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
therefore	NN	O	O
important	NN	O	O
to	NN	O	O
recognize	NN	O	O
this	NN	O	O
condition	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
quinine	NN	O	O
and	NN	O	O
4	NN	O	O
-	NN	O	O
aminopyridine	NN	O	O
on	NN	O	O
conditioned	NN	O	O
place	NN	O	O
preference	NN	O	O
and	NN	O	O
changes	NN	O	O
in	NN	O	O
motor	NN	O	O
activity	NN	O	O
induced	NN	O	O
by	NN	O	O
morphine	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

1	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
two	NN	O	O
unselective	NN	O	O
potassium	NN	O	O
(	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
)	NN	O	O
channel	NN	O	O
blockers	NN	O	O
,	NN	O	O
quinine	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
25	NN	O	O
and	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
4	NN	O	O
-	NN	O	O
aminopyridine	NN	O	O
(	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
on	NN	O	O
conditioned	NN	O	O
place	NN	O	O
preference	NN	O	O
and	NN	O	O
biphasic	NN	O	O
changes	NN	O	O
in	NN	O	O
motor	NN	O	O
activity	NN	O	O
induced	NN	O	O
by	NN	O	O
morphine	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
were	NN	O	O
tested	NN	O	O
in	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

Quinine	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
block	NN	O	O
voltage	NN	O	O
-	NN	O	O
,	NN	O	O
calcium	NN	O	O
-	NN	O	O
and	NN	O	O
ATP	NN	O	O
-	NN	O	O
sensitive	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
channels	NN	O	O
while	NN	O	O
4	NN	O	O
-	NN	O	O
aminopyridine	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
block	NN	O	O
voltage	NN	O	O
-	NN	O	O
sensitive	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
channels	NN	O	O
.	NN	O	O

2	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
counterbalanced	NN	O	O
method	NN	O	O
,	NN	O	O
quinine	NN	O	O
attenuated	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
place	NN	O	O
preference	NN	O	O
,	NN	O	O
whereas	NN	O	O
4	NN	O	O
-	NN	O	O
aminopyridine	NN	O	O
was	NN	O	O
ineffective	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
motor	NN	O	O
activity	NN	O	O
test	NN	O	O
measured	NN	O	O
with	NN	O	O
an	NN	O	O
Animex	NN	O	O
-	NN	O	O
activity	NN	O	O
meter	NN	O	O
neither	NN	O	O
of	NN	O	O
the	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
channel	NN	O	O
blockers	NN	O	O
affected	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypoactivity	NN	O	B
,	NN	O	O
but	NN	O	O
both	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
channel	NN	O	O
blockers	NN	O	O
prevented	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
secondary	NN	O	O
hyperactivity	NN	O	B
.	NN	O	O

3	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
quinine	NN	O	O
-	NN	O	O
sensitive	NN	O	O
but	NN	O	O
not	NN	O	O
4	NN	O	O
-	NN	O	O
aminopyridine	NN	O	O
-	NN	O	O
sensitive	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
channels	NN	O	O
in	NN	O	O
morphine	NN	O	O
reward	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
also	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
blockade	NN	O	O
of	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
channels	NN	O	O
sensitive	NN	O	O
to	NN	O	O
these	NN	O	O
blockers	NN	O	O
is	NN	O	O
not	NN	O	O
sufficient	NN	O	O
to	NN	O	O
prevent	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypoactivity	NN	O	B
whereas	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
seems	NN	O	O
to	NN	O	O
be	NN	O	O
connected	NN	O	O
to	NN	O	O
both	NN	O	O
quinine	NN	O	O
-	NN	O	O
and	NN	O	O
4	NN	O	O
-	NN	O	O
aminopyridine	NN	O	O
-	NN	O	O
sensitive	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
channels	NN	O	O
.	NN	O	O

Nociceptin	NN	O	O
/	NN	O	O
orphanin	NN	O	O
FQ	NN	O	O
and	NN	O	O
nocistatin	NN	O	O
on	NN	O	O
learning	NN	O	B
and	NN	O	I
memory	NN	O	I
impairment	NN	O	I
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

1	NN	O	O
.	NN	O	O

Nociceptin	NN	O	O
,	NN	O	O
also	NN	O	O
known	NN	O	O
as	NN	O	O
orphanin	NN	O	O
FQ	NN	O	O
,	NN	O	O
is	NN	O	O
an	NN	O	O
endogenous	NN	O	O
ligand	NN	O	O
for	NN	O	O
the	NN	O	O
orphan	NN	O	O
opioid	NN	O	O
receptor	NN	O	O
-	NN	O	O
like	NN	O	O
receptor	NN	O	O
1	NN	O	O
(	NN	O	O
ORL1	NN	O	O
)	NN	O	O
and	NN	O	O
involves	NN	O	O
in	NN	O	O
various	NN	O	O
functions	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
nocistatin	NN	O	O
is	NN	O	O
recently	NN	O	O
isolated	NN	O	O
from	NN	O	O
the	NN	O	O
same	NN	O	O
precursor	NN	O	O
as	NN	O	O
nociceptin	NN	O	O
and	NN	O	O
blocks	NN	O	O
nociceptin	NN	O	O
-	NN	O	O
induced	NN	O	O
allodynia	NN	O	B
and	NN	O	O
hyperalgesia	NN	O	B
.	NN	O	O

2	NN	O	O
.	NN	O	O

Although	NN	O	O
ORL1	NN	O	O
receptors	NN	O	O
which	NN	O	O
display	NN	O	O
a	NN	O	O
high	NN	O	O
degree	NN	O	O
of	NN	O	O
sequence	NN	O	O
homology	NN	O	O
with	NN	O	O
classical	NN	O	O
opioid	NN	O	O
receptors	NN	O	O
are	NN	O	O
abundant	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
,	NN	O	O
little	NN	O	O
is	NN	O	O
known	NN	O	O
regarding	NN	O	O
their	NN	O	O
role	NN	O	O
in	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
.	NN	O	O

3	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
nociceptin	NN	O	O
/	NN	O	O
orphanin	NN	O	O
FQ	NN	O	O
and	NN	O	O
nocistatin	NN	O	O
could	NN	O	O
modulate	NN	O	O
impairment	NN	O	B
of	NN	O	I
learning	NN	O	I
and	NN	O	I
memory	NN	O	I
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
,	NN	O	O
a	NN	O	O
muscarinic	NN	O	O
cholinergic	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
using	NN	O	O
spontaneous	NN	O	O
alternation	NN	O	O
of	NN	O	O
Y	NN	O	O
-	NN	O	O
maze	NN	O	O
and	NN	O	O
step	NN	O	O
-	NN	O	O
down	NN	O	O
type	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
tasks	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

4	NN	O	O
.	NN	O	O

While	NN	O	O
nocistatin	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
nmol	NN	O	O
mouse	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
administered	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
spontaneous	NN	O	O
alternation	NN	O	O
performance	NN	O	O
or	NN	O	O
the	NN	O	O
training	NN	O	O
session	NN	O	O
of	NN	O	O
the	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
,	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
spontaneous	NN	O	O
alternation	NN	O	O
or	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
behaviours	NN	O	O
,	NN	O	O
a	NN	O	O
lower	NN	O	O
per	NN	O	O
cent	NN	O	O
alternation	NN	O	O
and	NN	O	O
shorter	NN	O	O
median	NN	O	O
step	NN	O	O
-	NN	O	O
down	NN	O	O
latency	NN	O	O
in	NN	O	O
the	NN	O	O
retention	NN	O	O
test	NN	O	O
were	NN	O	O
obtained	NN	O	O
in	NN	O	O
nociceptin	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
nmol	NN	O	O
mouse	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
-	NN	O	O
treated	NN	O	O
normal	NN	O	O
mice	NN	O	O
.	NN	O	O

5	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
nocistatin	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
nmol	NN	O	O
mouse	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
spontaneous	NN	O	O
alternation	NN	O	O
performance	NN	O	O
or	NN	O	O
the	NN	O	O
training	NN	O	O
session	NN	O	O
of	NN	O	O
the	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
,	NN	O	O
attenuated	NN	O	O
the	NN	O	O
scopolamine	NN	O	O
-	NN	O	O
induced	NN	O	O
impairment	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
alternation	NN	O	O
and	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
behaviours	NN	O	O
.	NN	O	O

6	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicated	NN	O	O
that	NN	O	O
nocistatin	NN	O	O
,	NN	O	O
a	NN	O	O
new	NN	O	O
biologically	NN	O	O
active	NN	O	O
peptide	NN	O	O
,	NN	O	O
ameliorates	NN	O	O
impairments	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
alternation	NN	O	O
and	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
,	NN	O	O
and	NN	O	O
suggested	NN	O	O
that	NN	O	O
these	NN	O	O
peptides	NN	O	O
play	NN	O	O
opposite	NN	O	O
roles	NN	O	O
in	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
.	NN	O	O

Meloxicam	NN	O	O
-	NN	O	O
induced	NN	O	O
liver	NN	O	B
toxicity	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
female	NN	O	O
patient	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
who	NN	O	O
developed	NN	O	O
acute	NN	O	O
cytolytic	NN	O	O
hepatitis	NN	O	B
due	NN	O	O
to	NN	O	O
meloxicam	NN	O	O
.	NN	O	O

Recently	NN	O	O
introduced	NN	O	O
in	NN	O	O
Belgium	NN	O	O
,	NN	O	O
meloxicam	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
nonsteroidal	NN	O	O
antiinflammatory	NN	O	O
drug	NN	O	O
with	NN	O	O
selective	NN	O	O
action	NN	O	O
on	NN	O	O
the	NN	O	O
inducible	NN	O	O
form	NN	O	O
of	NN	O	O
cyclooxygenase	NN	O	O
2	NN	O	O
.	NN	O	O

The	NN	O	O
acute	NN	O	O
cytolytic	NN	O	O
hepatitis	NN	O	B
occurred	NN	O	O
rapidly	NN	O	O
after	NN	O	O
meloxicam	NN	O	O
administration	NN	O	O
and	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
antinuclear	NN	O	O
antibodies	NN	O	O
suggesting	NN	O	O
a	NN	O	O
hypersensitivity	NN	O	B
mechanism	NN	O	O
.	NN	O	O

This	NN	O	O
first	NN	O	O
case	NN	O	O
of	NN	O	O
meloxicam	NN	O	O
related	NN	O	O
liver	NN	O	B
toxicity	NN	O	I
demonstrates	NN	O	O
the	NN	O	O
potential	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
to	NN	O	O
induce	NN	O	O
hepatic	NN	O	B
damage	NN	O	I
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
by	NN	O	O
remoxipride	NN	O	O
metabolites	NN	O	O
in	NN	O	O
HL60	NN	O	O
and	NN	O	O
CD34	NN	O	O
+	NN	O	O
/	NN	O	O
CD19	NN	O	O
-	NN	O	O
human	NN	O	O
bone	NN	O	O
marrow	NN	O	O
progenitor	NN	O	O
cells	NN	O	O
:	NN	O	O
potential	NN	O	O
relevance	NN	O	O
to	NN	O	O
remoxipride	NN	O	O
-	NN	O	O
induced	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
.	NN	O	O

The	NN	O	O
antipsychotic	NN	O	O
agent	NN	O	O
,	NN	O	O
remoxipride	NN	O	O
[	NN	O	O
(	NN	O	O
S	NN	O	O
)	NN	O	O
-	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
bromo	NN	O	O
-	NN	O	O
N	NN	O	O
-	NN	O	O
[	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
ethyl	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
pyrrolidinyl	NN	O	O
)	NN	O	O
methyl	NN	O	O
]	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
6	NN	O	O
-	NN	O	O
dimethoxybenz	NN	O	O
amide	NN	O	O
]	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
acquired	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
.	NN	O	O

We	NN	O	O
have	NN	O	O
examined	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
remoxipride	NN	O	O
,	NN	O	O
three	NN	O	O
pyrrolidine	NN	O	O
ring	NN	O	O
metabolites	NN	O	O
and	NN	O	O
five	NN	O	O
aromatic	NN	O	O
ring	NN	O	O
metabolites	NN	O	O
of	NN	O	O
the	NN	O	O
parent	NN	O	O
compound	NN	O	O
to	NN	O	O
induce	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
HL60	NN	O	O
cells	NN	O	O
and	NN	O	O
human	NN	O	O
bone	NN	O	O
marrow	NN	O	O
progenitor	NN	O	O
(	NN	O	O
HBMP	NN	O	O
)	NN	O	O
cells	NN	O	O
.	NN	O	O

Cells	NN	O	O
were	NN	O	O
treated	NN	O	O
for	NN	O	O
0	NN	O	O
-	NN	O	O
24	NN	O	O
h	NN	O	O
with	NN	O	O
each	NN	O	O
compound	NN	O	O
(	NN	O	O
0	NN	O	O
-	NN	O	O
200	NN	O	O
microM	NN	O	O
)	NN	O	O
.	NN	O	O

Apoptosis	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
fluorescence	NN	O	O
microscopy	NN	O	O
in	NN	O	O
Hoechst	NN	O	O
33342	NN	O	O
-	NN	O	O
and	NN	O	O
propidium	NN	O	O
iodide	NN	O	O
stained	NN	O	O
cell	NN	O	O
samples	NN	O	O
.	NN	O	O

Results	NN	O	O
were	NN	O	O
confirmed	NN	O	O
by	NN	O	O
determination	NN	O	O
of	NN	O	O
internucleosomal	NN	O	O
DNA	NN	O	O
fragmentation	NN	O	O
using	NN	O	O
gel	NN	O	O
electrophoresis	NN	O	O
for	NN	O	O
HL60	NN	O	O
cell	NN	O	O
samples	NN	O	O
and	NN	O	O
terminal	NN	O	O
deoxynucleotidyl	NN	O	O
transferase	NN	O	O
assay	NN	O	O
in	NN	O	O
HBMP	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
catechol	NN	O	O
and	NN	O	O
hydroquinone	NN	O	O
metabolites	NN	O	O
,	NN	O	O
NCQ436	NN	O	O
and	NN	O	O
NCQ344	NN	O	O
,	NN	O	O
induced	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
HL60	NN	O	O
and	NN	O	O
HBMP	NN	O	O
cells	NN	O	O
in	NN	O	O
a	NN	O	O
time	NN	O	O
-	NN	O	O
and	NN	O	O
concentration	NN	O	O
dependent	NN	O	O
manner	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
phenols	NN	O	O
,	NN	O	O
NCR181	NN	O	O
,	NN	O	O
FLA873	NN	O	O
,	NN	O	O
and	NN	O	O
FLA797	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
derivatives	NN	O	O
formed	NN	O	O
by	NN	O	O
oxidation	NN	O	O
of	NN	O	O
the	NN	O	O
pyrrolidine	NN	O	O
ring	NN	O	O
,	NN	O	O
FLA838	NN	O	O
,	NN	O	O
NCM001	NN	O	O
,	NN	O	O
and	NN	O	O
NCL118	NN	O	O
,	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
.	NN	O	O

No	NN	O	O
necrosis	NN	O	B
was	NN	O	O
observed	NN	O	O
in	NN	O	O
cells	NN	O	O
treated	NN	O	O
with	NN	O	O
NCQ436	NN	O	O
but	NN	O	O
NCQ344	NN	O	O
had	NN	O	O
a	NN	O	O
biphasic	NN	O	O
effect	NN	O	O
in	NN	O	O
both	NN	O	O
cell	NN	O	O
types	NN	O	O
,	NN	O	O
inducing	NN	O	O
apoptosis	NN	O	O
at	NN	O	O
lower	NN	O	O
concentrations	NN	O	O
and	NN	O	O
necrosis	NN	O	B
at	NN	O	O
higher	NN	O	O
concentrations	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
catechol	NN	O	O
and	NN	O	O
hydroquinone	NN	O	O
metabolites	NN	O	O
of	NN	O	O
remoxipride	NN	O	O
have	NN	O	O
direct	NN	O	O
toxic	NN	O	O
effects	NN	O	O
in	NN	O	O
HL60	NN	O	O
and	NN	O	O
HBMP	NN	O	O
cells	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
apoptosis	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
phenol	NN	O	O
metabolites	NN	O	O
were	NN	O	O
inactive	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
benzene	NN	O	O
-	NN	O	O
derived	NN	O	O
catechol	NN	O	O
and	NN	O	O
hydroquinone	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
phenol	NN	O	O
,	NN	O	O
induce	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
HBMP	NN	O	O
cells	NN	O	O
[	NN	O	O
Moran	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O
,	NN	O	O
Mol	NN	O	O
.	NN	O	O
Pharmacol	NN	O	O
.	NN	O	O
,	NN	O	O
50	NN	O	O
(	NN	O	O
1996	NN	O	O
)	NN	O	O
610	NN	O	O
-	NN	O	O
615	NN	O	O
]	NN	O	O
.	NN	O	O

We	NN	O	O
propose	NN	O	O
that	NN	O	O
remoxipride	NN	O	O
and	NN	O	O
benzene	NN	O	O
may	NN	O	O
induce	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
via	NN	O	O
production	NN	O	O
of	NN	O	O
similar	NN	O	O
reactive	NN	O	O
metabolites	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
NCQ436	NN	O	O
and	NN	O	O
NCQ344	NN	O	O
to	NN	O	O
induce	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
HBMP	NN	O	O
cells	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
mechanism	NN	O	O
underlying	NN	O	O
acquired	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
that	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
remoxipride	NN	O	O
.	NN	O	O

Synthesis	NN	O	O
and	NN	O	O
preliminary	NN	O	O
pharmacological	NN	O	O
investigations	NN	O	O
of	NN	O	O
1	NN	O	O
-	NN	O	O
(	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
dihydro	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
acenaphthylenyl	NN	O	O
)	NN	O	O
piperazine	NN	O	O
derivatives	NN	O	O
as	NN	O	O
potential	NN	O	O
atypical	NN	O	O
antipsychotic	NN	O	O
agents	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
research	NN	O	O
towards	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
new	NN	O	O
atypical	NN	O	O
antipsychotic	NN	O	O
agents	NN	O	O
,	NN	O	O
one	NN	O	O
strategy	NN	O	O
is	NN	O	O
that	NN	O	O
the	NN	O	O
dopaminergic	NN	O	O
system	NN	O	O
can	NN	O	O
be	NN	O	O
modulated	NN	O	O
through	NN	O	O
manipulation	NN	O	O
of	NN	O	O
the	NN	O	O
serotonergic	NN	O	O
system	NN	O	O
.	NN	O	O

The	NN	O	O
synthesis	NN	O	O
and	NN	O	O
preliminary	NN	O	O
pharmacological	NN	O	O
evaluation	NN	O	O
of	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
potential	NN	O	O
atypical	NN	O	O
antipsychotic	NN	O	O
agents	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
structure	NN	O	O
of	NN	O	O
1	NN	O	O
-	NN	O	O
(	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
dihydro	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
acenaphthylenyl	NN	O	O
)	NN	O	O
piperazine	NN	O	O
(	NN	O	O
7	NN	O	O
)	NN	O	O
is	NN	O	O
described	NN	O	O
.	NN	O	O

Compound	NN	O	O
7e	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
{	NN	O	O
2	NN	O	O
-	NN	O	O
[	NN	O	O
4	NN	O	O
-	NN	O	O
(	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
dihydro	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
acenaphthylenyl	NN	O	O
)	NN	O	O
piperazinyl	NN	O	O
]	NN	O	O
ethyl	NN	O	O
}	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
dihy	NN	O	O
dro	NN	O	O
-	NN	O	O
1H	NN	O	O
-	NN	O	O
indol	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
one	NN	O	O
,	NN	O	O
from	NN	O	O
this	NN	O	O
series	NN	O	O
showed	NN	O	O
significant	NN	O	O
affinities	NN	O	O
at	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
HT1A	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
HT2A	NN	O	O
receptors	NN	O	O
and	NN	O	O
moderate	NN	O	O
affinity	NN	O	O
at	NN	O	O
the	NN	O	O
D2	NN	O	O
receptor	NN	O	O
.	NN	O	O

7e	NN	O	O
exhibits	NN	O	O
a	NN	O	O
high	NN	O	O
reversal	NN	O	O
of	NN	O	O
catalepsy	NN	O	B
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	O
indicating	NN	O	O
its	NN	O	O
atypical	NN	O	O
antipsychotic	NN	O	O
nature	NN	O	O
.	NN	O	O

Sub	NN	O	O
-	NN	O	O
chronic	NN	O	O
inhibition	NN	O	O
of	NN	O	O
nitric	NN	O	O
-	NN	O	O
oxide	NN	O	O
synthesis	NN	O	O
modifies	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
and	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
NADPH	NN	O	O
-	NN	O	O
diaphorase	NN	O	O
neurons	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

RATIONALE	NN	O	O
:	NN	O	O
NG	NN	O	O
-	NN	O	O
nitro	NN	O	O
-	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
(	NN	O	O
L	NN	O	O
-	NN	O	O
NOARG	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
nitric	NN	O	O
-	NN	O	O
oxide	NN	O	O
synthase	NN	O	O
(	NN	O	O
NOS	NN	O	O
)	NN	O	O
,	NN	O	O
induces	NN	O	O
catalepsy	NN	O	B
in	NN	O	O
mice	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
undergoes	NN	O	O
rapid	NN	O	O
tolerance	NN	O	O
,	NN	O	O
showing	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
after	NN	O	O
2	NN	O	O
days	NN	O	O
of	NN	O	O
sub	NN	O	O
-	NN	O	O
chronic	NN	O	O
L	NN	O	O
-	NN	O	O
NOARG	NN	O	O
treatment	NN	O	O
.	NN	O	O

Nitric	NN	O	O
oxide	NN	O	O
(	NN	O	O
NO	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
influence	NN	O	O
dopaminergic	NN	O	O
neurotransmission	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
.	NN	O	O

Neuroleptic	NN	O	O
drugs	NN	O	O
such	NN	O	O
as	NN	O	O
haloperidol	NN	O	O
,	NN	O	O
which	NN	O	O
block	NN	O	O
dopamine	NN	O	O
receptors	NN	O	O
,	NN	O	O
also	NN	O	O
cause	NN	O	O
catalepsy	NN	O	B
in	NN	O	O
rodents	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
investigate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
subchronic	NN	O	O
L	NN	O	O
-	NN	O	O
NOARG	NN	O	O
treatment	NN	O	O
in	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
and	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
NOS	NN	O	O
neurons	NN	O	O
in	NN	O	O
areas	NN	O	O
related	NN	O	O
to	NN	O	O
motor	NN	O	O
control	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Male	NN	O	O
albino	NN	O	O
Swiss	NN	O	O
mice	NN	O	O
were	NN	O	O
treated	NN	O	O
sub	NN	O	O
-	NN	O	O
chronically	NN	O	O
(	NN	O	O
twice	NN	O	O
a	NN	O	O
day	NN	O	O
for	NN	O	O
4	NN	O	O
days	NN	O	O
)	NN	O	O
with	NN	O	O
L	NN	O	O
-	NN	O	O
NOARG	NN	O	O
(	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
or	NN	O	O
haloperidol	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

Catalepsy	NN	O	B
was	NN	O	O
evaluated	NN	O	O
at	NN	O	O
the	NN	O	O
beginning	NN	O	O
and	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
treatments	NN	O	O
.	NN	O	O

Reduced	NN	O	O
nicotinamide	NN	O	O
adenine	NN	O	O
dinucleotide	NN	O	O
phosphate	NN	O	O
-	NN	O	O
diaphorase	NN	O	O
(	NN	O	O
NADPH	NN	O	O
-	NN	O	O
d	NN	O	O
)	NN	O	O
histochemistry	NN	O	O
was	NN	O	O
also	NN	O	O
employed	NN	O	O
to	NN	O	O
visualize	NN	O	O
NOS	NN	O	O
as	NN	O	O
an	NN	O	O
index	NN	O	O
of	NN	O	O
enzyme	NN	O	O
expression	NN	O	O
in	NN	O	O
mice	NN	O	O
brain	NN	O	O
regions	NN	O	O
related	NN	O	O
to	NN	O	O
motor	NN	O	O
control	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
L	NN	O	O
-	NN	O	O
NOARG	NN	O	O
sub	NN	O	O
-	NN	O	O
chronic	NN	O	O
administration	NN	O	O
produced	NN	O	O
tolerance	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
NOARG	NN	O	O
and	NN	O	O
of	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
.	NN	O	O

It	NN	O	O
also	NN	O	O
induced	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
NADPH	NN	O	O
-	NN	O	O
d	NN	O	O
-	NN	O	O
positive	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
dorsal	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
caudate	NN	O	O
and	NN	O	O
accumbens	NN	O	O
nuclei	NN	O	O
compared	NN	O	O
with	NN	O	O
haloperidol	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
pedunculopontine	NN	O	O
tegmental	NN	O	O
nucleus	NN	O	O
compared	NN	O	O
with	NN	O	O
saline	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
NADPH	NN	O	O
-	NN	O	O
d	NN	O	O
neuron	NN	O	O
number	NN	O	O
in	NN	O	O
the	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
,	NN	O	O
pars	NN	O	O
compacta	NN	O	O
in	NN	O	O
both	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
treated	NN	O	O
and	NN	O	O
L	NN	O	O
-	NN	O	O
NOARG	NN	O	O
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
give	NN	O	O
further	NN	O	O
support	NN	O	O
to	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
NO	NN	O	O
plays	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
motor	NN	O	O
behavior	NN	O	O
control	NN	O	O
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
it	NN	O	O
may	NN	O	O
take	NN	O	O
part	NN	O	O
in	NN	O	O
the	NN	O	O
synaptic	NN	O	O
changes	NN	O	O
produced	NN	O	O
by	NN	O	O
antipsychotic	NN	O	O
treatment	NN	O	O
.	NN	O	O

Prolonged	NN	O	O
left	NN	O	B
ventricular	NN	O	I
dysfunction	NN	O	I
occurs	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
after	NN	O	O
both	NN	O	O
dobutamine	NN	O	O
and	NN	O	O
exercise	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischaemia	NN	O	I
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
whether	NN	O	O
pharmacological	NN	O	O
stress	NN	O	O
leads	NN	O	O
to	NN	O	O
prolonged	NN	O	O
but	NN	O	O
reversible	NN	O	O
left	NN	O	B
ventricular	NN	O	I
dysfunction	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
,	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
seen	NN	O	O
after	NN	O	O
exercise	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
A	NN	O	O
randomised	NN	O	O
crossover	NN	O	O
study	NN	O	O
of	NN	O	O
recovery	NN	O	O
time	NN	O	O
of	NN	O	O
systolic	NN	O	O
and	NN	O	O
diastolic	NN	O	O
left	NN	O	O
ventricular	NN	O	O
function	NN	O	O
after	NN	O	O
exercise	NN	O	O
and	NN	O	O
dobutamine	NN	O	O
induced	NN	O	O
ischaemia	NN	O	B
.	NN	O	O

SUBJECTS	NN	O	O
:	NN	O	O
10	NN	O	O
patients	NN	O	O
with	NN	O	O
stable	NN	O	B
angina	NN	O	I
,	NN	O	O
angiographically	NN	O	O
proven	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
,	NN	O	O
and	NN	O	O
normal	NN	O	O
left	NN	O	O
ventricular	NN	O	O
function	NN	O	O
.	NN	O	O

INTERVENTIONS	NN	O	O
:	NN	O	O
Treadmill	NN	O	O
exercise	NN	O	O
and	NN	O	O
dobutamine	NN	O	O
stress	NN	O	O
were	NN	O	O
performed	NN	O	O
on	NN	O	O
different	NN	O	O
days	NN	O	O
.	NN	O	O

Quantitative	NN	O	O
assessment	NN	O	O
of	NN	O	O
systolic	NN	O	O
and	NN	O	O
diastolic	NN	O	O
left	NN	O	O
ventricular	NN	O	O
function	NN	O	O
was	NN	O	O
performed	NN	O	O
using	NN	O	O
transthoracic	NN	O	O
echocardiography	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
at	NN	O	O
regular	NN	O	O
intervals	NN	O	O
after	NN	O	O
each	NN	O	O
test	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Both	NN	O	O
forms	NN	O	O
of	NN	O	O
stress	NN	O	O
led	NN	O	O
to	NN	O	O
prolonged	NN	O	O
but	NN	O	O
reversible	NN	O	O
systolic	NN	O	O
and	NN	O	O
diastolic	NN	O	O
dysfunction	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
maximum	NN	O	O
double	NN	O	O
product	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
53	NN	O	O
)	NN	O	O
or	NN	O	O
ST	NN	O	O
depression	NN	O	B
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
63	NN	O	O
)	NN	O	O
with	NN	O	O
either	NN	O	O
form	NN	O	O
of	NN	O	O
stress	NN	O	O
.	NN	O	O

After	NN	O	O
exercise	NN	O	O
,	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
was	NN	O	O
reduced	NN	O	O
at	NN	O	O
15	NN	O	O
and	NN	O	O
30	NN	O	O
minutes	NN	O	O
compared	NN	O	O
with	NN	O	O
baseline	NN	O	O
(	NN	O	O
mean	NN	O	O
(	NN	O	O
SEM	NN	O	O
)	NN	O	O
,	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
6	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
;	NN	O	O
and	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
1	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
at	NN	O	O
30	NN	O	O
and	NN	O	O
45	NN	O	O
minutes	NN	O	O
after	NN	O	O
dobutamine	NN	O	O
(	NN	O	O
-	NN	O	O
10	NN	O	O
.	NN	O	O
8	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
%	NN	O	O
and	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
5	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
%	NN	O	O
,	NN	O	O
both	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Regional	NN	O	O
analysis	NN	O	O
showed	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
worst	NN	O	O
affected	NN	O	O
segment	NN	O	O
15	NN	O	O
and	NN	O	O
30	NN	O	O
minutes	NN	O	O
after	NN	O	O
exercise	NN	O	O
(	NN	O	O
-	NN	O	O
27	NN	O	O
.	NN	O	O
9	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
%	NN	O	O
and	NN	O	O
-	NN	O	O
28	NN	O	O
.	NN	O	O
6	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
%	NN	O	O
,	NN	O	O
both	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
at	NN	O	O
30	NN	O	O
minutes	NN	O	O
after	NN	O	O
dobutamine	NN	O	O
(	NN	O	O
-	NN	O	O
32	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
3	NN	O	O
)	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
isovolumic	NN	O	O
relaxation	NN	O	O
period	NN	O	O
was	NN	O	O
prolonged	NN	O	O
45	NN	O	O
minutes	NN	O	O
after	NN	O	O
each	NN	O	O
form	NN	O	O
of	NN	O	O
stress	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
,	NN	O	O
dobutamine	NN	O	O
induced	NN	O	O
ischaemia	NN	O	B
results	NN	O	O
in	NN	O	O
prolonged	NN	O	O
reversible	NN	O	O
left	NN	O	B
ventricular	NN	O	I
dysfunction	NN	O	I
,	NN	O	O
presumed	NN	O	O
to	NN	O	O
be	NN	O	O
myocardial	NN	O	B
stunning	NN	O	I
,	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
seen	NN	O	O
after	NN	O	O
exercise	NN	O	O
.	NN	O	O

Dobutamine	NN	O	O
induced	NN	O	O
ischaemia	NN	O	B
could	NN	O	O
therefore	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
this	NN	O	O
phenomenon	NN	O	O
further	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
.	NN	O	O

Anorexigens	NN	O	O
and	NN	O	O
pulmonary	NN	O	B
hypertension	NN	O	I
in	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
:	NN	O	O
results	NN	O	O
from	NN	O	O
the	NN	O	O
surveillance	NN	O	O
of	NN	O	O
North	NN	O	O
American	NN	O	O
pulmonary	NN	O	B
hypertension	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
use	NN	O	O
of	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
in	NN	O	O
Europe	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
primary	NN	O	B
pulmonary	NN	O	I
hypertension	NN	O	I
(	NN	O	O
PPH	NN	O	B
)	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
fenfluramine	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
became	NN	O	O
widely	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
but	NN	O	O
were	NN	O	O
withdrawn	NN	O	O
in	NN	O	O
September	NN	O	O
1997	NN	O	O
because	NN	O	O
of	NN	O	O
concerns	NN	O	O
over	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
conducted	NN	O	O
a	NN	O	O
prospective	NN	O	O
surveillance	NN	O	O
study	NN	O	O
on	NN	O	O
patients	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
pulmonary	NN	O	B
hypertension	NN	O	I
at	NN	O	O
12	NN	O	O
large	NN	O	O
referral	NN	O	O
centers	NN	O	O
in	NN	O	O
North	NN	O	O
America	NN	O	O
.	NN	O	O

Data	NN	O	O
collected	NN	O	O
on	NN	O	O
patients	NN	O	O
seen	NN	O	O
from	NN	O	O
September	NN	O	O
1	NN	O	O
,	NN	O	O
1996	NN	O	O
,	NN	O	O
to	NN	O	O
December	NN	O	O
31	NN	O	O
,	NN	O	O
1997	NN	O	O
,	NN	O	O
included	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
pulmonary	NN	O	B
hypertension	NN	O	I
and	NN	O	O
its	NN	O	O
severity	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
no	NN	O	O
identifiable	NN	O	O
cause	NN	O	O
of	NN	O	O
pulmonary	NN	O	B
hypertension	NN	O	I
were	NN	O	O
classed	NN	O	O
as	NN	O	O
PPH	NN	O	B
.	NN	O	O

A	NN	O	O
history	NN	O	O
of	NN	O	O
drug	NN	O	O
exposure	NN	O	O
also	NN	O	O
was	NN	O	O
taken	NN	O	O
with	NN	O	O
special	NN	O	O
attention	NN	O	O
on	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
antidepressants	NN	O	O
,	NN	O	O
anorexigens	NN	O	O
,	NN	O	O
and	NN	O	O
amphetamines	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Five	NN	O	O
hundred	NN	O	O
seventy	NN	O	O
-	NN	O	O
nine	NN	O	O
patients	NN	O	O
were	NN	O	O
studied	NN	O	O
,	NN	O	O
205	NN	O	O
with	NN	O	O
PPH	NN	O	B
and	NN	O	O
374	NN	O	O
with	NN	O	O
pulmonary	NN	O	B
hypertension	NN	O	I
from	NN	O	O
other	NN	O	O
causes	NN	O	O
(	NN	O	O
secondary	NN	O	O
pulmonary	NN	O	B
hypertension	NN	O	I
[	NN	O	O
SPH	NN	O	O
]	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
anorexigens	NN	O	O
was	NN	O	O
common	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
of	NN	O	O
the	NN	O	O
medications	NN	O	O
surveyed	NN	O	O
,	NN	O	O
only	NN	O	O
the	NN	O	O
fenfluramines	NN	O	O
had	NN	O	O
a	NN	O	O
significant	NN	O	O
preferential	NN	O	O
association	NN	O	O
with	NN	O	O
PPH	NN	O	B
as	NN	O	O
compared	NN	O	O
with	NN	O	O
SPH	NN	O	O
(	NN	O	O
adjusted	NN	O	O
odds	NN	O	O
ratio	NN	O	O
for	NN	O	O
use	NN	O	O
>	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
to	NN	O	O
32	NN	O	O
.	NN	O	O
4	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
association	NN	O	O
was	NN	O	O
stronger	NN	O	O
with	NN	O	O
longer	NN	O	O
duration	NN	O	O
of	NN	O	O
use	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
shorter	NN	O	O
duration	NN	O	O
of	NN	O	O
use	NN	O	O
and	NN	O	O
was	NN	O	O
more	NN	O	O
pronounced	NN	O	O
in	NN	O	O
recent	NN	O	O
users	NN	O	O
than	NN	O	O
in	NN	O	O
remote	NN	O	O
users	NN	O	O
.	NN	O	O

An	NN	O	O
unexpectedly	NN	O	O
high	NN	O	O
(	NN	O	O
11	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
number	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
SPH	NN	O	O
had	NN	O	O
used	NN	O	O
anorexigens	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
magnitude	NN	O	O
of	NN	O	O
the	NN	O	O
association	NN	O	O
with	NN	O	O
PPH	NN	O	B
,	NN	O	O
the	NN	O	O
increase	NN	O	O
of	NN	O	O
association	NN	O	O
with	NN	O	O
increasing	NN	O	O
duration	NN	O	O
of	NN	O	O
use	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
specificity	NN	O	O
for	NN	O	O
fenfluramines	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
previous	NN	O	O
studies	NN	O	O
indicating	NN	O	O
that	NN	O	O
fenfluramines	NN	O	O
are	NN	O	O
causally	NN	O	O
related	NN	O	O
to	NN	O	O
PPH	NN	O	B
.	NN	O	O

The	NN	O	O
high	NN	O	O
prevalence	NN	O	O
of	NN	O	O
anorexigen	NN	O	O
use	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
SPH	NN	O	O
also	NN	O	O
raises	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
these	NN	O	O
drugs	NN	O	O
precipitate	NN	O	O
pulmonary	NN	O	B
hypertension	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
underlying	NN	O	O
conditions	NN	O	O
associated	NN	O	O
with	NN	O	O
SPH	NN	O	O
.	NN	O	O

Clinical	NN	O	O
aspects	NN	O	O
of	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
and	NN	O	O
thrombosis	NN	O	B
and	NN	O	O
other	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
heparin	NN	O	O
therapy	NN	O	O
.	NN	O	O

Heparin	NN	O	O
,	NN	O	O
first	NN	O	O
used	NN	O	O
to	NN	O	O
prevent	NN	O	O
the	NN	O	O
clotting	NN	O	O
of	NN	O	O
blood	NN	O	O
in	NN	O	O
vitro	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
clinically	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
thrombosis	NN	O	B
for	NN	O	O
more	NN	O	O
than	NN	O	O
50	NN	O	O
years	NN	O	O
.	NN	O	O

Although	NN	O	O
several	NN	O	O
new	NN	O	O
anticoagulant	NN	O	O
drugs	NN	O	O
are	NN	O	O
in	NN	O	O
development	NN	O	O
,	NN	O	O
heparin	NN	O	O
remains	NN	O	O
the	NN	O	O
anticoagulant	NN	O	O
of	NN	O	O
choice	NN	O	O
to	NN	O	O
treat	NN	O	O
acute	NN	O	O
thrombotic	NN	O	B
episodes	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
effects	NN	O	O
of	NN	O	O
heparin	NN	O	O
are	NN	O	O
meritorious	NN	O	O
,	NN	O	O
but	NN	O	O
side	NN	O	O
effects	NN	O	O
do	NN	O	O
exist	NN	O	O
.	NN	O	O

Bleeding	NN	O	B
is	NN	O	O
the	NN	O	O
primary	NN	O	O
untoward	NN	O	O
effect	NN	O	O
of	NN	O	O
heparin	NN	O	O
.	NN	O	O

Major	NN	O	O
bleeding	NN	O	B
is	NN	O	O
of	NN	O	O
primary	NN	O	O
concern	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
heparin	NN	O	O
therapy	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
additional	NN	O	O
important	NN	O	O
untoward	NN	O	O
effects	NN	O	O
of	NN	O	O
heparin	NN	O	O
therapy	NN	O	O
include	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
,	NN	O	O
heparin	NN	O	O
-	NN	O	O
associated	NN	O	O
osteoporosis	NN	O	B
,	NN	O	O
eosinophilia	NN	O	B
,	NN	O	O
skin	NN	O	B
reactions	NN	O	I
,	NN	O	O
allergic	NN	O	B
reactions	NN	O	I
other	NN	O	O
than	NN	O	O
thrombocytopenia	NN	O	B
,	NN	O	O
alopecia	NN	O	B
,	NN	O	O
transaminasemia	NN	O	O
,	NN	O	O
hyperkalemia	NN	O	B
,	NN	O	O
hypoaldosteronism	NN	O	B
,	NN	O	O
and	NN	O	O
priapism	NN	O	B
.	NN	O	O

These	NN	O	O
side	NN	O	O
effects	NN	O	O
are	NN	O	O
relatively	NN	O	O
rare	NN	O	O
in	NN	O	O
a	NN	O	O
given	NN	O	O
individual	NN	O	O
,	NN	O	O
but	NN	O	O
given	NN	O	O
the	NN	O	O
extremely	NN	O	O
widespread	NN	O	O
use	NN	O	O
of	NN	O	O
heparin	NN	O	O
,	NN	O	O
some	NN	O	O
are	NN	O	O
quite	NN	O	O
common	NN	O	O
,	NN	O	O
particularly	NN	O	O
HITT	NN	O	B
and	NN	O	O
osteoporosis	NN	O	B
.	NN	O	O

Although	NN	O	O
reasonable	NN	O	O
incidences	NN	O	O
of	NN	O	O
many	NN	O	O
of	NN	O	O
these	NN	O	O
side	NN	O	O
effects	NN	O	O
can	NN	O	O
be	NN	O	O
"	NN	O	O
softly	NN	O	O
"	NN	O	O
deduced	NN	O	O
from	NN	O	O
current	NN	O	O
reports	NN	O	O
dealing	NN	O	O
with	NN	O	O
unfractionated	NN	O	O
heparin	NN	O	O
,	NN	O	O
at	NN	O	O
present	NN	O	O
the	NN	O	O
incidences	NN	O	O
of	NN	O	O
these	NN	O	O
side	NN	O	O
effects	NN	O	O
with	NN	O	O
newer	NN	O	O
low	NN	O	O
molecular	NN	O	O
weight	NN	O	O
heparins	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
much	NN	O	O
less	NN	O	O
common	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
only	NN	O	O
longer	NN	O	O
experience	NN	O	O
will	NN	O	O
more	NN	O	O
clearly	NN	O	O
define	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
each	NN	O	O
side	NN	O	O
effect	NN	O	O
with	NN	O	O
low	NN	O	O
molecular	NN	O	O
weight	NN	O	O
preparations	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
bilateral	NN	O	O
optic	NN	O	B
neuropathy	NN	O	I
in	NN	O	O
a	NN	O	O
patient	NN	O	O
on	NN	O	O
tacrolimus	NN	O	O
(	NN	O	O
FK506	NN	O	O
)	NN	O	O
therapy	NN	O	O
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
bilateral	NN	O	O
optic	NN	O	B
neuropathy	NN	O	I
in	NN	O	O
a	NN	O	O
patient	NN	O	O
receiving	NN	O	O
tacrolimus	NN	O	O
(	NN	O	O
FK	NN	O	O
506	NN	O	O
,	NN	O	O
Prograf	NN	O	O
;	NN	O	O
Fujisawa	NN	O	O
USA	NN	O	O
,	NN	O	O
Inc	NN	O	O
,	NN	O	O
Deerfield	NN	O	O
,	NN	O	O
Illinois	NN	O	O
)	NN	O	O
for	NN	O	O
immunosuppression	NN	O	O
after	NN	O	O
orthotropic	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Case	NN	O	O
report	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
58	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
receiving	NN	O	O
tacrolimus	NN	O	O
after	NN	O	O
orthotropic	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
,	NN	O	O
serial	NN	O	O
neuro	NN	O	O
-	NN	O	O
ophthalmologic	NN	O	O
examinations	NN	O	O
and	NN	O	O
laboratory	NN	O	O
studies	NN	O	O
were	NN	O	O
performed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
patient	NN	O	O
had	NN	O	O
episodic	NN	O	O
deterioration	NN	O	O
of	NN	O	O
vision	NN	O	O
in	NN	O	O
both	NN	O	O
eyes	NN	O	O
,	NN	O	O
with	NN	O	O
clinical	NN	O	O
features	NN	O	O
resembling	NN	O	O
ischemic	NN	O	B
optic	NN	O	I
neuropathies	NN	O	I
.	NN	O	O

Deterioration	NN	O	B
of	NN	O	I
vision	NN	O	I
occurred	NN	O	O
despite	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
tacrolimus	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Tacrolimus	NN	O	O
and	NN	O	O
other	NN	O	O
immunosuppressive	NN	O	O
agents	NN	O	O
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
optic	NN	O	B
nerve	NN	O	I
toxicity	NN	O	I
.	NN	O	O

Hypercalcemia	NN	O	B
,	NN	O	O
arrhythmia	NN	O	B
,	NN	O	O
and	NN	O	O
mood	NN	O	O
stabilizers	NN	O	O
.	NN	O	O

Recent	NN	O	O
findings	NN	O	O
in	NN	O	O
a	NN	O	O
bipolar	NN	O	B
patient	NN	O	O
receiving	NN	O	O
maintenance	NN	O	O
lithium	NN	O	O
therapy	NN	O	O
who	NN	O	O
developed	NN	O	O
hypercalcemia	NN	O	B
and	NN	O	O
severe	NN	O	O
bradyarrhythmia	NN	O	B
prompted	NN	O	O
the	NN	O	O
authors	NN	O	O
to	NN	O	O
conduct	NN	O	O
a	NN	O	O
retrospective	NN	O	O
study	NN	O	O
of	NN	O	O
bipolar	NN	O	B
patients	NN	O	O
with	NN	O	O
lithium	NN	O	O
-	NN	O	O
associated	NN	O	O
hypercalcemia	NN	O	B
.	NN	O	O

A	NN	O	O
printout	NN	O	O
of	NN	O	O
all	NN	O	O
cases	NN	O	O
of	NN	O	O
hypercalcemia	NN	O	B
that	NN	O	O
presented	NN	O	O
during	NN	O	O
a	NN	O	O
1	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
was	NN	O	O
generated	NN	O	O
.	NN	O	O

After	NN	O	O
eliminating	NN	O	O
spurious	NN	O	O
hypercalcemias	NN	O	B
or	NN	O	O
those	NN	O	O
associated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
fluids	NN	O	O
,	NN	O	O
the	NN	O	O
authors	NN	O	O
identified	NN	O	O
18	NN	O	O
non	NN	O	O
-	NN	O	O
lithium	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
with	NN	O	O
hypercalcemias	NN	O	B
related	NN	O	O
to	NN	O	O
malignancies	NN	O	B
and	NN	O	O
other	NN	O	O
medical	NN	O	O
conditions	NN	O	O
(	NN	O	O
group	NN	O	O
A	NN	O	O
)	NN	O	O
and	NN	O	O
12	NN	O	O
patients	NN	O	O
with	NN	O	O
lithium	NN	O	O
-	NN	O	O
associated	NN	O	O
hypercalcemia	NN	O	B
(	NN	O	O
group	NN	O	O
B	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
in	NN	O	O
group	NN	O	O
B	NN	O	O
were	NN	O	O
not	NN	O	O
comparable	NN	O	O
to	NN	O	O
those	NN	O	O
in	NN	O	O
group	NN	O	O
A	NN	O	O
,	NN	O	O
as	NN	O	O
the	NN	O	O
latter	NN	O	O
were	NN	O	O
medically	NN	O	O
compromised	NN	O	O
and	NN	O	O
were	NN	O	O
receiving	NN	O	O
multiple	NN	O	O
pharmacotherapies	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
two	NN	O	O
control	NN	O	O
groups	NN	O	O
were	NN	O	O
generated	NN	O	O
:	NN	O	O
group	NN	O	O
C1	NN	O	O
,	NN	O	O
which	NN	O	O
included	NN	O	O
age	NN	O	O
-	NN	O	O
and	NN	O	O
sex	NN	O	O
-	NN	O	O
comparable	NN	O	O
lithium	NN	O	O
-	NN	O	O
treated	NN	O	O
bipolar	NN	O	B
normocalcemic	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
group	NN	O	O
C2	NN	O	O
,	NN	O	O
which	NN	O	O
included	NN	O	O
bipolar	NN	O	B
normocalcemic	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
anticonvulsant	NN	O	O
mood	NN	O	O
stabilizers	NN	O	O
.	NN	O	O

The	NN	O	O
electrocardiographic	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
findings	NN	O	O
for	NN	O	O
patients	NN	O	O
in	NN	O	O
group	NN	O	O
B	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
groups	NN	O	O
C1	NN	O	O
and	NN	O	O
C2	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
found	NN	O	O
that	NN	O	O
these	NN	O	O
groups	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
in	NN	O	O
their	NN	O	O
overall	NN	O	O
frequency	NN	O	O
of	NN	O	O
ECG	NN	O	O
abnormalities	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
conduction	NN	O	O
defects	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
hypercalcemia	NN	O	B
resulting	NN	O	O
from	NN	O	O
medical	NN	O	O
diseases	NN	O	O
and	NN	O	O
bipolar	NN	O	B
patients	NN	O	O
with	NN	O	O
lithium	NN	O	O
-	NN	O	O
associated	NN	O	O
hypercalcemia	NN	O	B
had	NN	O	O
significantly	NN	O	O
higher	NN	O	O
frequencies	NN	O	O
of	NN	O	O
conduction	NN	O	O
defects	NN	O	O
.	NN	O	O

Patients	NN	O	O
in	NN	O	O
group	NN	O	O
A	NN	O	O
had	NN	O	O
significant	NN	O	O
mortality	NN	O	O
at	NN	O	O
2	NN	O	O
-	NN	O	O
year	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
(	NN	O	O
28	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
zero	NN	O	O
mortality	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
three	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
implications	NN	O	O
of	NN	O	O
these	NN	O	O
findings	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Attenuation	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B
by	NN	O	O
a	NN	O	O
novel	NN	O	O
lipid	NN	O	O
nanosphere	NN	O	O
(	NN	O	O
NS	NN	O	O
-	NN	O	O
718	NN	O	O
)	NN	O	O
incorporating	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
.	NN	O	O

NS	NN	O	O
-	NN	O	O
718	NN	O	O
,	NN	O	O
a	NN	O	O
lipid	NN	O	O
nanosphere	NN	O	O
incorporating	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
,	NN	O	O
is	NN	O	O
effective	NN	O	O
against	NN	O	O
pathogenic	NN	O	O
fungi	NN	O	O
and	NN	O	O
has	NN	O	O
low	NN	O	O
toxicity	NN	O	B
.	NN	O	O

We	NN	O	O
compared	NN	O	O
the	NN	O	O
toxicity	NN	O	B
of	NN	O	O
NS	NN	O	O
-	NN	O	O
718	NN	O	O
with	NN	O	O
that	NN	O	O
of	NN	O	O
Fungizone	NN	O	O
(	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
-	NN	O	O
sodium	NN	O	O
deoxycholate	NN	O	O
;	NN	O	O
D	NN	O	O
-	NN	O	O
AmB	NN	O	O
)	NN	O	O
in	NN	O	O
vitro	NN	O	O
using	NN	O	O
renal	NN	O	O
cell	NN	O	O
cultures	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
by	NN	O	O
biochemical	NN	O	O
analysis	NN	O	O
,	NN	O	O
histopathological	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
kidney	NN	O	O
and	NN	O	O
pharmacokinetic	NN	O	O
study	NN	O	O
of	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
following	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
the	NN	O	O
formulation	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Incubation	NN	O	O
with	NN	O	O
NS	NN	O	O
-	NN	O	O
718	NN	O	O
resulted	NN	O	O
in	NN	O	O
significantly	NN	O	O
less	NN	O	O
damage	NN	O	O
of	NN	O	O
cultured	NN	O	O
human	NN	O	O
renal	NN	O	O
proximal	NN	O	O
tubular	NN	O	O
epithelial	NN	O	O
cells	NN	O	O
compared	NN	O	O
with	NN	O	O
D	NN	O	O
-	NN	O	O
AmB	NN	O	O
.	NN	O	O

Serum	NN	O	O
blood	NN	O	O
urea	NN	O	O
and	NN	O	O
creatinine	NN	O	O
concentrations	NN	O	O
increased	NN	O	O
significantly	NN	O	O
in	NN	O	O
rats	NN	O	O
given	NN	O	O
an	NN	O	O
iv	NN	O	O
infusion	NN	O	O
of	NN	O	O
D	NN	O	O
-	NN	O	O
AmB	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
those	NN	O	O
given	NN	O	O
the	NN	O	O
same	NN	O	O
dose	NN	O	O
of	NN	O	O
NS	NN	O	O
-	NN	O	O
718	NN	O	O
.	NN	O	O

Histopathological	NN	O	O
examination	NN	O	O
of	NN	O	O
the	NN	O	O
kidney	NN	O	O
showed	NN	O	O
tubular	NN	O	B
necrosis	NN	O	I
in	NN	O	O
D	NN	O	O
-	NN	O	O
AmB	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
but	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
NS	NN	O	O
-	NN	O	O
718	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Amphotericin	NN	O	O
B	NN	O	O
concentrations	NN	O	O
in	NN	O	O
the	NN	O	O
kidney	NN	O	O
in	NN	O	O
NS	NN	O	O
-	NN	O	O
718	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
were	NN	O	O
higher	NN	O	O
than	NN	O	O
those	NN	O	O
in	NN	O	O
D	NN	O	O
-	NN	O	O
AmB	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Our	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
incorporation	NN	O	O
of	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
into	NN	O	O
lipid	NN	O	O
nanospheres	NN	O	O
of	NN	O	O
NS	NN	O	O
-	NN	O	O
718	NN	O	O
attenuates	NN	O	O
the	NN	O	O
nephrotoxicity	NN	O	B
of	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
.	NN	O	O

Patterns	NN	O	O
of	NN	O	O
sulfadiazine	NN	O	O
acute	NN	O	B
nephrotoxicity	NN	O	I
.	NN	O	O

Sulfadiazine	NN	O	O
acute	NN	O	B
nephrotoxicity	NN	O	I
is	NN	O	O
reviving	NN	O	O
specially	NN	O	O
because	NN	O	O
of	NN	O	O
its	NN	O	O
use	NN	O	O
in	NN	O	O
toxoplasmosis	NN	O	B
in	NN	O	O
HIV	NN	O	O
-	NN	O	O
positive	NN	O	O
patients	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
4	NN	O	O
cases	NN	O	O
,	NN	O	O
one	NN	O	O
of	NN	O	O
them	NN	O	O
in	NN	O	O
a	NN	O	O
previously	NN	O	O
healthy	NN	O	O
person	NN	O	O
.	NN	O	O

Under	NN	O	O
treatment	NN	O	O
with	NN	O	O
sulfadiazine	NN	O	O
they	NN	O	O
developed	NN	O	O
oliguria	NN	O	B
,	NN	O	O
abdominal	NN	O	B
pain	NN	O	I
,	NN	O	O
renal	NN	O	B
failure	NN	O	I
and	NN	O	O
showed	NN	O	O
multiple	NN	O	O
radiolucent	NN	O	O
renal	NN	O	B
calculi	NN	O	I
in	NN	O	O
echography	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
recovered	NN	O	O
their	NN	O	O
previous	NN	O	O
normal	NN	O	O
renal	NN	O	O
function	NN	O	O
after	NN	O	O
adequate	NN	O	O
hydration	NN	O	O
and	NN	O	O
alcalinization	NN	O	O
.	NN	O	O

A	NN	O	O
nephrostomy	NN	O	O
tube	NN	O	O
had	NN	O	O
to	NN	O	O
be	NN	O	O
placed	NN	O	O
in	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
for	NN	O	O
ureteral	NN	O	B
lithiasis	NN	O	I
in	NN	O	O
a	NN	O	O
single	NN	O	O
functional	NN	O	O
kidney	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
them	NN	O	O
needed	NN	O	O
dialysis	NN	O	O
or	NN	O	O
a	NN	O	O
renal	NN	O	O
biopsy	NN	O	O
because	NN	O	O
of	NN	O	O
a	NN	O	O
typical	NN	O	O
benign	NN	O	O
course	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
sulfadiazine	NN	O	O
requires	NN	O	O
exquisite	NN	O	O
control	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
,	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
water	NN	O	O
ingestion	NN	O	O
and	NN	O	O
possibly	NN	O	O
the	NN	O	O
alcalinization	NN	O	O
of	NN	O	O
the	NN	O	O
urine	NN	O	O
.	NN	O	O

We	NN	O	O
communicate	NN	O	O
a	NN	O	O
case	NN	O	O
in	NN	O	O
a	NN	O	O
previously	NN	O	O
healthy	NN	O	O
person	NN	O	O
,	NN	O	O
a	NN	O	O
fact	NN	O	O
not	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
recent	NN	O	O
literature	NN	O	O
.	NN	O	O

Probably	NN	O	O
many	NN	O	O
more	NN	O	O
cases	NN	O	O
are	NN	O	O
not	NN	O	O
detected	NN	O	O
.	NN	O	O

We	NN	O	O
think	NN	O	O
that	NN	O	O
a	NN	O	O
prospective	NN	O	O
study	NN	O	O
would	NN	O	O
be	NN	O	O
useful	NN	O	O
.	NN	O	O

Downbeat	NN	O	B
nystagmus	NN	O	I
associated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
patient	NN	O	O
-	NN	O	O
controlled	NN	O	O
administration	NN	O	O
of	NN	O	O
morphine	NN	O	O
.	NN	O	O

IMPLICATIONS	NN	O	O
:	NN	O	O
This	NN	O	O
case	NN	O	O
documents	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
dizziness	NN	O	B
with	NN	O	O
downbeating	NN	O	B
nystagmus	NN	O	I
while	NN	O	O
receiving	NN	O	O
a	NN	O	O
relatively	NN	O	O
large	NN	O	O
dose	NN	O	O
of	NN	O	O
IV	NN	O	O
patient	NN	O	O
-	NN	O	O
controlled	NN	O	O
analgesia	NN	O	O
morphine	NN	O	O
.	NN	O	O

Although	NN	O	O
there	NN	O	O
have	NN	O	O
been	NN	O	O
case	NN	O	O
reports	NN	O	O
of	NN	O	O
epidural	NN	O	O
morphine	NN	O	O
with	NN	O	O
these	NN	O	O
symptoms	NN	O	O
and	NN	O	O
signs	NN	O	O
,	NN	O	O
this	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
previously	NN	O	O
documented	NN	O	O
with	NN	O	O
IV	NN	O	O
or	NN	O	O
patient	NN	O	O
-	NN	O	O
controlled	NN	O	O
analgesia	NN	O	O
morphine	NN	O	O
.	NN	O	O

Hemodynamic	NN	O	O
and	NN	O	O
antiadrenergic	NN	O	O
effects	NN	O	O
of	NN	O	O
dronedarone	NN	O	O
and	NN	O	O
amiodarone	NN	O	O
in	NN	O	O
animals	NN	O	O
with	NN	O	O
a	NN	O	O
healed	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

The	NN	O	O
hemodynamic	NN	O	O
and	NN	O	O
antiadrenergic	NN	O	O
effects	NN	O	O
of	NN	O	O
dronedarone	NN	O	O
,	NN	O	O
a	NN	O	O
noniodinated	NN	O	O
compound	NN	O	O
structurally	NN	O	O
related	NN	O	O
to	NN	O	O
amiodarone	NN	O	O
,	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
after	NN	O	O
prolonged	NN	O	O
oral	NN	O	O
administration	NN	O	O
,	NN	O	O
both	NN	O	O
at	NN	O	O
rest	NN	O	O
and	NN	O	O
during	NN	O	O
sympathetic	NN	O	O
stimulation	NN	O	O
in	NN	O	O
conscious	NN	O	O
dogs	NN	O	O
with	NN	O	O
a	NN	O	O
healed	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

All	NN	O	O
dogs	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
randomly	NN	O	O
received	NN	O	O
orally	NN	O	O
dronedarone	NN	O	O
(	NN	O	O
10	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
amiodarone	NN	O	O
(	NN	O	O
10	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
placebo	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
week	NN	O	O
washout	NN	O	O
between	NN	O	O
consecutive	NN	O	O
treatments	NN	O	O
.	NN	O	O

Heart	NN	O	O
rate	NN	O	O
(	NN	O	O
HR	NN	O	O
)	NN	O	O
,	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
MBP	NN	O	O
)	NN	O	O
,	NN	O	O
positive	NN	O	O
rate	NN	O	O
of	NN	O	O
increase	NN	O	O
of	NN	O	O
left	NN	O	O
ventricular	NN	O	O
pressure	NN	O	O
(	NN	O	O
+	NN	O	O
LVdP	NN	O	O
/	NN	O	O
dt	NN	O	O
)	NN	O	O
,	NN	O	O
echocardiographically	NN	O	O
assessed	NN	O	O
left	NN	O	O
ventricular	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
(	NN	O	O
LVEF	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
fractional	NN	O	O
shortening	NN	O	O
(	NN	O	O
FS	NN	O	O
)	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
chronotropic	NN	O	O
response	NN	O	O
to	NN	O	O
isoproterenol	NN	O	O
and	NN	O	O
exercise	NN	O	O
-	NN	O	O
induced	NN	O	O
sympathetic	NN	O	O
stimulation	NN	O	O
were	NN	O	O
evaluated	NN	O	O
under	NN	O	O
baseline	NN	O	O
and	NN	O	O
posttreatment	NN	O	O
conditions	NN	O	O
.	NN	O	O

Resting	NN	O	O
values	NN	O	O
of	NN	O	O
LVEF	NN	O	O
,	NN	O	O
FS	NN	O	O
,	NN	O	O
+	NN	O	O
LVdP	NN	O	O
/	NN	O	O
dt	NN	O	O
,	NN	O	O
and	NN	O	O
MBP	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
whatever	NN	O	O
the	NN	O	O
drug	NN	O	O
and	NN	O	O
the	NN	O	O
dosing	NN	O	O
regimen	NN	O	O
,	NN	O	O
whereas	NN	O	O
resting	NN	O	O
HR	NN	O	O
was	NN	O	O
significantly	NN	O	O
and	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
lowered	NN	O	O
after	NN	O	O
dronedarone	NN	O	O
and	NN	O	O
to	NN	O	O
a	NN	O	O
lesser	NN	O	O
extent	NN	O	O
after	NN	O	O
amiodarone	NN	O	O
.	NN	O	O

Both	NN	O	O
dronedarone	NN	O	O
and	NN	O	O
amiodarone	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
exercise	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
and	NN	O	O
,	NN	O	O
at	NN	O	O
the	NN	O	O
highest	NN	O	O
dose	NN	O	O
,	NN	O	O
decreased	NN	O	O
the	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
dronedarone	NN	O	O
and	NN	O	O
amiodarone	NN	O	O
displayed	NN	O	O
a	NN	O	O
similar	NN	O	O
level	NN	O	O
of	NN	O	O
antiadrenergic	NN	O	O
effect	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
impair	NN	O	O
the	NN	O	O
resting	NN	O	O
left	NN	O	O
ventricular	NN	O	O
function	NN	O	O
.	NN	O	O

Consequently	NN	O	O
,	NN	O	O
dronedarone	NN	O	O
might	NN	O	O
be	NN	O	O
particularly	NN	O	O
suitable	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
and	NN	O	O
prevention	NN	O	O
of	NN	O	O
various	NN	O	O
clinical	NN	O	O
arrhythmias	NN	O	B
,	NN	O	O
without	NN	O	O
compromising	NN	O	O
the	NN	O	O
left	NN	O	O
ventricular	NN	O	O
function	NN	O	O
.	NN	O	O

Phase	NN	O	O
2	NN	O	O
trial	NN	O	O
of	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
in	NN	O	O
platinum	NN	O	O
/	NN	O	O
paclitaxel	NN	O	O
-	NN	O	O
refractory	NN	O	O
ovarian	NN	O	B
and	NN	O	I
fallopian	NN	O	I
tube	NN	O	I
cancers	NN	O	I
and	NN	O	O
primary	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
peritoneum	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Several	NN	O	O
studies	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
Doxil	NN	O	O
)	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
active	NN	O	O
antineoplastic	NN	O	O
agent	NN	O	O
in	NN	O	O
platinum	NN	O	O
-	NN	O	O
resistant	NN	O	O
ovarian	NN	O	B
cancer	NN	O	I
,	NN	O	O
with	NN	O	O
dose	NN	O	O
limiting	NN	O	O
toxicity	NN	O	B
of	NN	O	O
the	NN	O	O
standard	NN	O	O
dosing	NN	O	O
regimen	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
q	NN	O	O
4	NN	O	O
weeks	NN	O	O
)	NN	O	O
being	NN	O	O
severe	NN	O	O
erythrodysesthesia	NN	O	B
(	NN	O	O
"	NN	O	O
hand	NN	O	B
-	NN	O	I
foot	NN	O	I
syndrome	NN	O	I
"	NN	O	O
)	NN	O	O
and	NN	O	O
stomatitis	NN	O	B
.	NN	O	O

We	NN	O	O
wished	NN	O	O
to	NN	O	O
develop	NN	O	O
a	NN	O	O
more	NN	O	O
tolerable	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
treatment	NN	O	O
regimen	NN	O	O
and	NN	O	O
document	NN	O	O
its	NN	O	O
level	NN	O	O
of	NN	O	O
activity	NN	O	O
in	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
defined	NN	O	O
patient	NN	O	O
population	NN	O	O
with	NN	O	O
platinum	NN	O	O
/	NN	O	O
paclitaxel	NN	O	O
-	NN	O	O
refractory	NN	O	O
disease	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
MATERIALS	NN	O	O
:	NN	O	O
Patients	NN	O	O
with	NN	O	O
ovarian	NN	O	B
or	NN	O	I
fallopian	NN	O	I
tube	NN	O	I
cancers	NN	O	I
or	NN	O	O
primary	NN	O	O
peritoneal	NN	O	B
carcinoma	NN	O	I
with	NN	O	O
platinum	NN	O	O
/	NN	O	O
paclitaxel	NN	O	O
-	NN	O	O
refractory	NN	O	O
disease	NN	O	O
(	NN	O	O
stable	NN	O	O
or	NN	O	O
progressive	NN	O	O
disease	NN	O	O
following	NN	O	O
treatment	NN	O	O
with	NN	O	O
these	NN	O	O
agents	NN	O	O
or	NN	O	O
previous	NN	O	O
objective	NN	O	O
response	NN	O	O
<	NN	O	O
3	NN	O	O
months	NN	O	O
in	NN	O	O
duration	NN	O	O
)	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
q	NN	O	O
4	NN	O	O
weeks	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
49	NN	O	O
patients	NN	O	O
(	NN	O	O
median	NN	O	O
age	NN	O	O
:	NN	O	O
60	NN	O	O
;	NN	O	O
range	NN	O	O
41	NN	O	O
-	NN	O	O
81	NN	O	O
)	NN	O	O
entered	NN	O	O
this	NN	O	O
phase	NN	O	O
2	NN	O	O
trial	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
number	NN	O	O
of	NN	O	O
prior	NN	O	O
regimens	NN	O	O
was	NN	O	O
2	NN	O	O
(	NN	O	O
range	NN	O	O
:	NN	O	O
1	NN	O	O
-	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

Six	NN	O	O
(	NN	O	O
12	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
4	NN	O	O
(	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
experienced	NN	O	O
grade	NN	O	O
2	NN	O	O
hand	NN	O	B
-	NN	O	I
foot	NN	O	I
syndrome	NN	O	I
and	NN	O	O
stomatitis	NN	O	B
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
no	NN	O	O
episodes	NN	O	O
of	NN	O	O
grade	NN	O	O
3	NN	O	O
)	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
developed	NN	O	O
grade	NN	O	O
3	NN	O	O
diarrhea	NN	O	B
requiring	NN	O	O
hospitalization	NN	O	O
for	NN	O	O
hydration	NN	O	O
.	NN	O	O

Six	NN	O	O
(	NN	O	O
12	NN	O	O
%	NN	O	O
)	NN	O	O
individuals	NN	O	O
required	NN	O	O
dose	NN	O	O
reductions	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
number	NN	O	O
of	NN	O	O
courses	NN	O	O
of	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
administered	NN	O	O
on	NN	O	O
this	NN	O	O
protocol	NN	O	O
was	NN	O	O
2	NN	O	O
(	NN	O	O
range	NN	O	O
:	NN	O	O
1	NN	O	O
-	NN	O	O
12	NN	O	O
)	NN	O	O
.	NN	O	O

Four	NN	O	O
of	NN	O	O
44	NN	O	O
patients	NN	O	O
(	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
evaluable	NN	O	O
for	NN	O	O
response	NN	O	O
exhibited	NN	O	O
objective	NN	O	O
and	NN	O	O
subjective	NN	O	O
evidence	NN	O	O
of	NN	O	O
an	NN	O	O
antineoplastic	NN	O	O
effect	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
modified	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
regimen	NN	O	O
results	NN	O	O
in	NN	O	O
less	NN	O	O
toxicity	NN	O	B
(	NN	O	O
stomatitis	NN	O	B
,	NN	O	O
hand	NN	O	B
-	NN	O	I
foot	NN	O	I
syndrome	NN	O	I
)	NN	O	O
than	NN	O	O
the	NN	O	O
standard	NN	O	O
FDA	NN	O	O
-	NN	O	O
approved	NN	O	O
dose	NN	O	O
schedule	NN	O	O
.	NN	O	O

Definite	NN	O	O
,	NN	O	O
although	NN	O	O
limited	NN	O	O
,	NN	O	O
antineoplastic	NN	O	O
activity	NN	O	O
is	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
well	NN	O	O
-	NN	O	O
defined	NN	O	O
platinum	NN	O	O
-	NN	O	O
and	NN	O	O
paclitaxel	NN	O	O
-	NN	O	O
refractory	NN	O	O
ovarian	NN	O	B
cancer	NN	O	I
.	NN	O	O

Efficacy	NN	O	O
of	NN	O	O
olanzapine	NN	O	O
in	NN	O	O
acute	NN	O	O
bipolar	NN	O	B
mania	NN	O	I
:	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
Olanzipine	NN	O	O
HGGW	NN	O	O
Study	NN	O	O
Group	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
We	NN	O	O
compared	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
olanzapine	NN	O	O
vs	NN	O	O
placebo	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	O
bipolar	NN	O	B
mania	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Four	NN	O	O
-	NN	O	O
week	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
parallel	NN	O	O
study	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
115	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
DSM	NN	O	O
-	NN	O	O
IV	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
bipolar	NN	O	B
disorder	NN	O	I
,	NN	O	O
manic	NN	O	B
or	NN	O	O
mixed	NN	O	O
,	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
olanzapine	NN	O	O
,	NN	O	O
5	NN	O	O
to	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
55	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
placebo	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
60	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
efficacy	NN	O	O
measure	NN	O	O
was	NN	O	O
the	NN	O	O
Young	NN	O	O
-	NN	O	O
Mania	NN	O	B
Rating	NN	O	O
Scale	NN	O	O
(	NN	O	O
Y	NN	O	O
-	NN	O	O
MRS	NN	O	O
)	NN	O	O
total	NN	O	O
score	NN	O	O
.	NN	O	O

Response	NN	O	O
and	NN	O	O
euthymia	NN	O	O
were	NN	O	O
defined	NN	O	O
,	NN	O	O
a	NN	O	O
priori	NN	O	O
,	NN	O	O
as	NN	O	O
at	NN	O	O
least	NN	O	O
a	NN	O	O
50	NN	O	O
%	NN	O	O
improvement	NN	O	O
from	NN	O	O
baseline	NN	O	O
to	NN	O	O
end	NN	O	O
point	NN	O	O
and	NN	O	O
as	NN	O	O
a	NN	O	O
score	NN	O	O
of	NN	O	O
no	NN	O	O
less	NN	O	O
than	NN	O	O
12	NN	O	O
at	NN	O	O
end	NN	O	O
point	NN	O	O
in	NN	O	O
the	NN	O	O
Y	NN	O	O
-	NN	O	O
MRS	NN	O	O
total	NN	O	O
score	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Safety	NN	O	O
was	NN	O	O
assessed	NN	O	O
using	NN	O	O
adverse	NN	O	O
events	NN	O	O
,	NN	O	O
Extrapyramidal	NN	O	B
Symptom	NN	O	I
(	NN	O	O
EPS	NN	O	B
)	NN	O	O
rating	NN	O	O
scales	NN	O	O
,	NN	O	O
laboratory	NN	O	O
values	NN	O	O
,	NN	O	O
electrocardiograms	NN	O	O
,	NN	O	O
vital	NN	O	O
signs	NN	O	O
,	NN	O	O
and	NN	O	O
weight	NN	O	O
change	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Olanzapine	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
greater	NN	O	O
mean	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
improvement	NN	O	O
in	NN	O	O
Y	NN	O	O
-	NN	O	O
MRS	NN	O	O
total	NN	O	O
score	NN	O	O
than	NN	O	O
placebo	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
(	NN	O	O
-	NN	O	O
14	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
.	NN	O	O
7	NN	O	O
,	NN	O	O
respectively	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
evident	NN	O	O
at	NN	O	O
the	NN	O	O
first	NN	O	O
postbaseline	NN	O	O
observation	NN	O	O
1	NN	O	O
week	NN	O	O
after	NN	O	O
randomization	NN	O	O
and	NN	O	O
was	NN	O	O
maintained	NN	O	O
throughout	NN	O	O
the	NN	O	O
study	NN	O	O
(	NN	O	O
last	NN	O	O
observation	NN	O	O
carried	NN	O	O
forward	NN	O	O
)	NN	O	O
.	NN	O	O

Olanzapine	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
higher	NN	O	O
rate	NN	O	O
of	NN	O	O
response	NN	O	O
(	NN	O	O
65	NN	O	O
%	NN	O	O
vs	NN	O	O
43	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
and	NN	O	O
euthymia	NN	O	O
(	NN	O	O
61	NN	O	O
%	NN	O	O
vs	NN	O	O
36	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
than	NN	O	O
placebo	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
EPSs	NN	O	B
between	NN	O	O
groups	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
olanzapine	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
greater	NN	O	O
mean	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
weight	NN	O	B
gain	NN	O	I
than	NN	O	O
placebo	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
8	NN	O	O
vs	NN	O	O
0	NN	O	O
.	NN	O	O
45	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
kg	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
and	NN	O	O
also	NN	O	O
experienced	NN	O	O
more	NN	O	O
treatment	NN	O	O
-	NN	O	O
emergent	NN	O	O
somnolence	NN	O	B
(	NN	O	O
21	NN	O	O
patients	NN	O	O
[	NN	O	O
38	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
]	NN	O	O
vs	NN	O	O
5	NN	O	O
[	NN	O	O
8	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
]	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Olanzapine	NN	O	O
demonstrated	NN	O	O
greater	NN	O	O
efficacy	NN	O	O
than	NN	O	O
placebo	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	O
bipolar	NN	O	B
mania	NN	O	I
and	NN	O	O
was	NN	O	O
generally	NN	O	O
well	NN	O	O
tolerated	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
pupil	NN	O	B
dilation	NN	O	I
with	NN	O	O
tropicamide	NN	O	O
on	NN	O	O
vision	NN	O	O
and	NN	O	O
driving	NN	O	O
simulator	NN	O	O
performance	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
pupil	NN	O	B
dilation	NN	O	I
on	NN	O	O
vision	NN	O	O
and	NN	O	O
driving	NN	O	O
ability	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
series	NN	O	O
of	NN	O	O
tests	NN	O	O
on	NN	O	O
various	NN	O	O
parameters	NN	O	O
of	NN	O	O
visual	NN	O	O
function	NN	O	O
and	NN	O	O
driving	NN	O	O
simulator	NN	O	O
performance	NN	O	O
were	NN	O	O
performed	NN	O	O
on	NN	O	O
12	NN	O	O
healthy	NN	O	O
drivers	NN	O	O
,	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
pupil	NN	O	B
dilation	NN	O	I
using	NN	O	O
guttae	NN	O	O
tropicamide	NN	O	O
1	NN	O	O
%	NN	O	O
.	NN	O	O

A	NN	O	O
driving	NN	O	O
simulator	NN	O	O
(	NN	O	O
Transport	NN	O	O
Research	NN	O	O
Laboratory	NN	O	O
)	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
measure	NN	O	O
reaction	NN	O	O
time	NN	O	O
(	NN	O	O
RT	NN	O	O
)	NN	O	O
,	NN	O	O
speed	NN	O	O
maintenance	NN	O	O
and	NN	O	O
steering	NN	O	O
accuracy	NN	O	O
.	NN	O	O

Tests	NN	O	O
of	NN	O	O
basic	NN	O	O
visual	NN	O	O
function	NN	O	O
included	NN	O	O
high	NN	O	O
-	NN	O	O
and	NN	O	O
low	NN	O	O
-	NN	O	O
contrast	NN	O	O
visual	NN	O	O
acuity	NN	O	O
(	NN	O	O
HCVA	NN	O	O
and	NN	O	O
LCVA	NN	O	O
)	NN	O	O
,	NN	O	O
Pelli	NN	O	O
-	NN	O	O
Robson	NN	O	O
contrast	NN	O	O
threshold	NN	O	O
(	NN	O	O
CT	NN	O	O
)	NN	O	O
and	NN	O	O
Goldmann	NN	O	O
perimetry	NN	O	O
(	NN	O	O
FIELDS	NN	O	O
)	NN	O	O
.	NN	O	O

Useful	NN	O	O
Field	NN	O	O
of	NN	O	O
View	NN	O	O
(	NN	O	O
UFOV	NN	O	O
-	NN	O	O
-	NN	O	O
a	NN	O	O
test	NN	O	O
of	NN	O	O
visual	NN	O	O
attention	NN	O	O
)	NN	O	O
was	NN	O	O
also	NN	O	O
undertaken	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
pre	NN	O	O
-	NN	O	O
and	NN	O	O
post	NN	O	O
-	NN	O	O
dilatation	NN	O	O
measurements	NN	O	O
were	NN	O	O
tested	NN	O	O
for	NN	O	O
statistical	NN	O	O
significance	NN	O	O
at	NN	O	O
the	NN	O	O
95	NN	O	O
%	NN	O	O
level	NN	O	O
using	NN	O	O
one	NN	O	O
-	NN	O	O
tail	NN	O	O
paired	NN	O	O
t	NN	O	O
-	NN	O	O
tests	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Pupillary	NN	O	B
dilation	NN	O	I
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
deterioration	NN	O	O
in	NN	O	O
CT	NN	O	O
and	NN	O	O
HCVA	NN	O	O
only	NN	O	O
.	NN	O	O

Five	NN	O	O
of	NN	O	O
12	NN	O	O
drivers	NN	O	O
also	NN	O	O
exhibited	NN	O	O
deterioration	NN	O	O
in	NN	O	O
LCVA	NN	O	O
,	NN	O	O
CT	NN	O	O
and	NN	O	O
RT	NN	O	O
.	NN	O	O

Little	NN	O	O
evidence	NN	O	O
emerged	NN	O	O
for	NN	O	O
deterioration	NN	O	O
in	NN	O	O
FIELDS	NN	O	O
and	NN	O	O
UFOV	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
7	NN	O	O
of	NN	O	O
12	NN	O	O
drivers	NN	O	O
appeared	NN	O	O
to	NN	O	O
adjust	NN	O	O
their	NN	O	O
driving	NN	O	O
behaviour	NN	O	O
by	NN	O	O
reducing	NN	O	O
their	NN	O	O
speed	NN	O	O
on	NN	O	O
the	NN	O	O
driving	NN	O	O
simulator	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
improved	NN	O	O
steering	NN	O	O
accuracy	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Pupillary	NN	O	B
dilation	NN	O	I
may	NN	O	O
lead	NN	O	O
to	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
vision	NN	O	O
and	NN	O	O
daylight	NN	O	O
driving	NN	O	O
performance	NN	O	O
in	NN	O	O
young	NN	O	O
people	NN	O	O
.	NN	O	O

A	NN	O	O
larger	NN	O	O
study	NN	O	O
,	NN	O	O
including	NN	O	O
a	NN	O	O
broader	NN	O	O
spectrum	NN	O	O
of	NN	O	O
subjects	NN	O	O
,	NN	O	O
is	NN	O	O
warranted	NN	O	O
before	NN	O	O
guidelines	NN	O	O
can	NN	O	O
be	NN	O	O
recommended	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
isotretinoin	NN	O	B
embryopathy	NN	O	I
with	NN	O	O
bilateral	NN	O	O
anotia	NN	O	B
and	NN	O	O
Taussig	NN	O	B
-	NN	O	I
Bing	NN	O	I
malformation	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
newborn	NN	O	O
infant	NN	O	O
with	NN	O	O
multiple	NN	O	O
congenital	NN	O	O
anomalies	NN	O	O
(	NN	O	O
anotia	NN	O	B
and	NN	O	O
Taussig	NN	O	B
-	NN	O	I
Bing	NN	O	I
malformation	NN	O	I
)	NN	O	O
due	NN	O	O
to	NN	O	O
exposure	NN	O	O
to	NN	O	O
isotretinoin	NN	O	O
within	NN	O	O
the	NN	O	O
first	NN	O	O
trimester	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
paper	NN	O	O
we	NN	O	O
aim	NN	O	O
to	NN	O	O
draw	NN	O	O
to	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
caution	NN	O	O
is	NN	O	O
needed	NN	O	O
when	NN	O	O
prescribing	NN	O	O
vitamin	NN	O	O
A	NN	O	O
-	NN	O	O
containing	NN	O	O
drugs	NN	O	O
to	NN	O	O
women	NN	O	O
of	NN	O	O
childbearing	NN	O	O
years	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
methoxamine	NN	O	O
on	NN	O	O
maximum	NN	O	O
urethral	NN	O	O
pressure	NN	O	O
in	NN	O	O
women	NN	O	O
with	NN	O	O
genuine	NN	O	O
stress	NN	O	B
incontinence	NN	O	I
:	NN	O	O
a	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
crossover	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
potential	NN	O	O
role	NN	O	O
for	NN	O	O
a	NN	O	O
selective	NN	O	O
alpha1	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
agonist	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
urinary	NN	O	B
stress	NN	O	I
incontinence	NN	O	I
.	NN	O	O

A	NN	O	O
randomised	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
crossover	NN	O	O
study	NN	O	O
design	NN	O	O
was	NN	O	O
employed	NN	O	O
.	NN	O	O

Half	NN	O	O
log	NN	O	O
incremental	NN	O	O
doses	NN	O	O
of	NN	O	O
intravenous	NN	O	O
methoxamine	NN	O	O
or	NN	O	O
placebo	NN	O	O
(	NN	O	O
saline	NN	O	O
)	NN	O	O
were	NN	O	O
administered	NN	O	O
to	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
women	NN	O	O
with	NN	O	O
genuine	NN	O	O
stress	NN	O	B
incontinence	NN	O	I
while	NN	O	O
measuring	NN	O	O
maximum	NN	O	O
urethral	NN	O	O
pressure	NN	O	O
(	NN	O	O
MUP	NN	O	O
)	NN	O	O
,	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
and	NN	O	O
symptomatic	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Methoxamine	NN	O	O
evoked	NN	O	O
non	NN	O	O
-	NN	O	O
significant	NN	O	O
increases	NN	O	O
in	NN	O	O
MUP	NN	O	O
and	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
but	NN	O	O
caused	NN	O	O
a	NN	O	B
significant	NN	O	I
rise	NN	O	I
in	NN	O	I
systolic	NN	O	I
blood	NN	O	I
pressure	NN	O	I
and	NN	O	O
significant	NN	O	O
fall	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
at	NN	O	O
maximum	NN	O	O
dosage	NN	O	O
.	NN	O	O

Systemic	NN	O	O
side	NN	O	O
effects	NN	O	O
including	NN	O	O
piloerection	NN	O	O
,	NN	O	O
headache	NN	O	B
,	NN	O	O
and	NN	O	O
cold	NN	O	O
extremities	NN	O	O
were	NN	O	O
experienced	NN	O	O
in	NN	O	O
all	NN	O	O
subjects	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
clinical	NN	O	O
usefulness	NN	O	O
of	NN	O	O
direct	NN	O	O
,	NN	O	O
peripherally	NN	O	O
acting	NN	O	O
sub	NN	O	O
-	NN	O	O
type	NN	O	O
-	NN	O	O
selective	NN	O	O
alpha1	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
agonists	NN	O	O
in	NN	O	O
the	NN	O	O
medical	NN	O	O
treatment	NN	O	O
of	NN	O	O
stress	NN	O	B
incontinence	NN	O	I
may	NN	O	O
be	NN	O	O
limited	NN	O	O
by	NN	O	O
associated	NN	O	O
piloerection	NN	O	O
and	NN	O	O
cardiovascular	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Hyperglycemic	NN	O	B
effect	NN	O	O
of	NN	O	O
amino	NN	O	O
compounds	NN	O	O
structurally	NN	O	O
related	NN	O	O
to	NN	O	O
caproate	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
chronic	NN	O	O
feeding	NN	O	O
of	NN	O	O
small	NN	O	O
amounts	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
3	NN	O	O
%	NN	O	O
of	NN	O	O
diet	NN	O	O
weight	NN	O	O
)	NN	O	O
of	NN	O	O
certain	NN	O	O
amino	NN	O	O
derivatives	NN	O	O
of	NN	O	O
caproate	NN	O	O
resulted	NN	O	O
in	NN	O	O
hyperglycemia	NN	O	B
,	NN	O	O
an	NN	O	O
elevated	NN	O	O
glucose	NN	O	O
tolerance	NN	O	O
curve	NN	O	O
and	NN	O	O
,	NN	O	O
occasionally	NN	O	O
,	NN	O	O
glucosuria	NN	O	B
.	NN	O	O

Effective	NN	O	O
compounds	NN	O	O
included	NN	O	O
norleucine	NN	O	O
,	NN	O	O
norvaline	NN	O	O
,	NN	O	O
glutamate	NN	O	O
,	NN	O	O
epsilon	NN	O	O
-	NN	O	O
aminocaproate	NN	O	O
,	NN	O	O
methionine	NN	O	O
,	NN	O	O
and	NN	O	O
leucine	NN	O	O
.	NN	O	O

Toleration	NN	O	O
of	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitors	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
heart	NN	O	B
failure	NN	O	I
:	NN	O	O
results	NN	O	O
from	NN	O	O
the	NN	O	O
ATLAS	NN	O	O
trial	NN	O	O
.	NN	O	O

The	NN	O	O
Assessment	NN	O	O
of	NN	O	O
Treatment	NN	O	O
with	NN	O	O
Lisinopril	NN	O	O
and	NN	O	O
Survival	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Treatment	NN	O	O
with	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
inhibitors	NN	O	O
reduces	NN	O	O
mortality	NN	O	O
and	NN	O	O
morbidity	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
heart	NN	O	B
failure	NN	O	I
(	NN	O	O
CHF	NN	O	B
)	NN	O	O
,	NN	O	O
but	NN	O	O
most	NN	O	O
affected	NN	O	O
patients	NN	O	O
are	NN	O	O
not	NN	O	O
receiving	NN	O	O
these	NN	O	O
agents	NN	O	O
or	NN	O	O
are	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
doses	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
efficacious	NN	O	O
in	NN	O	O
trials	NN	O	O
,	NN	O	O
primarily	NN	O	O
because	NN	O	O
of	NN	O	O
concerns	NN	O	O
about	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
these	NN	O	O
agents	NN	O	O
,	NN	O	O
especially	NN	O	O
at	NN	O	O
the	NN	O	O
recommended	NN	O	O
doses	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
examines	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
compared	NN	O	O
with	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
lisinopril	NN	O	O
in	NN	O	O
CHF	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
Assessment	NN	O	O
of	NN	O	O
Lisinopril	NN	O	O
and	NN	O	O
Survival	NN	O	O
study	NN	O	O
was	NN	O	O
a	NN	O	O
multicenter	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trial	NN	O	O
in	NN	O	O
which	NN	O	O
patients	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
previous	NN	O	O
ACE	NN	O	O
inhibitor	NN	O	O
treatment	NN	O	O
were	NN	O	O
stabilized	NN	O	O
receiving	NN	O	O
medium	NN	O	O
-	NN	O	O
dose	NN	O	O
lisinopril	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
or	NN	O	O
15	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
once	NN	O	O
daily	NN	O	O
[	NN	O	O
OD	NN	O	O
]	NN	O	O
)	NN	O	O
for	NN	O	O
2	NN	O	O
to	NN	O	O
4	NN	O	O
weeks	NN	O	O
and	NN	O	O
then	NN	O	O
randomized	NN	O	O
to	NN	O	O
high	NN	O	O
-	NN	O	O
(	NN	O	O
35	NN	O	O
.	NN	O	O
0	NN	O	O
or	NN	O	O
32	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
OD	NN	O	O
)	NN	O	O
or	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
or	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
OD	NN	O	O
)	NN	O	O
groups	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
New	NN	O	O
York	NN	O	O
Heart	NN	O	O
Association	NN	O	O
classes	NN	O	O
II	NN	O	O
to	NN	O	O
IV	NN	O	O
CHF	NN	O	B
and	NN	O	O
left	NN	O	O
ventricular	NN	O	O
ejection	NN	O	O
fractions	NN	O	O
of	NN	O	O
no	NN	O	O
greater	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
30	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
3164	NN	O	O
)	NN	O	O
were	NN	O	O
randomized	NN	O	O
and	NN	O	O
followed	NN	O	O
up	NN	O	O
for	NN	O	O
a	NN	O	O
median	NN	O	O
of	NN	O	O
46	NN	O	O
months	NN	O	O
.	NN	O	O

We	NN	O	O
examined	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
adverse	NN	O	O
events	NN	O	O
and	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
discontinuation	NN	O	O
and	NN	O	O
dose	NN	O	O
reduction	NN	O	O
during	NN	O	O
treatment	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
focus	NN	O	O
on	NN	O	O
hypotension	NN	O	B
and	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Of	NN	O	O
405	NN	O	O
patients	NN	O	O
not	NN	O	O
previously	NN	O	O
receiving	NN	O	O
an	NN	O	O
ACE	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
doses	NN	O	O
in	NN	O	O
only	NN	O	O
4	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
titrated	NN	O	O
to	NN	O	O
the	NN	O	O
medium	NN	O	O
doses	NN	O	O
required	NN	O	O
for	NN	O	O
randomization	NN	O	O
because	NN	O	O
of	NN	O	O
symptoms	NN	O	O
possibly	NN	O	O
related	NN	O	O
to	NN	O	O
hypotension	NN	O	B
(	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
)	NN	O	O
or	NN	O	O
because	NN	O	O
of	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
or	NN	O	O
hyperkalemia	NN	O	B
(	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Doses	NN	O	O
in	NN	O	O
more	NN	O	O
than	NN	O	O
90	NN	O	O
%	NN	O	O
of	NN	O	O
randomized	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
and	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
groups	NN	O	O
were	NN	O	O
titrated	NN	O	O
to	NN	O	O
their	NN	O	O
assigned	NN	O	O
target	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
mean	NN	O	O
doses	NN	O	O
of	NN	O	O
blinded	NN	O	O
medication	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
remained	NN	O	O
similar	NN	O	O
throughout	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Withdrawals	NN	O	O
occurred	NN	O	O
in	NN	O	O
27	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
and	NN	O	O
30	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
groups	NN	O	O
.	NN	O	O

Subgroups	NN	O	O
presumed	NN	O	O
to	NN	O	O
be	NN	O	O
at	NN	O	O
higher	NN	O	O
risk	NN	O	O
for	NN	O	O
ACE	NN	O	O
inhibitor	NN	O	O
intolerance	NN	O	O
(	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
<	NN	O	O
120	NN	O	O
mm	NN	O	O
Hg	NN	O	O
;	NN	O	O
creatinine	NN	O	O
,	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
132	NN	O	O
.	NN	O	O
6	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
[	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
]	NN	O	O
;	NN	O	O
age	NN	O	O
,	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
70	NN	O	O
years	NN	O	O
;	NN	O	O
and	NN	O	O
patients	NN	O	O
with	NN	O	O
diabetes	NN	O	B
)	NN	O	O
generally	NN	O	O
tolerated	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
strategy	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
findings	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
ACE	NN	O	O
inhibitor	NN	O	O
therapy	NN	O	O
in	NN	O	O
most	NN	O	O
patients	NN	O	O
with	NN	O	O
CHF	NN	O	B
can	NN	O	O
be	NN	O	O
successfully	NN	O	O
titrated	NN	O	O
to	NN	O	O
and	NN	O	O
maintained	NN	O	O
at	NN	O	O
high	NN	O	O
doses	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
more	NN	O	O
aggressive	NN	O	O
use	NN	O	O
of	NN	O	O
these	NN	O	O
agents	NN	O	O
is	NN	O	O
warranted	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
,	NN	O	O
ethanol	NN	O	O
,	NN	O	O
and	NN	O	O
cocaethylene	NN	O	O
cardiotoxity	NN	O	B
in	NN	O	O
an	NN	O	O
animal	NN	O	O
model	NN	O	O
of	NN	O	O
cocaine	NN	O	B
and	NN	O	I
ethanol	NN	O	I
abuse	NN	O	I
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
Simultaneous	NN	O	O
abuse	NN	O	B
of	NN	O	I
cocaine	NN	O	I
and	NN	O	I
ethanol	NN	O	I
affects	NN	O	O
12	NN	O	O
million	NN	O	O
Americans	NN	O	O
annually	NN	O	O
.	NN	O	O

In	NN	O	O
combination	NN	O	O
,	NN	O	O
these	NN	O	O
substances	NN	O	O
are	NN	O	O
substantially	NN	O	O
more	NN	O	O
toxic	NN	O	O
than	NN	O	O
either	NN	O	O
drug	NN	O	O
alone	NN	O	O
.	NN	O	O

Their	NN	O	O
combined	NN	O	O
cardiac	NN	O	B
toxicity	NN	O	I
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
independent	NN	O	O
effects	NN	O	O
of	NN	O	O
each	NN	O	O
drug	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
they	NN	O	O
may	NN	O	O
also	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
cocaethylene	NN	O	O
(	NN	O	O
CE	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
cocaine	NN	O	O
metabolite	NN	O	O
formed	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
ethanol	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
delineate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
CE	NN	O	O
in	NN	O	O
the	NN	O	O
combined	NN	O	O
cardiotoxicity	NN	O	B
of	NN	O	O
cocaine	NN	O	O
and	NN	O	O
ethanol	NN	O	O
in	NN	O	O
a	NN	O	O
model	NN	O	O
simulating	NN	O	O
their	NN	O	O
abuse	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
three	NN	O	O
dogs	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
1	NN	O	O
)	NN	O	O
three	NN	O	O
intravenous	NN	O	O
(	NN	O	O
IV	NN	O	O
)	NN	O	O
boluses	NN	O	O
of	NN	O	O
cocaine	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
with	NN	O	O
ethanol	NN	O	O
(	NN	O	O
1	NN	O	O
g	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
as	NN	O	O
an	NN	O	O
IV	NN	O	O
infusion	NN	O	O
(	NN	O	O
C	NN	O	O
+	NN	O	O
E	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
2	NN	O	O
)	NN	O	O
three	NN	O	O
cocaine	NN	O	O
boluses	NN	O	O
only	NN	O	O
(	NN	O	O
C	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
3	NN	O	O
)	NN	O	O
ethanol	NN	O	O
infusion	NN	O	O
only	NN	O	O
(	NN	O	O
E	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
5	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
4	NN	O	O
)	NN	O	O
placebo	NN	O	O
boluses	NN	O	O
and	NN	O	O
infusion	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
.	NN	O	O

Hemodynamic	NN	O	O
measurements	NN	O	O
,	NN	O	O
electrocardiograms	NN	O	O
,	NN	O	O
and	NN	O	O
serum	NN	O	O
drug	NN	O	O
concentrations	NN	O	O
were	NN	O	O
obtained	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
and	NN	O	O
then	NN	O	O
at	NN	O	O
fixed	NN	O	O
time	NN	O	O
intervals	NN	O	O
after	NN	O	O
each	NN	O	O
drug	NN	O	O
was	NN	O	O
administered	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Two	NN	O	O
of	NN	O	O
eight	NN	O	O
dogs	NN	O	O
in	NN	O	O
the	NN	O	O
C	NN	O	O
+	NN	O	O
E	NN	O	O
group	NN	O	O
experienced	NN	O	O
cardiovascular	NN	O	B
collapse	NN	O	I
.	NN	O	O

The	NN	O	O
most	NN	O	O
dramatic	NN	O	O
hemodynamic	NN	O	O
changes	NN	O	O
occurred	NN	O	O
after	NN	O	O
each	NN	O	O
cocaine	NN	O	O
bolus	NN	O	O
in	NN	O	O
the	NN	O	O
C	NN	O	O
+	NN	O	O
E	NN	O	O
and	NN	O	O
C	NN	O	O
only	NN	O	O
groups	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
persistent	NN	O	O
hemodynamic	NN	O	O
changes	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
C	NN	O	O
+	NN	O	O
E	NN	O	O
group	NN	O	O
.	NN	O	O

Peak	NN	O	O
CE	NN	O	O
levels	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
45	NN	O	O
%	NN	O	O
(	NN	O	O
SD	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
22	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
22	NN	O	O
%	NN	O	O
to	NN	O	O
69	NN	O	O
%	NN	O	O
)	NN	O	O
decrease	NN	O	B
in	NN	O	I
cardiac	NN	O	I
output	NN	O	I
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
56	NN	O	O
%	NN	O	O
(	NN	O	O
SD	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
23	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
32	NN	O	O
%	NN	O	O
to	NN	O	O
80	NN	O	O
%	NN	O	O
)	NN	O	O
decrease	NN	O	O
in	NN	O	O
dP	NN	O	O
/	NN	O	O
dt	NN	O	O
(	NN	O	O
max	NN	O	O
)	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
.	NN	O	O
006	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
23	NN	O	O
%	NN	O	O
(	NN	O	O
SD	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
15	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
7	NN	O	O
%	NN	O	O
to	NN	O	O
49	NN	O	O
%	NN	O	O
)	NN	O	O
decrease	NN	O	O
in	NN	O	O
SVO	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
025	NN	O	O
)	NN	O	O
.	NN	O	O

Ventricular	NN	O	B
arrhythmias	NN	O	I
were	NN	O	O
primarily	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
C	NN	O	O
+	NN	O	O
E	NN	O	O
group	NN	O	O
,	NN	O	O
in	NN	O	O
which	NN	O	O
four	NN	O	O
of	NN	O	O
eight	NN	O	O
dogs	NN	O	O
experienced	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Cocaine	NN	O	O
and	NN	O	O
ethanol	NN	O	O
in	NN	O	O
combination	NN	O	O
were	NN	O	O
more	NN	O	O
toxic	NN	O	O
than	NN	O	O
either	NN	O	O
substance	NN	O	O
alone	NN	O	O
.	NN	O	O

Co	NN	O	O
-	NN	O	O
administration	NN	O	O
resulted	NN	O	O
in	NN	O	O
prolonged	NN	O	O
cardiac	NN	O	B
toxicity	NN	O	I
and	NN	O	O
was	NN	O	O
dysrhythmogenic	NN	O	O
.	NN	O	O

Peak	NN	O	O
serum	NN	O	O
cocaethylene	NN	O	O
concentrations	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
prolonged	NN	O	O
myocardial	NN	O	B
depression	NN	O	I
.	NN	O	O

Worsening	NN	O	O
of	NN	O	O
Parkinsonism	NN	O	B
after	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
veralipride	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
menopause	NN	O	O
:	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
female	NN	O	O
patient	NN	O	O
with	NN	O	O
stable	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
who	NN	O	O
has	NN	O	O
shown	NN	O	O
a	NN	O	O
marked	NN	O	O
worsening	NN	O	O
of	NN	O	O
her	NN	O	O
motor	NN	O	O
functions	NN	O	O
following	NN	O	O
therapy	NN	O	O
of	NN	O	O
menopause	NN	O	O
related	NN	O	O
symptoms	NN	O	O
with	NN	O	O
veralipride	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
improvement	NN	O	O
of	NN	O	O
her	NN	O	O
symptoms	NN	O	O
back	NN	O	O
to	NN	O	O
baseline	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

We	NN	O	O
emphasize	NN	O	O
the	NN	O	O
anti	NN	O	O
-	NN	O	O
dopaminergic	NN	O	O
effect	NN	O	O
of	NN	O	O
veralipride	NN	O	O
.	NN	O	O

Viracept	NN	O	O
and	NN	O	O
irregular	NN	O	B
heartbeat	NN	O	I
warning	NN	O	O
.	NN	O	O

A	NN	O	O
group	NN	O	O
of	NN	O	O
doctors	NN	O	O
in	NN	O	O
Boston	NN	O	O
warn	NN	O	O
that	NN	O	O
the	NN	O	O
protease	NN	O	O
inhibitor	NN	O	O
Viracept	NN	O	O
may	NN	O	O
cause	NN	O	O
an	NN	O	O
irregular	NN	O	B
heart	NN	O	I
beat	NN	O	I
,	NN	O	O
known	NN	O	O
as	NN	O	O
bradycardia	NN	O	B
,	NN	O	O
in	NN	O	O
people	NN	O	O
with	NN	O	O
HIV	NN	O	O
.	NN	O	O

Bradycardia	NN	O	B
occurred	NN	O	O
in	NN	O	O
a	NN	O	O
45	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
patient	NN	O	O
who	NN	O	O
was	NN	O	O
Viracept	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
other	NN	O	O
anti	NN	O	O
-	NN	O	O
HIV	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
symptoms	NN	O	O
ceased	NN	O	O
after	NN	O	O
switching	NN	O	O
to	NN	O	O
another	NN	O	O
drug	NN	O	O
combination	NN	O	O
.	NN	O	O

Frequency	NN	O	O
of	NN	O	O
appearance	NN	O	O
of	NN	O	O
myeloperoxidase	NN	O	O
-	NN	O	O
antineutrophil	NN	O	O
cytoplasmic	NN	O	O
antibody	NN	O	O
(	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
)	NN	O	O
in	NN	O	O
Graves	NN	O	B
'	NN	O	I
disease	NN	O	I
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
propylthiouracil	NN	O	O
and	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
and	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
Myeloperoxidase	NN	O	O
antineutrophil	NN	O	O
cytoplasmic	NN	O	O
antibody	NN	O	O
(	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
)	NN	O	O
-	NN	O	O
positive	NN	O	O
vasculitis	NN	O	B
has	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Graves	NN	O	B
'	NN	O	I
disease	NN	O	I
who	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
propylthiouracil	NN	O	O
(	NN	O	O
PTU	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
appearance	NN	O	O
of	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
in	NN	O	O
these	NN	O	O
cases	NN	O	O
was	NN	O	O
suspected	NN	O	O
of	NN	O	O
being	NN	O	O
related	NN	O	O
to	NN	O	O
PTU	NN	O	O
because	NN	O	O
the	NN	O	O
titres	NN	O	O
of	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
decreased	NN	O	O
when	NN	O	O
PTU	NN	O	O
was	NN	O	O
stopped	NN	O	O
.	NN	O	O

Nevertheless	NN	O	O
,	NN	O	O
there	NN	O	O
have	NN	O	O
been	NN	O	O
no	NN	O	O
studies	NN	O	O
on	NN	O	O
the	NN	O	O
temporal	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
and	NN	O	O
vasculitis	NN	O	B
during	NN	O	O
PTU	NN	O	O
therapy	NN	O	O
,	NN	O	O
or	NN	O	O
on	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
in	NN	O	O
untreated	NN	O	O
Graves	NN	O	B
'	NN	O	I
disease	NN	O	I
patients	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
we	NN	O	O
sought	NN	O	O
to	NN	O	O
address	NN	O	O
these	NN	O	O
parameters	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Graves	NN	O	B
'	NN	O	I
disease	NN	O	I
.	NN	O	O

PATIENTS	NN	O	O
:	NN	O	O
We	NN	O	O
investigated	NN	O	O
102	NN	O	O
untreated	NN	O	O
patients	NN	O	O
with	NN	O	O
hyperthyroidism	NN	O	B
due	NN	O	O
to	NN	O	O
Graves	NN	O	B
'	NN	O	I
disease	NN	O	I
for	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
,	NN	O	O
and	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
vasculitis	NN	O	B
after	NN	O	O
starting	NN	O	O
PTU	NN	O	O
therapy	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
nine	NN	O	O
of	NN	O	O
them	NN	O	O
were	NN	O	O
later	NN	O	O
excluded	NN	O	O
because	NN	O	O
of	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
PTU	NN	O	O
or	NN	O	O
because	NN	O	O
the	NN	O	O
observation	NN	O	O
period	NN	O	O
was	NN	O	O
less	NN	O	O
than	NN	O	O
3	NN	O	O
months	NN	O	O
.	NN	O	O

The	NN	O	O
remaining	NN	O	O
73	NN	O	O
patients	NN	O	O
(	NN	O	O
55	NN	O	O
women	NN	O	O
and	NN	O	O
18	NN	O	O
men	NN	O	O
)	NN	O	O
,	NN	O	O
all	NN	O	O
of	NN	O	O
whom	NN	O	O
were	NN	O	O
examined	NN	O	O
for	NN	O	O
more	NN	O	O
than	NN	O	O
3	NN	O	O
months	NN	O	O
,	NN	O	O
were	NN	O	O
adopted	NN	O	O
as	NN	O	O
the	NN	O	O
subjects	NN	O	O
of	NN	O	O
the	NN	O	O
investigation	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
observation	NN	O	O
period	NN	O	O
was	NN	O	O
23	NN	O	O
.	NN	O	O
6	NN	O	O
months	NN	O	O
(	NN	O	O
range	NN	O	O
:	NN	O	O
3	NN	O	O
-	NN	O	O
37	NN	O	O
months	NN	O	O
)	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
:	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
was	NN	O	O
measured	NN	O	O
at	NN	O	O
intervals	NN	O	O
of	NN	O	O
2	NN	O	O
-	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Before	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
titres	NN	O	O
of	NN	O	O
all	NN	O	O
102	NN	O	O
untreated	NN	O	O
Graves	NN	O	B
'	NN	O	I
disease	NN	O	I
patients	NN	O	O
were	NN	O	O
within	NN	O	O
the	NN	O	O
reference	NN	O	O
range	NN	O	O
(	NN	O	O
below	NN	O	O
10	NN	O	O
U	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
.	NN	O	O

Three	NN	O	O
(	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
73	NN	O	O
patients	NN	O	O
were	NN	O	O
positive	NN	O	O
for	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
at	NN	O	O
13	NN	O	O
,	NN	O	O
16	NN	O	O
and	NN	O	O
17	NN	O	O
months	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
after	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
PTU	NN	O	O
therapy	NN	O	O
.	NN	O	O

In	NN	O	O
two	NN	O	O
of	NN	O	O
them	NN	O	O
,	NN	O	O
the	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
titres	NN	O	O
transiently	NN	O	O
increased	NN	O	O
to	NN	O	O
12	NN	O	O
.	NN	O	O
8	NN	O	O
and	NN	O	O
15	NN	O	O
.	NN	O	O
0	NN	O	O
U	NN	O	O
/	NN	O	O
ml	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
despite	NN	O	O
continued	NN	O	O
PTU	NN	O	O
therapy	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
vasculitic	NN	O	B
disorders	NN	O	I
developed	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
third	NN	O	O
patient	NN	O	O
,	NN	O	O
the	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
titre	NN	O	O
increased	NN	O	O
to	NN	O	O
204	NN	O	O
U	NN	O	O
/	NN	O	O
ml	NN	O	O
and	NN	O	O
she	NN	O	O
developed	NN	O	O
a	NN	O	O
higher	NN	O	O
fever	NN	O	B
,	NN	O	O
oral	NN	O	B
ulcers	NN	O	I
and	NN	O	O
polyarthralgia	NN	O	B
,	NN	O	O
but	NN	O	O
the	NN	O	O
symptoms	NN	O	O
resolved	NN	O	O
2	NN	O	O
weeks	NN	O	O
after	NN	O	O
stopping	NN	O	O
PTU	NN	O	O
therapy	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
titre	NN	O	O
decreased	NN	O	O
to	NN	O	O
20	NN	O	O
.	NN	O	O
7	NN	O	O
U	NN	O	O
/	NN	O	O
ml	NN	O	O
by	NN	O	O
4	NN	O	O
months	NN	O	O
after	NN	O	O
discontinuing	NN	O	O
PTU	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
PTU	NN	O	O
therapy	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
,	NN	O	O
but	NN	O	O
MPO	NN	O	O
-	NN	O	O
ANCA	NN	O	O
does	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
closely	NN	O	O
related	NN	O	O
to	NN	O	O
vasculitis	NN	O	B
.	NN	O	O

Prevalence	NN	O	O
of	NN	O	O
heart	NN	O	B
disease	NN	O	I
in	NN	O	O
asymptomatic	NN	O	O
chronic	NN	O	O
cocaine	NN	O	O
users	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
heart	NN	O	B
disease	NN	O	I
in	NN	O	O
outpatient	NN	O	O
young	NN	O	O
asymptomatic	NN	O	O
chronic	NN	O	O
cocaine	NN	O	O
users	NN	O	O
,	NN	O	O
35	NN	O	O
cocaine	NN	O	O
users	NN	O	O
and	NN	O	O
32	NN	O	O
age	NN	O	O
-	NN	O	O
matched	NN	O	O
controls	NN	O	O
underwent	NN	O	O
resting	NN	O	O
and	NN	O	O
exercise	NN	O	O
electrocardiography	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
and	NN	O	O
Doppler	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Findings	NN	O	O
consistent	NN	O	O
with	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
were	NN	O	O
detected	NN	O	O
in	NN	O	O
12	NN	O	O
(	NN	O	O
34	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
and	NN	O	O
3	NN	O	O
(	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
controls	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Decreased	NN	O	O
left	NN	O	O
ventricular	NN	O	O
systolic	NN	O	O
function	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
in	NN	O	O
5	NN	O	O
(	NN	O	O
14	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
controls	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
055	NN	O	O
)	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
resting	NN	O	O
and	NN	O	O
peak	NN	O	O
exercise	NN	O	O
abnormal	NN	O	B
left	NN	O	I
ventricular	NN	O	I
filling	NN	O	I
was	NN	O	O
detected	NN	O	O
in	NN	O	O
38	NN	O	O
and	NN	O	O
35	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
19	NN	O	O
and	NN	O	O
9	NN	O	O
%	NN	O	O
of	NN	O	O
controls	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
11	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
coronary	NN	O	B
artery	NN	O	I
or	NN	O	I
myocardial	NN	O	I
disease	NN	O	I
is	NN	O	O
common	NN	O	O
(	NN	O	O
38	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
young	NN	O	O
asymptomatic	NN	O	O
chronic	NN	O	O
cocaine	NN	O	O
users	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
screening	NN	O	O
ECG	NN	O	O
and	NN	O	O
echocardiography	NN	O	O
may	NN	O	O
be	NN	O	O
warranted	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

Cardioprotective	NN	O	O
effects	NN	O	O
of	NN	O	O
Picrorrhiza	NN	O	O
kurroa	NN	O	O
against	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	O
stress	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
cardioprotective	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
ethanol	NN	O	O
extract	NN	O	O
of	NN	O	O
Picrorrhiza	NN	O	O
kurroa	NN	O	O
rhizomes	NN	O	O
and	NN	O	O
roots	NN	O	O
(	NN	O	O
PK	NN	O	O
)	NN	O	O
on	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
rats	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
lipid	NN	O	O
metabolism	NN	O	O
in	NN	O	O
serum	NN	O	O
and	NN	O	O
heart	NN	O	O
tissue	NN	O	O
has	NN	O	O
been	NN	O	O
investigated	NN	O	O
.	NN	O	O

Oral	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
PK	NN	O	O
(	NN	O	O
80	NN	O	O
mg	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
day	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
for	NN	O	O
15	NN	O	O
days	NN	O	O
)	NN	O	O
significantly	NN	O	O
prevented	NN	O	O
the	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
and	NN	O	O
maintained	NN	O	O
the	NN	O	O
rats	NN	O	O
at	NN	O	O
near	NN	O	O
normal	NN	O	O
status	NN	O	O
.	NN	O	O

Phase	NN	O	O
2	NN	O	O
early	NN	O	O
afterdepolarization	NN	O	O
as	NN	O	O
a	NN	O	O
trigger	NN	O	O
of	NN	O	O
polymorphic	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
in	NN	O	O
acquired	NN	O	O
long	NN	O	B
-	NN	O	I
QT	NN	O	I
syndrome	NN	O	I
:	NN	O	O
direct	NN	O	O
evidence	NN	O	O
from	NN	O	O
intracellular	NN	O	O
recordings	NN	O	O
in	NN	O	O
the	NN	O	O
intact	NN	O	O
left	NN	O	O
ventricular	NN	O	O
wall	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
examined	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
phase	NN	O	O
2	NN	O	O
early	NN	O	O
afterdepolarization	NN	O	O
(	NN	O	O
EAD	NN	O	O
)	NN	O	O
in	NN	O	O
producing	NN	O	O
a	NN	O	O
trigger	NN	O	O
to	NN	O	O
initiate	NN	O	O
torsade	NN	O	B
de	NN	O	I
pointes	NN	O	I
(	NN	O	O
TdP	NN	O	B
)	NN	O	O
with	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
induced	NN	O	O
by	NN	O	O
dl	NN	O	O
-	NN	O	O
sotalol	NN	O	O
and	NN	O	O
azimilide	NN	O	O
.	NN	O	O

The	NN	O	O
contribution	NN	O	O
of	NN	O	O
transmural	NN	O	O
dispersion	NN	O	O
of	NN	O	O
repolarization	NN	O	O
(	NN	O	O
TDR	NN	O	O
)	NN	O	O
to	NN	O	O
transmural	NN	O	O
propagation	NN	O	O
of	NN	O	O
EAD	NN	O	O
and	NN	O	O
the	NN	O	O
maintenance	NN	O	O
of	NN	O	O
TdP	NN	O	B
was	NN	O	O
also	NN	O	O
evaluated	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
Transmembrane	NN	O	O
action	NN	O	O
potentials	NN	O	O
from	NN	O	O
epicardium	NN	O	O
,	NN	O	O
midmyocardium	NN	O	O
,	NN	O	O
and	NN	O	O
endocardium	NN	O	O
were	NN	O	O
recorded	NN	O	O
simultaneously	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
a	NN	O	O
transmural	NN	O	O
ECG	NN	O	O
,	NN	O	O
in	NN	O	O
arterially	NN	O	O
perfused	NN	O	O
canine	NN	O	O
and	NN	O	O
rabbit	NN	O	O
left	NN	O	O
ventricular	NN	O	O
preparations	NN	O	O
.	NN	O	O

dl	NN	O	O
-	NN	O	O
Sotalol	NN	O	O
preferentially	NN	O	O
prolonged	NN	O	O
action	NN	O	O
potential	NN	O	O
duration	NN	O	O
(	NN	O	O
APD	NN	O	O
)	NN	O	O
in	NN	O	O
M	NN	O	O
cells	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
(	NN	O	O
1	NN	O	O
to	NN	O	O
100	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
TDR	NN	O	O
.	NN	O	O

Azimilide	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
significantly	NN	O	O
prolonged	NN	O	O
APD	NN	O	O
and	NN	O	O
QT	NN	O	O
interval	NN	O	O
at	NN	O	O
concentrations	NN	O	O
from	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
to	NN	O	O
10	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
but	NN	O	O
shortened	NN	O	O
them	NN	O	O
at	NN	O	O
30	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
.	NN	O	O

Unlike	NN	O	O
dl	NN	O	O
-	NN	O	O
sotalol	NN	O	O
,	NN	O	O
azimilide	NN	O	O
(	NN	O	O
>	NN	O	O
3	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
increased	NN	O	O
epicardial	NN	O	O
APD	NN	O	O
markedly	NN	O	O
,	NN	O	O
causing	NN	O	O
a	NN	O	O
diminished	NN	O	O
TDR	NN	O	O
.	NN	O	O

Although	NN	O	O
both	NN	O	O
dl	NN	O	O
-	NN	O	O
sotalol	NN	O	O
and	NN	O	O
azimilide	NN	O	O
rarely	NN	O	O
induced	NN	O	O
EADs	NN	O	O
in	NN	O	O
canine	NN	O	O
left	NN	O	O
ventricles	NN	O	O
,	NN	O	O
they	NN	O	O
produced	NN	O	O
frequent	NN	O	O
EADs	NN	O	O
in	NN	O	O
rabbits	NN	O	O
,	NN	O	O
in	NN	O	O
which	NN	O	O
more	NN	O	O
pronounced	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
was	NN	O	O
seen	NN	O	O
.	NN	O	O

An	NN	O	O
increase	NN	O	O
in	NN	O	O
TDR	NN	O	O
by	NN	O	O
dl	NN	O	O
-	NN	O	O
sotalol	NN	O	O
facilitated	NN	O	O
transmural	NN	O	O
propagation	NN	O	O
of	NN	O	O
EADs	NN	O	O
that	NN	O	O
initiated	NN	O	O
multiple	NN	O	O
episodes	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
TdP	NN	O	B
in	NN	O	O
3	NN	O	O
of	NN	O	O
6	NN	O	O
rabbit	NN	O	O
left	NN	O	O
ventricles	NN	O	O
.	NN	O	O

Of	NN	O	O
note	NN	O	O
,	NN	O	O
although	NN	O	O
azimilide	NN	O	O
(	NN	O	O
3	NN	O	O
to	NN	O	O
10	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
increased	NN	O	O
APD	NN	O	O
more	NN	O	O
than	NN	O	O
dl	NN	O	O
-	NN	O	O
sotalol	NN	O	O
,	NN	O	O
its	NN	O	O
EADs	NN	O	O
often	NN	O	O
failed	NN	O	O
to	NN	O	O
propagate	NN	O	O
transmurally	NN	O	O
,	NN	O	O
probably	NN	O	O
because	NN	O	O
of	NN	O	O
a	NN	O	O
diminished	NN	O	O
TDR	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
provides	NN	O	O
the	NN	O	O
first	NN	O	O
direct	NN	O	O
evidence	NN	O	O
from	NN	O	O
intracellular	NN	O	O
action	NN	O	O
potential	NN	O	O
recordings	NN	O	O
that	NN	O	O
phase	NN	O	O
2	NN	O	O
EAD	NN	O	O
can	NN	O	O
be	NN	O	O
generated	NN	O	O
from	NN	O	O
intact	NN	O	O
ventricular	NN	O	O
wall	NN	O	O
and	NN	O	O
produce	NN	O	O
a	NN	O	O
trigger	NN	O	O
to	NN	O	O
initiate	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
TdP	NN	O	B
under	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
.	NN	O	O

A	NN	O	O
pilot	NN	O	O
study	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
dobutamine	NN	O	O
stress	NN	O	O
echocardiography	NN	O	O
in	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
evaluation	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
.	NN	O	O

STUDY	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
Chest	NN	O	B
pain	NN	O	I
in	NN	O	O
the	NN	O	O
setting	NN	O	O
of	NN	O	O
cocaine	NN	O	O
use	NN	O	O
poses	NN	O	O
a	NN	O	O
diagnostic	NN	O	O
dilemma	NN	O	O
.	NN	O	O

Dobutamine	NN	O	O
stress	NN	O	O
echocardiography	NN	O	O
(	NN	O	O
DSE	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
widely	NN	O	O
available	NN	O	O
and	NN	O	O
sensitive	NN	O	O
test	NN	O	O
for	NN	O	O
evaluating	NN	O	O
cardiac	NN	O	O
ischemia	NN	O	B
.	NN	O	O

Because	NN	O	O
of	NN	O	O
the	NN	O	O
theoretical	NN	O	O
concern	NN	O	O
regarding	NN	O	O
administration	NN	O	O
of	NN	O	O
dobutamine	NN	O	O
in	NN	O	O
the	NN	O	O
setting	NN	O	O
of	NN	O	O
cocaine	NN	O	O
use	NN	O	O
,	NN	O	O
we	NN	O	O
conducted	NN	O	O
a	NN	O	O
pilot	NN	O	O
study	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
DSE	NN	O	O
in	NN	O	O
emergency	NN	O	O
department	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
prospective	NN	O	O
case	NN	O	O
series	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
the	NN	O	O
intensive	NN	O	O
diagnostic	NN	O	O
and	NN	O	O
treatment	NN	O	O
unit	NN	O	O
in	NN	O	O
the	NN	O	O
ED	NN	O	O
of	NN	O	O
an	NN	O	O
urban	NN	O	O
tertiary	NN	O	O
-	NN	O	O
care	NN	O	O
teaching	NN	O	O
hospital	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
eligible	NN	O	O
for	NN	O	O
DSE	NN	O	O
if	NN	O	O
they	NN	O	O
had	NN	O	O
used	NN	O	O
cocaine	NN	O	O
within	NN	O	O
24	NN	O	O
hours	NN	O	O
preceding	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
chest	NN	O	B
pain	NN	O	I
and	NN	O	O
had	NN	O	O
a	NN	O	O
normal	NN	O	O
ECG	NN	O	O
and	NN	O	O
tropinin	NN	O	O
I	NN	O	O
level	NN	O	O
.	NN	O	O

Patients	NN	O	O
exhibiting	NN	O	O
signs	NN	O	O
of	NN	O	O
continuing	NN	O	O
cocaine	NN	O	O
toxicity	NN	O	B
were	NN	O	O
excluded	NN	O	O
from	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
for	NN	O	O
serial	NN	O	O
testing	NN	O	O
after	NN	O	O
the	NN	O	O
DSE	NN	O	O
testing	NN	O	O
in	NN	O	O
the	NN	O	O
intensive	NN	O	O
diagnostic	NN	O	O
and	NN	O	O
treatment	NN	O	O
unit	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
four	NN	O	O
patients	NN	O	O
were	NN	O	O
enrolled	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
had	NN	O	O
inadequate	NN	O	O
resting	NN	O	O
images	NN	O	O
,	NN	O	O
one	NN	O	O
DSE	NN	O	O
was	NN	O	O
terminated	NN	O	O
because	NN	O	O
of	NN	O	O
inferior	NN	O	O
hypokinesis	NN	O	B
,	NN	O	O
another	NN	O	O
DSE	NN	O	O
was	NN	O	O
terminated	NN	O	O
because	NN	O	O
of	NN	O	O
a	NN	O	O
rate	NN	O	O
-	NN	O	O
related	NN	O	O
atrial	NN	O	O
conduction	NN	O	O
deficit	NN	O	O
,	NN	O	O
and	NN	O	O
1	NN	O	O
patient	NN	O	O
did	NN	O	O
not	NN	O	O
reach	NN	O	O
the	NN	O	O
target	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
19	NN	O	O
patients	NN	O	O
completed	NN	O	O
a	NN	O	O
DSE	NN	O	O
and	NN	O	O
reached	NN	O	O
their	NN	O	O
target	NN	O	O
heart	NN	O	O
rates	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
experienced	NN	O	O
signs	NN	O	O
of	NN	O	O
exaggerated	NN	O	O
adrenergic	NN	O	O
response	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
a	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
of	NN	O	O
greater	NN	O	O
than	NN	O	O
200	NN	O	O
mm	NN	O	O
Hg	NN	O	O
or	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
tachydysrhythmias	NN	O	B
(	NN	O	O
excluding	NN	O	O
sinus	NN	O	B
tachycardia	NN	O	I
)	NN	O	O
.	NN	O	O

Further	NN	O	O
suggesting	NN	O	O
lack	NN	O	O
of	NN	O	O
exaggerated	NN	O	O
adrenergic	NN	O	O
response	NN	O	O
,	NN	O	O
13	NN	O	O
(	NN	O	O
65	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
20	NN	O	O
patients	NN	O	O
required	NN	O	O
supplemental	NN	O	O
atropine	NN	O	O
to	NN	O	O
reach	NN	O	O
their	NN	O	O
target	NN	O	O
heart	NN	O	O
rates	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
No	NN	O	O
exaggerated	NN	O	O
adrenergic	NN	O	O
response	NN	O	O
was	NN	O	O
detected	NN	O	O
when	NN	O	O
dobutamine	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
related	NN	O	O
chest	NN	O	B
pain	NN	O	I
.	NN	O	O

Prenatal	NN	O	O
cocaine	NN	O	O
exposure	NN	O	O
and	NN	O	O
cranial	NN	O	O
sonographic	NN	O	O
findings	NN	O	O
in	NN	O	O
preterm	NN	O	B
infants	NN	O	I
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
Prenatal	NN	O	O
cocaine	NN	O	O
exposure	NN	O	O
has	NN	O	O
been	NN	O	O
linked	NN	O	O
with	NN	O	O
subependymal	NN	O	O
hemorrhage	NN	O	B
and	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
cysts	NN	O	B
that	NN	O	O
are	NN	O	O
detectable	NN	O	O
on	NN	O	O
cranial	NN	O	O
sonography	NN	O	O
in	NN	O	O
neonates	NN	O	O
born	NN	O	O
at	NN	O	O
term	NN	O	O
.	NN	O	O

We	NN	O	O
sought	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
prenatal	NN	O	O
cocaine	NN	O	O
exposure	NN	O	O
increases	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
subependymal	NN	O	B
cysts	NN	O	I
in	NN	O	O
preterm	NN	O	B
infants	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
retrospectively	NN	O	O
reviewed	NN	O	O
the	NN	O	O
medical	NN	O	O
records	NN	O	O
and	NN	O	O
cranial	NN	O	O
sonograms	NN	O	O
obtained	NN	O	O
during	NN	O	O
a	NN	O	O
1	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
on	NN	O	O
122	NN	O	O
premature	NN	O	B
(	NN	O	I
<	NN	O	I
36	NN	O	I
weeks	NN	O	I
of	NN	O	I
gestation	NN	O	I
)	NN	O	I
infants	NN	O	I
.	NN	O	O

Infants	NN	O	O
were	NN	O	O
categorized	NN	O	O
into	NN	O	O
1	NN	O	O
of	NN	O	O
2	NN	O	O
groups	NN	O	O
:	NN	O	O
those	NN	O	O
exposed	NN	O	O
to	NN	O	O
cocaine	NN	O	O
and	NN	O	O
those	NN	O	O
not	NN	O	O
exposed	NN	O	O
to	NN	O	O
cocaine	NN	O	O
.	NN	O	O

Infants	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
the	NN	O	O
cocaine	NN	O	O
-	NN	O	O
exposed	NN	O	O
group	NN	O	O
if	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
maternal	NN	O	O
history	NN	O	O
of	NN	O	O
cocaine	NN	O	B
abuse	NN	O	I
during	NN	O	O
pregnancy	NN	O	O
or	NN	O	O
if	NN	O	O
maternal	NN	O	O
or	NN	O	O
neonatal	NN	O	O
urine	NN	O	O
toxicology	NN	O	O
results	NN	O	O
were	NN	O	O
positive	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
delivery	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Five	NN	O	O
of	NN	O	O
the	NN	O	O
122	NN	O	O
infants	NN	O	O
were	NN	O	O
excluded	NN	O	O
from	NN	O	O
the	NN	O	O
study	NN	O	O
because	NN	O	O
of	NN	O	O
insufficient	NN	O	O
medical	NN	O	O
and	NN	O	O
drug	NN	O	O
histories	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
subependymal	NN	O	B
cysts	NN	O	I
in	NN	O	O
the	NN	O	O
117	NN	O	O
remaining	NN	O	O
infants	NN	O	O
was	NN	O	O
14	NN	O	O
%	NN	O	O
(	NN	O	O
16	NN	O	O
of	NN	O	O
117	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
subependymal	NN	O	B
cysts	NN	O	I
in	NN	O	O
infants	NN	O	O
exposed	NN	O	O
to	NN	O	O
cocaine	NN	O	O
prenatally	NN	O	O
was	NN	O	O
44	NN	O	O
%	NN	O	O
(	NN	O	O
8	NN	O	O
of	NN	O	O
18	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
8	NN	O	O
%	NN	O	O
(	NN	O	O
8	NN	O	O
of	NN	O	O
99	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
unexposed	NN	O	O
group	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
We	NN	O	O
found	NN	O	O
an	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
subependymal	NN	O	B
cyst	NN	O	I
formation	NN	O	O
in	NN	O	O
preterm	NN	O	B
infants	NN	O	I
who	NN	O	O
were	NN	O	O
exposed	NN	O	O
to	NN	O	O
cocaine	NN	O	O
prenatally	NN	O	O
.	NN	O	O

This	NN	O	O
result	NN	O	O
is	NN	O	O
consistent	NN	O	O
with	NN	O	O
results	NN	O	O
of	NN	O	O
similar	NN	O	O
studies	NN	O	O
in	NN	O	O
term	NN	O	O
infants	NN	O	O
.	NN	O	O

Thalidomide	NN	O	O
neuropathy	NN	O	B
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
for	NN	O	O
metastatic	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
.	NN	O	O

We	NN	O	O
prospectively	NN	O	O
evaluated	NN	O	O
thalidomide	NN	O	O
-	NN	O	O
induced	NN	O	O
neuropathy	NN	O	B
using	NN	O	O
electrodiagnostic	NN	O	O
studies	NN	O	O
.	NN	O	O

Sixty	NN	O	O
-	NN	O	O
seven	NN	O	O
men	NN	O	O
with	NN	O	O
metastatic	NN	O	O
androgen	NN	O	O
-	NN	O	O
independent	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
in	NN	O	O
an	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
trial	NN	O	O
of	NN	O	O
oral	NN	O	O
thalidomide	NN	O	O
underwent	NN	O	O
neurologic	NN	O	O
examinations	NN	O	O
and	NN	O	O
nerve	NN	O	O
conduction	NN	O	O
studies	NN	O	O
(	NN	O	O
NCS	NN	O	O
)	NN	O	O
prior	NN	O	O
to	NN	O	O
and	NN	O	O
at	NN	O	O
3	NN	O	O
-	NN	O	O
month	NN	O	O
intervals	NN	O	O
during	NN	O	O
treatment	NN	O	O
.	NN	O	O

NCS	NN	O	O
included	NN	O	O
recording	NN	O	O
of	NN	O	O
sensory	NN	O	O
nerve	NN	O	O
action	NN	O	O
potentials	NN	O	O
(	NN	O	O
SNAPs	NN	O	O
)	NN	O	O
from	NN	O	O
median	NN	O	O
,	NN	O	O
radial	NN	O	O
,	NN	O	O
ulnar	NN	O	O
,	NN	O	O
and	NN	O	O
sural	NN	O	O
nerves	NN	O	O
.	NN	O	O

SNAP	NN	O	O
amplitudes	NN	O	O
for	NN	O	O
each	NN	O	O
nerve	NN	O	O
were	NN	O	O
expressed	NN	O	O
as	NN	O	O
the	NN	O	O
percentage	NN	O	O
of	NN	O	O
its	NN	O	O
baseline	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
mean	NN	O	O
of	NN	O	O
the	NN	O	O
four	NN	O	O
was	NN	O	O
termed	NN	O	O
the	NN	O	O
SNAP	NN	O	O
index	NN	O	O
.	NN	O	O

A	NN	O	O
40	NN	O	O
%	NN	O	O
decline	NN	O	O
in	NN	O	O
the	NN	O	O
SNAP	NN	O	O
index	NN	O	O
was	NN	O	O
considered	NN	O	O
clinically	NN	O	O
significant	NN	O	O
.	NN	O	O

Thalidomide	NN	O	O
was	NN	O	O
discontinued	NN	O	O
in	NN	O	O
55	NN	O	O
patients	NN	O	O
for	NN	O	O
lack	NN	O	O
of	NN	O	O
therapeutic	NN	O	O
response	NN	O	O
.	NN	O	O

Of	NN	O	O
67	NN	O	O
patients	NN	O	O
initially	NN	O	O
enrolled	NN	O	O
,	NN	O	O
24	NN	O	O
remained	NN	O	O
on	NN	O	O
thalidomide	NN	O	O
for	NN	O	O
3	NN	O	O
months	NN	O	O
,	NN	O	O
8	NN	O	O
remained	NN	O	O
at	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
remained	NN	O	O
at	NN	O	O
9	NN	O	O
months	NN	O	O
.	NN	O	O

Six	NN	O	O
patients	NN	O	O
developed	NN	O	O
neuropathy	NN	O	B
.	NN	O	O

Clinical	NN	O	O
symptoms	NN	O	O
and	NN	O	O
a	NN	O	O
decline	NN	O	O
in	NN	O	O
the	NN	O	O
SNAP	NN	O	O
index	NN	O	O
occurred	NN	O	O
concurrently	NN	O	O
.	NN	O	O

Older	NN	O	O
age	NN	O	O
and	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
were	NN	O	O
possible	NN	O	O
contributing	NN	O	O
factors	NN	O	O
.	NN	O	O

Neuropathy	NN	O	B
may	NN	O	O
thus	NN	O	O
be	NN	O	O
a	NN	O	O
common	NN	O	O
complication	NN	O	O
of	NN	O	O
thalidomide	NN	O	O
in	NN	O	O
older	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
SNAP	NN	O	O
index	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
monitor	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
,	NN	O	O
but	NN	O	O
not	NN	O	O
for	NN	O	O
early	NN	O	O
detection	NN	O	O
.	NN	O	O

Overexpression	NN	O	O
of	NN	O	O
copper	NN	O	O
/	NN	O	O
zinc	NN	O	O
-	NN	O	O
superoxide	NN	O	O
dismutase	NN	O	O
protects	NN	O	O
from	NN	O	O
kanamycin	NN	O	O
-	NN	O	O
induced	NN	O	O
hearing	NN	O	B
loss	NN	O	I
.	NN	O	O

The	NN	O	O
participation	NN	O	O
of	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
in	NN	O	O
aminoglycoside	NN	O	O
-	NN	O	O
induced	NN	O	O
ototoxicity	NN	O	B
has	NN	O	O
been	NN	O	O
deduced	NN	O	O
from	NN	O	O
observations	NN	O	O
that	NN	O	O
aminoglycoside	NN	O	O
-	NN	O	O
iron	NN	O	O
complexes	NN	O	O
catalyze	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
superoxide	NN	O	O
radicals	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
that	NN	O	O
antioxidants	NN	O	O
attenuate	NN	O	O
ototoxicity	NN	O	B
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
overexpression	NN	O	O
of	NN	O	O
Cu	NN	O	O
/	NN	O	O
Zn	NN	O	O
-	NN	O	O
superoxide	NN	O	O
dismutase	NN	O	O
(	NN	O	O
h	NN	O	O
-	NN	O	O
SOD1	NN	O	O
)	NN	O	O
should	NN	O	O
protect	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
from	NN	O	O
ototoxicity	NN	O	B
.	NN	O	O

Immunocytochemistry	NN	O	O
confirmed	NN	O	O
expression	NN	O	O
of	NN	O	O
h	NN	O	O
-	NN	O	O
SOD1	NN	O	O
in	NN	O	O
inner	NN	O	O
ear	NN	O	O
tissues	NN	O	O
of	NN	O	O
transgenic	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
-	NN	O	O
TgN	NN	O	O
[	NN	O	O
SOD1	NN	O	O
]	NN	O	O
3Cje	NN	O	O
mice	NN	O	O
.	NN	O	O

Transgenic	NN	O	O
and	NN	O	O
nontransgenic	NN	O	O
littermates	NN	O	O
received	NN	O	O
kanamycin	NN	O	O
(	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
beginning	NN	O	O
on	NN	O	O
day	NN	O	O
10	NN	O	O
after	NN	O	O
birth	NN	O	O
.	NN	O	O

Auditory	NN	O	O
thresholds	NN	O	O
were	NN	O	O
tested	NN	O	O
by	NN	O	O
evoked	NN	O	O
auditory	NN	O	O
brain	NN	O	O
stem	NN	O	O
responses	NN	O	O
at	NN	O	O
1	NN	O	O
month	NN	O	O
after	NN	O	O
birth	NN	O	O
.	NN	O	O

In	NN	O	O
nontransgenic	NN	O	O
animals	NN	O	O
,	NN	O	O
the	NN	O	O
threshold	NN	O	O
in	NN	O	O
the	NN	O	O
kanamycin	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
was	NN	O	O
45	NN	O	O
-	NN	O	O
50	NN	O	O
dB	NN	O	O
higher	NN	O	O
than	NN	O	O
in	NN	O	O
saline	NN	O	O
-	NN	O	O
injected	NN	O	O
controls	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
transgenic	NN	O	O
group	NN	O	O
,	NN	O	O
kanamycin	NN	O	O
increased	NN	O	O
the	NN	O	O
threshold	NN	O	O
by	NN	O	O
only	NN	O	O
15	NN	O	O
dB	NN	O	O
over	NN	O	O
the	NN	O	O
respective	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
were	NN	O	O
similar	NN	O	O
at	NN	O	O
12	NN	O	O
and	NN	O	O
24	NN	O	O
kHz	NN	O	O
.	NN	O	O

The	NN	O	O
protection	NN	O	O
by	NN	O	O
overexpression	NN	O	O
of	NN	O	O
superoxide	NN	O	O
dismutase	NN	O	O
supports	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
oxidant	NN	O	O
stress	NN	O	O
plays	NN	O	O
a	NN	O	O
significant	NN	O	O
role	NN	O	O
in	NN	O	O
aminoglycoside	NN	O	O
-	NN	O	O
induced	NN	O	O
ototoxicity	NN	O	B
.	NN	O	O

The	NN	O	O
results	NN	O	O
also	NN	O	O
suggest	NN	O	O
transgenic	NN	O	O
animals	NN	O	O
as	NN	O	O
suitable	NN	O	O
models	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
underlying	NN	O	O
mechanisms	NN	O	O
and	NN	O	O
possible	NN	O	O
strategies	NN	O	O
for	NN	O	O
prevention	NN	O	O
.	NN	O	O

Fatty	NN	O	B
liver	NN	O	I
induced	NN	O	O
by	NN	O	O
tetracycline	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Dose	NN	O	O
-	NN	O	O
response	NN	O	O
relationships	NN	O	O
and	NN	O	O
effect	NN	O	O
of	NN	O	O
sex	NN	O	O
.	NN	O	O

Dose	NN	O	O
-	NN	O	O
response	NN	O	O
relationships	NN	O	O
,	NN	O	O
biochemical	NN	O	O
mechanisms	NN	O	O
,	NN	O	O
and	NN	O	O
sex	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
experimental	NN	O	O
fatty	NN	O	B
liver	NN	O	I
induced	NN	O	O
by	NN	O	O
tetracycline	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
the	NN	O	O
intact	NN	O	O
rat	NN	O	O
and	NN	O	O
with	NN	O	O
the	NN	O	O
isolated	NN	O	O
perfused	NN	O	O
rat	NN	O	O
liver	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
intact	NN	O	O
male	NN	O	O
and	NN	O	O
female	NN	O	O
rat	NN	O	O
,	NN	O	O
no	NN	O	O
direct	NN	O	O
relationship	NN	O	O
was	NN	O	O
observed	NN	O	O
between	NN	O	O
dose	NN	O	O
of	NN	O	O
tetracycline	NN	O	O
and	NN	O	O
hepatic	NN	O	O
accumulation	NN	O	O
of	NN	O	O
triglyceride	NN	O	O
.	NN	O	O

With	NN	O	O
provision	NN	O	O
of	NN	O	O
adequate	NN	O	O
oleic	NN	O	O
acid	NN	O	O
as	NN	O	O
a	NN	O	O
substrate	NN	O	O
for	NN	O	O
the	NN	O	O
isolated	NN	O	O
perfused	NN	O	O
liver	NN	O	O
,	NN	O	O
a	NN	O	O
direct	NN	O	O
relationship	NN	O	O
was	NN	O	O
observed	NN	O	O
between	NN	O	O
dose	NN	O	O
of	NN	O	O
tetracycline	NN	O	O
and	NN	O	O
both	NN	O	O
accumulation	NN	O	O
of	NN	O	O
triglyceride	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
and	NN	O	O
depression	NN	O	B
of	NN	O	O
output	NN	O	O
of	NN	O	O
triglyceride	NN	O	O
by	NN	O	O
livers	NN	O	O
from	NN	O	O
male	NN	O	O
and	NN	O	O
female	NN	O	O
rats	NN	O	O
.	NN	O	O

Marked	NN	O	O
differences	NN	O	O
were	NN	O	O
observed	NN	O	O
between	NN	O	O
female	NN	O	O
and	NN	O	O
male	NN	O	O
rats	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
base	NN	O	O
line	NN	O	O
(	NN	O	O
control	NN	O	O
)	NN	O	O
hepatic	NN	O	O
concentration	NN	O	O
of	NN	O	O
triglyceride	NN	O	O
and	NN	O	O
output	NN	O	O
of	NN	O	O
triglyceride	NN	O	O
.	NN	O	O

Accumulation	NN	O	O
of	NN	O	O
hepatic	NN	O	O
triglyceride	NN	O	O
,	NN	O	O
as	NN	O	O
a	NN	O	O
per	NN	O	O
cent	NN	O	O
of	NN	O	O
control	NN	O	O
values	NN	O	O
,	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
graded	NN	O	O
doses	NN	O	O
of	NN	O	O
tetracycline	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
between	NN	O	O
male	NN	O	O
,	NN	O	O
female	NN	O	O
and	NN	O	O
pregnant	NN	O	O
rat	NN	O	O
livers	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
livers	NN	O	O
from	NN	O	O
female	NN	O	O
,	NN	O	O
and	NN	O	O
especially	NN	O	O
pregnant	NN	O	O
female	NN	O	O
rats	NN	O	O
,	NN	O	O
were	NN	O	O
strikingly	NN	O	O
resistant	NN	O	O
to	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
tetracycline	NN	O	O
on	NN	O	O
depression	NN	O	B
of	NN	O	O
output	NN	O	O
of	NN	O	O
triglyceride	NN	O	O
under	NN	O	O
these	NN	O	O
experimental	NN	O	O
conditions	NN	O	O
.	NN	O	O

These	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
sexes	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
altered	NN	O	O
disposition	NN	O	O
of	NN	O	O
tetracycline	NN	O	O
or	NN	O	O
altered	NN	O	O
uptake	NN	O	O
of	NN	O	O
oleic	NN	O	O
acid	NN	O	O
.	NN	O	O

Depressed	NN	O	O
hepatic	NN	O	O
secretion	NN	O	O
of	NN	O	O
triglyceride	NN	O	O
accounted	NN	O	O
only	NN	O	O
for	NN	O	O
30	NN	O	O
to	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
accumulated	NN	O	O
hepatic	NN	O	O
triglyceride	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
additional	NN	O	O
mechanisms	NN	O	O
must	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
the	NN	O	O
triglyceride	NN	O	O
-	NN	O	O
rich	NN	O	O
fatty	NN	O	B
liver	NN	O	I
in	NN	O	O
response	NN	O	O
to	NN	O	O
tetracycline	NN	O	O
.	NN	O	O

Prednisone	NN	O	O
induces	NN	O	O
anxiety	NN	O	B
and	NN	O	O
glial	NN	O	O
cerebral	NN	O	O
changes	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
whether	NN	O	O
prednisone	NN	O	O
(	NN	O	O
PDN	NN	O	O
)	NN	O	O
produces	NN	O	O
anxiety	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
cerebral	NN	O	O
glial	NN	O	O
changes	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
studied	NN	O	O
and	NN	O	O
3	NN	O	O
groups	NN	O	O
were	NN	O	O
formed	NN	O	O
(	NN	O	O
8	NN	O	O
rats	NN	O	O
per	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
moderate	NN	O	O
-	NN	O	O
dose	NN	O	O
group	NN	O	O
received	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
PDN	NN	O	O
released	NN	O	O
from	NN	O	O
a	NN	O	O
subcutaneous	NN	O	O
implant	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
group	NN	O	O
,	NN	O	O
implants	NN	O	O
containing	NN	O	O
PDN	NN	O	O
equivalent	NN	O	O
to	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
were	NN	O	O
applied	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
implants	NN	O	O
contained	NN	O	O
no	NN	O	O
PDN	NN	O	O
.	NN	O	O

Anxiety	NN	O	B
was	NN	O	O
assessed	NN	O	O
using	NN	O	O
an	NN	O	O
open	NN	O	O
field	NN	O	O
and	NN	O	O
elevated	NN	O	O
plus	NN	O	O
-	NN	O	O
maze	NN	O	O
devices	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
cells	NN	O	O
and	NN	O	O
cytoplasmic	NN	O	O
transformation	NN	O	O
of	NN	O	O
astrocytes	NN	O	O
and	NN	O	O
microglia	NN	O	O
cells	NN	O	O
were	NN	O	O
assessed	NN	O	O
by	NN	O	O
immunohistochemical	NN	O	O
analyses	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Anxiety	NN	O	B
was	NN	O	O
documented	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
of	NN	O	O
PDN	NN	O	O
treated	NN	O	O
rats	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
magnitude	NN	O	O
of	NN	O	O
transformation	NN	O	O
of	NN	O	O
the	NN	O	O
microglia	NN	O	O
assessed	NN	O	O
by	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
intersections	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
PDN	NN	O	O
groups	NN	O	O
than	NN	O	O
in	NN	O	O
controls	NN	O	O
in	NN	O	O
the	NN	O	O
prefrontal	NN	O	O
cortex	NN	O	O
(	NN	O	O
moderate	NN	O	O
-	NN	O	O
dose	NN	O	O
,	NN	O	O
24	NN	O	O
.	NN	O	O
1	NN	O	O
;	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
,	NN	O	O
23	NN	O	O
.	NN	O	O
6	NN	O	O
;	NN	O	O
controls	NN	O	O
18	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
and	NN	O	O
striatum	NN	O	O
(	NN	O	O
moderate	NN	O	O
-	NN	O	O
dose	NN	O	O
25	NN	O	O
.	NN	O	O
6	NN	O	O
;	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
26	NN	O	O
.	NN	O	O
3	NN	O	O
;	NN	O	O
controls	NN	O	O
18	NN	O	O
.	NN	O	O
9	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
hippocampus	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
stained	NN	O	O
microglia	NN	O	O
cells	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
PDN	NN	O	O
treated	NN	O	O
groups	NN	O	O
in	NN	O	O
the	NN	O	O
prefrontal	NN	O	O
cortex	NN	O	O
than	NN	O	O
in	NN	O	O
controls	NN	O	O
(	NN	O	O
moderate	NN	O	O
-	NN	O	O
dose	NN	O	O
,	NN	O	O
29	NN	O	O
.	NN	O	O
1	NN	O	O
;	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
,	NN	O	O
28	NN	O	O
.	NN	O	O
4	NN	O	O
;	NN	O	O
control	NN	O	O
,	NN	O	O
17	NN	O	O
.	NN	O	O
7	NN	O	O
cells	NN	O	O
per	NN	O	O
field	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Stained	NN	O	O
microglia	NN	O	O
cells	NN	O	O
were	NN	O	O
significantly	NN	O	O
more	NN	O	O
numerous	NN	O	O
striatum	NN	O	O
and	NN	O	O
hippocampus	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
group	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Subacute	NN	O	O
exposure	NN	O	O
to	NN	O	O
PDN	NN	O	O
induced	NN	O	O
anxiety	NN	O	B
and	NN	O	O
reactivity	NN	O	O
of	NN	O	O
microglia	NN	O	O
.	NN	O	O

The	NN	O	O
relevance	NN	O	O
of	NN	O	O
these	NN	O	O
features	NN	O	O
for	NN	O	O
patients	NN	O	O
using	NN	O	O
PDN	NN	O	O
remains	NN	O	O
to	NN	O	O
be	NN	O	O
elucidated	NN	O	O
.	NN	O	O

Phase	NN	O	O
II	NN	O	O
study	NN	O	O
of	NN	O	O
carboplatin	NN	O	O
and	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
recurrent	NN	O	O
squamous	NN	O	B
cell	NN	O	I
carcinoma	NN	O	I
of	NN	O	I
the	NN	O	I
cervix	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
carboplatin	NN	O	O
and	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
was	NN	O	O
tested	NN	O	O
in	NN	O	O
a	NN	O	O
Phase	NN	O	O
II	NN	O	O
study	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
recurrent	NN	O	O
cervical	NN	O	B
carcinoma	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
combination	NN	O	O
of	NN	O	O
carboplatin	NN	O	O
(	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
concentration	NN	O	O
curve	NN	O	O
[	NN	O	O
AUC	NN	O	O
]	NN	O	O
,	NN	O	O
5	NN	O	O
)	NN	O	O
and	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
Doxil	NN	O	O
;	NN	O	O
starting	NN	O	O
dose	NN	O	O
,	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
intravenously	NN	O	O
every	NN	O	O
28	NN	O	O
days	NN	O	O
to	NN	O	O
37	NN	O	O
patients	NN	O	O
with	NN	O	O
recurrent	NN	O	O
squamous	NN	O	B
cell	NN	O	I
cervical	NN	O	I
carcinoma	NN	O	I
to	NN	O	O
determine	NN	O	O
antitumor	NN	O	O
activity	NN	O	O
and	NN	O	O
toxicity	NN	O	B
profile	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
nine	NN	O	O
patients	NN	O	O
were	NN	O	O
assessable	NN	O	O
for	NN	O	O
response	NN	O	O
,	NN	O	O
and	NN	O	O
35	NN	O	O
patients	NN	O	O
were	NN	O	O
assessable	NN	O	O
for	NN	O	O
toxicity	NN	O	B
.	NN	O	O

The	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
was	NN	O	O
38	NN	O	O
%	NN	O	O
,	NN	O	O
the	NN	O	O
median	NN	O	O
time	NN	O	O
to	NN	O	O
response	NN	O	O
was	NN	O	O
10	NN	O	O
weeks	NN	O	O
,	NN	O	O
the	NN	O	O
median	NN	O	O
duration	NN	O	O
of	NN	O	O
response	NN	O	O
was	NN	O	O
26	NN	O	O
weeks	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
median	NN	O	O
survival	NN	O	O
was	NN	O	O
37	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
main	NN	O	O
toxic	NN	O	O
effect	NN	O	O
was	NN	O	O
myelosuppression	NN	O	B
,	NN	O	O
with	NN	O	O
Grade	NN	O	O
3	NN	O	O
and	NN	O	O
4	NN	O	O
neutropenia	NN	O	B
in	NN	O	O
16	NN	O	O
patients	NN	O	O
,	NN	O	O
anemia	NN	O	B
in	NN	O	O
12	NN	O	O
patients	NN	O	O
,	NN	O	O
thrombocytopenia	NN	O	B
in	NN	O	O
11	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
neutropenic	NN	O	B
fever	NN	O	I
in	NN	O	O
3	NN	O	O
patients	NN	O	O
.	NN	O	O

Four	NN	O	O
patients	NN	O	O
had	NN	O	O
five	NN	O	O
infusion	NN	O	O
-	NN	O	O
related	NN	O	O
reactions	NN	O	O
during	NN	O	O
the	NN	O	O
infusion	NN	O	O
of	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
treatment	NN	O	O
discontinuation	NN	O	O
in	NN	O	O
three	NN	O	O
patients	NN	O	O
.	NN	O	O

Grade	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
2	NN	O	O
nonhematologic	NN	O	O
toxicity	NN	O	B
included	NN	O	O
nausea	NN	O	B
in	NN	O	O
17	NN	O	O
patients	NN	O	O
,	NN	O	O
emesis	NN	O	B
in	NN	O	O
14	NN	O	O
patients	NN	O	O
,	NN	O	O
fatigue	NN	O	B
in	NN	O	O
9	NN	O	O
patients	NN	O	O
,	NN	O	O
mucositis	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
stomatitis	NN	O	B
in	NN	O	O
8	NN	O	O
patients	NN	O	O
,	NN	O	O
constipation	NN	O	B
in	NN	O	O
6	NN	O	O
patients	NN	O	O
,	NN	O	O
weight	NN	O	B
loss	NN	O	I
in	NN	O	O
5	NN	O	O
patients	NN	O	O
,	NN	O	O
hand	NN	O	B
-	NN	O	I
foot	NN	O	I
syndrome	NN	O	I
in	NN	O	O
2	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
skin	NN	O	B
reactions	NN	O	I
in	NN	O	O
3	NN	O	O
patients	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
combination	NN	O	O
of	NN	O	O
carboplatin	NN	O	O
and	NN	O	O
liposomal	NN	O	O
doxorubicin	NN	O	O
has	NN	O	O
modest	NN	O	O
activity	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
recurrent	NN	O	O
cervical	NN	O	B
carcinoma	NN	O	I
.	NN	O	O

Antimicrobial	NN	O	O
-	NN	O	O
induced	NN	O	O
mania	NN	O	B
(	NN	O	O
antibiomania	NN	O	B
)	NN	O	O
:	NN	O	O
a	NN	O	O
review	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
reports	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
reviewed	NN	O	O
reported	NN	O	O
cases	NN	O	O
of	NN	O	O
antibiotic	NN	O	O
-	NN	O	O
induced	NN	O	O
manic	NN	O	B
episodes	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
a	NN	O	O
MEDLINE	NN	O	O
and	NN	O	O
PsychLit	NN	O	O
search	NN	O	O
for	NN	O	O
reports	NN	O	O
of	NN	O	O
antibiotic	NN	O	O
-	NN	O	O
induced	NN	O	O
mania	NN	O	B
.	NN	O	O

Unpublished	NN	O	O
reports	NN	O	O
were	NN	O	O
requested	NN	O	O
from	NN	O	O
the	NN	O	O
World	NN	O	O
Health	NN	O	O
Organization	NN	O	O
(	NN	O	O
WHO	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
Food	NN	O	O
and	NN	O	O
Drug	NN	O	O
Administration	NN	O	O
(	NN	O	O
FDA	NN	O	O
)	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
one	NN	O	O
reports	NN	O	O
of	NN	O	O
antimicrobial	NN	O	O
-	NN	O	O
induced	NN	O	O
mania	NN	O	B
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
6	NN	O	O
cases	NN	O	O
implicating	NN	O	O
clarithromycin	NN	O	O
,	NN	O	O
13	NN	O	O
implicating	NN	O	O
isoniazid	NN	O	O
,	NN	O	O
and	NN	O	O
1	NN	O	O
case	NN	O	O
each	NN	O	O
implicating	NN	O	O
erythromycin	NN	O	O
and	NN	O	O
amoxicillin	NN	O	O
.	NN	O	O

The	NN	O	O
WHO	NN	O	O
reported	NN	O	O
82	NN	O	O
cases	NN	O	O
.	NN	O	O

Of	NN	O	O
these	NN	O	O
,	NN	O	O
clarithromycin	NN	O	O
was	NN	O	O
implicated	NN	O	O
in	NN	O	O
23	NN	O	O
(	NN	O	O
27	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
cases	NN	O	O
,	NN	O	O
ciprofloxacin	NN	O	O
in	NN	O	O
12	NN	O	O
(	NN	O	O
14	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
cases	NN	O	O
,	NN	O	O
and	NN	O	O
ofloxacin	NN	O	O
in	NN	O	O
10	NN	O	O
(	NN	O	O
12	NN	O	O
%	NN	O	O
)	NN	O	O
cases	NN	O	O
.	NN	O	O

Cotrimoxazole	NN	O	O
,	NN	O	O
metronidazole	NN	O	O
,	NN	O	O
and	NN	O	O
erythromycin	NN	O	O
were	NN	O	O
involved	NN	O	O
in	NN	O	O
15	NN	O	O
reported	NN	O	O
manic	NN	O	B
episodes	NN	O	O
.	NN	O	O

Cases	NN	O	O
reported	NN	O	O
by	NN	O	O
the	NN	O	O
FDA	NN	O	O
showed	NN	O	O
clarithromycin	NN	O	O
and	NN	O	O
ciprofloxacin	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
most	NN	O	O
frequently	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
mania	NN	O	B
.	NN	O	O

Statistical	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
data	NN	O	O
would	NN	O	O
not	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
significant	NN	O	O
statistical	NN	O	O
correlative	NN	O	O
risk	NN	O	O
and	NN	O	O
was	NN	O	O
therefore	NN	O	O
not	NN	O	O
undertaken	NN	O	O
.	NN	O	O

Patients	NN	O	O
have	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
developing	NN	O	O
mania	NN	O	B
while	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
antimicrobials	NN	O	O
.	NN	O	O

Although	NN	O	O
this	NN	O	O
is	NN	O	O
not	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
risk	NN	O	O
,	NN	O	O
physicians	NN	O	O
must	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
effect	NN	O	O
and	NN	O	O
reversibility	NN	O	O
.	NN	O	O

Further	NN	O	O
research	NN	O	O
clearly	NN	O	O
is	NN	O	O
required	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
antimicrobial	NN	O	O
-	NN	O	O
induced	NN	O	O
mania	NN	O	B
,	NN	O	O
the	NN	O	O
relative	NN	O	O
risk	NN	O	O
factors	NN	O	O
of	NN	O	O
developing	NN	O	O
an	NN	O	O
antimicrobial	NN	O	O
-	NN	O	O
induced	NN	O	O
manic	NN	O	B
episode	NN	O	O
among	NN	O	O
various	NN	O	O
demographic	NN	O	O
populations	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
continue	NN	O	O
to	NN	O	O
have	NN	O	O
persistent	NN	O	O
affective	NN	O	O
disorders	NN	O	O
once	NN	O	O
the	NN	O	O
initial	NN	O	O
episode	NN	O	O
,	NN	O	O
which	NN	O	O
occurs	NN	O	O
while	NN	O	O
the	NN	O	O
patient	NN	O	O
is	NN	O	O
taking	NN	O	O
antibiotics	NN	O	O
,	NN	O	O
subsides	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
elected	NN	O	O
to	NN	O	O
name	NN	O	O
this	NN	O	O
syndrome	NN	O	O
"	NN	O	O
antibiomania	NN	O	B
.	NN	O	O
"	NN	O	O

Levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
ocular	NN	O	B
dyskinesias	NN	O	I
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

Levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
ocular	NN	O	B
dyskinesias	NN	O	I
are	NN	O	O
very	NN	O	O
uncommon	NN	O	O
.	NN	O	O

Usually	NN	O	O
they	NN	O	O
occur	NN	O	O
simultaneously	NN	O	O
with	NN	O	O
limb	NN	O	O
peak	NN	O	O
-	NN	O	O
dose	NN	O	O
choreatic	NN	O	B
dyskinesias	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
leftward	NN	O	O
and	NN	O	O
upward	NN	O	O
deviations	NN	O	O
of	NN	O	O
gaze	NN	O	O
during	NN	O	O
the	NN	O	O
peak	NN	O	O
effect	NN	O	O
of	NN	O	O
levodopa	NN	O	O
,	NN	O	O
and	NN	O	O
hypothesize	NN	O	O
that	NN	O	O
a	NN	O	O
severe	NN	O	O
dopaminergic	NN	O	O
denervation	NN	O	O
in	NN	O	O
the	NN	O	O
caudate	NN	O	O
nucleus	NN	O	O
is	NN	O	O
needed	NN	O	O
for	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
these	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induce	NN	O	O
ocular	NN	O	B
dyskinesias	NN	O	I
.	NN	O	O

A	NN	O	O
comparison	NN	O	O
of	NN	O	O
glyceryl	NN	O	O
trinitrate	NN	O	O
with	NN	O	O
diclofenac	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
primary	NN	O	O
dysmenorrhea	NN	O	B
:	NN	O	O
an	NN	O	O
open	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
cross	NN	O	O
-	NN	O	O
over	NN	O	O
trial	NN	O	O
.	NN	O	O

Primary	NN	O	O
dysmenorrhea	NN	O	B
is	NN	O	O
a	NN	O	O
syndrome	NN	O	O
characterized	NN	O	O
by	NN	O	O
painful	NN	O	O
uterine	NN	O	O
contractility	NN	O	O
caused	NN	O	O
by	NN	O	O
a	NN	O	O
hypersecretion	NN	O	O
of	NN	O	O
endometrial	NN	O	O
prostaglandins	NN	O	O
;	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
are	NN	O	O
the	NN	O	O
first	NN	O	O
choice	NN	O	O
for	NN	O	O
its	NN	O	O
treatment	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
in	NN	O	O
vivo	NN	O	O
and	NN	O	O
in	NN	O	O
vitro	NN	O	O
studies	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
myometrial	NN	O	O
cells	NN	O	O
are	NN	O	O
also	NN	O	O
targets	NN	O	O
of	NN	O	O
the	NN	O	O
relaxant	NN	O	O
effects	NN	O	O
of	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
(	NN	O	O
NO	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
glyceryl	NN	O	O
trinitrate	NN	O	O
(	NN	O	O
GTN	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
NO	NN	O	O
donor	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
resolution	NN	O	O
of	NN	O	O
primary	NN	O	O
dysmenorrhea	NN	O	B
in	NN	O	O
comparison	NN	O	O
with	NN	O	O
diclofenac	NN	O	O
(	NN	O	O
DCF	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
24	NN	O	O
patients	NN	O	O
with	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
severe	NN	O	O
primary	NN	O	O
dysmenorrhea	NN	O	B
were	NN	O	O
studied	NN	O	O
during	NN	O	O
two	NN	O	O
consecutive	NN	O	O
menstrual	NN	O	O
cycles	NN	O	O
.	NN	O	O

In	NN	O	O
an	NN	O	O
open	NN	O	O
,	NN	O	O
cross	NN	O	O
-	NN	O	O
over	NN	O	O
,	NN	O	O
controlled	NN	O	O
design	NN	O	O
,	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
DCF	NN	O	O
per	NN	O	O
os	NN	O	O
or	NN	O	O
GTN	NN	O	O
patches	NN	O	O
the	NN	O	O
first	NN	O	O
days	NN	O	O
of	NN	O	O
menses	NN	O	O
,	NN	O	O
when	NN	O	O
menstrual	NN	O	O
cramps	NN	O	O
became	NN	O	O
unendurable	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
subsequent	NN	O	O
cycle	NN	O	O
the	NN	O	O
other	NN	O	O
treatment	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

Patients	NN	O	O
received	NN	O	O
up	NN	O	O
to	NN	O	O
3	NN	O	O
doses	NN	O	O
/	NN	O	O
day	NN	O	O
of	NN	O	O
50	NN	O	O
mg	NN	O	O
DCF	NN	O	O
or	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
24	NN	O	O
h	NN	O	O
transdermal	NN	O	O
GTN	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
3	NN	O	O
days	NN	O	O
of	NN	O	O
the	NN	O	O
cycle	NN	O	O
,	NN	O	O
according	NN	O	O
to	NN	O	O
their	NN	O	O
needs	NN	O	O
.	NN	O	O

The	NN	O	O
participants	NN	O	O
recorded	NN	O	O
menstrual	NN	O	O
symptoms	NN	O	O
and	NN	O	O
possible	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
at	NN	O	O
different	NN	O	O
times	NN	O	O
(	NN	O	O
0	NN	O	O
,	NN	O	O
30	NN	O	O
,	NN	O	O
60	NN	O	O
,	NN	O	O
120	NN	O	O
minutes	NN	O	O
)	NN	O	O
after	NN	O	O
the	NN	O	O
first	NN	O	O
dose	NN	O	O
of	NN	O	O
medication	NN	O	O
on	NN	O	O
the	NN	O	O
first	NN	O	O
day	NN	O	O
of	NN	O	O
the	NN	O	O
cycle	NN	O	O
,	NN	O	O
with	NN	O	O
both	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
difference	NN	O	O
in	NN	O	O
pain	NN	O	B
intensity	NN	O	O
score	NN	O	O
(	NN	O	O
DPI	NN	O	O
)	NN	O	O
was	NN	O	O
the	NN	O	O
main	NN	O	O
outcome	NN	O	O
variable	NN	O	O
.	NN	O	O

Both	NN	O	O
treatments	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
DPI	NN	O	O
by	NN	O	O
the	NN	O	O
30th	NN	O	O
minute	NN	O	O
(	NN	O	O
GTN	NN	O	O
,	NN	O	O
-	NN	O	O
12	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
17	NN	O	O
.	NN	O	O
9	NN	O	O
;	NN	O	O
DCF	NN	O	O
,	NN	O	O
-	NN	O	O
18	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
16	NN	O	O
.	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
DCF	NN	O	O
continued	NN	O	O
to	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
reducing	NN	O	O
pelvic	NN	O	B
pain	NN	O	I
for	NN	O	O
two	NN	O	O
hours	NN	O	O
,	NN	O	O
whereas	NN	O	O
GTN	NN	O	O
scores	NN	O	O
remained	NN	O	O
more	NN	O	O
or	NN	O	O
less	NN	O	O
stable	NN	O	O
after	NN	O	O
30	NN	O	O
min	NN	O	O
and	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
those	NN	O	O
for	NN	O	O
DFC	NN	O	O
(	NN	O	O
after	NN	O	O
one	NN	O	O
hour	NN	O	O
:	NN	O	O
GTN	NN	O	O
,	NN	O	O
-	NN	O	O
12	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
17	NN	O	O
.	NN	O	O
9	NN	O	O
;	NN	O	O
DFC	NN	O	O
,	NN	O	O
-	NN	O	O
18	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
16	NN	O	O
.	NN	O	O
6	NN	O	O
and	NN	O	O
after	NN	O	O
two	NN	O	O
hours	NN	O	O
:	NN	O	O
GTN	NN	O	O
,	NN	O	O
-	NN	O	O
23	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
20	NN	O	O
.	NN	O	O
5	NN	O	O
;	NN	O	O
DFC	NN	O	O
,	NN	O	O
-	NN	O	O
59	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
17	NN	O	O
.	NN	O	O
9	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
.	NN	O	O

Low	NN	O	B
back	NN	O	I
pain	NN	O	I
was	NN	O	O
also	NN	O	O
relieved	NN	O	O
by	NN	O	O
both	NN	O	O
drugs	NN	O	O
.	NN	O	O

Headache	NN	O	B
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
by	NN	O	O
GTN	NN	O	O
but	NN	O	O
not	NN	O	O
by	NN	O	O
DCF	NN	O	O
.	NN	O	O

Eight	NN	O	O
patients	NN	O	O
stopped	NN	O	O
using	NN	O	O
GTN	NN	O	O
because	NN	O	O
headache	NN	O	B
-	NN	O	O
-	NN	O	O
attributed	NN	O	O
to	NN	O	O
its	NN	O	O
use	NN	O	O
-	NN	O	O
-	NN	O	O
became	NN	O	O
intolerable	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
GTN	NN	O	O
has	NN	O	O
a	NN	O	O
reduced	NN	O	O
efficacy	NN	O	O
and	NN	O	O
tolerability	NN	O	O
by	NN	O	O
comparison	NN	O	O
with	NN	O	O
DCF	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
primary	NN	O	O
dysmenorrhea	NN	O	B
.	NN	O	O

Temocapril	NN	O	O
,	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
acting	NN	O	O
non	NN	O	O
-	NN	O	O
SH	NN	O	O
group	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
modulates	NN	O	O
glomerular	NN	O	B
injury	NN	O	I
in	NN	O	O
chronic	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
nephrosis	NN	O	B
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
chronic	NN	O	O
administration	NN	O	O
of	NN	O	O
temocapril	NN	O	O
,	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
acting	NN	O	O
non	NN	O	O
-	NN	O	O
SH	NN	O	O
group	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
reduced	NN	O	O
proteinuria	NN	O	B
,	NN	O	O
inhibited	NN	O	O
glomerular	NN	O	O
hypertrophy	NN	O	B
and	NN	O	O
prevented	NN	O	O
glomerulosclerosis	NN	O	B
in	NN	O	O
chronic	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
(	NN	O	O
PAN	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotic	NN	O	B
rats	NN	O	O
.	NN	O	O

Nephrosis	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
injection	NN	O	O
of	NN	O	O
PAN	NN	O	O
(	NN	O	O
15mg	NN	O	O
/	NN	O	O
100g	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
in	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
(	NN	O	O
SD	NN	O	O
)	NN	O	O
rats	NN	O	O
.	NN	O	O

Four	NN	O	O
groups	NN	O	O
were	NN	O	O
used	NN	O	O
,	NN	O	O
i	NN	O	O
)	NN	O	O
the	NN	O	O
PAN	NN	O	O
group	NN	O	O
(	NN	O	O
14	NN	O	O
)	NN	O	O
,	NN	O	O
ii	NN	O	O
)	NN	O	O
PAN	NN	O	O
/	NN	O	O
temocapril	NN	O	O
(	NN	O	O
13	NN	O	O
)	NN	O	O
,	NN	O	O
iii	NN	O	O
)	NN	O	O
temocapril	NN	O	O
(	NN	O	O
14	NN	O	O
)	NN	O	O
and	NN	O	O
iv	NN	O	O
)	NN	O	O
untreated	NN	O	O
controls	NN	O	O
(	NN	O	O
15	NN	O	O
)	NN	O	O
.	NN	O	O

Temocapril	NN	O	O
(	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
the	NN	O	O
rats	NN	O	O
which	NN	O	O
were	NN	O	O
killed	NN	O	O
at	NN	O	O
weeks	NN	O	O
4	NN	O	O
,	NN	O	O
14	NN	O	O
or	NN	O	O
20	NN	O	O
.	NN	O	O

At	NN	O	O
each	NN	O	O
time	NN	O	O
point	NN	O	O
,	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
BP	NN	O	O
)	NN	O	O
,	NN	O	O
urinary	NN	O	O
protein	NN	O	O
excretion	NN	O	O
and	NN	O	O
renal	NN	O	O
histopathological	NN	O	O
findings	NN	O	O
were	NN	O	O
evaluated	NN	O	O
,	NN	O	O
and	NN	O	O
morphometric	NN	O	O
image	NN	O	O
analysis	NN	O	O
was	NN	O	O
done	NN	O	O
.	NN	O	O

Systolic	NN	O	O
BP	NN	O	O
in	NN	O	O
the	NN	O	O
PAN	NN	O	O
group	NN	O	O
was	NN	O	O
significantly	NN	O	O
high	NN	O	O
at	NN	O	O
4	NN	O	O
,	NN	O	O
14	NN	O	O
and	NN	O	O
20	NN	O	O
weeks	NN	O	O
,	NN	O	O
but	NN	O	O
was	NN	O	O
normal	NN	O	O
in	NN	O	O
the	NN	O	O
PAN	NN	O	O
/	NN	O	O
temocapril	NN	O	O
group	NN	O	O
.	NN	O	O

Urinary	NN	O	O
protein	NN	O	O
excretion	NN	O	O
in	NN	O	O
the	NN	O	O
PAN	NN	O	O
group	NN	O	O
increased	NN	O	O
significantly	NN	O	O
,	NN	O	O
peaking	NN	O	O
at	NN	O	O
8	NN	O	O
days	NN	O	O
,	NN	O	O
then	NN	O	O
decreased	NN	O	O
at	NN	O	O
4	NN	O	O
weeks	NN	O	O
,	NN	O	O
but	NN	O	O
rose	NN	O	O
again	NN	O	O
significantly	NN	O	O
at	NN	O	O
14	NN	O	O
and	NN	O	O
20	NN	O	O
weeks	NN	O	O
.	NN	O	O

Temocapril	NN	O	O
did	NN	O	O
not	NN	O	O
attenuate	NN	O	O
proteinuria	NN	O	B
at	NN	O	O
8	NN	O	O
days	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
did	NN	O	O
markedly	NN	O	O
lower	NN	O	O
it	NN	O	O
from	NN	O	O
weeks	NN	O	O
4	NN	O	O
to	NN	O	O
20	NN	O	O
.	NN	O	O

The	NN	O	O
glomerulosclerosis	NN	O	B
index	NN	O	O
(	NN	O	O
GSI	NN	O	O
)	NN	O	O
was	NN	O	O
6	NN	O	O
.	NN	O	O
21	NN	O	O
%	NN	O	O
at	NN	O	O
4	NN	O	O
weeks	NN	O	O
and	NN	O	O
respectively	NN	O	O
25	NN	O	O
.	NN	O	O
35	NN	O	O
%	NN	O	O
and	NN	O	O
30	NN	O	O
.	NN	O	O
49	NN	O	O
%	NN	O	O
at	NN	O	O
14	NN	O	O
and	NN	O	O
20	NN	O	O
weeks	NN	O	O
in	NN	O	O
the	NN	O	O
PAN	NN	O	O
group	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
correlation	NN	O	O
between	NN	O	O
urinary	NN	O	O
protein	NN	O	O
excretion	NN	O	O
and	NN	O	O
GSI	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
808	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
ratio	NN	O	O
of	NN	O	O
glomerular	NN	O	O
tuft	NN	O	O
area	NN	O	O
to	NN	O	O
the	NN	O	O
area	NN	O	O
of	NN	O	O
Bowman	NN	O	O
'	NN	O	O
s	NN	O	O
capsules	NN	O	O
(	NN	O	O
GT	NN	O	O
/	NN	O	O
BC	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
PAN	NN	O	O
group	NN	O	O
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
PAN	NN	O	O
/	NN	O	O
temocapril	NN	O	O
group	NN	O	O
.	NN	O	O

It	NN	O	O
appears	NN	O	O
that	NN	O	O
temocapril	NN	O	O
was	NN	O	O
effective	NN	O	O
in	NN	O	O
retarding	NN	O	O
renal	NN	O	O
progression	NN	O	O
and	NN	O	O
protected	NN	O	O
renal	NN	O	O
function	NN	O	O
in	NN	O	O
PAN	NN	O	O
neprotic	NN	O	B
rats	NN	O	O
.	NN	O	O

Pulmonary	NN	O	B
hypertension	NN	O	I
after	NN	O	O
ibuprofen	NN	O	O
prophylaxis	NN	O	O
in	NN	O	O
very	NN	O	O
preterm	NN	O	O
infants	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
three	NN	O	O
cases	NN	O	O
of	NN	O	O
severe	NN	O	O
hypoxaemia	NN	O	B
after	NN	O	O
ibuprofen	NN	O	O
administration	NN	O	O
during	NN	O	O
a	NN	O	O
randomised	NN	O	O
controlled	NN	O	O
trial	NN	O	O
of	NN	O	O
prophylactic	NN	O	O
treatment	NN	O	O
of	NN	O	O
patent	NN	O	B
ductus	NN	O	I
arteriosus	NN	O	I
with	NN	O	O
ibuprofen	NN	O	O
in	NN	O	O
premature	NN	O	O
infants	NN	O	O
born	NN	O	O
at	NN	O	O
less	NN	O	O
than	NN	O	O
28	NN	O	O
weeks	NN	O	O
of	NN	O	O
gestation	NN	O	O
.	NN	O	O

Echocardiography	NN	O	O
showed	NN	O	O
severely	NN	O	O
decreased	NN	O	O
pulmonary	NN	O	O
blood	NN	O	O
flow	NN	O	O
.	NN	O	O

Hypoxaemia	NN	O	B
resolved	NN	O	O
quickly	NN	O	O
on	NN	O	O
inhaled	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
investigators	NN	O	O
involved	NN	O	O
in	NN	O	O
similar	NN	O	O
trials	NN	O	O
pay	NN	O	O
close	NN	O	O
attention	NN	O	O
to	NN	O	O
pulmonary	NN	O	O
pressure	NN	O	O
if	NN	O	O
hypoxaemia	NN	O	B
occurs	NN	O	O
after	NN	O	O
prophylactic	NN	O	O
administration	NN	O	O
of	NN	O	O
ibuprofen	NN	O	O
.	NN	O	O

Hyponatremia	NN	O	B
and	NN	O	O
syndrome	NN	O	B
of	NN	O	I
inappropriate	NN	O	I
anti	NN	O	I
-	NN	O	I
diuretic	NN	O	I
hormone	NN	O	I
reported	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
Vincristine	NN	O	O
:	NN	O	O
an	NN	O	O
over	NN	O	O
-	NN	O	O
representation	NN	O	O
of	NN	O	O
Asians	NN	O	O
?	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
This	NN	O	O
retrospective	NN	O	O
study	NN	O	O
used	NN	O	O
a	NN	O	O
pharmaceutical	NN	O	O
company	NN	O	O
'	NN	O	O
s	NN	O	O
global	NN	O	O
safety	NN	O	O
database	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
reporting	NN	O	O
rate	NN	O	O
of	NN	O	O
hyponatremia	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
syndrome	NN	O	B
of	NN	O	I
inappropriate	NN	O	I
secretion	NN	O	I
of	NN	O	I
anti	NN	O	I
-	NN	O	I
diuretic	NN	O	I
hormone	NN	O	I
(	NN	O	O
SIADH	NN	O	B
)	NN	O	O
among	NN	O	O
vincristine	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
and	NN	O	O
to	NN	O	O
explore	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
at	NN	O	O
-	NN	O	O
risk	NN	O	O
population	NN	O	O
subgroups	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
We	NN	O	O
searched	NN	O	O
the	NN	O	O
Eli	NN	O	O
Lilly	NN	O	O
and	NN	O	O
Company	NN	O	O
'	NN	O	O
s	NN	O	O
computerized	NN	O	O
adverse	NN	O	O
event	NN	O	O
database	NN	O	O
for	NN	O	O
all	NN	O	O
reported	NN	O	O
cases	NN	O	O
of	NN	O	O
hyponatremia	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
SIADH	NN	O	B
as	NN	O	O
of	NN	O	O
1	NN	O	O
November	NN	O	O
1999	NN	O	O
that	NN	O	O
had	NN	O	O
been	NN	O	O
reported	NN	O	O
during	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
vincristine	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
76	NN	O	O
cases	NN	O	O
of	NN	O	O
hyponatremia	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
SIADH	NN	O	B
associated	NN	O	O
with	NN	O	O
vincristine	NN	O	O
use	NN	O	O
were	NN	O	O
identified	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
reporting	NN	O	O
rate	NN	O	O
was	NN	O	O
estimated	NN	O	O
to	NN	O	O
be	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
/	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
treated	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
average	NN	O	O
age	NN	O	O
of	NN	O	O
patients	NN	O	O
was	NN	O	O
35	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
28	NN	O	O
.	NN	O	O
3	NN	O	O
years	NN	O	O
,	NN	O	O
and	NN	O	O
62	NN	O	O
%	NN	O	O
were	NN	O	O
males	NN	O	O
.	NN	O	O

Approximately	NN	O	O
75	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
receiving	NN	O	O
treatment	NN	O	O
for	NN	O	O
leukemia	NN	O	B
or	NN	O	O
lymphoma	NN	O	B
.	NN	O	O

Among	NN	O	O
the	NN	O	O
39	NN	O	O
reports	NN	O	O
that	NN	O	O
included	NN	O	O
information	NN	O	O
on	NN	O	O
race	NN	O	O
,	NN	O	O
the	NN	O	O
racial	NN	O	O
distribution	NN	O	O
was	NN	O	O
:	NN	O	O
1	NN	O	O
Black	NN	O	O
,	NN	O	O
3	NN	O	O
Caucasian	NN	O	O
,	NN	O	O
and	NN	O	O
35	NN	O	O
Asian	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Our	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
Asian	NN	O	O
patients	NN	O	O
may	NN	O	O
be	NN	O	O
at	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
hyponatremia	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
SIADH	NN	O	B
associated	NN	O	O
with	NN	O	O
vincristine	NN	O	O
use	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
overall	NN	O	O
reported	NN	O	O
rate	NN	O	O
of	NN	O	O
SIADH	NN	O	B
associated	NN	O	O
with	NN	O	O
vincristine	NN	O	O
is	NN	O	O
very	NN	O	O
low	NN	O	O
,	NN	O	O
physicians	NN	O	O
caring	NN	O	O
for	NN	O	O
Asian	NN	O	O
oncology	NN	O	O
patients	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
potential	NN	O	O
serious	NN	O	O
but	NN	O	O
reversible	NN	O	O
adverse	NN	O	O
event	NN	O	O
.	NN	O	O

Delayed	NN	O	O
toxicity	NN	O	B
of	NN	O	O
cyclophosphamide	NN	O	O
on	NN	O	O
the	NN	O	O
bladder	NN	O	O
of	NN	O	O
DBA	NN	O	O
/	NN	O	O
2	NN	O	O
and	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
female	NN	O	O
mouse	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
describes	NN	O	O
the	NN	O	O
delayed	NN	O	O
development	NN	O	O
of	NN	O	O
a	NN	O	O
severe	NN	O	O
bladder	NN	O	O
pathology	NN	O	O
in	NN	O	O
a	NN	O	O
susceptible	NN	O	O
strain	NN	O	O
of	NN	O	O
mice	NN	O	O
(	NN	O	O
DBA	NN	O	O
/	NN	O	O
2	NN	O	O
)	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
a	NN	O	O
resistant	NN	O	O
strain	NN	O	O
(	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
)	NN	O	O
when	NN	O	O
both	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
single	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
dose	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	O
(	NN	O	O
CY	NN	O	O
)	NN	O	O
.	NN	O	O

Inbred	NN	O	O
DBA	NN	O	O
/	NN	O	O
2	NN	O	O
and	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
female	NN	O	O
mice	NN	O	O
were	NN	O	O
injected	NN	O	O
with	NN	O	O
CY	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
on	NN	O	O
the	NN	O	O
bladder	NN	O	O
was	NN	O	O
assessed	NN	O	O
during	NN	O	O
100	NN	O	O
days	NN	O	O
by	NN	O	O
light	NN	O	O
microscopy	NN	O	O
using	NN	O	O
different	NN	O	O
staining	NN	O	O
procedures	NN	O	O
,	NN	O	O
and	NN	O	O
after	NN	O	O
30	NN	O	O
days	NN	O	O
by	NN	O	O
conventional	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
.	NN	O	O

Early	NN	O	O
CY	NN	O	O
toxicity	NN	O	B
caused	NN	O	O
a	NN	O	O
typical	NN	O	O
haemorrhagic	NN	O	B
cystitis	NN	O	B
in	NN	O	O
both	NN	O	O
strains	NN	O	O
that	NN	O	O
was	NN	O	O
completely	NN	O	O
repaired	NN	O	O
in	NN	O	O
about	NN	O	O
7	NN	O	O
-	NN	O	O
10	NN	O	O
days	NN	O	O
.	NN	O	O

After	NN	O	O
30	NN	O	O
days	NN	O	O
of	NN	O	O
CY	NN	O	O
injection	NN	O	O
ulcerous	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
ulcerous	NN	O	O
forms	NN	O	O
of	NN	O	O
chronic	NN	O	O
cystitis	NN	O	B
appeared	NN	O	O
in	NN	O	O
86	NN	O	O
%	NN	O	O
of	NN	O	O
DBA	NN	O	O
/	NN	O	O
2	NN	O	O
mice	NN	O	O
but	NN	O	O
only	NN	O	O
in	NN	O	O
4	NN	O	O
%	NN	O	O
of	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
mice	NN	O	O
.	NN	O	O

Delayed	NN	O	O
cystitis	NN	O	B
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
infiltration	NN	O	O
and	NN	O	O
transepithelial	NN	O	O
passage	NN	O	O
into	NN	O	O
the	NN	O	O
lumen	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
cells	NN	O	O
and	NN	O	O
by	NN	O	O
frequent	NN	O	O
exfoliation	NN	O	O
of	NN	O	O
the	NN	O	O
urothelium	NN	O	O
.	NN	O	O

Mast	NN	O	O
cells	NN	O	O
appeared	NN	O	O
in	NN	O	O
the	NN	O	O
connective	NN	O	O
and	NN	O	O
muscular	NN	O	O
layers	NN	O	O
of	NN	O	O
the	NN	O	O
bladder	NN	O	O
at	NN	O	O
a	NN	O	O
much	NN	O	O
higher	NN	O	O
number	NN	O	O
in	NN	O	O
DBA	NN	O	O
/	NN	O	O
2	NN	O	O
mice	NN	O	O
than	NN	O	O
in	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
mice	NN	O	O
or	NN	O	O
untreated	NN	O	O
controls	NN	O	O
.	NN	O	O

Electron	NN	O	O
microscopy	NN	O	O
disclosed	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
the	NN	O	O
typical	NN	O	O
discoidal	NN	O	O
vesicles	NN	O	O
normally	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
cytoplasm	NN	O	O
of	NN	O	O
surface	NN	O	O
cells	NN	O	O
.	NN	O	O

Instead	NN	O	O
,	NN	O	O
numerous	NN	O	O
abnormal	NN	O	O
vesicles	NN	O	O
containing	NN	O	O
one	NN	O	O
or	NN	O	O
several	NN	O	O
dark	NN	O	O
granules	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
cytoplasm	NN	O	O
of	NN	O	O
cells	NN	O	O
from	NN	O	O
all	NN	O	O
the	NN	O	O
epithelial	NN	O	O
layers	NN	O	O
.	NN	O	O

Delayed	NN	O	O
cystitis	NN	O	B
still	NN	O	O
persisted	NN	O	O
in	NN	O	O
DBA	NN	O	O
/	NN	O	O
2	NN	O	O
mice	NN	O	O
100	NN	O	O
days	NN	O	O
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
delayed	NN	O	O
toxicity	NN	O	B
of	NN	O	O
CY	NN	O	O
in	NN	O	O
female	NN	O	O
DBA	NN	O	O
/	NN	O	O
2	NN	O	O
mice	NN	O	O
causes	NN	O	O
a	NN	O	O
bladder	NN	O	O
pathology	NN	O	O
that	NN	O	O
is	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
mice	NN	O	O
.	NN	O	O

This	NN	O	O
pathology	NN	O	O
resembles	NN	O	O
interstitial	NN	O	B
cystitis	NN	O	I
in	NN	O	O
humans	NN	O	O
and	NN	O	O
could	NN	O	O
perhaps	NN	O	O
be	NN	O	O
used	NN	O	O
as	NN	O	O
an	NN	O	O
animal	NN	O	O
model	NN	O	O
for	NN	O	O
studies	NN	O	O
on	NN	O	O
the	NN	O	O
disease	NN	O	O
.	NN	O	O

High	NN	O	O
-	NN	O	O
dose	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
/	NN	O	O
folinic	NN	O	O
acid	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
three	NN	O	O
-	NN	O	O
weekly	NN	O	O
mitomycin	NN	O	O
C	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
advanced	NN	O	O
gastric	NN	O	B
cancer	NN	O	I
.	NN	O	O

A	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
)	NN	O	O
and	NN	O	O
folinic	NN	O	O
acid	NN	O	O
(	NN	O	O
FA	NN	O	O
)	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
several	NN	O	O
new	NN	O	O
multidrug	NN	O	O
chemotherapy	NN	O	O
regimens	NN	O	O
in	NN	O	O
advanced	NN	O	O
gastric	NN	O	B
cancer	NN	O	I
(	NN	O	O
AGC	NN	O	B
)	NN	O	O
has	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
effective	NN	O	O
,	NN	O	O
with	NN	O	O
low	NN	O	O
toxicity	NN	O	B
.	NN	O	O

In	NN	O	O
a	NN	O	O
previous	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
with	NN	O	O
3	NN	O	O
-	NN	O	O
weekly	NN	O	O
bolus	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
,	NN	O	O
FA	NN	O	O
and	NN	O	O
mitomycin	NN	O	O
C	NN	O	O
(	NN	O	O
MMC	NN	O	O
)	NN	O	O
we	NN	O	O
found	NN	O	O
a	NN	O	O
low	NN	O	O
toxicity	NN	O	B
rate	NN	O	O
and	NN	O	O
response	NN	O	O
rates	NN	O	O
comparable	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
regimens	NN	O	O
such	NN	O	O
as	NN	O	O
ELF	NN	O	O
,	NN	O	O
FAM	NN	O	O
or	NN	O	O
FAMTX	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
promising	NN	O	O
median	NN	O	O
overall	NN	O	O
survival	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
improve	NN	O	O
this	NN	O	O
MMC	NN	O	O
-	NN	O	O
dependent	NN	O	O
schedule	NN	O	O
we	NN	O	O
initiated	NN	O	O
a	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
/	NN	O	O
FA	NN	O	O
and	NN	O	O
3	NN	O	O
-	NN	O	O
weekly	NN	O	O
bolus	NN	O	O
MMC	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
From	NN	O	O
February	NN	O	O
,	NN	O	O
1998	NN	O	O
to	NN	O	O
September	NN	O	O
,	NN	O	O
2000	NN	O	O
we	NN	O	O
recruited	NN	O	O
33	NN	O	O
patients	NN	O	O
with	NN	O	O
AGC	NN	O	B
to	NN	O	O
receive	NN	O	O
weekly	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
2	NN	O	O
,	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
preceded	NN	O	O
by	NN	O	O
2	NN	O	O
-	NN	O	O
hour	NN	O	O
FA	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
for	NN	O	O
6	NN	O	O
weeks	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
week	NN	O	O
rest	NN	O	O
period	NN	O	O
.	NN	O	O

Bolus	NN	O	O
MMC	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
was	NN	O	O
added	NN	O	O
in	NN	O	O
3	NN	O	O
-	NN	O	O
weekly	NN	O	O
intervals	NN	O	O
.	NN	O	O

Treatment	NN	O	O
given	NN	O	O
on	NN	O	O
an	NN	O	O
outpatient	NN	O	O
basis	NN	O	O
,	NN	O	O
using	NN	O	O
portable	NN	O	O
pump	NN	O	O
systems	NN	O	O
,	NN	O	O
was	NN	O	O
repeated	NN	O	O
on	NN	O	O
day	NN	O	O
57	NN	O	O
.	NN	O	O

Patients	NN	O	O
'	NN	O	O
characteristics	NN	O	O
were	NN	O	O
:	NN	O	O
male	NN	O	O
/	NN	O	O
female	NN	O	O
ratio	NN	O	O
20	NN	O	O
/	NN	O	O
13	NN	O	O
;	NN	O	O
median	NN	O	O
age	NN	O	O
57	NN	O	O
(	NN	O	O
27	NN	O	O
-	NN	O	O
75	NN	O	O
)	NN	O	O
years	NN	O	O
;	NN	O	O
median	NN	O	O
WHO	NN	O	O
status	NN	O	O
1	NN	O	O
(	NN	O	O
0	NN	O	O
-	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

18	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
primary	NN	O	O
AGC	NN	O	B
,	NN	O	O
and	NN	O	O
15	NN	O	O
showed	NN	O	O
a	NN	O	O
relapsed	NN	O	O
AGC	NN	O	B
.	NN	O	O

Median	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
was	NN	O	O
11	NN	O	O
.	NN	O	O
8	NN	O	O
months	NN	O	O
(	NN	O	O
range	NN	O	O
of	NN	O	O
those	NN	O	O
surviving	NN	O	O
:	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
11	NN	O	O
.	NN	O	O
8	NN	O	O
months	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
32	NN	O	O
patients	NN	O	O
were	NN	O	O
evaluable	NN	O	O
for	NN	O	O
response	NN	O	O
-	NN	O	O
complete	NN	O	O
remission	NN	O	O
9	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
3	NN	O	O
)	NN	O	O
,	NN	O	O
partial	NN	O	O
remission	NN	O	O
45	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
15	NN	O	O
)	NN	O	O
,	NN	O	O
no	NN	O	O
change	NN	O	O
27	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
9	NN	O	O
)	NN	O	O
,	NN	O	O
progressive	NN	O	O
disease	NN	O	O
15	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
5	NN	O	O
)	NN	O	O
.	NN	O	O

Median	NN	O	O
overall	NN	O	O
survival	NN	O	O
time	NN	O	O
was	NN	O	O
10	NN	O	O
.	NN	O	O
2	NN	O	O
months	NN	O	O
[	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	NN	O	O
CI	NN	O	O
)	NN	O	O
:	NN	O	O
8	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
11	NN	O	O
.	NN	O	O
6	NN	O	O
]	NN	O	O
,	NN	O	O
and	NN	O	O
median	NN	O	O
progression	NN	O	O
-	NN	O	O
free	NN	O	O
survival	NN	O	O
time	NN	O	O
was	NN	O	O
7	NN	O	O
.	NN	O	O
6	NN	O	O
months	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
4	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
10	NN	O	O
.	NN	O	O
9	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
worst	NN	O	O
toxicities	NN	O	B
(	NN	O	O
%	NN	O	O
)	NN	O	O
observed	NN	O	O
were	NN	O	O
(	NN	O	O
CTC	NN	O	O
-	NN	O	O
NCI	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
/	NN	O	O
3	NN	O	O
)	NN	O	O
:	NN	O	O
leukopenia	NN	O	B
45	NN	O	O
.	NN	O	O
5	NN	O	O
/	NN	O	O
18	NN	O	O
.	NN	O	O
2	NN	O	O
/	NN	O	O
6	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
thrombocytopenia	NN	O	B
33	NN	O	O
.	NN	O	O
3	NN	O	O
/	NN	O	O
9	NN	O	O
.	NN	O	O
1	NN	O	O
/	NN	O	O
6	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
vomitus	NN	O	B
24	NN	O	O
.	NN	O	O
2	NN	O	O
/	NN	O	O
9	NN	O	O
.	NN	O	O
1	NN	O	O
/	NN	O	O
0	NN	O	O
,	NN	O	O
diarrhea	NN	O	B
36	NN	O	O
.	NN	O	O
4	NN	O	O
/	NN	O	O
6	NN	O	O
.	NN	O	O
1	NN	O	O
/	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
,	NN	O	O
stomatitis	NN	O	B
18	NN	O	O
.	NN	O	O
2	NN	O	O
/	NN	O	O
9	NN	O	O
.	NN	O	O
1	NN	O	O
/	NN	O	O
0	NN	O	O
,	NN	O	O
hand	NN	O	B
-	NN	O	I
foot	NN	O	I
syndrome	NN	O	I
12	NN	O	O
.	NN	O	O
1	NN	O	O
/	NN	O	O
0	NN	O	O
/	NN	O	O
0	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
developed	NN	O	O
hemolytic	NN	O	B
-	NN	O	I
uremic	NN	O	I
syndrome	NN	O	I
(	NN	O	O
HUS	NN	O	B
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
High	NN	O	O
-	NN	O	O
dose	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
/	NN	O	O
FA	NN	O	O
/	NN	O	O
MMC	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
and	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
outpatient	NN	O	O
regimen	NN	O	O
for	NN	O	O
AGC	NN	O	B
(	NN	O	O
objective	NN	O	O
response	NN	O	O
rate	NN	O	O
54	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

It	NN	O	O
may	NN	O	O
serve	NN	O	O
as	NN	O	O
an	NN	O	O
alternative	NN	O	O
to	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
containing	NN	O	O
regimens	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
it	NN	O	O
has	NN	O	O
to	NN	O	O
be	NN	O	O
considered	NN	O	O
that	NN	O	O
possibly	NN	O	O
HUS	NN	O	B
may	NN	O	O
occur	NN	O	O
.	NN	O	O

Persistent	NN	O	O
sterile	NN	O	O
leukocyturia	NN	O	B
is	NN	O	O
associated	NN	O	O
with	NN	O	O
impaired	NN	O	B
renal	NN	O	I
function	NN	O	I
in	NN	O	O
human	NN	O	B
immunodeficiency	NN	O	I
virus	NN	O	I
type	NN	O	I
1	NN	O	I
-	NN	O	I
infected	NN	O	I
children	NN	O	O
treated	NN	O	O
with	NN	O	O
indinavir	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Prolonged	NN	O	O
administration	NN	O	O
of	NN	O	O
indinavir	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
renal	NN	O	O
complications	NN	O	O
in	NN	O	O
adults	NN	O	O
.	NN	O	O

These	NN	O	O
well	NN	O	O
-	NN	O	O
documented	NN	O	O
side	NN	O	O
effects	NN	O	O
have	NN	O	O
restricted	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
this	NN	O	O
potent	NN	O	O
protease	NN	O	O
inhibitor	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
A	NN	O	O
prospective	NN	O	O
study	NN	O	O
to	NN	O	O
monitor	NN	O	O
indinavir	NN	O	O
-	NN	O	O
related	NN	O	O
nephrotoxicity	NN	O	B
in	NN	O	O
a	NN	O	O
cohort	NN	O	O
of	NN	O	O
30	NN	O	O
human	NN	O	B
immunodeficiency	NN	O	I
virus	NN	O	I
type	NN	O	I
1	NN	O	I
-	NN	O	I
infected	NN	O	I
children	NN	O	O
treated	NN	O	O
with	NN	O	O
indinavir	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Urinary	NN	O	O
pH	NN	O	O
,	NN	O	O
albumin	NN	O	O
,	NN	O	O
creatinine	NN	O	O
,	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
erythrocytes	NN	O	O
,	NN	O	O
leukocytes	NN	O	O
,	NN	O	O
bacteria	NN	O	O
and	NN	O	O
crystals	NN	O	O
,	NN	O	O
and	NN	O	O
culture	NN	O	O
were	NN	O	O
analyzed	NN	O	O
every	NN	O	O
3	NN	O	O
months	NN	O	O
for	NN	O	O
96	NN	O	O
weeks	NN	O	O
.	NN	O	O

Serum	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
were	NN	O	O
routinely	NN	O	O
determined	NN	O	O
at	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
points	NN	O	O
.	NN	O	O

Steady	NN	O	O
-	NN	O	O
state	NN	O	O
pharmacokinetics	NN	O	O
of	NN	O	O
indinavir	NN	O	O
were	NN	O	O
done	NN	O	O
at	NN	O	O
week	NN	O	O
4	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
indinavir	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
cumulative	NN	O	O
incidence	NN	O	O
of	NN	O	O
persistent	NN	O	O
sterile	NN	O	O
leukocyturia	NN	O	B
(	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
75	NN	O	O
cells	NN	O	O
/	NN	O	O
micro	NN	O	O
L	NN	O	O
in	NN	O	O
at	NN	O	O
least	NN	O	O
2	NN	O	O
consecutive	NN	O	O
visits	NN	O	O
)	NN	O	O
after	NN	O	O
96	NN	O	O
weeks	NN	O	O
was	NN	O	O
53	NN	O	O
%	NN	O	O
.	NN	O	O

Persistent	NN	O	O
sterile	NN	O	O
leukocyturia	NN	O	B
was	NN	O	O
frequently	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
mild	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
urine	NN	O	O
albumin	NN	O	O
/	NN	O	O
creatinine	NN	O	O
ratio	NN	O	O
and	NN	O	O
by	NN	O	O
microscopic	NN	O	O
hematuria	NN	O	B
.	NN	O	O

The	NN	O	O
cumulative	NN	O	O
incidence	NN	O	O
of	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
>	NN	O	O
50	NN	O	O
%	NN	O	O
above	NN	O	O
normal	NN	O	O
was	NN	O	O
33	NN	O	O
%	NN	O	O
after	NN	O	O
96	NN	O	O
weeks	NN	O	O
.	NN	O	O

Children	NN	O	O
with	NN	O	O
persistent	NN	O	O
sterile	NN	O	O
leukocyturia	NN	O	B
more	NN	O	O
frequently	NN	O	O
had	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
of	NN	O	O
50	NN	O	O
%	NN	O	O
above	NN	O	O
normal	NN	O	O
than	NN	O	O
those	NN	O	O
children	NN	O	O
without	NN	O	O
persistent	NN	O	O
sterile	NN	O	O
leukocyturia	NN	O	B
.	NN	O	O

In	NN	O	O
children	NN	O	O
younger	NN	O	O
than	NN	O	O
5	NN	O	O
.	NN	O	O
6	NN	O	O
years	NN	O	O
,	NN	O	O
persistent	NN	O	O
sterile	NN	O	O
leukocyturia	NN	O	B
was	NN	O	O
significantly	NN	O	O
more	NN	O	O
frequent	NN	O	O
than	NN	O	O
in	NN	O	O
older	NN	O	O
children	NN	O	O
.	NN	O	O

A	NN	O	O
higher	NN	O	O
cumulative	NN	O	O
incidence	NN	O	O
of	NN	O	O
persistent	NN	O	O
leukocyturia	NN	O	B
was	NN	O	O
found	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
an	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
curve	NN	O	O
>	NN	O	O
19	NN	O	O
mg	NN	O	O
/	NN	O	O
L	NN	O	O
x	NN	O	O
h	NN	O	O
or	NN	O	O
a	NN	O	O
peak	NN	O	O
serum	NN	O	O
level	NN	O	O
of	NN	O	O
indinavir	NN	O	O
>	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
L	NN	O	O
.	NN	O	O

In	NN	O	O
4	NN	O	O
children	NN	O	O
,	NN	O	O
indinavir	NN	O	O
was	NN	O	O
discontinued	NN	O	O
because	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

Subsequently	NN	O	O
,	NN	O	O
the	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
decreased	NN	O	O
,	NN	O	O
the	NN	O	O
urine	NN	O	O
albumin	NN	O	O
/	NN	O	O
creatinine	NN	O	O
ratios	NN	O	O
returned	NN	O	O
to	NN	O	O
zero	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
leukocyturia	NN	O	B
disappeared	NN	O	O
within	NN	O	O
3	NN	O	O
months	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Children	NN	O	O
treated	NN	O	O
with	NN	O	O
indinavir	NN	O	O
have	NN	O	O
a	NN	O	O
high	NN	O	O
cumulative	NN	O	O
incidence	NN	O	O
of	NN	O	O
persistent	NN	O	O
sterile	NN	O	O
leukocyturia	NN	O	B
.	NN	O	O

Children	NN	O	O
with	NN	O	O
persistent	NN	O	O
sterile	NN	O	O
leukocyturia	NN	O	B
more	NN	O	O
frequently	NN	O	O
had	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
of	NN	O	O
>	NN	O	O
50	NN	O	O
%	NN	O	O
above	NN	O	O
normal	NN	O	O
.	NN	O	O

Younger	NN	O	O
children	NN	O	O
have	NN	O	O
an	NN	O	O
additional	NN	O	O
risk	NN	O	O
for	NN	O	O
renal	NN	O	O
complications	NN	O	O
.	NN	O	O

The	NN	O	O
impairment	NN	O	B
of	NN	O	I
the	NN	O	I
renal	NN	O	I
function	NN	O	I
in	NN	O	O
these	NN	O	O
children	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
clinical	NN	O	O
symptoms	NN	O	O
of	NN	O	O
nephrolithiasis	NN	O	B
.	NN	O	O

Indinavir	NN	O	O
-	NN	O	O
associated	NN	O	O
nephrotoxicity	NN	O	B
must	NN	O	O
be	NN	O	O
monitored	NN	O	O
closely	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
risk	NN	O	O
factors	NN	O	O
such	NN	O	O
as	NN	O	O
persistent	NN	O	O
sterile	NN	O	O
leukocyturia	NN	O	B
,	NN	O	O
age	NN	O	O
<	NN	O	O
5	NN	O	O
.	NN	O	O
6	NN	O	O
years	NN	O	O
,	NN	O	O
an	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
curve	NN	O	O
of	NN	O	O
indinavir	NN	O	O
>	NN	O	O
19	NN	O	O
mg	NN	O	O
/	NN	O	O
L	NN	O	O
x	NN	O	O
h	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
C	NN	O	O
(	NN	O	O
max	NN	O	O
)	NN	O	O
>	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
L	NN	O	O
.	NN	O	O

Utility	NN	O	O
of	NN	O	O
troponin	NN	O	O
I	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
.	NN	O	O

Baseline	NN	O	O
electrocardiogram	NN	O	O
abnormalities	NN	O	O
and	NN	O	O
market	NN	O	O
elevations	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
myocardial	NN	O	B
necrosis	NN	O	I
make	NN	O	O
accurate	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
(	NN	O	O
MI	NN	O	B
)	NN	O	O
difficult	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
.	NN	O	O

Troponin	NN	O	O
sampling	NN	O	O
may	NN	O	O
offer	NN	O	O
greater	NN	O	O
diagnostic	NN	O	O
utility	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
outcomes	NN	O	O
based	NN	O	O
on	NN	O	O
troponin	NN	O	O
positivity	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
chest	NN	O	B
pain	NN	O	I
admitted	NN	O	O
for	NN	O	O
exclusion	NN	O	O
of	NN	O	O
MI	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Outcomes	NN	O	O
were	NN	O	O
examined	NN	O	O
in	NN	O	O
patients	NN	O	O
admitted	NN	O	O
for	NN	O	O
possible	NN	O	O
MI	NN	O	B
after	NN	O	O
cocaine	NN	O	O
use	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
underwent	NN	O	O
a	NN	O	O
rapid	NN	O	O
rule	NN	O	O
-	NN	O	O
in	NN	O	O
protocol	NN	O	O
that	NN	O	O
included	NN	O	O
serial	NN	O	O
sampling	NN	O	O
of	NN	O	O
creatine	NN	O	O
kinase	NN	O	O
(	NN	O	O
CK	NN	O	O
)	NN	O	O
,	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
,	NN	O	O
and	NN	O	O
cardiac	NN	O	O
troponin	NN	O	O
I	NN	O	O
(	NN	O	O
cTnI	NN	O	O
)	NN	O	O
over	NN	O	O
eight	NN	O	O
hours	NN	O	O
.	NN	O	O

Outcomes	NN	O	O
included	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
MI	NN	O	B
(	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
8	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
with	NN	O	O
a	NN	O	O
relative	NN	O	O
index	NN	O	O
[	NN	O	O
(	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
x	NN	O	O
100	NN	O	O
)	NN	O	O
/	NN	O	O
total	NN	O	O
CK	NN	O	O
]	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
4	NN	O	O
,	NN	O	O
cardiac	NN	O	B
death	NN	O	I
,	NN	O	O
and	NN	O	O
significant	NN	O	O
coronary	NN	O	B
disease	NN	O	I
(	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Of	NN	O	O
the	NN	O	O
246	NN	O	O
admitted	NN	O	O
patients	NN	O	O
,	NN	O	O
34	NN	O	O
(	NN	O	O
14	NN	O	O
%	NN	O	O
)	NN	O	O
met	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
criteria	NN	O	O
for	NN	O	O
MI	NN	O	B
and	NN	O	O
38	NN	O	O
(	NN	O	O
16	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
cTnI	NN	O	O
elevations	NN	O	O
.	NN	O	O

Angiography	NN	O	O
was	NN	O	O
performed	NN	O	O
in	NN	O	O
29	NN	O	O
of	NN	O	O
38	NN	O	O
patients	NN	O	O
who	NN	O	O
were	NN	O	O
cTnI	NN	O	O
-	NN	O	O
positive	NN	O	O
,	NN	O	O
with	NN	O	O
significant	NN	O	O
disease	NN	O	O
present	NN	O	O
in	NN	O	O
25	NN	O	O
(	NN	O	O
86	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Three	NN	O	O
of	NN	O	O
the	NN	O	O
four	NN	O	O
patients	NN	O	O
without	NN	O	O
significant	NN	O	O
disease	NN	O	O
who	NN	O	O
had	NN	O	O
cTnI	NN	O	O
elevations	NN	O	O
met	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
criteria	NN	O	O
for	NN	O	O
MI	NN	O	B
,	NN	O	O
and	NN	O	O
the	NN	O	O
other	NN	O	O
had	NN	O	O
a	NN	O	O
peak	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
level	NN	O	O
of	NN	O	O
13	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
.	NN	O	O

Sensitivities	NN	O	O
,	NN	O	O
specificities	NN	O	O
,	NN	O	O
and	NN	O	O
positive	NN	O	O
and	NN	O	O
negative	NN	O	O
likelihood	NN	O	O
ratios	NN	O	O
for	NN	O	O
predicting	NN	O	O
cardiac	NN	O	B
death	NN	O	I
or	NN	O	O
significant	NN	O	O
disease	NN	O	O
were	NN	O	O
high	NN	O	O
for	NN	O	O
both	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
MI	NN	O	B
and	NN	O	O
cTnI	NN	O	O
and	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Most	NN	O	O
patients	NN	O	O
with	NN	O	O
cTnI	NN	O	O
elevations	NN	O	O
meet	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
criteria	NN	O	O
for	NN	O	O
MI	NN	O	B
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
have	NN	O	O
a	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
underlying	NN	O	O
significant	NN	O	O
disease	NN	O	O
.	NN	O	O

Troponin	NN	O	O
appears	NN	O	O
to	NN	O	O
have	NN	O	O
an	NN	O	O
equivalent	NN	O	O
diagnostic	NN	O	O
accuracy	NN	O	O
compared	NN	O	O
with	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
for	NN	O	O
diagnosing	NN	O	O
necrosis	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
and	NN	O	O
suspected	NN	O	O
MI	NN	O	B
.	NN	O	O

Acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
due	NN	O	O
to	NN	O	O
nicergoline	NN	O	O
(	NN	O	O
Sermion	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
(	NN	O	O
AIN	NN	O	B
)	NN	O	O
due	NN	O	O
to	NN	O	O
nicergoline	NN	O	O
(	NN	O	O
Sermion	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
50	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
admitted	NN	O	O
to	NN	O	O
our	NN	O	O
hospital	NN	O	O
for	NN	O	O
fever	NN	O	B
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
.	NN	O	O

Before	NN	O	O
admission	NN	O	O
,	NN	O	O
he	NN	O	O
had	NN	O	O
been	NN	O	O
taking	NN	O	O
nicergoline	NN	O	O
and	NN	O	O
bendazac	NN	O	O
lysine	NN	O	O
due	NN	O	O
to	NN	O	O
retinal	NN	O	B
vein	NN	O	I
occlusion	NN	O	I
at	NN	O	O
ophthalmologic	NN	O	O
department	NN	O	O
.	NN	O	O

Thereafter	NN	O	O
,	NN	O	O
he	NN	O	O
experienced	NN	O	O
intermittent	NN	O	O
fever	NN	O	B
and	NN	O	O
skin	NN	O	B
rash	NN	O	I
.	NN	O	O

On	NN	O	O
admission	NN	O	O
,	NN	O	O
clinical	NN	O	O
symptoms	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
arthralgia	NN	O	B
and	NN	O	O
fever	NN	O	B
)	NN	O	O
and	NN	O	O
laboratory	NN	O	O
findings	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
eosinophilia	NN	O	B
and	NN	O	O
renal	NN	O	B
failure	NN	O	I
)	NN	O	O
suggested	NN	O	O
AIN	NN	O	B
,	NN	O	O
and	NN	O	O
which	NN	O	O
was	NN	O	O
confirmed	NN	O	O
by	NN	O	O
pathologic	NN	O	O
findings	NN	O	O
on	NN	O	O
renal	NN	O	O
biopsy	NN	O	O
.	NN	O	O

A	NN	O	O
lymphocyte	NN	O	O
transformation	NN	O	O
test	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
positive	NN	O	O
result	NN	O	O
against	NN	O	O
nicergoline	NN	O	O
.	NN	O	O

Treatment	NN	O	O
was	NN	O	O
consisted	NN	O	O
of	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
nicergoline	NN	O	O
and	NN	O	O
intravenous	NN	O	O
methylprednisolone	NN	O	O
,	NN	O	O
and	NN	O	O
his	NN	O	O
renal	NN	O	O
function	NN	O	O
was	NN	O	O
completely	NN	O	O
recovered	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
report	NN	O	O
of	NN	O	O
nicergoline	NN	O	O
-	NN	O	O
associated	NN	O	O
AIN	NN	O	B
.	NN	O	O

Neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
complicated	NN	O	O
by	NN	O	O
massive	NN	O	O
intestinal	NN	O	O
bleeding	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
.	NN	O	O

A	NN	O	O
patient	NN	O	O
with	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
(	NN	O	O
CRF	NN	O	B
)	NN	O	O
developed	NN	O	O
neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
(	NN	O	O
NMS	NN	O	B
)	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
risperidone	NN	O	O
and	NN	O	O
levomepromazine	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
the	NN	O	O
typical	NN	O	O
symptoms	NN	O	O
of	NN	O	O
NMS	NN	O	B
,	NN	O	O
massive	NN	O	O
intestinal	NN	O	O
bleeding	NN	O	B
was	NN	O	O
observed	NN	O	O
during	NN	O	O
the	NN	O	O
episode	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
suggests	NN	O	O
that	NN	O	O
NMS	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
CRF	NN	O	B
may	NN	O	O
be	NN	O	O
complicated	NN	O	O
by	NN	O	O
intestinal	NN	O	O
bleeding	NN	O	B
and	NN	O	O
needs	NN	O	O
special	NN	O	O
caution	NN	O	O
for	NN	O	O
this	NN	O	O
complication	NN	O	O
.	NN	O	O

Blood	NN	O	O
brain	NN	O	O
barrier	NN	O	O
in	NN	O	O
right	NN	O	O
-	NN	O	O
and	NN	O	O
left	NN	O	O
-	NN	O	O
pawed	NN	O	O
female	NN	O	O
rats	NN	O	O
assessed	NN	O	O
by	NN	O	O
a	NN	O	O
new	NN	O	O
staining	NN	O	O
method	NN	O	O
.	NN	O	O

The	NN	O	O
asymmetrical	NN	O	O
breakdown	NN	O	O
of	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
(	NN	O	O
BBB	NN	O	O
)	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
female	NN	O	O
rats	NN	O	O
.	NN	O	O

Paw	NN	O	O
preference	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
a	NN	O	O
food	NN	O	O
reaching	NN	O	O
test	NN	O	O
.	NN	O	O

Adrenaline	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
was	NN	O	O
used	NN	O	O
to	NN	O	O
destroy	NN	O	O
the	NN	O	O
BBB	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
evaluated	NN	O	O
using	NN	O	O
triphenyltetrazolium	NN	O	O
(	NN	O	O
TTC	NN	O	O
)	NN	O	O
staining	NN	O	O
of	NN	O	O
the	NN	O	O
brain	NN	O	O
slices	NN	O	O
just	NN	O	O
after	NN	O	O
giving	NN	O	O
adrenaline	NN	O	O
for	NN	O	O
30	NN	O	O
s	NN	O	O
.	NN	O	O

In	NN	O	O
normal	NN	O	O
rats	NN	O	O
,	NN	O	O
the	NN	O	O
whole	NN	O	O
brain	NN	O	O
sections	NN	O	O
exhibited	NN	O	O
complete	NN	O	O
staining	NN	O	O
with	NN	O	O
TTC	NN	O	O
.	NN	O	O

After	NN	O	O
adrenaline	NN	O	O
infusion	NN	O	O
for	NN	O	O
30	NN	O	O
s	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
large	NN	O	O
unstained	NN	O	O
areas	NN	O	O
in	NN	O	O
the	NN	O	O
left	NN	O	O
brain	NN	O	O
in	NN	O	O
right	NN	O	O
-	NN	O	O
pawed	NN	O	O
animals	NN	O	O
,	NN	O	O
and	NN	O	O
vice	NN	O	O
versa	NN	O	O
in	NN	O	O
left	NN	O	O
-	NN	O	O
pawed	NN	O	O
animals	NN	O	O
.	NN	O	O

Similar	NN	O	O
results	NN	O	O
were	NN	O	O
obtained	NN	O	O
in	NN	O	O
seizure	NN	O	B
-	NN	O	O
induced	NN	O	O
breakdown	NN	O	O
of	NN	O	O
BBB	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
were	NN	O	O
explained	NN	O	O
by	NN	O	O
an	NN	O	O
asymmetric	NN	O	O
cerebral	NN	O	O
blood	NN	O	O
flow	NN	O	O
depending	NN	O	O
upon	NN	O	O
the	NN	O	O
paw	NN	O	O
preference	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
suggested	NN	O	O
that	NN	O	O
this	NN	O	O
new	NN	O	O
method	NN	O	O
and	NN	O	O
the	NN	O	O
results	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
contralateral	NN	O	O
motor	NN	O	O
control	NN	O	O
that	NN	O	O
may	NN	O	O
be	NN	O	O
important	NN	O	O
in	NN	O	O
determining	NN	O	O
the	NN	O	O
dominant	NN	O	O
cerebral	NN	O	O
hemisphere	NN	O	O
in	NN	O	O
animals	NN	O	O
.	NN	O	O

Carvedilol	NN	O	O
protects	NN	O	O
against	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
mitochondrial	NN	O	O
cardiomyopathy	NN	O	B
.	NN	O	O

Several	NN	O	O
cytopathic	NN	O	O
mechanisms	NN	O	O
have	NN	O	O
been	NN	O	O
suggested	NN	O	O
to	NN	O	O
mediate	NN	O	O
the	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
cumulative	NN	O	O
and	NN	O	O
irreversible	NN	O	O
cardiomyopathy	NN	O	B
caused	NN	O	O
by	NN	O	O
doxorubicin	NN	O	O
.	NN	O	O

Recent	NN	O	O
evidence	NN	O	O
indicates	NN	O	O
that	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
mitochondrial	NN	O	B
dysfunction	NN	O	I
are	NN	O	O
key	NN	O	O
factors	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenic	NN	O	O
process	NN	O	O
.	NN	O	O

The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
investigation	NN	O	O
was	NN	O	O
to	NN	O	O
test	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
carvedilol	NN	O	O
,	NN	O	O
a	NN	O	O
nonselective	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
with	NN	O	O
potent	NN	O	O
antioxidant	NN	O	O
properties	NN	O	O
,	NN	O	O
protects	NN	O	O
against	NN	O	O
the	NN	O	O
cardiac	NN	O	O
and	NN	O	O
hepatic	NN	O	O
mitochondrial	NN	O	O
bioenergetic	NN	O	O
dysfunction	NN	O	O
associated	NN	O	O
with	NN	O	O
subchronic	NN	O	O
doxorubicin	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Heart	NN	O	O
and	NN	O	O
liver	NN	O	O
mitochondria	NN	O	O
were	NN	O	O
isolated	NN	O	O
from	NN	O	O
rats	NN	O	O
treated	NN	O	O
for	NN	O	O
7	NN	O	O
weeks	NN	O	O
with	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
sc	NN	O	O
/	NN	O	O
week	NN	O	O
)	NN	O	O
,	NN	O	O
carvedilol	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
/	NN	O	O
week	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
drugs	NN	O	O
.	NN	O	O

Heart	NN	O	O
mitochondria	NN	O	O
isolated	NN	O	O
from	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
exhibited	NN	O	O
depressed	NN	O	O
rates	NN	O	O
for	NN	O	O
state	NN	O	O
3	NN	O	O
respiration	NN	O	O
(	NN	O	O
336	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
26	NN	O	O
versus	NN	O	O
425	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
53	NN	O	O
natom	NN	O	O
O	NN	O	O
/	NN	O	O
min	NN	O	O
/	NN	O	O
mg	NN	O	O
protein	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
lower	NN	O	O
respiratory	NN	O	O
control	NN	O	O
ratio	NN	O	O
(	NN	O	O
RCR	NN	O	O
)	NN	O	O
(	NN	O	O
4	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
versus	NN	O	O
5	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
cardiac	NN	O	O
mitochondria	NN	O	O
isolated	NN	O	O
from	NN	O	O
saline	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Mitochondrial	NN	O	O
calcium	NN	O	O
-	NN	O	O
loading	NN	O	O
capacity	NN	O	O
and	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
NADH	NN	O	O
-	NN	O	O
dehydrogenase	NN	O	O
were	NN	O	O
also	NN	O	O
suppressed	NN	O	O
in	NN	O	O
cardiac	NN	O	O
mitochondria	NN	O	O
from	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Doxorubicin	NN	O	O
treatment	NN	O	O
also	NN	O	O
caused	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
RCR	NN	O	O
for	NN	O	O
liver	NN	O	O
mitochondria	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
versus	NN	O	O
5	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
for	NN	O	O
control	NN	O	O
rats	NN	O	O
)	NN	O	O
and	NN	O	O
inhibition	NN	O	O
of	NN	O	O
hepatic	NN	O	O
cytochrome	NN	O	O
oxidase	NN	O	O
activity	NN	O	O
.	NN	O	O

Coadministration	NN	O	O
of	NN	O	O
carvedilol	NN	O	O
decreased	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
cellular	NN	O	O
vacuolization	NN	O	O
in	NN	O	O
cardiac	NN	O	O
myocytes	NN	O	O
and	NN	O	O
prevented	NN	O	O
the	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
of	NN	O	O
doxorubicin	NN	O	O
on	NN	O	O
mitochondrial	NN	O	O
respiration	NN	O	O
in	NN	O	O
both	NN	O	O
heart	NN	O	O
and	NN	O	O
liver	NN	O	O
.	NN	O	O

Carvedilol	NN	O	O
also	NN	O	O
prevented	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
mitochondrial	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
loading	NN	O	O
capacity	NN	O	O
and	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
the	NN	O	O
respiratory	NN	O	O
complexes	NN	O	O
of	NN	O	O
heart	NN	O	O
mitochondria	NN	O	O
caused	NN	O	O
by	NN	O	O
doxorubicin	NN	O	O
.	NN	O	O

Carvedilol	NN	O	O
by	NN	O	O
itself	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
parameters	NN	O	O
measured	NN	O	O
for	NN	O	O
heart	NN	O	O
or	NN	O	O
liver	NN	O	O
mitochondria	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
this	NN	O	O
protection	NN	O	O
by	NN	O	O
carvedilol	NN	O	O
against	NN	O	O
both	NN	O	O
the	NN	O	O
structural	NN	O	O
and	NN	O	O
functional	NN	O	O
cardiac	NN	O	O
tissue	NN	O	O
damage	NN	O	O
may	NN	O	O
afford	NN	O	O
significant	NN	O	O
clinical	NN	O	O
advantage	NN	O	O
in	NN	O	O
minimizing	NN	O	O
the	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
mitochondrial	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
cardiomyopathy	NN	O	B
that	NN	O	O
accompanies	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
doxorubicin	NN	O	O
therapy	NN	O	O
in	NN	O	O
cancer	NN	O	B
patients	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
is	NN	O	O
more	NN	O	O
influenced	NN	O	O
by	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
than	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
.	NN	O	O

The	NN	O	O
influence	NN	O	O
of	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
and	NN	O	O
antagonists	NN	O	O
on	NN	O	O
cocaine	NN	O	O
-	NN	O	O
and	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
was	NN	O	O
examined	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

All	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
significantly	NN	O	O
decreased	NN	O	B
the	NN	O	I
locomotor	NN	O	I
activity	NN	O	I
in	NN	O	O
mice	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
effects	NN	O	O
were	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
.	NN	O	O

It	NN	O	O
seems	NN	O	O
that	NN	O	O
adenosine	NN	O	O
A1	NN	O	O
and	NN	O	O
A2	NN	O	O
receptors	NN	O	O
might	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
this	NN	O	O
reaction	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
all	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
:	NN	O	O
2	NN	O	O
-	NN	O	O
p	NN	O	O
-	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
carboxyethyl	NN	O	O
)	NN	O	O
phenethylamino	NN	O	O
-	NN	O	O
5	NN	O	O
'	NN	O	O
-	NN	O	O
N	NN	O	O
-	NN	O	O
ethylcarboxamidoadenosine	NN	O	O
(	NN	O	O
CGS	NN	O	O
21680	NN	O	O
)	NN	O	O
,	NN	O	O
A2A	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
,	NN	O	O
N6	NN	O	O
-	NN	O	O
cyclopentyladenosine	NN	O	O
(	NN	O	O
CPA	NN	O	O
)	NN	O	O
,	NN	O	O
A1	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
,	NN	O	O
and	NN	O	O
5	NN	O	O
'	NN	O	O
-	NN	O	O
N	NN	O	O
-	NN	O	O
ethylcarboxamidoadenosine	NN	O	O
(	NN	O	O
NECA	NN	O	O
)	NN	O	O
,	NN	O	O
A2	NN	O	O
/	NN	O	O
A1	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
significantly	NN	O	O
and	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
decreased	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
.	NN	O	O

CPA	NN	O	O
reduced	NN	O	O
cocaine	NN	O	O
action	NN	O	O
at	NN	O	O
the	NN	O	O
doses	NN	O	O
which	NN	O	O
,	NN	O	O
given	NN	O	O
alone	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
influence	NN	O	O
motility	NN	O	O
,	NN	O	O
while	NN	O	O
CGS	NN	O	O
21680	NN	O	O
and	NN	O	O
NECA	NN	O	O
decreased	NN	O	O
the	NN	O	O
action	NN	O	O
of	NN	O	O
cocaine	NN	O	O
at	NN	O	O
the	NN	O	O
doses	NN	O	O
which	NN	O	O
,	NN	O	O
given	NN	O	O
alone	NN	O	O
,	NN	O	O
decreased	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
in	NN	O	O
animals	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
both	NN	O	O
adenosine	NN	O	O
receptors	NN	O	O
in	NN	O	O
the	NN	O	O
action	NN	O	O
of	NN	O	O
cocaine	NN	O	O
although	NN	O	O
agonists	NN	O	O
of	NN	O	O
A1	NN	O	O
receptors	NN	O	O
seem	NN	O	O
to	NN	O	O
have	NN	O	O
stronger	NN	O	O
influence	NN	O	O
on	NN	O	O
it	NN	O	O
.	NN	O	O

The	NN	O	O
selective	NN	O	O
blockade	NN	O	O
of	NN	O	O
A2	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
by	NN	O	O
DMPX	NN	O	O
(	NN	O	O
3	NN	O	O
,	NN	O	O
7	NN	O	O
-	NN	O	O
dimethyl	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
propargylxanthine	NN	O	O
)	NN	O	O
significantly	NN	O	O
enhanced	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
of	NN	O	O
animals	NN	O	O
.	NN	O	O

Caffeine	NN	O	O
had	NN	O	O
similar	NN	O	O
action	NN	O	O
but	NN	O	O
the	NN	O	O
effect	NN	O	O
was	NN	O	O
not	NN	O	O
significant	NN	O	O
.	NN	O	O

CPT	NN	O	O
(	NN	O	O
8	NN	O	O
-	NN	O	O
cyclopentyltheophylline	NN	O	O
)	NN	O	O
-	NN	O	O
-	NN	O	O
A1	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
show	NN	O	O
any	NN	O	O
influence	NN	O	O
in	NN	O	O
this	NN	O	O
test	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
all	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
decreased	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
,	NN	O	O
but	NN	O	O
at	NN	O	O
the	NN	O	O
higher	NN	O	O
doses	NN	O	O
than	NN	O	O
those	NN	O	O
which	NN	O	O
were	NN	O	O
active	NN	O	O
in	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
.	NN	O	O

The	NN	O	O
selective	NN	O	O
blockade	NN	O	O
of	NN	O	O
A2	NN	O	O
adenosine	NN	O	O
receptors	NN	O	O
(	NN	O	O
DMPX	NN	O	O
)	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
blockade	NN	O	O
of	NN	O	O
adenosine	NN	O	O
receptors	NN	O	O
(	NN	O	O
caffeine	NN	O	O
)	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
action	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
in	NN	O	O
the	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
test	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
all	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
(	NN	O	O
A1	NN	O	O
and	NN	O	O
A2	NN	O	O
)	NN	O	O
reduce	NN	O	O
cocaine	NN	O	O
-	NN	O	O
and	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
and	NN	O	O
indicate	NN	O	O
that	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
is	NN	O	O
more	NN	O	O
influenced	NN	O	O
by	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
(	NN	O	O
particularly	NN	O	O
A1	NN	O	O
receptors	NN	O	O
)	NN	O	O
than	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
.	NN	O	O

Amiodarone	NN	O	O
and	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
bradyarrhythmia	NN	O	B
requiring	NN	O	O
permanent	NN	O	O
pacemaker	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
with	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
and	NN	O	O
prior	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
(	NN	O	O
AF	NN	O	B
)	NN	O	O
increases	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
bradyarrhythmia	NN	O	B
requiring	NN	O	O
a	NN	O	O
permanent	NN	O	O
pacemaker	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Reports	NN	O	O
of	NN	O	O
severe	NN	O	O
bradyarrhythmia	NN	O	B
during	NN	O	O
amiodarone	NN	O	O
therapy	NN	O	O
are	NN	O	O
infrequent	NN	O	O
and	NN	O	O
limited	NN	O	O
to	NN	O	O
studies	NN	O	O
assessing	NN	O	O
the	NN	O	O
therapy	NN	O	O
'	NN	O	O
s	NN	O	O
use	NN	O	O
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
ventricular	NN	O	B
arrhythmias	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
study	NN	O	O
cohort	NN	O	O
of	NN	O	O
8	NN	O	O
,	NN	O	O
770	NN	O	O
patients	NN	O	O
age	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
65	NN	O	O
years	NN	O	O
with	NN	O	O
a	NN	O	O
new	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
AF	NN	O	B
was	NN	O	O
identified	NN	O	O
from	NN	O	O
a	NN	O	O
provincewide	NN	O	O
database	NN	O	O
of	NN	O	O
Quebec	NN	O	O
residents	NN	O	O
with	NN	O	O
a	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
(	NN	O	O
MI	NN	O	B
)	NN	O	O
between	NN	O	O
1991	NN	O	O
and	NN	O	O
1999	NN	O	O
.	NN	O	O

Using	NN	O	O
a	NN	O	O
nested	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
design	NN	O	O
,	NN	O	O
477	NN	O	O
cases	NN	O	O
of	NN	O	O
bradyarrhythmia	NN	O	B
requiring	NN	O	O
a	NN	O	O
permanent	NN	O	O
pacemaker	NN	O	O
were	NN	O	O
matched	NN	O	O
(	NN	O	O
1	NN	O	O
:	NN	O	O
4	NN	O	O
)	NN	O	O
to	NN	O	O
1	NN	O	O
,	NN	O	O
908	NN	O	O
controls	NN	O	O
.	NN	O	O

Multivariable	NN	O	O
logistic	NN	O	O
regression	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
estimate	NN	O	O
the	NN	O	O
odds	NN	O	O
ratio	NN	O	O
(	NN	O	O
OR	NN	O	O
)	NN	O	O
of	NN	O	O
pacemaker	NN	O	O
insertion	NN	O	O
associated	NN	O	O
with	NN	O	O
amiodarone	NN	O	O
use	NN	O	O
,	NN	O	O
controlling	NN	O	O
for	NN	O	O
baseline	NN	O	O
risk	NN	O	O
factors	NN	O	O
and	NN	O	O
exposure	NN	O	O
to	NN	O	O
sotalol	NN	O	O
,	NN	O	O
Class	NN	O	O
I	NN	O	O
antiarrhythmic	NN	O	O
agents	NN	O	O
,	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
,	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
,	NN	O	O
and	NN	O	O
digoxin	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
amiodarone	NN	O	O
use	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
pacemaker	NN	O	O
insertion	NN	O	O
(	NN	O	O
OR	NN	O	O
:	NN	O	O
2	NN	O	O
.	NN	O	O
14	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
:	NN	O	O
1	NN	O	O
.	NN	O	O
30	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O
54	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
was	NN	O	O
modified	NN	O	O
by	NN	O	O
gender	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
greater	NN	O	O
risk	NN	O	O
in	NN	O	O
women	NN	O	O
versus	NN	O	O
men	NN	O	O
(	NN	O	O
OR	NN	O	O
:	NN	O	O
3	NN	O	O
.	NN	O	O
86	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
1	NN	O	O
.	NN	O	O
70	NN	O	O
to	NN	O	O
8	NN	O	O
.	NN	O	O
75	NN	O	O
vs	NN	O	O
.	NN	O	O
OR	NN	O	O
:	NN	O	O
1	NN	O	O
.	NN	O	O
52	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
80	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
89	NN	O	O
)	NN	O	O
.	NN	O	O

Digoxin	NN	O	O
was	NN	O	O
the	NN	O	O
only	NN	O	O
other	NN	O	O
medication	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
pacemaker	NN	O	O
insertion	NN	O	O
(	NN	O	O
OR	NN	O	O
:	NN	O	O
1	NN	O	O
.	NN	O	O
78	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
1	NN	O	O
.	NN	O	O
37	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
31	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
suggests	NN	O	O
that	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
with	NN	O	O
AF	NN	O	B
and	NN	O	O
a	NN	O	O
previous	NN	O	O
MI	NN	O	B
increases	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
bradyarrhythmia	NN	O	B
requiring	NN	O	O
a	NN	O	O
permanent	NN	O	O
pacemaker	NN	O	O
.	NN	O	O

The	NN	O	O
finding	NN	O	O
of	NN	O	O
an	NN	O	O
augmented	NN	O	O
risk	NN	O	O
of	NN	O	O
pacemaker	NN	O	O
insertion	NN	O	O
in	NN	O	O
elderly	NN	O	O
women	NN	O	O
receiving	NN	O	O
amiodarone	NN	O	O
requires	NN	O	O
further	NN	O	O
investigation	NN	O	O
.	NN	O	O

Indomethacin	NN	O	O
-	NN	O	O
induced	NN	O	O
morphologic	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
epithelium	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
morphologic	NN	O	O
changes	NN	O	O
in	NN	O	O
rat	NN	O	O
urothelium	NN	O	O
induced	NN	O	O
by	NN	O	O
indomethacin	NN	O	O
.	NN	O	O

Nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
is	NN	O	O
a	NN	O	O
poorly	NN	O	O
recognized	NN	O	O
and	NN	O	O
under	NN	O	O
-	NN	O	O
reported	NN	O	O
condition	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
tiaprofenic	NN	O	O
acid	NN	O	O
,	NN	O	O
indomethacin	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
this	NN	O	O
condition	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Three	NN	O	O
groups	NN	O	O
were	NN	O	O
established	NN	O	O
:	NN	O	O
a	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
,	NN	O	O
treated	NN	O	O
with	NN	O	O
one	NN	O	O
intraperitoneal	NN	O	O
injection	NN	O	O
of	NN	O	O
indomethacin	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
therapeutic	NN	O	O
dose	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
in	NN	O	O
which	NN	O	O
oral	NN	O	O
indomethacin	NN	O	O
was	NN	O	O
administered	NN	O	O
3	NN	O	O
.	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
daily	NN	O	O
for	NN	O	O
3	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
animals	NN	O	O
were	NN	O	O
then	NN	O	O
killed	NN	O	O
and	NN	O	O
the	NN	O	O
bladders	NN	O	O
removed	NN	O	O
for	NN	O	O
light	NN	O	O
and	NN	O	O
electron	NN	O	O
microscopic	NN	O	O
studies	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
light	NN	O	O
microscopic	NN	O	O
findings	NN	O	O
showed	NN	O	O
some	NN	O	O
focal	NN	O	O
epithelial	NN	O	O
degeneration	NN	O	O
that	NN	O	O
was	NN	O	O
more	NN	O	O
prominent	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
group	NN	O	O
.	NN	O	O

When	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
both	NN	O	O
indomethacin	NN	O	O
groups	NN	O	O
revealed	NN	O	O
statistically	NN	O	O
increased	NN	O	O
numbers	NN	O	O
of	NN	O	O
mast	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
mucosa	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
and	NN	O	O
penetration	NN	O	O
of	NN	O	O
lanthanum	NN	O	O
nitrate	NN	O	O
through	NN	O	O
intercellular	NN	O	O
areas	NN	O	O
of	NN	O	O
the	NN	O	O
epithelium	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
difference	NN	O	O
in	NN	O	O
mast	NN	O	O
cell	NN	O	O
counts	NN	O	O
between	NN	O	O
the	NN	O	O
high	NN	O	O
and	NN	O	O
therapeutic	NN	O	O
dose	NN	O	O
groups	NN	O	O
was	NN	O	O
also	NN	O	O
statistically	NN	O	O
significant	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Indomethacin	NN	O	O
resulted	NN	O	O
in	NN	O	O
histopathologic	NN	O	O
findings	NN	O	O
typical	NN	O	O
of	NN	O	O
interstitial	NN	O	B
cystitis	NN	O	I
,	NN	O	O
such	NN	O	O
as	NN	O	O
leaky	NN	O	O
bladder	NN	O	O
epithelium	NN	O	O
and	NN	O	O
mucosal	NN	O	O
mastocytosis	NN	O	B
.	NN	O	O

The	NN	O	O
true	NN	O	O
incidence	NN	O	O
of	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
in	NN	O	O
humans	NN	O	O
must	NN	O	O
be	NN	O	O
clarified	NN	O	O
by	NN	O	O
prospective	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O

An	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
of	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
thalidomide	NN	O	O
in	NN	O	O
androgen	NN	O	O
-	NN	O	O
independent	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
.	NN	O	O

The	NN	O	O
antiangiogenic	NN	O	O
effects	NN	O	O
of	NN	O	O
thalidomide	NN	O	O
have	NN	O	O
been	NN	O	O
assessed	NN	O	O
in	NN	O	O
clinical	NN	O	O
trials	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
various	NN	O	O
solid	NN	O	O
and	NN	O	O
haematological	NN	O	B
malignancies	NN	O	I
.	NN	O	O

Thalidomide	NN	O	O
blocks	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
angiogenic	NN	O	O
agents	NN	O	O
including	NN	O	O
bFGF	NN	O	O
,	NN	O	O
VEGF	NN	O	O
and	NN	O	O
IL	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O

We	NN	O	O
undertook	NN	O	O
an	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
study	NN	O	O
using	NN	O	O
thalidomide	NN	O	O
100	NN	O	O
mg	NN	O	O
once	NN	O	O
daily	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
6	NN	O	O
months	NN	O	O
in	NN	O	O
20	NN	O	O
men	NN	O	O
with	NN	O	O
androgen	NN	O	O
-	NN	O	O
independent	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
.	NN	O	O

The	NN	O	O
mean	NN	O	O
time	NN	O	O
of	NN	O	O
study	NN	O	O
was	NN	O	O
109	NN	O	O
days	NN	O	O
(	NN	O	O
median	NN	O	O
107	NN	O	O
,	NN	O	O
range	NN	O	O
4	NN	O	O
-	NN	O	O
184	NN	O	O
days	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
underwent	NN	O	O
regular	NN	O	O
measurement	NN	O	O
of	NN	O	O
prostate	NN	O	O
-	NN	O	O
specific	NN	O	O
antigen	NN	O	O
(	NN	O	O
PSA	NN	O	O
)	NN	O	O
,	NN	O	O
urea	NN	O	O
and	NN	O	O
electrolytes	NN	O	O
,	NN	O	O
serum	NN	O	O
bFGF	NN	O	O
and	NN	O	O
VEGF	NN	O	O
.	NN	O	O

Three	NN	O	O
men	NN	O	O
(	NN	O	O
15	NN	O	O
%	NN	O	O
)	NN	O	O
showed	NN	O	O
a	NN	O	O
decline	NN	O	O
in	NN	O	O
serum	NN	O	O
PSA	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
50	NN	O	O
%	NN	O	O
,	NN	O	O
sustained	NN	O	O
throughout	NN	O	O
treatment	NN	O	O
.	NN	O	O

Of	NN	O	O
16	NN	O	O
men	NN	O	O
treated	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
2	NN	O	O
months	NN	O	O
,	NN	O	O
six	NN	O	O
(	NN	O	O
37	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
showed	NN	O	O
a	NN	O	O
fall	NN	O	O
in	NN	O	O
absolute	NN	O	O
PSA	NN	O	O
by	NN	O	O
a	NN	O	O
median	NN	O	O
of	NN	O	O
48	NN	O	O
%	NN	O	O
.	NN	O	O

Increasing	NN	O	O
levels	NN	O	O
of	NN	O	O
serum	NN	O	O
bFGF	NN	O	O
and	NN	O	O
VEGF	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
progressive	NN	O	O
disease	NN	O	O
;	NN	O	O
five	NN	O	O
of	NN	O	O
six	NN	O	O
men	NN	O	O
who	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
fall	NN	O	O
in	NN	O	O
PSA	NN	O	O
also	NN	O	O
showed	NN	O	O
a	NN	O	O
decline	NN	O	O
in	NN	O	O
bFGF	NN	O	O
and	NN	O	O
VEGF	NN	O	O
levels	NN	O	O
,	NN	O	O
and	NN	O	O
three	NN	O	O
of	NN	O	O
four	NN	O	O
men	NN	O	O
with	NN	O	O
a	NN	O	O
rising	NN	O	O
PSA	NN	O	O
showed	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
both	NN	O	O
growth	NN	O	O
factors	NN	O	O
.	NN	O	O

Adverse	NN	O	O
effects	NN	O	O
included	NN	O	O
constipation	NN	O	B
,	NN	O	O
morning	NN	O	O
drowsiness	NN	O	B
,	NN	O	O
dizziness	NN	O	B
and	NN	O	O
rash	NN	O	B
,	NN	O	O
and	NN	O	O
resulted	NN	O	O
in	NN	O	O
withdrawal	NN	O	O
from	NN	O	O
the	NN	O	O
study	NN	O	O
by	NN	O	O
three	NN	O	O
men	NN	O	O
.	NN	O	O

Evidence	NN	O	O
of	NN	O	O
peripheral	NN	O	B
sensory	NN	O	I
neuropathy	NN	O	I
was	NN	O	O
found	NN	O	O
in	NN	O	O
nine	NN	O	O
of	NN	O	O
13	NN	O	O
men	NN	O	O
before	NN	O	O
treatment	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
seven	NN	O	O
men	NN	O	O
who	NN	O	O
completed	NN	O	O
six	NN	O	O
months	NN	O	O
on	NN	O	O
thalidomide	NN	O	O
,	NN	O	O
subclinical	NN	O	O
evidence	NN	O	O
of	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
was	NN	O	O
found	NN	O	O
in	NN	O	O
four	NN	O	O
before	NN	O	O
treatment	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
all	NN	O	O
seven	NN	O	O
at	NN	O	O
repeat	NN	O	O
testing	NN	O	O
.	NN	O	O

The	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
thalidomide	NN	O	O
may	NN	O	O
be	NN	O	O
an	NN	O	O
option	NN	O	O
for	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
failed	NN	O	O
other	NN	O	O
forms	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
provided	NN	O	O
close	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
is	NN	O	O
maintained	NN	O	O
for	NN	O	O
development	NN	O	O
of	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

Central	NN	O	B
nervous	NN	O	I
system	NN	O	I
toxicity	NN	O	I
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
levobupivacaine	NN	O	O
for	NN	O	O
lumbar	NN	O	O
plexus	NN	O	O
block	NN	O	O
:	NN	O	O
A	NN	O	O
report	NN	O	O
of	NN	O	O
two	NN	O	O
cases	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
OBJECTIVES	NN	O	O
:	NN	O	O
Central	NN	O	B
nervous	NN	O	I
system	NN	O	I
and	NN	O	I
cardiac	NN	O	I
toxicity	NN	O	I
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
local	NN	O	O
anesthetics	NN	O	O
is	NN	O	O
a	NN	O	O
recognized	NN	O	O
complication	NN	O	O
of	NN	O	O
regional	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

Levobupivacaine	NN	O	O
,	NN	O	O
the	NN	O	O
pure	NN	O	O
S	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
enantiomer	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
,	NN	O	O
was	NN	O	O
developed	NN	O	O
to	NN	O	O
improve	NN	O	O
the	NN	O	O
cardiac	NN	O	O
safety	NN	O	O
profile	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
2	NN	O	O
cases	NN	O	O
of	NN	O	O
grand	NN	O	B
mal	NN	O	I
seizures	NN	O	I
following	NN	O	O
accidental	NN	O	O
intravascular	NN	O	O
injection	NN	O	O
of	NN	O	O
levobupivacaine	NN	O	O
.	NN	O	O

CASE	NN	O	O
REPORT	NN	O	O
:	NN	O	O
Two	NN	O	O
patients	NN	O	O
presenting	NN	O	O
for	NN	O	O
elective	NN	O	O
orthopedic	NN	O	O
surgery	NN	O	O
of	NN	O	O
the	NN	O	O
lower	NN	O	O
limb	NN	O	O
underwent	NN	O	O
blockade	NN	O	O
of	NN	O	O
the	NN	O	O
lumbar	NN	O	O
plexus	NN	O	O
via	NN	O	O
the	NN	O	O
posterior	NN	O	O
approach	NN	O	O
.	NN	O	O

Immediately	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
levobupivacaine	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
with	NN	O	O
epinephrine	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
microgram	NN	O	O
/	NN	O	O
mL	NN	O	O
,	NN	O	O
the	NN	O	O
patients	NN	O	O
developed	NN	O	O
grand	NN	O	B
mal	NN	O	I
seizures	NN	O	I
,	NN	O	O
despite	NN	O	O
negative	NN	O	O
aspiration	NN	O	O
for	NN	O	O
blood	NN	O	O
and	NN	O	O
no	NN	O	O
clinical	NN	O	O
signs	NN	O	O
of	NN	O	O
intravenous	NN	O	O
epinephrine	NN	O	O
administration	NN	O	O
.	NN	O	O

The	NN	O	O
seizures	NN	O	B
were	NN	O	O
successfully	NN	O	O
treated	NN	O	O
with	NN	O	O
sodium	NN	O	O
thiopental	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
succinylcholine	NN	O	O
in	NN	O	O
1	NN	O	O
patient	NN	O	O
.	NN	O	O

Neither	NN	O	O
patient	NN	O	O
developed	NN	O	O
signs	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B
toxicity	NN	O	I
.	NN	O	O

Both	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
preoperatively	NN	O	O
with	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
antagonist	NN	O	O
medications	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
have	NN	O	O
masked	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
signs	NN	O	O
of	NN	O	O
the	NN	O	O
unintentional	NN	O	O
intravascular	NN	O	O
administration	NN	O	O
of	NN	O	O
levobupivacaine	NN	O	O
with	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Although	NN	O	O
levobupivacaine	NN	O	O
may	NN	O	O
have	NN	O	O
a	NN	O	O
safer	NN	O	O
cardiac	NN	O	B
toxicity	NN	O	I
profile	NN	O	O
than	NN	O	O
racemic	NN	O	O
bupivacaine	NN	O	O
,	NN	O	O
if	NN	O	O
adequate	NN	O	O
amounts	NN	O	O
of	NN	O	O
levobupivacaine	NN	O	O
reach	NN	O	O
the	NN	O	O
circulation	NN	O	O
,	NN	O	O
it	NN	O	O
will	NN	O	O
result	NN	O	O
in	NN	O	O
convulsions	NN	O	B
.	NN	O	O

Plasma	NN	O	O
concentrations	NN	O	O
sufficient	NN	O	O
to	NN	O	O
result	NN	O	O
in	NN	O	O
central	NN	O	B
nervous	NN	O	I
system	NN	O	I
toxicity	NN	O	I
did	NN	O	O
not	NN	O	O
produce	NN	O	O
manifestations	NN	O	O
of	NN	O	O
cardiac	NN	O	B
toxicity	NN	O	I
in	NN	O	O
these	NN	O	O
2	NN	O	O
patients	NN	O	O
.	NN	O	O

Amiodarone	NN	O	O
-	NN	O	O
induced	NN	O	O
torsade	NN	O	B
de	NN	O	I
pointes	NN	O	I
during	NN	O	O
bladder	NN	O	O
irrigation	NN	O	O
:	NN	O	O
an	NN	O	O
unusual	NN	O	O
presentation	NN	O	O
-	NN	O	O
-	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
early	NN	O	O
(	NN	O	O
within	NN	O	O
4	NN	O	O
days	NN	O	O
)	NN	O	O
development	NN	O	O
of	NN	O	O
torsade	NN	O	B
de	NN	O	I
pointes	NN	O	I
(	NN	O	O
TdP	NN	O	B
)	NN	O	O
associated	NN	O	O
with	NN	O	O
oral	NN	O	O
amiodarone	NN	O	O
therapy	NN	O	O
.	NN	O	O

Consistent	NN	O	O
with	NN	O	O
other	NN	O	O
reports	NN	O	O
this	NN	O	O
case	NN	O	O
of	NN	O	O
TdP	NN	O	B
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
context	NN	O	O
of	NN	O	O
multiple	NN	O	O
exacerbating	NN	O	O
factors	NN	O	O
including	NN	O	O
hypokalemia	NN	O	B
and	NN	O	O
digoxin	NN	O	O
excess	NN	O	O
.	NN	O	O

Transient	NN	O	O
prolongation	NN	O	O
of	NN	O	O
the	NN	O	O
QT	NN	O	O
during	NN	O	O
bladder	NN	O	O
irrigation	NN	O	O
prompted	NN	O	O
the	NN	O	O
episode	NN	O	O
of	NN	O	O
TdP	NN	O	B
.	NN	O	O

It	NN	O	O
is	NN	O	O
well	NN	O	O
known	NN	O	O
that	NN	O	O
bradycardia	NN	O	B
exacerbates	NN	O	O
acquired	NN	O	O
TdP	NN	O	B
.	NN	O	O

The	NN	O	O
authors	NN	O	O
speculate	NN	O	O
that	NN	O	O
the	NN	O	O
increased	NN	O	O
vagal	NN	O	O
tone	NN	O	O
during	NN	O	O
bladder	NN	O	O
irrigation	NN	O	O
,	NN	O	O
a	NN	O	O
vagal	NN	O	O
maneuver	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
context	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
therapy	NN	O	O
resulted	NN	O	O
in	NN	O	O
amiodarone	NN	O	O
-	NN	O	O
induced	NN	O	O
proarrhythmia	NN	O	B
.	NN	O	O

In	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
therapy	NN	O	O
,	NN	O	O
a	NN	O	O
second	NN	O	O
bladder	NN	O	O
irrigation	NN	O	O
did	NN	O	O
not	NN	O	O
induce	NN	O	O
TdP	NN	O	B
despite	NN	O	O
hypokalemia	NN	O	B
and	NN	O	O
hypomagnesemia	NN	O	B
.	NN	O	O

Anaesthetic	NN	O	O
complications	NN	O	O
associated	NN	O	O
with	NN	O	O
myotonia	NN	O	B
congenita	NN	O	I
:	NN	O	O
case	NN	O	O
study	NN	O	O
and	NN	O	O
comparison	NN	O	O
with	NN	O	O
other	NN	O	O
myotonic	NN	O	B
disorders	NN	O	I
.	NN	O	O

Myotonia	NN	O	B
congenita	NN	O	I
(	NN	O	O
MC	NN	O	B
)	NN	O	O
is	NN	O	O
caused	NN	O	O
by	NN	O	O
a	NN	O	O
defect	NN	O	O
in	NN	O	O
the	NN	O	O
skeletal	NN	O	O
muscle	NN	O	O
chloride	NN	O	O
channel	NN	O	O
function	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
cause	NN	O	O
sustained	NN	O	B
membrane	NN	O	I
depolarisation	NN	O	I
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
previously	NN	O	O
healthy	NN	O	O
32	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
who	NN	O	O
developed	NN	O	O
a	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
muscle	NN	O	B
spasm	NN	O	I
and	NN	O	O
secondary	NN	O	O
ventilation	NN	O	O
difficulties	NN	O	O
following	NN	O	O
a	NN	O	O
preoperative	NN	O	O
injection	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
.	NN	O	O

The	NN	O	O
muscle	NN	O	B
spasms	NN	O	I
disappeared	NN	O	O
spontaneously	NN	O	O
and	NN	O	O
the	NN	O	O
surgery	NN	O	O
proceeded	NN	O	O
without	NN	O	O
further	NN	O	O
problems	NN	O	O
.	NN	O	O

When	NN	O	O
subsequently	NN	O	O
questioned	NN	O	O
,	NN	O	O
she	NN	O	O
reported	NN	O	O
minor	NN	O	O
symptoms	NN	O	O
suggesting	NN	O	O
a	NN	O	O
myotonic	NN	O	B
condition	NN	O	I
.	NN	O	O

Myotonia	NN	O	B
was	NN	O	O
found	NN	O	O
on	NN	O	O
clinical	NN	O	O
examination	NN	O	O
and	NN	O	O
EMG	NN	O	O
.	NN	O	O

The	NN	O	O
diagnosis	NN	O	O
MC	NN	O	B
was	NN	O	O
confirmed	NN	O	O
genetically	NN	O	O
.	NN	O	O

Neither	NN	O	O
the	NN	O	O
patient	NN	O	O
nor	NN	O	O
the	NN	O	O
anaesthetist	NN	O	O
were	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
before	NN	O	O
this	NN	O	O
potentially	NN	O	O
lethal	NN	O	O
complication	NN	O	O
occurred	NN	O	O
.	NN	O	O

We	NN	O	O
give	NN	O	O
a	NN	O	O
brief	NN	O	O
overview	NN	O	O
of	NN	O	O
ion	NN	O	B
channel	NN	O	I
disorders	NN	O	I
including	NN	O	O
malignant	NN	O	B
hyperthermia	NN	O	I
and	NN	O	O
their	NN	O	O
anaesthetic	NN	O	O
considerations	NN	O	O
.	NN	O	O

Respiratory	NN	O	O
pattern	NN	O	O
in	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
epilepsy	NN	O	B
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
Apnea	NN	O	B
is	NN	O	O
known	NN	O	O
to	NN	O	O
occur	NN	O	O
during	NN	O	O
seizures	NN	O	B
,	NN	O	O
but	NN	O	O
systematic	NN	O	O
studies	NN	O	O
of	NN	O	O
ictal	NN	O	O
respiratory	NN	O	O
changes	NN	O	O
in	NN	O	O
adults	NN	O	O
are	NN	O	O
few	NN	O	O
.	NN	O	O

Data	NN	O	O
regarding	NN	O	O
respiratory	NN	O	O
pattern	NN	O	O
defects	NN	O	O
during	NN	O	O
interictal	NN	O	O
periods	NN	O	O
also	NN	O	O
are	NN	O	O
scarce	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
sought	NN	O	O
to	NN	O	O
generate	NN	O	O
information	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
the	NN	O	O
interictal	NN	O	O
period	NN	O	O
in	NN	O	O
animals	NN	O	O
with	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
epilepsy	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Twelve	NN	O	O
rats	NN	O	O
(	NN	O	O
six	NN	O	O
chronically	NN	O	O
epileptic	NN	O	B
animals	NN	O	O
and	NN	O	O
six	NN	O	O
controls	NN	O	O
)	NN	O	O
were	NN	O	O
anesthetized	NN	O	O
,	NN	O	O
given	NN	O	O
tracheotomies	NN	O	O
,	NN	O	O
and	NN	O	O
subjected	NN	O	O
to	NN	O	O
hyperventilation	NN	O	B
or	NN	O	O
hypoventilation	NN	O	O
conditions	NN	O	O
.	NN	O	O

Breathing	NN	O	O
movements	NN	O	O
caused	NN	O	O
changes	NN	O	O
in	NN	O	O
thoracic	NN	O	O
volume	NN	O	O
and	NN	O	O
forced	NN	O	O
air	NN	O	O
to	NN	O	O
flow	NN	O	O
tidally	NN	O	O
through	NN	O	O
a	NN	O	O
pneumotachograph	NN	O	O
.	NN	O	O

This	NN	O	O
flow	NN	O	O
was	NN	O	O
measured	NN	O	O
by	NN	O	O
using	NN	O	O
a	NN	O	O
differential	NN	O	O
pressure	NN	O	O
transducer	NN	O	O
,	NN	O	O
passed	NN	O	O
through	NN	O	O
a	NN	O	O
polygraph	NN	O	O
,	NN	O	O
and	NN	O	O
from	NN	O	O
this	NN	O	O
to	NN	O	O
a	NN	O	O
computer	NN	O	O
with	NN	O	O
custom	NN	O	O
software	NN	O	O
that	NN	O	O
derived	NN	O	O
ventilation	NN	O	O
(	NN	O	O
VE	NN	O	O
)	NN	O	O
,	NN	O	O
tidal	NN	O	O
volume	NN	O	O
(	NN	O	O
VT	NN	O	O
)	NN	O	O
,	NN	O	O
inspiratory	NN	O	O
time	NN	O	O
(	NN	O	O
TI	NN	O	O
)	NN	O	O
,	NN	O	O
expiratory	NN	O	O
time	NN	O	O
(	NN	O	O
TE	NN	O	O
)	NN	O	O
,	NN	O	O
breathing	NN	O	O
frequency	NN	O	O
(	NN	O	O
f	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
mean	NN	O	O
inspiratory	NN	O	O
flow	NN	O	O
(	NN	O	O
VT	NN	O	O
/	NN	O	O
TI	NN	O	O
)	NN	O	O
on	NN	O	O
a	NN	O	O
breath	NN	O	O
-	NN	O	O
by	NN	O	O
-	NN	O	O
breath	NN	O	O
basis	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
hyperventilation	NN	O	B
maneuver	NN	O	O
caused	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
spontaneous	NN	O	O
ventilation	NN	O	O
in	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
treated	NN	O	O
and	NN	O	O
control	NN	O	O
rats	NN	O	O
.	NN	O	O

Although	NN	O	O
VE	NN	O	O
had	NN	O	O
a	NN	O	O
similar	NN	O	O
decrease	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
epileptic	NN	O	B
group	NN	O	O
,	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
VE	NN	O	O
was	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
increase	NN	O	O
in	NN	O	O
TE	NN	O	O
peak	NN	O	O
in	NN	O	O
relation	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
animals	NN	O	O
.	NN	O	O

The	NN	O	O
hypoventilation	NN	O	O
maneuver	NN	O	O
led	NN	O	O
to	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
arterial	NN	O	O
Paco2	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
VE	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
epileptic	NN	O	B
group	NN	O	O
,	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
VE	NN	O	O
was	NN	O	O
mediated	NN	O	O
by	NN	O	O
a	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
decrease	NN	O	O
in	NN	O	O
TE	NN	O	O
peak	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

Systemic	NN	O	O
application	NN	O	O
of	NN	O	O
KCN	NN	O	O
,	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
peripheral	NN	O	O
chemoreception	NN	O	O
activation	NN	O	O
on	NN	O	O
ventilation	NN	O	O
,	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
similar	NN	O	O
increase	NN	O	O
in	NN	O	O
VE	NN	O	O
for	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
have	NN	O	O
an	NN	O	O
altered	NN	O	O
ability	NN	O	O
to	NN	O	O
react	NN	O	O
to	NN	O	O
(	NN	O	O
or	NN	O	O
compensate	NN	O	O
for	NN	O	O
)	NN	O	O
blood	NN	O	O
gas	NN	O	O
changes	NN	O	O
with	NN	O	O
changes	NN	O	O
in	NN	O	O
ventilation	NN	O	O
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
it	NN	O	O
is	NN	O	O
centrally	NN	O	O
determined	NN	O	O
.	NN	O	O

We	NN	O	O
speculate	NN	O	O
on	NN	O	O
the	NN	O	O
possible	NN	O	O
relation	NN	O	O
of	NN	O	O
the	NN	O	O
current	NN	O	O
findings	NN	O	O
on	NN	O	O
treating	NN	O	O
different	NN	O	O
epilepsy	NN	O	B
-	NN	O	O
associated	NN	O	O
conditions	NN	O	O
.	NN	O	O

Fatal	NN	O	O
myeloencephalopathy	NN	O	B
due	NN	O	O
to	NN	O	O
intrathecal	NN	O	O
vincristine	NN	O	O
administration	NN	O	O
.	NN	O	O

Vincristine	NN	O	O
was	NN	O	O
accidentally	NN	O	O
given	NN	O	O
intrathecally	NN	O	O
to	NN	O	O
a	NN	O	O
child	NN	O	O
with	NN	O	O
leukaemia	NN	O	B
,	NN	O	O
producing	NN	O	O
sensory	NN	O	B
and	NN	O	I
motor	NN	O	I
dysfunction	NN	O	I
followed	NN	O	O
by	NN	O	O
encephalopathy	NN	O	B
and	NN	O	O
death	NN	O	O
.	NN	O	O

Separate	NN	O	O
times	NN	O	O
for	NN	O	O
administering	NN	O	O
vincristine	NN	O	O
and	NN	O	O
intrathecal	NN	O	O
therapy	NN	O	O
is	NN	O	O
recommended	NN	O	O
.	NN	O	O

Progesterone	NN	O	O
potentiation	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
arrhythmogenicity	NN	O	O
in	NN	O	O
pentobarbital	NN	O	O
-	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
and	NN	O	O
beating	NN	O	O
rat	NN	O	O
heart	NN	O	O
cell	NN	O	O
cultures	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
progesterone	NN	O	O
treatment	NN	O	O
on	NN	O	O
bupivacaine	NN	O	O
arrhythmogenicity	NN	O	O
in	NN	O	O
beating	NN	O	O
rat	NN	O	O
heart	NN	O	O
myocyte	NN	O	O
cultures	NN	O	O
and	NN	O	O
on	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
were	NN	O	O
determined	NN	O	O
.	NN	O	O

After	NN	O	O
determining	NN	O	O
the	NN	O	O
bupivacaine	NN	O	O
AD50	NN	O	O
(	NN	O	O
the	NN	O	O
concentration	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
that	NN	O	O
caused	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
all	NN	O	O
beating	NN	O	O
rat	NN	O	O
heart	NN	O	O
myocyte	NN	O	O
cultures	NN	O	O
to	NN	O	O
become	NN	O	O
arrhythmic	NN	O	B
)	NN	O	O
,	NN	O	O
we	NN	O	O
determined	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
1	NN	O	O
-	NN	O	O
hour	NN	O	O
progesterone	NN	O	O
HCl	NN	O	O
exposure	NN	O	O
on	NN	O	O
myocyte	NN	O	O
contractile	NN	O	O
rhythm	NN	O	O
.	NN	O	O

Each	NN	O	O
concentration	NN	O	O
of	NN	O	O
progesterone	NN	O	O
(	NN	O	O
6	NN	O	O
.	NN	O	O
25	NN	O	O
,	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
25	NN	O	O
,	NN	O	O
and	NN	O	O
50	NN	O	O
micrograms	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
caused	NN	O	O
a	NN	O	O
significant	NN	O	O
and	NN	O	O
concentration	NN	O	O
-	NN	O	O
dependent	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
AD50	NN	O	O
for	NN	O	O
bupivacaine	NN	O	O
.	NN	O	O

Estradiol	NN	O	O
treatment	NN	O	O
also	NN	O	O
increased	NN	O	O
the	NN	O	O
arrhythmogenicity	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
in	NN	O	O
myocyte	NN	O	O
cultures	NN	O	O
,	NN	O	O
but	NN	O	O
was	NN	O	O
only	NN	O	O
one	NN	O	O
fourth	NN	O	O
as	NN	O	O
potent	NN	O	O
as	NN	O	O
progesterone	NN	O	O
.	NN	O	O

Neither	NN	O	O
progesterone	NN	O	O
nor	NN	O	O
estradiol	NN	O	O
effects	NN	O	O
on	NN	O	O
bupivacaine	NN	O	O
arrhythmogenicity	NN	O	O
were	NN	O	O
potentiated	NN	O	O
by	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

Chronic	NN	O	O
progesterone	NN	O	O
pretreatment	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
21	NN	O	O
days	NN	O	O
)	NN	O	O
caused	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
bupivacaine	NN	O	O
arrhythmogenicity	NN	O	O
in	NN	O	O
intact	NN	O	O
pentobarbital	NN	O	O
-	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
time	NN	O	O
to	NN	O	O
onset	NN	O	O
of	NN	O	O
arrhythmia	NN	O	B
as	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
nonprogesterone	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
(	NN	O	O
6	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
vs	NN	O	O
.	NN	O	O
30	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
min	NN	O	O
,	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SE	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
indicate	NN	O	O
that	NN	O	O
progesterone	NN	O	O
can	NN	O	O
potentiate	NN	O	O
bupivacaine	NN	O	O
arrhythmogenicity	NN	O	O
both	NN	O	O
in	NN	O	O
vivo	NN	O	O
and	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

Potentiation	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
arrhythmia	NN	O	B
in	NN	O	O
myocyte	NN	O	O
cultures	NN	O	O
suggests	NN	O	O
that	NN	O	O
this	NN	O	O
effect	NN	O	O
is	NN	O	O
at	NN	O	O
least	NN	O	O
partly	NN	O	O
mediated	NN	O	O
at	NN	O	O
the	NN	O	O
myocyte	NN	O	O
level	NN	O	O
.	NN	O	O

Increased	NN	O	O
serum	NN	O	O
soluble	NN	O	O
Fas	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
due	NN	O	O
to	NN	O	O
paracetamol	NN	O	O
overdose	NN	O	B
.	NN	O	O

BACKGROUND	NN	O	O
/	NN	O	O
AIMS	NN	O	O
:	NN	O	O
Experimental	NN	O	O
studies	NN	O	O
have	NN	O	O
suggested	NN	O	O
that	NN	O	O
apoptosis	NN	O	O
via	NN	O	O
the	NN	O	O
Fas	NN	O	O
/	NN	O	O
Fas	NN	O	O
Ligand	NN	O	O
signaling	NN	O	O
system	NN	O	O
may	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
soluble	NN	O	O
form	NN	O	O
of	NN	O	O
Fas	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
.	NN	O	O

METHODOLOGY	NN	O	O
:	NN	O	O
Serum	NN	O	O
levels	NN	O	O
of	NN	O	O
sFas	NN	O	O
(	NN	O	O
soluble	NN	O	O
Fas	NN	O	O
)	NN	O	O
were	NN	O	O
measured	NN	O	O
by	NN	O	O
ELISA	NN	O	O
in	NN	O	O
24	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
and	NN	O	O
10	NN	O	O
normal	NN	O	O
control	NN	O	O
subjects	NN	O	O
.	NN	O	O

Serum	NN	O	O
levels	NN	O	O
of	NN	O	O
tumor	NN	O	B
necrosis	NN	O	B
factor	NN	O	O
-	NN	O	O
alpha	NN	O	O
and	NN	O	O
interferon	NN	O	O
-	NN	O	O
gamma	NN	O	O
were	NN	O	O
also	NN	O	O
determined	NN	O	O
by	NN	O	O
ELISA	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Serum	NN	O	O
sFas	NN	O	O
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
(	NN	O	O
median	NN	O	O
,	NN	O	O
26	NN	O	O
.	NN	O	O
8	NN	O	O
U	NN	O	O
/	NN	O	O
mL	NN	O	O
;	NN	O	O
range	NN	O	O
,	NN	O	O
6	NN	O	O
.	NN	O	O
9	NN	O	O
-	NN	O	O
52	NN	O	O
.	NN	O	O
7	NN	O	O
U	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
normal	NN	O	O
controls	NN	O	O
(	NN	O	O
median	NN	O	O
,	NN	O	O
8	NN	O	O
.	NN	O	O
6	NN	O	O
U	NN	O	O
/	NN	O	O
mL	NN	O	O
;	NN	O	O
range	NN	O	O
,	NN	O	O
6	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
12	NN	O	O
.	NN	O	O
0	NN	O	O
U	NN	O	O
/	NN	O	O
mL	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
.	NN	O	O

Levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
greater	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
due	NN	O	O
to	NN	O	O
paracetamol	NN	O	O
overdose	NN	O	B
(	NN	O	O
median	NN	O	O
,	NN	O	O
28	NN	O	O
.	NN	O	O
7	NN	O	O
U	NN	O	O
/	NN	O	O
mL	NN	O	O
;	NN	O	O
range	NN	O	O
,	NN	O	O
12	NN	O	O
.	NN	O	O
8	NN	O	O
-	NN	O	O
52	NN	O	O
.	NN	O	O
7	NN	O	O
U	NN	O	O
/	NN	O	O
mL	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
17	NN	O	O
)	NN	O	O
than	NN	O	O
those	NN	O	O
due	NN	O	O
to	NN	O	O
non	NN	O	O
-	NN	O	O
A	NN	O	O
to	NN	O	O
E	NN	O	O
hepatitis	NN	O	B
(	NN	O	O
median	NN	O	O
,	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
U	NN	O	O
/	NN	O	O
mL	NN	O	O
;	NN	O	O
range	NN	O	O
,	NN	O	O
6	NN	O	O
.	NN	O	O
9	NN	O	O
-	NN	O	O
46	NN	O	O
.	NN	O	O
0	NN	O	O
U	NN	O	O
/	NN	O	O
mL	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
relationship	NN	O	O
of	NN	O	O
sFas	NN	O	O
to	NN	O	O
eventual	NN	O	O
outcome	NN	O	O
in	NN	O	O
the	NN	O	O
patients	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
correlation	NN	O	O
was	NN	O	O
observed	NN	O	O
between	NN	O	O
serum	NN	O	O
sFas	NN	O	O
levels	NN	O	O
and	NN	O	O
aspartate	NN	O	O
aminotransferase	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
613	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
increased	NN	O	O
concentration	NN	O	O
of	NN	O	O
sFas	NN	O	O
in	NN	O	O
serum	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
may	NN	O	O
reflect	NN	O	O
activation	NN	O	O
of	NN	O	O
Fas	NN	O	O
-	NN	O	O
mediated	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
and	NN	O	O
this	NN	O	O
together	NN	O	O
with	NN	O	O
increased	NN	O	O
tumor	NN	O	B
necrosis	NN	O	B
factor	NN	O	O
-	NN	O	O
alpha	NN	O	O
may	NN	O	O
be	NN	O	O
an	NN	O	O
important	NN	O	O
factor	NN	O	O
in	NN	O	O
liver	NN	O	O
cell	NN	O	O
loss	NN	O	O
.	NN	O	O

Bilateral	NN	O	O
subthalamic	NN	O	O
nucleus	NN	O	O
stimulation	NN	O	O
for	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

High	NN	O	O
frequency	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
subthalamic	NN	O	O
nucleus	NN	O	O
(	NN	O	O
STN	NN	O	O
)	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
ameliorate	NN	O	O
the	NN	O	O
signs	NN	O	O
and	NN	O	O
symptoms	NN	O	O
of	NN	O	O
advanced	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
We	NN	O	O
studied	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
high	NN	O	O
frequency	NN	O	O
STN	NN	O	O
stimulation	NN	O	O
in	NN	O	O
23	NN	O	O
patients	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
three	NN	O	O
patients	NN	O	O
suffering	NN	O	O
from	NN	O	O
severe	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
Stages	NN	O	O
III	NN	O	O
-	NN	O	O
V	NN	O	O
on	NN	O	O
Hoehn	NN	O	O
and	NN	O	O
Yahr	NN	O	O
scale	NN	O	O
)	NN	O	O
and	NN	O	O
,	NN	O	O
particularly	NN	O	O
bradykinesia	NN	O	B
,	NN	O	O
rigidity	NN	O	B
,	NN	O	O
and	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
underwent	NN	O	O
bilateral	NN	O	O
implantation	NN	O	O
of	NN	O	O
electrodes	NN	O	O
in	NN	O	O
the	NN	O	O
STN	NN	O	O
.	NN	O	O

Preoperative	NN	O	O
and	NN	O	O
postoperative	NN	O	O
assessments	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
at	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
6	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
,	NN	O	O
in	NN	O	O
"	NN	O	O
on	NN	O	O
"	NN	O	O
and	NN	O	O
"	NN	O	O
off	NN	O	O
"	NN	O	O
drug	NN	O	O
conditions	NN	O	O
,	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
using	NN	O	O
Unified	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
Disease	NN	O	I
Rating	NN	O	O
Scale	NN	O	O
,	NN	O	O
Hoehn	NN	O	O
and	NN	O	O
Yahr	NN	O	O
staging	NN	O	O
,	NN	O	O
England	NN	O	O
activities	NN	O	O
of	NN	O	O
daily	NN	O	O
living	NN	O	O
score	NN	O	O
and	NN	O	O
video	NN	O	O
recordings	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
After	NN	O	O
one	NN	O	O
year	NN	O	O
of	NN	O	O
electrical	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
STN	NN	O	O
,	NN	O	O
the	NN	O	O
patients	NN	O	O
'	NN	O	O
scores	NN	O	O
for	NN	O	O
activities	NN	O	O
of	NN	O	O
daily	NN	O	O
living	NN	O	O
and	NN	O	O
motor	NN	O	O
examination	NN	O	O
scores	NN	O	O
(	NN	O	O
Unified	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
Disease	NN	O	I
Rating	NN	O	O
Scale	NN	O	O
parts	NN	O	O
II	NN	O	O
and	NN	O	O
III	NN	O	O
)	NN	O	O
off	NN	O	O
medication	NN	O	O
improved	NN	O	O
by	NN	O	O
62	NN	O	O
%	NN	O	O
and	NN	O	O
61	NN	O	O
%	NN	O	O
respectively	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0005	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
subscores	NN	O	O
for	NN	O	O
the	NN	O	O
akinesia	NN	O	B
,	NN	O	O
rigidity	NN	O	B
,	NN	O	O
tremor	NN	O	B
and	NN	O	O
gait	NN	O	O
also	NN	O	O
improved	NN	O	O
.	NN	O	O

(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0005	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
average	NN	O	O
levodopa	NN	O	O
dose	NN	O	O
decreased	NN	O	O
from	NN	O	O
813	NN	O	O
mg	NN	O	O
to	NN	O	O
359	NN	O	O
mg	NN	O	O
.	NN	O	O

The	NN	O	O
cognitive	NN	O	O
functions	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
developed	NN	O	O
device	NN	O	O
-	NN	O	O
related	NN	O	O
complications	NN	O	O
and	NN	O	O
two	NN	O	O
patients	NN	O	O
experienced	NN	O	O
abnormal	NN	O	O
weight	NN	O	O
gain	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Bilateral	NN	O	O
subthalamic	NN	O	O
nucleus	NN	O	O
stimulation	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
treatment	NN	O	O
for	NN	O	O
advanced	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

It	NN	O	O
reduces	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
"	NN	O	O
off	NN	O	O
"	NN	O	O
phase	NN	O	O
symptoms	NN	O	O
,	NN	O	O
improves	NN	O	O
the	NN	O	O
axial	NN	O	O
symptoms	NN	O	O
and	NN	O	O
reduces	NN	O	O
levodopa	NN	O	O
requirements	NN	O	O
.	NN	O	O

The	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
levodopa	NN	O	O
dose	NN	O	O
is	NN	O	O
useful	NN	O	O
in	NN	O	O
controlling	NN	O	O
drug	NN	O	B
-	NN	O	I
induced	NN	O	I
dyskinesias	NN	O	I
.	NN	O	O

Acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
occurring	NN	O	O
during	NN	O	O
intravenous	NN	O	O
desferrioxamine	NN	O	O
therapy	NN	O	O
:	NN	O	O
recovery	NN	O	O
after	NN	O	O
haemodialysis	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
with	NN	O	O
transfusion	NN	O	O
-	NN	O	O
dependent	NN	O	O
thalassemia	NN	O	B
was	NN	O	O
undergoing	NN	O	O
home	NN	O	O
intravenous	NN	O	O
desferrioxamine	NN	O	O
(	NN	O	O
DFX	NN	O	O
)	NN	O	O
treatment	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
a	NN	O	O
totally	NN	O	O
implanted	NN	O	O
system	NN	O	O
because	NN	O	O
of	NN	O	O
his	NN	O	O
poor	NN	O	O
compliance	NN	O	O
with	NN	O	O
the	NN	O	O
nightly	NN	O	O
subcutaneous	NN	O	O
therapy	NN	O	O
.	NN	O	O

Due	NN	O	O
to	NN	O	O
an	NN	O	O
accidental	NN	O	O
malfunctioning	NN	O	O
of	NN	O	O
the	NN	O	O
infusion	NN	O	O
pump	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
inadvertently	NN	O	O
administered	NN	O	O
a	NN	O	O
toxic	NN	O	O
dosage	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
which	NN	O	O
caused	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
.	NN	O	O

Given	NN	O	O
the	NN	O	O
progressive	NN	O	O
deterioration	NN	O	O
of	NN	O	O
the	NN	O	O
symptoms	NN	O	O
and	NN	O	O
of	NN	O	O
the	NN	O	O
laboratory	NN	O	O
values	NN	O	O
,	NN	O	O
despite	NN	O	O
adequate	NN	O	O
medical	NN	O	O
treatment	NN	O	O
,	NN	O	O
a	NN	O	O
decision	NN	O	O
was	NN	O	O
made	NN	O	O
to	NN	O	O
introduce	NN	O	O
haemodialytical	NN	O	O
therapy	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
remove	NN	O	O
the	NN	O	O
drug	NN	O	O
and	NN	O	O
therapy	NN	O	O
reduce	NN	O	O
the	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

From	NN	O	O
the	NN	O	O
results	NN	O	O
obtained	NN	O	O
,	NN	O	O
haemodialysis	NN	O	O
can	NN	O	O
therefore	NN	O	O
be	NN	O	O
suggested	NN	O	O
as	NN	O	O
a	NN	O	O
useful	NN	O	O
therapy	NN	O	O
in	NN	O	O
rare	NN	O	O
cases	NN	O	O
of	NN	O	O
progressive	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
caused	NN	O	O
by	NN	O	O
desferrioxamine	NN	O	O
.	NN	O	O

Ocular	NN	O	O
motility	NN	O	O
changes	NN	O	O
after	NN	O	O
subtenon	NN	O	O
carboplatin	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
retinoblastoma	NN	O	B
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Focal	NN	O	O
subtenon	NN	O	O
carboplatin	NN	O	O
injections	NN	O	O
have	NN	O	O
recently	NN	O	O
been	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
presumably	NN	O	O
toxicity	NN	O	B
-	NN	O	O
free	NN	O	O
adjunct	NN	O	O
to	NN	O	O
systemic	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
intraocular	NN	O	O
retinoblastoma	NN	O	B
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
our	NN	O	O
clinical	NN	O	O
experience	NN	O	O
with	NN	O	O
abnormal	NN	O	B
ocular	NN	O	I
motility	NN	O	I
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
subtenon	NN	O	O
carboplatin	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
noted	NN	O	O
abnormal	NN	O	B
ocular	NN	O	I
motility	NN	O	I
in	NN	O	O
10	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
with	NN	O	O
retinoblastoma	NN	O	B
who	NN	O	O
had	NN	O	O
received	NN	O	O
subtenon	NN	O	O
carboplatin	NN	O	O
.	NN	O	O

During	NN	O	O
ocular	NN	O	O
manipulation	NN	O	O
under	NN	O	O
general	NN	O	O
anesthesia	NN	O	O
,	NN	O	O
we	NN	O	O
assessed	NN	O	O
their	NN	O	O
eyes	NN	O	O
by	NN	O	O
forced	NN	O	O
duction	NN	O	O
testing	NN	O	O
,	NN	O	O
comparing	NN	O	O
ocular	NN	O	O
motility	NN	O	O
after	NN	O	O
tumor	NN	O	B
control	NN	O	O
with	NN	O	O
ocular	NN	O	O
motility	NN	O	O
at	NN	O	O
diagnosis	NN	O	O
.	NN	O	O

Eyes	NN	O	O
subsequently	NN	O	O
enucleated	NN	O	O
because	NN	O	O
of	NN	O	O
treatment	NN	O	O
failure	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
were	NN	O	O
examined	NN	O	O
histologically	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Limitation	NN	O	O
of	NN	O	O
ocular	NN	O	O
motility	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
all	NN	O	O
12	NN	O	O
eyes	NN	O	O
of	NN	O	O
10	NN	O	O
patients	NN	O	O
treated	NN	O	O
for	NN	O	O
intraocular	NN	O	O
retinoblastoma	NN	O	B
with	NN	O	O
1	NN	O	O
to	NN	O	O
6	NN	O	O
injections	NN	O	O
of	NN	O	O
subtenon	NN	O	O
carboplatin	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
multimodality	NN	O	O
therapy	NN	O	O
.	NN	O	O

Histopathological	NN	O	O
examination	NN	O	O
revealed	NN	O	O
many	NN	O	O
lipophages	NN	O	O
in	NN	O	O
the	NN	O	O
periorbital	NN	O	O
fat	NN	O	O
surrounding	NN	O	O
the	NN	O	O
optic	NN	O	O
nerve	NN	O	O
in	NN	O	O
1	NN	O	O
eye	NN	O	O
,	NN	O	O
indicative	NN	O	O
of	NN	O	O
phagocytosis	NN	O	O
of	NN	O	O
previously	NN	O	O
existing	NN	O	O
fat	NN	O	O
cells	NN	O	O
and	NN	O	O
suggesting	NN	O	O
prior	NN	O	O
fat	NN	O	O
necrosis	NN	O	B
.	NN	O	O

The	NN	O	O
enucleations	NN	O	O
were	NN	O	O
technically	NN	O	O
difficult	NN	O	O
and	NN	O	O
hazardous	NN	O	O
for	NN	O	O
globe	NN	O	O
rupture	NN	O	B
because	NN	O	O
of	NN	O	O
extensive	NN	O	O
orbital	NN	O	O
soft	NN	O	O
tissue	NN	O	O
adhesions	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Subtenon	NN	O	O
carboplatin	NN	O	O
chemotherapy	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
significant	NN	O	O
fibrosis	NN	O	B
of	NN	O	O
orbital	NN	O	O
soft	NN	O	O
tissues	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
mechanical	NN	O	O
restriction	NN	O	O
of	NN	O	O
eye	NN	O	O
movements	NN	O	O
and	NN	O	O
making	NN	O	O
subsequent	NN	O	O
enucleation	NN	O	O
difficult	NN	O	O
.	NN	O	O

Subtenon	NN	O	O
carboplatin	NN	O	O
is	NN	O	O
not	NN	O	O
free	NN	O	O
of	NN	O	O
toxicity	NN	O	B
,	NN	O	O
and	NN	O	O
its	NN	O	O
use	NN	O	O
is	NN	O	O
best	NN	O	O
restricted	NN	O	O
to	NN	O	O
specific	NN	O	O
indications	NN	O	O
.	NN	O	O

Ethambutol	NN	O	O
and	NN	O	O
optic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
ethambutol	NN	O	O
and	NN	O	O
optic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Thirteen	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
optic	NN	O	B
neuropathy	NN	O	I
after	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
ethambutol	NN	O	O
for	NN	O	O
tuberculosis	NN	O	B
of	NN	O	I
the	NN	O	I
lung	NN	O	I
or	NN	O	I
lymph	NN	O	I
node	NN	O	I
at	NN	O	O
Siriraj	NN	O	O
Hospital	NN	O	O
between	NN	O	O
1997	NN	O	O
and	NN	O	O
2001	NN	O	O
were	NN	O	O
retrospectively	NN	O	O
reviewed	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
characteristics	NN	O	O
and	NN	O	O
initial	NN	O	O
and	NN	O	O
final	NN	O	O
visual	NN	O	O
acuity	NN	O	O
were	NN	O	O
analyzed	NN	O	O
to	NN	O	O
determine	NN	O	O
visual	NN	O	O
outcome	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
All	NN	O	O
patients	NN	O	O
had	NN	O	O
optic	NN	O	B
neuropathy	NN	O	I
between	NN	O	O
1	NN	O	O
to	NN	O	O
6	NN	O	O
months	NN	O	O
(	NN	O	O
mean	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
9	NN	O	O
months	NN	O	O
)	NN	O	O
after	NN	O	O
starting	NN	O	O
ethambutol	NN	O	O
therapy	NN	O	O
at	NN	O	O
a	NN	O	O
dosage	NN	O	O
ranging	NN	O	O
from	NN	O	O
13	NN	O	O
to	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
mean	NN	O	O
=	NN	O	O
17	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
.	NN	O	O

Seven	NN	O	O
(	NN	O	O
54	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
13	NN	O	O
patients	NN	O	O
experienced	NN	O	O
visual	NN	O	O
recovery	NN	O	O
after	NN	O	O
stopping	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

Of	NN	O	O
6	NN	O	O
patients	NN	O	O
with	NN	O	O
irreversible	NN	O	O
visual	NN	O	B
impairment	NN	O	I
,	NN	O	O
4	NN	O	O
patients	NN	O	O
had	NN	O	O
diabetes	NN	O	B
mellitus	NN	O	I
,	NN	O	O
glaucoma	NN	O	B
and	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
heavy	NN	O	O
smoking	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Early	NN	O	O
recognition	NN	O	O
of	NN	O	O
optic	NN	O	B
neuropathy	NN	O	I
should	NN	O	O
be	NN	O	O
considered	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
ethambutol	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
low	NN	O	O
dose	NN	O	O
and	NN	O	O
prompt	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
is	NN	O	O
recommended	NN	O	O
particularly	NN	O	O
in	NN	O	O
individuals	NN	O	O
with	NN	O	O
diabetes	NN	O	B
mellitus	NN	O	I
,	NN	O	O
glaucoma	NN	O	B
or	NN	O	O
who	NN	O	O
are	NN	O	O
heavy	NN	O	O
smokers	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
compensatory	NN	O	O
gustatory	NN	O	B
hyperhidrosis	NN	O	I
with	NN	O	O
topical	NN	O	O
glycopyrrolate	NN	O	O
.	NN	O	O

Gustatory	NN	O	B
hyperhidrosis	NN	O	I
is	NN	O	O
facial	NN	O	O
sweating	NN	O	B
usually	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
eating	NN	O	O
of	NN	O	O
hot	NN	O	O
spicy	NN	O	O
food	NN	O	O
or	NN	O	O
even	NN	O	O
smelling	NN	O	O
this	NN	O	O
food	NN	O	O
.	NN	O	O

Current	NN	O	O
options	NN	O	O
of	NN	O	O
treatment	NN	O	O
include	NN	O	O
oral	NN	O	O
anticholinergic	NN	O	O
drugs	NN	O	O
,	NN	O	O
the	NN	O	O
topical	NN	O	O
application	NN	O	O
of	NN	O	O
anticholinergics	NN	O	O
or	NN	O	O
aluminum	NN	O	O
chloride	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
botulinum	NN	O	O
toxin	NN	O	O
.	NN	O	O

Thirteen	NN	O	O
patients	NN	O	O
have	NN	O	O
been	NN	O	O
treated	NN	O	O
to	NN	O	O
date	NN	O	O
with	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
or	NN	O	O
2	NN	O	O
%	NN	O	O
topical	NN	O	O
glycopyrrolate	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
had	NN	O	O
gustatory	NN	O	B
hyperhidrosis	NN	O	I
,	NN	O	O
which	NN	O	O
interfered	NN	O	O
with	NN	O	O
their	NN	O	O
social	NN	O	O
activities	NN	O	O
,	NN	O	O
after	NN	O	O
transthroacic	NN	O	O
endoscopic	NN	O	O
sympathectomy	NN	O	O
,	NN	O	O
and	NN	O	O
which	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
compensatory	NN	O	O
focal	NN	O	O
hyperhidrosis	NN	O	B
.	NN	O	O

After	NN	O	O
applying	NN	O	O
topical	NN	O	O
glycopyrrolate	NN	O	O
,	NN	O	O
the	NN	O	O
subjective	NN	O	O
effect	NN	O	O
was	NN	O	O
excellent	NN	O	O
(	NN	O	O
no	NN	O	O
sweating	NN	O	B
after	NN	O	O
eating	NN	O	O
hot	NN	O	O
spicy	NN	O	O
food	NN	O	O
)	NN	O	O
in	NN	O	O
10	NN	O	O
patients	NN	O	O
(	NN	O	O
77	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
fair	NN	O	O
(	NN	O	O
clearly	NN	O	O
reduced	NN	O	O
sweating	NN	O	B
)	NN	O	O
in	NN	O	O
3	NN	O	O
patients	NN	O	O
(	NN	O	O
23	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
had	NN	O	O
reported	NN	O	O
incidents	NN	O	O
of	NN	O	O
being	NN	O	O
very	NN	O	O
embarrassed	NN	O	O
whilst	NN	O	O
eating	NN	O	O
hot	NN	O	O
spicy	NN	O	O
foods	NN	O	O
.	NN	O	O

Adverse	NN	O	O
effects	NN	O	O
included	NN	O	O
a	NN	O	O
mildly	NN	O	O
dry	NN	O	B
mouth	NN	O	I
and	NN	O	O
a	NN	O	O
sore	NN	O	B
throat	NN	O	I
in	NN	O	O
2	NN	O	O
patients	NN	O	O
(	NN	O	O
2	NN	O	O
%	NN	O	O
glycopyrrolate	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
light	NN	O	O
headache	NN	O	B
in	NN	O	O
1	NN	O	O
patient	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
glycopyrrolate	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
topical	NN	O	O
application	NN	O	O
of	NN	O	O
a	NN	O	O
glycopyrrolate	NN	O	O
pad	NN	O	O
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
safe	NN	O	O
,	NN	O	O
efficacious	NN	O	O
,	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
convenient	NN	O	O
method	NN	O	O
of	NN	O	O
treatment	NN	O	O
for	NN	O	O
moderate	NN	O	O
to	NN	O	O
severe	NN	O	O
symptoms	NN	O	O
of	NN	O	O
gustatory	NN	O	B
hyperhidrosis	NN	O	I
in	NN	O	O
post	NN	O	O
transthoracic	NN	O	O
endoscopic	NN	O	O
sympathectomy	NN	O	O
or	NN	O	O
sympathicotomy	NN	O	O
patients	NN	O	O
,	NN	O	O
with	NN	O	O
few	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Neuroleptic	NN	O	O
-	NN	O	O
associated	NN	O	O
hyperprolactinemia	NN	O	B
.	NN	O	O

Can	NN	O	O
it	NN	O	O
be	NN	O	O
treated	NN	O	O
with	NN	O	O
bromocriptine	NN	O	O
?	NN	O	O

Six	NN	O	O
stable	NN	O	O
psychiatric	NN	O	O
outpatients	NN	O	O
with	NN	O	O
hyperprolactinemia	NN	O	B
and	NN	O	O
amenorrhea	NN	O	B
/	NN	O	O
oligomenorrhea	NN	O	B
associated	NN	O	O
with	NN	O	O
their	NN	O	O
neuroleptic	NN	O	O
medications	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
bromocriptine	NN	O	O
.	NN	O	O

Daily	NN	O	O
dosages	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
10	NN	O	O
mg	NN	O	O
corrected	NN	O	O
the	NN	O	O
hyperprolactinemia	NN	O	B
and	NN	O	O
restored	NN	O	O
menstruation	NN	O	O
in	NN	O	O
four	NN	O	O
of	NN	O	O
the	NN	O	O
six	NN	O	O
patients	NN	O	O
.	NN	O	O

One	NN	O	O
woman	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
developed	NN	O	O
worsened	NN	O	O
psychiatric	NN	O	B
symptoms	NN	O	I
while	NN	O	O
taking	NN	O	O
bromocriptine	NN	O	O
,	NN	O	O
and	NN	O	O
it	NN	O	O
was	NN	O	O
discontinued	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
three	NN	O	O
of	NN	O	O
six	NN	O	O
patients	NN	O	O
had	NN	O	O
their	NN	O	O
menstrual	NN	O	O
irregularity	NN	O	O
successfully	NN	O	O
corrected	NN	O	O
with	NN	O	O
bromocriptine	NN	O	O
.	NN	O	O

This	NN	O	O
suggests	NN	O	O
that	NN	O	O
bromocriptine	NN	O	O
should	NN	O	O
be	NN	O	O
further	NN	O	O
evaluated	NN	O	O
as	NN	O	O
potential	NN	O	O
therapy	NN	O	O
for	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
associated	NN	O	O
hyperprolactinemia	NN	O	B
and	NN	O	O
amenorrhea	NN	O	B
/	NN	O	O
galactorrhea	NN	O	B
.	NN	O	O

Ethacrynic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
and	NN	O	O
brain	NN	O	O
neurotransmitters	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Intracerebroventricular	NN	O	O
injection	NN	O	O
of	NN	O	O
ethacrynic	NN	O	O
acid	NN	O	O
(	NN	O	O
50	NN	O	O
%	NN	O	O
convulsive	NN	O	B
dose	NN	O	O
;	NN	O	O
50	NN	O	O
micrograms	NN	O	O
/	NN	O	O
mouse	NN	O	O
)	NN	O	O
accelerated	NN	O	O
the	NN	O	O
synthesis	NN	O	O
/	NN	O	O
turnover	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
hydroxytryptamine	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
)	NN	O	O
but	NN	O	O
suppressed	NN	O	O
the	NN	O	O
synthesis	NN	O	O
of	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acid	NN	O	O
and	NN	O	O
acetylcholine	NN	O	O
in	NN	O	O
mouse	NN	O	O
brain	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
were	NN	O	O
completely	NN	O	O
antagonized	NN	O	O
by	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
a	NN	O	O
glutamate	NN	O	O
/	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartate	NN	O	O
antagonist	NN	O	O
,	NN	O	O
aminophosphonovaleric	NN	O	O
acid	NN	O	O
.	NN	O	O

In	NN	O	O
ethacrynic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
,	NN	O	O
these	NN	O	O
neurotransmitter	NN	O	O
systems	NN	O	O
may	NN	O	O
be	NN	O	O
differentially	NN	O	O
modulated	NN	O	O
,	NN	O	O
probably	NN	O	O
through	NN	O	O
activation	NN	O	O
of	NN	O	O
glutaminergic	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

Pharmacology	NN	O	O
of	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acidA	NN	O	O
receptor	NN	O	O
complex	NN	O	O
after	NN	O	O
the	NN	O	O
in	NN	O	O
vivo	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
anxioselective	NN	O	O
and	NN	O	O
anticonvulsant	NN	O	O
beta	NN	O	O
-	NN	O	O
carboline	NN	O	O
derivative	NN	O	O
abecarnil	NN	O	O
.	NN	O	O

In	NN	O	O
rodents	NN	O	O
,	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
carboline	NN	O	O
derivative	NN	O	O
isopropyl	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
benzyloxy	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
methoxymethyl	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
carboline	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
carboxylate	NN	O	O
(	NN	O	O
abecarrnil	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
new	NN	O	O
ligand	NN	O	O
for	NN	O	O
benzodiazepine	NN	O	O
receptors	NN	O	O
possessing	NN	O	O
anxiolytic	NN	O	O
and	NN	O	O
anticonvulsant	NN	O	O
properties	NN	O	O
,	NN	O	O
was	NN	O	O
evaluated	NN	O	O
on	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
central	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acid	NN	O	O
(	NN	O	O
GABA	NN	O	O
)	NN	O	O
A	NN	O	O
receptor	NN	O	O
complex	NN	O	O
,	NN	O	O
both	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

Added	NN	O	O
in	NN	O	O
vitro	NN	O	O
to	NN	O	O
rat	NN	O	O
cortical	NN	O	O
membrane	NN	O	O
preparation	NN	O	O
,	NN	O	O
abecarnil	NN	O	O
increased	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
GABA	NN	O	O
binding	NN	O	O
,	NN	O	O
enhanced	NN	O	O
muscimol	NN	O	O
-	NN	O	O
stimulated	NN	O	O
36Cl	NN	O	O
-	NN	O	O
uptake	NN	O	O
and	NN	O	O
reduced	NN	O	O
the	NN	O	O
binding	NN	O	O
of	NN	O	O
t	NN	O	O
-	NN	O	O
[	NN	O	O
35S	NN	O	O
]	NN	O	O
butylbicyclophosphorothionate	NN	O	O
(	NN	O	O
[	NN	O	O
35S	NN	O	O
]	NN	O	O
TBPS	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
were	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
induced	NN	O	O
by	NN	O	O
diazepam	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
partial	NN	O	O
agonist	NN	O	O
Ro	NN	O	O
16	NN	O	O
-	NN	O	O
6028	NN	O	O
(	NN	O	O
tert	NN	O	O
-	NN	O	O
butyl	NN	O	O
-	NN	O	O
(	NN	O	O
S	NN	O	O
)	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
bromo	NN	O	O
-	NN	O	O
11	NN	O	O
,	NN	O	O
12	NN	O	O
,	NN	O	O
13	NN	O	O
,	NN	O	O
13a	NN	O	O
-	NN	O	O
tetrahydro	NN	O	O
-	NN	O	O
9	NN	O	O
-	NN	O	O
oxo	NN	O	O
-	NN	O	O
9H	NN	O	O
-	NN	O	O
imidazo	NN	O	O
[	NN	O	O
1	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
a	NN	O	O
]	NN	O	O
-	NN	O	O
pyrrolo	NN	O	O
-	NN	O	O
[	NN	O	O
2	NN	O	O
,	NN	O	O
1	NN	O	O
-	NN	O	O
c	NN	O	O
]	NN	O	O
[	NN	O	O
1	NN	O	O
,	NN	O	O
4	NN	O	O
]	NN	O	O
benzodiazepine	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
carboxylate	NN	O	O
)	NN	O	O
showed	NN	O	O
very	NN	O	O
weak	NN	O	O
efficacy	NN	O	O
in	NN	O	O
these	NN	O	O
biochemical	NN	O	O
tests	NN	O	O
.	NN	O	O

After	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
injection	NN	O	O
to	NN	O	O
rats	NN	O	O
,	NN	O	O
abecarnil	NN	O	O
and	NN	O	O
diazepam	NN	O	O
decreased	NN	O	O
in	NN	O	O
a	NN	O	O
time	NN	O	O
-	NN	O	O
dependent	NN	O	O
and	NN	O	O
dose	NN	O	O
-	NN	O	O
related	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
-	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
manner	NN	O	O
[	NN	O	O
35S	NN	O	O
]	NN	O	O
TBPS	NN	O	O
binding	NN	O	O
measured	NN	O	O
ex	NN	O	O
vivo	NN	O	O
in	NN	O	O
the	NN	O	O
cerebral	NN	O	O
cortex	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
both	NN	O	O
drugs	NN	O	O
at	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
antagonized	NN	O	O
completely	NN	O	O
the	NN	O	O
convulsant	NN	O	O
activity	NN	O	O
and	NN	O	O
the	NN	O	O
increase	NN	O	O
of	NN	O	O
[	NN	O	O
35S	NN	O	O
]	NN	O	O
TBPS	NN	O	O
binding	NN	O	O
induced	NN	O	O
by	NN	O	O
isoniazide	NN	O	O
(	NN	O	O
350	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
increase	NN	O	O
of	NN	O	O
[	NN	O	O
35S	NN	O	O
]	NN	O	O
TBPS	NN	O	O
binding	NN	O	O
induced	NN	O	O
by	NN	O	O
foot	NN	O	O
-	NN	O	O
shock	NN	O	O
stress	NN	O	O
.	NN	O	O

To	NN	O	O
better	NN	O	O
correlate	NN	O	O
the	NN	O	O
biochemical	NN	O	O
and	NN	O	O
the	NN	O	O
pharmacological	NN	O	O
effects	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
the	NN	O	O
action	NN	O	O
of	NN	O	O
abecarnil	NN	O	O
on	NN	O	O
[	NN	O	O
35S	NN	O	O
]	NN	O	O
TBPS	NN	O	O
binding	NN	O	O
,	NN	O	O
exploratory	NN	O	O
motility	NN	O	O
and	NN	O	O
on	NN	O	O
isoniazid	NN	O	O
-	NN	O	O
induced	NN	O	O
biochemical	NN	O	O
and	NN	O	O
pharmacological	NN	O	O
effects	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
these	NN	O	O
animals	NN	O	O
,	NN	O	O
abecarnil	NN	O	O
produced	NN	O	O
a	NN	O	O
paralleled	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
-	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
reduction	NN	O	O
of	NN	O	O
both	NN	O	O
motor	NN	O	O
behavior	NN	O	O
and	NN	O	O
cortical	NN	O	O
[	NN	O	O
35S	NN	O	O
]	NN	O	O
TBPS	NN	O	O
binding	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
this	NN	O	O
beta	NN	O	O
-	NN	O	O
carboline	NN	O	O
reduced	NN	O	O
markedly	NN	O	O
the	NN	O	O
increase	NN	O	O
of	NN	O	O
[	NN	O	O
35S	NN	O	O
]	NN	O	O
TBPS	NN	O	O
binding	NN	O	O
and	NN	O	O
the	NN	O	O
convulsions	NN	O	B
induced	NN	O	O
by	NN	O	O
isoniazid	NN	O	O
(	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Recurrent	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
a	NN	O	O
postpartum	NN	O	O
patient	NN	O	O
receiving	NN	O	O
bromocriptine	NN	O	O
.	NN	O	O

Myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
puerperium	NN	O	O
is	NN	O	O
infrequently	NN	O	O
reported	NN	O	O
.	NN	O	O

Spasm	NN	O	B
,	NN	O	O
coronary	NN	O	O
dissection	NN	O	O
,	NN	O	O
or	NN	O	O
atheromatous	NN	O	O
etiology	NN	O	O
has	NN	O	O
been	NN	O	O
described	NN	O	O
.	NN	O	O

Bromocriptine	NN	O	O
has	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
several	NN	O	O
previous	NN	O	O
case	NN	O	O
reports	NN	O	O
of	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
the	NN	O	O
puerperium	NN	O	O
.	NN	O	O

Our	NN	O	O
case	NN	O	O
(	NN	O	O
including	NN	O	O
an	NN	O	O
inadvertent	NN	O	O
rechallenge	NN	O	O
)	NN	O	O
suggests	NN	O	O
such	NN	O	O
a	NN	O	O
relationship	NN	O	O
.	NN	O	O

Although	NN	O	O
generally	NN	O	O
regarded	NN	O	O
as	NN	O	O
"	NN	O	O
safe	NN	O	O
,	NN	O	O
"	NN	O	O
possible	NN	O	O
serious	NN	O	O
cardiac	NN	O	O
effects	NN	O	O
of	NN	O	O
bromocriptine	NN	O	O
should	NN	O	O
be	NN	O	O
acknowledged	NN	O	O
.	NN	O	O

Asterixis	NN	O	B
induced	NN	O	O
by	NN	O	O
carbamazepine	NN	O	O
therapy	NN	O	O
.	NN	O	O

There	NN	O	O
are	NN	O	O
very	NN	O	O
few	NN	O	O
reports	NN	O	O
about	NN	O	O
asterixis	NN	O	B
as	NN	O	O
a	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
psychopharmacologic	NN	O	O
agents	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
we	NN	O	O
present	NN	O	O
four	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
different	NN	O	O
psychotropic	NN	O	O
drugs	NN	O	O
,	NN	O	O
in	NN	O	O
whom	NN	O	O
asterixis	NN	O	B
was	NN	O	O
triggered	NN	O	O
either	NN	O	O
by	NN	O	O
adding	NN	O	O
carbamazepine	NN	O	O
(	NN	O	O
CBZ	NN	O	O
)	NN	O	O
to	NN	O	O
a	NN	O	O
treatment	NN	O	O
regimen	NN	O	O
,	NN	O	O
or	NN	O	O
by	NN	O	O
increasing	NN	O	O
its	NN	O	O
dosage	NN	O	O
.	NN	O	O

Neither	NN	O	O
dosage	NN	O	O
nor	NN	O	O
serum	NN	O	O
levels	NN	O	O
of	NN	O	O
CBZ	NN	O	O
were	NN	O	O
in	NN	O	O
a	NN	O	O
higher	NN	O	O
range	NN	O	O
.	NN	O	O

We	NN	O	O
consider	NN	O	O
asterixis	NN	O	B
to	NN	O	O
be	NN	O	O
an	NN	O	O
easily	NN	O	O
overlooked	NN	O	O
sign	NN	O	O
of	NN	O	O
neurotoxicity	NN	O	B
,	NN	O	O
which	NN	O	O
may	NN	O	O
occur	NN	O	O
even	NN	O	O
at	NN	O	O
low	NN	O	O
or	NN	O	O
moderate	NN	O	O
dosage	NN	O	O
levels	NN	O	O
,	NN	O	O
if	NN	O	O
certain	NN	O	O
drugs	NN	O	O
as	NN	O	O
lithium	NN	O	O
or	NN	O	O
clozapine	NN	O	O
are	NN	O	O
used	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
CBZ	NN	O	O
.	NN	O	O

Pharmacodynamics	NN	O	O
of	NN	O	O
the	NN	O	O
hypotensive	NN	O	B
effect	NN	O	O
of	NN	O	O
levodopa	NN	O	O
in	NN	O	O
parkinsonian	NN	O	B
patients	NN	O	O
.	NN	O	O

Blood	NN	O	O
pressure	NN	O	O
effects	NN	O	O
of	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
levodopa	NN	O	O
were	NN	O	O
examined	NN	O	O
in	NN	O	O
parkinsonian	NN	O	B
patients	NN	O	O
with	NN	O	O
stable	NN	O	O
and	NN	O	O
fluctuating	NN	O	O
responses	NN	O	O
to	NN	O	O
levodopa	NN	O	O
.	NN	O	O

The	NN	O	O
magnitude	NN	O	O
of	NN	O	O
the	NN	O	O
hypotensive	NN	O	B
effect	NN	O	O
of	NN	O	O
levodopa	NN	O	O
was	NN	O	O
concentration	NN	O	O
dependent	NN	O	O
and	NN	O	O
was	NN	O	O
fit	NN	O	O
to	NN	O	O
an	NN	O	O
Emax	NN	O	O
model	NN	O	O
in	NN	O	O
fluctuating	NN	O	O
responders	NN	O	O
.	NN	O	O

Stable	NN	O	O
responders	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
small	NN	O	O
hypotensive	NN	O	B
response	NN	O	O
.	NN	O	O

Baseline	NN	O	O
blood	NN	O	O
pressures	NN	O	O
were	NN	O	O
higher	NN	O	O
in	NN	O	O
fluctuating	NN	O	O
patients	NN	O	O
;	NN	O	O
a	NN	O	O
higher	NN	O	O
baseline	NN	O	O
blood	NN	O	O
pressure	NN	O	O
correlated	NN	O	O
with	NN	O	O
greater	NN	O	O
hypotensive	NN	O	B
effects	NN	O	O
.	NN	O	O

Antiparkinsonian	NN	O	O
effects	NN	O	O
of	NN	O	O
levodopa	NN	O	O
temporally	NN	O	O
correlated	NN	O	O
with	NN	O	O
blood	NN	O	O
pressure	NN	O	O
changes	NN	O	O
.	NN	O	O

Phenylalanine	NN	O	O
,	NN	O	O
a	NN	O	O
large	NN	O	O
neutral	NN	O	O
amino	NN	O	O
acid	NN	O	O
(	NN	O	O
LNAA	NN	O	O
)	NN	O	O
competing	NN	O	O
with	NN	O	O
levodopa	NN	O	O
for	NN	O	O
transport	NN	O	O
across	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
,	NN	O	O
reduced	NN	O	O
the	NN	O	O
hypotensive	NN	O	B
and	NN	O	O
antiparkinsonian	NN	O	O
effects	NN	O	O
of	NN	O	O
levodopa	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
levodopa	NN	O	O
has	NN	O	O
a	NN	O	O
central	NN	O	O
hypotensive	NN	O	B
action	NN	O	O
that	NN	O	O
parallels	NN	O	O
the	NN	O	O
motor	NN	O	O
effects	NN	O	O
in	NN	O	O
fluctuating	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
hypotensive	NN	O	B
effect	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
higher	NN	O	O
baseline	NN	O	O
blood	NN	O	O
pressure	NN	O	O
we	NN	O	O
observed	NN	O	O
in	NN	O	O
fluctuating	NN	O	O
patients	NN	O	O
relative	NN	O	O
to	NN	O	O
stable	NN	O	O
patients	NN	O	O
.	NN	O	O

Syndrome	NN	O	B
of	NN	O	I
inappropriate	NN	O	I
secretion	NN	O	I
of	NN	O	I
antidiuretic	NN	O	I
hormone	NN	O	I
after	NN	O	O
infusional	NN	O	O
vincristine	NN	O	O
.	NN	O	O

A	NN	O	O
77	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
refractory	NN	O	O
multiple	NN	O	B
myeloma	NN	O	I
was	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
4	NN	O	O
-	NN	O	O
day	NN	O	O
continuous	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
vincristine	NN	O	O
and	NN	O	O
doxorubicin	NN	O	O
and	NN	O	O
4	NN	O	O
days	NN	O	O
of	NN	O	O
oral	NN	O	O
dexamethasone	NN	O	O
.	NN	O	O

Nine	NN	O	O
days	NN	O	O
after	NN	O	O
her	NN	O	O
second	NN	O	O
cycle	NN	O	O
she	NN	O	O
presented	NN	O	O
with	NN	O	O
lethargy	NN	O	B
and	NN	O	O
weakness	NN	O	B
associated	NN	O	O
with	NN	O	O
hyponatremia	NN	O	B
.	NN	O	O

Evaluation	NN	O	O
revealed	NN	O	O
the	NN	O	O
syndrome	NN	O	B
of	NN	O	I
inappropriate	NN	O	I
secretion	NN	O	I
of	NN	O	I
antidiuretic	NN	O	I
hormone	NN	O	I
,	NN	O	O
which	NN	O	O
was	NN	O	O
attributed	NN	O	O
to	NN	O	O
the	NN	O	O
vincristine	NN	O	O
infusion	NN	O	O
.	NN	O	O

After	NN	O	O
normal	NN	O	O
serum	NN	O	O
sodium	NN	O	O
levels	NN	O	O
returned	NN	O	O
,	NN	O	O
further	NN	O	O
doxorubicin	NN	O	O
and	NN	O	O
dexamethasone	NN	O	O
chemotherapy	NN	O	O
without	NN	O	O
vincristine	NN	O	O
did	NN	O	O
not	NN	O	O
produce	NN	O	O
this	NN	O	O
complication	NN	O	O
.	NN	O	O

Heart	NN	O	B
failure	NN	O	I
:	NN	O	O
to	NN	O	O
digitalise	NN	O	O
or	NN	O	O
not	NN	O	O
?	NN	O	O

The	NN	O	O
view	NN	O	O
against	NN	O	O
.	NN	O	O

Despite	NN	O	O
extensive	NN	O	O
clinical	NN	O	O
experience	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
digoxin	NN	O	O
is	NN	O	O
still	NN	O	O
not	NN	O	O
well	NN	O	O
defined	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
digoxin	NN	O	O
is	NN	O	O
beneficial	NN	O	O
for	NN	O	O
ventricular	NN	O	O
rate	NN	O	O
control	NN	O	O
.	NN	O	O

For	NN	O	O
patients	NN	O	O
in	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
and	NN	O	O
heart	NN	O	B
failure	NN	O	I
the	NN	O	O
situation	NN	O	O
is	NN	O	O
less	NN	O	O
clear	NN	O	O
.	NN	O	O

Digoxin	NN	O	O
has	NN	O	O
a	NN	O	O
narrow	NN	O	O
therapeutic	NN	O	O
:	NN	O	O
toxic	NN	O	O
ratio	NN	O	O
and	NN	O	O
concentrations	NN	O	O
are	NN	O	O
affected	NN	O	O
by	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
drugs	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
digoxin	NN	O	O
has	NN	O	O
undesirable	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
increasing	NN	O	O
peripheral	NN	O	O
resistance	NN	O	O
and	NN	O	O
myocardial	NN	O	O
demands	NN	O	O
,	NN	O	O
and	NN	O	O
causing	NN	O	O
arrhythmias	NN	O	B
.	NN	O	O

There	NN	O	O
is	NN	O	O
a	NN	O	O
paucity	NN	O	O
of	NN	O	O
data	NN	O	O
from	NN	O	O
well	NN	O	O
-	NN	O	O
designed	NN	O	O
trials	NN	O	O
.	NN	O	O

The	NN	O	O
trials	NN	O	O
that	NN	O	O
are	NN	O	O
available	NN	O	O
are	NN	O	O
generally	NN	O	O
small	NN	O	O
with	NN	O	O
limitations	NN	O	O
in	NN	O	O
design	NN	O	O
and	NN	O	O
these	NN	O	O
show	NN	O	O
variation	NN	O	O
in	NN	O	O
patient	NN	O	O
benefit	NN	O	O
.	NN	O	O

More	NN	O	O
convincing	NN	O	O
evidence	NN	O	O
is	NN	O	O
required	NN	O	O
showing	NN	O	O
that	NN	O	O
digoxin	NN	O	O
improves	NN	O	O
symptoms	NN	O	O
or	NN	O	O
exercise	NN	O	O
capacity	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
no	NN	O	O
trial	NN	O	O
has	NN	O	O
had	NN	O	O
sufficient	NN	O	O
power	NN	O	O
to	NN	O	O
evaluate	NN	O	O
mortality	NN	O	O
.	NN	O	O

Pooled	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
other	NN	O	O
inotropic	NN	O	O
drugs	NN	O	O
shows	NN	O	O
an	NN	O	O
excess	NN	O	O
mortality	NN	O	O
and	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
possibility	NN	O	O
that	NN	O	O
digoxin	NN	O	O
may	NN	O	O
increase	NN	O	O
mortality	NN	O	O
after	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
(	NN	O	O
MI	NN	O	B
)	NN	O	O
.	NN	O	O

Angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
inhibitors	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
first	NN	O	O
as	NN	O	O
they	NN	O	O
are	NN	O	O
safer	NN	O	O
,	NN	O	O
do	NN	O	O
not	NN	O	O
require	NN	O	O
blood	NN	O	O
level	NN	O	O
monitoring	NN	O	O
,	NN	O	O
modify	NN	O	O
progression	NN	O	O
of	NN	O	O
disease	NN	O	O
,	NN	O	O
relieve	NN	O	O
symptoms	NN	O	O
,	NN	O	O
improve	NN	O	O
exercise	NN	O	O
tolerance	NN	O	O
and	NN	O	O
reduce	NN	O	O
mortality	NN	O	O
.	NN	O	O

Caution	NN	O	O
should	NN	O	O
be	NN	O	O
exercised	NN	O	O
in	NN	O	O
using	NN	O	O
digoxin	NN	O	O
until	NN	O	O
large	NN	O	O
mortality	NN	O	O
trials	NN	O	O
are	NN	O	O
completed	NN	O	O
showing	NN	O	O
either	NN	O	O
benefit	NN	O	O
or	NN	O	O
harm	NN	O	O
.	NN	O	O

Until	NN	O	O
then	NN	O	O
digoxin	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
a	NN	O	O
third	NN	O	O
-	NN	O	O
line	NN	O	O
therapy	NN	O	O
.	NN	O	O

Isradipine	NN	O	O
treatment	NN	O	O
for	NN	O	O
hypertension	NN	O	B
in	NN	O	O
general	NN	O	O
practice	NN	O	O
in	NN	O	O
Hong	NN	O	O
Kong	NN	O	O
.	NN	O	O

A	NN	O	O
6	NN	O	O
-	NN	O	O
week	NN	O	O
open	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
introduction	NN	O	O
of	NN	O	O
isradipine	NN	O	O
treatment	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
general	NN	O	O
practice	NN	O	O
in	NN	O	O
Hong	NN	O	O
Kong	NN	O	O
.	NN	O	O

303	NN	O	O
Chinese	NN	O	O
patients	NN	O	O
with	NN	O	O
mild	NN	O	O
to	NN	O	O
moderate	NN	O	O
hypertension	NN	O	B
entered	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Side	NN	O	O
effects	NN	O	O
were	NN	O	O
reported	NN	O	O
in	NN	O	O
21	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
and	NN	O	O
caused	NN	O	O
withdrawal	NN	O	O
from	NN	O	O
the	NN	O	O
study	NN	O	O
in	NN	O	O
3	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
main	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
were	NN	O	O
headache	NN	O	B
,	NN	O	O
dizziness	NN	O	B
,	NN	O	O
palpitation	NN	O	B
and	NN	O	O
flushing	NN	O	B
and	NN	O	O
these	NN	O	O
were	NN	O	O
not	NN	O	O
more	NN	O	O
frequent	NN	O	O
than	NN	O	O
reported	NN	O	O
in	NN	O	O
other	NN	O	O
studies	NN	O	O
with	NN	O	O
isradipine	NN	O	O
or	NN	O	O
with	NN	O	O
placebo	NN	O	O
.	NN	O	O

Supine	NN	O	O
blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
reduced	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
from	NN	O	O
170	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
20	NN	O	O
/	NN	O	O
102	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
mmHg	NN	O	O
to	NN	O	O
153	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
19	NN	O	O
/	NN	O	O
92	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
,	NN	O	O
147	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
18	NN	O	O
/	NN	O	O
88	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
and	NN	O	O
144	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
14	NN	O	O
/	NN	O	O
87	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
mmHg	NN	O	O
at	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
and	NN	O	O
6	NN	O	O
weeks	NN	O	O
respectively	NN	O	O
in	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
.	NN	O	O

Similar	NN	O	O
reductions	NN	O	O
occurred	NN	O	O
in	NN	O	O
standing	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
postural	NN	O	B
hypotension	NN	O	I
.	NN	O	O

Normalization	NN	O	O
and	NN	O	O
responder	NN	O	O
rates	NN	O	O
at	NN	O	O
6	NN	O	O
weeks	NN	O	O
were	NN	O	O
86	NN	O	O
%	NN	O	O
and	NN	O	O
69	NN	O	O
%	NN	O	O
respectively	NN	O	O
.	NN	O	O

Dosage	NN	O	O
was	NN	O	O
increased	NN	O	O
from	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
b	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O
to	NN	O	O
5	NN	O	O
mg	NN	O	O
b	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O
at	NN	O	O
4	NN	O	O
weeks	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
greater	NN	O	O
than	NN	O	O
90	NN	O	O
mmHg	NN	O	O
and	NN	O	O
their	NN	O	O
further	NN	O	O
response	NN	O	O
was	NN	O	O
greater	NN	O	O
than	NN	O	O
those	NN	O	O
remaining	NN	O	O
on	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
b	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O

Pharmacological	NN	O	O
characteristics	NN	O	O
and	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
galenic	NN	O	O
formulation	NN	O	O
of	NN	O	O
propofol	NN	O	O
without	NN	O	O
soyabean	NN	O	O
oil	NN	O	O
.	NN	O	O

We	NN	O	O
compared	NN	O	O
the	NN	O	O
pharmacokinetics	NN	O	O
,	NN	O	O
pharmacodynamics	NN	O	O
and	NN	O	O
safety	NN	O	O
profile	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
galenic	NN	O	O
formulation	NN	O	O
of	NN	O	O
propofol	NN	O	O
(	NN	O	O
AM149	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
does	NN	O	O
not	NN	O	O
contain	NN	O	O
soyabean	NN	O	O
oil	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
standard	NN	O	O
formulation	NN	O	O
of	NN	O	O
propofol	NN	O	O
(	NN	O	O
Disoprivan	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
randomised	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
cross	NN	O	O
-	NN	O	O
over	NN	O	O
study	NN	O	O
,	NN	O	O
30	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
received	NN	O	O
a	NN	O	O
single	NN	O	O
intravenous	NN	O	O
bolus	NN	O	O
injection	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
propofol	NN	O	O
.	NN	O	O

Plasma	NN	O	O
propofol	NN	O	O
levels	NN	O	O
were	NN	O	O
measured	NN	O	O
for	NN	O	O
48	NN	O	O
h	NN	O	O
following	NN	O	O
drug	NN	O	O
administration	NN	O	O
and	NN	O	O
evaluated	NN	O	O
according	NN	O	O
to	NN	O	O
a	NN	O	O
three	NN	O	O
-	NN	O	O
compartment	NN	O	O
model	NN	O	O
.	NN	O	O

The	NN	O	O
pharmacodynamic	NN	O	O
parameters	NN	O	O
assessed	NN	O	O
included	NN	O	O
induction	NN	O	O
and	NN	O	O
emergence	NN	O	O
times	NN	O	O
,	NN	O	O
respiratory	NN	O	O
and	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
,	NN	O	O
and	NN	O	O
pain	NN	O	B
on	NN	O	O
injection	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
monitored	NN	O	O
for	NN	O	O
side	NN	O	O
effects	NN	O	O
over	NN	O	O
48	NN	O	O
h	NN	O	O
.	NN	O	O

Owing	NN	O	O
to	NN	O	O
a	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
thrombophlebitis	NN	O	B
,	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
terminated	NN	O	O
prematurely	NN	O	O
and	NN	O	O
only	NN	O	O
the	NN	O	O
data	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
parallel	NN	O	O
treatment	NN	O	O
groups	NN	O	O
(	NN	O	O
15	NN	O	O
patients	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
)	NN	O	O
were	NN	O	O
analysed	NN	O	O
.	NN	O	O

Plasma	NN	O	O
concentrations	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
formulations	NN	O	O
.	NN	O	O

Anaesthesia	NN	O	O
induction	NN	O	O
and	NN	O	O
emergence	NN	O	O
times	NN	O	O
,	NN	O	O
respiratory	NN	O	O
and	NN	O	O
cardiovascular	NN	O	O
variables	NN	O	O
showed	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
treatment	NN	O	O
groups	NN	O	O
.	NN	O	O

Pain	NN	O	B
on	NN	O	O
injection	NN	O	O
(	NN	O	O
80	NN	O	O
vs	NN	O	O
.	NN	O	O
20	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
and	NN	O	O
thrombophlebitis	NN	O	B
(	NN	O	O
93	NN	O	O
.	NN	O	O
3	NN	O	O
vs	NN	O	O
.	NN	O	O
6	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
occurred	NN	O	O
more	NN	O	O
frequently	NN	O	O
with	NN	O	O
AM149	NN	O	O
than	NN	O	O
with	NN	O	O
Disoprivan	NN	O	O
.	NN	O	O

Although	NN	O	O
both	NN	O	O
formulations	NN	O	O
had	NN	O	O
similar	NN	O	O
pharmacokinetic	NN	O	O
and	NN	O	O
pharmacodynamic	NN	O	O
profiles	NN	O	O
the	NN	O	O
new	NN	O	O
formulation	NN	O	O
is	NN	O	O
not	NN	O	O
suitable	NN	O	O
for	NN	O	O
clinical	NN	O	O
use	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
thrombophlebitis	NN	O	B
produced	NN	O	O
.	NN	O	O

Pure	NN	O	B
red	NN	O	I
cell	NN	O	I
aplasia	NN	O	I
,	NN	O	O
toxic	NN	O	B
dermatitis	NN	O	I
and	NN	O	O
lymphadenopathy	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
taking	NN	O	O
diphenylhydantoin	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
taking	NN	O	O
diphenylhydantoin	NN	O	O
for	NN	O	O
3	NN	O	O
weeks	NN	O	O
developed	NN	O	O
a	NN	O	O
generalized	NN	O	O
skin	NN	O	B
rash	NN	O	I
,	NN	O	O
lymphadenopathy	NN	O	B
and	NN	O	O
pure	NN	O	B
red	NN	O	I
cell	NN	O	I
aplasia	NN	O	I
.	NN	O	O

After	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
the	NN	O	O
pharmacon	NN	O	O
all	NN	O	O
symptoms	NN	O	O
disappeared	NN	O	O
spontaneously	NN	O	O
.	NN	O	O

Skin	NN	O	B
rash	NN	O	I
is	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
known	NN	O	O
complication	NN	O	O
of	NN	O	O
diphenylhydantoin	NN	O	O
treatment	NN	O	O
as	NN	O	O
is	NN	O	O
benign	NN	O	O
and	NN	O	O
malignant	NN	O	O
lymphadenopathy	NN	O	B
.	NN	O	O

Pure	NN	O	B
red	NN	O	I
cell	NN	O	I
aplasia	NN	O	I
associated	NN	O	O
with	NN	O	O
diphenylhydantoin	NN	O	O
medication	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
3	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
exact	NN	O	O
mechanism	NN	O	O
by	NN	O	O
which	NN	O	O
diphenylhydantoin	NN	O	O
exerts	NN	O	O
its	NN	O	O
toxic	NN	O	O
effects	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
patient	NN	O	O
the	NN	O	O
time	NN	O	O
relation	NN	O	O
between	NN	O	O
the	NN	O	O
ingestion	NN	O	O
of	NN	O	O
diphenylhydantoin	NN	O	O
and	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
the	NN	O	O
skin	NN	O	B
rash	NN	O	I
,	NN	O	O
lymphadenopathy	NN	O	B
and	NN	O	O
pure	NN	O	B
red	NN	O	I
cell	NN	O	I
aplasia	NN	O	I
is	NN	O	O
very	NN	O	O
suggestive	NN	O	O
of	NN	O	O
a	NN	O	O
direct	NN	O	O
connection	NN	O	O
.	NN	O	O

Vinorelbine	NN	O	O
-	NN	O	O
related	NN	O	O
cardiac	NN	O	O
events	NN	O	O
:	NN	O	O
a	NN	O	O
meta	NN	O	O
-	NN	O	O
analysis	NN	O	O
of	NN	O	O
randomized	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O

Several	NN	O	O
cases	NN	O	O
of	NN	O	O
cardiac	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
related	NN	O	O
to	NN	O	O
vinorelbine	NN	O	O
(	NN	O	O
VNR	NN	O	O
)	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
quantify	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
these	NN	O	O
cardiac	NN	O	O
events	NN	O	O
,	NN	O	O
we	NN	O	O
performed	NN	O	O
a	NN	O	O
meta	NN	O	O
-	NN	O	O
analysis	NN	O	O
of	NN	O	O
clinical	NN	O	O
trials	NN	O	O
comparing	NN	O	O
VNR	NN	O	O
with	NN	O	O
other	NN	O	O
chemotherapeutic	NN	O	O
agents	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
various	NN	O	O
malignancies	NN	O	B
.	NN	O	O

Randomized	NN	O	O
clinical	NN	O	O
trials	NN	O	O
comparing	NN	O	O
VNR	NN	O	O
with	NN	O	O
other	NN	O	O
drugs	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
cancer	NN	O	B
were	NN	O	O
searched	NN	O	O
in	NN	O	O
Medline	NN	O	O
,	NN	O	O
Embase	NN	O	O
,	NN	O	O
Evidence	NN	O	O
-	NN	O	O
based	NN	O	O
Medicine	NN	O	O
Reviews	NN	O	O
databases	NN	O	O
and	NN	O	O
the	NN	O	O
Cochrane	NN	O	O
library	NN	O	O
from	NN	O	O
1987	NN	O	O
to	NN	O	O
2002	NN	O	O
.	NN	O	O

Outcomes	NN	O	O
of	NN	O	O
interest	NN	O	O
were	NN	O	O
severe	NN	O	O
cardiac	NN	O	O
events	NN	O	O
,	NN	O	O
toxic	NN	O	O
deaths	NN	O	O
and	NN	O	O
cardiac	NN	O	O
event	NN	O	O
-	NN	O	O
related	NN	O	O
deaths	NN	O	O
reported	NN	O	O
in	NN	O	O
each	NN	O	O
publication	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
19	NN	O	O
trials	NN	O	O
,	NN	O	O
involving	NN	O	O
2441	NN	O	O
patients	NN	O	O
treated	NN	O	O
by	NN	O	O
VNR	NN	O	O
and	NN	O	O
2050	NN	O	O
control	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
cardiac	NN	O	O
events	NN	O	O
with	NN	O	O
VNR	NN	O	O
was	NN	O	O
1	NN	O	O
.	NN	O	O
19	NN	O	O
%	NN	O	O
[	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	NN	O	O
CI	NN	O	O
)	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
75	NN	O	O
;	NN	O	O
1	NN	O	O
.	NN	O	O
67	NN	O	O
)	NN	O	O
]	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
cardiac	NN	O	O
events	NN	O	O
between	NN	O	O
VNR	NN	O	O
and	NN	O	O
other	NN	O	O
drugs	NN	O	O
[	NN	O	O
odds	NN	O	O
ratio	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
92	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
54	NN	O	O
;	NN	O	O
1	NN	O	O
.	NN	O	O
55	NN	O	O
)	NN	O	O
]	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
of	NN	O	O
VNR	NN	O	O
cardiac	NN	O	O
events	NN	O	O
was	NN	O	O
similar	NN	O	O
to	NN	O	O
vindesine	NN	O	O
(	NN	O	O
VDS	NN	O	O
)	NN	O	O
and	NN	O	O
other	NN	O	O
cardiotoxic	NN	O	B
drugs	NN	O	O
[	NN	O	O
fluorouracil	NN	O	O
,	NN	O	O
anthracyclines	NN	O	O
,	NN	O	O
gemcitabine	NN	O	O
(	NN	O	O
GEM	NN	O	O
)	NN	O	O
em	NN	O	O
leader	NN	O	O
]	NN	O	O
.	NN	O	O

Even	NN	O	O
if	NN	O	O
it	NN	O	O
did	NN	O	O
not	NN	O	O
reach	NN	O	O
statistical	NN	O	O
significance	NN	O	O
because	NN	O	O
of	NN	O	O
a	NN	O	O
few	NN	O	O
number	NN	O	O
of	NN	O	O
cases	NN	O	O
,	NN	O	O
the	NN	O	O
risk	NN	O	O
was	NN	O	O
lower	NN	O	O
in	NN	O	O
trials	NN	O	O
excluding	NN	O	O
patients	NN	O	O
with	NN	O	O
cardiac	NN	O	O
history	NN	O	O
,	NN	O	O
and	NN	O	O
seemed	NN	O	O
to	NN	O	O
be	NN	O	O
higher	NN	O	O
in	NN	O	O
trials	NN	O	O
including	NN	O	O
patients	NN	O	O
with	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
cardiac	NN	O	B
diseases	NN	O	I
.	NN	O	O

Vinorelbine	NN	O	O
-	NN	O	O
related	NN	O	O
cardiac	NN	O	O
events	NN	O	O
concern	NN	O	O
about	NN	O	O
1	NN	O	O
%	NN	O	O
of	NN	O	O
treated	NN	O	O
patients	NN	O	O
in	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
risk	NN	O	O
associated	NN	O	O
with	NN	O	O
VNR	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
other	NN	O	O
chemotherapeutic	NN	O	O
agents	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
indications	NN	O	O
.	NN	O	O

MRI	NN	O	O
findings	NN	O	O
of	NN	O	O
hypoxic	NN	O	O
cortical	NN	O	O
laminar	NN	O	O
necrosis	NN	O	B
in	NN	O	O
a	NN	O	O
child	NN	O	O
with	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
crisis	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
findings	NN	O	O
of	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
who	NN	O	O
had	NN	O	O
a	NN	O	O
rapidly	NN	O	O
installing	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
crisis	NN	O	O
induced	NN	O	O
by	NN	O	O
trimethoprim	NN	O	O
-	NN	O	O
sulfomethoxazole	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
cerebral	NN	O	B
anoxia	NN	O	I
leading	NN	O	O
to	NN	O	O
permanent	NN	O	O
damage	NN	O	O
.	NN	O	O

Magnetic	NN	O	O
Resonance	NN	O	O
imaging	NN	O	O
revealed	NN	O	O
cortical	NN	O	O
laminar	NN	O	O
necrosis	NN	O	B
in	NN	O	O
arterial	NN	O	O
border	NN	O	O
zones	NN	O	O
in	NN	O	O
both	NN	O	O
cerebral	NN	O	O
hemispheres	NN	O	O
,	NN	O	O
ischemic	NN	O	O
changes	NN	O	O
in	NN	O	O
subcortical	NN	O	O
white	NN	O	O
matter	NN	O	O
of	NN	O	O
left	NN	O	O
cerebral	NN	O	O
hemisphere	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
left	NN	O	O
putamen	NN	O	O
.	NN	O	O

Although	NN	O	O
cortical	NN	O	O
laminar	NN	O	O
necrosis	NN	O	B
is	NN	O	O
a	NN	O	O
classic	NN	O	O
entity	NN	O	O
in	NN	O	O
adulthood	NN	O	O
related	NN	O	O
to	NN	O	O
conditions	NN	O	O
of	NN	O	O
energy	NN	O	O
depletions	NN	O	O
,	NN	O	O
there	NN	O	O
are	NN	O	O
few	NN	O	O
reports	NN	O	O
available	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

A	NN	O	O
wide	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
is	NN	O	O
also	NN	O	O
presented	NN	O	O
.	NN	O	O

The	NN	O	O
natural	NN	O	O
history	NN	O	O
of	NN	O	O
Vigabatrin	NN	O	O
associated	NN	O	O
visual	NN	O	B
field	NN	O	I
defects	NN	O	I
in	NN	O	O
patients	NN	O	O
electing	NN	O	O
to	NN	O	O
continue	NN	O	O
their	NN	O	O
medication	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
natural	NN	O	O
history	NN	O	O
of	NN	O	O
visual	NN	O	B
field	NN	O	I
defects	NN	O	I
in	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
known	NN	O	O
to	NN	O	O
have	NN	O	O
Vigabatrin	NN	O	O
-	NN	O	O
associated	NN	O	O
changes	NN	O	O
who	NN	O	O
elected	NN	O	O
to	NN	O	O
continue	NN	O	O
the	NN	O	O
medication	NN	O	O
because	NN	O	O
of	NN	O	O
good	NN	O	O
seizure	NN	O	B
control	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
All	NN	O	O
patients	NN	O	O
taking	NN	O	O
Vigabatrin	NN	O	O
alone	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
other	NN	O	O
antiepileptic	NN	O	O
drugs	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
5	NN	O	O
years	NN	O	O
(	NN	O	O
range	NN	O	O
5	NN	O	O
-	NN	O	O
12	NN	O	O
years	NN	O	O
)	NN	O	O
were	NN	O	O
entered	NN	O	O
into	NN	O	O
a	NN	O	O
visual	NN	O	O
surveillance	NN	O	O
programme	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
followed	NN	O	O
up	NN	O	O
at	NN	O	O
6	NN	O	O
-	NN	O	O
monthly	NN	O	O
intervals	NN	O	O
for	NN	O	O
not	NN	O	O
less	NN	O	O
than	NN	O	O
18	NN	O	O
months	NN	O	O
(	NN	O	O
range	NN	O	O
18	NN	O	O
-	NN	O	O
43	NN	O	O
months	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
,	NN	O	O
16	NN	O	O
patients	NN	O	O
with	NN	O	O
unequivocal	NN	O	O
defects	NN	O	O
continued	NN	O	O
the	NN	O	O
medication	NN	O	O
.	NN	O	O

Following	NN	O	O
already	NN	O	O
published	NN	O	O
methodology	NN	O	O
(	NN	O	O
Eye	NN	O	O
2002	NN	O	O
;	NN	O	O
16	NN	O	O
;	NN	O	O
567	NN	O	O
-	NN	O	O
571	NN	O	O
)	NN	O	O
monocular	NN	O	O
mean	NN	O	O
radial	NN	O	O
degrees	NN	O	O
(	NN	O	O
MRDs	NN	O	O
)	NN	O	O
to	NN	O	O
the	NN	O	O
I	NN	O	O
/	NN	O	O
4e	NN	O	O
isopter	NN	O	O
on	NN	O	O
Goldmann	NN	O	O
perimetry	NN	O	O
was	NN	O	O
calculated	NN	O	O
for	NN	O	O
the	NN	O	O
right	NN	O	O
eye	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
discovery	NN	O	O
of	NN	O	O
a	NN	O	O
visual	NN	O	B
field	NN	O	I
defect	NN	O	I
and	NN	O	O
again	NN	O	O
after	NN	O	O
not	NN	O	O
less	NN	O	O
than	NN	O	O
18	NN	O	O
months	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Mean	NN	O	O
right	NN	O	O
eye	NN	O	O
MRD	NN	O	O
at	NN	O	O
presentation	NN	O	O
was	NN	O	O
36	NN	O	O
.	NN	O	O
98	NN	O	O
degrees	NN	O	O
(	NN	O	O
range	NN	O	O
22	NN	O	O
.	NN	O	O
25	NN	O	O
-	NN	O	O
51	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
,	NN	O	O
compared	NN	O	O
to	NN	O	O
38	NN	O	O
.	NN	O	O
40	NN	O	O
degrees	NN	O	O
(	NN	O	O
range	NN	O	O
22	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
49	NN	O	O
.	NN	O	O
75	NN	O	O
)	NN	O	O
after	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
338	NN	O	O
unpaired	NN	O	O
t	NN	O	O
-	NN	O	O
test	NN	O	O
.	NN	O	O

Only	NN	O	O
one	NN	O	O
patient	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
deterioration	NN	O	B
in	NN	O	I
visual	NN	O	I
field	NN	O	I
during	NN	O	O
the	NN	O	O
study	NN	O	O
period	NN	O	O
and	NN	O	O
discontinued	NN	O	O
treatment	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Established	NN	O	O
visual	NN	O	B
field	NN	O	I
defects	NN	O	I
presumed	NN	O	O
to	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
Vigabatrin	NN	O	O
therapy	NN	O	O
did	NN	O	O
not	NN	O	O
usually	NN	O	O
progress	NN	O	O
in	NN	O	O
spite	NN	O	O
of	NN	O	O
continuing	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
medication	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
give	NN	O	O
support	NN	O	O
to	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
Vigabatrin	NN	O	O
-	NN	O	O
associated	NN	O	O
visual	NN	O	B
field	NN	O	I
defects	NN	O	I
may	NN	O	O
be	NN	O	O
an	NN	O	O
idiosyncratic	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reaction	NN	O	O
rather	NN	O	O
than	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
rosaceiform	NN	O	O
dermatitis	NN	O	B
during	NN	O	O
treatment	NN	O	O
of	NN	O	O
facial	NN	O	B
inflammatory	NN	O	I
dermatoses	NN	O	I
with	NN	O	O
tacrolimus	NN	O	O
ointment	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Tacrolimus	NN	O	O
ointment	NN	O	O
is	NN	O	O
increasingly	NN	O	O
used	NN	O	O
for	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
treatment	NN	O	O
of	NN	O	O
sensitive	NN	O	O
areas	NN	O	O
such	NN	O	O
as	NN	O	O
the	NN	O	O
face	NN	O	O
,	NN	O	O
and	NN	O	O
recent	NN	O	O
observations	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
treatment	NN	O	O
is	NN	O	O
effective	NN	O	O
in	NN	O	O
steroid	NN	O	O
-	NN	O	O
aggravated	NN	O	O
rosacea	NN	O	B
and	NN	O	O
perioral	NN	O	B
dermatitis	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
rosaceiform	NN	O	O
dermatitis	NN	O	B
as	NN	O	O
a	NN	O	O
complication	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
tacrolimus	NN	O	O
ointment	NN	O	O
.	NN	O	O

OBSERVATIONS	NN	O	O
:	NN	O	O
Six	NN	O	O
adult	NN	O	O
patients	NN	O	O
with	NN	O	O
inflammatory	NN	O	B
facial	NN	O	I
dermatoses	NN	O	I
were	NN	O	O
treated	NN	O	O
with	NN	O	O
tacrolimus	NN	O	O
ointment	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
ineffectiveness	NN	O	O
of	NN	O	O
standard	NN	O	O
treatments	NN	O	O
.	NN	O	O

Within	NN	O	O
2	NN	O	O
to	NN	O	O
3	NN	O	O
weeks	NN	O	O
of	NN	O	O
initially	NN	O	O
effective	NN	O	O
and	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
treatment	NN	O	O
,	NN	O	O
3	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
rosacea	NN	O	B
and	NN	O	O
1	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
acne	NN	O	B
experienced	NN	O	O
sudden	NN	O	O
worsening	NN	O	O
with	NN	O	O
pustular	NN	O	O
rosaceiform	NN	O	O
lesions	NN	O	O
.	NN	O	O

Biopsy	NN	O	O
revealed	NN	O	O
an	NN	O	O
abundance	NN	O	O
of	NN	O	O
Demodex	NN	O	O
mites	NN	O	O
in	NN	O	O
2	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

In	NN	O	O
1	NN	O	O
patient	NN	O	O
with	NN	O	O
eyelid	NN	O	O
eczema	NN	O	B
,	NN	O	O
rosaceiform	NN	O	O
periocular	NN	O	B
dermatitis	NN	O	I
gradually	NN	O	O
appeared	NN	O	O
after	NN	O	O
3	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

In	NN	O	O
1	NN	O	O
patient	NN	O	O
with	NN	O	O
atopic	NN	O	B
dermatitis	NN	O	I
,	NN	O	O
telangiectatic	NN	O	O
and	NN	O	O
papular	NN	O	B
rosacea	NN	O	I
insidiously	NN	O	O
appeared	NN	O	O
after	NN	O	O
5	NN	O	O
months	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Our	NN	O	O
observations	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
spectrum	NN	O	O
of	NN	O	O
rosaceiform	NN	O	O
dermatitis	NN	O	B
as	NN	O	O
a	NN	O	O
complication	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
tacrolimus	NN	O	O
ointment	NN	O	O
is	NN	O	O
heterogeneous	NN	O	O
.	NN	O	O

A	NN	O	O
variety	NN	O	O
of	NN	O	O
factors	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
vasoactive	NN	O	O
properties	NN	O	O
of	NN	O	O
tacrolimus	NN	O	O
,	NN	O	O
proliferation	NN	O	O
of	NN	O	O
Demodex	NN	O	O
due	NN	O	O
to	NN	O	O
local	NN	O	O
immunosuppression	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
occlusive	NN	O	O
properties	NN	O	O
of	NN	O	O
the	NN	O	O
ointment	NN	O	O
,	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
observed	NN	O	O
phenomena	NN	O	O
.	NN	O	O

Future	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
to	NN	O	O
identify	NN	O	O
individual	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

Intravascular	NN	O	O
hemolysis	NN	O	B
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
following	NN	O	O
intermittent	NN	O	O
rifampin	NN	O	O
therapy	NN	O	O
.	NN	O	O

Renal	NN	O	B
failure	NN	O	I
is	NN	O	O
a	NN	O	O
rare	NN	O	O
complication	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
rifampin	NN	O	O
.	NN	O	O

Intravascular	NN	O	O
hemolysis	NN	O	B
leading	NN	O	O
to	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
following	NN	O	O
rifampin	NN	O	O
therapy	NN	O	O
is	NN	O	O
extremely	NN	O	O
rare	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
with	NN	O	O
leprosy	NN	O	B
who	NN	O	O
developed	NN	O	O
hemolysis	NN	O	B
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
following	NN	O	O
rifampin	NN	O	O
are	NN	O	O
reported	NN	O	O
.	NN	O	O

Structural	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
the	NN	O	O
brains	NN	O	O
of	NN	O	O
human	NN	O	O
subjects	NN	O	O
who	NN	O	O
use	NN	O	O
methamphetamine	NN	O	O
.	NN	O	O

We	NN	O	O
visualize	NN	O	O
,	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
,	NN	O	O
the	NN	O	O
profile	NN	O	O
of	NN	O	O
structural	NN	O	B
deficits	NN	O	I
in	NN	O	I
the	NN	O	I
human	NN	O	I
brain	NN	O	I
associated	NN	O	O
with	NN	O	O
chronic	NN	O	O
methamphetamine	NN	O	O
(	NN	O	O
MA	NN	O	O
)	NN	O	O
abuse	NN	O	O
.	NN	O	O

Studies	NN	O	O
of	NN	O	O
human	NN	O	O
subjects	NN	O	O
who	NN	O	O
have	NN	O	O
used	NN	O	O
MA	NN	O	O
chronically	NN	O	O
have	NN	O	O
revealed	NN	O	O
deficits	NN	O	O
in	NN	O	O
dopaminergic	NN	O	O
and	NN	O	O
serotonergic	NN	O	O
systems	NN	O	O
and	NN	O	O
cerebral	NN	O	O
metabolic	NN	O	B
abnormalities	NN	O	I
.	NN	O	O

Using	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
MRI	NN	O	O
)	NN	O	O
and	NN	O	O
new	NN	O	O
computational	NN	O	O
brain	NN	O	O
-	NN	O	O
mapping	NN	O	O
techniques	NN	O	O
,	NN	O	O
we	NN	O	O
determined	NN	O	O
the	NN	O	O
pattern	NN	O	O
of	NN	O	O
structural	NN	O	O
brain	NN	O	O
alterations	NN	O	O
associated	NN	O	O
with	NN	O	O
chronic	NN	O	O
MA	NN	O	O
abuse	NN	O	O
in	NN	O	O
human	NN	O	O
subjects	NN	O	O
and	NN	O	O
related	NN	O	O
these	NN	O	O
deficits	NN	O	O
to	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
.	NN	O	O

We	NN	O	O
used	NN	O	O
high	NN	O	O
-	NN	O	O
resolution	NN	O	O
MRI	NN	O	O
and	NN	O	O
surface	NN	O	O
-	NN	O	O
based	NN	O	O
computational	NN	O	O
image	NN	O	O
analyses	NN	O	O
to	NN	O	O
map	NN	O	O
regional	NN	O	O
abnormalities	NN	O	B
in	NN	O	I
the	NN	O	I
cortex	NN	O	I
,	NN	O	I
hippocampus	NN	O	I
,	NN	O	I
white	NN	O	I
matter	NN	O	I
,	NN	O	I
and	NN	O	I
ventricles	NN	O	I
in	NN	O	O
22	NN	O	O
human	NN	O	O
subjects	NN	O	O
who	NN	O	O
used	NN	O	O
MA	NN	O	O
and	NN	O	O
21	NN	O	O
age	NN	O	O
-	NN	O	O
matched	NN	O	O
,	NN	O	O
healthy	NN	O	O
controls	NN	O	O
.	NN	O	O

Cortical	NN	O	O
maps	NN	O	O
revealed	NN	O	O
severe	NN	O	O
gray	NN	O	O
-	NN	O	O
matter	NN	O	O
deficits	NN	O	O
in	NN	O	O
the	NN	O	O
cingulate	NN	O	O
,	NN	O	O
limbic	NN	O	O
,	NN	O	O
and	NN	O	O
paralimbic	NN	O	O
cortices	NN	O	O
of	NN	O	O
MA	NN	O	O
abusers	NN	O	O
(	NN	O	O
averaging	NN	O	O
11	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
below	NN	O	O
control	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
average	NN	O	O
,	NN	O	O
MA	NN	O	O
abusers	NN	O	O
had	NN	O	O
7	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
smaller	NN	O	O
hippocampal	NN	O	O
volumes	NN	O	O
than	NN	O	O
control	NN	O	O
subjects	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
;	NN	O	O
left	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
;	NN	O	O
right	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
and	NN	O	O
significant	NN	O	O
white	NN	O	O
-	NN	O	O
matter	NN	O	O
hypertrophy	NN	O	B
(	NN	O	O
7	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Hippocampal	NN	O	O
deficits	NN	O	O
were	NN	O	O
mapped	NN	O	O
and	NN	O	O
correlated	NN	O	O
with	NN	O	O
memory	NN	O	O
performance	NN	O	O
on	NN	O	O
a	NN	O	O
word	NN	O	O
-	NN	O	O
recall	NN	O	O
test	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

MRI	NN	O	O
-	NN	O	O
based	NN	O	O
maps	NN	O	O
suggest	NN	O	O
that	NN	O	O
chronic	NN	O	O
methamphetamine	NN	O	O
abuse	NN	O	O
causes	NN	O	O
a	NN	O	O
selective	NN	O	O
pattern	NN	O	O
of	NN	O	O
cerebral	NN	O	O
deterioration	NN	O	O
that	NN	O	O
contributes	NN	O	O
to	NN	O	O
impaired	NN	O	B
memory	NN	O	I
performance	NN	O	I
.	NN	O	O

MA	NN	O	O
may	NN	O	O
selectively	NN	O	O
damage	NN	O	O
the	NN	O	O
medial	NN	O	O
temporal	NN	O	O
lobe	NN	O	O
and	NN	O	O
,	NN	O	O
consistent	NN	O	O
with	NN	O	O
metabolic	NN	O	O
studies	NN	O	O
,	NN	O	O
the	NN	O	O
cingulate	NN	O	O
-	NN	O	O
limbic	NN	O	O
cortex	NN	O	O
,	NN	O	O
inducing	NN	O	O
neuroadaptation	NN	O	O
,	NN	O	O
neuropil	NN	O	O
reduction	NN	O	O
,	NN	O	O
or	NN	O	O
cell	NN	O	O
death	NN	O	O
.	NN	O	O

Prominent	NN	O	O
white	NN	O	O
-	NN	O	O
matter	NN	O	O
hypertrophy	NN	O	B
may	NN	O	O
result	NN	O	O
from	NN	O	O
altered	NN	O	O
myelination	NN	O	O
and	NN	O	O
adaptive	NN	O	O
glial	NN	O	O
changes	NN	O	O
,	NN	O	O
including	NN	O	O
gliosis	NN	O	B
secondary	NN	O	O
to	NN	O	O
neuronal	NN	O	B
damage	NN	O	I
.	NN	O	O

These	NN	O	O
brain	NN	O	O
substrates	NN	O	O
may	NN	O	O
help	NN	O	O
account	NN	O	O
for	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
MA	NN	O	O
abuse	NN	O	O
,	NN	O	O
providing	NN	O	O
therapeutic	NN	O	O
targets	NN	O	O
for	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
brain	NN	O	B
injury	NN	O	I
.	NN	O	O

Disruption	NN	O	O
of	NN	O	O
hepatic	NN	O	O
lipid	NN	O	O
homeostasis	NN	O	O
in	NN	O	O
mice	NN	O	O
after	NN	O	O
amiodarone	NN	O	O
treatment	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
peroxisome	NN	O	O
proliferator	NN	O	O
-	NN	O	O
activated	NN	O	O
receptor	NN	O	O
-	NN	O	O
alpha	NN	O	O
target	NN	O	O
gene	NN	O	O
activation	NN	O	O
.	NN	O	O

Amiodarone	NN	O	O
,	NN	O	O
an	NN	O	O
efficacious	NN	O	O
and	NN	O	O
widely	NN	O	O
used	NN	O	O
antiarrhythmic	NN	O	O
agent	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
cause	NN	O	O
hepatotoxicity	NN	O	B
in	NN	O	O
some	NN	O	O
patients	NN	O	O
.	NN	O	O

To	NN	O	O
gain	NN	O	O
insight	NN	O	O
into	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
this	NN	O	O
unwanted	NN	O	O
effect	NN	O	O
,	NN	O	O
mice	NN	O	O
were	NN	O	O
administered	NN	O	O
various	NN	O	O
doses	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
and	NN	O	O
examined	NN	O	O
for	NN	O	O
changes	NN	O	O
in	NN	O	O
hepatic	NN	O	O
histology	NN	O	O
and	NN	O	O
gene	NN	O	O
regulation	NN	O	O
.	NN	O	O

Amiodarone	NN	O	O
induced	NN	O	O
hepatomegaly	NN	O	B
,	NN	O	O
hepatocyte	NN	O	O
microvesicular	NN	O	O
lipid	NN	O	O
accumulation	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
serum	NN	O	O
triglycerides	NN	O	O
and	NN	O	O
glucose	NN	O	O
.	NN	O	O

Northern	NN	O	O
blot	NN	O	O
analysis	NN	O	O
of	NN	O	O
hepatic	NN	O	O
RNA	NN	O	O
revealed	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
genes	NN	O	O
critical	NN	O	O
for	NN	O	O
fatty	NN	O	O
acid	NN	O	O
oxidation	NN	O	O
,	NN	O	O
lipoprotein	NN	O	O
assembly	NN	O	O
,	NN	O	O
and	NN	O	O
lipid	NN	O	O
transport	NN	O	O
.	NN	O	O

Many	NN	O	O
of	NN	O	O
these	NN	O	O
genes	NN	O	O
are	NN	O	O
regulated	NN	O	O
by	NN	O	O
the	NN	O	O
peroxisome	NN	O	O
proliferator	NN	O	O
-	NN	O	O
activated	NN	O	O
receptor	NN	O	O
-	NN	O	O
alpha	NN	O	O
(	NN	O	O
PPARalpha	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
ligand	NN	O	O
-	NN	O	O
activated	NN	O	O
nuclear	NN	O	O
hormone	NN	O	O
receptor	NN	O	O
transcription	NN	O	O
factor	NN	O	O
.	NN	O	O

The	NN	O	O
absence	NN	O	O
of	NN	O	O
induction	NN	O	O
of	NN	O	O
these	NN	O	O
genes	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
hepatomegaly	NN	O	B
in	NN	O	O
PPARalpha	NN	O	O
knockout	NN	O	O
[	NN	O	O
PPARalpha	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
]	NN	O	O
mice	NN	O	O
indicated	NN	O	O
that	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
were	NN	O	O
dependent	NN	O	O
upon	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
functional	NN	O	O
PPARalpha	NN	O	O
gene	NN	O	O
.	NN	O	O

Compared	NN	O	O
to	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
mice	NN	O	O
,	NN	O	O
treatment	NN	O	O
of	NN	O	O
PPARalpha	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
with	NN	O	O
amiodarone	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
increased	NN	O	O
rate	NN	O	O
and	NN	O	O
extent	NN	O	O
of	NN	O	O
total	NN	O	O
body	NN	O	O
weight	NN	O	B
loss	NN	O	I
.	NN	O	O

The	NN	O	O
inability	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
to	NN	O	O
directly	NN	O	O
activate	NN	O	O
either	NN	O	O
human	NN	O	O
or	NN	O	O
mouse	NN	O	O
PPARalpha	NN	O	O
transiently	NN	O	O
expressed	NN	O	O
in	NN	O	O
human	NN	O	O
HepG2	NN	O	O
hepatoma	NN	O	B
cells	NN	O	O
indicates	NN	O	O
that	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
on	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
this	NN	O	O
receptor	NN	O	O
were	NN	O	O
indirect	NN	O	O
.	NN	O	O

Based	NN	O	O
upon	NN	O	O
these	NN	O	O
results	NN	O	O
,	NN	O	O
we	NN	O	O
conclude	NN	O	O
that	NN	O	O
amiodarone	NN	O	O
disrupts	NN	O	O
hepatic	NN	O	O
lipid	NN	O	O
homeostasis	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
increased	NN	O	O
expression	NN	O	O
of	NN	O	O
PPARalpha	NN	O	O
target	NN	O	O
genes	NN	O	O
is	NN	O	O
secondary	NN	O	O
to	NN	O	O
this	NN	O	O
toxic	NN	O	O
effect	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
provide	NN	O	O
important	NN	O	O
new	NN	O	O
mechanistic	NN	O	O
information	NN	O	O
regarding	NN	O	O
the	NN	O	O
hepatotoxic	NN	O	B
effects	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
and	NN	O	O
indicate	NN	O	O
that	NN	O	O
PPARalpha	NN	O	O
protects	NN	O	O
against	NN	O	O
amiodarone	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatotoxicity	NN	O	B
.	NN	O	O

Safety	NN	O	O
and	NN	O	O
compliance	NN	O	O
with	NN	O	O
once	NN	O	O
-	NN	O	O
daily	NN	O	O
niacin	NN	O	O
extended	NN	O	O
-	NN	O	O
release	NN	O	O
/	NN	O	O
lovastatin	NN	O	O
as	NN	O	O
initial	NN	O	O
therapy	NN	O	O
in	NN	O	O
the	NN	O	O
Impact	NN	O	O
of	NN	O	O
Medical	NN	O	O
Subspecialty	NN	O	O
on	NN	O	O
Patient	NN	O	O
Compliance	NN	O	O
to	NN	O	O
Treatment	NN	O	O
(	NN	O	O
IMPACT	NN	O	O
)	NN	O	O
study	NN	O	O
.	NN	O	O

Niacin	NN	O	O
extended	NN	O	O
-	NN	O	O
release	NN	O	O
/	NN	O	O
lovastatin	NN	O	O
is	NN	O	O
a	NN	O	O
new	NN	O	O
combination	NN	O	O
product	NN	O	O
approved	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
primary	NN	O	O
hypercholesterolemia	NN	O	B
and	NN	O	O
mixed	NN	O	O
dyslipidemia	NN	O	B
.	NN	O	O

This	NN	O	O
open	NN	O	O
-	NN	O	O
labeled	NN	O	O
,	NN	O	O
multicenter	NN	O	O
study	NN	O	O
evaluated	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
bedtime	NN	O	O
niacin	NN	O	O
extended	NN	O	O
-	NN	O	O
release	NN	O	O
/	NN	O	O
lovastatin	NN	O	O
when	NN	O	O
dosed	NN	O	O
as	NN	O	O
initial	NN	O	O
therapy	NN	O	O
and	NN	O	O
patient	NN	O	O
compliance	NN	O	O
to	NN	O	O
treatment	NN	O	O
in	NN	O	O
various	NN	O	O
clinical	NN	O	O
practice	NN	O	O
settings	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
4	NN	O	O
,	NN	O	O
499	NN	O	O
patients	NN	O	O
with	NN	O	O
dyslipidemia	NN	O	B
requiring	NN	O	O
drug	NN	O	O
intervention	NN	O	O
was	NN	O	O
enrolled	NN	O	O
at	NN	O	O
1	NN	O	O
,	NN	O	O
081	NN	O	O
sites	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
1	NN	O	O
tablet	NN	O	O
(	NN	O	O
500	NN	O	O
mg	NN	O	O
of	NN	O	O
niacin	NN	O	O
extended	NN	O	O
-	NN	O	O
release	NN	O	O
/	NN	O	O
20	NN	O	O
mg	NN	O	O
of	NN	O	O
lovastatin	NN	O	O
)	NN	O	O
once	NN	O	O
nightly	NN	O	O
for	NN	O	O
4	NN	O	O
weeks	NN	O	O
and	NN	O	O
then	NN	O	O
2	NN	O	O
tablets	NN	O	O
for	NN	O	O
8	NN	O	O
weeks	NN	O	O
.	NN	O	O

Patients	NN	O	O
also	NN	O	O
received	NN	O	O
dietary	NN	O	O
counseling	NN	O	O
,	NN	O	O
educational	NN	O	O
materials	NN	O	O
,	NN	O	O
and	NN	O	O
reminders	NN	O	O
to	NN	O	O
call	NN	O	O
a	NN	O	O
toll	NN	O	O
-	NN	O	O
free	NN	O	O
number	NN	O	O
that	NN	O	O
provided	NN	O	O
further	NN	O	O
education	NN	O	O
about	NN	O	O
dyslipidemia	NN	O	B
and	NN	O	O
niacin	NN	O	O
extended	NN	O	O
-	NN	O	O
release	NN	O	O
/	NN	O	O
lovastatin	NN	O	O
.	NN	O	O

Primary	NN	O	O
end	NN	O	O
points	NN	O	O
were	NN	O	O
study	NN	O	O
compliance	NN	O	O
,	NN	O	O
increases	NN	O	O
in	NN	O	O
liver	NN	O	O
transaminases	NN	O	O
to	NN	O	O
>	NN	O	O
3	NN	O	O
times	NN	O	O
the	NN	O	O
upper	NN	O	O
limit	NN	O	O
of	NN	O	O
normal	NN	O	O
,	NN	O	O
and	NN	O	O
clinical	NN	O	O
myopathy	NN	O	B
.	NN	O	O

Final	NN	O	O
study	NN	O	O
status	NN	O	O
was	NN	O	O
available	NN	O	O
for	NN	O	O
4	NN	O	O
,	NN	O	O
217	NN	O	O
patients	NN	O	O
(	NN	O	O
94	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Compliance	NN	O	O
to	NN	O	O
niacin	NN	O	O
extended	NN	O	O
-	NN	O	O
release	NN	O	O
/	NN	O	O
lovastatin	NN	O	O
was	NN	O	O
77	NN	O	O
%	NN	O	O
,	NN	O	O
with	NN	O	O
3	NN	O	O
,	NN	O	O
245	NN	O	O
patients	NN	O	O
completing	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Patients	NN	O	O
in	NN	O	O
the	NN	O	O
southeast	NN	O	O
and	NN	O	O
those	NN	O	O
enrolled	NN	O	O
by	NN	O	O
endocrinologists	NN	O	O
had	NN	O	O
the	NN	O	O
lowest	NN	O	O
compliance	NN	O	O
and	NN	O	O
highest	NN	O	O
adverse	NN	O	O
event	NN	O	O
rates	NN	O	O
.	NN	O	O

Flushing	NN	O	B
was	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
adverse	NN	O	O
event	NN	O	O
,	NN	O	O
reported	NN	O	O
by	NN	O	O
18	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
and	NN	O	O
leading	NN	O	O
to	NN	O	O
discontinuation	NN	O	O
by	NN	O	O
6	NN	O	O
%	NN	O	O
.	NN	O	O

Incidence	NN	O	O
of	NN	O	O
increased	NN	O	O
aspartate	NN	O	O
aminotransferase	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
alanine	NN	O	O
aminotransferase	NN	O	O
>	NN	O	O
3	NN	O	O
times	NN	O	O
the	NN	O	O
upper	NN	O	O
limit	NN	O	O
of	NN	O	O
normal	NN	O	O
was	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
.	NN	O	O

An	NN	O	O
increase	NN	O	O
of	NN	O	O
creatine	NN	O	O
phosphokinase	NN	O	O
to	NN	O	O
>	NN	O	O
5	NN	O	O
times	NN	O	O
the	NN	O	O
upper	NN	O	O
limit	NN	O	O
of	NN	O	O
normal	NN	O	O
occurred	NN	O	O
in	NN	O	O
0	NN	O	O
.	NN	O	O
24	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
cases	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
myopathy	NN	O	B
were	NN	O	O
observed	NN	O	O
.	NN	O	O

Niacin	NN	O	O
extended	NN	O	O
-	NN	O	O
release	NN	O	O
/	NN	O	O
lovastatin	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
/	NN	O	O
40	NN	O	O
mg	NN	O	O
,	NN	O	O
dosed	NN	O	O
as	NN	O	O
initial	NN	O	O
therapy	NN	O	O
,	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
good	NN	O	O
compliance	NN	O	O
and	NN	O	O
safety	NN	O	O
and	NN	O	O
had	NN	O	O
very	NN	O	O
low	NN	O	O
incidences	NN	O	O
of	NN	O	O
increased	NN	O	O
liver	NN	O	O
and	NN	O	O
muscle	NN	O	O
enzymes	NN	O	O
.	NN	O	O

Protective	NN	O	O
effect	NN	O	O
of	NN	O	O
Terminalia	NN	O	O
chebula	NN	O	O
against	NN	O	O
experimental	NN	O	O
myocardial	NN	O	B
injury	NN	O	I
induced	NN	O	O
by	NN	O	O
isoproterenol	NN	O	O
.	NN	O	O

Cardioprotective	NN	O	O
effect	NN	O	O
of	NN	O	O
ethanolic	NN	O	O
extract	NN	O	O
of	NN	O	O
Terminalia	NN	O	O
chebula	NN	O	O
fruits	NN	O	O
(	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
wt	NN	O	O
)	NN	O	O
was	NN	O	O
examined	NN	O	O
in	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
wt	NN	O	O
)	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
damage	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
isoproterenol	NN	O	O
administered	NN	O	O
rats	NN	O	O
,	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
lipid	NN	O	O
peroxides	NN	O	O
increased	NN	O	O
significantly	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
and	NN	O	O
heart	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
decrease	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
myocardial	NN	O	O
marker	NN	O	O
enzymes	NN	O	O
with	NN	O	O
a	NN	O	O
concomitant	NN	O	O
increase	NN	O	O
in	NN	O	O
their	NN	O	O
activity	NN	O	O
in	NN	O	O
serum	NN	O	O
.	NN	O	O

Histopathological	NN	O	O
examination	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
to	NN	O	O
confirm	NN	O	O
the	NN	O	O
myocardial	NN	O	O
necrosis	NN	O	B
.	NN	O	O

T	NN	O	O
.	NN	O	O
chebula	NN	O	O
extract	NN	O	O
pretreatment	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
ameliorate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
on	NN	O	O
lipid	NN	O	O
peroxide	NN	O	O
formation	NN	O	O
and	NN	O	O
retained	NN	O	O
the	NN	O	O
activities	NN	O	O
of	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
marker	NN	O	O
enzymes	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
postoperative	NN	O	O
anxiety	NN	O	B
due	NN	O	O
to	NN	O	O
low	NN	O	O
dose	NN	O	O
droperidol	NN	O	O
used	NN	O	O
with	NN	O	O
patient	NN	O	O
-	NN	O	O
controlled	NN	O	O
analgesia	NN	O	O
.	NN	O	O

A	NN	O	O
multiparous	NN	O	O
woman	NN	O	O
in	NN	O	O
good	NN	O	O
psychological	NN	O	O
health	NN	O	O
underwent	NN	O	O
urgent	NN	O	O
caesarean	NN	O	O
section	NN	O	O
in	NN	O	O
labour	NN	O	O
.	NN	O	O

Postoperatively	NN	O	O
,	NN	O	O
she	NN	O	O
was	NN	O	O
given	NN	O	O
a	NN	O	O
patient	NN	O	O
-	NN	O	O
controlled	NN	O	O
analgesia	NN	O	O
device	NN	O	O
delivering	NN	O	O
boluses	NN	O	O
of	NN	O	O
diamorphine	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
and	NN	O	O
droperidol	NN	O	O
0	NN	O	O
.	NN	O	O
025	NN	O	O
mg	NN	O	O
.	NN	O	O

Whilst	NN	O	O
using	NN	O	O
the	NN	O	O
device	NN	O	O
she	NN	O	O
gradually	NN	O	O
became	NN	O	O
anxious	NN	O	O
,	NN	O	O
the	NN	O	O
feeling	NN	O	O
worsening	NN	O	O
after	NN	O	O
each	NN	O	O
bolus	NN	O	O
.	NN	O	O

The	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
droperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
psychological	NN	O	B
disturbance	NN	O	I
was	NN	O	O
not	NN	O	O
made	NN	O	O
straight	NN	O	O
away	NN	O	O
although	NN	O	O
on	NN	O	O
subsequent	NN	O	O
close	NN	O	O
questioning	NN	O	O
the	NN	O	O
patient	NN	O	O
gave	NN	O	O
a	NN	O	O
very	NN	O	O
clear	NN	O	O
history	NN	O	O
.	NN	O	O

After	NN	O	O
she	NN	O	O
had	NN	O	O
received	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
only	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
droperidol	NN	O	O
,	NN	O	O
a	NN	O	O
syringe	NN	O	O
containing	NN	O	O
diamorphine	NN	O	O
only	NN	O	O
was	NN	O	O
substituted	NN	O	O
and	NN	O	O
her	NN	O	O
unease	NN	O	O
resolved	NN	O	O
completely	NN	O	O
.	NN	O	O

We	NN	O	O
feel	NN	O	O
that	NN	O	O
,	NN	O	O
although	NN	O	O
the	NN	O	O
dramatic	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
dopaminergic	NN	O	O
antiemetics	NN	O	O
are	NN	O	O
well	NN	O	O
known	NN	O	O
,	NN	O	O
more	NN	O	O
subtle	NN	O	O
manifestations	NN	O	O
may	NN	O	O
easily	NN	O	O
be	NN	O	O
overlooked	NN	O	O
.	NN	O	O

Accurate	NN	O	O
patient	NN	O	O
history	NN	O	O
contributes	NN	O	O
to	NN	O	O
differentiating	NN	O	O
diabetes	NN	O	B
insipidus	NN	O	I
:	NN	O	O
a	NN	O	O
case	NN	O	O
study	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
study	NN	O	O
highlights	NN	O	O
the	NN	O	O
important	NN	O	O
contribution	NN	O	O
of	NN	O	O
nursing	NN	O	O
in	NN	O	O
obtaining	NN	O	O
an	NN	O	O
accurate	NN	O	O
health	NN	O	O
history	NN	O	O
.	NN	O	O

The	NN	O	O
case	NN	O	O
discussed	NN	O	O
herein	NN	O	O
initially	NN	O	O
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
neurogenic	NN	O	B
diabetes	NN	O	I
insipidus	NN	O	I
(	NN	O	O
DI	NN	O	B
)	NN	O	O
secondary	NN	O	O
to	NN	O	O
a	NN	O	O
traumatic	NN	O	B
brain	NN	O	I
injury	NN	O	I
.	NN	O	O

The	NN	O	O
nursing	NN	O	O
staff	NN	O	O
,	NN	O	O
by	NN	O	O
reviewing	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
health	NN	O	O
history	NN	O	O
with	NN	O	O
his	NN	O	O
family	NN	O	O
,	NN	O	O
discovered	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
polydipsia	NN	O	B
and	NN	O	O
long	NN	O	O
-	NN	O	O
standing	NN	O	O
lithium	NN	O	O
use	NN	O	O
.	NN	O	O

Lithium	NN	O	O
is	NN	O	O
implicated	NN	O	O
in	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrogenic	NN	O	B
DI	NN	O	I
,	NN	O	O
and	NN	O	O
because	NN	O	O
the	NN	O	O
patient	NN	O	O
had	NN	O	O
not	NN	O	O
received	NN	O	O
lithium	NN	O	O
since	NN	O	O
being	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
,	NN	O	O
his	NN	O	O
treatment	NN	O	O
changed	NN	O	O
to	NN	O	O
focus	NN	O	O
on	NN	O	O
nephrogenic	NN	O	B
DI	NN	O	I
.	NN	O	O

By	NN	O	O
combining	NN	O	O
information	NN	O	O
from	NN	O	O
the	NN	O	O
patient	NN	O	O
history	NN	O	O
,	NN	O	O
the	NN	O	O
physical	NN	O	O
examination	NN	O	O
,	NN	O	O
and	NN	O	O
radiologic	NN	O	O
and	NN	O	O
laboratory	NN	O	O
studies	NN	O	O
,	NN	O	O
the	NN	O	O
critical	NN	O	O
care	NN	O	O
team	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
the	NN	O	O
patient	NN	O	O
had	NN	O	O
been	NN	O	O
self	NN	O	O
-	NN	O	O
treating	NN	O	O
his	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrogenic	NN	O	B
DI	NN	O	I
and	NN	O	O
developed	NN	O	O
neurogenic	NN	O	B
DI	NN	O	I
secondary	NN	O	O
to	NN	O	O
brain	NN	O	B
trauma	NN	O	I
.	NN	O	O

Thus	NN	O	O
successful	NN	O	O
treatment	NN	O	O
required	NN	O	O
that	NN	O	O
nephrogenic	NN	O	O
and	NN	O	O
neurogenic	NN	O	B
DI	NN	O	I
be	NN	O	O
treated	NN	O	O
concomitantly	NN	O	O
.	NN	O	O

Factors	NN	O	O
contributing	NN	O	O
to	NN	O	O
ribavirin	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
AIM	NN	O	O
:	NN	O	O
Interferon	NN	O	O
and	NN	O	O
ribavirin	NN	O	O
combination	NN	O	O
therapy	NN	O	O
for	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
C	NN	O	I
produces	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
identify	NN	O	O
the	NN	O	O
factors	NN	O	O
contributing	NN	O	O
to	NN	O	O
ribavirin	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Eighty	NN	O	O
-	NN	O	O
eight	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
C	NN	O	I
who	NN	O	O
received	NN	O	O
interferon	NN	O	O
-	NN	O	O
alpha	NN	O	O
-	NN	O	O
2b	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
6	NN	O	O
MU	NN	O	O
administered	NN	O	O
intramuscularly	NN	O	O
for	NN	O	O
24	NN	O	O
weeks	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
ribavirin	NN	O	O
administered	NN	O	O
orally	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
600	NN	O	O
mg	NN	O	O
or	NN	O	O
800	NN	O	O
mg	NN	O	O
participated	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

A	NN	O	O
hemoglobin	NN	O	O
concentration	NN	O	O
of	NN	O	O
<	NN	O	O
10	NN	O	O
g	NN	O	O
/	NN	O	O
dL	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
ribavirin	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Ribavirin	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
occurred	NN	O	O
in	NN	O	O
18	NN	O	O
(	NN	O	O
20	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
during	NN	O	O
treatment	NN	O	O
.	NN	O	O

A	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
dL	NN	O	O
decrease	NN	O	O
in	NN	O	O
hemoglobin	NN	O	O
concentrations	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
anemia	NN	O	B
was	NN	O	O
observed	NN	O	O
at	NN	O	O
week	NN	O	O
2	NN	O	O
after	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
hemoglobin	NN	O	O
concentration	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
dL	NN	O	O
decrease	NN	O	O
at	NN	O	O
week	NN	O	O
2	NN	O	O
was	NN	O	O
observed	NN	O	O
to	NN	O	O
be	NN	O	O
significantly	NN	O	O
lower	NN	O	O
even	NN	O	O
after	NN	O	O
week	NN	O	O
2	NN	O	O
than	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
<	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
dL	NN	O	O
decrease	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
relationship	NN	O	O
was	NN	O	O
observed	NN	O	O
between	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
reduction	NN	O	O
of	NN	O	O
hemoglobin	NN	O	O
concentrations	NN	O	O
at	NN	O	O
week	NN	O	O
2	NN	O	O
and	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
anemia	NN	O	B
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Such	NN	O	O
factors	NN	O	O
as	NN	O	O
sex	NN	O	O
(	NN	O	O
female	NN	O	O
)	NN	O	O
,	NN	O	O
age	NN	O	O
(	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
60	NN	O	O
years	NN	O	O
old	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
ribavirin	NN	O	O
dose	NN	O	O
by	NN	O	O
body	NN	O	O
weight	NN	O	O
(	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
or	NN	O	O
more	NN	O	O
)	NN	O	O
were	NN	O	O
significant	NN	O	O
by	NN	O	O
univariate	NN	O	O
analysis	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Careful	NN	O	O
administration	NN	O	O
is	NN	O	O
necessary	NN	O	O
in	NN	O	O
patients	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
60	NN	O	O
years	NN	O	O
old	NN	O	O
,	NN	O	O
in	NN	O	O
female	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
a	NN	O	O
ribavirin	NN	O	O
dose	NN	O	O
of	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
or	NN	O	O
more	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
experience	NN	O	O
a	NN	O	O
fall	NN	O	O
in	NN	O	O
hemoglobin	NN	O	O
concentrations	NN	O	O
of	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
dL	NN	O	O
or	NN	O	O
more	NN	O	O
at	NN	O	O
week	NN	O	O
2	NN	O	O
after	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
treatment	NN	O	O
should	NN	O	O
be	NN	O	O
monitored	NN	O	O
with	NN	O	O
particular	NN	O	O
care	NN	O	O
.	NN	O	O

Zidovudine	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
induced	NN	O	O
by	NN	O	O
zidovudine	NN	O	O
in	NN	O	O
a	NN	O	O
38	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
with	NN	O	O
AIDS	NN	O	B
is	NN	O	O
presented	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
whereby	NN	O	O
the	NN	O	O
hepatitis	NN	O	B
was	NN	O	O
induced	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
tolerated	NN	O	O
well	NN	O	O
an	NN	O	O
alternative	NN	O	O
reverse	NN	O	O
transcriptase	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
2	NN	O	O
'	NN	O	O
3	NN	O	O
'	NN	O	O
dideoxyinosine	NN	O	O
.	NN	O	O

Physicians	NN	O	O
caring	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
AIDS	NN	O	B
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
hitherto	NN	O	O
rarely	NN	O	O
reported	NN	O	O
complication	NN	O	O
.	NN	O	O

Oxidative	NN	O	O
damage	NN	O	O
precedes	NN	O	O
nitrative	NN	O	O
damage	NN	O	O
in	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	O
mitochondrial	NN	O	B
injury	NN	O	I
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
elevated	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
(	NN	O	O
ROS	NN	O	O
)	NN	O	O
/	NN	O	O
nitrogen	NN	O	O
species	NN	O	O
(	NN	O	O
RNS	NN	O	O
)	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
present	NN	O	O
in	NN	O	O
adriamycin	NN	O	O
(	NN	O	O
ADR	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
actually	NN	O	O
resulted	NN	O	O
in	NN	O	O
cardiomyocyte	NN	O	O
oxidative	NN	O	O
/	NN	O	O
nitrative	NN	O	O
damage	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
quantitatively	NN	O	O
determine	NN	O	O
the	NN	O	O
time	NN	O	O
course	NN	O	O
and	NN	O	O
subcellular	NN	O	O
localization	NN	O	O
of	NN	O	O
these	NN	O	O
postulated	NN	O	O
damage	NN	O	O
products	NN	O	O
using	NN	O	O
an	NN	O	O
in	NN	O	O
vivo	NN	O	O
approach	NN	O	O
.	NN	O	O

B6C3	NN	O	O
mice	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
ADR	NN	O	O
.	NN	O	O

Ultrastructural	NN	O	O
damage	NN	O	O
and	NN	O	O
levels	NN	O	O
of	NN	O	O
4	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
nonenal	NN	O	O
(	NN	O	O
4HNE	NN	O	O
)	NN	O	O
-	NN	O	O
protein	NN	O	O
adducts	NN	O	O
and	NN	O	O
3	NN	O	O
-	NN	O	O
nitrotyrosine	NN	O	O
(	NN	O	O
3NT	NN	O	O
)	NN	O	O
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

Quantitative	NN	O	O
ultrastructural	NN	O	O
damage	NN	O	O
using	NN	O	O
computerized	NN	O	O
image	NN	O	O
techniques	NN	O	O
showed	NN	O	O
cardiomyocyte	NN	O	O
injury	NN	O	O
as	NN	O	O
early	NN	O	O
as	NN	O	O
3	NN	O	O
hours	NN	O	O
,	NN	O	O
with	NN	O	O
mitochondria	NN	O	O
being	NN	O	O
the	NN	O	O
most	NN	O	O
extensively	NN	O	O
and	NN	O	O
progressively	NN	O	O
injured	NN	O	O
subcellular	NN	O	O
organelle	NN	O	O
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
4HNE	NN	O	O
protein	NN	O	O
adducts	NN	O	O
by	NN	O	O
immunogold	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
showed	NN	O	O
appearance	NN	O	O
of	NN	O	O
4HNE	NN	O	O
protein	NN	O	O
adducts	NN	O	O
in	NN	O	O
mitochondria	NN	O	O
as	NN	O	O
early	NN	O	O
as	NN	O	O
3	NN	O	O
hours	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
peak	NN	O	O
at	NN	O	O
6	NN	O	O
hours	NN	O	O
and	NN	O	O
subsequent	NN	O	O
decline	NN	O	O
at	NN	O	O
24	NN	O	O
hours	NN	O	O
.	NN	O	O

3NT	NN	O	O
levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
all	NN	O	O
subcellular	NN	O	O
compartments	NN	O	O
at	NN	O	O
6	NN	O	O
hours	NN	O	O
and	NN	O	O
subsequently	NN	O	O
declined	NN	O	O
at	NN	O	O
24	NN	O	O
hours	NN	O	O
.	NN	O	O

Our	NN	O	O
data	NN	O	O
showed	NN	O	O
ADR	NN	O	O
induced	NN	O	O
4HNE	NN	O	O
-	NN	O	O
protein	NN	O	O
adducts	NN	O	O
in	NN	O	O
mitochondria	NN	O	O
at	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
point	NN	O	O
as	NN	O	O
when	NN	O	O
mitochondrial	NN	O	B
injury	NN	O	I
initially	NN	O	O
appeared	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
document	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
in	NN	O	O
vivo	NN	O	O
that	NN	O	O
mitochondrial	NN	O	B
oxidative	NN	O	I
damage	NN	O	I
precedes	NN	O	O
nitrative	NN	O	O
damage	NN	O	O
.	NN	O	O

The	NN	O	O
progressive	NN	O	O
nature	NN	O	O
of	NN	O	O
mitochondrial	NN	O	B
injury	NN	O	I
suggests	NN	O	O
that	NN	O	O
mitochondria	NN	O	O
,	NN	O	O
not	NN	O	O
other	NN	O	O
subcellular	NN	O	O
organelles	NN	O	O
,	NN	O	O
are	NN	O	O
the	NN	O	O
major	NN	O	O
site	NN	O	O
of	NN	O	O
intracellular	NN	O	O
injury	NN	O	O
.	NN	O	O

Sotalol	NN	O	O
-	NN	O	O
induced	NN	O	O
coronary	NN	O	B
spasm	NN	O	I
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
dilated	NN	O	B
cardiomyopathy	NN	O	I
associated	NN	O	O
with	NN	O	O
sustained	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
.	NN	O	O

A	NN	O	O
54	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
severe	NN	O	O
left	NN	O	O
ventricular	NN	O	B
dysfunction	NN	O	I
due	NN	O	O
to	NN	O	O
dilated	NN	O	B
cardiomyopathy	NN	O	I
was	NN	O	O
referred	NN	O	O
to	NN	O	O
our	NN	O	O
hospital	NN	O	O
for	NN	O	O
symptomatic	NN	O	O
incessant	NN	O	O
sustained	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
(	NN	O	O
VT	NN	O	B
)	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
nifekalant	NN	O	O
hydrochloride	NN	O	O
,	NN	O	O
sustained	NN	O	O
VT	NN	O	B
was	NN	O	O
terminated	NN	O	O
.	NN	O	O

An	NN	O	O
alternate	NN	O	O
class	NN	O	O
III	NN	O	O
agent	NN	O	O
,	NN	O	O
sotalol	NN	O	O
,	NN	O	O
was	NN	O	O
also	NN	O	O
effective	NN	O	O
for	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
VT	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
one	NN	O	O
month	NN	O	O
after	NN	O	O
switching	NN	O	O
over	NN	O	O
nifekalant	NN	O	O
to	NN	O	O
sotalol	NN	O	O
,	NN	O	O
a	NN	O	O
short	NN	O	O
duration	NN	O	O
of	NN	O	O
ST	NN	O	O
elevation	NN	O	O
was	NN	O	O
documented	NN	O	O
in	NN	O	O
ECG	NN	O	O
monitoring	NN	O	O
at	NN	O	O
almost	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
for	NN	O	O
three	NN	O	O
consecutive	NN	O	O
days	NN	O	O
.	NN	O	O

ST	NN	O	O
elevation	NN	O	O
with	NN	O	O
chest	NN	O	O
discomfort	NN	O	O
disappeared	NN	O	O
since	NN	O	O
he	NN	O	O
began	NN	O	O
taking	NN	O	O
long	NN	O	O
-	NN	O	O
acting	NN	O	O
diltiazem	NN	O	O
.	NN	O	O

Coronary	NN	O	B
vasospasm	NN	O	I
may	NN	O	O
be	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
beta	NN	O	O
-	NN	O	O
blocking	NN	O	O
properties	NN	O	O
of	NN	O	O
sotalol	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
the	NN	O	O
antidepressant	NN	O	O
trazodone	NN	O	O
,	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
2A	NN	O	O
/	NN	O	O
2C	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
on	NN	O	O
dopamine	NN	O	O
-	NN	O	O
dependent	NN	O	O
behaviors	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

RATIONALE	NN	O	O
:	NN	O	O
5	NN	O	O
-	NN	O	O
Hydroxytryptamine	NN	O	O
,	NN	O	O
via	NN	O	O
stimulation	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
2C	NN	O	O
receptors	NN	O	O
,	NN	O	O
exerts	NN	O	O
a	NN	O	O
tonic	NN	O	O
inhibitory	NN	O	O
influence	NN	O	O
on	NN	O	O
dopaminergic	NN	O	O
neurotransmission	NN	O	O
,	NN	O	O
whereas	NN	O	O
activation	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
2A	NN	O	O
receptors	NN	O	O
enhances	NN	O	O
stimulated	NN	O	O
DAergic	NN	O	O
neurotransmission	NN	O	O
.	NN	O	O

The	NN	O	O
antidepressant	NN	O	O
trazodone	NN	O	O
is	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
2A	NN	O	O
/	NN	O	O
2C	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
trazodone	NN	O	O
treatment	NN	O	O
on	NN	O	O
behaviors	NN	O	O
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
functional	NN	O	O
status	NN	O	O
of	NN	O	O
the	NN	O	O
nigrostriatal	NN	O	O
DAergic	NN	O	O
system	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
effect	NN	O	O
of	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
trazodone	NN	O	O
on	NN	O	O
dexamphetamine	NN	O	O
-	NN	O	O
and	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
oral	NN	O	B
stereotypies	NN	O	I
,	NN	O	O
on	NN	O	O
catalepsy	NN	O	B
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	O
and	NN	O	O
apomorphine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
,	NN	O	O
on	NN	O	O
ergometrine	NN	O	O
-	NN	O	O
induced	NN	O	O
wet	NN	O	O
dog	NN	O	O
shake	NN	O	O
(	NN	O	O
WDS	NN	O	O
)	NN	O	O
behavior	NN	O	O
and	NN	O	O
fluoxetine	NN	O	O
-	NN	O	O
induced	NN	O	O
penile	NN	O	O
erections	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
investigated	NN	O	O
whether	NN	O	O
trazodone	NN	O	O
induces	NN	O	O
catalepsy	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Trazodone	NN	O	O
at	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
did	NN	O	O
not	NN	O	O
induce	NN	O	O
catalepsy	NN	O	B
,	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
antagonize	NN	O	O
apomorphine	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
stereotypy	NN	O	O
and	NN	O	O
apomorphine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
5	NN	O	O
,	NN	O	O
10	NN	O	O
and	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
trazodone	NN	O	O
enhanced	NN	O	O
dexamphetamine	NN	O	O
stereotypy	NN	O	O
,	NN	O	O
and	NN	O	O
antagonized	NN	O	O
haloperidol	NN	O	O
catalepsy	NN	O	B
,	NN	O	O
ergometrine	NN	O	O
-	NN	O	O
induced	NN	O	O
WDS	NN	O	O
behavior	NN	O	O
and	NN	O	O
fluoxetine	NN	O	O
-	NN	O	O
induced	NN	O	O
penile	NN	O	O
erections	NN	O	O
.	NN	O	O

Trazodone	NN	O	O
at	NN	O	O
30	NN	O	O
,	NN	O	O
40	NN	O	O
and	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
and	NN	O	O
antagonized	NN	O	O
apomorphine	NN	O	O
and	NN	O	O
dexamphetamine	NN	O	O
stereotypies	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Our	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
trazodone	NN	O	O
at	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
does	NN	O	O
not	NN	O	O
block	NN	O	O
pre	NN	O	O
-	NN	O	O
and	NN	O	O
postsynaptic	NN	O	O
striatal	NN	O	O
D2	NN	O	O
DA	NN	O	O
receptors	NN	O	O
,	NN	O	O
while	NN	O	O
at	NN	O	O
30	NN	O	O
,	NN	O	O
40	NN	O	O
and	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
it	NN	O	O
blocks	NN	O	O
postsynaptic	NN	O	O
striatal	NN	O	O
D2	NN	O	O
DA	NN	O	O
receptors	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
at	NN	O	O
5	NN	O	O
,	NN	O	O
10	NN	O	O
and	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
trazodone	NN	O	O
blocks	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
2A	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
2C	NN	O	O
receptors	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
trazodone	NN	O	O
(	NN	O	O
5	NN	O	O
,	NN	O	O
10	NN	O	O
and	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
by	NN	O	O
blocking	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
2C	NN	O	O
receptors	NN	O	O
,	NN	O	O
releases	NN	O	O
the	NN	O	O
nigrostriatal	NN	O	O
DAergic	NN	O	O
neurons	NN	O	O
from	NN	O	O
tonic	NN	O	O
inhibition	NN	O	O
caused	NN	O	O
by	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
,	NN	O	O
and	NN	O	O
thereby	NN	O	O
potentiates	NN	O	O
dexamphetamine	NN	O	O
stereotypy	NN	O	O
and	NN	O	O
antagonizes	NN	O	O
haloperidol	NN	O	O
catalepsy	NN	O	B
.	NN	O	O

Swallowing	NN	O	B
abnormalities	NN	O	I
and	NN	O	O
dyskinesia	NN	O	B
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

Gastrointestinal	NN	O	B
abnormalities	NN	O	I
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
have	NN	O	O
been	NN	O	O
known	NN	O	O
for	NN	O	O
almost	NN	O	O
two	NN	O	O
centuries	NN	O	O
,	NN	O	O
but	NN	O	O
many	NN	O	O
aspects	NN	O	O
concerning	NN	O	O
their	NN	O	O
pathophysiology	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
completely	NN	O	O
clarified	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
characterize	NN	O	O
the	NN	O	O
oropharyngeal	NN	O	O
dynamics	NN	O	O
in	NN	O	O
PD	NN	O	B
patients	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B
.	NN	O	O

Fifteen	NN	O	O
dyskinetic	NN	O	B
,	NN	O	O
12	NN	O	O
nondyskinetic	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
control	NN	O	O
group	NN	O	O
were	NN	O	O
included	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
asked	NN	O	O
about	NN	O	O
dysphagia	NN	O	B
and	NN	O	O
evaluated	NN	O	O
with	NN	O	O
the	NN	O	O
Unified	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
Disease	NN	O	I
Rating	NN	O	O
Scale	NN	O	O
Parts	NN	O	O
II	NN	O	O
and	NN	O	O
III	NN	O	O
and	NN	O	O
the	NN	O	O
Hoehn	NN	O	O
and	NN	O	O
Yahr	NN	O	O
scale	NN	O	O
.	NN	O	O

Deglutition	NN	O	O
was	NN	O	O
assessed	NN	O	O
using	NN	O	O
modified	NN	O	O
barium	NN	O	O
swallow	NN	O	O
with	NN	O	O
videofluoroscopy	NN	O	O
.	NN	O	O

Nondyskinetic	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
dyskinetic	NN	O	B
ones	NN	O	O
,	NN	O	O
showed	NN	O	O
less	NN	O	O
oropharyngeal	NN	O	O
swallowing	NN	O	O
efficiency	NN	O	O
(	NN	O	O
OPSE	NN	O	O
)	NN	O	O
for	NN	O	O
liquid	NN	O	O
food	NN	O	O
than	NN	O	O
controls	NN	O	O
(	NN	O	O
Dunnett	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
.	NN	O	O

Dyskinetic	NN	O	B
patients	NN	O	O
tended	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
greater	NN	O	O
OPSE	NN	O	O
than	NN	O	O
nondyskinetic	NN	O	O
(	NN	O	O
Dunnett	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
06	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
were	NN	O	O
using	NN	O	O
a	NN	O	O
higher	NN	O	O
dose	NN	O	O
of	NN	O	O
levodopa	NN	O	O
had	NN	O	O
a	NN	O	O
greater	NN	O	O
OPSE	NN	O	O
and	NN	O	O
a	NN	O	O
trend	NN	O	O
toward	NN	O	O
a	NN	O	O
smaller	NN	O	O
oral	NN	O	O
transit	NN	O	O
time	NN	O	O
(	NN	O	O
Pearson	NN	O	O
'	NN	O	O
s	NN	O	O
correlation	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
08	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Neither	NN	O	O
the	NN	O	O
report	NN	O	O
of	NN	O	O
dysphagia	NN	O	B
nor	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
PD	NN	O	B
severity	NN	O	O
parameters	NN	O	O
correlated	NN	O	O
to	NN	O	O
the	NN	O	O
videofluoroscopic	NN	O	O
variables	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
,	NN	O	O
dyskinetic	NN	O	B
patients	NN	O	O
performed	NN	O	O
better	NN	O	O
in	NN	O	O
swallowing	NN	O	O
function	NN	O	O
,	NN	O	O
which	NN	O	O
could	NN	O	O
be	NN	O	O
explained	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
a	NN	O	O
greater	NN	O	O
levodopa	NN	O	O
dose	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
levodopa	NN	O	O
in	NN	O	O
the	NN	O	O
oral	NN	O	O
phase	NN	O	O
of	NN	O	O
deglutition	NN	O	O
and	NN	O	O
confirm	NN	O	O
that	NN	O	O
dysphagia	NN	O	B
is	NN	O	O
not	NN	O	O
a	NN	O	O
good	NN	O	O
predictor	NN	O	O
of	NN	O	O
deglutition	NN	O	O
alterations	NN	O	O
in	NN	O	O
PD	NN	O	B
.	NN	O	O

Inhibition	NN	O	O
of	NN	O	O
nuclear	NN	O	O
factor	NN	O	O
-	NN	O	O
kappaB	NN	O	O
activation	NN	O	O
attenuates	NN	O	O
tubulointerstitial	NN	O	B
nephritis	NN	O	I
induced	NN	O	O
by	NN	O	O
gentamicin	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Animals	NN	O	O
treated	NN	O	O
with	NN	O	O
gentamicin	NN	O	O
can	NN	O	O
show	NN	O	O
residual	NN	O	O
areas	NN	O	O
of	NN	O	O
interstitial	NN	O	O
fibrosis	NN	O	B
in	NN	O	O
the	NN	O	O
renal	NN	O	O
cortex	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
investigated	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
nuclear	NN	O	O
factor	NN	O	O
-	NN	O	O
kappaB	NN	O	O
(	NN	O	O
NF	NN	O	O
-	NN	O	O
kappaB	NN	O	O
)	NN	O	O
,	NN	O	O
mitogen	NN	O	O
-	NN	O	O
activated	NN	O	O
protein	NN	O	O
(	NN	O	O
MAP	NN	O	O
)	NN	O	O
kinases	NN	O	O
and	NN	O	O
macrophages	NN	O	O
in	NN	O	O
the	NN	O	O
renal	NN	O	O
cortex	NN	O	O
and	NN	O	O
structural	NN	O	O
and	NN	O	O
functional	NN	O	O
renal	NN	O	O
changes	NN	O	O
of	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
gentamicin	NN	O	O
or	NN	O	O
gentamicin	NN	O	O
+	NN	O	O
pyrrolidine	NN	O	O
dithiocarbamate	NN	O	O
(	NN	O	O
PDTC	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
NF	NN	O	O
-	NN	O	O
kappaB	NN	O	O
inhibitor	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
38	NN	O	O
female	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
injected	NN	O	O
with	NN	O	O
gentamicin	NN	O	O
,	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
twice	NN	O	O
a	NN	O	O
day	NN	O	O
for	NN	O	O
9	NN	O	O
days	NN	O	O
,	NN	O	O
38	NN	O	O
with	NN	O	O
gentamicin	NN	O	O
+	NN	O	O
PDTC	NN	O	O
,	NN	O	O
and	NN	O	O
28	NN	O	O
with	NN	O	O
0	NN	O	O
.	NN	O	O
15	NN	O	O
M	NN	O	O
NaCl	NN	O	O
solution	NN	O	O
.	NN	O	O

The	NN	O	O
animals	NN	O	O
were	NN	O	O
killed	NN	O	O
5	NN	O	O
and	NN	O	O
30	NN	O	O
days	NN	O	O
after	NN	O	O
these	NN	O	O
injections	NN	O	O
and	NN	O	O
the	NN	O	O
kidneys	NN	O	O
were	NN	O	O
removed	NN	O	O
for	NN	O	O
histological	NN	O	O
and	NN	O	O
immunohistochemical	NN	O	O
studies	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
immunohistochemical	NN	O	O
studies	NN	O	O
were	NN	O	O
scored	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
staining	NN	O	O
.	NN	O	O

The	NN	O	O
fractional	NN	O	O
interstitial	NN	O	O
area	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
morphometry	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Gentamicin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
presented	NN	O	O
a	NN	O	O
transitory	NN	O	O
increase	NN	O	O
in	NN	O	O
plasma	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
.	NN	O	O

Increased	NN	O	O
ED	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
MAP	NN	O	O
kinases	NN	O	O
and	NN	O	O
NF	NN	O	O
-	NN	O	O
kappaB	NN	O	O
staining	NN	O	O
were	NN	O	O
also	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
renal	NN	O	O
cortex	NN	O	O
from	NN	O	O
all	NN	O	O
gentamicin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
compared	NN	O	O
to	NN	O	O
control	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
animals	NN	O	O
killed	NN	O	O
on	NN	O	O
day	NN	O	O
30	NN	O	O
also	NN	O	O
presented	NN	O	O
fibrosis	NN	O	B
in	NN	O	O
the	NN	O	O
renal	NN	O	O
cortex	NN	O	O
despite	NN	O	O
the	NN	O	O
recovery	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
PDTC	NN	O	O
reduced	NN	O	O
the	NN	O	O
functional	NN	O	O
and	NN	O	O
structural	NN	O	O
changes	NN	O	O
induced	NN	O	O
by	NN	O	O
gentamicin	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
inhibition	NN	O	O
of	NN	O	O
NF	NN	O	O
-	NN	O	O
kappaB	NN	O	O
activation	NN	O	O
attenuates	NN	O	O
tubulointerstitial	NN	O	B
nephritis	NN	O	I
induced	NN	O	O
by	NN	O	O
gentamicin	NN	O	O
.	NN	O	O

Glucose	NN	O	O
metabolism	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
schizophrenia	NN	O	B
treated	NN	O	O
with	NN	O	O
atypical	NN	O	O
antipsychotic	NN	O	O
agents	NN	O	O
:	NN	O	O
a	NN	O	O
frequently	NN	O	O
sampled	NN	O	O
intravenous	NN	O	O
glucose	NN	O	O
tolerance	NN	O	O
test	NN	O	O
and	NN	O	O
minimal	NN	O	O
model	NN	O	O
analysis	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
While	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
new	NN	O	O
-	NN	O	O
onset	NN	O	O
diabetes	NN	O	B
mellitus	NN	O	I
may	NN	O	O
be	NN	O	O
increasing	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
schizophrenia	NN	O	B
treated	NN	O	O
with	NN	O	O
certain	NN	O	O
atypical	NN	O	O
antipsychotic	NN	O	O
agents	NN	O	O
,	NN	O	O
it	NN	O	O
remains	NN	O	O
unclear	NN	O	O
whether	NN	O	O
atypical	NN	O	O
agents	NN	O	O
are	NN	O	O
directly	NN	O	O
affecting	NN	O	O
glucose	NN	O	O
metabolism	NN	O	O
or	NN	O	O
simply	NN	O	O
increasing	NN	O	O
known	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
diabetes	NN	O	B
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
study	NN	O	O
the	NN	O	O
2	NN	O	O
drugs	NN	O	O
most	NN	O	O
clearly	NN	O	O
implicated	NN	O	O
(	NN	O	O
clozapine	NN	O	O
and	NN	O	O
olanzapine	NN	O	O
)	NN	O	O
and	NN	O	O
risperidone	NN	O	O
using	NN	O	O
a	NN	O	O
frequently	NN	O	O
sampled	NN	O	O
intravenous	NN	O	O
glucose	NN	O	O
tolerance	NN	O	O
test	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
A	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
design	NN	O	O
in	NN	O	O
stable	NN	O	O
,	NN	O	O
treated	NN	O	O
patients	NN	O	O
with	NN	O	O
schizophrenia	NN	O	B
evaluated	NN	O	O
using	NN	O	O
a	NN	O	O
frequently	NN	O	O
sampled	NN	O	O
intravenous	NN	O	O
glucose	NN	O	O
tolerance	NN	O	O
test	NN	O	O
and	NN	O	O
the	NN	O	O
Bergman	NN	O	O
minimal	NN	O	O
model	NN	O	O
analysis	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Subjects	NN	O	O
were	NN	O	O
recruited	NN	O	O
from	NN	O	O
an	NN	O	O
urban	NN	O	O
community	NN	O	O
mental	NN	O	O
health	NN	O	O
clinic	NN	O	O
and	NN	O	O
were	NN	O	O
studied	NN	O	O
at	NN	O	O
a	NN	O	O
general	NN	O	O
clinical	NN	O	O
research	NN	O	O
center	NN	O	O
.	NN	O	O

Patients	NN	O	O
Fifty	NN	O	O
subjects	NN	O	O
signed	NN	O	O
informed	NN	O	O
consent	NN	O	O
and	NN	O	O
41	NN	O	O
underwent	NN	O	O
the	NN	O	O
frequently	NN	O	O
sampled	NN	O	O
intravenous	NN	O	O
glucose	NN	O	O
tolerance	NN	O	O
test	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
six	NN	O	O
nonobese	NN	O	O
subjects	NN	O	O
with	NN	O	O
schizophrenia	NN	O	B
or	NN	O	O
schizoaffective	NN	O	B
disorder	NN	O	I
,	NN	O	O
matched	NN	O	O
by	NN	O	O
body	NN	O	O
mass	NN	O	O
index	NN	O	O
and	NN	O	O
treated	NN	O	O
with	NN	O	O
either	NN	O	O
clozapine	NN	O	O
,	NN	O	O
olanzapine	NN	O	O
,	NN	O	O
or	NN	O	O
risperidone	NN	O	O
,	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
analysis	NN	O	O
.	NN	O	O

MAIN	NN	O	O
OUTCOME	NN	O	O
MEASURES	NN	O	O
:	NN	O	O
Fasting	NN	O	O
plasma	NN	O	O
glucose	NN	O	O
and	NN	O	O
fasting	NN	O	O
serum	NN	O	O
insulin	NN	O	O
levels	NN	O	O
,	NN	O	O
insulin	NN	O	B
sensitivity	NN	O	I
index	NN	O	O
,	NN	O	O
homeostasis	NN	O	O
model	NN	O	O
assessment	NN	O	O
of	NN	O	O
insulin	NN	O	B
resistance	NN	O	I
,	NN	O	O
and	NN	O	O
glucose	NN	O	O
effectiveness	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
duration	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
the	NN	O	O
identified	NN	O	O
atypical	NN	O	O
antipsychotic	NN	O	O
agent	NN	O	O
was	NN	O	O
68	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
28	NN	O	O
.	NN	O	O
9	NN	O	O
months	NN	O	O
(	NN	O	O
clozapine	NN	O	O
)	NN	O	O
,	NN	O	O
29	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
17	NN	O	O
.	NN	O	O
5	NN	O	O
months	NN	O	O
(	NN	O	O
olanzapine	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
40	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
33	NN	O	O
.	NN	O	O
7	NN	O	O
(	NN	O	O
risperidone	NN	O	O
)	NN	O	O
.	NN	O	O

Fasting	NN	O	O
serum	NN	O	O
insulin	NN	O	O
concentrations	NN	O	O
differed	NN	O	O
among	NN	O	O
groups	NN	O	O
(	NN	O	O
F	NN	O	O
(	NN	O	O
33	NN	O	O
)	NN	O	O
=	NN	O	O
3	NN	O	O
.	NN	O	O
35	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
047	NN	O	O
)	NN	O	O
(	NN	O	O
clozapine	NN	O	O
>	NN	O	O
olanzapine	NN	O	O
>	NN	O	O
risperidone	NN	O	O
)	NN	O	O
with	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
clozapine	NN	O	O
and	NN	O	O
risperidone	NN	O	O
(	NN	O	O
t	NN	O	O
(	NN	O	O
33	NN	O	O
)	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
32	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
03	NN	O	O
)	NN	O	O
and	NN	O	O
olanzapine	NN	O	O
and	NN	O	O
risperidone	NN	O	O
(	NN	O	O
t	NN	O	O
(	NN	O	O
33	NN	O	O
)	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
15	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
04	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
insulin	NN	O	B
sensitivity	NN	O	I
index	NN	O	O
among	NN	O	O
groups	NN	O	O
(	NN	O	O
F	NN	O	O
(	NN	O	O
33	NN	O	O
)	NN	O	O
=	NN	O	O
10	NN	O	O
.	NN	O	O
66	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
(	NN	O	O
clozapine	NN	O	O
<	NN	O	O
olanzapine	NN	O	O
<	NN	O	O
risperidone	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
subjects	NN	O	O
who	NN	O	O
received	NN	O	O
clozapine	NN	O	O
and	NN	O	O
olanzapine	NN	O	O
exhibiting	NN	O	O
significant	NN	O	O
insulin	NN	O	B
resistance	NN	O	I
compared	NN	O	O
with	NN	O	O
subjects	NN	O	O
who	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
risperidone	NN	O	O
(	NN	O	O
clozapine	NN	O	O
vs	NN	O	O
risperidone	NN	O	O
,	NN	O	O
t	NN	O	O
(	NN	O	O
33	NN	O	O
)	NN	O	O
=	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
29	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
001	NN	O	O
;	NN	O	O
olanzapine	NN	O	O
vs	NN	O	O
risperidone	NN	O	O
,	NN	O	O
t	NN	O	O
(	NN	O	O
33	NN	O	O
)	NN	O	O
=	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
62	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
001	NN	O	O
[	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
001	NN	O	O
]	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
homeostasis	NN	O	O
model	NN	O	O
assessment	NN	O	O
of	NN	O	O
insulin	NN	O	B
resistance	NN	O	I
also	NN	O	O
differed	NN	O	O
significantly	NN	O	O
among	NN	O	O
groups	NN	O	O
(	NN	O	O
F	NN	O	O
(	NN	O	O
33	NN	O	O
)	NN	O	O
=	NN	O	O
4	NN	O	O
.	NN	O	O
92	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
(	NN	O	O
clozapine	NN	O	O
>	NN	O	O
olanzapine	NN	O	O
>	NN	O	O
risperidone	NN	O	O
)	NN	O	O
(	NN	O	O
clozapine	NN	O	O
vs	NN	O	O
risperidone	NN	O	O
,	NN	O	O
t	NN	O	O
(	NN	O	O
33	NN	O	O
)	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
94	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
006	NN	O	O
;	NN	O	O
olanzapine	NN	O	O
vs	NN	O	O
risperidone	NN	O	O
,	NN	O	O
t	NN	O	O
(	NN	O	O
33	NN	O	O
)	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
42	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
among	NN	O	O
groups	NN	O	O
in	NN	O	O
glucose	NN	O	O
effectiveness	NN	O	O
(	NN	O	O
F	NN	O	O
(	NN	O	O
30	NN	O	O
)	NN	O	O
=	NN	O	O
4	NN	O	O
.	NN	O	O
18	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
(	NN	O	O
clozapine	NN	O	O
<	NN	O	O
olanzapine	NN	O	O
<	NN	O	O
risperidone	NN	O	O
)	NN	O	O
with	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
clozapine	NN	O	O
and	NN	O	O
risperidone	NN	O	O
(	NN	O	O
t	NN	O	O
(	NN	O	O
30	NN	O	O
)	NN	O	O
=	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
59	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
and	NN	O	O
olanzapine	NN	O	O
and	NN	O	O
risperidone	NN	O	O
(	NN	O	O
t	NN	O	O
(	NN	O	O
30	NN	O	O
)	NN	O	O
=	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
34	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
03	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Both	NN	O	O
nonobese	NN	O	O
clozapine	NN	O	O
-	NN	O	O
and	NN	O	O
olanzapine	NN	O	O
-	NN	O	O
treated	NN	O	O
groups	NN	O	O
displayed	NN	O	O
significant	NN	O	O
insulin	NN	O	B
resistance	NN	O	I
and	NN	O	O
impairment	NN	O	O
of	NN	O	O
glucose	NN	O	O
effectiveness	NN	O	O
compared	NN	O	O
with	NN	O	O
risperidone	NN	O	O
-	NN	O	O
treated	NN	O	O
subjects	NN	O	O
.	NN	O	O

Patients	NN	O	O
taking	NN	O	O
clozapine	NN	O	O
and	NN	O	O
olanzapine	NN	O	O
must	NN	O	O
be	NN	O	O
examined	NN	O	O
for	NN	O	O
insulin	NN	O	B
resistance	NN	O	I
and	NN	O	O
its	NN	O	O
consequences	NN	O	O
.	NN	O	O

Thoracic	NN	O	B
hematomyelia	NN	O	I
secondary	NN	O	O
to	NN	O	O
coumadin	NN	O	O
anticoagulant	NN	O	O
therapy	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
thoracic	NN	O	B
hematomyelia	NN	O	I
secondary	NN	O	O
to	NN	O	O
anticoagulant	NN	O	O
therapy	NN	O	O
is	NN	O	O
presented	NN	O	O
.	NN	O	O

Clinical	NN	O	O
features	NN	O	O
,	NN	O	O
similar	NN	O	O
to	NN	O	O
2	NN	O	O
other	NN	O	O
previously	NN	O	O
reported	NN	O	O
cases	NN	O	O
,	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

A	NN	O	O
high	NN	O	O
index	NN	O	O
of	NN	O	O
suspicion	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
a	NN	O	O
quick	NN	O	O
diagnostic	NN	O	O
procedure	NN	O	O
and	NN	O	O
successful	NN	O	O
decompressive	NN	O	O
surgery	NN	O	O
.	NN	O	O

Mania	NN	O	B
associated	NN	O	O
with	NN	O	O
fluoxetine	NN	O	O
treatment	NN	O	O
in	NN	O	O
adolescents	NN	O	O
.	NN	O	O

Fluoxetine	NN	O	O
,	NN	O	O
a	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
is	NN	O	O
gaining	NN	O	O
increased	NN	O	O
acceptance	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
adolescent	NN	O	O
depression	NN	O	B
.	NN	O	O

Generally	NN	O	O
safe	NN	O	O
and	NN	O	O
well	NN	O	O
tolerated	NN	O	O
by	NN	O	O
adults	NN	O	O
,	NN	O	O
fluoxetine	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
induce	NN	O	O
mania	NN	O	B
.	NN	O	O

The	NN	O	O
cases	NN	O	O
of	NN	O	O
five	NN	O	O
depressed	NN	O	B
adolescents	NN	O	O
,	NN	O	O
14	NN	O	O
-	NN	O	O
16	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
who	NN	O	O
developed	NN	O	O
mania	NN	O	B
during	NN	O	O
pharmacotherapy	NN	O	O
with	NN	O	O
fluoxetine	NN	O	O
,	NN	O	O
are	NN	O	O
reported	NN	O	O
here	NN	O	O
.	NN	O	O

Apparent	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
mania	NN	O	B
or	NN	O	O
hypomania	NN	O	B
during	NN	O	O
fluoxetine	NN	O	O
pharmacotherapy	NN	O	O
in	NN	O	O
this	NN	O	O
population	NN	O	O
were	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
attention	NN	O	B
-	NN	O	I
deficit	NN	O	I
hyperactivity	NN	O	I
disorder	NN	O	I
and	NN	O	O
affective	NN	O	O
instability	NN	O	O
;	NN	O	O
major	NN	O	O
depression	NN	O	B
with	NN	O	O
psychotic	NN	O	B
features	NN	O	O
;	NN	O	O
a	NN	O	O
family	NN	O	O
history	NN	O	O
of	NN	O	O
affective	NN	O	B
disorder	NN	O	I
,	NN	O	O
especially	NN	O	O
bipolar	NN	O	B
disorder	NN	O	I
;	NN	O	O
and	NN	O	O
a	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
bipolar	NN	O	B
disorder	NN	O	I
.	NN	O	O

Further	NN	O	O
study	NN	O	O
is	NN	O	O
needed	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
optimal	NN	O	O
dosage	NN	O	O
and	NN	O	O
to	NN	O	O
identify	NN	O	O
risk	NN	O	O
factors	NN	O	O
that	NN	O	O
increase	NN	O	O
individual	NN	O	O
vulnerability	NN	O	O
to	NN	O	O
fluoxetine	NN	O	O
induced	NN	O	O
mania	NN	O	B
in	NN	O	O
adolescents	NN	O	O
.	NN	O	O

Acute	NN	O	B
renal	NN	O	I
insufficiency	NN	O	I
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
melphalan	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
primary	NN	O	B
systemic	NN	O	I
amyloidosis	NN	O	I
during	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Patients	NN	O	O
with	NN	O	O
primary	NN	O	B
systemic	NN	O	I
amyloidosis	NN	O	I
(	NN	O	O
AL	NN	O	B
)	NN	O	O
have	NN	O	O
a	NN	O	O
poor	NN	O	O
prognosis	NN	O	O
.	NN	O	O

Median	NN	O	O
survival	NN	O	O
time	NN	O	O
from	NN	O	O
standard	NN	O	O
treatments	NN	O	O
is	NN	O	O
only	NN	O	O
17	NN	O	O
months	NN	O	O
.	NN	O	O

High	NN	O	O
-	NN	O	O
dose	NN	O	O
intravenous	NN	O	O
melphalan	NN	O	O
followed	NN	O	O
by	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplant	NN	O	O
(	NN	O	O
PBSCT	NN	O	O
)	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
most	NN	O	O
promising	NN	O	O
therapy	NN	O	O
,	NN	O	O
but	NN	O	O
treatment	NN	O	O
mortality	NN	O	O
can	NN	O	O
be	NN	O	O
high	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
have	NN	O	O
noted	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
acute	NN	O	B
renal	NN	O	I
insufficiency	NN	O	I
immediately	NN	O	O
after	NN	O	O
melphalan	NN	O	O
conditioning	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
further	NN	O	O
examine	NN	O	O
its	NN	O	O
risk	NN	O	O
factors	NN	O	O
and	NN	O	O
impact	NN	O	O
on	NN	O	O
posttransplant	NN	O	O
mortality	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Consecutive	NN	O	O
AL	NN	O	B
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
PBSCT	NN	O	O
were	NN	O	O
studied	NN	O	O
retrospectively	NN	O	O
.	NN	O	O

Acute	NN	O	B
renal	NN	O	I
insufficiency	NN	O	I
(	NN	O	O
ARI	NN	O	B
)	NN	O	O
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
melphalan	NN	O	O
was	NN	O	O
defined	NN	O	O
by	NN	O	O
a	NN	O	O
minimum	NN	O	O
increase	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
(	NN	O	O
44	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
level	NN	O	O
that	NN	O	O
is	NN	O	O
greater	NN	O	O
than	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
baseline	NN	O	O
immediately	NN	O	O
after	NN	O	O
conditioning	NN	O	O
.	NN	O	O

Urine	NN	O	O
sediment	NN	O	O
score	NN	O	O
was	NN	O	O
the	NN	O	O
sum	NN	O	O
of	NN	O	O
the	NN	O	O
individual	NN	O	O
types	NN	O	O
of	NN	O	O
sediment	NN	O	O
identified	NN	O	O
on	NN	O	O
urine	NN	O	O
microscopy	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Of	NN	O	O
the	NN	O	O
80	NN	O	O
patients	NN	O	O
studied	NN	O	O
,	NN	O	O
ARI	NN	O	B
developed	NN	O	O
in	NN	O	O
18	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
melphalan	NN	O	O
.	NN	O	O

Univariate	NN	O	O
analysis	NN	O	O
identified	NN	O	O
age	NN	O	O
,	NN	O	O
hypoalbuminemia	NN	O	B
,	NN	O	O
heavy	NN	O	O
proteinuria	NN	O	B
,	NN	O	O
diuretic	NN	O	O
use	NN	O	O
,	NN	O	O
and	NN	O	O
urine	NN	O	O
sediment	NN	O	O
score	NN	O	O
(	NN	O	O
>	NN	O	O
3	NN	O	O
)	NN	O	O
as	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

Age	NN	O	O
and	NN	O	O
urine	NN	O	O
sediment	NN	O	O
score	NN	O	O
remained	NN	O	O
independently	NN	O	O
significant	NN	O	O
risk	NN	O	O
factors	NN	O	O
in	NN	O	O
the	NN	O	O
multivariate	NN	O	O
analysis	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
had	NN	O	O
ARI	NN	O	B
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
melphalan	NN	O	O
underwent	NN	O	O
dialysis	NN	O	O
more	NN	O	O
often	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
007	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
had	NN	O	O
a	NN	O	O
worse	NN	O	O
1	NN	O	O
-	NN	O	O
year	NN	O	O
survival	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
timing	NN	O	O
of	NN	O	O
renal	NN	O	B
injury	NN	O	I
strongly	NN	O	O
suggests	NN	O	O
melphalan	NN	O	O
as	NN	O	O
the	NN	O	O
causative	NN	O	O
agent	NN	O	O
.	NN	O	O

Ongoing	NN	O	O
tubular	NN	O	B
injury	NN	O	I
may	NN	O	O
be	NN	O	O
a	NN	O	O
prerequisite	NN	O	O
for	NN	O	O
renal	NN	O	B
injury	NN	O	I
by	NN	O	O
melphalan	NN	O	O
as	NN	O	O
evidenced	NN	O	O
by	NN	O	O
the	NN	O	O
active	NN	O	O
urinary	NN	O	O
sediment	NN	O	O
.	NN	O	O

Development	NN	O	O
of	NN	O	O
ARI	NN	O	B
adversely	NN	O	O
affected	NN	O	O
the	NN	O	O
outcome	NN	O	O
after	NN	O	O
PBSCT	NN	O	O
.	NN	O	O

Effective	NN	O	O
preventive	NN	O	O
measures	NN	O	O
may	NN	O	O
help	NN	O	O
decrease	NN	O	O
the	NN	O	O
treatment	NN	O	O
mortality	NN	O	O
of	NN	O	O
PBSCT	NN	O	O
in	NN	O	O
AL	NN	O	B
patients	NN	O	O
.	NN	O	O

Focal	NN	O	O
cerebral	NN	O	B
ischemia	NN	O	I
in	NN	O	O
rats	NN	O	O
:	NN	O	O
effect	NN	O	O
of	NN	O	O
phenylephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
during	NN	O	O
reperfusion	NN	O	O
.	NN	O	O

After	NN	O	O
180	NN	O	O
min	NN	O	O
of	NN	O	O
temporary	NN	O	O
middle	NN	O	B
cerebral	NN	O	I
artery	NN	O	I
occlusion	NN	O	I
in	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
,	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
phenylephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
on	NN	O	O
ischemic	NN	O	B
brain	NN	O	I
injury	NN	O	I
and	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
permeability	NN	O	O
was	NN	O	O
determined	NN	O	O
.	NN	O	O

Blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
manipulated	NN	O	O
by	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
following	NN	O	O
schedules	NN	O	O
during	NN	O	O
120	NN	O	O
min	NN	O	O
of	NN	O	O
reperfusion	NN	O	O
:	NN	O	O
Control	NN	O	O
,	NN	O	O
normotensive	NN	O	O
reperfusion	NN	O	O
;	NN	O	O
90	NN	O	O
/	NN	O	O
hypertension	NN	O	B
(	NN	O	O
90	NN	O	O
/	NN	O	O
HTN	NN	O	B
)	NN	O	O
,	NN	O	O
blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
increased	NN	O	O
by	NN	O	O
35	NN	O	O
mm	NN	O	O
Hg	NN	O	O
during	NN	O	O
the	NN	O	O
initial	NN	O	O
90	NN	O	O
min	NN	O	O
of	NN	O	O
reperfusion	NN	O	O
only	NN	O	O
;	NN	O	O
15	NN	O	O
/	NN	O	O
hypertension	NN	O	B
(	NN	O	O
15	NN	O	O
/	NN	O	O
HTN	NN	O	B
)	NN	O	O
,	NN	O	O
normotensive	NN	O	O
reperfusion	NN	O	O
for	NN	O	O
30	NN	O	O
min	NN	O	O
followed	NN	O	O
by	NN	O	O
15	NN	O	O
min	NN	O	O
of	NN	O	O
hypertension	NN	O	B
and	NN	O	O
75	NN	O	O
min	NN	O	O
of	NN	O	O
normotension	NN	O	O
.	NN	O	O

Part	NN	O	O
A	NN	O	O
,	NN	O	O
for	NN	O	O
eight	NN	O	O
rats	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
brain	NN	O	B
injury	NN	O	I
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
staining	NN	O	O
tissue	NN	O	O
using	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
triphenyltetrazolium	NN	O	O
chloride	NN	O	O
and	NN	O	O
edema	NN	O	B
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
microgravimetry	NN	O	O
.	NN	O	O

Part	NN	O	O
B	NN	O	O
,	NN	O	O
for	NN	O	O
eight	NN	O	O
different	NN	O	O
rats	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
permeability	NN	O	O
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
measuring	NN	O	O
the	NN	O	O
amount	NN	O	O
and	NN	O	O
extent	NN	O	O
of	NN	O	O
extravasation	NN	O	O
of	NN	O	O
Evans	NN	O	O
Blue	NN	O	O
dye	NN	O	O
.	NN	O	O

Brain	NN	O	B
injury	NN	O	I
(	NN	O	O
percentage	NN	O	O
of	NN	O	O
the	NN	O	O
ischemic	NN	O	B
hemisphere	NN	O	I
)	NN	O	O
was	NN	O	O
less	NN	O	O
in	NN	O	O
the	NN	O	O
15	NN	O	O
/	NN	O	O
HTN	NN	O	B
group	NN	O	O
(	NN	O	O
16	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
,	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
versus	NN	O	O
the	NN	O	O
90	NN	O	O
/	NN	O	O
HTN	NN	O	B
group	NN	O	O
(	NN	O	O
30	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
in	NN	O	O
turn	NN	O	O
less	NN	O	O
than	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
42	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
)	NN	O	O
.	NN	O	O

Specific	NN	O	O
gravity	NN	O	O
was	NN	O	O
greater	NN	O	O
in	NN	O	O
the	NN	O	O
15	NN	O	O
/	NN	O	O
HTN	NN	O	B
group	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
043	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
002	NN	O	O
)	NN	O	O
versus	NN	O	O
the	NN	O	O
90	NN	O	O
/	NN	O	O
HTN	NN	O	B
(	NN	O	O
1	NN	O	O
.	NN	O	O
036	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
003	NN	O	O
)	NN	O	O
and	NN	O	O
control	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
037	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
003	NN	O	O
)	NN	O	O
groups	NN	O	O
.	NN	O	O

Evans	NN	O	O
Blue	NN	O	O
(	NN	O	O
mug	NN	O	O
g	NN	O	O
-	NN	O	O
1	NN	O	O
of	NN	O	O
brain	NN	O	O
tissue	NN	O	O
)	NN	O	O
was	NN	O	O
greater	NN	O	O
in	NN	O	O
the	NN	O	O
90	NN	O	O
/	NN	O	O
HTN	NN	O	B
group	NN	O	O
(	NN	O	O
24	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
versus	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
in	NN	O	O
turn	NN	O	O
greater	NN	O	O
than	NN	O	O
the	NN	O	O
15	NN	O	O
/	NN	O	O
HTN	NN	O	B
group	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
supports	NN	O	O
a	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
during	NN	O	O
reperfusion	NN	O	O
,	NN	O	O
a	NN	O	O
short	NN	O	O
interval	NN	O	O
of	NN	O	O
hypertension	NN	O	B
decreases	NN	O	O
brain	NN	O	B
injury	NN	O	I
and	NN	O	O
edema	NN	O	B
;	NN	O	O
and	NN	O	O
that	NN	O	O
sustained	NN	O	O
hypertension	NN	O	B
increases	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
vasogenic	NN	O	B
edema	NN	O	I
.	NN	O	O

People	NN	O	O
aged	NN	O	O
over	NN	O	O
75	NN	O	O
in	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
on	NN	O	O
warfarin	NN	O	O
:	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
major	NN	O	O
hemorrhage	NN	O	B
and	NN	O	O
stroke	NN	O	B
in	NN	O	O
more	NN	O	O
than	NN	O	O
500	NN	O	O
patient	NN	O	O
-	NN	O	O
years	NN	O	O
of	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
major	NN	O	O
hemorrhage	NN	O	B
and	NN	O	O
stroke	NN	O	B
in	NN	O	O
people	NN	O	O
aged	NN	O	O
76	NN	O	O
and	NN	O	O
older	NN	O	O
with	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
on	NN	O	O
adjusted	NN	O	O
-	NN	O	O
dose	NN	O	O
warfarin	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
recently	NN	O	O
been	NN	O	O
admitted	NN	O	O
to	NN	O	O
hospital	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
A	NN	O	O
retrospective	NN	O	O
observational	NN	O	O
cohort	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
A	NN	O	O
major	NN	O	O
healthcare	NN	O	O
network	NN	O	O
involving	NN	O	O
four	NN	O	O
tertiary	NN	O	O
hospitals	NN	O	O
.	NN	O	O

PARTICIPANTS	NN	O	O
:	NN	O	O
Two	NN	O	O
hundred	NN	O	O
thirty	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
aged	NN	O	O
76	NN	O	O
and	NN	O	O
older	NN	O	O
admitted	NN	O	O
to	NN	O	O
a	NN	O	O
major	NN	O	O
healthcare	NN	O	O
network	NN	O	O
between	NN	O	O
July	NN	O	O
1	NN	O	O
,	NN	O	O
2001	NN	O	O
,	NN	O	O
and	NN	O	O
June	NN	O	O
30	NN	O	O
,	NN	O	O
2002	NN	O	O
,	NN	O	O
with	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
on	NN	O	O
warfarin	NN	O	O
were	NN	O	O
enrolled	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
:	NN	O	O
Information	NN	O	O
regarding	NN	O	O
major	NN	O	O
bleeding	NN	O	B
episodes	NN	O	O
,	NN	O	O
strokes	NN	O	B
,	NN	O	O
and	NN	O	O
warfarin	NN	O	O
use	NN	O	O
was	NN	O	O
obtained	NN	O	O
from	NN	O	O
patients	NN	O	O
,	NN	O	O
relatives	NN	O	O
,	NN	O	O
primary	NN	O	O
physicians	NN	O	O
,	NN	O	O
and	NN	O	O
medical	NN	O	O
records	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Two	NN	O	O
hundred	NN	O	O
twenty	NN	O	O
-	NN	O	O
eight	NN	O	O
patients	NN	O	O
(	NN	O	O
42	NN	O	O
%	NN	O	O
men	NN	O	O
)	NN	O	O
with	NN	O	O
a	NN	O	O
mean	NN	O	O
age	NN	O	O
of	NN	O	O
81	NN	O	O
.	NN	O	O
1	NN	O	O
(	NN	O	O
range	NN	O	O
76	NN	O	O
-	NN	O	O
94	NN	O	O
)	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
analysis	NN	O	O
.	NN	O	O

Total	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
on	NN	O	O
warfarin	NN	O	O
was	NN	O	O
530	NN	O	O
years	NN	O	O
(	NN	O	O
mean	NN	O	O
28	NN	O	O
months	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
53	NN	O	O
major	NN	O	O
hemorrhages	NN	O	B
,	NN	O	O
for	NN	O	O
an	NN	O	O
annual	NN	O	O
rate	NN	O	O
of	NN	O	O
10	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
,	NN	O	O
including	NN	O	O
24	NN	O	O
(	NN	O	O
45	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
and	NN	O	O
five	NN	O	O
(	NN	O	O
9	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
fatal	NN	O	O
bleeds	NN	O	O
.	NN	O	O

The	NN	O	O
annual	NN	O	O
stroke	NN	O	B
rate	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
warfarin	NN	O	O
was	NN	O	O
2	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
rate	NN	O	O
of	NN	O	O
major	NN	O	O
hemorrhage	NN	O	B
was	NN	O	O
high	NN	O	O
in	NN	O	O
this	NN	O	O
old	NN	O	O
,	NN	O	O
frail	NN	O	O
group	NN	O	O
,	NN	O	O
but	NN	O	O
excluding	NN	O	O
fatalities	NN	O	O
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
no	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
sequelae	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
stroke	NN	O	B
rate	NN	O	O
on	NN	O	O
warfarin	NN	O	O
was	NN	O	O
low	NN	O	O
,	NN	O	O
demonstrating	NN	O	O
how	NN	O	O
effective	NN	O	O
warfarin	NN	O	O
treatment	NN	O	O
is	NN	O	O
.	NN	O	O

Safety	NN	O	O
of	NN	O	O
celecoxib	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
adverse	NN	O	O
skin	NN	O	B
reactions	NN	O	I
to	NN	O	O
acetaminophen	NN	O	O
(	NN	O	O
paracetamol	NN	O	O
)	NN	O	O
and	NN	O	O
nimesulide	NN	O	O
associated	NN	O	O
or	NN	O	O
not	NN	O	O
with	NN	O	O
common	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Acetaminophen	NN	O	O
(	NN	O	O
paracetamol	NN	O	O
-	NN	O	O
-	NN	O	O
P	NN	O	O
)	NN	O	O
and	NN	O	O
Nimesulide	NN	O	O
(	NN	O	O
N	NN	O	O
)	NN	O	O
are	NN	O	O
widely	NN	O	O
used	NN	O	O
analgesic	NN	O	O
-	NN	O	O
antipyretic	NN	O	O
/	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
rate	NN	O	O
of	NN	O	O
adverse	NN	O	O
hypersensitivity	NN	O	B
reactions	NN	O	O
to	NN	O	O
these	NN	O	O
agents	NN	O	O
is	NN	O	O
generally	NN	O	O
low	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
contrary	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
(	NN	O	O
NSAIDs	NN	O	O
)	NN	O	O
are	NN	O	O
commonly	NN	O	O
involved	NN	O	O
in	NN	O	O
such	NN	O	O
reactions	NN	O	O
.	NN	O	O

Celecoxib	NN	O	O
(	NN	O	O
CE	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
drug	NN	O	O
,	NN	O	O
with	NN	O	O
high	NN	O	O
selectivity	NN	O	O
and	NN	O	O
affinity	NN	O	O
for	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
enzyme	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
We	NN	O	O
evaluated	NN	O	O
the	NN	O	O
tolerability	NN	O	O
of	NN	O	O
CE	NN	O	O
in	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
documented	NN	O	O
history	NN	O	O
of	NN	O	O
adverse	NN	O	O
cutaneous	NN	O	B
reactions	NN	O	I
to	NN	O	O
P	NN	O	O
and	NN	O	O
N	NN	O	O
associated	NN	O	O
or	NN	O	O
not	NN	O	O
to	NN	O	O
classic	NN	O	O
NSAIDs	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
studied	NN	O	O
9	NN	O	O
patients	NN	O	O
with	NN	O	O
hypersensitivity	NN	O	B
to	NN	O	O
P	NN	O	O
and	NN	O	O
N	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
associated	NN	O	O
reactions	NN	O	O
to	NN	O	O
classic	NN	O	O
NSAIDs	NN	O	O
.	NN	O	O

The	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
P	NN	O	O
and	NN	O	O
N	NN	O	O
-	NN	O	O
induced	NN	O	O
skin	NN	O	B
reactions	NN	O	I
was	NN	O	O
based	NN	O	O
in	NN	O	O
vivo	NN	O	O
challenge	NN	O	O
.	NN	O	O

The	NN	O	O
placebo	NN	O	O
was	NN	O	O
blindly	NN	O	O
administered	NN	O	O
at	NN	O	O
the	NN	O	O
beginning	NN	O	O
of	NN	O	O
each	NN	O	O
challenge	NN	O	O
.	NN	O	O

After	NN	O	O
three	NN	O	O
days	NN	O	O
,	NN	O	O
a	NN	O	O
cumulative	NN	O	O
dosage	NN	O	O
of	NN	O	O
200	NN	O	O
mg	NN	O	O
of	NN	O	O
CE	NN	O	O
in	NN	O	O
refracted	NN	O	O
doses	NN	O	O
were	NN	O	O
given	NN	O	O
.	NN	O	O

After	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
days	NN	O	O
,	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
200	NN	O	O
mg	NN	O	O
was	NN	O	O
administered	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
observed	NN	O	O
for	NN	O	O
6	NN	O	O
hours	NN	O	O
after	NN	O	O
each	NN	O	O
challenge	NN	O	O
,	NN	O	O
and	NN	O	O
controlled	NN	O	O
again	NN	O	O
after	NN	O	O
24	NN	O	O
hours	NN	O	O
to	NN	O	O
exclude	NN	O	O
delayed	NN	O	O
reactions	NN	O	O
.	NN	O	O

The	NN	O	O
challenge	NN	O	O
was	NN	O	O
considered	NN	O	O
positive	NN	O	O
if	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
of	NN	O	O
the	NN	O	O
following	NN	O	O
appeared	NN	O	O
:	NN	O	O
erythema	NN	O	B
,	NN	O	O
rush	NN	O	O
or	NN	O	O
urticaria	NN	O	B
-	NN	O	O
angioedema	NN	O	B
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
No	NN	O	O
reaction	NN	O	O
was	NN	O	O
observed	NN	O	O
with	NN	O	O
placebo	NN	O	O
and	NN	O	O
eight	NN	O	O
patients	NN	O	O
(	NN	O	O
88	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
tolerated	NN	O	O
CE	NN	O	O
.	NN	O	O

Only	NN	O	O
one	NN	O	O
patient	NN	O	O
developed	NN	O	O
a	NN	O	O
moderate	NN	O	O
angioedema	NN	O	B
of	NN	O	O
the	NN	O	O
lips	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Only	NN	O	O
one	NN	O	O
hypersensitivity	NN	O	B
reaction	NN	O	O
to	NN	O	O
CE	NN	O	O
was	NN	O	O
documented	NN	O	O
among	NN	O	O
9	NN	O	O
P	NN	O	O
and	NN	O	O
N	NN	O	O
-	NN	O	O
highly	NN	O	O
NSAIDs	NN	O	O
intolerant	NN	O	O
patients	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
we	NN	O	O
conclude	NN	O	O
that	NN	O	O
CE	NN	O	O
is	NN	O	O
a	NN	O	O
reasonably	NN	O	O
safe	NN	O	O
alternative	NN	O	O
to	NN	O	O
be	NN	O	O
used	NN	O	O
in	NN	O	O
subjects	NN	O	O
who	NN	O	O
do	NN	O	O
not	NN	O	O
tolerate	NN	O	O
P	NN	O	O
and	NN	O	O
N	NN	O	O
.	NN	O	O

Case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
of	NN	O	O
regular	NN	O	O
analgesic	NN	O	O
and	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
use	NN	O	O
and	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
renal	NN	O	I
disease	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Studies	NN	O	O
on	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
aspirin	NN	O	O
and	NN	O	O
other	NN	O	O
analgesic	NN	O	O
and	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
(	NN	O	O
NSAIDs	NN	O	O
)	NN	O	O
and	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
renal	NN	O	I
disease	NN	O	I
(	NN	O	O
ESRD	NN	O	B
)	NN	O	O
have	NN	O	O
given	NN	O	O
conflicting	NN	O	O
results	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
examine	NN	O	O
this	NN	O	O
association	NN	O	O
,	NN	O	O
a	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
with	NN	O	O
incident	NN	O	O
cases	NN	O	O
of	NN	O	O
ESRD	NN	O	B
was	NN	O	O
carried	NN	O	O
out	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
cases	NN	O	O
were	NN	O	O
all	NN	O	O
patients	NN	O	O
entering	NN	O	O
the	NN	O	O
local	NN	O	O
dialysis	NN	O	O
program	NN	O	O
because	NN	O	O
of	NN	O	O
ESRD	NN	O	B
in	NN	O	O
the	NN	O	O
study	NN	O	O
area	NN	O	O
between	NN	O	O
June	NN	O	O
1	NN	O	O
,	NN	O	O
1995	NN	O	O
and	NN	O	O
November	NN	O	O
30	NN	O	O
,	NN	O	O
1997	NN	O	O
.	NN	O	O

They	NN	O	O
were	NN	O	O
classified	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
underlying	NN	O	O
disease	NN	O	O
,	NN	O	O
which	NN	O	O
had	NN	O	O
presumably	NN	O	O
led	NN	O	O
them	NN	O	O
to	NN	O	O
ESRD	NN	O	B
.	NN	O	O

Controls	NN	O	O
were	NN	O	O
patients	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
same	NN	O	O
hospitals	NN	O	O
from	NN	O	O
where	NN	O	O
the	NN	O	O
cases	NN	O	O
arose	NN	O	O
,	NN	O	O
also	NN	O	O
matched	NN	O	O
by	NN	O	O
age	NN	O	O
and	NN	O	O
sex	NN	O	O
.	NN	O	O

Odds	NN	O	O
ratios	NN	O	O
were	NN	O	O
calculated	NN	O	O
using	NN	O	O
a	NN	O	O
conditional	NN	O	O
logistic	NN	O	O
model	NN	O	O
,	NN	O	O
including	NN	O	O
potential	NN	O	O
confounding	NN	O	O
factors	NN	O	O
,	NN	O	O
both	NN	O	O
for	NN	O	O
the	NN	O	O
whole	NN	O	O
study	NN	O	O
population	NN	O	O
and	NN	O	O
for	NN	O	O
the	NN	O	O
various	NN	O	O
underlying	NN	O	O
diseases	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Five	NN	O	O
hundred	NN	O	O
and	NN	O	O
eighty	NN	O	O
-	NN	O	O
three	NN	O	O
cases	NN	O	O
and	NN	O	O
1190	NN	O	O
controls	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
analysis	NN	O	O
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
any	NN	O	O
analgesic	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
overall	NN	O	O
odds	NN	O	O
ratio	NN	O	O
of	NN	O	O
1	NN	O	O
.	NN	O	O
22	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
89	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
66	NN	O	O
)	NN	O	O
.	NN	O	O

For	NN	O	O
specific	NN	O	O
groups	NN	O	O
of	NN	O	O
drugs	NN	O	O
,	NN	O	O
the	NN	O	O
risks	NN	O	O
were	NN	O	O
1	NN	O	O
.	NN	O	O
56	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
05	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
30	NN	O	O
)	NN	O	O
for	NN	O	O
aspirin	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
03	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
60	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
76	NN	O	O
)	NN	O	O
for	NN	O	O
pyrazolones	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
80	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
39	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
63	NN	O	O
)	NN	O	O
for	NN	O	O
paracetamol	NN	O	O
,	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
94	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
57	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
56	NN	O	O
)	NN	O	O
for	NN	O	O
nonaspirin	NN	O	O
NSAIDs	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
of	NN	O	O
ESRD	NN	O	B
associated	NN	O	O
with	NN	O	O
aspirin	NN	O	O
was	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
cumulated	NN	O	O
dose	NN	O	O
and	NN	O	O
duration	NN	O	O
of	NN	O	O
use	NN	O	O
,	NN	O	O
and	NN	O	O
it	NN	O	O
was	NN	O	O
particularly	NN	O	O
high	NN	O	O
among	NN	O	O
the	NN	O	O
subset	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
vascular	NN	O	O
nephropathy	NN	O	B
as	NN	O	O
underlying	NN	O	O
disease	NN	O	O
[	NN	O	O
2	NN	O	O
.	NN	O	O
35	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
17	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
72	NN	O	O
)	NN	O	O
]	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Our	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
nonaspirin	NN	O	O
analgesic	NN	O	O
drugs	NN	O	O
and	NN	O	O
NSAIDs	NN	O	O
is	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
ESRD	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
chronic	NN	O	O
use	NN	O	O
of	NN	O	O
aspirin	NN	O	O
may	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
ESRD	NN	O	B
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
of	NN	O	O
amisulpride	NN	O	O
overdose	NN	O	B
:	NN	O	O
a	NN	O	O
cause	NN	O	O
for	NN	O	O
prolonged	NN	O	B
QT	NN	O	I
syndrome	NN	O	I
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
of	NN	O	O
deliberate	NN	O	O
self	NN	O	O
-	NN	O	O
poisoning	NN	O	B
with	NN	O	O
5	NN	O	O
g	NN	O	O
and	NN	O	O
3	NN	O	O
.	NN	O	O
6	NN	O	O
g	NN	O	O
of	NN	O	O
amisulpride	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
are	NN	O	O
reported	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
cases	NN	O	O
,	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
and	NN	O	O
hypocalcaemia	NN	O	B
were	NN	O	O
noted	NN	O	O
.	NN	O	O

The	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
appeared	NN	O	O
to	NN	O	O
respond	NN	O	O
to	NN	O	O
administration	NN	O	O
of	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
calcium	NN	O	O
gluconate	NN	O	O
.	NN	O	O

Growth	NN	O	O
-	NN	O	O
associated	NN	O	O
protein	NN	O	O
43	NN	O	O
expression	NN	O	O
in	NN	O	O
hippocampal	NN	O	O
molecular	NN	O	O
layer	NN	O	O
of	NN	O	O
chronic	NN	O	O
epileptic	NN	O	B
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
cycloheximide	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
GAP43	NN	O	O
has	NN	O	O
been	NN	O	O
thought	NN	O	O
to	NN	O	O
be	NN	O	O
linked	NN	O	O
with	NN	O	O
mossy	NN	O	O
fiber	NN	O	O
sprouting	NN	O	O
(	NN	O	O
MFS	NN	O	O
)	NN	O	O
in	NN	O	O
various	NN	O	O
experimental	NN	O	O
models	NN	O	O
of	NN	O	O
epilepsy	NN	O	B
.	NN	O	O

To	NN	O	O
investigate	NN	O	O
how	NN	O	O
GAP43	NN	O	O
expression	NN	O	O
(	NN	O	O
GAP43	NN	O	O
-	NN	O	O
ir	NN	O	O
)	NN	O	O
correlates	NN	O	O
with	NN	O	O
MFS	NN	O	O
,	NN	O	O
we	NN	O	O
assessed	NN	O	O
the	NN	O	O
intensity	NN	O	O
(	NN	O	O
densitometry	NN	O	O
)	NN	O	O
and	NN	O	O
extension	NN	O	O
(	NN	O	O
width	NN	O	O
)	NN	O	O
of	NN	O	O
GAP43	NN	O	O
-	NN	O	O
ir	NN	O	O
in	NN	O	O
the	NN	O	O
inner	NN	O	O
molecular	NN	O	O
layer	NN	O	O
of	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
(	NN	O	O
IML	NN	O	O
)	NN	O	O
of	NN	O	O
rats	NN	O	O
subject	NN	O	O
to	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
induced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
(	NN	O	O
Pilo	NN	O	O
)	NN	O	O
,	NN	O	O
previously	NN	O	O
injected	NN	O	O
or	NN	O	O
not	NN	O	O
with	NN	O	O
cycloheximide	NN	O	O
(	NN	O	O
CHX	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
inhibit	NN	O	O
MFS	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
CHX	NN	O	O
was	NN	O	O
injected	NN	O	O
before	NN	O	O
the	NN	O	O
Pilo	NN	O	O
injection	NN	O	O
in	NN	O	O
adult	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
Pilo	NN	O	O
group	NN	O	O
was	NN	O	O
injected	NN	O	O
with	NN	O	O
the	NN	O	O
same	NN	O	O
drugs	NN	O	O
,	NN	O	O
except	NN	O	O
for	NN	O	O
CHX	NN	O	O
.	NN	O	O

Animals	NN	O	O
were	NN	O	O
killed	NN	O	O
between	NN	O	O
30	NN	O	O
and	NN	O	O
60	NN	O	O
days	NN	O	O
later	NN	O	O
,	NN	O	O
and	NN	O	O
brain	NN	O	O
sections	NN	O	O
were	NN	O	O
processed	NN	O	O
for	NN	O	O
GAP43	NN	O	O
immunohistochemistry	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Densitometry	NN	O	O
showed	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
regarding	NN	O	O
GAP43	NN	O	O
-	NN	O	O
ir	NN	O	O
in	NN	O	O
the	NN	O	O
IML	NN	O	O
between	NN	O	O
Pilo	NN	O	O
,	NN	O	O
CHX	NN	O	O
+	NN	O	O
Pilo	NN	O	O
,	NN	O	O
and	NN	O	O
control	NN	O	O
groups	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
width	NN	O	O
of	NN	O	O
the	NN	O	O
GAP43	NN	O	O
-	NN	O	O
ir	NN	O	O
band	NN	O	O
in	NN	O	O
the	NN	O	O
IML	NN	O	O
showed	NN	O	O
that	NN	O	O
CHX	NN	O	O
+	NN	O	O
Pilo	NN	O	O
and	NN	O	O
control	NN	O	O
animals	NN	O	O
had	NN	O	O
a	NN	O	O
significantly	NN	O	O
larger	NN	O	O
band	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
)	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
that	NN	O	O
in	NN	O	O
the	NN	O	O
Pilo	NN	O	O
group	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Our	NN	O	O
current	NN	O	O
finding	NN	O	O
that	NN	O	O
animals	NN	O	O
in	NN	O	O
the	NN	O	O
CHX	NN	O	O
+	NN	O	O
Pilo	NN	O	O
group	NN	O	O
have	NN	O	O
a	NN	O	O
GAP43	NN	O	O
-	NN	O	O
ir	NN	O	O
band	NN	O	O
in	NN	O	O
the	NN	O	O
IML	NN	O	O
,	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
controls	NN	O	O
,	NN	O	O
reinforces	NN	O	O
prior	NN	O	O
data	NN	O	O
on	NN	O	O
the	NN	O	O
blockade	NN	O	O
of	NN	O	O
MFS	NN	O	O
in	NN	O	O
these	NN	O	O
animals	NN	O	O
.	NN	O	O

The	NN	O	O
change	NN	O	O
in	NN	O	O
GAP43	NN	O	O
-	NN	O	O
ir	NN	O	O
present	NN	O	O
in	NN	O	O
Pilo	NN	O	O
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
was	NN	O	O
a	NN	O	O
thinning	NN	O	O
of	NN	O	O
the	NN	O	O
band	NN	O	O
to	NN	O	O
a	NN	O	O
very	NN	O	O
narrow	NN	O	O
layer	NN	O	O
just	NN	O	O
above	NN	O	O
the	NN	O	O
granule	NN	O	O
cell	NN	O	O
layer	NN	O	O
that	NN	O	O
is	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
loss	NN	O	O
of	NN	O	O
hilar	NN	O	O
cell	NN	O	O
projections	NN	O	O
that	NN	O	O
express	NN	O	O
GAP	NN	O	O
-	NN	O	O
43	NN	O	O
.	NN	O	O

Nicotine	NN	O	O
antagonizes	NN	O	O
caffeine	NN	O	O
-	NN	O	O
but	NN	O	O
not	NN	O	O
pentylenetetrazole	NN	O	O
-	NN	O	O
induced	NN	O	O
anxiogenic	NN	O	O
effect	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

RATIONALE	NN	O	O
:	NN	O	O
Nicotine	NN	O	O
and	NN	O	O
caffeine	NN	O	O
are	NN	O	O
widely	NN	O	O
consumed	NN	O	O
licit	NN	O	O
psychoactive	NN	O	O
drugs	NN	O	O
worldwide	NN	O	O
.	NN	O	O

Epidemiological	NN	O	O
studies	NN	O	O
showed	NN	O	O
that	NN	O	O
they	NN	O	O
were	NN	O	O
generally	NN	O	O
used	NN	O	O
concurrently	NN	O	O
.	NN	O	O

Although	NN	O	O
some	NN	O	O
studies	NN	O	O
in	NN	O	O
experimental	NN	O	O
animals	NN	O	O
indicate	NN	O	O
clear	NN	O	O
pharmacological	NN	O	O
interactions	NN	O	O
between	NN	O	O
them	NN	O	O
,	NN	O	O
no	NN	O	O
studies	NN	O	O
have	NN	O	O
shown	NN	O	O
a	NN	O	O
specific	NN	O	O
interaction	NN	O	O
on	NN	O	O
anxiety	NN	O	B
responses	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
The	NN	O	O
present	NN	O	O
study	NN	O	O
investigates	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
nicotine	NN	O	O
on	NN	O	O
anxiety	NN	O	B
induced	NN	O	O
by	NN	O	O
caffeine	NN	O	O
and	NN	O	O
another	NN	O	O
anxiogenic	NN	O	O
drug	NN	O	O
,	NN	O	O
pentylenetetrazole	NN	O	O
,	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
elevated	NN	O	O
plus	NN	O	O
-	NN	O	O
maze	NN	O	O
(	NN	O	O
EPM	NN	O	O
)	NN	O	O
test	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
drugs	NN	O	O
on	NN	O	O
anxiety	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Adult	NN	O	O
male	NN	O	O
Swiss	NN	O	O
Webster	NN	O	O
mice	NN	O	O
(	NN	O	O
25	NN	O	O
-	NN	O	O
32	NN	O	O
g	NN	O	O
)	NN	O	O
were	NN	O	O
given	NN	O	O
nicotine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
or	NN	O	O
saline	NN	O	O
10	NN	O	O
min	NN	O	O
before	NN	O	O
caffeine	NN	O	O
(	NN	O	O
70	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
or	NN	O	O
pentylenetetrazole	NN	O	O
(	NN	O	O
15	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
injections	NN	O	O
.	NN	O	O

After	NN	O	O
15	NN	O	O
min	NN	O	O
,	NN	O	O
mice	NN	O	O
were	NN	O	O
evaluated	NN	O	O
for	NN	O	O
their	NN	O	O
open	NN	O	O
-	NN	O	O
and	NN	O	O
closed	NN	O	O
-	NN	O	O
arm	NN	O	O
time	NN	O	O
and	NN	O	O
entries	NN	O	O
on	NN	O	O
the	NN	O	O
EPM	NN	O	O
for	NN	O	O
a	NN	O	O
10	NN	O	O
-	NN	O	O
min	NN	O	O
session	NN	O	O
.	NN	O	O

Locomotor	NN	O	O
activity	NN	O	O
was	NN	O	O
recorded	NN	O	O
for	NN	O	O
individual	NN	O	O
groups	NN	O	O
by	NN	O	O
using	NN	O	O
the	NN	O	O
same	NN	O	O
treatment	NN	O	O
protocol	NN	O	O
with	NN	O	O
the	NN	O	O
EPM	NN	O	O
test	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Nicotine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
itself	NN	O	O
did	NN	O	O
not	NN	O	O
produce	NN	O	O
any	NN	O	O
significant	NN	O	O
effect	NN	O	O
in	NN	O	O
the	NN	O	O
EPM	NN	O	O
test	NN	O	O
,	NN	O	O
whereas	NN	O	O
caffeine	NN	O	O
(	NN	O	O
70	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
pentylenetetrazole	NN	O	O
(	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
produced	NN	O	O
an	NN	O	O
anxiogenic	NN	O	O
effect	NN	O	O
,	NN	O	O
apparent	NN	O	O
with	NN	O	O
decreases	NN	O	O
in	NN	O	O
open	NN	O	O
-	NN	O	O
arm	NN	O	O
time	NN	O	O
and	NN	O	O
entry	NN	O	O
.	NN	O	O

Nicotine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
pretreatment	NN	O	O
blocked	NN	O	O
the	NN	O	O
caffeine	NN	O	O
-	NN	O	O
but	NN	O	O
not	NN	O	O
pentylenetetrazole	NN	O	O
-	NN	O	O
induced	NN	O	O
anxiety	NN	O	B
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
each	NN	O	O
drug	NN	O	O
and	NN	O	O
their	NN	O	O
combinations	NN	O	O
did	NN	O	O
not	NN	O	O
produce	NN	O	O
any	NN	O	O
effect	NN	O	O
on	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
antagonistic	NN	O	O
effect	NN	O	O
of	NN	O	O
nicotine	NN	O	O
on	NN	O	O
caffeine	NN	O	O
-	NN	O	O
induced	NN	O	O
anxiety	NN	O	B
is	NN	O	O
specific	NN	O	O
to	NN	O	O
caffeine	NN	O	O
,	NN	O	O
instead	NN	O	O
of	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
specific	NN	O	O
anxiolytic	NN	O	O
effect	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
it	NN	O	O
may	NN	O	O
extend	NN	O	O
the	NN	O	O
current	NN	O	O
findings	NN	O	O
on	NN	O	O
the	NN	O	O
interaction	NN	O	O
between	NN	O	O
nicotine	NN	O	O
and	NN	O	O
caffeine	NN	O	O
.	NN	O	O

Long	NN	O	O
term	NN	O	O
hormone	NN	O	O
therapy	NN	O	O
for	NN	O	O
perimenopausal	NN	O	O
and	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Hormone	NN	O	O
therapy	NN	O	O
(	NN	O	O
HT	NN	O	O
)	NN	O	O
is	NN	O	O
widely	NN	O	O
used	NN	O	O
for	NN	O	O
controlling	NN	O	O
menopausal	NN	O	B
symptoms	NN	O	I
.	NN	O	O

It	NN	O	O
has	NN	O	O
also	NN	O	O
been	NN	O	O
used	NN	O	O
for	NN	O	O
the	NN	O	O
management	NN	O	O
and	NN	O	O
prevention	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
,	NN	O	O
osteoporosis	NN	O	B
and	NN	O	O
dementia	NN	O	B
in	NN	O	O
older	NN	O	O
women	NN	O	O
but	NN	O	O
the	NN	O	O
evidence	NN	O	O
supporting	NN	O	O
its	NN	O	O
use	NN	O	O
for	NN	O	O
these	NN	O	O
indications	NN	O	O
is	NN	O	O
largely	NN	O	O
observational	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
HT	NN	O	O
on	NN	O	O
mortality	NN	O	O
,	NN	O	O
heart	NN	O	B
disease	NN	O	I
,	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
,	NN	O	O
stroke	NN	O	B
,	NN	O	O
transient	NN	O	B
ischaemic	NN	O	I
attacks	NN	O	I
,	NN	O	O
breast	NN	O	B
cancer	NN	O	I
,	NN	O	O
colorectal	NN	O	B
cancer	NN	O	I
,	NN	O	O
ovarian	NN	O	B
cancer	NN	O	I
,	NN	O	O
endometrial	NN	O	B
cancer	NN	O	I
,	NN	O	O
gallbladder	NN	O	B
disease	NN	O	I
,	NN	O	O
cognitive	NN	O	O
function	NN	O	O
,	NN	O	O
dementia	NN	O	B
,	NN	O	O
fractures	NN	O	B
and	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
.	NN	O	O

SEARCH	NN	O	O
STRATEGY	NN	O	O
:	NN	O	O
We	NN	O	O
searched	NN	O	O
the	NN	O	O
following	NN	O	O
databases	NN	O	O
up	NN	O	O
to	NN	O	O
November	NN	O	O
2004	NN	O	O
:	NN	O	O
the	NN	O	O
Cochrane	NN	O	O
Menstrual	NN	O	O
Disorders	NN	O	O
and	NN	O	O
Subfertility	NN	O	O
Group	NN	O	O
Trials	NN	O	O
Register	NN	O	O
,	NN	O	O
Cochrane	NN	O	O
Central	NN	O	O
Register	NN	O	O
of	NN	O	O
Controlled	NN	O	O
Trials	NN	O	O
(	NN	O	O
CENTRAL	NN	O	O
)	NN	O	O
,	NN	O	O
MEDLINE	NN	O	O
,	NN	O	O
EMBASE	NN	O	O
,	NN	O	O
Biological	NN	O	O
Abstracts	NN	O	O
.	NN	O	O

Relevant	NN	O	O
non	NN	O	O
-	NN	O	O
indexed	NN	O	O
journals	NN	O	O
and	NN	O	O
conference	NN	O	O
abstracts	NN	O	O
were	NN	O	O
also	NN	O	O
searched	NN	O	O
.	NN	O	O

SELECTION	NN	O	O
CRITERIA	NN	O	O
:	NN	O	O
Randomised	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trials	NN	O	O
of	NN	O	O
HT	NN	O	O
(	NN	O	O
oestrogens	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
progestogens	NN	O	O
)	NN	O	O
versus	NN	O	O
placebo	NN	O	O
,	NN	O	O
taken	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
year	NN	O	O
by	NN	O	O
perimenopausal	NN	O	O
or	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

DATA	NN	O	O
COLLECTION	NN	O	O
AND	NN	O	O
ANALYSIS	NN	O	O
:	NN	O	O
Fifteen	NN	O	O
RCTs	NN	O	O
were	NN	O	O
included	NN	O	O
.	NN	O	O

Trials	NN	O	O
were	NN	O	O
assessed	NN	O	O
for	NN	O	O
quality	NN	O	O
and	NN	O	O
two	NN	O	O
review	NN	O	O
authors	NN	O	O
extracted	NN	O	O
data	NN	O	O
independently	NN	O	O
.	NN	O	O

They	NN	O	O
calculated	NN	O	O
risk	NN	O	O
ratios	NN	O	O
for	NN	O	O
dichotomous	NN	O	O
outcomes	NN	O	O
and	NN	O	O
weighted	NN	O	O
mean	NN	O	O
differences	NN	O	O
for	NN	O	O
continuous	NN	O	O
outcomes	NN	O	O
.	NN	O	O

Clinical	NN	O	O
heterogeneity	NN	O	O
precluded	NN	O	O
meta	NN	O	O
-	NN	O	O
analysis	NN	O	O
for	NN	O	O
most	NN	O	O
outcomes	NN	O	O
.	NN	O	O

MAIN	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
All	NN	O	O
the	NN	O	O
statistically	NN	O	O
significant	NN	O	O
results	NN	O	O
were	NN	O	O
derived	NN	O	O
from	NN	O	O
the	NN	O	O
two	NN	O	O
biggest	NN	O	O
trials	NN	O	O
.	NN	O	O

In	NN	O	O
relatively	NN	O	O
healthy	NN	O	O
women	NN	O	O
,	NN	O	O
combined	NN	O	O
continuous	NN	O	O
HT	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
or	NN	O	O
coronary	NN	O	O
event	NN	O	O
(	NN	O	O
after	NN	O	O
one	NN	O	O
year	NN	O	O
'	NN	O	O
s	NN	O	O
use	NN	O	O
)	NN	O	O
,	NN	O	O
stroke	NN	O	B
(	NN	O	O
after	NN	O	O
3	NN	O	O
years	NN	O	O
)	NN	O	O
,	NN	O	O
breast	NN	O	B
cancer	NN	O	I
(	NN	O	O
after	NN	O	O
5	NN	O	O
years	NN	O	O
)	NN	O	O
and	NN	O	O
gallbladder	NN	O	B
disease	NN	O	I
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
oestrogen	NN	O	O
-	NN	O	O
only	NN	O	O
HT	NN	O	O
also	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
stroke	NN	O	B
and	NN	O	O
gallbladder	NN	O	B
disease	NN	O	I
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
the	NN	O	O
only	NN	O	O
statistically	NN	O	O
significant	NN	O	O
benefits	NN	O	O
of	NN	O	O
HT	NN	O	O
were	NN	O	O
a	NN	O	O
decreased	NN	O	O
incidence	NN	O	O
of	NN	O	O
fractures	NN	O	B
and	NN	O	O
colon	NN	O	B
cancer	NN	O	I
with	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
.	NN	O	O

Among	NN	O	O
relatively	NN	O	O
healthy	NN	O	O
women	NN	O	O
over	NN	O	O
65	NN	O	O
years	NN	O	O
taking	NN	O	O
continuous	NN	O	O
combined	NN	O	O
HT	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
dementia	NN	O	B
.	NN	O	O

Among	NN	O	O
women	NN	O	O
with	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
,	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
combined	NN	O	O
continuous	NN	O	O
HT	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
.	NN	O	O

No	NN	O	O
trials	NN	O	O
focussed	NN	O	O
specifically	NN	O	O
on	NN	O	O
younger	NN	O	O
women	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
one	NN	O	O
trial	NN	O	O
analysed	NN	O	O
subgroups	NN	O	O
of	NN	O	O
2839	NN	O	O
relatively	NN	O	O
healthy	NN	O	O
50	NN	O	O
to	NN	O	O
59	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
women	NN	O	O
taking	NN	O	O
combined	NN	O	O
continuous	NN	O	O
HT	NN	O	O
and	NN	O	O
1637	NN	O	O
taking	NN	O	O
oestrogen	NN	O	O
-	NN	O	O
only	NN	O	O
HT	NN	O	O
,	NN	O	O
versus	NN	O	O
similar	NN	O	O
-	NN	O	O
sized	NN	O	O
placebo	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
only	NN	O	O
significantly	NN	O	O
increased	NN	O	O
risk	NN	O	O
reported	NN	O	O
was	NN	O	O
for	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
in	NN	O	O
women	NN	O	O
taking	NN	O	O
combined	NN	O	O
continuous	NN	O	O
HT	NN	O	O
;	NN	O	O
their	NN	O	O
absolute	NN	O	O
risk	NN	O	O
remained	NN	O	O
very	NN	O	O
low	NN	O	O
.	NN	O	O

AUTHORS	NN	O	O
'	NN	O	O
CONCLUSIONS	NN	O	O
:	NN	O	O
HT	NN	O	O
is	NN	O	O
not	NN	O	O
indicated	NN	O	O
for	NN	O	O
the	NN	O	O
routine	NN	O	O
management	NN	O	O
of	NN	O	O
chronic	NN	O	B
disease	NN	O	I
.	NN	O	O

We	NN	O	O
need	NN	O	O
more	NN	O	O
evidence	NN	O	O
on	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
HT	NN	O	O
for	NN	O	O
menopausal	NN	O	O
symptom	NN	O	O
control	NN	O	O
,	NN	O	O
though	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
relatively	NN	O	O
safe	NN	O	O
for	NN	O	O
healthy	NN	O	O
younger	NN	O	O
women	NN	O	O
.	NN	O	O

Drug	NN	O	B
-	NN	O	I
induced	NN	O	I
liver	NN	O	I
injury	NN	O	I
:	NN	O	O
an	NN	O	O
analysis	NN	O	O
of	NN	O	O
461	NN	O	O
incidences	NN	O	O
submitted	NN	O	O
to	NN	O	O
the	NN	O	O
Spanish	NN	O	O
registry	NN	O	O
over	NN	O	O
a	NN	O	O
10	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
&	NN	O	O
AIMS	NN	O	O
:	NN	O	O
Progress	NN	O	O
in	NN	O	O
the	NN	O	O
understanding	NN	O	O
of	NN	O	O
susceptibility	NN	O	O
factors	NN	O	O
to	NN	O	O
drug	NN	O	B
-	NN	O	I
induced	NN	O	I
liver	NN	O	I
injury	NN	O	I
(	NN	O	O
DILI	NN	O	B
)	NN	O	O
and	NN	O	O
outcome	NN	O	O
predictability	NN	O	O
are	NN	O	O
hampered	NN	O	O
by	NN	O	O
the	NN	O	O
lack	NN	O	O
of	NN	O	O
systematic	NN	O	O
programs	NN	O	O
to	NN	O	O
detect	NN	O	O
bona	NN	O	O
fide	NN	O	O
cases	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
cooperative	NN	O	O
network	NN	O	O
was	NN	O	O
created	NN	O	O
in	NN	O	O
1994	NN	O	O
in	NN	O	O
Spain	NN	O	O
to	NN	O	O
identify	NN	O	O
all	NN	O	O
suspicions	NN	O	O
of	NN	O	O
DILI	NN	O	B
following	NN	O	O
a	NN	O	O
prospective	NN	O	O
structured	NN	O	O
report	NN	O	O
form	NN	O	O
.	NN	O	O

The	NN	O	O
liver	NN	O	B
damage	NN	O	I
was	NN	O	O
characterized	NN	O	O
according	NN	O	O
to	NN	O	O
hepatocellular	NN	O	O
,	NN	O	O
cholestatic	NN	O	B
,	NN	O	O
and	NN	O	O
mixed	NN	O	O
laboratory	NN	O	O
criteria	NN	O	O
and	NN	O	O
to	NN	O	O
histologic	NN	O	O
criteria	NN	O	O
when	NN	O	O
available	NN	O	O
.	NN	O	O

Further	NN	O	O
evaluation	NN	O	O
of	NN	O	O
causality	NN	O	O
assessment	NN	O	O
was	NN	O	O
centrally	NN	O	O
performed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Since	NN	O	O
April	NN	O	O
1994	NN	O	O
to	NN	O	O
August	NN	O	O
2004	NN	O	O
,	NN	O	O
461	NN	O	O
out	NN	O	O
of	NN	O	O
570	NN	O	O
submitted	NN	O	O
cases	NN	O	O
,	NN	O	O
involving	NN	O	O
505	NN	O	O
drugs	NN	O	O
,	NN	O	O
were	NN	O	O
deemed	NN	O	O
to	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
DILI	NN	O	B
.	NN	O	O

The	NN	O	O
antiinfective	NN	O	O
group	NN	O	O
of	NN	O	O
drugs	NN	O	O
was	NN	O	O
the	NN	O	O
more	NN	O	O
frequently	NN	O	O
incriminated	NN	O	O
,	NN	O	O
amoxicillin	NN	O	O
-	NN	O	O
clavulanate	NN	O	O
accounting	NN	O	O
for	NN	O	O
the	NN	O	O
12	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
whole	NN	O	O
series	NN	O	O
.	NN	O	O

The	NN	O	O
hepatocellular	NN	O	O
pattern	NN	O	O
of	NN	O	O
damage	NN	O	O
was	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
(	NN	O	O
58	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
was	NN	O	O
inversely	NN	O	O
correlated	NN	O	O
with	NN	O	O
age	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
had	NN	O	O
the	NN	O	O
worst	NN	O	O
outcome	NN	O	O
(	NN	O	O
Cox	NN	O	O
regression	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
034	NN	O	O
)	NN	O	O
.	NN	O	O

Indeed	NN	O	O
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
and	NN	O	O
death	NN	O	O
in	NN	O	O
this	NN	O	O
group	NN	O	O
was	NN	O	O
11	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
if	NN	O	O
patients	NN	O	O
had	NN	O	O
jaundice	NN	O	B
at	NN	O	O
presentation	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
corresponding	NN	O	O
figure	NN	O	O
was	NN	O	O
3	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
in	NN	O	O
nonjaundiced	NN	O	O
patients	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
04	NN	O	O
)	NN	O	O
.	NN	O	O

Factors	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
fulminant	NN	O	B
hepatic	NN	O	I
failure	NN	O	I
were	NN	O	O
female	NN	O	O
sex	NN	O	O
(	NN	O	O
OR	NN	O	O
=	NN	O	O
25	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
151	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
,	NN	O	O
hepatocellular	NN	O	O
damage	NN	O	O
(	NN	O	O
OR	NN	O	O
=	NN	O	O
7	NN	O	O
.	NN	O	O
9	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
-	NN	O	O
37	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
009	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
higher	NN	O	O
baseline	NN	O	O
plasma	NN	O	O
bilirubin	NN	O	O
value	NN	O	O
(	NN	O	O
OR	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
15	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
1	NN	O	O
.	NN	O	O
09	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
22	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Patients	NN	O	O
with	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatocellular	NN	O	O
jaundice	NN	O	B
have	NN	O	O
11	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
chance	NN	O	O
of	NN	O	O
progressing	NN	O	O
to	NN	O	O
death	NN	O	O
or	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Amoxicillin	NN	O	O
-	NN	O	O
clavulanate	NN	O	O
stands	NN	O	O
out	NN	O	O
as	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
drug	NN	O	O
related	NN	O	O
to	NN	O	O
DILI	NN	O	B
.	NN	O	O

Morphological	NN	O	O
evaluation	NN	O	O
of	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
d	NN	O	O
-	NN	O	O
ribose	NN	O	O
on	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
evoked	NN	O	O
cardiotoxicity	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
influence	NN	O	O
of	NN	O	O
d	NN	O	O
-	NN	O	O
ribose	NN	O	O
on	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardiopathy	NN	O	B
in	NN	O	O
rats	NN	O	O
was	NN	O	O
studied	NN	O	O
.	NN	O	O

Adriamycin	NN	O	O
in	NN	O	O
the	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
of	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
evoked	NN	O	O
fully	NN	O	O
developed	NN	O	O
cardiac	NN	O	B
toxicity	NN	O	I
.	NN	O	O

D	NN	O	O
-	NN	O	O
ribose	NN	O	O
in	NN	O	O
the	NN	O	O
multiple	NN	O	O
doses	NN	O	O
of	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
did	NN	O	O
not	NN	O	O
influence	NN	O	O
ADR	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

In	NN	O	O
vivo	NN	O	O
evidences	NN	O	O
suggesting	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
in	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
vancomycin	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
:	NN	O	O
protection	NN	O	O
by	NN	O	O
erdosteine	NN	O	O
.	NN	O	O

The	NN	O	O
aims	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
were	NN	O	O
to	NN	O	O
examine	NN	O	O
vancomycin	NN	O	O
(	NN	O	O
VCM	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
that	NN	O	O
promotes	NN	O	O
production	NN	O	O
of	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
(	NN	O	O
ROS	NN	O	O
)	NN	O	O
and	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
erdosteine	NN	O	O
,	NN	O	O
an	NN	O	O
expectorant	NN	O	O
agent	NN	O	O
,	NN	O	O
which	NN	O	O
has	NN	O	O
also	NN	O	O
antioxidant	NN	O	O
properties	NN	O	O
,	NN	O	O
on	NN	O	O
kidney	NN	O	O
tissue	NN	O	O
against	NN	O	O
the	NN	O	O
possible	NN	O	O
VCM	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
impairment	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
three	NN	O	O
groups	NN	O	O
:	NN	O	O
sham	NN	O	O
,	NN	O	O
VCM	NN	O	O
and	NN	O	O
VCM	NN	O	O
plus	NN	O	O
erdosteine	NN	O	O
.	NN	O	O

VCM	NN	O	O
was	NN	O	O
administrated	NN	O	O
intraperitoneally	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
with	NN	O	O
200mgkg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
.	NN	O	O

Erdosteine	NN	O	O
was	NN	O	O
administered	NN	O	O
orally	NN	O	O
.	NN	O	O

VCM	NN	O	O
administration	NN	O	O
to	NN	O	O
control	NN	O	O
rats	NN	O	O
significantly	NN	O	O
increased	NN	O	O
renal	NN	O	O
malondialdehyde	NN	O	O
(	NN	O	O
MDA	NN	O	O
)	NN	O	O
and	NN	O	O
urinary	NN	O	O
N	NN	O	O
-	NN	O	O
acetyl	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
d	NN	O	O
-	NN	O	O
glucosaminidase	NN	O	O
(	NN	O	O
NAG	NN	O	O
,	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
renal	NN	O	B
tubular	NN	O	I
injury	NN	O	I
)	NN	O	O
excretion	NN	O	O
but	NN	O	O
decreased	NN	O	O
superoxide	NN	O	O
dismutase	NN	O	O
(	NN	O	O
SOD	NN	O	O
)	NN	O	O
and	NN	O	O
catalase	NN	O	O
(	NN	O	O
CAT	NN	O	O
)	NN	O	O
activities	NN	O	O
.	NN	O	O

Erdosteine	NN	O	O
administration	NN	O	O
with	NN	O	O
VCM	NN	O	O
injections	NN	O	O
caused	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
renal	NN	O	O
MDA	NN	O	O
and	NN	O	O
urinary	NN	O	O
NAG	NN	O	O
excretion	NN	O	O
,	NN	O	O
and	NN	O	O
increased	NN	O	O
SOD	NN	O	O
activity	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
CAT	NN	O	O
activity	NN	O	O
in	NN	O	O
renal	NN	O	O
tissue	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
VCM	NN	O	O
alone	NN	O	O
.	NN	O	O

Erdosteine	NN	O	O
showed	NN	O	O
histopathological	NN	O	O
protection	NN	O	O
against	NN	O	O
VCM	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

There	NN	O	O
were	NN	O	O
a	NN	O	O
significant	NN	O	O
dilatation	NN	O	O
of	NN	O	O
tubular	NN	O	O
lumens	NN	O	O
,	NN	O	O
extensive	NN	O	O
epithelial	NN	O	O
cell	NN	O	O
vacuolization	NN	O	O
,	NN	O	O
atrophy	NN	O	B
,	NN	O	O
desquamation	NN	O	B
,	NN	O	O
and	NN	O	O
necrosis	NN	O	B
in	NN	O	O
VCM	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
more	NN	O	O
than	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
and	NN	O	O
the	NN	O	O
erdosteine	NN	O	O
groups	NN	O	O
.	NN	O	O

Erdosteine	NN	O	O
caused	NN	O	O
a	NN	O	O
marked	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
tubular	NN	O	O
damage	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
oxidative	NN	O	O
tubular	NN	O	O
damage	NN	O	O
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
VCM	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
and	NN	O	O
the	NN	O	O
modulation	NN	O	O
of	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
with	NN	O	O
erdosteine	NN	O	O
reduces	NN	O	O
the	NN	O	O
VCM	NN	O	O
-	NN	O	O
induced	NN	O	O
kidney	NN	O	B
damage	NN	O	I
both	NN	O	O
at	NN	O	O
the	NN	O	O
biochemical	NN	O	O
and	NN	O	O
histological	NN	O	O
levels	NN	O	O
.	NN	O	O

Gemfibrozil	NN	O	O
-	NN	O	O
lovastatin	NN	O	O
therapy	NN	O	O
for	NN	O	O
primary	NN	O	O
hyperlipoproteinemias	NN	O	B
.	NN	O	O

The	NN	O	O
specific	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
retrospective	NN	O	O
,	NN	O	O
observational	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
(	NN	O	O
21	NN	O	O
months	NN	O	O
/	NN	O	O
patient	NN	O	O
)	NN	O	O
,	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
,	NN	O	O
gemfibrozil	NN	O	O
-	NN	O	O
lovastatin	NN	O	O
treatment	NN	O	O
in	NN	O	O
80	NN	O	O
patients	NN	O	O
with	NN	O	O
primary	NN	O	O
mixed	NN	O	O
hyperlipidemia	NN	O	B
(	NN	O	O
68	NN	O	O
%	NN	O	O
of	NN	O	O
whom	NN	O	O
had	NN	O	O
atherosclerotic	NN	O	B
vascular	NN	O	I
disease	NN	O	I
)	NN	O	O
.	NN	O	O

Because	NN	O	O
ideal	NN	O	O
lipid	NN	O	O
targets	NN	O	O
were	NN	O	O
not	NN	O	O
reached	NN	O	O
(	NN	O	O
low	NN	O	O
-	NN	O	O
density	NN	O	O
lipoprotein	NN	O	O
(	NN	O	O
LDL	NN	O	O
)	NN	O	O
cholesterol	NN	O	O
less	NN	O	O
than	NN	O	O
130	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
density	NN	O	O
lipoprotein	NN	O	O
(	NN	O	O
HDL	NN	O	O
)	NN	O	O
cholesterol	NN	O	O
greater	NN	O	O
than	NN	O	O
35	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
or	NN	O	O
total	NN	O	O
cholesterol	NN	O	O
/	NN	O	O
HDL	NN	O	O
cholesterol	NN	O	O
less	NN	O	O
than	NN	O	O
4	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
)	NN	O	O
with	NN	O	O
diet	NN	O	O
plus	NN	O	O
a	NN	O	O
single	NN	O	O
drug	NN	O	O
,	NN	O	O
gemfibrozil	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
-	NN	O	O
lovastatin	NN	O	O
(	NN	O	O
primarily	NN	O	O
20	NN	O	O
or	NN	O	O
40	NN	O	O
mg	NN	O	O
)	NN	O	O
treatment	NN	O	O
was	NN	O	O
given	NN	O	O
.	NN	O	O

Follow	NN	O	O
-	NN	O	O
up	NN	O	O
visits	NN	O	O
were	NN	O	O
scheduled	NN	O	O
with	NN	O	O
2	NN	O	O
-	NN	O	O
drug	NN	O	O
therapy	NN	O	O
every	NN	O	O
6	NN	O	O
to	NN	O	O
8	NN	O	O
weeks	NN	O	O
,	NN	O	O
an	NN	O	O
average	NN	O	O
of	NN	O	O
10	NN	O	O
.	NN	O	O
3	NN	O	O
visits	NN	O	O
per	NN	O	O
patient	NN	O	O
,	NN	O	O
with	NN	O	O
741	NN	O	O
batteries	NN	O	O
of	NN	O	O
6	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
and	NN	O	O
714	NN	O	O
creatine	NN	O	O
phosphokinase	NN	O	O
levels	NN	O	O
measured	NN	O	O
.	NN	O	O

Only	NN	O	O
1	NN	O	O
of	NN	O	O
the	NN	O	O
4	NN	O	O
,	NN	O	O
446	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
gamma	NN	O	O
glutamyl	NN	O	O
transferase	NN	O	O
,	NN	O	O
was	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
3	NN	O	O
times	NN	O	O
the	NN	O	O
upper	NN	O	O
normal	NN	O	O
limit	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
714	NN	O	O
creatine	NN	O	O
phosphokinase	NN	O	O
levels	NN	O	O
,	NN	O	O
9	NN	O	O
%	NN	O	O
were	NN	O	O
high	NN	O	O
;	NN	O	O
only	NN	O	O
1	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
was	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
3	NN	O	O
times	NN	O	O
the	NN	O	O
upper	NN	O	O
normal	NN	O	O
limit	NN	O	O
.	NN	O	O

With	NN	O	O
2	NN	O	O
-	NN	O	O
drug	NN	O	O
therapy	NN	O	O
,	NN	O	O
mean	NN	O	O
total	NN	O	O
cholesterol	NN	O	O
decreased	NN	O	O
22	NN	O	O
%	NN	O	O
from	NN	O	O
255	NN	O	O
to	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
triglyceride	NN	O	O
levels	NN	O	O
decreased	NN	O	O
35	NN	O	O
%	NN	O	O
from	NN	O	O
236	NN	O	O
to	NN	O	O
154	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
LDL	NN	O	O
cholesterol	NN	O	O
decreased	NN	O	O
26	NN	O	O
%	NN	O	O
from	NN	O	O
176	NN	O	O
to	NN	O	O
131	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
total	NN	O	O
cholesterol	NN	O	O
/	NN	O	O
HDL	NN	O	O
cholesterol	NN	O	O
ratio	NN	O	O
decreased	NN	O	O
24	NN	O	O
%	NN	O	O
from	NN	O	O
7	NN	O	O
.	NN	O	O
1	NN	O	O
to	NN	O	O
5	NN	O	O
.	NN	O	O
4	NN	O	O
,	NN	O	O
all	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
.	NN	O	O

Myositis	NN	O	B
,	NN	O	O
attributable	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
combination	NN	O	O
and	NN	O	O
symptomatic	NN	O	O
enough	NN	O	O
to	NN	O	O
discontinue	NN	O	O
it	NN	O	O
,	NN	O	O
occurred	NN	O	O
in	NN	O	O
3	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
1	NN	O	O
%	NN	O	O
with	NN	O	O
concurrent	NN	O	O
high	NN	O	O
creatine	NN	O	O
phosphokinase	NN	O	O
(	NN	O	O
769	NN	O	O
U	NN	O	O
/	NN	O	O
liter	NN	O	O
)	NN	O	O
;	NN	O	O
no	NN	O	O
patients	NN	O	O
had	NN	O	O
rhabdomyolysis	NN	O	B
or	NN	O	O
myoglobinuria	NN	O	B
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Does	NN	O	O
domperidone	NN	O	O
potentiate	NN	O	O
mirtazapine	NN	O	O
-	NN	O	O
associated	NN	O	O
restless	NN	O	B
legs	NN	O	I
syndrome	NN	O	I
?	NN	O	O

There	NN	O	O
is	NN	O	O
now	NN	O	O
evidence	NN	O	O
to	NN	O	O
suggest	NN	O	O
a	NN	O	O
central	NN	O	O
role	NN	O	O
for	NN	O	O
the	NN	O	O
dopaminergic	NN	O	O
system	NN	O	O
in	NN	O	O
restless	NN	O	B
legs	NN	O	I
syndrome	NN	O	I
(	NN	O	O
RLS	NN	O	B
)	NN	O	O
.	NN	O	O

For	NN	O	O
example	NN	O	O
,	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
RLS	NN	O	B
can	NN	O	O
be	NN	O	O
dramatically	NN	O	O
improved	NN	O	O
by	NN	O	O
levodopa	NN	O	O
and	NN	O	O
dopamine	NN	O	O
agonists	NN	O	O
,	NN	O	O
whereas	NN	O	O
central	NN	O	O
dopamine	NN	O	O
D2	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
can	NN	O	O
induce	NN	O	O
or	NN	O	O
aggravate	NN	O	O
RLS	NN	O	B
symptoms	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
no	NN	O	O
previous	NN	O	O
report	NN	O	O
regarding	NN	O	O
whether	NN	O	O
domperidone	NN	O	O
,	NN	O	O
a	NN	O	O
peripheral	NN	O	O
dopamine	NN	O	O
D2	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
can	NN	O	O
also	NN	O	O
induce	NN	O	O
or	NN	O	O
aggravate	NN	O	O
symptoms	NN	O	O
of	NN	O	O
RLS	NN	O	B
.	NN	O	O

Mirtazapine	NN	O	O
,	NN	O	O
the	NN	O	O
first	NN	O	O
noradrenergic	NN	O	O
and	NN	O	O
specific	NN	O	O
serotonergic	NN	O	O
antidepressant	NN	O	O
(	NN	O	O
NaSSA	NN	O	O
)	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
RLS	NN	O	B
in	NN	O	O
several	NN	O	O
recent	NN	O	O
publications	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
report	NN	O	O
here	NN	O	O
a	NN	O	O
depressed	NN	O	O
patient	NN	O	O
comorbid	NN	O	O
with	NN	O	O
postprandial	NN	O	B
dyspepsia	NN	O	I
who	NN	O	O
developed	NN	O	O
RLS	NN	O	B
after	NN	O	O
mirtazapine	NN	O	O
had	NN	O	O
been	NN	O	O
added	NN	O	O
to	NN	O	O
his	NN	O	O
domperidone	NN	O	O
therapy	NN	O	O
.	NN	O	O

Our	NN	O	O
patient	NN	O	O
started	NN	O	O
to	NN	O	O
have	NN	O	O
symptoms	NN	O	O
of	NN	O	O
RLS	NN	O	B
only	NN	O	O
after	NN	O	O
he	NN	O	O
had	NN	O	O
been	NN	O	O
treated	NN	O	O
with	NN	O	O
mirtazapine	NN	O	O
,	NN	O	O
and	NN	O	O
his	NN	O	O
RLS	NN	O	B
symptoms	NN	O	O
resolved	NN	O	O
completely	NN	O	O
upon	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
his	NN	O	O
mirtazapine	NN	O	O
.	NN	O	O

Such	NN	O	O
a	NN	O	O
temporal	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
mirtazapine	NN	O	O
and	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
RLS	NN	O	B
in	NN	O	O
our	NN	O	O
patient	NN	O	O
did	NN	O	O
not	NN	O	O
support	NN	O	O
a	NN	O	O
potentiating	NN	O	O
effect	NN	O	O
of	NN	O	O
domperione	NN	O	O
on	NN	O	O
mirtazapine	NN	O	O
-	NN	O	O
associated	NN	O	O
RLS	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
physicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
mirtazapine	NN	O	O
can	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
RLS	NN	O	B
in	NN	O	O
some	NN	O	O
individuals	NN	O	O
,	NN	O	O
especially	NN	O	O
those	NN	O	O
receiving	NN	O	O
concomitant	NN	O	O
dopamine	NN	O	O
D2	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
.	NN	O	O

Antiandrogenic	NN	O	O
therapy	NN	O	O
can	NN	O	O
cause	NN	O	O
coronary	NN	O	B
arterial	NN	O	I
disease	NN	O	I
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
To	NN	O	O
study	NN	O	O
the	NN	O	O
change	NN	O	O
of	NN	O	O
lipid	NN	O	O
metabolism	NN	O	O
by	NN	O	O
antiandrogen	NN	O	O
therapy	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
studied	NN	O	O
with	NN	O	O
a	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
years	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
plasma	NN	O	O
cholesterols	NN	O	O
(	NN	O	O
C	NN	O	O
)	NN	O	O
,	NN	O	O
triglycerides	NN	O	O
(	NN	O	O
TG	NN	O	O
)	NN	O	O
,	NN	O	O
lipoproteins	NN	O	O
(	NN	O	O
LP	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
apolipoproteins	NN	O	O
(	NN	O	O
Apo	NN	O	O
)	NN	O	O
B	NN	O	O
-	NN	O	O
100	NN	O	O
,	NN	O	O
A	NN	O	O
-	NN	O	O
I	NN	O	O
,	NN	O	O
and	NN	O	O
A	NN	O	O
-	NN	O	O
II	NN	O	O
pro	NN	O	O
fi	NN	O	O
les	NN	O	O
in	NN	O	O
24	NN	O	O
patients	NN	O	O
of	NN	O	O
mean	NN	O	O
age	NN	O	O
60	NN	O	O
years	NN	O	O
with	NN	O	O
low	NN	O	O
risk	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
(	NN	O	O
stage	NN	O	O
:	NN	O	O
T1cN0M0	NN	O	O
,	NN	O	O
Gleason	NN	O	O
score	NN	O	O
:	NN	O	O
2	NN	O	O
-	NN	O	O
5	NN	O	O
)	NN	O	O
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
cyproterone	NN	O	O
acetate	NN	O	O
(	NN	O	O
CPA	NN	O	O
)	NN	O	O
without	NN	O	O
surgical	NN	O	O
management	NN	O	O
or	NN	O	O
radiation	NN	O	O
therapy	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Significant	NN	O	O
decreases	NN	O	O
of	NN	O	O
HDL	NN	O	O
-	NN	O	O
C	NN	O	O
,	NN	O	O
Apo	NN	O	O
A	NN	O	O
-	NN	O	O
I	NN	O	O
and	NN	O	O
Apo	NN	O	O
A	NN	O	O
-	NN	O	O
II	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
triglyceride	NN	O	O
levels	NN	O	O
in	NN	O	O
VLDL	NN	O	O
were	NN	O	O
induced	NN	O	O
by	NN	O	O
CPA	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
years	NN	O	O
on	NN	O	O
CPA	NN	O	O
treatment	NN	O	O
,	NN	O	O
four	NN	O	O
patients	NN	O	O
out	NN	O	O
of	NN	O	O
twenty	NN	O	O
-	NN	O	O
four	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
affected	NN	O	O
by	NN	O	O
coronary	NN	O	B
heart	NN	O	I
disease	NN	O	I
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Ischaemic	NN	O	O
coronary	NN	O	B
arteriosclerosis	NN	O	I
with	NN	O	O
an	NN	O	O
incidence	NN	O	O
rate	NN	O	O
of	NN	O	O
16	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
as	NN	O	O
caused	NN	O	O
by	NN	O	O
prolonged	NN	O	O
CPA	NN	O	O
therapy	NN	O	O
is	NN	O	O
mediated	NN	O	O
through	NN	O	O
changes	NN	O	O
in	NN	O	O
HDL	NN	O	O
cholesterol	NN	O	O
,	NN	O	O
Apo	NN	O	O
A	NN	O	O
-	NN	O	O
I	NN	O	O
and	NN	O	O
Apo	NN	O	O
A	NN	O	O
-	NN	O	O
II	NN	O	O
pro	NN	O	O
fi	NN	O	O
les	NN	O	O
,	NN	O	O
other	NN	O	O
than	NN	O	O
the	NN	O	O
well	NN	O	O
-	NN	O	O
known	NN	O	O
hyperglyceridemic	NN	O	B
effect	NN	O	I
caused	NN	O	O
by	NN	O	O
estrogen	NN	O	O
.	NN	O	O

5	NN	O	O
-	NN	O	O
Fluorouracil	NN	O	O
cardiotoxicity	NN	O	B
induced	NN	O	O
by	NN	O	O
alpha	NN	O	O
-	NN	O	O
fluoro	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
alanine	NN	O	O
.	NN	O	O

Cardiotoxicity	NN	O	B
is	NN	O	O
a	NN	O	O
rare	NN	O	O
complication	NN	O	O
occurring	NN	O	O
during	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
)	NN	O	O
treatment	NN	O	O
for	NN	O	O
malignancies	NN	O	B
.	NN	O	O

We	NN	O	O
herein	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
70	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
,	NN	O	O
in	NN	O	O
whom	NN	O	O
a	NN	O	O
high	NN	O	O
serum	NN	O	O
level	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
fluoro	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
alanine	NN	O	O
(	NN	O	O
FBAL	NN	O	O
)	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
,	NN	O	O
who	NN	O	O
had	NN	O	O
unresectable	NN	O	O
colon	NN	O	B
cancer	NN	O	I
metastases	NN	O	O
to	NN	O	O
the	NN	O	O
liver	NN	O	O
and	NN	O	O
lung	NN	O	O
,	NN	O	O
was	NN	O	O
referred	NN	O	O
to	NN	O	O
us	NN	O	O
for	NN	O	O
chemotherapy	NN	O	O
from	NN	O	O
an	NN	O	O
affiliated	NN	O	O
hospital	NN	O	O
;	NN	O	O
he	NN	O	O
had	NN	O	O
no	NN	O	O
cardiac	NN	O	O
history	NN	O	O
.	NN	O	O

After	NN	O	O
admission	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
received	NN	O	O
a	NN	O	O
continuous	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
(	NN	O	O
1000	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
,	NN	O	O
during	NN	O	O
which	NN	O	O
precordial	NN	O	B
pain	NN	O	I
with	NN	O	O
right	NN	O	B
bundle	NN	O	I
branch	NN	O	I
block	NN	O	I
occurred	NN	O	O
concomitantly	NN	O	O
with	NN	O	O
a	NN	O	O
high	NN	O	O
serum	NN	O	O
FBAL	NN	O	O
concentration	NN	O	O
of	NN	O	O
1955	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O

Both	NN	O	O
the	NN	O	O
precordial	NN	O	B
pain	NN	O	I
and	NN	O	O
the	NN	O	O
electrocardiographic	NN	O	O
changes	NN	O	O
disappeared	NN	O	O
spontaneously	NN	O	O
after	NN	O	O
the	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
.	NN	O	O

As	NN	O	O
the	NN	O	O
precordial	NN	O	B
pain	NN	O	I
in	NN	O	O
this	NN	O	O
patient	NN	O	O
was	NN	O	O
considered	NN	O	O
to	NN	O	O
have	NN	O	O
been	NN	O	O
due	NN	O	O
to	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
,	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
was	NN	O	O
abandoned	NN	O	O
.	NN	O	O

Instead	NN	O	O
,	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
S	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
a	NN	O	O
derivative	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
)	NN	O	O
,	NN	O	O
at	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
twice	NN	O	O
a	NN	O	O
week	NN	O	O
,	NN	O	O
was	NN	O	O
instituted	NN	O	O
,	NN	O	O
because	NN	O	O
S	NN	O	O
-	NN	O	O
1	NN	O	O
has	NN	O	O
a	NN	O	O
strong	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
on	NN	O	O
dihydropyrimidine	NN	O	O
dehydrogenase	NN	O	O
,	NN	O	O
which	NN	O	O
catalyzes	NN	O	O
the	NN	O	O
degradative	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
into	NN	O	O
FBAL	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	O
FBAL	NN	O	O
concentration	NN	O	O
subsequently	NN	O	O
decreased	NN	O	O
to	NN	O	O
352	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
,	NN	O	O
the	NN	O	O
same	NN	O	O
as	NN	O	O
the	NN	O	O
value	NN	O	O
measured	NN	O	O
on	NN	O	O
the	NN	O	O
first	NN	O	O
day	NN	O	O
of	NN	O	O
S	NN	O	O
-	NN	O	O
1	NN	O	O
administration	NN	O	O
.	NN	O	O

Thereafter	NN	O	O
,	NN	O	O
no	NN	O	O
cardiac	NN	O	B
symptoms	NN	O	I
were	NN	O	O
observed	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
achieved	NN	O	O
a	NN	O	O
partial	NN	O	O
response	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
the	NN	O	O
S	NN	O	O
-	NN	O	O
1	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
experience	NN	O	O
of	NN	O	O
this	NN	O	O
case	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
a	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
,	NN	O	O
suggests	NN	O	O
that	NN	O	O
FBAL	NN	O	O
is	NN	O	O
related	NN	O	O
to	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

S	NN	O	O
-	NN	O	O
1	NN	O	O
may	NN	O	O
be	NN	O	O
administered	NN	O	O
safely	NN	O	O
to	NN	O	O
patients	NN	O	O
with	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Hepatocellular	NN	O	B
carcinoma	NN	O	I
in	NN	O	O
Fanconi	NN	O	B
'	NN	O	I
s	NN	O	I
anemia	NN	O	I
treated	NN	O	O
with	NN	O	O
androgen	NN	O	O
and	NN	O	O
corticosteroid	NN	O	O
.	NN	O	O

The	NN	O	O
case	NN	O	O
of	NN	O	O
an	NN	O	O
11	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
is	NN	O	O
reported	NN	O	O
who	NN	O	O
was	NN	O	O
known	NN	O	O
to	NN	O	O
have	NN	O	O
Fanconi	NN	O	B
'	NN	O	I
s	NN	O	I
anemia	NN	O	I
for	NN	O	O
3	NN	O	O
years	NN	O	O
and	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
androgens	NN	O	O
,	NN	O	O
corticosteroids	NN	O	O
and	NN	O	O
transfusions	NN	O	O
.	NN	O	O

Two	NN	O	O
weeks	NN	O	O
before	NN	O	O
his	NN	O	O
death	NN	O	O
he	NN	O	O
was	NN	O	O
readmitted	NN	O	O
because	NN	O	O
of	NN	O	O
aplastic	NN	O	O
crisis	NN	O	O
with	NN	O	O
septicemia	NN	O	B
and	NN	O	O
marked	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
liver	NN	O	O
function	NN	O	O
and	NN	O	O
died	NN	O	O
of	NN	O	O
hemorrhagic	NN	O	B
bronchopneumonia	NN	O	I
.	NN	O	O

At	NN	O	O
autopsy	NN	O	O
peliosis	NN	O	B
and	NN	O	O
multiple	NN	O	O
hepatic	NN	O	B
tumors	NN	O	I
were	NN	O	O
found	NN	O	O
which	NN	O	O
histologically	NN	O	O
proved	NN	O	O
to	NN	O	O
be	NN	O	O
well	NN	O	O
-	NN	O	O
differentiated	NN	O	O
hepatocellular	NN	O	B
carcinoma	NN	O	I
.	NN	O	O

This	NN	O	O
case	NN	O	O
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
previous	NN	O	O
observations	NN	O	O
that	NN	O	O
non	NN	O	O
-	NN	O	O
metastasizing	NN	O	O
hepatic	NN	O	B
neoplasms	NN	O	I
and	NN	O	O
peliosis	NN	O	B
can	NN	O	O
develop	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
androgen	NN	O	O
-	NN	O	O
and	NN	O	O
corticosteroid	NN	O	O
-	NN	O	O
treated	NN	O	O
Fanconi	NN	O	B
'	NN	O	I
s	NN	O	I
anemia	NN	O	I
.	NN	O	O

The	NN	O	O
influence	NN	O	O
of	NN	O	O
the	NN	O	O
time	NN	O	O
interval	NN	O	O
between	NN	O	O
monoHER	NN	O	O
and	NN	O	O
doxorubicin	NN	O	O
administration	NN	O	O
on	NN	O	O
the	NN	O	O
protection	NN	O	O
against	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
in	NN	O	O
mice	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
Despite	NN	O	O
its	NN	O	O
well	NN	O	O
-	NN	O	O
known	NN	O	O
cardiotoxicity	NN	O	B
,	NN	O	O
the	NN	O	O
anthracyclin	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
DOX	NN	O	O
)	NN	O	O
continues	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
effective	NN	O	O
and	NN	O	O
widely	NN	O	O
used	NN	O	O
chemotherapeutic	NN	O	O
agent	NN	O	O
.	NN	O	O

DOX	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
damage	NN	O	I
presumably	NN	O	O
results	NN	O	O
from	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
free	NN	O	O
radicals	NN	O	O
by	NN	O	O
DOX	NN	O	O
.	NN	O	O

Reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
particularly	NN	O	O
affect	NN	O	O
the	NN	O	O
cardiac	NN	O	O
myocytes	NN	O	O
because	NN	O	O
these	NN	O	O
cells	NN	O	O
seem	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
relatively	NN	O	O
poor	NN	O	O
antioxidant	NN	O	O
defense	NN	O	O
system	NN	O	O
.	NN	O	O

The	NN	O	O
semisynthetic	NN	O	O
flavonoid	NN	O	O
monohydroxyethylrutoside	NN	O	O
(	NN	O	O
monoHER	NN	O	O
)	NN	O	O
showed	NN	O	O
cardioprotection	NN	O	O
against	NN	O	O
DOX	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
through	NN	O	O
its	NN	O	O
radical	NN	O	O
scavenging	NN	O	O
and	NN	O	O
iron	NN	O	O
chelating	NN	O	O
properties	NN	O	O
.	NN	O	O

Because	NN	O	O
of	NN	O	O
the	NN	O	O
relatively	NN	O	O
short	NN	O	O
final	NN	O	O
half	NN	O	O
-	NN	O	O
life	NN	O	O
of	NN	O	O
monoHER	NN	O	O
(	NN	O	O
about	NN	O	O
30	NN	O	O
min	NN	O	O
)	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
expected	NN	O	O
that	NN	O	O
the	NN	O	O
time	NN	O	O
interval	NN	O	O
between	NN	O	O
monoHER	NN	O	O
and	NN	O	O
DOX	NN	O	O
might	NN	O	O
be	NN	O	O
of	NN	O	O
influence	NN	O	O
on	NN	O	O
the	NN	O	O
cardioprotective	NN	O	O
effect	NN	O	O
of	NN	O	O
monoHER	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
the	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
this	NN	O	O
possible	NN	O	O
effect	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Six	NN	O	O
groups	NN	O	O
of	NN	O	O
6	NN	O	O
BALB	NN	O	O
/	NN	O	O
c	NN	O	O
mice	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
saline	NN	O	O
,	NN	O	O
DOX	NN	O	O
alone	NN	O	O
or	NN	O	O
DOX	NN	O	O
(	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
preceded	NN	O	O
by	NN	O	O
monoHER	NN	O	O
(	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
with	NN	O	O
an	NN	O	O
interval	NN	O	O
of	NN	O	O
10	NN	O	O
,	NN	O	O
30	NN	O	O
,	NN	O	O
60	NN	O	O
or	NN	O	O
120	NN	O	O
min	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
6	NN	O	O
-	NN	O	O
week	NN	O	O
treatment	NN	O	O
period	NN	O	O
and	NN	O	O
additional	NN	O	O
observation	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
,	NN	O	O
the	NN	O	O
mice	NN	O	O
were	NN	O	O
sacrificed	NN	O	O
.	NN	O	O

Their	NN	O	O
cardiac	NN	O	O
tissues	NN	O	O
were	NN	O	O
processed	NN	O	O
for	NN	O	O
light	NN	O	O
microscopy	NN	O	O
,	NN	O	O
after	NN	O	O
which	NN	O	O
cardiomyocyte	NN	O	B
damage	NN	O	I
was	NN	O	O
evaluated	NN	O	O
according	NN	O	O
to	NN	O	O
Billingham	NN	O	O
(	NN	O	O
in	NN	O	O
Cancer	NN	O	B
Treat	NN	O	O
Rep	NN	O	O
62	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
:	NN	O	O
865	NN	O	O
-	NN	O	O
872	NN	O	O
,	NN	O	O
1978	NN	O	O
)	NN	O	O
.	NN	O	O

Microscopic	NN	O	O
evaluation	NN	O	O
revealed	NN	O	O
that	NN	O	O
treatment	NN	O	O
with	NN	O	O
DOX	NN	O	O
alone	NN	O	O
induced	NN	O	O
significant	NN	O	O
cardiac	NN	O	B
damage	NN	O	I
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
the	NN	O	O
saline	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
number	NN	O	O
of	NN	O	O
damaged	NN	O	O
cardiomyocytes	NN	O	O
was	NN	O	O
9	NN	O	O
.	NN	O	O
6	NN	O	O
-	NN	O	O
fold	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
4	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
21	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
higher	NN	O	O
in	NN	O	O
mice	NN	O	O
treated	NN	O	O
with	NN	O	O
DOX	NN	O	O
alone	NN	O	O
than	NN	O	O
that	NN	O	O
in	NN	O	O
animals	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
ratio	NN	O	O
of	NN	O	O
aberrant	NN	O	O
cardiomyocytes	NN	O	O
in	NN	O	O
mice	NN	O	O
treated	NN	O	O
with	NN	O	O
DOX	NN	O	O
preceded	NN	O	O
by	NN	O	O
monoHER	NN	O	O
and	NN	O	O
those	NN	O	O
in	NN	O	O
mice	NN	O	O
treated	NN	O	O
with	NN	O	O
saline	NN	O	O
ranged	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
8	NN	O	O
(	NN	O	O
mean	NN	O	O
2	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
019	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
protective	NN	O	O
effect	NN	O	O
by	NN	O	O
adding	NN	O	O
monoHER	NN	O	O
before	NN	O	O
DOX	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
significant	NN	O	O
4	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
fold	NN	O	O
reduction	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
of	NN	O	O
abnormal	NN	O	O
cardiomyocytes	NN	O	O
.	NN	O	O

This	NN	O	O
protective	NN	O	O
effect	NN	O	O
did	NN	O	O
not	NN	O	O
depend	NN	O	O
on	NN	O	O
the	NN	O	O
time	NN	O	O
interval	NN	O	O
between	NN	O	O
monoHER	NN	O	O
and	NN	O	O
DOX	NN	O	O
administration	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
345	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
in	NN	O	O
an	NN	O	O
outpatient	NN	O	O
clinical	NN	O	O
setting	NN	O	O
monoHER	NN	O	O
may	NN	O	O
be	NN	O	O
administered	NN	O	O
shortly	NN	O	O
before	NN	O	O
DOX	NN	O	O
.	NN	O	O

Clinical	NN	O	O
evaluation	NN	O	O
of	NN	O	O
adverse	NN	O	O
effects	NN	O	O
during	NN	O	O
bepridil	NN	O	O
administration	NN	O	O
for	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
and	NN	O	I
flutter	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Bepridil	NN	O	O
hydrochloride	NN	O	O
(	NN	O	O
Bpd	NN	O	O
)	NN	O	O
has	NN	O	O
attracted	NN	O	O
attention	NN	O	O
as	NN	O	O
an	NN	O	O
effective	NN	O	O
drug	NN	O	O
for	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
(	NN	O	O
AF	NN	O	B
)	NN	O	O
and	NN	O	O
atrial	NN	O	B
flutter	NN	O	I
(	NN	O	O
AFL	NN	O	B
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
serious	NN	O	O
adverse	NN	O	O
effects	NN	O	O
,	NN	O	O
including	NN	O	O
torsade	NN	O	B
de	NN	O	I
pointes	NN	O	I
(	NN	O	O
Tdp	NN	O	B
)	NN	O	O
,	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
Adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
Bpd	NN	O	O
requiring	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
treatment	NN	O	O
were	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Bpd	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
459	NN	O	O
patients	NN	O	O
(	NN	O	O
361	NN	O	O
males	NN	O	O
,	NN	O	O
63	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
years	NN	O	O
old	NN	O	O
)	NN	O	O
comprising	NN	O	O
378	NN	O	O
AF	NN	O	B
and	NN	O	O
81	NN	O	O
AFL	NN	O	B
cases	NN	O	O
.	NN	O	O

Mean	NN	O	O
left	NN	O	O
ventricular	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
and	NN	O	O
atrial	NN	O	O
dimension	NN	O	O
(	NN	O	O
LAD	NN	O	O
)	NN	O	O
were	NN	O	O
66	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
11	NN	O	O
%	NN	O	O
and	NN	O	O
40	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
mm	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Adverse	NN	O	O
effects	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
19	NN	O	O
patients	NN	O	O
(	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
during	NN	O	O
an	NN	O	O
average	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
20	NN	O	O
months	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
marked	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
greater	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
55	NN	O	O
s	NN	O	O
in	NN	O	O
13	NN	O	O
patients	NN	O	O
,	NN	O	O
bradycardia	NN	O	B
less	NN	O	O
than	NN	O	O
40	NN	O	O
beats	NN	O	O
/	NN	O	O
min	NN	O	O
in	NN	O	O
6	NN	O	O
patients	NN	O	O
,	NN	O	O
dizziness	NN	O	B
and	NN	O	O
general	NN	O	O
fatigue	NN	O	B
in	NN	O	O
1	NN	O	O
patient	NN	O	O
each	NN	O	O
.	NN	O	O

In	NN	O	O
4	NN	O	O
of	NN	O	O
13	NN	O	O
patients	NN	O	O
with	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
,	NN	O	O
Tdp	NN	O	B
occurred	NN	O	O
.	NN	O	O

The	NN	O	O
major	NN	O	O
triggering	NN	O	O
factors	NN	O	O
of	NN	O	O
Tdp	NN	O	B
were	NN	O	O
hypokalemia	NN	O	B
and	NN	O	O
sudden	NN	O	O
decrease	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
clinical	NN	O	O
backgrounds	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
Tdp	NN	O	B
other	NN	O	O
than	NN	O	O
LAD	NN	O	O
and	NN	O	O
age	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
larger	NN	O	O
and	NN	O	O
older	NN	O	O
in	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
Tdp	NN	O	B
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Careful	NN	O	O
observation	NN	O	O
of	NN	O	O
serum	NN	O	O
potassium	NN	O	O
concentration	NN	O	O
and	NN	O	O
the	NN	O	O
ECG	NN	O	O
should	NN	O	O
always	NN	O	O
be	NN	O	O
done	NN	O	O
during	NN	O	O
Bpd	NN	O	O
administration	NN	O	O
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
.	NN	O	O

Enhanced	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
hypertrophy	NN	O	I
in	NN	O	O
transgenic	NN	O	O
rats	NN	O	O
with	NN	O	O
low	NN	O	O
brain	NN	O	O
angiotensinogen	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
previously	NN	O	O
shown	NN	O	O
that	NN	O	O
a	NN	O	O
permanent	NN	O	O
deficiency	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
renin	NN	O	O
-	NN	O	O
angiotensin	NN	O	O
system	NN	O	O
(	NN	O	O
RAS	NN	O	O
)	NN	O	O
may	NN	O	O
increase	NN	O	O
the	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
the	NN	O	O
baroreflex	NN	O	O
control	NN	O	O
of	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
we	NN	O	O
aimed	NN	O	O
at	NN	O	O
studying	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
the	NN	O	O
brain	NN	O	O
RAS	NN	O	O
in	NN	O	O
the	NN	O	O
cardiac	NN	O	O
reactivity	NN	O	O
to	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
(	NN	O	O
beta	NN	O	O
-	NN	O	O
AR	NN	O	O
)	NN	O	O
agonist	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
Iso	NN	O	O
)	NN	O	O
.	NN	O	O

Transgenic	NN	O	O
rats	NN	O	O
with	NN	O	O
low	NN	O	O
brain	NN	O	O
angiotensinogen	NN	O	O
(	NN	O	O
TGR	NN	O	O
)	NN	O	O
were	NN	O	O
used	NN	O	O
.	NN	O	O

In	NN	O	O
isolated	NN	O	O
hearts	NN	O	O
,	NN	O	O
Iso	NN	O	O
induced	NN	O	O
a	NN	O	O
significantly	NN	O	O
greater	NN	O	O
increase	NN	O	O
in	NN	O	O
left	NN	O	O
ventricular	NN	O	O
(	NN	O	O
LV	NN	O	O
)	NN	O	O
pressure	NN	O	O
and	NN	O	O
maximal	NN	O	O
contraction	NN	O	O
(	NN	O	O
+	NN	O	O
dP	NN	O	O
/	NN	O	O
dt	NN	O	O
(	NN	O	O
max	NN	O	O
)	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
TGR	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
(	NN	O	O
SD	NN	O	O
)	NN	O	O
rats	NN	O	O
.	NN	O	O

LV	NN	O	B
hypertrophy	NN	O	I
induced	NN	O	O
by	NN	O	O
Iso	NN	O	O
treatment	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
TGR	NN	O	O
than	NN	O	O
in	NN	O	O
SD	NN	O	O
rats	NN	O	O
(	NN	O	O
in	NN	O	O
g	NN	O	O
LV	NN	O	O
wt	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
body	NN	O	O
wt	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
28	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
004	NN	O	O
vs	NN	O	O
.	NN	O	O
0	NN	O	O
.	NN	O	O
24	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
004	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
greater	NN	O	O
LV	NN	O	B
hypertrophy	NN	O	I
in	NN	O	O
TGR	NN	O	O
rats	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
more	NN	O	O
pronounced	NN	O	O
downregulation	NN	O	O
of	NN	O	O
beta	NN	O	O
-	NN	O	O
AR	NN	O	O
and	NN	O	O
upregulation	NN	O	O
of	NN	O	O
LV	NN	O	O
beta	NN	O	O
-	NN	O	O
AR	NN	O	O
kinase	NN	O	O
-	NN	O	O
1	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
in	NN	O	O
SD	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
heart	NN	O	O
rate	NN	O	O
(	NN	O	O
HR	NN	O	O
)	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
AR	NN	O	O
antagonist	NN	O	O
metoprolol	NN	O	O
in	NN	O	O
conscious	NN	O	O
rats	NN	O	O
was	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
in	NN	O	O
TGR	NN	O	O
compared	NN	O	O
with	NN	O	O
SD	NN	O	O
rats	NN	O	O
(	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
vs	NN	O	O
.	NN	O	O
-	NN	O	O
18	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
parasympathetic	NN	O	O
blockade	NN	O	O
by	NN	O	O
atropine	NN	O	O
on	NN	O	O
HR	NN	O	O
was	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
strains	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
TGR	NN	O	O
are	NN	O	O
more	NN	O	O
sensitive	NN	O	O
to	NN	O	O
beta	NN	O	O
-	NN	O	O
AR	NN	O	O
agonist	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
inotropic	NN	O	I
response	NN	O	O
and	NN	O	O
hypertrophy	NN	O	B
,	NN	O	O
possibly	NN	O	O
due	NN	O	O
to	NN	O	O
chronically	NN	O	O
low	NN	O	O
sympathetic	NN	O	O
outflow	NN	O	O
directed	NN	O	O
to	NN	O	O
the	NN	O	O
heart	NN	O	O
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
induced	NN	O	O
long	NN	O	B
QT	NN	O	I
syndrome	NN	O	I
in	NN	O	O
injection	NN	O	O
drug	NN	O	O
users	NN	O	O
receiving	NN	O	O
methadone	NN	O	O
:	NN	O	O
high	NN	O	O
frequency	NN	O	O
in	NN	O	O
hospitalized	NN	O	O
patients	NN	O	O
and	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Drug	NN	O	O
-	NN	O	O
induced	NN	O	O
long	NN	O	B
QT	NN	O	I
syndrome	NN	O	I
is	NN	O	O
a	NN	O	O
serious	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reaction	NN	O	O
.	NN	O	O

Methadone	NN	O	O
prolongs	NN	O	O
the	NN	O	O
QT	NN	O	O
interval	NN	O	O
in	NN	O	O
vitro	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
inpatient	NN	O	O
setting	NN	O	O
,	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
QT	NN	O	B
interval	NN	O	I
prolongation	NN	O	I
with	NN	O	O
methadone	NN	O	O
treatment	NN	O	O
,	NN	O	O
its	NN	O	O
dose	NN	O	O
dependence	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
cofactors	NN	O	O
such	NN	O	O
as	NN	O	O
drug	NN	O	O
-	NN	O	O
drug	NN	O	O
interactions	NN	O	O
remain	NN	O	O
unknown	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
performed	NN	O	O
a	NN	O	O
systematic	NN	O	O
,	NN	O	O
retrospective	NN	O	O
study	NN	O	O
comparing	NN	O	O
active	NN	O	O
or	NN	O	O
former	NN	O	O
intravenous	NN	O	O
drug	NN	O	O
users	NN	O	O
receiving	NN	O	O
methadone	NN	O	O
and	NN	O	O
those	NN	O	O
not	NN	O	O
receiving	NN	O	O
methadone	NN	O	O
among	NN	O	O
all	NN	O	O
patients	NN	O	O
hospitalized	NN	O	O
over	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
in	NN	O	O
a	NN	O	O
tertiary	NN	O	O
care	NN	O	O
hospital	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
167	NN	O	O
patients	NN	O	O
receiving	NN	O	O
methadone	NN	O	O
fulfilled	NN	O	O
the	NN	O	O
inclusion	NN	O	O
criteria	NN	O	O
and	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
a	NN	O	O
control	NN	O	O
group	NN	O	O
of	NN	O	O
80	NN	O	O
injection	NN	O	O
drug	NN	O	O
users	NN	O	O
not	NN	O	O
receiving	NN	O	O
methadone	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
methadone	NN	O	O
dose	NN	O	O
,	NN	O	O
15	NN	O	O
demographic	NN	O	O
,	NN	O	O
biological	NN	O	O
,	NN	O	O
and	NN	O	O
pharmacological	NN	O	O
variables	NN	O	O
were	NN	O	O
considered	NN	O	O
as	NN	O	O
potential	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Among	NN	O	O
167	NN	O	O
methadone	NN	O	O
maintenance	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
QTc	NN	O	O
prolongation	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
50	NN	O	O
second	NN	O	O
(	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
or	NN	O	O
longer	NN	O	O
was	NN	O	O
16	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
compared	NN	O	O
with	NN	O	O
0	NN	O	O
%	NN	O	O
in	NN	O	O
80	NN	O	O
control	NN	O	O
subjects	NN	O	O
.	NN	O	O

Six	NN	O	O
patients	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
methadone	NN	O	O
group	NN	O	O
presented	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
.	NN	O	O

QTc	NN	O	O
length	NN	O	O
was	NN	O	O
weakly	NN	O	O
but	NN	O	O
significantly	NN	O	O
associated	NN	O	O
with	NN	O	O
methadone	NN	O	O
daily	NN	O	O
dose	NN	O	O
(	NN	O	O
Spearman	NN	O	O
rank	NN	O	O
correlation	NN	O	O
coefficient	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
20	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Multivariate	NN	O	O
regression	NN	O	O
analysis	NN	O	O
allowed	NN	O	O
attribution	NN	O	O
of	NN	O	O
31	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
of	NN	O	O
QTc	NN	O	O
variability	NN	O	O
to	NN	O	O
methadone	NN	O	O
dose	NN	O	O
,	NN	O	O
cytochrome	NN	O	O
P	NN	O	O
-	NN	O	O
450	NN	O	O
3A4	NN	O	O
drug	NN	O	O
-	NN	O	O
drug	NN	O	O
interactions	NN	O	O
,	NN	O	O
hypokalemia	NN	O	B
,	NN	O	O
and	NN	O	O
altered	NN	O	O
liver	NN	O	O
function	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
QT	NN	O	B
interval	NN	O	I
prolongation	NN	O	I
in	NN	O	O
methadone	NN	O	O
maintenance	NN	O	O
patients	NN	O	O
hospitalized	NN	O	O
in	NN	O	O
a	NN	O	O
tertiary	NN	O	O
care	NN	O	O
center	NN	O	O
is	NN	O	O
a	NN	O	O
frequent	NN	O	O
finding	NN	O	O
.	NN	O	O

Methadone	NN	O	O
dose	NN	O	O
,	NN	O	O
presence	NN	O	O
of	NN	O	O
cytochrome	NN	O	O
P	NN	O	O
-	NN	O	O
450	NN	O	O
3A4	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
potassium	NN	O	O
level	NN	O	O
,	NN	O	O
and	NN	O	O
liver	NN	O	O
function	NN	O	O
contribute	NN	O	O
to	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
.	NN	O	O

Long	NN	O	B
QT	NN	O	I
syndrome	NN	O	I
can	NN	O	O
occur	NN	O	O
with	NN	O	O
low	NN	O	O
doses	NN	O	O
of	NN	O	O
methadone	NN	O	O
.	NN	O	O

Mechanisms	NN	O	O
of	NN	O	O
hypertension	NN	O	B
induced	NN	O	O
by	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
(	NN	O	O
NO	NN	O	O
)	NN	O	O
deficiency	NN	O	O
:	NN	O	O
focus	NN	O	O
on	NN	O	O
venous	NN	O	O
function	NN	O	O
.	NN	O	O

Loss	NN	O	O
of	NN	O	O
endothelial	NN	O	O
cell	NN	O	O
-	NN	O	O
derived	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
(	NN	O	O
NO	NN	O	O
)	NN	O	O
in	NN	O	O
hypertension	NN	O	B
is	NN	O	O
a	NN	O	O
hallmark	NN	O	O
of	NN	O	O
arterial	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Experimental	NN	O	O
hypertension	NN	O	B
created	NN	O	O
by	NN	O	O
the	NN	O	O
removal	NN	O	O
of	NN	O	O
NO	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
involves	NN	O	O
mechanisms	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
decreased	NN	O	O
arterial	NN	O	O
vasodilator	NN	O	O
activity	NN	O	O
.	NN	O	O

These	NN	O	O
include	NN	O	O
augmented	NN	O	O
endothelin	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
ET	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
release	NN	O	O
,	NN	O	O
increased	NN	O	O
sympathetic	NN	O	O
nervous	NN	O	O
system	NN	O	O
activity	NN	O	O
,	NN	O	O
and	NN	O	O
elevated	NN	O	O
tissue	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O

We	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
increased	NN	O	O
venous	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
(	NN	O	O
venomotor	NN	O	O
)	NN	O	O
tone	NN	O	O
plays	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
Nomega	NN	O	O
-	NN	O	O
nitro	NN	O	O
-	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
(	NN	O	O
LNNA	NN	O	O
)	NN	O	O
hypertension	NN	O	B
through	NN	O	O
these	NN	O	O
mechanisms	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
NO	NN	O	O
synthase	NN	O	O
inhibitor	NN	O	O
LNNA	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
g	NN	O	O
/	NN	O	O
L	NN	O	O
in	NN	O	O
drinking	NN	O	O
water	NN	O	O
)	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
.	NN	O	O

Mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
of	NN	O	O
conscious	NN	O	O
rats	NN	O	O
was	NN	O	O
119	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
mm	NN	O	O
Hg	NN	O	O
in	NN	O	O
control	NN	O	O
and	NN	O	O
194	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
mm	NN	O	O
Hg	NN	O	O
in	NN	O	O
LNNA	NN	O	O
rats	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Carotid	NN	O	O
arteries	NN	O	O
and	NN	O	O
vena	NN	O	O
cava	NN	O	O
were	NN	O	O
removed	NN	O	O
for	NN	O	O
measurement	NN	O	O
of	NN	O	O
isometric	NN	O	O
contraction	NN	O	O
.	NN	O	O

Maximal	NN	O	O
contraction	NN	O	O
to	NN	O	O
norepinephrine	NN	O	O
was	NN	O	O
modestly	NN	O	O
reduced	NN	O	O
in	NN	O	O
arteries	NN	O	O
from	NN	O	O
LNNA	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
rats	NN	O	O
whereas	NN	O	O
the	NN	O	O
maximum	NN	O	O
contraction	NN	O	O
to	NN	O	O
ET	NN	O	O
-	NN	O	O
1	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
(	NN	O	O
54	NN	O	O
%	NN	O	O
control	NN	O	O
)	NN	O	O
.	NN	O	O

Maximum	NN	O	O
contraction	NN	O	O
of	NN	O	O
vena	NN	O	O
cava	NN	O	O
to	NN	O	O
norepinephrine	NN	O	O
(	NN	O	O
37	NN	O	O
%	NN	O	O
control	NN	O	O
)	NN	O	O
also	NN	O	O
was	NN	O	O
reduced	NN	O	O
but	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
ET	NN	O	O
-	NN	O	O
1	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Mean	NN	O	O
circulatory	NN	O	O
filling	NN	O	O
pressure	NN	O	O
,	NN	O	O
an	NN	O	O
in	NN	O	O
vivo	NN	O	O
measure	NN	O	O
of	NN	O	O
venomotor	NN	O	O
tone	NN	O	O
,	NN	O	O
was	NN	O	O
not	NN	O	O
elevated	NN	O	O
in	NN	O	O
LNNA	NN	O	O
hypertension	NN	O	B
at	NN	O	O
1	NN	O	O
or	NN	O	O
2	NN	O	O
weeks	NN	O	O
after	NN	O	O
LNNA	NN	O	O
.	NN	O	O

The	NN	O	O
superoxide	NN	O	O
scavenger	NN	O	O
tempol	NN	O	O
(	NN	O	O
30	NN	O	O
,	NN	O	O
100	NN	O	O
,	NN	O	O
and	NN	O	O
300	NN	O	O
micromol	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
IV	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
in	NN	O	O
control	NN	O	O
rats	NN	O	O
but	NN	O	O
caused	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
decrease	NN	O	O
in	NN	O	O
LNNA	NN	O	O
rats	NN	O	O
(	NN	O	O
-	NN	O	O
18	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
,	NN	O	O
-	NN	O	O
26	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
15	NN	O	O
,	NN	O	O
and	NN	O	O
-	NN	O	O
54	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
11	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
ganglionic	NN	O	O
blockade	NN	O	O
with	NN	O	O
hexamethonium	NN	O	O
caused	NN	O	O
a	NN	O	O
significantly	NN	O	O
greater	NN	O	O
fall	NN	O	O
in	NN	O	O
LNNA	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
(	NN	O	O
76	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
rats	NN	O	O
(	NN	O	O
35	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
.	NN	O	O

Carotid	NN	O	O
arteries	NN	O	O
,	NN	O	O
vena	NN	O	O
cava	NN	O	O
,	NN	O	O
and	NN	O	O
sympathetic	NN	O	O
ganglia	NN	O	O
from	NN	O	O
LNNA	NN	O	O
rats	NN	O	O
had	NN	O	O
higher	NN	O	O
basal	NN	O	O
levels	NN	O	O
of	NN	O	O
superoxide	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
from	NN	O	O
control	NN	O	O
rats	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
while	NN	O	O
NO	NN	O	O
deficiency	NN	O	O
increases	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
sympathetic	NN	O	O
activity	NN	O	O
in	NN	O	O
both	NN	O	O
arterial	NN	O	O
and	NN	O	O
venous	NN	O	O
vessels	NN	O	O
,	NN	O	O
the	NN	O	O
impact	NN	O	O
on	NN	O	O
veins	NN	O	O
does	NN	O	O
not	NN	O	O
make	NN	O	O
a	NN	O	O
major	NN	O	O
contribution	NN	O	O
to	NN	O	O
this	NN	O	O
form	NN	O	O
of	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Association	NN	O	O
of	NN	O	O
DRD2	NN	O	O
polymorphisms	NN	O	O
and	NN	O	O
chlorpromazine	NN	O	O
-	NN	O	O
induced	NN	O	O
extrapyramidal	NN	O	B
syndrome	NN	O	I
in	NN	O	O
Chinese	NN	O	O
schizophrenic	NN	O	B
patients	NN	O	O
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
Extrapyramidal	NN	O	B
syndrome	NN	O	I
(	NN	O	O
EPS	NN	O	B
)	NN	O	O
is	NN	O	O
most	NN	O	O
commonly	NN	O	O
affected	NN	O	O
by	NN	O	O
typical	NN	O	O
antipsychotic	NN	O	O
drugs	NN	O	O
that	NN	O	O
have	NN	O	O
a	NN	O	O
high	NN	O	O
affinity	NN	O	O
with	NN	O	O
the	NN	O	O
D2	NN	O	O
receptor	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
many	NN	O	O
research	NN	O	O
groups	NN	O	O
have	NN	O	O
reported	NN	O	O
on	NN	O	O
the	NN	O	O
positive	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
genetic	NN	O	O
variations	NN	O	O
in	NN	O	O
the	NN	O	O
DRD2	NN	O	O
gene	NN	O	O
and	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
response	NN	O	O
in	NN	O	O
schizophrenia	NN	O	B
patients	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
variations	NN	O	O
in	NN	O	O
the	NN	O	O
receptor	NN	O	O
in	NN	O	O
modulating	NN	O	O
receptor	NN	O	O
expression	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
evaluate	NN	O	O
the	NN	O	O
role	NN	O	O
DRD2	NN	O	O
plays	NN	O	O
in	NN	O	O
chlorpromazine	NN	O	O
-	NN	O	O
induced	NN	O	O
EPS	NN	O	B
in	NN	O	O
schizophrenic	NN	O	B
patients	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
identified	NN	O	O
seven	NN	O	O
SNP	NN	O	O
(	NN	O	O
single	NN	O	O
nucleotide	NN	O	O
polymorphism	NN	O	O
)	NN	O	O
(	NN	O	O
-	NN	O	O
141Cins	NN	O	O
>	NN	O	O
del	NN	O	O
,	NN	O	O
TaqIB	NN	O	O
,	NN	O	O
TaqID	NN	O	O
,	NN	O	O
Ser311Cys	NN	O	O
,	NN	O	O
rs6275	NN	O	O
,	NN	O	O
rs6277	NN	O	O
and	NN	O	O
TaqIA	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
DRD2	NN	O	O
gene	NN	O	O
in	NN	O	O
146	NN	O	O
schizophrenic	NN	O	B
inpatients	NN	O	O
(	NN	O	O
59	NN	O	O
with	NN	O	O
EPS	NN	O	B
and	NN	O	O
87	NN	O	O
without	NN	O	O
EPS	NN	O	B
according	NN	O	O
to	NN	O	O
the	NN	O	O
Simpson	NN	O	O
-	NN	O	O
Angus	NN	O	O
Scale	NN	O	O
)	NN	O	O
treated	NN	O	O
with	NN	O	O
chlorpromazine	NN	O	O
after	NN	O	O
8	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
alleles	NN	O	O
of	NN	O	O
all	NN	O	O
loci	NN	O	O
were	NN	O	O
determined	NN	O	O
by	NN	O	O
PCR	NN	O	O
(	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Polymorphisms	NN	O	O
TaqID	NN	O	O
,	NN	O	O
Ser311Cys	NN	O	O
and	NN	O	O
rs6277	NN	O	O
were	NN	O	O
not	NN	O	O
polymorphic	NN	O	O
in	NN	O	O
the	NN	O	O
population	NN	O	O
recruited	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
.	NN	O	O

No	NN	O	O
statistical	NN	O	O
significance	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
allele	NN	O	O
distribution	NN	O	O
of	NN	O	O
-	NN	O	O
141Cins	NN	O	O
>	NN	O	O
del	NN	O	O
,	NN	O	O
TaqIB	NN	O	O
,	NN	O	O
rs6275	NN	O	O
and	NN	O	O
TaqIA	NN	O	O
or	NN	O	O
in	NN	O	O
the	NN	O	O
estimated	NN	O	O
haplotypes	NN	O	O
(	NN	O	O
constituted	NN	O	O
by	NN	O	O
TaqIB	NN	O	O
,	NN	O	O
rs6275	NN	O	O
and	NN	O	O
TaqIA	NN	O	O
)	NN	O	O
in	NN	O	O
linkage	NN	O	O
disequilibrium	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Our	NN	O	O
results	NN	O	O
did	NN	O	O
not	NN	O	O
lend	NN	O	O
strong	NN	O	O
support	NN	O	O
to	NN	O	O
the	NN	O	O
view	NN	O	O
that	NN	O	O
the	NN	O	O
genetic	NN	O	O
variation	NN	O	O
of	NN	O	O
the	NN	O	O
DRD2	NN	O	O
gene	NN	O	O
plays	NN	O	O
a	NN	O	O
major	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
individually	NN	O	O
variable	NN	O	O
adverse	NN	O	O
effect	NN	O	O
induced	NN	O	O
by	NN	O	O
chlorpromazine	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
Chinese	NN	O	O
patients	NN	O	O
with	NN	O	O
schizophrenia	NN	O	B
.	NN	O	O

Our	NN	O	O
results	NN	O	O
confirmed	NN	O	O
a	NN	O	O
previous	NN	O	O
study	NN	O	O
on	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
DRD2	NN	O	O
and	NN	O	O
EPS	NN	O	B
in	NN	O	O
Caucasians	NN	O	O
.	NN	O	O

Physical	NN	O	O
training	NN	O	O
decreases	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
subsequent	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Regular	NN	O	O
motor	NN	O	O
activity	NN	O	O
has	NN	O	O
many	NN	O	O
benefits	NN	O	O
for	NN	O	O
mental	NN	O	O
and	NN	O	O
physical	NN	O	O
condition	NN	O	O
but	NN	O	O
its	NN	O	O
implications	NN	O	O
for	NN	O	O
epilepsy	NN	O	B
are	NN	O	O
still	NN	O	O
controversial	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
elucidate	NN	O	O
this	NN	O	O
problem	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
studied	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
physical	NN	O	O
activity	NN	O	O
on	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
subsequent	NN	O	O
seizures	NN	O	B
.	NN	O	O

Male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
repeated	NN	O	O
training	NN	O	O
sessions	NN	O	O
in	NN	O	O
a	NN	O	O
treadmill	NN	O	O
and	NN	O	O
swimming	NN	O	O
pool	NN	O	O
.	NN	O	O

Thereafter	NN	O	O
,	NN	O	O
seizures	NN	O	B
were	NN	O	O
induced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
injections	NN	O	O
in	NN	O	O
trained	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
trained	NN	O	O
control	NN	O	O
groups	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
acute	NN	O	O
period	NN	O	O
of	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
,	NN	O	O
we	NN	O	O
measured	NN	O	O
:	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
the	NN	O	O
latency	NN	O	O
of	NN	O	O
the	NN	O	O
first	NN	O	O
motor	NN	O	O
sign	NN	O	O
,	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
the	NN	O	O
intensity	NN	O	O
of	NN	O	O
seizures	NN	O	B
,	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
the	NN	O	O
time	NN	O	O
when	NN	O	O
it	NN	O	O
occurred	NN	O	O
within	NN	O	O
the	NN	O	O
6	NN	O	O
-	NN	O	O
h	NN	O	O
observation	NN	O	O
period	NN	O	O
,	NN	O	O
and	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
the	NN	O	O
time	NN	O	O
when	NN	O	O
the	NN	O	O
acute	NN	O	O
period	NN	O	O
ended	NN	O	O
.	NN	O	O

All	NN	O	O
these	NN	O	O
behavioral	NN	O	O
parameters	NN	O	O
showed	NN	O	O
statistically	NN	O	O
significant	NN	O	O
changes	NN	O	O
suggesting	NN	O	O
that	NN	O	O
regular	NN	O	O
physical	NN	O	O
exercises	NN	O	O
decrease	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
subsequently	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
ameliorate	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
experimentally	NN	O	O
induced	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
.	NN	O	O

Tonic	NN	O	O
dopaminergic	NN	O	O
stimulation	NN	O	O
impairs	NN	O	B
associative	NN	O	I
learning	NN	O	I
in	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
.	NN	O	O

Endogenous	NN	O	O
dopamine	NN	O	O
plays	NN	O	O
a	NN	O	O
central	NN	O	O
role	NN	O	O
in	NN	O	O
salience	NN	O	O
coding	NN	O	O
during	NN	O	O
associative	NN	O	O
learning	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
the	NN	O	O
dopamine	NN	O	O
precursor	NN	O	O
levodopa	NN	O	O
enhances	NN	O	O
learning	NN	O	O
in	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
and	NN	O	O
stroke	NN	O	B
patients	NN	O	O
.	NN	O	O

Because	NN	O	O
levodopa	NN	O	O
increases	NN	O	O
both	NN	O	O
phasic	NN	O	O
and	NN	O	O
tonic	NN	O	O
dopaminergic	NN	O	O
neurotransmission	NN	O	O
,	NN	O	O
the	NN	O	O
critical	NN	O	O
mechanism	NN	O	O
mediating	NN	O	O
the	NN	O	O
enhancement	NN	O	O
of	NN	O	O
learning	NN	O	O
is	NN	O	O
unresolved	NN	O	O
.	NN	O	O

We	NN	O	O
here	NN	O	O
probed	NN	O	O
how	NN	O	O
selective	NN	O	O
tonic	NN	O	O
dopaminergic	NN	O	O
stimulation	NN	O	O
affects	NN	O	O
associative	NN	O	O
learning	NN	O	O
.	NN	O	O

Forty	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
were	NN	O	O
trained	NN	O	O
in	NN	O	O
a	NN	O	O
novel	NN	O	O
vocabulary	NN	O	O
of	NN	O	O
45	NN	O	O
concrete	NN	O	O
nouns	NN	O	O
over	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
5	NN	O	O
consecutive	NN	O	O
training	NN	O	O
days	NN	O	O
in	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
design	NN	O	O
.	NN	O	O

Subjects	NN	O	O
received	NN	O	O
the	NN	O	O
tonically	NN	O	O
stimulating	NN	O	O
dopamine	NN	O	O
-	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
pergolide	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
mg	NN	O	O
)	NN	O	O
vs	NN	O	O
placebo	NN	O	O
120	NN	O	O
min	NN	O	O
before	NN	O	O
training	NN	O	O
on	NN	O	O
each	NN	O	O
training	NN	O	O
day	NN	O	O
.	NN	O	O

The	NN	O	O
dopamine	NN	O	O
agonist	NN	O	O
significantly	NN	O	O
impaired	NN	O	B
novel	NN	O	I
word	NN	O	I
learning	NN	O	I
compared	NN	O	O
to	NN	O	O
placebo	NN	O	O
.	NN	O	O

This	NN	O	O
learning	NN	O	O
decrement	NN	O	O
persisted	NN	O	O
up	NN	O	O
to	NN	O	O
the	NN	O	O
last	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
4	NN	O	O
weeks	NN	O	O
post	NN	O	O
-	NN	O	O
training	NN	O	O
.	NN	O	O

Subjects	NN	O	O
treated	NN	O	O
with	NN	O	O
pergolide	NN	O	O
also	NN	O	O
showed	NN	O	O
restricted	NN	O	O
emotional	NN	O	O
responses	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
PLACEBO	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
extent	NN	O	O
of	NN	O	O
'	NN	O	O
flattened	NN	O	O
'	NN	O	O
affect	NN	O	O
with	NN	O	O
pergolide	NN	O	O
was	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
learning	NN	O	O
inhibition	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
tonic	NN	O	O
occupation	NN	O	O
of	NN	O	O
dopamine	NN	O	O
receptors	NN	O	O
impairs	NN	O	O
learning	NN	O	O
by	NN	O	O
competition	NN	O	O
with	NN	O	O
phasic	NN	O	O
dopamine	NN	O	O
signals	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
phasic	NN	O	O
signaling	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
critical	NN	O	O
mechanism	NN	O	O
by	NN	O	O
which	NN	O	O
dopamine	NN	O	O
enhances	NN	O	O
associative	NN	O	O
learning	NN	O	O
in	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
and	NN	O	O
stroke	NN	O	B
patients	NN	O	O
.	NN	O	O

Minocycline	NN	O	O
-	NN	O	O
induced	NN	O	O
vasculitis	NN	O	B
fulfilling	NN	O	O
the	NN	O	O
criteria	NN	O	O
of	NN	O	O
polyarteritis	NN	O	B
nodosa	NN	O	I
.	NN	O	O

A	NN	O	O
47	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
taking	NN	O	O
minocycline	NN	O	O
for	NN	O	O
palmoplantar	NN	O	B
pustulosis	NN	O	I
developed	NN	O	O
fever	NN	O	B
,	NN	O	O
myalgias	NN	O	B
,	NN	O	O
polyneuropathy	NN	O	B
,	NN	O	O
and	NN	O	O
testicular	NN	O	B
pain	NN	O	I
,	NN	O	O
with	NN	O	O
elevated	NN	O	O
C	NN	O	O
-	NN	O	O
reactive	NN	O	O
protein	NN	O	O
(	NN	O	O
CRP	NN	O	O
)	NN	O	O
.	NN	O	O

Neither	NN	O	O
myeloperoxidase	NN	O	O
-	NN	O	O
nor	NN	O	O
proteinase	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
antineutrophil	NN	O	O
cytoplasmic	NN	O	O
antibody	NN	O	O
was	NN	O	O
positive	NN	O	O
.	NN	O	O

These	NN	O	O
manifestations	NN	O	O
met	NN	O	O
the	NN	O	O
American	NN	O	O
College	NN	O	O
of	NN	O	O
Rheumatology	NN	O	O
1990	NN	O	O
criteria	NN	O	O
for	NN	O	O
the	NN	O	O
classification	NN	O	O
of	NN	O	O
polyarteritis	NN	O	B
nodosa	NN	O	I
.	NN	O	O

Stopping	NN	O	O
minocycline	NN	O	O
led	NN	O	O
to	NN	O	O
amelioration	NN	O	O
of	NN	O	O
symptoms	NN	O	O
and	NN	O	O
normalization	NN	O	O
of	NN	O	O
CRP	NN	O	O
level	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
second	NN	O	O
case	NN	O	O
of	NN	O	O
minocycline	NN	O	O
-	NN	O	O
induced	NN	O	O
vasculitis	NN	O	B
satisfying	NN	O	O
the	NN	O	O
criteria	NN	O	O
.	NN	O	O

Differential	NN	O	O
diagnosis	NN	O	O
for	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
disease	NN	O	O
is	NN	O	O
invaluable	NN	O	O
even	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
classical	NN	O	O
polyarteritis	NN	O	B
nodosa	NN	O	I
.	NN	O	O

Intramuscular	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
immune	NN	O	O
globulin	NN	O	O
combined	NN	O	O
with	NN	O	O
lamivudine	NN	O	O
in	NN	O	O
prevention	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
recurrence	NN	O	O
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Combined	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
immune	NN	O	O
globulin	NN	O	O
(	NN	O	O
HBIg	NN	O	O
)	NN	O	O
and	NN	O	O
lamivudine	NN	O	O
in	NN	O	O
prophylaxis	NN	O	O
of	NN	O	O
the	NN	O	O
recurrence	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
has	NN	O	O
significantly	NN	O	O
improved	NN	O	O
the	NN	O	O
survival	NN	O	O
of	NN	O	O
HBsAg	NN	O	O
positive	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
outcomes	NN	O	O
of	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
(	NN	O	O
HBV	NN	O	O
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
retrospective	NN	O	O
chart	NN	O	O
analysis	NN	O	O
and	NN	O	O
a	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
organ	NN	O	O
transplant	NN	O	O
database	NN	O	O
identified	NN	O	O
51	NN	O	O
patients	NN	O	O
(	NN	O	O
43	NN	O	O
men	NN	O	O
and	NN	O	O
8	NN	O	O
women	NN	O	O
)	NN	O	O
transplanted	NN	O	O
for	NN	O	O
benign	NN	O	O
HBV	NN	O	O
-	NN	O	O
related	NN	O	O
cirrhotic	NN	O	B
diseases	NN	O	I
between	NN	O	O
June	NN	O	O
2002	NN	O	O
and	NN	O	O
December	NN	O	O
2004	NN	O	O
who	NN	O	O
had	NN	O	O
survived	NN	O	O
more	NN	O	O
than	NN	O	O
3	NN	O	O
months	NN	O	O
.	NN	O	O

HBIg	NN	O	O
was	NN	O	O
administered	NN	O	O
intravenously	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
week	NN	O	O
and	NN	O	O
intramuscularly	NN	O	O
thereafter	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
At	NN	O	O
a	NN	O	O
median	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
14	NN	O	O
.	NN	O	O
1	NN	O	O
months	NN	O	O
,	NN	O	O
the	NN	O	O
overall	NN	O	O
recurrence	NN	O	O
rate	NN	O	O
in	NN	O	O
the	NN	O	O
51	NN	O	O
patients	NN	O	O
was	NN	O	O
3	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
(	NN	O	O
2	NN	O	O
/	NN	O	O
51	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
patient	NN	O	O
survival	NN	O	O
was	NN	O	O
88	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
82	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
after	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
years	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

A	NN	O	O
daily	NN	O	O
oral	NN	O	O
dose	NN	O	O
of	NN	O	O
100	NN	O	O
mg	NN	O	O
lamivudine	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
before	NN	O	O
transplantation	NN	O	O
for	NN	O	O
10	NN	O	O
patients	NN	O	O
enabled	NN	O	O
57	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
(	NN	O	O
4	NN	O	O
/	NN	O	O
7	NN	O	O
)	NN	O	O
and	NN	O	O
62	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
(	NN	O	O
5	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
of	NN	O	O
HBV	NN	O	O
-	NN	O	O
DNA	NN	O	O
and	NN	O	O
HBeAg	NN	O	O
positive	NN	O	O
patients	NN	O	O
respectively	NN	O	O
to	NN	O	O
convert	NN	O	O
to	NN	O	O
be	NN	O	O
negative	NN	O	O
.	NN	O	O

Intramuscular	NN	O	O
HBIg	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Lamivudine	NN	O	O
combined	NN	O	O
with	NN	O	O
intramuscular	NN	O	O
HBIg	NN	O	O
can	NN	O	O
effectively	NN	O	O
prevent	NN	O	O
allograft	NN	O	O
from	NN	O	O
the	NN	O	O
recurrence	NN	O	O
of	NN	O	O
HBV	NN	O	O
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Anticonvulsant	NN	O	O
effect	NN	O	O
of	NN	O	O
eslicarbazepine	NN	O	O
acetate	NN	O	O
(	NN	O	O
BIA	NN	O	O
2	NN	O	O
-	NN	O	O
093	NN	O	O
)	NN	O	O
on	NN	O	O
seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
microperfusion	NN	O	O
of	NN	O	O
picrotoxin	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
of	NN	O	O
freely	NN	O	O
moving	NN	O	O
rats	NN	O	O
.	NN	O	O

Eslicarbazepine	NN	O	O
acetate	NN	O	O
(	NN	O	O
BIA	NN	O	O
2	NN	O	O
-	NN	O	O
093	NN	O	O
,	NN	O	O
S	NN	O	O
-	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
10	NN	O	O
-	NN	O	O
acetoxy	NN	O	O
-	NN	O	O
10	NN	O	O
,	NN	O	O
11	NN	O	O
-	NN	O	O
dihydro	NN	O	O
-	NN	O	O
5H	NN	O	O
-	NN	O	O
dibenzo	NN	O	O
/	NN	O	O
b	NN	O	O
,	NN	O	O
f	NN	O	O
/	NN	O	O
azepine	NN	O	O
-	NN	O	O
5	NN	O	O
-	NN	O	O
carboxamide	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
,	NN	O	O
now	NN	O	O
in	NN	O	O
Phase	NN	O	O
III	NN	O	O
clinical	NN	O	O
trials	NN	O	O
,	NN	O	O
designed	NN	O	O
with	NN	O	O
the	NN	O	O
aim	NN	O	O
of	NN	O	O
improving	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
in	NN	O	O
comparison	NN	O	O
with	NN	O	O
the	NN	O	O
structurally	NN	O	O
related	NN	O	O
drugs	NN	O	O
carbamazepine	NN	O	O
(	NN	O	O
CBZ	NN	O	O
)	NN	O	O
and	NN	O	O
oxcarbazepine	NN	O	O
(	NN	O	O
OXC	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
studied	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
oral	NN	O	O
treatment	NN	O	O
with	NN	O	O
eslicarbazepine	NN	O	O
acetate	NN	O	O
on	NN	O	O
a	NN	O	O
whole	NN	O	O
-	NN	O	O
animal	NN	O	O
model	NN	O	O
in	NN	O	O
which	NN	O	O
partial	NN	O	O
seizures	NN	O	B
can	NN	O	O
be	NN	O	O
elicited	NN	O	O
repeatedly	NN	O	O
on	NN	O	O
different	NN	O	O
days	NN	O	O
without	NN	O	O
changes	NN	O	O
in	NN	O	O
threshold	NN	O	O
or	NN	O	O
seizure	NN	O	B
patterns	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
threshold	NN	O	O
doses	NN	O	O
of	NN	O	O
picrotoxin	NN	O	O
,	NN	O	O
the	NN	O	O
average	NN	O	O
number	NN	O	O
of	NN	O	O
seizures	NN	O	B
was	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
and	NN	O	O
average	NN	O	O
seizure	NN	O	B
duration	NN	O	O
was	NN	O	O
39	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
4s	NN	O	O
.	NN	O	O

Pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
2h	NN	O	O
before	NN	O	O
picrotoxin	NN	O	O
microperfusion	NN	O	O
prevented	NN	O	O
seizures	NN	O	B
in	NN	O	O
the	NN	O	O
75	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
rats	NN	O	O
.	NN	O	O

Lower	NN	O	O
doses	NN	O	O
(	NN	O	O
3	NN	O	O
and	NN	O	O
10mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
suppress	NN	O	O
seizures	NN	O	B
,	NN	O	O
however	NN	O	O
,	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
10mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
significant	NN	O	O
reductions	NN	O	O
in	NN	O	O
seizures	NN	O	B
duration	NN	O	O
(	NN	O	O
24	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
8s	NN	O	O
)	NN	O	O
and	NN	O	O
seizure	NN	O	B
number	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
34	NN	O	O
)	NN	O	O
were	NN	O	O
found	NN	O	O
.	NN	O	O

No	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
eslicarbazepine	NN	O	O
acetate	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
behavioral	NN	O	O
/	NN	O	O
EEG	NN	O	O
patterns	NN	O	O
studied	NN	O	O
,	NN	O	O
including	NN	O	O
sleep	NN	O	O
/	NN	O	O
wakefulness	NN	O	O
cycle	NN	O	O
,	NN	O	O
at	NN	O	O
the	NN	O	O
doses	NN	O	O
studied	NN	O	O
.	NN	O	O

Acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
associated	NN	O	O
with	NN	O	O
prolonged	NN	O	O
intake	NN	O	O
of	NN	O	O
slimming	NN	O	O
pills	NN	O	O
containing	NN	O	O
anthraquinones	NN	O	O
.	NN	O	O

Chinese	NN	O	O
herbal	NN	O	O
medicine	NN	O	O
preparations	NN	O	O
are	NN	O	O
widely	NN	O	O
available	NN	O	O
and	NN	O	O
often	NN	O	O
regarded	NN	O	O
by	NN	O	O
the	NN	O	O
public	NN	O	O
as	NN	O	O
natural	NN	O	O
and	NN	O	O
safe	NN	O	O
remedies	NN	O	O
for	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
medical	NN	O	O
conditions	NN	O	O
.	NN	O	O

Nephropathy	NN	O	B
caused	NN	O	O
by	NN	O	O
Chinese	NN	O	O
herbs	NN	O	O
has	NN	O	O
previously	NN	O	O
been	NN	O	O
reported	NN	O	O
,	NN	O	O
usually	NN	O	O
involving	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
aristolochic	NN	O	O
acids	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
23	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
who	NN	O	O
developed	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
following	NN	O	O
prolonged	NN	O	O
use	NN	O	O
of	NN	O	O
a	NN	O	O
proprietary	NN	O	O
Chinese	NN	O	O
herbal	NN	O	O
slimming	NN	O	O
pill	NN	O	O
that	NN	O	O
contained	NN	O	O
anthraquinone	NN	O	O
derivatives	NN	O	O
,	NN	O	O
extracted	NN	O	O
from	NN	O	O
Rhizoma	NN	O	O
Rhei	NN	O	O
(	NN	O	O
rhubarb	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
renal	NN	O	B
injury	NN	O	I
was	NN	O	O
probably	NN	O	O
aggravated	NN	O	O
by	NN	O	O
the	NN	O	O
concomitant	NN	O	O
intake	NN	O	O
of	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drug	NN	O	O
,	NN	O	O
diclofenac	NN	O	O
.	NN	O	O

Renal	NN	O	O
pathology	NN	O	O
was	NN	O	O
that	NN	O	O
of	NN	O	O
hypocellular	NN	O	O
interstitial	NN	O	O
fibrosis	NN	O	B
.	NN	O	O

Spontaneous	NN	O	O
renal	NN	O	O
recovery	NN	O	O
occurred	NN	O	O
upon	NN	O	O
cessation	NN	O	O
of	NN	O	O
the	NN	O	O
slimming	NN	O	O
pills	NN	O	O
,	NN	O	O
but	NN	O	O
mild	NN	O	O
interstitial	NN	O	O
fibrosis	NN	O	B
and	NN	O	O
tubular	NN	O	O
atrophy	NN	O	B
was	NN	O	O
still	NN	O	O
evident	NN	O	O
histologically	NN	O	O
4	NN	O	O
months	NN	O	O
later	NN	O	O
.	NN	O	O

Although	NN	O	O
a	NN	O	O
causal	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
an	NN	O	O
anthraquinone	NN	O	O
-	NN	O	O
containing	NN	O	O
herbal	NN	O	O
agent	NN	O	O
and	NN	O	O
renal	NN	O	B
injury	NN	O	I
remains	NN	O	O
to	NN	O	O
be	NN	O	O
proven	NN	O	O
,	NN	O	O
phytotherapy	NN	O	O
-	NN	O	O
associated	NN	O	O
interstitial	NN	O	O
nephropathy	NN	O	B
should	NN	O	O
be	NN	O	O
considered	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
present	NN	O	O
with	NN	O	O
unexplained	NN	O	O
renal	NN	O	B
failure	NN	O	I
.	NN	O	O

Chloroacetaldehyde	NN	O	O
as	NN	O	O
a	NN	O	O
sulfhydryl	NN	O	O
reagent	NN	O	O
:	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
critical	NN	O	O
thiol	NN	O	O
groups	NN	O	O
in	NN	O	O
ifosfamide	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

Chloroacetaldehyde	NN	O	O
(	NN	O	O
CAA	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
metabolite	NN	O	O
of	NN	O	O
the	NN	O	O
alkylating	NN	O	O
agent	NN	O	O
ifosfamide	NN	O	O
(	NN	O	O
IFO	NN	O	O
)	NN	O	O
and	NN	O	O
putatively	NN	O	O
responsible	NN	O	O
for	NN	O	O
renal	NN	O	B
damage	NN	O	I
following	NN	O	O
anti	NN	O	O
-	NN	O	O
tumor	NN	O	B
therapy	NN	O	O
with	NN	O	O
IFO	NN	O	O
.	NN	O	O

Depletion	NN	O	O
of	NN	O	O
sulfhydryl	NN	O	O
(	NN	O	O
SH	NN	O	O
)	NN	O	O
groups	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
from	NN	O	O
cell	NN	O	O
culture	NN	O	O
,	NN	O	O
animal	NN	O	O
and	NN	O	O
clinical	NN	O	O
studies	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
work	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
CAA	NN	O	O
on	NN	O	O
human	NN	O	O
proximal	NN	O	O
tubule	NN	O	O
cells	NN	O	O
in	NN	O	O
primary	NN	O	O
culture	NN	O	O
(	NN	O	O
hRPTEC	NN	O	O
)	NN	O	O
was	NN	O	O
investigated	NN	O	O
.	NN	O	O

Toxicity	NN	O	B
of	NN	O	O
CAA	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
protein	NN	O	O
content	NN	O	O
,	NN	O	O
cell	NN	O	O
number	NN	O	O
,	NN	O	O
LDH	NN	O	O
release	NN	O	O
,	NN	O	O
trypan	NN	O	O
blue	NN	O	O
exclusion	NN	O	O
assay	NN	O	O
and	NN	O	O
caspase	NN	O	O
-	NN	O	O
3	NN	O	O
activity	NN	O	O
.	NN	O	O

Free	NN	O	O
thiols	NN	O	O
were	NN	O	O
measured	NN	O	O
by	NN	O	O
the	NN	O	O
method	NN	O	O
of	NN	O	O
Ellman	NN	O	O
.	NN	O	O

CAA	NN	O	O
reduced	NN	O	O
hRPTEC	NN	O	O
cell	NN	O	O
number	NN	O	O
and	NN	O	O
protein	NN	O	O
,	NN	O	O
induced	NN	O	O
a	NN	O	O
loss	NN	O	O
in	NN	O	O
free	NN	O	O
intracellular	NN	O	O
thiols	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
necrosis	NN	O	B
markers	NN	O	O
.	NN	O	O

CAA	NN	O	O
but	NN	O	O
not	NN	O	O
acrolein	NN	O	O
inhibited	NN	O	O
the	NN	O	O
cysteine	NN	O	O
proteases	NN	O	O
caspase	NN	O	O
-	NN	O	O
3	NN	O	O
,	NN	O	O
caspase	NN	O	O
-	NN	O	O
8	NN	O	O
and	NN	O	O
cathepsin	NN	O	O
B	NN	O	O
.	NN	O	O

Caspase	NN	O	O
activation	NN	O	O
by	NN	O	O
cisplatin	NN	O	O
was	NN	O	O
inhibited	NN	O	O
by	NN	O	O
CAA	NN	O	O
.	NN	O	O

In	NN	O	O
cells	NN	O	O
stained	NN	O	O
with	NN	O	O
fluorescent	NN	O	O
dyes	NN	O	O
targeting	NN	O	O
lysosomes	NN	O	O
,	NN	O	O
CAA	NN	O	O
induced	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
lysosomal	NN	O	O
size	NN	O	O
and	NN	O	O
lysosomal	NN	O	O
leakage	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
CAA	NN	O	O
on	NN	O	O
cysteine	NN	O	O
protease	NN	O	O
activities	NN	O	O
and	NN	O	O
thiols	NN	O	O
could	NN	O	O
be	NN	O	O
reproduced	NN	O	O
in	NN	O	O
cell	NN	O	O
lysate	NN	O	O
.	NN	O	O

Acidification	NN	O	O
,	NN	O	O
which	NN	O	O
slowed	NN	O	O
the	NN	O	O
reaction	NN	O	O
of	NN	O	O
CAA	NN	O	O
with	NN	O	O
thiol	NN	O	O
donors	NN	O	O
,	NN	O	O
could	NN	O	O
also	NN	O	O
attenuate	NN	O	O
effects	NN	O	O
of	NN	O	O
CAA	NN	O	O
on	NN	O	O
necrosis	NN	O	B
markers	NN	O	O
,	NN	O	O
thiol	NN	O	O
depletion	NN	O	O
and	NN	O	O
cysteine	NN	O	O
protease	NN	O	O
inhibition	NN	O	O
in	NN	O	O
living	NN	O	O
cells	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
CAA	NN	O	O
directly	NN	O	O
reacts	NN	O	O
with	NN	O	O
cellular	NN	O	O
protein	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
protein	NN	O	O
thiols	NN	O	O
,	NN	O	O
mediating	NN	O	O
its	NN	O	O
toxicity	NN	O	B
on	NN	O	O
hRPTEC	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
can	NN	O	O
be	NN	O	O
reduced	NN	O	O
by	NN	O	O
acidification	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
urinary	NN	O	O
acidification	NN	O	O
could	NN	O	O
be	NN	O	O
an	NN	O	O
option	NN	O	O
to	NN	O	O
prevent	NN	O	O
IFO	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
patients	NN	O	O
.	NN	O	O

Stereological	NN	O	O
methods	NN	O	O
reveal	NN	O	O
the	NN	O	O
robust	NN	O	O
size	NN	O	O
and	NN	O	O
stability	NN	O	O
of	NN	O	O
ectopic	NN	O	O
hilar	NN	O	O
granule	NN	O	O
cells	NN	O	O
after	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
in	NN	O	O
the	NN	O	O
adult	NN	O	O
rat	NN	O	O
.	NN	O	O

Following	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
in	NN	O	O
the	NN	O	O
rat	NN	O	O
,	NN	O	O
dentate	NN	O	O
granule	NN	O	O
cell	NN	O	O
neurogenesis	NN	O	O
increases	NN	O	O
greatly	NN	O	O
,	NN	O	O
and	NN	O	O
many	NN	O	O
of	NN	O	O
the	NN	O	O
new	NN	O	O
neurons	NN	O	O
appear	NN	O	O
to	NN	O	O
develop	NN	O	O
ectopically	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
hilar	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampal	NN	O	O
formation	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
ectopic	NN	O	O
hilar	NN	O	O
granule	NN	O	O
cells	NN	O	O
could	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
spontaneous	NN	O	O
seizures	NN	O	B
that	NN	O	O
ultimately	NN	O	O
develop	NN	O	O
after	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
population	NN	O	O
has	NN	O	O
never	NN	O	O
been	NN	O	O
quantified	NN	O	O
,	NN	O	O
so	NN	O	O
it	NN	O	O
is	NN	O	O
unclear	NN	O	O
whether	NN	O	O
it	NN	O	O
is	NN	O	O
substantial	NN	O	O
enough	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
strong	NN	O	O
influence	NN	O	O
on	NN	O	O
epileptogenesis	NN	O	O
.	NN	O	O

To	NN	O	O
quantify	NN	O	O
this	NN	O	O
population	NN	O	O
,	NN	O	O
the	NN	O	O
total	NN	O	O
number	NN	O	O
of	NN	O	O
ectopic	NN	O	O
hilar	NN	O	O
granule	NN	O	O
cells	NN	O	O
was	NN	O	O
estimated	NN	O	O
using	NN	O	O
unbiased	NN	O	O
stereology	NN	O	O
at	NN	O	O
different	NN	O	O
times	NN	O	O
after	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
hilar	NN	O	O
neurons	NN	O	O
immunoreactive	NN	O	O
for	NN	O	O
Prox	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
a	NN	O	O
granule	NN	O	O
-	NN	O	O
cell	NN	O	O
-	NN	O	O
specific	NN	O	O
marker	NN	O	O
,	NN	O	O
was	NN	O	O
estimated	NN	O	O
using	NN	O	O
the	NN	O	O
optical	NN	O	O
fractionator	NN	O	O
method	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
size	NN	O	O
of	NN	O	O
the	NN	O	O
hilar	NN	O	O
ectopic	NN	O	O
granule	NN	O	O
cell	NN	O	O
population	NN	O	O
after	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
is	NN	O	O
substantial	NN	O	O
,	NN	O	O
and	NN	O	O
stable	NN	O	O
over	NN	O	O
time	NN	O	O
.	NN	O	O

Interestingly	NN	O	O
,	NN	O	O
the	NN	O	O
size	NN	O	O
of	NN	O	O
the	NN	O	O
population	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
behavioral	NN	O	O
seizures	NN	O	B
,	NN	O	O
because	NN	O	O
animals	NN	O	O
with	NN	O	O
more	NN	O	O
ectopic	NN	O	O
granule	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
hilus	NN	O	O
have	NN	O	O
more	NN	O	O
frequent	NN	O	O
behavioral	NN	O	O
seizures	NN	O	B
.	NN	O	O

The	NN	O	O
hilar	NN	O	O
ectopic	NN	O	O
granule	NN	O	O
cell	NN	O	O
population	NN	O	O
does	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
vary	NN	O	O
systematically	NN	O	O
across	NN	O	O
the	NN	O	O
septotemporal	NN	O	O
axis	NN	O	O
,	NN	O	O
although	NN	O	O
it	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
volume	NN	O	O
of	NN	O	O
the	NN	O	O
hilus	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
provide	NN	O	O
new	NN	O	O
insight	NN	O	O
into	NN	O	O
the	NN	O	O
potential	NN	O	O
role	NN	O	O
of	NN	O	O
ectopic	NN	O	O
hilar	NN	O	O
granule	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
pilocarpine	NN	O	O
model	NN	O	O
of	NN	O	O
temporal	NN	O	B
lobe	NN	O	I
epilepsy	NN	O	I
.	NN	O	O

A	NN	O	O
prospective	NN	O	O
,	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
trial	NN	O	O
of	NN	O	O
galantamine	NN	O	O
in	NN	O	O
autistic	NN	O	B
disorder	NN	O	I
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
Post	NN	O	O
-	NN	O	O
mortem	NN	O	O
studies	NN	O	O
have	NN	O	O
reported	NN	O	O
abnormalities	NN	O	O
of	NN	O	O
the	NN	O	O
cholinergic	NN	O	O
system	NN	O	O
in	NN	O	O
autism	NN	O	B
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
galantamine	NN	O	O
,	NN	O	O
an	NN	O	O
acetylcholinesterase	NN	O	O
inhibitor	NN	O	O
and	NN	O	O
nicotinic	NN	O	O
receptor	NN	O	O
modulator	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
interfering	NN	O	O
behaviors	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
autism	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Thirteen	NN	O	O
medication	NN	O	O
-	NN	O	O
free	NN	O	O
children	NN	O	O
with	NN	O	O
autism	NN	O	B
(	NN	O	O
mean	NN	O	O
age	NN	O	O
,	NN	O	O
8	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
5	NN	O	O
years	NN	O	O
)	NN	O	O
participated	NN	O	O
in	NN	O	O
a	NN	O	O
12	NN	O	O
-	NN	O	O
week	NN	O	O
,	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
trial	NN	O	O
of	NN	O	O
galantamine	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
rated	NN	O	O
monthly	NN	O	O
by	NN	O	O
parents	NN	O	O
on	NN	O	O
the	NN	O	O
Aberrant	NN	O	O
Behavior	NN	O	O
Checklist	NN	O	O
(	NN	O	O
ABC	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
Conners	NN	O	O
'	NN	O	O
Parent	NN	O	O
Rating	NN	O	O
Scale	NN	O	O
-	NN	O	O
Revised	NN	O	O
,	NN	O	O
and	NN	O	O
by	NN	O	O
a	NN	O	O
physician	NN	O	O
using	NN	O	O
the	NN	O	O
Children	NN	O	O
'	NN	O	O
s	NN	O	O
Psychiatric	NN	O	O
Rating	NN	O	O
Scale	NN	O	O
and	NN	O	O
the	NN	O	O
Clinical	NN	O	O
Global	NN	O	O
Impressions	NN	O	O
scale	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Patients	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
parent	NN	O	O
-	NN	O	O
rated	NN	O	O
irritability	NN	O	B
and	NN	O	O
social	NN	O	O
withdrawal	NN	O	O
on	NN	O	O
the	NN	O	O
ABC	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
significant	NN	O	O
improvements	NN	O	O
in	NN	O	O
emotional	NN	O	O
lability	NN	O	O
and	NN	O	O
inattention	NN	O	O
on	NN	O	O
the	NN	O	O
Conners	NN	O	O
'	NN	O	O
Parent	NN	O	O
Rating	NN	O	O
Scale	NN	O	O
-	NN	O	O
-	NN	O	O
Revised	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
clinician	NN	O	O
ratings	NN	O	O
showed	NN	O	O
reductions	NN	O	O
in	NN	O	O
the	NN	O	O
anger	NN	O	O
subscale	NN	O	O
of	NN	O	O
the	NN	O	O
Children	NN	O	O
'	NN	O	O
s	NN	O	O
Psychiatric	NN	O	O
Rating	NN	O	O
Scale	NN	O	O
.	NN	O	O

Eight	NN	O	O
of	NN	O	O
13	NN	O	O
participants	NN	O	O
were	NN	O	O
rated	NN	O	O
as	NN	O	O
responders	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
their	NN	O	O
improvement	NN	O	O
scores	NN	O	O
on	NN	O	O
the	NN	O	O
Clinical	NN	O	O
Global	NN	O	O
Impressions	NN	O	O
scale	NN	O	O
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
galantamine	NN	O	O
was	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
significant	NN	O	O
adverse	NN	O	O
effects	NN	O	O
apart	NN	O	O
from	NN	O	O
headaches	NN	O	B
in	NN	O	O
one	NN	O	O
patient	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
open	NN	O	O
trial	NN	O	O
,	NN	O	O
galantamine	NN	O	O
was	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
and	NN	O	O
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
beneficial	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
interfering	NN	O	O
behaviors	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
autism	NN	O	B
,	NN	O	O
particularly	NN	O	O
aggression	NN	O	B
,	NN	O	O
behavioral	NN	O	B
dyscontrol	NN	O	I
,	NN	O	O
and	NN	O	O
inattention	NN	O	B
.	NN	O	O

Further	NN	O	O
controlled	NN	O	O
trials	NN	O	O
are	NN	O	O
warranted	NN	O	O
.	NN	O	O

Randomized	NN	O	O
comparison	NN	O	O
of	NN	O	O
olanzapine	NN	O	O
versus	NN	O	O
risperidone	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
first	NN	O	O
-	NN	O	O
episode	NN	O	O
schizophrenia	NN	O	B
:	NN	O	O
4	NN	O	O
-	NN	O	O
month	NN	O	O
outcomes	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
authors	NN	O	O
compared	NN	O	O
4	NN	O	O
-	NN	O	O
month	NN	O	O
treatment	NN	O	O
outcomes	NN	O	O
for	NN	O	O
olanzapine	NN	O	O
versus	NN	O	O
risperidone	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
first	NN	O	O
-	NN	O	O
episode	NN	O	O
schizophrenia	NN	O	B
spectrum	NN	O	O
disorders	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
One	NN	O	O
hundred	NN	O	O
twelve	NN	O	O
subjects	NN	O	O
(	NN	O	O
70	NN	O	O
%	NN	O	O
male	NN	O	O
;	NN	O	O
mean	NN	O	O
age	NN	O	O
=	NN	O	O
23	NN	O	O
.	NN	O	O
3	NN	O	O
years	NN	O	O
[	NN	O	O
SD	NN	O	O
=	NN	O	O
5	NN	O	O
.	NN	O	O
1	NN	O	O
]	NN	O	O
)	NN	O	O
with	NN	O	O
first	NN	O	O
-	NN	O	O
episode	NN	O	O
schizophrenia	NN	O	B
(	NN	O	O
75	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
schizophreniform	NN	O	B
disorder	NN	O	I
(	NN	O	O
17	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
schizoaffective	NN	O	B
disorder	NN	O	I
(	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
treatment	NN	O	O
with	NN	O	O
olanzapine	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
or	NN	O	O
risperidone	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
6	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Response	NN	O	O
rates	NN	O	O
did	NN	O	O
not	NN	O	O
significantly	NN	O	O
differ	NN	O	O
between	NN	O	O
olanzapine	NN	O	O
(	NN	O	O
43	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
28	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
-	NN	O	O
58	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
risperidone	NN	O	O
(	NN	O	O
54	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
39	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
-	NN	O	O
68	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Among	NN	O	O
those	NN	O	O
responding	NN	O	O
to	NN	O	O
treatment	NN	O	O
,	NN	O	O
more	NN	O	O
subjects	NN	O	O
in	NN	O	O
the	NN	O	O
olanzapine	NN	O	O
group	NN	O	O
(	NN	O	O
40	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
16	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
-	NN	O	O
65	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
risperidone	NN	O	O
group	NN	O	O
(	NN	O	O
18	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
0	NN	O	O
%	NN	O	O
-	NN	O	O
39	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
subsequent	NN	O	O
ratings	NN	O	O
not	NN	O	O
meeting	NN	O	O
response	NN	O	O
criteria	NN	O	O
.	NN	O	O

Negative	NN	O	O
symptom	NN	O	O
outcomes	NN	O	O
and	NN	O	O
measures	NN	O	O
of	NN	O	O
parkinsonism	NN	O	B
and	NN	O	O
akathisia	NN	O	B
did	NN	O	O
not	NN	O	O
differ	NN	O	O
between	NN	O	O
medications	NN	O	O
.	NN	O	O

Extrapyramidal	NN	O	B
symptom	NN	O	I
severity	NN	O	O
scores	NN	O	O
were	NN	O	O
1	NN	O	O
.	NN	O	O
4	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
)	NN	O	O
with	NN	O	O
risperidone	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
4	NN	O	O
)	NN	O	O
with	NN	O	O
olanzapine	NN	O	O
.	NN	O	O

Significantly	NN	O	O
more	NN	O	O
weight	NN	O	B
gain	NN	O	I
occurred	NN	O	O
with	NN	O	O
olanzapine	NN	O	O
than	NN	O	O
with	NN	O	O
risperidone	NN	O	O
:	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
weight	NN	O	O
at	NN	O	O
4	NN	O	O
months	NN	O	O
relative	NN	O	O
to	NN	O	O
baseline	NN	O	O
weight	NN	O	O
was	NN	O	O
17	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
14	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
-	NN	O	O
20	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
with	NN	O	O
olanzapine	NN	O	O
and	NN	O	O
11	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
8	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
-	NN	O	O
14	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
with	NN	O	O
risperidone	NN	O	O
.	NN	O	O

Body	NN	O	O
mass	NN	O	O
index	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
at	NN	O	O
4	NN	O	O
months	NN	O	O
was	NN	O	O
24	NN	O	O
.	NN	O	O
3	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
22	NN	O	O
.	NN	O	O
8	NN	O	O
-	NN	O	O
25	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
versus	NN	O	O
28	NN	O	O
.	NN	O	O
2	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
26	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
29	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
with	NN	O	O
olanzapine	NN	O	O
and	NN	O	O
23	NN	O	O
.	NN	O	O
9	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
22	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
25	NN	O	O
.	NN	O	O
3	NN	O	O
)	NN	O	O
versus	NN	O	O
26	NN	O	O
.	NN	O	O
7	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
25	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
28	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
with	NN	O	O
risperidone	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Clinical	NN	O	O
outcomes	NN	O	O
with	NN	O	O
risperidone	NN	O	O
were	NN	O	O
equal	NN	O	O
to	NN	O	O
those	NN	O	O
with	NN	O	O
olanzapine	NN	O	O
,	NN	O	O
and	NN	O	O
response	NN	O	O
may	NN	O	O
be	NN	O	O
more	NN	O	O
stable	NN	O	O
.	NN	O	O

Olanzapine	NN	O	O
may	NN	O	O
have	NN	O	O
an	NN	O	O
advantage	NN	O	O
for	NN	O	O
motor	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Both	NN	O	O
medications	NN	O	O
caused	NN	O	O
substantial	NN	O	O
rapid	NN	O	O
weight	NN	O	B
gain	NN	O	I
,	NN	O	O
but	NN	O	O
weight	NN	O	B
gain	NN	O	I
was	NN	O	O
greater	NN	O	O
with	NN	O	O
olanzapine	NN	O	O
.	NN	O	O

Early	NN	O	O
paracentral	NN	O	O
visual	NN	O	B
field	NN	O	I
loss	NN	O	I
in	NN	O	O
patients	NN	O	O
taking	NN	O	O
hydroxychloroquine	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
review	NN	O	O
the	NN	O	O
natural	NN	O	O
history	NN	O	O
and	NN	O	O
ocular	NN	O	O
and	NN	O	O
systemic	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
patients	NN	O	O
taking	NN	O	O
hydroxychloroquine	NN	O	O
sulfate	NN	O	O
who	NN	O	O
attended	NN	O	O
an	NN	O	O
ophthalmic	NN	O	O
screening	NN	O	O
program	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Retrospective	NN	O	O
study	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Records	NN	O	O
of	NN	O	O
262	NN	O	O
patients	NN	O	O
who	NN	O	O
were	NN	O	O
taking	NN	O	O
hydroxychloroquine	NN	O	O
and	NN	O	O
screened	NN	O	O
in	NN	O	O
the	NN	O	O
Department	NN	O	O
of	NN	O	O
Ophthalmology	NN	O	O
were	NN	O	O
reviewed	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
262	NN	O	O
patients	NN	O	O
,	NN	O	O
14	NN	O	O
(	NN	O	O
18	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
76	NN	O	O
who	NN	O	O
had	NN	O	O
stopped	NN	O	O
treatment	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
experienced	NN	O	O
documented	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O

Systemic	NN	O	O
adverse	NN	O	O
effects	NN	O	O
occurred	NN	O	O
in	NN	O	O
8	NN	O	O
patients	NN	O	O
(	NN	O	O
10	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
ocular	NN	O	O
adverse	NN	O	O
effects	NN	O	O
,	NN	O	O
in	NN	O	O
5	NN	O	O
(	NN	O	O
6	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
(	NN	O	O
13	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
visual	NN	O	B
field	NN	O	I
abnormalities	NN	O	I
,	NN	O	O
which	NN	O	O
were	NN	O	O
attributed	NN	O	O
to	NN	O	O
hydroxychloroquine	NN	O	O
treatment	NN	O	O
in	NN	O	O
4	NN	O	O
patients	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Three	NN	O	O
of	NN	O	O
the	NN	O	O
4	NN	O	O
patients	NN	O	O
were	NN	O	O
taking	NN	O	O
less	NN	O	O
than	NN	O	O
6	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
and	NN	O	O
all	NN	O	O
patients	NN	O	O
had	NN	O	O
normal	NN	O	O
renal	NN	O	O
and	NN	O	O
liver	NN	O	O
function	NN	O	O
test	NN	O	O
results	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
current	NN	O	O
study	NN	O	O
used	NN	O	O
a	NN	O	O
protocol	NN	O	O
of	NN	O	O
visual	NN	O	O
acuity	NN	O	O
and	NN	O	O
color	NN	O	O
vision	NN	O	O
assessment	NN	O	O
,	NN	O	O
funduscopy	NN	O	O
,	NN	O	O
and	NN	O	O
Humphrey	NN	O	O
10	NN	O	O
-	NN	O	O
2	NN	O	O
visual	NN	O	O
field	NN	O	O
testing	NN	O	O
and	NN	O	O
shows	NN	O	O
that	NN	O	O
visual	NN	O	B
field	NN	O	I
defects	NN	O	I
appeared	NN	O	O
before	NN	O	O
any	NN	O	O
corresponding	NN	O	O
changes	NN	O	O
in	NN	O	O
any	NN	O	O
other	NN	O	O
tested	NN	O	O
clinical	NN	O	O
parameters	NN	O	O
;	NN	O	O
the	NN	O	O
defects	NN	O	O
were	NN	O	O
reproducible	NN	O	O
and	NN	O	O
the	NN	O	O
test	NN	O	O
parameters	NN	O	O
were	NN	O	O
reliable	NN	O	O
.	NN	O	O

Patients	NN	O	O
taking	NN	O	O
hydroxychloroquine	NN	O	O
can	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
toxic	NN	O	O
reaction	NN	O	O
in	NN	O	O
the	NN	O	O
retina	NN	O	O
despite	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
known	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

Screening	NN	O	O
,	NN	O	O
including	NN	O	O
Humphrey	NN	O	O
10	NN	O	O
-	NN	O	O
2	NN	O	O
visual	NN	O	O
field	NN	O	O
assessment	NN	O	O
,	NN	O	O
is	NN	O	O
recommended	NN	O	O
2	NN	O	O
years	NN	O	O
after	NN	O	O
the	NN	O	O
initial	NN	O	O
baseline	NN	O	O
and	NN	O	O
yearly	NN	O	O
thereafter	NN	O	O
.	NN	O	O

Peri	NN	O	O
-	NN	O	O
operative	NN	O	O
atrioventricular	NN	O	B
block	NN	O	I
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
with	NN	O	O
epirubicin	NN	O	O
and	NN	O	O
paclitaxel	NN	O	O
.	NN	O	O

A	NN	O	O
47	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
presented	NN	O	O
for	NN	O	O
mastectomy	NN	O	O
and	NN	O	O
immediate	NN	O	O
latissimus	NN	O	O
dorsi	NN	O	O
flap	NN	O	O
reconstruction	NN	O	O
having	NN	O	O
been	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
breast	NN	O	I
6	NN	O	O
months	NN	O	O
previously	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
preceding	NN	O	O
months	NN	O	O
she	NN	O	O
had	NN	O	O
received	NN	O	O
neo	NN	O	O
-	NN	O	O
adjuvant	NN	O	O
chemotherapy	NN	O	O
with	NN	O	O
epirubicin	NN	O	O
,	NN	O	O
paclitaxel	NN	O	O
(	NN	O	O
Taxol	NN	O	O
)	NN	O	O
and	NN	O	O
cyclophosphamide	NN	O	O
.	NN	O	O

This	NN	O	O
had	NN	O	O
been	NN	O	O
apparently	NN	O	O
uncomplicated	NN	O	O
and	NN	O	O
she	NN	O	O
had	NN	O	O
maintained	NN	O	O
a	NN	O	O
remarkably	NN	O	O
high	NN	O	O
level	NN	O	O
of	NN	O	O
physical	NN	O	O
activity	NN	O	O
.	NN	O	O

She	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
bradycardic	NN	O	B
at	NN	O	O
pre	NN	O	O
-	NN	O	O
operative	NN	O	O
assessment	NN	O	O
but	NN	O	O
had	NN	O	O
no	NN	O	O
cardiac	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Second	NN	O	O
degree	NN	O	O
Mobitz	NN	O	O
type	NN	O	O
II	NN	O	O
atrioventricular	NN	O	B
block	NN	O	I
was	NN	O	O
diagnosed	NN	O	O
on	NN	O	O
electrocardiogram	NN	O	O
,	NN	O	O
and	NN	O	O
temporary	NN	O	O
transvenous	NN	O	O
ventricular	NN	O	O
pacing	NN	O	O
instituted	NN	O	O
in	NN	O	O
the	NN	O	O
peri	NN	O	O
-	NN	O	O
operative	NN	O	O
period	NN	O	O
.	NN	O	O

We	NN	O	O
discuss	NN	O	O
how	NN	O	O
evidence	NN	O	O
-	NN	O	O
based	NN	O	O
guidelines	NN	O	O
would	NN	O	O
not	NN	O	O
have	NN	O	O
been	NN	O	O
helpful	NN	O	O
in	NN	O	O
this	NN	O	O
case	NN	O	O
,	NN	O	O
and	NN	O	O
how	NN	O	O
chemotherapy	NN	O	O
can	NN	O	O
exhibit	NN	O	O
substantial	NN	O	O
cardiotoxicity	NN	O	B
that	NN	O	O
may	NN	O	O
develop	NN	O	O
over	NN	O	O
many	NN	O	O
years	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
received	NN	O	O
chemotherapy	NN	O	O
at	NN	O	O
any	NN	O	O
time	NN	O	O
should	NN	O	O
have	NN	O	O
a	NN	O	O
pre	NN	O	O
-	NN	O	O
operative	NN	O	O
electrocardiogram	NN	O	O
even	NN	O	O
if	NN	O	O
they	NN	O	O
are	NN	O	O
asymptomatic	NN	O	O
.	NN	O	O

Risks	NN	O	O
and	NN	O	O
benefits	NN	O	O
of	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
inhibitors	NN	O	O
vs	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
NSAIDs	NN	O	O
:	NN	O	O
does	NN	O	O
their	NN	O	O
cardiovascular	NN	O	O
risk	NN	O	O
exceed	NN	O	O
their	NN	O	O
gastrointestinal	NN	O	O
benefit	NN	O	O
?	NN	O	O

A	NN	O	O
retrospective	NN	O	O
cohort	NN	O	O
study	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
The	NN	O	O
risk	NN	O	O
of	NN	O	O
acute	NN	O	B
myocardial	NN	O	I
infarction	NN	O	I
(	NN	O	O
AMI	NN	O	B
)	NN	O	O
with	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
inhibitors	NN	O	O
may	NN	O	O
offset	NN	O	O
their	NN	O	O
gastrointestinal	NN	O	O
(	NN	O	O
GI	NN	O	O
)	NN	O	O
benefit	NN	O	O
compared	NN	O	O
with	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
(	NN	O	O
NS	NN	O	O
)	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
(	NN	O	O
NSAIDs	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
aimed	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
risks	NN	O	O
of	NN	O	O
hospitalization	NN	O	O
for	NN	O	O
AMI	NN	O	B
and	NN	O	O
GI	NN	O	B
bleeding	NN	O	I
among	NN	O	O
elderly	NN	O	O
patients	NN	O	O
using	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
NS	NN	O	O
-	NN	O	O
NSAIDs	NN	O	O
and	NN	O	O
acetaminophen	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
conducted	NN	O	O
a	NN	O	O
retrospective	NN	O	O
cohort	NN	O	O
study	NN	O	O
using	NN	O	O
administrative	NN	O	O
data	NN	O	O
of	NN	O	O
patients	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
65	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
who	NN	O	O
filled	NN	O	O
a	NN	O	O
prescription	NN	O	O
for	NN	O	O
NSAID	NN	O	O
or	NN	O	O
acetaminophen	NN	O	O
during	NN	O	O
1999	NN	O	O
-	NN	O	O
2002	NN	O	O
.	NN	O	O

Outcomes	NN	O	O
were	NN	O	O
compared	NN	O	O
using	NN	O	O
Cox	NN	O	O
regression	NN	O	O
models	NN	O	O
with	NN	O	O
time	NN	O	O
-	NN	O	O
dependent	NN	O	O
exposures	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Person	NN	O	O
-	NN	O	O
years	NN	O	O
of	NN	O	O
exposure	NN	O	O
among	NN	O	O
non	NN	O	O
-	NN	O	O
users	NN	O	O
of	NN	O	O
aspirin	NN	O	O
were	NN	O	O
:	NN	O	O
75	NN	O	O
,	NN	O	O
761	NN	O	O
to	NN	O	O
acetaminophen	NN	O	O
,	NN	O	O
42	NN	O	O
,	NN	O	O
671	NN	O	O
to	NN	O	O
rofecoxib	NN	O	O
65	NN	O	O
,	NN	O	O
860	NN	O	O
to	NN	O	O
celecoxib	NN	O	O
,	NN	O	O
and	NN	O	O
37	NN	O	O
,	NN	O	O
495	NN	O	O
to	NN	O	O
NS	NN	O	O
-	NN	O	O
NSAIDs	NN	O	O
.	NN	O	O

Among	NN	O	O
users	NN	O	O
of	NN	O	O
aspirin	NN	O	O
,	NN	O	O
they	NN	O	O
were	NN	O	O
:	NN	O	O
14	NN	O	O
,	NN	O	O
671	NN	O	O
to	NN	O	O
rofecoxib	NN	O	O
,	NN	O	O
22	NN	O	O
,	NN	O	O
875	NN	O	O
to	NN	O	O
celecoxib	NN	O	O
,	NN	O	O
9	NN	O	O
,	NN	O	O
832	NN	O	O
to	NN	O	O
NS	NN	O	O
-	NN	O	O
NSAIDs	NN	O	O
and	NN	O	O
38	NN	O	O
,	NN	O	O
048	NN	O	O
to	NN	O	O
acetaminophen	NN	O	O
.	NN	O	O

Among	NN	O	O
non	NN	O	O
-	NN	O	O
users	NN	O	O
of	NN	O	O
aspirin	NN	O	O
,	NN	O	O
the	NN	O	O
adjusted	NN	O	O
hazard	NN	O	O
ratios	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
)	NN	O	O
of	NN	O	O
hospitalization	NN	O	O
for	NN	O	O
AMI	NN	O	B
/	NN	O	O
GI	NN	O	O
vs	NN	O	O
the	NN	O	O
acetaminophen	NN	O	O
(	NN	O	O
with	NN	O	O
no	NN	O	O
aspirin	NN	O	O
)	NN	O	O
group	NN	O	O
were	NN	O	O
:	NN	O	O
rofecoxib	NN	O	O
1	NN	O	O
.	NN	O	O
27	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
13	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
42	NN	O	O
)	NN	O	O
,	NN	O	O
celecoxib	NN	O	O
0	NN	O	O
.	NN	O	O
93	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
83	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
03	NN	O	O
)	NN	O	O
,	NN	O	O
naproxen	NN	O	O
1	NN	O	O
.	NN	O	O
59	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
31	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
93	NN	O	O
)	NN	O	O
,	NN	O	O
diclofenac	NN	O	O
1	NN	O	O
.	NN	O	O
17	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
99	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
38	NN	O	O
)	NN	O	O
and	NN	O	O
ibuprofen	NN	O	O
1	NN	O	O
.	NN	O	O
05	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
74	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
51	NN	O	O
)	NN	O	O
.	NN	O	O

Among	NN	O	O
users	NN	O	O
of	NN	O	O
aspirin	NN	O	O
,	NN	O	O
they	NN	O	O
were	NN	O	O
:	NN	O	O
rofecoxib	NN	O	O
1	NN	O	O
.	NN	O	O
73	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
52	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
98	NN	O	O
)	NN	O	O
,	NN	O	O
celecoxib	NN	O	O
1	NN	O	O
.	NN	O	O
34	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
19	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
52	NN	O	O
)	NN	O	O
,	NN	O	O
ibuprofen	NN	O	O
1	NN	O	O
.	NN	O	O
51	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
95	NN	O	O
,	NN	O	O
2	NN	O	O
.	NN	O	O
41	NN	O	O
)	NN	O	O
,	NN	O	O
diclofenac	NN	O	O
1	NN	O	O
.	NN	O	O
69	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
35	NN	O	O
,	NN	O	O
2	NN	O	O
.	NN	O	O
10	NN	O	O
)	NN	O	O
,	NN	O	O
naproxen	NN	O	O
1	NN	O	O
.	NN	O	O
35	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
97	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
88	NN	O	O
)	NN	O	O
and	NN	O	O
acetaminophen	NN	O	O
1	NN	O	O
.	NN	O	O
29	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
17	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
42	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Among	NN	O	O
non	NN	O	O
-	NN	O	O
users	NN	O	O
of	NN	O	O
aspirin	NN	O	O
,	NN	O	O
naproxen	NN	O	O
seemed	NN	O	O
to	NN	O	O
carry	NN	O	O
the	NN	O	O
highest	NN	O	O
risk	NN	O	O
for	NN	O	O
AMI	NN	O	B
/	NN	O	O
GI	NN	O	B
bleeding	NN	O	I
.	NN	O	O

The	NN	O	O
AMI	NN	O	B
/	NN	O	O
GI	NN	O	O
toxicity	NN	O	B
of	NN	O	O
celecoxib	NN	O	O
was	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
acetaminophen	NN	O	O
and	NN	O	O
seemed	NN	O	O
to	NN	O	O
be	NN	O	O
better	NN	O	O
than	NN	O	O
those	NN	O	O
of	NN	O	O
rofecoxib	NN	O	O
and	NN	O	O
NS	NN	O	O
-	NN	O	O
NSAIDs	NN	O	O
.	NN	O	O

Among	NN	O	O
users	NN	O	O
of	NN	O	O
aspirin	NN	O	O
,	NN	O	O
both	NN	O	O
celecoxib	NN	O	O
and	NN	O	O
naproxen	NN	O	O
seemed	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
least	NN	O	O
toxic	NN	O	O
.	NN	O	O

Quinine	NN	O	O
-	NN	O	O
induced	NN	O	O
arrhythmia	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
severe	NN	O	B
malaria	NN	O	I
.	NN	O	O

It	NN	O	O
was	NN	O	O
reported	NN	O	O
that	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
severe	NN	O	B
malaria	NN	O	I
patient	NN	O	O
with	NN	O	O
jaundice	NN	O	B
who	NN	O	O
presented	NN	O	O
with	NN	O	O
arrhythmia	NN	O	B
(	NN	O	O
premature	NN	O	B
ventricular	NN	O	I
contraction	NN	O	I
)	NN	O	O
while	NN	O	O
getting	NN	O	O
quinine	NN	O	O
infusion	NN	O	O
was	NN	O	O
reported	NN	O	O
.	NN	O	O

A	NN	O	O
man	NN	O	O
,	NN	O	O
25	NN	O	O
years	NN	O	O
old	NN	O	O
,	NN	O	O
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
hospital	NN	O	O
with	NN	O	O
high	NN	O	O
fever	NN	O	B
,	NN	O	O
chill	NN	O	B
,	NN	O	O
vomiting	NN	O	B
,	NN	O	O
jaundice	NN	O	B
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
fully	NN	O	O
conscious	NN	O	O
,	NN	O	O
blood	NN	O	O
pressure	NN	O	O
120	NN	O	O
/	NN	O	O
80	NN	O	O
mmHg	NN	O	O
,	NN	O	O
pulse	NN	O	O
rate	NN	O	O
100	NN	O	O
x	NN	O	O
/	NN	O	O
minute	NN	O	O
,	NN	O	O
regular	NN	O	O
.	NN	O	O

On	NN	O	O
admission	NN	O	O
,	NN	O	O
laboratory	NN	O	O
examination	NN	O	O
showed	NN	O	O
Plasmodium	NN	O	O
falciparum	NN	O	O
(	NN	O	O
+	NN	O	O
+	NN	O	O
+	NN	O	O
+	NN	O	O
)	NN	O	O
,	NN	O	O
total	NN	O	O
bilirubin	NN	O	O
8	NN	O	O
.	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
,	NN	O	O
conjugated	NN	O	O
bilirubin	NN	O	O
4	NN	O	O
.	NN	O	O
36	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
,	NN	O	O
unconjugated	NN	O	O
bilirubin	NN	O	O
3	NN	O	O
.	NN	O	O
89	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
,	NN	O	O
potassium	NN	O	O
3	NN	O	O
.	NN	O	O
52	NN	O	O
meq	NN	O	O
/	NN	O	O
L	NN	O	O
Patient	NN	O	O
was	NN	O	O
diagnosed	NN	O	O
as	NN	O	O
severe	NN	O	B
malaria	NN	O	I
with	NN	O	O
jaundice	NN	O	B
and	NN	O	O
got	NN	O	O
quinine	NN	O	O
infusion	NN	O	O
in	NN	O	O
dextrose	NN	O	O
5	NN	O	O
%	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
8	NN	O	O
hour	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
second	NN	O	O
day	NN	O	O
the	NN	O	O
patient	NN	O	O
had	NN	O	O
vomitus	NN	O	B
,	NN	O	O
diarrhea	NN	O	B
,	NN	O	O
tinnitus	NN	O	B
,	NN	O	O
loss	NN	O	B
of	NN	O	I
hearing	NN	O	I
.	NN	O	O

After	NN	O	O
30	NN	O	O
hours	NN	O	O
of	NN	O	O
quinine	NN	O	O
infusion	NN	O	O
the	NN	O	O
patient	NN	O	O
felt	NN	O	O
palpitation	NN	O	B
and	NN	O	O
electrocardiography	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
recording	NN	O	O
showed	NN	O	O
premature	NN	O	B
ventricular	NN	O	I
contraction	NN	O	I
(	NN	O	O
PVC	NN	O	B
)	NN	O	O
>	NN	O	O
5	NN	O	O
x	NN	O	O
/	NN	O	O
minute	NN	O	O
,	NN	O	O
trigemini	NN	O	O
,	NN	O	O
constant	NN	O	O
type	NN	O	O
-	NN	O	O
-	NN	O	O
sinoatrial	NN	O	B
block	NN	O	I
,	NN	O	O
positive	NN	O	O
U	NN	O	O
wave	NN	O	O
.	NN	O	O

He	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
lidocaine	NN	O	O
50	NN	O	O
mg	NN	O	O
intravenously	NN	O	O
followed	NN	O	O
by	NN	O	O
infusion	NN	O	O
1500	NN	O	O
mg	NN	O	O
in	NN	O	O
dextrose	NN	O	O
5	NN	O	O
%	NN	O	O
/	NN	O	O
24	NN	O	O
hour	NN	O	O
and	NN	O	O
potassium	NN	O	O
aspartate	NN	O	O
tablet	NN	O	O
.	NN	O	O

Quinine	NN	O	O
infusion	NN	O	O
was	NN	O	O
discontinued	NN	O	O
and	NN	O	O
changed	NN	O	O
with	NN	O	O
sulfate	NN	O	O
quinine	NN	O	O
tablets	NN	O	O
.	NN	O	O

Three	NN	O	O
hours	NN	O	O
later	NN	O	O
the	NN	O	O
patient	NN	O	O
felt	NN	O	O
better	NN	O	O
,	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
PVC	NN	O	B
reduced	NN	O	O
to	NN	O	O
4	NN	O	O
-	NN	O	O
5	NN	O	O
x	NN	O	O
/	NN	O	O
minute	NN	O	O
and	NN	O	O
on	NN	O	O
the	NN	O	O
third	NN	O	O
day	NN	O	O
ECG	NN	O	O
was	NN	O	O
normal	NN	O	O
,	NN	O	O
potassium	NN	O	O
level	NN	O	O
was	NN	O	O
3	NN	O	O
.	NN	O	O
34	NN	O	O
meq	NN	O	O
/	NN	O	O
L	NN	O	O
.	NN	O	O

He	NN	O	O
was	NN	O	O
discharged	NN	O	O
on	NN	O	O
7th	NN	O	O
day	NN	O	O
in	NN	O	O
good	NN	O	O
condition	NN	O	O
.	NN	O	O

Quinine	NN	O	O
,	NN	O	O
like	NN	O	O
quinidine	NN	O	O
,	NN	O	O
is	NN	O	O
a	NN	O	O
chincona	NN	O	O
alkaloid	NN	O	O
that	NN	O	O
has	NN	O	O
anti	NN	O	O
-	NN	O	O
arrhythmic	NN	O	B
property	NN	O	O
,	NN	O	O
although	NN	O	O
it	NN	O	O
also	NN	O	O
pro	NN	O	O
-	NN	O	O
arrhythmic	NN	O	B
that	NN	O	O
can	NN	O	O
cause	NN	O	O
various	NN	O	O
arrhythmias	NN	O	B
,	NN	O	O
including	NN	O	O
severe	NN	O	O
arrhythmia	NN	O	B
such	NN	O	O
as	NN	O	O
multiple	NN	O	O
PVC	NN	O	B
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
parenteral	NN	O	O
quinine	NN	O	O
must	NN	O	O
be	NN	O	O
done	NN	O	O
carefully	NN	O	O
and	NN	O	O
with	NN	O	O
good	NN	O	O
observation	NN	O	O
because	NN	O	O
of	NN	O	O
its	NN	O	O
pro	NN	O	O
-	NN	O	O
arrhythmic	NN	O	B
effect	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
older	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
heart	NN	O	B
diseases	NN	O	I
or	NN	O	O
patients	NN	O	O
with	NN	O	O
electrolyte	NN	O	B
disorder	NN	O	I
(	NN	O	O
hypokalemia	NN	O	B
)	NN	O	O
which	NN	O	O
frequently	NN	O	O
occurs	NN	O	O
due	NN	O	O
to	NN	O	O
vomiting	NN	O	B
and	NN	O	O
or	NN	O	O
diarrhea	NN	O	B
in	NN	O	O
malaria	NN	O	B
cases	NN	O	O
.	NN	O	O

Penicillamine	NN	O	O
-	NN	O	O
related	NN	O	O
lichenoid	NN	O	B
dermatitis	NN	O	I
and	NN	O	O
utility	NN	O	O
of	NN	O	O
zinc	NN	O	O
acetate	NN	O	O
in	NN	O	O
a	NN	O	O
Wilson	NN	O	B
disease	NN	O	I
patient	NN	O	O
with	NN	O	O
hepatic	NN	O	O
presentation	NN	O	O
,	NN	O	O
anxiety	NN	O	B
and	NN	O	O
SPECT	NN	O	O
abnormalities	NN	O	O
.	NN	O	O

Wilson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
is	NN	O	O
an	NN	O	O
autosomal	NN	O	O
recessive	NN	O	O
disorder	NN	O	O
of	NN	O	O
hepatic	NN	O	O
copper	NN	O	O
metabolism	NN	O	O
with	NN	O	O
consequent	NN	O	O
copper	NN	O	O
accumulation	NN	O	O
and	NN	O	O
toxicity	NN	O	B
in	NN	O	O
many	NN	O	O
tissues	NN	O	O
and	NN	O	O
consequent	NN	O	O
hepatic	NN	O	B
,	NN	O	I
neurologic	NN	O	I
and	NN	O	I
psychiatric	NN	O	I
disorders	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
Wilson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
with	NN	O	O
chronic	NN	O	B
liver	NN	O	I
disease	NN	O	I
;	NN	O	O
moreover	NN	O	O
,	NN	O	O
in	NN	O	O
our	NN	O	O
patient	NN	O	O
,	NN	O	O
presenting	NN	O	O
also	NN	O	O
with	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
state	NN	O	O
anxiety	NN	O	B
without	NN	O	O
depression	NN	O	B
,	NN	O	O
99mTc	NN	O	O
-	NN	O	O
ECD	NN	O	O
-	NN	O	O
SPECT	NN	O	O
showed	NN	O	O
cortical	NN	O	O
hypoperfusion	NN	O	O
in	NN	O	O
frontal	NN	O	O
lobes	NN	O	O
,	NN	O	O
more	NN	O	O
marked	NN	O	O
on	NN	O	O
the	NN	O	O
left	NN	O	O
frontal	NN	O	O
lobe	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
our	NN	O	O
patient	NN	O	O
,	NN	O	O
penicillamine	NN	O	O
was	NN	O	O
interrupted	NN	O	O
after	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
a	NN	O	O
lichenoid	NN	O	B
dermatitis	NN	O	I
,	NN	O	O
and	NN	O	O
zinc	NN	O	O
acetate	NN	O	O
permitted	NN	O	O
to	NN	O	O
continue	NN	O	O
the	NN	O	O
successful	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
without	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
.	NN	O	O

In	NN	O	O
our	NN	O	O
case	NN	O	O
the	NN	O	O
therapy	NN	O	O
with	NN	O	O
zinc	NN	O	O
acetate	NN	O	O
represented	NN	O	O
an	NN	O	O
effective	NN	O	O
treatment	NN	O	O
for	NN	O	O
a	NN	O	O
Wilson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
patient	NN	O	O
in	NN	O	O
which	NN	O	O
penicillamine	NN	O	O
-	NN	O	O
related	NN	O	O
side	NN	O	O
effects	NN	O	O
appeared	NN	O	O
.	NN	O	O

The	NN	O	O
safety	NN	O	O
of	NN	O	O
the	NN	O	O
zinc	NN	O	O
acetate	NN	O	O
allowed	NN	O	O
us	NN	O	O
to	NN	O	O
avoid	NN	O	O
other	NN	O	O
potentially	NN	O	O
toxic	NN	O	O
chelating	NN	O	O
drugs	NN	O	O
;	NN	O	O
this	NN	O	O
observation	NN	O	O
is	NN	O	O
in	NN	O	O
line	NN	O	O
with	NN	O	O
the	NN	O	O
growing	NN	O	O
evidence	NN	O	O
on	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
Wilson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

Since	NN	O	O
most	NN	O	O
of	NN	O	O
Wilson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
penicillamine	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
do	NN	O	O
not	NN	O	O
seem	NN	O	O
to	NN	O	O
develop	NN	O	O
this	NN	O	O
skin	NN	O	B
lesion	NN	O	I
,	NN	O	O
it	NN	O	O
could	NN	O	O
be	NN	O	O
conceivable	NN	O	O
that	NN	O	O
a	NN	O	O
specific	NN	O	O
genetic	NN	O	O
factor	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
drug	NN	O	O
response	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
for	NN	O	O
a	NN	O	O
better	NN	O	O
clarification	NN	O	O
of	NN	O	O
Wilson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
therapy	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
particular	NN	O	O
to	NN	O	O
differentiate	NN	O	O
specific	NN	O	O
therapies	NN	O	O
for	NN	O	O
different	NN	O	O
Wilson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
phenotypes	NN	O	O
.	NN	O	O

A	NN	O	O
dramatic	NN	O	O
drop	NN	O	B
in	NN	O	I
blood	NN	O	I
pressure	NN	O	I
following	NN	O	O
prehospital	NN	O	O
GTN	NN	O	O
administration	NN	O	O
.	NN	O	O

A	NN	O	O
male	NN	O	O
in	NN	O	O
his	NN	O	O
sixties	NN	O	O
with	NN	O	O
no	NN	O	O
history	NN	O	O
of	NN	O	O
cardiac	NN	O	O
chest	NN	O	B
pain	NN	O	I
awoke	NN	O	O
with	NN	O	O
chest	NN	O	B
pain	NN	O	I
following	NN	O	O
an	NN	O	O
afternoon	NN	O	O
sleep	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
did	NN	O	O
not	NN	O	O
self	NN	O	O
medicate	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
observations	NN	O	O
were	NN	O	O
within	NN	O	O
normal	NN	O	O
limits	NN	O	O
,	NN	O	O
he	NN	O	O
was	NN	O	O
administered	NN	O	O
oxygen	NN	O	O
via	NN	O	O
a	NN	O	O
face	NN	O	O
mask	NN	O	O
and	NN	O	O
glyceryl	NN	O	O
trinitrate	NN	O	O
(	NN	O	O
GTN	NN	O	O
)	NN	O	O
.	NN	O	O

Several	NN	O	O
minutes	NN	O	O
after	NN	O	O
the	NN	O	O
GTN	NN	O	O
the	NN	O	O
patient	NN	O	O
experienced	NN	O	O
a	NN	O	O
sudden	NN	O	O
drop	NN	O	B
in	NN	O	I
blood	NN	O	I
pressure	NN	O	I
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
this	NN	O	O
was	NN	O	O
rectified	NN	O	O
by	NN	O	O
atropine	NN	O	O
sulphate	NN	O	O
and	NN	O	O
a	NN	O	O
fluid	NN	O	O
challenge	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
further	NN	O	O
deterioration	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
condition	NN	O	O
during	NN	O	O
transport	NN	O	O
to	NN	O	O
hospital	NN	O	O
.	NN	O	O

There	NN	O	O
are	NN	O	O
very	NN	O	O
few	NN	O	O
documented	NN	O	O
case	NN	O	O
like	NN	O	O
this	NN	O	O
in	NN	O	O
the	NN	O	O
prehospital	NN	O	O
scientific	NN	O	O
literature	NN	O	O
.	NN	O	O

The	NN	O	O
cause	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
Bezold	NN	O	O
-	NN	O	O
Jarish	NN	O	O
reflex	NN	O	O
,	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
ventricular	NN	O	O
walls	NN	O	O
which	NN	O	O
in	NN	O	O
turn	NN	O	O
decreases	NN	O	O
sympathetic	NN	O	O
outflow	NN	O	O
from	NN	O	O
the	NN	O	O
vasomotor	NN	O	O
centre	NN	O	O
.	NN	O	O

Prehospital	NN	O	O
care	NN	O	O
providers	NN	O	O
who	NN	O	O
are	NN	O	O
managing	NN	O	O
any	NN	O	O
patient	NN	O	O
with	NN	O	O
a	NN	O	O
syncopal	NN	O	B
episode	NN	O	I
that	NN	O	O
fails	NN	O	O
to	NN	O	O
recover	NN	O	O
within	NN	O	O
a	NN	O	O
reasonable	NN	O	O
time	NN	O	O
frame	NN	O	O
should	NN	O	O
consider	NN	O	O
the	NN	O	O
Bezold	NN	O	O
-	NN	O	O
Jarisch	NN	O	O
reflex	NN	O	O
as	NN	O	O
the	NN	O	O
cause	NN	O	O
and	NN	O	O
manage	NN	O	O
the	NN	O	O
patient	NN	O	O
accordingly	NN	O	O
.	NN	O	O

Chronic	NN	O	O
lesion	NN	O	O
of	NN	O	O
rostral	NN	O	O
ventrolateral	NN	O	O
medulla	NN	O	O
in	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
chronic	NN	O	O
selective	NN	O	O
neuronal	NN	O	O
lesion	NN	O	O
of	NN	O	O
rostral	NN	O	O
ventrolateral	NN	O	O
medulla	NN	O	O
on	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
,	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
and	NN	O	O
neurogenic	NN	O	O
tone	NN	O	O
in	NN	O	O
conscious	NN	O	O
,	NN	O	O
unrestrained	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
.	NN	O	O

The	NN	O	O
lesions	NN	O	O
were	NN	O	O
placed	NN	O	O
via	NN	O	O
bilateral	NN	O	O
microinjections	NN	O	O
of	NN	O	O
30	NN	O	O
nmol	NN	O	O
/	NN	O	O
200	NN	O	O
nl	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartic	NN	O	O
acid	NN	O	O
.	NN	O	O

The	NN	O	O
restimulation	NN	O	O
of	NN	O	O
this	NN	O	O
area	NN	O	O
with	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartic	NN	O	O
acid	NN	O	O
15	NN	O	O
days	NN	O	O
postlesion	NN	O	O
failed	NN	O	O
to	NN	O	O
produce	NN	O	O
a	NN	O	O
pressor	NN	O	O
response	NN	O	O
.	NN	O	O

One	NN	O	O
day	NN	O	O
postlesion	NN	O	O
,	NN	O	O
the	NN	O	O
resting	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
was	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
in	NN	O	O
lesioned	NN	O	O
rats	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
sham	NN	O	O
rats	NN	O	O
(	NN	O	O
100	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
versus	NN	O	O
173	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Fifteen	NN	O	O
days	NN	O	O
later	NN	O	O
,	NN	O	O
the	NN	O	O
lesioned	NN	O	O
group	NN	O	O
still	NN	O	O
showed	NN	O	O
values	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
the	NN	O	O
sham	NN	O	O
group	NN	O	O
(	NN	O	O
150	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
versus	NN	O	O
167	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
heart	NN	O	O
rate	NN	O	O
differences	NN	O	O
were	NN	O	O
observed	NN	O	O
between	NN	O	O
the	NN	O	O
sham	NN	O	O
and	NN	O	O
lesioned	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
ganglionic	NN	O	O
blocker	NN	O	O
trimethaphan	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
caused	NN	O	O
similar	NN	O	O
reductions	NN	O	O
in	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
in	NN	O	O
both	NN	O	O
lesioned	NN	O	O
and	NN	O	O
sham	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
trimethaphan	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
significant	NN	O	O
bradycardia	NN	O	B
in	NN	O	O
lesioned	NN	O	O
rats	NN	O	O
(	NN	O	O
-	NN	O	O
32	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
beats	NN	O	O
per	NN	O	O
minute	NN	O	O
)	NN	O	O
but	NN	O	O
a	NN	O	O
tachycardia	NN	O	B
in	NN	O	O
sham	NN	O	O
rats	NN	O	O
(	NN	O	O
+	NN	O	O
33	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
beats	NN	O	O
per	NN	O	O
minute	NN	O	O
)	NN	O	O
1	NN	O	O
day	NN	O	O
postlesion	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
rostral	NN	O	O
ventrolateral	NN	O	O
medulla	NN	O	O
neurons	NN	O	O
appear	NN	O	O
to	NN	O	O
play	NN	O	O
a	NN	O	O
significant	NN	O	O
role	NN	O	O
in	NN	O	O
maintaining	NN	O	O
hypertension	NN	O	B
in	NN	O	O
conscious	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
.	NN	O	O

Spinal	NN	O	O
or	NN	O	O
suprabulbar	NN	O	O
structures	NN	O	O
could	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
gradual	NN	O	O
recovery	NN	O	O
of	NN	O	O
the	NN	O	O
hypertension	NN	O	B
in	NN	O	O
the	NN	O	O
lesioned	NN	O	O
rats	NN	O	O
.	NN	O	O

Acute	NN	O	B
encephalopathy	NN	O	I
and	NN	O	O
cerebral	NN	O	B
vasospasm	NN	O	I
after	NN	O	O
multiagent	NN	O	O
chemotherapy	NN	O	O
including	NN	O	O
PEG	NN	O	O
-	NN	O	O
asparaginase	NN	O	O
and	NN	O	O
intrathecal	NN	O	O
cytarabine	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
.	NN	O	O

A	NN	O	O
7	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
with	NN	O	O
an	NN	O	O
unusual	NN	O	O
reaction	NN	O	O
to	NN	O	O
induction	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
precursor	NN	O	O
B	NN	O	O
-	NN	O	O
cell	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
(	NN	O	O
ALL	NN	O	B
)	NN	O	O
is	NN	O	O
described	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
developed	NN	O	O
acute	NN	O	B
encephalopathy	NN	O	I
evidenced	NN	O	O
by	NN	O	O
behavioral	NN	O	O
changes	NN	O	O
,	NN	O	O
aphasia	NN	O	B
,	NN	O	O
incontinence	NN	O	B
,	NN	O	O
visual	NN	O	B
hallucinations	NN	O	I
,	NN	O	O
and	NN	O	O
right	NN	O	O
-	NN	O	O
sided	NN	O	O
weakness	NN	O	B
with	NN	O	O
diffuse	NN	O	O
cerebral	NN	O	B
vasospasm	NN	O	I
on	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
angiography	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
intrathecal	NN	O	O
cytarabine	NN	O	O
.	NN	O	O

Vincristine	NN	O	O
,	NN	O	O
dexamethasone	NN	O	O
,	NN	O	O
and	NN	O	O
polyethylene	NN	O	O
glycol	NN	O	O
-	NN	O	O
asparaginase	NN	O	O
were	NN	O	O
also	NN	O	O
administered	NN	O	O
before	NN	O	O
the	NN	O	O
episode	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
induction	NN	O	O
therapy	NN	O	O
.	NN	O	O

Neurologic	NN	O	O
status	NN	O	O
returned	NN	O	O
to	NN	O	O
baseline	NN	O	O
within	NN	O	O
10	NN	O	O
days	NN	O	O
of	NN	O	O
the	NN	O	O
acute	NN	O	O
event	NN	O	O
,	NN	O	O
and	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
angiography	NN	O	O
findings	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
4	NN	O	O
months	NN	O	O
later	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
valsartan	NN	O	O
/	NN	O	O
hydrochlorothiazide	NN	O	O
combination	NN	O	O
therapy	NN	O	O
at	NN	O	O
doses	NN	O	O
up	NN	O	O
to	NN	O	O
320	NN	O	O
/	NN	O	O
25	NN	O	O
mg	NN	O	O
versus	NN	O	O
monotherapy	NN	O	O
:	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
study	NN	O	O
followed	NN	O	O
by	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
combination	NN	O	O
therapy	NN	O	O
in	NN	O	O
hypertensive	NN	O	B
adults	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
One	NN	O	O
third	NN	O	O
of	NN	O	O
patients	NN	O	O
treated	NN	O	O
for	NN	O	O
hypertension	NN	O	B
attain	NN	O	O
adequate	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
BP	NN	O	O
)	NN	O	O
control	NN	O	O
,	NN	O	O
and	NN	O	O
multidrug	NN	O	O
regimens	NN	O	O
are	NN	O	O
often	NN	O	O
required	NN	O	O
.	NN	O	O

Given	NN	O	O
the	NN	O	O
lifelong	NN	O	O
nature	NN	O	O
of	NN	O	O
hypertension	NN	O	B
,	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
need	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
efficacy	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
higher	NN	O	O
doses	NN	O	O
of	NN	O	O
combination	NN	O	O
anti	NN	O	O
-	NN	O	O
hypertensive	NN	O	B
therapies	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
investigated	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
valsartan	NN	O	O
(	NN	O	O
VAL	NN	O	O
)	NN	O	O
or	NN	O	O
hydrochlorothiazide	NN	O	O
(	NN	O	O
HCTZ	NN	O	O
)	NN	O	O
-	NN	O	O
monotherapy	NN	O	O
and	NN	O	O
higher	NN	O	O
-	NN	O	O
dose	NN	O	O
combinations	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
essential	NN	O	B
hypertension	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
first	NN	O	O
part	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
an	NN	O	O
8	NN	O	O
-	NN	O	O
week	NN	O	O
,	NN	O	O
multicenter	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
controlled	NN	O	O
,	NN	O	O
parallel	NN	O	O
-	NN	O	O
group	NN	O	O
trial	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
essential	NN	O	B
hypertension	NN	O	I
(	NN	O	O
mean	NN	O	O
sitting	NN	O	O
diastolic	NN	O	O
BP	NN	O	O
[	NN	O	O
MSDBP	NN	O	O
]	NN	O	O
,	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
95	NN	O	O
mm	NN	O	O
Hg	NN	O	O
and	NN	O	O
<	NN	O	O
110	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
1	NN	O	O
of	NN	O	O
8	NN	O	O
treatment	NN	O	O
groups	NN	O	O
:	NN	O	O
VAL	NN	O	O
160	NN	O	O
or	NN	O	O
320	NN	O	O
mg	NN	O	O
;	NN	O	O
HCTZ	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
or	NN	O	O
25	NN	O	O
mg	NN	O	O
;	NN	O	O
VAL	NN	O	O
/	NN	O	O
HCTZ	NN	O	O
160	NN	O	O
/	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
320	NN	O	O
/	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
or	NN	O	O
320	NN	O	O
/	NN	O	O
25	NN	O	O
mg	NN	O	O
;	NN	O	O
or	NN	O	O
placebo	NN	O	O
.	NN	O	O

Mean	NN	O	O
changes	NN	O	O
in	NN	O	O
MSDBP	NN	O	O
and	NN	O	O
mean	NN	O	O
sitting	NN	O	O
systolic	NN	O	O
BP	NN	O	O
(	NN	O	O
MSSBP	NN	O	O
)	NN	O	O
were	NN	O	O
analyzed	NN	O	O
at	NN	O	O
the	NN	O	O
8	NN	O	O
-	NN	O	O
week	NN	O	O
core	NN	O	O
study	NN	O	O
end	NN	O	O
point	NN	O	O
.	NN	O	O

VAL	NN	O	O
/	NN	O	O
HCTZ	NN	O	O
320	NN	O	O
/	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
320	NN	O	O
/	NN	O	O
25	NN	O	O
mg	NN	O	O
were	NN	O	O
further	NN	O	O
investigated	NN	O	O
in	NN	O	O
a	NN	O	O
54	NN	O	O
-	NN	O	O
week	NN	O	O
,	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
extension	NN	O	O
.	NN	O	O

Response	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
MSDBP	NN	O	O
<	NN	O	O
90	NN	O	O
mm	NN	O	O
Hg	NN	O	O
or	NN	O	O
a	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
10	NN	O	O
mm	NN	O	O
Hg	NN	O	O
decrease	NN	O	O
compared	NN	O	O
to	NN	O	O
baseline	NN	O	O
.	NN	O	O

Control	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
MSDBP	NN	O	O
<	NN	O	O
90	NN	O	O
mm	NN	O	O
Hg	NN	O	O
compared	NN	O	O
with	NN	O	O
baseline	NN	O	O
.	NN	O	O

Tolerability	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
monitoring	NN	O	O
adverse	NN	O	O
events	NN	O	O
at	NN	O	O
randomization	NN	O	O
and	NN	O	O
all	NN	O	O
subsequent	NN	O	O
study	NN	O	O
visits	NN	O	O
and	NN	O	O
regular	NN	O	O
evaluation	NN	O	O
of	NN	O	O
hematology	NN	O	O
and	NN	O	O
blood	NN	O	O
chemistry	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
1346	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
into	NN	O	O
the	NN	O	O
8	NN	O	O
-	NN	O	O
week	NN	O	O
core	NN	O	O
study	NN	O	O
(	NN	O	O
734	NN	O	O
men	NN	O	O
,	NN	O	O
612	NN	O	O
women	NN	O	O
;	NN	O	O
924	NN	O	O
white	NN	O	O
,	NN	O	O
291	NN	O	O
black	NN	O	O
,	NN	O	O
23	NN	O	O
Asian	NN	O	O
,	NN	O	O
108	NN	O	O
other	NN	O	O
;	NN	O	O
mean	NN	O	O
age	NN	O	O
,	NN	O	O
52	NN	O	O
.	NN	O	O
7	NN	O	O
years	NN	O	O
;	NN	O	O
mean	NN	O	O
weight	NN	O	O
,	NN	O	O
92	NN	O	O
.	NN	O	O
6	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
active	NN	O	O
treatments	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
MSSBP	NN	O	O
and	NN	O	O
MSDBP	NN	O	O
during	NN	O	O
the	NN	O	O
core	NN	O	O
8	NN	O	O
-	NN	O	O
week	NN	O	O
study	NN	O	O
,	NN	O	O
with	NN	O	O
each	NN	O	O
monotherapy	NN	O	O
significantly	NN	O	O
contributing	NN	O	O
to	NN	O	O
the	NN	O	O
overall	NN	O	O
effect	NN	O	O
of	NN	O	O
combination	NN	O	O
therapy	NN	O	O
(	NN	O	O
VAL	NN	O	O
and	NN	O	O
HCTZ	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Each	NN	O	O
combination	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
significantly	NN	O	O
greater	NN	O	O
reductions	NN	O	O
in	NN	O	O
MSSBP	NN	O	O
and	NN	O	O
MSDBP	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
monotherapies	NN	O	O
and	NN	O	O
placebo	NN	O	O
(	NN	O	O
all	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
reduction	NN	O	O
in	NN	O	O
MSSBP	NN	O	O
/	NN	O	O
MSDBP	NN	O	O
with	NN	O	O
VAL	NN	O	O
/	NN	O	O
HCTZ	NN	O	O
320	NN	O	O
/	NN	O	O
25	NN	O	O
mg	NN	O	O
was	NN	O	O
24	NN	O	O
.	NN	O	O
7	NN	O	O
/	NN	O	O
16	NN	O	O
.	NN	O	O
6	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
5	NN	O	O
.	NN	O	O
9	NN	O	O
/	NN	O	O
7	NN	O	O
.	NN	O	O
0	NN	O	O
mm	NN	O	O
Hg	NN	O	O
with	NN	O	O
placebo	NN	O	O
.	NN	O	O

The	NN	O	O
reduction	NN	O	O
in	NN	O	O
MSSBP	NN	O	O
was	NN	O	O
significantly	NN	O	O
greater	NN	O	O
with	NN	O	O
VAL	NN	O	O
/	NN	O	O
HCTZ	NN	O	O
320	NN	O	O
/	NN	O	O
25	NN	O	O
mg	NN	O	O
compared	NN	O	O
with	NN	O	O
VAL	NN	O	O
/	NN	O	O
HCTZ	NN	O	O
160	NN	O	O
/	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
002	NN	O	O
)	NN	O	O
.	NN	O	O

Rates	NN	O	O
of	NN	O	O
response	NN	O	O
and	NN	O	O
BP	NN	O	O
control	NN	O	O
were	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
groups	NN	O	O
that	NN	O	O
received	NN	O	O
combination	NN	O	O
treatment	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
that	NN	O	O
received	NN	O	O
monotherapy	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
hypokalemia	NN	O	B
was	NN	O	O
lower	NN	O	O
with	NN	O	O
VAL	NN	O	O
/	NN	O	O
HCTZ	NN	O	O
combinations	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
than	NN	O	O
with	NN	O	O
HCTZ	NN	O	O
monotherapies	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
-	NN	O	O
13	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
majority	NN	O	O
of	NN	O	O
adverse	NN	O	O
events	NN	O	O
in	NN	O	O
the	NN	O	O
core	NN	O	O
study	NN	O	O
were	NN	O	O
of	NN	O	O
mild	NN	O	O
to	NN	O	O
moderate	NN	O	O
severity	NN	O	O
.	NN	O	O

The	NN	O	O
efficacy	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
VAL	NN	O	O
/	NN	O	O
HCTZ	NN	O	O
combinations	NN	O	O
were	NN	O	O
maintained	NN	O	O
during	NN	O	O
the	NN	O	O
extension	NN	O	O
(	NN	O	O
797	NN	O	O
patients	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
study	NN	O	O
population	NN	O	O
,	NN	O	O
combination	NN	O	O
therapies	NN	O	O
with	NN	O	O
VAL	NN	O	O
/	NN	O	O
HCTZ	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
significantly	NN	O	O
greater	NN	O	O
BP	NN	O	O
reductions	NN	O	O
compared	NN	O	O
with	NN	O	O
either	NN	O	O
monotherapy	NN	O	O
,	NN	O	O
were	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
less	NN	O	O
hypokalemia	NN	O	B
than	NN	O	O
HCTZ	NN	O	O
alone	NN	O	O
.	NN	O	O

Succimer	NN	O	O
chelation	NN	O	O
improves	NN	O	O
learning	NN	O	O
,	NN	O	O
attention	NN	O	O
,	NN	O	O
and	NN	O	O
arousal	NN	O	O
regulation	NN	O	O
in	NN	O	O
lead	NN	O	O
-	NN	O	O
exposed	NN	O	O
rats	NN	O	O
but	NN	O	O
produces	NN	O	O
lasting	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
lead	NN	O	O
exposure	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
There	NN	O	O
is	NN	O	O
growing	NN	O	O
pressure	NN	O	O
for	NN	O	O
clinicians	NN	O	O
to	NN	O	O
prescribe	NN	O	O
chelation	NN	O	O
therapy	NN	O	O
at	NN	O	O
only	NN	O	O
slightly	NN	O	O
elevated	NN	O	O
blood	NN	O	O
lead	NN	O	O
levels	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
very	NN	O	O
few	NN	O	O
studies	NN	O	O
have	NN	O	O
evaluated	NN	O	O
whether	NN	O	O
chelation	NN	O	O
improves	NN	O	O
cognitive	NN	O	O
outcomes	NN	O	O
in	NN	O	O
Pb	NN	O	O
-	NN	O	O
exposed	NN	O	O
children	NN	O	O
,	NN	O	O
or	NN	O	O
whether	NN	O	O
these	NN	O	O
agents	NN	O	O
have	NN	O	O
adverse	NN	O	O
effects	NN	O	O
that	NN	O	O
may	NN	O	O
affect	NN	O	O
brain	NN	O	O
development	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
Pb	NN	O	O
exposure	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
answer	NN	O	O
these	NN	O	O
questions	NN	O	O
,	NN	O	O
using	NN	O	O
a	NN	O	O
rodent	NN	O	O
model	NN	O	O
of	NN	O	O
early	NN	O	O
childhood	NN	O	O
Pb	NN	O	O
exposure	NN	O	O
and	NN	O	O
treatment	NN	O	O
with	NN	O	O
succimer	NN	O	O
,	NN	O	O
a	NN	O	O
widely	NN	O	O
used	NN	O	O
chelating	NN	O	O
agent	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
Pb	NN	O	B
poisoning	NN	O	I
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Pb	NN	O	O
exposure	NN	O	O
produced	NN	O	O
lasting	NN	O	O
impairments	NN	O	B
in	NN	O	I
learning	NN	O	I
,	NN	O	I
attention	NN	O	I
,	NN	O	I
inhibitory	NN	O	I
control	NN	O	I
,	NN	O	I
and	NN	O	I
arousal	NN	O	I
regulation	NN	O	I
,	NN	O	O
paralleling	NN	O	O
the	NN	O	O
areas	NN	O	O
of	NN	O	O
dysfunction	NN	O	O
seen	NN	O	O
in	NN	O	O
Pb	NN	O	O
-	NN	O	O
exposed	NN	O	O
children	NN	O	O
.	NN	O	O

Succimer	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
Pb	NN	O	O
-	NN	O	O
exposed	NN	O	O
rats	NN	O	O
significantly	NN	O	O
improved	NN	O	O
learning	NN	O	O
,	NN	O	O
attention	NN	O	O
,	NN	O	O
and	NN	O	O
arousal	NN	O	O
regulation	NN	O	O
,	NN	O	O
although	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
varied	NN	O	O
as	NN	O	O
a	NN	O	O
function	NN	O	O
of	NN	O	O
the	NN	O	O
Pb	NN	O	O
exposure	NN	O	O
level	NN	O	O
and	NN	O	O
the	NN	O	O
specific	NN	O	O
functional	NN	O	O
deficit	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
succimer	NN	O	O
treatment	NN	O	O
of	NN	O	O
rats	NN	O	O
not	NN	O	O
previously	NN	O	O
exposed	NN	O	O
to	NN	O	O
Pb	NN	O	O
produced	NN	O	O
lasting	NN	O	O
and	NN	O	O
pervasive	NN	O	O
cognitive	NN	O	B
and	NN	O	I
affective	NN	O	I
dysfunction	NN	O	I
comparable	NN	O	O
in	NN	O	O
magnitude	NN	O	O
to	NN	O	O
that	NN	O	O
produced	NN	O	O
by	NN	O	O
the	NN	O	O
higher	NN	O	O
Pb	NN	O	O
exposure	NN	O	O
regimen	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
are	NN	O	O
the	NN	O	O
first	NN	O	O
data	NN	O	O
,	NN	O	O
to	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
to	NN	O	O
show	NN	O	O
that	NN	O	O
treatment	NN	O	O
with	NN	O	O
any	NN	O	O
chelating	NN	O	O
agent	NN	O	O
can	NN	O	O
alleviate	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
due	NN	O	O
to	NN	O	O
Pb	NN	O	O
exposure	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
possible	NN	O	O
to	NN	O	O
identify	NN	O	O
a	NN	O	O
succimer	NN	O	O
treatment	NN	O	O
protocol	NN	O	O
that	NN	O	O
improves	NN	O	O
cognitive	NN	O	O
outcomes	NN	O	O
in	NN	O	O
Pb	NN	O	O
-	NN	O	O
exposed	NN	O	O
children	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
they	NN	O	O
also	NN	O	O
suggest	NN	O	O
that	NN	O	O
succimer	NN	O	O
treatment	NN	O	O
should	NN	O	O
be	NN	O	O
strongly	NN	O	O
discouraged	NN	O	O
for	NN	O	O
children	NN	O	O
who	NN	O	O
do	NN	O	O
not	NN	O	O
have	NN	O	O
elevated	NN	O	O
tissue	NN	O	O
levels	NN	O	O
of	NN	O	O
Pb	NN	O	O
or	NN	O	O
other	NN	O	O
heavy	NN	O	O
metals	NN	O	O
.	NN	O	O

Caffeine	NN	O	O
challenge	NN	O	O
test	NN	O	O
in	NN	O	O
panic	NN	O	B
disorder	NN	O	I
and	NN	O	O
depression	NN	O	B
with	NN	O	O
panic	NN	O	B
attacks	NN	O	I
.	NN	O	O

Our	NN	O	O
aim	NN	O	O
was	NN	O	O
to	NN	O	O
observe	NN	O	O
if	NN	O	O
patients	NN	O	O
with	NN	O	O
panic	NN	O	B
disorder	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
and	NN	O	O
patients	NN	O	O
with	NN	O	O
major	NN	O	B
depression	NN	O	I
with	NN	O	O
panic	NN	O	B
attacks	NN	O	I
(	NN	O	O
MDP	NN	O	B
)	NN	O	O
(	NN	O	O
Diagnostic	NN	O	O
and	NN	O	O
Statistical	NN	O	O
Manual	NN	O	O
of	NN	O	O
Mental	NN	O	B
Disorders	NN	O	I
,	NN	O	O
Fourth	NN	O	O
Edition	NN	O	O
criteria	NN	O	O
)	NN	O	O
respond	NN	O	O
in	NN	O	O
a	NN	O	O
similar	NN	O	O
way	NN	O	O
to	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
panic	NN	O	B
attacks	NN	O	I
by	NN	O	O
an	NN	O	O
oral	NN	O	O
caffeine	NN	O	O
challenge	NN	O	O
test	NN	O	O
.	NN	O	O

We	NN	O	O
randomly	NN	O	O
selected	NN	O	O
29	NN	O	O
patients	NN	O	O
with	NN	O	O
PD	NN	O	B
,	NN	O	O
27	NN	O	O
with	NN	O	O
MDP	NN	O	B
,	NN	O	O
25	NN	O	O
with	NN	O	O
major	NN	O	B
depression	NN	O	I
without	NN	O	O
panic	NN	O	B
attacks	NN	O	I
(	NN	O	O
MD	NN	O	B
)	NN	O	O
,	NN	O	O
and	NN	O	O
28	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
had	NN	O	O
no	NN	O	O
psychotropic	NN	O	O
drug	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
a	NN	O	O
4	NN	O	O
-	NN	O	O
week	NN	O	O
period	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
randomized	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
experiment	NN	O	O
performed	NN	O	O
in	NN	O	O
2	NN	O	O
occasions	NN	O	O
7	NN	O	O
days	NN	O	O
apart	NN	O	O
,	NN	O	O
480	NN	O	O
mg	NN	O	O
caffeine	NN	O	O
and	NN	O	O
a	NN	O	O
caffeine	NN	O	O
-	NN	O	O
free	NN	O	O
(	NN	O	O
placebo	NN	O	O
)	NN	O	O
solution	NN	O	O
were	NN	O	O
administered	NN	O	O
in	NN	O	O
a	NN	O	O
coffee	NN	O	O
form	NN	O	O
and	NN	O	O
anxiety	NN	O	B
scales	NN	O	O
were	NN	O	O
applied	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
each	NN	O	O
test	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
58	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
17	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
PD	NN	O	B
,	NN	O	O
44	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
MDP	NN	O	B
,	NN	O	O
12	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
3	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
MD	NN	O	B
,	NN	O	O
and	NN	O	O
7	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
2	NN	O	O
)	NN	O	O
of	NN	O	O
control	NN	O	O
subjects	NN	O	O
had	NN	O	O
a	NN	O	O
panic	NN	O	B
attack	NN	O	I
after	NN	O	O
the	NN	O	O
480	NN	O	O
-	NN	O	O
mg	NN	O	O
caffeine	NN	O	O
challenge	NN	O	O
test	NN	O	O
(	NN	O	O
chi	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
=	NN	O	O
16	NN	O	O
.	NN	O	O
22	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
with	NN	O	O
PD	NN	O	B
and	NN	O	O
MDP	NN	O	B
were	NN	O	O
more	NN	O	O
sensitive	NN	O	O
to	NN	O	O
caffeine	NN	O	O
than	NN	O	O
were	NN	O	O
patients	NN	O	O
with	NN	O	O
MD	NN	O	B
and	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
.	NN	O	O

No	NN	O	O
panic	NN	O	B
attack	NN	O	I
was	NN	O	O
observed	NN	O	O
after	NN	O	O
the	NN	O	O
caffeine	NN	O	O
-	NN	O	O
free	NN	O	O
solution	NN	O	O
intake	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
with	NN	O	O
MD	NN	O	B
had	NN	O	O
a	NN	O	O
lower	NN	O	O
heart	NN	O	O
rate	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
test	NN	O	O
than	NN	O	O
all	NN	O	O
the	NN	O	O
other	NN	O	O
groups	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
way	NN	O	O
analysis	NN	O	O
of	NN	O	O
variance	NN	O	O
,	NN	O	O
group	NN	O	O
by	NN	O	O
time	NN	O	O
interaction	NN	O	O
with	NN	O	O
Greenhouse	NN	O	O
-	NN	O	O
Geisser	NN	O	O
correction	NN	O	O
:	NN	O	O
F	NN	O	O
(	NN	O	O
3	NN	O	O
,	NN	O	O
762	NN	O	O
)	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
85	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
026	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
there	NN	O	O
is	NN	O	O
an	NN	O	O
association	NN	O	O
between	NN	O	O
panic	NN	O	B
attacks	NN	O	I
,	NN	O	O
no	NN	O	O
matter	NN	O	O
if	NN	O	O
associated	NN	O	O
with	NN	O	O
PD	NN	O	B
or	NN	O	O
MDP	NN	O	B
,	NN	O	O
and	NN	O	O
hyperreactivity	NN	O	O
to	NN	O	O
an	NN	O	O
oral	NN	O	O
caffeine	NN	O	O
challenge	NN	O	O
test	NN	O	O
.	NN	O	O

Mitral	NN	O	O
annuloplasty	NN	O	O
as	NN	O	O
a	NN	O	O
ventricular	NN	O	O
restoration	NN	O	O
method	NN	O	O
for	NN	O	O
the	NN	O	O
failing	NN	O	B
left	NN	O	I
ventricle	NN	O	I
:	NN	O	O
a	NN	O	O
pilot	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
AIM	NN	O	O
OF	NN	O	O
THE	NN	O	O
STUDY	NN	O	O
:	NN	O	O
Undersized	NN	O	O
mitral	NN	O	O
annuloplasty	NN	O	O
(	NN	O	O
MAP	NN	O	O
)	NN	O	O
is	NN	O	O
effective	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
dilated	NN	O	B
cardiomyopathy	NN	O	I
and	NN	O	O
functional	NN	O	O
mitral	NN	O	B
regurgitation	NN	O	I
(	NN	O	O
MR	NN	O	B
)	NN	O	O
since	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
addressing	NN	O	O
the	NN	O	O
MR	NN	O	B
,	NN	O	O
the	NN	O	O
MAP	NN	O	O
may	NN	O	O
also	NN	O	O
reshape	NN	O	O
the	NN	O	O
dilated	NN	O	O
left	NN	O	O
ventricular	NN	O	O
(	NN	O	O
LV	NN	O	O
)	NN	O	O
base	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
direct	NN	O	O
benefits	NN	O	O
of	NN	O	O
this	NN	O	O
possible	NN	O	O
reshaping	NN	O	O
on	NN	O	O
LV	NN	O	O
function	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
underlying	NN	O	O
MR	NN	O	B
remain	NN	O	O
incompletely	NN	O	O
understood	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
aim	NN	O	O
was	NN	O	O
to	NN	O	O
identify	NN	O	O
these	NN	O	O
benefits	NN	O	O
in	NN	O	O
a	NN	O	O
canine	NN	O	O
model	NN	O	O
of	NN	O	O
acute	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Six	NN	O	O
dogs	NN	O	O
underwent	NN	O	O
MAP	NN	O	O
with	NN	O	O
a	NN	O	O
prosthetic	NN	O	O
band	NN	O	O
on	NN	O	O
the	NN	O	O
posterior	NN	O	O
mitral	NN	O	O
annulus	NN	O	O
,	NN	O	O
using	NN	O	O
four	NN	O	O
mattress	NN	O	O
sutures	NN	O	O
.	NN	O	O

The	NN	O	O
sutures	NN	O	O
were	NN	O	O
passed	NN	O	O
individually	NN	O	O
through	NN	O	O
four	NN	O	O
tourniquets	NN	O	O
and	NN	O	O
exteriorized	NN	O	O
untied	NN	O	O
via	NN	O	O
the	NN	O	O
left	NN	O	O
atriotomy	NN	O	O
.	NN	O	O

Sonomicrometry	NN	O	O
crystals	NN	O	O
were	NN	O	O
implanted	NN	O	O
around	NN	O	O
the	NN	O	O
mitral	NN	O	O
annulus	NN	O	O
and	NN	O	O
left	NN	O	O
ventricle	NN	O	O
to	NN	O	O
measure	NN	O	O
geometry	NN	O	O
and	NN	O	O
regional	NN	O	O
function	NN	O	O
.	NN	O	O

Acute	NN	O	O
heart	NN	O	B
failure	NN	O	I
was	NN	O	O
induced	NN	O	O
by	NN	O	O
propranolol	NN	O	O
and	NN	O	O
volume	NN	O	O
loading	NN	O	O
after	NN	O	O
weaning	NN	O	O
from	NN	O	O
cardiopulmonary	NN	O	O
bypass	NN	O	O
;	NN	O	O
an	NN	O	O
absence	NN	O	O
of	NN	O	O
MR	NN	O	B
was	NN	O	O
confirmed	NN	O	O
by	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

MAP	NN	O	O
was	NN	O	O
accomplished	NN	O	O
by	NN	O	O
cinching	NN	O	O
the	NN	O	O
tourniquets	NN	O	O
.	NN	O	O

Data	NN	O	O
were	NN	O	O
acquired	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
after	NN	O	O
induction	NN	O	O
of	NN	O	O
acute	NN	O	O
heart	NN	O	B
failure	NN	O	I
,	NN	O	O
and	NN	O	O
after	NN	O	O
MAP	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
MAP	NN	O	O
decreased	NN	O	O
mitral	NN	O	O
annular	NN	O	O
dimensions	NN	O	O
in	NN	O	O
both	NN	O	O
commissure	NN	O	O
-	NN	O	O
commissure	NN	O	O
and	NN	O	O
septal	NN	O	O
-	NN	O	O
lateral	NN	O	O
directions	NN	O	O
.	NN	O	O

Concomitantly	NN	O	O
,	NN	O	O
the	NN	O	O
diastolic	NN	O	O
diameter	NN	O	O
of	NN	O	O
the	NN	O	O
LV	NN	O	O
base	NN	O	O
and	NN	O	O
LV	NN	O	O
sphericity	NN	O	O
decreased	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
,	NN	O	O
improved	NN	O	O
)	NN	O	O
from	NN	O	O
37	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O
3	NN	O	O
to	NN	O	O
35	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
mm	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
063	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
from	NN	O	O
67	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
18	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
to	NN	O	O
65	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
18	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
016	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Decreases	NN	O	O
were	NN	O	O
evident	NN	O	O
in	NN	O	O
both	NN	O	O
LV	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
(	NN	O	O
from	NN	O	O
17	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
to	NN	O	O
15	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
mmHg	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0480	NN	O	O
and	NN	O	O
Tau	NN	O	O
(	NN	O	O
from	NN	O	O
48	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
to	NN	O	O
45	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
ms	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
fractional	NN	O	O
shortening	NN	O	O
at	NN	O	O
the	NN	O	O
LV	NN	O	O
base	NN	O	O
increased	NN	O	O
from	NN	O	O
7	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
to	NN	O	O
9	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
045	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
MAP	NN	O	O
,	NN	O	O
increases	NN	O	O
were	NN	O	O
identified	NN	O	O
in	NN	O	O
both	NN	O	O
cardiac	NN	O	O
output	NN	O	O
(	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
54	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
57	NN	O	O
to	NN	O	O
1	NN	O	O
.	NN	O	O
65	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
57	NN	O	O
1	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
and	NN	O	O
Emax	NN	O	O
(	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
86	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
41	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
31	NN	O	O
mmHg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
data	NN	O	O
acquired	NN	O	O
suggest	NN	O	O
that	NN	O	O
isolated	NN	O	O
MAP	NN	O	O
may	NN	O	O
have	NN	O	O
certain	NN	O	O
benefits	NN	O	O
on	NN	O	O
LV	NN	O	O
dimension	NN	O	O
/	NN	O	O
function	NN	O	O
in	NN	O	O
acute	NN	O	O
heart	NN	O	B
failure	NN	O	I
,	NN	O	O
even	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
MR	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
further	NN	O	O
investigations	NN	O	O
are	NN	O	O
warranted	NN	O	O
in	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
chronic	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

Piperacillin	NN	O	O
/	NN	O	O
tazobactam	NN	O	O
-	NN	O	O
induced	NN	O	O
seizure	NN	O	B
rapidly	NN	O	O
reversed	NN	O	O
by	NN	O	O
high	NN	O	O
flux	NN	O	O
hemodialysis	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
on	NN	O	O
peritoneal	NN	O	O
dialysis	NN	O	O
.	NN	O	O

Despite	NN	O	O
popular	NN	O	O
use	NN	O	O
of	NN	O	O
piperacillin	NN	O	O
,	NN	O	O
the	NN	O	O
dire	NN	O	O
neurotoxicity	NN	O	B
associated	NN	O	O
with	NN	O	O
piperacillin	NN	O	O
still	NN	O	O
goes	NN	O	O
unrecognized	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
a	NN	O	O
delay	NN	O	O
in	NN	O	O
appropriate	NN	O	O
management	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
57	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
renal	NN	O	I
disease	NN	O	I
receiving	NN	O	O
continuous	NN	O	O
ambulatory	NN	O	O
peritoneal	NN	O	O
dialysis	NN	O	O
(	NN	O	O
CAPD	NN	O	O
)	NN	O	O
,	NN	O	O
who	NN	O	O
developed	NN	O	O
slurred	NN	O	O
speech	NN	O	O
,	NN	O	O
tremor	NN	O	B
,	NN	O	O
bizarre	NN	O	O
behavior	NN	O	O
,	NN	O	O
progressive	NN	O	O
mental	NN	O	O
confusion	NN	O	B
,	NN	O	O
and	NN	O	O
2	NN	O	O
episodes	NN	O	O
of	NN	O	O
generalized	NN	O	O
tonic	NN	O	B
-	NN	O	I
clonic	NN	O	I
seizure	NN	O	I
(	NN	O	O
GTCS	NN	O	B
)	NN	O	O
after	NN	O	O
5	NN	O	O
doses	NN	O	O
of	NN	O	O
piperacillin	NN	O	O
/	NN	O	O
tazobactam	NN	O	O
(	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
250	NN	O	O
mg	NN	O	O
)	NN	O	O
were	NN	O	O
given	NN	O	O
for	NN	O	O
bronchiectasis	NN	O	B
with	NN	O	O
secondary	NN	O	B
infection	NN	O	I
.	NN	O	O

The	NN	O	O
laboratory	NN	O	O
data	NN	O	O
revealed	NN	O	O
normal	NN	O	O
plasma	NN	O	O
electrolyte	NN	O	O
and	NN	O	O
ammonia	NN	O	O
levels	NN	O	O
but	NN	O	O
leukocytosis	NN	O	B
.	NN	O	O

Neurologic	NN	O	O
examinations	NN	O	O
showed	NN	O	O
dysarthria	NN	O	B
and	NN	O	O
bilateral	NN	O	O
Babinski	NN	O	O
sign	NN	O	O
.	NN	O	O

Computed	NN	O	O
tomography	NN	O	O
of	NN	O	O
brain	NN	O	O
and	NN	O	O
electroencephalogram	NN	O	O
were	NN	O	O
unremarkable	NN	O	O
.	NN	O	O

Despite	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
antiepileptic	NN	O	O
agents	NN	O	O
,	NN	O	O
another	NN	O	O
GTCS	NN	O	B
episode	NN	O	O
recurred	NN	O	O
after	NN	O	O
the	NN	O	O
sixth	NN	O	O
dose	NN	O	O
of	NN	O	O
piperacillin	NN	O	O
/	NN	O	O
tazobactam	NN	O	O
.	NN	O	O

Brain	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
did	NN	O	O
not	NN	O	O
demonstrate	NN	O	O
acute	NN	O	O
infarction	NN	O	B
and	NN	O	O
organic	NN	O	B
brain	NN	O	I
lesions	NN	O	I
.	NN	O	O

Initiation	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
flux	NN	O	O
hemodialysis	NN	O	O
rapidly	NN	O	O
reversed	NN	O	O
the	NN	O	O
neurologic	NN	O	O
symptoms	NN	O	O
within	NN	O	O
4	NN	O	O
hours	NN	O	O
.	NN	O	O

Piperacillin	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
should	NN	O	O
be	NN	O	O
considered	NN	O	O
in	NN	O	O
any	NN	O	O
uremic	NN	O	B
patients	NN	O	O
with	NN	O	O
unexplained	NN	O	O
neurological	NN	O	O
manifestations	NN	O	O
.	NN	O	O

CAPD	NN	O	O
is	NN	O	O
inefficient	NN	O	O
in	NN	O	O
removing	NN	O	O
piperacillin	NN	O	O
,	NN	O	O
whereas	NN	O	O
hemodialysis	NN	O	O
can	NN	O	O
rapidly	NN	O	O
terminate	NN	O	O
the	NN	O	O
piperacillin	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
.	NN	O	O

Frequency	NN	O	O
of	NN	O	O
transient	NN	O	O
ipsilateral	NN	O	O
vocal	NN	O	B
cord	NN	O	I
paralysis	NN	O	I
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
carotid	NN	O	O
endarterectomy	NN	O	O
under	NN	O	O
local	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Especially	NN	O	O
because	NN	O	O
of	NN	O	O
improvements	NN	O	O
in	NN	O	O
clinical	NN	O	O
neurologic	NN	O	O
monitoring	NN	O	O
,	NN	O	O
carotid	NN	O	O
endarterectomy	NN	O	O
done	NN	O	O
under	NN	O	O
local	NN	O	O
anesthesia	NN	O	O
has	NN	O	O
become	NN	O	O
the	NN	O	O
technique	NN	O	O
of	NN	O	O
choice	NN	O	O
in	NN	O	O
several	NN	O	O
centers	NN	O	O
.	NN	O	O

Temporary	NN	O	O
ipsilateral	NN	O	O
vocal	NN	O	B
nerve	NN	O	I
palsies	NN	O	I
due	NN	O	O
to	NN	O	O
local	NN	O	O
anesthetics	NN	O	O
have	NN	O	O
been	NN	O	O
described	NN	O	O
,	NN	O	O
however	NN	O	O
.	NN	O	O

Such	NN	O	O
complications	NN	O	O
are	NN	O	O
most	NN	O	O
important	NN	O	O
in	NN	O	O
situations	NN	O	O
where	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
contralateral	NN	O	O
paralysis	NN	O	B
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
examined	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
local	NN	O	O
anesthesia	NN	O	O
on	NN	O	O
vocal	NN	O	O
cord	NN	O	O
function	NN	O	O
to	NN	O	O
better	NN	O	O
understand	NN	O	O
its	NN	O	O
possible	NN	O	O
consequences	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
prospective	NN	O	O
study	NN	O	O
included	NN	O	O
28	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
carotid	NN	O	O
endarterectomy	NN	O	O
under	NN	O	O
local	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

Vocal	NN	O	O
cord	NN	O	O
function	NN	O	O
was	NN	O	O
evaluated	NN	O	O
before	NN	O	O
,	NN	O	O
during	NN	O	O
,	NN	O	O
and	NN	O	O
after	NN	O	O
surgery	NN	O	O
(	NN	O	O
postoperative	NN	O	O
day	NN	O	O
1	NN	O	O
)	NN	O	O
using	NN	O	O
flexible	NN	O	O
laryngoscopy	NN	O	O
.	NN	O	O

Anesthesia	NN	O	O
was	NN	O	O
performed	NN	O	O
by	NN	O	O
injecting	NN	O	O
20	NN	O	O
to	NN	O	O
40	NN	O	O
mL	NN	O	O
of	NN	O	O
a	NN	O	O
mixture	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
acting	NN	O	O
(	NN	O	O
ropivacaine	NN	O	O
)	NN	O	O
and	NN	O	O
short	NN	O	O
-	NN	O	O
acting	NN	O	O
(	NN	O	O
prilocaine	NN	O	O
)	NN	O	O
anesthetic	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
All	NN	O	O
patients	NN	O	O
had	NN	O	O
normal	NN	O	O
vocal	NN	O	O
cord	NN	O	O
function	NN	O	O
preoperatively	NN	O	O
.	NN	O	O

Twelve	NN	O	O
patients	NN	O	O
(	NN	O	O
43	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
intraoperative	NN	O	O
ipsilateral	NN	O	O
vocal	NN	O	B
cord	NN	O	I
paralysis	NN	O	I
.	NN	O	O

It	NN	O	O
resolved	NN	O	O
in	NN	O	O
all	NN	O	O
cases	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
24	NN	O	O
hours	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
operating	NN	O	O
time	NN	O	O
or	NN	O	O
volume	NN	O	O
or	NN	O	O
frequency	NN	O	O
of	NN	O	O
anesthetic	NN	O	O
administration	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
temporary	NN	O	O
vocal	NN	O	B
cord	NN	O	I
paralysis	NN	O	I
compared	NN	O	O
with	NN	O	O
those	NN	O	O
without	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Local	NN	O	O
anesthesia	NN	O	O
led	NN	O	O
to	NN	O	O
temporary	NN	O	O
ipsilateral	NN	O	O
vocal	NN	O	B
cord	NN	O	I
paralysis	NN	O	I
in	NN	O	O
almost	NN	O	O
half	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

Because	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
paralysis	NN	O	B
is	NN	O	O
of	NN	O	O
a	NN	O	O
relevant	NN	O	O
frequency	NN	O	O
(	NN	O	O
up	NN	O	O
to	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
preoperative	NN	O	O
evaluation	NN	O	O
of	NN	O	O
vocal	NN	O	O
cord	NN	O	O
function	NN	O	O
before	NN	O	O
carotid	NN	O	O
endarterectomy	NN	O	O
under	NN	O	O
local	NN	O	O
anesthesia	NN	O	O
is	NN	O	O
recommended	NN	O	O
to	NN	O	O
avoid	NN	O	O
intraoperative	NN	O	O
bilateral	NN	O	O
paralysis	NN	O	B
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
preoperative	NN	O	O
contralateral	NN	O	O
vocal	NN	O	B
cord	NN	O	I
paralysis	NN	O	I
,	NN	O	O
surgery	NN	O	O
under	NN	O	O
general	NN	O	O
anesthesia	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
.	NN	O	O

Impaired	NN	O	B
fear	NN	O	I
recognition	NN	O	I
in	NN	O	O
regular	NN	O	O
recreational	NN	O	O
cocaine	NN	O	O
users	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
The	NN	O	O
ability	NN	O	O
to	NN	O	O
read	NN	O	O
facial	NN	O	O
expressions	NN	O	O
is	NN	O	O
essential	NN	O	O
for	NN	O	O
normal	NN	O	O
human	NN	O	O
social	NN	O	O
interaction	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
conduct	NN	O	O
the	NN	O	O
first	NN	O	O
investigation	NN	O	O
of	NN	O	O
facial	NN	O	O
expression	NN	O	O
recognition	NN	O	O
performance	NN	O	O
in	NN	O	O
recreational	NN	O	O
cocaine	NN	O	O
users	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Three	NN	O	O
groups	NN	O	O
,	NN	O	O
comprised	NN	O	O
of	NN	O	O
21	NN	O	O
cocaine	NN	O	O
naive	NN	O	O
participants	NN	O	O
(	NN	O	O
CN	NN	O	O
)	NN	O	O
,	NN	O	O
30	NN	O	O
occasional	NN	O	O
cocaine	NN	O	O
(	NN	O	O
OC	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
48	NN	O	O
regular	NN	O	O
recreational	NN	O	O
cocaine	NN	O	O
(	NN	O	O
RC	NN	O	O
)	NN	O	O
users	NN	O	O
,	NN	O	O
were	NN	O	O
compared	NN	O	O
.	NN	O	O

An	NN	O	O
emotional	NN	O	O
facial	NN	O	O
expression	NN	O	O
(	NN	O	O
EFE	NN	O	O
)	NN	O	O
task	NN	O	O
consisting	NN	O	O
of	NN	O	O
a	NN	O	O
male	NN	O	O
and	NN	O	O
female	NN	O	O
face	NN	O	O
expressing	NN	O	O
six	NN	O	O
basic	NN	O	O
emotions	NN	O	O
(	NN	O	O
happiness	NN	O	O
,	NN	O	O
surprise	NN	O	O
,	NN	O	O
sadness	NN	O	O
,	NN	O	O
anger	NN	O	O
,	NN	O	O
fear	NN	O	O
,	NN	O	O
and	NN	O	O
disgust	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
.	NN	O	O

Mean	NN	O	O
percent	NN	O	O
accuracy	NN	O	O
and	NN	O	O
latencies	NN	O	O
for	NN	O	O
correct	NN	O	O
responses	NN	O	O
across	NN	O	O
eight	NN	O	O
presentations	NN	O	O
of	NN	O	O
each	NN	O	O
basic	NN	O	O
emotion	NN	O	O
were	NN	O	O
derived	NN	O	O
.	NN	O	O

Participants	NN	O	O
were	NN	O	O
also	NN	O	O
assessed	NN	O	O
with	NN	O	O
the	NN	O	O
"	NN	O	O
Eyes	NN	O	O
task	NN	O	O
"	NN	O	O
to	NN	O	O
investigate	NN	O	O
their	NN	O	O
ability	NN	O	O
to	NN	O	O
recognize	NN	O	O
more	NN	O	O
complex	NN	O	O
emotional	NN	O	O
states	NN	O	O
and	NN	O	O
the	NN	O	O
Symptom	NN	O	O
CheckList	NN	O	O
-	NN	O	O
90	NN	O	O
-	NN	O	O
Revised	NN	O	O
to	NN	O	O
measure	NN	O	O
psychopathology	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
There	NN	O	O
were	NN	O	O
no	NN	O	O
group	NN	O	O
differences	NN	O	O
in	NN	O	O
psychopathology	NN	O	O
or	NN	O	O
"	NN	O	O
eyes	NN	O	O
task	NN	O	O
"	NN	O	O
performance	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
RC	NN	O	O
group	NN	O	O
,	NN	O	O
who	NN	O	O
otherwise	NN	O	O
had	NN	O	O
similar	NN	O	O
illicit	NN	O	O
substance	NN	O	O
use	NN	O	O
histories	NN	O	O
to	NN	O	O
the	NN	O	O
OC	NN	O	O
group	NN	O	O
,	NN	O	O
exhibited	NN	O	O
impaired	NN	O	B
fear	NN	O	I
recognition	NN	O	I
accuracy	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
OC	NN	O	O
and	NN	O	O
CN	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
RC	NN	O	O
group	NN	O	O
also	NN	O	O
correctly	NN	O	O
identified	NN	O	O
anger	NN	O	O
,	NN	O	O
fear	NN	O	O
,	NN	O	O
happiness	NN	O	O
,	NN	O	O
and	NN	O	O
surprise	NN	O	O
,	NN	O	O
more	NN	O	O
slowly	NN	O	O
than	NN	O	O
CN	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
OC	NN	O	O
participants	NN	O	O
.	NN	O	O

The	NN	O	O
OC	NN	O	O
group	NN	O	O
was	NN	O	O
slower	NN	O	O
than	NN	O	O
CN	NN	O	O
when	NN	O	O
correctly	NN	O	O
identifying	NN	O	O
disgust	NN	O	O
.	NN	O	O

The	NN	O	O
selective	NN	O	O
deficit	NN	O	B
in	NN	O	I
fear	NN	O	I
recognition	NN	O	I
accuracy	NN	O	O
manifested	NN	O	O
by	NN	O	O
the	NN	O	O
RC	NN	O	O
group	NN	O	O
cannot	NN	O	O
be	NN	O	O
explained	NN	O	O
by	NN	O	O
the	NN	O	O
subacute	NN	O	O
effects	NN	O	O
of	NN	O	O
cocaine	NN	O	O
,	NN	O	O
or	NN	O	O
ecstasy	NN	O	O
,	NN	O	O
because	NN	O	O
recent	NN	O	O
and	NN	O	O
less	NN	O	O
recent	NN	O	O
users	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
within	NN	O	O
this	NN	O	O
group	NN	O	O
were	NN	O	O
similarly	NN	O	O
impaired	NN	O	O
.	NN	O	O

Possible	NN	O	O
parallels	NN	O	O
between	NN	O	O
RC	NN	O	O
users	NN	O	O
and	NN	O	O
psychopaths	NN	O	B
with	NN	O	O
respect	NN	O	O
to	NN	O	O
impaired	NN	O	B
fear	NN	O	I
recognition	NN	O	I
,	NN	O	O
amygdala	NN	O	B
dysfunction	NN	O	I
,	NN	O	O
and	NN	O	O
etiology	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Damage	NN	O	B
of	NN	O	I
substantia	NN	O	I
nigra	NN	O	I
pars	NN	O	I
reticulata	NN	O	I
during	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
in	NN	O	O
the	NN	O	O
rat	NN	O	O
:	NN	O	O
immunohistochemical	NN	O	O
study	NN	O	O
of	NN	O	O
neurons	NN	O	O
,	NN	O	O
astrocytes	NN	O	O
and	NN	O	O
serum	NN	O	O
-	NN	O	O
protein	NN	O	O
extravasation	NN	O	O
.	NN	O	O

The	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
has	NN	O	O
a	NN	O	O
gating	NN	O	O
function	NN	O	O
controlling	NN	O	O
the	NN	O	O
spread	NN	O	O
of	NN	O	O
epileptic	NN	O	B
seizure	NN	O	I
activity	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
in	NN	O	O
models	NN	O	O
of	NN	O	O
prolonged	NN	O	B
status	NN	O	I
epilepticus	NN	O	I
the	NN	O	O
pars	NN	O	O
reticulata	NN	O	O
of	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
(	NN	O	O
SNR	NN	O	O
)	NN	O	O
suffers	NN	O	O
from	NN	O	O
a	NN	O	O
massive	NN	O	O
lesion	NN	O	O
which	NN	O	O
may	NN	O	O
arise	NN	O	O
from	NN	O	O
a	NN	O	O
massive	NN	O	O
metabolic	NN	O	B
derangement	NN	O	I
and	NN	O	O
hyperexcitation	NN	O	O
developing	NN	O	O
in	NN	O	O
the	NN	O	O
activated	NN	O	O
SNR	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
was	NN	O	O
induced	NN	O	O
by	NN	O	O
systemic	NN	O	O
injection	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
neuropathology	NN	O	O
of	NN	O	O
SNR	NN	O	O
was	NN	O	O
investigated	NN	O	O
using	NN	O	O
immunohistochemical	NN	O	O
techniques	NN	O	O
with	NN	O	O
the	NN	O	O
major	NN	O	O
emphasis	NN	O	O
on	NN	O	O
the	NN	O	O
time	NN	O	O
-	NN	O	O
course	NN	O	O
of	NN	O	O
changes	NN	O	O
in	NN	O	O
neurons	NN	O	O
and	NN	O	O
astrocytes	NN	O	O
.	NN	O	O

Animals	NN	O	O
surviving	NN	O	O
20	NN	O	O
,	NN	O	O
30	NN	O	O
,	NN	O	O
40	NN	O	O
,	NN	O	O
60	NN	O	O
min	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
6	NN	O	O
hours	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
days	NN	O	O
after	NN	O	O
induction	NN	O	O
of	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
were	NN	O	O
perfusion	NN	O	O
-	NN	O	O
fixed	NN	O	O
,	NN	O	O
and	NN	O	O
brains	NN	O	O
processed	NN	O	O
for	NN	O	O
immunohistochemical	NN	O	O
staining	NN	O	O
of	NN	O	O
SNR	NN	O	O
.	NN	O	O

Nissl	NN	O	O
-	NN	O	O
staining	NN	O	O
and	NN	O	O
antibodies	NN	O	O
against	NN	O	O
the	NN	O	O
neuron	NN	O	O
-	NN	O	O
specific	NN	O	O
calcium	NN	O	O
-	NN	O	O
binding	NN	O	O
protein	NN	O	O
,	NN	O	O
parvalbumin	NN	O	O
,	NN	O	O
served	NN	O	O
to	NN	O	O
detect	NN	O	O
neuronal	NN	O	B
damage	NN	O	I
in	NN	O	O
SNR	NN	O	O
.	NN	O	O

Antibodies	NN	O	O
against	NN	O	O
the	NN	O	O
astroglia	NN	O	O
-	NN	O	O
specific	NN	O	O
cytoskeletal	NN	O	O
protein	NN	O	O
,	NN	O	O
glial	NN	O	O
fibrillary	NN	O	O
acidic	NN	O	O
protein	NN	O	O
(	NN	O	O
GFAP	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
against	NN	O	O
the	NN	O	O
glial	NN	O	O
calcium	NN	O	O
-	NN	O	O
binding	NN	O	O
protein	NN	O	O
,	NN	O	O
S	NN	O	O
-	NN	O	O
100	NN	O	O
protein	NN	O	O
,	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
status	NN	O	O
of	NN	O	O
astrocytes	NN	O	O
.	NN	O	O

Immunohistochemical	NN	O	O
staining	NN	O	O
for	NN	O	O
serum	NN	O	O
-	NN	O	O
albumin	NN	O	O
and	NN	O	O
immunoglobulins	NN	O	O
in	NN	O	O
brain	NN	O	O
tissue	NN	O	O
was	NN	O	O
taken	NN	O	O
as	NN	O	O
indicator	NN	O	O
of	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
disturbances	NN	O	O
and	NN	O	O
vasogenic	NN	O	B
edema	NN	O	I
formation	NN	O	O
.	NN	O	O

Immunohistochemical	NN	O	O
staining	NN	O	O
indicated	NN	O	O
loss	NN	O	O
of	NN	O	O
GFAP	NN	O	O
-	NN	O	O
staining	NN	O	O
already	NN	O	O
at	NN	O	O
30	NN	O	O
min	NN	O	O
after	NN	O	O
induction	NN	O	O
of	NN	O	O
seizures	NN	O	B
in	NN	O	O
an	NN	O	O
oval	NN	O	O
focus	NN	O	O
situated	NN	O	O
in	NN	O	O
the	NN	O	O
center	NN	O	O
of	NN	O	O
SNR	NN	O	O
while	NN	O	O
sparing	NN	O	O
medial	NN	O	O
and	NN	O	O
lateral	NN	O	O
aspects	NN	O	O
.	NN	O	O

At	NN	O	O
1	NN	O	O
h	NN	O	O
there	NN	O	O
was	NN	O	O
additional	NN	O	O
vacuolation	NN	O	O
in	NN	O	O
S	NN	O	O
-	NN	O	O
100	NN	O	O
protein	NN	O	O
staining	NN	O	O
.	NN	O	O

By	NN	O	O
2	NN	O	O
hours	NN	O	O
,	NN	O	O
parvalbumin	NN	O	O
-	NN	O	O
staining	NN	O	O
changed	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
SNR	NN	O	O
indicating	NN	O	O
neuronal	NN	O	B
damage	NN	O	I
,	NN	O	O
and	NN	O	O
Nissl	NN	O	O
-	NN	O	O
staining	NN	O	O
visualized	NN	O	O
some	NN	O	O
neuronal	NN	O	O
distortion	NN	O	O
.	NN	O	O

Staining	NN	O	O
for	NN	O	O
serum	NN	O	O
-	NN	O	O
proteins	NN	O	O
occurred	NN	O	O
in	NN	O	O
a	NN	O	O
patchy	NN	O	O
manner	NN	O	O
throughout	NN	O	O
the	NN	O	O
forebrain	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
hours	NN	O	O
.	NN	O	O

By	NN	O	O
6	NN	O	O
h	NN	O	O
,	NN	O	O
vasogenic	NN	O	B
edema	NN	O	I
covered	NN	O	O
the	NN	O	O
lesioned	NN	O	B
SNR	NN	O	I
.	NN	O	O

By	NN	O	O
24	NN	O	O
h	NN	O	O
,	NN	O	O
glial	NN	O	O
and	NN	O	O
neuronal	NN	O	O
markers	NN	O	O
indicated	NN	O	O
a	NN	O	O
massive	NN	O	O
lesion	NN	O	O
in	NN	O	O
the	NN	O	O
center	NN	O	O
of	NN	O	O
SNR	NN	O	O
.	NN	O	O

By	NN	O	O
48	NN	O	O
-	NN	O	O
72	NN	O	O
h	NN	O	O
,	NN	O	O
astrocytes	NN	O	O
surrounding	NN	O	O
the	NN	O	O
lesion	NN	O	O
increased	NN	O	O
in	NN	O	O
size	NN	O	O
,	NN	O	O
and	NN	O	O
polymorphic	NN	O	O
phagocytotic	NN	O	O
cells	NN	O	O
invaded	NN	O	O
the	NN	O	O
damaged	NN	O	O
area	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
further	NN	O	O
group	NN	O	O
of	NN	O	O
animals	NN	O	O
surviving	NN	O	O
1	NN	O	O
to	NN	O	O
5	NN	O	O
days	NN	O	O
,	NN	O	O
conventional	NN	O	O
paraffin	NN	O	O
-	NN	O	O
sections	NN	O	O
confirmed	NN	O	O
the	NN	O	O
neuronal	NN	O	O
and	NN	O	O
glial	NN	O	O
damage	NN	O	B
of	NN	O	I
SNR	NN	O	I
.	NN	O	O

Additional	NN	O	O
pathology	NN	O	O
of	NN	O	O
similar	NN	O	O
quality	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
globus	NN	O	O
pallidus	NN	O	O
.	NN	O	O

Since	NN	O	O
astrocytes	NN	O	O
were	NN	O	O
always	NN	O	O
damaged	NN	O	O
in	NN	O	O
parallel	NN	O	O
with	NN	O	O
neurons	NN	O	O
in	NN	O	O
SNR	NN	O	O
it	NN	O	O
is	NN	O	O
proposed	NN	O	O
that	NN	O	O
the	NN	O	O
anatomical	NN	O	O
and	NN	O	O
functional	NN	O	O
interrelationship	NN	O	O
between	NN	O	O
neurons	NN	O	O
and	NN	O	O
astrocytes	NN	O	O
is	NN	O	O
particularly	NN	O	O
tight	NN	O	O
in	NN	O	O
SNR	NN	O	O
.	NN	O	O

Both	NN	O	O
cell	NN	O	O
elements	NN	O	O
may	NN	O	O
suffer	NN	O	O
in	NN	O	O
common	NN	O	O
from	NN	O	O
metabolic	NN	O	O
disturbance	NN	O	O
and	NN	O	O
neurotransmitter	NN	O	B
dysfunction	NN	O	I
as	NN	O	O
occur	NN	O	O
during	NN	O	O
massive	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
.	NN	O	O

Neuroprotective	NN	O	O
effects	NN	O	O
of	NN	O	O
melatonin	NN	O	O
upon	NN	O	O
the	NN	O	O
offspring	NN	O	O
cerebellar	NN	O	O
cortex	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
BCNU	NN	O	O
-	NN	O	O
induced	NN	O	O
cortical	NN	O	B
dysplasia	NN	O	I
.	NN	O	O

Cortical	NN	O	B
dysplasia	NN	O	I
is	NN	O	O
a	NN	O	O
malformation	NN	O	O
characterized	NN	O	O
by	NN	O	O
defects	NN	O	O
in	NN	O	O
proliferation	NN	O	O
,	NN	O	O
migration	NN	O	O
and	NN	O	O
maturation	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
alterations	NN	O	O
in	NN	O	O
offspring	NN	O	O
rat	NN	O	O
cerebellum	NN	O	O
induced	NN	O	O
by	NN	O	O
maternal	NN	O	O
exposure	NN	O	O
to	NN	O	O
carmustine	NN	O	O
-	NN	O	O
[	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
bis	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
chloroethyl	NN	O	O
)	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
nitrosoure	NN	O	O
]	NN	O	O
(	NN	O	O
BCNU	NN	O	O
)	NN	O	O
and	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
exogenous	NN	O	O
melatonin	NN	O	O
upon	NN	O	O
cerebellar	NN	O	O
BCNU	NN	O	O
-	NN	O	O
induced	NN	O	O
cortical	NN	O	B
dysplasia	NN	O	I
,	NN	O	O
using	NN	O	O
histological	NN	O	O
and	NN	O	O
biochemical	NN	O	O
analyses	NN	O	O
.	NN	O	O

Pregnant	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
five	NN	O	O
groups	NN	O	O
:	NN	O	O
intact	NN	O	O
-	NN	O	O
control	NN	O	O
,	NN	O	O
saline	NN	O	O
-	NN	O	O
control	NN	O	O
,	NN	O	O
melatonin	NN	O	O
-	NN	O	O
treated	NN	O	O
,	NN	O	O
BCNU	NN	O	O
-	NN	O	O
exposed	NN	O	O
and	NN	O	O
BCNU	NN	O	O
-	NN	O	O
exposed	NN	O	O
plus	NN	O	O
melatonin	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
exposed	NN	O	O
to	NN	O	O
BCNU	NN	O	O
on	NN	O	O
embryonic	NN	O	O
day	NN	O	O
15	NN	O	O
and	NN	O	O
melatonin	NN	O	O
was	NN	O	O
given	NN	O	O
until	NN	O	O
delivery	NN	O	O
.	NN	O	O

Immuno	NN	O	O
/	NN	O	O
histochemistry	NN	O	O
and	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
were	NN	O	O
carried	NN	O	O
out	NN	O	O
on	NN	O	O
the	NN	O	O
offspring	NN	O	O
cerebellum	NN	O	O
,	NN	O	O
and	NN	O	O
levels	NN	O	O
of	NN	O	O
malondialdehyde	NN	O	O
and	NN	O	O
superoxide	NN	O	O
dismutase	NN	O	O
were	NN	O	O
determined	NN	O	O
.	NN	O	O

Histopathologically	NN	O	O
,	NN	O	O
typical	NN	O	O
findings	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
cerebella	NN	O	O
from	NN	O	O
the	NN	O	O
control	NN	O	O
groups	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
findings	NN	O	O
consistent	NN	O	O
with	NN	O	O
early	NN	O	O
embryonic	NN	O	O
development	NN	O	O
were	NN	O	O
noted	NN	O	O
in	NN	O	O
BCNU	NN	O	O
-	NN	O	O
exposed	NN	O	O
cortical	NN	O	B
dysplasia	NN	O	I
group	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
marked	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
TUNEL	NN	O	O
positive	NN	O	O
cells	NN	O	O
and	NN	O	O
nestin	NN	O	O
positive	NN	O	O
cells	NN	O	O
in	NN	O	O
BCNU	NN	O	O
-	NN	O	O
exposed	NN	O	O
group	NN	O	O
,	NN	O	O
but	NN	O	O
a	NN	O	O
decreased	NN	O	O
immunoreactivity	NN	O	O
to	NN	O	O
glial	NN	O	O
fibrillary	NN	O	O
acidic	NN	O	O
protein	NN	O	O
,	NN	O	O
synaptophysin	NN	O	O
and	NN	O	O
transforming	NN	O	O
growth	NN	O	O
factor	NN	O	O
beta1	NN	O	O
was	NN	O	O
observed	NN	O	O
,	NN	O	O
indicating	NN	O	O
a	NN	O	O
delayed	NN	O	O
maturation	NN	O	O
,	NN	O	O
and	NN	O	O
melatonin	NN	O	O
significantly	NN	O	O
reversed	NN	O	O
these	NN	O	O
changes	NN	O	O
.	NN	O	O

Malondialdehyde	NN	O	O
level	NN	O	O
in	NN	O	O
BCNU	NN	O	O
-	NN	O	O
exposed	NN	O	O
group	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
those	NN	O	O
in	NN	O	O
control	NN	O	O
groups	NN	O	O
and	NN	O	O
melatonin	NN	O	O
decreased	NN	O	O
malondialdehyde	NN	O	O
levels	NN	O	O
in	NN	O	O
BCNU	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
superoxide	NN	O	O
dismutase	NN	O	O
levels	NN	O	O
between	NN	O	O
these	NN	O	O
groups	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
exposure	NN	O	O
of	NN	O	O
animals	NN	O	O
to	NN	O	O
BCNU	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
leads	NN	O	O
to	NN	O	O
delayed	NN	O	O
maturation	NN	O	O
of	NN	O	O
offspring	NN	O	O
cerebellum	NN	O	O
and	NN	O	O
melatonin	NN	O	O
protects	NN	O	O
the	NN	O	O
cerebellum	NN	O	O
against	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
BCNU	NN	O	O
.	NN	O	O

Reduced	NN	O	O
cardiotoxicity	NN	O	B
of	NN	O	O
doxorubicin	NN	O	O
given	NN	O	O
in	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
N	NN	O	O
-	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
hydroxypropyl	NN	O	O
)	NN	O	O
methacrylamide	NN	O	O
conjugates	NN	O	O
:	NN	O	O
and	NN	O	O
experimental	NN	O	O
study	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

A	NN	O	O
rat	NN	O	O
model	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
general	NN	O	O
acute	NN	O	O
toxicity	NN	O	B
and	NN	O	O
the	NN	O	O
late	NN	O	O
cardiotoxicity	NN	O	B
of	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
DOX	NN	O	O
)	NN	O	O
given	NN	O	O
either	NN	O	O
as	NN	O	O
free	NN	O	O
drug	NN	O	O
or	NN	O	O
in	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
three	NN	O	O
N	NN	O	O
-	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
hydroxypropyl	NN	O	O
)	NN	O	O
methacrylamide	NN	O	O
(	NN	O	O
HPMA	NN	O	O
)	NN	O	O
copolymer	NN	O	O
conjugates	NN	O	O
.	NN	O	O

In	NN	O	O
these	NN	O	O
HPMA	NN	O	O
copolymers	NN	O	O
,	NN	O	O
DOX	NN	O	O
was	NN	O	O
covalently	NN	O	O
bound	NN	O	O
via	NN	O	O
peptide	NN	O	O
linkages	NN	O	O
that	NN	O	O
were	NN	O	O
either	NN	O	O
non	NN	O	O
-	NN	O	O
biodegradable	NN	O	O
(	NN	O	O
Gly	NN	O	O
-	NN	O	O
Gly	NN	O	O
)	NN	O	O
or	NN	O	O
degradable	NN	O	O
by	NN	O	O
lysosomal	NN	O	O
proteinases	NN	O	O
(	NN	O	O
Gly	NN	O	O
-	NN	O	O
Phe	NN	O	O
-	NN	O	O
Leu	NN	O	O
-	NN	O	O
Gly	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
one	NN	O	O
biodegradable	NN	O	O
conjugate	NN	O	O
containing	NN	O	O
galactosamine	NN	O	O
was	NN	O	O
used	NN	O	O
;	NN	O	O
this	NN	O	O
residue	NN	O	O
was	NN	O	O
targeted	NN	O	O
to	NN	O	O
the	NN	O	O
liver	NN	O	O
.	NN	O	O

Over	NN	O	O
the	NN	O	O
first	NN	O	O
3	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
administration	NN	O	O
of	NN	O	O
free	NN	O	O
and	NN	O	O
polymer	NN	O	O
-	NN	O	O
bound	NN	O	O
DOX	NN	O	O
,	NN	O	O
all	NN	O	O
animals	NN	O	O
showed	NN	O	O
a	NN	O	O
transient	NN	O	O
reduction	NN	O	O
in	NN	O	O
body	NN	O	O
weight	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
maximal	NN	O	O
reduction	NN	O	O
in	NN	O	O
body	NN	O	O
weight	NN	O	O
seen	NN	O	O
in	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
polymer	NN	O	O
-	NN	O	O
bound	NN	O	O
DOX	NN	O	O
(	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
that	NN	O	O
observed	NN	O	O
in	NN	O	O
those	NN	O	O
that	NN	O	O
received	NN	O	O
free	NN	O	O
DOX	NN	O	O
(	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
a	NN	O	O
mixture	NN	O	O
of	NN	O	O
the	NN	O	O
unmodified	NN	O	O
parent	NN	O	O
HPMA	NN	O	O
copolymer	NN	O	O
and	NN	O	O
free	NN	O	O
DOX	NN	O	O
(	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Throughout	NN	O	O
the	NN	O	O
study	NN	O	O
(	NN	O	O
20	NN	O	O
weeks	NN	O	O
)	NN	O	O
,	NN	O	O
deaths	NN	O	O
related	NN	O	O
to	NN	O	O
cardiotoxicity	NN	O	B
were	NN	O	O
observed	NN	O	O
only	NN	O	O
in	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
either	NN	O	O
free	NN	O	O
DOX	NN	O	O
or	NN	O	O
the	NN	O	O
mixture	NN	O	O
of	NN	O	O
HPMA	NN	O	O
copolymer	NN	O	O
and	NN	O	O
free	NN	O	O
DOX	NN	O	O
;	NN	O	O
in	NN	O	O
these	NN	O	O
cases	NN	O	O
,	NN	O	O
histological	NN	O	O
investigations	NN	O	O
revealed	NN	O	O
marked	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
heart	NN	O	O
that	NN	O	O
were	NN	O	O
consistent	NN	O	O
with	NN	O	O
DOX	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Sequential	NN	O	O
measurements	NN	O	O
of	NN	O	O
cardiac	NN	O	O
output	NN	O	O
in	NN	O	O
surviving	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
either	NN	O	O
free	NN	O	O
DOX	NN	O	O
or	NN	O	O
the	NN	O	O
mixture	NN	O	O
of	NN	O	O
HPMA	NN	O	O
copolymer	NN	O	O
and	NN	O	O
free	NN	O	O
DOX	NN	O	O
showed	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
approximately	NN	O	O
30	NN	O	O
%	NN	O	O
in	NN	O	O
function	NN	O	O
beginning	NN	O	O
at	NN	O	O
the	NN	O	O
4th	NN	O	O
week	NN	O	O
after	NN	O	O
drug	NN	O	O
administration	NN	O	O
.	NN	O	O

The	NN	O	O
heart	NN	O	O
rate	NN	O	O
in	NN	O	O
these	NN	O	O
animals	NN	O	O
was	NN	O	O
approximately	NN	O	O
12	NN	O	O
%	NN	O	O
lower	NN	O	O
than	NN	O	O
that	NN	O	O
measured	NN	O	O
in	NN	O	O
age	NN	O	O
-	NN	O	O
matched	NN	O	O
control	NN	O	O
rats	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Animals	NN	O	O
that	NN	O	O
were	NN	O	O
given	NN	O	O
the	NN	O	O
HPMA	NN	O	O
copolymer	NN	O	O
conjugates	NN	O	O
containing	NN	O	O
DOX	NN	O	O
exhibited	NN	O	O
no	NN	O	O
significant	NN	O	O
change	NN	O	O
in	NN	O	O
cardiac	NN	O	O
output	NN	O	O
throughout	NN	O	O
the	NN	O	O
study	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
no	NN	O	O
significant	NN	O	O
histological	NN	O	O
change	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
heart	NN	O	O
of	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
DOX	NN	O	O
in	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
HPMA	NN	O	O
copolymer	NN	O	O
conjugates	NN	O	O
and	NN	O	O
were	NN	O	O
killed	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
these	NN	O	O
animals	NN	O	O
had	NN	O	O
shown	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
beginning	NN	O	O
at	NN	O	O
8	NN	O	O
weeks	NN	O	O
after	NN	O	O
drug	NN	O	O
administration	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
400	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Corneal	NN	O	B
ulcers	NN	O	I
associated	NN	O	O
with	NN	O	O
aerosolized	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
use	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
We	NN	O	O
report	NN	O	O
4	NN	O	O
cases	NN	O	O
of	NN	O	O
corneal	NN	O	B
ulcers	NN	O	I
associated	NN	O	O
with	NN	O	O
drug	NN	O	B
abuse	NN	O	I
.	NN	O	O

The	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
these	NN	O	O
ulcers	NN	O	B
and	NN	O	O
management	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
are	NN	O	O
also	NN	O	O
reviewed	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Review	NN	O	O
of	NN	O	O
all	NN	O	O
cases	NN	O	O
of	NN	O	O
corneal	NN	O	B
ulcers	NN	O	I
associated	NN	O	O
with	NN	O	O
drug	NN	O	B
abuse	NN	O	I
seen	NN	O	O
at	NN	O	O
our	NN	O	O
institution	NN	O	O
from	NN	O	O
July	NN	O	O
2006	NN	O	O
to	NN	O	O
December	NN	O	O
2006	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Four	NN	O	O
patients	NN	O	O
with	NN	O	O
corneal	NN	O	B
ulcers	NN	O	I
associated	NN	O	O
with	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
use	NN	O	O
were	NN	O	O
reviewed	NN	O	O
.	NN	O	O

All	NN	O	O
corneal	NN	O	B
ulcers	NN	O	I
were	NN	O	O
cultured	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
for	NN	O	O
intensive	NN	O	O
topical	NN	O	O
antibiotic	NN	O	O
treatment	NN	O	O
.	NN	O	O

Each	NN	O	O
patient	NN	O	O
received	NN	O	O
comprehensive	NN	O	O
health	NN	O	O
care	NN	O	O
,	NN	O	O
including	NN	O	O
medical	NN	O	O
and	NN	O	O
substance	NN	O	B
abuse	NN	O	I
consultations	NN	O	O
.	NN	O	O

Streptococcal	NN	O	O
organisms	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
3	NN	O	O
cases	NN	O	O
and	NN	O	O
Capnocytophaga	NN	O	O
and	NN	O	O
Brevibacterium	NN	O	O
casei	NN	O	O
in	NN	O	O
1	NN	O	O
patient	NN	O	O
.	NN	O	O

The	NN	O	O
infections	NN	O	B
responded	NN	O	O
to	NN	O	O
antibiotic	NN	O	O
treatment	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
needed	NN	O	O
a	NN	O	O
lateral	NN	O	O
tarsorrhaphy	NN	O	O
for	NN	O	O
persistent	NN	O	O
epithelial	NN	O	B
defects	NN	O	I
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Aerosolized	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
use	NN	O	O
can	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
corneal	NN	O	B
ulcers	NN	O	I
.	NN	O	O

Drug	NN	O	B
abuse	NN	O	I
provides	NN	O	O
additional	NN	O	O
challenges	NN	O	O
for	NN	O	O
management	NN	O	O
.	NN	O	O

Not	NN	O	O
only	NN	O	O
treatment	NN	O	O
of	NN	O	O
their	NN	O	O
infections	NN	O	B
but	NN	O	O
also	NN	O	O
the	NN	O	O
overall	NN	O	O
poor	NN	O	O
health	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
and	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
noncompliance	NN	O	O
need	NN	O	O
to	NN	O	O
be	NN	O	O
addressed	NN	O	O
.	NN	O	O

Comprehensive	NN	O	O
care	NN	O	O
may	NN	O	O
provide	NN	O	O
the	NN	O	O
patient	NN	O	O
the	NN	O	O
opportunity	NN	O	O
to	NN	O	O
discontinue	NN	O	O
their	NN	O	O
substance	NN	O	B
abuse	NN	O	I
,	NN	O	O
improve	NN	O	O
their	NN	O	O
overall	NN	O	O
health	NN	O	O
,	NN	O	O
and	NN	O	O
prevent	NN	O	O
future	NN	O	O
corneal	NN	O	O
complications	NN	O	O
.	NN	O	O

Topical	NN	O	O
0	NN	O	O
.	NN	O	O
025	NN	O	O
%	NN	O	O
capsaicin	NN	O	O
in	NN	O	O
chronic	NN	O	O
post	NN	O	B
-	NN	O	I
herpetic	NN	O	I
neuralgia	NN	O	I
:	NN	O	O
efficacy	NN	O	O
,	NN	O	O
predictors	NN	O	O
of	NN	O	O
response	NN	O	O
and	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
course	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
efficacy	NN	O	O
,	NN	O	O
time	NN	O	O
-	NN	O	O
course	NN	O	O
of	NN	O	O
action	NN	O	O
and	NN	O	O
predictors	NN	O	O
of	NN	O	O
response	NN	O	O
to	NN	O	O
topical	NN	O	O
capsaicin	NN	O	O
,	NN	O	O
39	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
post	NN	O	B
-	NN	O	I
herpetic	NN	O	I
neuralgia	NN	O	I
(	NN	O	O
PHN	NN	O	B
)	NN	O	O
,	NN	O	O
median	NN	O	O
duration	NN	O	O
24	NN	O	O
months	NN	O	O
,	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
0	NN	O	O
.	NN	O	O
025	NN	O	O
%	NN	O	O
capsaicin	NN	O	O
cream	NN	O	O
for	NN	O	O
8	NN	O	O
weeks	NN	O	O
.	NN	O	O

During	NN	O	O
therapy	NN	O	O
the	NN	O	O
patients	NN	O	O
rated	NN	O	O
their	NN	O	O
pain	NN	O	B
on	NN	O	O
a	NN	O	O
visual	NN	O	O
analogue	NN	O	O
scale	NN	O	O
(	NN	O	O
VAS	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
verbal	NN	O	O
outcome	NN	O	O
scale	NN	O	O
.	NN	O	O

A	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
investigation	NN	O	O
was	NN	O	O
performed	NN	O	O
10	NN	O	O
-	NN	O	O
12	NN	O	O
months	NN	O	O
after	NN	O	O
study	NN	O	O
onset	NN	O	O
on	NN	O	O
the	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
improved	NN	O	O
.	NN	O	O

Nineteen	NN	O	O
patients	NN	O	O
(	NN	O	O
48	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
substantially	NN	O	O
improved	NN	O	O
after	NN	O	O
the	NN	O	O
8	NN	O	O
-	NN	O	O
week	NN	O	O
trial	NN	O	O
;	NN	O	O
5	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
discontinued	NN	O	O
therapy	NN	O	O
due	NN	O	O
to	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
intolerable	NN	O	O
capsaicin	NN	O	O
-	NN	O	O
induced	NN	O	O
burning	NN	O	O
sensations	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
or	NN	O	O
mastitis	NN	O	B
(	NN	O	O
1	NN	O	O
)	NN	O	O
;	NN	O	O
15	NN	O	O
(	NN	O	O
38	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
reported	NN	O	O
no	NN	O	O
benefit	NN	O	O
.	NN	O	O

The	NN	O	O
decrease	NN	O	O
in	NN	O	O
VAS	NN	O	O
ratings	NN	O	O
was	NN	O	O
significant	NN	O	O
after	NN	O	O
2	NN	O	O
weeks	NN	O	O
of	NN	O	O
continuous	NN	O	O
application	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
responders	NN	O	O
72	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
were	NN	O	O
still	NN	O	O
improved	NN	O	O
at	NN	O	O
the	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
;	NN	O	O
only	NN	O	O
one	NN	O	O
-	NN	O	O
third	NN	O	O
of	NN	O	O
them	NN	O	O
had	NN	O	O
continued	NN	O	O
application	NN	O	O
irregularly	NN	O	O
.	NN	O	O

Treatment	NN	O	O
effect	NN	O	O
was	NN	O	O
not	NN	O	O
dependent	NN	O	O
on	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
age	NN	O	O
,	NN	O	O
duration	NN	O	O
or	NN	O	O
localization	NN	O	O
of	NN	O	O
PHN	NN	O	B
(	NN	O	O
trigeminal	NN	O	O
involvement	NN	O	O
was	NN	O	O
excluded	NN	O	O
)	NN	O	O
,	NN	O	O
sensory	NN	O	B
disturbance	NN	O	I
or	NN	O	O
pain	NN	O	B
character	NN	O	O
.	NN	O	O

Treatment	NN	O	O
response	NN	O	O
was	NN	O	O
not	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
incidence	NN	O	O
,	NN	O	O
time	NN	O	O
-	NN	O	O
course	NN	O	O
or	NN	O	O
severity	NN	O	O
of	NN	O	O
capsaicin	NN	O	O
-	NN	O	O
induced	NN	O	O
burning	NN	O	O
.	NN	O	O

If	NN	O	O
confirmed	NN	O	O
in	NN	O	O
controlled	NN	O	O
trials	NN	O	O
,	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
open	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
randomized	NN	O	O
study	NN	O	O
might	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
analgesic	NN	O	O
effect	NN	O	O
of	NN	O	O
capsaicin	NN	O	O
in	NN	O	O
PHN	NN	O	B
is	NN	O	O
mediated	NN	O	O
by	NN	O	O
both	NN	O	O
interference	NN	O	O
with	NN	O	O
neuropeptide	NN	O	O
metabolism	NN	O	O
and	NN	O	O
morphological	NN	O	O
changes	NN	O	O
(	NN	O	O
perhaps	NN	O	O
degeneration	NN	O	O
)	NN	O	O
of	NN	O	O
nociceptive	NN	O	O
afferents	NN	O	O
.	NN	O	O

Myo	NN	O	O
-	NN	O	O
inositol	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
phosphate	NN	O	O
(	NN	O	O
MIP	NN	O	O
)	NN	O	O
synthase	NN	O	O
inhibition	NN	O	O
:	NN	O	O
in	NN	O	O
-	NN	O	O
vivo	NN	O	O
study	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Lithium	NN	O	O
and	NN	O	O
valproate	NN	O	O
are	NN	O	O
the	NN	O	O
prototypic	NN	O	O
mood	NN	O	O
stabilizers	NN	O	O
and	NN	O	O
have	NN	O	O
diverse	NN	O	O
structures	NN	O	O
and	NN	O	O
targets	NN	O	O
.	NN	O	O

Both	NN	O	O
drugs	NN	O	O
influence	NN	O	O
inositol	NN	O	O
metabolism	NN	O	O
.	NN	O	O

Lithium	NN	O	O
inhibits	NN	O	O
IMPase	NN	O	O
and	NN	O	O
valproate	NN	O	O
inhibits	NN	O	O
MIP	NN	O	O
synthase	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
shows	NN	O	O
that	NN	O	O
MIP	NN	O	O
synthase	NN	O	O
inhibition	NN	O	O
does	NN	O	O
not	NN	O	O
replicate	NN	O	O
or	NN	O	O
augment	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
lithium	NN	O	O
in	NN	O	O
the	NN	O	O
inositol	NN	O	O
sensitive	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
model	NN	O	O
.	NN	O	O

This	NN	O	O
lack	NN	O	O
of	NN	O	O
effects	NN	O	O
may	NN	O	O
stem	NN	O	O
from	NN	O	O
the	NN	O	O
low	NN	O	O
contribution	NN	O	O
of	NN	O	O
de	NN	O	O
-	NN	O	O
novo	NN	O	O
synthesis	NN	O	O
to	NN	O	O
cellular	NN	O	O
inositol	NN	O	O
supply	NN	O	O
or	NN	O	O
to	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
the	NN	O	O
de	NN	O	O
-	NN	O	O
novo	NN	O	O
synthesis	NN	O	O
by	NN	O	O
lithium	NN	O	O
itself	NN	O	O
.	NN	O	O

Non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
-	NN	O	O
associated	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
with	NN	O	O
granular	NN	O	O
tubular	NN	O	O
basement	NN	O	O
membrane	NN	O	O
deposits	NN	O	O
.	NN	O	O

Acute	NN	O	B
tubulo	NN	O	I
-	NN	O	I
interstitial	NN	O	I
nephritis	NN	O	I
(	NN	O	O
ATIN	NN	O	B
)	NN	O	O
is	NN	O	O
an	NN	O	O
important	NN	O	O
cause	NN	O	O
of	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
resulting	NN	O	O
from	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
insults	NN	O	O
,	NN	O	O
including	NN	O	O
immune	NN	O	O
complex	NN	O	O
-	NN	O	O
mediated	NN	O	O
tubulo	NN	O	B
-	NN	O	I
interstitial	NN	O	I
injury	NN	O	I
,	NN	O	O
but	NN	O	O
drugs	NN	O	O
such	NN	O	O
as	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
(	NN	O	O
NSAIDs	NN	O	O
)	NN	O	O
are	NN	O	O
a	NN	O	O
far	NN	O	O
more	NN	O	O
frequent	NN	O	O
cause	NN	O	O
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
as	NN	O	O
an	NN	O	O
entity	NN	O	O
,	NN	O	O
ATIN	NN	O	B
remains	NN	O	O
under	NN	O	O
-	NN	O	O
diagnosed	NN	O	O
,	NN	O	O
as	NN	O	O
symptoms	NN	O	O
resolve	NN	O	O
spontaneously	NN	O	O
if	NN	O	O
the	NN	O	O
medication	NN	O	O
is	NN	O	O
stopped	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
a	NN	O	O
14	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
who	NN	O	O
developed	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
2	NN	O	O
weeks	NN	O	O
after	NN	O	O
aortic	NN	O	O
valve	NN	O	O
surgery	NN	O	O
.	NN	O	O

He	NN	O	O
was	NN	O	O
put	NN	O	O
on	NN	O	O
aspirin	NN	O	O
following	NN	O	O
surgery	NN	O	O
and	NN	O	O
took	NN	O	O
ibuprofen	NN	O	O
for	NN	O	O
fever	NN	O	B
for	NN	O	O
nearly	NN	O	O
a	NN	O	O
week	NN	O	O
prior	NN	O	O
to	NN	O	O
presentation	NN	O	O
.	NN	O	O

He	NN	O	O
then	NN	O	O
presented	NN	O	O
to	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
feeling	NN	O	O
quite	NN	O	O
ill	NN	O	O
and	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
blood	NN	O	O
urea	NN	O	O
nitrogen	NN	O	O
(	NN	O	O
BUN	NN	O	O
)	NN	O	O
concentration	NN	O	O
of	NN	O	O
of	NN	O	O
147	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
creatinine	NN	O	O
of	NN	O	O
15	NN	O	O
.	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
and	NN	O	O
serum	NN	O	O
potassium	NN	O	O
of	NN	O	O
8	NN	O	O
.	NN	O	O
7	NN	O	O
mEq	NN	O	O
/	NN	O	O
l	NN	O	O
.	NN	O	O

Dialysis	NN	O	O
was	NN	O	O
immediately	NN	O	O
initiated	NN	O	O
.	NN	O	O

A	NN	O	O
kidney	NN	O	O
biopsy	NN	O	O
showed	NN	O	O
inflammatory	NN	O	O
infiltrate	NN	O	O
consistent	NN	O	O
with	NN	O	O
ATIN	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
tubular	NN	O	O
basement	NN	O	O
membrane	NN	O	O
(	NN	O	O
TBM	NN	O	O
)	NN	O	O
,	NN	O	O
very	NN	O	O
intense	NN	O	O
granular	NN	O	O
deposits	NN	O	O
of	NN	O	O
polyclonal	NN	O	O
IgG	NN	O	O
and	NN	O	O
C3	NN	O	O
were	NN	O	O
noted	NN	O	O
.	NN	O	O

He	NN	O	O
needed	NN	O	O
dialysis	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
and	NN	O	O
was	NN	O	O
treated	NN	O	O
successfully	NN	O	O
with	NN	O	O
steroids	NN	O	O
for	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

His	NN	O	O
renal	NN	O	O
recovery	NN	O	O
and	NN	O	O
disappearance	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
took	NN	O	O
a	NN	O	O
year	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
a	NN	O	O
first	NN	O	O
report	NN	O	O
of	NN	O	O
NSAIDs	NN	O	O
-	NN	O	O
associated	NN	O	O
ATIN	NN	O	B
,	NN	O	O
showing	NN	O	O
deposits	NN	O	O
of	NN	O	O
granular	NN	O	O
immune	NN	O	O
complex	NN	O	O
present	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
TBM	NN	O	O
and	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
glomeruli	NN	O	O
.	NN	O	O

Rifampicin	NN	O	O
-	NN	O	O
associated	NN	O	O
segmental	NN	O	O
necrotizing	NN	O	O
glomerulonephritis	NN	O	B
in	NN	O	O
staphylococcal	NN	O	B
endocarditis	NN	O	I
.	NN	O	O

Segmental	NN	O	O
necrotising	NN	O	O
glomerulonephritis	NN	O	B
has	NN	O	O
been	NN	O	O
reported	NN	O	O
as	NN	O	O
complication	NN	O	O
of	NN	O	O
rifampicin	NN	O	O
therapy	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
treatment	NN	O	O
for	NN	O	O
tuberculosis	NN	O	B
.	NN	O	O

Changing	NN	O	O
epidemiology	NN	O	O
of	NN	O	O
infections	NN	O	B
such	NN	O	O
as	NN	O	O
infective	NN	O	B
endocarditis	NN	O	I
(	NN	O	O
IE	NN	O	B
)	NN	O	O
has	NN	O	O
led	NN	O	O
to	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
rifampicin	NN	O	O
for	NN	O	O
Staphylococcal	NN	O	B
infections	NN	O	I
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
Staphylococcal	NN	O	B
IE	NN	O	I
who	NN	O	O
developed	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
secondary	NN	O	O
to	NN	O	O
a	NN	O	O
segmental	NN	O	O
necrotising	NN	O	O
glomerulonephritis	NN	O	B
while	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
rifampicin	NN	O	O
,	NN	O	O
and	NN	O	O
review	NN	O	O
the	NN	O	O
literature	NN	O	O
regarding	NN	O	O
this	NN	O	O
complication	NN	O	O
of	NN	O	O
rifampicin	NN	O	O
therapy	NN	O	O
.	NN	O	O

Rate	NN	O	O
of	NN	O	O
YMDD	NN	O	O
motif	NN	O	O
mutants	NN	O	O
in	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
untreated	NN	O	O
Iranian	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
B	NN	O	I
virus	NN	O	I
infection	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Lamivudine	NN	O	O
is	NN	O	O
used	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
B	NN	O	I
patients	NN	O	O
.	NN	O	O

Recent	NN	O	O
studies	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
YMDD	NN	O	O
motif	NN	O	O
mutants	NN	O	O
(	NN	O	O
resistant	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
)	NN	O	O
occur	NN	O	O
as	NN	O	O
natural	NN	O	O
genome	NN	O	O
variability	NN	O	O
in	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
untreated	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
B	NN	O	I
patients	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
we	NN	O	O
aimed	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
YMDD	NN	O	O
motif	NN	O	O
mutants	NN	O	O
in	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
untreated	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
B	NN	O	I
patients	NN	O	O
in	NN	O	O
Iran	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
77	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
B	NN	O	I
patients	NN	O	O
who	NN	O	O
had	NN	O	O
not	NN	O	O
been	NN	O	O
treated	NN	O	O
with	NN	O	O
lamivudine	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Serum	NN	O	O
samples	NN	O	O
from	NN	O	O
patients	NN	O	O
were	NN	O	O
tested	NN	O	O
by	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
-	NN	O	O
restriction	NN	O	O
fragment	NN	O	O
length	NN	O	O
polymorphism	NN	O	O
(	NN	O	O
PCR	NN	O	O
-	NN	O	O
RFLP	NN	O	O
)	NN	O	O
for	NN	O	O
detection	NN	O	O
of	NN	O	O
YMDD	NN	O	O
motif	NN	O	O
mutants	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
also	NN	O	O
tested	NN	O	O
for	NN	O	O
liver	NN	O	O
enzymes	NN	O	O
,	NN	O	O
anti	NN	O	O
-	NN	O	O
HCV	NN	O	O
,	NN	O	O
HBeAg	NN	O	O
,	NN	O	O
and	NN	O	O
anti	NN	O	O
-	NN	O	O
HBe	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Of	NN	O	O
the	NN	O	O
77	NN	O	O
patients	NN	O	O
enrolled	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
73	NN	O	O
%	NN	O	O
were	NN	O	O
male	NN	O	O
and	NN	O	O
27	NN	O	O
%	NN	O	O
were	NN	O	O
female	NN	O	O
.	NN	O	O

Mean	NN	O	O
ALT	NN	O	O
and	NN	O	O
AST	NN	O	O
levels	NN	O	O
were	NN	O	O
124	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
73	NN	O	O
.	NN	O	O
4	NN	O	O
and	NN	O	O
103	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
81	NN	O	O
IU	NN	O	O
/	NN	O	O
l	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

HBeAg	NN	O	O
was	NN	O	O
positive	NN	O	O
in	NN	O	O
40	NN	O	O
%	NN	O	O
and	NN	O	O
anti	NN	O	O
-	NN	O	O
HBe	NN	O	O
in	NN	O	O
60	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
.	NN	O	O

Anti	NN	O	O
-	NN	O	O
HCV	NN	O	O
was	NN	O	O
negative	NN	O	O
in	NN	O	O
all	NN	O	O
of	NN	O	O
them	NN	O	O
.	NN	O	O

YMDD	NN	O	O
motif	NN	O	O
mutants	NN	O	O
were	NN	O	O
not	NN	O	O
detected	NN	O	O
in	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
despite	NN	O	O
the	NN	O	O
liver	NN	O	O
enzyme	NN	O	O
levels	NN	O	O
and	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
HBeAg	NN	O	O
or	NN	O	O
anti	NN	O	O
-	NN	O	O
HBe	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Although	NN	O	O
the	NN	O	O
natural	NN	O	O
occurrence	NN	O	O
of	NN	O	O
YMDD	NN	O	O
motif	NN	O	O
mutants	NN	O	O
in	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
untreated	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
B	NN	O	I
has	NN	O	O
been	NN	O	O
reported	NN	O	O
,	NN	O	O
these	NN	O	O
mutants	NN	O	O
were	NN	O	O
not	NN	O	O
detected	NN	O	O
in	NN	O	O
Iranian	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
untreated	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
B	NN	O	I
patients	NN	O	O
.	NN	O	O

Branch	NN	O	O
retinal	NN	O	B
vein	NN	O	I
occlusion	NN	O	I
and	NN	O	O
fluoxetine	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
branch	NN	O	O
retinal	NN	O	B
vein	NN	O	I
occlusion	NN	O	I
associated	NN	O	O
with	NN	O	O
fluoxetine	NN	O	O
-	NN	O	O
induced	NN	O	O
secondary	NN	O	O
hypertension	NN	O	B
is	NN	O	O
described	NN	O	O
.	NN	O	O

Although	NN	O	O
an	NN	O	O
infrequent	NN	O	O
complication	NN	O	O
of	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitor	NN	O	O
therapy	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
important	NN	O	O
that	NN	O	O
ophthalmologists	NN	O	O
are	NN	O	O
aware	NN	O	O
that	NN	O	O
these	NN	O	O
agents	NN	O	O
can	NN	O	O
cause	NN	O	O
hypertension	NN	O	B
because	NN	O	O
this	NN	O	O
class	NN	O	O
of	NN	O	O
drugs	NN	O	O
is	NN	O	O
widely	NN	O	O
prescribed	NN	O	O
.	NN	O	O

The	NN	O	O
differential	NN	O	O
effects	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
and	NN	O	O
lidocaine	NN	O	O
on	NN	O	O
prostaglandin	NN	O	O
E2	NN	O	O
release	NN	O	O
,	NN	O	O
cyclooxygenase	NN	O	O
gene	NN	O	O
expression	NN	O	O
and	NN	O	O
pain	NN	O	B
in	NN	O	O
a	NN	O	O
clinical	NN	O	O
pain	NN	O	B
model	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
In	NN	O	O
addition	NN	O	O
to	NN	O	O
blocking	NN	O	O
nociceptive	NN	O	O
input	NN	O	O
from	NN	O	O
surgical	NN	O	O
sites	NN	O	O
,	NN	O	O
long	NN	O	O
-	NN	O	O
acting	NN	O	O
local	NN	O	O
anesthetics	NN	O	O
might	NN	O	O
directly	NN	O	O
modulate	NN	O	O
inflammation	NN	O	B
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
the	NN	O	O
proinflammatory	NN	O	O
effects	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
on	NN	O	O
local	NN	O	O
prostaglandin	NN	O	O
E2	NN	O	O
(	NN	O	O
PGE2	NN	O	O
)	NN	O	O
production	NN	O	O
and	NN	O	O
cyclooxygenase	NN	O	O
(	NN	O	O
COX	NN	O	O
)	NN	O	O
gene	NN	O	O
expression	NN	O	O
that	NN	O	O
increases	NN	O	O
postoperative	NN	O	B
pain	NN	O	I
in	NN	O	O
human	NN	O	O
subjects	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Subjects	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
114	NN	O	O
)	NN	O	O
undergoing	NN	O	O
extraction	NN	O	O
of	NN	O	O
impacted	NN	O	O
third	NN	O	O
molars	NN	O	O
received	NN	O	O
either	NN	O	O
2	NN	O	O
%	NN	O	O
lidocaine	NN	O	O
or	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
bupivacaine	NN	O	O
before	NN	O	O
surgery	NN	O	O
and	NN	O	O
either	NN	O	O
rofecoxib	NN	O	O
50	NN	O	O
mg	NN	O	O
or	NN	O	O
placebo	NN	O	O
orally	NN	O	O
90	NN	O	O
min	NN	O	O
before	NN	O	O
surgery	NN	O	O
and	NN	O	O
for	NN	O	O
the	NN	O	O
following	NN	O	O
48	NN	O	O
h	NN	O	O
.	NN	O	O

Oral	NN	O	O
mucosal	NN	O	O
biopsies	NN	O	O
were	NN	O	O
taken	NN	O	O
before	NN	O	O
surgery	NN	O	O
and	NN	O	O
48	NN	O	O
h	NN	O	O
after	NN	O	O
surgery	NN	O	O
.	NN	O	O

After	NN	O	O
extraction	NN	O	O
,	NN	O	O
a	NN	O	O
microdialysis	NN	O	O
probe	NN	O	O
was	NN	O	O
placed	NN	O	O
at	NN	O	O
the	NN	O	O
surgical	NN	O	O
site	NN	O	O
for	NN	O	O
PGE2	NN	O	O
and	NN	O	O
thromboxane	NN	O	O
B2	NN	O	O
(	NN	O	O
TXB2	NN	O	O
)	NN	O	O
measurements	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
bupivacaine	NN	O	O
/	NN	O	O
rofecoxib	NN	O	O
group	NN	O	O
reported	NN	O	O
significantly	NN	O	O
less	NN	O	O
pain	NN	O	B
,	NN	O	O
as	NN	O	O
assessed	NN	O	O
by	NN	O	O
a	NN	O	O
visual	NN	O	O
analog	NN	O	O
scale	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
other	NN	O	O
three	NN	O	O
treatment	NN	O	O
groups	NN	O	O
over	NN	O	O
the	NN	O	O
first	NN	O	O
4	NN	O	O
h	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
bupivacaine	NN	O	O
/	NN	O	O
placebo	NN	O	O
group	NN	O	O
reported	NN	O	O
significantly	NN	O	O
more	NN	O	O
pain	NN	O	B
at	NN	O	O
24	NN	O	O
h	NN	O	O
and	NN	O	O
PGE2	NN	O	O
levels	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
4	NN	O	O
h	NN	O	O
were	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
the	NN	O	O
other	NN	O	O
three	NN	O	O
treatment	NN	O	O
groups	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
bupivacaine	NN	O	O
significantly	NN	O	O
increased	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
gene	NN	O	O
expression	NN	O	O
at	NN	O	O
48	NN	O	O
h	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
lidocaine	NN	O	O
/	NN	O	O
placebo	NN	O	O
group	NN	O	O
.	NN	O	O

Thromboxane	NN	O	O
levels	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
affected	NN	O	O
by	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
treatments	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
effects	NN	O	O
seen	NN	O	O
were	NN	O	O
attributable	NN	O	O
to	NN	O	O
inhibition	NN	O	O
of	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
COX	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
bupivacaine	NN	O	O
stimulates	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
gene	NN	O	O
expression	NN	O	O
after	NN	O	O
tissue	NN	O	B
injury	NN	O	I
,	NN	O	O
which	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
higher	NN	O	O
PGE2	NN	O	O
production	NN	O	O
and	NN	O	O
pain	NN	O	B
after	NN	O	O
the	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
effect	NN	O	O
dissipates	NN	O	O
.	NN	O	O

p75NTR	NN	O	O
expression	NN	O	O
in	NN	O	O
rat	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
sensory	NN	O	O
neurons	NN	O	O
and	NN	O	O
spinal	NN	O	O
cord	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
.	NN	O	O

A	NN	O	O
role	NN	O	O
for	NN	O	O
nerve	NN	O	O
growth	NN	O	O
factor	NN	O	O
(	NN	O	O
NGF	NN	O	O
)	NN	O	O
in	NN	O	O
contributing	NN	O	O
to	NN	O	O
increased	NN	O	O
voiding	NN	O	O
frequency	NN	O	O
and	NN	O	O
altered	NN	O	O
sensation	NN	O	O
from	NN	O	O
the	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
has	NN	O	O
been	NN	O	O
suggested	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
examined	NN	O	O
the	NN	O	O
expression	NN	O	O
and	NN	O	O
regulation	NN	O	O
of	NN	O	O
tyrosine	NN	O	O
kinase	NN	O	O
receptors	NN	O	O
(	NN	O	O
Trks	NN	O	O
)	NN	O	O
in	NN	O	O
micturition	NN	O	O
reflexes	NN	O	O
with	NN	O	O
urinary	NN	O	B
bladder	NN	O	I
inflammation	NN	O	I
.	NN	O	O

The	NN	O	O
present	NN	O	O
studies	NN	O	O
examine	NN	O	O
the	NN	O	O
expression	NN	O	O
and	NN	O	O
regulation	NN	O	O
of	NN	O	O
another	NN	O	O
receptor	NN	O	O
known	NN	O	O
to	NN	O	O
bind	NN	O	O
NGF	NN	O	O
,	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
,	NN	O	O
after	NN	O	O
various	NN	O	O
durations	NN	O	O
of	NN	O	O
bladder	NN	O	B
inflammation	NN	O	I
induced	NN	O	O
by	NN	O	O
cyclophosphamide	NN	O	O
(	NN	O	O
CYP	NN	O	O
)	NN	O	O
.	NN	O	O

CYP	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
increased	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
superficial	NN	O	O
lateral	NN	O	O
and	NN	O	O
medial	NN	O	O
dorsal	NN	O	O
horn	NN	O	O
in	NN	O	O
L1	NN	O	O
-	NN	O	O
L2	NN	O	O
and	NN	O	O
L6	NN	O	O
-	NN	O	O
S1	NN	O	O
spinal	NN	O	O
segments	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
-	NN	O	O
immunoreactive	NN	O	O
(	NN	O	O
-	NN	O	O
IR	NN	O	O
)	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
lumbosacral	NN	O	O
dorsal	NN	O	O
root	NN	O	O
ganglia	NN	O	O
(	NN	O	O
DRG	NN	O	O
)	NN	O	O
also	NN	O	O
increased	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
with	NN	O	O
CYP	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
(	NN	O	O
acute	NN	O	O
,	NN	O	O
intermediate	NN	O	O
,	NN	O	O
and	NN	O	O
chronic	NN	O	O
)	NN	O	O
.	NN	O	O

Quantitative	NN	O	O
,	NN	O	O
real	NN	O	O
-	NN	O	O
time	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
also	NN	O	O
demonstrated	NN	O	O
significant	NN	O	O
increases	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
in	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
mRNA	NN	O	O
in	NN	O	O
DRG	NN	O	O
with	NN	O	O
intermediate	NN	O	O
and	NN	O	O
chronic	NN	O	O
CYP	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
.	NN	O	O

Retrograde	NN	O	O
dye	NN	O	O
-	NN	O	O
tracing	NN	O	O
techniques	NN	O	O
with	NN	O	O
Fastblue	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
identify	NN	O	O
presumptive	NN	O	O
bladder	NN	O	O
afferent	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
lumbosacral	NN	O	O
DRG	NN	O	O
.	NN	O	O

In	NN	O	O
bladder	NN	O	O
afferent	NN	O	O
cells	NN	O	O
in	NN	O	O
DRG	NN	O	O
,	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
-	NN	O	O
IR	NN	O	O
was	NN	O	O
also	NN	O	O
increased	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
with	NN	O	O
cystitis	NN	O	B
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
increases	NN	O	O
in	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
-	NN	O	O
IR	NN	O	O
in	NN	O	O
DRG	NN	O	O
cell	NN	O	O
bodies	NN	O	O
,	NN	O	O
increases	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
in	NN	O	O
pericellular	NN	O	O
(	NN	O	O
encircling	NN	O	O
DRG	NN	O	O
cells	NN	O	O
)	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
-	NN	O	O
IR	NN	O	O
in	NN	O	O
DRG	NN	O	O
also	NN	O	O
increased	NN	O	O
.	NN	O	O

Confocal	NN	O	O
analyses	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
pericellular	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
-	NN	O	O
IR	NN	O	O
was	NN	O	O
not	NN	O	O
colocalized	NN	O	O
with	NN	O	O
the	NN	O	O
glial	NN	O	O
marker	NN	O	O
,	NN	O	O
glial	NN	O	O
fibrillary	NN	O	O
acidic	NN	O	O
protein	NN	O	O
(	NN	O	O
GFAP	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
studies	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
expression	NN	O	O
in	NN	O	O
micturition	NN	O	O
reflexes	NN	O	O
is	NN	O	O
present	NN	O	O
constitutively	NN	O	O
and	NN	O	O
modified	NN	O	O
by	NN	O	O
bladder	NN	O	B
inflammation	NN	O	I
.	NN	O	O

The	NN	O	O
functional	NN	O	O
significance	NN	O	O
of	NN	O	O
p75	NN	O	O
(	NN	O	O
NTR	NN	O	O
)	NN	O	O
expression	NN	O	O
in	NN	O	O
micturition	NN	O	O
reflexes	NN	O	O
remains	NN	O	O
to	NN	O	O
be	NN	O	O
determined	NN	O	O
.	NN	O	O

Azathioprine	NN	O	O
-	NN	O	O
induced	NN	O	O
suicidal	NN	O	O
erythrocyte	NN	O	O
death	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Azathioprine	NN	O	O
is	NN	O	O
widely	NN	O	O
used	NN	O	O
as	NN	O	O
an	NN	O	O
immunosuppressive	NN	O	O
drug	NN	O	O
.	NN	O	O

The	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
azathioprine	NN	O	O
include	NN	O	O
anemia	NN	O	B
,	NN	O	O
which	NN	O	O
has	NN	O	O
been	NN	O	O
attributed	NN	O	O
to	NN	O	O
bone	NN	O	O
marrow	NN	O	O
suppression	NN	O	O
.	NN	O	O

Alternatively	NN	O	O
,	NN	O	O
anemia	NN	O	B
could	NN	O	O
result	NN	O	O
from	NN	O	O
accelerated	NN	O	O
suicidal	NN	O	O
erythrocyte	NN	O	O
death	NN	O	O
or	NN	O	O
eryptosis	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
exposure	NN	O	O
of	NN	O	O
phosphatidylserine	NN	O	O
(	NN	O	O
PS	NN	O	O
)	NN	O	O
at	NN	O	O
the	NN	O	O
erythrocyte	NN	O	O
surface	NN	O	O
and	NN	O	O
by	NN	O	O
cell	NN	O	O
shrinkage	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
present	NN	O	O
experiments	NN	O	O
explored	NN	O	O
whether	NN	O	O
azathioprine	NN	O	O
influences	NN	O	O
eryptosis	NN	O	O
.	NN	O	O

According	NN	O	O
to	NN	O	O
annexin	NN	O	O
V	NN	O	O
binding	NN	O	O
,	NN	O	O
erythrocytes	NN	O	O
from	NN	O	O
patients	NN	O	O
indeed	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
of	NN	O	O
PS	NN	O	O
exposure	NN	O	O
within	NN	O	O
1	NN	O	O
week	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
azathioprine	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
second	NN	O	O
series	NN	O	O
,	NN	O	O
cytosolic	NN	O	O
Ca2	NN	O	O
+	NN	O	O
activity	NN	O	O
(	NN	O	O
Fluo3	NN	O	O
fluorescence	NN	O	O
)	NN	O	O
,	NN	O	O
cell	NN	O	O
volume	NN	O	O
(	NN	O	O
forward	NN	O	O
scatter	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
PS	NN	O	O
-	NN	O	O
exposure	NN	O	O
(	NN	O	O
annexin	NN	O	O
V	NN	O	O
binding	NN	O	O
)	NN	O	O
were	NN	O	O
determined	NN	O	O
by	NN	O	O
FACS	NN	O	O
analysis	NN	O	O
in	NN	O	O
erythrocytes	NN	O	O
from	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Exposure	NN	O	O
to	NN	O	O
azathioprine	NN	O	O
(	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
2	NN	O	O
microg	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
for	NN	O	O
48	NN	O	O
hours	NN	O	O
increased	NN	O	O
cytosolic	NN	O	O
Ca2	NN	O	O
+	NN	O	O
activity	NN	O	O
and	NN	O	O
annexin	NN	O	O
V	NN	O	O
binding	NN	O	O
and	NN	O	O
decreased	NN	O	O
forward	NN	O	O
scatter	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
azathioprine	NN	O	O
on	NN	O	O
both	NN	O	O
annexin	NN	O	O
V	NN	O	O
binding	NN	O	O
and	NN	O	O
forward	NN	O	O
scatter	NN	O	O
was	NN	O	O
significantly	NN	O	O
blunted	NN	O	O
in	NN	O	O
the	NN	O	O
nominal	NN	O	O
absence	NN	O	O
of	NN	O	O
extracellular	NN	O	O
Ca2	NN	O	O
+	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Azathioprine	NN	O	O
triggers	NN	O	O
suicidal	NN	O	O
erythrocyte	NN	O	O
death	NN	O	O
,	NN	O	O
an	NN	O	O
effect	NN	O	O
presumably	NN	O	O
contributing	NN	O	O
to	NN	O	O
azathioprine	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
.	NN	O	O

Levetiracetam	NN	O	O
as	NN	O	O
an	NN	O	O
adjunct	NN	O	O
to	NN	O	O
phenobarbital	NN	O	O
treatment	NN	O	O
in	NN	O	O
cats	NN	O	O
with	NN	O	O
suspected	NN	O	O
idiopathic	NN	O	B
epilepsy	NN	O	I
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
pharmacokinetics	NN	O	O
,	NN	O	O
efficacy	NN	O	O
,	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
oral	NN	O	O
levetiracetam	NN	O	O
administered	NN	O	O
as	NN	O	O
an	NN	O	O
adjunct	NN	O	O
to	NN	O	O
phenobarbital	NN	O	O
treatment	NN	O	O
in	NN	O	O
cats	NN	O	O
with	NN	O	O
poorly	NN	O	O
controlled	NN	O	O
suspected	NN	O	O
idiopathic	NN	O	B
epilepsy	NN	O	I
.	NN	O	O

DESIGN	NN	O	O
-	NN	O	O
Open	NN	O	O
-	NN	O	O
label	NN	O	O
,	NN	O	O
noncomparative	NN	O	O
clinical	NN	O	O
trial	NN	O	O
.	NN	O	O

ANIMALS	NN	O	O
:	NN	O	O
12	NN	O	O
cats	NN	O	O
suspected	NN	O	O
to	NN	O	O
have	NN	O	O
idiopathic	NN	O	B
epilepsy	NN	O	I
that	NN	O	O
was	NN	O	O
poorly	NN	O	O
controlled	NN	O	O
with	NN	O	O
phenobarbital	NN	O	O
or	NN	O	O
that	NN	O	O
had	NN	O	O
unacceptable	NN	O	O
adverse	NN	O	O
effects	NN	O	O
when	NN	O	O
treated	NN	O	O
with	NN	O	O
phenobarbital	NN	O	O
.	NN	O	O

PROCEDURES	NN	O	O
:	NN	O	O
Cats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
levetiracetam	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
[	NN	O	O
9	NN	O	O
.	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
lb	NN	O	O
]	NN	O	O
,	NN	O	O
PO	NN	O	O
,	NN	O	O
q	NN	O	O
8	NN	O	O
h	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
minimum	NN	O	O
of	NN	O	O
1	NN	O	O
week	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
serum	NN	O	O
levetiracetam	NN	O	O
concentrations	NN	O	O
were	NN	O	O
measured	NN	O	O
before	NN	O	O
and	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
and	NN	O	O
6	NN	O	O
hours	NN	O	O
after	NN	O	O
drug	NN	O	O
administration	NN	O	O
,	NN	O	O
and	NN	O	O
maximum	NN	O	O
and	NN	O	O
minimum	NN	O	O
serum	NN	O	O
concentrations	NN	O	O
and	NN	O	O
elimination	NN	O	O
half	NN	O	O
-	NN	O	O
life	NN	O	O
were	NN	O	O
calculated	NN	O	O
.	NN	O	O

Seizure	NN	O	B
frequencies	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
levetiracetam	NN	O	O
treatment	NN	O	O
were	NN	O	O
compared	NN	O	O
,	NN	O	O
and	NN	O	O
adverse	NN	O	O
effects	NN	O	O
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Median	NN	O	O
maximum	NN	O	O
serum	NN	O	O
levetiracetam	NN	O	O
concentration	NN	O	O
was	NN	O	O
25	NN	O	O
.	NN	O	O
5	NN	O	O
microg	NN	O	O
/	NN	O	O
mL	NN	O	O
,	NN	O	O
median	NN	O	O
minimum	NN	O	O
serum	NN	O	O
levetiracetam	NN	O	O
concentration	NN	O	O
was	NN	O	O
8	NN	O	O
.	NN	O	O
3	NN	O	O
microg	NN	O	O
/	NN	O	O
mL	NN	O	O
,	NN	O	O
and	NN	O	O
median	NN	O	O
elimination	NN	O	O
half	NN	O	O
-	NN	O	O
life	NN	O	O
was	NN	O	O
2	NN	O	O
.	NN	O	O
9	NN	O	O
hours	NN	O	O
.	NN	O	O

Median	NN	O	O
seizure	NN	O	B
frequency	NN	O	O
prior	NN	O	O
to	NN	O	O
treatment	NN	O	O
with	NN	O	O
levetiracetam	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
seizures	NN	O	B
/	NN	O	O
mo	NN	O	O
)	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
median	NN	O	O
seizure	NN	O	B
frequency	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
levetiracetam	NN	O	O
treatment	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
42	NN	O	O
seizures	NN	O	B
/	NN	O	O
mo	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
7	NN	O	O
of	NN	O	O
10	NN	O	O
cats	NN	O	O
were	NN	O	O
classified	NN	O	O
as	NN	O	O
having	NN	O	O
responded	NN	O	O
to	NN	O	O
levetiracetam	NN	O	O
treatment	NN	O	O
(	NN	O	O
ie	NN	O	O
,	NN	O	O
reduction	NN	O	O
in	NN	O	O
seizure	NN	O	B
frequency	NN	O	O
of	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Two	NN	O	O
cats	NN	O	O
had	NN	O	O
transient	NN	O	O
lethargy	NN	O	B
and	NN	O	O
inappetence	NN	O	B
.	NN	O	O

CONCLUSIONS	NN	O	O
AND	NN	O	O
CLINICAL	NN	O	O
RELEVANCE	NN	O	O
:	NN	O	O
Results	NN	O	O
suggested	NN	O	O
that	NN	O	O
levetiracetam	NN	O	O
is	NN	O	O
well	NN	O	O
tolerated	NN	O	O
in	NN	O	O
cats	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
as	NN	O	O
an	NN	O	O
adjunct	NN	O	O
to	NN	O	O
phenobarbital	NN	O	O
treatment	NN	O	O
in	NN	O	O
cats	NN	O	O
with	NN	O	O
idiopathic	NN	O	B
epilepsy	NN	O	I
.	NN	O	O

Serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
paranoia	NN	O	B
,	NN	O	O
and	NN	O	O
the	NN	O	O
ventral	NN	O	O
basal	NN	O	O
ganglia	NN	O	O
.	NN	O	O

Antidepressants	NN	O	O
have	NN	O	O
previously	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
paranoid	NN	O	B
reactions	NN	O	O
in	NN	O	O
psychiatric	NN	O	O
patients	NN	O	O
.	NN	O	O

Five	NN	O	O
cases	NN	O	O
of	NN	O	O
paranoid	NN	O	B
exacerbation	NN	O	O
with	NN	O	O
the	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NN	O	O
fluoxetine	NN	O	O
and	NN	O	O
amitriptyline	NN	O	O
are	NN	O	O
reported	NN	O	O
here	NN	O	O
.	NN	O	O

Elements	NN	O	O
common	NN	O	O
to	NN	O	O
these	NN	O	O
cases	NN	O	O
included	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
paranoid	NN	O	B
symptomatology	NN	O	O
and	NN	O	O
the	NN	O	O
concomitant	NN	O	O
occurrence	NN	O	O
of	NN	O	O
depressive	NN	O	B
and	NN	O	I
psychotic	NN	O	I
symptoms	NN	O	I
.	NN	O	O

Complicated	NN	O	O
depressive	NN	O	B
disorders	NN	O	I
(	NN	O	O
including	NN	O	O
atypicality	NN	O	O
of	NN	O	O
course	NN	O	O
and	NN	O	O
symptomatology	NN	O	O
,	NN	O	O
chronicity	NN	O	O
,	NN	O	O
psychosis	NN	O	B
,	NN	O	O
bipolarity	NN	O	O
,	NN	O	O
and	NN	O	O
secondary	NN	O	O
onset	NN	O	O
in	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
a	NN	O	O
primary	NN	O	O
psychosis	NN	O	B
)	NN	O	O
may	NN	O	O
present	NN	O	O
particular	NN	O	O
vulnerability	NN	O	O
to	NN	O	O
paranoid	NN	O	B
exacerbations	NN	O	O
associated	NN	O	O
with	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
pharmacology	NN	O	O
and	NN	O	O
neurobiology	NN	O	O
of	NN	O	O
paranoia	NN	O	B
remain	NN	O	O
cryptic	NN	O	O
,	NN	O	O
several	NN	O	O
mechanisms	NN	O	O
,	NN	O	O
including	NN	O	O
5HT3	NN	O	O
receptor	NN	O	O
-	NN	O	O
mediated	NN	O	O
dopamine	NN	O	O
release	NN	O	O
,	NN	O	O
beta	NN	O	O
-	NN	O	O
noradrenergic	NN	O	O
receptor	NN	O	O
downregulation	NN	O	O
,	NN	O	O
or	NN	O	O
GABAB	NN	O	O
receptor	NN	O	O
upregulation	NN	O	O
acting	NN	O	O
in	NN	O	O
the	NN	O	O
vicinity	NN	O	O
of	NN	O	O
the	NN	O	O
ventral	NN	O	O
basal	NN	O	O
ganglia	NN	O	O
(	NN	O	O
possibly	NN	O	O
in	NN	O	O
lateral	NN	O	O
orbitofrontal	NN	O	O
or	NN	O	O
anterior	NN	O	O
cingulate	NN	O	O
circuits	NN	O	O
)	NN	O	O
,	NN	O	O
might	NN	O	O
apply	NN	O	O
to	NN	O	O
this	NN	O	O
phenomenon	NN	O	O
.	NN	O	O

These	NN	O	O
cases	NN	O	O
call	NN	O	O
attention	NN	O	O
to	NN	O	O
possible	NN	O	O
paranoid	NN	O	B
exacerbations	NN	O	O
with	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
blockers	NN	O	O
in	NN	O	O
select	NN	O	O
patients	NN	O	O
and	NN	O	O
raise	NN	O	O
neurobiological	NN	O	O
considerations	NN	O	O
regarding	NN	O	O
paranoia	NN	O	B
.	NN	O	O

Clinical	NN	O	O
comparison	NN	O	O
of	NN	O	O
cardiorespiratory	NN	O	O
effects	NN	O	O
during	NN	O	O
unilateral	NN	O	O
and	NN	O	O
conventional	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Spinal	NN	O	O
anaesthesia	NN	O	O
is	NN	O	O
widely	NN	O	O
employed	NN	O	O
in	NN	O	O
clinical	NN	O	O
practice	NN	O	O
but	NN	O	O
has	NN	O	O
the	NN	O	O
main	NN	O	O
drawback	NN	O	O
of	NN	O	O
post	NN	O	O
-	NN	O	O
spinal	NN	O	O
block	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Efforts	NN	O	O
must	NN	O	O
therefore	NN	O	O
continue	NN	O	O
to	NN	O	O
be	NN	O	O
made	NN	O	O
to	NN	O	O
obviate	NN	O	O
this	NN	O	O
setback	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
and	NN	O	O
respiratory	NN	O	O
changes	NN	O	O
during	NN	O	O
unilateral	NN	O	O
and	NN	O	O
conventional	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
With	NN	O	O
ethical	NN	O	O
approval	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
74	NN	O	O
American	NN	O	O
Society	NN	O	O
of	NN	O	O
Anesthesiologists	NN	O	O
(	NN	O	O
ASA	NN	O	O
)	NN	O	O
,	NN	O	O
physical	NN	O	O
status	NN	O	O
class	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
patients	NN	O	O
scheduled	NN	O	O
for	NN	O	O
elective	NN	O	O
unilateral	NN	O	O
lower	NN	O	O
limb	NN	O	O
surgery	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
into	NN	O	O
one	NN	O	O
of	NN	O	O
two	NN	O	O
groups	NN	O	O
:	NN	O	O
lateral	NN	O	O
and	NN	O	O
conventional	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
lateral	NN	O	O
position	NN	O	O
with	NN	O	O
operative	NN	O	O
side	NN	O	O
down	NN	O	O
,	NN	O	O
patients	NN	O	O
recived	NN	O	O
10	NN	O	O
mg	NN	O	O
(	NN	O	O
2mls	NN	O	O
)	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
hyperbaric	NN	O	O
bupivacaine	NN	O	O
through	NN	O	O
a	NN	O	O
25	NN	O	O
-	NN	O	O
gauge	NN	O	O
spinal	NN	O	O
needle	NN	O	O
.	NN	O	O

Patients	NN	O	O
in	NN	O	O
the	NN	O	O
unilateral	NN	O	O
group	NN	O	O
were	NN	O	O
maintained	NN	O	O
in	NN	O	O
the	NN	O	O
lateral	NN	O	O
position	NN	O	O
for	NN	O	O
15	NN	O	O
minutes	NN	O	O
following	NN	O	O
spinal	NN	O	O
injection	NN	O	O
while	NN	O	O
those	NN	O	O
in	NN	O	O
the	NN	O	O
conventional	NN	O	O
group	NN	O	O
were	NN	O	O
turned	NN	O	O
supine	NN	O	O
immediately	NN	O	O
after	NN	O	O
injection	NN	O	O
.	NN	O	O

Blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
respiratory	NN	O	O
rate	NN	O	O
and	NN	O	O
oxygen	NN	O	O
saturation	NN	O	O
were	NN	O	O
monitored	NN	O	O
over	NN	O	O
1	NN	O	O
hour	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Three	NN	O	O
patients	NN	O	O
(	NN	O	O
8	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
unilateral	NN	O	O
group	NN	O	O
and	NN	O	O
5	NN	O	O
(	NN	O	O
13	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
conventional	NN	O	O
group	NN	O	O
developed	NN	O	O
hypotension	NN	O	B
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
71	NN	O	O
.	NN	O	O

Four	NN	O	O
(	NN	O	O
10	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
conventional	NN	O	O
group	NN	O	O
and	NN	O	O
1	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
unilateral	NN	O	O
group	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
17	NN	O	O
required	NN	O	O
epinephrine	NN	O	O
infusion	NN	O	O
to	NN	O	O
treat	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Patients	NN	O	O
in	NN	O	O
the	NN	O	O
conventional	NN	O	O
group	NN	O	O
had	NN	O	O
statistically	NN	O	O
significant	NN	O	O
greater	NN	O	O
fall	NN	O	O
in	NN	O	O
the	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressures	NN	O	O
at	NN	O	O
15	NN	O	O
,	NN	O	O
30	NN	O	O
and	NN	O	O
45	NN	O	O
minutes	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
baseline	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
003	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
004	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
respiratory	NN	O	O
rate	NN	O	O
and	NN	O	O
oxygen	NN	O	O
saturations	NN	O	O
in	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
were	NN	O	O
similar	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Compared	NN	O	O
to	NN	O	O
conventional	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
,	NN	O	O
unilateral	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
fewer	NN	O	O
cardiovascular	NN	O	O
perturbations	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
the	NN	O	O
type	NN	O	O
of	NN	O	O
spinal	NN	O	O
block	NN	O	O
instituted	NN	O	O
affected	NN	O	O
neither	NN	O	O
the	NN	O	O
respiratory	NN	O	O
rate	NN	O	O
nor	NN	O	O
the	NN	O	O
arterial	NN	O	O
oxygen	NN	O	O
saturation	NN	O	O
.	NN	O	O

Spectrum	NN	O	O
of	NN	O	O
adverse	NN	O	O
events	NN	O	O
after	NN	O	O
generic	NN	O	O
HAART	NN	O	O
in	NN	O	O
southern	NN	O	O
Indian	NN	O	O
HIV	NN	O	B
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
clinically	NN	O	O
significant	NN	O	O
adverse	NN	O	O
events	NN	O	O
after	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
,	NN	O	O
fixed	NN	O	O
-	NN	O	O
dose	NN	O	O
,	NN	O	O
generic	NN	O	O
highly	NN	O	O
active	NN	O	O
antiretroviral	NN	O	O
therapy	NN	O	O
(	NN	O	O
HAART	NN	O	O
)	NN	O	O
use	NN	O	O
among	NN	O	O
HIV	NN	O	B
-	NN	O	I
infected	NN	O	I
individuals	NN	O	O
in	NN	O	O
South	NN	O	O
India	NN	O	O
,	NN	O	O
we	NN	O	O
examined	NN	O	O
the	NN	O	O
experiences	NN	O	O
of	NN	O	O
3154	NN	O	O
HIV	NN	O	B
-	NN	O	I
infected	NN	O	I
individuals	NN	O	O
who	NN	O	O
received	NN	O	O
a	NN	O	O
minimum	NN	O	O
of	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
generic	NN	O	O
HAART	NN	O	O
between	NN	O	O
February	NN	O	O
1996	NN	O	O
and	NN	O	O
December	NN	O	O
2006	NN	O	O
at	NN	O	O
a	NN	O	O
tertiary	NN	O	O
HIV	NN	O	O
care	NN	O	O
referral	NN	O	O
center	NN	O	O
in	NN	O	O
South	NN	O	O
India	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
regimens	NN	O	O
were	NN	O	O
3TC	NN	O	O
+	NN	O	O
d4T	NN	O	O
+	NN	O	O
nevirapine	NN	O	O
(	NN	O	O
NVP	NN	O	O
)	NN	O	O
(	NN	O	O
54	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
zidovudine	NN	O	O
(	NN	O	O
AZT	NN	O	O
)	NN	O	O
+	NN	O	O
3TC	NN	O	O
+	NN	O	O
NVP	NN	O	O
(	NN	O	O
14	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
3TC	NN	O	O
+	NN	O	O
d4T	NN	O	O
+	NN	O	O
efavirenz	NN	O	O
(	NN	O	O
EFV	NN	O	O
)	NN	O	O
(	NN	O	O
20	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
AZT	NN	O	O
+	NN	O	O
3TC	NN	O	O
+	NN	O	O
EFV	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
adverse	NN	O	O
events	NN	O	O
and	NN	O	O
median	NN	O	O
CD4	NN	O	O
at	NN	O	O
time	NN	O	O
of	NN	O	O
event	NN	O	O
were	NN	O	O
rash	NN	O	B
(	NN	O	O
15	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
;	NN	O	O
CD4	NN	O	O
,	NN	O	O
285	NN	O	O
cells	NN	O	O
/	NN	O	O
microL	NN	O	O
)	NN	O	O
and	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
(	NN	O	O
9	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
and	NN	O	O
348	NN	O	O
cells	NN	O	O
/	NN	O	O
microL	NN	O	O
)	NN	O	O
.	NN	O	O

Clinically	NN	O	O
significant	NN	O	O
anemia	NN	O	B
(	NN	O	O
hemoglobin	NN	O	O
<	NN	O	O
7	NN	O	O
g	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
5	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
(	NN	O	O
CD4	NN	O	O
,	NN	O	O
165	NN	O	O
cells	NN	O	O
/	NN	O	O
microL	NN	O	O
)	NN	O	O
and	NN	O	O
hepatitis	NN	O	B
(	NN	O	O
clinical	NN	O	O
jaundice	NN	O	B
with	NN	O	O
alanine	NN	O	O
aminotransferase	NN	O	O
>	NN	O	O
5	NN	O	O
times	NN	O	O
upper	NN	O	O
limits	NN	O	O
of	NN	O	O
normal	NN	O	O
)	NN	O	O
in	NN	O	O
3	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
(	NN	O	O
CD4	NN	O	O
,	NN	O	O
260	NN	O	O
cells	NN	O	O
/	NN	O	O
microL	NN	O	O
)	NN	O	O
.	NN	O	O

Women	NN	O	O
were	NN	O	O
significantly	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
experience	NN	O	O
lactic	NN	O	B
acidosis	NN	O	I
,	NN	O	O
while	NN	O	O
men	NN	O	O
were	NN	O	O
significantly	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
experience	NN	O	O
immune	NN	O	B
reconstitution	NN	O	I
syndrome	NN	O	I
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
1	NN	O	O
year	NN	O	O
of	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
,	NN	O	O
NVP	NN	O	O
therapy	NN	O	O
was	NN	O	O
significantly	NN	O	O
associated	NN	O	O
with	NN	O	O
developing	NN	O	O
rash	NN	O	B
and	NN	O	O
d4T	NN	O	O
therapy	NN	O	O
with	NN	O	O
developing	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Anemia	NN	O	B
and	NN	O	O
hepatitis	NN	O	B
often	NN	O	O
occur	NN	O	O
within	NN	O	O
12	NN	O	O
weeks	NN	O	O
of	NN	O	O
initiating	NN	O	O
generic	NN	O	O
HAART	NN	O	O
.	NN	O	O

Frequent	NN	O	O
and	NN	O	O
early	NN	O	O
monitoring	NN	O	O
for	NN	O	O
these	NN	O	O
toxicities	NN	O	B
is	NN	O	O
warranted	NN	O	O
in	NN	O	O
developing	NN	O	O
countries	NN	O	O
where	NN	O	O
generic	NN	O	O
HAART	NN	O	O
is	NN	O	O
increasingly	NN	O	O
available	NN	O	O
.	NN	O	O

Thalidomide	NN	O	O
and	NN	O	O
sensory	NN	O	B
neurotoxicity	NN	O	I
:	NN	O	O
a	NN	O	O
neurophysiological	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Recent	NN	O	O
studies	NN	O	O
confirmed	NN	O	O
a	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
sensory	NN	O	B
axonal	NN	O	I
neuropathy	NN	O	I
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
different	NN	O	O
doses	NN	O	O
of	NN	O	O
thalidomide	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
'	NN	O	O
s	NN	O	O
aims	NN	O	O
were	NN	O	O
to	NN	O	O
measure	NN	O	O
variations	NN	O	O
in	NN	O	O
sural	NN	O	O
nerve	NN	O	O
sensory	NN	O	O
action	NN	O	O
potential	NN	O	O
(	NN	O	O
SAP	NN	O	O
)	NN	O	O
amplitude	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
refractory	NN	O	O
cutaneous	NN	O	B
lupus	NN	O	I
erythematosus	NN	O	I
(	NN	O	O
CLE	NN	O	B
)	NN	O	O
treated	NN	O	O
with	NN	O	O
thalidomide	NN	O	O
and	NN	O	O
use	NN	O	O
these	NN	O	O
findings	NN	O	O
to	NN	O	O
identify	NN	O	O
the	NN	O	O
neurotoxic	NN	O	B
potential	NN	O	O
of	NN	O	O
thalidomide	NN	O	O
and	NN	O	O
the	NN	O	O
recovery	NN	O	O
capacity	NN	O	O
of	NN	O	O
sensory	NN	O	O
fibres	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Clinical	NN	O	O
and	NN	O	O
electrophysiological	NN	O	O
data	NN	O	O
in	NN	O	O
12	NN	O	O
female	NN	O	O
patients	NN	O	O
with	NN	O	O
CLE	NN	O	B
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
thalidomide	NN	O	O
and	NN	O	O
up	NN	O	O
to	NN	O	O
47	NN	O	O
months	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
treatment	NN	O	O
were	NN	O	O
analysed	NN	O	O
.	NN	O	O

Sural	NN	O	O
nerve	NN	O	O
SAP	NN	O	O
amplitude	NN	O	O
reduction	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
40	NN	O	O
%	NN	O	O
was	NN	O	O
the	NN	O	O
criteria	NN	O	O
for	NN	O	O
discontinuing	NN	O	O
therapy	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
During	NN	O	O
treatment	NN	O	O
,	NN	O	O
11	NN	O	O
patients	NN	O	O
showed	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
sural	NN	O	O
nerve	NN	O	O
SAP	NN	O	O
amplitude	NN	O	O
compared	NN	O	O
to	NN	O	O
baseline	NN	O	O
values	NN	O	O
(	NN	O	O
9	NN	O	O
with	NN	O	O
a	NN	O	O
reduction	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
50	NN	O	O
%	NN	O	O
and	NN	O	O
2	NN	O	O
<	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
showed	NN	O	O
no	NN	O	O
changes	NN	O	O
in	NN	O	O
SAP	NN	O	O
amplitude	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
complained	NN	O	O
of	NN	O	O
paresthesias	NN	O	B
and	NN	O	O
leg	NN	O	O
cramps	NN	O	B
.	NN	O	O

After	NN	O	O
thalidomide	NN	O	O
treatment	NN	O	O
,	NN	O	O
sural	NN	O	O
SAP	NN	O	O
amplitude	NN	O	O
recovered	NN	O	O
in	NN	O	O
3	NN	O	O
patients	NN	O	O
.	NN	O	O

At	NN	O	O
detection	NN	O	O
of	NN	O	O
reduction	NN	O	O
in	NN	O	O
sural	NN	O	O
nerve	NN	O	O
SAP	NN	O	O
amplitude	NN	O	O
,	NN	O	O
the	NN	O	O
median	NN	O	O
thalidomide	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
was	NN	O	O
21	NN	O	O
.	NN	O	O
4	NN	O	O
g	NN	O	O
.	NN	O	O

The	NN	O	O
threshold	NN	O	O
neurotoxic	NN	O	B
dosage	NN	O	O
is	NN	O	O
lower	NN	O	O
than	NN	O	O
previously	NN	O	O
reported	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Sural	NN	O	O
nerve	NN	O	O
SAP	NN	O	O
amplitude	NN	O	O
reduction	NN	O	O
is	NN	O	O
a	NN	O	O
reliable	NN	O	O
and	NN	O	O
sensitive	NN	O	O
marker	NN	O	O
of	NN	O	O
degeneration	NN	O	O
and	NN	O	O
recovery	NN	O	O
of	NN	O	O
sensory	NN	O	O
fibres	NN	O	O
.	NN	O	O

This	NN	O	O
electrophysiological	NN	O	O
parameter	NN	O	O
provides	NN	O	O
information	NN	O	O
about	NN	O	O
subclinical	NN	O	O
neurotoxic	NN	O	B
potential	NN	O	O
of	NN	O	O
thalidomide	NN	O	O
but	NN	O	O
is	NN	O	O
not	NN	O	O
helpful	NN	O	O
in	NN	O	O
predicting	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
sensory	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Five	NN	O	O
cases	NN	O	O
of	NN	O	O
encephalitis	NN	O	B
during	NN	O	O
treatment	NN	O	O
of	NN	O	O
loiasis	NN	O	B
with	NN	O	O
diethylcarbamazine	NN	O	O
.	NN	O	O

Five	NN	O	O
cases	NN	O	O
of	NN	O	O
encephalitis	NN	O	B
following	NN	O	O
treatment	NN	O	O
with	NN	O	O
diethylcarbamazine	NN	O	O
(	NN	O	O
DEC	NN	O	O
)	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
Congolese	NN	O	O
patients	NN	O	O
with	NN	O	O
Loa	NN	O	O
loa	NN	O	O
filariasis	NN	O	B
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
had	NN	O	O
a	NN	O	O
fatal	NN	O	O
outcome	NN	O	O
and	NN	O	O
one	NN	O	O
resulted	NN	O	O
in	NN	O	O
severe	NN	O	O
sequelae	NN	O	O
.	NN	O	O

The	NN	O	O
notable	NN	O	O
fact	NN	O	O
was	NN	O	O
that	NN	O	O
this	NN	O	O
complication	NN	O	O
occurred	NN	O	O
in	NN	O	O
three	NN	O	O
patients	NN	O	O
hospitalized	NN	O	O
before	NN	O	O
treatment	NN	O	O
began	NN	O	O
,	NN	O	O
with	NN	O	O
whom	NN	O	O
particularly	NN	O	O
strict	NN	O	O
therapeutic	NN	O	O
precautions	NN	O	O
were	NN	O	O
taken	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
,	NN	O	O
initial	NN	O	O
dose	NN	O	O
less	NN	O	O
than	NN	O	O
10	NN	O	O
mg	NN	O	O
of	NN	O	O
DEC	NN	O	O
,	NN	O	O
very	NN	O	O
gradual	NN	O	O
dose	NN	O	O
increases	NN	O	O
,	NN	O	O
and	NN	O	O
associated	NN	O	O
anti	NN	O	O
-	NN	O	O
allergic	NN	O	O
treatment	NN	O	O
.	NN	O	O

This	NN	O	O
type	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
complication	NN	O	O
may	NN	O	O
not	NN	O	O
be	NN	O	O
that	NN	O	O
uncommon	NN	O	O
in	NN	O	O
highly	NN	O	O
endemic	NN	O	O
regions	NN	O	O
.	NN	O	O

It	NN	O	O
occurs	NN	O	O
primarily	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
exclusively	NN	O	O
,	NN	O	O
in	NN	O	O
subjects	NN	O	O
presenting	NN	O	O
with	NN	O	O
a	NN	O	O
high	NN	O	O
microfilarial	NN	O	O
load	NN	O	O
.	NN	O	O

The	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
encephalitis	NN	O	B
and	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
microfilaremia	NN	O	B
is	NN	O	O
evident	NN	O	O
.	NN	O	O

The	NN	O	O
pathophysiological	NN	O	O
mechanisms	NN	O	O
are	NN	O	O
discussed	NN	O	O
in	NN	O	O
the	NN	O	O
light	NN	O	O
of	NN	O	O
these	NN	O	O
observations	NN	O	O
and	NN	O	O
the	NN	O	O
few	NN	O	O
other	NN	O	O
comments	NN	O	O
on	NN	O	O
this	NN	O	O
subject	NN	O	O
published	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

Amiodarone	NN	O	O
-	NN	O	O
related	NN	O	O
pulmonary	NN	O	B
mass	NN	O	I
and	NN	O	O
unique	NN	O	O
membranous	NN	O	B
glomerulonephritis	NN	O	I
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
valvular	NN	O	B
heart	NN	O	I
disease	NN	O	I
:	NN	O	O
Diagnostic	NN	O	O
pitfall	NN	O	O
and	NN	O	O
new	NN	O	O
findings	NN	O	O
.	NN	O	O

Amiodarone	NN	O	O
is	NN	O	O
an	NN	O	O
anti	NN	O	O
-	NN	O	O
arrhythmic	NN	O	B
drug	NN	O	O
for	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
tachycardia	NN	O	B
,	NN	O	O
but	NN	O	O
various	NN	O	O
adverse	NN	O	O
effects	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

Reported	NN	O	O
herein	NN	O	O
is	NN	O	O
an	NN	O	O
autopsy	NN	O	O
case	NN	O	O
of	NN	O	O
valvular	NN	O	B
heart	NN	O	I
disease	NN	O	I
,	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
a	NN	O	O
lung	NN	O	B
mass	NN	O	I
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
cm	NN	O	O
in	NN	O	O
diameter	NN	O	O
)	NN	O	O
and	NN	O	O
proteinuria	NN	O	B
(	NN	O	O
2	NN	O	O
.	NN	O	O
76	NN	O	O
g	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
amiodarone	NN	O	O
for	NN	O	O
a	NN	O	O
long	NN	O	O
time	NN	O	O
.	NN	O	O

The	NN	O	O
lung	NN	O	B
mass	NN	O	I
was	NN	O	O
highly	NN	O	O
suspected	NN	O	O
to	NN	O	O
be	NN	O	O
lung	NN	O	B
cancer	NN	O	I
on	NN	O	O
CT	NN	O	O
and	NN	O	O
positron	NN	O	O
emission	NN	O	O
tomography	NN	O	O
,	NN	O	O
but	NN	O	O
histologically	NN	O	O
the	NN	O	O
lesion	NN	O	O
was	NN	O	O
composed	NN	O	O
of	NN	O	O
lymphoplasmacytic	NN	O	O
infiltrates	NN	O	O
in	NN	O	O
alveolar	NN	O	O
walls	NN	O	O
and	NN	O	O
intra	NN	O	O
-	NN	O	O
alveolar	NN	O	O
accumulation	NN	O	O
of	NN	O	O
foamy	NN	O	O
macrophages	NN	O	O
containing	NN	O	O
characteristic	NN	O	O
myelinoid	NN	O	O
bodies	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
it	NN	O	O
was	NN	O	O
an	NN	O	O
amiodarone	NN	O	O
-	NN	O	O
related	NN	O	O
lesion	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
lung	NN	O	O
tissue	NN	O	O
had	NN	O	O
unevenly	NN	O	O
distributed	NN	O	O
hemosiderin	NN	O	B
deposition	NN	O	O
,	NN	O	O
and	NN	O	O
abnormally	NN	O	O
tortuous	NN	O	O
capillaries	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
the	NN	O	O
mass	NN	O	O
and	NN	O	O
in	NN	O	O
heavily	NN	O	O
hemosiderotic	NN	O	B
lung	NN	O	O
portions	NN	O	O
outside	NN	O	O
the	NN	O	O
mass	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
kidneys	NN	O	O
,	NN	O	O
glomeruli	NN	O	O
had	NN	O	O
membrane	NN	O	O
spikes	NN	O	O
,	NN	O	O
prominent	NN	O	O
swelling	NN	O	O
of	NN	O	O
podocytes	NN	O	O
and	NN	O	O
subepithelial	NN	O	O
deposits	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
sometimes	NN	O	O
large	NN	O	O
and	NN	O	O
hump	NN	O	O
-	NN	O	O
like	NN	O	O
.	NN	O	O

Autoimmune	NN	O	B
diseases	NN	O	I
,	NN	O	O
viral	NN	O	B
hepatitis	NN	O	I
,	NN	O	O
malignant	NN	O	O
neoplasms	NN	O	B
or	NN	O	O
other	NN	O	O
diseases	NN	O	O
with	NN	O	O
a	NN	O	O
known	NN	O	O
relationship	NN	O	O
to	NN	O	O
membranous	NN	O	B
glomerulonephritis	NN	O	I
were	NN	O	O
not	NN	O	O
found	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
case	NN	O	O
highlights	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
differential	NN	O	O
diagnosis	NN	O	O
between	NN	O	O
an	NN	O	O
amiodarone	NN	O	O
-	NN	O	O
related	NN	O	O
pulmonary	NN	O	B
lesion	NN	O	I
and	NN	O	O
a	NN	O	O
neoplasm	NN	O	B
can	NN	O	O
be	NN	O	O
very	NN	O	O
difficult	NN	O	O
radiologically	NN	O	O
,	NN	O	O
and	NN	O	O
suggests	NN	O	O
that	NN	O	O
membranous	NN	O	B
glomerulonephritis	NN	O	I
might	NN	O	O
be	NN	O	O
another	NN	O	O
possible	NN	O	O
complication	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
treatment	NN	O	O
.	NN	O	O

Risk	NN	O	O
of	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
associated	NN	O	O
with	NN	O	O
initial	NN	O	O
sulphonylurea	NN	O	O
treatment	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
type	NN	O	B
2	NN	O	I
diabetes	NN	O	I
:	NN	O	O
a	NN	O	O
matched	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
.	NN	O	O

AIMS	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
sought	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
developing	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
(	NN	O	O
CAD	NN	O	B
)	NN	O	O
associated	NN	O	O
with	NN	O	O
initial	NN	O	O
treatment	NN	O	O
of	NN	O	O
type	NN	O	B
2	NN	O	I
diabetes	NN	O	I
with	NN	O	O
different	NN	O	O
sulphonylureas	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
In	NN	O	O
type	NN	O	B
2	NN	O	I
diabetic	NN	O	I
patients	NN	O	O
,	NN	O	O
cases	NN	O	O
who	NN	O	O
developed	NN	O	O
CAD	NN	O	B
were	NN	O	O
compared	NN	O	O
retrospectively	NN	O	O
with	NN	O	O
controls	NN	O	O
that	NN	O	O
did	NN	O	O
not	NN	O	O
.	NN	O	O

The	NN	O	O
20	NN	O	O
-	NN	O	O
year	NN	O	O
risk	NN	O	O
of	NN	O	O
CAD	NN	O	B
at	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
diabetes	NN	O	B
,	NN	O	O
using	NN	O	O
the	NN	O	O
UKPDS	NN	O	O
risk	NN	O	O
engine	NN	O	O
,	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
match	NN	O	O
cases	NN	O	O
with	NN	O	O
controls	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
76	NN	O	O
cases	NN	O	O
of	NN	O	O
CAD	NN	O	B
were	NN	O	O
compared	NN	O	O
with	NN	O	O
152	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
hazard	NN	O	O
of	NN	O	O
developing	NN	O	O
CAD	NN	O	B
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
)	NN	O	O
associated	NN	O	O
with	NN	O	O
initial	NN	O	O
treatment	NN	O	O
increased	NN	O	O
by	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
fold	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
004	NN	O	O
)	NN	O	O
with	NN	O	O
glibenclamide	NN	O	O
;	NN	O	O
2	NN	O	O
-	NN	O	O
fold	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
6	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
099	NN	O	O
)	NN	O	O
with	NN	O	O
glipizide	NN	O	O
;	NN	O	O
2	NN	O	O
.	NN	O	O
9	NN	O	O
-	NN	O	O
fold	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
000	NN	O	O
)	NN	O	O
with	NN	O	O
either	NN	O	O
,	NN	O	O
and	NN	O	O
was	NN	O	O
unchanged	NN	O	O
with	NN	O	O
metformin	NN	O	O
.	NN	O	O

The	NN	O	O
hazard	NN	O	O
decreased	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
fold	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
385	NN	O	O
)	NN	O	O
with	NN	O	O
glimepiride	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
fold	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
192	NN	O	O
)	NN	O	O
with	NN	O	O
gliclazide	NN	O	O
,	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
fold	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
09	NN	O	O
)	NN	O	O
with	NN	O	O
either	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Initiating	NN	O	O
treatment	NN	O	O
of	NN	O	O
type	NN	O	B
2	NN	O	I
diabetes	NN	O	I
with	NN	O	O
glibenclamide	NN	O	O
or	NN	O	O
glipizide	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
CAD	NN	O	B
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
gliclazide	NN	O	O
or	NN	O	O
glimepiride	NN	O	O
.	NN	O	O

If	NN	O	O
confirmed	NN	O	O
,	NN	O	O
this	NN	O	O
may	NN	O	O
be	NN	O	O
important	NN	O	O
because	NN	O	O
most	NN	O	O
Indian	NN	O	O
patients	NN	O	O
receive	NN	O	O
the	NN	O	O
cheaper	NN	O	O
older	NN	O	O
sulphonylureas	NN	O	O
,	NN	O	O
and	NN	O	O
present	NN	O	O
guidelines	NN	O	O
do	NN	O	O
not	NN	O	O
distinguish	NN	O	O
between	NN	O	O
individual	NN	O	O
agents	NN	O	O
.	NN	O	O

Reduced	NN	O	O
progression	NN	O	O
of	NN	O	O
adriamycin	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
treated	NN	O	O
by	NN	O	O
losartan	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
antihypertensive	NN	O	O
effects	NN	O	O
of	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
type	NN	O	O
-	NN	O	O
1	NN	O	O
receptor	NN	O	O
blocker	NN	O	O
,	NN	O	O
losartan	NN	O	O
,	NN	O	O
and	NN	O	O
its	NN	O	O
potential	NN	O	O
in	NN	O	O
slowing	NN	O	O
down	NN	O	O
renal	NN	O	B
disease	NN	O	I
progression	NN	O	O
in	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
(	NN	O	O
SHR	NN	O	O
)	NN	O	O
with	NN	O	O
adriamycin	NN	O	O
(	NN	O	O
ADR	NN	O	O
)	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Six	NN	O	O
-	NN	O	O
month	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
SHR	NN	O	O
were	NN	O	O
randomly	NN	O	O
selected	NN	O	O
in	NN	O	O
six	NN	O	O
groups	NN	O	O
.	NN	O	O

Two	NN	O	O
control	NN	O	O
groups	NN	O	O
(	NN	O	O
SH	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
SH	NN	O	O
(	NN	O	O
12	NN	O	O
)	NN	O	O
)	NN	O	O
received	NN	O	O
vehicle	NN	O	O
.	NN	O	O

Groups	NN	O	O
ADR	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
ADR	NN	O	O
+	NN	O	O
LOS	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
and	NN	O	O
ADR	NN	O	O
(	NN	O	O
12	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
ADR	NN	O	O
+	NN	O	O
LOS	NN	O	O
(	NN	O	O
12	NN	O	O
)	NN	O	O
received	NN	O	O
ADR	NN	O	O
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
b	NN	O	O
.	NN	O	O
w	NN	O	O
.	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
twice	NN	O	O
in	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
week	NN	O	O
interval	NN	O	O
.	NN	O	O

Group	NN	O	O
ADR	NN	O	O
+	NN	O	O
LOS	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
received	NN	O	O
losartan	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
b	NN	O	O
.	NN	O	O
w	NN	O	O
.	NN	O	O
/	NN	O	O
day	NN	O	O
by	NN	O	O
gavages	NN	O	O
)	NN	O	O
for	NN	O	O
6	NN	O	O
weeks	NN	O	O
and	NN	O	O
group	NN	O	O
ADR	NN	O	O
+	NN	O	O
LOS	NN	O	O
(	NN	O	O
12	NN	O	O
)	NN	O	O
for	NN	O	O
12	NN	O	O
weeks	NN	O	O
after	NN	O	O
second	NN	O	O
injection	NN	O	O
of	NN	O	O
ADR	NN	O	O
.	NN	O	O

Animals	NN	O	O
were	NN	O	O
killed	NN	O	O
after	NN	O	O
6	NN	O	O
or	NN	O	O
12	NN	O	O
weeks	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Haemodynamic	NN	O	O
measurements	NN	O	O
were	NN	O	O
performed	NN	O	O
on	NN	O	O
anaesthetized	NN	O	O
animals	NN	O	O
,	NN	O	O
blood	NN	O	O
and	NN	O	O
urine	NN	O	O
samples	NN	O	O
were	NN	O	O
taken	NN	O	O
for	NN	O	O
biochemical	NN	O	O
analysis	NN	O	O
and	NN	O	O
the	NN	O	O
left	NN	O	O
kidney	NN	O	O
was	NN	O	O
processed	NN	O	O
for	NN	O	O
morphological	NN	O	O
studies	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Short	NN	O	O
-	NN	O	O
term	NN	O	O
losartan	NN	O	O
treatment	NN	O	O
,	NN	O	O
besides	NN	O	O
antihypertensive	NN	O	O
effect	NN	O	O
,	NN	O	O
improved	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
and	NN	O	O
ameliorated	NN	O	O
glomerulosclerosis	NN	O	B
resulting	NN	O	O
in	NN	O	O
decreased	NN	O	O
proteinuria	NN	O	B
.	NN	O	O

Prolonged	NN	O	O
treatment	NN	O	O
with	NN	O	O
losartan	NN	O	O
showed	NN	O	O
further	NN	O	O
reduction	NN	O	O
of	NN	O	O
glomerulosclerosis	NN	O	B
associated	NN	O	O
with	NN	O	O
reduced	NN	O	O
progression	NN	O	O
of	NN	O	O
tubular	NN	O	O
atrophy	NN	O	B
and	NN	O	O
interstitial	NN	O	B
fibrosis	NN	O	I
,	NN	O	O
thus	NN	O	O
preventing	NN	O	O
heavy	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
.	NN	O	O

Losartan	NN	O	O
reduced	NN	O	O
uraemia	NN	O	B
and	NN	O	O
increased	NN	O	O
urea	NN	O	O
clearance	NN	O	O
in	NN	O	O
advanced	NN	O	O
ADR	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
SHR	NN	O	O
.	NN	O	O

Histological	NN	O	O
examination	NN	O	O
showed	NN	O	O
that	NN	O	O
losartan	NN	O	O
could	NN	O	O
prevent	NN	O	O
tubular	NN	O	O
atrophy	NN	O	B
,	NN	O	O
interstitial	NN	O	O
infiltration	NN	O	O
and	NN	O	O
fibrosis	NN	O	B
in	NN	O	O
ADR	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Losartan	NN	O	O
reduces	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
progression	NN	O	O
of	NN	O	O
ADR	NN	O	O
-	NN	O	O
induced	NN	O	O
focal	NN	O	B
segmental	NN	O	I
glomerulosclerosis	NN	O	I
to	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
renal	NN	O	I
disease	NN	O	I
in	NN	O	O
SHR	NN	O	O
.	NN	O	O

The	NN	O	O
risks	NN	O	O
of	NN	O	O
aprotinin	NN	O	O
and	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
in	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
:	NN	O	O
a	NN	O	O
one	NN	O	O
-	NN	O	O
year	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
1188	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Our	NN	O	O
aim	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
postoperative	NN	O	O
complications	NN	O	O
and	NN	O	O
mortality	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
aprotinin	NN	O	O
compared	NN	O	O
to	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
in	NN	O	O
an	NN	O	O
unselected	NN	O	O
,	NN	O	O
consecutive	NN	O	O
cohort	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Perioperative	NN	O	O
data	NN	O	O
from	NN	O	O
consecutive	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
patients	NN	O	O
were	NN	O	O
prospectively	NN	O	O
collected	NN	O	O
between	NN	O	O
September	NN	O	O
2005	NN	O	O
and	NN	O	O
June	NN	O	O
2006	NN	O	O
in	NN	O	O
a	NN	O	O
university	NN	O	O
-	NN	O	O
affiliated	NN	O	O
clinic	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
1188	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
first	NN	O	O
5	NN	O	O
mo	NN	O	O
,	NN	O	O
596	NN	O	O
patients	NN	O	O
received	NN	O	O
aprotinin	NN	O	O
(	NN	O	O
Group	NN	O	O
A	NN	O	O
)	NN	O	O
;	NN	O	O
in	NN	O	O
the	NN	O	O
next	NN	O	O
5	NN	O	O
mo	NN	O	O
,	NN	O	O
592	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
(	NN	O	O
Group	NN	O	O
T	NN	O	O
)	NN	O	O
.	NN	O	O

Except	NN	O	O
for	NN	O	O
antifibrinolytic	NN	O	O
therapy	NN	O	O
,	NN	O	O
the	NN	O	O
anesthetic	NN	O	O
and	NN	O	O
surgical	NN	O	O
protocols	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
pre	NN	O	O
-	NN	O	O
and	NN	O	O
intraoperative	NN	O	O
variables	NN	O	O
were	NN	O	O
comparable	NN	O	O
between	NN	O	O
the	NN	O	O
treatment	NN	O	O
groups	NN	O	O
.	NN	O	O

Postoperatively	NN	O	O
,	NN	O	O
a	NN	O	O
significantly	NN	O	O
higher	NN	O	O
incidence	NN	O	O
of	NN	O	O
seizures	NN	O	B
was	NN	O	O
found	NN	O	O
in	NN	O	O
Group	NN	O	O
T	NN	O	O
(	NN	O	O
4	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
vs	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
difference	NN	O	O
was	NN	O	O
also	NN	O	O
significant	NN	O	O
in	NN	O	O
the	NN	O	O
primary	NN	O	O
valve	NN	O	O
surgery	NN	O	O
and	NN	O	O
the	NN	O	O
high	NN	O	O
risk	NN	O	O
surgery	NN	O	O
subgroups	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
vs	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
003	NN	O	O
;	NN	O	O
7	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
vs	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
035	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Persistent	NN	O	O
atrial	NN	O	O
fibrillation	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
vs	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
020	NN	O	O
)	NN	O	O
and	NN	O	O
renal	NN	O	B
failure	NN	O	I
(	NN	O	O
9	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
vs	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
002	NN	O	O
)	NN	O	O
were	NN	O	O
also	NN	O	O
more	NN	O	O
common	NN	O	O
in	NN	O	O
Group	NN	O	O
T	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
primary	NN	O	O
valve	NN	O	O
surgery	NN	O	O
subgroup	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
contrary	NN	O	O
,	NN	O	O
among	NN	O	O
primary	NN	O	O
coronary	NN	O	O
artery	NN	O	O
bypass	NN	O	O
surgery	NN	O	O
patients	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
more	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
infarctions	NN	O	I
and	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
in	NN	O	O
Group	NN	O	O
A	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
vs	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
027	NN	O	O
;	NN	O	O
22	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
vs	NN	O	O
15	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
036	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
1	NN	O	O
-	NN	O	O
yr	NN	O	O
mortality	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
after	NN	O	O
aprotinin	NN	O	O
treatment	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
risk	NN	O	O
surgery	NN	O	O
group	NN	O	O
(	NN	O	O
17	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
vs	NN	O	O
9	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
034	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Both	NN	O	O
antifibrinolytic	NN	O	O
drugs	NN	O	O
bear	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
adverse	NN	O	O
outcome	NN	O	O
depending	NN	O	O
on	NN	O	O
the	NN	O	O
type	NN	O	O
of	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
aprotinin	NN	O	O
should	NN	O	O
be	NN	O	O
avoided	NN	O	O
in	NN	O	O
coronary	NN	O	O
artery	NN	O	O
bypass	NN	O	O
graft	NN	O	O
and	NN	O	O
high	NN	O	O
risk	NN	O	O
patients	NN	O	O
,	NN	O	O
whereas	NN	O	O
administration	NN	O	O
of	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
is	NN	O	O
not	NN	O	O
recommended	NN	O	O
in	NN	O	O
valve	NN	O	O
surgery	NN	O	O
.	NN	O	O

Delirium	NN	O	B
in	NN	O	O
an	NN	O	O
elderly	NN	O	O
woman	NN	O	O
possibly	NN	O	O
associated	NN	O	O
with	NN	O	O
administration	NN	O	O
of	NN	O	O
misoprostol	NN	O	O
.	NN	O	O

Misoprostol	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
,	NN	O	O
including	NN	O	O
gastrointestinal	NN	O	O
symptoms	NN	O	O
,	NN	O	O
gynecologic	NN	O	O
problems	NN	O	O
,	NN	O	O
and	NN	O	O
headache	NN	O	B
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
mental	NN	O	O
status	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
in	NN	O	O
which	NN	O	O
an	NN	O	O
89	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
in	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
care	NN	O	O
facility	NN	O	O
became	NN	O	O
confused	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
misoprostol	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
change	NN	O	O
in	NN	O	O
mental	NN	O	O
status	NN	O	O
was	NN	O	O
first	NN	O	O
reported	NN	O	O
nine	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

Her	NN	O	O
delirium	NN	O	B
significantly	NN	O	O
improved	NN	O	O
after	NN	O	O
misoprostol	NN	O	O
was	NN	O	O
discontinued	NN	O	O
and	NN	O	O
her	NN	O	O
mental	NN	O	O
status	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
within	NN	O	O
a	NN	O	O
week	NN	O	O
.	NN	O	O

Because	NN	O	O
no	NN	O	O
other	NN	O	O
factors	NN	O	O
related	NN	O	O
to	NN	O	O
this	NN	O	O
patient	NN	O	O
changed	NN	O	O
significantly	NN	O	O
,	NN	O	O
the	NN	O	O
delirium	NN	O	B
experienced	NN	O	O
by	NN	O	O
this	NN	O	O
patient	NN	O	O
possibly	NN	O	O
resulted	NN	O	O
from	NN	O	O
misoprostol	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
biological	NN	O	O
properties	NN	O	O
of	NN	O	O
the	NN	O	O
optical	NN	O	O
isomers	NN	O	O
of	NN	O	O
propranolol	NN	O	O
and	NN	O	O
their	NN	O	O
effects	NN	O	O
on	NN	O	O
cardiac	NN	O	B
arrhythmias	NN	O	I
.	NN	O	O

1	NN	O	O
.	NN	O	O

The	NN	O	O
optical	NN	O	O
isomers	NN	O	O
of	NN	O	O
propranolol	NN	O	O
have	NN	O	O
been	NN	O	O
compared	NN	O	O
for	NN	O	O
their	NN	O	O
beta	NN	O	O
-	NN	O	O
blocking	NN	O	O
and	NN	O	O
antiarrhythmic	NN	O	O
activities	NN	O	O
.	NN	O	O
2	NN	O	O
.	NN	O	O

In	NN	O	O
blocking	NN	O	O
the	NN	O	O
positive	NN	O	O
inotropic	NN	O	O
and	NN	O	O
chronotropic	NN	O	O
responses	NN	O	O
to	NN	O	O
isoprenaline	NN	O	O
,	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
propranolol	NN	O	O
had	NN	O	O
less	NN	O	O
than	NN	O	O
one	NN	O	O
hundredth	NN	O	O
the	NN	O	O
potency	NN	O	O
of	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
propranolol	NN	O	O
.	NN	O	O

At	NN	O	O
dose	NN	O	O
levels	NN	O	O
of	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
propranolol	NN	O	O
which	NN	O	O
attenuated	NN	O	O
the	NN	O	O
responses	NN	O	O
to	NN	O	O
isoprenaline	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
prolongation	NN	O	O
of	NN	O	O
the	NN	O	O
PR	NN	O	O
interval	NN	O	O
of	NN	O	O
the	NN	O	O
electrocardiogram	NN	O	O
.	NN	O	O
3	NN	O	O
.	NN	O	O

The	NN	O	O
metabolic	NN	O	O
responses	NN	O	O
to	NN	O	O
isoprenaline	NN	O	O
in	NN	O	O
dogs	NN	O	O
(	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
circulating	NN	O	O
glucose	NN	O	O
,	NN	O	O
lactate	NN	O	O
and	NN	O	O
free	NN	O	O
fatty	NN	O	O
acids	NN	O	O
)	NN	O	O
were	NN	O	O
all	NN	O	O
blocked	NN	O	O
by	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
propranolol	NN	O	O
.	NN	O	O

(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
Propranolol	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
fatty	NN	O	O
acid	NN	O	O
mobilization	NN	O	O
but	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
increments	NN	O	O
in	NN	O	O
both	NN	O	O
lactate	NN	O	O
and	NN	O	O
glucose	NN	O	O
.	NN	O	O
4	NN	O	O
.	NN	O	O

Both	NN	O	O
isomers	NN	O	O
of	NN	O	O
propranolol	NN	O	O
possessed	NN	O	O
similar	NN	O	O
depressant	NN	O	O
potency	NN	O	O
on	NN	O	O
isolated	NN	O	O
atrial	NN	O	O
muscle	NN	O	O
taken	NN	O	O
from	NN	O	O
guinea	NN	O	O
-	NN	O	O
pigs	NN	O	O
.	NN	O	O
5	NN	O	O
.	NN	O	O

The	NN	O	O
isomers	NN	O	O
of	NN	O	O
propranolol	NN	O	O
exhibited	NN	O	O
similar	NN	O	O
local	NN	O	O
anaesthetic	NN	O	O
potencies	NN	O	O
on	NN	O	O
an	NN	O	O
isolated	NN	O	O
frog	NN	O	O
nerve	NN	O	O
preparation	NN	O	O
at	NN	O	O
a	NN	O	O
level	NN	O	O
approximately	NN	O	O
three	NN	O	O
times	NN	O	O
that	NN	O	O
of	NN	O	O
procaine	NN	O	O
.	NN	O	O

The	NN	O	O
racemic	NN	O	O
compound	NN	O	O
was	NN	O	O
significantly	NN	O	O
less	NN	O	O
potent	NN	O	O
than	NN	O	O
either	NN	O	O
isomer	NN	O	O
.	NN	O	O
6	NN	O	O
.	NN	O	O

Both	NN	O	O
isomers	NN	O	O
of	NN	O	O
propranolol	NN	O	O
were	NN	O	O
capable	NN	O	O
of	NN	O	O
preventing	NN	O	O
adrenaline	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
arrhythmias	NN	O	I
in	NN	O	O
cats	NN	O	O
anaesthetized	NN	O	O
with	NN	O	O
halothane	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
mean	NN	O	O
dose	NN	O	O
of	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
propranolol	NN	O	O
was	NN	O	O
0	NN	O	O
.	NN	O	O
09	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
whereas	NN	O	O
that	NN	O	O
of	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
propranolol	NN	O	O
was	NN	O	O
4	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
effective	NN	O	O
dose	NN	O	O
level	NN	O	O
of	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
propranolol	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
prolongation	NN	O	O
of	NN	O	O
the	NN	O	O
PR	NN	O	O
interval	NN	O	O
of	NN	O	O
the	NN	O	O
electrocardiogram	NN	O	O
.	NN	O	O

Blockade	NN	O	O
of	NN	O	O
arrhythmias	NN	O	B
with	NN	O	O
both	NN	O	O
isomers	NN	O	O
was	NN	O	O
surmountable	NN	O	O
by	NN	O	O
increasing	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
adrenaline	NN	O	O
.	NN	O	O
7	NN	O	O
.	NN	O	O

Both	NN	O	O
isomers	NN	O	O
of	NN	O	O
propranolol	NN	O	O
were	NN	O	O
also	NN	O	O
capable	NN	O	O
of	NN	O	O
reversing	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
caused	NN	O	O
by	NN	O	O
ouabain	NN	O	O
in	NN	O	O
anaesthetized	NN	O	O
cats	NN	O	O
and	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
of	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
propranolol	NN	O	O
was	NN	O	O
significantly	NN	O	O
smaller	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
propranolol	NN	O	O
in	NN	O	O
both	NN	O	O
species	NN	O	O
but	NN	O	O
much	NN	O	O
higher	NN	O	O
than	NN	O	O
that	NN	O	O
required	NN	O	O
to	NN	O	O
produce	NN	O	O
evidence	NN	O	O
of	NN	O	O
beta	NN	O	O
-	NN	O	O
blockade	NN	O	O
.	NN	O	O
8	NN	O	O
.	NN	O	O

The	NN	O	O
implications	NN	O	O
of	NN	O	O
these	NN	O	O
results	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Topotecan	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
radiotherapy	NN	O	O
in	NN	O	O
unresectable	NN	O	O
glioblastoma	NN	O	B
:	NN	O	O
a	NN	O	O
phase	NN	O	O
2	NN	O	O
study	NN	O	O
.	NN	O	O

Improving	NN	O	O
glioblastoma	NN	O	B
multiforme	NN	O	I
(	NN	O	O
GBM	NN	O	B
)	NN	O	O
treatment	NN	O	O
with	NN	O	O
radio	NN	O	O
-	NN	O	O
chemotherapy	NN	O	O
remains	NN	O	O
a	NN	O	O
challenge	NN	O	O
.	NN	O	O

Topotecan	NN	O	O
is	NN	O	O
an	NN	O	O
attractive	NN	O	O
option	NN	O	O
as	NN	O	O
it	NN	O	O
exhibits	NN	O	O
growth	NN	O	O
inhibition	NN	O	O
of	NN	O	O
human	NN	O	O
glioma	NN	O	B
as	NN	O	O
well	NN	O	O
as	NN	O	O
brain	NN	O	O
penetration	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
assessed	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
radiotherapy	NN	O	O
(	NN	O	O
60	NN	O	O
Gy	NN	O	O
/	NN	O	O
30	NN	O	O
fractions	NN	O	O
/	NN	O	O
40	NN	O	O
days	NN	O	O
)	NN	O	O
and	NN	O	O
topotecan	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
/	NN	O	O
day	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
-	NN	O	O
5	NN	O	O
on	NN	O	O
weeks	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
and	NN	O	O
5	NN	O	O
)	NN	O	O
in	NN	O	O
50	NN	O	O
adults	NN	O	O
with	NN	O	O
histologically	NN	O	O
proven	NN	O	O
and	NN	O	O
untreated	NN	O	O
GBM	NN	O	B
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
hematological	NN	O	O
toxicities	NN	O	B
was	NN	O	O
low	NN	O	O
and	NN	O	O
grade	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
hematological	NN	O	O
toxicities	NN	O	B
were	NN	O	O
reported	NN	O	O
in	NN	O	O
20	NN	O	O
patients	NN	O	O
(	NN	O	O
mainly	NN	O	O
lymphopenia	NN	O	B
and	NN	O	O
neutropenia	NN	O	B
)	NN	O	O
.	NN	O	O

Partial	NN	O	O
response	NN	O	O
and	NN	O	O
stabilization	NN	O	O
rates	NN	O	O
were	NN	O	O
2	NN	O	O
%	NN	O	O
and	NN	O	O
32	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
with	NN	O	O
an	NN	O	O
overall	NN	O	O
time	NN	O	O
to	NN	O	O
progression	NN	O	O
of	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

One	NN	O	O
-	NN	O	O
year	NN	O	O
overall	NN	O	O
survival	NN	O	O
(	NN	O	O
OS	NN	O	O
)	NN	O	O
rate	NN	O	O
was	NN	O	O
42	NN	O	O
%	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
median	NN	O	O
OS	NN	O	O
of	NN	O	O
40	NN	O	O
weeks	NN	O	O
.	NN	O	O

Topotecan	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
radiotherapy	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
while	NN	O	O
response	NN	O	O
and	NN	O	O
stabilization	NN	O	O
concerned	NN	O	O
one	NN	O	O
-	NN	O	O
third	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
study	NN	O	O
did	NN	O	O
not	NN	O	O
show	NN	O	O
increased	NN	O	O
benefits	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
survival	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
unresectable	NN	O	O
GBM	NN	O	B
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
lithium	NN	O	O
therapy	NN	O	O
leading	NN	O	O
to	NN	O	O
hyperparathyroidism	NN	O	B
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
This	NN	O	O
paper	NN	O	O
reviews	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
chronic	NN	O	O
lithium	NN	O	O
therapy	NN	O	O
on	NN	O	O
serum	NN	O	O
calcium	NN	O	O
level	NN	O	O
and	NN	O	O
parathyroid	NN	O	O
glands	NN	O	O
,	NN	O	O
its	NN	O	O
pathogenesis	NN	O	O
,	NN	O	O
and	NN	O	O
treatment	NN	O	O
options	NN	O	O
.	NN	O	O

We	NN	O	O
examined	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
lithium	NN	O	O
-	NN	O	O
treated	NN	O	O
patient	NN	O	O
who	NN	O	O
had	NN	O	O
recurrent	NN	O	O
hypercalcemia	NN	O	B
to	NN	O	O
better	NN	O	O
understand	NN	O	O
the	NN	O	O
disease	NN	O	O
process	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Primary	NN	O	B
hyperparathyroidism	NN	O	I
is	NN	O	O
a	NN	O	O
rare	NN	O	O
but	NN	O	O
potentially	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
lithium	NN	O	O
therapy	NN	O	O
.	NN	O	O

Careful	NN	O	O
patient	NN	O	O
selection	NN	O	O
and	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
can	NN	O	O
reduce	NN	O	O
morbidity	NN	O	O
.	NN	O	O

PRACTICAL	NN	O	O
IMPLICATIONS	NN	O	O
:	NN	O	O
As	NN	O	O
much	NN	O	O
as	NN	O	O
15	NN	O	O
%	NN	O	O
of	NN	O	O
lithium	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
become	NN	O	O
hypercalcemic	NN	O	B
.	NN	O	O

By	NN	O	O
routinely	NN	O	O
monitoring	NN	O	O
serum	NN	O	O
calcium	NN	O	O
levels	NN	O	O
,	NN	O	O
healthcare	NN	O	O
providers	NN	O	O
can	NN	O	O
improve	NN	O	O
the	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
of	NN	O	O
this	NN	O	O
patient	NN	O	O
group	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
laryngeal	NN	O	O
mask	NN	O	O
with	NN	O	O
endotracheal	NN	O	O
tube	NN	O	O
for	NN	O	O
anesthesia	NN	O	O
in	NN	O	O
endoscopic	NN	O	O
sinus	NN	O	O
surgery	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
compare	NN	O	O
surgical	NN	O	O
conditions	NN	O	O
,	NN	O	O
including	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
intraoperative	NN	O	O
bleeding	NN	O	B
as	NN	O	O
well	NN	O	O
as	NN	O	O
intraoperative	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
during	NN	O	O
functional	NN	O	O
endoscopic	NN	O	O
sinus	NN	O	O
surgery	NN	O	O
(	NN	O	O
FESS	NN	O	O
)	NN	O	O
using	NN	O	O
flexible	NN	O	O
reinforced	NN	O	O
laryngeal	NN	O	O
mask	NN	O	O
airway	NN	O	O
(	NN	O	O
FRLMA	NN	O	O
)	NN	O	O
versus	NN	O	O
endotracheal	NN	O	O
tube	NN	O	O
(	NN	O	O
ETT	NN	O	O
)	NN	O	O
in	NN	O	O
maintaining	NN	O	O
controlled	NN	O	O
hypotension	NN	O	B
anesthesia	NN	O	O
induced	NN	O	O
by	NN	O	O
propofol	NN	O	O
-	NN	O	O
remifentanil	NN	O	O
total	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
anesthesia	NN	O	O
(	NN	O	O
TIVA	NN	O	O
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Sixty	NN	O	O
normotensive	NN	O	O
American	NN	O	O
Society	NN	O	O
of	NN	O	O
Anesthesiologists	NN	O	O
I	NN	O	O
-	NN	O	O
II	NN	O	O
adult	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
FESS	NN	O	O
under	NN	O	O
controlled	NN	O	O
hypotension	NN	O	B
anesthesia	NN	O	O
caused	NN	O	O
by	NN	O	O
propofol	NN	O	O
-	NN	O	O
remifentanil	NN	O	O
-	NN	O	O
TIVA	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
into	NN	O	O
two	NN	O	O
groups	NN	O	O
:	NN	O	O
group	NN	O	O
I	NN	O	O
,	NN	O	O
FRLMA	NN	O	O
;	NN	O	O
group	NN	O	O
II	NN	O	O
,	NN	O	O
ETT	NN	O	O
.	NN	O	O

Hemorrhage	NN	O	B
was	NN	O	O
measured	NN	O	O
and	NN	O	O
the	NN	O	O
visibility	NN	O	O
of	NN	O	O
the	NN	O	O
operative	NN	O	O
field	NN	O	O
was	NN	O	O
evaluated	NN	O	O
according	NN	O	O
to	NN	O	O
a	NN	O	O
six	NN	O	O
-	NN	O	O
point	NN	O	O
scale	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Controlled	NN	O	O
hypotension	NN	O	B
was	NN	O	O
achieved	NN	O	O
within	NN	O	O
a	NN	O	O
shorter	NN	O	O
period	NN	O	O
using	NN	O	O
laryngeal	NN	O	O
mask	NN	O	O
using	NN	O	O
lower	NN	O	O
rates	NN	O	O
of	NN	O	O
remifentanil	NN	O	O
infusion	NN	O	O
and	NN	O	O
lower	NN	O	O
total	NN	O	O
dose	NN	O	O
of	NN	O	O
remifentanil	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
summary	NN	O	O
,	NN	O	O
our	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
airway	NN	O	O
management	NN	O	O
using	NN	O	O
FRLMA	NN	O	O
during	NN	O	O
controlled	NN	O	O
hypotension	NN	O	B
anesthesia	NN	O	O
provided	NN	O	O
better	NN	O	O
surgical	NN	O	O
conditions	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
quality	NN	O	O
of	NN	O	O
operative	NN	O	O
field	NN	O	O
and	NN	O	O
blood	NN	O	O
loss	NN	O	O
and	NN	O	O
allowed	NN	O	O
for	NN	O	O
convenient	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
with	NN	O	O
low	NN	O	O
doses	NN	O	O
of	NN	O	O
remifentanil	NN	O	O
during	NN	O	O
TIVA	NN	O	O
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
FESS	NN	O	O
.	NN	O	O

Nonalcoholic	NN	O	B
fatty	NN	O	I
liver	NN	O	I
disease	NN	O	I
during	NN	O	O
valproate	NN	O	O
therapy	NN	O	O
.	NN	O	O

Valproic	NN	O	O
acid	NN	O	O
(	NN	O	O
VPA	NN	O	O
)	NN	O	O
is	NN	O	O
effective	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
many	NN	O	O
types	NN	O	O
of	NN	O	O
epilepsy	NN	O	B
,	NN	O	O
but	NN	O	O
its	NN	O	O
use	NN	O	O
can	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
body	NN	O	O
weight	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
nonalcoholic	NN	O	B
fatty	NN	O	I
liver	NN	O	I
disease	NN	O	I
(	NN	O	O
NAFLD	NN	O	B
)	NN	O	O
arising	NN	O	O
in	NN	O	O
a	NN	O	O
child	NN	O	O
who	NN	O	O
developed	NN	O	O
obesity	NN	O	B
during	NN	O	O
VPA	NN	O	O
treatment	NN	O	O
.	NN	O	O

Laboratory	NN	O	O
data	NN	O	O
revealed	NN	O	O
hyperinsulinemia	NN	O	B
with	NN	O	O
insulin	NN	O	B
resistance	NN	O	I
.	NN	O	O

After	NN	O	O
the	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
VPA	NN	O	O
therapy	NN	O	O
,	NN	O	O
our	NN	O	O
patient	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
weight	NN	O	B
loss	NN	O	I
,	NN	O	O
a	NN	O	O
decrease	NN	O	O
of	NN	O	O
body	NN	O	O
mass	NN	O	O
index	NN	O	O
,	NN	O	O
and	NN	O	O
normalization	NN	O	O
of	NN	O	O
metabolic	NN	O	O
and	NN	O	O
endocrine	NN	O	O
parameters	NN	O	O
;	NN	O	O
moreover	NN	O	O
,	NN	O	O
ultrasound	NN	O	O
measurements	NN	O	O
showed	NN	O	O
a	NN	O	O
complete	NN	O	O
normalization	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
case	NN	O	O
suggests	NN	O	O
that	NN	O	O
obesity	NN	O	B
,	NN	O	O
hyperinsulinemia	NN	O	B
,	NN	O	O
insulin	NN	O	B
resistance	NN	O	I
,	NN	O	O
and	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
treatment	NN	O	O
with	NN	O	O
VPA	NN	O	O
may	NN	O	O
be	NN	O	O
all	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
NAFLD	NN	O	B
;	NN	O	O
this	NN	O	O
side	NN	O	O
effect	NN	O	O
is	NN	O	O
reversible	NN	O	O
after	NN	O	O
VPA	NN	O	O
withdrawal	NN	O	O
.	NN	O	O

Carbimazole	NN	O	O
induced	NN	O	O
ANCA	NN	O	B
positive	NN	O	I
vasculitis	NN	O	I
.	NN	O	O

Anti	NN	O	O
-	NN	O	O
thyroid	NN	O	O
drugs	NN	O	O
,	NN	O	O
like	NN	O	O
carbimazole	NN	O	O
and	NN	O	O
propylthiouracil	NN	O	O
(	NN	O	O
PTU	NN	O	O
)	NN	O	O
are	NN	O	O
commonly	NN	O	O
prescribed	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
hyperthyroidism	NN	O	B
.	NN	O	O

One	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
antithyroid	NN	O	O
medications	NN	O	O
.	NN	O	O

Antineutrophil	NN	O	B
cytoplasmic	NN	O	I
antibody	NN	O	I
(	NN	O	I
ANCA	NN	O	I
)	NN	O	I
-	NN	O	I
-	NN	O	I
associated	NN	O	I
vasculitis	NN	O	I
is	NN	O	O
a	NN	O	O
potentially	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
antithyroidmedications	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
Graves	NN	O	B
'	NN	O	I
disease	NN	O	I
who	NN	O	O
developed	NN	O	O
ANCA	NN	O	O
positive	NN	O	O
carbimazole	NN	O	O
induced	NN	O	O
vasculitis	NN	O	B
.	NN	O	O

The	NN	O	O
episode	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
vasculitic	NN	O	B
skin	NN	O	B
rash	NN	O	I
associated	NN	O	O
with	NN	O	O
large	NN	O	O
joint	NN	O	O
arthritis	NN	O	B
,	NN	O	O
pyrexia	NN	O	B
and	NN	O	O
parotiditis	NN	O	B
but	NN	O	O
no	NN	O	O
renal	NN	O	O
or	NN	O	O
pulmonary	NN	O	O
involvement	NN	O	O
.	NN	O	O

He	NN	O	O
was	NN	O	O
referred	NN	O	O
to	NN	O	O
us	NN	O	O
for	NN	O	O
neurological	NN	O	O
evaluation	NN	O	O
because	NN	O	O
he	NN	O	O
had	NN	O	O
difficulty	NN	O	O
in	NN	O	O
getting	NN	O	O
up	NN	O	O
from	NN	O	O
squatting	NN	O	O
position	NN	O	O
and	NN	O	O
was	NN	O	O
suspected	NN	O	O
to	NN	O	O
have	NN	O	O
myositis	NN	O	B
.	NN	O	O

Carbimazole	NN	O	O
and	NN	O	O
methimazole	NN	O	O
have	NN	O	O
a	NN	O	O
lower	NN	O	O
incidence	NN	O	O
of	NN	O	O
reported	NN	O	O
ANCA	NN	O	O
positive	NN	O	O
side	NN	O	O
effects	NN	O	O
than	NN	O	O
PUT	NN	O	O
.	NN	O	O

To	NN	O	O
the	NN	O	O
best	NN	O	O
of	NN	O	O
our	NN	O	O
knowledge	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
ANCA	NN	O	O
positive	NN	O	O
carbimazole	NN	O	O
induced	NN	O	O
vasculitis	NN	O	B
case	NN	O	O
reported	NN	O	O
from	NN	O	O
India	NN	O	O
.	NN	O	O

Aspirin	NN	O	O
for	NN	O	O
the	NN	O	O
primary	NN	O	O
prevention	NN	O	O
of	NN	O	O
cardiovascular	NN	O	O
events	NN	O	O
:	NN	O	O
an	NN	O	O
update	NN	O	O
of	NN	O	O
the	NN	O	O
evidence	NN	O	O
for	NN	O	O
the	NN	O	O
U	NN	O	O
.	NN	O	O
S	NN	O	O
.	NN	O	O

Preventive	NN	O	O
Services	NN	O	O
Task	NN	O	O
Force	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Coronary	NN	O	B
heart	NN	O	I
disease	NN	O	I
and	NN	O	O
cerebrovascular	NN	O	B
disease	NN	O	I
are	NN	O	O
leading	NN	O	O
causes	NN	O	O
of	NN	O	O
death	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
.	NN	O	O

In	NN	O	O
2002	NN	O	O
,	NN	O	O
the	NN	O	O
U	NN	O	O
.	NN	O	O
S	NN	O	O
.	NN	O	O

Preventive	NN	O	O
Services	NN	O	O
Task	NN	O	O
Force	NN	O	O
(	NN	O	O
USPSTF	NN	O	O
)	NN	O	O
strongly	NN	O	O
recommended	NN	O	O
that	NN	O	O
clinicians	NN	O	O
discuss	NN	O	O
aspirin	NN	O	O
with	NN	O	O
adults	NN	O	O
who	NN	O	O
are	NN	O	O
at	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
coronary	NN	O	B
heart	NN	O	I
disease	NN	O	I
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
benefits	NN	O	O
and	NN	O	O
harms	NN	O	O
of	NN	O	O
taking	NN	O	O
aspirin	NN	O	O
for	NN	O	O
the	NN	O	O
primary	NN	O	O
prevention	NN	O	O
of	NN	O	O
myocardial	NN	O	B
infarctions	NN	O	I
,	NN	O	O
strokes	NN	O	B
,	NN	O	O
and	NN	O	O
death	NN	O	O
.	NN	O	O

DATA	NN	O	O
SOURCES	NN	O	O
:	NN	O	O
MEDLINE	NN	O	O
and	NN	O	O
Cochrane	NN	O	O
Library	NN	O	O
(	NN	O	O
search	NN	O	O
dates	NN	O	O
,	NN	O	O
1	NN	O	O
January	NN	O	O
2001	NN	O	O
to	NN	O	O
28	NN	O	O
August	NN	O	O
2008	NN	O	O
)	NN	O	O
,	NN	O	O
recent	NN	O	O
systematic	NN	O	O
reviews	NN	O	O
,	NN	O	O
reference	NN	O	O
lists	NN	O	O
of	NN	O	O
retrieved	NN	O	O
articles	NN	O	O
,	NN	O	O
and	NN	O	O
suggestions	NN	O	O
from	NN	O	O
experts	NN	O	O
.	NN	O	O

STUDY	NN	O	O
SELECTION	NN	O	O
:	NN	O	O
English	NN	O	O
-	NN	O	O
language	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
trials	NN	O	O
(	NN	O	O
RCTs	NN	O	O
)	NN	O	O
;	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
studies	NN	O	O
;	NN	O	O
meta	NN	O	O
-	NN	O	O
analyses	NN	O	O
;	NN	O	O
and	NN	O	O
systematic	NN	O	O
reviews	NN	O	O
of	NN	O	O
aspirin	NN	O	O
versus	NN	O	O
control	NN	O	O
for	NN	O	O
the	NN	O	O
primary	NN	O	O
prevention	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
(	NN	O	O
CVD	NN	O	B
)	NN	O	O
were	NN	O	O
selected	NN	O	O
to	NN	O	O
answer	NN	O	O
the	NN	O	O
following	NN	O	O
questions	NN	O	O
:	NN	O	O
Does	NN	O	O
aspirin	NN	O	O
decrease	NN	O	O
coronary	NN	O	O
heart	NN	O	O
events	NN	O	O
,	NN	O	O
strokes	NN	O	B
,	NN	O	O
death	NN	O	O
from	NN	O	O
coronary	NN	O	O
heart	NN	O	O
events	NN	O	O
or	NN	O	O
stroke	NN	O	B
,	NN	O	O
or	NN	O	O
all	NN	O	O
-	NN	O	O
cause	NN	O	O
mortality	NN	O	O
in	NN	O	O
adults	NN	O	O
without	NN	O	O
known	NN	O	O
CVD	NN	O	B
?	NN	O	O

Does	NN	O	O
aspirin	NN	O	O
increase	NN	O	O
gastrointestinal	NN	O	B
bleeding	NN	O	I
or	NN	O	O
hemorrhagic	NN	O	B
strokes	NN	O	I
?	NN	O	O

DATA	NN	O	O
EXTRACTION	NN	O	O
:	NN	O	O
All	NN	O	O
studies	NN	O	O
were	NN	O	O
reviewed	NN	O	O
,	NN	O	O
abstracted	NN	O	O
,	NN	O	O
and	NN	O	O
rated	NN	O	O
for	NN	O	O
quality	NN	O	O
by	NN	O	O
using	NN	O	O
predefined	NN	O	O
USPSTF	NN	O	O
criteria	NN	O	O
.	NN	O	O

DATA	NN	O	O
SYNTHESIS	NN	O	O
:	NN	O	O
New	NN	O	O
evidence	NN	O	O
from	NN	O	O
1	NN	O	O
good	NN	O	O
-	NN	O	O
quality	NN	O	O
RCT	NN	O	O
,	NN	O	O
1	NN	O	O
good	NN	O	O
-	NN	O	O
quality	NN	O	O
meta	NN	O	O
-	NN	O	O
analysis	NN	O	O
,	NN	O	O
and	NN	O	O
2	NN	O	O
fair	NN	O	O
-	NN	O	O
quality	NN	O	O
subanalyses	NN	O	O
of	NN	O	O
RCTs	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
aspirin	NN	O	O
use	NN	O	O
reduces	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
CVD	NN	O	B
events	NN	O	O
in	NN	O	O
patients	NN	O	O
without	NN	O	O
known	NN	O	O
CVD	NN	O	B
.	NN	O	O

Men	NN	O	O
in	NN	O	O
these	NN	O	O
studies	NN	O	O
experienced	NN	O	O
fewer	NN	O	O
myocardial	NN	O	B
infarctions	NN	O	I
and	NN	O	O
women	NN	O	O
experienced	NN	O	O
fewer	NN	O	O
ischemic	NN	O	O
strokes	NN	O	B
.	NN	O	O

Aspirin	NN	O	O
does	NN	O	O
not	NN	O	O
seem	NN	O	O
to	NN	O	O
affect	NN	O	O
CVD	NN	O	B
mortality	NN	O	O
or	NN	O	O
all	NN	O	O
-	NN	O	O
cause	NN	O	O
mortality	NN	O	O
in	NN	O	O
either	NN	O	O
men	NN	O	O
or	NN	O	O
women	NN	O	O
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
aspirin	NN	O	O
for	NN	O	O
primary	NN	O	O
prevention	NN	O	O
increases	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
major	NN	O	O
bleeding	NN	O	B
events	NN	O	O
,	NN	O	O
primarily	NN	O	O
gastrointestinal	NN	O	B
bleeding	NN	O	I
events	NN	O	O
,	NN	O	O
in	NN	O	O
both	NN	O	O
men	NN	O	O
and	NN	O	O
women	NN	O	O
.	NN	O	O

Men	NN	O	O
have	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
hemorrhagic	NN	O	B
strokes	NN	O	I
with	NN	O	O
aspirin	NN	O	O
use	NN	O	O
.	NN	O	O

A	NN	O	O
new	NN	O	O
RCT	NN	O	O
and	NN	O	O
meta	NN	O	O
-	NN	O	O
analysis	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
hemorrhagic	NN	O	B
strokes	NN	O	I
in	NN	O	O
women	NN	O	O
is	NN	O	O
not	NN	O	O
statistically	NN	O	O
significantly	NN	O	O
increased	NN	O	O
.	NN	O	O

LIMITATIONS	NN	O	O
:	NN	O	O
New	NN	O	O
evidence	NN	O	O
on	NN	O	O
aspirin	NN	O	O
for	NN	O	O
the	NN	O	O
primary	NN	O	O
prevention	NN	O	O
of	NN	O	O
CVD	NN	O	B
is	NN	O	O
limited	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
of	NN	O	O
aspirin	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
RCTs	NN	O	O
varied	NN	O	O
,	NN	O	O
which	NN	O	O
prevented	NN	O	O
the	NN	O	O
estimation	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
appropriate	NN	O	O
dose	NN	O	O
for	NN	O	O
primary	NN	O	O
prevention	NN	O	O
.	NN	O	O

Several	NN	O	O
of	NN	O	O
the	NN	O	O
RCTs	NN	O	O
were	NN	O	O
conducted	NN	O	O
within	NN	O	O
populations	NN	O	O
of	NN	O	O
health	NN	O	O
professionals	NN	O	O
,	NN	O	O
which	NN	O	O
potentially	NN	O	O
limits	NN	O	O
generalizability	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Aspirin	NN	O	O
reduces	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
men	NN	O	O
and	NN	O	O
strokes	NN	O	B
in	NN	O	O
women	NN	O	O
.	NN	O	O

Aspirin	NN	O	O
use	NN	O	O
increases	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
serious	NN	O	O
bleeding	NN	O	B
events	NN	O	O
.	NN	O	O

Reducing	NN	O	O
harm	NN	O	O
associated	NN	O	O
with	NN	O	O
anticoagulation	NN	O	O
:	NN	O	O
practical	NN	O	O
considerations	NN	O	O
of	NN	O	O
argatroban	NN	O	O
therapy	NN	O	O
in	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
.	NN	O	O

Argatroban	NN	O	O
is	NN	O	O
a	NN	O	O
hepatically	NN	O	O
metabolized	NN	O	O
,	NN	O	O
direct	NN	O	O
thrombin	NN	O	O
inhibitor	NN	O	O
used	NN	O	O
for	NN	O	O
prophylaxis	NN	O	O
or	NN	O	O
treatment	NN	O	O
of	NN	O	O
thrombosis	NN	O	B
in	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
(	NN	O	O
HIT	NN	O	B
)	NN	O	O
and	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
or	NN	O	O
at	NN	O	O
risk	NN	O	O
of	NN	O	O
HIT	NN	O	B
undergoing	NN	O	O
percutaneous	NN	O	O
coronary	NN	O	O
intervention	NN	O	O
(	NN	O	O
PCI	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
review	NN	O	O
is	NN	O	O
to	NN	O	O
summarize	NN	O	O
practical	NN	O	O
considerations	NN	O	O
of	NN	O	O
argatroban	NN	O	O
therapy	NN	O	O
in	NN	O	O
HIT	NN	O	B
.	NN	O	O

The	NN	O	O
US	NN	O	O
FDA	NN	O	O
-	NN	O	O
recommended	NN	O	O
argatroban	NN	O	O
dose	NN	O	O
in	NN	O	O
HIT	NN	O	B
is	NN	O	O
2	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
(	NN	O	O
reduced	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
hepatic	NN	O	B
impairment	NN	O	I
and	NN	O	O
in	NN	O	O
paediatric	NN	O	O
patients	NN	O	O
)	NN	O	O
,	NN	O	O
adjusted	NN	O	O
to	NN	O	O
achieve	NN	O	O
activated	NN	O	O
partial	NN	O	O
thromboplastin	NN	O	O
times	NN	O	O
(	NN	O	O
aPTTs	NN	O	O
)	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
3	NN	O	O
times	NN	O	O
baseline	NN	O	O
(	NN	O	O
not	NN	O	O
>	NN	O	O
100	NN	O	O
seconds	NN	O	O
)	NN	O	O
.	NN	O	O

Contemporary	NN	O	O
experiences	NN	O	O
indicate	NN	O	O
that	NN	O	O
reduced	NN	O	O
doses	NN	O	O
are	NN	O	O
also	NN	O	O
needed	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
conditions	NN	O	O
associated	NN	O	O
with	NN	O	O
hepatic	NN	O	O
hypoperfusion	NN	O	O
,	NN	O	O
e	NN	O	O
.	NN	O	O
g	NN	O	O
.	NN	O	O
heart	NN	O	B
failure	NN	O	I
,	NN	O	O
yet	NN	O	O
are	NN	O	O
unnecessary	NN	O	O
for	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
,	NN	O	O
adult	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
race	NN	O	O
/	NN	O	O
ethnicity	NN	O	O
or	NN	O	O
obesity	NN	O	B
.	NN	O	O

Argatroban	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
typically	NN	O	O
supports	NN	O	O
therapeutic	NN	O	O
aPTTs	NN	O	O
.	NN	O	O

The	NN	O	O
FDA	NN	O	O
-	NN	O	O
recommended	NN	O	O
dose	NN	O	O
during	NN	O	O
PCI	NN	O	O
is	NN	O	O
25	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
(	NN	O	O
350	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
initial	NN	O	O
bolus	NN	O	O
)	NN	O	O
,	NN	O	O
adjusted	NN	O	O
to	NN	O	O
achieve	NN	O	O
activated	NN	O	O
clotting	NN	O	O
times	NN	O	O
(	NN	O	O
ACTs	NN	O	O
)	NN	O	O
of	NN	O	O
300	NN	O	O
-	NN	O	O
450	NN	O	O
sec	NN	O	O
.	NN	O	O

For	NN	O	O
PCI	NN	O	O
,	NN	O	O
argatroban	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
investigated	NN	O	O
in	NN	O	O
hepatically	NN	O	O
impaired	NN	O	O
patients	NN	O	O
;	NN	O	O
dose	NN	O	O
adjustment	NN	O	O
is	NN	O	O
unnecessary	NN	O	O
for	NN	O	O
adult	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
race	NN	O	O
/	NN	O	O
ethnicity	NN	O	O
or	NN	O	O
obesity	NN	O	B
,	NN	O	O
and	NN	O	O
lesser	NN	O	O
doses	NN	O	O
may	NN	O	O
be	NN	O	O
adequate	NN	O	O
with	NN	O	O
concurrent	NN	O	O
glycoprotein	NN	O	O
IIb	NN	O	O
/	NN	O	O
IIIa	NN	O	O
inhibition	NN	O	O
.	NN	O	O

Argatroban	NN	O	O
prolongs	NN	O	O
the	NN	O	O
International	NN	O	O
Normalized	NN	O	O
Ratio	NN	O	O
,	NN	O	O
and	NN	O	O
published	NN	O	O
approaches	NN	O	O
for	NN	O	O
monitoring	NN	O	O
the	NN	O	O
argatroban	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
warfarin	NN	O	O
transition	NN	O	O
should	NN	O	O
be	NN	O	O
followed	NN	O	O
.	NN	O	O

Major	NN	O	O
bleeding	NN	O	B
with	NN	O	O
argatroban	NN	O	O
is	NN	O	O
0	NN	O	O
-	NN	O	O
10	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
interventional	NN	O	O
setting	NN	O	O
and	NN	O	O
0	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
periprocedurally	NN	O	O
.	NN	O	O

Argatroban	NN	O	O
has	NN	O	O
no	NN	O	O
specific	NN	O	O
antidote	NN	O	O
,	NN	O	O
and	NN	O	O
if	NN	O	O
excessive	NN	O	O
anticoagulation	NN	O	O
occurs	NN	O	O
,	NN	O	O
argatroban	NN	O	O
infusion	NN	O	O
should	NN	O	O
be	NN	O	O
stopped	NN	O	O
or	NN	O	O
reduced	NN	O	O
.	NN	O	O

Improved	NN	O	O
familiarity	NN	O	O
of	NN	O	O
healthcare	NN	O	O
professionals	NN	O	O
with	NN	O	O
argatroban	NN	O	O
therapy	NN	O	O
in	NN	O	O
HIT	NN	O	B
,	NN	O	O
including	NN	O	O
in	NN	O	O
special	NN	O	O
populations	NN	O	O
and	NN	O	O
during	NN	O	O
PCI	NN	O	O
,	NN	O	O
may	NN	O	O
facilitate	NN	O	O
reduction	NN	O	O
of	NN	O	O
harm	NN	O	O
associated	NN	O	O
with	NN	O	O
HIT	NN	O	B
(	NN	O	O
e	NN	O	O
.	NN	O	O
g	NN	O	O
.	NN	O	O
fewer	NN	O	O
thromboses	NN	O	O
)	NN	O	O
or	NN	O	O
its	NN	O	O
treatment	NN	O	O
(	NN	O	O
e	NN	O	O
.	NN	O	O
g	NN	O	O
.	NN	O	O
fewer	NN	O	O
argatroban	NN	O	O
medication	NN	O	O
errors	NN	O	O
)	NN	O	O
.	NN	O	O

Rhabdomyolysis	NN	O	B
and	NN	O	O
brain	NN	O	O
ischemic	NN	O	B
stroke	NN	O	I
in	NN	O	O
a	NN	O	O
heroin	NN	O	O
-	NN	O	O
dependent	NN	O	O
male	NN	O	O
under	NN	O	O
methadone	NN	O	O
maintenance	NN	O	O
therapy	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
There	NN	O	O
are	NN	O	O
several	NN	O	O
complications	NN	O	O
associated	NN	O	O
with	NN	O	O
heroin	NN	O	B
abuse	NN	O	I
,	NN	O	O
some	NN	O	O
of	NN	O	O
which	NN	O	O
are	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
.	NN	O	O

Methadone	NN	O	O
may	NN	O	O
aggravate	NN	O	O
this	NN	O	O
problem	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
A	NN	O	O
clinical	NN	O	O
case	NN	O	O
description	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
33	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
presented	NN	O	O
with	NN	O	O
rhabdomyolysis	NN	O	B
and	NN	O	O
cerebral	NN	O	O
ischemic	NN	O	B
stroke	NN	O	I
after	NN	O	O
intravenous	NN	O	O
heroin	NN	O	O
.	NN	O	O

He	NN	O	O
had	NN	O	O
used	NN	O	O
heroin	NN	O	O
since	NN	O	O
age	NN	O	O
20	NN	O	O
,	NN	O	O
and	NN	O	O
had	NN	O	O
used	NN	O	O
150	NN	O	O
mg	NN	O	O
methadone	NN	O	O
daily	NN	O	O
for	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

He	NN	O	O
was	NN	O	O
found	NN	O	O
unconsciousness	NN	O	B
at	NN	O	O
home	NN	O	O
and	NN	O	O
was	NN	O	O
sent	NN	O	O
to	NN	O	O
our	NN	O	O
hospital	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
ER	NN	O	O
,	NN	O	O
his	NN	O	O
opiate	NN	O	O
level	NN	O	O
was	NN	O	O
4497	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
ICU	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
rhabdomyolysis	NN	O	B
,	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
and	NN	O	O
acute	NN	O	O
respiratory	NN	O	B
failure	NN	O	I
.	NN	O	O

After	NN	O	O
transfer	NN	O	O
to	NN	O	O
an	NN	O	O
internal	NN	O	O
ward	NN	O	O
,	NN	O	O
we	NN	O	O
noted	NN	O	O
aphasia	NN	O	B
and	NN	O	O
weakness	NN	O	B
of	NN	O	O
his	NN	O	O
left	NN	O	O
limbs	NN	O	O
.	NN	O	O

After	NN	O	O
MRI	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
cerebral	NN	O	B
ischemic	NN	O	I
infarction	NN	O	I
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Those	NN	O	O
using	NN	O	O
methadone	NN	O	O
and	NN	O	O
heroin	NN	O	O
simultaneously	NN	O	O
may	NN	O	O
increase	NN	O	O
risk	NN	O	O
of	NN	O	O
rhabdomyolysis	NN	O	B
and	NN	O	O
ischemic	NN	O	B
stroke	NN	O	I
.	NN	O	O

Patients	NN	O	O
under	NN	O	O
methadone	NN	O	O
maintenance	NN	O	O
therapy	NN	O	O
should	NN	O	O
be	NN	O	O
warned	NN	O	O
regarding	NN	O	O
these	NN	O	O
serious	NN	O	O
adverse	NN	O	O
events	NN	O	O
.	NN	O	O

Hypotheses	NN	O	O
of	NN	O	O
heroin	NN	O	O
-	NN	O	O
related	NN	O	O
rhabdomyolysis	NN	O	B
and	NN	O	O
stroke	NN	O	B
in	NN	O	O
heroin	NN	O	O
abusers	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Increased	NN	O	O
vulnerability	NN	O	O
to	NN	O	O
6	NN	O	O
-	NN	O	O
hydroxydopamine	NN	O	O
lesion	NN	O	O
and	NN	O	O
reduced	NN	O	O
development	NN	O	O
of	NN	O	O
dyskinesias	NN	O	B
in	NN	O	O
mice	NN	O	O
lacking	NN	O	O
CB1	NN	O	O
cannabinoid	NN	O	O
receptors	NN	O	O
.	NN	O	O

Motor	NN	O	O
impairment	NN	O	O
,	NN	O	O
dopamine	NN	O	O
(	NN	O	O
DA	NN	O	O
)	NN	O	O
neuronal	NN	O	O
activity	NN	O	O
and	NN	O	O
proenkephalin	NN	O	O
(	NN	O	O
PENK	NN	O	O
)	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
caudate	NN	O	O
-	NN	O	O
putamen	NN	O	O
(	NN	O	O
CPu	NN	O	O
)	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
6	NN	O	O
-	NN	O	O
OHDA	NN	O	O
-	NN	O	O
lesioned	NN	O	O
and	NN	O	O
treated	NN	O	O
(	NN	O	O
L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
+	NN	O	O
benserazide	NN	O	O
)	NN	O	O
CB1	NN	O	O
KO	NN	O	O
and	NN	O	O
WT	NN	O	O
mice	NN	O	O
.	NN	O	O

A	NN	O	O
lesion	NN	O	O
induced	NN	O	O
by	NN	O	O
6	NN	O	O
-	NN	O	O
OHDA	NN	O	O
produced	NN	O	O
more	NN	O	O
severe	NN	O	O
motor	NN	O	O
deterioration	NN	O	O
in	NN	O	O
CB1	NN	O	O
KO	NN	O	O
mice	NN	O	O
accompanied	NN	O	O
by	NN	O	O
more	NN	O	O
loss	NN	O	O
of	NN	O	O
DA	NN	O	O
neurons	NN	O	O
and	NN	O	O
increased	NN	O	O
PENK	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
CPu	NN	O	O
.	NN	O	O

Oxidative	NN	O	O
/	NN	O	O
nitrosative	NN	O	O
and	NN	O	O
neuroinflammatory	NN	O	O
parameters	NN	O	O
were	NN	O	O
estimated	NN	O	O
in	NN	O	O
the	NN	O	O
CPu	NN	O	O
and	NN	O	O
cingulate	NN	O	O
cortex	NN	O	O
(	NN	O	O
Cg	NN	O	O
)	NN	O	O
.	NN	O	O

CB1	NN	O	O
KO	NN	O	O
mice	NN	O	O
exhibited	NN	O	O
higher	NN	O	O
MDA	NN	O	O
levels	NN	O	O
and	NN	O	O
iNOS	NN	O	O
protein	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
CPu	NN	O	O
and	NN	O	O
Cg	NN	O	O
compared	NN	O	O
to	NN	O	O
WT	NN	O	O
mice	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
+	NN	O	O
benserazide	NN	O	O
(	NN	O	O
12	NN	O	O
weeks	NN	O	O
)	NN	O	O
resulted	NN	O	O
in	NN	O	O
less	NN	O	O
severe	NN	O	O
dyskinesias	NN	O	B
in	NN	O	O
CB1	NN	O	O
KO	NN	O	O
than	NN	O	O
in	NN	O	O
WT	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
lack	NN	O	O
of	NN	O	O
cannabinoid	NN	O	O
CB1	NN	O	O
receptors	NN	O	O
increased	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
motor	NN	O	O
impairment	NN	O	O
and	NN	O	O
DA	NN	O	O
lesion	NN	O	O
,	NN	O	O
and	NN	O	O
reduced	NN	O	O
L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
activation	NN	O	O
of	NN	O	O
CB1	NN	O	O
receptors	NN	O	O
offers	NN	O	O
neuroprotection	NN	O	O
against	NN	O	O
dopaminergic	NN	O	O
lesion	NN	O	O
and	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
.	NN	O	O

Hepatocellular	NN	O	O
oxidant	NN	O	O
stress	NN	O	O
following	NN	O	O
intestinal	NN	O	O
ischemia	NN	O	B
-	NN	O	O
reperfusion	NN	O	B
injury	NN	O	I
.	NN	O	O

Reperfusion	NN	O	O
of	NN	O	O
ischemic	NN	O	B
intestine	NN	O	O
results	NN	O	O
in	NN	O	O
acute	NN	O	O
liver	NN	O	B
dysfunction	NN	O	I
characterized	NN	O	O
by	NN	O	O
hepatocellular	NN	O	O
enzyme	NN	O	O
release	NN	O	O
into	NN	O	O
plasma	NN	O	O
,	NN	O	O
reduction	NN	O	O
in	NN	O	O
bile	NN	O	O
flow	NN	O	O
rate	NN	O	O
,	NN	O	O
and	NN	O	O
neutrophil	NN	O	O
sequestration	NN	O	O
within	NN	O	O
the	NN	O	O
liver	NN	O	O
.	NN	O	O

The	NN	O	O
pathophysiology	NN	O	O
underlying	NN	O	O
this	NN	O	O
acute	NN	O	O
hepatic	NN	O	B
injury	NN	O	I
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
oxidants	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
hepatic	NN	O	B
injury	NN	O	I
and	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
relative	NN	O	O
value	NN	O	O
of	NN	O	O
several	NN	O	O
indirect	NN	O	O
methods	NN	O	O
of	NN	O	O
assessing	NN	O	O
oxidant	NN	O	O
exposure	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
a	NN	O	O
standardized	NN	O	O
intestinal	NN	O	O
ischemia	NN	O	B
-	NN	O	O
reperfusion	NN	O	B
injury	NN	O	I
.	NN	O	O

Hepatic	NN	O	O
tissue	NN	O	O
was	NN	O	O
assayed	NN	O	O
for	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
products	NN	O	O
and	NN	O	O
oxidized	NN	O	O
and	NN	O	O
reduced	NN	O	O
glutathione	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
hepatic	NN	O	O
tissue	NN	O	O
total	NN	O	O
glutathione	NN	O	O
following	NN	O	O
intestinal	NN	O	O
ischemia	NN	O	B
-	NN	O	O
reperfusion	NN	O	B
injury	NN	O	I
.	NN	O	O

Oxidized	NN	O	O
glutathione	NN	O	O
(	NN	O	O
GSSG	NN	O	O
)	NN	O	O
increased	NN	O	O
significantly	NN	O	O
following	NN	O	O
30	NN	O	O
and	NN	O	O
60	NN	O	O
min	NN	O	O
of	NN	O	O
reperfusion	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
increase	NN	O	O
in	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
products	NN	O	O
of	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
associated	NN	O	O
with	NN	O	O
this	NN	O	O
injury	NN	O	O
.	NN	O	O

An	NN	O	O
increase	NN	O	O
in	NN	O	O
GSSG	NN	O	O
within	NN	O	O
hepatic	NN	O	O
tissue	NN	O	O
during	NN	O	O
intestinal	NN	O	O
reperfusion	NN	O	O
suggests	NN	O	O
exposure	NN	O	O
of	NN	O	O
hepatocytes	NN	O	O
to	NN	O	O
an	NN	O	O
oxidant	NN	O	O
stress	NN	O	O
.	NN	O	O

The	NN	O	O
lack	NN	O	O
of	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
products	NN	O	O
of	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
suggests	NN	O	O
that	NN	O	O
the	NN	O	O
oxidant	NN	O	O
stress	NN	O	O
is	NN	O	O
of	NN	O	O
insufficient	NN	O	O
magnitude	NN	O	O
to	NN	O	O
result	NN	O	O
in	NN	O	O
irreversible	NN	O	O
injury	NN	O	O
to	NN	O	O
hepatocyte	NN	O	O
cell	NN	O	O
membranes	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
also	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
measurement	NN	O	O
of	NN	O	O
tissue	NN	O	O
GSSG	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
more	NN	O	O
sensitive	NN	O	O
indicator	NN	O	O
of	NN	O	O
oxidant	NN	O	O
stress	NN	O	O
than	NN	O	O
measurement	NN	O	O
of	NN	O	O
products	NN	O	O
of	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
.	NN	O	O

Animal	NN	O	O
model	NN	O	O
of	NN	O	O
mania	NN	O	B
induced	NN	O	O
by	NN	O	O
ouabain	NN	O	O
:	NN	O	O
Evidence	NN	O	O
of	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
in	NN	O	O
submitochondrial	NN	O	O
particles	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
brain	NN	O	O
.	NN	O	O

The	NN	O	O
intracerebroventricular	NN	O	O
(	NN	O	O
ICV	NN	O	O
)	NN	O	O
administration	NN	O	O
of	NN	O	O
ouabain	NN	O	O
(	NN	O	O
a	NN	O	O
Na	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
/	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
ATPase	NN	O	O
inhibitor	NN	O	O
)	NN	O	O
in	NN	O	O
rats	NN	O	O
has	NN	O	O
been	NN	O	O
suggested	NN	O	O
to	NN	O	O
mimic	NN	O	O
some	NN	O	O
symptoms	NN	O	O
of	NN	O	O
human	NN	O	O
bipolar	NN	O	B
mania	NN	O	I
.	NN	O	O

Clinical	NN	O	O
studies	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
bipolar	NN	O	B
disorder	NN	O	I
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
mitochondrial	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Herein	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
behavioral	NN	O	O
and	NN	O	O
biochemical	NN	O	O
effects	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
ICV	NN	O	O
administration	NN	O	O
of	NN	O	O
ouabain	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

To	NN	O	O
achieve	NN	O	O
this	NN	O	O
aim	NN	O	O
,	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
ouabain	NN	O	O
injection	NN	O	O
immediately	NN	O	O
after	NN	O	O
and	NN	O	O
7	NN	O	O
days	NN	O	O
following	NN	O	O
a	NN	O	O
single	NN	O	O
ICV	NN	O	O
administration	NN	O	O
(	NN	O	O
at	NN	O	O
concentrations	NN	O	O
of	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
2	NN	O	O
)	NN	O	O
and	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
3	NN	O	O
)	NN	O	O
M	NN	O	O
)	NN	O	O
on	NN	O	O
locomotion	NN	O	O
was	NN	O	O
measured	NN	O	O
using	NN	O	O
the	NN	O	O
open	NN	O	O
-	NN	O	O
field	NN	O	O
test	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
thiobarbituric	NN	O	O
acid	NN	O	O
reactive	NN	O	O
substances	NN	O	O
(	NN	O	O
TBARSs	NN	O	O
)	NN	O	O
and	NN	O	O
superoxide	NN	O	O
production	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
submitochondrial	NN	O	O
particles	NN	O	O
of	NN	O	O
the	NN	O	O
prefrontal	NN	O	O
cortex	NN	O	O
,	NN	O	O
hippocampus	NN	O	O
,	NN	O	O
striatum	NN	O	O
and	NN	O	O
amygdala	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
ouabain	NN	O	O
at	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
2	NN	O	O
)	NN	O	O
and	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
3	NN	O	O
)	NN	O	O
M	NN	O	O
induced	NN	O	O
hyperlocomotion	NN	O	B
in	NN	O	O
rats	NN	O	O
,	NN	O	O
and	NN	O	O
this	NN	O	O
response	NN	O	O
remained	NN	O	O
up	NN	O	O
to	NN	O	O
7	NN	O	O
days	NN	O	O
following	NN	O	O
a	NN	O	O
single	NN	O	O
ICV	NN	O	O
injection	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
we	NN	O	O
observed	NN	O	O
that	NN	O	O
the	NN	O	O
persistent	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
spontaneous	NN	O	O
locomotion	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
TBARS	NN	O	O
levels	NN	O	O
and	NN	O	O
superoxide	NN	O	O
generation	NN	O	O
in	NN	O	O
submitochondrial	NN	O	O
particles	NN	O	O
in	NN	O	O
the	NN	O	O
prefrontal	NN	O	O
cortex	NN	O	O
,	NN	O	O
striatum	NN	O	O
and	NN	O	O
amygdala	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
ouabain	NN	O	O
-	NN	O	O
induced	NN	O	O
mania	NN	O	B
-	NN	O	O
like	NN	O	O
behavior	NN	O	O
may	NN	O	O
provide	NN	O	O
a	NN	O	O
useful	NN	O	O
animal	NN	O	O
model	NN	O	O
to	NN	O	O
test	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
of	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
in	NN	O	O
bipolar	NN	O	B
disorder	NN	O	I
.	NN	O	O

Intraoperative	NN	O	O
dialysis	NN	O	O
during	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
with	NN	O	O
citrate	NN	O	O
dialysate	NN	O	O
.	NN	O	O

Liver	NN	O	O
transplantation	NN	O	O
for	NN	O	O
acutely	NN	O	O
ill	NN	O	O
patients	NN	O	O
with	NN	O	O
fulminant	NN	O	B
liver	NN	O	I
failure	NN	O	I
carries	NN	O	O
high	NN	O	O
intraoperative	NN	O	O
and	NN	O	O
immediate	NN	O	O
postoperative	NN	O	O
risks	NN	O	O
.	NN	O	O

These	NN	O	O
are	NN	O	O
increased	NN	O	O
with	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
concomitant	NN	O	O
acute	NN	O	B
kidney	NN	O	I
injury	NN	O	I
(	NN	O	O
AKI	NN	O	B
)	NN	O	O
and	NN	O	O
intraoperative	NN	O	O
dialysis	NN	O	O
is	NN	O	O
sometimes	NN	O	O
required	NN	O	O
to	NN	O	O
allow	NN	O	O
the	NN	O	O
transplant	NN	O	O
to	NN	O	O
proceed	NN	O	O
.	NN	O	O

The	NN	O	O
derangements	NN	O	O
in	NN	O	O
the	NN	O	O
procoagulant	NN	O	O
and	NN	O	O
anticoagulant	NN	O	O
pathways	NN	O	O
during	NN	O	O
fulminant	NN	O	B
liver	NN	O	I
failure	NN	O	I
can	NN	O	O
lead	NN	O	O
to	NN	O	O
difficulties	NN	O	O
with	NN	O	O
anticoagulation	NN	O	O
during	NN	O	O
dialysis	NN	O	O
,	NN	O	O
especially	NN	O	O
when	NN	O	O
continued	NN	O	O
in	NN	O	O
the	NN	O	O
operating	NN	O	O
room	NN	O	O
.	NN	O	O

Systemic	NN	O	O
anticoagulation	NN	O	O
is	NN	O	O
unsafe	NN	O	O
and	NN	O	O
regional	NN	O	O
citrate	NN	O	O
anticoagulation	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
a	NN	O	O
functional	NN	O	O
liver	NN	O	O
carries	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
citrate	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Citrate	NN	O	O
dialysate	NN	O	O
,	NN	O	O
a	NN	O	O
new	NN	O	O
dialysate	NN	O	O
with	NN	O	O
citric	NN	O	O
acid	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
for	NN	O	O
anticoagulation	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
cannot	NN	O	O
tolerate	NN	O	O
heparin	NN	O	O
or	NN	O	O
regional	NN	O	O
citrate	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
40	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
with	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
fulminant	NN	O	B
liver	NN	O	I
failure	NN	O	I
with	NN	O	O
associated	NN	O	O
AKI	NN	O	B
who	NN	O	O
underwent	NN	O	O
intraoperative	NN	O	O
dialytic	NN	O	O
support	NN	O	O
during	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
anticoagulated	NN	O	O
with	NN	O	O
citrate	NN	O	O
dialysate	NN	O	O
during	NN	O	O
the	NN	O	O
entire	NN	O	O
procedure	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
tolerated	NN	O	O
the	NN	O	O
procedure	NN	O	O
well	NN	O	O
without	NN	O	O
any	NN	O	O
signs	NN	O	O
of	NN	O	O
citrate	NN	O	O
toxicity	NN	O	B
and	NN	O	O
maintained	NN	O	O
adequate	NN	O	O
anticoagulation	NN	O	O
for	NN	O	O
patency	NN	O	O
of	NN	O	O
the	NN	O	O
dialysis	NN	O	O
circuit	NN	O	O
.	NN	O	O

Citrate	NN	O	O
dialysate	NN	O	O
is	NN	O	O
a	NN	O	O
safe	NN	O	O
alternative	NN	O	O
for	NN	O	O
intradialytic	NN	O	O
support	NN	O	O
of	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
in	NN	O	O
fulminant	NN	O	B
liver	NN	O	I
failure	NN	O	I
.	NN	O	O

Delirium	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
toxic	NN	O	O
flecainide	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
:	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
a	NN	O	O
pharmacokinetic	NN	O	O
drug	NN	O	O
interaction	NN	O	O
with	NN	O	O
paroxetine	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
describe	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
flecainide	NN	O	O
-	NN	O	O
induced	NN	O	O
delirium	NN	O	B
associated	NN	O	O
with	NN	O	O
a	NN	O	O
pharmacokinetic	NN	O	O
drug	NN	O	O
interaction	NN	O	O
with	NN	O	O
paroxetine	NN	O	O
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
69	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
white	NN	O	O
female	NN	O	O
presented	NN	O	O
to	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
confusion	NN	O	B
and	NN	O	O
paranoia	NN	O	B
over	NN	O	O
the	NN	O	O
past	NN	O	O
several	NN	O	O
days	NN	O	O
.	NN	O	O

On	NN	O	O
admission	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
taking	NN	O	O
carvedilol	NN	O	O
12	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
,	NN	O	O
warfarin	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
folic	NN	O	O
acid	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
levothyroxine	NN	O	O
100	NN	O	O
microg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
pantoprazole	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
paroxetine	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
and	NN	O	O
flecainide	NN	O	O
100	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
.	NN	O	O

Flecainide	NN	O	O
had	NN	O	O
been	NN	O	O
started	NN	O	O
2	NN	O	O
weeks	NN	O	O
prior	NN	O	O
for	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
.	NN	O	O

Laboratory	NN	O	O
test	NN	O	O
findings	NN	O	O
on	NN	O	O
admission	NN	O	O
were	NN	O	O
notable	NN	O	O
only	NN	O	O
for	NN	O	O
a	NN	O	O
flecainide	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
of	NN	O	O
1360	NN	O	O
microg	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
reference	NN	O	O
range	NN	O	O
200	NN	O	O
-	NN	O	O
1000	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
metabolic	NN	O	O
drug	NN	O	O
interaction	NN	O	O
between	NN	O	O
flecainide	NN	O	O
and	NN	O	O
paroxetine	NN	O	O
,	NN	O	O
which	NN	O	O
the	NN	O	O
patient	NN	O	O
had	NN	O	O
been	NN	O	O
taking	NN	O	O
for	NN	O	O
more	NN	O	O
than	NN	O	O
5	NN	O	O
years	NN	O	O
,	NN	O	O
was	NN	O	O
considered	NN	O	O
.	NN	O	O

Paroxetine	NN	O	O
was	NN	O	O
discontinued	NN	O	O
and	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
flecainide	NN	O	O
was	NN	O	O
reduced	NN	O	O
to	NN	O	O
50	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
.	NN	O	O

Her	NN	O	O
delirium	NN	O	B
resolved	NN	O	O
3	NN	O	O
days	NN	O	O
later	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Flecainide	NN	O	O
and	NN	O	O
pharmacologically	NN	O	O
similar	NN	O	O
agents	NN	O	O
that	NN	O	O
interact	NN	O	O
with	NN	O	O
sodium	NN	O	O
channels	NN	O	O
may	NN	O	O
cause	NN	O	O
delirium	NN	O	B
in	NN	O	O
susceptible	NN	O	O
patients	NN	O	O
.	NN	O	O

A	NN	O	O
MEDLINE	NN	O	O
search	NN	O	O
(	NN	O	O
1966	NN	O	O
-	NN	O	O
January	NN	O	O
2009	NN	O	O
)	NN	O	O
revealed	NN	O	O
one	NN	O	O
in	NN	O	O
vivo	NN	O	O
pharmacokinetic	NN	O	O
study	NN	O	O
on	NN	O	O
the	NN	O	O
interaction	NN	O	O
between	NN	O	O
flecainide	NN	O	O
,	NN	O	O
a	NN	O	O
CYP2D6	NN	O	O
substrate	NN	O	O
,	NN	O	O
and	NN	O	O
paroxetine	NN	O	O
,	NN	O	O
a	NN	O	O
CYP2D6	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
3	NN	O	O
case	NN	O	O
reports	NN	O	O
of	NN	O	O
flecainide	NN	O	O
-	NN	O	O
induced	NN	O	O
delirium	NN	O	B
.	NN	O	O

According	NN	O	O
to	NN	O	O
the	NN	O	O
Naranjo	NN	O	O
probability	NN	O	O
scale	NN	O	O
,	NN	O	O
flecainide	NN	O	O
was	NN	O	O
the	NN	O	O
probable	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
delirium	NN	O	B
;	NN	O	O
the	NN	O	O
Horn	NN	O	O
Drug	NN	O	O
Interaction	NN	O	O
Probability	NN	O	O
Scale	NN	O	O
indicates	NN	O	O
a	NN	O	O
possible	NN	O	O
pharmacokinetic	NN	O	O
drug	NN	O	O
interaction	NN	O	O
between	NN	O	O
flecainide	NN	O	O
and	NN	O	O
paroxetine	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Supratherapeutic	NN	O	O
flecainide	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
may	NN	O	O
cause	NN	O	O
delirium	NN	O	B
.	NN	O	O

Because	NN	O	O
toxicity	NN	O	B
may	NN	O	O
occur	NN	O	O
when	NN	O	O
flecainide	NN	O	O
is	NN	O	O
prescribed	NN	O	O
with	NN	O	O
paroxetine	NN	O	O
and	NN	O	O
other	NN	O	O
potent	NN	O	O
CYP2D6	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
flecainide	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
should	NN	O	O
be	NN	O	O
monitored	NN	O	O
closely	NN	O	O
with	NN	O	O
commencement	NN	O	O
of	NN	O	O
CYP2D6	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

Efficacy	NN	O	O
of	NN	O	O
everolimus	NN	O	O
(	NN	O	O
RAD001	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
NSCLC	NN	O	B
previously	NN	O	O
treated	NN	O	O
with	NN	O	O
chemotherapy	NN	O	O
alone	NN	O	O
or	NN	O	O
with	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
EGFR	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Treatment	NN	O	O
options	NN	O	O
are	NN	O	O
scarce	NN	O	O
in	NN	O	O
pretreated	NN	O	O
advanced	NN	O	O
non	NN	O	B
-	NN	O	I
small	NN	O	I
-	NN	O	I
cell	NN	O	I
lung	NN	O	I
cancer	NN	O	I
(	NN	O	O
NSCLC	NN	O	B
)	NN	O	O
patients	NN	O	O
.	NN	O	O

RAD001	NN	O	O
,	NN	O	O
an	NN	O	O
oral	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
the	NN	O	O
mammalian	NN	O	O
target	NN	O	O
of	NN	O	O
rapamycin	NN	O	O
(	NN	O	O
mTOR	NN	O	O
)	NN	O	O
,	NN	O	O
has	NN	O	O
shown	NN	O	O
phase	NN	O	O
I	NN	O	O
efficacy	NN	O	O
in	NN	O	O
NSCLC	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Stage	NN	O	O
IIIb	NN	O	O
or	NN	O	O
IV	NN	O	O
NSCLC	NN	O	B
patients	NN	O	O
,	NN	O	O
with	NN	O	O
two	NN	O	O
or	NN	O	O
fewer	NN	O	O
prior	NN	O	O
chemotherapy	NN	O	O
regimens	NN	O	O
,	NN	O	O
one	NN	O	O
platinum	NN	O	O
based	NN	O	O
(	NN	O	O
stratum	NN	O	O
1	NN	O	O
)	NN	O	O
or	NN	O	O
both	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
epidermal	NN	O	O
growth	NN	O	O
factor	NN	O	O
receptor	NN	O	O
tyrosine	NN	O	O
kinase	NN	O	O
inhibitors	NN	O	O
(	NN	O	O
stratum	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
received	NN	O	O
RAD001	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
until	NN	O	O
progression	NN	O	O
or	NN	O	O
unacceptable	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Primary	NN	O	O
objective	NN	O	O
was	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
(	NN	O	O
ORR	NN	O	O
)	NN	O	O
.	NN	O	O

Analyses	NN	O	O
of	NN	O	O
markers	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
mTOR	NN	O	O
pathway	NN	O	O
were	NN	O	O
carried	NN	O	O
out	NN	O	O
on	NN	O	O
archival	NN	O	O
tumor	NN	O	B
from	NN	O	O
a	NN	O	O
subgroup	NN	O	O
using	NN	O	O
immunohistochemistry	NN	O	O
(	NN	O	O
IHC	NN	O	O
)	NN	O	O
and	NN	O	O
direct	NN	O	O
mutation	NN	O	O
sequencing	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Eighty	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
were	NN	O	O
enrolled	NN	O	O
,	NN	O	O
42	NN	O	O
in	NN	O	O
stratum	NN	O	O
1	NN	O	O
and	NN	O	O
43	NN	O	O
in	NN	O	O
stratum	NN	O	O
.	NN	O	O

ORR	NN	O	O
was	NN	O	O
4	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
stratum	NN	O	O
1	NN	O	O
;	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
stratum	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

Overall	NN	O	O
disease	NN	O	O
control	NN	O	O
rate	NN	O	O
was	NN	O	O
47	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
.	NN	O	O

Median	NN	O	O
progression	NN	O	O
-	NN	O	O
free	NN	O	O
survivals	NN	O	O
(	NN	O	O
PFSs	NN	O	O
)	NN	O	O
were	NN	O	O
2	NN	O	O
.	NN	O	O
6	NN	O	O
(	NN	O	O
stratum	NN	O	O
1	NN	O	O
)	NN	O	O
and	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
months	NN	O	O
(	NN	O	O
stratum	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

Common	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
grade	NN	O	O
3	NN	O	O
events	NN	O	O
were	NN	O	O
fatigue	NN	O	B
,	NN	O	O
dyspnea	NN	O	B
,	NN	O	O
stomatitis	NN	O	B
,	NN	O	O
anemia	NN	O	B
,	NN	O	O
and	NN	O	O
thrombocytopenia	NN	O	B
.	NN	O	O

Pneumonitis	NN	O	B
,	NN	O	O
probably	NN	O	O
or	NN	O	O
possibly	NN	O	O
related	NN	O	O
,	NN	O	O
mainly	NN	O	O
grade	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
,	NN	O	O
occurred	NN	O	O
in	NN	O	O
25	NN	O	O
%	NN	O	O
.	NN	O	O

Cox	NN	O	O
regression	NN	O	O
analysis	NN	O	O
of	NN	O	O
IHC	NN	O	O
scores	NN	O	O
found	NN	O	O
that	NN	O	O
only	NN	O	O
phospho	NN	O	O
AKT	NN	O	O
(	NN	O	O
pAKT	NN	O	O
)	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
independent	NN	O	O
predictor	NN	O	O
of	NN	O	O
worse	NN	O	O
PFS	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
RAD001	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
showing	NN	O	O
modest	NN	O	O
clinical	NN	O	O
activity	NN	O	O
in	NN	O	O
pretreated	NN	O	O
NSCLC	NN	O	B
.	NN	O	O

Evaluation	NN	O	O
of	NN	O	O
RAD001	NN	O	O
plus	NN	O	O
standard	NN	O	O
therapy	NN	O	O
for	NN	O	O
metastatic	NN	O	O
NSCLC	NN	O	B
continues	NN	O	O
.	NN	O	O

Posttransplant	NN	O	O
anemia	NN	O	B
:	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
.	NN	O	O

Posttransplant	NN	O	O
anemia	NN	O	B
is	NN	O	O
a	NN	O	O
common	NN	O	O
problem	NN	O	O
that	NN	O	O
may	NN	O	O
hinder	NN	O	O
patients	NN	O	O
'	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
.	NN	O	O

It	NN	O	O
occurs	NN	O	O
in	NN	O	O
12	NN	O	O
to	NN	O	O
76	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
is	NN	O	O
most	NN	O	O
common	NN	O	O
in	NN	O	O
the	NN	O	O
immediate	NN	O	O
posttransplant	NN	O	O
period	NN	O	O
.	NN	O	O

A	NN	O	O
variety	NN	O	O
of	NN	O	O
factors	NN	O	O
have	NN	O	O
been	NN	O	O
identified	NN	O	O
that	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
posttransplant	NN	O	O
anemia	NN	O	B
,	NN	O	O
of	NN	O	O
which	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
is	NN	O	O
most	NN	O	O
important	NN	O	O
.	NN	O	O

Sirolimus	NN	O	O
,	NN	O	O
a	NN	O	O
mammalian	NN	O	O
target	NN	O	O
of	NN	O	O
rapamycin	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
implicated	NN	O	O
as	NN	O	O
playing	NN	O	O
a	NN	O	O
special	NN	O	O
role	NN	O	O
in	NN	O	O
posttransplant	NN	O	O
anemia	NN	O	B
.	NN	O	O

This	NN	O	O
review	NN	O	O
considers	NN	O	O
anemia	NN	O	B
associated	NN	O	O
with	NN	O	O
sirolimus	NN	O	O
,	NN	O	O
including	NN	O	O
its	NN	O	O
presentation	NN	O	O
,	NN	O	O
mechanisms	NN	O	O
,	NN	O	O
and	NN	O	O
management	NN	O	O
.	NN	O	O

Coronary	NN	O	O
computerized	NN	O	O
tomography	NN	O	O
angiography	NN	O	O
for	NN	O	O
rapid	NN	O	O
discharge	NN	O	O
of	NN	O	O
low	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Most	NN	O	O
patients	NN	O	O
presenting	NN	O	O
to	NN	O	O
emergency	NN	O	O
departments	NN	O	O
(	NN	O	O
EDs	NN	O	O
)	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
are	NN	O	O
admitted	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
12	NN	O	O
hours	NN	O	O
and	NN	O	O
receive	NN	O	O
a	NN	O	O
"	NN	O	O
rule	NN	O	O
out	NN	O	O
acute	NN	O	B
coronary	NN	O	I
syndrome	NN	O	I
"	NN	O	O
protocol	NN	O	O
,	NN	O	O
often	NN	O	O
with	NN	O	O
noninvasive	NN	O	O
testing	NN	O	O
prior	NN	O	O
to	NN	O	O
discharge	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
without	NN	O	O
cocaine	NN	O	O
use	NN	O	O
,	NN	O	O
coronary	NN	O	O
computerized	NN	O	O
tomography	NN	O	O
angiography	NN	O	O
(	NN	O	O
CTA	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
useful	NN	O	O
for	NN	O	O
identifying	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
at	NN	O	O
low	NN	O	O
risk	NN	O	O
for	NN	O	O
cardiac	NN	O	O
events	NN	O	O
who	NN	O	O
can	NN	O	O
be	NN	O	O
safely	NN	O	O
discharged	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
unclear	NN	O	O
whether	NN	O	O
a	NN	O	O
coronary	NN	O	O
CTA	NN	O	O
strategy	NN	O	O
would	NN	O	O
be	NN	O	O
efficacious	NN	O	O
in	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
,	NN	O	O
as	NN	O	O
coronary	NN	O	B
vasospasm	NN	O	I
may	NN	O	O
account	NN	O	O
for	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
ischemia	NN	O	B
.	NN	O	O

We	NN	O	O
studied	NN	O	O
whether	NN	O	O
a	NN	O	O
negative	NN	O	O
coronary	NN	O	O
CTA	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
could	NN	O	O
identify	NN	O	O
a	NN	O	O
subset	NN	O	O
safe	NN	O	O
for	NN	O	O
discharge	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
prospectively	NN	O	O
evaluated	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
coronary	NN	O	O
CTA	NN	O	O
for	NN	O	O
low	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
who	NN	O	O
presented	NN	O	O
to	NN	O	O
the	NN	O	O
ED	NN	O	O
with	NN	O	O
cocaineassociated	NN	O	O
chest	NN	O	B
pain	NN	O	I
(	NN	O	O
self	NN	O	O
-	NN	O	O
reported	NN	O	O
or	NN	O	O
positive	NN	O	O
urine	NN	O	O
test	NN	O	O
)	NN	O	O
.	NN	O	O

Consecutive	NN	O	O
patients	NN	O	O
received	NN	O	O
either	NN	O	O
immediate	NN	O	O
coronary	NN	O	O
CTA	NN	O	O
in	NN	O	O
the	NN	O	O
ED	NN	O	O
(	NN	O	O
without	NN	O	O
serial	NN	O	O
markers	NN	O	O
)	NN	O	O
or	NN	O	O
underwent	NN	O	O
coronary	NN	O	O
CTA	NN	O	O
after	NN	O	O
a	NN	O	O
brief	NN	O	O
observation	NN	O	O
period	NN	O	O
with	NN	O	O
serial	NN	O	O
cardiac	NN	O	O
marker	NN	O	O
measurements	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
negative	NN	O	O
coronary	NN	O	O
CTA	NN	O	O
(	NN	O	O
maximal	NN	O	O
stenosis	NN	O	B
less	NN	O	O
than	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
discharged	NN	O	O
.	NN	O	O

The	NN	O	O
main	NN	O	O
outcome	NN	O	O
was	NN	O	O
30	NN	O	O
-	NN	O	O
day	NN	O	O
cardiovascular	NN	O	O
death	NN	O	O
or	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
59	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
were	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Patients	NN	O	O
had	NN	O	O
a	NN	O	O
mean	NN	O	O
age	NN	O	O
of	NN	O	O
45	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
6	NN	O	O
yrs	NN	O	O
and	NN	O	O
were	NN	O	O
86	NN	O	O
%	NN	O	O
black	NN	O	O
,	NN	O	O
66	NN	O	O
%	NN	O	O
male	NN	O	O
.	NN	O	O

Seventy	NN	O	O
-	NN	O	O
nine	NN	O	O
percent	NN	O	O
had	NN	O	O
a	NN	O	O
normal	NN	O	O
or	NN	O	O
nonspecific	NN	O	O
ECG	NN	O	O
and	NN	O	O
85	NN	O	O
%	NN	O	O
had	NN	O	O
a	NN	O	O
TIMI	NN	O	O
score	NN	O	O
<	NN	O	O
2	NN	O	O
.	NN	O	O

Twenty	NN	O	O
patients	NN	O	O
received	NN	O	O
coronary	NN	O	O
CTA	NN	O	O
immediately	NN	O	O
in	NN	O	O
the	NN	O	O
ED	NN	O	O
,	NN	O	O
18	NN	O	O
of	NN	O	O
whom	NN	O	O
were	NN	O	O
discharged	NN	O	O
following	NN	O	O
CTA	NN	O	O
(	NN	O	O
90	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
nine	NN	O	O
received	NN	O	O
coronary	NN	O	O
CTA	NN	O	O
after	NN	O	O
a	NN	O	O
brief	NN	O	O
observation	NN	O	O
period	NN	O	O
,	NN	O	O
with	NN	O	O
37	NN	O	O
discharged	NN	O	O
home	NN	O	O
following	NN	O	O
CTA	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Six	NN	O	O
patients	NN	O	O
had	NN	O	O
coronary	NN	O	B
stenosis	NN	O	I
>	NN	O	O
or	NN	O	O
=	NN	O	O
50	NN	O	O
%	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
30	NN	O	O
-	NN	O	O
day	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
,	NN	O	O
no	NN	O	O
patients	NN	O	O
died	NN	O	O
of	NN	O	O
a	NN	O	O
cardiovascular	NN	O	O
event	NN	O	O
(	NN	O	O
0	NN	O	O
%	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
no	NN	O	O
patient	NN	O	O
sustained	NN	O	O
a	NN	O	O
nonfatal	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
(	NN	O	O
0	NN	O	O
%	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Although	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
can	NN	O	O
result	NN	O	O
from	NN	O	O
coronary	NN	O	O
vasoconstriction	NN	O	O
,	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
associated	NN	O	O
chest	NN	O	B
pain	NN	O	I
,	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
ischemic	NN	O	B
ECG	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
TIMI	NN	O	O
risk	NN	O	O
score	NN	O	O
<	NN	O	O
2	NN	O	O
may	NN	O	O
be	NN	O	O
safely	NN	O	O
discharged	NN	O	O
from	NN	O	O
the	NN	O	O
ED	NN	O	O
after	NN	O	O
a	NN	O	O
negative	NN	O	O
coronary	NN	O	O
CTA	NN	O	O
with	NN	O	O
a	NN	O	O
low	NN	O	O
risk	NN	O	O
of	NN	O	O
30	NN	O	O
-	NN	O	O
day	NN	O	O
adverse	NN	O	O
events	NN	O	O
.	NN	O	O

Bilateral	NN	O	O
haemorrhagic	NN	O	B
infarction	NN	O	I
of	NN	O	I
the	NN	O	I
globus	NN	O	I
pallidus	NN	O	I
after	NN	O	O
cocaine	NN	O	O
and	NN	O	O
alcohol	NN	O	O
intoxication	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
is	NN	O	O
a	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
both	NN	O	O
ischemic	NN	O	B
and	NN	O	I
haemorrhagic	NN	O	I
stroke	NN	O	I
.	NN	O	O

We	NN	O	O
present	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
31	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
bilateral	NN	O	O
ischemia	NN	O	B
of	NN	O	I
the	NN	O	I
globus	NN	O	I
pallidus	NN	O	I
after	NN	O	O
excessive	NN	O	O
alcohol	NN	O	O
and	NN	O	O
intranasal	NN	O	O
cocaine	NN	O	O
use	NN	O	O
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
related	NN	O	O
globus	NN	O	B
pallidus	NN	O	I
infarctions	NN	O	I
are	NN	O	O
most	NN	O	O
often	NN	O	O
associated	NN	O	O
with	NN	O	O
heroin	NN	O	O
.	NN	O	O

Bilateral	NN	O	O
basal	NN	O	B
ganglia	NN	O	I
infarcts	NN	O	I
after	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
cocaine	NN	O	O
,	NN	O	O
without	NN	O	O
concurrent	NN	O	O
heroin	NN	O	O
use	NN	O	O
,	NN	O	O
have	NN	O	O
never	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

In	NN	O	O
our	NN	O	O
patient	NN	O	O
,	NN	O	O
transient	NN	O	O
cardiac	NN	O	B
arrhythmia	NN	O	I
or	NN	O	O
respiratory	NN	O	B
dysfunction	NN	O	I
related	NN	O	O
to	NN	O	O
cocaine	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
ethanol	NN	O	O
use	NN	O	O
were	NN	O	O
the	NN	O	O
most	NN	O	O
likely	NN	O	O
causes	NN	O	O
of	NN	O	O
cerebral	NN	O	B
hypoperfusion	NN	O	I
.	NN	O	O

Late	NN	O	O
fulminant	NN	O	O
posterior	NN	O	B
reversible	NN	O	I
encephalopathy	NN	O	I
syndrome	NN	O	I
after	NN	O	O
liver	NN	O	O
transplant	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
Posterior	NN	O	B
leukoencephalopathy	NN	O	I
due	NN	O	O
to	NN	O	O
calcineurin	NN	O	O
-	NN	O	O
inhibitor	NN	O	O
-	NN	O	O
related	NN	O	O
neurotoxicity	NN	O	B
is	NN	O	O
a	NN	O	O
rare	NN	O	O
but	NN	O	O
severe	NN	O	O
complication	NN	O	O
that	NN	O	O
results	NN	O	O
from	NN	O	O
treatment	NN	O	O
with	NN	O	O
immunosuppressive	NN	O	O
agents	NN	O	O
(	NN	O	O
primarily	NN	O	O
those	NN	O	O
administered	NN	O	O
after	NN	O	O
a	NN	O	O
liver	NN	O	O
or	NN	O	O
kidney	NN	O	O
transplant	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
pathophysiologic	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
that	NN	O	O
disorder	NN	O	O
remain	NN	O	O
unknown	NN	O	O
.	NN	O	O

CASE	NN	O	O
:	NN	O	O
We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
46	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
who	NN	O	O
received	NN	O	O
a	NN	O	O
liver	NN	O	O
transplant	NN	O	O
in	NN	O	O
our	NN	O	O
center	NN	O	O
as	NN	O	O
treatment	NN	O	O
for	NN	O	O
alcoholic	NN	O	B
cirrhosis	NN	O	I
and	NN	O	O
in	NN	O	O
whom	NN	O	O
either	NN	O	O
a	NN	O	O
fulminant	NN	O	O
course	NN	O	O
of	NN	O	O
posterior	NN	O	B
leukoencephalopathy	NN	O	I
or	NN	O	O
posterior	NN	O	B
reversible	NN	O	I
encephalopathy	NN	O	I
syndrome	NN	O	I
developed	NN	O	O
110	NN	O	O
days	NN	O	O
after	NN	O	O
transplant	NN	O	O
.	NN	O	O

After	NN	O	O
an	NN	O	O
initially	NN	O	O
uneventful	NN	O	O
course	NN	O	O
after	NN	O	O
the	NN	O	O
transplant	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
rapidly	NN	O	O
fell	NN	O	O
into	NN	O	O
deep	NN	O	O
coma	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Cerebral	NN	O	O
MRI	NN	O	O
scan	NN	O	O
showed	NN	O	O
typical	NN	O	O
signs	NN	O	O
of	NN	O	O
enhancement	NN	O	O
in	NN	O	O
the	NN	O	O
pontine	NN	O	O
and	NN	O	O
posterior	NN	O	O
regions	NN	O	O
.	NN	O	O

Switching	NN	O	O
the	NN	O	O
immunosuppressive	NN	O	O
regimen	NN	O	O
from	NN	O	O
tacrolimus	NN	O	O
to	NN	O	O
cyclosporine	NN	O	O
did	NN	O	O
not	NN	O	O
improve	NN	O	O
the	NN	O	O
clinical	NN	O	O
situation	NN	O	O
.	NN	O	O

The	NN	O	O
termination	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
any	NN	O	O
calcineurin	NN	O	O
inhibitor	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
complete	NN	O	O
resolution	NN	O	O
of	NN	O	O
that	NN	O	O
complication	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Posterior	NN	O	B
reversible	NN	O	I
encephalopathy	NN	O	I
syndrome	NN	O	I
after	NN	O	O
liver	NN	O	O
transplant	NN	O	O
is	NN	O	O
rare	NN	O	O
.	NN	O	O

We	NN	O	O
recommend	NN	O	O
a	NN	O	O
complete	NN	O	O
cessation	NN	O	O
of	NN	O	O
any	NN	O	O
calcineurin	NN	O	O
inhibitor	NN	O	O
rather	NN	O	O
than	NN	O	O
a	NN	O	O
dose	NN	O	O
reduction	NN	O	O
.	NN	O	O

Prolonged	NN	O	O
hypothermia	NN	O	B
as	NN	O	O
a	NN	O	O
bridge	NN	O	O
to	NN	O	O
recovery	NN	O	O
for	NN	O	O
cerebral	NN	O	B
edema	NN	O	I
and	NN	O	O
intracranial	NN	O	B
hypertension	NN	O	I
associated	NN	O	O
with	NN	O	O
fulminant	NN	O	B
hepatic	NN	O	I
failure	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
To	NN	O	O
review	NN	O	O
evidence	NN	O	O
-	NN	O	O
based	NN	O	O
treatment	NN	O	O
options	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cerebral	NN	O	B
edema	NN	O	I
complicating	NN	O	O
fulminant	NN	O	B
hepatic	NN	O	I
failure	NN	O	I
(	NN	O	O
FHF	NN	O	B
)	NN	O	O
and	NN	O	O
discuss	NN	O	O
the	NN	O	O
potential	NN	O	O
applications	NN	O	O
of	NN	O	O
hypothermia	NN	O	B
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Case	NN	O	O
-	NN	O	O
based	NN	O	O
observations	NN	O	O
from	NN	O	O
a	NN	O	O
medical	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
(	NN	O	O
MICU	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
tertiary	NN	O	O
care	NN	O	O
facility	NN	O	O
in	NN	O	O
a	NN	O	O
27	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
with	NN	O	O
FHF	NN	O	B
from	NN	O	O
acetaminophen	NN	O	O
and	NN	O	O
resultant	NN	O	O
cerebral	NN	O	B
edema	NN	O	I
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Our	NN	O	O
patient	NN	O	O
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
MICU	NN	O	O
after	NN	O	O
being	NN	O	O
found	NN	O	O
unresponsive	NN	O	O
with	NN	O	O
presumed	NN	O	O
toxicity	NN	O	B
from	NN	O	O
acetaminophen	NN	O	O
which	NN	O	O
was	NN	O	O
ingested	NN	O	O
over	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
day	NN	O	O
period	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
had	NN	O	O
depressed	NN	O	O
of	NN	O	O
mental	NN	O	O
status	NN	O	O
lasting	NN	O	O
at	NN	O	O
least	NN	O	O
24	NN	O	O
h	NN	O	O
prior	NN	O	O
to	NN	O	O
admission	NN	O	O
.	NN	O	O

Initial	NN	O	O
evaluation	NN	O	O
confirmed	NN	O	O
FHF	NN	O	B
from	NN	O	O
acetaminophen	NN	O	O
and	NN	O	O
cerebral	NN	O	B
edema	NN	O	I
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
hyperosmolar	NN	O	O
therapy	NN	O	O
,	NN	O	O
hyperventilation	NN	O	B
,	NN	O	O
sedation	NN	O	O
,	NN	O	O
and	NN	O	O
chemical	NN	O	O
paralysis	NN	O	B
.	NN	O	O

Her	NN	O	O
intracranial	NN	O	O
pressure	NN	O	O
remained	NN	O	O
elevated	NN	O	O
despite	NN	O	O
maximal	NN	O	O
medical	NN	O	O
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
then	NN	O	O
initiated	NN	O	O
therapeutic	NN	O	O
hypothermia	NN	O	B
which	NN	O	O
was	NN	O	O
continued	NN	O	O
for	NN	O	O
5	NN	O	O
days	NN	O	O
.	NN	O	O

At	NN	O	O
re	NN	O	O
-	NN	O	O
warming	NN	O	O
,	NN	O	O
patient	NN	O	O
had	NN	O	O
resolution	NN	O	O
of	NN	O	O
her	NN	O	O
cerebral	NN	O	B
edema	NN	O	I
and	NN	O	O
intracranial	NN	O	B
hypertension	NN	O	I
.	NN	O	O

At	NN	O	O
discharge	NN	O	O
,	NN	O	O
she	NN	O	O
had	NN	O	O
complete	NN	O	O
recovery	NN	O	O
of	NN	O	O
neurological	NN	O	O
and	NN	O	O
hepatic	NN	O	O
functions	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
patients	NN	O	O
with	NN	O	O
FHF	NN	O	B
and	NN	O	O
cerebral	NN	O	B
edema	NN	O	I
from	NN	O	O
acetaminophen	NN	O	O
overdose	NN	O	B
,	NN	O	O
prolonged	NN	O	O
therapeutic	NN	O	O
hypothermia	NN	O	B
could	NN	O	O
potentially	NN	O	O
be	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
life	NN	O	O
saving	NN	O	O
therapy	NN	O	O
and	NN	O	O
a	NN	O	O
bridge	NN	O	O
to	NN	O	O
hepatic	NN	O	O
and	NN	O	O
neurological	NN	O	O
recovery	NN	O	O
.	NN	O	O

A	NN	O	O
clinical	NN	O	O
trial	NN	O	O
of	NN	O	O
hypothermia	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
this	NN	O	O
condition	NN	O	O
is	NN	O	O
warranted	NN	O	O
.	NN	O	O

Binasal	NN	O	B
visual	NN	O	I
field	NN	O	I
defects	NN	O	I
are	NN	O	O
not	NN	O	O
specific	NN	O	O
to	NN	O	O
vigabatrin	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
investigated	NN	O	O
the	NN	O	O
visual	NN	O	B
defects	NN	O	I
associated	NN	O	O
with	NN	O	O
the	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
vigabatrin	NN	O	O
(	NN	O	O
VGB	NN	O	O
)	NN	O	O
.	NN	O	O

Two	NN	O	O
hundred	NN	O	O
four	NN	O	O
people	NN	O	O
with	NN	O	O
epilepsy	NN	O	B
were	NN	O	O
grouped	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
therapy	NN	O	O
(	NN	O	O
current	NN	O	O
,	NN	O	O
previous	NN	O	O
,	NN	O	O
or	NN	O	O
no	NN	O	O
exposure	NN	O	O
to	NN	O	O
VGB	NN	O	O
)	NN	O	O
.	NN	O	O

Groups	NN	O	O
were	NN	O	O
matched	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
age	NN	O	O
,	NN	O	O
gender	NN	O	O
,	NN	O	O
and	NN	O	O
seizure	NN	O	B
frequency	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
underwent	NN	O	O
objective	NN	O	O
assessment	NN	O	O
of	NN	O	O
electrophysiological	NN	O	O
function	NN	O	O
(	NN	O	O
wide	NN	O	O
-	NN	O	O
field	NN	O	O
multifocal	NN	O	O
electroretinography	NN	O	O
)	NN	O	O
and	NN	O	O
conventional	NN	O	O
visual	NN	O	O
field	NN	O	O
testing	NN	O	O
(	NN	O	O
static	NN	O	O
perimetry	NN	O	O
)	NN	O	O
.	NN	O	O

Bilateral	NN	O	O
visual	NN	O	O
field	NN	O	O
constriction	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
59	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
currently	NN	O	O
taking	NN	O	O
VGB	NN	O	O
,	NN	O	O
43	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
previously	NN	O	O
took	NN	O	O
VGB	NN	O	O
,	NN	O	O
and	NN	O	O
24	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
no	NN	O	O
exposure	NN	O	O
to	NN	O	O
VGB	NN	O	O
.	NN	O	O

Assessment	NN	O	O
of	NN	O	O
retinal	NN	O	O
function	NN	O	O
revealed	NN	O	O
abnormal	NN	O	O
responses	NN	O	O
in	NN	O	O
48	NN	O	O
%	NN	O	O
of	NN	O	O
current	NN	O	O
VGB	NN	O	O
users	NN	O	O
and	NN	O	O
22	NN	O	O
%	NN	O	O
of	NN	O	O
prior	NN	O	O
VGB	NN	O	O
users	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
without	NN	O	O
previous	NN	O	O
exposure	NN	O	O
to	NN	O	O
VGB	NN	O	O
.	NN	O	O

Bilateral	NN	O	B
visual	NN	O	I
field	NN	O	I
abnormalities	NN	O	I
are	NN	O	O
common	NN	O	O
in	NN	O	O
the	NN	O	O
treated	NN	O	O
epilepsy	NN	O	B
population	NN	O	O
,	NN	O	O
irrespective	NN	O	O
of	NN	O	O
drug	NN	O	O
history	NN	O	O
.	NN	O	O

Assessment	NN	O	O
by	NN	O	O
conventional	NN	O	O
static	NN	O	O
perimetry	NN	O	O
may	NN	O	O
neither	NN	O	O
be	NN	O	O
sufficiently	NN	O	O
sensitive	NN	O	O
nor	NN	O	O
specific	NN	O	O
to	NN	O	O
reliably	NN	O	O
identify	NN	O	O
retinal	NN	O	B
toxicity	NN	O	I
associated	NN	O	O
with	NN	O	O
VGB	NN	O	O
.	NN	O	O

Smoking	NN	O	O
of	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
as	NN	O	O
a	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
HIV	NN	O	B
infection	NN	O	I
among	NN	O	O
people	NN	O	O
who	NN	O	O
use	NN	O	O
injection	NN	O	O
drugs	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Little	NN	O	O
is	NN	O	O
known	NN	O	O
about	NN	O	O
the	NN	O	O
possible	NN	O	O
role	NN	O	O
that	NN	O	O
smoking	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
has	NN	O	O
on	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
HIV	NN	O	B
infection	NN	O	I
.	NN	O	O

Given	NN	O	O
the	NN	O	O
increasing	NN	O	O
use	NN	O	O
of	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
,	NN	O	O
we	NN	O	O
sought	NN	O	O
to	NN	O	O
examine	NN	O	O
whether	NN	O	O
use	NN	O	O
of	NN	O	O
this	NN	O	O
illicit	NN	O	O
drug	NN	O	O
has	NN	O	O
become	NN	O	O
a	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
HIV	NN	O	B
infection	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
included	NN	O	O
data	NN	O	O
from	NN	O	O
people	NN	O	O
participating	NN	O	O
in	NN	O	O
the	NN	O	O
Vancouver	NN	O	O
Injection	NN	O	O
Drug	NN	O	O
Users	NN	O	O
Study	NN	O	O
who	NN	O	O
reported	NN	O	O
injecting	NN	O	O
illicit	NN	O	O
drugs	NN	O	O
at	NN	O	O
least	NN	O	O
once	NN	O	O
in	NN	O	O
the	NN	O	O
month	NN	O	O
before	NN	O	O
enrolment	NN	O	O
,	NN	O	O
lived	NN	O	O
in	NN	O	O
the	NN	O	O
greater	NN	O	O
Vancouver	NN	O	O
area	NN	O	O
,	NN	O	O
were	NN	O	O
HIV	NN	O	O
-	NN	O	O
negative	NN	O	O
at	NN	O	O
enrolment	NN	O	O
and	NN	O	O
completed	NN	O	O
at	NN	O	O
least	NN	O	O
1	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
study	NN	O	O
visit	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
whether	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
HIV	NN	O	B
seroconversion	NN	O	I
among	NN	O	O
daily	NN	O	O
smokers	NN	O	O
of	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
changed	NN	O	O
over	NN	O	O
time	NN	O	O
,	NN	O	O
we	NN	O	O
used	NN	O	O
Cox	NN	O	O
proportional	NN	O	O
hazards	NN	O	O
regression	NN	O	O
and	NN	O	O
divided	NN	O	O
the	NN	O	O
study	NN	O	O
into	NN	O	O
3	NN	O	O
periods	NN	O	O
:	NN	O	O
May	NN	O	O
1	NN	O	O
,	NN	O	O
1996	NN	O	O
-	NN	O	O
Nov	NN	O	O
.	NN	O	O

30	NN	O	O
,	NN	O	O
1999	NN	O	O
(	NN	O	O
period	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
Dec	NN	O	O
.	NN	O	O

1	NN	O	O
,	NN	O	O
1999	NN	O	O
-	NN	O	O
Nov	NN	O	O
.	NN	O	O

30	NN	O	O
,	NN	O	O
2002	NN	O	O
(	NN	O	O
period	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
Dec	NN	O	O
.	NN	O	O

1	NN	O	O
,	NN	O	O
2002	NN	O	O
-	NN	O	O
Dec	NN	O	O
.	NN	O	O

30	NN	O	O
,	NN	O	O
2005	NN	O	O
(	NN	O	O
period	NN	O	O
3	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Overall	NN	O	O
,	NN	O	O
1048	NN	O	O
eligible	NN	O	O
injection	NN	O	O
drug	NN	O	O
users	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
our	NN	O	O
study	NN	O	O
.	NN	O	O

Of	NN	O	O
these	NN	O	O
,	NN	O	O
137	NN	O	O
acquired	NN	O	O
HIV	NN	O	B
infection	NN	O	I
during	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
proportion	NN	O	O
of	NN	O	O
participants	NN	O	O
who	NN	O	O
reported	NN	O	O
daily	NN	O	O
smoking	NN	O	O
of	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
increased	NN	O	O
from	NN	O	O
11	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
in	NN	O	O
period	NN	O	O
1	NN	O	O
to	NN	O	O
39	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
in	NN	O	O
period	NN	O	O
3	NN	O	O
.	NN	O	O

After	NN	O	O
adjusting	NN	O	O
for	NN	O	O
potential	NN	O	O
confounders	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
HIV	NN	O	B
seroconversion	NN	O	I
among	NN	O	O
participants	NN	O	O
who	NN	O	O
were	NN	O	O
daily	NN	O	O
smokers	NN	O	O
of	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
increased	NN	O	O
over	NN	O	O
time	NN	O	O
(	NN	O	O
period	NN	O	O
1	NN	O	O
:	NN	O	O
hazard	NN	O	O
ratio	NN	O	O
[	NN	O	O
HR	NN	O	O
]	NN	O	O
1	NN	O	O
.	NN	O	O
03	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
0	NN	O	O
.	NN	O	O
57	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
85	NN	O	O
;	NN	O	O
period	NN	O	O
2	NN	O	O
:	NN	O	O
HR	NN	O	O
1	NN	O	O
.	NN	O	O
68	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1	NN	O	O
.	NN	O	O
01	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
80	NN	O	O
;	NN	O	O
and	NN	O	O
period	NN	O	O
3	NN	O	O
:	NN	O	O
HR	NN	O	O
2	NN	O	O
.	NN	O	O
74	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1	NN	O	O
.	NN	O	O
06	NN	O	O
-	NN	O	O
7	NN	O	O
.	NN	O	O
11	NN	O	O
)	NN	O	O
.	NN	O	O

INTERPRETATION	NN	O	O
:	NN	O	O
Smoking	NN	O	O
of	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
independent	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
HIV	NN	O	B
seroconversion	NN	O	I
among	NN	O	O
people	NN	O	O
who	NN	O	O
were	NN	O	O
injection	NN	O	O
drug	NN	O	O
users	NN	O	O
.	NN	O	O

This	NN	O	O
finding	NN	O	O
points	NN	O	O
to	NN	O	O
the	NN	O	O
urgent	NN	O	O
need	NN	O	O
for	NN	O	O
evidence	NN	O	O
-	NN	O	O
based	NN	O	O
public	NN	O	O
health	NN	O	O
initiatives	NN	O	O
targeted	NN	O	O
at	NN	O	O
people	NN	O	O
who	NN	O	O
smoke	NN	O	O
crack	NN	O	O
cocaine	NN	O	O
.	NN	O	O

Fluoxetine	NN	O	O
improves	NN	O	O
the	NN	O	O
memory	NN	O	B
deficits	NN	O	I
caused	NN	O	O
by	NN	O	O
the	NN	O	O
chemotherapy	NN	O	O
agent	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
.	NN	O	O

Cancer	NN	O	B
patients	NN	O	O
who	NN	O	O
have	NN	O	O
been	NN	O	O
treated	NN	O	O
with	NN	O	O
systemic	NN	O	O
adjuvant	NN	O	O
chemotherapy	NN	O	O
have	NN	O	O
described	NN	O	O
experiencing	NN	O	O
deteriorations	NN	O	O
in	NN	O	O
cognition	NN	O	O
.	NN	O	O

A	NN	O	O
widely	NN	O	O
used	NN	O	O
chemotherapeutic	NN	O	O
agent	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
)	NN	O	O
,	NN	O	O
readily	NN	O	O
crosses	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
and	NN	O	O
so	NN	O	O
could	NN	O	O
have	NN	O	O
a	NN	O	O
direct	NN	O	O
effect	NN	O	O
on	NN	O	O
brain	NN	O	O
function	NN	O	O
.	NN	O	O

In	NN	O	O
particular	NN	O	O
this	NN	O	O
anti	NN	O	O
mitotic	NN	O	O
drug	NN	O	O
could	NN	O	O
reduce	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
in	NN	O	O
the	NN	O	O
neurogenic	NN	O	O
regions	NN	O	O
of	NN	O	O
the	NN	O	O
adult	NN	O	O
brain	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
reports	NN	O	O
indicate	NN	O	O
that	NN	O	O
hippocampal	NN	O	O
dependent	NN	O	O
neurogenesis	NN	O	O
and	NN	O	O
cognition	NN	O	O
are	NN	O	O
enhanced	NN	O	O
by	NN	O	O
the	NN	O	O
SSRI	NN	O	O
antidepressant	NN	O	O
Fluoxetine	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
investigation	NN	O	O
the	NN	O	O
behavioural	NN	O	O
effects	NN	O	O
of	NN	O	O
chronic	NN	O	O
(	NN	O	O
two	NN	O	O
week	NN	O	O
)	NN	O	O
treatment	NN	O	O
with	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
and	NN	O	O
(	NN	O	O
three	NN	O	O
weeks	NN	O	O
)	NN	O	O
with	NN	O	O
Fluoxetine	NN	O	O
either	NN	O	O
separately	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
were	NN	O	O
tested	NN	O	O
on	NN	O	O
adult	NN	O	O
Lister	NN	O	O
hooded	NN	O	O
rats	NN	O	O
.	NN	O	O

Behavioural	NN	O	O
effects	NN	O	O
were	NN	O	O
tested	NN	O	O
using	NN	O	O
a	NN	O	O
context	NN	O	O
dependent	NN	O	O
conditioned	NN	O	O
emotional	NN	O	O
response	NN	O	O
test	NN	O	O
(	NN	O	O
CER	NN	O	O
)	NN	O	O
which	NN	O	O
showed	NN	O	O
that	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
had	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
freezing	NN	O	O
time	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
.	NN	O	O

A	NN	O	O
separate	NN	O	O
group	NN	O	O
of	NN	O	O
animals	NN	O	O
was	NN	O	O
tested	NN	O	O
using	NN	O	O
a	NN	O	O
hippocampal	NN	O	O
dependent	NN	O	O
spatial	NN	O	O
working	NN	O	O
memory	NN	O	O
test	NN	O	O
,	NN	O	O
the	NN	O	O
object	NN	O	O
location	NN	O	O
recognition	NN	O	O
test	NN	O	O
(	NN	O	O
OLR	NN	O	O
)	NN	O	O
.	NN	O	O

Animals	NN	O	O
treated	NN	O	O
only	NN	O	O
with	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
showed	NN	O	O
significant	NN	O	O
deficits	NN	O	O
in	NN	O	O
their	NN	O	O
ability	NN	O	O
to	NN	O	O
carry	NN	O	O
out	NN	O	O
the	NN	O	O
OLR	NN	O	O
task	NN	O	O
but	NN	O	O
co	NN	O	O
administration	NN	O	O
of	NN	O	O
Fluoxetine	NN	O	O
improved	NN	O	O
their	NN	O	O
performance	NN	O	O
.	NN	O	O

5	NN	O	O
-	NN	O	O
FU	NN	O	O
chemotherapy	NN	O	O
caused	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
proliferating	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
sub	NN	O	O
granular	NN	O	O
zone	NN	O	O
of	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
.	NN	O	O

This	NN	O	O
reduction	NN	O	O
was	NN	O	O
eliminated	NN	O	O
when	NN	O	O
Fluoxetine	NN	O	O
was	NN	O	O
co	NN	O	O
administered	NN	O	O
with	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
.	NN	O	O

Fluoxetine	NN	O	O
on	NN	O	O
its	NN	O	O
own	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
proliferating	NN	O	O
cell	NN	O	O
number	NN	O	O
or	NN	O	O
behaviour	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
can	NN	O	O
negatively	NN	O	O
affect	NN	O	O
both	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
and	NN	O	O
hippocampal	NN	O	O
dependent	NN	O	O
working	NN	O	O
memory	NN	O	O
and	NN	O	O
that	NN	O	O
these	NN	O	O
deficits	NN	O	O
can	NN	O	O
be	NN	O	O
reversed	NN	O	O
by	NN	O	O
the	NN	O	O
simultaneous	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
antidepressant	NN	O	O
Fluoxetine	NN	O	O
.	NN	O	O

Liver	NN	O	O
-	NN	O	O
specific	NN	O	O
ablation	NN	O	O
of	NN	O	O
integrin	NN	O	O
-	NN	O	O
linked	NN	O	O
kinase	NN	O	O
in	NN	O	O
mice	NN	O	O
results	NN	O	O
in	NN	O	O
enhanced	NN	O	O
and	NN	O	O
prolonged	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
and	NN	O	O
hepatomegaly	NN	O	B
after	NN	O	O
phenobarbital	NN	O	O
administration	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
recently	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
disruption	NN	O	O
of	NN	O	O
extracellular	NN	O	O
matrix	NN	O	O
(	NN	O	O
ECM	NN	O	O
)	NN	O	O
/	NN	O	O
integrin	NN	O	O
signaling	NN	O	O
via	NN	O	O
elimination	NN	O	O
of	NN	O	O
integrin	NN	O	O
-	NN	O	O
linked	NN	O	O
kinase	NN	O	O
(	NN	O	O
ILK	NN	O	O
)	NN	O	O
in	NN	O	O
hepatocytes	NN	O	O
interferes	NN	O	O
with	NN	O	O
signals	NN	O	O
leading	NN	O	O
to	NN	O	O
termination	NN	O	O
of	NN	O	O
liver	NN	O	O
regeneration	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
investigates	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
ILK	NN	O	O
in	NN	O	O
liver	NN	O	O
enlargement	NN	O	O
induced	NN	O	O
by	NN	O	O
phenobarbital	NN	O	O
(	NN	O	O
PB	NN	O	O
)	NN	O	O
.	NN	O	O

Wild	NN	O	O
-	NN	O	O
type	NN	O	O
(	NN	O	O
WT	NN	O	O
)	NN	O	O
and	NN	O	O
ILK	NN	O	O
:	NN	O	O
liver	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
were	NN	O	O
given	NN	O	O
PB	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
in	NN	O	O
drinking	NN	O	O
water	NN	O	O
)	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
.	NN	O	O

Livers	NN	O	O
were	NN	O	O
harvested	NN	O	O
on	NN	O	O
2	NN	O	O
,	NN	O	O
5	NN	O	O
,	NN	O	O
and	NN	O	O
10	NN	O	O
days	NN	O	O
during	NN	O	O
PB	NN	O	O
administration	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
hepatocyte	NN	O	O
-	NN	O	O
specific	NN	O	O
ILK	NN	O	O
/	NN	O	O
liver	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
,	NN	O	O
the	NN	O	O
liver	NN	O	O
:	NN	O	O
body	NN	O	O
weight	NN	O	O
ratio	NN	O	O
was	NN	O	O
more	NN	O	O
than	NN	O	O
double	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
0	NN	O	O
h	NN	O	O
at	NN	O	O
day	NN	O	O
2	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
times	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
at	NN	O	O
days	NN	O	O
5	NN	O	O
and	NN	O	O
10	NN	O	O
,	NN	O	O
it	NN	O	O
was	NN	O	O
enlarged	NN	O	O
three	NN	O	O
times	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
WT	NN	O	O
mice	NN	O	O
,	NN	O	O
the	NN	O	O
increase	NN	O	O
was	NN	O	O
as	NN	O	O
expected	NN	O	O
from	NN	O	O
previous	NN	O	O
literature	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
8	NN	O	O
times	NN	O	O
)	NN	O	O
and	NN	O	O
seems	NN	O	O
to	NN	O	O
have	NN	O	O
leveled	NN	O	O
off	NN	O	O
after	NN	O	O
day	NN	O	O
2	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
slightly	NN	O	O
increased	NN	O	O
proliferating	NN	O	O
cell	NN	O	O
nuclear	NN	O	O
antigen	NN	O	O
-	NN	O	O
positive	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
ILK	NN	O	O
/	NN	O	O
liver	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
animals	NN	O	O
at	NN	O	O
day	NN	O	O
2	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
WT	NN	O	O
after	NN	O	O
PB	NN	O	O
administration	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
WT	NN	O	O
animals	NN	O	O
,	NN	O	O
the	NN	O	O
proliferative	NN	O	O
response	NN	O	O
had	NN	O	O
come	NN	O	O
back	NN	O	O
to	NN	O	O
normal	NN	O	O
by	NN	O	O
days	NN	O	O
5	NN	O	O
and	NN	O	O
10	NN	O	O
.	NN	O	O

Hepatocytes	NN	O	O
of	NN	O	O
the	NN	O	O
ILK	NN	O	O
/	NN	O	O
liver	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
continued	NN	O	O
to	NN	O	O
proliferate	NN	O	O
up	NN	O	O
until	NN	O	O
day	NN	O	O
10	NN	O	O
.	NN	O	O

ILK	NN	O	O
/	NN	O	O
liver	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
also	NN	O	O
showed	NN	O	O
increased	NN	O	O
expression	NN	O	O
of	NN	O	O
key	NN	O	O
genes	NN	O	O
involved	NN	O	O
in	NN	O	O
hepatocyte	NN	O	O
proliferation	NN	O	O
at	NN	O	O
different	NN	O	O
time	NN	O	O
points	NN	O	O
during	NN	O	O
PB	NN	O	O
administration	NN	O	O
.	NN	O	O

In	NN	O	O
summary	NN	O	O
,	NN	O	O
ECM	NN	O	O
proteins	NN	O	O
communicate	NN	O	O
with	NN	O	O
the	NN	O	O
signaling	NN	O	O
machinery	NN	O	O
of	NN	O	O
dividing	NN	O	O
cells	NN	O	O
via	NN	O	O
ILK	NN	O	O
to	NN	O	O
regulate	NN	O	O
hepatocyte	NN	O	O
proliferation	NN	O	O
and	NN	O	O
termination	NN	O	O
of	NN	O	O
the	NN	O	O
proliferative	NN	O	O
response	NN	O	O
.	NN	O	O

Lack	NN	O	O
of	NN	O	O
ILK	NN	O	O
in	NN	O	O
the	NN	O	O
hepatocytes	NN	O	O
imparts	NN	O	O
prolonged	NN	O	O
proliferative	NN	O	O
response	NN	O	O
not	NN	O	O
only	NN	O	O
to	NN	O	O
stimuli	NN	O	O
related	NN	O	O
to	NN	O	O
liver	NN	O	O
regeneration	NN	O	O
but	NN	O	O
also	NN	O	O
to	NN	O	O
xenobiotic	NN	O	O
chemical	NN	O	O
mitogens	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
PB	NN	O	O
.	NN	O	O

Decreased	NN	O	O
Expression	NN	O	O
of	NN	O	O
Na	NN	O	O
/	NN	O	O
K	NN	O	O
-	NN	O	O
ATPase	NN	O	O
,	NN	O	O
NHE3	NN	O	O
,	NN	O	O
NBC1	NN	O	O
,	NN	O	O
AQP1	NN	O	O
and	NN	O	O
OAT	NN	O	O
in	NN	O	O
Gentamicin	NN	O	O
-	NN	O	O
induced	NN	O	O
Nephropathy	NN	O	B
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
aimed	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
there	NN	O	O
is	NN	O	O
an	NN	O	O
altered	NN	O	O
regulation	NN	O	O
of	NN	O	O
tubular	NN	O	O
transporters	NN	O	O
in	NN	O	O
gentamicin	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
male	NN	O	O
rats	NN	O	O
(	NN	O	O
200	NN	O	O
~	NN	O	O
250	NN	O	O
g	NN	O	O
)	NN	O	O
were	NN	O	O
subcutaneously	NN	O	O
injected	NN	O	O
with	NN	O	O
gentamicin	NN	O	O
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
)	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
tubular	NN	O	O
transporters	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
immunoblotting	NN	O	O
and	NN	O	O
immunohistochemistry	NN	O	O
.	NN	O	O

The	NN	O	O
mRNA	NN	O	O
and	NN	O	O
protein	NN	O	O
expression	NN	O	O
of	NN	O	O
OAT	NN	O	O
was	NN	O	O
also	NN	O	O
determined	NN	O	O
.	NN	O	O

Gentamicin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
exhibited	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
along	NN	O	O
with	NN	O	O
increased	NN	O	O
plasma	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
.	NN	O	O

Accordingly	NN	O	O
,	NN	O	O
the	NN	O	O
fractional	NN	O	O
excretion	NN	O	O
of	NN	O	O
sodium	NN	O	O
increased	NN	O	O
.	NN	O	O

Urine	NN	O	O
volume	NN	O	O
was	NN	O	O
increased	NN	O	O
,	NN	O	O
while	NN	O	O
urine	NN	O	O
osmolality	NN	O	O
and	NN	O	O
free	NN	O	O
water	NN	O	O
reabsorption	NN	O	O
were	NN	O	O
decreased	NN	O	O
.	NN	O	O

Immunoblotting	NN	O	O
and	NN	O	O
immunohistochemistry	NN	O	O
revealed	NN	O	O
decreased	NN	O	O
expression	NN	O	O
of	NN	O	O
Na	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
/	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
ATPase	NN	O	O
,	NN	O	O
NHE3	NN	O	O
,	NN	O	O
NBC1	NN	O	O
,	NN	O	O
and	NN	O	O
AQP1	NN	O	O
in	NN	O	O
the	NN	O	O
kidney	NN	O	O
of	NN	O	O
gentamicin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
expression	NN	O	O
of	NN	O	O
OAT1	NN	O	O
and	NN	O	O
OAT3	NN	O	O
was	NN	O	O
also	NN	O	O
decreased	NN	O	O
.	NN	O	O

Gentamicin	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
may	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
part	NN	O	O
be	NN	O	O
causally	NN	O	O
related	NN	O	O
with	NN	O	O
a	NN	O	O
decreased	NN	O	O
expression	NN	O	O
of	NN	O	O
Na	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
/	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
ATPase	NN	O	O
,	NN	O	O
NHE3	NN	O	O
,	NN	O	O
NBC1	NN	O	O
,	NN	O	O
AQP1	NN	O	O
and	NN	O	O
OAT	NN	O	O
.	NN	O	O

Acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
methotrexate	NN	O	O
therapy	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
ileostomy	NN	O	O
.	NN	O	O

High	NN	O	O
-	NN	O	O
dose	NN	O	O
methotrexate	NN	O	O
(	NN	O	O
HD	NN	O	O
-	NN	O	O
MTX	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
important	NN	O	O
treatment	NN	O	O
for	NN	O	O
Burkitt	NN	O	B
lymphoma	NN	O	I
,	NN	O	O
but	NN	O	O
can	NN	O	O
cause	NN	O	O
hepatic	NN	O	B
and	NN	O	I
renal	NN	O	I
toxicity	NN	O	I
when	NN	O	O
its	NN	O	O
clearance	NN	O	O
is	NN	O	O
delayed	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
after	NN	O	O
HD	NN	O	O
-	NN	O	O
MTX	NN	O	O
therapy	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
ileostomy	NN	O	O
,	NN	O	O
The	NN	O	O
patient	NN	O	O
was	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
who	NN	O	O
had	NN	O	O
received	NN	O	O
a	NN	O	O
living	NN	O	O
-	NN	O	O
related	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
for	NN	O	O
congenital	NN	O	O
biliary	NN	O	B
atresia	NN	O	I
.	NN	O	O

At	NN	O	O
day	NN	O	O
833	NN	O	O
after	NN	O	O
the	NN	O	O
transplantation	NN	O	O
,	NN	O	O
he	NN	O	O
was	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
PTLD	NN	O	B
(	NN	O	O
post	NN	O	B
-	NN	O	I
transplantation	NN	O	I
lymphoproliferative	NN	O	I
disorder	NN	O	I
,	NN	O	O
Burkitt	NN	O	B
-	NN	O	I
type	NN	O	I
malignant	NN	O	I
lymphoma	NN	O	I
)	NN	O	O
.	NN	O	O

During	NN	O	O
induction	NN	O	O
therapy	NN	O	O
,	NN	O	O
he	NN	O	O
suffered	NN	O	O
ileal	NN	O	O
perforation	NN	O	O
and	NN	O	O
ileostomy	NN	O	O
was	NN	O	O
performed	NN	O	O
.	NN	O	O

Subsequent	NN	O	O
HD	NN	O	O
-	NN	O	O
MTX	NN	O	O
therapy	NN	O	O
caused	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
that	NN	O	O
required	NN	O	O
continuous	NN	O	O
hemodialysis	NN	O	O
.	NN	O	O

We	NN	O	O
supposed	NN	O	O
that	NN	O	O
intravascular	NN	O	O
hypovolemia	NN	O	B
due	NN	O	O
to	NN	O	O
substantial	NN	O	O
drainage	NN	O	O
from	NN	O	O
the	NN	O	O
ileostoma	NN	O	O
caused	NN	O	O
acute	NN	O	B
prerenal	NN	O	I
failure	NN	O	I
.	NN	O	O

After	NN	O	O
recovery	NN	O	O
of	NN	O	O
his	NN	O	O
renal	NN	O	O
function	NN	O	O
,	NN	O	O
we	NN	O	O
could	NN	O	O
safely	NN	O	O
treat	NN	O	O
the	NN	O	O
patient	NN	O	O
with	NN	O	O
HD	NN	O	O
-	NN	O	O
MTX	NN	O	O
therapy	NN	O	O
by	NN	O	O
controlling	NN	O	O
drainage	NN	O	O
from	NN	O	O
ileostoma	NN	O	O
with	NN	O	O
total	NN	O	O
parenteral	NN	O	O
nutrition	NN	O	O
.	NN	O	O

Longitudinal	NN	O	O
association	NN	O	O
of	NN	O	O
alcohol	NN	O	O
use	NN	O	O
with	NN	O	O
HIV	NN	O	B
disease	NN	O	I
progression	NN	O	O
and	NN	O	O
psychological	NN	O	O
health	NN	O	O
of	NN	O	O
women	NN	O	O
with	NN	O	O
HIV	NN	O	O
.	NN	O	O

We	NN	O	O
evaluated	NN	O	O
the	NN	O	O
association	NN	O	O
of	NN	O	O
alcohol	NN	O	O
consumption	NN	O	O
and	NN	O	O
depression	NN	O	B
,	NN	O	O
and	NN	O	O
their	NN	O	O
effects	NN	O	O
on	NN	O	O
HIV	NN	O	B
disease	NN	O	I
progression	NN	O	O
among	NN	O	O
women	NN	O	O
with	NN	O	O
HIV	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
included	NN	O	O
871	NN	O	O
women	NN	O	O
with	NN	O	O
HIV	NN	O	O
who	NN	O	O
were	NN	O	O
recruited	NN	O	O
from	NN	O	O
1993	NN	O	O
-	NN	O	O
1995	NN	O	O
in	NN	O	O
four	NN	O	O
US	NN	O	O
cities	NN	O	O
.	NN	O	O

The	NN	O	O
participants	NN	O	O
had	NN	O	O
physical	NN	O	O
examination	NN	O	O
,	NN	O	O
medical	NN	O	O
record	NN	O	O
extraction	NN	O	O
,	NN	O	O
and	NN	O	O
venipuncture	NN	O	O
,	NN	O	O
CD4	NN	O	O
+	NN	O	O
T	NN	O	O
-	NN	O	O
cell	NN	O	O
counts	NN	O	O
determination	NN	O	O
,	NN	O	O
measurement	NN	O	O
of	NN	O	O
depression	NN	O	B
symptoms	NN	O	O
(	NN	O	O
using	NN	O	O
the	NN	O	O
self	NN	O	O
-	NN	O	O
report	NN	O	O
Center	NN	O	O
for	NN	O	O
Epidemiological	NN	O	O
Studies	NN	O	O
-	NN	O	O
Depression	NN	O	B
Scale	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
alcohol	NN	O	O
use	NN	O	O
assessment	NN	O	O
at	NN	O	O
enrollment	NN	O	O
,	NN	O	O
and	NN	O	O
semiannually	NN	O	O
until	NN	O	O
March	NN	O	O
2000	NN	O	O
.	NN	O	O

Multilevel	NN	O	O
random	NN	O	O
coefficient	NN	O	O
ordinal	NN	O	O
models	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
multilevel	NN	O	O
models	NN	O	O
with	NN	O	O
joint	NN	O	O
responses	NN	O	O
were	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
analysis	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
association	NN	O	O
between	NN	O	O
level	NN	O	O
of	NN	O	O
alcohol	NN	O	O
use	NN	O	O
and	NN	O	O
CD4	NN	O	O
+	NN	O	O
T	NN	O	O
-	NN	O	O
cell	NN	O	O
counts	NN	O	O
.	NN	O	O

When	NN	O	O
participants	NN	O	O
were	NN	O	O
stratified	NN	O	O
by	NN	O	O
antiretroviral	NN	O	O
therapy	NN	O	O
(	NN	O	O
ART	NN	O	O
)	NN	O	O
use	NN	O	O
,	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
alcohol	NN	O	O
and	NN	O	O
CD4	NN	O	O
+	NN	O	O
T	NN	O	O
-	NN	O	O
cell	NN	O	O
did	NN	O	O
not	NN	O	O
reach	NN	O	O
statistical	NN	O	O
significance	NN	O	O
.	NN	O	O

The	NN	O	O
association	NN	O	O
between	NN	O	O
alcohol	NN	O	O
consumption	NN	O	O
and	NN	O	O
depression	NN	O	B
was	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Depression	NN	O	B
had	NN	O	O
a	NN	O	O
significant	NN	O	O
negative	NN	O	O
effect	NN	O	O
on	NN	O	O
CD4	NN	O	O
+	NN	O	O
T	NN	O	O
-	NN	O	O
cell	NN	O	O
counts	NN	O	O
over	NN	O	O
time	NN	O	O
regardless	NN	O	O
of	NN	O	O
ART	NN	O	O
use	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
alcohol	NN	O	O
consumption	NN	O	O
has	NN	O	O
a	NN	O	O
direct	NN	O	O
association	NN	O	O
with	NN	O	O
depression	NN	O	B
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
depression	NN	O	B
is	NN	O	O
associated	NN	O	O
with	NN	O	O
HIV	NN	O	B
disease	NN	O	I
progression	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
have	NN	O	O
implications	NN	O	O
for	NN	O	O
the	NN	O	O
provision	NN	O	O
of	NN	O	O
alcohol	NN	O	O
use	NN	O	O
interventions	NN	O	O
and	NN	O	O
psychological	NN	O	O
resources	NN	O	O
to	NN	O	O
improve	NN	O	O
the	NN	O	O
health	NN	O	O
of	NN	O	O
women	NN	O	O
with	NN	O	O
HIV	NN	O	O
.	NN	O	O

Chemokine	NN	O	O
CCL2	NN	O	O
and	NN	O	O
its	NN	O	O
receptor	NN	O	O
CCR2	NN	O	O
are	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
following	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Neuroinflammation	NN	O	B
occurs	NN	O	O
after	NN	O	O
seizures	NN	O	B
and	NN	O	O
is	NN	O	O
implicated	NN	O	O
in	NN	O	O
epileptogenesis	NN	O	O
.	NN	O	O

CCR2	NN	O	O
is	NN	O	O
a	NN	O	O
chemokine	NN	O	O
receptor	NN	O	O
for	NN	O	O
CCL2	NN	O	O
and	NN	O	O
their	NN	O	O
interaction	NN	O	O
mediates	NN	O	O
monocyte	NN	O	O
infiltration	NN	O	O
in	NN	O	O
the	NN	O	O
neuroinflammatory	NN	O	B
cascade	NN	O	O
triggered	NN	O	O
in	NN	O	O
different	NN	O	O
brain	NN	O	O
pathologies	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
work	NN	O	O
CCR2	NN	O	O
and	NN	O	O
CCL2	NN	O	O
expression	NN	O	O
were	NN	O	O
examined	NN	O	O
following	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
(	NN	O	O
SE	NN	O	B
)	NN	O	O
induced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
injection	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
SE	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
injection	NN	O	O
.	NN	O	O

Control	NN	O	O
rats	NN	O	O
were	NN	O	O
injected	NN	O	O
with	NN	O	O
saline	NN	O	O
instead	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
.	NN	O	O

Five	NN	O	O
days	NN	O	O
after	NN	O	O
SE	NN	O	B
,	NN	O	O
CCR2	NN	O	O
staining	NN	O	O
in	NN	O	O
neurons	NN	O	O
and	NN	O	O
glial	NN	O	O
cells	NN	O	O
was	NN	O	O
examined	NN	O	O
using	NN	O	O
imunohistochemical	NN	O	O
analyses	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
CCR2	NN	O	O
positive	NN	O	O
cells	NN	O	O
was	NN	O	O
determined	NN	O	O
using	NN	O	O
stereology	NN	O	O
probes	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
.	NN	O	O

CCL2	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
was	NN	O	O
examined	NN	O	O
by	NN	O	O
molecular	NN	O	O
assay	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Increased	NN	O	O
CCR2	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
after	NN	O	O
SE	NN	O	B
.	NN	O	O

Seizures	NN	O	B
also	NN	O	O
resulted	NN	O	O
in	NN	O	O
alterations	NN	O	O
to	NN	O	O
the	NN	O	O
cell	NN	O	O
types	NN	O	O
expressing	NN	O	O
CCR2	NN	O	O
.	NN	O	O

Increased	NN	O	O
numbers	NN	O	O
of	NN	O	O
neurons	NN	O	O
that	NN	O	O
expressed	NN	O	O
CCR2	NN	O	O
was	NN	O	O
observed	NN	O	O
following	NN	O	O
SE	NN	O	B
.	NN	O	O

Microglial	NN	O	O
cells	NN	O	O
were	NN	O	O
more	NN	O	O
closely	NN	O	O
apposed	NN	O	O
to	NN	O	O
the	NN	O	O
CCR2	NN	O	O
-	NN	O	O
labeled	NN	O	O
cells	NN	O	O
in	NN	O	O
SE	NN	O	B
rats	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
rats	NN	O	O
that	NN	O	O
experienced	NN	O	O
SE	NN	O	B
exhibited	NN	O	O
CCR2	NN	O	O
-	NN	O	O
labeling	NN	O	O
in	NN	O	O
populations	NN	O	O
of	NN	O	O
hypertrophied	NN	O	B
astrocytes	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
CA1	NN	O	O
and	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
.	NN	O	O

These	NN	O	O
CCR2	NN	O	O
+	NN	O	O
astroctytes	NN	O	O
were	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
control	NN	O	O
rats	NN	O	O
.	NN	O	O

Examination	NN	O	O
of	NN	O	O
CCL2	NN	O	O
expression	NN	O	O
showed	NN	O	O
that	NN	O	O
it	NN	O	O
was	NN	O	O
elevated	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
following	NN	O	O
SE	NN	O	B
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
CCR2	NN	O	O
and	NN	O	O
CCL2	NN	O	O
are	NN	O	O
up	NN	O	O
-	NN	O	O
regulated	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
after	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
SE	NN	O	B
.	NN	O	O

Seizures	NN	O	B
also	NN	O	O
result	NN	O	O
in	NN	O	O
changes	NN	O	O
to	NN	O	O
CCR2	NN	O	O
receptor	NN	O	O
expression	NN	O	O
in	NN	O	O
neurons	NN	O	O
and	NN	O	O
astrocytes	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
might	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
detrimental	NN	O	O
neuroplasticity	NN	O	O
and	NN	O	O
neuroinflammatory	NN	O	B
changes	NN	O	O
that	NN	O	O
occur	NN	O	O
following	NN	O	O
seizures	NN	O	B
.	NN	O	O

Metallothionein	NN	O	O
induction	NN	O	O
reduces	NN	O	O
caspase	NN	O	O
-	NN	O	O
3	NN	O	O
activity	NN	O	O
and	NN	O	O
TNFalpha	NN	O	O
levels	NN	O	O
with	NN	O	O
preservation	NN	O	O
of	NN	O	O
cognitive	NN	O	O
function	NN	O	O
and	NN	O	O
intact	NN	O	O
hippocampal	NN	O	O
neurons	NN	O	O
in	NN	O	O
carmustine	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Hippocampal	NN	O	O
integrity	NN	O	O
is	NN	O	O
essential	NN	O	O
for	NN	O	O
cognitive	NN	O	O
functions	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
induction	NN	O	O
of	NN	O	O
metallothionein	NN	O	O
(	NN	O	O
MT	NN	O	O
)	NN	O	O
by	NN	O	O
ZnSO	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
and	NN	O	O
its	NN	O	O
role	NN	O	O
in	NN	O	O
neuroprotection	NN	O	O
has	NN	O	O
been	NN	O	O
documented	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
explore	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
MT	NN	O	O
induction	NN	O	O
on	NN	O	O
carmustine	NN	O	O
(	NN	O	O
BCNU	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
hippocampal	NN	O	O
cognitive	NN	O	B
dysfunction	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
60	NN	O	O
male	NN	O	O
Wistar	NN	O	O
albino	NN	O	O
rats	NN	O	O
were	NN	O	O
randomly	NN	O	O
divided	NN	O	O
into	NN	O	O
four	NN	O	O
groups	NN	O	O
(	NN	O	O
15	NN	O	O
/	NN	O	O
group	NN	O	O
)	NN	O	O
:	NN	O	O
The	NN	O	O
control	NN	O	O
group	NN	O	O
injected	NN	O	O
with	NN	O	O
single	NN	O	O
doses	NN	O	O
of	NN	O	O
normal	NN	O	O
saline	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
)	NN	O	O
followed	NN	O	O
24	NN	O	O
h	NN	O	O
later	NN	O	O
by	NN	O	O
BCNU	NN	O	O
solvent	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
second	NN	O	O
group	NN	O	O
administered	NN	O	O
ZnSO	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
micromol	NN	O	O
/	NN	O	O
10	NN	O	O
microl	NN	O	O
normal	NN	O	O
saline	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
,	NN	O	O
once	NN	O	O
)	NN	O	O
then	NN	O	O
BCNU	NN	O	O
solvent	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
)	NN	O	O
after	NN	O	O
24	NN	O	O
h	NN	O	O
.	NN	O	O

Third	NN	O	O
group	NN	O	O
received	NN	O	O
BCNU	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
,	NN	O	O
once	NN	O	O
)	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
injection	NN	O	O
with	NN	O	O
normal	NN	O	O
saline	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
)	NN	O	O
.	NN	O	O

Fourth	NN	O	O
group	NN	O	O
received	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
ZnSO	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
micromol	NN	O	O
/	NN	O	O
10	NN	O	O
microl	NN	O	O
normal	NN	O	O
saline	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
)	NN	O	O
then	NN	O	O
BCNU	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
,	NN	O	O
once	NN	O	O
)	NN	O	O
after	NN	O	O
24	NN	O	O
h	NN	O	O
.	NN	O	O

The	NN	O	O
obtained	NN	O	O
data	NN	O	O
revealed	NN	O	O
that	NN	O	O
BCNU	NN	O	O
administration	NN	O	O
resulted	NN	O	O
in	NN	O	O
deterioration	NN	O	B
of	NN	O	I
learning	NN	O	I
and	NN	O	I
short	NN	O	I
-	NN	O	I
term	NN	O	I
memory	NN	O	I
(	NN	O	O
STM	NN	O	O
)	NN	O	O
,	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
using	NN	O	O
radial	NN	O	O
arm	NN	O	O
water	NN	O	O
maze	NN	O	O
,	NN	O	O
accompanied	NN	O	O
with	NN	O	O
decreased	NN	O	O
hippocampal	NN	O	O
glutathione	NN	O	O
reductase	NN	O	O
(	NN	O	O
GR	NN	O	O
)	NN	O	O
activity	NN	O	O
and	NN	O	O
reduced	NN	O	O
glutathione	NN	O	O
(	NN	O	O
GSH	NN	O	O
)	NN	O	O
content	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
BCNU	NN	O	O
administration	NN	O	O
increased	NN	O	O
serum	NN	O	O
tumor	NN	O	B
necrosis	NN	O	B
factor	NN	O	O
-	NN	O	O
alpha	NN	O	O
(	NN	O	O
TNFalpha	NN	O	O
)	NN	O	O
,	NN	O	O
hippocampal	NN	O	O
MT	NN	O	O
and	NN	O	O
malondialdehyde	NN	O	O
(	NN	O	O
MDA	NN	O	O
)	NN	O	O
contents	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
caspase	NN	O	O
-	NN	O	O
3	NN	O	O
activity	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
histological	NN	O	O
alterations	NN	O	O
.	NN	O	O

ZnSO	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
pretreatment	NN	O	O
counteracted	NN	O	O
BCNU	NN	O	O
-	NN	O	O
induced	NN	O	O
inhibition	NN	O	O
of	NN	O	O
GR	NN	O	O
and	NN	O	O
depletion	NN	O	O
of	NN	O	O
GSH	NN	O	O
and	NN	O	O
resulted	NN	O	O
in	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
MDA	NN	O	O
and	NN	O	O
TNFalpha	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
caspase	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O

The	NN	O	O
histological	NN	O	O
features	NN	O	O
were	NN	O	O
improved	NN	O	O
in	NN	O	O
hippocampus	NN	O	O
of	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
ZnSO	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
+	NN	O	O
BCNU	NN	O	O
compared	NN	O	O
to	NN	O	O
only	NN	O	O
BCNU	NN	O	O
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
MT	NN	O	O
induction	NN	O	O
halts	NN	O	O
BCNU	NN	O	O
-	NN	O	O
induced	NN	O	O
hippocampal	NN	O	O
toxicity	NN	O	B
as	NN	O	O
it	NN	O	O
prevented	NN	O	O
GR	NN	O	O
inhibition	NN	O	O
and	NN	O	O
GSH	NN	O	O
depletion	NN	O	O
and	NN	O	O
counteracted	NN	O	O
the	NN	O	O
increased	NN	O	O
levels	NN	O	O
of	NN	O	O
TNFalpha	NN	O	O
,	NN	O	O
MDA	NN	O	O
and	NN	O	O
caspase	NN	O	O
-	NN	O	O
3	NN	O	O
activity	NN	O	O
with	NN	O	O
subsequent	NN	O	O
preservation	NN	O	O
of	NN	O	O
cognition	NN	O	O
.	NN	O	O

Fatal	NN	O	O
carbamazepine	NN	O	O
induced	NN	O	O
fulminant	NN	O	B
eosinophilic	NN	O	I
(	NN	O	O
hypersensitivity	NN	O	B
)	NN	O	O
myocarditis	NN	O	B
:	NN	O	O
emphasis	NN	O	O
on	NN	O	O
anatomical	NN	O	O
and	NN	O	O
histological	NN	O	O
characteristics	NN	O	O
,	NN	O	O
mechanisms	NN	O	O
and	NN	O	O
genetics	NN	O	O
of	NN	O	O
drug	NN	O	B
hypersensitivity	NN	O	I
and	NN	O	O
differential	NN	O	O
diagnosis	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
severe	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
to	NN	O	O
carbamazepine	NN	O	O
have	NN	O	O
been	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
haemopoietic	NN	O	O
system	NN	O	O
,	NN	O	O
the	NN	O	O
liver	NN	O	O
and	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
system	NN	O	O
.	NN	O	O

A	NN	O	O
frequently	NN	O	O
fatal	NN	O	O
,	NN	O	O
although	NN	O	O
exceptionally	NN	O	O
rare	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
carbamazepine	NN	O	O
is	NN	O	O
necrotizing	NN	O	O
eosinophilic	NN	O	O
(	NN	O	O
hypersensitivity	NN	O	B
)	NN	O	O
myocarditis	NN	O	B
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
hypersensitivity	NN	O	B
myocarditis	NN	O	B
secondary	NN	O	O
to	NN	O	O
administration	NN	O	O
of	NN	O	O
carbamazepine	NN	O	O
.	NN	O	O

Acute	NN	O	O
hypersensitivity	NN	O	B
myocarditis	NN	O	B
was	NN	O	O
not	NN	O	O
suspected	NN	O	O
clinically	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
was	NN	O	O
made	NN	O	O
post	NN	O	O
-	NN	O	O
mortem	NN	O	O
.	NN	O	O

Histology	NN	O	O
revealed	NN	O	O
diffuse	NN	O	O
infiltration	NN	O	O
of	NN	O	O
the	NN	O	O
myocardium	NN	O	O
by	NN	O	O
eosinophils	NN	O	O
and	NN	O	O
lymphocytes	NN	O	O
with	NN	O	O
myocyte	NN	O	O
damage	NN	O	O
.	NN	O	O

Clinically	NN	O	O
,	NN	O	O
death	NN	O	O
was	NN	O	O
due	NN	O	O
to	NN	O	O
cardiogenic	NN	O	B
shock	NN	O	I
.	NN	O	O

To	NN	O	O
best	NN	O	O
of	NN	O	O
our	NN	O	O
knowledge	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
second	NN	O	O
case	NN	O	O
of	NN	O	O
fatal	NN	O	O
carbamazepine	NN	O	O
induced	NN	O	O
myocarditis	NN	O	B
reported	NN	O	O
in	NN	O	O
English	NN	O	O
literature	NN	O	O
.	NN	O	O

Neuropsychiatric	NN	O	O
behaviors	NN	O	O
in	NN	O	O
the	NN	O	O
MPTP	NN	O	O
marmoset	NN	O	O
model	NN	O	O
of	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
Neuropsychiatric	NN	O	O
symptoms	NN	O	O
are	NN	O	O
increasingly	NN	O	O
recognised	NN	O	O
as	NN	O	O
a	NN	O	O
significant	NN	O	O
problem	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
.	NN	O	O

These	NN	O	O
symptoms	NN	O	O
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
'	NN	O	O
sensitisation	NN	O	O
'	NN	O	O
following	NN	O	O
repeated	NN	O	O
levodopa	NN	O	O
treatment	NN	O	O
or	NN	O	O
a	NN	O	O
direct	NN	O	O
effect	NN	O	O
of	NN	O	O
dopamine	NN	O	O
on	NN	O	O
the	NN	O	O
disease	NN	O	O
state	NN	O	O
.	NN	O	O

The	NN	O	O
levodopa	NN	O	O
-	NN	O	O
treated	NN	O	O
MPTP	NN	O	O
-	NN	O	O
lesioned	NN	O	O
marmoset	NN	O	O
was	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
neuropsychiatric	NN	O	B
symptoms	NN	O	I
in	NN	O	O
PD	NN	O	B
patients	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
compare	NN	O	O
the	NN	O	O
time	NN	O	O
course	NN	O	O
of	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
motor	NN	O	O
fluctuations	NN	O	O
and	NN	O	O
neuropsychiatric	NN	O	B
-	NN	O	I
like	NN	O	I
behaviors	NN	O	I
to	NN	O	O
determine	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
duration	NN	O	O
of	NN	O	O
treatment	NN	O	O
and	NN	O	O
onset	NN	O	O
of	NN	O	O
symptoms	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Marmosets	NN	O	O
were	NN	O	O
administered	NN	O	O
1	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
phenyl	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
6	NN	O	O
-	NN	O	O
tetrahydropyridine	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
for	NN	O	O
five	NN	O	O
days	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
stable	NN	O	O
parkinsonism	NN	O	B
.	NN	O	O

Levodopa	NN	O	O
(	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
and	NN	O	O
benserazide	NN	O	O
,	NN	O	O
3	NN	O	O
.	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O

b	NN	O	O
.	NN	O	O
i	NN	O	O
.	NN	O	O
d	NN	O	O
,	NN	O	O
was	NN	O	O
administered	NN	O	O
for	NN	O	O
30	NN	O	O
days	NN	O	O
.	NN	O	O

Animals	NN	O	O
were	NN	O	O
evaluated	NN	O	O
for	NN	O	O
parkinsonian	NN	O	B
disability	NN	O	I
,	NN	O	O
dyskinesia	NN	O	B
and	NN	O	O
on	NN	O	O
-	NN	O	O
time	NN	O	O
(	NN	O	O
motor	NN	O	O
fluctuations	NN	O	O
)	NN	O	O
and	NN	O	O
neuropsychiatric	NN	O	B
-	NN	O	I
like	NN	O	I
behaviors	NN	O	I
on	NN	O	O
Day	NN	O	O
0	NN	O	O
(	NN	O	O
prior	NN	O	O
to	NN	O	O
levodopa	NN	O	O
)	NN	O	O
and	NN	O	O
on	NN	O	O
Days	NN	O	O
1	NN	O	O
,	NN	O	O
7	NN	O	O
,	NN	O	O
13	NN	O	O
,	NN	O	O
27	NN	O	O
and	NN	O	O
30	NN	O	O
of	NN	O	O
treatment	NN	O	O
using	NN	O	O
post	NN	O	O
hoc	NN	O	O
DVD	NN	O	O
analysis	NN	O	O
by	NN	O	O
a	NN	O	O
trained	NN	O	O
rater	NN	O	O
,	NN	O	O
blind	NN	O	O
to	NN	O	O
the	NN	O	O
treatment	NN	O	O
day	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
neuropsychiatric	NN	O	B
-	NN	O	I
like	NN	O	I
behavior	NN	O	I
rating	NN	O	O
scale	NN	O	O
demonstrated	NN	O	O
high	NN	O	O
interrater	NN	O	O
reliability	NN	O	O
between	NN	O	O
three	NN	O	O
trained	NN	O	O
raters	NN	O	O
of	NN	O	O
differing	NN	O	O
professional	NN	O	O
backgrounds	NN	O	O
.	NN	O	O

As	NN	O	O
anticipated	NN	O	O
,	NN	O	O
animals	NN	O	O
exhibited	NN	O	O
a	NN	O	O
progressive	NN	O	O
increase	NN	O	O
in	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
motor	NN	O	O
fluctuations	NN	O	O
,	NN	O	O
dyskinesia	NN	O	B
and	NN	O	O
wearing	NN	O	O
-	NN	O	O
off	NN	O	O
,	NN	O	O
that	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
neuropsychiatric	NN	O	B
-	NN	O	I
like	NN	O	I
behaviors	NN	O	I
were	NN	O	O
present	NN	O	O
on	NN	O	O
Day	NN	O	O
1	NN	O	O
of	NN	O	O
levodopa	NN	O	O
treatment	NN	O	O
and	NN	O	O
their	NN	O	O
severity	NN	O	O
did	NN	O	O
not	NN	O	O
correlate	NN	O	O
with	NN	O	O
duration	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
neuropsychiatric	NN	O	B
disorders	NN	O	I
in	NN	O	O
PD	NN	O	B
are	NN	O	O
more	NN	O	O
likely	NN	O	O
an	NN	O	O
interaction	NN	O	O
between	NN	O	O
levodopa	NN	O	O
and	NN	O	O
the	NN	O	O
disease	NN	O	O
state	NN	O	O
than	NN	O	O
a	NN	O	O
consequence	NN	O	O
of	NN	O	O
sensitisation	NN	O	O
to	NN	O	O
repeated	NN	O	O
dopaminergic	NN	O	O
therapy	NN	O	O
.	NN	O	O

Contrast	NN	O	O
medium	NN	O	O
nephrotoxicity	NN	O	B
after	NN	O	O
renal	NN	O	O
artery	NN	O	O
and	NN	O	O
coronary	NN	O	O
angioplasty	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Renal	NN	O	B
dysfunction	NN	O	I
induced	NN	O	O
by	NN	O	O
iodinated	NN	O	O
contrast	NN	O	O
medium	NN	O	O
(	NN	O	O
CM	NN	O	O
)	NN	O	O
administration	NN	O	O
can	NN	O	O
minimize	NN	O	O
the	NN	O	O
benefit	NN	O	O
of	NN	O	O
the	NN	O	O
interventional	NN	O	O
procedure	NN	O	O
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
renal	NN	O	O
angioplasty	NN	O	O
(	NN	O	O
PTRA	NN	O	O
)	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
compare	NN	O	O
the	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
nephrotoxic	NN	O	B
effect	NN	O	O
of	NN	O	O
CM	NN	O	O
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
PTRA	NN	O	O
with	NN	O	O
that	NN	O	O
of	NN	O	O
patients	NN	O	O
submitted	NN	O	O
to	NN	O	O
percutaneous	NN	O	O
coronary	NN	O	O
intervention	NN	O	O
(	NN	O	O
PCI	NN	O	O
)	NN	O	O
.	NN	O	O

MATERIAL	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
33	NN	O	O
patients	NN	O	O
successfully	NN	O	O
treated	NN	O	O
with	NN	O	O
PTRA	NN	O	O
(	NN	O	O
PTRA	NN	O	O
group	NN	O	O
,	NN	O	O
mean	NN	O	O
age	NN	O	O
70	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
years	NN	O	O
,	NN	O	O
23	NN	O	O
female	NN	O	O
,	NN	O	O
basal	NN	O	O
creatinine	NN	O	O
1	NN	O	O
.	NN	O	O
46	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
79	NN	O	O
,	NN	O	O
range	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
)	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
33	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
successful	NN	O	O
PCI	NN	O	O
(	NN	O	O
PCI	NN	O	O
group	NN	O	O
)	NN	O	O
,	NN	O	O
matched	NN	O	O
for	NN	O	O
basal	NN	O	O
creatinine	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
44	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
,	NN	O	O
range	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
)	NN	O	O
,	NN	O	O
gender	NN	O	O
,	NN	O	O
and	NN	O	O
age	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
groups	NN	O	O
postprocedural	NN	O	O
(	NN	O	O
48	NN	O	O
h	NN	O	O
)	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
was	NN	O	O
measured	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Postprocedural	NN	O	O
creatinine	NN	O	O
level	NN	O	O
decreased	NN	O	O
nonsignificantly	NN	O	O
in	NN	O	O
the	NN	O	O
PTRA	NN	O	O
group	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
46	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
vs	NN	O	O
.	NN	O	O
1	NN	O	O
.	NN	O	O
34	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
NS	NN	O	O
)	NN	O	O
and	NN	O	O
increased	NN	O	O
significantly	NN	O	O
in	NN	O	O
the	NN	O	O
PCI	NN	O	O
group	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
44	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
vs	NN	O	O
.	NN	O	O
1	NN	O	O
.	NN	O	O
57	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
after	NN	O	O
intervention	NN	O	O
(	NN	O	O
after	NN	O	O
-	NN	O	O
before	NN	O	O
)	NN	O	O
were	NN	O	O
significantly	NN	O	O
different	NN	O	O
between	NN	O	O
the	NN	O	O
PTRA	NN	O	O
and	NN	O	O
PCI	NN	O	O
groups	NN	O	O
(	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
12	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
vs	NN	O	O
.	NN	O	O
0	NN	O	O
.	NN	O	O
13	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
014	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
difference	NN	O	O
was	NN	O	O
not	NN	O	O
related	NN	O	O
to	NN	O	O
either	NN	O	O
a	NN	O	O
different	NN	O	O
clinical	NN	O	O
risk	NN	O	O
profile	NN	O	O
or	NN	O	O
to	NN	O	O
the	NN	O	O
volume	NN	O	O
of	NN	O	O
CM	NN	O	O
administered	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
preliminary	NN	O	O
study	NN	O	O
patients	NN	O	O
submitted	NN	O	O
to	NN	O	O
PTRA	NN	O	O
showed	NN	O	O
a	NN	O	O
lower	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
renal	NN	O	B
damage	NN	O	I
induced	NN	O	O
by	NN	O	O
CM	NN	O	O
administration	NN	O	O
than	NN	O	O
PCI	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
PTRA	NN	O	O
on	NN	O	O
renal	NN	O	O
function	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
barely	NN	O	O
influenced	NN	O	O
by	NN	O	O
CM	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Diphenhydramine	NN	O	O
prevents	NN	O	O
the	NN	O	O
haemodynamic	NN	O	O
changes	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
in	NN	O	O
ICU	NN	O	O
patients	NN	O	O
.	NN	O	O

Cimetidine	NN	O	O
,	NN	O	O
a	NN	O	O
histamine	NN	O	O
2	NN	O	O
(	NN	O	O
H2	NN	O	O
)	NN	O	O
antagonist	NN	O	O
,	NN	O	O
produces	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
due	NN	O	O
to	NN	O	O
vasodilatation	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
critically	NN	O	O
ill	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
may	NN	O	O
be	NN	O	O
because	NN	O	O
cimetidine	NN	O	O
acts	NN	O	O
as	NN	O	O
a	NN	O	O
histamine	NN	O	O
agonist	NN	O	O
.	NN	O	O

We	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
histamine	NN	O	O
1	NN	O	O
(	NN	O	O
H1	NN	O	O
)	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
diphenhydramine	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
haemodynamic	NN	O	O
changes	NN	O	O
observed	NN	O	O
after	NN	O	O
cimetidine	NN	O	O
in	NN	O	O
ICU	NN	O	O
patients	NN	O	O
.	NN	O	O

Each	NN	O	O
patient	NN	O	O
was	NN	O	O
studied	NN	O	O
on	NN	O	O
two	NN	O	O
separate	NN	O	O
days	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
random	NN	O	O
fashion	NN	O	O
,	NN	O	O
they	NN	O	O
received	NN	O	O
cimetidine	NN	O	O
200	NN	O	O
mg	NN	O	O
iv	NN	O	O
on	NN	O	O
one	NN	O	O
day	NN	O	O
,	NN	O	O
and	NN	O	O
on	NN	O	O
the	NN	O	O
other	NN	O	O
,	NN	O	O
a	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
diphenhydramine	NN	O	O
40	NN	O	O
mg	NN	O	O
iv	NN	O	O
with	NN	O	O
cimetidine	NN	O	O
200	NN	O	O
mg	NN	O	O
iv	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
pretreatment	NN	O	O
group	NN	O	O
,	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
MAP	NN	O	O
)	NN	O	O
decreased	NN	O	O
from	NN	O	O
107	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
4	NN	O	O
mmHg	NN	O	O
to	NN	O	O
86	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
11	NN	O	O
.	NN	O	O
4	NN	O	O
mmHg	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
two	NN	O	O
minutes	NN	O	O
after	NN	O	O
cimetidine	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
(	NN	O	O
SVR	NN	O	O
)	NN	O	O
decreased	NN	O	O
during	NN	O	O
the	NN	O	O
eight	NN	O	O
-	NN	O	O
minute	NN	O	O
observation	NN	O	O
period	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
pretreatment	NN	O	O
group	NN	O	O
,	NN	O	O
little	NN	O	O
haemodynamic	NN	O	O
change	NN	O	O
was	NN	O	O
seen	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
an	NN	O	O
H1	NN	O	O
antagonist	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
in	NN	O	O
preventing	NN	O	O
hypotension	NN	O	B
caused	NN	O	O
by	NN	O	O
iv	NN	O	O
cimetidine	NN	O	O
,	NN	O	O
since	NN	O	O
the	NN	O	O
vasodilating	NN	O	O
activity	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
is	NN	O	O
mediated	NN	O	O
,	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
through	NN	O	O
the	NN	O	O
H1	NN	O	O
receptor	NN	O	O
.	NN	O	O

Medical	NN	O	O
and	NN	O	O
psychiatric	NN	O	O
outcomes	NN	O	O
for	NN	O	O
patients	NN	O	O
transplanted	NN	O	O
for	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
:	NN	O	O
a	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatotoxicity	NN	O	B
is	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
cause	NN	O	O
of	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
(	NN	O	O
ALF	NN	O	B
)	NN	O	O
in	NN	O	O
the	NN	O	O
UK	NN	O	O
.	NN	O	O

Patients	NN	O	O
often	NN	O	O
consume	NN	O	O
the	NN	O	O
drug	NN	O	O
with	NN	O	O
suicidal	NN	O	O
intent	NN	O	O
or	NN	O	O
with	NN	O	O
a	NN	O	O
background	NN	O	O
of	NN	O	O
substance	NN	O	O
dependence	NN	O	O
.	NN	O	O

AIMS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
compared	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
pretransplant	NN	O	O
illness	NN	O	O
,	NN	O	O
psychiatric	NN	O	O
co	NN	O	O
-	NN	O	O
morbidity	NN	O	O
,	NN	O	O
medical	NN	O	O
and	NN	O	O
psychosocial	NN	O	O
outcomes	NN	O	O
of	NN	O	O
all	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
undergone	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
(	NN	O	O
LT	NN	O	O
)	NN	O	O
emergently	NN	O	O
between	NN	O	O
1999	NN	O	O
-	NN	O	O
2004	NN	O	O
for	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
36	NN	O	O
)	NN	O	O
with	NN	O	O
age	NN	O	O
-	NN	O	O
and	NN	O	O
sex	NN	O	O
-	NN	O	O
matched	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
emergent	NN	O	O
LT	NN	O	O
for	NN	O	O
non	NN	O	O
-	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
35	NN	O	O
)	NN	O	O
and	NN	O	O
elective	NN	O	O
LT	NN	O	O
for	NN	O	O
chronic	NN	O	B
liver	NN	O	I
disease	NN	O	I
(	NN	O	O
CLD	NN	O	B
,	NN	O	O
n	NN	O	O
=	NN	O	O
34	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
patients	NN	O	O
undergoing	NN	O	O
LT	NN	O	O
had	NN	O	O
a	NN	O	O
greater	NN	O	O
severity	NN	O	O
of	NN	O	O
pre	NN	O	O
-	NN	O	O
LT	NN	O	O
illness	NN	O	O
reflected	NN	O	O
by	NN	O	O
higher	NN	O	O
Acute	NN	O	O
Physiology	NN	O	O
and	NN	O	O
Chronic	NN	O	O
Health	NN	O	O
Evaluation	NN	O	O
II	NN	O	O
scores	NN	O	O
and	NN	O	O
requirement	NN	O	O
for	NN	O	O
organ	NN	O	O
support	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
other	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Twenty	NN	O	O
(	NN	O	O
56	NN	O	O
%	NN	O	O
)	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
patients	NN	O	O
had	NN	O	O
a	NN	O	O
formal	NN	O	O
psychiatric	NN	O	O
diagnosis	NN	O	O
before	NN	O	O
LT	NN	O	O
(	NN	O	O
non	NN	O	O
-	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
=	NN	O	O
0	NN	O	O
/	NN	O	O
35	NN	O	O
,	NN	O	O
CLD	NN	O	B
=	NN	O	O
2	NN	O	O
/	NN	O	O
34	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
for	NN	O	O
all	NN	O	O
)	NN	O	O
and	NN	O	O
nine	NN	O	O
(	NN	O	O
25	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
a	NN	O	O
previous	NN	O	O
suicide	NN	O	O
attempt	NN	O	O
.	NN	O	O

During	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
(	NN	O	O
median	NN	O	O
5	NN	O	O
years	NN	O	O
)	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
rejection	NN	O	O
(	NN	O	O
acute	NN	O	O
and	NN	O	O
chronic	NN	O	O
)	NN	O	O
,	NN	O	O
graft	NN	O	O
failure	NN	O	O
or	NN	O	O
survival	NN	O	O
between	NN	O	O
the	NN	O	O
groups	NN	O	O
(	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
1	NN	O	O
year	NN	O	O
87	NN	O	O
%	NN	O	O
,	NN	O	O
5	NN	O	O
years	NN	O	O
75	NN	O	O
%	NN	O	O
;	NN	O	O
non	NN	O	O
-	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
88	NN	O	O
%	NN	O	O
,	NN	O	O
78	NN	O	O
%	NN	O	O
;	NN	O	O
CLD	NN	O	B
93	NN	O	O
%	NN	O	O
,	NN	O	O
82	NN	O	O
%	NN	O	O
:	NN	O	O
P	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
log	NN	O	O
rank	NN	O	O
)	NN	O	O
.	NN	O	O

Two	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
patients	NN	O	O
reattempted	NN	O	O
suicide	NN	O	O
post	NN	O	O
-	NN	O	O
LT	NN	O	O
(	NN	O	O
one	NN	O	O
died	NN	O	O
8	NN	O	O
years	NN	O	O
post	NN	O	O
-	NN	O	O
LT	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Despite	NN	O	O
a	NN	O	O
high	NN	O	O
prevalence	NN	O	O
of	NN	O	O
psychiatric	NN	O	O
disturbance	NN	O	O
,	NN	O	O
outcomes	NN	O	O
for	NN	O	O
patients	NN	O	O
transplanted	NN	O	O
emergently	NN	O	O
for	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
were	NN	O	O
comparable	NN	O	O
to	NN	O	O
those	NN	O	O
transplanted	NN	O	O
for	NN	O	O
non	NN	O	O
-	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
and	NN	O	O
electively	NN	O	O
for	NN	O	O
CLD	NN	O	B
.	NN	O	O

Multidisciplinary	NN	O	O
approaches	NN	O	O
with	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
psychiatric	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
low	NN	O	O
post	NN	O	O
-	NN	O	O
transplant	NN	O	O
suicide	NN	O	O
rates	NN	O	O
seen	NN	O	O
and	NN	O	O
low	NN	O	O
rates	NN	O	O
of	NN	O	O
graft	NN	O	O
loss	NN	O	O
because	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
compliance	NN	O	O
.	NN	O	O

Antithrombotic	NN	O	O
drug	NN	O	O
use	NN	O	O
,	NN	O	O
cerebral	NN	O	B
microbleeds	NN	O	I
,	NN	O	O
and	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
:	NN	O	O
a	NN	O	O
systematic	NN	O	O
review	NN	O	O
of	NN	O	O
published	NN	O	O
and	NN	O	O
unpublished	NN	O	O
studies	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
PURPOSE	NN	O	O
:	NN	O	O
Cerebral	NN	O	B
microbleeds	NN	O	I
(	NN	O	O
MB	NN	O	B
)	NN	O	O
are	NN	O	O
potential	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
(	NN	O	O
ICH	NN	O	B
)	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
is	NN	O	O
unclear	NN	O	O
if	NN	O	O
they	NN	O	O
are	NN	O	O
a	NN	O	O
contraindication	NN	O	O
to	NN	O	O
using	NN	O	O
antithrombotic	NN	O	O
drugs	NN	O	O
.	NN	O	O

Insights	NN	O	O
could	NN	O	O
be	NN	O	O
gained	NN	O	O
by	NN	O	O
pooling	NN	O	O
data	NN	O	O
on	NN	O	O
MB	NN	O	B
frequency	NN	O	O
stratified	NN	O	O
by	NN	O	O
antithrombotic	NN	O	O
use	NN	O	O
in	NN	O	O
cohorts	NN	O	O
with	NN	O	O
ICH	NN	O	B
and	NN	O	O
ischemic	NN	O	B
stroke	NN	O	I
(	NN	O	O
IS	NN	O	B
)	NN	O	O
/	NN	O	O
transient	NN	O	B
ischemic	NN	O	I
attack	NN	O	I
(	NN	O	O
TIA	NN	O	B
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
performed	NN	O	O
a	NN	O	O
systematic	NN	O	O
review	NN	O	O
of	NN	O	O
published	NN	O	O
and	NN	O	O
unpublished	NN	O	O
data	NN	O	O
from	NN	O	O
cohorts	NN	O	O
with	NN	O	O
stroke	NN	O	B
or	NN	O	O
TIA	NN	O	B
to	NN	O	O
compare	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
MB	NN	O	B
in	NN	O	O
:	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
antithrombotic	NN	O	O
users	NN	O	O
vs	NN	O	O
nonantithrombotic	NN	O	O
users	NN	O	O
with	NN	O	O
ICH	NN	O	B
;	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
antithrombotic	NN	O	O
users	NN	O	O
vs	NN	O	O
nonusers	NN	O	O
with	NN	O	O
IS	NN	O	B
/	NN	O	O
TIA	NN	O	B
;	NN	O	O
and	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
ICH	NN	O	B
vs	NN	O	O
ischemic	NN	O	B
events	NN	O	O
stratified	NN	O	O
by	NN	O	O
antithrombotic	NN	O	O
use	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
analyzed	NN	O	O
published	NN	O	O
and	NN	O	O
unpublished	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
data	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
ICH	NN	O	B
in	NN	O	O
antithrombotic	NN	O	O
users	NN	O	O
with	NN	O	O
MB	NN	O	B
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
a	NN	O	O
pooled	NN	O	O
analysis	NN	O	O
of	NN	O	O
1460	NN	O	O
ICH	NN	O	B
and	NN	O	O
3817	NN	O	O
IS	NN	O	B
/	NN	O	O
TIA	NN	O	B
,	NN	O	O
MB	NN	O	B
were	NN	O	O
more	NN	O	O
frequent	NN	O	O
in	NN	O	O
ICH	NN	O	B
vs	NN	O	O
IS	NN	O	B
/	NN	O	O
TIA	NN	O	B
in	NN	O	O
all	NN	O	O
treatment	NN	O	O
groups	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
excess	NN	O	O
increased	NN	O	O
from	NN	O	O
2	NN	O	O
.	NN	O	O
8	NN	O	O
(	NN	O	O
odds	NN	O	O
ratio	NN	O	O
;	NN	O	O
range	NN	O	O
,	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
in	NN	O	O
nonantithrombotic	NN	O	O
users	NN	O	O
to	NN	O	O
5	NN	O	O
.	NN	O	O
7	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
in	NN	O	O
antiplatelet	NN	O	O
users	NN	O	O
and	NN	O	O
8	NN	O	O
.	NN	O	O
0	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
3	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
17	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
in	NN	O	O
warfarin	NN	O	O
users	NN	O	O
(	NN	O	O
P	NN	O	O
difference	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
also	NN	O	O
an	NN	O	O
excess	NN	O	O
of	NN	O	O
MB	NN	O	B
in	NN	O	O
warfarin	NN	O	O
users	NN	O	O
vs	NN	O	O
nonusers	NN	O	O
with	NN	O	O
ICH	NN	O	B
(	NN	O	O
OR	NN	O	O
,	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
4	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
but	NN	O	O
none	NN	O	O
in	NN	O	O
warfarin	NN	O	O
users	NN	O	O
with	NN	O	O
IS	NN	O	B
/	NN	O	O
TIA	NN	O	B
(	NN	O	O
OR	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
33	NN	O	O
;	NN	O	O
P	NN	O	O
difference	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
smaller	NN	O	O
excess	NN	O	O
of	NN	O	O
MB	NN	O	B
in	NN	O	O
antiplatelet	NN	O	O
users	NN	O	O
vs	NN	O	O
nonusers	NN	O	O
with	NN	O	O
ICH	NN	O	B
(	NN	O	O
OR	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
findings	NN	O	O
were	NN	O	O
similar	NN	O	O
for	NN	O	O
antiplatelet	NN	O	O
users	NN	O	O
with	NN	O	O
IS	NN	O	B
/	NN	O	O
TIA	NN	O	B
(	NN	O	O
OR	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
4	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
;	NN	O	O
P	NN	O	O
difference	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
pooled	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
data	NN	O	O
for	NN	O	O
768	NN	O	O
antithrombotic	NN	O	O
users	NN	O	O
,	NN	O	O
presence	NN	O	O
of	NN	O	O
MB	NN	O	B
at	NN	O	O
baseline	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
substantially	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
subsequent	NN	O	O
ICH	NN	O	B
(	NN	O	O
OR	NN	O	O
,	NN	O	O
12	NN	O	O
.	NN	O	O
1	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
42	NN	O	O
.	NN	O	O
5	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
excess	NN	O	O
of	NN	O	O
MB	NN	O	B
in	NN	O	O
warfarin	NN	O	O
users	NN	O	O
with	NN	O	O
ICH	NN	O	B
compared	NN	O	O
to	NN	O	O
other	NN	O	O
groups	NN	O	O
suggests	NN	O	O
that	NN	O	O
MB	NN	O	B
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
warfarin	NN	O	O
-	NN	O	O
associated	NN	O	O
ICH	NN	O	B
.	NN	O	O

Limited	NN	O	O
prospective	NN	O	O
data	NN	O	O
corroborate	NN	O	O
these	NN	O	O
findings	NN	O	O
,	NN	O	O
but	NN	O	O
larger	NN	O	O
prospective	NN	O	O
studies	NN	O	O
are	NN	O	O
urgently	NN	O	O
required	NN	O	O
.	NN	O	O

Studies	NN	O	O
of	NN	O	O
synergy	NN	O	O
between	NN	O	O
morphine	NN	O	O
and	NN	O	O
a	NN	O	O
novel	NN	O	O
sodium	NN	O	O
channel	NN	O	O
blocker	NN	O	O
,	NN	O	O
CNSB002	NN	O	O
,	NN	O	O
in	NN	O	O
rat	NN	O	O
models	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
and	NN	O	O
neuropathic	NN	O	B
pain	NN	O	I
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
determined	NN	O	O
the	NN	O	O
antihyperalgesic	NN	O	O
effect	NN	O	O
of	NN	O	O
CNSB002	NN	O	O
,	NN	O	O
a	NN	O	O
sodium	NN	O	O
channel	NN	O	O
blocker	NN	O	O
with	NN	O	O
antioxidant	NN	O	O
properties	NN	O	O
given	NN	O	O
alone	NN	O	O
and	NN	O	O
in	NN	O	O
combinations	NN	O	O
with	NN	O	O
morphine	NN	O	O
in	NN	O	O
rat	NN	O	O
models	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
and	NN	O	O
neuropathic	NN	O	B
pain	NN	O	I
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Dose	NN	O	O
response	NN	O	O
curves	NN	O	O
for	NN	O	O
nonsedating	NN	O	O
doses	NN	O	O
of	NN	O	O
morphine	NN	O	O
and	NN	O	O
CNSB002	NN	O	O
given	NN	O	O
intraperitoneally	NN	O	O
alone	NN	O	O
and	NN	O	O
together	NN	O	O
in	NN	O	O
combinations	NN	O	O
were	NN	O	O
constructed	NN	O	O
for	NN	O	O
antihyperalgesic	NN	O	O
effect	NN	O	O
using	NN	O	O
paw	NN	O	O
withdrawal	NN	O	O
from	NN	O	O
noxious	NN	O	O
heat	NN	O	O
in	NN	O	O
two	NN	O	O
rat	NN	O	O
pain	NN	O	B
models	NN	O	O
:	NN	O	O
carrageenan	NN	O	O
-	NN	O	O
induced	NN	O	O
paw	NN	O	O
inflammation	NN	O	B
and	NN	O	O
streptozotocin	NN	O	O
(	NN	O	O
STZ	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
maximum	NN	O	O
nonsedating	NN	O	O
doses	NN	O	O
were	NN	O	O
:	NN	O	O
morphine	NN	O	O
,	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
CNSB002	NN	O	O
10	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
CNSB002	NN	O	O
with	NN	O	O
morphine	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
in	NN	O	O
combination	NN	O	O
.	NN	O	O

The	NN	O	O
doses	NN	O	O
calculated	NN	O	O
to	NN	O	O
cause	NN	O	O
50	NN	O	O
%	NN	O	O
reversal	NN	O	O
of	NN	O	O
hyperalgesia	NN	O	B
(	NN	O	O
ED50	NN	O	O
)	NN	O	O
were	NN	O	O
7	NN	O	O
.	NN	O	O
54	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
81	NN	O	O
)	NN	O	O
and	NN	O	O
4	NN	O	O
.	NN	O	O
83	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
54	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
carrageenan	NN	O	O
model	NN	O	O
and	NN	O	O
44	NN	O	O
.	NN	O	O
18	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
37	NN	O	O
)	NN	O	O
and	NN	O	O
9	NN	O	O
.	NN	O	O
14	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
24	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
STZ	NN	O	O
-	NN	O	O
induced	NN	O	O
neuropathy	NN	O	B
model	NN	O	O
for	NN	O	O
CNSB002	NN	O	O
and	NN	O	O
morphine	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
mean	NN	O	O
,	NN	O	O
SEM	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
values	NN	O	O
were	NN	O	O
greater	NN	O	O
than	NN	O	O
the	NN	O	O
maximum	NN	O	O
nonsedating	NN	O	O
doses	NN	O	O
.	NN	O	O

The	NN	O	O
ED50	NN	O	O
values	NN	O	O
for	NN	O	O
morphine	NN	O	O
when	NN	O	O
given	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
CNSB002	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
were	NN	O	O
less	NN	O	O
than	NN	O	O
the	NN	O	O
maximum	NN	O	O
nonsedating	NN	O	O
dose	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
56	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
55	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
carrageenan	NN	O	O
model	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
37	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
23	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
neuropathy	NN	O	B
model	NN	O	O
(	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
mean	NN	O	O
,	NN	O	O
SEM	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
antinociception	NN	O	O
after	NN	O	O
morphine	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
increased	NN	O	O
by	NN	O	O
co	NN	O	O
-	NN	O	O
administration	NN	O	O
with	NN	O	O
CNSB002	NN	O	O
from	NN	O	O
28	NN	O	O
.	NN	O	O
0	NN	O	O
and	NN	O	O
31	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
to	NN	O	O
114	NN	O	O
.	NN	O	O
6	NN	O	O
and	NN	O	O
56	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
reversal	NN	O	O
of	NN	O	O
hyperalgesia	NN	O	B
in	NN	O	O
the	NN	O	O
inflammatory	NN	O	O
and	NN	O	O
neuropathic	NN	O	B
models	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
;	NN	O	O
one	NN	O	O
-	NN	O	O
way	NN	O	O
analysis	NN	O	O
of	NN	O	O
variance	NN	O	O
-	NN	O	O
significantly	NN	O	O
greater	NN	O	O
than	NN	O	O
either	NN	O	O
drug	NN	O	O
given	NN	O	O
alone	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
maximum	NN	O	O
antihyperalgesic	NN	O	O
effect	NN	O	O
achievable	NN	O	O
with	NN	O	O
nonsedating	NN	O	O
doses	NN	O	O
of	NN	O	O
morphine	NN	O	O
may	NN	O	O
be	NN	O	O
increased	NN	O	O
significantly	NN	O	O
when	NN	O	O
the	NN	O	O
drug	NN	O	O
is	NN	O	O
used	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
CNSB002	NN	O	O
.	NN	O	O

Heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
:	NN	O	O
a	NN	O	O
practical	NN	O	O
review	NN	O	O
.	NN	O	O

Heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
(	NN	O	O
HIT	NN	O	B
)	NN	O	O
remains	NN	O	O
under	NN	O	O
-	NN	O	O
recognized	NN	O	O
despite	NN	O	O
its	NN	O	O
potentially	NN	O	O
devastating	NN	O	O
outcomes	NN	O	O
.	NN	O	O

It	NN	O	O
begins	NN	O	O
when	NN	O	O
heparin	NN	O	O
exposure	NN	O	O
stimulates	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
heparin	NN	O	O
-	NN	O	O
platelet	NN	O	O
factor	NN	O	O
4	NN	O	O
antibodies	NN	O	O
,	NN	O	O
which	NN	O	O
in	NN	O	O
turn	NN	O	O
triggers	NN	O	O
the	NN	O	O
release	NN	O	O
of	NN	O	O
procoagulant	NN	O	O
platelet	NN	O	O
particles	NN	O	O
.	NN	O	O

Thrombosis	NN	O	B
and	NN	O	O
thrombocytopenia	NN	O	B
that	NN	O	O
follow	NN	O	O
comprise	NN	O	O
the	NN	O	O
2	NN	O	O
hallmark	NN	O	O
traits	NN	O	O
of	NN	O	O
HIT	NN	O	B
,	NN	O	O
with	NN	O	O
the	NN	O	O
former	NN	O	O
largely	NN	O	O
responsible	NN	O	O
for	NN	O	O
significant	NN	O	O
vascular	NN	O	O
complications	NN	O	O
.	NN	O	O

The	NN	O	O
prevalence	NN	O	O
of	NN	O	O
HIT	NN	O	B
varies	NN	O	O
among	NN	O	O
several	NN	O	O
subgroups	NN	O	O
,	NN	O	O
with	NN	O	O
greater	NN	O	O
incidence	NN	O	O
in	NN	O	O
surgical	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
medical	NN	O	O
populations	NN	O	O
.	NN	O	O

HIT	NN	O	B
must	NN	O	O
be	NN	O	O
acknowledged	NN	O	O
for	NN	O	O
its	NN	O	O
intense	NN	O	O
predilection	NN	O	O
for	NN	O	O
thrombosis	NN	O	B
and	NN	O	O
suspected	NN	O	O
whenever	NN	O	O
thrombosis	NN	O	B
occurs	NN	O	O
after	NN	O	O
heparin	NN	O	O
exposure	NN	O	O
.	NN	O	O

Early	NN	O	O
recognition	NN	O	O
that	NN	O	O
incorporates	NN	O	O
the	NN	O	O
clinical	NN	O	O
and	NN	O	O
serologic	NN	O	O
clues	NN	O	O
is	NN	O	O
paramount	NN	O	O
to	NN	O	O
timely	NN	O	O
institution	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
as	NN	O	O
its	NN	O	O
delay	NN	O	O
may	NN	O	O
result	NN	O	O
in	NN	O	O
catastrophic	NN	O	O
outcomes	NN	O	O
.	NN	O	O

The	NN	O	O
treatment	NN	O	O
of	NN	O	O
HIT	NN	O	B
mandates	NN	O	O
an	NN	O	O
immediate	NN	O	O
cessation	NN	O	O
of	NN	O	O
all	NN	O	O
heparin	NN	O	O
exposure	NN	O	O
and	NN	O	O
the	NN	O	O
institution	NN	O	O
of	NN	O	O
an	NN	O	O
antithrombotic	NN	O	O
therapy	NN	O	O
,	NN	O	O
most	NN	O	O
commonly	NN	O	O
using	NN	O	O
a	NN	O	O
direct	NN	O	O
thrombin	NN	O	O
inhibitor	NN	O	O
.	NN	O	O

Current	NN	O	O
"	NN	O	O
diagnostic	NN	O	O
"	NN	O	O
tests	NN	O	O
,	NN	O	O
which	NN	O	O
primarily	NN	O	O
include	NN	O	O
functional	NN	O	O
and	NN	O	O
antigenic	NN	O	O
assays	NN	O	O
,	NN	O	O
have	NN	O	O
more	NN	O	O
of	NN	O	O
a	NN	O	O
confirmatory	NN	O	O
than	NN	O	O
diagnostic	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
HIT	NN	O	B
.	NN	O	O

Special	NN	O	O
attention	NN	O	O
must	NN	O	O
be	NN	O	O
paid	NN	O	O
to	NN	O	O
cardiac	NN	O	O
patients	NN	O	O
who	NN	O	O
are	NN	O	O
often	NN	O	O
exposed	NN	O	O
to	NN	O	O
heparin	NN	O	O
multiple	NN	O	O
times	NN	O	O
during	NN	O	O
their	NN	O	O
course	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Direct	NN	O	O
thrombin	NN	O	O
inhibitors	NN	O	O
are	NN	O	O
appropriate	NN	O	O
,	NN	O	O
evidence	NN	O	O
-	NN	O	O
based	NN	O	O
alternatives	NN	O	O
to	NN	O	O
heparin	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
HIT	NN	O	B
,	NN	O	O
who	NN	O	O
need	NN	O	O
to	NN	O	O
undergo	NN	O	O
percutaneous	NN	O	O
coronary	NN	O	O
intervention	NN	O	O
.	NN	O	O

As	NN	O	O
heparin	NN	O	O
remains	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
frequently	NN	O	O
used	NN	O	O
medications	NN	O	O
today	NN	O	O
with	NN	O	O
potential	NN	O	O
for	NN	O	O
HIT	NN	O	B
with	NN	O	O
every	NN	O	O
heparin	NN	O	O
exposure	NN	O	O
,	NN	O	O
a	NN	O	O
close	NN	O	O
vigilance	NN	O	O
of	NN	O	O
platelet	NN	O	O
counts	NN	O	O
must	NN	O	O
be	NN	O	O
practiced	NN	O	O
whenever	NN	O	O
heparin	NN	O	O
is	NN	O	O
initiated	NN	O	O
.	NN	O	O

Abductor	NN	O	O
paralysis	NN	O	B
after	NN	O	O
botox	NN	O	O
injection	NN	O	O
for	NN	O	O
adductor	NN	O	B
spasmodic	NN	O	I
dysphonia	NN	O	I
.	NN	O	O

OBJECTIVES	NN	O	O
/	NN	O	O
HYPOTHESIS	NN	O	O
:	NN	O	O
Botulinum	NN	O	O
toxin	NN	O	O
(	NN	O	O
Botox	NN	O	O
)	NN	O	O
injections	NN	O	O
into	NN	O	O
the	NN	O	O
thyroarytenoid	NN	O	O
muscles	NN	O	O
are	NN	O	O
the	NN	O	O
current	NN	O	O
standard	NN	O	O
of	NN	O	O
care	NN	O	O
for	NN	O	O
adductor	NN	O	B
spasmodic	NN	O	I
dysphonia	NN	O	I
(	NN	O	O
ADSD	NN	O	B
)	NN	O	O
.	NN	O	O

Reported	NN	O	O
adverse	NN	O	O
effects	NN	O	O
include	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
breathiness	NN	O	O
,	NN	O	O
throat	NN	O	B
pain	NN	O	I
,	NN	O	O
and	NN	O	O
difficulty	NN	O	O
with	NN	O	O
swallowing	NN	O	O
liquids	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
multiple	NN	O	O
cases	NN	O	O
of	NN	O	O
bilateral	NN	O	O
abductor	NN	O	O
paralysis	NN	O	B
following	NN	O	O
Botox	NN	O	O
injections	NN	O	O
for	NN	O	O
ADSD	NN	O	B
,	NN	O	O
a	NN	O	O
complication	NN	O	O
previously	NN	O	O
unreported	NN	O	O
.	NN	O	O

STUDY	NN	O	O
DESIGN	NN	O	O
:	NN	O	O
Retrospective	NN	O	O
case	NN	O	O
series	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Patients	NN	O	O
that	NN	O	O
received	NN	O	O
Botox	NN	O	O
injections	NN	O	O
for	NN	O	O
spasmodic	NN	O	B
dysphonia	NN	O	I
between	NN	O	O
January	NN	O	O
2000	NN	O	O
and	NN	O	O
October	NN	O	O
2009	NN	O	O
were	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
ADSD	NN	O	B
were	NN	O	O
identified	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
treatments	NN	O	O
received	NN	O	O
and	NN	O	O
adverse	NN	O	O
effects	NN	O	O
were	NN	O	O
noted	NN	O	O
.	NN	O	O

For	NN	O	O
patients	NN	O	O
with	NN	O	O
bilateral	NN	O	O
abductor	NN	O	O
paralysis	NN	O	B
,	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
paralytic	NN	O	O
Botox	NN	O	O
dose	NN	O	O
,	NN	O	O
prior	NN	O	O
Botox	NN	O	O
dose	NN	O	O
,	NN	O	O
and	NN	O	O
course	NN	O	O
following	NN	O	O
paralysis	NN	O	B
were	NN	O	O
noted	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
From	NN	O	O
a	NN	O	O
database	NN	O	O
of	NN	O	O
452	NN	O	O
patients	NN	O	O
receiving	NN	O	O
Botox	NN	O	O
,	NN	O	O
352	NN	O	O
patients	NN	O	O
had	NN	O	O
been	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
ADSD	NN	O	B
.	NN	O	O

Of	NN	O	O
these	NN	O	O
352	NN	O	O
patients	NN	O	O
,	NN	O	O
eight	NN	O	O
patients	NN	O	O
suffered	NN	O	O
bilateral	NN	O	O
abductor	NN	O	O
paralysis	NN	O	B
,	NN	O	O
and	NN	O	O
two	NN	O	O
suffered	NN	O	O
this	NN	O	O
complication	NN	O	O
twice	NN	O	O
.	NN	O	O

All	NN	O	O
affected	NN	O	O
patients	NN	O	O
were	NN	O	O
females	NN	O	O
over	NN	O	O
the	NN	O	O
age	NN	O	O
of	NN	O	O
50	NN	O	O
years	NN	O	O
.	NN	O	O

Most	NN	O	O
patients	NN	O	O
had	NN	O	O
received	NN	O	O
treatments	NN	O	O
prior	NN	O	O
to	NN	O	O
abductor	NN	O	O
paralysis	NN	O	B
and	NN	O	O
continued	NN	O	O
receiving	NN	O	O
after	NN	O	O
paralysis	NN	O	B
.	NN	O	O

Seven	NN	O	O
patients	NN	O	O
recovered	NN	O	O
after	NN	O	O
a	NN	O	O
brief	NN	O	O
period	NN	O	O
of	NN	O	O
activity	NN	O	O
restrictions	NN	O	O
,	NN	O	O
and	NN	O	O
one	NN	O	O
underwent	NN	O	O
a	NN	O	O
tracheotomy	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
abductor	NN	O	O
paralysis	NN	O	B
after	NN	O	O
Botox	NN	O	O
injection	NN	O	O
for	NN	O	O
ADSD	NN	O	B
was	NN	O	O
0	NN	O	O
.	NN	O	O
34	NN	O	O
%	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Bilateral	NN	O	O
abductor	NN	O	O
paralysis	NN	O	B
is	NN	O	O
a	NN	O	O
rare	NN	O	O
complication	NN	O	O
of	NN	O	O
Botox	NN	O	O
injections	NN	O	O
for	NN	O	O
ADSD	NN	O	B
,	NN	O	O
causing	NN	O	O
difficulty	NN	O	O
with	NN	O	O
breathing	NN	O	O
upon	NN	O	O
exertion	NN	O	O
.	NN	O	O

The	NN	O	O
likely	NN	O	O
mechanism	NN	O	O
of	NN	O	O
paralysis	NN	O	B
is	NN	O	O
diffusion	NN	O	O
of	NN	O	O
Botox	NN	O	O
around	NN	O	O
the	NN	O	O
muscular	NN	O	O
process	NN	O	O
of	NN	O	O
the	NN	O	O
arytenoid	NN	O	O
to	NN	O	O
the	NN	O	O
posterior	NN	O	O
cricoarytenoid	NN	O	O
muscles	NN	O	O
.	NN	O	O

The	NN	O	O
paralysis	NN	O	B
is	NN	O	O
temporary	NN	O	O
,	NN	O	O
and	NN	O	O
watchful	NN	O	O
waiting	NN	O	O
with	NN	O	O
restriction	NN	O	O
of	NN	O	O
activity	NN	O	O
is	NN	O	O
the	NN	O	O
recommended	NN	O	O
management	NN	O	O
.	NN	O	O

Mitochondrial	NN	O	B
impairment	NN	O	I
contributes	NN	O	O
to	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
dysfunction	NN	O	I
:	NN	O	O
Prevention	NN	O	O
by	NN	O	O
the	NN	O	O
targeted	NN	O	O
antioxidant	NN	O	O
MitoQ	NN	O	O
.	NN	O	O

The	NN	O	O
goal	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
mitochondrial	NN	O	O
function	NN	O	O
and	NN	O	O
ROS	NN	O	O
production	NN	O	O
in	NN	O	O
an	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

We	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
cocaine	NN	O	B
abuse	NN	O	I
may	NN	O	O
lead	NN	O	O
to	NN	O	O
altered	NN	O	O
mitochondrial	NN	O	O
function	NN	O	O
that	NN	O	O
in	NN	O	O
turn	NN	O	O
may	NN	O	O
cause	NN	O	O
left	NN	O	B
ventricular	NN	O	I
dysfunction	NN	O	I
.	NN	O	O

Seven	NN	O	O
days	NN	O	O
of	NN	O	O
cocaine	NN	O	O
administration	NN	O	O
to	NN	O	O
rats	NN	O	O
led	NN	O	O
to	NN	O	O
an	NN	O	O
increased	NN	O	O
oxygen	NN	O	O
consumption	NN	O	O
detected	NN	O	O
in	NN	O	O
cardiac	NN	O	O
fibers	NN	O	O
,	NN	O	O
specifically	NN	O	O
through	NN	O	O
complex	NN	O	O
I	NN	O	O
and	NN	O	O
complex	NN	O	O
III	NN	O	O
.	NN	O	O

ROS	NN	O	O
levels	NN	O	O
were	NN	O	O
increased	NN	O	O
,	NN	O	O
specifically	NN	O	O
in	NN	O	O
interfibrillar	NN	O	O
mitochondria	NN	O	O
.	NN	O	O

In	NN	O	O
parallel	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
ATP	NN	O	O
synthesis	NN	O	O
,	NN	O	O
whereas	NN	O	O
no	NN	O	O
difference	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
subsarcolemmal	NN	O	O
mitochondria	NN	O	O
.	NN	O	O

This	NN	O	O
uncoupling	NN	O	O
effect	NN	O	O
on	NN	O	O
oxidative	NN	O	O
phosphorylation	NN	O	O
was	NN	O	O
not	NN	O	O
detectable	NN	O	O
after	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
exposure	NN	O	O
to	NN	O	O
cocaine	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
these	NN	O	O
mitochondrial	NN	O	B
abnormalities	NN	O	I
were	NN	O	O
a	NN	O	O
late	NN	O	O
rather	NN	O	O
than	NN	O	O
a	NN	O	O
primary	NN	O	O
event	NN	O	O
in	NN	O	O
the	NN	O	O
pathological	NN	O	O
response	NN	O	O
to	NN	O	O
cocaine	NN	O	O
.	NN	O	O

MitoQ	NN	O	O
,	NN	O	O
a	NN	O	O
mitochondrial	NN	O	O
-	NN	O	O
targeted	NN	O	O
antioxidant	NN	O	O
,	NN	O	O
was	NN	O	O
shown	NN	O	O
to	NN	O	O
completely	NN	O	O
prevent	NN	O	O
these	NN	O	O
mitochondrial	NN	O	B
abnormalities	NN	O	I
as	NN	O	O
well	NN	O	O
as	NN	O	O
cardiac	NN	O	B
dysfunction	NN	O	I
characterized	NN	O	O
here	NN	O	O
by	NN	O	O
a	NN	O	O
diastolic	NN	O	B
dysfunction	NN	O	I
studied	NN	O	O
with	NN	O	O
a	NN	O	O
conductance	NN	O	O
catheter	NN	O	O
to	NN	O	O
obtain	NN	O	O
pressure	NN	O	O
-	NN	O	O
volume	NN	O	O
data	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
these	NN	O	O
results	NN	O	O
extend	NN	O	O
previous	NN	O	O
studies	NN	O	O
and	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
dysfunction	NN	O	I
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
mitochondrial	NN	O	B
defect	NN	O	I
.	NN	O	O

Trimethoprim	NN	O	O
-	NN	O	O
induced	NN	O	O
immune	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
in	NN	O	O
a	NN	O	O
pediatric	NN	O	O
oncology	NN	O	O
patient	NN	O	O
presenting	NN	O	O
as	NN	O	O
an	NN	O	O
acute	NN	O	O
hemolytic	NN	O	O
transfusion	NN	O	O
reaction	NN	O	O
.	NN	O	O

A	NN	O	O
10	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
with	NN	O	O
acute	NN	O	B
leukemia	NN	O	I
presented	NN	O	O
with	NN	O	O
post	NN	O	O
-	NN	O	O
chemotherapy	NN	O	O
anemia	NN	O	B
.	NN	O	O

During	NN	O	O
red	NN	O	O
cell	NN	O	O
transfusion	NN	O	O
,	NN	O	O
he	NN	O	O
developed	NN	O	O
hemoglobinuria	NN	O	B
.	NN	O	O

Transfusion	NN	O	O
reaction	NN	O	O
workup	NN	O	O
was	NN	O	O
negative	NN	O	O
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
induced	NN	O	O
immune	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
was	NN	O	O
suspected	NN	O	O
because	NN	O	O
of	NN	O	O
positive	NN	O	O
direct	NN	O	O
antiglobulin	NN	O	O
test	NN	O	O
,	NN	O	O
negative	NN	O	O
eluate	NN	O	O
,	NN	O	O
and	NN	O	O
microspherocytes	NN	O	O
on	NN	O	O
smear	NN	O	O
pre	NN	O	O
-	NN	O	O
and	NN	O	O
post	NN	O	O
-	NN	O	O
transfusion	NN	O	O
.	NN	O	O

Drug	NN	O	O
studies	NN	O	O
using	NN	O	O
the	NN	O	O
indirect	NN	O	O
antiglobulin	NN	O	O
test	NN	O	O
were	NN	O	O
strongly	NN	O	O
positive	NN	O	O
with	NN	O	O
trimethoprim	NN	O	O
and	NN	O	O
trimethoprim	NN	O	O
-	NN	O	O
sulfamethoxazole	NN	O	O
but	NN	O	O
negative	NN	O	O
with	NN	O	O
sulfamethoxazole	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
recovered	NN	O	O
after	NN	O	O
discontinuing	NN	O	O
the	NN	O	O
drug	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
recurrence	NN	O	O
in	NN	O	O
2	NN	O	O
years	NN	O	O
.	NN	O	O

Other	NN	O	O
causes	NN	O	O
of	NN	O	O
anemia	NN	O	B
should	NN	O	O
be	NN	O	O
considered	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
worse	NN	O	O
-	NN	O	O
than	NN	O	O
-	NN	O	O
expected	NN	O	O
anemia	NN	O	B
after	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
hemolysis	NN	O	B
during	NN	O	O
transfusion	NN	O	O
is	NN	O	O
not	NN	O	O
always	NN	O	O
a	NN	O	O
transfusion	NN	O	O
reaction	NN	O	O
.	NN	O	O

Verapamil	NN	O	O
stimulation	NN	O	O
test	NN	O	O
in	NN	O	O
hyperprolactinemia	NN	O	B
:	NN	O	O
loss	NN	O	O
of	NN	O	O
prolactin	NN	O	O
response	NN	O	O
in	NN	O	O
anatomic	NN	O	O
or	NN	O	O
functional	NN	O	O
stalk	NN	O	O
effect	NN	O	O
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
Verapamil	NN	O	O
stimulation	NN	O	O
test	NN	O	O
was	NN	O	O
previously	NN	O	O
investigated	NN	O	O
as	NN	O	O
a	NN	O	O
tool	NN	O	O
for	NN	O	O
differential	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B
,	NN	O	O
but	NN	O	O
with	NN	O	O
conflicting	NN	O	O
results	NN	O	O
.	NN	O	O

Macroprolactinemia	NN	O	B
was	NN	O	O
never	NN	O	O
considered	NN	O	O
in	NN	O	O
those	NN	O	O
previous	NN	O	O
studies	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
aimed	NN	O	O
to	NN	O	O
re	NN	O	O
-	NN	O	O
investigate	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
value	NN	O	O
of	NN	O	O
verapamil	NN	O	O
in	NN	O	O
a	NN	O	O
population	NN	O	O
who	NN	O	O
were	NN	O	O
all	NN	O	O
screened	NN	O	O
for	NN	O	O
macroprolactinemia	NN	O	B
.	NN	O	O

Prolactin	NN	O	O
responses	NN	O	O
to	NN	O	O
verapamil	NN	O	O
in	NN	O	O
65	NN	O	O
female	NN	O	O
patients	NN	O	O
(	NN	O	O
age	NN	O	O
:	NN	O	O
29	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
1	NN	O	O
years	NN	O	O
)	NN	O	O
with	NN	O	O
hyperprolactinemia	NN	O	B
were	NN	O	O
tested	NN	O	O
in	NN	O	O
a	NN	O	O
descriptive	NN	O	O
,	NN	O	O
matched	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Verapamil	NN	O	O
80	NN	O	O
mg	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
was	NN	O	O
administered	NN	O	O
,	NN	O	O
and	NN	O	O
then	NN	O	O
PRL	NN	O	O
levels	NN	O	O
were	NN	O	O
measured	NN	O	O
at	NN	O	O
8th	NN	O	O
and	NN	O	O
16th	NN	O	O
hours	NN	O	O
,	NN	O	O
by	NN	O	O
immunometric	NN	O	O
chemiluminescence	NN	O	O
.	NN	O	O

Verapamil	NN	O	O
responsiveness	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
peak	NN	O	O
percent	NN	O	O
change	NN	O	O
in	NN	O	O
basal	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
(	NN	O	O
PRL	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Verapamil	NN	O	O
significantly	NN	O	O
increased	NN	O	O
PRL	NN	O	O
levels	NN	O	O
in	NN	O	O
healthy	NN	O	O
controls	NN	O	O
(	NN	O	O
N	NN	O	O
.	NN	O	O
8	NN	O	O
,	NN	O	O
PRL	NN	O	O
:	NN	O	O
183	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
macroprolactinoma	NN	O	B
(	NN	O	O
N	NN	O	O
.	NN	O	O
8	NN	O	O
,	NN	O	O
PRL	NN	O	O
:	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
microprolactinoma	NN	O	B
(	NN	O	O
N	NN	O	O
.	NN	O	O
19	NN	O	O
,	NN	O	O
PRL	NN	O	O
:	NN	O	O
21	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
macroprolactinemia	NN	O	B
(	NN	O	O
N	NN	O	O
.	NN	O	O
23	NN	O	O
,	NN	O	O
PRL	NN	O	O
:	NN	O	O
126	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
pseudoprolactinoma	NN	O	B
(	NN	O	O
N	NN	O	O
.	NN	O	O
8	NN	O	O
,	NN	O	O
PRL	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
risperidone	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B
(	NN	O	O
N	NN	O	O
.	NN	O	O
7	NN	O	O
,	NN	O	O
PRL	NN	O	O
:	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

ROC	NN	O	O
curve	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
that	NN	O	O
unresponsiveness	NN	O	O
to	NN	O	O
verapamil	NN	O	O
defined	NN	O	O
as	NN	O	O
PRL	NN	O	O
<	NN	O	O
7	NN	O	O
%	NN	O	O
,	NN	O	O
discriminated	NN	O	O
anatomical	NN	O	O
or	NN	O	O
functional	NN	O	O
stalk	NN	O	O
effect	NN	O	O
(	NN	O	O
sensitivity	NN	O	O
:	NN	O	O
74	NN	O	O
%	NN	O	O
,	NN	O	O
specificity	NN	O	O
:	NN	O	O
73	NN	O	O
%	NN	O	O
,	NN	O	O
AUC	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
855	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
04	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
,	NN	O	O
CI	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
768	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
942	NN	O	O
)	NN	O	O
associated	NN	O	O
with	NN	O	O
pseudoprolactinoma	NN	O	B
or	NN	O	O
risperidone	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Verapamil	NN	O	O
responsiveness	NN	O	O
is	NN	O	O
not	NN	O	O
a	NN	O	O
reliable	NN	O	O
finding	NN	O	O
for	NN	O	O
the	NN	O	O
differential	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
verapamil	NN	O	O
unresponsiveness	NN	O	O
discriminates	NN	O	O
stalk	NN	O	O
effect	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
,	NN	O	O
anatomically	NN	O	O
or	NN	O	O
functionally	NN	O	O
inhibited	NN	O	O
dopaminergic	NN	O	O
tonus	NN	O	O
)	NN	O	O
from	NN	O	O
other	NN	O	O
causes	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B
with	NN	O	O
varying	NN	O	O
degrees	NN	O	O
of	NN	O	O
responsiveness	NN	O	O
.	NN	O	O

Blockade	NN	O	O
of	NN	O	O
endothelial	NN	O	O
-	NN	O	O
mesenchymal	NN	O	O
transition	NN	O	O
by	NN	O	O
a	NN	O	O
Smad3	NN	O	O
inhibitor	NN	O	O
delays	NN	O	O
the	NN	O	O
early	NN	O	O
development	NN	O	O
of	NN	O	O
streptozotocin	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
A	NN	O	O
multicenter	NN	O	O
,	NN	O	O
controlled	NN	O	O
trial	NN	O	O
showed	NN	O	O
that	NN	O	O
early	NN	O	O
blockade	NN	O	O
of	NN	O	O
the	NN	O	O
renin	NN	O	O
-	NN	O	O
angiotensin	NN	O	O
system	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
type	NN	O	B
1	NN	O	I
diabetes	NN	O	I
and	NN	O	O
normoalbuminuria	NN	O	O
did	NN	O	O
not	NN	O	O
retard	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
nephropathy	NN	O	B
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
other	NN	O	O
mechanism	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
early	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
(	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
)	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
previously	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
endothelial	NN	O	O
-	NN	O	O
mesenchymal	NN	O	O
-	NN	O	O
transition	NN	O	O
(	NN	O	O
EndoMT	NN	O	O
)	NN	O	O
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
early	NN	O	O
development	NN	O	O
of	NN	O	O
renal	NN	O	O
interstitial	NN	O	O
fibrosis	NN	O	B
independently	NN	O	O
of	NN	O	O
microalbuminuria	NN	O	O
in	NN	O	O
mice	NN	O	O
with	NN	O	O
streptozotocin	NN	O	O
(	NN	O	O
STZ	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
blocking	NN	O	O
EndoMT	NN	O	O
reduces	NN	O	O
the	NN	O	O
early	NN	O	O
development	NN	O	O
of	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
.	NN	O	O

RESEARCH	NN	O	O
DESIGN	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
EndoMT	NN	O	O
was	NN	O	O
induced	NN	O	O
in	NN	O	O
a	NN	O	O
mouse	NN	O	O
pancreatic	NN	O	O
microvascular	NN	O	O
endothelial	NN	O	O
cell	NN	O	O
line	NN	O	O
(	NN	O	O
MMEC	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
advanced	NN	O	O
glycation	NN	O	O
end	NN	O	O
products	NN	O	O
(	NN	O	O
AGEs	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
endothelial	NN	O	O
lineage	NN	O	O
-	NN	O	O
traceble	NN	O	O
mouse	NN	O	O
line	NN	O	O
Tie2	NN	O	O
-	NN	O	O
Cre	NN	O	O
;	NN	O	O
Loxp	NN	O	O
-	NN	O	O
EGFP	NN	O	O
by	NN	O	O
administration	NN	O	O
of	NN	O	O
AGEs	NN	O	O
,	NN	O	O
with	NN	O	O
nonglycated	NN	O	O
mouse	NN	O	O
albumin	NN	O	O
serving	NN	O	O
as	NN	O	O
a	NN	O	O
control	NN	O	O
.	NN	O	O

Phosphorylated	NN	O	O
Smad3	NN	O	O
was	NN	O	O
detected	NN	O	O
by	NN	O	O
immunoprecipitation	NN	O	O
/	NN	O	O
Western	NN	O	O
blotting	NN	O	O
and	NN	O	O
confocal	NN	O	O
microscopy	NN	O	O
.	NN	O	O

Blocking	NN	O	O
studies	NN	O	O
using	NN	O	O
receptor	NN	O	O
for	NN	O	O
AGE	NN	O	O
siRNA	NN	O	O
and	NN	O	O
a	NN	O	O
specific	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
Smad3	NN	O	O
(	NN	O	O
SIS3	NN	O	O
)	NN	O	O
were	NN	O	O
performed	NN	O	O
in	NN	O	O
MMECs	NN	O	O
and	NN	O	O
in	NN	O	O
STZ	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
in	NN	O	O
Tie2	NN	O	O
-	NN	O	O
Cre	NN	O	O
;	NN	O	O
Loxp	NN	O	O
-	NN	O	O
EGFP	NN	O	O
mice	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Confocal	NN	O	O
microscopy	NN	O	O
and	NN	O	O
real	NN	O	O
-	NN	O	O
time	NN	O	O
PCR	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
AGEs	NN	O	O
induced	NN	O	O
EndoMT	NN	O	O
in	NN	O	O
MMECs	NN	O	O
and	NN	O	O
in	NN	O	O
Tie2	NN	O	O
-	NN	O	O
Cre	NN	O	O
;	NN	O	O
Loxp	NN	O	O
-	NN	O	O
EGFP	NN	O	O
mice	NN	O	O
.	NN	O	O

Immunoprecipitation	NN	O	O
/	NN	O	O
Western	NN	O	O
blotting	NN	O	O
showed	NN	O	O
that	NN	O	O
Smad3	NN	O	O
was	NN	O	O
activated	NN	O	O
by	NN	O	O
AGEs	NN	O	O
but	NN	O	O
was	NN	O	O
inhibited	NN	O	O
by	NN	O	O
SIS3	NN	O	O
in	NN	O	O
MMECs	NN	O	O
and	NN	O	O
in	NN	O	O
STZ	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
.	NN	O	O

Confocal	NN	O	O
microscopy	NN	O	O
and	NN	O	O
real	NN	O	O
-	NN	O	O
time	NN	O	O
PCR	NN	O	O
further	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
SIS3	NN	O	O
abrogated	NN	O	O
EndoMT	NN	O	O
,	NN	O	O
reduced	NN	O	O
renal	NN	O	O
fibrosis	NN	O	B
,	NN	O	O
and	NN	O	O
retarded	NN	O	O
progression	NN	O	O
of	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
EndoMT	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
pathway	NN	O	O
leading	NN	O	O
to	NN	O	O
early	NN	O	O
development	NN	O	O
of	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
.	NN	O	O

Blockade	NN	O	O
of	NN	O	O
EndoMT	NN	O	O
by	NN	O	O
SIS3	NN	O	O
may	NN	O	O
provide	NN	O	O
a	NN	O	O
new	NN	O	O
strategy	NN	O	O
to	NN	O	O
retard	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
and	NN	O	O
other	NN	O	O
diabetes	NN	O	B
complications	NN	O	I
.	NN	O	O

Cytostatic	NN	O	O
and	NN	O	O
anti	NN	O	O
-	NN	O	O
angiogenic	NN	O	O
effects	NN	O	O
of	NN	O	O
temsirolimus	NN	O	O
in	NN	O	O
refractory	NN	O	O
mantle	NN	O	B
cell	NN	O	I
lymphoma	NN	O	I
.	NN	O	O

Mantle	NN	O	B
cell	NN	O	I
lymphoma	NN	O	I
(	NN	O	O
MCL	NN	O	B
)	NN	O	O
is	NN	O	O
a	NN	O	O
rare	NN	O	O
and	NN	O	O
aggressive	NN	O	O
type	NN	O	O
of	NN	O	O
B	NN	O	B
-	NN	O	I
cell	NN	O	I
non	NN	O	I
-	NN	O	I
Hodgkin	NN	O	I
'	NN	O	I
s	NN	O	I
lymphoma	NN	O	I
.	NN	O	O

Patients	NN	O	O
become	NN	O	O
progressively	NN	O	O
refractory	NN	O	O
to	NN	O	O
conventional	NN	O	O
chemotherapy	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
prognosis	NN	O	O
is	NN	O	O
poor	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
a	NN	O	O
38	NN	O	O
%	NN	O	O
remission	NN	O	O
rate	NN	O	O
has	NN	O	O
been	NN	O	O
recently	NN	O	O
reported	NN	O	O
in	NN	O	O
refractory	NN	O	O
MCL	NN	O	B
treated	NN	O	O
with	NN	O	O
temsirolimus	NN	O	O
,	NN	O	O
a	NN	O	O
mTOR	NN	O	O
inhibitor	NN	O	O
.	NN	O	O
Here	NN	O	O
we	NN	O	O
had	NN	O	O
the	NN	O	O
opportunity	NN	O	O
to	NN	O	O
study	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
refractory	NN	O	O
MCL	NN	O	B
who	NN	O	O
had	NN	O	O
tumor	NN	O	B
regression	NN	O	O
two	NN	O	O
months	NN	O	O
after	NN	O	O
temsirolimus	NN	O	O
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
progression	NN	O	O
-	NN	O	O
free	NN	O	O
survival	NN	O	O
of	NN	O	O
10	NN	O	O
months	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
case	NN	O	O
,	NN	O	O
lymph	NN	O	O
node	NN	O	O
biopsies	NN	O	O
were	NN	O	O
performed	NN	O	O
before	NN	O	O
and	NN	O	O
six	NN	O	O
months	NN	O	O
after	NN	O	O
temsirolimus	NN	O	O
therapy	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
biopsies	NN	O	O
showed	NN	O	O
that	NN	O	O
temsirolimus	NN	O	O
inhibited	NN	O	O
tumor	NN	O	B
cell	NN	O	O
proliferation	NN	O	O
through	NN	O	O
cell	NN	O	O
cycle	NN	O	O
arrest	NN	O	O
,	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
induce	NN	O	O
any	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
apoptotic	NN	O	O
tumor	NN	O	B
cells	NN	O	O
.	NN	O	O

Apart	NN	O	O
from	NN	O	O
this	NN	O	O
cytostatic	NN	O	O
effect	NN	O	O
,	NN	O	O
temsirolimus	NN	O	O
had	NN	O	O
an	NN	O	O
antiangiogenic	NN	O	O
effect	NN	O	O
with	NN	O	O
decrease	NN	O	O
of	NN	O	O
tumor	NN	O	B
microvessel	NN	O	O
density	NN	O	O
and	NN	O	O
of	NN	O	O
VEGF	NN	O	O
expression	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
numerous	NN	O	O
patchy	NN	O	O
,	NN	O	O
well	NN	O	O
-	NN	O	O
limited	NN	O	O
fibrotic	NN	O	O
areas	NN	O	O
,	NN	O	O
compatible	NN	O	O
with	NN	O	O
post	NN	O	O
-	NN	O	O
necrotic	NN	O	B
tissue	NN	O	O
repair	NN	O	O
,	NN	O	O
were	NN	O	O
found	NN	O	O
after	NN	O	O
6	NN	O	O
-	NN	O	O
month	NN	O	O
temsirolimus	NN	O	O
therapy	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
temsirolimus	NN	O	O
reduced	NN	O	O
tumor	NN	O	B
burden	NN	O	O
through	NN	O	O
associated	NN	O	O
cytostatic	NN	O	O
and	NN	O	O
anti	NN	O	O
-	NN	O	O
angiogenic	NN	O	O
effects	NN	O	O
.	NN	O	O
This	NN	O	O
dual	NN	O	O
effect	NN	O	O
of	NN	O	O
temsirolimus	NN	O	O
on	NN	O	O
tumor	NN	O	B
tissue	NN	O	O
could	NN	O	O
contribute	NN	O	O
to	NN	O	O
its	NN	O	O
recently	NN	O	O
reported	NN	O	O
efficiency	NN	O	O
in	NN	O	O
refractory	NN	O	O
MCL	NN	O	B
resistant	NN	O	O
to	NN	O	O
conventional	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
due	NN	O	O
to	NN	O	O
rifampicin	NN	O	O
.	NN	O	O

A	NN	O	O
23	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
patient	NN	O	O
with	NN	O	O
bacteriologically	NN	O	O
proven	NN	O	O
pulmonary	NN	O	B
tuberculosis	NN	O	I
was	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
various	NN	O	O
regimens	NN	O	O
of	NN	O	O
antituberculosis	NN	O	O
drugs	NN	O	O
for	NN	O	O
nearly	NN	O	O
15	NN	O	O
months	NN	O	O
.	NN	O	O

Rifampicin	NN	O	O
was	NN	O	O
administered	NN	O	O
thrice	NN	O	O
as	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
drug	NN	O	O
regimen	NN	O	O
and	NN	O	O
each	NN	O	O
time	NN	O	O
he	NN	O	O
developed	NN	O	O
untoward	NN	O	O
side	NN	O	O
effects	NN	O	O
like	NN	O	O
nausea	NN	O	B
,	NN	O	O
vomiting	NN	O	B
and	NN	O	O
fever	NN	O	B
with	NN	O	O
chills	NN	O	O
and	NN	O	O
rigors	NN	O	O
.	NN	O	O

The	NN	O	O
last	NN	O	O
such	NN	O	O
episode	NN	O	O
was	NN	O	O
of	NN	O	O
acute	NN	O	O
renal	NN	O	O
failure	NN	O	O
at	NN	O	O
which	NN	O	O
stage	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
seen	NN	O	O
by	NN	O	O
the	NN	O	O
authors	NN	O	O
of	NN	O	O
this	NN	O	O
report	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
made	NN	O	O
a	NN	O	O
full	NN	O	O
recovery	NN	O	O
.	NN	O	O

Syncope	NN	O	B
caused	NN	O	O
by	NN	O	O
hyperkalemia	NN	O	B
during	NN	O	O
use	NN	O	O
of	NN	O	O
a	NN	O	O
combined	NN	O	O
therapy	NN	O	O
with	NN	O	O
the	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
and	NN	O	O
spironolactone	NN	O	O
.	NN	O	O

A	NN	O	O
76	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
coronary	NN	O	O
artery	NN	O	O
bypass	NN	O	O
grafting	NN	O	O
and	NN	O	O
prior	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
was	NN	O	O
transferred	NN	O	O
to	NN	O	O
the	NN	O	O
emergency	NN	O	O
room	NN	O	O
with	NN	O	O
loss	NN	O	B
of	NN	O	I
consciousness	NN	O	I
due	NN	O	O
to	NN	O	O
marked	NN	O	O
bradycardia	NN	O	B
caused	NN	O	O
by	NN	O	O
hyperkalemia	NN	O	B
.	NN	O	O

The	NN	O	O
concentration	NN	O	O
of	NN	O	O
serum	NN	O	O
potassium	NN	O	O
was	NN	O	O
high	NN	O	O
,	NN	O	O
and	NN	O	O
normal	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
was	NN	O	O
restored	NN	O	O
after	NN	O	O
correction	NN	O	O
of	NN	O	O
the	NN	O	O
serum	NN	O	O
potassium	NN	O	O
level	NN	O	O
.	NN	O	O

The	NN	O	O
cause	NN	O	O
of	NN	O	O
hyperkalemia	NN	O	B
was	NN	O	O
considered	NN	O	O
to	NN	O	O
be	NN	O	O
several	NN	O	O
doses	NN	O	O
of	NN	O	O
spiranolactone	NN	O	O
,	NN	O	O
an	NN	O	O
aldosterone	NN	O	O
antagonist	NN	O	O
,	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
intake	NN	O	O
of	NN	O	O
ramipril	NN	O	O
,	NN	O	O
an	NN	O	O
ACE	NN	O	O
inhibitor	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
is	NN	O	O
a	NN	O	O
good	NN	O	O
example	NN	O	O
of	NN	O	O
electrolyte	NN	O	O
imbalance	NN	O	O
causing	NN	O	O
acute	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
cardiac	NN	O	O
events	NN	O	O
.	NN	O	O

Clinicians	NN	O	O
should	NN	O	O
be	NN	O	O
alert	NN	O	O
to	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
hyperkalemia	NN	O	B
,	NN	O	O
especially	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
using	NN	O	O
ACE	NN	O	O
/	NN	O	O
ARB	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
potassium	NN	O	O
sparing	NN	O	O
agents	NN	O	O
and	NN	O	O
who	NN	O	O
have	NN	O	O
mild	NN	O	O
renal	NN	O	B
disturbance	NN	O	I
.	NN	O	O

Diffuse	NN	O	O
skeletal	NN	O	O
pain	NN	O	B
after	NN	O	O
administration	NN	O	O
of	NN	O	O
alendronate	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Osteoporosis	NN	O	B
is	NN	O	O
caused	NN	O	O
by	NN	O	O
bone	NN	O	O
resorption	NN	O	O
in	NN	O	O
excess	NN	O	O
of	NN	O	O
bone	NN	O	O
formation	NN	O	O
,	NN	O	O
and	NN	O	O
bisphosphonates	NN	O	O
,	NN	O	O
are	NN	O	O
used	NN	O	O
to	NN	O	O
inhibit	NN	O	O
bone	NN	O	O
resorption	NN	O	O
.	NN	O	O

Alendronate	NN	O	O
,	NN	O	O
a	NN	O	O
biphosphonate	NN	O	O
,	NN	O	O
is	NN	O	O
effective	NN	O	O
for	NN	O	O
both	NN	O	O
the	NN	O	O
treatment	NN	O	O
and	NN	O	O
prevention	NN	O	O
of	NN	O	O
osteoporosis	NN	O	B
in	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

Side	NN	O	O
effects	NN	O	O
are	NN	O	O
relatively	NN	O	O
few	NN	O	O
and	NN	O	O
prominently	NN	O	O
gastrointestinal	NN	O	O
.	NN	O	O

Musculoskeletal	NN	O	B
pain	NN	O	I
may	NN	O	O
be	NN	O	O
an	NN	O	O
important	NN	O	O
side	NN	O	O
effect	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

We	NN	O	O
presented	NN	O	O
a	NN	O	O
patient	NN	O	O
admitted	NN	O	O
to	NN	O	O
our	NN	O	O
out	NN	O	O
-	NN	O	O
patient	NN	O	O
clinic	NN	O	O
with	NN	O	O
diffuse	NN	O	O
skeletal	NN	O	O
pain	NN	O	B
after	NN	O	O
three	NN	O	O
consecutive	NN	O	O
administration	NN	O	O
of	NN	O	O
alendronate	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
We	NN	O	O
conclude	NN	O	O
that	NN	O	O
patients	NN	O	O
with	NN	O	O
osteoporosis	NN	O	B
can	NN	O	O
report	NN	O	O
pain	NN	O	B
,	NN	O	O
and	NN	O	O
bisphosphonate	NN	O	O
-	NN	O	O
related	NN	O	O
pain	NN	O	B
should	NN	O	O
also	NN	O	O
be	NN	O	O
considered	NN	O	O
before	NN	O	O
ascribing	NN	O	O
this	NN	O	O
complaint	NN	O	O
to	NN	O	O
osteoporosis	NN	O	B
.	NN	O	O

Cerebrospinal	NN	O	O
fluid	NN	O	O
penetration	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
daptomycin	NN	O	O
in	NN	O	O
suspected	NN	O	O
Staphylococcus	NN	O	O
aureus	NN	O	O
meningitis	NN	O	B
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
methicillin	NN	O	O
-	NN	O	O
sensitive	NN	O	O
Staphylococcus	NN	O	O
aureus	NN	O	O
(	NN	O	O
MSSA	NN	O	O
)	NN	O	O
bacteremia	NN	O	B
with	NN	O	O
suspected	NN	O	O
MSSA	NN	O	O
meningitis	NN	O	B
treated	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
daptomycin	NN	O	O
assessed	NN	O	O
with	NN	O	O
concurrent	NN	O	O
serum	NN	O	O
and	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
(	NN	O	O
CSF	NN	O	O
)	NN	O	O
concentrations	NN	O	O
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
54	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
presented	NN	O	O
to	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
with	NN	O	O
generalized	NN	O	O
weakness	NN	O	B
and	NN	O	O
presumed	NN	O	O
health	NN	O	O
-	NN	O	O
care	NN	O	O
-	NN	O	O
associated	NN	O	O
pneumonia	NN	O	B
shown	NN	O	O
on	NN	O	O
chest	NN	O	O
radiograph	NN	O	O
.	NN	O	O

Treatment	NN	O	O
was	NN	O	O
empirically	NN	O	O
initiated	NN	O	O
with	NN	O	O
vancomycin	NN	O	O
,	NN	O	O
levofloxacin	NN	O	O
,	NN	O	O
and	NN	O	O
piperacillin	NN	O	O
/	NN	O	O
tazobactam	NN	O	O
.	NN	O	O

Blood	NN	O	O
cultures	NN	O	O
revealed	NN	O	O
S	NN	O	O
.	NN	O	O
aureus	NN	O	O
susceptible	NN	O	O
to	NN	O	O
oxacillin	NN	O	O
.	NN	O	O

Empiric	NN	O	O
antibiotic	NN	O	O
treatment	NN	O	O
was	NN	O	O
narrowed	NN	O	O
to	NN	O	O
nafcillin	NN	O	O
on	NN	O	O
day	NN	O	O
4	NN	O	O
.	NN	O	O

On	NN	O	O
day	NN	O	O
8	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
developed	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
(	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
,	NN	O	O
increased	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
the	NN	O	O
previous	NN	O	O
day	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
on	NN	O	O
admission	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
Glasgow	NN	O	O
Coma	NN	O	O
Score	NN	O	O
was	NN	O	O
3	NN	O	O
,	NN	O	O
with	NN	O	O
normal	NN	O	O
findings	NN	O	O
shown	NN	O	O
on	NN	O	O
computed	NN	O	O
tomography	NN	O	O
scan	NN	O	O
of	NN	O	O
the	NN	O	O
head	NN	O	O
72	NN	O	O
hours	NN	O	O
following	NN	O	O
an	NN	O	O
episode	NN	O	O
of	NN	O	O
cardiac	NN	O	B
arrest	NN	O	I
on	NN	O	O
day	NN	O	O
10	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
experienced	NN	O	O
relapsing	NN	O	O
MSSA	NN	O	O
bacteremia	NN	O	B
on	NN	O	O
day	NN	O	O
9	NN	O	O
,	NN	O	O
increasing	NN	O	O
the	NN	O	O
suspicion	NN	O	O
for	NN	O	O
a	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
infection	NN	O	B
.	NN	O	O

Nafcillin	NN	O	O
was	NN	O	O
discontinued	NN	O	O
and	NN	O	O
daptomycin	NN	O	O
9	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
daily	NN	O	O
was	NN	O	O
initiated	NN	O	O
for	NN	O	O
suspected	NN	O	O
meningitis	NN	O	B
and	NN	O	O
was	NN	O	O
continued	NN	O	O
until	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
death	NN	O	O
on	NN	O	O
day	NN	O	O
16	NN	O	O
.	NN	O	O

Daptomycin	NN	O	O
serum	NN	O	O
and	NN	O	O
CSF	NN	O	O
trough	NN	O	O
concentrations	NN	O	O
were	NN	O	O
11	NN	O	O
.	NN	O	O
21	NN	O	O
ug	NN	O	O
/	NN	O	O
mL	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
52	NN	O	O
ug	NN	O	O
/	NN	O	O
mL	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
prior	NN	O	O
to	NN	O	O
the	NN	O	O
third	NN	O	O
dose	NN	O	O
.	NN	O	O

Lumbar	NN	O	O
puncture	NN	O	O
results	NN	O	O
were	NN	O	O
inconclusive	NN	O	O
and	NN	O	O
no	NN	O	O
further	NN	O	O
blood	NN	O	O
cultures	NN	O	O
were	NN	O	O
positive	NN	O	O
for	NN	O	O
MSSA	NN	O	O
.	NN	O	O

Creatine	NN	O	O
kinase	NN	O	O
levels	NN	O	O
were	NN	O	O
normal	NN	O	O
prior	NN	O	O
to	NN	O	O
daptomycin	NN	O	O
therapy	NN	O	O
and	NN	O	O
were	NN	O	O
not	NN	O	O
reassessed	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Daptomycin	NN	O	O
was	NN	O	O
initiated	NN	O	O
in	NN	O	O
our	NN	O	O
patient	NN	O	O
secondary	NN	O	O
to	NN	O	O
possible	NN	O	O
nafcillin	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
and	NN	O	O
relapsing	NN	O	O
bacteremia	NN	O	B
.	NN	O	O

At	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
9	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
resultant	NN	O	O
penetration	NN	O	O
of	NN	O	O
5	NN	O	O
%	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
in	NN	O	O
previous	NN	O	O
reports	NN	O	O
,	NN	O	O
more	NN	O	O
consistent	NN	O	O
with	NN	O	O
inflamed	NN	O	O
meninges	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
High	NN	O	O
-	NN	O	O
dose	NN	O	O
daptomycin	NN	O	O
may	NN	O	O
be	NN	O	O
an	NN	O	O
alternative	NN	O	O
option	NN	O	O
for	NN	O	O
MSSA	NN	O	O
bacteremia	NN	O	B
with	NN	O	O
or	NN	O	O
without	NN	O	O
a	NN	O	O
CNS	NN	O	O
source	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
failed	NN	O	O
or	NN	O	O
cannot	NN	O	O
tolerate	NN	O	O
standard	NN	O	O
therapy	NN	O	O
.	NN	O	O

Further	NN	O	O
clinical	NN	O	O
evaluation	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
confirmed	NN	O	O
meningitis	NN	O	B
is	NN	O	O
warranted	NN	O	O
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
in	NN	O	O
convulsions	NN	O	B
induced	NN	O	O
by	NN	O	O
lindane	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Lindane	NN	O	O
is	NN	O	O
an	NN	O	O
organochloride	NN	O	O
pesticide	NN	O	O
and	NN	O	O
scabicide	NN	O	O
.	NN	O	O

It	NN	O	O
evokes	NN	O	O
convulsions	NN	O	B
mainly	NN	O	O
trough	NN	O	O
the	NN	O	O
blockage	NN	O	O
of	NN	O	O
GABA	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
receptors	NN	O	O
.	NN	O	O

Nitric	NN	O	O
oxide	NN	O	O
(	NN	O	O
NO	NN	O	O
)	NN	O	O
,	NN	O	O
gaseous	NN	O	O
neurotransmitter	NN	O	O
,	NN	O	O
has	NN	O	O
contradictor	NN	O	O
role	NN	O	O
in	NN	O	O
epileptogenesis	NN	O	O
due	NN	O	O
to	NN	O	O
opposite	NN	O	O
effects	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
,	NN	O	O
precursor	NN	O	O
of	NN	O	O
NO	NN	O	O
syntheses	NN	O	O
(	NN	O	O
NOS	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
L	NN	O	O
-	NN	O	O
NAME	NN	O	O
(	NN	O	O
NOS	NN	O	O
inhibitor	NN	O	O
)	NN	O	O
observed	NN	O	O
in	NN	O	O
different	NN	O	O
epilepsy	NN	O	B
models	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
NO	NN	O	O
on	NN	O	O
the	NN	O	O
behavioral	NN	O	O
and	NN	O	O
EEG	NN	O	O
characteristics	NN	O	O
of	NN	O	O
lindane	NN	O	O
-	NN	O	O
induced	NN	O	O
epilepsy	NN	O	B
in	NN	O	O
male	NN	O	O
Wistar	NN	O	O
albino	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
(	NN	O	O
600	NN	O	O
,	NN	O	O
800	NN	O	O
and	NN	O	O
1000	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
in	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
significantly	NN	O	O
increased	NN	O	O
convulsion	NN	O	B
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
and	NN	O	O
shortened	NN	O	O
latency	NN	O	O
time	NN	O	O
to	NN	O	O
first	NN	O	O
convulsion	NN	O	B
elicited	NN	O	O
by	NN	O	O
lower	NN	O	O
lindane	NN	O	O
dose	NN	O	O
(	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
contrary	NN	O	O
,	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
L	NN	O	O
-	NN	O	O
NAME	NN	O	O
(	NN	O	O
500	NN	O	O
,	NN	O	O
700	NN	O	O
and	NN	O	O
900	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
decreased	NN	O	O
convulsion	NN	O	B
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
and	NN	O	O
prolonged	NN	O	O
latency	NN	O	O
time	NN	O	O
to	NN	O	O
convulsion	NN	O	B
following	NN	O	O
injection	NN	O	O
with	NN	O	O
a	NN	O	O
convulsive	NN	O	B
dose	NN	O	O
of	NN	O	O
lindane	NN	O	O
(	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

EEG	NN	O	O
analyses	NN	O	O
showed	NN	O	O
increase	NN	O	O
of	NN	O	O
number	NN	O	O
and	NN	O	O
duration	NN	O	O
of	NN	O	O
ictal	NN	O	O
periods	NN	O	O
in	NN	O	O
EEG	NN	O	O
of	NN	O	O
rats	NN	O	O
receiving	NN	O	O
l	NN	O	O
-	NN	O	O
arginine	NN	O	O
prior	NN	O	O
to	NN	O	O
lindane	NN	O	O
and	NN	O	O
decrease	NN	O	O
of	NN	O	O
this	NN	O	O
number	NN	O	O
in	NN	O	O
rats	NN	O	O
pretreated	NN	O	O
with	NN	O	O
L	NN	O	O
-	NN	O	O
NAME	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
support	NN	O	O
the	NN	O	O
conclusion	NN	O	O
that	NN	O	O
NO	NN	O	O
plays	NN	O	O
a	NN	O	O
role	NN	O	O
of	NN	O	O
endogenous	NN	O	O
convulsant	NN	O	O
in	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
lindane	NN	O	O
seizures	NN	O	B
.	NN	O	O

Severe	NN	O	O
polyneuropathy	NN	O	B
and	NN	O	O
motor	NN	O	O
loss	NN	O	O
after	NN	O	O
intrathecal	NN	O	O
thiotepa	NN	O	O
combination	NN	O	O
chemotherapy	NN	O	O
:	NN	O	O
description	NN	O	O
of	NN	O	O
two	NN	O	O
cases	NN	O	O
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
of	NN	O	O
severe	NN	O	O
delayed	NN	O	O
neurologic	NN	O	B
toxicity	NN	O	I
related	NN	O	O
to	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
intrathecal	NN	O	O
(	NN	O	O
IT	NN	O	O
)	NN	O	O
combination	NN	O	O
chemotherapy	NN	O	O
including	NN	O	O
thiotepa	NN	O	O
(	NN	O	O
TSPA	NN	O	O
)	NN	O	O
are	NN	O	O
presented	NN	O	O
.	NN	O	O

Both	NN	O	O
cases	NN	O	O
developed	NN	O	O
axonal	NN	O	B
neuropathy	NN	O	I
with	NN	O	O
motor	NN	O	O
predominance	NN	O	O
in	NN	O	O
the	NN	O	O
lower	NN	O	O
extremities	NN	O	O
1	NN	O	O
and	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
IT	NN	O	O
chemotherapy	NN	O	O
was	NN	O	O
administered	NN	O	O
.	NN	O	O

Neurologic	NN	O	B
toxicities	NN	O	I
have	NN	O	O
been	NN	O	O
described	NN	O	O
with	NN	O	O
IT	NN	O	O
-	NN	O	O
methotrexate	NN	O	O
,	NN	O	O
IT	NN	O	O
-	NN	O	O
cytosine	NN	O	O
arabinoside	NN	O	O
and	NN	O	O
IT	NN	O	O
-	NN	O	O
TSPA	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
axonal	NN	O	B
neuropathy	NN	O	I
following	NN	O	O
administration	NN	O	O
of	NN	O	O
these	NN	O	O
three	NN	O	O
agents	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
previously	NN	O	O
described	NN	O	O
.	NN	O	O

In	NN	O	O
spite	NN	O	O
of	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
TSPA	NN	O	O
is	NN	O	O
a	NN	O	O
useful	NN	O	O
IT	NN	O	O
agent	NN	O	O
,	NN	O	O
its	NN	O	O
combination	NN	O	O
with	NN	O	O
MTX	NN	O	O
,	NN	O	O
ara	NN	O	O
-	NN	O	O
C	NN	O	O
and	NN	O	O
radiotherapy	NN	O	O
could	NN	O	O
cause	NN	O	O
severe	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

This	NN	O	O
unexpected	NN	O	O
complication	NN	O	O
indicates	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
further	NN	O	O
toxicology	NN	O	O
research	NN	O	O
on	NN	O	O
IT	NN	O	O
-	NN	O	O
TSPA	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
cromakalim	NN	O	O
and	NN	O	O
pinacidil	NN	O	O
on	NN	O	O
large	NN	O	O
epicardial	NN	O	O
and	NN	O	O
small	NN	O	O
coronary	NN	O	O
arteries	NN	O	O
in	NN	O	O
conscious	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
bolus	NN	O	O
administration	NN	O	O
of	NN	O	O
cromakalim	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
pinacidil	NN	O	O
(	NN	O	O
3	NN	O	O
-	NN	O	O
100	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
on	NN	O	O
large	NN	O	O
(	NN	O	O
circumflex	NN	O	O
artery	NN	O	O
)	NN	O	O
and	NN	O	O
small	NN	O	O
coronary	NN	O	O
arteries	NN	O	O
and	NN	O	O
on	NN	O	O
systemic	NN	O	O
hemodynamics	NN	O	O
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
chronically	NN	O	O
instrumented	NN	O	O
conscious	NN	O	O
dogs	NN	O	O
and	NN	O	O
compared	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
nitroglycerin	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
-	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

Nitroglycerin	NN	O	O
,	NN	O	O
up	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
selectively	NN	O	O
increased	NN	O	O
circumflex	NN	O	O
artery	NN	O	O
diameter	NN	O	O
(	NN	O	O
CxAD	NN	O	O
)	NN	O	O
without	NN	O	O
simultaneously	NN	O	O
affecting	NN	O	O
any	NN	O	O
other	NN	O	O
cardiac	NN	O	O
or	NN	O	O
systemic	NN	O	O
hemodynamic	NN	O	O
parameter	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
cromakalim	NN	O	O
and	NN	O	O
pinacidil	NN	O	O
at	NN	O	O
all	NN	O	O
doses	NN	O	O
and	NN	O	O
nitroglycerin	NN	O	O
at	NN	O	O
doses	NN	O	O
higher	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
simultaneously	NN	O	O
and	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
increased	NN	O	O
CxAD	NN	O	O
,	NN	O	O
coronary	NN	O	O
blood	NN	O	O
flow	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
decreased	NN	O	O
coronary	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
and	NN	O	O
aortic	NN	O	O
pressure	NN	O	O
.	NN	O	O

Cromakalim	NN	O	O
was	NN	O	O
approximately	NN	O	O
8	NN	O	O
-	NN	O	O
to	NN	O	O
9	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
fold	NN	O	O
more	NN	O	O
potent	NN	O	O
than	NN	O	O
pinacidil	NN	O	O
in	NN	O	O
increasing	NN	O	O
CxAD	NN	O	O
.	NN	O	O

Vasodilation	NN	O	O
of	NN	O	O
large	NN	O	O
and	NN	O	O
small	NN	O	O
coronary	NN	O	O
vessels	NN	O	O
and	NN	O	O
hypotension	NN	O	B
induced	NN	O	O
by	NN	O	O
cromakalim	NN	O	O
and	NN	O	O
pinacidil	NN	O	O
were	NN	O	O
not	NN	O	O
affected	NN	O	O
by	NN	O	O
prior	NN	O	O
combined	NN	O	O
beta	NN	O	O
adrenergic	NN	O	O
and	NN	O	O
muscarinic	NN	O	O
receptors	NN	O	O
blockade	NN	O	O
but	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
was	NN	O	O
abolished	NN	O	O
.	NN	O	O

When	NN	O	O
circumflex	NN	O	O
artery	NN	O	O
blood	NN	O	O
flow	NN	O	O
was	NN	O	O
maintained	NN	O	O
constant	NN	O	O
,	NN	O	O
the	NN	O	O
increases	NN	O	O
in	NN	O	O
CxAD	NN	O	O
induced	NN	O	O
by	NN	O	O
cromakalim	NN	O	O
(	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
pinacidil	NN	O	O
(	NN	O	O
30	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
nitroglycerin	NN	O	O
(	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
were	NN	O	O
reduced	NN	O	O
by	NN	O	O
68	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
,	NN	O	O
54	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9	NN	O	O
and	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
whereas	NN	O	O
nitroglycerin	NN	O	O
preferentially	NN	O	O
and	NN	O	O
flow	NN	O	O
-	NN	O	O
independently	NN	O	O
dilates	NN	O	O
large	NN	O	O
coronary	NN	O	O
arteries	NN	O	O
,	NN	O	O
cromakalim	NN	O	O
and	NN	O	O
pinacidil	NN	O	O
dilate	NN	O	O
both	NN	O	O
large	NN	O	O
and	NN	O	O
small	NN	O	O
coronary	NN	O	O
arteries	NN	O	O
and	NN	O	O
this	NN	O	O
effect	NN	O	O
is	NN	O	O
not	NN	O	O
dependent	NN	O	O
upon	NN	O	O
the	NN	O	O
simultaneous	NN	O	O
beta	NN	O	O
adrenoceptors	NN	O	O
-	NN	O	O
mediated	NN	O	O
rise	NN	O	O
in	NN	O	O
myocardial	NN	O	O
metabolic	NN	O	O
demand	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
two	NN	O	O
mechanisms	NN	O	O
at	NN	O	O
least	NN	O	O
,	NN	O	O
direct	NN	O	O
vasodilation	NN	O	O
and	NN	O	O
flow	NN	O	O
dependency	NN	O	O
,	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
cromakalim	NN	O	O
-	NN	O	O
and	NN	O	O
pinacidil	NN	O	O
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
in	NN	O	O
CxAD	NN	O	O
.	NN	O	O

Mefenamic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
neutropenia	NN	O	B
and	NN	O	O
renal	NN	O	B
failure	NN	O	I
in	NN	O	O
elderly	NN	O	O
females	NN	O	O
with	NN	O	O
hypothyroidism	NN	O	B
.	NN	O	O

We	NN	O	O
report	NN	O	O
mefenamic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
non	NN	O	O
-	NN	O	O
oliguric	NN	O	O
renal	NN	O	B
failure	NN	O	I
and	NN	O	O
severe	NN	O	O
neutropenia	NN	O	B
occurring	NN	O	O
simultaneously	NN	O	O
in	NN	O	O
two	NN	O	O
elderly	NN	O	O
females	NN	O	O
.	NN	O	O

The	NN	O	O
neutropenia	NN	O	B
was	NN	O	O
due	NN	O	O
to	NN	O	O
maturation	NN	O	O
arrest	NN	O	O
of	NN	O	O
the	NN	O	O
myeloid	NN	O	O
series	NN	O	O
in	NN	O	O
one	NN	O	O
patient	NN	O	O
.	NN	O	O

Both	NN	O	O
patients	NN	O	O
were	NN	O	O
also	NN	O	O
hypothyroid	NN	O	B
,	NN	O	O
but	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
clear	NN	O	O
whether	NN	O	O
this	NN	O	O
was	NN	O	O
a	NN	O	O
predisposing	NN	O	O
factor	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
these	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
it	NN	O	O
would	NN	O	O
seem	NN	O	O
prudent	NN	O	O
not	NN	O	O
to	NN	O	O
use	NN	O	O
mefenamic	NN	O	O
acid	NN	O	O
in	NN	O	O
hypothyroid	NN	O	B
patients	NN	O	O
until	NN	O	O
the	NN	O	O
hypothyroidism	NN	O	B
has	NN	O	O
been	NN	O	O
corrected	NN	O	O
.	NN	O	O

Etiology	NN	O	O
of	NN	O	O
hypercalcemia	NN	O	B
in	NN	O	O
hemodialysis	NN	O	O
patients	NN	O	O
on	NN	O	O
calcium	NN	O	O
carbonate	NN	O	O
therapy	NN	O	O
.	NN	O	O

Fourteen	NN	O	O
of	NN	O	O
39	NN	O	O
dialysis	NN	O	O
patients	NN	O	O
(	NN	O	O
36	NN	O	O
%	NN	O	O
)	NN	O	O
became	NN	O	O
hypercalcemic	NN	O	B
after	NN	O	O
switching	NN	O	O
to	NN	O	O
calcium	NN	O	O
carbonate	NN	O	O
as	NN	O	O
their	NN	O	O
principal	NN	O	O
phosphate	NN	O	O
binder	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
identify	NN	O	O
risk	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
hypercalcemia	NN	O	B
,	NN	O	O
indirect	NN	O	O
parameters	NN	O	O
of	NN	O	O
intestinal	NN	O	O
calcium	NN	O	O
reabsorption	NN	O	O
and	NN	O	O
bone	NN	O	O
turnover	NN	O	O
rate	NN	O	O
in	NN	O	O
these	NN	O	O
14	NN	O	O
patients	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
results	NN	O	O
in	NN	O	O
14	NN	O	O
eucalcemic	NN	O	O
patients	NN	O	O
matched	NN	O	O
for	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
length	NN	O	O
of	NN	O	O
time	NN	O	O
on	NN	O	O
dialysis	NN	O	O
,	NN	O	O
and	NN	O	O
etiology	NN	O	O
of	NN	O	O
renal	NN	O	B
disease	NN	O	I
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
experiencing	NN	O	O
hypercalcemic	NN	O	B
episodes	NN	O	O
with	NN	O	O
peak	NN	O	O
calcium	NN	O	O
values	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O
8	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
10	NN	O	O
.	NN	O	O
7	NN	O	O
to	NN	O	O
15	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
,	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
hypercalcemic	NN	O	B
group	NN	O	O
exhibited	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
mean	NN	O	O
calcium	NN	O	O
concentration	NN	O	O
obtained	NN	O	O
during	NN	O	O
6	NN	O	O
months	NN	O	O
before	NN	O	O
the	NN	O	O
switch	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
mean	NN	O	O
value	NN	O	O
obtained	NN	O	O
during	NN	O	O
the	NN	O	O
7	NN	O	O
months	NN	O	O
of	NN	O	O
observation	NN	O	O
after	NN	O	O
the	NN	O	O
switch	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
[	NN	O	O
9	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
to	NN	O	O
10	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
]	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
006	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
eucalcemic	NN	O	O
patients	NN	O	O
exhibited	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
mean	NN	O	O
calcium	NN	O	O
values	NN	O	O
over	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
period	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
[	NN	O	O
9	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
to	NN	O	O
9	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
]	NN	O	O
)	NN	O	O
.	NN	O	O

CaCO3	NN	O	O
dosage	NN	O	O
,	NN	O	O
calculated	NN	O	O
dietary	NN	O	O
calcium	NN	O	O
intake	NN	O	O
,	NN	O	O
and	NN	O	O
circulating	NN	O	O
levels	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D	NN	O	O
metabolites	NN	O	O
were	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Physical	NN	O	O
activity	NN	O	O
index	NN	O	O
and	NN	O	O
predialysis	NN	O	O
serum	NN	O	O
bicarbonate	NN	O	O
levels	NN	O	O
also	NN	O	O
were	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
parameters	NN	O	O
reflecting	NN	O	O
bone	NN	O	O
turnover	NN	O	O
rates	NN	O	O
between	NN	O	O
groups	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Late	NN	O	O
-	NN	O	O
onset	NN	O	O
scleroderma	NN	O	B
renal	NN	O	I
crisis	NN	O	I
induced	NN	O	O
by	NN	O	O
tacrolimus	NN	O	O
and	NN	O	O
prednisolone	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

Scleroderma	NN	O	B
renal	NN	O	I
crisis	NN	O	I
(	NN	O	O
SRC	NN	O	B
)	NN	O	O
is	NN	O	O
a	NN	O	O
rare	NN	O	O
complication	NN	O	O
of	NN	O	O
systemic	NN	O	B
sclerosis	NN	O	I
(	NN	O	O
SSc	NN	O	B
)	NN	O	O
but	NN	O	O
can	NN	O	O
be	NN	O	O
severe	NN	O	O
enough	NN	O	O
to	NN	O	O
require	NN	O	O
temporary	NN	O	O
or	NN	O	O
permanent	NN	O	O
renal	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
.	NN	O	O

Moderate	NN	O	O
to	NN	O	O
high	NN	O	O
dose	NN	O	O
corticosteroid	NN	O	O
use	NN	O	O
is	NN	O	O
recognized	NN	O	O
as	NN	O	O
a	NN	O	O
major	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
SRC	NN	O	B
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
there	NN	O	O
have	NN	O	O
been	NN	O	O
reports	NN	O	O
of	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
precipitated	NN	O	O
by	NN	O	O
cyclosporine	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
SSc	NN	O	B
.	NN	O	O

In	NN	O	O
this	NN	O	O
article	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
SRC	NN	O	B
induced	NN	O	O
by	NN	O	O
tacrolimus	NN	O	O
and	NN	O	O
corticosteroids	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
work	NN	O	O
is	NN	O	O
to	NN	O	O
call	NN	O	O
attention	NN	O	O
to	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
tacrolimus	NN	O	O
use	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
SSc	NN	O	B
.	NN	O	O

Methyldopa	NN	O	O
-	NN	O	O
induced	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
in	NN	O	O
a	NN	O	O
15	NN	O	O
year	NN	O	O
old	NN	O	O
presenting	NN	O	O
as	NN	O	O
near	NN	O	O
-	NN	O	O
syncope	NN	O	B
.	NN	O	O

Methyldopa	NN	O	O
is	NN	O	O
an	NN	O	O
antihypertensive	NN	O	O
medication	NN	O	O
which	NN	O	O
is	NN	O	O
available	NN	O	O
generically	NN	O	O
and	NN	O	O
under	NN	O	O
the	NN	O	O
trade	NN	O	O
name	NN	O	O
Aldomet	NN	O	O
that	NN	O	O
is	NN	O	O
widely	NN	O	O
prescribed	NN	O	O
in	NN	O	O
the	NN	O	O
adult	NN	O	O
population	NN	O	O
and	NN	O	O
infrequently	NN	O	O
used	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

Methyldopa	NN	O	O
causes	NN	O	O
an	NN	O	O
autoimmune	NN	O	B
hemolytic	NN	O	I
anemia	NN	O	I
in	NN	O	O
a	NN	O	O
small	NN	O	O
percentage	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
take	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
methyldopa	NN	O	O
-	NN	O	O
induced	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
in	NN	O	O
a	NN	O	O
15	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
who	NN	O	O
presented	NN	O	O
to	NN	O	O
the	NN	O	O
emergency	NN	O	B
department	NN	O	I
with	NN	O	O
near	NN	O	O
-	NN	O	O
syncope	NN	O	B
.	NN	O	O

The	NN	O	O
boy	NN	O	O
had	NN	O	O
been	NN	O	O
treated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
methyldopa	NN	O	O
during	NN	O	O
a	NN	O	O
trauma	NN	O	B
admission	NN	O	O
seven	NN	O	O
weeks	NN	O	O
prior	NN	O	O
to	NN	O	O
presentation	NN	O	O
.	NN	O	O

Evaluation	NN	O	O
revealed	NN	O	O
a	NN	O	O
hemoglobin	NN	O	O
of	NN	O	O
three	NN	O	O
grams	NN	O	O
,	NN	O	O
3	NN	O	O
+	NN	O	O
Coombs	NN	O	O
'	NN	O	O
test	NN	O	O
with	NN	O	O
polyspecific	NN	O	O
anti	NN	O	O
-	NN	O	O
human	NN	O	O
globulin	NN	O	O
and	NN	O	O
monospecific	NN	O	O
IgG	NN	O	O
reagents	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
warm	NN	O	O
reacting	NN	O	O
autoantibody	NN	O	O
.	NN	O	O

Transfusion	NN	O	O
and	NN	O	O
corticosteroid	NN	O	O
therapy	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
complete	NN	O	O
recovery	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
.	NN	O	O

Emergency	NN	O	O
physicians	NN	O	O
treating	NN	O	O
children	NN	O	O
must	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
syndrome	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
diagnose	NN	O	O
and	NN	O	O
treat	NN	O	O
it	NN	O	O
correctly	NN	O	O
.	NN	O	O

A	NN	O	O
brief	NN	O	O
review	NN	O	O
of	NN	O	O
autoimmune	NN	O	O
and	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hemolytic	NN	O	B
anemias	NN	O	I
is	NN	O	O
provided	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
and	NN	O	O
associated	NN	O	O
factors	NN	O	O
of	NN	O	O
methamphetamine	NN	O	O
psychosis	NN	O	B
in	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
dependent	NN	O	O
patients	NN	O	O
in	NN	O	O
Malaysia	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
lifetime	NN	O	O
and	NN	O	O
current	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
methamphetamine	NN	O	O
dependence	NN	O	O
.	NN	O	O

The	NN	O	O
association	NN	O	O
between	NN	O	O
psychiatric	NN	O	O
co	NN	O	O
-	NN	O	O
morbidity	NN	O	O
and	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B
was	NN	O	O
also	NN	O	O
studied	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
was	NN	O	O
a	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
study	NN	O	O
conducted	NN	O	O
concurrently	NN	O	O
at	NN	O	O
a	NN	O	O
teaching	NN	O	O
hospital	NN	O	O
and	NN	O	O
a	NN	O	O
drug	NN	O	O
rehabilitation	NN	O	O
center	NN	O	O
in	NN	O	O
Malaysia	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
methamphetamine	NN	O	O
based	NN	O	O
on	NN	O	O
DSM	NN	O	O
-	NN	O	O
IV	NN	O	O
were	NN	O	O
interviewed	NN	O	O
using	NN	O	O
the	NN	O	O
Mini	NN	O	O
International	NN	O	O
Neuropsychiatric	NN	O	O
Interview	NN	O	O
(	NN	O	O
M	NN	O	O
.	NN	O	O
I	NN	O	O
.	NN	O	O
N	NN	O	O
.	NN	O	O
I	NN	O	O
.	NN	O	O
)	NN	O	O
for	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B
and	NN	O	O
other	NN	O	O
Axis	NN	O	O
I	NN	O	O
psychiatric	NN	O	B
disorders	NN	O	I
.	NN	O	O

The	NN	O	O
information	NN	O	O
on	NN	O	O
sociodemographic	NN	O	O
background	NN	O	O
and	NN	O	O
drug	NN	O	O
use	NN	O	O
history	NN	O	O
was	NN	O	O
obtained	NN	O	O
from	NN	O	O
interview	NN	O	O
or	NN	O	O
medical	NN	O	O
records	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Of	NN	O	O
292	NN	O	O
subjects	NN	O	O
,	NN	O	O
47	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
subjects	NN	O	O
had	NN	O	O
a	NN	O	O
past	NN	O	O
history	NN	O	O
of	NN	O	O
psychotic	NN	O	B
symptoms	NN	O	I
and	NN	O	O
13	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
having	NN	O	O
current	NN	O	O
psychotic	NN	O	B
symptoms	NN	O	I
.	NN	O	O

Co	NN	O	O
-	NN	O	O
morbid	NN	O	O
major	NN	O	O
depressive	NN	O	B
disorder	NN	O	I
(	NN	O	O
OR	NN	O	O
=	NN	O	O
7	NN	O	O
.	NN	O	O
18	NN	O	O
,	NN	O	O
95	NN	O	O
CI	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
612	NN	O	O
-	NN	O	O
19	NN	O	O
.	NN	O	O
708	NN	O	O
)	NN	O	O
,	NN	O	O
bipolar	NN	O	B
disorder	NN	O	I
(	NN	O	O
OR	NN	O	O
=	NN	O	O
13	NN	O	O
.	NN	O	O
807	NN	O	O
,	NN	O	O
95	NN	O	O
CI	NN	O	O
=	NN	O	O
5	NN	O	O
.	NN	O	O
194	NN	O	O
-	NN	O	O
36	NN	O	O
.	NN	O	O
706	NN	O	O
)	NN	O	O
,	NN	O	O
antisocial	NN	O	B
personality	NN	O	I
disorder	NN	O	I
(	NN	O	O
OR	NN	O	O
=	NN	O	O
12	NN	O	O
.	NN	O	O
619	NN	O	O
,	NN	O	O
95	NN	O	O
CI	NN	O	O
=	NN	O	O
6	NN	O	O
.	NN	O	O
702	NN	O	O
-	NN	O	O
23	NN	O	O
.	NN	O	O
759	NN	O	O
)	NN	O	O
and	NN	O	O
heavy	NN	O	O
methamphetamine	NN	O	O
uses	NN	O	O
were	NN	O	O
significantly	NN	O	O
associated	NN	O	O
with	NN	O	O
lifetime	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B
after	NN	O	O
adjusted	NN	O	O
for	NN	O	O
other	NN	O	O
factors	NN	O	O
.	NN	O	O

Major	NN	O	B
depressive	NN	O	I
disorder	NN	O	I
(	NN	O	O
OR	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
870	NN	O	O
,	NN	O	O
CI	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
154	NN	O	O
-	NN	O	O
7	NN	O	O
.	NN	O	O
142	NN	O	O
)	NN	O	O
and	NN	O	O
antisocial	NN	O	B
personality	NN	O	I
disorder	NN	O	I
(	NN	O	O
OR	NN	O	O
=	NN	O	O
3	NN	O	O
.	NN	O	O
299	NN	O	O
,	NN	O	O
95	NN	O	O
CI	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
375	NN	O	O
-	NN	O	O
7	NN	O	O
.	NN	O	O
914	NN	O	O
)	NN	O	O
were	NN	O	O
the	NN	O	O
only	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
current	NN	O	O
psychosis	NN	O	B
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
There	NN	O	O
was	NN	O	O
a	NN	O	O
high	NN	O	O
risk	NN	O	O
of	NN	O	O
psychosis	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
methamphetamine	NN	O	O
dependence	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
co	NN	O	O
-	NN	O	O
morbid	NN	O	O
affective	NN	O	B
disorder	NN	O	I
,	NN	O	O
antisocial	NN	O	B
personality	NN	O	I
,	NN	O	O
and	NN	O	O
heavy	NN	O	O
methamphetamine	NN	O	O
use	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
recommended	NN	O	O
that	NN	O	O
all	NN	O	O
cases	NN	O	O
of	NN	O	O
methamphetamine	NN	O	O
dependence	NN	O	O
should	NN	O	O
be	NN	O	O
screened	NN	O	O
for	NN	O	O
psychotic	NN	O	B
symptoms	NN	O	I
.	NN	O	O

Cerebellar	NN	O	O
sensory	NN	O	O
processing	NN	O	O
alterations	NN	O	O
impact	NN	O	O
motor	NN	O	O
cortical	NN	O	O
plasticity	NN	O	O
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
:	NN	O	O
clues	NN	O	O
from	NN	O	O
dyskinetic	NN	O	B
patients	NN	O	O
.	NN	O	O

The	NN	O	O
plasticity	NN	O	O
of	NN	O	O
primary	NN	O	O
motor	NN	O	O
cortex	NN	O	O
(	NN	O	O
M1	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
and	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
(	NN	O	O
LIDs	NN	O	B
)	NN	O	O
is	NN	O	O
severely	NN	O	O
impaired	NN	O	O
.	NN	O	O

We	NN	O	O
recently	NN	O	O
reported	NN	O	O
in	NN	O	O
young	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
that	NN	O	O
inhibitory	NN	O	O
cerebellar	NN	O	O
stimulation	NN	O	O
enhanced	NN	O	O
the	NN	O	O
sensorimotor	NN	O	O
plasticity	NN	O	O
of	NN	O	O
M1	NN	O	O
that	NN	O	O
was	NN	O	O
induced	NN	O	O
by	NN	O	O
paired	NN	O	O
associative	NN	O	O
stimulation	NN	O	O
(	NN	O	O
PAS	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
the	NN	O	O
deficient	NN	O	O
sensorimotor	NN	O	O
M1	NN	O	O
plasticity	NN	O	O
in	NN	O	O
16	NN	O	O
patients	NN	O	O
with	NN	O	O
LIDs	NN	O	B
could	NN	O	O
be	NN	O	O
reinstated	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
session	NN	O	O
of	NN	O	O
real	NN	O	O
inhibitory	NN	O	O
cerebellar	NN	O	O
stimulation	NN	O	O
but	NN	O	O
not	NN	O	O
sham	NN	O	O
stimulation	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
evident	NN	O	O
only	NN	O	O
when	NN	O	O
a	NN	O	O
sensory	NN	O	O
component	NN	O	O
was	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
plasticity	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
cerebellar	NN	O	O
sensory	NN	O	O
processing	NN	O	O
function	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
resurgence	NN	O	O
of	NN	O	O
M1	NN	O	O
plasticity	NN	O	O
.	NN	O	O

The	NN	O	O
benefit	NN	O	O
of	NN	O	O
inhibitory	NN	O	O
cerebellar	NN	O	O
stimulation	NN	O	O
on	NN	O	O
LIDs	NN	O	B
is	NN	O	O
known	NN	O	O
.	NN	O	O

To	NN	O	O
explore	NN	O	O
whether	NN	O	O
this	NN	O	O
benefit	NN	O	O
is	NN	O	O
linked	NN	O	O
to	NN	O	O
the	NN	O	O
restoration	NN	O	O
of	NN	O	O
sensorimotor	NN	O	O
plasticity	NN	O	O
of	NN	O	O
M1	NN	O	O
,	NN	O	O
we	NN	O	O
conducted	NN	O	O
an	NN	O	O
additional	NN	O	O
study	NN	O	O
looking	NN	O	O
at	NN	O	O
changes	NN	O	O
in	NN	O	O
LIDs	NN	O	B
and	NN	O	O
PAS	NN	O	O
-	NN	O	O
induced	NN	O	O
plasticity	NN	O	O
after	NN	O	O
10	NN	O	O
sessions	NN	O	O
of	NN	O	O
either	NN	O	O
bilateral	NN	O	O
,	NN	O	O
real	NN	O	O
inhibitory	NN	O	O
cerebellar	NN	O	O
stimulation	NN	O	O
or	NN	O	O
sham	NN	O	O
stimulation	NN	O	O
.	NN	O	O

Only	NN	O	O
real	NN	O	O
and	NN	O	O
not	NN	O	O
sham	NN	O	O
stimulation	NN	O	O
had	NN	O	O
an	NN	O	O
antidyskinetic	NN	O	O
effect	NN	O	O
and	NN	O	O
it	NN	O	O
was	NN	O	O
paralleled	NN	O	O
by	NN	O	O
a	NN	O	O
resurgence	NN	O	O
in	NN	O	O
the	NN	O	O
sensorimotor	NN	O	O
plasticity	NN	O	O
of	NN	O	O
M1	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
alterations	NN	O	O
in	NN	O	O
cerebellar	NN	O	O
sensory	NN	O	O
processing	NN	O	O
function	NN	O	O
,	NN	O	O
occurring	NN	O	O
secondary	NN	O	O
to	NN	O	O
abnormal	NN	O	O
basal	NN	O	O
ganglia	NN	O	O
signals	NN	O	O
reaching	NN	O	O
it	NN	O	O
,	NN	O	O
may	NN	O	O
be	NN	O	O
an	NN	O	O
important	NN	O	O
element	NN	O	O
contributing	NN	O	O
to	NN	O	O
the	NN	O	O
maladaptive	NN	O	O
sensorimotor	NN	O	O
plasticity	NN	O	O
of	NN	O	O
M1	NN	O	O
and	NN	O	O
the	NN	O	O
emergence	NN	O	O
of	NN	O	O
abnormal	NN	O	B
involuntary	NN	O	I
movements	NN	O	I
.	NN	O	O

The	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
safety	NN	O	O
of	NN	O	O
danazol	NN	O	O
in	NN	O	O
women	NN	O	O
with	NN	O	O
hereditary	NN	O	B
angioedema	NN	O	I
.	NN	O	O

Although	NN	O	O
the	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
safety	NN	O	O
(	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
6	NN	O	O
months	NN	O	O
)	NN	O	O
of	NN	O	O
danazol	NN	O	O
has	NN	O	O
been	NN	O	O
established	NN	O	O
in	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
settings	NN	O	O
,	NN	O	O
no	NN	O	O
information	NN	O	O
exists	NN	O	O
as	NN	O	O
to	NN	O	O
its	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
safety	NN	O	O
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
investigated	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
safety	NN	O	O
of	NN	O	O
danazol	NN	O	O
by	NN	O	O
performing	NN	O	O
a	NN	O	O
retrospective	NN	O	O
chart	NN	O	O
review	NN	O	O
of	NN	O	O
60	NN	O	O
female	NN	O	O
patients	NN	O	O
with	NN	O	O
hereditary	NN	O	B
angioedema	NN	O	I
treated	NN	O	O
with	NN	O	O
danazol	NN	O	O
for	NN	O	O
a	NN	O	O
continuous	NN	O	O
period	NN	O	O
of	NN	O	O
6	NN	O	O
months	NN	O	O
or	NN	O	O
longer	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
age	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
was	NN	O	O
35	NN	O	O
.	NN	O	O
2	NN	O	O
years	NN	O	O
and	NN	O	O
the	NN	O	O
mean	NN	O	O
duration	NN	O	O
of	NN	O	O
therapy	NN	O	O
was	NN	O	O
59	NN	O	O
.	NN	O	O
7	NN	O	O
months	NN	O	O
.	NN	O	O

Virtually	NN	O	O
all	NN	O	O
patients	NN	O	O
experienced	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
.	NN	O	O

Menstrual	NN	O	B
abnormalities	NN	O	I
(	NN	O	O
79	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
weight	NN	O	B
gain	NN	O	I
(	NN	O	O
60	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
muscle	NN	O	B
cramps	NN	O	I
/	NN	O	O
myalgias	NN	O	B
(	NN	O	O
40	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
transaminase	NN	O	O
elevations	NN	O	O
(	NN	O	O
40	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
.	NN	O	O

The	NN	O	O
drug	NN	O	O
was	NN	O	O
discontinued	NN	O	O
due	NN	O	O
to	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
in	NN	O	O
8	NN	O	O
patients	NN	O	O
.	NN	O	O

No	NN	O	O
patient	NN	O	O
has	NN	O	O
died	NN	O	O
or	NN	O	O
suffered	NN	O	O
any	NN	O	O
apparent	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
sequelae	NN	O	O
that	NN	O	O
were	NN	O	O
directly	NN	O	O
attributable	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
,	NN	O	O
despite	NN	O	O
a	NN	O	O
relatively	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
,	NN	O	O
danazol	NN	O	O
has	NN	O	O
proven	NN	O	O
to	NN	O	O
be	NN	O	O
remarkably	NN	O	O
safe	NN	O	O
over	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
in	NN	O	O
this	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
function	NN	O	O
of	NN	O	O
P2X3	NN	O	O
receptor	NN	O	O
and	NN	O	O
NK1	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
on	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
explore	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
P2X3	NN	O	O
and	NN	O	O
NK1	NN	O	O
receptors	NN	O	O
antagonists	NN	O	O
on	NN	O	O
cyclophosphamide	NN	O	O
(	NN	O	O
CYP	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Sixty	NN	O	O
female	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
(	NN	O	O
SD	NN	O	O
)	NN	O	O
rats	NN	O	O
were	NN	O	O
randomly	NN	O	O
divided	NN	O	O
into	NN	O	O
three	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
rats	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
were	NN	O	O
intraperitoneally	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
injected	NN	O	O
with	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
saline	NN	O	O
(	NN	O	O
4	NN	O	O
ml	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
;	NN	O	O
the	NN	O	O
rats	NN	O	O
in	NN	O	O
the	NN	O	O
model	NN	O	O
group	NN	O	O
were	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
injected	NN	O	O
with	NN	O	O
CYP	NN	O	O
(	NN	O	O
150	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
;	NN	O	O
and	NN	O	O
the	NN	O	O
rats	NN	O	O
in	NN	O	O
the	NN	O	O
intervention	NN	O	O
group	NN	O	O
were	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
injected	NN	O	O
with	NN	O	O
CYP	NN	O	O
with	NN	O	O
subsequently	NN	O	O
perfusion	NN	O	O
of	NN	O	O
bladder	NN	O	O
with	NN	O	O
P2X3	NN	O	O
and	NN	O	O
NK1	NN	O	O
receptors	NN	O	O
'	NN	O	O
antagonists	NN	O	O
,	NN	O	O
Suramin	NN	O	O
and	NN	O	O
GR	NN	O	O
82334	NN	O	O
.	NN	O	O

Spontaneous	NN	O	O
pain	NN	O	B
behaviors	NN	O	O
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
CYP	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

Urodynamic	NN	O	O
parameters	NN	O	O
,	NN	O	O
bladder	NN	O	O
pressure	NN	O	O
-	NN	O	O
volume	NN	O	O
curve	NN	O	O
,	NN	O	O
maximum	NN	O	O
voiding	NN	O	O
pressure	NN	O	O
(	NN	O	O
MVP	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
maximum	NN	O	O
cystometric	NN	O	O
capacity	NN	O	O
(	NN	O	O
MCC	NN	O	O
)	NN	O	O
,	NN	O	O
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

Pathological	NN	O	O
changes	NN	O	O
in	NN	O	O
bladder	NN	O	O
tissue	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

Immunofluorescence	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
detect	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
P2X3	NN	O	O
and	NN	O	O
NK1	NN	O	O
receptors	NN	O	O
in	NN	O	O
bladder	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Cyclophosphamide	NN	O	O
treatment	NN	O	O
increased	NN	O	O
the	NN	O	O
spontaneous	NN	O	O
pain	NN	O	B
behaviors	NN	O	O
scores	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
bladder	NN	O	O
instability	NN	O	O
during	NN	O	O
urine	NN	O	O
storage	NN	O	O
period	NN	O	O
of	NN	O	O
model	NN	O	O
group	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
intervention	NN	O	O
group	NN	O	O
(	NN	O	O
X	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
=	NN	O	O
7	NN	O	O
.	NN	O	O
619	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
007	NN	O	O
)	NN	O	O
and	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
X	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
=	NN	O	O
13	NN	O	O
.	NN	O	O
755	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
000	NN	O	O
)	NN	O	O
.	NN	O	O

MCC	NN	O	O
in	NN	O	O
the	NN	O	O
model	NN	O	O
group	NN	O	O
was	NN	O	O
lower	NN	O	O
than	NN	O	O
the	NN	O	O
control	NN	O	O
and	NN	O	O
intervention	NN	O	O
groups	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Histological	NN	O	O
changes	NN	O	O
evident	NN	O	O
in	NN	O	O
model	NN	O	O
and	NN	O	O
intervention	NN	O	O
groups	NN	O	O
rats	NN	O	O
'	NN	O	O
bladder	NN	O	O
included	NN	O	O
edema	NN	O	B
,	NN	O	O
vasodilation	NN	O	O
,	NN	O	O
and	NN	O	O
infiltration	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
cells	NN	O	O
.	NN	O	O

In	NN	O	O
model	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
P2X3	NN	O	O
receptor	NN	O	O
increased	NN	O	O
in	NN	O	O
urothelium	NN	O	O
and	NN	O	O
suburothelium	NN	O	O
,	NN	O	O
and	NN	O	O
NK1	NN	O	O
receptor	NN	O	O
increased	NN	O	O
in	NN	O	O
suburothelium	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
them	NN	O	O
in	NN	O	O
intervention	NN	O	O
group	NN	O	O
was	NN	O	O
lower	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
CYP	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
,	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
P2X3	NN	O	O
and	NN	O	O
NK1	NN	O	O
receptors	NN	O	O
increased	NN	O	O
in	NN	O	O
urothelium	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
suburothelium	NN	O	O
.	NN	O	O

Perfusion	NN	O	O
of	NN	O	O
bladder	NN	O	O
with	NN	O	O
P2X3	NN	O	O
and	NN	O	O
NK1	NN	O	O
receptors	NN	O	O
antagonists	NN	O	O
ameliorated	NN	O	O
the	NN	O	O
bladder	NN	O	O
function	NN	O	O
.	NN	O	O

Patient	NN	O	O
tolerance	NN	O	O
study	NN	O	O
of	NN	O	O
topical	NN	O	O
chlorhexidine	NN	O	O
diphosphanilate	NN	O	O
:	NN	O	O
a	NN	O	O
new	NN	O	O
topical	NN	O	O
agent	NN	O	O
for	NN	O	O
burns	NN	O	B
.	NN	O	O

Effective	NN	O	O
topical	NN	O	O
antimicrobial	NN	O	O
agents	NN	O	O
decrease	NN	O	O
infection	NN	O	B
and	NN	O	O
mortality	NN	O	O
in	NN	O	O
burn	NN	O	B
patients	NN	O	O
.	NN	O	O

Chlorhexidine	NN	O	O
phosphanilate	NN	O	O
(	NN	O	O
CHP	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
new	NN	O	O
broad	NN	O	O
-	NN	O	O
spectrum	NN	O	O
antimicrobial	NN	O	O
agent	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
evaluated	NN	O	O
as	NN	O	O
a	NN	O	O
topical	NN	O	O
burn	NN	O	B
wound	NN	O	O
dressing	NN	O	O
in	NN	O	O
cream	NN	O	O
form	NN	O	O
,	NN	O	O
but	NN	O	O
preliminary	NN	O	O
clinical	NN	O	O
trials	NN	O	O
reported	NN	O	O
that	NN	O	O
it	NN	O	O
was	NN	O	O
painful	NN	O	O
upon	NN	O	O
application	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
compared	NN	O	O
various	NN	O	O
concentrations	NN	O	O
of	NN	O	O
CHP	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
a	NN	O	O
tolerable	NN	O	O
concentration	NN	O	O
could	NN	O	O
be	NN	O	O
identified	NN	O	O
with	NN	O	O
retention	NN	O	O
of	NN	O	O
antimicrobial	NN	O	O
efficacy	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
nine	NN	O	O
burn	NN	O	B
patients	NN	O	O
,	NN	O	O
each	NN	O	O
with	NN	O	O
two	NN	O	O
similar	NN	O	O
burns	NN	O	B
which	NN	O	O
could	NN	O	O
be	NN	O	O
separately	NN	O	O
treated	NN	O	O
,	NN	O	O
were	NN	O	O
given	NN	O	O
pairs	NN	O	O
of	NN	O	O
treatments	NN	O	O
at	NN	O	O
successive	NN	O	O
12	NN	O	O
-	NN	O	O
h	NN	O	O
intervals	NN	O	O
over	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
day	NN	O	O
period	NN	O	O
.	NN	O	O

One	NN	O	O
burn	NN	O	B
site	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
each	NN	O	O
of	NN	O	O
four	NN	O	O
different	NN	O	O
CHP	NN	O	O
concentrations	NN	O	O
,	NN	O	O
from	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
per	NN	O	O
cent	NN	O	O
to	NN	O	O
2	NN	O	O
per	NN	O	O
cent	NN	O	O
,	NN	O	O
their	NN	O	O
vehicle	NN	O	O
,	NN	O	O
and	NN	O	O
1	NN	O	O
per	NN	O	O
cent	NN	O	O
silver	NN	O	O
sulphadiazine	NN	O	O
(	NN	O	O
AgSD	NN	O	O
)	NN	O	O
cream	NN	O	O
,	NN	O	O
an	NN	O	O
antimicrobial	NN	O	O
agent	NN	O	O
frequently	NN	O	O
used	NN	O	O
for	NN	O	O
topical	NN	O	O
treatment	NN	O	O
of	NN	O	O
burn	NN	O	B
wounds	NN	O	O
.	NN	O	O

The	NN	O	O
other	NN	O	O
site	NN	O	O
was	NN	O	O
always	NN	O	O
treated	NN	O	O
with	NN	O	O
AgSD	NN	O	O
cream	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
direct	NN	O	O
relationship	NN	O	O
between	NN	O	O
CHP	NN	O	O
concentration	NN	O	O
and	NN	O	O
patients	NN	O	O
'	NN	O	O
ratings	NN	O	O
of	NN	O	O
pain	NN	O	B
on	NN	O	O
an	NN	O	O
analogue	NN	O	O
scale	NN	O	O
.	NN	O	O

The	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
per	NN	O	O
cent	NN	O	O
CHP	NN	O	O
cream	NN	O	O
was	NN	O	O
closest	NN	O	O
to	NN	O	O
AgSD	NN	O	O
in	NN	O	O
pain	NN	O	B
tolerance	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
treatments	NN	O	O
differed	NN	O	O
statistically	NN	O	O
from	NN	O	O
AgSD	NN	O	O
or	NN	O	O
from	NN	O	O
each	NN	O	O
other	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
ease	NN	O	O
of	NN	O	O
application	NN	O	O
of	NN	O	O
CHP	NN	O	O
creams	NN	O	O
was	NN	O	O
less	NN	O	O
satisfactory	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
AgSD	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
concluded	NN	O	O
that	NN	O	O
formulations	NN	O	O
at	NN	O	O
or	NN	O	O
below	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
per	NN	O	O
cent	NN	O	O
CHP	NN	O	O
may	NN	O	O
prove	NN	O	O
acceptable	NN	O	O
for	NN	O	O
wound	NN	O	O
care	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
vehicle	NN	O	O
system	NN	O	O
needs	NN	O	O
pharmaceutical	NN	O	O
improvement	NN	O	O
to	NN	O	O
render	NN	O	O
it	NN	O	O
more	NN	O	O
tolerable	NN	O	O
and	NN	O	O
easier	NN	O	O
to	NN	O	O
use	NN	O	O
.	NN	O	O

Acute	NN	O	O
hepatitis	NN	O	B
associated	NN	O	O
with	NN	O	O
clopidogrel	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
and	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatotoxicity	NN	O	B
is	NN	O	O
a	NN	O	O
common	NN	O	O
cause	NN	O	O
of	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
,	NN	O	O
and	NN	O	O
the	NN	O	O
recognition	NN	O	O
of	NN	O	O
the	NN	O	O
responsible	NN	O	O
drug	NN	O	O
may	NN	O	O
be	NN	O	O
difficult	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
clopidogrel	NN	O	O
-	NN	O	O
related	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

The	NN	O	O
diagnosis	NN	O	O
is	NN	O	O
strongly	NN	O	O
suggested	NN	O	O
by	NN	O	O
an	NN	O	O
accurate	NN	O	O
medical	NN	O	O
history	NN	O	O
and	NN	O	O
liver	NN	O	O
biopsy	NN	O	O
.	NN	O	O

Reports	NN	O	O
about	NN	O	O
cases	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B
due	NN	O	O
to	NN	O	O
clopidogrel	NN	O	O
are	NN	O	O
increasing	NN	O	O
in	NN	O	O
the	NN	O	O
last	NN	O	O
few	NN	O	O
years	NN	O	O
,	NN	O	O
after	NN	O	O
the	NN	O	O
increased	NN	O	O
use	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
we	NN	O	O
believe	NN	O	O
that	NN	O	O
physicians	NN	O	O
should	NN	O	O
carefully	NN	O	O
consider	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatic	NN	O	B
injury	NN	O	I
when	NN	O	O
clopidogrel	NN	O	O
is	NN	O	O
prescribed	NN	O	O
.	NN	O	O

Bortezomib	NN	O	O
and	NN	O	O
dexamethasone	NN	O	O
as	NN	O	O
salvage	NN	O	O
therapy	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
relapsed	NN	O	O
/	NN	O	O
refractory	NN	O	O
multiple	NN	O	B
myeloma	NN	O	I
:	NN	O	O
analysis	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
clinical	NN	O	O
outcomes	NN	O	O
.	NN	O	O

Bortezomib	NN	O	O
(	NN	O	O
bort	NN	O	O
)	NN	O	O
-	NN	O	O
dexamethasone	NN	O	O
(	NN	O	O
dex	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
therapy	NN	O	O
for	NN	O	O
relapsed	NN	O	O
/	NN	O	O
refractory	NN	O	O
(	NN	O	O
R	NN	O	O
/	NN	O	O
R	NN	O	O
)	NN	O	O
multiple	NN	O	B
myeloma	NN	O	I
(	NN	O	O
MM	NN	O	B
)	NN	O	O
.	NN	O	O

This	NN	O	O
retrospective	NN	O	O
study	NN	O	O
investigated	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
bort	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
and	NN	O	O
11	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
)	NN	O	O
and	NN	O	O
dex	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
on	NN	O	O
the	NN	O	O
day	NN	O	O
of	NN	O	O
and	NN	O	O
the	NN	O	O
day	NN	O	O
after	NN	O	O
bort	NN	O	O
)	NN	O	O
as	NN	O	O
salvage	NN	O	O
treatment	NN	O	O
in	NN	O	O
85	NN	O	O
patients	NN	O	O
with	NN	O	O
R	NN	O	O
/	NN	O	O
R	NN	O	O
MM	NN	O	B
after	NN	O	O
prior	NN	O	O
autologous	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
or	NN	O	O
conventional	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
number	NN	O	O
of	NN	O	O
prior	NN	O	O
lines	NN	O	O
of	NN	O	O
therapy	NN	O	O
was	NN	O	O
2	NN	O	O
.	NN	O	O

Eighty	NN	O	O
-	NN	O	O
seven	NN	O	O
percent	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
had	NN	O	O
received	NN	O	O
immunomodulatory	NN	O	O
drugs	NN	O	O
included	NN	O	O
in	NN	O	O
some	NN	O	O
line	NN	O	O
of	NN	O	O
therapy	NN	O	O
before	NN	O	O
bort	NN	O	O
-	NN	O	O
dex	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
number	NN	O	O
of	NN	O	O
bort	NN	O	O
-	NN	O	O
dex	NN	O	O
cycles	NN	O	O
was	NN	O	O
6	NN	O	O
,	NN	O	O
up	NN	O	O
to	NN	O	O
a	NN	O	O
maximum	NN	O	O
of	NN	O	O
12	NN	O	O
cycles	NN	O	O
.	NN	O	O

On	NN	O	O
an	NN	O	O
intention	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
treat	NN	O	O
basis	NN	O	O
,	NN	O	O
55	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
achieved	NN	O	O
at	NN	O	O
least	NN	O	O
partial	NN	O	O
response	NN	O	O
,	NN	O	O
including	NN	O	O
19	NN	O	O
%	NN	O	O
CR	NN	O	O
and	NN	O	O
35	NN	O	O
%	NN	O	O
achieved	NN	O	O
at	NN	O	O
least	NN	O	O
very	NN	O	O
good	NN	O	O
partial	NN	O	O
response	NN	O	O
.	NN	O	O

Median	NN	O	O
durations	NN	O	O
of	NN	O	O
response	NN	O	O
,	NN	O	O
time	NN	O	O
to	NN	O	O
next	NN	O	O
therapy	NN	O	O
and	NN	O	O
treatment	NN	O	O
-	NN	O	O
free	NN	O	O
interval	NN	O	O
were	NN	O	O
8	NN	O	O
,	NN	O	O
11	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
and	NN	O	O
5	NN	O	O
.	NN	O	O
1	NN	O	O
months	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
relevant	NN	O	O
adverse	NN	O	O
event	NN	O	O
was	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
,	NN	O	O
which	NN	O	O
occurred	NN	O	O
in	NN	O	O
78	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
(	NN	O	O
grade	NN	O	O
II	NN	O	O
,	NN	O	O
38	NN	O	O
%	NN	O	O
;	NN	O	O
grade	NN	O	O
III	NN	O	O
,	NN	O	O
21	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
led	NN	O	O
to	NN	O	O
treatment	NN	O	O
discontinuation	NN	O	O
in	NN	O	O
6	NN	O	O
%	NN	O	O
.	NN	O	O

With	NN	O	O
a	NN	O	O
median	NN	O	O
follow	NN	O	O
up	NN	O	O
of	NN	O	O
22	NN	O	O
months	NN	O	O
,	NN	O	O
median	NN	O	O
time	NN	O	O
to	NN	O	O
progression	NN	O	O
,	NN	O	O
progression	NN	O	O
-	NN	O	O
free	NN	O	O
survival	NN	O	O
(	NN	O	O
PFS	NN	O	O
)	NN	O	O
and	NN	O	O
overall	NN	O	O
survival	NN	O	O
(	NN	O	O
OS	NN	O	O
)	NN	O	O
were	NN	O	O
8	NN	O	O
.	NN	O	O
9	NN	O	O
,	NN	O	O
8	NN	O	O
.	NN	O	O
7	NN	O	O
,	NN	O	O
and	NN	O	O
22	NN	O	O
months	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Prolonged	NN	O	O
PFS	NN	O	O
and	NN	O	O
OS	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
achieving	NN	O	O
CR	NN	O	O
and	NN	O	O
receiving	NN	O	O
bort	NN	O	O
-	NN	O	O
dex	NN	O	O
a	NN	O	O
single	NN	O	O
line	NN	O	O
of	NN	O	O
prior	NN	O	O
therapy	NN	O	O
.	NN	O	O

Bort	NN	O	O
-	NN	O	O
dex	NN	O	O
was	NN	O	O
an	NN	O	O
effective	NN	O	O
salvage	NN	O	O
treatment	NN	O	O
for	NN	O	O
MM	NN	O	B
patients	NN	O	O
,	NN	O	O
particularly	NN	O	O
for	NN	O	O
those	NN	O	O
in	NN	O	O
first	NN	O	O
relapse	NN	O	O
.	NN	O	O

Pubertal	NN	O	O
exposure	NN	O	O
to	NN	O	O
Bisphenol	NN	O	O
A	NN	O	O
increases	NN	O	O
anxiety	NN	O	B
-	NN	O	O
like	NN	O	O
behavior	NN	O	O
and	NN	O	O
decreases	NN	O	O
acetylcholinesterase	NN	O	O
activity	NN	O	O
of	NN	O	O
hippocampus	NN	O	O
in	NN	O	O
adult	NN	O	O
male	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
negative	NN	O	O
effects	NN	O	O
of	NN	O	O
Bisphenol	NN	O	O
A	NN	O	O
(	NN	O	O
BPA	NN	O	O
)	NN	O	O
on	NN	O	O
neurodevelopment	NN	O	O
and	NN	O	O
behaviors	NN	O	O
have	NN	O	O
been	NN	O	O
well	NN	O	O
established	NN	O	O
.	NN	O	O

Acetylcholinesterase	NN	O	O
(	NN	O	O
AChE	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
regulatory	NN	O	O
enzyme	NN	O	O
which	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
anxiety	NN	O	B
-	NN	O	O
like	NN	O	O
behavior	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
investigated	NN	O	O
behavioral	NN	O	O
phenotypes	NN	O	O
and	NN	O	O
AChE	NN	O	O
activity	NN	O	O
in	NN	O	O
male	NN	O	O
mice	NN	O	O
following	NN	O	O
BPA	NN	O	O
exposure	NN	O	O
during	NN	O	O
puberty	NN	O	O
.	NN	O	O

On	NN	O	O
postnatal	NN	O	O
day	NN	O	O
(	NN	O	O
PND	NN	O	O
)	NN	O	O
35	NN	O	O
,	NN	O	O
male	NN	O	O
mice	NN	O	O
were	NN	O	O
exposed	NN	O	O
to	NN	O	O
50mg	NN	O	O
BPA	NN	O	O
/	NN	O	O
kg	NN	O	O
diet	NN	O	O
per	NN	O	O
day	NN	O	O
for	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
35	NN	O	O
days	NN	O	O
.	NN	O	O

On	NN	O	O
PND71	NN	O	O
,	NN	O	O
a	NN	O	O
behavioral	NN	O	O
assay	NN	O	O
was	NN	O	O
performed	NN	O	O
using	NN	O	O
the	NN	O	O
elevated	NN	O	O
plus	NN	O	O
maze	NN	O	O
(	NN	O	O
EPM	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
light	NN	O	O
/	NN	O	O
dark	NN	O	O
test	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
AChE	NN	O	O
activity	NN	O	O
was	NN	O	O
measured	NN	O	O
in	NN	O	O
the	NN	O	O
prefrontal	NN	O	O
cortex	NN	O	O
,	NN	O	O
hypothalamus	NN	O	O
,	NN	O	O
cerebellum	NN	O	O
and	NN	O	O
hippocampus	NN	O	O
.	NN	O	O

Results	NN	O	O
from	NN	O	O
our	NN	O	O
behavioral	NN	O	O
phenotyping	NN	O	O
indicated	NN	O	O
that	NN	O	O
anxiety	NN	O	B
-	NN	O	O
like	NN	O	O
behavior	NN	O	O
was	NN	O	O
increased	NN	O	O
in	NN	O	O
mice	NN	O	O
exposed	NN	O	O
to	NN	O	O
BPA	NN	O	O
.	NN	O	O

AChE	NN	O	O
activity	NN	O	O
was	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
of	NN	O	O
mice	NN	O	O
with	NN	O	O
BPA	NN	O	O
compared	NN	O	O
to	NN	O	O
control	NN	O	O
mice	NN	O	O
,	NN	O	O
whereas	NN	O	O
no	NN	O	O
difference	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
prefrontal	NN	O	O
cortex	NN	O	O
,	NN	O	O
hypothalamus	NN	O	O
and	NN	O	O
cerebellum	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
showed	NN	O	O
that	NN	O	O
pubertal	NN	O	O
BPA	NN	O	O
exposure	NN	O	O
increased	NN	O	O
anxiety	NN	O	B
-	NN	O	O
like	NN	O	O
behavior	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
decreased	NN	O	O
AChE	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
in	NN	O	O
adult	NN	O	O
male	NN	O	O
mice	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
are	NN	O	O
necessary	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
cholinergic	NN	O	O
signaling	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
in	NN	O	O
PBE	NN	O	O
induced	NN	O	O
anxiety	NN	O	B
-	NN	O	O
like	NN	O	O
behaviors	NN	O	O
.	NN	O	O

Biochemical	NN	O	O
effects	NN	O	O
of	NN	O	O
Solidago	NN	O	O
virgaurea	NN	O	O
extract	NN	O	O
on	NN	O	O
experimental	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Cardiovascular	NN	O	B
diseases	NN	O	I
(	NN	O	O
CVDs	NN	O	B
)	NN	O	O
are	NN	O	O
the	NN	O	O
major	NN	O	O
health	NN	O	O
problem	NN	O	O
of	NN	O	O
advanced	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
developing	NN	O	O
countries	NN	O	O
of	NN	O	O
the	NN	O	O
world	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
Solidago	NN	O	O
virgaurea	NN	O	O
extract	NN	O	O
on	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
subcutaneous	NN	O	O
injection	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
into	NN	O	O
rats	NN	O	O
twice	NN	O	O
at	NN	O	O
an	NN	O	O
interval	NN	O	O
of	NN	O	O
24	NN	O	O
h	NN	O	O
,	NN	O	O
for	NN	O	O
two	NN	O	O
consecutive	NN	O	O
days	NN	O	O
,	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
serum	NN	O	O
lactate	NN	O	O
dehydrogenase	NN	O	O
,	NN	O	O
creatine	NN	O	O
phosphokinase	NN	O	O
,	NN	O	O
alanine	NN	O	O
transaminase	NN	O	O
,	NN	O	O
aspartate	NN	O	O
transaminase	NN	O	O
,	NN	O	O
and	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
activities	NN	O	O
,	NN	O	O
total	NN	O	O
cholesterol	NN	O	O
,	NN	O	O
triglycerides	NN	O	O
,	NN	O	O
free	NN	O	O
serum	NN	O	O
fatty	NN	O	O
acid	NN	O	O
,	NN	O	O
cardiac	NN	O	O
tissue	NN	O	O
malondialdehyde	NN	O	O
(	NN	O	O
MDA	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
levels	NN	O	O
and	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
levels	NN	O	O
of	NN	O	O
glutathione	NN	O	O
and	NN	O	O
superoxide	NN	O	O
dismutase	NN	O	O
in	NN	O	O
cardiac	NN	O	O
tissue	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
normal	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
S	NN	O	O
.	NN	O	O
virgaurea	NN	O	O
extract	NN	O	O
for	NN	O	O
5	NN	O	O
weeks	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
followed	NN	O	O
by	NN	O	O
isoproterenol	NN	O	O
injection	NN	O	O
significantly	NN	O	O
prevented	NN	O	O
the	NN	O	O
observed	NN	O	O
alterations	NN	O	O
.	NN	O	O

Captopril	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
given	NN	O	O
orally	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
standard	NN	O	O
cardioprotective	NN	O	O
drug	NN	O	O
,	NN	O	O
was	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
positive	NN	O	O
control	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
suggest	NN	O	O
that	NN	O	O
S	NN	O	O
.	NN	O	O
virgaurea	NN	O	O
extract	NN	O	O
exerts	NN	O	O
its	NN	O	O
protective	NN	O	O
effect	NN	O	O
by	NN	O	O
decreasing	NN	O	O
MDA	NN	O	O
level	NN	O	O
and	NN	O	O
increasing	NN	O	O
the	NN	O	O
antioxidant	NN	O	O
status	NN	O	O
in	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
emphasizes	NN	O	O
the	NN	O	O
beneficial	NN	O	O
action	NN	O	O
of	NN	O	O
S	NN	O	O
.	NN	O	O
virgaurea	NN	O	O
extract	NN	O	O
as	NN	O	O
a	NN	O	O
cardioprotective	NN	O	O
agent	NN	O	O
.	NN	O	O

"	NN	O	O
Real	NN	O	O
-	NN	O	O
world	NN	O	O
"	NN	O	O
data	NN	O	O
on	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
lenalidomide	NN	O	O
and	NN	O	O
dexamethasone	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
relapsed	NN	O	O
/	NN	O	O
refractory	NN	O	O
multiple	NN	O	B
myeloma	NN	O	I
who	NN	O	O
were	NN	O	O
treated	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
standard	NN	O	O
clinical	NN	O	O
practice	NN	O	O
:	NN	O	O
a	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
Greek	NN	O	O
Myeloma	NN	O	B
Study	NN	O	O
Group	NN	O	O
.	NN	O	O

Lenalidomide	NN	O	O
and	NN	O	O
dexamethasone	NN	O	O
(	NN	O	O
RD	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
standard	NN	O	O
of	NN	O	O
care	NN	O	O
for	NN	O	O
relapsed	NN	O	O
/	NN	O	O
refractory	NN	O	O
multiple	NN	O	B
myeloma	NN	O	I
(	NN	O	O
RRMM	NN	O	B
)	NN	O	O
,	NN	O	O
but	NN	O	O
there	NN	O	O
is	NN	O	O
limited	NN	O	O
published	NN	O	O
data	NN	O	O
on	NN	O	O
its	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
in	NN	O	O
the	NN	O	O
"	NN	O	O
real	NN	O	O
world	NN	O	O
"	NN	O	O
(	NN	O	O
RW	NN	O	O
)	NN	O	O
,	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
International	NN	O	O
Society	NN	O	O
of	NN	O	O
Pharmacoeconomics	NN	O	O
and	NN	O	O
Outcomes	NN	O	O
Research	NN	O	O
definition	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
212	NN	O	O
RRMM	NN	O	B
patients	NN	O	O
who	NN	O	O
received	NN	O	O
RD	NN	O	O
in	NN	O	O
RW	NN	O	O
.	NN	O	O

Objective	NN	O	O
response	NN	O	O
(	NN	O	O
>	NN	O	O
PR	NN	O	O
(	NN	O	O
partial	NN	O	O
response	NN	O	O
)	NN	O	O
)	NN	O	O
rate	NN	O	O
was	NN	O	O
77	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
(	NN	O	O
complete	NN	O	O
response	NN	O	O
(	NN	O	O
CR	NN	O	O
)	NN	O	O
,	NN	O	O
20	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Median	NN	O	O
time	NN	O	O
to	NN	O	O
first	NN	O	O
and	NN	O	O
best	NN	O	O
response	NN	O	O
was	NN	O	O
2	NN	O	O
and	NN	O	O
5	NN	O	O
months	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Median	NN	O	O
time	NN	O	O
to	NN	O	O
CR	NN	O	O
when	NN	O	O
RD	NN	O	O
was	NN	O	O
given	NN	O	O
as	NN	O	O
2nd	NN	O	O
or	NN	O	O
>	NN	O	O
2	NN	O	O
(	NN	O	O
nd	NN	O	O
)	NN	O	O
-	NN	O	O
line	NN	O	O
treatment	NN	O	O
at	NN	O	O
4	NN	O	O
and	NN	O	O
11	NN	O	O
months	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Quality	NN	O	O
of	NN	O	O
response	NN	O	O
was	NN	O	O
independent	NN	O	O
of	NN	O	O
previous	NN	O	O
lines	NN	O	O
of	NN	O	O
therapies	NN	O	O
or	NN	O	O
previous	NN	O	O
exposure	NN	O	O
to	NN	O	O
thalidomide	NN	O	O
or	NN	O	O
bortezomib	NN	O	O
.	NN	O	O

Median	NN	O	O
duration	NN	O	O
of	NN	O	O
response	NN	O	O
was	NN	O	O
34	NN	O	O
.	NN	O	O
4	NN	O	O
months	NN	O	O
,	NN	O	O
and	NN	O	O
it	NN	O	O
was	NN	O	O
higher	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
RD	NN	O	O
until	NN	O	O
progression	NN	O	O
(	NN	O	O
not	NN	O	O
reached	NN	O	O
versus	NN	O	O
19	NN	O	O
months	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Improvement	NN	O	O
of	NN	O	O
humoral	NN	O	O
immunity	NN	O	O
occurred	NN	O	O
in	NN	O	O
60	NN	O	O
%	NN	O	O
of	NN	O	O
responders	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
majority	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
achieved	NN	O	O
stable	NN	O	O
disease	NN	O	O
.	NN	O	O

Adverse	NN	O	O
events	NN	O	O
were	NN	O	O
reported	NN	O	O
in	NN	O	O
68	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
(	NN	O	O
myelosuppression	NN	O	B
in	NN	O	O
49	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
12	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
needed	NN	O	O
hospitalization	NN	O	O
.	NN	O	O

Peripheral	NN	O	B
neuropathy	NN	O	I
was	NN	O	O
observed	NN	O	O
only	NN	O	O
in	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
and	NN	O	O
deep	NN	O	B
vein	NN	O	I
thrombosis	NN	O	I
in	NN	O	O
5	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
.	NN	O	O

Dose	NN	O	O
reductions	NN	O	O
were	NN	O	O
needed	NN	O	O
in	NN	O	O
31	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
and	NN	O	O
permanent	NN	O	O
discontinuation	NN	O	O
in	NN	O	O
38	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
.	NN	O	O

Median	NN	O	O
time	NN	O	O
to	NN	O	O
treatment	NN	O	O
discontinuation	NN	O	O
was	NN	O	O
16	NN	O	O
.	NN	O	O
8	NN	O	O
months	NN	O	O
.	NN	O	O

Performance	NN	O	O
status	NN	O	O
(	NN	O	O
PS	NN	O	O
)	NN	O	O
and	NN	O	O
initial	NN	O	O
lenalidomide	NN	O	O
dose	NN	O	O
predicted	NN	O	O
for	NN	O	O
treatment	NN	O	O
discontinuation	NN	O	O
.	NN	O	O

Extra	NN	O	O
-	NN	O	O
medullary	NN	O	O
relapses	NN	O	O
occurred	NN	O	O
in	NN	O	O
3	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Our	NN	O	O
study	NN	O	O
confirms	NN	O	O
that	NN	O	O
RD	NN	O	O
is	NN	O	O
effective	NN	O	O
and	NN	O	O
safe	NN	O	O
in	NN	O	O
RRMM	NN	O	B
in	NN	O	O
the	NN	O	O
RW	NN	O	O
;	NN	O	O
it	NN	O	O
produces	NN	O	O
durable	NN	O	O
responses	NN	O	O
especially	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
continue	NN	O	O
on	NN	O	O
treatment	NN	O	O
till	NN	O	O
progression	NN	O	O
and	NN	O	O
improves	NN	O	O
humoral	NN	O	O
immunity	NN	O	O
even	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
stable	NN	O	O
disease	NN	O	O
.	NN	O	O

The	NN	O	O
cytogenetic	NN	O	O
action	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
,	NN	O	O
mesna	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
combination	NN	O	O
on	NN	O	O
peripheral	NN	O	O
rabbit	NN	O	O
lymphocytes	NN	O	O
:	NN	O	O
an	NN	O	O
in	NN	O	O
vivo	NN	O	O
/	NN	O	O
in	NN	O	O
vitro	NN	O	O
cytogenetic	NN	O	O
study	NN	O	O
.	NN	O	O

Ifosfamide	NN	O	O
(	NN	O	O
IFO	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
alkylating	NN	O	O
nitrogen	NN	O	O
mustard	NN	O	O
,	NN	O	O
administrated	NN	O	O
as	NN	O	O
an	NN	O	O
antineoplasmic	NN	O	O
agent	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
its	NN	O	O
intense	NN	O	O
urotoxic	NN	O	O
action	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
hemorrhagic	NN	O	B
cystitis	NN	O	I
.	NN	O	O

This	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
IFO	NN	O	O
raises	NN	O	O
the	NN	O	O
requirement	NN	O	O
for	NN	O	O
the	NN	O	O
co	NN	O	O
-	NN	O	O
administration	NN	O	O
with	NN	O	O
sodium	NN	O	O
2	NN	O	O
-	NN	O	O
sulfanylethanesulfonate	NN	O	O
(	NN	O	O
Mesna	NN	O	O
)	NN	O	O
aiming	NN	O	O
to	NN	O	O
avoid	NN	O	O
or	NN	O	O
minimize	NN	O	O
this	NN	O	O
effect	NN	O	O
.	NN	O	O

IFO	NN	O	O
and	NN	O	O
Mesna	NN	O	O
were	NN	O	O
administrated	NN	O	O
separately	NN	O	O
on	NN	O	O
rabbit	NN	O	O
'	NN	O	O
s	NN	O	O
lymphocytes	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
later	NN	O	O
developed	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

Cytogenetic	NN	O	O
markers	NN	O	O
for	NN	O	O
sister	NN	O	O
chromatid	NN	O	O
exchanges	NN	O	O
(	NN	O	O
SCEs	NN	O	O
)	NN	O	O
,	NN	O	O
proliferation	NN	O	O
rate	NN	O	O
index	NN	O	O
(	NN	O	O
PRI	NN	O	O
)	NN	O	O
and	NN	O	O
Mitotic	NN	O	O
Index	NN	O	O
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

Mesna	NN	O	O
'	NN	O	O
s	NN	O	O
action	NN	O	O
,	NN	O	O
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
IFO	NN	O	O
reduces	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
SCEs	NN	O	O
,	NN	O	O
in	NN	O	O
comparison	NN	O	O
with	NN	O	O
the	NN	O	O
SCEs	NN	O	O
recordings	NN	O	O
obtained	NN	O	O
when	NN	O	O
IFO	NN	O	O
is	NN	O	O
administered	NN	O	O
alone	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
this	NN	O	O
,	NN	O	O
when	NN	O	O
high	NN	O	O
concentrations	NN	O	O
of	NN	O	O
Mesna	NN	O	O
were	NN	O	O
administered	NN	O	O
alone	NN	O	O
significant	NN	O	O
reductions	NN	O	O
of	NN	O	O
the	NN	O	O
PRI	NN	O	O
were	NN	O	O
noted	NN	O	O
,	NN	O	O
than	NN	O	O
with	NN	O	O
IFO	NN	O	O
acting	NN	O	O
at	NN	O	O
the	NN	O	O
same	NN	O	O
concentration	NN	O	O
on	NN	O	O
the	NN	O	O
lymphocytes	NN	O	O
.	NN	O	O

Mesna	NN	O	O
significantly	NN	O	O
reduces	NN	O	O
IFO	NN	O	O
'	NN	O	O
s	NN	O	O
genotoxicity	NN	O	B
,	NN	O	O
while	NN	O	O
when	NN	O	O
administered	NN	O	O
in	NN	O	O
high	NN	O	O
concentrations	NN	O	O
it	NN	O	O
acts	NN	O	O
in	NN	O	O
an	NN	O	O
inhibitory	NN	O	O
fashion	NN	O	O
on	NN	O	O
the	NN	O	O
cytostatic	NN	O	O
action	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

Risk	NN	O	O
factors	NN	O	O
and	NN	O	O
predictors	NN	O	O
of	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B
among	NN	O	O
multiethnic	NN	O	O
Malaysians	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

Chronic	NN	O	O
pulsatile	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
for	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
leads	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
motor	NN	O	O
fluctuations	NN	O	O
and	NN	O	O
dyskinesia	NN	O	B
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
prevalence	NN	O	O
and	NN	O	O
predictors	NN	O	O
of	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B
among	NN	O	O
multiethnic	NN	O	O
Malaysian	NN	O	O
patients	NN	O	O
with	NN	O	O
PD	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
is	NN	O	O
a	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
study	NN	O	O
involving	NN	O	O
95	NN	O	O
patients	NN	O	O
with	NN	O	O
PD	NN	O	B
on	NN	O	O
uninterrupted	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

The	NN	O	O
instrument	NN	O	O
used	NN	O	O
was	NN	O	O
the	NN	O	O
UPDRS	NN	O	O
questionnaires	NN	O	O
.	NN	O	O

The	NN	O	O
predictors	NN	O	O
of	NN	O	O
dyskinesia	NN	O	B
were	NN	O	O
determined	NN	O	O
using	NN	O	O
multivariate	NN	O	O
logistic	NN	O	O
regression	NN	O	O
analysis	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
mean	NN	O	O
age	NN	O	O
was	NN	O	O
65	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
8	NN	O	O
.	NN	O	O
5	NN	O	O
years	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
onset	NN	O	O
age	NN	O	O
was	NN	O	O
58	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
9	NN	O	O
.	NN	O	O
8	NN	O	O
years	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
disease	NN	O	O
duration	NN	O	O
was	NN	O	O
6	NN	O	O
(	NN	O	O
7	NN	O	O
)	NN	O	O
years	NN	O	O
.	NN	O	O

Dyskinesia	NN	O	B
was	NN	O	O
present	NN	O	O
in	NN	O	O
44	NN	O	O
%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
42	NN	O	O
)	NN	O	O
with	NN	O	O
median	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
of	NN	O	O
3	NN	O	O
years	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
64	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
Chinese	NN	O	O
,	NN	O	O
31	NN	O	O
%	NN	O	O
Malays	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
Indians	NN	O	O
and	NN	O	O
other	NN	O	O
ethnic	NN	O	O
groups	NN	O	O
.	NN	O	O

Eighty	NN	O	O
-	NN	O	O
one	NN	O	O
percent	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
dyskinesia	NN	O	B
had	NN	O	O
clinical	NN	O	O
fluctuations	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
dyskinesia	NN	O	B
had	NN	O	O
lower	NN	O	O
onset	NN	O	O
age	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
longer	NN	O	O
duration	NN	O	O
of	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
longer	NN	O	O
disease	NN	O	O
duration	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
higher	NN	O	O
total	NN	O	O
daily	NN	O	O
levodopa	NN	O	O
dose	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
higher	NN	O	O
total	NN	O	O
UPDRS	NN	O	O
scores	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
than	NN	O	O
patients	NN	O	O
without	NN	O	O
dyskinesia	NN	O	B
.	NN	O	O

The	NN	O	O
three	NN	O	O
significant	NN	O	O
predictors	NN	O	O
of	NN	O	O
dyskinesia	NN	O	B
were	NN	O	O
duration	NN	O	O
of	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
,	NN	O	O
onset	NN	O	O
age	NN	O	O
,	NN	O	O
and	NN	O	O
total	NN	O	O
daily	NN	O	O
levodopa	NN	O	O
dose	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
prevalence	NN	O	O
of	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B
in	NN	O	O
our	NN	O	O
patients	NN	O	O
was	NN	O	O
44	NN	O	O
%	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
significant	NN	O	O
predictors	NN	O	O
were	NN	O	O
duration	NN	O	O
of	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
,	NN	O	O
total	NN	O	O
daily	NN	O	O
levodopa	NN	O	O
dose	NN	O	O
,	NN	O	O
and	NN	O	O
onset	NN	O	O
age	NN	O	O
.	NN	O	O

Dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
neurotoxicity	NN	O	B
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
busulfan	NN	O	O
in	NN	O	O
children	NN	O	O
:	NN	O	O
a	NN	O	O
clinical	NN	O	O
and	NN	O	O
pharmacological	NN	O	O
study	NN	O	O
.	NN	O	O

Busulfan	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
be	NN	O	O
neurotoxic	NN	O	B
in	NN	O	O
animals	NN	O	O
and	NN	O	O
humans	NN	O	O
,	NN	O	O
but	NN	O	O
its	NN	O	O
acute	NN	O	O
neurotoxicity	NN	O	B
remains	NN	O	O
poorly	NN	O	O
characterized	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
here	NN	O	O
a	NN	O	O
retrospective	NN	O	O
study	NN	O	O
of	NN	O	O
123	NN	O	O
children	NN	O	O
(	NN	O	O
median	NN	O	O
age	NN	O	O
,	NN	O	O
6	NN	O	O
.	NN	O	O
5	NN	O	O
years	NN	O	O
)	NN	O	O
receiving	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
busulfan	NN	O	O
in	NN	O	O
combined	NN	O	O
chemotherapy	NN	O	O
before	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
for	NN	O	O
malignant	NN	O	O
solid	NN	O	O
tumors	NN	O	B
,	NN	O	O
brain	NN	O	B
tumors	NN	O	I
excluded	NN	O	O
.	NN	O	O

Busulfan	NN	O	O
was	NN	O	O
given	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
,	NN	O	O
every	NN	O	O
6	NN	O	O
hours	NN	O	O
for	NN	O	O
16	NN	O	O
doses	NN	O	O
over	NN	O	O
4	NN	O	O
days	NN	O	O
.	NN	O	O

Two	NN	O	O
total	NN	O	O
doses	NN	O	O
were	NN	O	O
consecutively	NN	O	O
used	NN	O	O
:	NN	O	O
16	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
then	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
calculation	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
results	NN	O	O
in	NN	O	O
higher	NN	O	O
doses	NN	O	O
in	NN	O	O
young	NN	O	O
children	NN	O	O
than	NN	O	O
in	NN	O	O
older	NN	O	O
patients	NN	O	O
(	NN	O	O
16	NN	O	O
to	NN	O	O
28	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

Ninety	NN	O	O
-	NN	O	O
six	NN	O	O
patients	NN	O	O
were	NN	O	O
not	NN	O	O
given	NN	O	O
anticonvulsive	NN	O	O
prophylaxis	NN	O	O
;	NN	O	O
7	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
seizures	NN	O	B
during	NN	O	O
the	NN	O	O
4	NN	O	O
days	NN	O	O
of	NN	O	O
the	NN	O	O
busulfan	NN	O	O
course	NN	O	O
or	NN	O	O
within	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
the	NN	O	O
last	NN	O	O
dosing	NN	O	O
.	NN	O	O

When	NN	O	O
the	NN	O	O
total	NN	O	O
busulfan	NN	O	O
dose	NN	O	O
was	NN	O	O
taken	NN	O	O
into	NN	O	O
account	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
neurotoxicity	NN	O	B
incidence	NN	O	O
among	NN	O	O
patients	NN	O	O
under	NN	O	O
16	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
1	NN	O	O
of	NN	O	O
57	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
patients	NN	O	O
under	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
(	NN	O	O
6	NN	O	O
of	NN	O	O
39	NN	O	O
,	NN	O	O
15	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
seven	NN	O	O
patients	NN	O	O
were	NN	O	O
given	NN	O	O
a	NN	O	O
600	NN	O	O
-	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
busulfan	NN	O	O
total	NN	O	O
dose	NN	O	O
with	NN	O	O
continuous	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
infusion	NN	O	O
of	NN	O	O
clonazepam	NN	O	O
;	NN	O	O
none	NN	O	O
had	NN	O	O
any	NN	O	O
neurological	NN	O	B
symptoms	NN	O	I
.	NN	O	O

Busulfan	NN	O	O
levels	NN	O	O
were	NN	O	O
measured	NN	O	O
by	NN	O	O
a	NN	O	O
gas	NN	O	O
chromatographic	NN	O	O
-	NN	O	O
mass	NN	O	O
spectrometry	NN	O	O
assay	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
and	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
of	NN	O	O
9	NN	O	O
children	NN	O	O
without	NN	O	O
central	NN	O	B
nervous	NN	O	I
system	NN	O	I
disease	NN	O	I
under	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
busulfan	NN	O	O
with	NN	O	O
clonazepam	NN	O	O
:	NN	O	O
busulfan	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
:	NN	O	O
plasma	NN	O	O
ratio	NN	O	O
was	NN	O	O
1	NN	O	O
.	NN	O	O
39	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
significantly	NN	O	O
different	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
from	NN	O	O
the	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
:	NN	O	O
plasma	NN	O	O
ratio	NN	O	O
previously	NN	O	O
defined	NN	O	O
in	NN	O	O
children	NN	O	O
receiving	NN	O	O
a	NN	O	O
16	NN	O	O
-	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
total	NN	O	O
dose	NN	O	O
of	NN	O	O
busulfan	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
shows	NN	O	O
that	NN	O	O
busulfan	NN	O	O
neurotoxicity	NN	O	B
is	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
in	NN	O	O
children	NN	O	O
and	NN	O	O
efficiently	NN	O	O
prevented	NN	O	O
by	NN	O	O
clonazepam	NN	O	O
.	NN	O	O

A	NN	O	O
busulfan	NN	O	O
dose	NN	O	O
calculated	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
higher	NN	O	O
doses	NN	O	O
in	NN	O	O
young	NN	O	O
children	NN	O	O
,	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
increased	NN	O	O
neurotoxicity	NN	O	B
,	NN	O	O
close	NN	O	O
to	NN	O	O
neurotoxicity	NN	O	B
incidence	NN	O	O
observed	NN	O	O
in	NN	O	O
adults	NN	O	O
.	NN	O	O

Since	NN	O	O
plasma	NN	O	O
pharmacokinetic	NN	O	O
studies	NN	O	O
showed	NN	O	O
a	NN	O	O
faster	NN	O	O
busulfan	NN	O	O
clearance	NN	O	O
in	NN	O	O
children	NN	O	O
than	NN	O	O
in	NN	O	O
adults	NN	O	O
,	NN	O	O
this	NN	O	O
new	NN	O	O
dose	NN	O	O
may	NN	O	O
approximate	NN	O	O
more	NN	O	O
closely	NN	O	O
the	NN	O	O
adult	NN	O	O
systemic	NN	O	O
exposure	NN	O	O
obtained	NN	O	O
after	NN	O	O
the	NN	O	O
usual	NN	O	O
16	NN	O	O
-	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
total	NN	O	O
dose	NN	O	O
,	NN	O	O
with	NN	O	O
potential	NN	O	O
inferences	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
anticancer	NN	O	O
or	NN	O	O
myeloablative	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
busulfan	NN	O	O
dose	NN	O	O
in	NN	O	O
children	NN	O	O
and	NN	O	O
infants	NN	O	O
undergoing	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
should	NN	O	O
be	NN	O	O
reconsidered	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
pharmacokinetic	NN	O	O
studies	NN	O	O
.	NN	O	O

An	NN	O	O
unexpected	NN	O	O
diagnosis	NN	O	O
in	NN	O	O
a	NN	O	O
renal	NN	O	O
-	NN	O	O
transplant	NN	O	O
patient	NN	O	O
with	NN	O	O
proteinuria	NN	O	B
treated	NN	O	O
with	NN	O	O
everolimus	NN	O	O
:	NN	O	O
AL	NN	O	B
amyloidosis	NN	O	B
.	NN	O	O

Proteinuria	NN	O	B
is	NN	O	O
an	NN	O	O
expected	NN	O	O
complication	NN	O	O
in	NN	O	O
transplant	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
mammalian	NN	O	O
target	NN	O	O
of	NN	O	O
rapamycin	NN	O	O
inhibitors	NN	O	O
(	NN	O	O
mTOR	NN	O	O
-	NN	O	O
i	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
clinical	NN	O	O
suspicion	NN	O	O
should	NN	O	O
always	NN	O	O
be	NN	O	O
supported	NN	O	O
by	NN	O	O
histological	NN	O	O
evidence	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
investigate	NN	O	O
potential	NN	O	O
alternate	NN	O	O
diagnoses	NN	O	O
such	NN	O	O
as	NN	O	O
acute	NN	O	O
or	NN	O	O
chronic	NN	O	O
rejection	NN	O	O
,	NN	O	O
interstitial	NN	O	O
fibrosis	NN	O	B
and	NN	O	O
tubular	NN	O	O
atrophy	NN	O	B
,	NN	O	O
or	NN	O	O
recurrent	NN	O	O
or	NN	O	O
de	NN	O	O
novo	NN	O	O
glomerulopathy	NN	O	B
.	NN	O	O

In	NN	O	O
this	NN	O	O
case	NN	O	O
we	NN	O	O
report	NN	O	O
the	NN	O	O
unexpected	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
amyloidosis	NN	O	B
in	NN	O	O
a	NN	O	O
renal	NN	O	O
-	NN	O	O
transplant	NN	O	O
patient	NN	O	O
with	NN	O	O
pre	NN	O	O
-	NN	O	O
transplant	NN	O	O
monoclonal	NN	O	O
gammapathy	NN	O	O
of	NN	O	O
undetermined	NN	O	O
significance	NN	O	O
who	NN	O	O
developed	NN	O	O
proteinuria	NN	O	B
after	NN	O	O
conversion	NN	O	O
from	NN	O	O
tacrolimus	NN	O	O
to	NN	O	O
everolimus	NN	O	O
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
oral	NN	O	O
galactose	NN	O	O
treatment	NN	O	O
prevents	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
in	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
treated	NN	O	O
intracerebroventricularly	NN	O	O
with	NN	O	O
streptozotocin	NN	O	O
.	NN	O	O

Basic	NN	O	O
and	NN	O	O
clinical	NN	O	O
research	NN	O	O
has	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
dementia	NN	O	B
of	NN	O	O
sporadic	NN	O	O
Alzheimer	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
sAD	NN	O	O
)	NN	O	O
type	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
dysfunction	NN	O	O
of	NN	O	O
the	NN	O	O
insulin	NN	O	O
-	NN	O	O
receptor	NN	O	O
(	NN	O	O
IR	NN	O	O
)	NN	O	O
system	NN	O	O
followed	NN	O	O
by	NN	O	O
decreased	NN	O	O
glucose	NN	O	O
transport	NN	O	O
via	NN	O	O
glucose	NN	O	O
transporter	NN	O	O
GLUT4	NN	O	O
and	NN	O	O
decreased	NN	O	O
glucose	NN	O	O
metabolism	NN	O	O
in	NN	O	O
brain	NN	O	O
cells	NN	O	O
.	NN	O	O

An	NN	O	O
alternative	NN	O	O
source	NN	O	O
of	NN	O	O
energy	NN	O	O
is	NN	O	O
d	NN	O	O
-	NN	O	O
galactose	NN	O	O
(	NN	O	O
the	NN	O	O
C	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
epimer	NN	O	O
of	NN	O	O
d	NN	O	O
-	NN	O	O
glucose	NN	O	O
)	NN	O	O
which	NN	O	O
is	NN	O	O
transported	NN	O	O
into	NN	O	O
the	NN	O	O
brain	NN	O	O
by	NN	O	O
insulin	NN	O	O
-	NN	O	O
independent	NN	O	O
GLUT3	NN	O	O
transporter	NN	O	O
where	NN	O	O
it	NN	O	O
might	NN	O	O
be	NN	O	O
metabolized	NN	O	O
to	NN	O	O
glucose	NN	O	O
via	NN	O	O
the	NN	O	O
Leloir	NN	O	O
pathway	NN	O	O
.	NN	O	O

Exclusively	NN	O	O
parenteral	NN	O	O
daily	NN	O	O
injections	NN	O	O
of	NN	O	O
galactose	NN	O	O
induce	NN	O	O
memory	NN	O	B
deterioration	NN	O	I
in	NN	O	O
rodents	NN	O	O
and	NN	O	O
are	NN	O	O
used	NN	O	O
to	NN	O	O
generate	NN	O	O
animal	NN	O	O
aging	NN	O	O
model	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
oral	NN	O	O
galactose	NN	O	O
treatment	NN	O	O
on	NN	O	O
cognitive	NN	O	O
functions	NN	O	O
have	NN	O	O
never	NN	O	O
been	NN	O	O
tested	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
continuous	NN	O	O
daily	NN	O	O
oral	NN	O	O
galactose	NN	O	O
(	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
treatment	NN	O	O
on	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
in	NN	O	O
streptozotocin	NN	O	O
-	NN	O	O
induced	NN	O	O
(	NN	O	O
STZ	NN	O	O
-	NN	O	O
icv	NN	O	O
)	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
sAD	NN	O	O
,	NN	O	O
tested	NN	O	O
by	NN	O	O
Morris	NN	O	O
Water	NN	O	O
Maze	NN	O	O
and	NN	O	O
Passive	NN	O	O
Avoidance	NN	O	O
test	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

One	NN	O	O
month	NN	O	O
of	NN	O	O
oral	NN	O	O
galactose	NN	O	O
treatment	NN	O	O
initiated	NN	O	O
immediately	NN	O	O
after	NN	O	O
the	NN	O	O
STZ	NN	O	O
-	NN	O	O
icv	NN	O	O
administration	NN	O	O
,	NN	O	O
successfully	NN	O	O
prevented	NN	O	O
development	NN	O	O
of	NN	O	O
the	NN	O	O
STZ	NN	O	O
-	NN	O	O
icv	NN	O	O
-	NN	O	O
induced	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
.	NN	O	O

Beneficial	NN	O	O
effect	NN	O	O
of	NN	O	O
oral	NN	O	O
galactose	NN	O	O
was	NN	O	O
independent	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
age	NN	O	O
and	NN	O	O
of	NN	O	O
the	NN	O	O
galactose	NN	O	O
dose	NN	O	O
ranging	NN	O	O
from	NN	O	O
100	NN	O	O
to	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
oral	NN	O	O
galactose	NN	O	O
administration	NN	O	O
led	NN	O	O
to	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
galactose	NN	O	O
in	NN	O	O
the	NN	O	O
blood	NN	O	O
.	NN	O	O

The	NN	O	O
increase	NN	O	O
of	NN	O	O
galactose	NN	O	O
concentration	NN	O	O
in	NN	O	O
the	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
was	NN	O	O
several	NN	O	O
times	NN	O	O
lower	NN	O	O
after	NN	O	O
oral	NN	O	O
than	NN	O	O
after	NN	O	O
parenteral	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
same	NN	O	O
galactose	NN	O	O
dose	NN	O	O
.	NN	O	O

Oral	NN	O	O
galactose	NN	O	O
exposure	NN	O	O
might	NN	O	O
have	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
on	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
ability	NN	O	O
and	NN	O	O
could	NN	O	O
be	NN	O	O
worth	NN	O	O
investigating	NN	O	O
for	NN	O	O
improvement	NN	O	O
of	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
associated	NN	O	O
with	NN	O	O
glucose	NN	O	B
hypometabolism	NN	O	I
in	NN	O	O
AD	NN	O	B
.	NN	O	O

An	NN	O	O
investigation	NN	O	O
of	NN	O	O
the	NN	O	O
pattern	NN	O	O
of	NN	O	O
kidney	NN	O	B
injury	NN	O	I
in	NN	O	O
HIV	NN	O	O
-	NN	O	O
positive	NN	O	O
persons	NN	O	O
exposed	NN	O	O
to	NN	O	O
tenofovir	NN	O	O
disoproxil	NN	O	O
fumarate	NN	O	O
:	NN	O	O
an	NN	O	O
examination	NN	O	O
of	NN	O	O
a	NN	O	O
large	NN	O	O
population	NN	O	O
database	NN	O	O
(	NN	O	O
MHRA	NN	O	O
database	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
potential	NN	O	O
for	NN	O	O
tenofovir	NN	O	O
to	NN	O	O
cause	NN	O	O
a	NN	O	O
range	NN	O	O
of	NN	O	O
kidney	NN	O	O
syndromes	NN	O	O
has	NN	O	O
been	NN	O	O
established	NN	O	O
from	NN	O	O
mechanistic	NN	O	O
and	NN	O	O
randomised	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
exact	NN	O	O
pattern	NN	O	O
of	NN	O	O
kidney	NN	O	O
involvement	NN	O	O
is	NN	O	O
still	NN	O	O
uncertain	NN	O	O
.	NN	O	O

We	NN	O	O
undertook	NN	O	O
a	NN	O	O
descriptive	NN	O	O
analysis	NN	O	O
of	NN	O	O
Yellow	NN	O	O
Card	NN	O	O
records	NN	O	O
of	NN	O	O
407	NN	O	O
HIV	NN	O	O
-	NN	O	O
positive	NN	O	O
persons	NN	O	O
taking	NN	O	O
tenofovir	NN	O	O
disoproxil	NN	O	O
fumarate	NN	O	O
(	NN	O	O
TDF	NN	O	O
)	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
their	NN	O	O
antiretroviral	NN	O	O
therapy	NN	O	O
regimen	NN	O	O
and	NN	O	O
submitted	NN	O	O
to	NN	O	O
the	NN	O	O
Medicines	NN	O	O
and	NN	O	O
Healthcare	NN	O	O
Products	NN	O	O
Regulatory	NN	O	O
Agency	NN	O	O
(	NN	O	O
MHRA	NN	O	O
)	NN	O	O
with	NN	O	O
suspected	NN	O	O
kidney	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O

Reports	NN	O	O
that	NN	O	O
satisfy	NN	O	O
defined	NN	O	O
criteria	NN	O	O
were	NN	O	O
classified	NN	O	O
as	NN	O	O
acute	NN	O	B
kidney	NN	O	I
injury	NN	O	I
,	NN	O	O
kidney	NN	O	B
tubular	NN	O	I
dysfunction	NN	O	I
and	NN	O	O
Fanconi	NN	O	B
syndrome	NN	O	I
.	NN	O	O

Of	NN	O	O
the	NN	O	O
407	NN	O	O
Yellow	NN	O	O
Card	NN	O	O
records	NN	O	O
analysed	NN	O	O
,	NN	O	O
106	NN	O	O
satisfied	NN	O	O
criteria	NN	O	O
for	NN	O	O
TDF	NN	O	O
-	NN	O	O
related	NN	O	O
kidney	NN	O	B
disease	NN	O	I
,	NN	O	O
of	NN	O	O
which	NN	O	O
53	NN	O	O
(	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
features	NN	O	O
of	NN	O	O
kidney	NN	O	B
tubular	NN	O	I
dysfunction	NN	O	I
,	NN	O	O
35	NN	O	O
(	NN	O	O
33	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
features	NN	O	O
of	NN	O	O
glomerular	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
18	NN	O	O
(	NN	O	O
17	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
Fanconi	NN	O	B
syndrome	NN	O	I
.	NN	O	O

The	NN	O	O
median	NN	O	O
TDF	NN	O	O
exposure	NN	O	O
was	NN	O	O
316	NN	O	O
days	NN	O	O
(	NN	O	O
interquartile	NN	O	O
range	NN	O	O
120	NN	O	O
-	NN	O	O
740	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
hospitalisation	NN	O	O
for	NN	O	O
TDF	NN	O	O
kidney	NN	O	O
adverse	NN	O	O
effects	NN	O	O
was	NN	O	O
high	NN	O	O
,	NN	O	O
particularly	NN	O	O
amongst	NN	O	O
patients	NN	O	O
with	NN	O	O
features	NN	O	O
of	NN	O	O
Fanconi	NN	O	B
syndrome	NN	O	I
.	NN	O	O

The	NN	O	O
pattern	NN	O	O
of	NN	O	O
kidney	NN	O	O
syndromes	NN	O	O
in	NN	O	O
this	NN	O	O
population	NN	O	O
series	NN	O	O
mirrors	NN	O	O
that	NN	O	O
reported	NN	O	O
in	NN	O	O
randomised	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O

Cessation	NN	O	O
of	NN	O	O
TDF	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
complete	NN	O	O
restoration	NN	O	O
of	NN	O	O
kidney	NN	O	O
function	NN	O	O
in	NN	O	O
up	NN	O	O
half	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
in	NN	O	O
this	NN	O	O
report	NN	O	O
.	NN	O	O

Incidence	NN	O	O
of	NN	O	O
postoperative	NN	O	B
delirium	NN	O	I
is	NN	O	O
high	NN	O	O
even	NN	O	O
in	NN	O	O
a	NN	O	O
population	NN	O	O
without	NN	O	O
known	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
Postoperative	NN	O	B
delirium	NN	O	I
is	NN	O	O
a	NN	O	O
recognized	NN	O	O
complication	NN	O	O
in	NN	O	O
populations	NN	O	O
at	NN	O	O
risk	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
early	NN	O	O
postoperative	NN	O	B
delirium	NN	O	I
in	NN	O	O
a	NN	O	O
population	NN	O	O
without	NN	O	O
known	NN	O	O
risk	NN	O	O
factors	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
ICU	NN	O	O
for	NN	O	O
postoperative	NN	O	O
monitoring	NN	O	O
after	NN	O	O
elective	NN	O	O
major	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
secondary	NN	O	O
outcome	NN	O	O
investigated	NN	O	O
is	NN	O	O
to	NN	O	O
identify	NN	O	O
eventual	NN	O	O
independent	NN	O	O
risk	NN	O	O
factors	NN	O	O
among	NN	O	O
demographic	NN	O	O
data	NN	O	O
and	NN	O	O
anesthetic	NN	O	O
drugs	NN	O	O
used	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
An	NN	O	O
observational	NN	O	O
,	NN	O	O
prospective	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
on	NN	O	O
a	NN	O	O
consecutive	NN	O	O
cohort	NN	O	O
of	NN	O	O
patients	NN	O	O
admitted	NN	O	O
to	NN	O	O
our	NN	O	O
ICU	NN	O	O
within	NN	O	O
and	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
major	NN	O	O
surgical	NN	O	O
procedures	NN	O	O
.	NN	O	O

Exclusion	NN	O	O
criteria	NN	O	O
were	NN	O	O
any	NN	O	O
preexisting	NN	O	O
predisposing	NN	O	O
factor	NN	O	O
for	NN	O	O
delirium	NN	O	B
or	NN	O	O
other	NN	O	O
potentially	NN	O	O
confounding	NN	O	O
neurological	NN	O	B
dysfunctions	NN	O	I
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
assessed	NN	O	O
daily	NN	O	O
using	NN	O	O
the	NN	O	O
confusion	NN	O	B
assessment	NN	O	O
method	NN	O	O
for	NN	O	O
the	NN	O	O
ICU	NN	O	O
scale	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
surgical	NN	O	O
procedure	NN	O	O
.	NN	O	O

Early	NN	O	O
postoperative	NN	O	B
delirium	NN	O	I
incidence	NN	O	O
risk	NN	O	O
factors	NN	O	O
were	NN	O	O
then	NN	O	O
assessed	NN	O	O
through	NN	O	O
three	NN	O	O
different	NN	O	O
multiple	NN	O	O
regression	NN	O	O
models	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
According	NN	O	O
to	NN	O	O
the	NN	O	O
confusion	NN	O	O
assessment	NN	O	O
method	NN	O	O
for	NN	O	O
the	NN	O	O
ICU	NN	O	O
scale	NN	O	O
,	NN	O	O
28	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
were	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
early	NN	O	O
postoperative	NN	O	B
delirium	NN	O	I
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
thiopentone	NN	O	O
was	NN	O	O
significantly	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
eight	NN	O	O
-	NN	O	O
fold	NN	O	O
-	NN	O	O
higher	NN	O	O
risk	NN	O	O
for	NN	O	O
delirium	NN	O	B
compared	NN	O	O
to	NN	O	O
propofol	NN	O	O
(	NN	O	O
57	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
vs	NN	O	O
.	NN	O	O
7	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
,	NN	O	O
RR	NN	O	O
=	NN	O	O
8	NN	O	O
.	NN	O	O
0	NN	O	O
,	NN	O	O
X2	NN	O	O
=	NN	O	O
4	NN	O	O
.	NN	O	O
256	NN	O	O
;	NN	O	O
df	NN	O	O
=	NN	O	O
1	NN	O	O
;	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
<	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
study	NN	O	O
early	NN	O	O
postoperative	NN	O	B
delirium	NN	O	I
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
very	NN	O	O
common	NN	O	O
complication	NN	O	O
after	NN	O	O
major	NN	O	O
surgery	NN	O	O
,	NN	O	O
even	NN	O	O
in	NN	O	O
a	NN	O	O
population	NN	O	O
without	NN	O	O
known	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

Thiopentone	NN	O	O
was	NN	O	O
independently	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
its	NN	O	O
relative	NN	O	O
risk	NN	O	O
.	NN	O	O

A	NN	O	O
single	NN	O	O
neurotoxic	NN	O	B
dose	NN	O	O
of	NN	O	O
methamphetamine	NN	O	O
induces	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
lasting	NN	O	O
depressive	NN	O	B
-	NN	O	O
like	NN	O	O
behaviour	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Methamphetamine	NN	O	O
(	NN	O	O
METH	NN	O	O
)	NN	O	O
triggers	NN	O	O
a	NN	O	O
disruption	NN	O	O
of	NN	O	O
the	NN	O	O
monoaminergic	NN	O	O
system	NN	O	O
and	NN	O	O
METH	NN	O	O
abuse	NN	O	O
leads	NN	O	O
to	NN	O	O
negative	NN	O	O
emotional	NN	O	O
states	NN	O	O
including	NN	O	O
depressive	NN	O	B
symptoms	NN	O	I
during	NN	O	O
drug	NN	O	O
withdrawal	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
currently	NN	O	O
unknown	NN	O	O
if	NN	O	O
the	NN	O	O
acute	NN	O	O
toxic	NN	O	O
dosage	NN	O	O
of	NN	O	O
METH	NN	O	O
also	NN	O	O
causes	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
lasting	NN	O	O
depressive	NN	O	B
phenotype	NN	O	O
and	NN	O	O
persistent	NN	O	O
monoaminergic	NN	O	O
deficits	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
we	NN	O	O
now	NN	O	O
assessed	NN	O	O
the	NN	O	O
depressive	NN	O	B
-	NN	O	O
like	NN	O	O
behaviour	NN	O	O
in	NN	O	O
mice	NN	O	O
at	NN	O	O
early	NN	O	O
and	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
periods	NN	O	O
following	NN	O	O
a	NN	O	O
single	NN	O	O
high	NN	O	O
METH	NN	O	O
dose	NN	O	O
(	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

METH	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
the	NN	O	O
motor	NN	O	O
function	NN	O	O
and	NN	O	O
procedural	NN	O	O
memory	NN	O	O
of	NN	O	O
mice	NN	O	O
as	NN	O	O
assessed	NN	O	O
by	NN	O	O
swimming	NN	O	O
speed	NN	O	O
and	NN	O	O
escape	NN	O	O
latency	NN	O	O
to	NN	O	O
find	NN	O	O
the	NN	O	O
platform	NN	O	O
in	NN	O	O
a	NN	O	O
cued	NN	O	O
version	NN	O	O
of	NN	O	O
the	NN	O	O
water	NN	O	O
maze	NN	O	O
task	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
METH	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
immobility	NN	O	O
time	NN	O	O
in	NN	O	O
the	NN	O	O
tail	NN	O	O
suspension	NN	O	O
test	NN	O	O
at	NN	O	O
3	NN	O	O
and	NN	O	O
49	NN	O	O
days	NN	O	O
post	NN	O	O
-	NN	O	O
administration	NN	O	O
.	NN	O	O

This	NN	O	O
depressive	NN	O	B
-	NN	O	O
like	NN	O	O
profile	NN	O	O
induced	NN	O	O
by	NN	O	O
METH	NN	O	O
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
marked	NN	O	O
depletion	NN	O	O
of	NN	O	O
frontostriatal	NN	O	O
dopaminergic	NN	O	O
and	NN	O	O
serotonergic	NN	O	O
neurotransmission	NN	O	O
,	NN	O	O
indicated	NN	O	O
by	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
dopamine	NN	O	O
,	NN	O	O
DOPAC	NN	O	O
and	NN	O	O
HVA	NN	O	O
,	NN	O	O
tyrosine	NN	O	O
hydroxylase	NN	O	O
and	NN	O	O
serotonin	NN	O	O
,	NN	O	O
observed	NN	O	O
at	NN	O	O
both	NN	O	O
3	NN	O	O
and	NN	O	O
49	NN	O	O
days	NN	O	O
post	NN	O	O
-	NN	O	O
administration	NN	O	O
.	NN	O	O

In	NN	O	O
parallel	NN	O	O
,	NN	O	O
another	NN	O	O
neurochemical	NN	O	O
feature	NN	O	O
of	NN	O	O
depression	NN	O	B
-	NN	O	O
-	NN	O	O
astroglial	NN	O	O
dysfunction	NN	O	O
-	NN	O	O
-	NN	O	O
was	NN	O	O
unaffected	NN	O	O
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
and	NN	O	O
the	NN	O	O
striatal	NN	O	O
levels	NN	O	O
of	NN	O	O
the	NN	O	O
astrocytic	NN	O	O
protein	NN	O	O
marker	NN	O	O
,	NN	O	O
glial	NN	O	O
fibrillary	NN	O	O
acidic	NN	O	O
protein	NN	O	O
,	NN	O	O
were	NN	O	O
only	NN	O	O
transiently	NN	O	O
increased	NN	O	O
at	NN	O	O
3	NN	O	O
days	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
demonstrate	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
that	NN	O	O
a	NN	O	O
single	NN	O	O
high	NN	O	O
dose	NN	O	O
of	NN	O	O
METH	NN	O	O
induces	NN	O	O
long	NN	O	O
-	NN	O	O
lasting	NN	O	O
depressive	NN	O	B
-	NN	O	O
like	NN	O	O
behaviour	NN	O	O
in	NN	O	O
mice	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
persistent	NN	O	O
disruption	NN	O	O
of	NN	O	O
frontostriatal	NN	O	O
dopaminergic	NN	O	O
and	NN	O	O
serotonergic	NN	O	O
homoeostasis	NN	O	O
.	NN	O	O

Linezolid	NN	O	O
-	NN	O	O
induced	NN	O	O
optic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

Many	NN	O	O
systemic	NN	O	O
antimicrobials	NN	O	O
have	NN	O	O
been	NN	O	O
implicated	NN	O	O
to	NN	O	O
cause	NN	O	O
ocular	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
especially	NN	O	O
relevant	NN	O	O
in	NN	O	O
multidrug	NN	O	O
therapy	NN	O	O
where	NN	O	O
more	NN	O	O
than	NN	O	O
one	NN	O	O
drug	NN	O	O
can	NN	O	O
cause	NN	O	O
a	NN	O	O
similar	NN	O	O
ocular	NN	O	O
adverse	NN	O	O
effect	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
progressive	NN	O	O
loss	NN	O	B
of	NN	O	I
vision	NN	O	I
associated	NN	O	O
with	NN	O	O
linezolid	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
45	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
patient	NN	O	O
who	NN	O	O
was	NN	O	O
on	NN	O	O
treatment	NN	O	O
with	NN	O	O
multiple	NN	O	O
second	NN	O	O
-	NN	O	O
line	NN	O	O
anti	NN	O	O
-	NN	O	O
tuberculous	NN	O	O
drugs	NN	O	O
including	NN	O	O
linezolid	NN	O	O
and	NN	O	O
ethambutol	NN	O	O
for	NN	O	O
extensively	NN	O	B
drug	NN	O	I
-	NN	O	I
resistant	NN	O	I
tuberculosis	NN	O	I
(	NN	O	O
XDR	NN	O	B
-	NN	O	I
TB	NN	O	I
)	NN	O	O
presented	NN	O	O
to	NN	O	O
us	NN	O	O
with	NN	O	O
painless	NN	O	O
progressive	NN	O	O
loss	NN	O	B
of	NN	O	I
vision	NN	O	I
in	NN	O	O
both	NN	O	O
eyes	NN	O	O
.	NN	O	O

Color	NN	O	O
vision	NN	O	O
was	NN	O	O
defective	NN	O	O
and	NN	O	O
fundus	NN	O	O
examination	NN	O	O
revealed	NN	O	O
optic	NN	O	B
disc	NN	O	I
edema	NN	O	I
in	NN	O	O
both	NN	O	O
eyes	NN	O	O
.	NN	O	O

Ethambutol	NN	O	O
-	NN	O	O
induced	NN	O	O
toxic	NN	O	B
optic	NN	O	I
neuropathy	NN	O	I
was	NN	O	O
suspected	NN	O	O
and	NN	O	O
tablet	NN	O	O
ethambutol	NN	O	O
was	NN	O	O
withdrawn	NN	O	O
.	NN	O	O

Deterioration	NN	O	B
of	NN	O	I
vision	NN	O	I
occurred	NN	O	O
despite	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
ethambutol	NN	O	O
.	NN	O	O

Discontinuation	NN	O	O
of	NN	O	O
linezolid	NN	O	O
resulted	NN	O	O
in	NN	O	O
marked	NN	O	O
improvement	NN	O	O
of	NN	O	O
vision	NN	O	O
.	NN	O	O

Our	NN	O	O
report	NN	O	O
emphasizes	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
monitoring	NN	O	O
of	NN	O	O
visual	NN	O	O
function	NN	O	O
in	NN	O	O
patients	NN	O	O
on	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
linezolid	NN	O	O
treatment	NN	O	O
.	NN	O	O

Resuscitation	NN	O	O
with	NN	O	O
lipid	NN	O	O
,	NN	O	O
epinephrine	NN	O	O
,	NN	O	O
or	NN	O	O
both	NN	O	O
in	NN	O	O
levobupivacaine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
toxicity	NN	O	I
in	NN	O	O
newborn	NN	O	O
piglets	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
optimal	NN	O	O
dosing	NN	O	O
regimens	NN	O	O
of	NN	O	O
lipid	NN	O	O
emulsion	NN	O	O
,	NN	O	O
epinephrine	NN	O	O
,	NN	O	O
or	NN	O	O
both	NN	O	O
are	NN	O	O
not	NN	O	O
yet	NN	O	O
determined	NN	O	O
in	NN	O	O
neonates	NN	O	O
in	NN	O	O
cases	NN	O	O
of	NN	O	O
local	NN	O	O
anaesthetic	NN	O	O
systemic	NN	O	O
toxicity	NN	O	B
(	NN	O	O
LAST	NN	O	O
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Newborn	NN	O	O
piglets	NN	O	O
received	NN	O	O
levobupivacaine	NN	O	O
until	NN	O	O
cardiovascular	NN	O	B
collapse	NN	O	I
occurred	NN	O	O
.	NN	O	O

Standard	NN	O	O
cardiopulmonary	NN	O	O
resuscitation	NN	O	O
was	NN	O	O
started	NN	O	O
and	NN	O	O
electrocardiogram	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
was	NN	O	O
monitored	NN	O	O
for	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
,	NN	O	O
fibrillation	NN	O	B
,	NN	O	O
or	NN	O	O
QRS	NN	O	O
prolongation	NN	O	O
.	NN	O	O

Piglets	NN	O	O
were	NN	O	O
then	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
four	NN	O	O
groups	NN	O	O
:	NN	O	O
control	NN	O	O
(	NN	O	O
saline	NN	O	O
)	NN	O	O
,	NN	O	O
Intralipid	NN	O	O
(	NN	O	O
)	NN	O	O
alone	NN	O	O
,	NN	O	O
epinephrine	NN	O	O
alone	NN	O	O
,	NN	O	O
or	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
Intralipd	NN	O	O
plus	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

Resuscitation	NN	O	O
continued	NN	O	O
for	NN	O	O
30	NN	O	O
min	NN	O	O
or	NN	O	O
until	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
return	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
circulation	NN	O	O
(	NN	O	O
ROSC	NN	O	O
)	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
at	NN	O	O
or	NN	O	O
superior	NN	O	O
to	NN	O	O
the	NN	O	O
baseline	NN	O	O
pressure	NN	O	O
and	NN	O	O
normal	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
for	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
30	NN	O	O
min	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
ROSC	NN	O	O
was	NN	O	O
achieved	NN	O	O
in	NN	O	O
only	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
piglets	NN	O	O
compared	NN	O	O
with	NN	O	O
most	NN	O	O
of	NN	O	O
the	NN	O	O
treated	NN	O	O
piglets	NN	O	O
.	NN	O	O

Mortality	NN	O	O
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
between	NN	O	O
the	NN	O	O
three	NN	O	O
treatment	NN	O	O
groups	NN	O	O
,	NN	O	O
but	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
all	NN	O	O
the	NN	O	O
treatment	NN	O	O
groups	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
ECG	NN	O	O
abnormalities	NN	O	O
was	NN	O	O
zero	NN	O	O
in	NN	O	O
the	NN	O	O
Intralipid	NN	O	O
only	NN	O	O
group	NN	O	O
,	NN	O	O
but	NN	O	O
14	NN	O	O
and	NN	O	O
17	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
epinephrine	NN	O	O
and	NN	O	O
epinephrine	NN	O	O
plus	NN	O	O
lipid	NN	O	O
groups	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Lipid	NN	O	O
emulsion	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
epinephrine	NN	O	O
,	NN	O	O
or	NN	O	O
epinephrine	NN	O	O
alone	NN	O	O
were	NN	O	O
equally	NN	O	O
effective	NN	O	O
in	NN	O	O
achieving	NN	O	O
a	NN	O	O
return	NN	O	O
to	NN	O	O
spontaneous	NN	O	O
circulation	NN	O	O
in	NN	O	O
this	NN	O	O
model	NN	O	O
of	NN	O	O
LAST	NN	O	O
.	NN	O	O

Epinephrine	NN	O	O
alone	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
lipid	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
number	NN	O	O
of	NN	O	O
ECG	NN	O	O
abnormalities	NN	O	O
compared	NN	O	O
with	NN	O	O
lipid	NN	O	O
emulsion	NN	O	O
alone	NN	O	O
.	NN	O	O

Incidence	NN	O	O
of	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
type	NN	O	I
II	NN	O	I
and	NN	O	O
postoperative	NN	O	O
recovery	NN	O	O
of	NN	O	O
platelet	NN	O	O
count	NN	O	O
in	NN	O	O
liver	NN	O	O
graft	NN	O	O
recipients	NN	O	O
:	NN	O	O
a	NN	O	O
retrospective	NN	O	O
cohort	NN	O	O
analysis	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Thrombocytopenia	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
liver	NN	O	I
disease	NN	O	I
is	NN	O	O
a	NN	O	O
common	NN	O	O
disorder	NN	O	O
caused	NN	O	O
mainly	NN	O	O
by	NN	O	O
portal	NN	O	B
hypertension	NN	O	I
,	NN	O	O
low	NN	O	O
levels	NN	O	O
of	NN	O	O
thrombopoetin	NN	O	O
,	NN	O	O
and	NN	O	O
endotoxemia	NN	O	B
.	NN	O	O

The	NN	O	O
impact	NN	O	O
of	NN	O	O
immune	NN	O	O
-	NN	O	O
mediated	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
type	NN	O	I
II	NN	O	I
(	NN	O	O
HIT	NN	O	B
type	NN	O	I
II	NN	O	I
)	NN	O	O
as	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
thrombocytopenia	NN	O	B
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
is	NN	O	O
not	NN	O	O
yet	NN	O	O
understood	NN	O	O
,	NN	O	O
with	NN	O	O
few	NN	O	O
literature	NN	O	O
citations	NN	O	O
reporting	NN	O	O
contradictory	NN	O	O
results	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
our	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
perioperative	NN	O	O
course	NN	O	O
of	NN	O	O
thrombocytopenia	NN	O	B
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
and	NN	O	O
determine	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
clinical	NN	O	O
HIT	NN	O	B
type	NN	O	I
II	NN	O	I
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
We	NN	O	O
retrospectively	NN	O	O
evaluated	NN	O	O
the	NN	O	O
medical	NN	O	O
records	NN	O	O
of	NN	O	O
205	NN	O	O
consecutive	NN	O	O
adult	NN	O	O
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
full	NN	O	O
-	NN	O	O
size	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
between	NN	O	O
January	NN	O	O
2006	NN	O	O
and	NN	O	O
December	NN	O	O
2010	NN	O	O
due	NN	O	O
to	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
or	NN	O	I
malignant	NN	O	I
liver	NN	O	I
disease	NN	O	I
.	NN	O	O

Preoperative	NN	O	O
platelet	NN	O	O
count	NN	O	O
,	NN	O	O
postoperative	NN	O	O
course	NN	O	O
of	NN	O	O
platelets	NN	O	O
,	NN	O	O
and	NN	O	O
clinical	NN	O	O
signs	NN	O	O
of	NN	O	O
HIT	NN	O	B
type	NN	O	I
II	NN	O	I
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
155	NN	O	O
(	NN	O	O
75	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
205	NN	O	O
patients	NN	O	O
had	NN	O	O
thrombocytopenia	NN	O	B
before	NN	O	O
transplantation	NN	O	O
,	NN	O	O
significantly	NN	O	O
influenced	NN	O	O
by	NN	O	O
Model	NN	O	O
of	NN	O	O
End	NN	O	B
-	NN	O	I
Stage	NN	O	I
Liver	NN	O	I
Disease	NN	O	I
score	NN	O	O
and	NN	O	O
liver	NN	O	B
cirrhosis	NN	O	I
.	NN	O	O

The	NN	O	O
platelet	NN	O	O
count	NN	O	O
exceeded	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
/	NN	O	O
uL	NN	O	O
in	NN	O	O
most	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
193	NN	O	O
)	NN	O	O
at	NN	O	O
a	NN	O	O
medium	NN	O	O
of	NN	O	O
7	NN	O	O
d	NN	O	O
.	NN	O	O

Regarding	NN	O	O
HIT	NN	O	B
II	NN	O	I
,	NN	O	O
there	NN	O	O
were	NN	O	O
four	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
95	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
background	NN	O	O
of	NN	O	O
HIT	NN	O	B
type	NN	O	I
II	NN	O	I
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
incidence	NN	O	O
of	NN	O	O
HIT	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
hepatic	NN	O	I
failure	NN	O	I
is	NN	O	O
,	NN	O	O
with	NN	O	O
about	NN	O	O
1	NN	O	O
.	NN	O	O
95	NN	O	O
%	NN	O	O
,	NN	O	O
rare	NN	O	O
.	NN	O	O

For	NN	O	O
further	NN	O	O
reduction	NN	O	O
of	NN	O	O
HIT	NN	O	B
type	NN	O	I
II	NN	O	I
,	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
intravenous	NN	O	O
heparin	NN	O	O
should	NN	O	O
be	NN	O	O
avoided	NN	O	O
and	NN	O	O
the	NN	O	O
prophylactic	NN	O	O
anticoagulation	NN	O	O
should	NN	O	O
be	NN	O	O
performed	NN	O	O
with	NN	O	O
low	NN	O	O
-	NN	O	O
molecular	NN	O	O
-	NN	O	O
weight	NN	O	O
heparin	NN	O	O
after	NN	O	O
normalization	NN	O	O
of	NN	O	O
platelet	NN	O	O
count	NN	O	O
.	NN	O	O

Takotsubo	NN	O	B
syndrome	NN	O	I
(	NN	O	O
or	NN	O	O
apical	NN	O	B
ballooning	NN	O	I
syndrome	NN	O	I
)	NN	O	O
secondary	NN	O	O
to	NN	O	O
Zolmitriptan	NN	O	O
.	NN	O	O

Takotsubo	NN	O	B
syndrome	NN	O	I
(	NN	O	O
TS	NN	O	B
)	NN	O	O
,	NN	O	O
also	NN	O	O
known	NN	O	O
as	NN	O	O
broken	NN	O	B
heart	NN	O	I
syndrome	NN	O	I
,	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
left	NN	O	O
ventricle	NN	O	O
apical	NN	O	O
ballooning	NN	O	O
with	NN	O	O
elevated	NN	O	O
cardiac	NN	O	O
biomarkers	NN	O	O
and	NN	O	O
electrocardiographic	NN	O	O
changes	NN	O	O
suggestive	NN	O	O
of	NN	O	O
an	NN	O	O
acute	NN	O	B
coronary	NN	O	I
syndrome	NN	O	I
(	NN	O	O
ie	NN	O	O
,	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
elevation	NN	O	O
,	NN	O	O
T	NN	O	O
wave	NN	O	O
inversions	NN	O	O
,	NN	O	O
and	NN	O	O
pathologic	NN	O	O
Q	NN	O	O
waves	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
54	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
medical	NN	O	O
history	NN	O	O
of	NN	O	O
mitral	NN	O	B
valve	NN	O	I
prolapse	NN	O	I
and	NN	O	O
migraines	NN	O	B
,	NN	O	O
who	NN	O	O
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
for	NN	O	O
substernal	NN	O	O
chest	NN	O	B
pain	NN	O	I
and	NN	O	O
electrocardiogram	NN	O	O
demonstrated	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
mm	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
elevation	NN	O	O
in	NN	O	O
leads	NN	O	O
II	NN	O	O
,	NN	O	O
III	NN	O	O
,	NN	O	O
aVF	NN	O	O
,	NN	O	O
V5	NN	O	O
,	NN	O	O
and	NN	O	O
V6	NN	O	O
and	NN	O	O
positive	NN	O	O
troponin	NN	O	O
I	NN	O	O
.	NN	O	O

Emergent	NN	O	O
coronary	NN	O	O
angiogram	NN	O	O
revealed	NN	O	O
normal	NN	O	O
coronary	NN	O	O
arteries	NN	O	O
with	NN	O	O
moderately	NN	O	O
reduced	NN	O	O
left	NN	O	O
ventricular	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
with	NN	O	O
wall	NN	O	O
motion	NN	O	O
abnormalities	NN	O	O
consistent	NN	O	O
with	NN	O	O
TS	NN	O	B
.	NN	O	O

Detailed	NN	O	O
history	NN	O	O
obtained	NN	O	O
retrospectively	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
patient	NN	O	O
took	NN	O	O
zolmitriptan	NN	O	O
sparingly	NN	O	O
only	NN	O	O
when	NN	O	O
she	NN	O	O
had	NN	O	O
migraines	NN	O	B
.	NN	O	O

But	NN	O	O
before	NN	O	O
this	NN	O	O
event	NN	O	O
,	NN	O	O
she	NN	O	O
was	NN	O	O
taking	NN	O	O
zolmitriptan	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
times	NN	O	O
daily	NN	O	O
for	NN	O	O
several	NN	O	O
days	NN	O	O
because	NN	O	O
of	NN	O	O
a	NN	O	O
persistent	NN	O	O
migraine	NN	O	B
headache	NN	O	I
.	NN	O	O

She	NN	O	O
otherwise	NN	O	O
reported	NN	O	O
that	NN	O	O
she	NN	O	O
is	NN	O	O
quite	NN	O	O
active	NN	O	O
,	NN	O	O
rides	NN	O	O
horses	NN	O	O
,	NN	O	O
and	NN	O	O
does	NN	O	O
show	NN	O	O
jumping	NN	O	O
without	NN	O	O
any	NN	O	O
limitations	NN	O	O
in	NN	O	O
her	NN	O	O
physical	NN	O	O
activity	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
any	NN	O	O
recent	NN	O	O
stress	NN	O	O
or	NN	O	O
status	NN	O	B
migrainosus	NN	O	I
.	NN	O	O

Extensive	NN	O	O
literature	NN	O	O
search	NN	O	O
revealed	NN	O	O
multiple	NN	O	O
cases	NN	O	O
of	NN	O	O
coronary	NN	O	B
artery	NN	O	I
vasospasm	NN	O	I
secondary	NN	O	O
to	NN	O	O
zolmitriptan	NN	O	O
,	NN	O	O
but	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
TS	NN	O	B
.	NN	O	O

Depression	NN	O	B
,	NN	O	O
impulsiveness	NN	O	B
,	NN	O	O
sleep	NN	O	O
,	NN	O	O
and	NN	O	O
memory	NN	O	O
in	NN	O	O
past	NN	O	O
and	NN	O	O
present	NN	O	O
polydrug	NN	O	O
users	NN	O	O
of	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
methylenedioxymethamphetamine	NN	O	O
(	NN	O	O
MDMA	NN	O	O
,	NN	O	O
ecstasy	NN	O	O
)	NN	O	O
.	NN	O	O

RATIONALE	NN	O	O
:	NN	O	O
Ecstasy	NN	O	O
(	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
methylenedioxymethamphetamine	NN	O	O
,	NN	O	O
MDMA	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
worldwide	NN	O	O
recreational	NN	O	O
drug	NN	O	O
of	NN	O	O
abuse	NN	O	O
.	NN	O	O

Unfortunately	NN	O	O
,	NN	O	O
the	NN	O	O
results	NN	O	O
from	NN	O	O
human	NN	O	O
research	NN	O	O
investigating	NN	O	O
its	NN	O	O
psychological	NN	O	O
effects	NN	O	O
have	NN	O	O
been	NN	O	O
inconsistent	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
The	NN	O	O
present	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
largest	NN	O	O
to	NN	O	O
date	NN	O	O
in	NN	O	O
sample	NN	O	O
size	NN	O	O
and	NN	O	O
5HT	NN	O	O
-	NN	O	O
related	NN	O	O
behaviors	NN	O	O
;	NN	O	O
the	NN	O	O
first	NN	O	O
to	NN	O	O
compare	NN	O	O
present	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
with	NN	O	O
past	NN	O	O
users	NN	O	O
after	NN	O	O
an	NN	O	O
abstinence	NN	O	O
of	NN	O	O
4	NN	O	O
or	NN	O	O
more	NN	O	O
years	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
first	NN	O	O
to	NN	O	O
include	NN	O	O
robust	NN	O	O
controls	NN	O	O
for	NN	O	O
other	NN	O	O
recreational	NN	O	O
substances	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
sample	NN	O	O
of	NN	O	O
997	NN	O	O
participants	NN	O	O
(	NN	O	O
52	NN	O	O
%	NN	O	O
male	NN	O	O
)	NN	O	O
was	NN	O	O
recruited	NN	O	O
to	NN	O	O
four	NN	O	O
control	NN	O	O
groups	NN	O	O
(	NN	O	O
non	NN	O	O
-	NN	O	O
drug	NN	O	O
(	NN	O	O
ND	NN	O	O
)	NN	O	O
,	NN	O	O
alcohol	NN	O	O
/	NN	O	O
nicotine	NN	O	O
(	NN	O	O
AN	NN	O	O
)	NN	O	O
,	NN	O	O
cannabis	NN	O	O
/	NN	O	O
alcohol	NN	O	O
/	NN	O	O
nicotine	NN	O	O
(	NN	O	O
CAN	NN	O	O
)	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
ecstasy	NN	O	O
polydrug	NN	O	O
(	NN	O	O
PD	NN	O	O
)	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
two	NN	O	O
ecstasy	NN	O	O
polydrug	NN	O	O
groups	NN	O	O
(	NN	O	O
present	NN	O	O
(	NN	O	O
MDMA	NN	O	O
)	NN	O	O
and	NN	O	O
past	NN	O	O
users	NN	O	O
(	NN	O	O
EX	NN	O	O
-	NN	O	O
MDMA	NN	O	O
)	NN	O	O
.	NN	O	O

Participants	NN	O	O
completed	NN	O	O
a	NN	O	O
drug	NN	O	O
history	NN	O	O
questionnaire	NN	O	O
,	NN	O	O
Beck	NN	O	O
Depression	NN	O	B
Inventory	NN	O	O
,	NN	O	O
Barratt	NN	O	O
Impulsiveness	NN	O	B
Scale	NN	O	O
,	NN	O	O
Pittsburgh	NN	O	O
Sleep	NN	O	O
Quality	NN	O	O
Index	NN	O	O
,	NN	O	O
and	NN	O	O
Wechsler	NN	O	O
Memory	NN	O	O
Scale	NN	O	O
-	NN	O	O
Revised	NN	O	O
which	NN	O	O
,	NN	O	O
in	NN	O	O
total	NN	O	O
,	NN	O	O
provided	NN	O	O
13	NN	O	O
psychometric	NN	O	O
measures	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
While	NN	O	O
the	NN	O	O
CAN	NN	O	O
and	NN	O	O
PD	NN	O	O
groups	NN	O	O
tended	NN	O	O
to	NN	O	O
record	NN	O	O
greater	NN	O	O
deficits	NN	O	O
than	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
drug	NN	O	O
controls	NN	O	O
,	NN	O	O
the	NN	O	O
MDMA	NN	O	O
and	NN	O	O
EX	NN	O	O
-	NN	O	O
MDMA	NN	O	O
groups	NN	O	O
recorded	NN	O	O
greater	NN	O	O
deficits	NN	O	O
than	NN	O	O
all	NN	O	O
the	NN	O	O
control	NN	O	O
groups	NN	O	O
on	NN	O	O
ten	NN	O	O
of	NN	O	O
the	NN	O	O
13	NN	O	O
psychometric	NN	O	O
measures	NN	O	O
.	NN	O	O

Strikingly	NN	O	O
,	NN	O	O
despite	NN	O	O
prolonged	NN	O	O
abstinence	NN	O	O
(	NN	O	O
mean	NN	O	O
,	NN	O	O
4	NN	O	O
.	NN	O	O
98	NN	O	O
;	NN	O	O
range	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
9	NN	O	O
years	NN	O	O
)	NN	O	O
,	NN	O	O
past	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
showed	NN	O	O
few	NN	O	O
signs	NN	O	O
of	NN	O	O
recovery	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
present	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
,	NN	O	O
the	NN	O	O
past	NN	O	O
users	NN	O	O
showed	NN	O	O
no	NN	O	O
change	NN	O	O
for	NN	O	O
ten	NN	O	O
measures	NN	O	O
,	NN	O	O
increased	NN	O	O
impairment	NN	O	O
for	NN	O	O
two	NN	O	O
measures	NN	O	O
,	NN	O	O
and	NN	O	O
improvement	NN	O	O
on	NN	O	O
just	NN	O	O
one	NN	O	O
measure	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Given	NN	O	O
this	NN	O	O
record	NN	O	O
of	NN	O	O
impaired	NN	O	B
memory	NN	O	I
and	NN	O	O
clinically	NN	O	O
significant	NN	O	O
levels	NN	O	O
of	NN	O	O
depression	NN	O	B
,	NN	O	O
impulsiveness	NN	O	B
,	NN	O	O
and	NN	O	O
sleep	NN	O	B
disturbance	NN	O	I
,	NN	O	O
the	NN	O	O
prognosis	NN	O	O
for	NN	O	O
the	NN	O	O
current	NN	O	O
generation	NN	O	O
of	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
is	NN	O	O
a	NN	O	O
major	NN	O	O
cause	NN	O	O
for	NN	O	O
concern	NN	O	O
.	NN	O	O

Association	NN	O	O
of	NN	O	O
common	NN	O	O
genetic	NN	O	O
variants	NN	O	O
of	NN	O	O
HOMER1	NN	O	O
gene	NN	O	O
with	NN	O	O
levodopa	NN	O	O
adverse	NN	O	O
effects	NN	O	O
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
patients	NN	O	O
.	NN	O	O

Levodopa	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
effective	NN	O	O
symptomatic	NN	O	O
therapy	NN	O	O
for	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
,	NN	O	O
but	NN	O	O
its	NN	O	O
chronic	NN	O	O
use	NN	O	O
could	NN	O	O
lead	NN	O	O
to	NN	O	O
chronic	NN	O	O
adverse	NN	O	O
outcomes	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
motor	NN	O	O
fluctuations	NN	O	O
,	NN	O	O
dyskinesia	NN	O	B
and	NN	O	O
visual	NN	O	B
hallucinations	NN	O	I
.	NN	O	O

HOMER1	NN	O	O
is	NN	O	O
a	NN	O	O
protein	NN	O	O
with	NN	O	O
pivotal	NN	O	O
function	NN	O	O
in	NN	O	O
glutamate	NN	O	O
transmission	NN	O	O
,	NN	O	O
which	NN	O	O
has	NN	O	O
been	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
these	NN	O	O
complications	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
investigates	NN	O	O
whether	NN	O	O
polymorphisms	NN	O	O
in	NN	O	O
the	NN	O	O
HOMER1	NN	O	O
gene	NN	O	O
promoter	NN	O	O
region	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
the	NN	O	O
chronic	NN	O	O
complications	NN	O	O
of	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
205	NN	O	O
patients	NN	O	O
with	NN	O	O
idiopathic	NN	O	B
Parkinson	NN	O	I
'	NN	O	I
s	NN	O	I
disease	NN	O	I
were	NN	O	O
investigated	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
genotyped	NN	O	O
for	NN	O	O
rs4704559	NN	O	O
,	NN	O	O
rs10942891	NN	O	O
and	NN	O	O
rs4704560	NN	O	O
by	NN	O	O
allelic	NN	O	O
discrimination	NN	O	O
with	NN	O	O
Taqman	NN	O	O
assays	NN	O	O
.	NN	O	O

The	NN	O	O
rs4704559	NN	O	O
G	NN	O	O
allele	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
lower	NN	O	O
prevalence	NN	O	O
of	NN	O	O
dyskinesia	NN	O	B
(	NN	O	O
prevalence	NN	O	O
ratio	NN	O	O
(	NN	O	O
PR	NN	O	O
)	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
615	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	NN	O	O
CI	NN	O	O
)	NN	O	O
0	NN	O	O
.	NN	O	O
426	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
887	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
009	NN	O	O
)	NN	O	O
and	NN	O	O
visual	NN	O	B
hallucinations	NN	O	I
(	NN	O	O
PR	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
515	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0	NN	O	O
.	NN	O	O
295	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
899	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
020	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
HOMER1	NN	O	O
rs4704559	NN	O	O
G	NN	O	O
allele	NN	O	O
has	NN	O	O
a	NN	O	O
protective	NN	O	O
role	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
levodopa	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O

Crocin	NN	O	O
improves	NN	O	O
lipid	NN	O	O
dysregulation	NN	O	O
in	NN	O	O
subacute	NN	O	O
diazinon	NN	O	O
exposure	NN	O	O
through	NN	O	O
ERK1	NN	O	O
/	NN	O	O
2	NN	O	O
pathway	NN	O	O
in	NN	O	O
rat	NN	O	O
liver	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
Diazinon	NN	O	O
Yis	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
broadly	NN	O	O
used	NN	O	O
organophosphorus	NN	O	O
insecticides	NN	O	O
in	NN	O	O
agriculture	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
that	NN	O	O
exposure	NN	O	O
to	NN	O	O
diazinon	NN	O	O
may	NN	O	O
interfere	NN	O	O
with	NN	O	O
lipid	NN	O	O
metabolism	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
the	NN	O	O
hypolipidemic	NN	O	O
effect	NN	O	O
of	NN	O	O
crocin	NN	O	O
has	NN	O	O
been	NN	O	O
established	NN	O	O
.	NN	O	O

Earlier	NN	O	O
studies	NN	O	O
revealed	NN	O	O
the	NN	O	O
major	NN	O	O
role	NN	O	O
of	NN	O	O
Extracellular	NN	O	O
signal	NN	O	O
-	NN	O	O
regulated	NN	O	O
kinase	NN	O	O
(	NN	O	O
ERK	NN	O	O
)	NN	O	O
pathways	NN	O	O
in	NN	O	O
low	NN	O	O
-	NN	O	O
density	NN	O	O
lipoprotein	NN	O	O
receptor	NN	O	O
(	NN	O	O
LDLr	NN	O	O
)	NN	O	O
expression	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
lipid	NN	O	O
metabolism	NN	O	O
,	NN	O	O
ERK	NN	O	O
and	NN	O	O
LDLr	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
of	NN	O	O
rats	NN	O	O
exposed	NN	O	O
to	NN	O	O
subacute	NN	O	O
diazinon	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
ameliorating	NN	O	O
effect	NN	O	O
of	NN	O	O
crocin	NN	O	O
on	NN	O	O
diazinon	NN	O	O
induced	NN	O	O
disturbed	NN	O	O
cholesterol	NN	O	O
homeostasis	NN	O	O
was	NN	O	O
studied	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
24	NN	O	O
Rats	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
4	NN	O	O
groups	NN	O	O
and	NN	O	O
received	NN	O	O
following	NN	O	O
treatments	NN	O	O
for	NN	O	O
4	NN	O	O
weeks	NN	O	O
;	NN	O	O
Corn	NN	O	O
oil	NN	O	O
(	NN	O	O
control	NN	O	O
)	NN	O	O
,	NN	O	O
diazinon	NN	O	O
(	NN	O	O
15mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
,	NN	O	O
orally	NN	O	O
)	NN	O	O
and	NN	O	O
crocin	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
25mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
,	NN	O	O
intraperitoneally	NN	O	O
)	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
diazinon	NN	O	O
(	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
levels	NN	O	O
of	NN	O	O
cholesterol	NN	O	O
,	NN	O	O
triglyceride	NN	O	O
and	NN	O	O
LDL	NN	O	O
in	NN	O	O
blood	NN	O	O
of	NN	O	O
rats	NN	O	O
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

Moreover	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
of	NN	O	O
LDLr	NN	O	O
and	NN	O	O
ERK1	NN	O	O
/	NN	O	O
2	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
protein	NN	O	O
levels	NN	O	O
of	NN	O	O
total	NN	O	O
and	NN	O	O
activated	NN	O	O
forms	NN	O	O
of	NN	O	O
ERK1	NN	O	O
/	NN	O	O
2	NN	O	O
in	NN	O	O
rat	NN	O	O
liver	NN	O	O
were	NN	O	O
evaluated	NN	O	O
by	NN	O	O
Western	NN	O	O
blotting	NN	O	O
and	NN	O	O
quantitative	NN	O	O
real	NN	O	O
time	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
analysis	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Our	NN	O	O
data	NN	O	O
showed	NN	O	O
that	NN	O	O
subacute	NN	O	O
exposure	NN	O	O
to	NN	O	O
diazinon	NN	O	O
significantly	NN	O	O
increased	NN	O	O
concentrations	NN	O	O
of	NN	O	O
cholesterol	NN	O	O
,	NN	O	O
triglyceride	NN	O	O
and	NN	O	O
LDL	NN	O	O
.	NN	O	O

Moreover	NN	O	O
diazinon	NN	O	O
decreased	NN	O	O
ERK1	NN	O	O
/	NN	O	O
2	NN	O	O
protein	NN	O	O
phosphorylation	NN	O	O
and	NN	O	O
LDLr	NN	O	O
transcript	NN	O	O
.	NN	O	O

Crocin	NN	O	O
reduced	NN	O	O
inhibition	NN	O	O
of	NN	O	O
ERK	NN	O	O
activation	NN	O	O
and	NN	O	O
diazinon	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperlipemia	NN	O	B
and	NN	O	O
increased	NN	O	O
levels	NN	O	O
of	NN	O	O
LDLr	NN	O	O
transcript	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Crocin	NN	O	O
may	NN	O	O
be	NN	O	O
considered	NN	O	O
as	NN	O	O
a	NN	O	O
novel	NN	O	O
protective	NN	O	O
agent	NN	O	O
in	NN	O	O
diazinon	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperlipemia	NN	O	B
through	NN	O	O
modulating	NN	O	O
of	NN	O	O
ERK	NN	O	O
pathway	NN	O	O
and	NN	O	O
increase	NN	O	O
of	NN	O	O
LDLr	NN	O	O
expression	NN	O	O
.	NN	O	O

GEM	NN	O	O
-	NN	O	O
P	NN	O	O
chemotherapy	NN	O	O
is	NN	O	O
active	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
relapsed	NN	O	O
Hodgkin	NN	O	B
lymphoma	NN	O	I
.	NN	O	O

Hodgkin	NN	O	B
lymphoma	NN	O	I
(	NN	O	O
HL	NN	O	B
)	NN	O	O
is	NN	O	O
a	NN	O	O
relatively	NN	O	O
chemosensitive	NN	O	O
malignancy	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
for	NN	O	O
those	NN	O	O
who	NN	O	O
relapse	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
chemotherapy	NN	O	O
with	NN	O	O
autologous	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplant	NN	O	O
is	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
choice	NN	O	O
which	NN	O	O
relies	NN	O	O
on	NN	O	O
adequate	NN	O	O
disease	NN	O	O
control	NN	O	O
with	NN	O	O
salvage	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Regimens	NN	O	O
commonly	NN	O	O
used	NN	O	O
often	NN	O	O
require	NN	O	O
inpatient	NN	O	O
administration	NN	O	O
and	NN	O	O
can	NN	O	O
be	NN	O	O
difficult	NN	O	O
to	NN	O	O
deliver	NN	O	O
due	NN	O	O
to	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Gemcitabine	NN	O	O
and	NN	O	O
cisplatin	NN	O	O
have	NN	O	O
activity	NN	O	O
in	NN	O	O
HL	NN	O	B
,	NN	O	O
non	NN	O	O
-	NN	O	O
overlapping	NN	O	O
toxicity	NN	O	B
with	NN	O	O
first	NN	O	O
-	NN	O	O
line	NN	O	O
chemotherapeutics	NN	O	O
,	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
delivered	NN	O	O
in	NN	O	O
an	NN	O	O
outpatient	NN	O	O
setting	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
retrospective	NN	O	O
single	NN	O	O
-	NN	O	O
centre	NN	O	O
analysis	NN	O	O
,	NN	O	O
patients	NN	O	O
with	NN	O	O
relapsed	NN	O	O
or	NN	O	O
refractory	NN	O	O
HL	NN	O	B
treated	NN	O	O
with	NN	O	O
gemcitabine	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
day	NN	O	O
(	NN	O	O
D	NN	O	O
)	NN	O	O
1	NN	O	O
,	NN	O	O
D8	NN	O	O
and	NN	O	O
D15	NN	O	O
;	NN	O	O
methylprednisolone	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
mg	NN	O	O
D1	NN	O	O
-	NN	O	O
5	NN	O	O
;	NN	O	O
and	NN	O	O
cisplatin	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
D15	NN	O	O
,	NN	O	O
every	NN	O	O
28	NN	O	O
days	NN	O	O
(	NN	O	O
GEM	NN	O	O
-	NN	O	O
P	NN	O	O
)	NN	O	O
were	NN	O	O
included	NN	O	O
.	NN	O	O

Demographic	NN	O	O
,	NN	O	O
survival	NN	O	O
,	NN	O	O
response	NN	O	O
and	NN	O	O
toxicity	NN	O	B
data	NN	O	O
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
one	NN	O	O
eligible	NN	O	O
patients	NN	O	O
were	NN	O	O
identified	NN	O	O
:	NN	O	O
median	NN	O	O
age	NN	O	O
27	NN	O	O
.	NN	O	O

One	NN	O	O
hundred	NN	O	O
and	NN	O	O
twenty	NN	O	O
-	NN	O	O
two	NN	O	O
cycles	NN	O	O
of	NN	O	O
GEM	NN	O	O
-	NN	O	O
P	NN	O	O
were	NN	O	O
administered	NN	O	O
in	NN	O	O
total	NN	O	O
(	NN	O	O
median	NN	O	O
3	NN	O	O
cycles	NN	O	O
;	NN	O	O
range	NN	O	O
1	NN	O	O
-	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

Twenty	NN	O	O
of	NN	O	O
41	NN	O	O
(	NN	O	O
48	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
received	NN	O	O
GEM	NN	O	O
-	NN	O	O
P	NN	O	O
as	NN	O	O
second	NN	O	O
-	NN	O	O
line	NN	O	O
treatment	NN	O	O
and	NN	O	O
11	NN	O	O
/	NN	O	O
41	NN	O	O
(	NN	O	O
27	NN	O	O
%	NN	O	O
)	NN	O	O
as	NN	O	O
third	NN	O	O
-	NN	O	O
line	NN	O	O
therapy	NN	O	O
.	NN	O	O

Overall	NN	O	O
response	NN	O	O
rate	NN	O	O
(	NN	O	O
ORR	NN	O	O
)	NN	O	O
to	NN	O	O
GEM	NN	O	O
-	NN	O	O
P	NN	O	O
in	NN	O	O
the	NN	O	O
entire	NN	O	O
cohort	NN	O	O
was	NN	O	O
80	NN	O	O
%	NN	O	O
(	NN	O	O
complete	NN	O	O
response	NN	O	O
(	NN	O	O
CR	NN	O	O
)	NN	O	O
37	NN	O	O
%	NN	O	O
,	NN	O	O
partial	NN	O	O
response	NN	O	O
44	NN	O	O
%	NN	O	O
)	NN	O	O
with	NN	O	O
14	NN	O	O
/	NN	O	O
15	NN	O	O
CR	NN	O	O
confirmed	NN	O	O
as	NN	O	O
a	NN	O	O
metabolic	NN	O	O
CR	NN	O	O
on	NN	O	O
PET	NN	O	O
and	NN	O	O
ORR	NN	O	O
of	NN	O	O
85	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
20	NN	O	O
second	NN	O	O
-	NN	O	O
line	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
grade	NN	O	O
3	NN	O	O
/	NN	O	O
4	NN	O	O
toxicities	NN	O	B
were	NN	O	O
haematological	NN	O	O
:	NN	O	O
neutropenia	NN	O	B
54	NN	O	O
%	NN	O	O
and	NN	O	O
thrombocytopenia	NN	O	B
51	NN	O	O
%	NN	O	O
.	NN	O	O

Median	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
from	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
GEM	NN	O	O
-	NN	O	O
P	NN	O	O
was	NN	O	O
4	NN	O	O
.	NN	O	O
5	NN	O	O
years	NN	O	O
.	NN	O	O

Following	NN	O	O
GEM	NN	O	O
-	NN	O	O
P	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
year	NN	O	O
progression	NN	O	O
-	NN	O	O
free	NN	O	O
survival	NN	O	O
was	NN	O	O
46	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	NN	O	O
CI	NN	O	O
)	NN	O	O
,	NN	O	O
30	NN	O	O
-	NN	O	O
62	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
year	NN	O	O
overall	NN	O	O
survival	NN	O	O
was	NN	O	O
59	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
43	NN	O	O
-	NN	O	O
74	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Fourteen	NN	O	O
of	NN	O	O
41	NN	O	O
patients	NN	O	O
proceeded	NN	O	O
directly	NN	O	O
to	NN	O	O
autologous	NN	O	O
transplant	NN	O	O
.	NN	O	O

GEM	NN	O	O
-	NN	O	O
P	NN	O	O
is	NN	O	O
a	NN	O	O
salvage	NN	O	O
chemotherapy	NN	O	O
with	NN	O	O
relatively	NN	O	O
high	NN	O	O
response	NN	O	O
rates	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
successful	NN	O	O
transplantation	NN	O	O
in	NN	O	O
appropriate	NN	O	O
patients	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
relapsed	NN	O	O
or	NN	O	O
refractory	NN	O	O
HL	NN	O	B
.	NN	O	O

Basal	NN	O	O
functioning	NN	O	O
of	NN	O	O
the	NN	O	O
hypothalamic	NN	O	O
-	NN	O	O
pituitary	NN	O	O
-	NN	O	O
adrenal	NN	O	O
(	NN	O	O
HPA	NN	O	O
)	NN	O	O
axis	NN	O	O
and	NN	O	O
psychological	NN	O	O
distress	NN	O	O
in	NN	O	O
recreational	NN	O	O
ecstasy	NN	O	O
polydrug	NN	O	O
users	NN	O	O
.	NN	O	O

RATIONALE	NN	O	O
:	NN	O	O
Ecstasy	NN	O	O
(	NN	O	O
MDMA	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
psychostimulant	NN	O	O
drug	NN	O	O
which	NN	O	O
is	NN	O	O
increasingly	NN	O	O
associated	NN	O	O
with	NN	O	O
psychobiological	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

While	NN	O	O
some	NN	O	O
recent	NN	O	O
studies	NN	O	O
suggest	NN	O	O
acute	NN	O	O
changes	NN	O	O
in	NN	O	O
neuroendocrine	NN	O	O
function	NN	O	O
,	NN	O	O
less	NN	O	O
is	NN	O	O
known	NN	O	O
about	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
changes	NN	O	O
in	NN	O	O
HPA	NN	O	O
functionality	NN	O	O
in	NN	O	O
recreational	NN	O	O
users	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
The	NN	O	O
current	NN	O	O
study	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
to	NN	O	O
explore	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
ecstasy	NN	O	O
-	NN	O	O
polydrug	NN	O	O
use	NN	O	O
on	NN	O	O
psychological	NN	O	O
distress	NN	O	O
and	NN	O	O
basal	NN	O	O
functioning	NN	O	O
of	NN	O	O
the	NN	O	O
HPA	NN	O	O
axis	NN	O	O
through	NN	O	O
assessing	NN	O	O
the	NN	O	O
secretion	NN	O	O
of	NN	O	O
cortisol	NN	O	O
across	NN	O	O
the	NN	O	O
diurnal	NN	O	O
period	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Seventy	NN	O	O
-	NN	O	O
six	NN	O	O
participants	NN	O	O
(	NN	O	O
21	NN	O	O
nonusers	NN	O	O
,	NN	O	O
29	NN	O	O
light	NN	O	O
ecstasy	NN	O	O
-	NN	O	O
polydrug	NN	O	O
users	NN	O	O
,	NN	O	O
26	NN	O	O
heavy	NN	O	O
ecstasy	NN	O	O
-	NN	O	O
polydrug	NN	O	O
users	NN	O	O
)	NN	O	O
completed	NN	O	O
a	NN	O	O
substance	NN	O	O
use	NN	O	O
inventory	NN	O	O
and	NN	O	O
measures	NN	O	O
of	NN	O	O
psychological	NN	O	O
distress	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
then	NN	O	O
two	NN	O	O
consecutive	NN	O	O
days	NN	O	O
of	NN	O	O
cortisol	NN	O	O
sampling	NN	O	O
(	NN	O	O
on	NN	O	O
awakening	NN	O	O
,	NN	O	O
30	NN	O	O
min	NN	O	O
post	NN	O	O
awakening	NN	O	O
,	NN	O	O
between	NN	O	O
1400	NN	O	O
and	NN	O	O
1600	NN	O	O
hours	NN	O	O
and	NN	O	O
pre	NN	O	O
bedtime	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
day	NN	O	O
2	NN	O	O
,	NN	O	O
participants	NN	O	O
also	NN	O	O
attended	NN	O	O
the	NN	O	O
laboratory	NN	O	O
to	NN	O	O
complete	NN	O	O
a	NN	O	O
20	NN	O	O
-	NN	O	O
min	NN	O	O
multitasking	NN	O	O
stressor	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Both	NN	O	O
user	NN	O	O
groups	NN	O	O
exhibited	NN	O	O
significantly	NN	O	O
greater	NN	O	O
levels	NN	O	O
of	NN	O	O
anxiety	NN	O	B
and	NN	O	O
depression	NN	O	B
than	NN	O	O
nonusers	NN	O	O
.	NN	O	O

On	NN	O	O
day	NN	O	O
1	NN	O	O
,	NN	O	O
all	NN	O	O
participants	NN	O	O
exhibited	NN	O	O
a	NN	O	O
typical	NN	O	O
cortisol	NN	O	O
profile	NN	O	O
,	NN	O	O
though	NN	O	O
light	NN	O	O
users	NN	O	O
had	NN	O	O
significantly	NN	O	O
elevated	NN	O	O
levels	NN	O	O
pre	NN	O	O
-	NN	O	O
bed	NN	O	O
.	NN	O	O

On	NN	O	O
day	NN	O	O
2	NN	O	O
,	NN	O	O
heavy	NN	O	O
users	NN	O	O
demonstrated	NN	O	O
elevated	NN	O	O
levels	NN	O	O
upon	NN	O	O
awakening	NN	O	O
and	NN	O	O
all	NN	O	O
ecstasy	NN	O	O
-	NN	O	O
polydrug	NN	O	O
users	NN	O	O
demonstrated	NN	O	O
elevated	NN	O	O
pre	NN	O	O
-	NN	O	O
bed	NN	O	O
levels	NN	O	O
compared	NN	O	O
to	NN	O	O
non	NN	O	O
-	NN	O	O
users	NN	O	O
.	NN	O	O

Significant	NN	O	O
between	NN	O	O
group	NN	O	O
differences	NN	O	O
were	NN	O	O
also	NN	O	O
observed	NN	O	O
in	NN	O	O
afternoon	NN	O	O
cortisol	NN	O	O
levels	NN	O	O
and	NN	O	O
in	NN	O	O
overall	NN	O	O
cortisol	NN	O	O
secretion	NN	O	O
across	NN	O	O
the	NN	O	O
day	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
increases	NN	O	O
in	NN	O	O
anxiety	NN	O	B
and	NN	O	O
depression	NN	O	B
are	NN	O	O
in	NN	O	O
line	NN	O	O
with	NN	O	O
previous	NN	O	O
observations	NN	O	O
in	NN	O	O
recreational	NN	O	O
ecstasy	NN	O	O
-	NN	O	O
polydrug	NN	O	O
users	NN	O	O
.	NN	O	O

Dysregulated	NN	O	O
diurnal	NN	O	O
cortisol	NN	O	O
may	NN	O	O
be	NN	O	O
indicative	NN	O	O
of	NN	O	O
inappropriate	NN	O	O
anticipation	NN	O	O
of	NN	O	O
forthcoming	NN	O	O
demands	NN	O	O
and	NN	O	O
hypersecretion	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
the	NN	O	O
increased	NN	O	O
psychological	NN	O	O
and	NN	O	O
physical	NN	O	O
morbidity	NN	O	O
associated	NN	O	O
with	NN	O	O
heavy	NN	O	O
recreational	NN	O	O
use	NN	O	O
of	NN	O	O
ecstasy	NN	O	O
.	NN	O	O

Ifosfamide	NN	O	O
related	NN	O	O
encephalopathy	NN	O	B
:	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
a	NN	O	O
timely	NN	O	O
EEG	NN	O	O
evaluation	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Ifosfamide	NN	O	O
is	NN	O	O
an	NN	O	O
alkylating	NN	O	O
agent	NN	O	O
useful	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
a	NN	O	O
wide	NN	O	O
range	NN	O	O
of	NN	O	O
cancers	NN	O	B
including	NN	O	O
sarcomas	NN	O	B
,	NN	O	O
lymphoma	NN	O	B
,	NN	O	O
gynecologic	NN	O	B
and	NN	O	I
testicular	NN	O	I
cancers	NN	O	I
.	NN	O	O

Encephalopathy	NN	O	B
has	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
10	NN	O	O
-	NN	O	O
40	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
receiving	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
IV	NN	O	O
ifosfamide	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
highlight	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
electroencephalogram	NN	O	O
(	NN	O	O
EEG	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
detection	NN	O	O
and	NN	O	O
management	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
related	NN	O	O
encephalopathy	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Retrospective	NN	O	O
chart	NN	O	O
review	NN	O	O
including	NN	O	O
clinical	NN	O	O
data	NN	O	O
and	NN	O	O
EEG	NN	O	O
recordings	NN	O	O
was	NN	O	O
done	NN	O	O
on	NN	O	O
five	NN	O	O
patients	NN	O	O
,	NN	O	O
admitted	NN	O	O
to	NN	O	O
MD	NN	O	O
Anderson	NN	O	O
Cancer	NN	O	B
Center	NN	O	O
between	NN	O	O
years	NN	O	O
2009	NN	O	O
and	NN	O	O
2012	NN	O	O
,	NN	O	O
who	NN	O	O
developed	NN	O	O
ifosfamide	NN	O	O
related	NN	O	O
acute	NN	O	O
encephalopathy	NN	O	B
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
All	NN	O	O
five	NN	O	O
patients	NN	O	O
experienced	NN	O	O
symptoms	NN	O	O
of	NN	O	O
encephalopathy	NN	O	B
soon	NN	O	O
after	NN	O	O
(	NN	O	O
within	NN	O	O
12	NN	O	O
h	NN	O	O
-	NN	O	O
2	NN	O	O
days	NN	O	O
)	NN	O	O
receiving	NN	O	O
ifosfamide	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
developed	NN	O	O
generalized	NN	O	O
convulsions	NN	O	B
while	NN	O	O
one	NN	O	O
patient	NN	O	O
developed	NN	O	O
continuous	NN	O	O
non	NN	O	B
-	NN	O	I
convulsive	NN	O	I
status	NN	O	I
epilepticus	NN	O	I
(	NN	O	O
NCSE	NN	O	B
)	NN	O	O
that	NN	O	O
required	NN	O	O
ICU	NN	O	O
admission	NN	O	O
and	NN	O	O
intubation	NN	O	O
.	NN	O	O

Initial	NN	O	O
EEG	NN	O	O
showed	NN	O	O
epileptiform	NN	O	O
discharges	NN	O	O
in	NN	O	O
three	NN	O	O
patients	NN	O	O
;	NN	O	O
run	NN	O	O
of	NN	O	O
triphasic	NN	O	O
waves	NN	O	O
in	NN	O	O
one	NN	O	O
patient	NN	O	O
and	NN	O	O
moderate	NN	O	O
degree	NN	O	O
diffuse	NN	O	O
generalized	NN	O	O
slowing	NN	O	O
.	NN	O	O

Mixed	NN	O	O
pattern	NN	O	O
with	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
both	NN	O	O
sharps	NN	O	O
and	NN	O	O
triphasic	NN	O	O
waves	NN	O	O
were	NN	O	O
also	NN	O	O
noted	NN	O	O
.	NN	O	O

Repeat	NN	O	O
EEGs	NN	O	O
within	NN	O	O
24	NN	O	O
_	NN	O	O
h	NN	O	O
of	NN	O	O
symptom	NN	O	O
onset	NN	O	O
showed	NN	O	O
marked	NN	O	O
improvement	NN	O	O
that	NN	O	O
was	NN	O	O
correlated	NN	O	O
with	NN	O	O
clinical	NN	O	O
improvement	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Severity	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
related	NN	O	O
encephalopathy	NN	O	B
correlates	NN	O	O
with	NN	O	O
EEG	NN	O	O
changes	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
a	NN	O	O
timely	NN	O	O
EEG	NN	O	O
evaluation	NN	O	O
for	NN	O	O
patients	NN	O	O
receiving	NN	O	O
ifosfamide	NN	O	O
who	NN	O	O
develop	NN	O	O
features	NN	O	O
of	NN	O	O
encephalopathy	NN	O	B
.	NN	O	O

Incidence	NN	O	O
of	NN	O	O
contrast	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
hospitalised	NN	O	O
patients	NN	O	O
with	NN	O	O
cancer	NN	O	B
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
and	NN	O	O
possible	NN	O	O
factors	NN	O	O
related	NN	O	O
to	NN	O	O
contrast	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
(	NN	O	O
CIN	NN	O	O
)	NN	O	O
in	NN	O	O
hospitalised	NN	O	O
patients	NN	O	O
with	NN	O	O
cancer	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Ninety	NN	O	O
adult	NN	O	O
patients	NN	O	O
were	NN	O	O
enrolled	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
were	NN	O	O
excluded	NN	O	O
.	NN	O	O

Blood	NN	O	O
samples	NN	O	O
were	NN	O	O
examined	NN	O	O
the	NN	O	O
day	NN	O	O
before	NN	O	O
contrast	NN	O	O
-	NN	O	O
enhanced	NN	O	O
computed	NN	O	O
tomography	NN	O	O
(	NN	O	O
CT	NN	O	O
)	NN	O	O
and	NN	O	O
serially	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
thereafter	NN	O	O
.	NN	O	O

CIN	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
(	NN	O	O
Cr	NN	O	O
)	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
or	NN	O	O
elevation	NN	O	O
of	NN	O	O
Cr	NN	O	O
to	NN	O	O
25	NN	O	O
%	NN	O	O
over	NN	O	O
baseline	NN	O	O
.	NN	O	O

Relationships	NN	O	O
between	NN	O	O
CIN	NN	O	O
and	NN	O	O
possible	NN	O	O
risk	NN	O	O
factors	NN	O	O
were	NN	O	O
investigated	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
CIN	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
18	NN	O	O
/	NN	O	O
90	NN	O	O
(	NN	O	O
20	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
.	NN	O	O

CIN	NN	O	O
developed	NN	O	O
in	NN	O	O
25	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
in	NN	O	O
11	NN	O	O
%	NN	O	O
patients	NN	O	O
who	NN	O	O
did	NN	O	O
not	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

CIN	NN	O	O
more	NN	O	O
frequently	NN	O	O
developed	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
undergone	NN	O	O
CT	NN	O	O
within	NN	O	O
45	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
last	NN	O	O
chemotherapy	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
;	NN	O	O
it	NN	O	O
was	NN	O	O
also	NN	O	O
an	NN	O	O
independent	NN	O	O
risk	NN	O	O
factor	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
017	NN	O	O
)	NN	O	O
.	NN	O	O

CIN	NN	O	O
was	NN	O	O
significantly	NN	O	O
more	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
bevacizumab	NN	O	O
/	NN	O	O
irinotecan	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
021	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
hypertension	NN	O	B
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
044	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
incidence	NN	O	O
of	NN	O	O
CIN	NN	O	O
after	NN	O	O
CT	NN	O	O
in	NN	O	O
hospitalised	NN	O	O
oncological	NN	O	O
patients	NN	O	O
was	NN	O	O
20	NN	O	O
%	NN	O	O
.	NN	O	O

CIN	NN	O	O
developed	NN	O	O
4	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
times	NN	O	O
more	NN	O	O
frequently	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cancer	NN	O	B
who	NN	O	O
had	NN	O	O
undergone	NN	O	O
recent	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Hypertension	NN	O	B
and	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
bevacizumab	NN	O	O
/	NN	O	O
irinotecan	NN	O	O
may	NN	O	O
be	NN	O	O
additional	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
CIN	NN	O	O
development	NN	O	O
.	NN	O	O

KEY	NN	O	O
POINTS	NN	O	O
:	NN	O	O
.	NN	O	O

Contrast	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
(	NN	O	O
CIN	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
concern	NN	O	O
for	NN	O	O
oncological	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
CT	NN	O	O
.	NN	O	O

.	NN	O	O
CIN	NN	O	O
occurs	NN	O	O
more	NN	O	O
often	NN	O	O
when	NN	O	O
CT	NN	O	O
is	NN	O	O
performed	NN	O	O
<	NN	O	O
45	NN	O	O
days	NN	O	O
after	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

.	NN	O	O
Hypertension	NN	O	B
and	NN	O	O
treatment	NN	O	O
with	NN	O	O
bevacizumab	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
additional	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

Syndrome	NN	O	B
of	NN	O	I
inappropriate	NN	O	I
antidiuretic	NN	O	I
hormone	NN	O	I
secretion	NN	O	O
associated	NN	O	O
with	NN	O	O
desvenlafaxine	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
syndrome	NN	O	B
of	NN	O	I
inappropriate	NN	O	I
anti	NN	O	I
-	NN	O	I
diuretic	NN	O	I
hormone	NN	O	I
(	NN	O	O
SIADH	NN	O	B
)	NN	O	O
secretion	NN	O	O
associated	NN	O	O
with	NN	O	O
desvenlafaxine	NN	O	O
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
57	NN	O	O
-	NN	O	O
year	NN	O	O
old	NN	O	O
female	NN	O	O
with	NN	O	O
hyponatraemia	NN	O	B
.	NN	O	O

Her	NN	O	O
medications	NN	O	O
included	NN	O	O
desvenlafaxine	NN	O	O
,	NN	O	O
and	NN	O	O
symptoms	NN	O	O
included	NN	O	O
nausea	NN	O	B
,	NN	O	O
anxiety	NN	O	B
and	NN	O	O
confusion	NN	O	B
.	NN	O	O

The	NN	O	O
serum	NN	O	O
sodium	NN	O	O
at	NN	O	O
this	NN	O	O
time	NN	O	O
was	NN	O	O
120	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
serum	NN	O	O
osmolality	NN	O	O
was	NN	O	O
263	NN	O	O
mosmol	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
urine	NN	O	O
osmolality	NN	O	O
410	NN	O	O
mosmol	NN	O	O
/	NN	O	O
kg	NN	O	O
and	NN	O	O
urine	NN	O	O
sodium	NN	O	O
63	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
consistent	NN	O	O
with	NN	O	O
a	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
SIADH	NN	O	B
.	NN	O	O

Desvenlafaxine	NN	O	O
was	NN	O	O
ceased	NN	O	O
and	NN	O	O
fluid	NN	O	O
restriction	NN	O	O
implemented	NN	O	O
.	NN	O	O

After	NN	O	O
4	NN	O	O
days	NN	O	O
the	NN	O	O
sodium	NN	O	O
increased	NN	O	O
to	NN	O	O
128	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
and	NN	O	O
fluid	NN	O	O
restriction	NN	O	O
was	NN	O	O
relaxed	NN	O	O
.	NN	O	O

During	NN	O	O
her	NN	O	O
further	NN	O	O
3	NN	O	O
weeks	NN	O	O
inpatient	NN	O	O
admission	NN	O	O
the	NN	O	O
serum	NN	O	O
sodium	NN	O	O
ranged	NN	O	O
from	NN	O	O
134	NN	O	O
to	NN	O	O
137	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
mirtazapine	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
SIADH	NN	O	B
has	NN	O	O
been	NN	O	O
widely	NN	O	O
reported	NN	O	O
with	NN	O	O
a	NN	O	O
range	NN	O	O
of	NN	O	O
antidepressants	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
report	NN	O	O
suggests	NN	O	O
that	NN	O	O
desvenlafaxine	NN	O	O
might	NN	O	O
cause	NN	O	O
clinically	NN	O	O
significant	NN	O	O
hyponatremia	NN	O	B
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Clinicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
potential	NN	O	O
for	NN	O	O
antidepressants	NN	O	O
to	NN	O	O
cause	NN	O	O
hyponatremia	NN	O	B
,	NN	O	O
and	NN	O	O
take	NN	O	O
appropriate	NN	O	O
corrective	NN	O	O
action	NN	O	O
where	NN	O	O
necessary	NN	O	O
.	NN	O	O

Oxidative	NN	O	O
stress	NN	O	O
on	NN	O	O
cardiotoxicity	NN	O	B
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
single	NN	O	O
and	NN	O	O
multiple	NN	O	O
doses	NN	O	O
of	NN	O	O
doxorubicin	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
DOX	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
remains	NN	O	O
controversial	NN	O	O
.	NN	O	O

Wistar	NN	O	O
rats	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
66	NN	O	O
)	NN	O	O
received	NN	O	O
DOX	NN	O	O
injections	NN	O	O
intraperitoneally	NN	O	O
and	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
2	NN	O	O
experimental	NN	O	O
protocols	NN	O	O
:	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
rats	NN	O	O
were	NN	O	O
killed	NN	O	O
before	NN	O	O
(	NN	O	O
-	NN	O	O
24	NN	O	O
h	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
and	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
(	NN	O	O
+	NN	O	O
24	NN	O	O
h	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
DOX	NN	O	O
(	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
DOX	NN	O	O
acute	NN	O	O
effect	NN	O	O
and	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
rats	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
58	NN	O	O
)	NN	O	O
received	NN	O	O
4	NN	O	O
injections	NN	O	O
of	NN	O	O
DOX	NN	O	O
(	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
/	NN	O	O
week	NN	O	O
)	NN	O	O
and	NN	O	O
were	NN	O	O
killed	NN	O	O
before	NN	O	O
the	NN	O	O
first	NN	O	O
injection	NN	O	O
(	NN	O	O
M0	NN	O	O
)	NN	O	O
and	NN	O	O
1	NN	O	O
week	NN	O	O
after	NN	O	O
each	NN	O	O
injection	NN	O	O
(	NN	O	O
M1	NN	O	O
,	NN	O	O
M2	NN	O	O
,	NN	O	O
M3	NN	O	O
,	NN	O	O
and	NN	O	O
M4	NN	O	O
)	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
chronological	NN	O	O
effects	NN	O	O
.	NN	O	O

Animals	NN	O	O
used	NN	O	O
at	NN	O	O
M0	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
were	NN	O	O
also	NN	O	O
used	NN	O	O
at	NN	O	O
moment	NN	O	O
-	NN	O	O
24	NN	O	O
h	NN	O	O
of	NN	O	O
acute	NN	O	O
study	NN	O	O
.	NN	O	O

Cardiac	NN	O	O
total	NN	O	O
antioxidant	NN	O	O
performance	NN	O	O
(	NN	O	O
TAP	NN	O	O
)	NN	O	O
,	NN	O	O
DNA	NN	O	O
damage	NN	O	O
,	NN	O	O
and	NN	O	O
morphology	NN	O	O
analyses	NN	O	O
were	NN	O	O
carried	NN	O	O
out	NN	O	O
at	NN	O	O
each	NN	O	O
time	NN	O	O
point	NN	O	O
.	NN	O	O

Single	NN	O	O
dose	NN	O	O
of	NN	O	O
DOX	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
cardiac	NN	O	B
disarrangement	NN	O	I
,	NN	O	O
necrosis	NN	O	B
,	NN	O	O
and	NN	O	O
DNA	NN	O	O
damage	NN	O	O
(	NN	O	O
strand	NN	O	O
breaks	NN	O	O
(	NN	O	O
SBs	NN	O	O
)	NN	O	O
and	NN	O	O
oxidized	NN	O	O
pyrimidines	NN	O	O
)	NN	O	O
and	NN	O	O
decreased	NN	O	O
TAP	NN	O	O
.	NN	O	O

The	NN	O	O
chronological	NN	O	O
study	NN	O	O
showed	NN	O	O
an	NN	O	O
effect	NN	O	O
of	NN	O	O
a	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
on	NN	O	O
body	NN	O	O
weight	NN	O	O
(	NN	O	O
R	NN	O	O
=	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
99	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
011	NN	O	O
)	NN	O	O
,	NN	O	O
necrosis	NN	O	B
(	NN	O	O
R	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
00	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
004	NN	O	O
)	NN	O	O
,	NN	O	O
TAP	NN	O	O
(	NN	O	O
R	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
95	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
049	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
DNA	NN	O	O
SBs	NN	O	O
(	NN	O	O
R	NN	O	O
=	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
95	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
049	NN	O	O
)	NN	O	O
.	NN	O	O

DNA	NN	O	O
SBs	NN	O	O
damage	NN	O	O
was	NN	O	O
negatively	NN	O	O
associated	NN	O	O
with	NN	O	O
TAP	NN	O	O
(	NN	O	O
R	NN	O	O
=	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
98	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
018	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
necrosis	NN	O	B
(	NN	O	O
R	NN	O	O
=	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
97	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
027	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
oxidative	NN	O	O
damage	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
acute	NN	O	O
cardiotoxicity	NN	O	B
induced	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
DOX	NN	O	O
only	NN	O	O
.	NN	O	O

Increased	NN	O	O
resistance	NN	O	O
to	NN	O	O
the	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
is	NN	O	O
plausible	NN	O	O
for	NN	O	O
the	NN	O	O
multiple	NN	O	O
dose	NN	O	O
of	NN	O	O
DOX	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
different	NN	O	O
mechanisms	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
acute	NN	O	O
toxicity	NN	O	B
versus	NN	O	O
chronic	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Tacrolimus	NN	O	O
-	NN	O	O
related	NN	O	O
seizure	NN	O	B
after	NN	O	O
pediatric	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
-	NN	O	O
-	NN	O	O
a	NN	O	O
single	NN	O	O
-	NN	O	O
center	NN	O	O
experience	NN	O	O
.	NN	O	O

To	NN	O	O
identify	NN	O	O
the	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
new	NN	O	O
-	NN	O	O
onset	NN	O	O
seizures	NN	O	B
after	NN	O	O
pediatric	NN	O	O
LT	NN	O	O
and	NN	O	O
to	NN	O	O
assess	NN	O	O
their	NN	O	O
clinical	NN	O	O
implications	NN	O	O
and	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
prognosis	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
and	NN	O	O
laboratory	NN	O	O
data	NN	O	O
of	NN	O	O
27	NN	O	O
consecutive	NN	O	O
children	NN	O	O
who	NN	O	O
underwent	NN	O	O
LT	NN	O	O
from	NN	O	O
January	NN	O	O
2007	NN	O	O
to	NN	O	O
December	NN	O	O
2010	NN	O	O
in	NN	O	O
our	NN	O	O
center	NN	O	O
were	NN	O	O
analyzed	NN	O	O
retrospectively	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
seizures	NN	O	B
group	NN	O	O
and	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
seizures	NN	O	B
group	NN	O	O
.	NN	O	O

Pre	NN	O	O
-	NN	O	O
operative	NN	O	O
,	NN	O	O
intra	NN	O	O
-	NN	O	O
operative	NN	O	O
,	NN	O	O
and	NN	O	O
post	NN	O	O
-	NN	O	O
operative	NN	O	O
data	NN	O	O
were	NN	O	O
collected	NN	O	O
.	NN	O	O

Seizures	NN	O	B
occurred	NN	O	O
in	NN	O	O
four	NN	O	O
children	NN	O	O
,	NN	O	O
an	NN	O	O
incidence	NN	O	O
of	NN	O	O
14	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
.	NN	O	O

All	NN	O	O
exhibited	NN	O	O
generalized	NN	O	O
tonic	NN	O	B
-	NN	O	I
clonic	NN	O	I
seizures	NN	O	I
within	NN	O	O
the	NN	O	O
first	NN	O	O
two	NN	O	O
wk	NN	O	O
after	NN	O	O
LT	NN	O	O
.	NN	O	O

Univariate	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
risk	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
seizures	NN	O	B
after	NN	O	O
pediatric	NN	O	O
LT	NN	O	O
included	NN	O	O
gender	NN	O	O
,	NN	O	O
pediatric	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
liver	NN	O	I
disease	NN	O	I
score	NN	O	O
before	NN	O	O
surgery	NN	O	O
,	NN	O	O
Child	NN	O	O
-	NN	O	O
Pugh	NN	O	O
score	NN	O	O
before	NN	O	O
surgery	NN	O	O
,	NN	O	O
serum	NN	O	O
total	NN	O	O
bilirubin	NN	O	O
after	NN	O	O
surgery	NN	O	O
,	NN	O	O
and	NN	O	O
trough	NN	O	O
TAC	NN	O	O
level	NN	O	O
.	NN	O	O

Multivariate	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
trough	NN	O	O
TAC	NN	O	O
level	NN	O	O
was	NN	O	O
the	NN	O	O
only	NN	O	O
independent	NN	O	O
risk	NN	O	O
factor	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
seizures	NN	O	B
.	NN	O	O

All	NN	O	O
children	NN	O	O
who	NN	O	O
experienced	NN	O	O
seizures	NN	O	B
survived	NN	O	O
with	NN	O	O
good	NN	O	O
graft	NN	O	O
function	NN	O	O
and	NN	O	O
remained	NN	O	O
seizure	NN	O	B
-	NN	O	O
free	NN	O	O
without	NN	O	O
anti	NN	O	O
-	NN	O	O
epileptic	NN	O	B
drugs	NN	O	O
over	NN	O	O
a	NN	O	O
mean	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
of	NN	O	O
33	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
14	NN	O	O
.	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

High	NN	O	O
trough	NN	O	O
TAC	NN	O	O
level	NN	O	O
was	NN	O	O
the	NN	O	O
predominant	NN	O	O
factor	NN	O	O
that	NN	O	O
contributed	NN	O	O
to	NN	O	O
seizures	NN	O	B
in	NN	O	O
the	NN	O	O
early	NN	O	O
post	NN	O	O
-	NN	O	O
operative	NN	O	O
period	NN	O	O
after	NN	O	O
pediatric	NN	O	O
LT	NN	O	O
.	NN	O	O

High	NN	O	O
PELD	NN	O	O
and	NN	O	O
Child	NN	O	O
-	NN	O	O
Pugh	NN	O	O
scores	NN	O	O
before	NN	O	O
LT	NN	O	O
and	NN	O	O
high	NN	O	O
post	NN	O	O
-	NN	O	O
operative	NN	O	O
serum	NN	O	O
Tbil	NN	O	O
may	NN	O	O
be	NN	O	O
contributory	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
TAC	NN	O	O
-	NN	O	O
related	NN	O	O
seizures	NN	O	B
.	NN	O	O

The	NN	O	O
flavonoid	NN	O	O
apigenin	NN	O	O
delays	NN	O	O
forgetting	NN	O	O
of	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
conditioning	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
experiments	NN	O	O
were	NN	O	O
performed	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
flavonoid	NN	O	O
apigenin	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
intraperitoneally	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
,	NN	O	O
1	NN	O	O
h	NN	O	O
before	NN	O	O
acquisition	NN	O	O
)	NN	O	O
,	NN	O	O
on	NN	O	O
24	NN	O	O
h	NN	O	O
retention	NN	O	O
performance	NN	O	O
and	NN	O	O
forgetting	NN	O	O
of	NN	O	O
a	NN	O	O
step	NN	O	O
-	NN	O	O
through	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
,	NN	O	O
in	NN	O	O
young	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
differences	NN	O	O
between	NN	O	O
saline	NN	O	O
-	NN	O	O
and	NN	O	O
apigenin	NN	O	O
-	NN	O	O
treated	NN	O	O
groups	NN	O	O
in	NN	O	O
the	NN	O	O
24	NN	O	O
h	NN	O	O
retention	NN	O	O
trial	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
apigenin	NN	O	O
did	NN	O	O
not	NN	O	O
prevent	NN	O	O
the	NN	O	O
amnesia	NN	O	B
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
(	NN	O	O
1mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
,	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
the	NN	O	O
acquisition	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
saline	NN	O	O
-	NN	O	O
and	NN	O	O
apigenin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
that	NN	O	O
did	NN	O	O
not	NN	O	O
step	NN	O	O
through	NN	O	O
into	NN	O	O
the	NN	O	O
dark	NN	O	O
compartment	NN	O	O
during	NN	O	O
the	NN	O	O
cut	NN	O	O
-	NN	O	O
off	NN	O	O
time	NN	O	O
(	NN	O	O
540	NN	O	O
s	NN	O	O
)	NN	O	O
were	NN	O	O
retested	NN	O	O
weekly	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
eight	NN	O	O
weeks	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
saline	NN	O	O
treated	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
first	NN	O	O
significant	NN	O	O
decline	NN	O	O
in	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
response	NN	O	O
was	NN	O	O
observed	NN	O	O
at	NN	O	O
four	NN	O	O
weeks	NN	O	O
,	NN	O	O
and	NN	O	O
complete	NN	O	O
memory	NN	O	B
loss	NN	O	I
was	NN	O	O
found	NN	O	O
five	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
acquisition	NN	O	O
of	NN	O	O
the	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
experimental	NN	O	O
period	NN	O	O
,	NN	O	O
60	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
apigenin	NN	O	O
still	NN	O	O
did	NN	O	O
not	NN	O	O
step	NN	O	O
through	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
1	NN	O	O
)	NN	O	O
apigenin	NN	O	O
delays	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
forgetting	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
modulate	NN	O	O
the	NN	O	O
24	NN	O	O
h	NN	O	O
retention	NN	O	O
of	NN	O	O
fear	NN	O	O
memory	NN	O	O
and	NN	O	O
2	NN	O	O
)	NN	O	O
the	NN	O	O
obtained	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
of	NN	O	O
apigenin	NN	O	O
on	NN	O	O
the	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
conditioning	NN	O	O
is	NN	O	O
mediated	NN	O	O
by	NN	O	O
mechanisms	NN	O	O
that	NN	O	O
do	NN	O	O
not	NN	O	O
implicate	NN	O	O
its	NN	O	O
action	NN	O	O
on	NN	O	O
the	NN	O	O
muscarinic	NN	O	O
cholinergic	NN	O	O
system	NN	O	O
.	NN	O	O

Histamine	NN	O	O
antagonists	NN	O	O
and	NN	O	O
d	NN	O	O
-	NN	O	O
tubocurarine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
in	NN	O	O
cardiac	NN	O	O
surgical	NN	O	O
patients	NN	O	O
.	NN	O	O

Hemodynamic	NN	O	O
effects	NN	O	O
and	NN	O	O
histamine	NN	O	O
release	NN	O	O
by	NN	O	O
bolus	NN	O	O
injection	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
35	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
d	NN	O	O
-	NN	O	O
tubocurarine	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
24	NN	O	O
patients	NN	O	O
.	NN	O	O

H1	NN	O	O
-	NN	O	O
and	NN	O	O
H2	NN	O	O
-	NN	O	O
histamine	NN	O	O
antagonists	NN	O	O
or	NN	O	O
placebo	NN	O	O
were	NN	O	O
given	NN	O	O
before	NN	O	O
dosing	NN	O	O
with	NN	O	O
d	NN	O	O
-	NN	O	O
tubocurarine	NN	O	O
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
fashion	NN	O	O
to	NN	O	O
four	NN	O	O
groups	NN	O	O
:	NN	O	O
group	NN	O	O
1	NN	O	O
-	NN	O	O
-	NN	O	O
placebo	NN	O	O
;	NN	O	O
group	NN	O	O
2	NN	O	O
-	NN	O	O
-	NN	O	O
cimetidine	NN	O	O
,	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
plus	NN	O	O
placebo	NN	O	O
;	NN	O	O
group	NN	O	O
3	NN	O	O
-	NN	O	O
-	NN	O	O
chlorpheniramine	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
plus	NN	O	O
placebo	NN	O	O
;	NN	O	O
and	NN	O	O
group	NN	O	O
4	NN	O	O
-	NN	O	O
-	NN	O	O
cimetidine	NN	O	O
plus	NN	O	O
chlorpheniramine	NN	O	O
.	NN	O	O

Histamine	NN	O	O
release	NN	O	O
occurred	NN	O	O
in	NN	O	O
most	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
highest	NN	O	O
level	NN	O	O
2	NN	O	O
minutes	NN	O	O
after	NN	O	O
d	NN	O	O
-	NN	O	O
tubocurarine	NN	O	O
dosing	NN	O	O
.	NN	O	O

Group	NN	O	O
1	NN	O	O
had	NN	O	O
a	NN	O	O
moderate	NN	O	O
negative	NN	O	O
correlation	NN	O	O
between	NN	O	O
plasma	NN	O	O
histamine	NN	O	O
change	NN	O	O
and	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
58	NN	O	O
;	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
not	NN	O	O
present	NN	O	O
in	NN	O	O
group	NN	O	O
4	NN	O	O
.	NN	O	O

Prior	NN	O	O
dosing	NN	O	O
with	NN	O	O
antagonists	NN	O	O
partially	NN	O	O
prevented	NN	O	O
the	NN	O	O
fall	NN	O	O
in	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
the	NN	O	O
hemodynamic	NN	O	O
changes	NN	O	O
associated	NN	O	O
with	NN	O	O
d	NN	O	O
-	NN	O	O
tubocurarine	NN	O	O
dosing	NN	O	O
are	NN	O	O
only	NN	O	O
partially	NN	O	O
explained	NN	O	O
by	NN	O	O
histamine	NN	O	O
release	NN	O	O
.	NN	O	O

Thus	NN	O	O
prior	NN	O	O
dosing	NN	O	O
with	NN	O	O
H1	NN	O	O
-	NN	O	O
and	NN	O	O
H2	NN	O	O
-	NN	O	O
antagonists	NN	O	O
provides	NN	O	O
only	NN	O	O
partial	NN	O	O
protection	NN	O	O
.	NN	O	O

Cholecystokinin	NN	O	O
-	NN	O	O
octapeptide	NN	O	O
restored	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
hippocampal	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
potentiation	NN	O	O
impairment	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Cholecystokinin	NN	O	O
-	NN	O	O
octapeptide	NN	O	O
(	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
a	NN	O	O
typical	NN	O	O
brain	NN	O	O
-	NN	O	O
gut	NN	O	O
peptide	NN	O	O
,	NN	O	O
exerts	NN	O	O
a	NN	O	O
wide	NN	O	O
range	NN	O	O
of	NN	O	O
biological	NN	O	O
activities	NN	O	O
on	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
previously	NN	O	O
reported	NN	O	O
that	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
significantly	NN	O	O
alleviated	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B
and	NN	O	O
reversed	NN	O	O
spine	NN	O	O
density	NN	O	O
decreases	NN	O	O
in	NN	O	O
the	NN	O	O
CA1	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
in	NN	O	O
morphine	NN	O	O
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
on	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
potentiation	NN	O	O
(	NN	O	O
LTP	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
lateral	NN	O	O
perforant	NN	O	O
path	NN	O	O
(	NN	O	O
LPP	NN	O	O
)	NN	O	O
-	NN	O	O
granule	NN	O	O
cell	NN	O	O
synapse	NN	O	O
of	NN	O	O
rat	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
(	NN	O	O
DG	NN	O	O
)	NN	O	O
in	NN	O	O
acute	NN	O	O
saline	NN	O	O
or	NN	O	O
morphine	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Population	NN	O	O
spikes	NN	O	O
(	NN	O	O
PS	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
evoked	NN	O	O
by	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
LPP	NN	O	O
,	NN	O	O
were	NN	O	O
recorded	NN	O	O
in	NN	O	O
the	NN	O	O
DG	NN	O	O
region	NN	O	O
.	NN	O	O

Acute	NN	O	O
morphine	NN	O	O
(	NN	O	O
30mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
treatment	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
hippocampal	NN	O	O
LTP	NN	O	O
and	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
(	NN	O	O
1ug	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
restored	NN	O	O
the	NN	O	O
amplitude	NN	O	O
of	NN	O	O
PS	NN	O	O
that	NN	O	O
was	NN	O	O
attenuated	NN	O	O
by	NN	O	O
morphine	NN	O	O
injection	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
microinjection	NN	O	O
of	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
and	NN	O	O
1ug	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
also	NN	O	O
significantly	NN	O	O
augmented	NN	O	O
hippocampal	NN	O	O
LTP	NN	O	O
in	NN	O	O
saline	NN	O	O
-	NN	O	O
treated	NN	O	O
(	NN	O	O
1ml	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
rats	NN	O	O
.	NN	O	O

Pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
CCK2	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
L	NN	O	O
-	NN	O	O
365	NN	O	O
,	NN	O	O
260	NN	O	O
(	NN	O	O
10ug	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
)	NN	O	O
reversed	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
CCK1	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
L	NN	O	O
-	NN	O	O
364	NN	O	O
,	NN	O	O
718	NN	O	O
(	NN	O	O
10ug	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
attenuates	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
morphine	NN	O	O
on	NN	O	O
hippocampal	NN	O	O
LTP	NN	O	O
through	NN	O	O
CCK2	NN	O	O
receptors	NN	O	O
and	NN	O	O
suggest	NN	O	O
an	NN	O	O
ameliorative	NN	O	O
function	NN	O	O
of	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
on	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
memory	NN	O	B
impairment	NN	O	I
.	NN	O	O

Glial	NN	O	O
activation	NN	O	O
and	NN	O	O
post	NN	O	O
-	NN	O	O
synaptic	NN	O	O
neurotoxicity	NN	O	B
:	NN	O	O
the	NN	O	O
key	NN	O	O
events	NN	O	O
in	NN	O	O
Streptozotocin	NN	O	O
(	NN	O	O
ICV	NN	O	O
)	NN	O	O
induced	NN	O	O
memory	NN	O	B
impairment	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
glial	NN	O	O
activation	NN	O	O
and	NN	O	O
post	NN	O	O
synaptic	NN	O	O
toxicity	NN	O	B
in	NN	O	O
ICV	NN	O	O
Streptozotocin	NN	O	O
(	NN	O	O
STZ	NN	O	O
)	NN	O	O
induced	NN	O	O
memory	NN	O	B
impaired	NN	O	I
rats	NN	O	O
was	NN	O	O
explored	NN	O	O
.	NN	O	O

In	NN	O	O
experiment	NN	O	O
set	NN	O	O
up	NN	O	O
1	NN	O	O
:	NN	O	O
Memory	NN	O	B
deficit	NN	O	I
was	NN	O	O
found	NN	O	O
in	NN	O	O
Morris	NN	O	O
water	NN	O	O
maze	NN	O	O
test	NN	O	O
on	NN	O	O
14	NN	O	O
-	NN	O	O
16	NN	O	O
days	NN	O	O
after	NN	O	O
STZ	NN	O	O
(	NN	O	O
ICV	NN	O	O
;	NN	O	O
3mg	NN	O	O
/	NN	O	O
Kg	NN	O	O
)	NN	O	O
administration	NN	O	O
.	NN	O	O

STZ	NN	O	O
causes	NN	O	O
increased	NN	O	O
expression	NN	O	O
of	NN	O	O
GFAP	NN	O	O
,	NN	O	O
CD11b	NN	O	O
and	NN	O	O
TNF	NN	O	O
-	NN	O	O
a	NN	O	O
indicating	NN	O	O
glial	NN	O	O
activation	NN	O	O
and	NN	O	O
neuroinflammation	NN	O	B
.	NN	O	O

STZ	NN	O	O
also	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
ROS	NN	O	O
,	NN	O	O
nitrite	NN	O	O
,	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
and	NN	O	O
reduced	NN	O	O
the	NN	O	O
mitochondrial	NN	O	O
activity	NN	O	O
in	NN	O	O
synaptosomal	NN	O	O
preparation	NN	O	O
illustrating	NN	O	O
free	NN	O	O
radical	NN	O	O
generation	NN	O	O
and	NN	O	O
excitotoxicity	NN	O	B
.	NN	O	O

Increased	NN	O	O
expression	NN	O	O
and	NN	O	O
activity	NN	O	O
of	NN	O	O
Caspase	NN	O	O
-	NN	O	O
3	NN	O	O
was	NN	O	O
also	NN	O	O
observed	NN	O	O
in	NN	O	O
STZ	NN	O	O
treated	NN	O	O
rat	NN	O	O
which	NN	O	O
specify	NN	O	O
apoptotic	NN	O	O
cell	NN	O	O
death	NN	O	O
in	NN	O	O
hippocampus	NN	O	O
and	NN	O	O
cortex	NN	O	O
.	NN	O	O

STZ	NN	O	O
treatment	NN	O	O
showed	NN	O	O
decrease	NN	O	O
expression	NN	O	O
of	NN	O	O
post	NN	O	O
synaptic	NN	O	O
markers	NN	O	O
CaMKIIa	NN	O	O
and	NN	O	O
PSD	NN	O	O
-	NN	O	O
95	NN	O	O
,	NN	O	O
while	NN	O	O
,	NN	O	O
expression	NN	O	O
of	NN	O	O
pre	NN	O	O
synaptic	NN	O	O
markers	NN	O	O
(	NN	O	O
synaptophysin	NN	O	O
and	NN	O	O
SNAP	NN	O	O
-	NN	O	O
25	NN	O	O
)	NN	O	O
remains	NN	O	O
unaltered	NN	O	O
indicating	NN	O	O
selective	NN	O	O
post	NN	O	O
synaptic	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

Oral	NN	O	O
treatment	NN	O	O
with	NN	O	O
Memantine	NN	O	O
(	NN	O	O
10mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
Ibuprofen	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
daily	NN	O	O
for	NN	O	O
13	NN	O	O
days	NN	O	O
attenuated	NN	O	O
STZ	NN	O	O
induced	NN	O	O
glial	NN	O	O
activation	NN	O	O
,	NN	O	O
apoptotic	NN	O	O
cell	NN	O	O
death	NN	O	O
and	NN	O	O
post	NN	O	O
synaptic	NN	O	O
neurotoxicity	NN	O	B
in	NN	O	O
rat	NN	O	O
brain	NN	O	O
.	NN	O	O

Further	NN	O	O
,	NN	O	O
in	NN	O	O
experiment	NN	O	O
set	NN	O	O
up	NN	O	O
2	NN	O	O
:	NN	O	O
where	NN	O	O
memory	NN	O	O
function	NN	O	O
was	NN	O	O
not	NN	O	O
affected	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
9	NN	O	O
days	NN	O	O
after	NN	O	O
STZ	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
level	NN	O	O
of	NN	O	O
GFAP	NN	O	O
,	NN	O	O
CD11b	NN	O	O
,	NN	O	O
TNF	NN	O	O
-	NN	O	O
a	NN	O	O
,	NN	O	O
ROS	NN	O	O
and	NN	O	O
nitrite	NN	O	O
levels	NN	O	O
were	NN	O	O
increased	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
apoptotic	NN	O	O
marker	NN	O	O
,	NN	O	O
synaptic	NN	O	O
markers	NN	O	O
,	NN	O	O
mitochondrial	NN	O	O
activity	NN	O	O
and	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
levels	NN	O	O
remained	NN	O	O
unaffected	NN	O	O
.	NN	O	O

Collective	NN	O	O
data	NN	O	O
indicates	NN	O	O
that	NN	O	O
neuroinflammatory	NN	O	B
process	NN	O	O
and	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
occurs	NN	O	O
earlier	NN	O	O
to	NN	O	O
apoptosis	NN	O	O
and	NN	O	O
does	NN	O	O
not	NN	O	O
affect	NN	O	O
memory	NN	O	O
function	NN	O	O
.	NN	O	O

Present	NN	O	O
study	NN	O	O
clearly	NN	O	O
suggests	NN	O	O
that	NN	O	O
glial	NN	O	O
activation	NN	O	O
and	NN	O	O
post	NN	O	O
synaptic	NN	O	O
neurotoxicity	NN	O	B
are	NN	O	O
the	NN	O	O
key	NN	O	O
factors	NN	O	O
in	NN	O	O
STZ	NN	O	O
induced	NN	O	O
memory	NN	O	B
impairment	NN	O	I
and	NN	O	O
neuronal	NN	O	O
cell	NN	O	O
death	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
effects	NN	O	O
of	NN	O	O
isotonic	NN	O	O
sodium	NN	O	O
chloride	NN	O	O
with	NN	O	O
diltiazem	NN	O	O
in	NN	O	O
prevention	NN	O	O
of	NN	O	O
contrast	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

INTRODUCTION	NN	O	O
AND	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
Contrast	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
(	NN	O	O
CIN	NN	O	O
)	NN	O	O
significantly	NN	O	O
increases	NN	O	O
the	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
investigate	NN	O	O
and	NN	O	O
compare	NN	O	O
the	NN	O	O
protective	NN	O	O
effects	NN	O	O
of	NN	O	O
isotonic	NN	O	O
sodium	NN	O	O
chloride	NN	O	O
with	NN	O	O
sodium	NN	O	O
bicarbonate	NN	O	O
infusion	NN	O	O
and	NN	O	O
isotonic	NN	O	O
sodium	NN	O	O
chloride	NN	O	O
infusion	NN	O	O
with	NN	O	O
diltiazem	NN	O	O
,	NN	O	O
a	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blocker	NN	O	O
,	NN	O	O
in	NN	O	O
preventing	NN	O	O
CIN	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Our	NN	O	O
study	NN	O	O
included	NN	O	O
patients	NN	O	O
who	NN	O	O
were	NN	O	O
administered	NN	O	O
30	NN	O	O
-	NN	O	O
60	NN	O	O
mL	NN	O	O
of	NN	O	O
iodinated	NN	O	O
contrast	NN	O	O
agent	NN	O	O
for	NN	O	O
percutaneous	NN	O	O
coronary	NN	O	O
angiography	NN	O	O
(	NN	O	O
PCAG	NN	O	O
)	NN	O	O
,	NN	O	O
all	NN	O	O
with	NN	O	O
creatinine	NN	O	O
values	NN	O	O
between	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
and	NN	O	O
3	NN	O	O
.	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
three	NN	O	O
groups	NN	O	O
and	NN	O	O
each	NN	O	O
group	NN	O	O
had	NN	O	O
20	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
first	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
was	NN	O	O
administered	NN	O	O
isotonic	NN	O	O
sodium	NN	O	O
chloride	NN	O	O
;	NN	O	O
the	NN	O	O
second	NN	O	O
group	NN	O	O
was	NN	O	O
administered	NN	O	O
a	NN	O	O
solution	NN	O	O
that	NN	O	O
of	NN	O	O
5	NN	O	O
%	NN	O	O
dextrose	NN	O	O
and	NN	O	O
sodium	NN	O	O
bicarbonate	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
third	NN	O	O
group	NN	O	O
was	NN	O	O
administered	NN	O	O
isotonic	NN	O	O
sodium	NN	O	O
chloride	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
contrast	NN	O	O
injection	NN	O	O
.	NN	O	O

The	NN	O	O
third	NN	O	O
group	NN	O	O
received	NN	O	O
an	NN	O	O
additional	NN	O	O
injection	NN	O	O
of	NN	O	O
diltiazem	NN	O	O
the	NN	O	O
day	NN	O	O
before	NN	O	O
and	NN	O	O
first	NN	O	O
2	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
contrast	NN	O	O
injection	NN	O	O
.	NN	O	O

All	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
'	NN	O	O
plasma	NN	O	O
blood	NN	O	O
urea	NN	O	O
nitrogen	NN	O	O
(	NN	O	O
BUN	NN	O	O
)	NN	O	O
and	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
were	NN	O	O
measured	NN	O	O
on	NN	O	O
the	NN	O	O
second	NN	O	O
and	NN	O	O
seventh	NN	O	O
day	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
intravenous	NN	O	O
contrast	NN	O	O
material	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
basal	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
were	NN	O	O
similar	NN	O	O
for	NN	O	O
all	NN	O	O
three	NN	O	O
groups	NN	O	O
(	NN	O	O
p	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Among	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
60	NN	O	O
patients	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
16	NN	O	O
patients	NN	O	O
developed	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
(	NN	O	O
ARF	NN	O	B
)	NN	O	O
on	NN	O	O
the	NN	O	O
second	NN	O	O
day	NN	O	O
after	NN	O	O
contrast	NN	O	O
material	NN	O	O
was	NN	O	O
injected	NN	O	O
(	NN	O	O
26	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
ARF	NN	O	B
on	NN	O	O
the	NN	O	O
second	NN	O	O
day	NN	O	O
after	NN	O	O
the	NN	O	O
injection	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
group	NN	O	O
was	NN	O	O
five	NN	O	O
(	NN	O	O
25	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
second	NN	O	O
group	NN	O	O
was	NN	O	O
six	NN	O	O
(	NN	O	O
30	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
third	NN	O	O
group	NN	O	O
was	NN	O	O
five	NN	O	O
(	NN	O	O
25	NN	O	O
%	NN	O	O
)	NN	O	O
(	NN	O	O
p	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
isotonic	NN	O	O
sodium	NN	O	O
chloride	NN	O	O
,	NN	O	O
sodium	NN	O	O
bicarbonate	NN	O	O
and	NN	O	O
isotonic	NN	O	O
sodium	NN	O	O
chloride	NN	O	O
with	NN	O	O
diltiazem	NN	O	O
application	NN	O	O
in	NN	O	O
prevention	NN	O	O
of	NN	O	O
CIN	NN	O	O
.	NN	O	O

Neurocognitive	NN	O	O
and	NN	O	O
neuroradiologic	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
late	NN	O	O
effects	NN	O	O
in	NN	O	O
children	NN	O	O
treated	NN	O	O
on	NN	O	O
Pediatric	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
(	NN	O	O
POG	NN	O	O
)	NN	O	O
P9605	NN	O	O
(	NN	O	O
standard	NN	O	O
risk	NN	O	O
)	NN	O	O
and	NN	O	O
P9201	NN	O	O
(	NN	O	O
lesser	NN	O	O
risk	NN	O	O
)	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
protocols	NN	O	O
(	NN	O	O
ACCL0131	NN	O	O
)	NN	O	O
:	NN	O	O
a	NN	O	O
methotrexate	NN	O	O
consequence	NN	O	O
?	NN	O	O

A	NN	O	O
report	NN	O	O
from	NN	O	O
the	NN	O	O
Children	NN	O	O
'	NN	O	O
s	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
.	NN	O	O

Concerns	NN	O	O
about	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
methotrexate	NN	O	O
(	NN	O	O
MTX	NN	O	O
)	NN	O	O
neurotoxicity	NN	O	B
in	NN	O	O
the	NN	O	O
1990s	NN	O	O
led	NN	O	O
to	NN	O	O
modifications	NN	O	O
in	NN	O	O
intrathecal	NN	O	O
(	NN	O	O
IT	NN	O	O
)	NN	O	O
therapy	NN	O	O
,	NN	O	O
leucovorin	NN	O	O
rescue	NN	O	O
,	NN	O	O
and	NN	O	O
frequency	NN	O	O
of	NN	O	O
systemic	NN	O	O
MTX	NN	O	O
administration	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
neurocognitive	NN	O	O
outcomes	NN	O	O
and	NN	O	O
neuroradiologic	NN	O	O
evidence	NN	O	O
of	NN	O	O
leukoencephalopathy	NN	O	B
were	NN	O	O
compared	NN	O	O
in	NN	O	O
children	NN	O	O
treated	NN	O	O
with	NN	O	O
intense	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
-	NN	O	O
directed	NN	O	O
therapy	NN	O	O
(	NN	O	O
P9605	NN	O	O
)	NN	O	O
versus	NN	O	O
those	NN	O	O
receiving	NN	O	O
fewer	NN	O	O
CNS	NN	O	O
-	NN	O	O
directed	NN	O	O
treatment	NN	O	O
days	NN	O	O
during	NN	O	O
intensive	NN	O	O
consolidation	NN	O	O
(	NN	O	O
P9201	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
66	NN	O	O
children	NN	O	O
from	NN	O	O
16	NN	O	O
Pediatric	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
institutions	NN	O	O
with	NN	O	O
"	NN	O	O
standard	NN	O	O
-	NN	O	O
risk	NN	O	O
"	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
,	NN	O	O
1	NN	O	O
.	NN	O	O
00	NN	O	O
to	NN	O	O
9	NN	O	O
.	NN	O	O
99	NN	O	O
years	NN	O	O
at	NN	O	O
diagnosis	NN	O	O
,	NN	O	O
without	NN	O	O
evidence	NN	O	O
of	NN	O	O
CNS	NN	O	O
leukemia	NN	O	B
at	NN	O	O
diagnosis	NN	O	O
were	NN	O	O
enrolled	NN	O	O
on	NN	O	O
ACCL0131	NN	O	O
:	NN	O	O
28	NN	O	O
from	NN	O	O
P9201	NN	O	O
and	NN	O	O
38	NN	O	O
from	NN	O	O
P9605	NN	O	O
.	NN	O	O

Magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
scans	NN	O	O
and	NN	O	O
standard	NN	O	O
neuropsychological	NN	O	O
tests	NN	O	O
were	NN	O	O
performed	NN	O	O
>	NN	O	O
2	NN	O	O
.	NN	O	O
6	NN	O	O
years	NN	O	O
after	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Significantly	NN	O	O
more	NN	O	O
P9605	NN	O	O
patients	NN	O	O
developed	NN	O	O
leukoencephalopathy	NN	O	B
compared	NN	O	O
with	NN	O	O
P9201	NN	O	O
patients	NN	O	O
(	NN	O	O
68	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
49	NN	O	O
%	NN	O	O
-	NN	O	O
83	NN	O	O
%	NN	O	O
vs	NN	O	O
.	NN	O	O
22	NN	O	O
%	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
5	NN	O	O
%	NN	O	O
-	NN	O	O
44	NN	O	O
%	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
identified	NN	O	O
as	NN	O	O
late	NN	O	O
as	NN	O	O
7	NN	O	O
.	NN	O	O
7	NN	O	O
years	NN	O	O
after	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
40	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
scored	NN	O	O
<	NN	O	O
85	NN	O	O
on	NN	O	O
either	NN	O	O
Verbal	NN	O	O
or	NN	O	O
Performance	NN	O	O
IQ	NN	O	O
.	NN	O	O

Children	NN	O	O
on	NN	O	O
both	NN	O	O
studies	NN	O	O
had	NN	O	O
significant	NN	O	O
attention	NN	O	B
problems	NN	O	I
,	NN	O	O
but	NN	O	O
P9605	NN	O	O
children	NN	O	O
scored	NN	O	O
below	NN	O	O
average	NN	O	O
on	NN	O	O
more	NN	O	O
neurocognitive	NN	O	O
measures	NN	O	O
than	NN	O	O
those	NN	O	O
treated	NN	O	O
on	NN	O	O
P9201	NN	O	O
(	NN	O	O
82	NN	O	O
%	NN	O	O
,	NN	O	O
14	NN	O	O
/	NN	O	O
17	NN	O	O
measures	NN	O	O
vs	NN	O	O
.	NN	O	O
24	NN	O	O
%	NN	O	O
,	NN	O	O
4	NN	O	O
/	NN	O	O
17	NN	O	O
measures	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
supports	NN	O	O
ongoing	NN	O	O
concerns	NN	O	O
about	NN	O	O
intensive	NN	O	O
MTX	NN	O	O
exposure	NN	O	O
as	NN	O	O
a	NN	O	O
major	NN	O	O
contributor	NN	O	O
to	NN	O	O
CNS	NN	O	O
late	NN	O	O
effects	NN	O	O
.	NN	O	O

Tranexamic	NN	O	O
acid	NN	O	O
overdosage	NN	O	O
-	NN	O	O
induced	NN	O	O
generalized	NN	O	O
seizure	NN	O	B
in	NN	O	O
renal	NN	O	B
failure	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
45	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
lady	NN	O	O
with	NN	O	O
chronic	NN	O	B
kidney	NN	O	I
disease	NN	O	I
stage	NN	O	O
4	NN	O	O
due	NN	O	O
to	NN	O	O
chronic	NN	O	O
tubulointerstial	NN	O	B
disease	NN	O	I
.	NN	O	O

She	NN	O	O
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
our	NN	O	O
center	NN	O	O
for	NN	O	O
severe	NN	O	O
anemia	NN	O	B
due	NN	O	O
to	NN	O	O
menorrhagia	NN	O	B
and	NN	O	O
deterioration	NN	O	B
of	NN	O	I
renal	NN	O	I
function	NN	O	I
.	NN	O	O

She	NN	O	O
was	NN	O	O
infused	NN	O	O
three	NN	O	O
units	NN	O	O
of	NN	O	O
packed	NN	O	O
cells	NN	O	O
during	NN	O	O
a	NN	O	O
session	NN	O	O
of	NN	O	O
hemodialysis	NN	O	O
.	NN	O	O

Tranexamic	NN	O	O
acid	NN	O	O
(	NN	O	O
TNA	NN	O	O
)	NN	O	O
1	NN	O	O
g	NN	O	O
8	NN	O	O
-	NN	O	O
hourly	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
her	NN	O	O
to	NN	O	O
control	NN	O	O
bleeding	NN	O	B
per	NN	O	O
vaginum	NN	O	O
.	NN	O	O

Two	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
sixth	NN	O	O
dose	NN	O	O
of	NN	O	O
TNA	NN	O	O
,	NN	O	O
she	NN	O	O
had	NN	O	O
an	NN	O	O
episode	NN	O	O
of	NN	O	O
generalized	NN	O	O
tonic	NN	O	B
clonic	NN	O	I
convulsions	NN	O	I
.	NN	O	O

TNA	NN	O	O
was	NN	O	O
discontinued	NN	O	O
.	NN	O	O

Investigations	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
revealed	NN	O	O
no	NN	O	O
biochemical	NN	O	O
or	NN	O	O
structural	NN	O	O
central	NN	O	O
nervous	NN	O	B
system	NN	O	I
abnormalities	NN	O	I
that	NN	O	O
could	NN	O	O
have	NN	O	O
provoked	NN	O	O
the	NN	O	O
convulsions	NN	O	B
.	NN	O	O

She	NN	O	O
did	NN	O	O
not	NN	O	O
require	NN	O	O
any	NN	O	O
further	NN	O	O
dialytic	NN	O	O
support	NN	O	O
.	NN	O	O

She	NN	O	O
had	NN	O	O
no	NN	O	O
further	NN	O	O
episodes	NN	O	O
of	NN	O	O
convulsion	NN	O	B
till	NN	O	O
dis	NN	O	O
-	NN	O	O
charge	NN	O	O
and	NN	O	O
during	NN	O	O
the	NN	O	O
two	NN	O	O
months	NN	O	O
of	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
precipitating	NN	O	O
cause	NN	O	O
of	NN	O	O
convulsions	NN	O	B
was	NN	O	O
believed	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
overdose	NN	O	B
of	NN	O	O
TNA	NN	O	O
.	NN	O	O

Pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiovascular	NN	O	B
depression	NN	O	I
using	NN	O	O
different	NN	O	O
lipid	NN	O	O
formulations	NN	O	O
of	NN	O	O
propofol	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
lipid	NN	O	O
emulsions	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
increase	NN	O	O
lethal	NN	O	O
doses	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
lipid	NN	O	O
content	NN	O	O
of	NN	O	O
propofol	NN	O	O
may	NN	O	O
alleviate	NN	O	O
bupivacaine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
propofol	NN	O	O
in	NN	O	O
intralipid	NN	O	O
or	NN	O	O
medialipid	NN	O	O
emulsions	NN	O	O
on	NN	O	O
bupivacaine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Rats	NN	O	O
were	NN	O	O
anaesthetised	NN	O	O
with	NN	O	O
ketamine	NN	O	O
and	NN	O	O
were	NN	O	O
given	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
propofol	NN	O	O
in	NN	O	O
intralipid	NN	O	O
(	NN	O	O
Group	NN	O	O
P	NN	O	O
)	NN	O	O
,	NN	O	O
propofol	NN	O	O
in	NN	O	O
medialipid	NN	O	O
(	NN	O	O
Group	NN	O	O
L	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
saline	NN	O	O
(	NN	O	O
Group	NN	O	O
C	NN	O	O
)	NN	O	O
over	NN	O	O
20	NN	O	O
min	NN	O	O
.	NN	O	O

Thereafter	NN	O	O
,	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
bupivacaine	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
was	NN	O	O
infused	NN	O	O
.	NN	O	O

We	NN	O	O
recorded	NN	O	O
time	NN	O	O
to	NN	O	O
first	NN	O	O
dysrhythmia	NN	O	B
occurrence	NN	O	O
,	NN	O	O
respective	NN	O	O
times	NN	O	O
to	NN	O	O
25	NN	O	O
%	NN	O	O
and	NN	O	O
50	NN	O	O
%	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
heart	NN	O	O
rate	NN	O	O
(	NN	O	O
HR	NN	O	O
)	NN	O	O
and	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
,	NN	O	O
and	NN	O	O
time	NN	O	O
to	NN	O	O
asystole	NN	O	B
and	NN	O	O
total	NN	O	O
amount	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
consumption	NN	O	O
.	NN	O	O

Blood	NN	O	O
and	NN	O	O
tissue	NN	O	O
samples	NN	O	O
were	NN	O	O
collected	NN	O	O
following	NN	O	O
asystole	NN	O	B
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
time	NN	O	O
to	NN	O	O
first	NN	O	O
dysrhythmia	NN	O	B
occurrence	NN	O	O
,	NN	O	O
time	NN	O	O
to	NN	O	O
25	NN	O	O
%	NN	O	O
and	NN	O	O
50	NN	O	O
%	NN	O	O
reductions	NN	O	O
in	NN	O	O
HR	NN	O	O
,	NN	O	O
and	NN	O	O
time	NN	O	O
to	NN	O	O
asystole	NN	O	B
were	NN	O	O
longer	NN	O	O
in	NN	O	O
Group	NN	O	O
P	NN	O	O
than	NN	O	O
the	NN	O	O
other	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
cumulative	NN	O	O
bupivacaine	NN	O	O
dose	NN	O	O
given	NN	O	O
at	NN	O	O
those	NN	O	O
time	NN	O	O
points	NN	O	O
was	NN	O	O
higher	NN	O	O
in	NN	O	O
Group	NN	O	O
P	NN	O	O
.	NN	O	O
Plasma	NN	O	O
bupivacaine	NN	O	O
levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
Group	NN	O	O
P	NN	O	O
than	NN	O	O
in	NN	O	O
Group	NN	O	O
C	NN	O	O
.	NN	O	O
Bupivacaine	NN	O	O
levels	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
and	NN	O	O
heart	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
Group	NN	O	O
P	NN	O	O
and	NN	O	O
Group	NN	O	O
L	NN	O	O
than	NN	O	O
in	NN	O	O
Group	NN	O	O
C	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
We	NN	O	O
conclude	NN	O	O
that	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
propofol	NN	O	O
in	NN	O	O
intralipid	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
propofol	NN	O	O
in	NN	O	O
medialipid	NN	O	O
or	NN	O	O
saline	NN	O	O
,	NN	O	O
delayed	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxic	NN	O	B
effects	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
reduced	NN	O	O
plasma	NN	O	O
bupivacaine	NN	O	O
levels	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
to	NN	O	O
explore	NN	O	O
tissue	NN	O	O
bupivacaine	NN	O	O
levels	NN	O	O
of	NN	O	O
propofol	NN	O	O
in	NN	O	O
medialipid	NN	O	O
and	NN	O	O
adapt	NN	O	O
these	NN	O	O
results	NN	O	O
to	NN	O	O
clinical	NN	O	O
practice	NN	O	O
.	NN	O	O

Drug	NN	O	B
-	NN	O	I
Induced	NN	O	I
Acute	NN	O	I
Liver	NN	O	I
Injury	NN	O	I
Within	NN	O	O
12	NN	O	O
Hours	NN	O	O
After	NN	O	O
Fluvastatin	NN	O	O
Therapy	NN	O	O
.	NN	O	O

Although	NN	O	O
statins	NN	O	O
are	NN	O	O
generally	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
drugs	NN	O	O
,	NN	O	O
recent	NN	O	O
cases	NN	O	O
of	NN	O	O
drug	NN	O	B
-	NN	O	I
induced	NN	O	I
liver	NN	O	I
injury	NN	O	I
associated	NN	O	O
with	NN	O	O
their	NN	O	O
use	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

A	NN	O	O
52	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Chinese	NN	O	O
man	NN	O	O
reported	NN	O	O
with	NN	O	O
liver	NN	O	B
damage	NN	O	I
,	NN	O	O
which	NN	O	O
appeared	NN	O	O
12	NN	O	O
hours	NN	O	O
after	NN	O	O
beginning	NN	O	O
treatment	NN	O	O
with	NN	O	O
fluvastatin	NN	O	O
.	NN	O	O

Patient	NN	O	O
presented	NN	O	O
with	NN	O	O
complaints	NN	O	O
of	NN	O	O
increasing	NN	O	O
nausea	NN	O	B
,	NN	O	O
anorexia	NN	O	B
,	NN	O	O
and	NN	O	O
upper	NN	O	O
abdominal	NN	O	B
pain	NN	O	I
.	NN	O	O

His	NN	O	O
laboratory	NN	O	O
values	NN	O	O
showed	NN	O	O
elevated	NN	O	O
creatine	NN	O	O
kinase	NN	O	O
and	NN	O	O
transaminases	NN	O	O
.	NN	O	O

Testing	NN	O	O
for	NN	O	O
autoantibodies	NN	O	O
was	NN	O	O
also	NN	O	O
negative	NN	O	O
.	NN	O	O

The	NN	O	O
liver	NN	O	O
biochemistries	NN	O	O
eventually	NN	O	O
normalized	NN	O	O
within	NN	O	O
3	NN	O	O
weeks	NN	O	O
of	NN	O	O
stopping	NN	O	O
the	NN	O	O
fluvastatin	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
when	NN	O	O
prescribing	NN	O	O
statins	NN	O	O
,	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
hepatic	NN	O	B
damage	NN	O	I
should	NN	O	O
be	NN	O	O
taken	NN	O	O
into	NN	O	O
account	NN	O	O
.	NN	O	O

Fluconazole	NN	O	O
associated	NN	O	O
agranulocytosis	NN	O	B
and	NN	O	O
thrombocytopenia	NN	O	B
.	NN	O	O

CASE	NN	O	O
:	NN	O	O
We	NN	O	O
describe	NN	O	O
a	NN	O	O
second	NN	O	O
case	NN	O	O
of	NN	O	O
fluconazole	NN	O	O
associated	NN	O	O
agranulocytosis	NN	O	B
with	NN	O	O
thrombocytopenia	NN	O	B
and	NN	O	O
recovery	NN	O	O
upon	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
began	NN	O	O
to	NN	O	O
have	NN	O	O
changes	NN	O	O
in	NN	O	O
white	NN	O	O
blood	NN	O	O
cells	NN	O	O
and	NN	O	O
platelets	NN	O	O
within	NN	O	O
48	NN	O	O
h	NN	O	O
of	NN	O	O
administration	NN	O	O
of	NN	O	O
fluconazole	NN	O	O
and	NN	O	O
began	NN	O	O
to	NN	O	O
recover	NN	O	O
with	NN	O	O
48	NN	O	O
h	NN	O	O
of	NN	O	O
discontinuation	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
highlights	NN	O	O
that	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
blood	NN	O	B
dyscrasias	NN	O	I
can	NN	O	O
occur	NN	O	O
unexpectedly	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
a	NN	O	O
commonly	NN	O	O
used	NN	O	O
drug	NN	O	O
thought	NN	O	O
to	NN	O	O
be	NN	O	O
"	NN	O	O
safe	NN	O	O
"	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
According	NN	O	O
to	NN	O	O
Naranjo	NN	O	O
'	NN	O	O
s	NN	O	O
algorithm	NN	O	O
the	NN	O	O
likelihood	NN	O	O
that	NN	O	O
our	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
agranulocytosis	NN	O	B
and	NN	O	O
thrombocytopenia	NN	O	B
occurred	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
therapy	NN	O	O
with	NN	O	O
fluconazole	NN	O	O
is	NN	O	O
probable	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
six	NN	O	O
points	NN	O	O
.	NN	O	O

We	NN	O	O
feel	NN	O	O
that	NN	O	O
the	NN	O	O
weight	NN	O	O
of	NN	O	O
the	NN	O	O
overall	NN	O	O
evidence	NN	O	O
of	NN	O	O
this	NN	O	O
evidence	NN	O	O
is	NN	O	O
strong	NN	O	O
.	NN	O	O

In	NN	O	O
particular	NN	O	O
the	NN	O	O
temporal	NN	O	O
relationship	NN	O	O
of	NN	O	O
bone	NN	O	B
marrow	NN	O	I
suppression	NN	O	I
to	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
fluconazole	NN	O	O
and	NN	O	O
the	NN	O	O
abatement	NN	O	O
of	NN	O	O
symptoms	NN	O	O
that	NN	O	O
rapidly	NN	O	O
reversed	NN	O	O
immediately	NN	O	O
following	NN	O	O
discontinuation	NN	O	O
.	NN	O	O

Two	NN	O	O
-	NN	O	O
dimensional	NN	O	O
speckle	NN	O	O
tracking	NN	O	O
echocardiography	NN	O	O
combined	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
sensitive	NN	O	O
cardiac	NN	O	O
troponin	NN	O	O
T	NN	O	O
in	NN	O	O
early	NN	O	O
detection	NN	O	O
and	NN	O	O
prediction	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B
during	NN	O	O
epirubicine	NN	O	O
-	NN	O	O
based	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

AIMS	NN	O	O
:	NN	O	O
To	NN	O	O
investigate	NN	O	O
whether	NN	O	O
alterations	NN	O	O
of	NN	O	O
myocardial	NN	O	B
strain	NN	O	I
and	NN	O	O
high	NN	O	O
-	NN	O	O
sensitive	NN	O	O
cardiac	NN	O	O
troponin	NN	O	O
T	NN	O	O
(	NN	O	O
cTnT	NN	O	O
)	NN	O	O
could	NN	O	O
predict	NN	O	O
future	NN	O	O
cardiac	NN	O	B
dysfunction	NN	O	I
in	NN	O	O
patients	NN	O	O
after	NN	O	O
epirubicin	NN	O	O
exposure	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Seventy	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
with	NN	O	O
non	NN	O	B
-	NN	O	I
Hodgkin	NN	O	I
lymphoma	NN	O	I
treated	NN	O	O
with	NN	O	O
epirubicin	NN	O	O
were	NN	O	O
studied	NN	O	O
.	NN	O	O

Blood	NN	O	O
collection	NN	O	O
and	NN	O	O
echocardiography	NN	O	O
were	NN	O	O
performed	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
1	NN	O	O
day	NN	O	O
after	NN	O	O
the	NN	O	O
third	NN	O	O
cycle	NN	O	O
,	NN	O	O
and	NN	O	O
1	NN	O	O
day	NN	O	O
after	NN	O	O
completion	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
studied	NN	O	O
using	NN	O	O
echocardiography	NN	O	O
during	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

Global	NN	O	O
longitudinal	NN	O	O
(	NN	O	O
GLS	NN	O	O
)	NN	O	O
,	NN	O	O
circumferential	NN	O	O
(	NN	O	O
GCS	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
radial	NN	O	O
strain	NN	O	O
(	NN	O	O
GRS	NN	O	O
)	NN	O	O
were	NN	O	O
calculated	NN	O	O
using	NN	O	O
speckle	NN	O	O
tracking	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Left	NN	O	O
ventricular	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
was	NN	O	O
analysed	NN	O	O
by	NN	O	O
real	NN	O	O
-	NN	O	O
time	NN	O	O
3D	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Cardiotoxicity	NN	O	B
was	NN	O	O
defined	NN	O	O
as	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
LVEF	NN	O	O
of	NN	O	O
>	NN	O	O
5	NN	O	O
%	NN	O	O
to	NN	O	O
<	NN	O	O
55	NN	O	O
%	NN	O	O
with	NN	O	O
symptoms	NN	O	O
of	NN	O	O
heart	NN	O	B
failure	NN	O	I
or	NN	O	O
an	NN	O	O
asymptomatic	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
LVEF	NN	O	O
of	NN	O	O
>	NN	O	O
10	NN	O	O
%	NN	O	O
to	NN	O	O
<	NN	O	O
55	NN	O	O
%	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Fourteen	NN	O	O
patients	NN	O	O
(	NN	O	O
18	NN	O	O
.	NN	O	O
67	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
cardiotoxicity	NN	O	B
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

GLS	NN	O	O
(	NN	O	O
-	NN	O	O
18	NN	O	O
.	NN	O	O
48	NN	O	O
+	NN	O	O
1	NN	O	O
.	NN	O	O
72	NN	O	O
%	NN	O	O
vs	NN	O	O
.	NN	O	O
-	NN	O	O
15	NN	O	O
.	NN	O	O
96	NN	O	O
+	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
GCS	NN	O	O
(	NN	O	O
-	NN	O	O
20	NN	O	O
.	NN	O	O
93	NN	O	O
+	NN	O	O
2	NN	O	O
.	NN	O	O
86	NN	O	O
%	NN	O	O
vs	NN	O	O
.	NN	O	O
-	NN	O	O
19	NN	O	O
.	NN	O	O
20	NN	O	O
+	NN	O	O
3	NN	O	O
.	NN	O	O
21	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
GRS	NN	O	O
(	NN	O	O
39	NN	O	O
.	NN	O	O
23	NN	O	O
+	NN	O	O
6	NN	O	O
.	NN	O	O
44	NN	O	O
%	NN	O	O
vs	NN	O	O
.	NN	O	O
34	NN	O	O
.	NN	O	O
98	NN	O	O
+	NN	O	O
6	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
markedly	NN	O	O
reduced	NN	O	O
and	NN	O	O
cTnT	NN	O	O
was	NN	O	O
elevated	NN	O	O
from	NN	O	O
0	NN	O	O
.	NN	O	O
0010	NN	O	O
+	NN	O	O
0	NN	O	O
.	NN	O	O
0020	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
0073	NN	O	O
+	NN	O	O
0	NN	O	O
.	NN	O	O
0038	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
(	NN	O	O
P	NN	O	O
all	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
at	NN	O	O
the	NN	O	O
completion	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
compared	NN	O	O
with	NN	O	O
baseline	NN	O	O
values	NN	O	O
.	NN	O	O

A	NN	O	O
>	NN	O	O
15	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
decrease	NN	O	O
in	NN	O	O
GLS	NN	O	O
[	NN	O	O
sensitivity	NN	O	O
,	NN	O	O
86	NN	O	O
%	NN	O	O
;	NN	O	O
specificity	NN	O	O
,	NN	O	O
75	NN	O	O
%	NN	O	O
;	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
curve	NN	O	O
(	NN	O	O
AUC	NN	O	O
)	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
815	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
]	NN	O	O
and	NN	O	O
a	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
004	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
elevation	NN	O	O
in	NN	O	O
cTnT	NN	O	O
(	NN	O	O
sensitivity	NN	O	O
,	NN	O	O
79	NN	O	O
%	NN	O	O
;	NN	O	O
specificity	NN	O	O
,	NN	O	O
64	NN	O	O
%	NN	O	O
;	NN	O	O
AUC	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
757	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
from	NN	O	O
baseline	NN	O	O
to	NN	O	O
the	NN	O	O
third	NN	O	O
cycle	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
predicted	NN	O	O
later	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

The	NN	O	O
decrease	NN	O	O
in	NN	O	O
GLS	NN	O	O
remained	NN	O	O
the	NN	O	O
only	NN	O	O
independent	NN	O	O
predictor	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
000	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
GLS	NN	O	O
combined	NN	O	O
with	NN	O	O
cTnT	NN	O	O
may	NN	O	O
provide	NN	O	O
a	NN	O	O
reliable	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
invasive	NN	O	O
method	NN	O	O
to	NN	O	O
predict	NN	O	O
cardiac	NN	O	B
dysfunction	NN	O	I
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
anthracycline	NN	O	O
-	NN	O	O
based	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Prevention	NN	O	O
of	NN	O	O
etomidate	NN	O	O
-	NN	O	O
induced	NN	O	O
myoclonus	NN	O	B
:	NN	O	O
which	NN	O	O
is	NN	O	O
superior	NN	O	O
:	NN	O	O
Fentanyl	NN	O	O
,	NN	O	O
midazolam	NN	O	O
,	NN	O	O
or	NN	O	O
a	NN	O	O
combination	NN	O	O
?	NN	O	O

A	NN	O	O
Retrospective	NN	O	O
comparative	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
retrospective	NN	O	O
comparative	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
aimed	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
fentanyl	NN	O	O
,	NN	O	O
midazolam	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
fentanyl	NN	O	O
and	NN	O	O
midazolam	NN	O	O
to	NN	O	O
prevent	NN	O	O
etomidate	NN	O	O
-	NN	O	O
induced	NN	O	O
myoclonus	NN	O	B
.	NN	O	O

MATERIAL	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
based	NN	O	O
on	NN	O	O
anesthesia	NN	O	O
records	NN	O	O
.	NN	O	O

Depending	NN	O	O
on	NN	O	O
the	NN	O	O
drugs	NN	O	O
that	NN	O	O
would	NN	O	O
be	NN	O	O
given	NN	O	O
before	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
with	NN	O	O
etomidate	NN	O	O
,	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
separated	NN	O	O
into	NN	O	O
4	NN	O	O
groups	NN	O	O
:	NN	O	O
no	NN	O	O
pretreatment	NN	O	O
(	NN	O	O
Group	NN	O	O
NP	NN	O	O
)	NN	O	O
,	NN	O	O
fentanyl	NN	O	O
1	NN	O	O
ug	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
Group	NN	O	O
F	NN	O	O
)	NN	O	O
,	NN	O	O
midazolam	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
Group	NN	O	O
M	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
midazolam	NN	O	O
0	NN	O	O
.	NN	O	O
015	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
+	NN	O	O
fentanyl	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
ug	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
Group	NN	O	O
FM	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
received	NN	O	O
the	NN	O	O
same	NN	O	O
anesthetic	NN	O	O
procedure	NN	O	O
were	NN	O	O
selected	NN	O	O
:	NN	O	O
2	NN	O	O
minutes	NN	O	O
after	NN	O	O
intravenous	NN	O	O
injections	NN	O	O
of	NN	O	O
the	NN	O	O
pretreatment	NN	O	O
drugs	NN	O	O
,	NN	O	O
anesthesia	NN	O	O
is	NN	O	O
induced	NN	O	O
with	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
etomidate	NN	O	O
injected	NN	O	O
intravenously	NN	O	O
over	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
20	NN	O	O
-	NN	O	O
30	NN	O	O
seconds	NN	O	O
.	NN	O	O

Myoclonic	NN	O	B
movements	NN	O	I
are	NN	O	O
evaluated	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
observed	NN	O	O
and	NN	O	O
graded	NN	O	O
according	NN	O	O
to	NN	O	O
clinical	NN	O	O
severity	NN	O	O
during	NN	O	O
the	NN	O	O
2	NN	O	O
minutes	NN	O	O
after	NN	O	O
etomidate	NN	O	O
injection	NN	O	O
.	NN	O	O

The	NN	O	O
severity	NN	O	O
of	NN	O	O
pain	NN	O	B
due	NN	O	O
to	NN	O	O
etomidate	NN	O	O
injection	NN	O	O
,	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
,	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
and	NN	O	O
adverse	NN	O	O
effects	NN	O	O
were	NN	O	O
also	NN	O	O
evaluated	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Study	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
myoclonus	NN	O	B
incidence	NN	O	O
was	NN	O	O
85	NN	O	O
%	NN	O	O
,	NN	O	O
40	NN	O	O
%	NN	O	O
,	NN	O	O
70	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
25	NN	O	O
%	NN	O	O
in	NN	O	O
Group	NN	O	O
NP	NN	O	O
,	NN	O	O
Group	NN	O	O
F	NN	O	O
,	NN	O	O
Group	NN	O	O
M	NN	O	O
,	NN	O	O
and	NN	O	O
Group	NN	O	O
FM	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
Group	NN	O	O
F	NN	O	O
and	NN	O	O
Group	NN	O	O
FM	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
We	NN	O	O
conclude	NN	O	O
that	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
fentanyl	NN	O	O
or	NN	O	O
combination	NN	O	O
of	NN	O	O
fentanyl	NN	O	O
and	NN	O	O
midazolam	NN	O	O
was	NN	O	O
effective	NN	O	O
in	NN	O	O
preventing	NN	O	O
etomidate	NN	O	O
-	NN	O	O
induced	NN	O	O
myoclonus	NN	O	B
.	NN	O	O

Convulsant	NN	O	O
effect	NN	O	O
of	NN	O	O
lindane	NN	O	O
and	NN	O	O
regional	NN	O	O
brain	NN	O	O
concentration	NN	O	O
of	NN	O	O
GABA	NN	O	O
and	NN	O	O
dopamine	NN	O	O
.	NN	O	O

Lindane	NN	O	O
(	NN	O	O
gamma	NN	O	O
-	NN	O	O
hexachlorocyclohexane	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
organochlorine	NN	O	O
insecticide	NN	O	O
with	NN	O	O
known	NN	O	O
neurotoxic	NN	O	B
effects	NN	O	O
.	NN	O	O

Its	NN	O	O
mechanism	NN	O	O
of	NN	O	O
action	NN	O	O
is	NN	O	O
not	NN	O	O
well	NN	O	O
understood	NN	O	O
although	NN	O	O
it	NN	O	O
has	NN	O	O
been	NN	O	O
proposed	NN	O	O
that	NN	O	O
lindane	NN	O	O
acts	NN	O	O
as	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
competitive	NN	O	O
antagonist	NN	O	O
at	NN	O	O
the	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acid	NN	O	O
(	NN	O	O
GABA	NN	O	O
)	NN	O	O
-	NN	O	O
A	NN	O	O
receptor	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
lindane	NN	O	O
(	NN	O	O
150	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
GABAergic	NN	O	O
and	NN	O	O
dopaminergic	NN	O	O
systems	NN	O	O
by	NN	O	O
measuring	NN	O	O
the	NN	O	O
concentration	NN	O	O
of	NN	O	O
GABA	NN	O	O
,	NN	O	O
dopamine	NN	O	O
and	NN	O	O
its	NN	O	O
metabolites	NN	O	O
in	NN	O	O
7	NN	O	O
brain	NN	O	O
areas	NN	O	O
at	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
seizures	NN	O	B
.	NN	O	O

All	NN	O	O
animals	NN	O	O
suffered	NN	O	O
tonic	NN	O	O
convulsions	NN	O	B
at	NN	O	O
18	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
4	NN	O	O
min	NN	O	O
after	NN	O	O
lindane	NN	O	O
administration	NN	O	O
.	NN	O	O

The	NN	O	O
concentration	NN	O	O
of	NN	O	O
GABA	NN	O	O
was	NN	O	O
only	NN	O	O
slightly	NN	O	O
but	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
in	NN	O	O
the	NN	O	O
colliculi	NN	O	O
without	NN	O	O
modifications	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
areas	NN	O	O
.	NN	O	O

The	NN	O	O
concentration	NN	O	O
of	NN	O	O
dopamine	NN	O	O
was	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
mesencephalon	NN	O	O
and	NN	O	O
that	NN	O	O
of	NN	O	O
its	NN	O	O
metabolite	NN	O	O
DOPAC	NN	O	O
was	NN	O	O
also	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
mesencephalon	NN	O	O
and	NN	O	O
the	NN	O	O
striatum	NN	O	O
.	NN	O	O

Cholestatic	NN	O	B
presentation	NN	O	O
of	NN	O	O
yellow	NN	O	O
phosphorus	NN	O	O
poisoning	NN	O	B
.	NN	O	O

Yellow	NN	O	O
phosphorus	NN	O	O
,	NN	O	O
a	NN	O	O
component	NN	O	O
of	NN	O	O
certain	NN	O	O
pesticide	NN	O	O
pastes	NN	O	O
and	NN	O	O
fireworks	NN	O	O
,	NN	O	O
is	NN	O	O
well	NN	O	O
known	NN	O	O
to	NN	O	O
cause	NN	O	O
hepatotoxicity	NN	O	B
.	NN	O	O

Poisoning	NN	O	B
with	NN	O	O
yellow	NN	O	O
phosphorus	NN	O	O
classically	NN	O	O
manifests	NN	O	O
with	NN	O	O
acute	NN	O	B
hepatitis	NN	O	I
leading	NN	O	O
to	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
which	NN	O	O
may	NN	O	O
need	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
yellow	NN	O	O
phosphorus	NN	O	O
poisoning	NN	O	B
in	NN	O	O
which	NN	O	O
a	NN	O	O
patient	NN	O	O
presented	NN	O	O
with	NN	O	O
florid	NN	O	O
clinical	NN	O	O
features	NN	O	O
of	NN	O	O
cholestasis	NN	O	B
highlighting	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
cholestasis	NN	O	B
can	NN	O	O
rarely	NN	O	O
be	NN	O	O
a	NN	O	O
presenting	NN	O	O
feature	NN	O	O
of	NN	O	O
yellow	NN	O	O
phosphorus	NN	O	O
hepatotoxicity	NN	O	B
.	NN	O	O

Vasovagal	NN	O	B
syncope	NN	O	I
and	NN	O	O
severe	NN	O	O
bradycardia	NN	O	B
following	NN	O	O
intranasal	NN	O	O
dexmedetomidine	NN	O	O
for	NN	O	O
pediatric	NN	O	O
procedural	NN	O	O
sedation	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
syncope	NN	O	B
and	NN	O	O
bradycardia	NN	O	B
in	NN	O	O
an	NN	O	O
11	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
following	NN	O	O
administration	NN	O	O
of	NN	O	O
intranasal	NN	O	O
dexmedetomidine	NN	O	O
for	NN	O	O
sedation	NN	O	O
for	NN	O	O
a	NN	O	O
voiding	NN	O	O
cystourethrogram	NN	O	O
.	NN	O	O

Following	NN	O	O
successful	NN	O	O
completion	NN	O	O
of	NN	O	O
VCUG	NN	O	O
and	NN	O	O
a	NN	O	O
60	NN	O	O
-	NN	O	O
min	NN	O	O
recovery	NN	O	O
period	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
level	NN	O	O
of	NN	O	O
consciousness	NN	O	O
and	NN	O	O
vital	NN	O	O
signs	NN	O	O
returned	NN	O	O
to	NN	O	O
presedation	NN	O	O
levels	NN	O	O
.	NN	O	O

Upon	NN	O	O
leaving	NN	O	O
the	NN	O	O
sedation	NN	O	O
area	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
collapsed	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
apparent	NN	O	O
inciting	NN	O	O
event	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
quickly	NN	O	O
regained	NN	O	O
consciousness	NN	O	O
and	NN	O	O
no	NN	O	O
injury	NN	O	O
occurred	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
abnormality	NN	O	O
found	NN	O	O
was	NN	O	O
persistent	NN	O	O
bradycardia	NN	O	B
,	NN	O	O
and	NN	O	O
she	NN	O	O
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
for	NN	O	O
telemetric	NN	O	O
observation	NN	O	O
.	NN	O	O

The	NN	O	O
bradycardia	NN	O	B
lasted	NN	O	O
~	NN	O	O
2	NN	O	O
h	NN	O	O
,	NN	O	O
and	NN	O	O
further	NN	O	O
cardiac	NN	O	O
workup	NN	O	O
revealed	NN	O	O
no	NN	O	O
underlying	NN	O	O
abnormality	NN	O	O
.	NN	O	O

Unanticipated	NN	O	O
and	NN	O	O
previously	NN	O	O
unreported	NN	O	O
outcomes	NN	O	O
may	NN	O	O
be	NN	O	O
witnessed	NN	O	O
as	NN	O	O
we	NN	O	O
expand	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
certain	NN	O	O
sedatives	NN	O	O
to	NN	O	O
alternative	NN	O	O
routes	NN	O	O
of	NN	O	O
administration	NN	O	O
.	NN	O	O

Paradoxical	NN	O	O
severe	NN	O	O
agitation	NN	O	B
induced	NN	O	O
by	NN	O	O
add	NN	O	O
-	NN	O	O
on	NN	O	O
high	NN	O	O
-	NN	O	O
doses	NN	O	O
quetiapine	NN	O	O
in	NN	O	O
schizo	NN	O	B
-	NN	O	I
affective	NN	O	I
disorder	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
35	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
suffering	NN	O	O
from	NN	O	O
schizo	NN	O	B
-	NN	O	I
affective	NN	O	I
disorder	NN	O	I
since	NN	O	O
the	NN	O	O
age	NN	O	O
of	NN	O	O
19	NN	O	O
years	NN	O	O
,	NN	O	O
treated	NN	O	O
by	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
first	NN	O	O
-	NN	O	O
generation	NN	O	O
antipsychotics	NN	O	O
,	NN	O	O
zuclopenthixol	NN	O	O
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
and	NN	O	O
lithium	NN	O	O
(	NN	O	O
1200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
(	NN	O	O
serum	NN	O	O
lithium	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
85	NN	O	O
mEq	NN	O	O
/	NN	O	O
l	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
patient	NN	O	O
had	NN	O	O
no	NN	O	O
associated	NN	O	O
personality	NN	O	B
disorder	NN	O	I
(	NN	O	O
particularly	NN	O	O
no	NN	O	O
antisocial	NN	O	B
disorder	NN	O	I
)	NN	O	O
and	NN	O	O
no	NN	O	O
substance	NN	O	B
abuse	NN	O	I
disorder	NN	O	I
.	NN	O	O

Within	NN	O	O
the	NN	O	O
48	NN	O	O
h	NN	O	O
following	NN	O	O
the	NN	O	O
gradual	NN	O	O
introduction	NN	O	O
of	NN	O	O
quetiapine	NN	O	O
(	NN	O	O
up	NN	O	O
to	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
presented	NN	O	O
severe	NN	O	O
agitation	NN	O	B
without	NN	O	O
an	NN	O	O
environmental	NN	O	O
explanation	NN	O	O
,	NN	O	O
contrasting	NN	O	O
with	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
aggressiveness	NN	O	B
or	NN	O	O
personality	NN	O	B
disorder	NN	O	I
.	NN	O	O

The	NN	O	O
diagnoses	NN	O	O
of	NN	O	O
manic	NN	O	B
shift	NN	O	O
and	NN	O	O
akathisia	NN	O	B
were	NN	O	O
dismissed	NN	O	O
.	NN	O	O

The	NN	O	O
withdrawal	NN	O	O
and	NN	O	O
the	NN	O	O
gradual	NN	O	O
reintroduction	NN	O	O
of	NN	O	O
quetiapine	NN	O	O
2	NN	O	O
weeks	NN	O	O
later	NN	O	O
,	NN	O	O
which	NN	O	O
led	NN	O	O
to	NN	O	O
another	NN	O	O
severe	NN	O	O
agitation	NN	O	B
,	NN	O	O
enabled	NN	O	O
us	NN	O	O
to	NN	O	O
attribute	NN	O	O
the	NN	O	O
agitation	NN	O	B
specifically	NN	O	O
to	NN	O	O
quetiapine	NN	O	O
.	NN	O	O

Antioxidant	NN	O	O
effects	NN	O	O
of	NN	O	O
bovine	NN	O	O
lactoferrin	NN	O	O
on	NN	O	O
dexamethasone	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
in	NN	O	O
rat	NN	O	O
.	NN	O	O

Dexamethasone	NN	O	O
-	NN	O	O
(	NN	O	O
Dex	NN	O	O
-	NN	O	O
)	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
is	NN	O	O
associated	NN	O	O
with	NN	O	O
enhanced	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O

Lactoferrin	NN	O	O
(	NN	O	O
LF	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
iron	NN	O	O
-	NN	O	O
binding	NN	O	O
glycoprotein	NN	O	O
with	NN	O	O
antihypertensive	NN	O	O
properties	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
chronic	NN	O	O
administration	NN	O	O
of	NN	O	O
LF	NN	O	O
on	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
hypertension	NN	O	B
upon	NN	O	O
Dex	NN	O	O
administration	NN	O	O
.	NN	O	O

Male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
treated	NN	O	O
by	NN	O	O
Dex	NN	O	O
(	NN	O	O
30	NN	O	O
u	NN	O	O
g	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
subcutaneously	NN	O	O
)	NN	O	O
or	NN	O	O
saline	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
.	NN	O	O

Oral	NN	O	O
bovine	NN	O	O
LF	NN	O	O
(	NN	O	O
30	NN	O	O
,	NN	O	O
100	NN	O	O
,	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
given	NN	O	O
from	NN	O	O
day	NN	O	O
8	NN	O	O
to	NN	O	O
14	NN	O	O
in	NN	O	O
a	NN	O	O
reversal	NN	O	O
study	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
prevention	NN	O	O
study	NN	O	O
,	NN	O	O
rats	NN	O	O
received	NN	O	O
4	NN	O	O
days	NN	O	O
of	NN	O	O
LF	NN	O	O
treatment	NN	O	O
followed	NN	O	O
by	NN	O	O
Dex	NN	O	O
and	NN	O	O
continued	NN	O	O
during	NN	O	O
the	NN	O	O
test	NN	O	O
period	NN	O	O
.	NN	O	O

Systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
SBP	NN	O	O
)	NN	O	O
was	NN	O	O
measured	NN	O	O
using	NN	O	O
tail	NN	O	O
-	NN	O	O
cuff	NN	O	O
method	NN	O	O
.	NN	O	O

Thymus	NN	O	O
weight	NN	O	O
was	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	O
activity	NN	O	O
.	NN	O	O

Plasma	NN	O	O
hydrogen	NN	O	O
peroxide	NN	O	O
(	NN	O	O
H2O2	NN	O	O
)	NN	O	O
concentration	NN	O	O
and	NN	O	O
ferric	NN	O	O
reducing	NN	O	O
antioxidant	NN	O	O
power	NN	O	O
(	NN	O	O
FRAP	NN	O	O
)	NN	O	O
value	NN	O	O
were	NN	O	O
determined	NN	O	O
.	NN	O	O

Dexamethasone	NN	O	O
significantly	NN	O	O
increased	NN	O	O
SBP	NN	O	O
and	NN	O	O
plasma	NN	O	O
H2O2	NN	O	O
level	NN	O	O
and	NN	O	O
decreased	NN	O	O
thymus	NN	O	O
and	NN	O	O
body	NN	O	O
weights	NN	O	O
.	NN	O	O

LF	NN	O	O
lowered	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
and	NN	O	O
dose	NN	O	O
dependently	NN	O	O
prevented	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
Dex	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
.	NN	O	O

LF	NN	O	O
prevented	NN	O	O
body	NN	O	O
weight	NN	O	B
loss	NN	O	I
and	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
elevated	NN	O	O
plasma	NN	O	O
H2O2	NN	O	O
and	NN	O	O
increased	NN	O	O
FRAP	NN	O	O
values	NN	O	O
.	NN	O	O

Chronic	NN	O	O
administration	NN	O	O
of	NN	O	O
LF	NN	O	O
strongly	NN	O	O
reduced	NN	O	O
the	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
production	NN	O	O
of	NN	O	O
ROS	NN	O	O
and	NN	O	O
improved	NN	O	O
antioxidant	NN	O	O
capacity	NN	O	O
in	NN	O	O
Dex	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
inhibition	NN	O	O
of	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
as	NN	O	O
another	NN	O	O
mechanism	NN	O	O
of	NN	O	O
antihypertensive	NN	O	O
action	NN	O	O
of	NN	O	O
LF	NN	O	O
.	NN	O	O

The	NN	O	O
association	NN	O	O
between	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
and	NN	O	O
convulsive	NN	O	B
seizures	NN	O	B
after	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
:	NN	O	O
a	NN	O	O
multivariate	NN	O	O
analysis	NN	O	O
in	NN	O	O
11	NN	O	O
529	NN	O	O
patients	NN	O	O
.	NN	O	O

Because	NN	O	O
of	NN	O	O
a	NN	O	O
lack	NN	O	O
of	NN	O	O
contemporary	NN	O	O
data	NN	O	O
regarding	NN	O	O
seizures	NN	O	B
after	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
,	NN	O	O
we	NN	O	O
undertook	NN	O	O
a	NN	O	O
retrospective	NN	O	O
analysis	NN	O	O
of	NN	O	O
prospectively	NN	O	O
collected	NN	O	O
data	NN	O	O
from	NN	O	O
11	NN	O	O
529	NN	O	O
patients	NN	O	O
in	NN	O	O
whom	NN	O	O
cardiopulmonary	NN	O	O
bypass	NN	O	O
was	NN	O	O
used	NN	O	O
from	NN	O	O
January	NN	O	O
2004	NN	O	O
to	NN	O	O
December	NN	O	O
2010	NN	O	O
.	NN	O	O

A	NN	O	O
convulsive	NN	O	B
seizure	NN	O	B
was	NN	O	O
defined	NN	O	O
as	NN	O	O
a	NN	O	O
transient	NN	O	O
episode	NN	O	O
of	NN	O	O
disturbed	NN	O	O
brain	NN	O	O
function	NN	O	O
characterised	NN	O	O
by	NN	O	O
abnormal	NN	O	B
involuntary	NN	O	I
motor	NN	O	I
movements	NN	O	I
.	NN	O	O

Multivariate	NN	O	O
regression	NN	O	O
analysis	NN	O	O
was	NN	O	O
performed	NN	O	O
to	NN	O	O
identify	NN	O	O
independent	NN	O	O
predictors	NN	O	O
of	NN	O	O
postoperative	NN	O	O
seizures	NN	O	B
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
100	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
developed	NN	O	O
postoperative	NN	O	O
convulsive	NN	O	B
seizures	NN	O	B
.	NN	O	O

Generalised	NN	O	B
and	NN	O	I
focal	NN	O	I
seizures	NN	O	I
were	NN	O	O
identified	NN	O	O
in	NN	O	O
68	NN	O	O
and	NN	O	O
32	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
(	NN	O	O
IQR	NN	O	O
[	NN	O	O
range	NN	O	O
]	NN	O	O
)	NN	O	O
time	NN	O	O
after	NN	O	O
surgery	NN	O	O
when	NN	O	O
the	NN	O	O
seizure	NN	O	B
occurred	NN	O	O
was	NN	O	O
7	NN	O	O
(	NN	O	O
6	NN	O	O
-	NN	O	O
12	NN	O	O
[	NN	O	O
1	NN	O	O
-	NN	O	O
216	NN	O	O
]	NN	O	O
)	NN	O	O
h	NN	O	O
and	NN	O	O
8	NN	O	O
(	NN	O	O
6	NN	O	O
-	NN	O	O
11	NN	O	O
[	NN	O	O
4	NN	O	O
-	NN	O	O
18	NN	O	O
]	NN	O	O
)	NN	O	O
h	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Epileptiform	NN	O	O
findings	NN	O	O
on	NN	O	O
electroencephalography	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
19	NN	O	O
patients	NN	O	O
.	NN	O	O

Independent	NN	O	O
predictors	NN	O	O
of	NN	O	O
postoperative	NN	O	O
seizures	NN	O	B
included	NN	O	O
age	NN	O	O
,	NN	O	O
female	NN	O	O
sex	NN	O	O
,	NN	O	O
redo	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
,	NN	O	O
calcification	NN	O	O
of	NN	O	O
ascending	NN	O	O
aorta	NN	O	O
,	NN	O	O
congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
,	NN	O	O
deep	NN	O	O
hypothermic	NN	O	B
circulatory	NN	O	O
arrest	NN	O	O
,	NN	O	O
duration	NN	O	O
of	NN	O	O
aortic	NN	O	O
cross	NN	O	O
-	NN	O	O
clamp	NN	O	O
and	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
.	NN	O	O

When	NN	O	O
tested	NN	O	O
in	NN	O	O
a	NN	O	O
multivariate	NN	O	O
regression	NN	O	O
analysis	NN	O	O
,	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
was	NN	O	O
a	NN	O	O
strong	NN	O	O
independent	NN	O	O
predictor	NN	O	O
of	NN	O	O
seizures	NN	O	B
(	NN	O	O
OR	NN	O	O
14	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
5	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
36	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
convulsive	NN	O	B
seizures	NN	O	B
had	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
times	NN	O	O
higher	NN	O	O
in	NN	O	O
-	NN	O	O
hospital	NN	O	O
mortality	NN	O	O
rates	NN	O	O
and	NN	O	O
twice	NN	O	O
the	NN	O	O
length	NN	O	O
of	NN	O	O
hospital	NN	O	O
stay	NN	O	O
compared	NN	O	O
with	NN	O	O
patients	NN	O	O
without	NN	O	O
convulsive	NN	O	B
seizures	NN	O	B
.	NN	O	O

Mean	NN	O	O
(	NN	O	O
IQR	NN	O	O
[	NN	O	O
range	NN	O	O
]	NN	O	O
)	NN	O	O
length	NN	O	O
of	NN	O	O
stay	NN	O	O
in	NN	O	O
the	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
was	NN	O	O
115	NN	O	O
(	NN	O	O
49	NN	O	O
-	NN	O	O
228	NN	O	O
[	NN	O	O
32	NN	O	O
-	NN	O	O
481	NN	O	O
]	NN	O	O
)	NN	O	O
h	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
convulsive	NN	O	B
seizures	NN	O	B
compared	NN	O	O
with	NN	O	O
26	NN	O	O
(	NN	O	O
22	NN	O	O
-	NN	O	O
69	NN	O	O
[	NN	O	O
14	NN	O	O
-	NN	O	O
1080	NN	O	O
]	NN	O	O
)	NN	O	O
h	NN	O	O
in	NN	O	O
patients	NN	O	O
without	NN	O	O
seizures	NN	O	B
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Convulsive	NN	O	B
seizures	NN	O	B
are	NN	O	O
a	NN	O	O
serious	NN	O	O
postoperative	NN	O	B
complication	NN	O	I
after	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
.	NN	O	O

As	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
is	NN	O	O
the	NN	O	O
only	NN	O	O
modifiable	NN	O	O
factor	NN	O	O
,	NN	O	O
its	NN	O	O
administration	NN	O	O
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
doses	NN	O	O
exceeding	NN	O	O
80	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
should	NN	O	O
be	NN	O	O
weighed	NN	O	O
against	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
postoperative	NN	O	O
seizures	NN	O	B
.	NN	O	O

Dysfunctional	NN	O	B
overnight	NN	O	I
memory	NN	O	I
consolidation	NN	O	O
in	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
.	NN	O	O

Sleep	NN	O	O
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
consolidation	NN	O	O
and	NN	O	O
integration	NN	O	O
of	NN	O	O
memory	NN	O	O
in	NN	O	O
a	NN	O	O
process	NN	O	O
called	NN	O	O
overnight	NN	O	O
memory	NN	O	O
consolidation	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
indicate	NN	O	O
that	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
have	NN	O	O
marked	NN	O	O
and	NN	O	O
persistent	NN	O	O
neurocognitive	NN	O	O
and	NN	O	O
sleep	NN	O	B
-	NN	O	I
related	NN	O	I
impairments	NN	O	I
.	NN	O	O

We	NN	O	O
extend	NN	O	O
past	NN	O	O
research	NN	O	O
by	NN	O	O
examining	NN	O	O
overnight	NN	O	O
memory	NN	O	O
consolidation	NN	O	O
among	NN	O	O
regular	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
)	NN	O	O
and	NN	O	O
drug	NN	O	O
naive	NN	O	O
healthy	NN	O	O
controls	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
26	NN	O	O
)	NN	O	O
.	NN	O	O

Memory	NN	O	O
recall	NN	O	O
of	NN	O	O
word	NN	O	O
pairs	NN	O	O
was	NN	O	O
evaluated	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
sleep	NN	O	O
,	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
interference	NN	O	O
prior	NN	O	O
to	NN	O	O
testing	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
we	NN	O	O
assessed	NN	O	O
neurocognitive	NN	O	O
performances	NN	O	O
across	NN	O	O
tasks	NN	O	O
of	NN	O	O
learning	NN	O	O
,	NN	O	O
memory	NN	O	O
and	NN	O	O
executive	NN	O	O
functioning	NN	O	O
.	NN	O	O

Ecstasy	NN	O	O
users	NN	O	O
demonstrated	NN	O	O
impaired	NN	O	B
overnight	NN	O	I
memory	NN	O	I
consolidation	NN	O	O
,	NN	O	O
a	NN	O	O
finding	NN	O	O
that	NN	O	O
was	NN	O	O
more	NN	O	O
pronounced	NN	O	O
following	NN	O	O
associative	NN	O	O
interference	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
demonstrated	NN	O	O
impairments	NN	O	O
on	NN	O	O
tasks	NN	O	O
recruiting	NN	O	O
frontostriatal	NN	O	O
and	NN	O	O
hippocampal	NN	O	O
neural	NN	O	O
circuitry	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
domains	NN	O	O
of	NN	O	O
proactive	NN	O	O
interference	NN	O	O
memory	NN	O	O
,	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
memory	NN	O	O
,	NN	O	O
encoding	NN	O	O
,	NN	O	O
working	NN	O	O
memory	NN	O	O
and	NN	O	O
complex	NN	O	O
planning	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
ecstasy	NN	O	O
-	NN	O	O
associated	NN	O	O
dysfunction	NN	O	O
in	NN	O	O
fronto	NN	O	O
-	NN	O	O
temporal	NN	O	O
circuitry	NN	O	O
may	NN	O	O
underlie	NN	O	O
overnight	NN	O	O
consolidation	NN	O	O
memory	NN	O	B
impairments	NN	O	I
in	NN	O	O
regular	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
.	NN	O	O

Normoammonemic	NN	O	O
encephalopathy	NN	O	B
:	NN	O	O
solely	NN	O	O
valproate	NN	O	O
induced	NN	O	O
or	NN	O	O
multiple	NN	O	O
mechanisms	NN	O	O
?	NN	O	O

A	NN	O	O
77	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
presented	NN	O	O
with	NN	O	O
subacute	NN	O	O
onset	NN	O	O
progressive	NN	O	O
confusion	NN	O	B
,	NN	O	O
aggression	NN	O	B
,	NN	O	O
auditory	NN	O	B
hallucinations	NN	O	I
and	NN	O	O
delusions	NN	O	B
.	NN	O	O

In	NN	O	O
the	NN	O	O
preceding	NN	O	O
months	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
had	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
admissions	NN	O	O
with	NN	O	O
transient	NN	O	O
unilateral	NN	O	O
hemiparesis	NN	O	B
with	NN	O	O
facial	NN	O	O
droop	NN	O	O
,	NN	O	O
and	NN	O	O
had	NN	O	O
been	NN	O	O
started	NN	O	O
on	NN	O	O
valproate	NN	O	O
for	NN	O	O
presumed	NN	O	O
hemiplegic	NN	O	B
migraine	NN	O	I
.	NN	O	O

Valproate	NN	O	O
was	NN	O	O
withdrawn	NN	O	O
soon	NN	O	O
after	NN	O	O
admission	NN	O	O
and	NN	O	O
her	NN	O	O
cognitive	NN	O	O
abilities	NN	O	O
have	NN	O	O
gradually	NN	O	O
improved	NN	O	O
over	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

Valproate	NN	O	O
levels	NN	O	O
taken	NN	O	O
prior	NN	O	O
to	NN	O	O
withdrawal	NN	O	O
were	NN	O	O
subtherapeutic	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
normoammonaemic	NN	O	O
.	NN	O	O

EEG	NN	O	O
undertaken	NN	O	O
during	NN	O	O
inpatient	NN	O	O
stay	NN	O	O
showed	NN	O	O
changes	NN	O	O
consistent	NN	O	O
with	NN	O	O
encephalopathy	NN	O	B
,	NN	O	O
and	NN	O	O
low	NN	O	O
titre	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartate	NN	O	O
(	NN	O	O
NMDA	NN	O	O
)	NN	O	O
receptor	NN	O	O
antibodies	NN	O	O
were	NN	O	O
present	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
.	NN	O	O

The	NN	O	O
possible	NN	O	O
aetiologies	NN	O	O
of	NN	O	O
valproate	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
and	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
-	NN	O	O
associated	NN	O	O
encephalitis	NN	O	B
present	NN	O	O
a	NN	O	O
diagnostic	NN	O	O
dilemma	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
putative	NN	O	O
combinatorial	NN	O	O
hypothesis	NN	O	O
to	NN	O	O
explain	NN	O	O
this	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Cerebellar	NN	O	B
and	NN	O	I
oculomotor	NN	O	I
dysfunction	NN	O	I
induced	NN	O	O
by	NN	O	O
rapid	NN	O	O
infusion	NN	O	O
of	NN	O	O
pethidine	NN	O	O
.	NN	O	O

Pethidine	NN	O	O
is	NN	O	O
an	NN	O	O
opioid	NN	O	O
that	NN	O	O
gains	NN	O	O
its	NN	O	O
popularity	NN	O	O
for	NN	O	O
the	NN	O	O
effective	NN	O	O
pain	NN	O	B
control	NN	O	O
through	NN	O	O
acting	NN	O	O
on	NN	O	O
the	NN	O	O
opioid	NN	O	O
-	NN	O	O
receptors	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
rapid	NN	O	O
pain	NN	O	B
relief	NN	O	O
sometimes	NN	O	O
brings	NN	O	O
about	NN	O	O
unfavourable	NN	O	O
side	NN	O	O
effects	NN	O	O
that	NN	O	O
largely	NN	O	O
limit	NN	O	O
its	NN	O	O
clinical	NN	O	O
utility	NN	O	O
.	NN	O	O

Common	NN	O	O
side	NN	O	O
effects	NN	O	O
include	NN	O	O
nausea	NN	O	B
,	NN	O	O
vomiting	NN	O	B
and	NN	O	O
hypotension	NN	O	B
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
impaired	NN	O	B
renal	NN	O	I
and	NN	O	I
liver	NN	O	I
function	NN	O	I
,	NN	O	O
and	NN	O	O
those	NN	O	O
who	NN	O	O
need	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
pain	NN	O	B
control	NN	O	O
,	NN	O	O
pethidine	NN	O	O
may	NN	O	O
cause	NN	O	O
excitatory	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
effects	NN	O	O
through	NN	O	O
its	NN	O	O
neurotoxic	NN	O	B
metabolite	NN	O	O
,	NN	O	O
norpethidine	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
irritability	NN	O	B
and	NN	O	O
seizure	NN	O	B
attack	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
contrary	NN	O	O
,	NN	O	O
though	NN	O	O
not	NN	O	O
clinically	NN	O	O
apparent	NN	O	O
,	NN	O	O
pethidine	NN	O	O
potentially	NN	O	O
causes	NN	O	O
inhibitory	NN	O	O
impacts	NN	O	O
on	NN	O	O
the	NN	O	O
CNS	NN	O	O
and	NN	O	O
impairs	NN	O	O
normal	NN	O	O
cerebellar	NN	O	O
and	NN	O	O
oculomotor	NN	O	O
function	NN	O	O
in	NN	O	O
the	NN	O	O
short	NN	O	O
term	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
case	NN	O	O
report	NN	O	O
,	NN	O	O
we	NN	O	O
highlight	NN	O	O
opioid	NN	O	O
'	NN	O	O
s	NN	O	O
inhibitory	NN	O	O
side	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
cerebellar	NN	O	O
structure	NN	O	O
that	NN	O	O
causes	NN	O	O
dysmetria	NN	O	B
,	NN	O	O
dysarthria	NN	O	B
,	NN	O	O
reduced	NN	O	O
smooth	NN	O	O
pursuit	NN	O	O
gain	NN	O	O
and	NN	O	O
decreased	NN	O	O
saccadic	NN	O	O
velocity	NN	O	O
.	NN	O	O

Baboon	NN	O	B
syndrome	NN	O	I
induced	NN	O	O
by	NN	O	O
ketoconazole	NN	O	O
.	NN	O	O

A	NN	O	O
27	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
patient	NN	O	O
presented	NN	O	O
with	NN	O	O
a	NN	O	O
maculopapular	NN	O	B
eruption	NN	O	I
on	NN	O	O
the	NN	O	O
flexural	NN	O	O
areas	NN	O	O
and	NN	O	O
buttocks	NN	O	O
after	NN	O	O
using	NN	O	O
oral	NN	O	O
ketoconazole	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
baboon	NN	O	B
syndrome	NN	O	I
based	NN	O	O
on	NN	O	O
his	NN	O	O
history	NN	O	O
,	NN	O	O
which	NN	O	O
included	NN	O	O
prior	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
topical	NN	O	O
ketoconazole	NN	O	O
,	NN	O	O
a	NN	O	O
physical	NN	O	O
examination	NN	O	O
,	NN	O	O
and	NN	O	O
histopathological	NN	O	O
findings	NN	O	O
.	NN	O	O

Baboon	NN	O	B
syndrome	NN	O	I
is	NN	O	O
a	NN	O	O
drug	NN	O	O
-	NN	O	O
or	NN	O	O
contact	NN	O	O
allergen	NN	O	O
-	NN	O	O
related	NN	O	O
maculopapular	NN	O	B
eruption	NN	O	I
that	NN	O	O
typically	NN	O	O
involves	NN	O	O
the	NN	O	O
flexural	NN	O	O
and	NN	O	O
gluteal	NN	O	O
areas	NN	O	O
.	NN	O	O

To	NN	O	O
the	NN	O	O
best	NN	O	O
of	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
case	NN	O	O
of	NN	O	O
ketoconazole	NN	O	O
-	NN	O	O
induced	NN	O	O
baboon	NN	O	B
syndrome	NN	O	I
in	NN	O	O
the	NN	O	O
English	NN	O	O
literature	NN	O	O
.	NN	O	O

A	NN	O	O
Case	NN	O	O
of	NN	O	O
Sudden	NN	O	B
Cardiac	NN	O	I
Death	NN	O	I
due	NN	O	O
to	NN	O	O
Pilsicainide	NN	O	O
-	NN	O	O
Induced	NN	O	O
Torsades	NN	O	B
de	NN	O	I
Pointes	NN	O	I
.	NN	O	O

An	NN	O	O
84	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
received	NN	O	O
oral	NN	O	O
pilsicainide	NN	O	O
,	NN	O	O
a	NN	O	O
pure	NN	O	O
sodium	NN	O	O
channel	NN	O	O
blocker	NN	O	O
with	NN	O	O
slow	NN	O	O
recovery	NN	O	O
kinetics	NN	O	O
,	NN	O	O
to	NN	O	O
convert	NN	O	O
his	NN	O	O
paroxysmal	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
to	NN	O	O
a	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
;	NN	O	O
the	NN	O	O
patient	NN	O	O
developed	NN	O	O
sudden	NN	O	B
cardiac	NN	O	I
death	NN	O	I
two	NN	O	O
days	NN	O	O
later	NN	O	O
.	NN	O	O

The	NN	O	O
Holter	NN	O	O
electrocardiogram	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
worn	NN	O	O
by	NN	O	O
chance	NN	O	O
,	NN	O	O
revealed	NN	O	O
torsade	NN	O	B
de	NN	O	I
pointes	NN	O	I
with	NN	O	O
gradually	NN	O	O
prolonged	NN	O	O
QT	NN	O	O
intervals	NN	O	O
.	NN	O	O

This	NN	O	O
drug	NN	O	O
is	NN	O	O
rapidly	NN	O	O
absorbed	NN	O	O
from	NN	O	O
the	NN	O	O
gastrointestinal	NN	O	O
tract	NN	O	O
,	NN	O	O
and	NN	O	O
most	NN	O	O
of	NN	O	O
it	NN	O	O
is	NN	O	O
excreted	NN	O	O
from	NN	O	O
the	NN	O	O
kidney	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
renal	NN	O	O
function	NN	O	O
was	NN	O	O
not	NN	O	O
highly	NN	O	O
impaired	NN	O	O
and	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
pilsicainide	NN	O	O
was	NN	O	O
low	NN	O	O
,	NN	O	O
the	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
of	NN	O	O
pilsicainide	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
high	NN	O	O
,	NN	O	O
which	NN	O	O
can	NN	O	O
produce	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
in	NN	O	O
the	NN	O	O
octogenarian	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
class	NN	O	O
IC	NN	O	O
drugs	NN	O	O
,	NN	O	O
including	NN	O	O
pilsicainide	NN	O	O
,	NN	O	O
is	NN	O	O
effective	NN	O	O
to	NN	O	O
terminate	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
,	NN	O	O
careful	NN	O	O
consideration	NN	O	O
must	NN	O	O
be	NN	O	O
taken	NN	O	O
before	NN	O	O
giving	NN	O	O
these	NN	O	O
drugs	NN	O	O
to	NN	O	O
octogenarians	NN	O	O
.	NN	O	O

All	NN	O	O
-	NN	O	O
trans	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
inflammatory	NN	O	O
myositis	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
acute	NN	O	B
promyelocytic	NN	O	I
leukemia	NN	O	I
.	NN	O	O

All	NN	O	O
-	NN	O	O
trans	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
(	NN	O	O
ATRA	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
component	NN	O	O
of	NN	O	O
standard	NN	O	O
therapy	NN	O	O
for	NN	O	O
acute	NN	O	B
promyelocytic	NN	O	I
leukemia	NN	O	I
(	NN	O	O
APL	NN	O	B
)	NN	O	O
,	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
potentially	NN	O	O
serious	NN	O	O
but	NN	O	O
treatable	NN	O	O
adverse	NN	O	O
effects	NN	O	O
involving	NN	O	O
numerous	NN	O	O
organ	NN	O	O
systems	NN	O	O
,	NN	O	O
including	NN	O	O
rare	NN	O	O
skeletal	NN	O	O
muscle	NN	O	O
involvement	NN	O	O
.	NN	O	O

Only	NN	O	O
a	NN	O	O
handful	NN	O	O
of	NN	O	O
cases	NN	O	O
of	NN	O	O
ATRA	NN	O	O
-	NN	O	O
induced	NN	O	O
myositis	NN	O	B
in	NN	O	O
children	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
,	NN	O	O
and	NN	O	O
none	NN	O	O
in	NN	O	O
the	NN	O	O
radiology	NN	O	O
literature	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
such	NN	O	O
a	NN	O	O
case	NN	O	O
in	NN	O	O
a	NN	O	O
15	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
with	NN	O	O
APL	NN	O	B
,	NN	O	O
where	NN	O	O
recognition	NN	O	O
of	NN	O	O
imaging	NN	O	O
findings	NN	O	O
played	NN	O	O
a	NN	O	O
crucial	NN	O	O
role	NN	O	O
in	NN	O	O
making	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
and	NN	O	O
facilitated	NN	O	O
prompt	NN	O	O
,	NN	O	O
effective	NN	O	O
treatment	NN	O	O
.	NN	O	O

Tolerability	NN	O	O
of	NN	O	O
lomustine	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	O
in	NN	O	O
dogs	NN	O	O
with	NN	O	O
lymphoma	NN	O	B
.	NN	O	O

This	NN	O	O
retrospective	NN	O	O
study	NN	O	O
describes	NN	O	O
toxicity	NN	O	B
associated	NN	O	O
with	NN	O	O
a	NN	O	O
protocol	NN	O	O
of	NN	O	O
lomustine	NN	O	O
(	NN	O	O
CCNU	NN	O	O
)	NN	O	O
and	NN	O	O
cyclophosphamide	NN	O	O
(	NN	O	O
CTX	NN	O	O
)	NN	O	O
in	NN	O	O
dogs	NN	O	O
with	NN	O	O
lymphoma	NN	O	B
.	NN	O	O

CCNU	NN	O	O
was	NN	O	O
administered	NN	O	O
per	NN	O	O
os	NN	O	O
(	NN	O	O
PO	NN	O	O
)	NN	O	O
at	NN	O	O
a	NN	O	O
targeted	NN	O	O
dosage	NN	O	O
of	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
on	NN	O	O
day	NN	O	O
0	NN	O	O
,	NN	O	O
CTX	NN	O	O
was	NN	O	O
administered	NN	O	O
PO	NN	O	O
at	NN	O	O
a	NN	O	O
targeted	NN	O	O
dosage	NN	O	O
of	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
divided	NN	O	O
over	NN	O	O
days	NN	O	O
0	NN	O	O
through	NN	O	O
4	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
dogs	NN	O	O
received	NN	O	O
prophylactic	NN	O	O
antibiotics	NN	O	O
.	NN	O	O

Ninety	NN	O	O
treatments	NN	O	O
were	NN	O	O
given	NN	O	O
to	NN	O	O
the	NN	O	O
57	NN	O	O
dogs	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Neutropenia	NN	O	B
was	NN	O	O
the	NN	O	O
principal	NN	O	O
toxic	NN	O	O
effect	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
overall	NN	O	O
frequency	NN	O	O
of	NN	O	O
grade	NN	O	O
4	NN	O	O
neutropenia	NN	O	B
after	NN	O	O
the	NN	O	O
first	NN	O	O
treatment	NN	O	O
of	NN	O	O
CCNU	NN	O	O
/	NN	O	O
CTX	NN	O	O
was	NN	O	O
30	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
19	NN	O	O
-	NN	O	O
43	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
body	NN	O	O
weight	NN	O	O
of	NN	O	O
dogs	NN	O	O
with	NN	O	O
grade	NN	O	O
4	NN	O	O
neutropenia	NN	O	B
(	NN	O	O
19	NN	O	O
.	NN	O	O
7	NN	O	O
kg	NN	O	O
+	NN	O	O
13	NN	O	O
.	NN	O	O
4	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
significantly	NN	O	O
less	NN	O	O
than	NN	O	O
the	NN	O	O
mean	NN	O	O
body	NN	O	O
weight	NN	O	O
of	NN	O	O
dogs	NN	O	O
that	NN	O	O
did	NN	O	O
not	NN	O	O
develop	NN	O	O
grade	NN	O	O
4	NN	O	O
neutropenia	NN	O	B
(	NN	O	O
31	NN	O	O
.	NN	O	O
7	NN	O	O
kg	NN	O	O
+	NN	O	O
12	NN	O	O
.	NN	O	O
4	NN	O	O
kg	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
.	NN	O	O

One	NN	O	O
dog	NN	O	O
(	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
hematologic	NN	O	O
changes	NN	O	O
suggestive	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B
.	NN	O	O

No	NN	O	O
dogs	NN	O	O
had	NN	O	O
evidence	NN	O	O
of	NN	O	O
either	NN	O	O
renal	NN	O	B
toxicity	NN	O	I
or	NN	O	O
hemorrhagic	NN	O	B
cystitis	NN	O	I
.	NN	O	O

Adverse	NN	O	O
gastrointestinal	NN	O	O
effects	NN	O	O
were	NN	O	O
uncommon	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
the	NN	O	O
findings	NN	O	O
reported	NN	O	O
herein	NN	O	O
,	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
of	NN	O	O
CCNU	NN	O	O
combined	NN	O	O
with	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
of	NN	O	O
CTX	NN	O	O
(	NN	O	O
divided	NN	O	O
over	NN	O	O
5	NN	O	O
days	NN	O	O
)	NN	O	O
q	NN	O	O
4	NN	O	O
wk	NN	O	O
is	NN	O	O
tolerable	NN	O	O
in	NN	O	O
tumor	NN	O	B
-	NN	O	O
bearing	NN	O	O
dogs	NN	O	O
.	NN	O	O

Nelarabine	NN	O	O
neurotoxicity	NN	O	B
with	NN	O	O
concurrent	NN	O	O
intrathecal	NN	O	O
chemotherapy	NN	O	O
:	NN	O	O
Case	NN	O	O
report	NN	O	O
and	NN	O	O
review	NN	O	O
of	NN	O	O
literature	NN	O	O
.	NN	O	O

Severe	NN	O	O
nelarabine	NN	O	O
neurotoxicity	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
received	NN	O	O
concurrent	NN	O	O
intrathecal	NN	O	O
(	NN	O	O
IT	NN	O	O
)	NN	O	O
chemotherapy	NN	O	O
is	NN	O	O
reported	NN	O	O
.	NN	O	O

A	NN	O	O
37	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Caucasian	NN	O	O
woman	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
T	NN	O	B
-	NN	O	I
cell	NN	O	I
lymphoblastic	NN	O	I
lymphoma	NN	O	I
was	NN	O	O
admitted	NN	O	O
for	NN	O	O
relapsed	NN	O	O
disease	NN	O	O
.	NN	O	O

She	NN	O	O
was	NN	O	O
originally	NN	O	O
treated	NN	O	O
with	NN	O	O
induction	NN	O	O
chemotherapy	NN	O	O
followed	NN	O	O
by	NN	O	O
an	NN	O	O
autologous	NN	O	O
transplant	NN	O	O
.	NN	O	O

She	NN	O	O
developed	NN	O	O
relapsed	NN	O	O
disease	NN	O	O
10	NN	O	O
months	NN	O	O
later	NN	O	O
with	NN	O	O
leukemic	NN	O	B
involvement	NN	O	O
.	NN	O	O

She	NN	O	O
was	NN	O	O
re	NN	O	O
-	NN	O	O
induced	NN	O	O
with	NN	O	O
nelarabine	NN	O	O
1500	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
5	NN	O	O
with	NN	O	O
1	NN	O	O
dose	NN	O	O
of	NN	O	O
IT	NN	O	O
cytarabine	NN	O	O
100	NN	O	O
mg	NN	O	O
on	NN	O	O
day	NN	O	O
2	NN	O	O
as	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
prophylaxis	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
she	NN	O	O
was	NN	O	O
on	NN	O	O
continuous	NN	O	O
renal	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
due	NN	O	O
to	NN	O	O
sequelae	NN	O	O
of	NN	O	O
tumor	NN	O	B
lysis	NN	O	I
syndrome	NN	O	I
(	NN	O	O
TLS	NN	O	B
)	NN	O	O
.	NN	O	O

She	NN	O	O
tolerated	NN	O	O
therapy	NN	O	O
well	NN	O	O
,	NN	O	O
entered	NN	O	O
a	NN	O	O
complete	NN	O	O
remission	NN	O	O
,	NN	O	O
and	NN	O	O
recovered	NN	O	O
her	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

She	NN	O	O
received	NN	O	O
a	NN	O	O
second	NN	O	O
cycle	NN	O	O
of	NN	O	O
nelarabine	NN	O	O
without	NN	O	O
additional	NN	O	O
IT	NN	O	O
prophylaxis	NN	O	O
one	NN	O	O
month	NN	O	O
later	NN	O	O
.	NN	O	O

A	NN	O	O
week	NN	O	O
after	NN	O	O
this	NN	O	O
second	NN	O	O
cycle	NN	O	O
,	NN	O	O
she	NN	O	O
noted	NN	O	O
numbness	NN	O	O
in	NN	O	O
her	NN	O	O
lower	NN	O	O
extremities	NN	O	O
.	NN	O	O

Predominantly	NN	O	O
sensory	NN	O	O
,	NN	O	O
though	NN	O	O
also	NN	O	O
motor	NN	O	O
and	NN	O	O
autonomic	NN	O	O
,	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
started	NN	O	O
in	NN	O	O
her	NN	O	O
feet	NN	O	O
,	NN	O	O
ascended	NN	O	O
proximally	NN	O	O
to	NN	O	O
the	NN	O	O
mid	NN	O	O
-	NN	O	O
thoracic	NN	O	O
region	NN	O	O
,	NN	O	O
and	NN	O	O
eventually	NN	O	O
included	NN	O	O
her	NN	O	O
distal	NN	O	O
upper	NN	O	O
extremities	NN	O	O
.	NN	O	O

A	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
MRI	NN	O	O
)	NN	O	O
of	NN	O	O
her	NN	O	O
spine	NN	O	O
demonstrated	NN	O	O
changes	NN	O	O
from	NN	O	O
C2	NN	O	O
to	NN	O	O
C6	NN	O	O
consistent	NN	O	O
with	NN	O	O
subacute	NN	O	O
combined	NN	O	O
degeneration	NN	O	O
.	NN	O	O

Nelarabine	NN	O	O
was	NN	O	O
felt	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
her	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Her	NN	O	O
neuropathy	NN	O	B
stabilized	NN	O	O
and	NN	O	O
showed	NN	O	O
slight	NN	O	O
improvement	NN	O	O
and	NN	O	O
ultimately	NN	O	O
received	NN	O	O
an	NN	O	O
unrelated	NN	O	O
,	NN	O	O
reduced	NN	O	O
-	NN	O	O
intensity	NN	O	O
allogeneic	NN	O	O
transplant	NN	O	O
while	NN	O	O
in	NN	O	O
complete	NN	O	O
remission	NN	O	O
,	NN	O	O
but	NN	O	O
relapsed	NN	O	O
disease	NN	O	O
10	NN	O	O
weeks	NN	O	O
later	NN	O	O
.	NN	O	O

She	NN	O	O
is	NN	O	O
currently	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
best	NN	O	O
supportive	NN	O	O
care	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
published	NN	O	O
case	NN	O	O
report	NN	O	O
of	NN	O	O
severe	NN	O	O
neurotoxicity	NN	O	B
caused	NN	O	O
by	NN	O	O
nelarabine	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
received	NN	O	O
concurrent	NN	O	O
IT	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Valproate	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperammonemic	NN	O	B
encephalopathy	NN	O	B
in	NN	O	O
a	NN	O	O
renal	NN	O	O
transplanted	NN	O	O
patient	NN	O	O
.	NN	O	O

Neurological	NN	O	B
complications	NN	O	I
after	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
constitute	NN	O	O
an	NN	O	O
important	NN	O	O
cause	NN	O	O
of	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
.	NN	O	O

Their	NN	O	O
differential	NN	O	O
diagnosis	NN	O	O
is	NN	O	O
difficult	NN	O	O
and	NN	O	O
essential	NN	O	O
for	NN	O	O
subsequent	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
management	NN	O	O
.	NN	O	O

Valproate	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperammonemic	NN	O	B
encephalopathy	NN	O	B
is	NN	O	O
an	NN	O	O
uncommon	NN	O	O
but	NN	O	O
serious	NN	O	O
effect	NN	O	O
of	NN	O	O
valproate	NN	O	O
treatment	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
15	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
who	NN	O	O
was	NN	O	O
on	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
therapy	NN	O	O
with	NN	O	O
valproate	NN	O	O
due	NN	O	O
to	NN	O	O
epilepsy	NN	O	B
and	NN	O	O
revealed	NN	O	O
impaired	NN	O	B
consciousness	NN	O	I
with	NN	O	O
hyperammonemia	NN	O	B
12	NN	O	O
days	NN	O	O
after	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
.	NN	O	O

After	NN	O	O
withdraw	NN	O	O
of	NN	O	O
valproate	NN	O	O
,	NN	O	O
patients	NN	O	O
'	NN	O	O
symptoms	NN	O	O
resolved	NN	O	O
within	NN	O	O
24	NN	O	O
h	NN	O	O
.	NN	O	O

Clinicians	NN	O	O
should	NN	O	O
increase	NN	O	O
their	NN	O	O
awareness	NN	O	O
for	NN	O	O
potential	NN	O	O
complication	NN	O	O
of	NN	O	O
valproate	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
transplanted	NN	O	O
patients	NN	O	O
.	NN	O	O

Necrotising	NN	O	B
fasciitis	NN	O	I
after	NN	O	O
bortezomib	NN	O	O
and	NN	O	O
dexamethasone	NN	O	O
-	NN	O	O
containing	NN	O	O
regimen	NN	O	O
in	NN	O	O
an	NN	O	O
elderly	NN	O	O
patient	NN	O	O
of	NN	O	O
Waldenstrom	NN	O	B
macroglobulinaemia	NN	O	I
.	NN	O	O

Bortezomib	NN	O	O
and	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
dexamethasone	NN	O	O
-	NN	O	O
containing	NN	O	O
regimens	NN	O	O
are	NN	O	O
considered	NN	O	O
to	NN	O	O
be	NN	O	O
generally	NN	O	O
tolerable	NN	O	O
with	NN	O	O
few	NN	O	O
severe	NN	O	O
bacterial	NN	O	B
infections	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
B	NN	O	O
-	NN	O	O
cell	NN	O	O
malignancies	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
information	NN	O	O
is	NN	O	O
limited	NN	O	O
concerning	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
the	NN	O	O
regimen	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
76	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
Waldenstrom	NN	O	B
macroglobulinaemia	NN	O	I
who	NN	O	O
suffered	NN	O	O
necrotising	NN	O	B
fasciitis	NN	O	I
without	NN	O	O
neutropenia	NN	O	B
after	NN	O	O
the	NN	O	O
combination	NN	O	O
treatment	NN	O	O
with	NN	O	O
bortezomib	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
dexamethasone	NN	O	O
and	NN	O	O
rituximab	NN	O	O
.	NN	O	O

Despite	NN	O	O
immediate	NN	O	O
intravenous	NN	O	O
antimicrobial	NN	O	O
therapy	NN	O	O
,	NN	O	O
he	NN	O	O
succumbed	NN	O	O
23	NN	O	O
h	NN	O	O
after	NN	O	O
the	NN	O	O
onset	NN	O	O
.	NN	O	O

Physicians	NN	O	O
should	NN	O	O
recognise	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
fatal	NN	O	O
bacterial	NN	O	B
infections	NN	O	I
related	NN	O	O
to	NN	O	O
bortezomib	NN	O	O
plus	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
dexamethasone	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
we	NN	O	O
believe	NN	O	O
this	NN	O	O
case	NN	O	O
warrants	NN	O	O
further	NN	O	O
investigation	NN	O	O
.	NN	O	O

An	NN	O	O
integrated	NN	O	O
characterization	NN	O	O
of	NN	O	O
serological	NN	O	O
,	NN	O	O
pathological	NN	O	O
,	NN	O	O
and	NN	O	O
functional	NN	O	O
events	NN	O	O
in	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Many	NN	O	O
efficacious	NN	O	O
cancer	NN	O	B
treatments	NN	O	O
cause	NN	O	O
significant	NN	O	O
cardiac	NN	O	O
morbidity	NN	O	O
,	NN	O	O
yet	NN	O	O
biomarkers	NN	O	O
or	NN	O	O
functional	NN	O	O
indices	NN	O	O
of	NN	O	O
early	NN	O	O
damage	NN	O	O
,	NN	O	O
which	NN	O	O
would	NN	O	O
allow	NN	O	O
monitoring	NN	O	O
and	NN	O	O
intervention	NN	O	O
,	NN	O	O
are	NN	O	O
lacking	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
utilized	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
progressive	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
DOX	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B
,	NN	O	O
applying	NN	O	O
multiple	NN	O	O
approaches	NN	O	O
,	NN	O	O
including	NN	O	O
cardiac	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
MRI	NN	O	O
)	NN	O	O
,	NN	O	O
to	NN	O	O
provide	NN	O	O
the	NN	O	O
most	NN	O	O
comprehensive	NN	O	O
characterization	NN	O	O
to	NN	O	O
date	NN	O	O
of	NN	O	O
the	NN	O	O
timecourse	NN	O	O
of	NN	O	O
serological	NN	O	O
,	NN	O	O
pathological	NN	O	O
,	NN	O	O
and	NN	O	O
functional	NN	O	O
events	NN	O	O
underlying	NN	O	O
this	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Hannover	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
dosed	NN	O	O
with	NN	O	O
1	NN	O	O
.	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
DOX	NN	O	O
weekly	NN	O	O
for	NN	O	O
8	NN	O	O
weeks	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
4	NN	O	O
week	NN	O	O
off	NN	O	O
-	NN	O	O
dosing	NN	O	O
"	NN	O	O
recovery	NN	O	O
"	NN	O	O
period	NN	O	O
.	NN	O	O

Electron	NN	O	O
microscopy	NN	O	O
of	NN	O	O
the	NN	O	O
myocardium	NN	O	O
revealed	NN	O	O
subcellular	NN	O	B
degeneration	NN	O	I
and	NN	O	O
marked	NN	O	O
mitochondrial	NN	O	O
changes	NN	O	O
after	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
.	NN	O	O

Histopathological	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
progressive	NN	O	O
cardiomyocyte	NN	O	B
degeneration	NN	O	I
,	NN	O	O
hypertrophy	NN	O	B
/	NN	O	O
cytomegaly	NN	O	O
,	NN	O	O
and	NN	O	O
extensive	NN	O	O
vacuolation	NN	O	O
after	NN	O	O
two	NN	O	O
doses	NN	O	O
.	NN	O	O

Extensive	NN	O	O
replacement	NN	O	O
fibrosis	NN	O	B
(	NN	O	O
quantified	NN	O	O
by	NN	O	O
Sirius	NN	O	O
red	NN	O	O
staining	NN	O	O
)	NN	O	O
developed	NN	O	O
during	NN	O	O
the	NN	O	O
off	NN	O	O
-	NN	O	O
dosing	NN	O	O
period	NN	O	O
.	NN	O	O

Functional	NN	O	O
indices	NN	O	O
assessed	NN	O	O
by	NN	O	O
cardiac	NN	O	O
MRI	NN	O	O
(	NN	O	O
including	NN	O	O
left	NN	O	O
ventricular	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
(	NN	O	O
LVEF	NN	O	O
)	NN	O	O
,	NN	O	O
cardiac	NN	O	O
output	NN	O	O
,	NN	O	O
and	NN	O	O
E	NN	O	O
/	NN	O	O
A	NN	O	O
ratio	NN	O	O
)	NN	O	O
declined	NN	O	O
progressively	NN	O	O
,	NN	O	O
reaching	NN	O	O
statistical	NN	O	O
significance	NN	O	O
after	NN	O	O
two	NN	O	O
doses	NN	O	O
and	NN	O	O
culminating	NN	O	O
in	NN	O	O
"	NN	O	O
clinical	NN	O	O
"	NN	O	O
LV	NN	O	B
dysfunction	NN	O	I
by	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

Significant	NN	O	O
increases	NN	O	O
in	NN	O	O
peak	NN	O	O
myocardial	NN	O	O
contrast	NN	O	O
enhancement	NN	O	O
and	NN	O	O
serological	NN	O	O
cardiac	NN	O	O
troponin	NN	O	O
I	NN	O	O
(	NN	O	O
cTnI	NN	O	O
)	NN	O	O
emerged	NN	O	O
after	NN	O	O
eight	NN	O	O
doses	NN	O	O
,	NN	O	O
importantly	NN	O	O
preceding	NN	O	O
the	NN	O	O
LVEF	NN	O	O
decline	NN	O	O
to	NN	O	O
<	NN	O	O
50	NN	O	O
%	NN	O	O
.	NN	O	O

Troponin	NN	O	O
I	NN	O	O
levels	NN	O	O
positively	NN	O	O
correlated	NN	O	O
with	NN	O	O
delayed	NN	O	O
and	NN	O	O
peak	NN	O	O
gadolinium	NN	O	O
contrast	NN	O	O
enhancement	NN	O	O
,	NN	O	O
histopathological	NN	O	O
grading	NN	O	O
,	NN	O	O
and	NN	O	O
diastolic	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

In	NN	O	O
summary	NN	O	O
,	NN	O	O
subcellular	NN	O	O
cardiomyocyte	NN	O	B
degeneration	NN	O	I
was	NN	O	O
the	NN	O	O
earliest	NN	O	O
marker	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
progressive	NN	O	O
functional	NN	O	O
decline	NN	O	O
and	NN	O	O
histopathological	NN	O	O
manifestations	NN	O	O
.	NN	O	O

Myocardial	NN	O	O
contrast	NN	O	O
enhancement	NN	O	O
and	NN	O	O
elevations	NN	O	O
in	NN	O	O
cTnI	NN	O	O
occurred	NN	O	O
later	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
all	NN	O	O
indices	NN	O	O
predated	NN	O	O
"	NN	O	O
clinical	NN	O	O
"	NN	O	O
LV	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
thus	NN	O	O
warrant	NN	O	O
further	NN	O	O
evaluation	NN	O	O
as	NN	O	O
predictive	NN	O	O
biomarkers	NN	O	O
.	NN	O	O

Intradermal	NN	O	O
glutamate	NN	O	O
and	NN	O	O
capsaicin	NN	O	O
injections	NN	O	O
:	NN	O	O
intra	NN	O	O
-	NN	O	O
and	NN	O	O
interindividual	NN	O	O
variability	NN	O	O
of	NN	O	O
provoked	NN	O	O
hyperalgesia	NN	O	B
and	NN	O	O
allodynia	NN	O	B
.	NN	O	O

Intradermal	NN	O	O
injections	NN	O	O
of	NN	O	O
glutamate	NN	O	O
and	NN	O	O
capsaicin	NN	O	O
are	NN	O	O
attractive	NN	O	O
to	NN	O	O
use	NN	O	O
in	NN	O	O
human	NN	O	O
experimental	NN	O	O
pain	NN	O	B
models	NN	O	O
because	NN	O	O
hyperalgesia	NN	O	B
and	NN	O	O
allodynia	NN	O	B
mimic	NN	O	O
isolated	NN	O	O
aspects	NN	O	O
of	NN	O	O
clinical	NN	O	O
pain	NN	O	B
disorders	NN	O	I
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
reproducibility	NN	O	O
of	NN	O	O
these	NN	O	O
models	NN	O	O
.	NN	O	O

Twenty	NN	O	O
healthy	NN	O	O
male	NN	O	O
volunteers	NN	O	O
(	NN	O	O
mean	NN	O	O
age	NN	O	O
24	NN	O	O
years	NN	O	O
;	NN	O	O
range	NN	O	O
18	NN	O	O
-	NN	O	O
38	NN	O	O
years	NN	O	O
)	NN	O	O
received	NN	O	O
intradermal	NN	O	O
injections	NN	O	O
of	NN	O	O
glutamate	NN	O	O
and	NN	O	O
capsaicin	NN	O	O
in	NN	O	O
the	NN	O	O
volar	NN	O	O
forearm	NN	O	O
.	NN	O	O

Magnitudes	NN	O	O
of	NN	O	O
secondary	NN	O	O
pinprick	NN	O	O
hyperalgesia	NN	O	B
and	NN	O	O
brush	NN	O	O
-	NN	O	O
evoked	NN	O	O
allodynia	NN	O	B
were	NN	O	O
investigated	NN	O	O
using	NN	O	O
von	NN	O	O
Frey	NN	O	O
filaments	NN	O	O
(	NN	O	O
gauges	NN	O	O
10	NN	O	O
,	NN	O	O
15	NN	O	O
,	NN	O	O
60	NN	O	O
and	NN	O	O
100	NN	O	O
g	NN	O	O
)	NN	O	O
and	NN	O	O
brush	NN	O	O
strokes	NN	O	O
.	NN	O	O

Areas	NN	O	O
of	NN	O	O
secondary	NN	O	B
hyperalgesia	NN	O	I
and	NN	O	O
allodynia	NN	O	B
were	NN	O	O
quantified	NN	O	O
immediately	NN	O	O
after	NN	O	O
injection	NN	O	O
and	NN	O	O
after	NN	O	O
15	NN	O	O
,	NN	O	O
30	NN	O	O
and	NN	O	O
60	NN	O	O
min	NN	O	O
.	NN	O	O

Two	NN	O	O
identical	NN	O	O
experiments	NN	O	O
separated	NN	O	O
by	NN	O	O
at	NN	O	O
least	NN	O	O
7	NN	O	O
days	NN	O	O
were	NN	O	O
performed	NN	O	O
.	NN	O	O

Reproducibility	NN	O	O
across	NN	O	O
and	NN	O	O
within	NN	O	O
volunteers	NN	O	O
(	NN	O	O
inter	NN	O	O
-	NN	O	O
and	NN	O	O
intra	NN	O	O
-	NN	O	O
individual	NN	O	O
variation	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
was	NN	O	O
assessed	NN	O	O
using	NN	O	O
intraclass	NN	O	O
correlation	NN	O	O
coefficient	NN	O	O
(	NN	O	O
ICC	NN	O	O
)	NN	O	O
and	NN	O	O
coefficient	NN	O	O
of	NN	O	O
variation	NN	O	O
(	NN	O	O
CV	NN	O	O
)	NN	O	O
.	NN	O	O

Secondary	NN	O	O
pinprick	NN	O	O
hyperalgesia	NN	O	B
was	NN	O	O
observed	NN	O	O
as	NN	O	O
a	NN	O	O
marked	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
visual	NN	O	O
analogue	NN	O	O
scale	NN	O	O
(	NN	O	O
VAS	NN	O	O
)	NN	O	O
response	NN	O	O
to	NN	O	O
von	NN	O	O
Frey	NN	O	O
gauges	NN	O	O
60	NN	O	O
and	NN	O	O
100	NN	O	O
g	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
after	NN	O	O
glutamate	NN	O	O
injection	NN	O	O
.	NN	O	O

For	NN	O	O
capsaicin	NN	O	O
,	NN	O	O
secondary	NN	O	O
pinprick	NN	O	O
hyperalgesia	NN	O	B
was	NN	O	O
detected	NN	O	O
with	NN	O	O
all	NN	O	O
von	NN	O	O
Frey	NN	O	O
gauges	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Glutamate	NN	O	O
evoked	NN	O	O
reproducible	NN	O	O
VAS	NN	O	O
response	NN	O	O
to	NN	O	O
all	NN	O	O
von	NN	O	O
Frey	NN	O	O
gauges	NN	O	O
(	NN	O	O
ICC	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
60	NN	O	O
)	NN	O	O
and	NN	O	O
brush	NN	O	O
strokes	NN	O	O
(	NN	O	O
ICC	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
83	NN	O	O
)	NN	O	O
.	NN	O	O

Capsaicin	NN	O	O
injection	NN	O	O
was	NN	O	O
reproducible	NN	O	O
for	NN	O	O
secondary	NN	O	B
hyperalgesia	NN	O	I
(	NN	O	O
ICC	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
70	NN	O	O
)	NN	O	O
and	NN	O	O
allodynia	NN	O	B
(	NN	O	O
ICC	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
71	NN	O	O
)	NN	O	O
.	NN	O	O

Intra	NN	O	O
-	NN	O	O
individual	NN	O	O
variability	NN	O	O
was	NN	O	O
generally	NN	O	O
lower	NN	O	O
for	NN	O	O
the	NN	O	O
VAS	NN	O	O
response	NN	O	O
to	NN	O	O
von	NN	O	O
Frey	NN	O	O
and	NN	O	O
brush	NN	O	O
compared	NN	O	O
with	NN	O	O
areas	NN	O	O
of	NN	O	O
secondary	NN	O	B
hyperalgesia	NN	O	I
and	NN	O	O
allodynia	NN	O	B
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
glutamate	NN	O	O
and	NN	O	O
capsaicin	NN	O	O
yield	NN	O	O
reproducible	NN	O	O
hyperalgesic	NN	O	B
and	NN	O	O
allodynic	NN	O	B
responses	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
present	NN	O	O
model	NN	O	O
is	NN	O	O
well	NN	O	O
suited	NN	O	O
for	NN	O	O
basic	NN	O	O
research	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
for	NN	O	O
assessing	NN	O	O
the	NN	O	O
modulation	NN	O	O
of	NN	O	O
central	NN	O	O
phenomena	NN	O	O
.	NN	O	O

Ocular	NN	O	O
-	NN	O	O
specific	NN	O	O
ER	NN	O	O
stress	NN	O	O
reduction	NN	O	O
rescues	NN	O	O
glaucoma	NN	O	B
in	NN	O	O
murine	NN	O	O
glucocorticoid	NN	O	O
-	NN	O	O
induced	NN	O	O
glaucoma	NN	O	B
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
glucocorticoids	NN	O	O
induces	NN	O	O
ocular	NN	O	B
hypertension	NN	O	I
in	NN	O	O
some	NN	O	O
patients	NN	O	O
.	NN	O	O

If	NN	O	O
untreated	NN	O	O
,	NN	O	O
these	NN	O	O
patients	NN	O	O
can	NN	O	O
develop	NN	O	O
a	NN	O	O
secondary	NN	O	O
glaucoma	NN	O	B
that	NN	O	O
resembles	NN	O	O
primary	NN	O	B
open	NN	O	I
-	NN	O	I
angle	NN	O	I
glaucoma	NN	O	I
(	NN	O	O
POAG	NN	O	B
)	NN	O	O
.	NN	O	O

The	NN	O	O
underlying	NN	O	O
pathology	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	O
-	NN	O	O
induced	NN	O	O
glaucoma	NN	O	B
is	NN	O	O
not	NN	O	O
fully	NN	O	O
understood	NN	O	O
,	NN	O	O
due	NN	O	O
in	NN	O	O
part	NN	O	O
to	NN	O	O
lack	NN	O	O
of	NN	O	O
an	NN	O	O
appropriate	NN	O	O
animal	NN	O	O
model	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
developed	NN	O	O
a	NN	O	O
murine	NN	O	O
model	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	O
-	NN	O	O
induced	NN	O	O
glaucoma	NN	O	B
that	NN	O	O
exhibits	NN	O	O
glaucoma	NN	O	B
features	NN	O	O
that	NN	O	O
are	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
WT	NN	O	O
mice	NN	O	O
with	NN	O	O
topical	NN	O	O
ocular	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
dexamethasone	NN	O	O
led	NN	O	O
to	NN	O	O
elevation	NN	O	O
of	NN	O	O
intraocular	NN	O	O
pressure	NN	O	O
(	NN	O	O
IOP	NN	O	O
)	NN	O	O
,	NN	O	O
functional	NN	O	O
and	NN	O	O
structural	NN	O	O
loss	NN	O	O
of	NN	O	O
retinal	NN	O	B
ganglion	NN	O	I
cells	NN	O	O
,	NN	O	O
and	NN	O	O
axonal	NN	O	B
degeneration	NN	O	I
,	NN	O	O
resembling	NN	O	O
glucocorticoid	NN	O	O
-	NN	O	O
induced	NN	O	O
glaucoma	NN	O	B
in	NN	O	O
human	NN	O	O
patients	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
dexamethasone	NN	O	O
-	NN	O	O
induced	NN	O	O
ocular	NN	O	B
hypertension	NN	O	I
was	NN	O	O
associated	NN	O	O
with	NN	O	O
chronic	NN	O	O
ER	NN	O	O
stress	NN	O	O
of	NN	O	O
the	NN	O	O
trabecular	NN	O	O
meshwork	NN	O	O
(	NN	O	O
TM	NN	O	O
)	NN	O	O
.	NN	O	O

Similar	NN	O	O
to	NN	O	O
patients	NN	O	O
,	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
dexamethasone	NN	O	O
treatment	NN	O	O
reduced	NN	O	O
elevated	NN	O	O
IOP	NN	O	O
and	NN	O	O
ER	NN	O	O
stress	NN	O	O
in	NN	O	O
this	NN	O	O
animal	NN	O	O
model	NN	O	O
.	NN	O	O

Dexamethasone	NN	O	O
induced	NN	O	O
the	NN	O	O
transcriptional	NN	O	O
factor	NN	O	O
CHOP	NN	O	O
,	NN	O	O
a	NN	O	O
marker	NN	O	O
for	NN	O	O
chronic	NN	O	O
ER	NN	O	O
stress	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
anterior	NN	O	O
segment	NN	O	O
tissues	NN	O	O
,	NN	O	O
and	NN	O	O
Chop	NN	O	O
deletion	NN	O	O
reduced	NN	O	O
ER	NN	O	O
stress	NN	O	O
in	NN	O	O
these	NN	O	O
tissues	NN	O	O
and	NN	O	O
prevented	NN	O	O
dexamethasone	NN	O	O
-	NN	O	O
induced	NN	O	O
ocular	NN	O	B
hypertension	NN	O	I
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
reduction	NN	O	O
of	NN	O	O
ER	NN	O	O
stress	NN	O	O
in	NN	O	O
the	NN	O	O
TM	NN	O	O
with	NN	O	O
sodium	NN	O	O
4	NN	O	O
-	NN	O	O
phenylbutyrate	NN	O	O
prevented	NN	O	O
dexamethasone	NN	O	O
-	NN	O	O
induced	NN	O	O
ocular	NN	O	B
hypertension	NN	O	I
in	NN	O	O
WT	NN	O	O
mice	NN	O	O
.	NN	O	O

Our	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
ER	NN	O	O
stress	NN	O	O
contributes	NN	O	O
to	NN	O	O
glucocorticoid	NN	O	O
-	NN	O	O
induced	NN	O	O
ocular	NN	O	B
hypertension	NN	O	I
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
reducing	NN	O	O
ER	NN	O	O
stress	NN	O	O
has	NN	O	O
potential	NN	O	O
as	NN	O	O
a	NN	O	O
therapeutic	NN	O	O
strategy	NN	O	O
for	NN	O	O
treating	NN	O	O
glucocorticoid	NN	O	O
-	NN	O	O
induced	NN	O	O
glaucoma	NN	O	B
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
ginsenosides	NN	O	O
on	NN	O	O
opioid	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperalgesia	NN	O	B
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Opioid	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperalgesia	NN	O	B
(	NN	O	O
OIH	NN	O	B
)	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
nociceptive	NN	O	O
sensitization	NN	O	O
caused	NN	O	O
by	NN	O	O
the	NN	O	O
cessation	NN	O	O
of	NN	O	O
chronic	NN	O	O
opioid	NN	O	O
use	NN	O	O
.	NN	O	O

OIH	NN	O	B
can	NN	O	O
limit	NN	O	O
the	NN	O	O
clinical	NN	O	O
use	NN	O	O
of	NN	O	O
opioid	NN	O	O
analgesics	NN	O	O
and	NN	O	O
complicate	NN	O	O
withdrawal	NN	O	O
from	NN	O	O
opioid	NN	O	B
addiction	NN	O	I
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
Re	NN	O	O
,	NN	O	O
Rg1	NN	O	O
,	NN	O	O
and	NN	O	O
Rb1	NN	O	O
ginsenosides	NN	O	O
,	NN	O	O
the	NN	O	O
bioactive	NN	O	O
components	NN	O	O
of	NN	O	O
ginseng	NN	O	O
,	NN	O	O
on	NN	O	O
OIH	NN	O	B
.	NN	O	O

OIH	NN	O	B
was	NN	O	O
achieved	NN	O	O
in	NN	O	O
mice	NN	O	O
after	NN	O	O
subcutaneous	NN	O	O
administration	NN	O	O
of	NN	O	O
morphine	NN	O	O
for	NN	O	O
7	NN	O	O
consecutive	NN	O	O
days	NN	O	O
three	NN	O	O
times	NN	O	O
per	NN	O	O
day	NN	O	O
.	NN	O	O

During	NN	O	O
withdrawal	NN	O	O
(	NN	O	O
days	NN	O	O
8	NN	O	O
and	NN	O	O
9	NN	O	O
)	NN	O	O
,	NN	O	O
these	NN	O	O
mice	NN	O	O
were	NN	O	O
administered	NN	O	O
Re	NN	O	O
,	NN	O	O
Rg1	NN	O	O
,	NN	O	O
or	NN	O	O
Rb1	NN	O	O
intragastrically	NN	O	O
two	NN	O	O
times	NN	O	O
per	NN	O	O
day	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
test	NN	O	O
day	NN	O	O
(	NN	O	O
day	NN	O	O
10	NN	O	O
)	NN	O	O
,	NN	O	O
mice	NN	O	O
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
the	NN	O	O
thermal	NN	O	O
sensitivity	NN	O	O
test	NN	O	O
and	NN	O	O
the	NN	O	O
acetic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
writhing	NN	O	O
test	NN	O	O
.	NN	O	O

Re	NN	O	O
(	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
inhibited	NN	O	O
OIH	NN	O	B
in	NN	O	O
both	NN	O	O
the	NN	O	O
thermal	NN	O	O
sensitivity	NN	O	O
test	NN	O	O
and	NN	O	O
the	NN	O	O
acetic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
writhing	NN	O	O
test	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
Rg1	NN	O	O
and	NN	O	O
Rb1	NN	O	O
ginsenosides	NN	O	O
failed	NN	O	O
to	NN	O	O
prevent	NN	O	O
OIH	NN	O	B
in	NN	O	O
either	NN	O	O
test	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
Rg1	NN	O	O
showed	NN	O	O
a	NN	O	O
tendency	NN	O	O
to	NN	O	O
aggravate	NN	O	O
OIH	NN	O	B
in	NN	O	O
the	NN	O	O
acetic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
writhing	NN	O	O
test	NN	O	O
.	NN	O	O

Our	NN	O	O
data	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
ginsenoside	NN	O	O
Re	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
Rg1	NN	O	O
or	NN	O	O
Rb1	NN	O	O
,	NN	O	O
may	NN	O	O
contribute	NN	O	O
toward	NN	O	O
reversal	NN	O	O
of	NN	O	O
OIH	NN	O	B
.	NN	O	O

A	NN	O	O
comparison	NN	O	O
of	NN	O	O
severe	NN	O	O
hemodynamic	NN	O	O
disturbances	NN	O	O
between	NN	O	O
dexmedetomidine	NN	O	O
and	NN	O	O
propofol	NN	O	O
for	NN	O	O
sedation	NN	O	O
in	NN	O	O
neurocritical	NN	O	O
care	NN	O	O
patients	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
Dexmedetomidine	NN	O	O
and	NN	O	O
propofol	NN	O	O
are	NN	O	O
commonly	NN	O	O
used	NN	O	O
sedatives	NN	O	O
in	NN	O	O
neurocritical	NN	O	O
care	NN	O	O
as	NN	O	O
they	NN	O	O
allow	NN	O	O
for	NN	O	O
frequent	NN	O	O
neurologic	NN	O	O
examinations	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
both	NN	O	O
agents	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
significant	NN	O	O
hemodynamic	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
severe	NN	O	O
hemodynamic	NN	O	O
effects	NN	O	O
in	NN	O	O
neurocritical	NN	O	O
care	NN	O	O
patients	NN	O	O
receiving	NN	O	O
dexmedetomidine	NN	O	O
and	NN	O	O
propofol	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Multicenter	NN	O	O
,	NN	O	O
retrospective	NN	O	O
,	NN	O	O
propensity	NN	O	O
-	NN	O	O
matched	NN	O	O
cohort	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Neurocritical	NN	O	O
care	NN	O	O
units	NN	O	O
at	NN	O	O
two	NN	O	O
academic	NN	O	O
medical	NN	O	O
centers	NN	O	O
with	NN	O	O
dedicated	NN	O	O
neurocritical	NN	O	O
care	NN	O	O
teams	NN	O	O
and	NN	O	O
board	NN	O	O
-	NN	O	O
certified	NN	O	O
neurointensivists	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
:	NN	O	O
Neurocritical	NN	O	O
care	NN	O	O
patients	NN	O	O
admitted	NN	O	O
between	NN	O	O
July	NN	O	O
2009	NN	O	O
and	NN	O	O
September	NN	O	O
2012	NN	O	O
were	NN	O	O
evaluated	NN	O	O
and	NN	O	O
then	NN	O	O
matched	NN	O	O
1	NN	O	O
:	NN	O	O
1	NN	O	O
based	NN	O	O
on	NN	O	O
propensity	NN	O	O
scoring	NN	O	O
of	NN	O	O
baseline	NN	O	O
characteristics	NN	O	O
.	NN	O	O

INTERVENTIONS	NN	O	O
:	NN	O	O
Continuous	NN	O	O
sedation	NN	O	O
with	NN	O	O
dexmedetomidine	NN	O	O
or	NN	O	O
propofol	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
AND	NN	O	O
MAIN	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
342	NN	O	O
patients	NN	O	O
(	NN	O	O
105	NN	O	O
dexmedetomidine	NN	O	O
and	NN	O	O
237	NN	O	O
propofol	NN	O	O
)	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
analysis	NN	O	O
,	NN	O	O
with	NN	O	O
190	NN	O	O
matched	NN	O	O
(	NN	O	O
95	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
)	NN	O	O
by	NN	O	O
propensity	NN	O	O
score	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
a	NN	O	O
composite	NN	O	O
of	NN	O	O
severe	NN	O	O
hypotension	NN	O	B
(	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
<	NN	O	O
60	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
and	NN	O	O
bradycardia	NN	O	B
(	NN	O	O
heart	NN	O	O
rate	NN	O	O
<	NN	O	O
50	NN	O	O
beats	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
during	NN	O	O
sedative	NN	O	O
infusion	NN	O	O
.	NN	O	O

No	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
primary	NN	O	O
composite	NN	O	O
outcome	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
unmatched	NN	O	O
(	NN	O	O
30	NN	O	O
%	NN	O	O
vs	NN	O	O
30	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
94	NN	O	O
)	NN	O	O
or	NN	O	O
matched	NN	O	O
cohorts	NN	O	O
(	NN	O	O
28	NN	O	O
%	NN	O	O
vs	NN	O	O
34	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
35	NN	O	O
)	NN	O	O
could	NN	O	O
be	NN	O	O
found	NN	O	O
.	NN	O	O

When	NN	O	O
analyzed	NN	O	O
separately	NN	O	O
,	NN	O	O
no	NN	O	O
differences	NN	O	O
could	NN	O	O
be	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
severe	NN	O	O
hypotension	NN	O	B
or	NN	O	O
bradycardia	NN	O	B
in	NN	O	O
either	NN	O	O
the	NN	O	O
unmatched	NN	O	O
or	NN	O	O
matched	NN	O	O
cohorts	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Severe	NN	O	O
hypotension	NN	O	B
and	NN	O	O
bradycardia	NN	O	B
occur	NN	O	O
at	NN	O	O
similar	NN	O	O
prevalence	NN	O	O
in	NN	O	O
neurocritical	NN	O	O
care	NN	O	O
patients	NN	O	O
who	NN	O	O
receive	NN	O	O
dexmedetomidine	NN	O	O
or	NN	O	O
propofol	NN	O	O
.	NN	O	O

Providers	NN	O	O
should	NN	O	O
similarly	NN	O	O
consider	NN	O	O
the	NN	O	O
likelihood	NN	O	O
of	NN	O	O
hypotension	NN	O	B
or	NN	O	O
bradycardia	NN	O	B
before	NN	O	O
starting	NN	O	O
either	NN	O	O
sedative	NN	O	O
.	NN	O	O

Hydroxytyrosol	NN	O	O
ameliorates	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
mitochondrial	NN	O	B
dysfunction	NN	O	I
in	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
in	NN	O	O
rats	NN	O	O
with	NN	O	O
breast	NN	O	B
cancer	NN	O	I
.	NN	O	O

Oxidative	NN	O	O
stress	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
several	NN	O	O
processes	NN	O	O
including	NN	O	O
cancer	NN	O	B
,	NN	O	O
aging	NN	O	O
and	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
,	NN	O	O
and	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
potentiate	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
effect	NN	O	O
of	NN	O	O
drugs	NN	O	O
such	NN	O	O
as	NN	O	O
doxorubicin	NN	O	O
.	NN	O	O

Doxorubicin	NN	O	O
causes	NN	O	O
significant	NN	O	O
cardiotoxicity	NN	O	B
characterized	NN	O	O
by	NN	O	O
marked	NN	O	O
increases	NN	O	O
in	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
mitochondrial	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Herein	NN	O	O
,	NN	O	O
we	NN	O	O
investigate	NN	O	O
whether	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
associated	NN	O	O
chronic	NN	O	O
cardiac	NN	O	B
toxicity	NN	O	I
can	NN	O	O
be	NN	O	O
ameliorated	NN	O	O
with	NN	O	O
the	NN	O	O
antioxidant	NN	O	O
hydroxytyrosol	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
breast	NN	O	B
cancer	NN	O	I
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
six	NN	O	O
rats	NN	O	O
bearing	NN	O	O
breast	NN	O	B
tumors	NN	O	I
induced	NN	O	O
chemically	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
4	NN	O	O
groups	NN	O	O
:	NN	O	O
control	NN	O	O
,	NN	O	O
hydroxytyrosol	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
5days	NN	O	O
/	NN	O	O
week	NN	O	O
)	NN	O	O
,	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
1mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
week	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
doxorubicin	NN	O	O
plus	NN	O	O
hydroxytyrosol	NN	O	O
.	NN	O	O

Cardiac	NN	O	B
disturbances	NN	O	I
at	NN	O	O
the	NN	O	O
cellular	NN	O	O
and	NN	O	O
mitochondrial	NN	O	O
level	NN	O	O
,	NN	O	O
mitochondrial	NN	O	O
electron	NN	O	O
transport	NN	O	O
chain	NN	O	O
complexes	NN	O	O
I	NN	O	O
-	NN	O	O
IV	NN	O	O
and	NN	O	O
apoptosis	NN	O	O
-	NN	O	O
inducing	NN	O	O
factor	NN	O	O
,	NN	O	O
and	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
markers	NN	O	O
have	NN	O	O
been	NN	O	O
analyzed	NN	O	O
.	NN	O	O

Hydroxytyrosol	NN	O	O
improved	NN	O	O
the	NN	O	O
cardiac	NN	O	B
disturbances	NN	O	I
enhanced	NN	O	O
by	NN	O	O
doxorubicin	NN	O	O
by	NN	O	O
significantly	NN	O	O
reducing	NN	O	O
the	NN	O	O
percentage	NN	O	O
of	NN	O	O
altered	NN	O	O
mitochondria	NN	O	O
and	NN	O	O
oxidative	NN	O	O
damage	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
hydroxytyrosol	NN	O	O
improve	NN	O	O
the	NN	O	O
mitochondrial	NN	O	O
electron	NN	O	O
transport	NN	O	O
chain	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
hydroxytyrosol	NN	O	O
protect	NN	O	O
rat	NN	O	O
heart	NN	O	B
damage	NN	O	I
provoked	NN	O	O
by	NN	O	O
doxorubicin	NN	O	O
decreasing	NN	O	O
oxidative	NN	O	O
damage	NN	O	O
and	NN	O	O
mitochondrial	NN	O	O
alterations	NN	O	O
.	NN	O	O

Amiodarone	NN	O	O
-	NN	O	O
induced	NN	O	O
myxoedema	NN	O	B
coma	NN	O	I
.	NN	O	O

A	NN	O	O
62	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
bradycardia	NN	O	B
,	NN	O	O
hypothermia	NN	O	B
and	NN	O	O
respiratory	NN	O	B
failure	NN	O	I
3	NN	O	O
weeks	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
therapy	NN	O	O
for	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
.	NN	O	O

Thyroid	NN	O	O
-	NN	O	O
stimulating	NN	O	O
hormone	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
168	NN	O	O
uIU	NN	O	O
/	NN	O	O
mL	NN	O	O
(	NN	O	O
nl	NN	O	O
.	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
5	NN	O	O
uIU	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
and	NN	O	O
free	NN	O	O
thyroxine	NN	O	O
(	NN	O	O
FT4	NN	O	O
)	NN	O	O
was	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
ng	NN	O	O
/	NN	O	O
dL	NN	O	O
(	NN	O	O
nl	NN	O	O
.	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
8	NN	O	O
ng	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
.	NN	O	O

He	NN	O	O
received	NN	O	O
intravenous	NN	O	O
fluids	NN	O	O
,	NN	O	O
vasopressor	NN	O	O
therapy	NN	O	O
and	NN	O	O
stress	NN	O	O
dose	NN	O	O
steroids	NN	O	O
;	NN	O	O
he	NN	O	O
was	NN	O	O
intubated	NN	O	O
and	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
.	NN	O	O

He	NN	O	O
received	NN	O	O
500	NN	O	O
ug	NN	O	O
of	NN	O	O
intravenous	NN	O	O
levothyroxine	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
18	NN	O	O
h	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
and	NN	O	O
150	NN	O	O
ug	NN	O	O
intravenous	NN	O	O
daily	NN	O	O
thereafter	NN	O	O
.	NN	O	O

Haemodynamic	NN	O	O
improvement	NN	O	O
,	NN	O	O
along	NN	O	O
with	NN	O	O
complete	NN	O	O
recovery	NN	O	O
of	NN	O	O
mental	NN	O	O
status	NN	O	O
,	NN	O	O
occurred	NN	O	O
after	NN	O	O
48	NN	O	O
h	NN	O	O
.	NN	O	O

Twelve	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
FT4	NN	O	O
was	NN	O	O
0	NN	O	O
.	NN	O	O
96	NN	O	O
ng	NN	O	O
/	NN	O	O
dL	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
maintained	NN	O	O
on	NN	O	O
levothyroxine	NN	O	O
175	NN	O	O
(	NN	O	O
g	NN	O	O
POorally	NN	O	O
daily	NN	O	O
.	NN	O	O

A	NN	O	O
thyroid	NN	O	O
ultrasound	NN	O	O
showed	NN	O	O
diffuse	NN	O	O
heterogeneity	NN	O	O
.	NN	O	O

The	NN	O	O
24	NN	O	O
hour	NN	O	O
excretion	NN	O	O
of	NN	O	O
iodine	NN	O	O
was	NN	O	O
3657	NN	O	O
(	NN	O	O
mcg	NN	O	O
(	NN	O	O
25	NN	O	O
-	NN	O	O
756	NN	O	O
(	NN	O	O
mcg	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
only	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
-	NN	O	O
induced	NN	O	O
myxoedema	NN	O	B
coma	NN	O	I
in	NN	O	O
the	NN	O	O
literature	NN	O	O
report	NN	O	O
patient	NN	O	O
death	NN	O	O
despite	NN	O	O
supportive	NN	O	O
therapy	NN	O	O
and	NN	O	O
thyroid	NN	O	O
hormone	NN	O	O
replacement	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
represents	NN	O	O
the	NN	O	O
most	NN	O	O
thoroughly	NN	O	O
investigated	NN	O	O
case	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
-	NN	O	O
induced	NN	O	O
myxoedema	NN	O	B
coma	NN	O	I
with	NN	O	O
a	NN	O	O
history	NN	O	O
significant	NN	O	O
for	NN	O	O
subclinical	NN	O	O
thyroid	NN	O	B
disease	NN	O	I
.	NN	O	O

Use	NN	O	O
of	NN	O	O
argatroban	NN	O	O
and	NN	O	O
catheter	NN	O	O
-	NN	O	O
directed	NN	O	O
thrombolysis	NN	O	B
with	NN	O	O
alteplase	NN	O	O
in	NN	O	O
an	NN	O	O
oncology	NN	O	O
patient	NN	O	O
with	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
with	NN	O	O
thrombosis	NN	O	B
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
The	NN	O	O
case	NN	O	O
of	NN	O	O
an	NN	O	O
oncology	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
with	NN	O	O
thrombosis	NN	O	B
(	NN	O	O
HITT	NN	O	B
)	NN	O	O
and	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
argatroban	NN	O	O
plus	NN	O	O
catheter	NN	O	O
-	NN	O	O
directed	NN	O	O
thrombolysis	NN	O	B
(	NN	O	O
CDT	NN	O	O
)	NN	O	O
with	NN	O	O
alteplase	NN	O	O
is	NN	O	O
presented	NN	O	O
.	NN	O	O

SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
63	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Caucasian	NN	O	O
man	NN	O	O
with	NN	O	O
renal	NN	O	O
amyloidosis	NN	O	B
undergoing	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
stem	NN	O	O
cell	NN	O	O
collection	NN	O	O
for	NN	O	O
an	NN	O	O
autologous	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplant	NN	O	O
developed	NN	O	O
extensive	NN	O	O
bilateral	NN	O	O
upper	NN	O	B
-	NN	O	I
extremity	NN	O	I
deep	NN	O	I
venous	NN	O	I
thrombosis	NN	O	I
(	NN	O	O
DVT	NN	O	B
)	NN	O	O
and	NN	O	O
pulmonary	NN	O	B
embolism	NN	O	I
secondary	NN	O	O
to	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
.	NN	O	O

A	NN	O	O
continuous	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
infusion	NN	O	O
of	NN	O	O
argatroban	NN	O	O
was	NN	O	O
initiated	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
managed	NN	O	O
on	NN	O	O
the	NN	O	O
general	NN	O	O
medical	NN	O	O
floor	NN	O	O
.	NN	O	O

After	NN	O	O
one	NN	O	O
week	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
he	NN	O	O
was	NN	O	O
transferred	NN	O	O
to	NN	O	O
the	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
with	NN	O	O
cardiopulmonary	NN	O	O
compromise	NN	O	O
related	NN	O	O
to	NN	O	O
superior	NN	O	B
vena	NN	O	I
cava	NN	O	I
(	NN	O	I
SVC	NN	O	I
)	NN	O	I
syndrome	NN	O	I
.	NN	O	O

A	NN	O	O
percutaneous	NN	O	O
mechanical	NN	O	O
thrombectomy	NN	O	O
and	NN	O	O
CDT	NN	O	O
with	NN	O	O
alteplase	NN	O	O
were	NN	O	O
attempted	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
procedure	NN	O	O
was	NN	O	O
aborted	NN	O	O
due	NN	O	O
to	NN	O	O
epistaxis	NN	O	B
.	NN	O	O

The	NN	O	O
epistaxis	NN	O	B
resolved	NN	O	O
the	NN	O	O
next	NN	O	O
day	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
restarted	NN	O	O
on	NN	O	O
argatroban	NN	O	O
.	NN	O	O

A	NN	O	O
second	NN	O	O
percutaneous	NN	O	O
mechanical	NN	O	O
thrombectomy	NN	O	O
was	NN	O	O
performed	NN	O	O
six	NN	O	O
days	NN	O	O
later	NN	O	O
and	NN	O	O
resulted	NN	O	O
in	NN	O	O
partial	NN	O	O
revascularization	NN	O	O
of	NN	O	O
the	NN	O	O
SVC	NN	O	O
and	NN	O	O
central	NN	O	O
veins	NN	O	O
.	NN	O	O

Postthrombectomy	NN	O	O
continuous	NN	O	O
CDT	NN	O	O
with	NN	O	O
alteplase	NN	O	O
was	NN	O	O
commenced	NN	O	O
while	NN	O	O
argatroban	NN	O	O
was	NN	O	O
withheld	NN	O	O
,	NN	O	O
and	NN	O	O
complete	NN	O	O
patency	NN	O	O
of	NN	O	O
the	NN	O	O
SVC	NN	O	O
and	NN	O	O
central	NN	O	O
veins	NN	O	O
was	NN	O	O
achieved	NN	O	O
after	NN	O	O
three	NN	O	O
days	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

Alteplase	NN	O	O
was	NN	O	O
discontinued	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
reinitiated	NN	O	O
on	NN	O	O
argatroban	NN	O	O
;	NN	O	O
ultimately	NN	O	O
,	NN	O	O
he	NN	O	O
was	NN	O	O
transitioned	NN	O	O
to	NN	O	O
warfarin	NN	O	O
for	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
anticoagulation	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
patient	NN	O	O
recovered	NN	O	O
,	NN	O	O
he	NN	O	O
experienced	NN	O	O
permanent	NN	O	O
vision	NN	O	B
and	NN	O	I
hearing	NN	O	I
loss	NN	O	I
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
renal	NN	O	I
disease	NN	O	I
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
A	NN	O	O
63	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
renal	NN	O	O
amyloidosis	NN	O	B
and	NN	O	O
SVC	NN	O	B
syndrome	NN	O	I
secondary	NN	O	O
to	NN	O	O
HITT	NN	O	B
was	NN	O	O
successfully	NN	O	O
treated	NN	O	O
with	NN	O	O
argatroban	NN	O	O
and	NN	O	O
CDT	NN	O	O
with	NN	O	O
alteplase	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
dehydroepiandrosterone	NN	O	O
in	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
schizophrenia	NN	O	B
models	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
examine	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
dehydroepiandrosterone	NN	O	O
(	NN	O	O
DHEA	NN	O	O
)	NN	O	O
on	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Seventy	NN	O	O
Swiss	NN	O	O
albino	NN	O	O
female	NN	O	O
mice	NN	O	O
(	NN	O	O
25	NN	O	O
-	NN	O	O
35	NN	O	O
g	NN	O	O
)	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
4	NN	O	O
groups	NN	O	O
:	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
free	NN	O	O
(	NN	O	O
control	NN	O	O
)	NN	O	O
,	NN	O	O
amphetamine	NN	O	O
,	NN	O	O
50	NN	O	O
,	NN	O	O
and	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
DHEA	NN	O	O
.	NN	O	O

The	NN	O	O
DHEA	NN	O	O
was	NN	O	O
administered	NN	O	O
intraperitoneally	NN	O	O
(	NN	O	O
ip	NN	O	O
)	NN	O	O
for	NN	O	O
5	NN	O	O
days	NN	O	O
.	NN	O	O

Amphetamine	NN	O	O
(	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
)	NN	O	O
induced	NN	O	O
hyper	NN	O	B
locomotion	NN	O	O
,	NN	O	O
apomorphine	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
subcutaneously	NN	O	O
[	NN	O	O
sc	NN	O	O
]	NN	O	O
)	NN	O	O
induced	NN	O	O
climbing	NN	O	O
,	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
sc	NN	O	O
)	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
tests	NN	O	O
were	NN	O	O
used	NN	O	O
as	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B
.	NN	O	O

The	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
at	NN	O	O
the	NN	O	O
Animal	NN	O	O
Experiment	NN	O	O
Laboratories	NN	O	O
,	NN	O	O
Department	NN	O	O
of	NN	O	O
Pharmacology	NN	O	O
,	NN	O	O
Medical	NN	O	O
School	NN	O	O
,	NN	O	O
Eskisehir	NN	O	O
Osmangazi	NN	O	O
University	NN	O	O
,	NN	O	O
Eskisehir	NN	O	O
,	NN	O	O
Turkey	NN	O	O
between	NN	O	O
March	NN	O	O
and	NN	O	O
May	NN	O	O
2012	NN	O	O
.	NN	O	O

Statistical	NN	O	O
analysis	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
using	NN	O	O
Kruskal	NN	O	O
-	NN	O	O
Wallis	NN	O	O
test	NN	O	O
for	NN	O	O
hyper	NN	O	B
locomotion	NN	O	O
,	NN	O	O
and	NN	O	O
one	NN	O	O
-	NN	O	O
way	NN	O	O
ANOVA	NN	O	O
for	NN	O	O
climbing	NN	O	O
and	NN	O	O
catalepsy	NN	O	B
tests	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
the	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotion	NN	O	O
test	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
significant	NN	O	O
increases	NN	O	O
in	NN	O	O
all	NN	O	O
movements	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
free	NN	O	O
group	NN	O	O
.	NN	O	O

Both	NN	O	O
DHEA	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
all	NN	O	O
movements	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotion	NN	O	O
group	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
groups	NN	O	O
in	NN	O	O
the	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
test	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
groups	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
total	NN	O	O
climbing	NN	O	O
time	NN	O	O
in	NN	O	O
the	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
climbing	NN	O	O
test	NN	O	O
(	NN	O	O
p	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
We	NN	O	O
observed	NN	O	O
that	NN	O	O
DHEA	NN	O	O
reduced	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
and	NN	O	O
increased	NN	O	O
catalepsy	NN	O	B
at	NN	O	O
both	NN	O	O
doses	NN	O	O
,	NN	O	O
while	NN	O	O
it	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
climbing	NN	O	O
behavior	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
DHEA	NN	O	O
displays	NN	O	O
typical	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
like	NN	O	O
effects	NN	O	O
,	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B
.	NN	O	O

Availability	NN	O	O
of	NN	O	O
human	NN	O	O
induced	NN	O	O
pluripotent	NN	O	O
stem	NN	O	O
cell	NN	O	O
-	NN	O	O
derived	NN	O	O
cardiomyocytes	NN	O	O
in	NN	O	O
assessment	NN	O	O
of	NN	O	O
drug	NN	O	O
potential	NN	O	O
for	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
.	NN	O	O

Field	NN	O	O
potential	NN	O	O
duration	NN	O	O
(	NN	O	O
FPD	NN	O	O
)	NN	O	O
in	NN	O	O
human	NN	O	O
-	NN	O	O
induced	NN	O	O
pluripotent	NN	O	O
stem	NN	O	O
cell	NN	O	O
-	NN	O	O
derived	NN	O	O
cardiomyocytes	NN	O	O
(	NN	O	O
hiPS	NN	O	O
-	NN	O	O
CMs	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
can	NN	O	O
express	NN	O	O
QT	NN	O	O
interval	NN	O	O
in	NN	O	O
an	NN	O	O
electrocardiogram	NN	O	O
,	NN	O	O
is	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
tool	NN	O	O
to	NN	O	O
predict	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
channel	NN	O	O
and	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
channel	NN	O	O
blocker	NN	O	O
effects	NN	O	O
on	NN	O	O
QT	NN	O	O
interval	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
no	NN	O	O
report	NN	O	O
showing	NN	O	O
that	NN	O	O
this	NN	O	O
technique	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
predict	NN	O	O
multichannel	NN	O	O
blocker	NN	O	O
potential	NN	O	O
for	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
show	NN	O	O
that	NN	O	O
FPD	NN	O	O
from	NN	O	O
MEA	NN	O	O
(	NN	O	O
Multielectrode	NN	O	O
array	NN	O	O
)	NN	O	O
of	NN	O	O
hiPS	NN	O	O
-	NN	O	O
CMs	NN	O	O
can	NN	O	O
detect	NN	O	O
QT	NN	O	B
prolongation	NN	O	I
induced	NN	O	O
by	NN	O	O
multichannel	NN	O	O
blockers	NN	O	O
.	NN	O	O

hiPS	NN	O	O
-	NN	O	O
CMs	NN	O	O
were	NN	O	O
seeded	NN	O	O
onto	NN	O	O
MEA	NN	O	O
and	NN	O	O
FPD	NN	O	O
was	NN	O	O
measured	NN	O	O
for	NN	O	O
2min	NN	O	O
every	NN	O	O
10min	NN	O	O
for	NN	O	O
30min	NN	O	O
after	NN	O	O
drug	NN	O	O
exposure	NN	O	O
for	NN	O	O
the	NN	O	O
vehicle	NN	O	O
and	NN	O	O
each	NN	O	O
drug	NN	O	O
concentration	NN	O	O
.	NN	O	O

IKr	NN	O	O
and	NN	O	O
IKs	NN	O	O
blockers	NN	O	O
concentration	NN	O	O
-	NN	O	O
dependently	NN	O	O
prolonged	NN	O	O
corrected	NN	O	O
FPD	NN	O	O
(	NN	O	O
FPDc	NN	O	O
)	NN	O	O
,	NN	O	O
whereas	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
channel	NN	O	O
blockers	NN	O	O
concentration	NN	O	O
-	NN	O	O
dependently	NN	O	O
shortened	NN	O	O
FPDc	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
the	NN	O	O
multichannel	NN	O	O
blockers	NN	O	O
Amiodarone	NN	O	O
,	NN	O	O
Paroxetine	NN	O	O
,	NN	O	O
Terfenadine	NN	O	O
and	NN	O	O
Citalopram	NN	O	O
prolonged	NN	O	O
FPDc	NN	O	O
in	NN	O	O
a	NN	O	O
concentration	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
the	NN	O	O
IKr	NN	O	O
blockers	NN	O	O
,	NN	O	O
Terfenadine	NN	O	O
and	NN	O	O
Citalopram	NN	O	O
,	NN	O	O
which	NN	O	O
are	NN	O	O
reported	NN	O	O
to	NN	O	O
cause	NN	O	O
Torsade	NN	O	B
de	NN	O	I
Pointes	NN	O	I
(	NN	O	O
TdP	NN	O	B
)	NN	O	O
in	NN	O	O
clinical	NN	O	O
practice	NN	O	O
,	NN	O	O
produced	NN	O	O
early	NN	O	O
afterdepolarization	NN	O	O
(	NN	O	O
EAD	NN	O	O
)	NN	O	O
.	NN	O	O

hiPS	NN	O	O
-	NN	O	O
CMs	NN	O	O
using	NN	O	O
MEA	NN	O	O
system	NN	O	O
and	NN	O	O
FPDc	NN	O	O
can	NN	O	O
predict	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
drug	NN	O	O
candidates	NN	O	O
on	NN	O	O
QT	NN	O	O
interval	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
also	NN	O	O
shows	NN	O	O
that	NN	O	O
this	NN	O	O
assay	NN	O	O
can	NN	O	O
help	NN	O	O
detect	NN	O	O
EAD	NN	O	O
for	NN	O	O
drugs	NN	O	O
with	NN	O	O
TdP	NN	O	B
potential	NN	O	O
.	NN	O	O

Dermal	NN	O	O
developmental	NN	O	O
toxicity	NN	O	B
of	NN	O	O
N	NN	O	O
-	NN	O	O
phenylimide	NN	O	O
herbicides	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
S	NN	O	O
-	NN	O	O
53482	NN	O	O
and	NN	O	O
S	NN	O	O
-	NN	O	O
23121	NN	O	O
are	NN	O	O
N	NN	O	O
-	NN	O	O
phenylimide	NN	O	O
herbicides	NN	O	O
and	NN	O	O
produced	NN	O	O
embryolethality	NN	O	B
,	NN	O	O
teratogenicity	NN	O	B
(	NN	O	O
mainly	NN	O	O
ventricular	NN	O	B
septal	NN	O	I
defects	NN	O	I
and	NN	O	O
wavy	NN	O	O
ribs	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
growth	NN	O	B
retardation	NN	O	I
in	NN	O	O
rats	NN	O	O
in	NN	O	O
conventional	NN	O	O
oral	NN	O	O
developmental	NN	O	O
toxicity	NN	O	B
studies	NN	O	O
.	NN	O	O

Our	NN	O	O
objective	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
the	NN	O	O
compounds	NN	O	O
induce	NN	O	O
developmental	NN	O	O
toxicity	NN	O	B
via	NN	O	O
the	NN	O	O
dermal	NN	O	O
route	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
more	NN	O	O
relevant	NN	O	O
to	NN	O	O
occupational	NN	O	O
exposure	NN	O	O
,	NN	O	O
hence	NN	O	O
better	NN	O	O
addressing	NN	O	O
human	NN	O	O
health	NN	O	O
risks	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
S	NN	O	O
-	NN	O	O
53482	NN	O	O
was	NN	O	O
administered	NN	O	O
dermally	NN	O	O
to	NN	O	O
rats	NN	O	O
at	NN	O	O
30	NN	O	O
,	NN	O	O
100	NN	O	O
,	NN	O	O
and	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
during	NN	O	O
organogenesis	NN	O	O
,	NN	O	O
and	NN	O	O
S	NN	O	O
-	NN	O	O
23121	NN	O	O
was	NN	O	O
administered	NN	O	O
at	NN	O	O
200	NN	O	O
,	NN	O	O
400	NN	O	O
,	NN	O	O
and	NN	O	O
800	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
the	NN	O	O
maximum	NN	O	O
applicable	NN	O	O
dose	NN	O	O
level	NN	O	O
)	NN	O	O
.	NN	O	O

Fetuses	NN	O	O
were	NN	O	O
obtained	NN	O	O
by	NN	O	O
a	NN	O	O
Cesarean	NN	O	O
section	NN	O	O
and	NN	O	O
examined	NN	O	O
for	NN	O	O
external	NN	O	O
,	NN	O	O
visceral	NN	O	O
,	NN	O	O
and	NN	O	O
skeletal	NN	O	O
alterations	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Dermal	NN	O	O
exposure	NN	O	O
of	NN	O	O
rats	NN	O	O
to	NN	O	O
S	NN	O	O
-	NN	O	O
53482	NN	O	O
at	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
produced	NN	O	O
patterns	NN	O	O
of	NN	O	O
developmental	NN	O	O
toxicity	NN	O	B
similar	NN	O	O
to	NN	O	O
those	NN	O	O
resulting	NN	O	O
from	NN	O	O
oral	NN	O	O
exposure	NN	O	O
.	NN	O	O

Toxicity	NN	O	B
included	NN	O	O
embryolethality	NN	O	B
,	NN	O	O
teratogenicity	NN	O	B
,	NN	O	O
and	NN	O	O
growth	NN	O	B
retardation	NN	O	I
.	NN	O	O

Dermal	NN	O	O
administration	NN	O	O
of	NN	O	O
S	NN	O	O
-	NN	O	O
23121	NN	O	O
at	NN	O	O
800	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
embryonic	NN	O	B
death	NN	O	I
and	NN	O	O
ventricular	NN	O	B
septal	NN	O	I
defect	NN	O	I
,	NN	O	O
but	NN	O	O
retarded	NN	O	O
fetal	NN	O	O
growth	NN	O	O
was	NN	O	O
not	NN	O	O
observed	NN	O	O
as	NN	O	O
it	NN	O	O
was	NN	O	O
following	NN	O	O
oral	NN	O	O
exposure	NN	O	O
to	NN	O	O
S	NN	O	O
-	NN	O	O
23121	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Based	NN	O	O
on	NN	O	O
the	NN	O	O
results	NN	O	O
,	NN	O	O
S	NN	O	O
-	NN	O	O
53482	NN	O	O
and	NN	O	O
S	NN	O	O
-	NN	O	O
23121	NN	O	O
were	NN	O	O
teratogenic	NN	O	B
when	NN	O	O
administered	NN	O	O
dermally	NN	O	O
to	NN	O	O
pregnant	NN	O	O
rats	NN	O	O
as	NN	O	O
were	NN	O	O
the	NN	O	O
compounds	NN	O	O
administered	NN	O	O
orally	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
investigation	NN	O	O
of	NN	O	O
the	NN	O	O
mechanism	NN	O	O
and	NN	O	O
its	NN	O	O
human	NN	O	O
relevancy	NN	O	O
become	NN	O	O
more	NN	O	O
important	NN	O	O
.	NN	O	O

Rates	NN	O	O
of	NN	O	O
Renal	NN	O	B
Toxicity	NN	O	I
in	NN	O	O
Cancer	NN	O	B
Patients	NN	O	O
Receiving	NN	O	O
Cisplatin	NN	O	O
With	NN	O	O
and	NN	O	O
Without	NN	O	O
Mannitol	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Cisplatin	NN	O	O
is	NN	O	O
a	NN	O	O
widely	NN	O	O
used	NN	O	O
antineoplastic	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
major	NN	O	O
complications	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
use	NN	O	O
is	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

There	NN	O	O
are	NN	O	O
many	NN	O	O
strategies	NN	O	O
to	NN	O	O
prevent	NN	O	O
this	NN	O	O
toxicity	NN	O	B
,	NN	O	O
including	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
mannitol	NN	O	O
as	NN	O	O
a	NN	O	O
nephroprotectant	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
hydration	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
We	NN	O	O
aimed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
rates	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
in	NN	O	O
cancer	NN	O	B
patients	NN	O	O
receiving	NN	O	O
single	NN	O	O
-	NN	O	O
agent	NN	O	O
cisplatin	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
mannitol	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
single	NN	O	O
-	NN	O	O
center	NN	O	O
retrospective	NN	O	O
analysis	NN	O	O
was	NN	O	O
a	NN	O	O
quasi	NN	O	O
experiment	NN	O	O
created	NN	O	O
by	NN	O	O
the	NN	O	O
national	NN	O	O
mannitol	NN	O	O
shortage	NN	O	O
.	NN	O	O

Data	NN	O	O
were	NN	O	O
collected	NN	O	O
on	NN	O	O
adult	NN	O	O
cancer	NN	O	B
patients	NN	O	O
receiving	NN	O	O
single	NN	O	O
-	NN	O	O
agent	NN	O	O
cisplatin	NN	O	O
as	NN	O	O
an	NN	O	O
outpatient	NN	O	O
from	NN	O	O
January	NN	O	O
2011	NN	O	O
to	NN	O	O
September	NN	O	O
2012	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
was	NN	O	O
acute	NN	O	B
kidney	NN	O	I
injury	NN	O	I
(	NN	O	O
AKI	NN	O	B
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
We	NN	O	O
evaluated	NN	O	O
143	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
single	NN	O	O
-	NN	O	O
agent	NN	O	O
cisplatin	NN	O	O
;	NN	O	O
97	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
had	NN	O	O
head	NN	O	B
and	NN	O	I
neck	NN	O	I
cancer	NN	O	I
as	NN	O	O
their	NN	O	O
primary	NN	O	O
malignancy	NN	O	B
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
did	NN	O	O
not	NN	O	O
receive	NN	O	O
mannitol	NN	O	O
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
develop	NN	O	O
nephrotoxicity	NN	O	B
:	NN	O	O
odds	NN	O	O
ratio	NN	O	O
[	NN	O	O
OR	NN	O	O
]	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
646	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
008	NN	O	O
,	NN	O	O
6	NN	O	O
.	NN	O	O
944	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
048	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
received	NN	O	O
the	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
dosing	NN	O	O
and	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
hypertension	NN	O	B
also	NN	O	O
had	NN	O	O
a	NN	O	O
higher	NN	O	O
likelihood	NN	O	O
of	NN	O	O
developing	NN	O	O
nephrotoxicity	NN	O	B
:	NN	O	O
OR	NN	O	O
=	NN	O	O
11	NN	O	O
.	NN	O	O
494	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
4	NN	O	O
.	NN	O	O
149	NN	O	O
,	NN	O	O
32	NN	O	O
.	NN	O	O
258	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
and	NN	O	O
OR	NN	O	O
=	NN	O	O
3	NN	O	O
.	NN	O	O
219	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
228	NN	O	O
,	NN	O	O
8	NN	O	O
.	NN	O	O
439	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
017	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
When	NN	O	O
limited	NN	O	O
quantities	NN	O	O
of	NN	O	O
mannitol	NN	O	O
are	NN	O	O
available	NN	O	O
,	NN	O	O
it	NN	O	O
should	NN	O	O
preferentially	NN	O	O
be	NN	O	O
given	NN	O	O
to	NN	O	O
patients	NN	O	O
at	NN	O	O
particularly	NN	O	O
high	NN	O	O
risk	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

Our	NN	O	O
analysis	NN	O	O
suggests	NN	O	O
that	NN	O	O
those	NN	O	O
patients	NN	O	O
receiving	NN	O	O
the	NN	O	O
dosing	NN	O	O
schedule	NN	O	O
of	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
cisplatin	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
and	NN	O	O
those	NN	O	O
with	NN	O	O
hypertension	NN	O	B
are	NN	O	O
at	NN	O	O
the	NN	O	O
greatest	NN	O	O
risk	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B
and	NN	O	O
would	NN	O	O
benefit	NN	O	O
from	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
mannitol	NN	O	O
.	NN	O	O

Metformin	NN	O	O
protects	NN	O	O
against	NN	O	O
seizures	NN	O	B
,	NN	O	O
learning	NN	O	B
and	NN	O	I
memory	NN	O	I
impairments	NN	O	I
and	NN	O	O
oxidative	NN	O	O
damage	NN	O	O
induced	NN	O	O
by	NN	O	O
pentylenetetrazole	NN	O	O
-	NN	O	O
induced	NN	O	O
kindling	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Cognitive	NN	O	B
impairment	NN	O	I
,	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
and	NN	O	O
severe	NN	O	O
comorbidity	NN	O	O
of	NN	O	O
epilepsy	NN	O	B
,	NN	O	O
greatly	NN	O	O
diminishes	NN	O	O
the	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
current	NN	O	O
therapeutic	NN	O	O
interventions	NN	O	O
for	NN	O	O
epilepsy	NN	O	B
can	NN	O	O
also	NN	O	O
cause	NN	O	O
untoward	NN	O	O
cognitive	NN	O	O
effects	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
an	NN	O	O
urgent	NN	O	O
need	NN	O	O
for	NN	O	O
new	NN	O	O
kinds	NN	O	O
of	NN	O	O
agents	NN	O	O
targeting	NN	O	O
both	NN	O	O
seizures	NN	O	B
and	NN	O	O
cognition	NN	O	B
deficits	NN	O	I
.	NN	O	O

Oxidative	NN	O	O
stress	NN	O	O
is	NN	O	O
considered	NN	O	O
to	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
epileptogenesis	NN	O	O
and	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
,	NN	O	O
and	NN	O	O
antioxidants	NN	O	O
have	NN	O	O
a	NN	O	O
putative	NN	O	O
antiepileptic	NN	O	O
potential	NN	O	O
.	NN	O	O

Metformin	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
commonly	NN	O	O
prescribed	NN	O	O
antidiabetic	NN	O	O
oral	NN	O	O
drug	NN	O	O
,	NN	O	O
has	NN	O	O
antioxidant	NN	O	O
properties	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
ameliorative	NN	O	O
effects	NN	O	O
of	NN	O	O
metformin	NN	O	O
on	NN	O	O
seizures	NN	O	B
,	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
and	NN	O	O
brain	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
markers	NN	O	O
observed	NN	O	O
in	NN	O	O
pentylenetetrazole	NN	O	O
-	NN	O	O
induced	NN	O	O
kindling	NN	O	O
animals	NN	O	O
.	NN	O	O

Male	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
mice	NN	O	O
were	NN	O	O
administered	NN	O	O
with	NN	O	O
subconvulsive	NN	O	O
dose	NN	O	O
of	NN	O	O
pentylenetetrazole	NN	O	O
(	NN	O	O
37	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
every	NN	O	O
other	NN	O	O
day	NN	O	O
for	NN	O	O
14	NN	O	O
injections	NN	O	O
.	NN	O	O

Metformin	NN	O	O
was	NN	O	O
injected	NN	O	O
intraperitoneally	NN	O	O
in	NN	O	O
dose	NN	O	O
of	NN	O	O
200mg	NN	O	O
/	NN	O	O
kg	NN	O	O
along	NN	O	O
with	NN	O	O
alternate	NN	O	O
-	NN	O	O
day	NN	O	O
PTZ	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
metformin	NN	O	O
suppressed	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
kindling	NN	O	O
,	NN	O	O
ameliorated	NN	O	O
the	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
and	NN	O	O
decreased	NN	O	O
brain	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O

Thus	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
concluded	NN	O	O
that	NN	O	O
metformin	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
potential	NN	O	O
agent	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
epilepsy	NN	O	B
as	NN	O	O
well	NN	O	O
as	NN	O	O
a	NN	O	O
protective	NN	O	O
medicine	NN	O	O
against	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
induced	NN	O	O
by	NN	O	O
seizures	NN	O	B
.	NN	O	O

P53	NN	O	O
inhibition	NN	O	O
exacerbates	NN	O	O
late	NN	O	O
-	NN	O	O
stage	NN	O	O
anthracycline	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

AIMS	NN	O	O
:	NN	O	O
Doxorubicin	NN	O	O
(	NN	O	O
DOX	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
anti	NN	O	O
-	NN	O	O
cancer	NN	O	B
therapeutic	NN	O	O
,	NN	O	O
but	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
both	NN	O	O
acute	NN	O	O
and	NN	O	O
late	NN	O	O
-	NN	O	O
stage	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Children	NN	O	O
are	NN	O	O
particularly	NN	O	O
sensitive	NN	O	O
to	NN	O	O
DOX	NN	O	O
-	NN	O	O
induced	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

Here	NN	O	O
,	NN	O	O
the	NN	O	O
impact	NN	O	O
of	NN	O	O
p53	NN	O	O
inhibition	NN	O	O
on	NN	O	O
acute	NN	O	O
vs	NN	O	O
.	NN	O	O
late	NN	O	O
-	NN	O	O
stage	NN	O	O
DOX	NN	O	O
cardiotoxicity	NN	O	B
was	NN	O	O
examined	NN	O	O
in	NN	O	O
a	NN	O	O
juvenile	NN	O	O
model	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
Two	NN	O	O
-	NN	O	O
week	NN	O	O
-	NN	O	O
old	NN	O	O
MHC	NN	O	O
-	NN	O	O
CB7	NN	O	O
mice	NN	O	O
(	NN	O	O
which	NN	O	O
express	NN	O	O
dominant	NN	O	O
-	NN	O	O
interfering	NN	O	O
p53	NN	O	O
in	NN	O	O
cardiomyocytes	NN	O	O
)	NN	O	O
and	NN	O	O
their	NN	O	O
non	NN	O	O
-	NN	O	O
transgenic	NN	O	O
(	NN	O	O
NON	NN	O	O
-	NN	O	O
TXG	NN	O	O
)	NN	O	O
littermates	NN	O	O
received	NN	O	O
weekly	NN	O	O
DOX	NN	O	O
injections	NN	O	O
for	NN	O	O
5	NN	O	O
weeks	NN	O	O
(	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
)	NN	O	O
.	NN	O	O

One	NN	O	O
week	NN	O	O
after	NN	O	O
the	NN	O	O
last	NN	O	O
DOX	NN	O	O
treatment	NN	O	O
(	NN	O	O
acute	NN	O	O
stage	NN	O	O
)	NN	O	O
,	NN	O	O
MHC	NN	O	O
-	NN	O	O
CB7	NN	O	O
mice	NN	O	O
exhibited	NN	O	O
improved	NN	O	O
cardiac	NN	O	O
function	NN	O	O
and	NN	O	O
lower	NN	O	O
levels	NN	O	O
of	NN	O	O
cardiomyocyte	NN	O	O
apoptosis	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
NON	NN	O	O
-	NN	O	O
TXG	NN	O	O
mice	NN	O	O
.	NN	O	O

Surprisingly	NN	O	O
,	NN	O	O
by	NN	O	O
13	NN	O	O
weeks	NN	O	O
following	NN	O	O
the	NN	O	O
last	NN	O	O
DOX	NN	O	O
treatment	NN	O	O
(	NN	O	O
late	NN	O	O
stage	NN	O	O
)	NN	O	O
,	NN	O	O
MHC	NN	O	O
-	NN	O	O
CB7	NN	O	O
exhibited	NN	O	O
a	NN	O	O
progressive	NN	O	O
decrease	NN	O	O
in	NN	O	O
cardiac	NN	O	O
function	NN	O	O
and	NN	O	O
higher	NN	O	O
rates	NN	O	O
of	NN	O	O
cardiomyocyte	NN	O	O
apoptosis	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
NON	NN	O	O
-	NN	O	O
TXG	NN	O	O
mice	NN	O	O
.	NN	O	O

p53	NN	O	O
inhibition	NN	O	O
blocked	NN	O	O
transient	NN	O	O
DOX	NN	O	O
-	NN	O	O
induced	NN	O	O
STAT3	NN	O	O
activation	NN	O	O
in	NN	O	O
MHC	NN	O	O
-	NN	O	O
CB7	NN	O	O
mice	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
enhanced	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
DNA	NN	O	O
repair	NN	O	O
proteins	NN	O	O
Ku70	NN	O	O
and	NN	O	O
Ku80	NN	O	O
.	NN	O	O

Mice	NN	O	O
with	NN	O	O
cardiomyocyte	NN	O	O
-	NN	O	O
restricted	NN	O	O
deletion	NN	O	O
of	NN	O	O
STAT3	NN	O	O
exhibited	NN	O	O
worse	NN	O	O
cardiac	NN	O	O
function	NN	O	O
,	NN	O	O
higher	NN	O	O
levels	NN	O	O
of	NN	O	O
cardiomyocyte	NN	O	O
apoptosis	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
greater	NN	O	O
induction	NN	O	O
of	NN	O	O
Ku70	NN	O	O
and	NN	O	O
Ku80	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
DOX	NN	O	O
treatment	NN	O	O
during	NN	O	O
the	NN	O	O
acute	NN	O	O
stage	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
animals	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
These	NN	O	O
data	NN	O	O
support	NN	O	O
a	NN	O	O
model	NN	O	O
wherein	NN	O	O
a	NN	O	O
p53	NN	O	O
-	NN	O	O
dependent	NN	O	O
cardioprotective	NN	O	O
pathway	NN	O	O
,	NN	O	O
mediated	NN	O	O
via	NN	O	O
STAT3	NN	O	O
activation	NN	O	O
,	NN	O	O
mitigates	NN	O	O
DOX	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	O
stress	NN	O	O
during	NN	O	O
drug	NN	O	O
delivery	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
these	NN	O	O
data	NN	O	O
suggest	NN	O	O
an	NN	O	O
explanation	NN	O	O
as	NN	O	O
to	NN	O	O
how	NN	O	O
p53	NN	O	O
inhibition	NN	O	O
can	NN	O	O
result	NN	O	O
in	NN	O	O
cardioprotection	NN	O	O
during	NN	O	O
drug	NN	O	O
treatment	NN	O	O
and	NN	O	O
,	NN	O	O
paradoxically	NN	O	O
,	NN	O	O
enhanced	NN	O	O
cardiotoxicity	NN	O	B
long	NN	O	O
after	NN	O	O
the	NN	O	O
cessation	NN	O	O
of	NN	O	O
drug	NN	O	O
treatment	NN	O	O
.	NN	O	O

Metronidazole	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
:	NN	O	O
an	NN	O	O
uncommon	NN	O	O
scenario	NN	O	O
.	NN	O	O

Metronidazole	NN	O	O
can	NN	O	O
produce	NN	O	O
neurological	NN	O	O
complications	NN	O	O
although	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
a	NN	O	O
common	NN	O	O
scenario	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
where	NN	O	O
a	NN	O	O
patient	NN	O	O
developed	NN	O	O
features	NN	O	O
of	NN	O	O
encephalopathy	NN	O	B
following	NN	O	O
prolonged	NN	O	O
metronidazole	NN	O	O
intake	NN	O	O
.	NN	O	O

Magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
MRI	NN	O	O
)	NN	O	O
brain	NN	O	O
showed	NN	O	O
abnormal	NN	O	O
signal	NN	O	O
intensity	NN	O	O
involving	NN	O	O
both	NN	O	O
dentate	NN	O	O
nuclei	NN	O	O
of	NN	O	O
cerebellum	NN	O	O
and	NN	O	O
splenium	NN	O	O
of	NN	O	O
corpus	NN	O	O
callosum	NN	O	O
.	NN	O	O

The	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
metronidazole	NN	O	O
toxicity	NN	O	B
was	NN	O	O
made	NN	O	O
by	NN	O	O
the	NN	O	O
MRI	NN	O	O
findings	NN	O	O
and	NN	O	O
supported	NN	O	O
clinically	NN	O	O
.	NN	O	O

Aconitine	NN	O	O
-	NN	O	O
induced	NN	O	O
Ca2	NN	O	O
+	NN	O	O
overload	NN	O	O
causes	NN	O	O
arrhythmia	NN	O	B
and	NN	O	O
triggers	NN	O	O
apoptosis	NN	O	O
through	NN	O	O
p38	NN	O	O
MAPK	NN	O	O
signaling	NN	O	O
pathway	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Aconitine	NN	O	O
is	NN	O	O
a	NN	O	O
major	NN	O	O
bioactive	NN	O	O
diterpenoid	NN	O	O
alkaloid	NN	O	O
with	NN	O	O
high	NN	O	O
content	NN	O	O
derived	NN	O	O
from	NN	O	O
herbal	NN	O	O
aconitum	NN	O	O
plants	NN	O	O
.	NN	O	O

Emerging	NN	O	O
evidence	NN	O	O
indicates	NN	O	O
that	NN	O	O
voltage	NN	O	O
-	NN	O	O
dependent	NN	O	O
Na	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
channels	NN	O	O
have	NN	O	O
pivotal	NN	O	O
roles	NN	O	O
in	NN	O	O
the	NN	O	O
cardiotoxicity	NN	O	B
of	NN	O	O
aconitine	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
no	NN	O	O
reports	NN	O	O
are	NN	O	O
available	NN	O	O
on	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
in	NN	O	O
aconitine	NN	O	O
poisoning	NN	O	B
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
explored	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
pathological	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
signaling	NN	O	O
in	NN	O	O
aconitine	NN	O	O
poisoning	NN	O	B
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
overload	NN	O	O
lead	NN	O	O
to	NN	O	O
accelerated	NN	O	O
beating	NN	O	O
rhythm	NN	O	O
in	NN	O	O
adult	NN	O	O
rat	NN	O	O
ventricular	NN	O	O
myocytes	NN	O	O
and	NN	O	O
caused	NN	O	O
arrhythmia	NN	O	B
in	NN	O	O
conscious	NN	O	O
freely	NN	O	O
moving	NN	O	O
rats	NN	O	O
.	NN	O	O

To	NN	O	O
investigate	NN	O	O
effects	NN	O	O
of	NN	O	O
aconitine	NN	O	O
on	NN	O	O
myocardial	NN	O	B
injury	NN	O	I
,	NN	O	O
we	NN	O	O
performed	NN	O	O
cytotoxicity	NN	O	B
assay	NN	O	O
in	NN	O	O
neonatal	NN	O	O
rat	NN	O	O
ventricular	NN	O	O
myocytes	NN	O	O
(	NN	O	O
NRVMs	NN	O	O
)	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
measured	NN	O	O
lactate	NN	O	O
dehydrogenase	NN	O	O
level	NN	O	O
in	NN	O	O
the	NN	O	O
culture	NN	O	O
medium	NN	O	O
of	NN	O	O
NRVMs	NN	O	O
and	NN	O	O
activities	NN	O	O
of	NN	O	O
serum	NN	O	O
cardiac	NN	O	O
enzymes	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
aconitine	NN	O	O
resulted	NN	O	O
in	NN	O	O
myocardial	NN	O	B
injury	NN	O	I
and	NN	O	O
reduced	NN	O	O
NRVMs	NN	O	O
viability	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
.	NN	O	O

To	NN	O	O
confirm	NN	O	O
the	NN	O	O
pro	NN	O	O
-	NN	O	O
apoptotic	NN	O	O
effects	NN	O	O
,	NN	O	O
we	NN	O	O
performed	NN	O	O
flow	NN	O	O
cytometric	NN	O	O
detection	NN	O	O
,	NN	O	O
cardiac	NN	O	O
histology	NN	O	O
,	NN	O	O
transmission	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
and	NN	O	O
terminal	NN	O	O
deoxynucleotidyl	NN	O	O
transferase	NN	O	O
-	NN	O	O
mediated	NN	O	O
dUTP	NN	O	O
-	NN	O	O
biotin	NN	O	O
nick	NN	O	O
end	NN	O	O
labeling	NN	O	O
assay	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
aconitine	NN	O	O
stimulated	NN	O	O
apoptosis	NN	O	O
time	NN	O	O
-	NN	O	O
dependently	NN	O	O
.	NN	O	O

The	NN	O	O
expression	NN	O	O
analysis	NN	O	O
of	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
handling	NN	O	O
proteins	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
aconitine	NN	O	O
promoted	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
overload	NN	O	O
through	NN	O	O
the	NN	O	O
expression	NN	O	O
regulation	NN	O	O
of	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
handling	NN	O	O
proteins	NN	O	O
.	NN	O	O

The	NN	O	O
expression	NN	O	O
analysis	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
-	NN	O	O
related	NN	O	O
proteins	NN	O	O
revealed	NN	O	O
that	NN	O	O
pro	NN	O	O
-	NN	O	O
apoptotic	NN	O	O
protein	NN	O	O
expression	NN	O	O
was	NN	O	O
upregulated	NN	O	O
,	NN	O	O
and	NN	O	O
anti	NN	O	O
-	NN	O	O
apoptotic	NN	O	O
protein	NN	O	O
BCL	NN	O	O
-	NN	O	O
2	NN	O	O
expression	NN	O	O
was	NN	O	O
downregulated	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
increased	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
MAPK	NN	O	O
family	NN	O	O
members	NN	O	O
,	NN	O	O
especially	NN	O	O
the	NN	O	O
P	NN	O	O
-	NN	O	O
P38	NN	O	O
/	NN	O	O
P38	NN	O	O
ratio	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
cardiac	NN	O	O
tissues	NN	O	O
.	NN	O	O

Hence	NN	O	O
,	NN	O	O
our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
aconitine	NN	O	O
significantly	NN	O	O
aggravates	NN	O	O
Ca	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
overload	NN	O	O
and	NN	O	O
causes	NN	O	O
arrhythmia	NN	O	B
and	NN	O	O
finally	NN	O	O
promotes	NN	O	O
apoptotic	NN	O	O
development	NN	O	O
via	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
P38	NN	O	O
mitogen	NN	O	O
-	NN	O	O
activated	NN	O	O
protein	NN	O	O
kinase	NN	O	O
.	NN	O	O

Chronic	NN	O	O
treatment	NN	O	O
with	NN	O	O
metformin	NN	O	O
suppresses	NN	O	O
toll	NN	O	O
-	NN	O	O
like	NN	O	O
receptor	NN	O	O
4	NN	O	O
signaling	NN	O	O
and	NN	O	O
attenuates	NN	O	O
left	NN	O	B
ventricular	NN	O	I
dysfunction	NN	O	I
following	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

Acute	NN	O	O
treatment	NN	O	O
with	NN	O	O
metformin	NN	O	O
has	NN	O	O
a	NN	O	O
protective	NN	O	O
effect	NN	O	O
in	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
by	NN	O	O
suppression	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
responses	NN	O	O
due	NN	O	O
to	NN	O	O
activation	NN	O	O
of	NN	O	O
AMP	NN	O	O
-	NN	O	O
activated	NN	O	O
protein	NN	O	O
kinase	NN	O	O
(	NN	O	O
AMPK	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
chronic	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
metformin	NN	O	O
on	NN	O	O
cardiac	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
toll	NN	O	O
-	NN	O	O
like	NN	O	O
receptor	NN	O	O
4	NN	O	O
(	NN	O	O
TLR4	NN	O	O
)	NN	O	O
activities	NN	O	O
following	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
and	NN	O	O
their	NN	O	O
relation	NN	O	O
with	NN	O	O
AMPK	NN	O	O
were	NN	O	O
assessed	NN	O	O
.	NN	O	O

Male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
one	NN	O	O
of	NN	O	O
5	NN	O	O
groups	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
:	NN	O	O
normal	NN	O	O
control	NN	O	O
and	NN	O	O
groups	NN	O	O
were	NN	O	O
injected	NN	O	O
isoproterenol	NN	O	O
after	NN	O	O
chronic	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
0	NN	O	O
,	NN	O	O
25	NN	O	O
,	NN	O	O
50	NN	O	O
,	NN	O	O
or	NN	O	O
100mg	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
metformin	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
.	NN	O	O

Isoproterenol	NN	O	O
(	NN	O	O
100mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
injected	NN	O	O
subcutaneously	NN	O	O
on	NN	O	O
the	NN	O	O
13th	NN	O	O
and	NN	O	O
14th	NN	O	O
days	NN	O	O
to	NN	O	O
induce	NN	O	O
acute	NN	O	B
myocardial	NN	O	I
infarction	NN	O	I
.	NN	O	O

Isoproterenol	NN	O	O
alone	NN	O	O
decreased	NN	O	O
left	NN	O	O
ventricular	NN	O	O
systolic	NN	O	O
pressure	NN	O	O
and	NN	O	O
myocardial	NN	O	O
contractility	NN	O	O
indexed	NN	O	O
as	NN	O	O
LVdp	NN	O	O
/	NN	O	O
dtmax	NN	O	O
and	NN	O	O
LVdp	NN	O	O
/	NN	O	O
dtmin	NN	O	O
.	NN	O	O

The	NN	O	O
left	NN	O	B
ventricular	NN	O	I
dysfunction	NN	O	I
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
groups	NN	O	O
treated	NN	O	O
with	NN	O	O
25	NN	O	O
and	NN	O	O
50mg	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
metformin	NN	O	O
.	NN	O	O

Metfromin	NN	O	O
markedly	NN	O	O
lowered	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
elevation	NN	O	O
in	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
TLR4	NN	O	O
mRNA	NN	O	O
,	NN	O	O
myeloid	NN	O	O
differentiation	NN	O	O
protein	NN	O	O
88	NN	O	O
(	NN	O	O
MyD88	NN	O	O
)	NN	O	O
,	NN	O	O
tumor	NN	O	B
necrosis	NN	O	B
factor	NN	O	O
-	NN	O	O
alpha	NN	O	O
(	NN	O	O
TNF	NN	O	O
-	NN	O	O
a	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
interleukin	NN	O	O
6	NN	O	O
(	NN	O	O
IL	NN	O	O
-	NN	O	O
6	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
heart	NN	O	O
tissues	NN	O	O
.	NN	O	O

Similar	NN	O	O
changes	NN	O	O
were	NN	O	O
also	NN	O	O
seen	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
levels	NN	O	O
of	NN	O	O
TNF	NN	O	O
-	NN	O	O
a	NN	O	O
and	NN	O	O
IL	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
lower	NN	O	O
doses	NN	O	O
of	NN	O	O
25	NN	O	O
and	NN	O	O
50mg	NN	O	O
/	NN	O	O
kg	NN	O	O
were	NN	O	O
more	NN	O	O
effective	NN	O	O
than	NN	O	O
100mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Phosphorylated	NN	O	O
AMPKa	NN	O	O
(	NN	O	O
p	NN	O	O
-	NN	O	O
AMPK	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
myocardium	NN	O	O
was	NN	O	O
significantly	NN	O	O
elevated	NN	O	O
by	NN	O	O
25mg	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
metformin	NN	O	O
,	NN	O	O
slightly	NN	O	O
by	NN	O	O
50mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
by	NN	O	O
100mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Chronic	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
metformin	NN	O	O
reduces	NN	O	O
post	NN	O	O
-	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
cardiac	NN	O	O
dysfunction	NN	O	O
and	NN	O	O
suppresses	NN	O	O
inflammatory	NN	O	O
responses	NN	O	O
,	NN	O	O
possibly	NN	O	O
through	NN	O	O
inhibition	NN	O	O
of	NN	O	O
TLR4	NN	O	O
activities	NN	O	O
.	NN	O	O

This	NN	O	O
mechanism	NN	O	O
can	NN	O	O
be	NN	O	O
considered	NN	O	O
as	NN	O	O
a	NN	O	O
target	NN	O	O
to	NN	O	O
protect	NN	O	O
infarcted	NN	O	O
myocardium	NN	O	O
.	NN	O	O

Unusual	NN	O	O
complications	NN	O	O
of	NN	O	O
antithyroid	NN	O	O
drug	NN	O	O
therapy	NN	O	O
:	NN	O	O
four	NN	O	O
case	NN	O	O
reports	NN	O	O
and	NN	O	O
review	NN	O	O
of	NN	O	O
literature	NN	O	O
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
of	NN	O	O
propylthiouracil	NN	O	O
-	NN	O	O
associated	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
,	NN	O	O
one	NN	O	O
case	NN	O	O
of	NN	O	O
fatal	NN	O	O
methimazole	NN	O	O
-	NN	O	O
associated	NN	O	O
hepatocellular	NN	O	B
necrosis	NN	O	I
and	NN	O	O
one	NN	O	O
case	NN	O	O
of	NN	O	O
propylthiouracil	NN	O	O
-	NN	O	O
associated	NN	O	O
lupus	NN	O	B
-	NN	O	I
like	NN	O	I
syndrome	NN	O	I
are	NN	O	O
described	NN	O	O
.	NN	O	O

The	NN	O	O
literature	NN	O	O
related	NN	O	O
to	NN	O	O
antithyroid	NN	O	O
drug	NN	O	O
side	NN	O	O
effects	NN	O	O
and	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
for	NN	O	O
their	NN	O	O
occurrence	NN	O	O
are	NN	O	O
reviewed	NN	O	O
and	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
complications	NN	O	O
of	NN	O	O
thyroidectomy	NN	O	O
and	NN	O	O
radioiodine	NN	O	O
compared	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
antithyroid	NN	O	O
drugs	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
in	NN	O	O
most	NN	O	O
circumstances	NN	O	O
131I	NN	O	O
is	NN	O	O
the	NN	O	O
therapy	NN	O	O
of	NN	O	O
choice	NN	O	O
for	NN	O	O
hyperthyroidism	NN	O	B
.	NN	O	O

Neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
induced	NN	O	O
by	NN	O	O
combination	NN	O	O
therapy	NN	O	O
with	NN	O	O
tetrabenazine	NN	O	O
and	NN	O	O
tiapride	NN	O	O
in	NN	O	O
a	NN	O	O
Japanese	NN	O	O
patient	NN	O	O
with	NN	O	O
Huntington	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
at	NN	O	O
the	NN	O	O
terminal	NN	O	O
stage	NN	O	O
of	NN	O	O
recurrent	NN	O	O
breast	NN	O	B
cancer	NN	O	I
.	NN	O	O

We	NN	O	O
herein	NN	O	O
describe	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
an	NN	O	O
81	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Japanese	NN	O	O
woman	NN	O	O
with	NN	O	O
neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
that	NN	O	O
occurred	NN	O	O
36	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
combination	NN	O	O
therapy	NN	O	O
with	NN	O	O
tiapride	NN	O	O
(	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
and	NN	O	O
tetrabenazine	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
for	NN	O	O
Huntington	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

The	NN	O	O
patient	NN	O	O
had	NN	O	O
been	NN	O	O
treated	NN	O	O
with	NN	O	O
tiapride	NN	O	O
or	NN	O	O
tetrabenazine	NN	O	O
alone	NN	O	O
without	NN	O	O
any	NN	O	O
adverse	NN	O	O
effects	NN	O	O
before	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
combination	NN	O	O
therapy	NN	O	O
.	NN	O	O

She	NN	O	O
also	NN	O	O
had	NN	O	O
advanced	NN	O	O
breast	NN	O	B
cancer	NN	O	I
when	NN	O	O
the	NN	O	O
combination	NN	O	O
therapy	NN	O	O
was	NN	O	O
initiated	NN	O	O
.	NN	O	O

To	NN	O	O
the	NN	O	O
best	NN	O	O
of	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
due	NN	O	O
to	NN	O	O
combination	NN	O	O
therapy	NN	O	O
with	NN	O	O
tetrabenazine	NN	O	O
and	NN	O	O
tiapride	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
previously	NN	O	O
reported	NN	O	O
.	NN	O	O

Tetrabenazine	NN	O	O
should	NN	O	O
be	NN	O	O
administered	NN	O	O
very	NN	O	O
carefully	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
other	NN	O	O
neuroleptic	NN	O	O
drugs	NN	O	O
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
worsening	NN	O	O
general	NN	O	O
condition	NN	O	O
.	NN	O	O

A	NN	O	O
metoprolol	NN	O	O
-	NN	O	O
terbinafine	NN	O	O
combination	NN	O	O
induced	NN	O	O
bradycardia	NN	O	B
.	NN	O	O

To	NN	O	O
report	NN	O	O
a	NN	O	O
sinus	NN	O	B
bradycardia	NN	O	I
induced	NN	O	O
by	NN	O	O
metoprolol	NN	O	O
and	NN	O	O
terbinafine	NN	O	O
drug	NN	O	O
-	NN	O	O
drug	NN	O	O
interaction	NN	O	O
and	NN	O	O
its	NN	O	O
management	NN	O	O
.	NN	O	O

A	NN	O	O
63	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Caucasian	NN	O	O
man	NN	O	O
on	NN	O	O
metoprolol	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
stable	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
was	NN	O	O
prescribed	NN	O	O
a	NN	O	O
90	NN	O	O
-	NN	O	O
day	NN	O	O
course	NN	O	O
of	NN	O	O
oral	NN	O	O
terbinafine	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
onychomycosis	NN	O	B
.	NN	O	O

On	NN	O	O
the	NN	O	O
49th	NN	O	O
day	NN	O	O
of	NN	O	O
terbinafine	NN	O	O
therapy	NN	O	O
,	NN	O	O
he	NN	O	O
was	NN	O	O
brought	NN	O	O
to	NN	O	O
the	NN	O	O
emergency	NN	O	O
room	NN	O	O
for	NN	O	O
a	NN	O	O
decrease	NN	O	O
of	NN	O	O
his	NN	O	O
global	NN	O	O
health	NN	O	O
status	NN	O	O
,	NN	O	O
confusion	NN	O	B
and	NN	O	O
falls	NN	O	O
.	NN	O	O

The	NN	O	O
electrocardiogram	NN	O	O
revealed	NN	O	O
a	NN	O	O
37	NN	O	O
beats	NN	O	O
/	NN	O	O
min	NN	O	O
sinus	NN	O	B
bradycardia	NN	O	I
.	NN	O	O

A	NN	O	O
score	NN	O	O
of	NN	O	O
7	NN	O	O
on	NN	O	O
the	NN	O	O
Naranjo	NN	O	O
adverse	NN	O	B
drug	NN	O	I
reaction	NN	O	I
probability	NN	O	O
scale	NN	O	O
indicates	NN	O	O
a	NN	O	O
probable	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
sinus	NN	O	B
bradycardia	NN	O	I
and	NN	O	O
the	NN	O	O
drug	NN	O	O
interaction	NN	O	O
between	NN	O	O
metoprolol	NN	O	O
and	NN	O	O
terbinafine	NN	O	O
.	NN	O	O

The	NN	O	O
heart	NN	O	O
rate	NN	O	O
ameliorated	NN	O	O
first	NN	O	O
with	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
metoprolol	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
subsequently	NN	O	O
changed	NN	O	O
to	NN	O	O
bisoprolol	NN	O	O
and	NN	O	O
the	NN	O	O
heart	NN	O	O
rate	NN	O	O
remained	NN	O	O
normal	NN	O	O
.	NN	O	O

By	NN	O	O
inhibiting	NN	O	O
the	NN	O	O
cytochrome	NN	O	O
P450	NN	O	O
2D6	NN	O	O
,	NN	O	O
terbinafine	NN	O	O
had	NN	O	O
decreased	NN	O	O
metoprolol	NN	O	O
'	NN	O	O
s	NN	O	O
clearance	NN	O	O
,	NN	O	O
leading	NN	O	O
in	NN	O	O
metoprolol	NN	O	O
accumulation	NN	O	O
which	NN	O	O
has	NN	O	O
resulted	NN	O	O
in	NN	O	O
clinically	NN	O	O
significant	NN	O	O
sinus	NN	O	B
bradycardia	NN	O	I
.	NN	O	O

Optochiasmatic	NN	O	O
and	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
due	NN	O	O
to	NN	O	O
ethambutol	NN	O	O
overtreatment	NN	O	O
.	NN	O	O

Ethambutol	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
cause	NN	O	O
optic	NN	O	B
neuropathy	NN	O	I
and	NN	O	O
,	NN	O	O
more	NN	O	O
rarely	NN	O	O
,	NN	O	O
axonal	NN	O	O
polyneuropathy	NN	O	B
.	NN	O	O

We	NN	O	O
characterize	NN	O	O
the	NN	O	O
clinical	NN	O	O
,	NN	O	O
neurophysiological	NN	O	O
,	NN	O	O
and	NN	O	O
neuroimaging	NN	O	O
findings	NN	O	O
in	NN	O	O
a	NN	O	O
72	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
who	NN	O	O
developed	NN	O	O
visual	NN	O	B
loss	NN	O	I
and	NN	O	O
paresthesias	NN	O	B
after	NN	O	O
11	NN	O	O
weeks	NN	O	O
of	NN	O	O
exposure	NN	O	O
to	NN	O	O
a	NN	O	O
supratherapeutic	NN	O	O
dose	NN	O	O
of	NN	O	O
ethambutol	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
demonstrates	NN	O	O
the	NN	O	O
selective	NN	O	O
vulnerability	NN	O	O
of	NN	O	O
the	NN	O	O
anterior	NN	O	O
visual	NN	O	O
pathways	NN	O	O
and	NN	O	O
peripheral	NN	O	O
nerves	NN	O	O
to	NN	O	O
ethambutol	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Testosterone	NN	O	O
ameliorates	NN	O	O
streptozotocin	NN	O	O
-	NN	O	O
induced	NN	O	O
memory	NN	O	B
impairment	NN	O	I
in	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
To	NN	O	O
study	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
testosterone	NN	O	O
on	NN	O	O
streptozotocin	NN	O	O
(	NN	O	O
STZ	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
memory	NN	O	B
impairment	NN	O	I
in	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Adult	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
intracerebroventricularly	NN	O	O
(	NN	O	O
icv	NN	O	O
)	NN	O	O
infused	NN	O	O
with	NN	O	O
STZ	NN	O	O
(	NN	O	O
750	NN	O	O
ug	NN	O	O
)	NN	O	O
on	NN	O	O
d	NN	O	O
1	NN	O	O
and	NN	O	O
d	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
was	NN	O	O
assessed	NN	O	O
2	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
first	NN	O	O
injection	NN	O	O
of	NN	O	O
STZ	NN	O	O
.	NN	O	O

Castration	NN	O	O
surgery	NN	O	O
was	NN	O	O
performed	NN	O	O
in	NN	O	O
another	NN	O	O
group	NN	O	O
of	NN	O	O
rats	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
was	NN	O	O
assessed	NN	O	O
4	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
operation	NN	O	O
.	NN	O	O

Testosterone	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O
d	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
sc	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
androgen	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
flutamide	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O
d	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
ip	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
estrogen	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
tamoxifen	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O
d	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
ip	NN	O	O
)	NN	O	O
or	NN	O	O
the	NN	O	O
aromatase	NN	O	O
inhibitor	NN	O	O
letrozole	NN	O	O
(	NN	O	O
4	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O
d	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
ip	NN	O	O
)	NN	O	O
were	NN	O	O
administered	NN	O	O
for	NN	O	O
6	NN	O	O
d	NN	O	O
after	NN	O	O
the	NN	O	O
first	NN	O	O
injection	NN	O	O
of	NN	O	O
STZ	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
STZ	NN	O	O
administration	NN	O	O
and	NN	O	O
castration	NN	O	O
markedly	NN	O	O
decreased	NN	O	O
both	NN	O	O
STL1	NN	O	O
(	NN	O	O
the	NN	O	O
short	NN	O	O
memory	NN	O	O
)	NN	O	O
and	NN	O	O
STL2	NN	O	O
(	NN	O	O
the	NN	O	O
long	NN	O	O
memory	NN	O	O
)	NN	O	O
in	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
tests	NN	O	O
.	NN	O	O

Testosterone	NN	O	O
replacement	NN	O	O
almost	NN	O	O
restored	NN	O	O
the	NN	O	O
STL1	NN	O	O
and	NN	O	O
STL2	NN	O	O
in	NN	O	O
castrated	NN	O	O
rats	NN	O	O
,	NN	O	O
and	NN	O	O
significantly	NN	O	O
prolonged	NN	O	O
the	NN	O	O
STL1	NN	O	O
and	NN	O	O
STL2	NN	O	O
in	NN	O	O
STZ	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
flutamide	NN	O	O
,	NN	O	O
letrozole	NN	O	O
or	NN	O	O
tamoxifen	NN	O	O
significantly	NN	O	O
impaired	NN	O	B
the	NN	O	I
memory	NN	O	I
in	NN	O	O
intact	NN	O	O
rats	NN	O	O
,	NN	O	O
and	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
the	NN	O	O
testosterone	NN	O	O
replacement	NN	O	O
in	NN	O	O
improving	NN	O	O
STZ	NN	O	O
-	NN	O	O
and	NN	O	O
castration	NN	O	O
-	NN	O	O
induced	NN	O	O
memory	NN	O	B
impairment	NN	O	I
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Testosterone	NN	O	O
administration	NN	O	O
ameliorates	NN	O	O
STZ	NN	O	O
-	NN	O	O
and	NN	O	O
castration	NN	O	O
-	NN	O	O
induced	NN	O	O
memory	NN	O	B
impairment	NN	O	I
in	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

Behavioral	NN	O	O
and	NN	O	O
neurochemical	NN	O	O
studies	NN	O	O
in	NN	O	O
mice	NN	O	O
pretreated	NN	O	O
with	NN	O	O
garcinielliptone	NN	O	O
FC	NN	O	O
in	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
.	NN	O	O

Garcinielliptone	NN	O	O
FC	NN	O	O
(	NN	O	O
GFC	NN	O	O
)	NN	O	O
isolated	NN	O	O
from	NN	O	O
hexanic	NN	O	O
fraction	NN	O	O
seed	NN	O	O
extract	NN	O	O
of	NN	O	O
species	NN	O	O
Platonia	NN	O	O
insignis	NN	O	O
Mart	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
widely	NN	O	O
used	NN	O	O
in	NN	O	O
folk	NN	O	O
medicine	NN	O	O
to	NN	O	O
treat	NN	O	O
skin	NN	O	B
diseases	NN	O	I
in	NN	O	O
both	NN	O	O
humans	NN	O	O
and	NN	O	O
animals	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
seed	NN	O	O
decoction	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
diarrheas	NN	O	B
and	NN	O	O
inflammatory	NN	O	B
diseases	NN	O	I
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
no	NN	O	O
research	NN	O	O
on	NN	O	O
GFC	NN	O	O
effects	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
of	NN	O	O
rodents	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
GFC	NN	O	O
effects	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
25	NN	O	O
,	NN	O	O
50	NN	O	O
or	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
on	NN	O	O
seizure	NN	O	B
parameters	NN	O	O
to	NN	O	O
determine	NN	O	O
their	NN	O	O
anticonvulsant	NN	O	O
activity	NN	O	O
and	NN	O	O
its	NN	O	O
effects	NN	O	O
on	NN	O	O
amino	NN	O	O
acid	NN	O	O
(	NN	O	O
r	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acid	NN	O	O
(	NN	O	O
GABA	NN	O	O
)	NN	O	O
,	NN	O	O
glutamine	NN	O	O
,	NN	O	O
aspartate	NN	O	O
and	NN	O	O
glutathione	NN	O	O
)	NN	O	O
levels	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
on	NN	O	O
acetylcholinesterase	NN	O	O
(	NN	O	O
AChE	NN	O	O
)	NN	O	O
activity	NN	O	O
in	NN	O	O
mice	NN	O	O
hippocampus	NN	O	O
after	NN	O	O
seizures	NN	O	B
.	NN	O	O

GFC	NN	O	O
produced	NN	O	O
an	NN	O	O
increased	NN	O	O
latency	NN	O	O
to	NN	O	O
first	NN	O	O
seizure	NN	O	B
,	NN	O	O
at	NN	O	O
doses	NN	O	O
25mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
20	NN	O	O
.	NN	O	O
12	NN	O	O
+	NN	O	O
2	NN	O	O
.	NN	O	O
20	NN	O	O
min	NN	O	O
)	NN	O	O
,	NN	O	O
50mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
20	NN	O	O
.	NN	O	O
95	NN	O	O
+	NN	O	O
2	NN	O	O
.	NN	O	O
21	NN	O	O
min	NN	O	O
)	NN	O	O
or	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
23	NN	O	O
.	NN	O	O
43	NN	O	O
+	NN	O	O
1	NN	O	O
.	NN	O	O
99	NN	O	O
min	NN	O	O
)	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
seized	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
GABA	NN	O	O
content	NN	O	O
of	NN	O	O
mice	NN	O	O
hippocampus	NN	O	O
treated	NN	O	O
with	NN	O	O
GFC75	NN	O	O
plus	NN	O	O
P400	NN	O	O
showed	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
46	NN	O	O
.	NN	O	O
90	NN	O	O
%	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
seized	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
aspartate	NN	O	O
,	NN	O	O
glutamine	NN	O	O
and	NN	O	O
glutamate	NN	O	O
levels	NN	O	O
detected	NN	O	O
a	NN	O	O
decrease	NN	O	O
of	NN	O	O
5	NN	O	O
.	NN	O	O
21	NN	O	O
%	NN	O	O
,	NN	O	O
13	NN	O	O
.	NN	O	O
55	NN	O	O
%	NN	O	O
and	NN	O	O
21	NN	O	O
.	NN	O	O
80	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
in	NN	O	O
mice	NN	O	O
hippocampus	NN	O	O
treated	NN	O	O
with	NN	O	O
GFC75	NN	O	O
plus	NN	O	O
P400	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
seized	NN	O	O
mice	NN	O	O
.	NN	O	O

Hippocampus	NN	O	O
mice	NN	O	O
treated	NN	O	O
with	NN	O	O
GFC75	NN	O	O
plus	NN	O	O
P400	NN	O	O
showed	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
AChE	NN	O	O
activity	NN	O	O
(	NN	O	O
63	NN	O	O
.	NN	O	O
30	NN	O	O
%	NN	O	O
)	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
seized	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
GFC	NN	O	O
can	NN	O	O
exert	NN	O	O
anticonvulsant	NN	O	O
activity	NN	O	O
and	NN	O	O
reduce	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
installation	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
,	NN	O	O
as	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
increase	NN	O	O
in	NN	O	O
latency	NN	O	O
to	NN	O	O
first	NN	O	O
seizure	NN	O	B
and	NN	O	O
decrease	NN	O	O
in	NN	O	O
mortality	NN	O	O
rate	NN	O	O
of	NN	O	O
animals	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
our	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
GFC	NN	O	O
may	NN	O	O
influence	NN	O	O
in	NN	O	O
epileptogenesis	NN	O	O
and	NN	O	O
promote	NN	O	O
anticonvulsant	NN	O	O
actions	NN	O	O
in	NN	O	O
pilocarpine	NN	O	O
model	NN	O	O
by	NN	O	O
modulating	NN	O	O
the	NN	O	O
GABA	NN	O	O
and	NN	O	O
glutamate	NN	O	O
contents	NN	O	O
and	NN	O	O
of	NN	O	O
AChE	NN	O	O
activity	NN	O	O
in	NN	O	O
seized	NN	O	O
mice	NN	O	O
hippocampus	NN	O	O
.	NN	O	O

This	NN	O	O
compound	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
to	NN	O	O
produce	NN	O	O
neuronal	NN	O	O
protection	NN	O	O
and	NN	O	O
it	NN	O	O
can	NN	O	O
be	NN	O	O
considered	NN	O	O
as	NN	O	O
an	NN	O	O
anticonvulsant	NN	O	O
agent	NN	O	O
.	NN	O	O

Standard	NN	O	O
operating	NN	O	O
procedures	NN	O	O
for	NN	O	O
antibiotic	NN	O	O
therapy	NN	O	O
and	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
acute	NN	O	B
kidney	NN	O	I
injury	NN	O	I
:	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
clinical	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
interventional	NN	O	O
,	NN	O	O
observational	NN	O	O
study	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
Acute	NN	O	B
kidney	NN	O	I
injury	NN	O	I
(	NN	O	O
AKI	NN	O	B
)	NN	O	O
occurs	NN	O	O
in	NN	O	O
7	NN	O	O
%	NN	O	O
of	NN	O	O
hospitalized	NN	O	O
and	NN	O	O
66	NN	O	O
%	NN	O	O
of	NN	O	O
Intensive	NN	O	O
Care	NN	O	O
Unit	NN	O	O
(	NN	O	O
ICU	NN	O	O
)	NN	O	O
patients	NN	O	O
.	NN	O	O

It	NN	O	O
increases	NN	O	O
mortality	NN	O	O
,	NN	O	O
hospital	NN	O	O
length	NN	O	O
of	NN	O	O
stay	NN	O	O
,	NN	O	O
and	NN	O	O
costs	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
,	NN	O	O
whether	NN	O	O
there	NN	O	O
is	NN	O	O
an	NN	O	O
association	NN	O	O
between	NN	O	O
adherence	NN	O	O
to	NN	O	O
guidelines	NN	O	O
(	NN	O	O
standard	NN	O	O
operating	NN	O	O
procedures	NN	O	O
(	NN	O	O
SOP	NN	O	O
)	NN	O	O
)	NN	O	O
for	NN	O	O
potentially	NN	O	O
nephrotoxic	NN	O	B
antibiotics	NN	O	O
and	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
AKI	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
as	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
clinical	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
interventional	NN	O	O
,	NN	O	O
observational	NN	O	O
study	NN	O	O
.	NN	O	O

Data	NN	O	O
collection	NN	O	O
was	NN	O	O
performed	NN	O	O
over	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
170	NN	O	O
days	NN	O	O
in	NN	O	O
three	NN	O	O
ICUs	NN	O	O
at	NN	O	O
Charite	NN	O	O
-	NN	O	O
Universitaetsmedizin	NN	O	O
Berlin	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
675	NN	O	O
patients	NN	O	O
were	NN	O	O
included	NN	O	O
;	NN	O	O
163	NN	O	O
of	NN	O	O
these	NN	O	O
had	NN	O	O
therapy	NN	O	O
with	NN	O	O
vancomycin	NN	O	O
,	NN	O	O
gentamicin	NN	O	O
,	NN	O	O
or	NN	O	O
tobramycin	NN	O	O
;	NN	O	O
were	NN	O	O
>	NN	O	O
18	NN	O	O
years	NN	O	O
;	NN	O	O
and	NN	O	O
treated	NN	O	O
in	NN	O	O
the	NN	O	O
ICU	NN	O	O
for	NN	O	O
>	NN	O	O
24	NN	O	O
hours	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
an	NN	O	O
adherence	NN	O	O
to	NN	O	O
SOP	NN	O	O
>	NN	O	O
70	NN	O	O
%	NN	O	O
were	NN	O	O
classified	NN	O	O
into	NN	O	O
the	NN	O	O
high	NN	O	O
adherence	NN	O	O
group	NN	O	O
(	NN	O	O
HAG	NN	O	O
)	NN	O	O
and	NN	O	O
patients	NN	O	O
with	NN	O	O
an	NN	O	O
adherence	NN	O	O
of	NN	O	O
<	NN	O	O
70	NN	O	O
%	NN	O	O
into	NN	O	O
the	NN	O	O
low	NN	O	O
adherence	NN	O	O
group	NN	O	O
(	NN	O	O
LAG	NN	O	O
)	NN	O	O
.	NN	O	O

AKI	NN	O	B
was	NN	O	O
defined	NN	O	O
according	NN	O	O
to	NN	O	O
RIFLE	NN	O	O
criteria	NN	O	O
.	NN	O	O

Adherence	NN	O	O
to	NN	O	O
SOPs	NN	O	O
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
retrospective	NN	O	O
expert	NN	O	O
audit	NN	O	O
.	NN	O	O

Development	NN	O	O
of	NN	O	O
AKI	NN	O	B
was	NN	O	O
compared	NN	O	O
between	NN	O	O
groups	NN	O	O
with	NN	O	O
exact	NN	O	O
Chi2	NN	O	O
-	NN	O	O
test	NN	O	O
and	NN	O	O
multivariate	NN	O	O
logistic	NN	O	O
regression	NN	O	O
analysis	NN	O	O
(	NN	O	O
two	NN	O	O
-	NN	O	O
sided	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
LAG	NN	O	O
consisted	NN	O	O
of	NN	O	O
75	NN	O	O
patients	NN	O	O
(	NN	O	O
46	NN	O	O
%	NN	O	O
)	NN	O	O
versus	NN	O	O
88	NN	O	O
HAG	NN	O	O
patients	NN	O	O
(	NN	O	O
54	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

AKI	NN	O	B
occurred	NN	O	O
significantly	NN	O	O
more	NN	O	O
often	NN	O	O
in	NN	O	O
LAG	NN	O	O
with	NN	O	O
36	NN	O	O
%	NN	O	O
versus	NN	O	O
21	NN	O	O
%	NN	O	O
in	NN	O	O
HAG	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
035	NN	O	O
)	NN	O	O
.	NN	O	O

Basic	NN	O	O
characteristics	NN	O	O
were	NN	O	O
comparable	NN	O	O
,	NN	O	O
except	NN	O	O
an	NN	O	O
increased	NN	O	O
rate	NN	O	O
of	NN	O	O
soft	NN	O	O
tissue	NN	O	O
infections	NN	O	B
in	NN	O	O
LAG	NN	O	O
.	NN	O	O

Multivariate	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
an	NN	O	O
odds	NN	O	O
ratio	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
fold	NN	O	O
for	NN	O	O
LAG	NN	O	O
to	NN	O	O
develop	NN	O	O
AKI	NN	O	B
compared	NN	O	O
with	NN	O	O
HAG	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
1	NN	O	O
.	NN	O	O
195	NN	O	O
to	NN	O	O
5	NN	O	O
.	NN	O	O
124	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
039	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Low	NN	O	O
adherence	NN	O	O
to	NN	O	O
SOPs	NN	O	O
for	NN	O	O
potentially	NN	O	O
nephrotoxic	NN	O	B
antibiotics	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
higher	NN	O	O
occurrence	NN	O	O
of	NN	O	O
AKI	NN	O	B
.	NN	O	O

TRIAL	NN	O	O
REGISTRATION	NN	O	O
:	NN	O	O
Current	NN	O	O
Controlled	NN	O	O
Trials	NN	O	O
ISRCTN54598675	NN	O	O
.	NN	O	O

Registered	NN	O	O
17	NN	O	O
August	NN	O	O
2007	NN	O	O
.	NN	O	O

Rhabdomyolysis	NN	O	B
in	NN	O	O
a	NN	O	O
hepatitis	NN	O	B
C	NN	O	I
virus	NN	O	I
infected	NN	O	I
patient	NN	O	O
treated	NN	O	O
with	NN	O	O
telaprevir	NN	O	O
and	NN	O	O
simvastatin	NN	O	O
.	NN	O	O

A	NN	O	O
46	NN	O	O
-	NN	O	O
year	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
a	NN	O	O
chronic	NN	O	O
hepatitis	NN	O	B
C	NN	O	I
virus	NN	O	I
infection	NN	O	I
received	NN	O	O
triple	NN	O	O
therapy	NN	O	O
with	NN	O	O
ribavirin	NN	O	O
,	NN	O	O
pegylated	NN	O	O
interferon	NN	O	O
and	NN	O	O
telaprevir	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
also	NN	O	O
received	NN	O	O
simvastatin	NN	O	O
.	NN	O	O

One	NN	O	O
month	NN	O	O
after	NN	O	O
starting	NN	O	O
the	NN	O	O
antiviral	NN	O	O
therapy	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
because	NN	O	O
he	NN	O	O
developed	NN	O	O
rhabdomyolysis	NN	O	B
.	NN	O	O

At	NN	O	O
admission	NN	O	O
simvastatin	NN	O	O
and	NN	O	O
all	NN	O	O
antiviral	NN	O	O
drugs	NN	O	O
were	NN	O	O
discontinued	NN	O	O
because	NN	O	O
toxicity	NN	O	B
due	NN	O	O
to	NN	O	O
a	NN	O	O
drug	NN	O	O
-	NN	O	O
drug	NN	O	O
interaction	NN	O	O
was	NN	O	O
suspected	NN	O	O
.	NN	O	O

The	NN	O	O
creatine	NN	O	O
kinase	NN	O	O
peaked	NN	O	O
at	NN	O	O
62	NN	O	O
,	NN	O	O
246	NN	O	O
IU	NN	O	O
/	NN	O	O
L	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
normal	NN	O	O
saline	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
renal	NN	O	O
function	NN	O	O
remained	NN	O	O
unaffected	NN	O	O
.	NN	O	O

Fourteen	NN	O	O
days	NN	O	O
after	NN	O	O
hospitalization	NN	O	O
,	NN	O	O
creatine	NN	O	O
kinase	NN	O	O
level	NN	O	O
had	NN	O	O
returned	NN	O	O
to	NN	O	O
230	NN	O	O
IU	NN	O	O
/	NN	O	O
L	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
discharged	NN	O	O
.	NN	O	O

Telaprevir	NN	O	O
was	NN	O	O
considered	NN	O	O
the	NN	O	O
probable	NN	O	O
causative	NN	O	O
agent	NN	O	O
of	NN	O	O
an	NN	O	O
interaction	NN	O	O
with	NN	O	O
simvastatin	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
Drug	NN	O	O
Interaction	NN	O	O
Probability	NN	O	O
Scale	NN	O	O
.	NN	O	O

The	NN	O	O
interaction	NN	O	O
is	NN	O	O
due	NN	O	O
to	NN	O	O
inhibition	NN	O	O
of	NN	O	O
CYP3A4	NN	O	O
-	NN	O	O
mediated	NN	O	O
simvastatin	NN	O	O
clearance	NN	O	O
.	NN	O	O

Simvastatin	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
increased	NN	O	O
30	NN	O	O
times	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
and	NN	O	O
statin	NN	O	O
induced	NN	O	O
muscle	NN	O	B
toxicity	NN	O	I
is	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
concentration	NN	O	O
of	NN	O	O
the	NN	O	O
statin	NN	O	O
in	NN	O	O
blood	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
with	NN	O	O
this	NN	O	O
case	NN	O	O
we	NN	O	O
illustrate	NN	O	O
that	NN	O	O
telaprevir	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
statins	NN	O	O
are	NN	O	O
susceptible	NN	O	O
to	NN	O	O
clinical	NN	O	O
relevant	NN	O	O
drug	NN	O	O
-	NN	O	O
drug	NN	O	O
interactions	NN	O	O
.	NN	O	O

Combination	NN	O	O
of	NN	O	O
bortezomib	NN	O	O
,	NN	O	O
thalidomide	NN	O	O
,	NN	O	O
and	NN	O	O
dexamethasone	NN	O	O
(	NN	O	O
VTD	NN	O	O
)	NN	O	O
as	NN	O	O
a	NN	O	O
consolidation	NN	O	O
therapy	NN	O	O
after	NN	O	O
autologous	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
for	NN	O	O
symptomatic	NN	O	O
multiple	NN	O	B
myeloma	NN	O	I
in	NN	O	O
Japanese	NN	O	O
patients	NN	O	O
.	NN	O	O

Consolidation	NN	O	O
therapy	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
multiple	NN	O	B
myeloma	NN	O	I
(	NN	O	O
MM	NN	O	B
)	NN	O	O
has	NN	O	O
been	NN	O	O
widely	NN	O	O
adopted	NN	O	O
to	NN	O	O
improve	NN	O	O
treatment	NN	O	O
response	NN	O	O
following	NN	O	O
autologous	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
retrospectively	NN	O	O
analyzed	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
combination	NN	O	O
regimen	NN	O	O
of	NN	O	O
bortezomib	NN	O	O
,	NN	O	O
thalidomide	NN	O	O
,	NN	O	O
and	NN	O	O
dexamethasone	NN	O	O
(	NN	O	O
VTD	NN	O	O
)	NN	O	O
as	NN	O	O
consolidation	NN	O	O
therapy	NN	O	O
in	NN	O	O
24	NN	O	O
Japanese	NN	O	O
patients	NN	O	O
with	NN	O	O
newly	NN	O	O
diagnosed	NN	O	O
MM	NN	O	B
.	NN	O	O

VTD	NN	O	O
consisted	NN	O	O
of	NN	O	O
bortezomib	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
and	NN	O	O
dexamethasone	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
15	NN	O	O
,	NN	O	O
and	NN	O	O
22	NN	O	O
of	NN	O	O
a	NN	O	O
35	NN	O	O
-	NN	O	O
day	NN	O	O
cycle	NN	O	O
,	NN	O	O
with	NN	O	O
daily	NN	O	O
oral	NN	O	O
thalidomide	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

Grade	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
neutropenia	NN	O	B
and	NN	O	O
thrombocytopenia	NN	O	B
were	NN	O	O
documented	NN	O	O
in	NN	O	O
four	NN	O	O
and	NN	O	O
three	NN	O	O
patients	NN	O	O
(	NN	O	O
17	NN	O	O
and	NN	O	O
13	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
but	NN	O	O
drug	NN	O	O
dose	NN	O	O
reduction	NN	O	O
due	NN	O	O
to	NN	O	O
cytopenia	NN	O	B
was	NN	O	O
not	NN	O	O
required	NN	O	O
in	NN	O	O
any	NN	O	O
case	NN	O	O
.	NN	O	O

Peripheral	NN	O	B
neuropathy	NN	O	I
was	NN	O	O
common	NN	O	O
(	NN	O	O
63	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
severe	NN	O	O
grade	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
was	NN	O	O
not	NN	O	O
observed	NN	O	O
.	NN	O	O

Very	NN	O	O
good	NN	O	O
partial	NN	O	O
response	NN	O	O
or	NN	O	O
better	NN	O	O
response	NN	O	O
(	NN	O	O
>	NN	O	O
VGPR	NN	O	O
)	NN	O	O
rates	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
consolidation	NN	O	O
therapy	NN	O	O
were	NN	O	O
54	NN	O	O
and	NN	O	O
79	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Patients	NN	O	O
had	NN	O	O
a	NN	O	O
significant	NN	O	O
probability	NN	O	O
of	NN	O	O
improving	NN	O	O
from	NN	O	O
<	NN	O	O
VGPR	NN	O	O
before	NN	O	O
consolidation	NN	O	O
therapy	NN	O	O
to	NN	O	O
>	NN	O	O
VGPR	NN	O	O
after	NN	O	O
consolidation	NN	O	O
therapy	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
041	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
VTD	NN	O	O
regimen	NN	O	O
may	NN	O	O
be	NN	O	O
safe	NN	O	O
and	NN	O	O
effective	NN	O	O
as	NN	O	O
a	NN	O	O
consolidation	NN	O	O
therapy	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
MM	NN	O	O
in	NN	O	O
Japanese	NN	O	O
population	NN	O	O
.	NN	O	O

Conversion	NN	O	O
to	NN	O	O
sirolimus	NN	O	O
ameliorates	NN	O	O
cyclosporine	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
the	NN	O	O
rat	NN	O	O
:	NN	O	O
focus	NN	O	O
on	NN	O	O
serum	NN	O	O
,	NN	O	O
urine	NN	O	O
,	NN	O	O
gene	NN	O	O
,	NN	O	O
and	NN	O	O
protein	NN	O	O
renal	NN	O	O
expression	NN	O	O
biomarkers	NN	O	O
.	NN	O	O

Protocols	NN	O	O
of	NN	O	O
conversion	NN	O	O
from	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
(	NN	O	O
CsA	NN	O	O
)	NN	O	O
to	NN	O	O
sirolimus	NN	O	O
(	NN	O	O
SRL	NN	O	O
)	NN	O	O
have	NN	O	O
been	NN	O	O
widely	NN	O	O
used	NN	O	O
in	NN	O	O
immunotherapy	NN	O	O
after	NN	O	O
transplantation	NN	O	O
to	NN	O	O
prevent	NN	O	O
CsA	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
,	NN	O	O
but	NN	O	O
the	NN	O	O
molecular	NN	O	O
mechanisms	NN	O	O
underlying	NN	O	O
these	NN	O	O
protocols	NN	O	O
remain	NN	O	O
nuclear	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
identify	NN	O	O
the	NN	O	O
molecular	NN	O	O
pathways	NN	O	O
and	NN	O	O
putative	NN	O	O
biomarkers	NN	O	O
of	NN	O	O
CsA	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
SRL	NN	O	O
conversion	NN	O	O
in	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
.	NN	O	O

Four	NN	O	O
animal	NN	O	O
groups	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
were	NN	O	O
tested	NN	O	O
during	NN	O	O
9	NN	O	O
weeks	NN	O	O
:	NN	O	O
control	NN	O	O
,	NN	O	O
CsA	NN	O	O
,	NN	O	O
SRL	NN	O	O
,	NN	O	O
and	NN	O	O
conversion	NN	O	O
(	NN	O	O
CsA	NN	O	O
for	NN	O	O
3	NN	O	O
weeks	NN	O	O
followed	NN	O	O
by	NN	O	O
SRL	NN	O	O
for	NN	O	O
6	NN	O	O
weeks	NN	O	O
)	NN	O	O
.	NN	O	O

Classical	NN	O	O
and	NN	O	O
emergent	NN	O	O
serum	NN	O	O
,	NN	O	O
urinary	NN	O	O
,	NN	O	O
and	NN	O	O
kidney	NN	O	O
tissue	NN	O	O
(	NN	O	O
gene	NN	O	O
and	NN	O	O
protein	NN	O	O
expression	NN	O	O
)	NN	O	O
markers	NN	O	O
were	NN	O	O
assessed	NN	O	O
.	NN	O	O

Renal	NN	O	B
lesions	NN	O	I
were	NN	O	O
analyzed	NN	O	O
in	NN	O	O
hematoxylin	NN	O	O
and	NN	O	O
eosin	NN	O	O
,	NN	O	O
periodic	NN	O	O
acid	NN	O	O
-	NN	O	O
Schiff	NN	O	O
,	NN	O	O
and	NN	O	O
Masson	NN	O	O
'	NN	O	O
s	NN	O	O
trichrome	NN	O	O
stains	NN	O	O
.	NN	O	O

SRL	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
presented	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
NGAL	NN	O	O
(	NN	O	O
serum	NN	O	O
and	NN	O	O
urinary	NN	O	O
)	NN	O	O
as	NN	O	O
the	NN	O	O
best	NN	O	O
markers	NN	O	O
of	NN	O	O
renal	NN	O	B
impairment	NN	O	I
.	NN	O	O

Short	NN	O	O
CsA	NN	O	O
treatment	NN	O	O
presented	NN	O	O
slight	NN	O	O
or	NN	O	O
even	NN	O	O
absent	NN	O	O
kidney	NN	O	B
lesions	NN	O	I
and	NN	O	O
TGF	NN	O	O
-	NN	O	O
b	NN	O	O
,	NN	O	O
NF	NN	O	O
-	NN	O	O
kb	NN	O	O
,	NN	O	O
mTOR	NN	O	O
,	NN	O	O
PCNA	NN	O	O
,	NN	O	O
TP53	NN	O	O
,	NN	O	O
KIM	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
and	NN	O	O
CTGF	NN	O	O
as	NN	O	O
relevant	NN	O	O
gene	NN	O	O
and	NN	O	O
protein	NN	O	O
changes	NN	O	O
.	NN	O	O

Prolonged	NN	O	O
CsA	NN	O	O
exposure	NN	O	O
aggravated	NN	O	O
renal	NN	O	B
damage	NN	O	I
,	NN	O	O
without	NN	O	O
clear	NN	O	O
changes	NN	O	O
on	NN	O	O
the	NN	O	O
traditional	NN	O	O
markers	NN	O	O
,	NN	O	O
but	NN	O	O
with	NN	O	O
changes	NN	O	O
in	NN	O	O
serums	NN	O	O
TGF	NN	O	O
-	NN	O	O
b	NN	O	O
and	NN	O	O
IL	NN	O	O
-	NN	O	O
7	NN	O	O
,	NN	O	O
TBARs	NN	O	O
clearance	NN	O	O
,	NN	O	O
and	NN	O	O
kidney	NN	O	O
TGF	NN	O	O
-	NN	O	O
b	NN	O	O
and	NN	O	O
mTOR	NN	O	O
.	NN	O	O

Conversion	NN	O	O
to	NN	O	O
SRL	NN	O	O
prevented	NN	O	O
CsA	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
damage	NN	O	I
evolution	NN	O	O
(	NN	O	O
absent	NN	O	O
/	NN	O	O
mild	NN	O	O
grade	NN	O	O
lesions	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
NGAL	NN	O	O
(	NN	O	O
serum	NN	O	O
versus	NN	O	O
urine	NN	O	O
)	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
feasible	NN	O	O
biomarker	NN	O	O
of	NN	O	O
CsA	NN	O	O
replacement	NN	O	O
to	NN	O	O
SRL	NN	O	O
.	NN	O	O

Kinin	NN	O	O
B2	NN	O	O
receptor	NN	O	O
deletion	NN	O	O
and	NN	O	O
blockage	NN	O	O
ameliorates	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	B
renal	NN	O	I
injury	NN	O	I
.	NN	O	O

Cisplatin	NN	O	O
treatment	NN	O	O
has	NN	O	O
been	NN	O	O
adopted	NN	O	O
in	NN	O	O
some	NN	O	O
chemotherapies	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
this	NN	O	O
drug	NN	O	O
can	NN	O	O
induce	NN	O	O
acute	NN	O	B
kidney	NN	O	I
injury	NN	O	I
due	NN	O	O
its	NN	O	O
ability	NN	O	O
to	NN	O	O
negatively	NN	O	O
affect	NN	O	O
renal	NN	O	O
function	NN	O	O
,	NN	O	O
augment	NN	O	O
serum	NN	O	O
levels	NN	O	O
of	NN	O	O
creatinine	NN	O	O
and	NN	O	O
urea	NN	O	O
,	NN	O	O
increase	NN	O	O
the	NN	O	O
acute	NN	O	B
tubular	NN	O	I
necrosis	NN	O	I
score	NN	O	O
and	NN	O	O
up	NN	O	O
-	NN	O	O
regulate	NN	O	O
cytokines	NN	O	O
(	NN	O	O
e	NN	O	O
.	NN	O	O
g	NN	O	O
.	NN	O	O
,	NN	O	O
IL	NN	O	O
-	NN	O	O
1b	NN	O	O
and	NN	O	O
TNF	NN	O	O
-	NN	O	O
a	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
kinin	NN	O	O
B2	NN	O	O
receptor	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
inflammation	NN	O	B
process	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
cytokine	NN	O	O
expression	NN	O	O
,	NN	O	O
and	NN	O	O
its	NN	O	O
deletion	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
status	NN	O	O
.	NN	O	O

To	NN	O	O
examine	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
kinin	NN	O	O
B2	NN	O	O
receptor	NN	O	O
in	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	B
kidney	NN	O	I
injury	NN	O	I
,	NN	O	O
kinin	NN	O	O
B2	NN	O	O
receptor	NN	O	O
knockout	NN	O	O
mice	NN	O	O
were	NN	O	O
challenged	NN	O	O
with	NN	O	O
cisplatin	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
WT	NN	O	O
mice	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
B2	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
after	NN	O	O
cisplatin	NN	O	O
administration	NN	O	O
.	NN	O	O

B2	NN	O	O
receptor	NN	O	O
-	NN	O	O
deficient	NN	O	O
mice	NN	O	O
were	NN	O	O
less	NN	O	O
sensitive	NN	O	O
to	NN	O	O
this	NN	O	O
drug	NN	O	O
than	NN	O	O
the	NN	O	O
WT	NN	O	O
mice	NN	O	O
,	NN	O	O
as	NN	O	O
shown	NN	O	O
by	NN	O	O
reduced	NN	O	O
weight	NN	O	B
loss	NN	O	I
,	NN	O	O
better	NN	O	O
preservation	NN	O	O
of	NN	O	O
kidney	NN	O	O
function	NN	O	O
,	NN	O	O
down	NN	O	O
regulation	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
cytokines	NN	O	O
and	NN	O	O
less	NN	O	O
acute	NN	O	B
tubular	NN	O	I
necrosis	NN	O	I
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
treatment	NN	O	O
with	NN	O	O
the	NN	O	O
kinin	NN	O	O
B2	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
effectively	NN	O	O
reduced	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
and	NN	O	O
blood	NN	O	O
urea	NN	O	O
after	NN	O	O
cisplatin	NN	O	O
administration	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
our	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
kinin	NN	O	O
B2	NN	O	O
receptor	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	B
kidney	NN	O	I
injury	NN	O	I
by	NN	O	O
mediating	NN	O	O
the	NN	O	O
necrotic	NN	O	B
process	NN	O	O
and	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
cytokines	NN	O	O
,	NN	O	O
thus	NN	O	O
resulting	NN	O	O
in	NN	O	O
declined	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
highlight	NN	O	O
the	NN	O	O
kinin	NN	O	O
B2	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
treatment	NN	O	O
in	NN	O	O
amelioration	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B
induced	NN	O	O
by	NN	O	O
cisplatin	NN	O	O
therapy	NN	O	O
.	NN	O	O

Safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
fluocinolone	NN	O	O
acetonide	NN	O	O
intravitreal	NN	O	O
implant	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
59	NN	O	O
mg	NN	O	O
)	NN	O	O
in	NN	O	O
birdshot	NN	O	B
retinochoroidopathy	NN	O	I
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
the	NN	O	O
treatment	NN	O	O
outcomes	NN	O	O
of	NN	O	O
the	NN	O	O
fluocinolone	NN	O	O
acetonide	NN	O	O
intravitreal	NN	O	O
implant	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
59	NN	O	O
mg	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
birdshot	NN	O	B
retinochoroidopathy	NN	O	I
whose	NN	O	O
disease	NN	O	O
is	NN	O	O
refractory	NN	O	O
or	NN	O	O
intolerant	NN	O	O
to	NN	O	O
conventional	NN	O	O
immunomodulatory	NN	O	O
therapy	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
retrospective	NN	O	O
case	NN	O	O
series	NN	O	O
involving	NN	O	O
11	NN	O	O
birdshot	NN	O	B
retinochoroidopathy	NN	O	I
patients	NN	O	O
(	NN	O	O
11	NN	O	O
eyes	NN	O	O
)	NN	O	O
.	NN	O	O

Eleven	NN	O	O
patients	NN	O	O
(	NN	O	O
11	NN	O	O
eyes	NN	O	O
)	NN	O	O
underwent	NN	O	O
surgery	NN	O	O
for	NN	O	O
fluocinolone	NN	O	O
acetonide	NN	O	O
implant	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
59	NN	O	O
mg	NN	O	O
)	NN	O	O
.	NN	O	O

Treatment	NN	O	O
outcomes	NN	O	O
of	NN	O	O
interest	NN	O	O
were	NN	O	O
noted	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
before	NN	O	O
fluocinolone	NN	O	O
acetonide	NN	O	O
implant	NN	O	O
,	NN	O	O
and	NN	O	O
then	NN	O	O
at	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
1	NN	O	O
year	NN	O	O
,	NN	O	O
2	NN	O	O
years	NN	O	O
,	NN	O	O
3	NN	O	O
years	NN	O	O
,	NN	O	O
and	NN	O	O
beyond	NN	O	O
3	NN	O	O
years	NN	O	O
.	NN	O	O

Disease	NN	O	O
activity	NN	O	O
markers	NN	O	O
,	NN	O	O
including	NN	O	O
signs	NN	O	O
of	NN	O	O
ocular	NN	O	O
inflammation	NN	O	B
,	NN	O	O
evidence	NN	O	O
of	NN	O	O
retinal	NN	O	B
vasculitis	NN	O	I
,	NN	O	O
Swedish	NN	O	O
interactive	NN	O	O
threshold	NN	O	O
algorithm	NN	O	O
-	NN	O	O
short	NN	O	O
wavelength	NN	O	O
automated	NN	O	O
perimetry	NN	O	O
Humphrey	NN	O	O
visual	NN	O	O
field	NN	O	O
analysis	NN	O	O
,	NN	O	O
electroretinographic	NN	O	O
parameters	NN	O	O
,	NN	O	O
and	NN	O	O
optical	NN	O	O
coherence	NN	O	O
tomography	NN	O	O
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

Data	NN	O	O
on	NN	O	O
occurrence	NN	O	O
of	NN	O	O
cataract	NN	O	B
and	NN	O	O
raised	NN	O	B
intraocular	NN	O	I
pressure	NN	O	I
were	NN	O	O
collected	NN	O	O
in	NN	O	O
all	NN	O	O
eyes	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Intraocular	NN	O	O
inflammation	NN	O	B
was	NN	O	O
present	NN	O	O
in	NN	O	O
54	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
9	NN	O	O
.	NN	O	O
9	NN	O	O
,	NN	O	O
11	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
and	NN	O	O
0	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
1	NN	O	O
year	NN	O	O
,	NN	O	O
2	NN	O	O
years	NN	O	O
,	NN	O	O
3	NN	O	O
years	NN	O	O
,	NN	O	O
and	NN	O	O
beyond	NN	O	O
3	NN	O	O
years	NN	O	O
after	NN	O	O
receiving	NN	O	O
the	NN	O	O
implant	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Active	NN	O	O
vasculitis	NN	O	B
was	NN	O	O
noted	NN	O	O
in	NN	O	O
36	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
patients	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
0	NN	O	O
%	NN	O	O
at	NN	O	O
3	NN	O	O
years	NN	O	O
of	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

More	NN	O	O
than	NN	O	O
20	NN	O	O
%	NN	O	O
(	NN	O	O
47	NN	O	O
.	NN	O	O
61	NN	O	O
-	NN	O	O
67	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
reduction	NN	O	O
in	NN	O	O
central	NN	O	O
retinal	NN	O	O
thickness	NN	O	O
was	NN	O	O
noted	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
with	NN	O	O
cystoid	NN	O	B
macular	NN	O	I
edema	NN	O	I
at	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
1	NN	O	O
year	NN	O	O
,	NN	O	O
2	NN	O	O
years	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
years	NN	O	O
postimplant	NN	O	O
.	NN	O	O

At	NN	O	O
baseline	NN	O	O
,	NN	O	O
54	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
patients	NN	O	O
were	NN	O	O
on	NN	O	O
immunomodulatory	NN	O	O
agents	NN	O	O
.	NN	O	O

This	NN	O	O
percentage	NN	O	O
decreased	NN	O	O
to	NN	O	O
45	NN	O	O
.	NN	O	O
45	NN	O	O
,	NN	O	O
44	NN	O	O
.	NN	O	O
4	NN	O	O
,	NN	O	O
and	NN	O	O
14	NN	O	O
.	NN	O	O
28	NN	O	O
%	NN	O	O
at	NN	O	O
1	NN	O	O
year	NN	O	O
,	NN	O	O
2	NN	O	O
years	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
years	NN	O	O
postimplant	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Adverse	NN	O	O
events	NN	O	O
included	NN	O	O
increased	NN	O	B
intraocular	NN	O	I
pressure	NN	O	I
(	NN	O	O
54	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
cataract	NN	O	B
formation	NN	O	O
(	NN	O	O
100	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
fluocinolone	NN	O	O
acetonide	NN	O	O
implant	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
59	NN	O	O
mg	NN	O	O
)	NN	O	O
helps	NN	O	O
to	NN	O	O
control	NN	O	O
inflammation	NN	O	B
in	NN	O	O
otherwise	NN	O	O
treatment	NN	O	O
-	NN	O	O
refractory	NN	O	O
cases	NN	O	O
of	NN	O	O
birdshot	NN	O	B
retinochoroidopathy	NN	O	I
.	NN	O	O

It	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
significant	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
cataract	NN	O	B
and	NN	O	O
ocular	NN	O	B
hypertension	NN	O	I
requiring	NN	O	O
treatment	NN	O	O
.	NN	O	O

Optimal	NN	O	O
precurarizing	NN	O	O
dose	NN	O	O
of	NN	O	O
rocuronium	NN	O	O
to	NN	O	O
decrease	NN	O	O
fasciculation	NN	O	B
and	NN	O	O
myalgia	NN	O	B
following	NN	O	O
succinylcholine	NN	O	O
administration	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Succinylcholine	NN	O	O
commonly	NN	O	O
produces	NN	O	O
frequent	NN	O	O
adverse	NN	O	O
effects	NN	O	O
,	NN	O	O
including	NN	O	O
muscle	NN	O	B
fasciculation	NN	O	I
and	NN	O	O
myalgia	NN	O	B
.	NN	O	O

The	NN	O	O
current	NN	O	O
study	NN	O	O
identified	NN	O	O
the	NN	O	O
optimal	NN	O	O
dose	NN	O	O
of	NN	O	O
rocuronium	NN	O	O
to	NN	O	O
prevent	NN	O	O
succinylcholine	NN	O	O
-	NN	O	O
induced	NN	O	O
fasciculation	NN	O	B
and	NN	O	O
myalgia	NN	O	B
and	NN	O	O
evaluated	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
rocuronium	NN	O	O
on	NN	O	O
the	NN	O	O
speed	NN	O	O
of	NN	O	O
onset	NN	O	O
produced	NN	O	O
by	NN	O	O
succinylcholine	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blinded	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
100	NN	O	O
patients	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
into	NN	O	O
five	NN	O	O
groups	NN	O	O
of	NN	O	O
20	NN	O	O
patients	NN	O	O
each	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
04	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
06	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
rocuronium	NN	O	O
as	NN	O	O
a	NN	O	O
precurarizing	NN	O	O
dose	NN	O	O
.	NN	O	O

Neuromuscular	NN	O	O
monitoring	NN	O	O
after	NN	O	O
each	NN	O	O
precurarizing	NN	O	O
dose	NN	O	O
was	NN	O	O
recorded	NN	O	O
from	NN	O	O
the	NN	O	O
adductor	NN	O	O
pollicis	NN	O	O
muscle	NN	O	O
using	NN	O	O
acceleromyography	NN	O	O
with	NN	O	O
train	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
four	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
ulnar	NN	O	O
nerve	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
received	NN	O	O
succinylcholine	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
at	NN	O	O
2	NN	O	O
minutes	NN	O	O
after	NN	O	O
the	NN	O	O
precurarization	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
assessed	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
fasciculations	NN	O	B
,	NN	O	O
while	NN	O	O
myalgia	NN	O	B
was	NN	O	O
assessed	NN	O	O
at	NN	O	O
24	NN	O	O
hours	NN	O	O
after	NN	O	O
surgery	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
visible	NN	O	O
muscle	NN	O	B
fasciculation	NN	O	I
was	NN	O	O
significantly	NN	O	O
less	NN	O	O
with	NN	O	O
increasing	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
precurarizing	NN	O	O
dose	NN	O	O
of	NN	O	O
rocuronium	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Those	NN	O	O
of	NN	O	O
myalgia	NN	O	B
tend	NN	O	O
to	NN	O	O
decrease	NN	O	O
according	NN	O	O
to	NN	O	O
increasing	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
precurarizing	NN	O	O
dose	NN	O	O
of	NN	O	O
rocuronium	NN	O	O
,	NN	O	O
but	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
significance	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
072	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
onset	NN	O	O
time	NN	O	O
of	NN	O	O
succinylcholine	NN	O	O
was	NN	O	O
significantly	NN	O	O
longer	NN	O	O
with	NN	O	O
increasing	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
precurarizing	NN	O	O
dose	NN	O	O
of	NN	O	O
rocuronium	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Precurarization	NN	O	O
with	NN	O	O
0	NN	O	O
.	NN	O	O
04	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
rocuronium	NN	O	O
was	NN	O	O
the	NN	O	O
optimal	NN	O	O
dose	NN	O	O
considering	NN	O	O
the	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
fasciculation	NN	O	B
and	NN	O	O
myalgia	NN	O	B
with	NN	O	O
acceptable	NN	O	O
onset	NN	O	O
time	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
safe	NN	O	O
and	NN	O	O
effective	NN	O	O
precurarization	NN	O	O
.	NN	O	O

Absence	NN	O	O
of	NN	O	O
PKC	NN	O	O
-	NN	O	O
alpha	NN	O	O
attenuates	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrogenic	NN	O	B
diabetes	NN	O	I
insipidus	NN	O	I
.	NN	O	O

Lithium	NN	O	O
,	NN	O	O
an	NN	O	O
effective	NN	O	O
antipsychotic	NN	O	O
,	NN	O	O
induces	NN	O	O
nephrogenic	NN	O	B
diabetes	NN	O	I
insipidus	NN	O	I
(	NN	O	O
NDI	NN	O	B
)	NN	O	O
in	NN	O	O
40	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
decreased	NN	O	O
capacity	NN	O	O
to	NN	O	O
concentrate	NN	O	O
urine	NN	O	O
is	NN	O	O
likely	NN	O	O
due	NN	O	O
to	NN	O	O
lithium	NN	O	O
acutely	NN	O	O
disrupting	NN	O	O
the	NN	O	O
cAMP	NN	O	O
pathway	NN	O	O
and	NN	O	O
chronically	NN	O	O
reducing	NN	O	O
urea	NN	O	O
transporter	NN	O	O
(	NN	O	O
UT	NN	O	O
-	NN	O	O
A1	NN	O	O
)	NN	O	O
and	NN	O	O
water	NN	O	O
channel	NN	O	O
(	NN	O	O
AQP2	NN	O	O
)	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
inner	NN	O	O
medulla	NN	O	O
.	NN	O	O

Targeting	NN	O	O
an	NN	O	O
alternative	NN	O	O
signaling	NN	O	O
pathway	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
PKC	NN	O	O
-	NN	O	O
mediated	NN	O	O
signaling	NN	O	O
,	NN	O	O
may	NN	O	O
be	NN	O	O
an	NN	O	O
effective	NN	O	O
method	NN	O	O
of	NN	O	O
treating	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
polyuria	NN	O	B
.	NN	O	O

PKC	NN	O	O
-	NN	O	O
alpha	NN	O	O
null	NN	O	O
mice	NN	O	O
(	NN	O	O
PKCa	NN	O	O
KO	NN	O	O
)	NN	O	O
and	NN	O	O
strain	NN	O	O
-	NN	O	O
matched	NN	O	O
wild	NN	O	O
type	NN	O	O
(	NN	O	O
WT	NN	O	O
)	NN	O	O
controls	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
lithium	NN	O	O
for	NN	O	O
0	NN	O	O
,	NN	O	O
3	NN	O	O
or	NN	O	O
5	NN	O	O
days	NN	O	O
.	NN	O	O

WT	NN	O	O
mice	NN	O	O
had	NN	O	O
increased	NN	O	O
urine	NN	O	O
output	NN	O	O
and	NN	O	O
lowered	NN	O	O
urine	NN	O	O
osmolality	NN	O	O
after	NN	O	O
3	NN	O	O
and	NN	O	O
5	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
whereas	NN	O	O
PKCa	NN	O	O
KO	NN	O	O
mice	NN	O	O
had	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
urine	NN	O	O
output	NN	O	O
or	NN	O	O
concentration	NN	O	O
.	NN	O	O

Western	NN	O	O
blot	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
that	NN	O	O
AQP2	NN	O	O
expression	NN	O	O
in	NN	O	O
medullary	NN	O	O
tissues	NN	O	O
was	NN	O	O
lowered	NN	O	O
after	NN	O	O
3	NN	O	O
and	NN	O	O
5	NN	O	O
days	NN	O	O
in	NN	O	O
WT	NN	O	O
mice	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
AQP2	NN	O	O
was	NN	O	O
unchanged	NN	O	O
in	NN	O	O
PKCa	NN	O	O
KO	NN	O	O
.	NN	O	O

Similar	NN	O	O
results	NN	O	O
were	NN	O	O
observed	NN	O	O
with	NN	O	O
UT	NN	O	O
-	NN	O	O
A1	NN	O	O
expression	NN	O	O
.	NN	O	O

Animals	NN	O	O
were	NN	O	O
also	NN	O	O
treated	NN	O	O
with	NN	O	O
lithium	NN	O	O
for	NN	O	O
6	NN	O	O
weeks	NN	O	O
.	NN	O	O

Lithium	NN	O	O
-	NN	O	O
treated	NN	O	O
WT	NN	O	O
mice	NN	O	O
had	NN	O	O
19	NN	O	O
-	NN	O	O
fold	NN	O	O
increased	NN	O	O
urine	NN	O	O
output	NN	O	O
whereas	NN	O	O
treated	NN	O	O
PKCa	NN	O	O
KO	NN	O	O
animals	NN	O	O
had	NN	O	O
a	NN	O	O
4	NN	O	O
-	NN	O	O
fold	NN	O	O
increase	NN	O	O
in	NN	O	O
output	NN	O	O
.	NN	O	O

AQP2	NN	O	O
and	NN	O	O
UT	NN	O	O
-	NN	O	O
A1	NN	O	O
expression	NN	O	O
was	NN	O	O
lowered	NN	O	O
in	NN	O	O
6	NN	O	O
week	NN	O	O
lithium	NN	O	O
-	NN	O	O
treated	NN	O	O
WT	NN	O	O
animals	NN	O	O
whereas	NN	O	O
in	NN	O	O
treated	NN	O	O
PKCa	NN	O	O
KO	NN	O	O
mice	NN	O	O
,	NN	O	O
AQP2	NN	O	O
was	NN	O	O
only	NN	O	O
reduced	NN	O	O
by	NN	O	O
2	NN	O	O
-	NN	O	O
fold	NN	O	O
and	NN	O	O
UT	NN	O	O
-	NN	O	O
A1	NN	O	O
expression	NN	O	O
was	NN	O	O
unaffected	NN	O	O
.	NN	O	O

Urinary	NN	O	O
sodium	NN	O	O
,	NN	O	O
potassium	NN	O	O
and	NN	O	O
calcium	NN	O	O
were	NN	O	O
elevated	NN	O	O
in	NN	O	O
lithium	NN	O	O
-	NN	O	O
fed	NN	O	O
WT	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
lithium	NN	O	O
-	NN	O	O
fed	NN	O	O
PKCa	NN	O	O
KO	NN	O	O
mice	NN	O	O
.	NN	O	O

Our	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
ablation	NN	O	O
of	NN	O	O
PKCa	NN	O	O
preserves	NN	O	O
AQP2	NN	O	O
and	NN	O	O
UT	NN	O	O
-	NN	O	O
A1	NN	O	O
protein	NN	O	O
expression	NN	O	O
and	NN	O	O
localization	NN	O	O
in	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
NDI	NN	O	B
,	NN	O	O
and	NN	O	O
prevents	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
the	NN	O	O
severe	NN	O	O
polyuria	NN	O	B
associated	NN	O	O
with	NN	O	O
lithium	NN	O	O
therapy	NN	O	O
.	NN	O	O

Is	NN	O	O
Dysguesia	NN	O	B
Going	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
Rare	NN	O	O
or	NN	O	O
a	NN	O	O
Common	NN	O	O
Side	NN	O	O
-	NN	O	O
effect	NN	O	O
of	NN	O	O
Amlodipine	NN	O	O
?	NN	O	O

A	NN	O	O
very	NN	O	O
rare	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
of	NN	O	O
amlodipine	NN	O	O
is	NN	O	O
dysguesia	NN	O	B
.	NN	O	O

A	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
produced	NN	O	O
only	NN	O	O
one	NN	O	O
case	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
about	NN	O	O
a	NN	O	O
female	NN	O	O
with	NN	O	O
essential	NN	O	O
hypertension	NN	O	B
on	NN	O	O
drug	NN	O	O
treatment	NN	O	O
with	NN	O	O
amlodipine	NN	O	O
developed	NN	O	O
loss	NN	O	B
of	NN	O	I
taste	NN	O	I
sensation	NN	O	I
.	NN	O	O

Condition	NN	O	O
moderately	NN	O	O
improved	NN	O	O
on	NN	O	O
stoppage	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
for	NN	O	O
25	NN	O	O
days	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
amlodipine	NN	O	O
can	NN	O	O
cause	NN	O	O
dysguesia	NN	O	B
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
the	NN	O	O
clinical	NN	O	O
presentation	NN	O	O
and	NN	O	O
review	NN	O	O
the	NN	O	O
relevant	NN	O	O
literature	NN	O	O
on	NN	O	O
amlodipine	NN	O	O
and	NN	O	O
dysguesia	NN	O	B
.	NN	O	O

Rhabdomyolysis	NN	O	B
in	NN	O	O
association	NN	O	O
with	NN	O	O
simvastatin	NN	O	O
and	NN	O	O
dosage	NN	O	O
increment	NN	O	O
in	NN	O	O
clarithromycin	NN	O	O
.	NN	O	O

Clarithromycin	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
documented	NN	O	O
cytochrome	NN	O	O
P450	NN	O	O
3A4	NN	O	O
(	NN	O	O
CYP3A4	NN	O	O
)	NN	O	O
inhibitor	NN	O	O
to	NN	O	O
cause	NN	O	O
an	NN	O	O
adverse	NN	O	O
interaction	NN	O	O
with	NN	O	O
simvastatin	NN	O	O
.	NN	O	O

This	NN	O	O
particular	NN	O	O
case	NN	O	O
is	NN	O	O
of	NN	O	O
interest	NN	O	O
as	NN	O	O
rhabdomyolysis	NN	O	B
only	NN	O	O
occurred	NN	O	O
after	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
clarithromycin	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
developed	NN	O	O
raised	NN	O	O
cardiac	NN	O	O
biomarkers	NN	O	O
without	NN	O	O
any	NN	O	O
obvious	NN	O	O
cardiac	NN	O	O
issues	NN	O	O
,	NN	O	O
a	NN	O	O
phenomenon	NN	O	O
that	NN	O	O
has	NN	O	O
been	NN	O	O
linked	NN	O	O
to	NN	O	O
rhabdomyolysis	NN	O	B
previously	NN	O	O
.	NN	O	O

To	NN	O	O
date	NN	O	O
,	NN	O	O
there	NN	O	O
has	NN	O	O
been	NN	O	O
no	NN	O	O
reported	NN	O	O
effect	NN	O	O
of	NN	O	O
rhabdomyolysis	NN	O	B
on	NN	O	O
the	NN	O	O
structure	NN	O	O
and	NN	O	O
function	NN	O	O
of	NN	O	O
cardiac	NN	O	O
muscle	NN	O	O
.	NN	O	O

Clinicians	NN	O	O
need	NN	O	O
to	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
prescribing	NN	O	O
concomitant	NN	O	O
medications	NN	O	O
that	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
myopathy	NN	O	B
or	NN	O	O
inhibit	NN	O	O
the	NN	O	O
CYP3A4	NN	O	O
enzyme	NN	O	O
.	NN	O	O

Our	NN	O	O
case	NN	O	O
suggests	NN	O	O
that	NN	O	O
troponin	NN	O	O
elevation	NN	O	O
could	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
statin	NN	O	O
induced	NN	O	O
rhabdomyolysis	NN	O	B
,	NN	O	O
which	NN	O	O
may	NN	O	O
warrant	NN	O	O
further	NN	O	O
studies	NN	O	O
.	NN	O	O

Characterization	NN	O	O
of	NN	O	O
a	NN	O	O
novel	NN	O	O
BCHE	NN	O	O
"	NN	O	O
silent	NN	O	O
"	NN	O	O
allele	NN	O	O
:	NN	O	O
point	NN	O	O
mutation	NN	O	O
(	NN	O	O
p	NN	O	O
.	NN	O	O
Val204Asp	NN	O	O
)	NN	O	O
causes	NN	O	O
loss	NN	O	O
of	NN	O	O
activity	NN	O	O
and	NN	O	O
prolonged	NN	O	O
apnea	NN	O	B
with	NN	O	O
suxamethonium	NN	O	O
.	NN	O	O

Butyrylcholinesterase	NN	O	B
deficiency	NN	O	I
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
prolonged	NN	O	O
apnea	NN	O	B
after	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
muscle	NN	O	O
relaxants	NN	O	O
(	NN	O	O
suxamethonium	NN	O	O
or	NN	O	O
mivacurium	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
mutations	NN	O	O
in	NN	O	O
the	NN	O	O
BCHE	NN	O	O
gene	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
prolonged	NN	O	O
neuromuscular	NN	O	O
block	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
leading	NN	O	O
to	NN	O	O
the	NN	O	O
discovery	NN	O	O
of	NN	O	O
a	NN	O	O
novel	NN	O	O
BCHE	NN	O	O
variant	NN	O	O
(	NN	O	O
c	NN	O	O
.	NN	O	O
695T	NN	O	O
>	NN	O	O
A	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
Val204Asp	NN	O	O
)	NN	O	O
.	NN	O	O

Inhibition	NN	O	O
studies	NN	O	O
,	NN	O	O
kinetic	NN	O	O
analysis	NN	O	O
and	NN	O	O
molecular	NN	O	O
dynamics	NN	O	O
were	NN	O	O
undertaken	NN	O	O
to	NN	O	O
understand	NN	O	O
how	NN	O	O
this	NN	O	O
mutation	NN	O	O
disrupts	NN	O	O
the	NN	O	O
catalytic	NN	O	O
triad	NN	O	O
and	NN	O	O
determines	NN	O	O
a	NN	O	O
"	NN	O	O
silent	NN	O	O
"	NN	O	O
phenotype	NN	O	O
.	NN	O	O

Low	NN	O	O
activity	NN	O	O
of	NN	O	O
patient	NN	O	O
plasma	NN	O	O
butyrylcholinesterase	NN	O	O
with	NN	O	O
butyrylthiocholine	NN	O	O
(	NN	O	O
BTC	NN	O	O
)	NN	O	O
and	NN	O	O
benzoylcholine	NN	O	O
,	NN	O	O
and	NN	O	O
values	NN	O	O
of	NN	O	O
dibucaine	NN	O	O
and	NN	O	O
fluoride	NN	O	O
numbers	NN	O	O
fit	NN	O	O
with	NN	O	O
heterozygous	NN	O	O
atypical	NN	O	O
silent	NN	O	O
genotype	NN	O	O
.	NN	O	O

Electrophoretic	NN	O	O
analysis	NN	O	O
of	NN	O	O
plasma	NN	O	O
BChE	NN	O	O
of	NN	O	O
the	NN	O	O
proband	NN	O	O
and	NN	O	O
his	NN	O	O
mother	NN	O	O
showed	NN	O	O
that	NN	O	O
patient	NN	O	O
has	NN	O	O
a	NN	O	O
reduced	NN	O	O
amount	NN	O	O
of	NN	O	O
tetrameric	NN	O	O
enzyme	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
that	NN	O	O
minor	NN	O	O
fast	NN	O	O
-	NN	O	O
moving	NN	O	O
BChE	NN	O	O
components	NN	O	O
:	NN	O	O
monomer	NN	O	O
,	NN	O	O
dimer	NN	O	O
,	NN	O	O
and	NN	O	O
monomer	NN	O	O
-	NN	O	O
albumin	NN	O	O
conjugate	NN	O	O
are	NN	O	O
missing	NN	O	O
.	NN	O	O

Kinetic	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
p	NN	O	O
.	NN	O	O
Val204Asp	NN	O	O
/	NN	O	O
p	NN	O	O
.	NN	O	O
Asp70Gly	NN	O	O
-	NN	O	O
p	NN	O	O
.	NN	O	O
Ala539Thr	NN	O	O
BChE	NN	O	O
displays	NN	O	O
a	NN	O	O
pure	NN	O	O
Michaelian	NN	O	O
behavior	NN	O	O
with	NN	O	O
BTC	NN	O	O
as	NN	O	O
the	NN	O	O
substrate	NN	O	O
.	NN	O	O

Both	NN	O	O
catalytic	NN	O	O
parameters	NN	O	O
Km	NN	O	O
=	NN	O	O
265	NN	O	O
uM	NN	O	O
for	NN	O	O
BTC	NN	O	O
,	NN	O	O
two	NN	O	O
times	NN	O	O
higher	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
atypical	NN	O	O
enzyme	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
low	NN	O	O
Vmax	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
activity	NN	O	O
against	NN	O	O
suxamethonium	NN	O	O
.	NN	O	O

Molecular	NN	O	O
dynamic	NN	O	O
(	NN	O	O
MD	NN	O	O
)	NN	O	O
simulations	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
overall	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
mutation	NN	O	O
p	NN	O	O
.	NN	O	O
Val204Asp	NN	O	O
is	NN	O	O
disruption	NN	O	O
of	NN	O	O
hydrogen	NN	O	O
bonding	NN	O	O
between	NN	O	O
Gln223	NN	O	O
and	NN	O	O
Glu441	NN	O	O
,	NN	O	O
leading	NN	O	O
Ser198	NN	O	O
and	NN	O	O
His438	NN	O	O
to	NN	O	O
move	NN	O	O
away	NN	O	O
from	NN	O	O
each	NN	O	O
other	NN	O	O
with	NN	O	O
subsequent	NN	O	O
disruption	NN	O	O
of	NN	O	O
the	NN	O	O
catalytic	NN	O	O
triad	NN	O	O
functionality	NN	O	O
regardless	NN	O	O
of	NN	O	O
the	NN	O	O
type	NN	O	O
of	NN	O	O
substrate	NN	O	O
.	NN	O	O

MD	NN	O	O
also	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
enzyme	NN	O	O
volume	NN	O	O
is	NN	O	O
increased	NN	O	O
,	NN	O	O
suggesting	NN	O	O
a	NN	O	O
pre	NN	O	O
-	NN	O	O
denaturation	NN	O	O
state	NN	O	O
.	NN	O	O

This	NN	O	O
fits	NN	O	O
with	NN	O	O
the	NN	O	O
reduced	NN	O	O
concentration	NN	O	O
of	NN	O	O
p	NN	O	O
.	NN	O	O
Ala204Asp	NN	O	O
/	NN	O	O
p	NN	O	O
.	NN	O	O
Asp70Gly	NN	O	O
-	NN	O	O
p	NN	O	O
.	NN	O	O
Ala539Thr	NN	O	O
tetrameric	NN	O	O
enzyme	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
detectable	NN	O	O
fast	NN	O	O
moving	NN	O	O
-	NN	O	O
bands	NN	O	O
on	NN	O	O
electrophoresis	NN	O	O
gels	NN	O	O
.	NN	O	O

Delayed	NN	O	O
anemia	NN	O	B
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
injectable	NN	O	O
artesunate	NN	O	O
in	NN	O	O
the	NN	O	O
Democratic	NN	O	O
Republic	NN	O	O
of	NN	O	O
the	NN	O	O
Congo	NN	O	O
:	NN	O	O
a	NN	O	O
manageable	NN	O	O
issue	NN	O	O
.	NN	O	O

Cases	NN	O	O
of	NN	O	O
delayed	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
have	NN	O	O
been	NN	O	O
described	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
injectable	NN	O	O
artesunate	NN	O	O
,	NN	O	O
the	NN	O	O
current	NN	O	O
World	NN	O	O
Health	NN	O	O
Organization	NN	O	O
(	NN	O	O
WHO	NN	O	O
)	NN	O	O
-	NN	O	O
recommended	NN	O	O
first	NN	O	O
-	NN	O	O
line	NN	O	O
drug	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
severe	NN	O	O
malaria	NN	O	B
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
350	NN	O	O
patients	NN	O	O
(	NN	O	O
215	NN	O	O
[	NN	O	O
61	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
]	NN	O	O
<	NN	O	O
5	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
and	NN	O	O
135	NN	O	O
[	NN	O	O
38	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
]	NN	O	O
>	NN	O	O
5	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
)	NN	O	O
were	NN	O	O
followed	NN	O	O
-	NN	O	O
up	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
injectable	NN	O	O
artesunate	NN	O	O
for	NN	O	O
severe	NN	O	O
malaria	NN	O	B
in	NN	O	O
hospitals	NN	O	O
and	NN	O	O
health	NN	O	O
centers	NN	O	O
of	NN	O	O
the	NN	O	O
Democratic	NN	O	O
Republic	NN	O	O
of	NN	O	O
the	NN	O	O
Congo	NN	O	O
.	NN	O	O

Complete	NN	O	O
series	NN	O	O
of	NN	O	O
hemoglobin	NN	O	O
(	NN	O	O
Hb	NN	O	O
)	NN	O	O
measurements	NN	O	O
were	NN	O	O
available	NN	O	O
for	NN	O	O
201	NN	O	O
patients	NN	O	O
.	NN	O	O

A	NN	O	O
decrease	NN	O	O
in	NN	O	O
Hb	NN	O	O
levels	NN	O	O
between	NN	O	O
2	NN	O	O
and	NN	O	O
5	NN	O	O
g	NN	O	O
/	NN	O	O
dL	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
23	NN	O	O
(	NN	O	O
11	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
during	NN	O	O
the	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
.	NN	O	O

For	NN	O	O
five	NN	O	O
patients	NN	O	O
,	NN	O	O
Hb	NN	O	O
levels	NN	O	O
decreased	NN	O	O
below	NN	O	O
5	NN	O	O
g	NN	O	O
/	NN	O	O
dL	NN	O	O
during	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
visit	NN	O	O
.	NN	O	O

All	NN	O	O
cases	NN	O	O
of	NN	O	O
delayed	NN	O	O
anemia	NN	O	B
were	NN	O	O
clinically	NN	O	O
manageable	NN	O	O
and	NN	O	O
resolved	NN	O	O
within	NN	O	O
one	NN	O	O
month	NN	O	O
.	NN	O	O

Regulation	NN	O	O
of	NN	O	O
signal	NN	O	O
transducer	NN	O	O
and	NN	O	O
activator	NN	O	O
of	NN	O	O
transcription	NN	O	O
3	NN	O	O
and	NN	O	O
apoptotic	NN	O	O
pathways	NN	O	O
by	NN	O	O
betaine	NN	O	O
attenuates	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
injury	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
cardioprotective	NN	O	O
effects	NN	O	O
of	NN	O	O
betaine	NN	O	O
on	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
induced	NN	O	O
experimentally	NN	O	O
in	NN	O	O
rats	NN	O	O
focusing	NN	O	O
on	NN	O	O
regulation	NN	O	O
of	NN	O	O
signal	NN	O	O
transducer	NN	O	O
and	NN	O	O
activator	NN	O	O
of	NN	O	O
transcription	NN	O	O
3	NN	O	O
(	NN	O	O
STAT3	NN	O	O
)	NN	O	O
and	NN	O	O
apoptotic	NN	O	O
pathways	NN	O	O
as	NN	O	O
the	NN	O	O
potential	NN	O	O
mechanism	NN	O	O
underlying	NN	O	O
the	NN	O	O
drug	NN	O	O
effect	NN	O	O
.	NN	O	O

Male	NN	O	O
Sprague	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
betaine	NN	O	O
(	NN	O	O
100	NN	O	O
,	NN	O	O
200	NN	O	O
,	NN	O	O
and	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
orally	NN	O	O
for	NN	O	O
40	NN	O	O
days	NN	O	O
.	NN	O	O

Acute	NN	O	O
myocardial	NN	O	B
ischemic	NN	O	I
injury	NN	O	I
was	NN	O	O
induced	NN	O	O
in	NN	O	O
rats	NN	O	O
by	NN	O	O
subcutaneous	NN	O	O
injection	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
85	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
for	NN	O	O
two	NN	O	O
consecutive	NN	O	O
days	NN	O	O
.	NN	O	O

Serum	NN	O	O
cardiac	NN	O	O
marker	NN	O	O
enzyme	NN	O	O
,	NN	O	O
histopathological	NN	O	O
variables	NN	O	O
and	NN	O	O
expression	NN	O	O
of	NN	O	O
protein	NN	O	O
levels	NN	O	O
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

Oral	NN	O	O
administration	NN	O	O
of	NN	O	O
betaine	NN	O	O
(	NN	O	O
200	NN	O	O
and	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
cardiac	NN	O	O
marker	NN	O	O
enzyme	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
and	NN	O	O
prevented	NN	O	O
left	NN	O	O
ventricular	NN	O	B
remodeling	NN	O	I
.	NN	O	O

Western	NN	O	O
blot	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
phosphorylation	NN	O	O
of	NN	O	O
STAT3	NN	O	O
was	NN	O	O
maintained	NN	O	O
or	NN	O	O
further	NN	O	O
enhanced	NN	O	O
by	NN	O	O
betaine	NN	O	O
treatment	NN	O	O
in	NN	O	O
myocardium	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
betaine	NN	O	O
(	NN	O	O
200	NN	O	O
and	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
treatment	NN	O	O
increased	NN	O	O
the	NN	O	O
ventricular	NN	O	O
expression	NN	O	O
of	NN	O	O
Bcl	NN	O	O
-	NN	O	O
2	NN	O	O
and	NN	O	O
reduced	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
Bax	NN	O	O
,	NN	O	O
therefore	NN	O	O
causing	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
ratio	NN	O	O
of	NN	O	O
Bcl	NN	O	O
-	NN	O	O
2	NN	O	O
/	NN	O	O
Bax	NN	O	O
.	NN	O	O

The	NN	O	O
protective	NN	O	O
role	NN	O	O
of	NN	O	O
betaine	NN	O	O
on	NN	O	O
myocardial	NN	O	B
damage	NN	O	I
was	NN	O	O
further	NN	O	O
confirmed	NN	O	O
by	NN	O	O
histopathological	NN	O	O
examination	NN	O	O
.	NN	O	O

In	NN	O	O
summary	NN	O	O
,	NN	O	O
our	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
betaine	NN	O	O
pretreatment	NN	O	O
attenuated	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
via	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
STAT3	NN	O	O
and	NN	O	O
apoptotic	NN	O	O
pathways	NN	O	O
.	NN	O	O

Quetiapine	NN	O	O
-	NN	O	O
induced	NN	O	O
neutropenia	NN	O	B
in	NN	O	O
a	NN	O	O
bipolar	NN	O	B
patient	NN	O	O
with	NN	O	O
hepatocellular	NN	O	B
carcinoma	NN	O	I
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
Quetiapine	NN	O	O
is	NN	O	O
a	NN	O	O
dibenzothiazepine	NN	O	O
derivative	NN	O	O
,	NN	O	O
similar	NN	O	O
to	NN	O	O
clozapine	NN	O	O
,	NN	O	O
which	NN	O	O
has	NN	O	O
the	NN	O	O
highest	NN	O	O
risk	NN	O	O
of	NN	O	O
causing	NN	O	O
blood	NN	O	B
dyscrasias	NN	O	I
,	NN	O	O
especially	NN	O	O
neutropenia	NN	O	B
.	NN	O	O

There	NN	O	O
are	NN	O	O
some	NN	O	O
case	NN	O	O
reports	NN	O	O
about	NN	O	O
this	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
quetiapine	NN	O	O
,	NN	O	O
but	NN	O	O
possible	NN	O	O
risk	NN	O	O
factors	NN	O	O
are	NN	O	O
seldom	NN	O	O
discussed	NN	O	O
and	NN	O	O
identified	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
hepatocellular	NN	O	B
carcinoma	NN	O	I
that	NN	O	O
developed	NN	O	O
neutropenia	NN	O	B
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
quetiapine	NN	O	O
is	NN	O	O
described	NN	O	O
here	NN	O	O
.	NN	O	O

CASE	NN	O	O
REPORT	NN	O	O
:	NN	O	O
A	NN	O	O
62	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Taiwanese	NN	O	O
widow	NN	O	O
with	NN	O	O
bipolar	NN	O	B
disorder	NN	O	I
was	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
hepatocellular	NN	O	B
carcinoma	NN	O	I
at	NN	O	O
age	NN	O	O
60	NN	O	O
.	NN	O	O

She	NN	O	O
developed	NN	O	O
leucopenia	NN	O	B
after	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
quetiapine	NN	O	O
.	NN	O	O

After	NN	O	O
quetiapine	NN	O	O
was	NN	O	O
discontinued	NN	O	O
,	NN	O	O
her	NN	O	O
white	NN	O	O
blood	NN	O	O
cell	NN	O	O
count	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Although	NN	O	O
neutropenia	NN	O	B
is	NN	O	O
not	NN	O	O
a	NN	O	O
common	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
quetiapine	NN	O	O
,	NN	O	O
physicians	NN	O	O
should	NN	O	O
be	NN	O	O
cautious	NN	O	O
about	NN	O	O
its	NN	O	O
presentation	NN	O	O
and	NN	O	O
associated	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

Hepatic	NN	O	B
dysfunction	NN	O	I
may	NN	O	O
be	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
possible	NN	O	O
risk	NN	O	O
factors	NN	O	O
,	NN	O	O
and	NN	O	O
concomitant	NN	O	O
fever	NN	O	B
may	NN	O	O
be	NN	O	O
a	NN	O	O
diagnostic	NN	O	O
marker	NN	O	O
for	NN	O	O
adverse	NN	O	O
reaction	NN	O	O
to	NN	O	O
quetiapine	NN	O	O
.	NN	O	O

Lateral	NN	O	O
antebrachial	NN	O	O
cutaneous	NN	O	O
neuropathy	NN	O	B
after	NN	O	O
steroid	NN	O	O
injection	NN	O	O
at	NN	O	O
lateral	NN	O	O
epicondyle	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
OBJECTIVES	NN	O	O
:	NN	O	O
This	NN	O	O
report	NN	O	O
aimed	NN	O	O
to	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
lateral	NN	O	O
antebrachial	NN	O	O
cutaneous	NN	O	O
neuropathy	NN	O	B
(	NN	O	O
LACNP	NN	O	O
)	NN	O	O
that	NN	O	O
occurred	NN	O	O
after	NN	O	O
a	NN	O	O
steroid	NN	O	O
injection	NN	O	O
in	NN	O	O
the	NN	O	O
lateral	NN	O	O
epicondyle	NN	O	O
to	NN	O	O
treat	NN	O	O
lateral	NN	O	B
epicondylitis	NN	O	I
in	NN	O	O
a	NN	O	O
40	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
.	NN	O	O

MATERIAL	NN	O	O
AND	NN	O	O
METHOD	NN	O	O
:	NN	O	O
A	NN	O	O
40	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
presented	NN	O	O
with	NN	O	O
decreased	NN	O	O
sensation	NN	O	O
and	NN	O	O
paresthesia	NN	O	B
over	NN	O	O
her	NN	O	O
right	NN	O	O
lateral	NN	O	O
forearm	NN	O	O
;	NN	O	O
the	NN	O	O
paresthesia	NN	O	B
had	NN	O	O
occurred	NN	O	O
after	NN	O	O
a	NN	O	O
steroid	NN	O	O
injection	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
lateral	NN	O	O
epicondyle	NN	O	O
3	NN	O	O
months	NN	O	O
before	NN	O	O
.	NN	O	O

Her	NN	O	O
sensation	NN	O	O
of	NN	O	O
light	NN	O	O
touch	NN	O	O
and	NN	O	O
pain	NN	O	B
was	NN	O	O
diminished	NN	O	O
over	NN	O	O
the	NN	O	O
lateral	NN	O	O
side	NN	O	O
of	NN	O	O
the	NN	O	O
right	NN	O	O
forearm	NN	O	O
and	NN	O	O
wrist	NN	O	O
area	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
sensory	NN	O	O
action	NN	O	O
potential	NN	O	O
amplitude	NN	O	O
of	NN	O	O
the	NN	O	O
right	NN	O	O
lateral	NN	O	O
antebrachial	NN	O	O
cutaneous	NN	O	O
nerve	NN	O	O
(	NN	O	O
LACN	NN	O	O
)	NN	O	O
(	NN	O	O
6	NN	O	O
.	NN	O	O
2	NN	O	O
uV	NN	O	O
)	NN	O	O
was	NN	O	O
lower	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
left	NN	O	O
(	NN	O	O
13	NN	O	O
.	NN	O	O
1	NN	O	O
uV	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
difference	NN	O	O
of	NN	O	O
amplitude	NN	O	O
between	NN	O	O
both	NN	O	O
sides	NN	O	O
was	NN	O	O
significant	NN	O	O
because	NN	O	O
there	NN	O	O
was	NN	O	O
more	NN	O	O
than	NN	O	O
a	NN	O	O
50	NN	O	O
%	NN	O	O
reduction	NN	O	O
.	NN	O	O

She	NN	O	O
was	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
right	NN	O	O
LACNP	NN	O	O
(	NN	O	O
mainly	NN	O	O
axonal	NN	O	O
involvement	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
the	NN	O	O
clinical	NN	O	O
manifestation	NN	O	O
and	NN	O	O
the	NN	O	O
electrodiagnostic	NN	O	O
findings	NN	O	O
.	NN	O	O

Her	NN	O	O
symptoms	NN	O	O
improved	NN	O	O
through	NN	O	O
physical	NN	O	O
therapy	NN	O	O
but	NN	O	O
persisted	NN	O	O
to	NN	O	O
some	NN	O	O
degree	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
report	NN	O	O
describes	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
woman	NN	O	O
with	NN	O	O
LACNP	NN	O	O
that	NN	O	O
developed	NN	O	O
after	NN	O	O
a	NN	O	O
steroid	NN	O	O
injection	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
lateral	NN	O	B
epicondylitis	NN	O	I
.	NN	O	O

An	NN	O	O
electrodiagnostic	NN	O	O
study	NN	O	O
,	NN	O	O
including	NN	O	O
a	NN	O	O
nerve	NN	O	O
conduction	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
LACN	NN	O	O
,	NN	O	O
was	NN	O	O
helpful	NN	O	O
to	NN	O	O
diagnose	NN	O	O
right	NN	O	O
LACNP	NN	O	O
and	NN	O	O
to	NN	O	O
find	NN	O	O
the	NN	O	O
passage	NN	O	O
of	NN	O	O
the	NN	O	O
LACN	NN	O	O
on	NN	O	O
the	NN	O	O
lateral	NN	O	O
epicondyle	NN	O	O
.	NN	O	O

Curcumin	NN	O	O
prevents	NN	O	O
maleate	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
:	NN	O	O
relation	NN	O	O
to	NN	O	O
hemodynamic	NN	O	O
alterations	NN	O	O
,	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
,	NN	O	O
mitochondrial	NN	O	O
oxygen	NN	O	O
consumption	NN	O	O
and	NN	O	O
activity	NN	O	O
of	NN	O	O
respiratory	NN	O	O
complex	NN	O	O
I	NN	O	O
.	NN	O	O

The	NN	O	O
potential	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
dietary	NN	O	O
antioxidant	NN	O	O
curcumin	NN	O	O
(	NN	O	O
120	NN	O	O
mg	NN	O	O
/	NN	O	O
Kg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
6	NN	O	O
days	NN	O	O
)	NN	O	O
against	NN	O	O
the	NN	O	O
renal	NN	O	B
injury	NN	O	I
induced	NN	O	O
by	NN	O	O
maleate	NN	O	O
was	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Tubular	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
were	NN	O	O
induced	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
injection	NN	O	O
of	NN	O	O
maleate	NN	O	O
(	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Maleate	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
injury	NN	O	I
included	NN	O	O
increase	NN	O	O
in	NN	O	O
renal	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
urinary	NN	O	O
excretion	NN	O	O
of	NN	O	O
total	NN	O	O
protein	NN	O	O
,	NN	O	O
glucose	NN	O	O
,	NN	O	O
sodium	NN	O	O
,	NN	O	O
neutrophil	NN	O	O
gelatinase	NN	O	O
-	NN	O	O
associated	NN	O	O
lipocalin	NN	O	O
(	NN	O	O
NGAL	NN	O	O
)	NN	O	O
and	NN	O	O
N	NN	O	O
-	NN	O	O
acetyl	NN	O	O
b	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
glucosaminidase	NN	O	O
(	NN	O	O
NAG	NN	O	O
)	NN	O	O
,	NN	O	O
upregulation	NN	O	O
of	NN	O	O
kidney	NN	O	B
injury	NN	O	I
molecule	NN	O	O
(	NN	O	O
KIM	NN	O	O
)	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
decrease	NN	O	O
in	NN	O	O
renal	NN	O	O
blood	NN	O	O
flow	NN	O	O
and	NN	O	O
claudin	NN	O	O
-	NN	O	O
2	NN	O	O
expression	NN	O	O
besides	NN	O	O
of	NN	O	O
necrosis	NN	O	B
and	NN	O	O
apoptosis	NN	O	O
of	NN	O	O
tubular	NN	O	O
cells	NN	O	O
on	NN	O	O
24	NN	O	O
h	NN	O	O
.	NN	O	O

Oxidative	NN	O	O
stress	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
measuring	NN	O	O
the	NN	O	O
oxidation	NN	O	O
of	NN	O	O
lipids	NN	O	O
and	NN	O	O
proteins	NN	O	O
and	NN	O	O
diminution	NN	O	O
in	NN	O	O
renal	NN	O	O
Nrf2	NN	O	O
levels	NN	O	O
.	NN	O	O

Studies	NN	O	O
were	NN	O	O
also	NN	O	O
conducted	NN	O	O
in	NN	O	O
renal	NN	O	O
epithelial	NN	O	O
LLC	NN	O	O
-	NN	O	O
PK1	NN	O	O
cells	NN	O	O
and	NN	O	O
in	NN	O	O
mitochondria	NN	O	O
isolated	NN	O	O
from	NN	O	O
kidneys	NN	O	O
of	NN	O	O
all	NN	O	O
the	NN	O	O
experimental	NN	O	O
groups	NN	O	O
.	NN	O	O

Maleate	NN	O	O
induced	NN	O	O
cell	NN	O	O
damage	NN	O	O
and	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
(	NN	O	O
ROS	NN	O	O
)	NN	O	O
production	NN	O	O
in	NN	O	O
LLC	NN	O	O
-	NN	O	O
PK1	NN	O	O
cells	NN	O	O
in	NN	O	O
culture	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
maleate	NN	O	O
treatment	NN	O	O
reduced	NN	O	O
oxygen	NN	O	O
consumption	NN	O	O
in	NN	O	O
ADP	NN	O	O
-	NN	O	O
stimulated	NN	O	O
mitochondria	NN	O	O
and	NN	O	O
diminished	NN	O	O
respiratory	NN	O	O
control	NN	O	O
index	NN	O	O
when	NN	O	O
using	NN	O	O
malate	NN	O	O
/	NN	O	O
glutamate	NN	O	O
as	NN	O	O
substrate	NN	O	O
.	NN	O	O

The	NN	O	O
activities	NN	O	O
of	NN	O	O
both	NN	O	O
complex	NN	O	O
I	NN	O	O
and	NN	O	O
aconitase	NN	O	O
were	NN	O	O
also	NN	O	O
diminished	NN	O	O
.	NN	O	O

All	NN	O	O
the	NN	O	O
above	NN	O	O
-	NN	O	O
described	NN	O	O
alterations	NN	O	O
were	NN	O	O
prevented	NN	O	O
by	NN	O	O
curcumin	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
curcumin	NN	O	O
is	NN	O	O
able	NN	O	O
to	NN	O	O
attenuate	NN	O	O
in	NN	O	O
vivo	NN	O	O
maleate	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
and	NN	O	O
in	NN	O	O
vitro	NN	O	O
cell	NN	O	O
damage	NN	O	O
.	NN	O	O

The	NN	O	O
in	NN	O	O
vivo	NN	O	O
protection	NN	O	O
was	NN	O	O
associated	NN	O	O
to	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
preservation	NN	O	O
of	NN	O	O
mitochondrial	NN	O	O
oxygen	NN	O	O
consumption	NN	O	O
and	NN	O	O
activity	NN	O	O
of	NN	O	O
respiratory	NN	O	O
complex	NN	O	O
I	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
in	NN	O	O
vitro	NN	O	O
protection	NN	O	O
was	NN	O	O
associated	NN	O	O
to	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
ROS	NN	O	O
production	NN	O	O
.	NN	O	O

Anticonvulsant	NN	O	O
actions	NN	O	O
of	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
on	NN	O	O
the	NN	O	O
lithium	NN	O	O
-	NN	O	O
pilocarpine	NN	O	O
model	NN	O	O
of	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

MK	NN	O	O
-	NN	O	O
801	NN	O	O
,	NN	O	O
a	NN	O	O
noncompetitive	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartate	NN	O	O
(	NN	O	O
NMDA	NN	O	O
)	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
was	NN	O	O
tested	NN	O	O
for	NN	O	O
anticonvulsant	NN	O	O
effects	NN	O	O
in	NN	O	O
rats	NN	O	O
using	NN	O	O
two	NN	O	O
seizure	NN	O	B
models	NN	O	O
,	NN	O	O
coadministration	NN	O	O
of	NN	O	O
lithium	NN	O	O
and	NN	O	O
pilocarpine	NN	O	O
and	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
high	NN	O	O
dose	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
alone	NN	O	O
.	NN	O	O

Three	NN	O	O
major	NN	O	O
results	NN	O	O
are	NN	O	O
reported	NN	O	O
.	NN	O	O

First	NN	O	O
,	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
produced	NN	O	O
an	NN	O	O
effective	NN	O	O
and	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
anticonvulsant	NN	O	O
action	NN	O	O
with	NN	O	O
the	NN	O	O
lithium	NN	O	O
-	NN	O	O
pilocarpine	NN	O	O
model	NN	O	O
but	NN	O	O
not	NN	O	O
with	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
pilocarpine	NN	O	O
alone	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
different	NN	O	O
biochemical	NN	O	O
mechanisms	NN	O	O
control	NN	O	O
seizures	NN	O	B
in	NN	O	O
these	NN	O	O
two	NN	O	O
models	NN	O	O
.	NN	O	O

Second	NN	O	O
,	NN	O	O
the	NN	O	O
anticonvulsant	NN	O	O
effect	NN	O	O
of	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
in	NN	O	O
the	NN	O	O
lithium	NN	O	O
-	NN	O	O
pilocarpine	NN	O	O
model	NN	O	O
only	NN	O	O
occurred	NN	O	O
after	NN	O	O
initial	NN	O	O
periods	NN	O	O
of	NN	O	O
seizure	NN	O	B
activity	NN	O	O
.	NN	O	O

This	NN	O	O
observation	NN	O	O
is	NN	O	O
suggested	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
in	NN	O	O
vivo	NN	O	O
demonstration	NN	O	O
of	NN	O	O
the	NN	O	O
conclusion	NN	O	O
derived	NN	O	O
from	NN	O	O
in	NN	O	O
vitro	NN	O	O
experiments	NN	O	O
that	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
binding	NN	O	O
requires	NN	O	O
agonist	NN	O	O
-	NN	O	O
induced	NN	O	O
opening	NN	O	O
of	NN	O	O
the	NN	O	O
channel	NN	O	O
sites	NN	O	O
of	NN	O	O
the	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
.	NN	O	O

Third	NN	O	O
,	NN	O	O
although	NN	O	O
it	NN	O	O
is	NN	O	O
relatively	NN	O	O
easy	NN	O	O
to	NN	O	O
block	NN	O	O
seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
lithium	NN	O	O
and	NN	O	O
pilocarpine	NN	O	O
by	NN	O	O
administration	NN	O	O
of	NN	O	O
anticonvulsants	NN	O	O
prior	NN	O	O
to	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
more	NN	O	O
difficult	NN	O	O
to	NN	O	O
terminate	NN	O	O
ongoing	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
and	NN	O	O
block	NN	O	O
the	NN	O	O
lethality	NN	O	O
of	NN	O	O
the	NN	O	O
seizures	NN	O	B
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
30	NN	O	O
or	NN	O	O
60	NN	O	O
min	NN	O	O
after	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
,	NN	O	O
during	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
,	NN	O	O
gradually	NN	O	O
reduced	NN	O	O
electrical	NN	O	O
and	NN	O	O
behavioral	NN	O	O
seizure	NN	O	B
activity	NN	O	O
and	NN	O	O
greatly	NN	O	O
enhanced	NN	O	O
the	NN	O	O
survival	NN	O	O
rate	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
activation	NN	O	O
of	NN	O	O
NMDA	NN	O	O
receptors	NN	O	O
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
and	NN	O	O
brain	NN	O	B
damage	NN	O	I
in	NN	O	O
the	NN	O	O
lithium	NN	O	O
-	NN	O	O
pilocarpine	NN	O	O
model	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
further	NN	O	O
supported	NN	O	O
by	NN	O	O
results	NN	O	O
showing	NN	O	O
that	NN	O	O
nonconvulsive	NN	O	O
doses	NN	O	O
of	NN	O	O
NMDA	NN	O	O
and	NN	O	O
pilocarpine	NN	O	O
were	NN	O	O
synergistic	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
and	NN	O	O
subsequent	NN	O	O
mortality	NN	O	O
.	NN	O	O

Continuous	NN	O	O
infusion	NN	O	O
tobramycin	NN	O	O
combined	NN	O	O
with	NN	O	O
carbenicillin	NN	O	O
for	NN	O	O
infections	NN	O	B
in	NN	O	O
cancer	NN	O	B
patients	NN	O	O
.	NN	O	O

The	NN	O	O
cure	NN	O	O
rate	NN	O	O
of	NN	O	O
infections	NN	O	B
in	NN	O	O
cancer	NN	O	B
patients	NN	O	O
is	NN	O	O
adversely	NN	O	O
affected	NN	O	O
by	NN	O	O
neutropenia	NN	O	B
(	NN	O	O
less	NN	O	O
than	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
/	NN	O	O
mm3	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
particular	NN	O	O
,	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
neutropenia	NN	O	B
(	NN	O	O
less	NN	O	O
than	NN	O	O
100	NN	O	O
/	NN	O	O
mm3	NN	O	O
)	NN	O	O
have	NN	O	O
shown	NN	O	O
a	NN	O	O
poor	NN	O	O
response	NN	O	O
to	NN	O	O
antibiotics	NN	O	O
.	NN	O	O

To	NN	O	O
overcome	NN	O	O
the	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
neutropenia	NN	O	B
,	NN	O	O
tobramycin	NN	O	O
was	NN	O	O
given	NN	O	O
by	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
and	NN	O	O
combined	NN	O	O
with	NN	O	O
intermittent	NN	O	O
carbenicillin	NN	O	O
.	NN	O	O

Tobramycin	NN	O	O
was	NN	O	O
given	NN	O	O
to	NN	O	O
a	NN	O	O
total	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
and	NN	O	O
carbenicillin	NN	O	O
was	NN	O	O
given	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
5	NN	O	O
gm	NN	O	O
every	NN	O	O
four	NN	O	O
hours	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
125	NN	O	O
infectious	NN	O	O
episodes	NN	O	O
in	NN	O	O
116	NN	O	O
cancer	NN	O	B
patients	NN	O	O
receiving	NN	O	O
myelosuppressive	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
cure	NN	O	O
rate	NN	O	O
was	NN	O	O
70	NN	O	O
%	NN	O	O
.	NN	O	O

Pneumonia	NN	O	B
was	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
infection	NN	O	B
and	NN	O	O
61	NN	O	O
%	NN	O	O
of	NN	O	O
59	NN	O	O
episodes	NN	O	O
were	NN	O	O
cured	NN	O	O
.	NN	O	O

Gram	NN	O	O
-	NN	O	O
negative	NN	O	O
bacilli	NN	O	O
were	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
causative	NN	O	O
organisms	NN	O	O
and	NN	O	O
69	NN	O	O
%	NN	O	O
of	NN	O	O
these	NN	O	O
infections	NN	O	B
were	NN	O	O
cured	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
pathogen	NN	O	O
was	NN	O	O
Klebsiella	NN	O	O
pneumoniae	NN	O	B
and	NN	O	O
this	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
Escherichia	NN	O	O
coli	NN	O	O
and	NN	O	O
Pseudomonas	NN	O	O
aeruginosa	NN	O	O
,	NN	O	O
accounted	NN	O	O
for	NN	O	O
74	NN	O	O
%	NN	O	O
of	NN	O	O
all	NN	O	O
gram	NN	O	B
-	NN	O	I
negative	NN	O	I
bacillary	NN	O	I
infections	NN	O	I
.	NN	O	O

Response	NN	O	O
was	NN	O	O
not	NN	O	O
influenced	NN	O	O
by	NN	O	O
the	NN	O	O
initial	NN	O	O
neutrophil	NN	O	O
count	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
62	NN	O	O
%	NN	O	O
cure	NN	O	O
rate	NN	O	O
for	NN	O	O
39	NN	O	O
episodes	NN	O	O
associated	NN	O	O
with	NN	O	O
severe	NN	O	O
neutropenia	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
failure	NN	O	O
of	NN	O	O
the	NN	O	O
neutrophil	NN	O	O
count	NN	O	O
to	NN	O	O
increase	NN	O	O
during	NN	O	O
therapy	NN	O	O
adversely	NN	O	O
affected	NN	O	O
response	NN	O	O
.	NN	O	O

Azotemia	NN	O	B
was	NN	O	O
the	NN	O	O
major	NN	O	O
side	NN	O	O
effect	NN	O	O
recognized	NN	O	O
,	NN	O	O
and	NN	O	O
it	NN	O	O
occurred	NN	O	O
in	NN	O	O
11	NN	O	O
%	NN	O	O
of	NN	O	O
episodes	NN	O	O
.	NN	O	O

Major	NN	O	O
azotemia	NN	O	B
(	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
greater	NN	O	O
than	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
or	NN	O	O
BUN	NN	O	O
greater	NN	O	O
than	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
)	NN	O	O
occurred	NN	O	O
in	NN	O	O
only	NN	O	O
2	NN	O	O
%	NN	O	O
.	NN	O	O

Azotemia	NN	O	B
was	NN	O	O
not	NN	O	O
related	NN	O	O
to	NN	O	O
duration	NN	O	O
of	NN	O	O
therapy	NN	O	O
or	NN	O	O
serum	NN	O	O
tobramycin	NN	O	O
concentration	NN	O	O
.	NN	O	O

This	NN	O	O
antibiotic	NN	O	O
regimen	NN	O	O
showed	NN	O	O
both	NN	O	O
therapeutic	NN	O	O
efficacy	NN	O	O
and	NN	O	O
acceptable	NN	O	O
renal	NN	O	B
toxicity	NN	O	I
for	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

Incidence	NN	O	O
of	NN	O	O
solid	NN	O	O
tumours	NN	O	B
among	NN	O	O
pesticide	NN	O	O
applicators	NN	O	O
exposed	NN	O	O
to	NN	O	O
the	NN	O	O
organophosphate	NN	O	O
insecticide	NN	O	O
diazinon	NN	O	O
in	NN	O	O
the	NN	O	O
Agricultural	NN	O	O
Health	NN	O	O
Study	NN	O	O
:	NN	O	O
an	NN	O	O
updated	NN	O	O
analysis	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
Diazinon	NN	O	O
,	NN	O	O
a	NN	O	O
common	NN	O	O
organophosphate	NN	O	O
insecticide	NN	O	O
with	NN	O	O
genotoxic	NN	O	O
properties	NN	O	O
,	NN	O	O
was	NN	O	O
previously	NN	O	O
associated	NN	O	O
with	NN	O	O
lung	NN	O	B
cancer	NN	O	I
in	NN	O	O
the	NN	O	O
Agricultural	NN	O	O
Health	NN	O	O
Study	NN	O	O
(	NN	O	O
AHS	NN	O	O
)	NN	O	O
cohort	NN	O	O
,	NN	O	O
but	NN	O	O
few	NN	O	O
other	NN	O	O
epidemiological	NN	O	O
studies	NN	O	O
have	NN	O	O
examined	NN	O	O
diazinon	NN	O	O
-	NN	O	O
associated	NN	O	O
cancer	NN	O	B
risk	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
updated	NN	O	O
diazinon	NN	O	O
exposure	NN	O	O
and	NN	O	O
cancer	NN	O	B
incidence	NN	O	O
information	NN	O	O
to	NN	O	O
evaluate	NN	O	O
solid	NN	O	O
tumour	NN	O	B
risk	NN	O	O
in	NN	O	O
the	NN	O	O
AHS	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Male	NN	O	O
pesticide	NN	O	O
applicators	NN	O	O
in	NN	O	O
Iowa	NN	O	O
and	NN	O	O
North	NN	O	O
Carolina	NN	O	O
reported	NN	O	O
lifetime	NN	O	O
diazinon	NN	O	O
use	NN	O	O
at	NN	O	O
enrolment	NN	O	O
(	NN	O	O
1993	NN	O	O
-	NN	O	O
1997	NN	O	O
)	NN	O	O
and	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
(	NN	O	O
1998	NN	O	O
-	NN	O	O
2005	NN	O	O
)	NN	O	O
;	NN	O	O
cancer	NN	O	B
incidence	NN	O	O
was	NN	O	O
assessed	NN	O	O
through	NN	O	O
2010	NN	O	O
(	NN	O	O
North	NN	O	O
Carolina	NN	O	O
)	NN	O	O
/	NN	O	O
2011	NN	O	O
(	NN	O	O
Iowa	NN	O	O
)	NN	O	O
.	NN	O	O

Among	NN	O	O
applicators	NN	O	O
with	NN	O	O
usage	NN	O	O
information	NN	O	O
sufficient	NN	O	O
to	NN	O	O
evaluate	NN	O	O
exposure	NN	O	O
-	NN	O	O
response	NN	O	O
patterns	NN	O	O
,	NN	O	O
we	NN	O	O
used	NN	O	O
Poisson	NN	O	O
regression	NN	O	O
to	NN	O	O
estimate	NN	O	O
adjusted	NN	O	O
rate	NN	O	O
ratios	NN	O	O
(	NN	O	O
RRs	NN	O	O
)	NN	O	O
and	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
for	NN	O	O
cancer	NN	O	B
sites	NN	O	O
with	NN	O	O
>	NN	O	O
10	NN	O	O
exposed	NN	O	O
cases	NN	O	O
for	NN	O	O
both	NN	O	O
lifetime	NN	O	O
(	NN	O	O
LT	NN	O	O
)	NN	O	O
exposure	NN	O	O
days	NN	O	O
and	NN	O	O
intensity	NN	O	O
-	NN	O	O
weighted	NN	O	O
(	NN	O	O
IW	NN	O	O
)	NN	O	O
lifetime	NN	O	O
exposure	NN	O	O
days	NN	O	O
(	NN	O	O
accounting	NN	O	O
for	NN	O	O
factors	NN	O	O
impacting	NN	O	O
exposure	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
We	NN	O	O
observed	NN	O	O
elevated	NN	O	O
lung	NN	O	B
cancer	NN	O	I
risks	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
283	NN	O	O
)	NN	O	O
among	NN	O	O
applicators	NN	O	O
with	NN	O	O
the	NN	O	O
greatest	NN	O	O
number	NN	O	O
of	NN	O	O
LT	NN	O	O
(	NN	O	O
RR	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
60	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1	NN	O	O
.	NN	O	O
11	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
31	NN	O	O
;	NN	O	O
Ptrend	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
and	NN	O	O
IW	NN	O	O
days	NN	O	O
of	NN	O	O
diazinon	NN	O	O
use	NN	O	O
(	NN	O	O
RR	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
41	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0	NN	O	O
.	NN	O	O
98	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
04	NN	O	O
;	NN	O	O
Ptrend	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
08	NN	O	O
)	NN	O	O
.	NN	O	O

Kidney	NN	O	B
cancer	NN	O	I
(	NN	O	O
N	NN	O	O
=	NN	O	O
94	NN	O	O
)	NN	O	O
risks	NN	O	O
were	NN	O	O
non	NN	O	O
-	NN	O	O
significantly	NN	O	O
elevated	NN	O	O
(	NN	O	O
RRLT	NN	O	O
days	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
77	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0	NN	O	O
.	NN	O	O
90	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O
51	NN	O	O
;	NN	O	O
Ptrend	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
09	NN	O	O
;	NN	O	O
RRIW	NN	O	O
days	NN	O	O
1	NN	O	O
.	NN	O	O
37	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0	NN	O	O
.	NN	O	O
64	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
92	NN	O	O
;	NN	O	O
Ptrend	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
50	NN	O	O
)	NN	O	O
,	NN	O	O
as	NN	O	O
were	NN	O	O
risks	NN	O	O
for	NN	O	O
aggressive	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
(	NN	O	O
N	NN	O	O
=	NN	O	O
656	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Our	NN	O	O
updated	NN	O	O
evaluation	NN	O	O
of	NN	O	O
diazinon	NN	O	O
provides	NN	O	O
additional	NN	O	O
evidence	NN	O	O
of	NN	O	O
an	NN	O	O
association	NN	O	O
with	NN	O	O
lung	NN	O	B
cancer	NN	O	I
risk	NN	O	O
.	NN	O	O

Newly	NN	O	O
identified	NN	O	O
links	NN	O	O
to	NN	O	O
kidney	NN	O	B
cancer	NN	O	I
and	NN	O	O
associations	NN	O	O
with	NN	O	O
aggressive	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
require	NN	O	O
further	NN	O	O
evaluation	NN	O	O
.	NN	O	O

Associations	NN	O	O
of	NN	O	O
Ozone	NN	O	O
and	NN	O	O
PM2	NN	O	O
.	NN	O	O
5	NN	O	O
Concentrations	NN	O	O
With	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
Disease	NN	O	I
Among	NN	O	O
Participants	NN	O	O
in	NN	O	O
the	NN	O	O
Agricultural	NN	O	O
Health	NN	O	O
Study	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
describes	NN	O	O
associations	NN	O	O
of	NN	O	O
ozone	NN	O	O
and	NN	O	O
fine	NN	O	O
particulate	NN	O	O
matter	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
observed	NN	O	O
among	NN	O	O
farmers	NN	O	O
in	NN	O	O
North	NN	O	O
Carolina	NN	O	O
and	NN	O	O
Iowa	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
used	NN	O	O
logistic	NN	O	O
regression	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
associations	NN	O	O
of	NN	O	O
these	NN	O	O
pollutants	NN	O	O
with	NN	O	O
self	NN	O	O
-	NN	O	O
reported	NN	O	O
,	NN	O	O
doctor	NN	O	O
-	NN	O	O
diagnosed	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

Daily	NN	O	O
predicted	NN	O	O
pollutant	NN	O	O
concentrations	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
derive	NN	O	O
surrogates	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
exposure	NN	O	O
and	NN	O	O
link	NN	O	O
them	NN	O	O
to	NN	O	O
study	NN	O	O
participants	NN	O	O
'	NN	O	O
geocoded	NN	O	O
addresses	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
We	NN	O	O
observed	NN	O	O
positive	NN	O	O
associations	NN	O	O
of	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
with	NN	O	O
ozone	NN	O	O
(	NN	O	O
odds	NN	O	O
ratio	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
39	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
98	NN	O	O
to	NN	O	O
1	NN	O	O
.	NN	O	O
98	NN	O	O
)	NN	O	O
and	NN	O	O
fine	NN	O	O
particulate	NN	O	O
matter	NN	O	O
(	NN	O	O
odds	NN	O	O
ratio	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
34	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
93	NN	O	O
to	NN	O	O
1	NN	O	O
.	NN	O	O
93	NN	O	O
)	NN	O	O
in	NN	O	O
North	NN	O	O
Carolina	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
Iowa	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
plausibility	NN	O	O
of	NN	O	O
an	NN	O	O
effect	NN	O	O
of	NN	O	O
ambient	NN	O	O
concentrations	NN	O	O
of	NN	O	O
these	NN	O	O
pollutants	NN	O	O
on	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
risk	NN	O	O
is	NN	O	O
supported	NN	O	O
by	NN	O	O
experimental	NN	O	O
data	NN	O	O
demonstrating	NN	O	O
damage	NN	O	O
to	NN	O	O
dopaminergic	NN	O	O
neurons	NN	O	O
at	NN	O	O
relevant	NN	O	O
concentrations	NN	O	O
.	NN	O	O

Additional	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
to	NN	O	O
address	NN	O	O
uncertainties	NN	O	O
related	NN	O	O
to	NN	O	O
confounding	NN	O	O
and	NN	O	O
to	NN	O	O
examine	NN	O	O
temporal	NN	O	O
aspects	NN	O	O
of	NN	O	O
the	NN	O	O
associations	NN	O	O
we	NN	O	O
observed	NN	O	O
.	NN	O	O

Low	NN	O	O
functional	NN	O	O
programming	NN	O	O
of	NN	O	O
renal	NN	O	O
AT2R	NN	O	O
mediates	NN	O	O
the	NN	O	O
developmental	NN	O	O
origin	NN	O	O
of	NN	O	O
glomerulosclerosis	NN	O	B
in	NN	O	O
adult	NN	O	O
offspring	NN	O	O
induced	NN	O	O
by	NN	O	O
prenatal	NN	O	O
caffeine	NN	O	O
exposure	NN	O	O
.	NN	O	O

UNASSIGNED	NN	O	O
:	NN	O	O
Our	NN	O	O
previous	NN	O	O
study	NN	O	O
has	NN	O	O
indicated	NN	O	O
that	NN	O	O
prenatal	NN	O	O
caffeine	NN	O	O
exposure	NN	O	O
(	NN	O	O
PCE	NN	O	O
)	NN	O	O
could	NN	O	O
induce	NN	O	O
intrauterine	NN	O	B
growth	NN	O	I
retardation	NN	O	I
(	NN	O	O
IUGR	NN	O	B
)	NN	O	O
of	NN	O	O
offspring	NN	O	O
.	NN	O	O

Recent	NN	O	O
research	NN	O	O
suggested	NN	O	O
that	NN	O	O
IUGR	NN	O	B
is	NN	O	O
a	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
glomerulosclerosis	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
whether	NN	O	O
PCE	NN	O	O
could	NN	O	O
induce	NN	O	O
glomerulosclerosis	NN	O	B
and	NN	O	O
its	NN	O	O
underlying	NN	O	O
mechanisms	NN	O	O
remain	NN	O	O
unknown	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
induction	NN	O	O
to	NN	O	O
glomerulosclerosis	NN	O	B
in	NN	O	O
adult	NN	O	O
offspring	NN	O	O
by	NN	O	O
PCE	NN	O	O
and	NN	O	O
its	NN	O	O
intrauterine	NN	O	O
programming	NN	O	O
mechanisms	NN	O	O
.	NN	O	O

A	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
IUGR	NN	O	B
was	NN	O	O
established	NN	O	O
by	NN	O	O
PCE	NN	O	O
,	NN	O	O
male	NN	O	O
fetuses	NN	O	O
and	NN	O	O
adult	NN	O	O
offspring	NN	O	O
at	NN	O	O
the	NN	O	O
age	NN	O	O
of	NN	O	O
postnatal	NN	O	O
week	NN	O	O
24	NN	O	O
were	NN	O	O
euthanized	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
adult	NN	O	O
offspring	NN	O	O
kidneys	NN	O	O
in	NN	O	O
the	NN	O	O
PCE	NN	O	O
group	NN	O	O
exhibited	NN	O	O
glomerulosclerosis	NN	O	B
as	NN	O	O
well	NN	O	O
as	NN	O	O
interstitial	NN	O	B
fibrosis	NN	O	I
,	NN	O	O
accompanied	NN	O	O
by	NN	O	O
elevated	NN	O	O
levels	NN	O	O
of	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
and	NN	O	O
urine	NN	O	O
protein	NN	O	O
.	NN	O	O

Renal	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
receptor	NN	O	O
type	NN	O	O
2	NN	O	O
(	NN	O	O
AT2R	NN	O	O
)	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
adult	NN	O	O
offspring	NN	O	O
was	NN	O	O
reduced	NN	O	O
by	NN	O	O
PCE	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
renal	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
receptor	NN	O	O
type	NN	O	O
1a	NN	O	O
(	NN	O	O
AT1aR	NN	O	O
)	NN	O	O
/	NN	O	O
AT2R	NN	O	O
expression	NN	O	O
ratio	NN	O	O
was	NN	O	O
increased	NN	O	O
.	NN	O	O

The	NN	O	O
fetal	NN	O	O
kidneys	NN	O	O
in	NN	O	O
the	NN	O	O
PCE	NN	O	O
group	NN	O	O
displayed	NN	O	O
an	NN	O	O
enlarged	NN	O	O
Bowman	NN	O	O
'	NN	O	O
s	NN	O	O
space	NN	O	O
and	NN	O	O
a	NN	O	O
shrunken	NN	O	O
glomerular	NN	O	O
tuft	NN	O	O
,	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
reduced	NN	O	O
cortex	NN	O	O
width	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
nephrogenic	NN	O	O
zone	NN	O	O
/	NN	O	O
cortical	NN	O	O
zone	NN	O	O
ratio	NN	O	O
.	NN	O	O

Observation	NN	O	O
by	NN	O	O
electronic	NN	O	O
microscope	NN	O	O
revealed	NN	O	O
structural	NN	O	O
damage	NN	O	O
of	NN	O	O
podocytes	NN	O	O
;	NN	O	O
the	NN	O	O
reduced	NN	O	O
expression	NN	O	O
level	NN	O	O
of	NN	O	O
podocyte	NN	O	O
marker	NN	O	O
genes	NN	O	O
,	NN	O	O
nephrin	NN	O	O
and	NN	O	O
podocin	NN	O	O
,	NN	O	O
was	NN	O	O
also	NN	O	O
detected	NN	O	O
by	NN	O	O
q	NN	O	O
-	NN	O	O
PCR	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
AT2R	NN	O	O
gene	NN	O	O
and	NN	O	O
protein	NN	O	O
expressions	NN	O	O
in	NN	O	O
fetal	NN	O	O
kidneys	NN	O	O
were	NN	O	O
inhibited	NN	O	O
by	NN	O	O
PCE	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
repression	NN	O	O
of	NN	O	O
the	NN	O	O
gene	NN	O	O
expression	NN	O	O
of	NN	O	O
glial	NN	O	O
-	NN	O	O
cell	NN	O	O
-	NN	O	O
line	NN	O	O
-	NN	O	O
derived	NN	O	O
neurotrophic	NN	O	O
factor	NN	O	O
(	NN	O	O
GDNF	NN	O	O
)	NN	O	O
/	NN	O	O
tyrosine	NN	O	O
kinase	NN	O	O
receptor	NN	O	O
(	NN	O	O
c	NN	O	O
-	NN	O	O
Ret	NN	O	O
)	NN	O	O
signaling	NN	O	O
pathway	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
PCE	NN	O	O
could	NN	O	O
induce	NN	O	O
dysplasia	NN	O	B
of	NN	O	I
fetal	NN	O	I
kidneys	NN	O	I
as	NN	O	O
well	NN	O	O
as	NN	O	O
glomerulosclerosis	NN	O	B
of	NN	O	O
adult	NN	O	O
offspring	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
low	NN	O	O
functional	NN	O	O
programming	NN	O	O
of	NN	O	O
renal	NN	O	O
AT2R	NN	O	O
might	NN	O	O
mediate	NN	O	O
the	NN	O	O
developmental	NN	O	O
origin	NN	O	O
of	NN	O	O
adult	NN	O	O
glomerulosclerosis	NN	O	B
.	NN	O	O

1	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
Butadiene	NN	O	O
,	NN	O	O
CML	NN	O	B
and	NN	O	O
the	NN	O	O
t	NN	O	O
(	NN	O	O
9	NN	O	O
:	NN	O	O
22	NN	O	O
)	NN	O	O
translocation	NN	O	O
:	NN	O	O
A	NN	O	O
reality	NN	O	O
check	NN	O	O
.	NN	O	O

UNASSIGNED	NN	O	O
:	NN	O	O
Epidemiological	NN	O	O
studies	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
butadiene	NN	O	O
have	NN	O	O
suggest	NN	O	O
that	NN	O	O
exposures	NN	O	O
to	NN	O	O
humans	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
chronic	NN	O	B
myeloid	NN	O	I
leukemia	NN	O	I
(	NN	O	O
CML	NN	O	B
)	NN	O	O
.	NN	O	O

CML	NN	O	B
has	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
documented	NN	O	O
association	NN	O	O
with	NN	O	O
ionizing	NN	O	O
radiation	NN	O	O
,	NN	O	O
but	NN	O	O
reports	NN	O	O
of	NN	O	O
associations	NN	O	O
with	NN	O	O
chemical	NN	O	O
exposures	NN	O	O
have	NN	O	O
been	NN	O	O
questioned	NN	O	O
.	NN	O	O

Ionizing	NN	O	O
radiation	NN	O	O
is	NN	O	O
capable	NN	O	O
of	NN	O	O
inducing	NN	O	O
the	NN	O	O
requisite	NN	O	O
CML	NN	O	B
-	NN	O	O
associated	NN	O	O
t	NN	O	O
(	NN	O	O
9	NN	O	O
:	NN	O	O
22	NN	O	O
)	NN	O	O
translocation	NN	O	O
(	NN	O	O
Philadelphia	NN	O	B
chromosome	NN	O	I
)	NN	O	O
in	NN	O	O
appropriate	NN	O	O
cells	NN	O	O
in	NN	O	O
vitro	NN	O	O
but	NN	O	O
,	NN	O	O
thus	NN	O	O
far	NN	O	O
,	NN	O	O
chemicals	NN	O	O
have	NN	O	O
not	NN	O	O
shown	NN	O	O
this	NN	O	O
capacity	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
proposed	NN	O	O
that	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
butadiene	NN	O	O
metabolites	NN	O	O
be	NN	O	O
so	NN	O	O
tested	NN	O	O
as	NN	O	O
a	NN	O	O
reality	NN	O	O
check	NN	O	O
on	NN	O	O
the	NN	O	O
epidemiological	NN	O	O
reports	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
conduct	NN	O	O
reliable	NN	O	O
testing	NN	O	O
in	NN	O	O
this	NN	O	O
regard	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
essential	NN	O	O
that	NN	O	O
a	NN	O	O
positive	NN	O	O
control	NN	O	O
for	NN	O	O
induction	NN	O	O
be	NN	O	O
available	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
used	NN	O	O
ionizing	NN	O	O
radiation	NN	O	O
to	NN	O	O
develop	NN	O	O
such	NN	O	O
a	NN	O	O
control	NN	O	O
.	NN	O	O

Results	NN	O	O
described	NN	O	O
here	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
this	NN	O	O
agent	NN	O	O
does	NN	O	O
in	NN	O	O
fact	NN	O	O
induce	NN	O	O
pathogenic	NN	O	O
t	NN	O	O
(	NN	O	O
9	NN	O	O
:	NN	O	O
22	NN	O	O
)	NN	O	O
translocations	NN	O	O
in	NN	O	O
a	NN	O	O
human	NN	O	O
myeloid	NN	O	O
cell	NN	O	O
line	NN	O	O
in	NN	O	O
vitro	NN	O	O
,	NN	O	O
but	NN	O	O
does	NN	O	O
so	NN	O	O
at	NN	O	O
low	NN	O	O
frequencies	NN	O	O
.	NN	O	O

Conditions	NN	O	O
that	NN	O	O
will	NN	O	O
be	NN	O	O
required	NN	O	O
for	NN	O	O
studies	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
butadiene	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Cancer	NN	O	B
incidence	NN	O	O
and	NN	O	O
metolachlor	NN	O	O
use	NN	O	O
in	NN	O	O
the	NN	O	O
Agricultural	NN	O	O
Health	NN	O	O
Study	NN	O	O
:	NN	O	O
An	NN	O	O
update	NN	O	O
.	NN	O	O

UNASSIGNED	NN	O	O
:	NN	O	O
Metolachlor	NN	O	O
,	NN	O	O
a	NN	O	O
widely	NN	O	O
used	NN	O	O
herbicide	NN	O	O
,	NN	O	O
is	NN	O	O
classified	NN	O	O
as	NN	O	O
a	NN	O	O
Group	NN	O	O
C	NN	O	O
carcinogen	NN	O	O
by	NN	O	O
the	NN	O	O
U	NN	O	O
.	NN	O	O
S	NN	O	O
.	NN	O	O

Environmental	NN	O	O
Protection	NN	O	O
Agency	NN	O	O
based	NN	O	O
on	NN	O	O
increased	NN	O	O
liver	NN	O	B
neoplasms	NN	O	I
in	NN	O	O
female	NN	O	O
rats	NN	O	O
.	NN	O	O

Epidemiologic	NN	O	O
studies	NN	O	O
of	NN	O	O
the	NN	O	O
health	NN	O	O
effects	NN	O	O
of	NN	O	O
metolachlor	NN	O	O
have	NN	O	O
been	NN	O	O
limited	NN	O	O
.	NN	O	O

The	NN	O	O
Agricultural	NN	O	O
Health	NN	O	O
Study	NN	O	O
(	NN	O	O
AHS	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
prospective	NN	O	O
cohort	NN	O	O
study	NN	O	O
including	NN	O	O
licensed	NN	O	O
private	NN	O	O
and	NN	O	O
commercial	NN	O	O
pesticide	NN	O	O
applicators	NN	O	O
in	NN	O	O
Iowa	NN	O	O
and	NN	O	O
North	NN	O	O
Carolina	NN	O	O
enrolled	NN	O	O
1993	NN	O	O
-	NN	O	O
1997	NN	O	O
.	NN	O	O

We	NN	O	O
evaluated	NN	O	O
cancer	NN	O	B
incidence	NN	O	O
through	NN	O	O
2010	NN	O	O
/	NN	O	O
2011	NN	O	O
(	NN	O	O
NC	NN	O	O
/	NN	O	O
IA	NN	O	O
)	NN	O	O
for	NN	O	O
49	NN	O	O
,	NN	O	O
616	NN	O	O
applicators	NN	O	O
,	NN	O	O
53	NN	O	O
%	NN	O	O
of	NN	O	O
whom	NN	O	O
reported	NN	O	O
ever	NN	O	O
using	NN	O	O
metolachlor	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
Poisson	NN	O	O
regression	NN	O	O
to	NN	O	O
evaluate	NN	O	O
relations	NN	O	O
between	NN	O	O
two	NN	O	O
metrics	NN	O	O
of	NN	O	O
metolachlor	NN	O	O
use	NN	O	O
(	NN	O	O
lifetime	NN	O	O
days	NN	O	O
,	NN	O	O
intensity	NN	O	O
-	NN	O	O
weighted	NN	O	O
lifetime	NN	O	O
days	NN	O	O
)	NN	O	O
and	NN	O	O
cancer	NN	O	B
incidence	NN	O	O
.	NN	O	O

We	NN	O	O
saw	NN	O	O
no	NN	O	O
association	NN	O	O
between	NN	O	O
metolachlor	NN	O	O
use	NN	O	O
and	NN	O	O
incidence	NN	O	O
of	NN	O	O
all	NN	O	O
cancers	NN	O	B
combined	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
5	NN	O	O
,	NN	O	O
701	NN	O	O
with	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
year	NN	O	O
lag	NN	O	O
)	NN	O	O
or	NN	O	O
most	NN	O	O
site	NN	O	O
-	NN	O	O
specific	NN	O	O
cancers	NN	O	B
.	NN	O	O

For	NN	O	O
liver	NN	O	B
cancer	NN	O	I
,	NN	O	O
in	NN	O	O
analyses	NN	O	O
restricted	NN	O	O
to	NN	O	O
exposed	NN	O	O
workers	NN	O	O
,	NN	O	O
elevations	NN	O	O
observed	NN	O	O
at	NN	O	O
higher	NN	O	O
categories	NN	O	O
of	NN	O	O
use	NN	O	O
were	NN	O	O
not	NN	O	O
statistically	NN	O	O
significant	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
trends	NN	O	O
for	NN	O	O
both	NN	O	O
lifetime	NN	O	O
and	NN	O	O
intensity	NN	O	O
-	NN	O	O
weighted	NN	O	O
lifetime	NN	O	O
days	NN	O	O
of	NN	O	O
metolachor	NN	O	O
use	NN	O	O
were	NN	O	O
positive	NN	O	O
and	NN	O	O
statistically	NN	O	O
significant	NN	O	O
with	NN	O	O
an	NN	O	O
unexposed	NN	O	O
reference	NN	O	O
group	NN	O	O
.	NN	O	O

A	NN	O	O
similar	NN	O	O
pattern	NN	O	O
was	NN	O	O
observed	NN	O	O
for	NN	O	O
follicular	NN	O	B
cell	NN	O	I
lymphoma	NN	O	I
,	NN	O	O
but	NN	O	O
no	NN	O	O
other	NN	O	O
lymphoma	NN	O	B
subtypes	NN	O	O
.	NN	O	O

An	NN	O	O
earlier	NN	O	O
suggestion	NN	O	O
of	NN	O	O
increased	NN	O	O
lung	NN	O	B
cancer	NN	O	I
risk	NN	O	O
at	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
metolachlor	NN	O	O
use	NN	O	O
in	NN	O	O
this	NN	O	O
cohort	NN	O	O
was	NN	O	O
not	NN	O	O
confirmed	NN	O	O
in	NN	O	O
this	NN	O	O
update	NN	O	O
.	NN	O	O

This	NN	O	O
suggestion	NN	O	O
of	NN	O	O
an	NN	O	O
association	NN	O	O
between	NN	O	O
metolachlor	NN	O	O
and	NN	O	O
liver	NN	O	B
cancer	NN	O	I
among	NN	O	O
pesticide	NN	O	O
applicators	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
finding	NN	O	O
and	NN	O	O
echoes	NN	O	O
observation	NN	O	O
of	NN	O	O
increased	NN	O	O
liver	NN	O	B
neoplasms	NN	O	I
in	NN	O	O
some	NN	O	O
animal	NN	O	O
studies	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
our	NN	O	O
findings	NN	O	O
for	NN	O	O
both	NN	O	O
liver	NN	O	B
cancer	NN	O	I
and	NN	O	O
follicular	NN	O	O
cell	NN	O	O
lymphoma	NN	O	B
warrant	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
to	NN	O	O
better	NN	O	O
differentiate	NN	O	O
effects	NN	O	O
of	NN	O	O
metolachlor	NN	O	O
use	NN	O	O
from	NN	O	O
other	NN	O	O
factors	NN	O	O
.	NN	O	O

Mechanisms	NN	O	O
Underlying	NN	O	O
Latent	NN	O	O
Disease	NN	O	O
Risk	NN	O	O
Associated	NN	O	O
with	NN	O	O
Early	NN	O	O
-	NN	O	O
Life	NN	O	O
Arsenic	NN	O	O
Exposure	NN	O	O
:	NN	O	O
Current	NN	O	O
Research	NN	O	O
Trends	NN	O	O
and	NN	O	O
Scientific	NN	O	O
Gaps	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Millions	NN	O	O
of	NN	O	O
individuals	NN	O	O
worldwide	NN	O	O
,	NN	O	O
particularly	NN	O	O
those	NN	O	O
living	NN	O	O
in	NN	O	O
rural	NN	O	O
and	NN	O	O
developing	NN	O	O
areas	NN	O	O
,	NN	O	O
are	NN	O	O
exposed	NN	O	O
to	NN	O	O
harmful	NN	O	O
levels	NN	O	O
of	NN	O	O
inorganic	NN	O	O
arsenic	NN	O	O
(	NN	O	O
iAs	NN	O	O
)	NN	O	O
in	NN	O	O
their	NN	O	O
drinking	NN	O	O
water	NN	O	O
.	NN	O	O

Inorganic	NN	O	O
As	NN	O	O
exposure	NN	O	O
during	NN	O	O
key	NN	O	O
developmental	NN	O	O
periods	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
adverse	NN	O	O
health	NN	O	O
effects	NN	O	O
including	NN	O	O
those	NN	O	O
that	NN	O	O
are	NN	O	O
evident	NN	O	O
in	NN	O	O
adulthood	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
considerable	NN	O	O
interest	NN	O	O
in	NN	O	O
identifying	NN	O	O
the	NN	O	O
molecular	NN	O	O
mechanisms	NN	O	O
that	NN	O	O
relate	NN	O	O
early	NN	O	O
-	NN	O	O
life	NN	O	O
iAs	NN	O	O
exposure	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
these	NN	O	O
latent	NN	O	O
diseases	NN	O	O
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
relationship	NN	O	O
to	NN	O	O
cancer	NN	O	B
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
This	NN	O	O
work	NN	O	O
summarizes	NN	O	O
research	NN	O	O
on	NN	O	O
the	NN	O	O
molecular	NN	O	O
mechanisms	NN	O	O
that	NN	O	O
underlie	NN	O	O
the	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
cancer	NN	O	B
development	NN	O	O
in	NN	O	O
adulthood	NN	O	O
that	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
early	NN	O	O
-	NN	O	O
life	NN	O	O
iAs	NN	O	O
exposure	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Epigenetic	NN	O	O
reprogramming	NN	O	O
that	NN	O	O
imparts	NN	O	O
functional	NN	O	O
changes	NN	O	O
in	NN	O	O
gene	NN	O	O
expression	NN	O	O
,	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
cancer	NN	O	B
stem	NN	O	O
cells	NN	O	O
,	NN	O	O
and	NN	O	O
immunomodulation	NN	O	O
are	NN	O	O
plausible	NN	O	O
underlying	NN	O	O
mechanisms	NN	O	O
by	NN	O	O
which	NN	O	O
early	NN	O	O
-	NN	O	O
life	NN	O	O
iAs	NN	O	O
exposure	NN	O	O
elicits	NN	O	O
latent	NN	O	O
carcinogenic	NN	O	O
effects	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Evidence	NN	O	O
is	NN	O	O
mounting	NN	O	O
that	NN	O	O
relates	NN	O	O
early	NN	O	O
-	NN	O	O
life	NN	O	O
iAs	NN	O	O
exposure	NN	O	O
and	NN	O	O
cancer	NN	O	B
development	NN	O	O
later	NN	O	O
in	NN	O	O
life	NN	O	O
.	NN	O	O

Future	NN	O	O
research	NN	O	O
should	NN	O	O
include	NN	O	O
animal	NN	O	O
studies	NN	O	O
that	NN	O	O
address	NN	O	O
mechanistic	NN	O	O
hypotheses	NN	O	O
and	NN	O	O
studies	NN	O	O
of	NN	O	O
human	NN	O	O
populations	NN	O	O
that	NN	O	O
integrate	NN	O	O
early	NN	O	O
-	NN	O	O
life	NN	O	O
exposure	NN	O	O
,	NN	O	O
molecular	NN	O	O
alterations	NN	O	O
,	NN	O	O
and	NN	O	O
latent	NN	O	O
disease	NN	O	O
outcomes	NN	O	O
.	NN	O	O

Nifedipine	NN	O	O
induced	NN	O	O
bradycardia	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
autonomic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

An	NN	O	O
80	NN	O	O
year	NN	O	O
old	NN	O	O
diabetic	NN	O	B
male	NN	O	O
with	NN	O	O
evidence	NN	O	O
of	NN	O	O
peripheral	NN	O	B
and	NN	O	I
autonomic	NN	O	I
neuropathy	NN	O	I
was	NN	O	O
admitted	NN	O	O
with	NN	O	O
chest	NN	O	B
pain	NN	O	I
.	NN	O	O

He	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
atrial	NN	O	B
flutter	NN	O	I
at	NN	O	O
a	NN	O	O
ventricular	NN	O	O
rate	NN	O	O
of	NN	O	O
70	NN	O	O
/	NN	O	O
min	NN	O	O
which	NN	O	O
slowed	NN	O	O
down	NN	O	O
to	NN	O	O
30	NN	O	O
-	NN	O	O
40	NN	O	O
/	NN	O	O
min	NN	O	O
when	NN	O	O
nifedipine	NN	O	O
(	NN	O	O
60	NN	O	O
mg	NN	O	O
)	NN	O	O
in	NN	O	O
3	NN	O	O
divided	NN	O	O
doses	NN	O	O
,	NN	O	O
during	NN	O	O
which	NN	O	O
he	NN	O	O
was	NN	O	O
paced	NN	O	O
at	NN	O	O
a	NN	O	O
rate	NN	O	O
of	NN	O	O
70	NN	O	O
/	NN	O	O
min	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
inconsistent	NN	O	O
with	NN	O	O
the	NN	O	O
well	NN	O	O
-	NN	O	O
established	NN	O	O
finding	NN	O	O
that	NN	O	O
nifedipine	NN	O	O
induces	NN	O	O
tachycardia	NN	O	B
in	NN	O	O
normally	NN	O	O
innervated	NN	O	O
hearts	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
in	NN	O	O
hearts	NN	O	O
deprived	NN	O	O
of	NN	O	O
compensatory	NN	O	O
sympathetic	NN	O	O
drive	NN	O	O
,	NN	O	O
it	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
bradycardia	NN	O	B
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
haloperidol	NN	O	O
in	NN	O	O
cocaine	NN	O	O
and	NN	O	O
amphetamine	NN	O	O
intoxication	NN	O	O
.	NN	O	O

The	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
haloperidol	NN	O	O
pretreatment	NN	O	O
in	NN	O	O
preventing	NN	O	O
the	NN	O	O
toxic	NN	O	O
effects	NN	O	O
of	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
and	NN	O	O
cocaine	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
model	NN	O	O
,	NN	O	O
toxic	NN	O	O
effects	NN	O	O
were	NN	O	O
induced	NN	O	O
by	NN	O	O
intraperitoneal	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
injection	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
100	NN	O	O
%	NN	O	O
death	NN	O	O
rate	NN	O	O
)	NN	O	O
or	NN	O	O
cocaine	NN	O	O
70	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
82	NN	O	O
%	NN	O	O
death	NN	O	O
rate	NN	O	O
)	NN	O	O
.	NN	O	O

Haloperidol	NN	O	O
failed	NN	O	O
to	NN	O	O
prevent	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
,	NN	O	O
but	NN	O	O
did	NN	O	O
lower	NN	O	O
the	NN	O	O
mortality	NN	O	O
rate	NN	O	O
at	NN	O	O
most	NN	O	O
doses	NN	O	O
tested	NN	O	O
.	NN	O	O

Haloperidol	NN	O	O
decreased	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
at	NN	O	O
the	NN	O	O
two	NN	O	O
highest	NN	O	O
doses	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
lowering	NN	O	O
of	NN	O	O
the	NN	O	O
mortality	NN	O	O
rate	NN	O	O
did	NN	O	O
not	NN	O	O
reach	NN	O	O
statistical	NN	O	O
significance	NN	O	O
at	NN	O	O
any	NN	O	O
dose	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
a	NN	O	O
protective	NN	O	O
role	NN	O	O
for	NN	O	O
the	NN	O	O
central	NN	O	O
dopamine	NN	O	O
blocker	NN	O	O
haloperidol	NN	O	O
against	NN	O	O
death	NN	O	O
from	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
amphetamine	NN	O	O
exposure	NN	O	O
without	NN	O	O
reducing	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
seizures	NN	O	B
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
haloperidol	NN	O	O
demonstrated	NN	O	O
an	NN	O	O
ability	NN	O	O
to	NN	O	O
reduce	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
without	NN	O	O
significantly	NN	O	O
reducing	NN	O	O
mortality	NN	O	O
.	NN	O	O

Autoradiographic	NN	O	O
evidence	NN	O	O
of	NN	O	O
estrogen	NN	O	O
binding	NN	O	O
sites	NN	O	O
in	NN	O	O
nuclei	NN	O	O
of	NN	O	O
diethylstilbesterol	NN	O	O
induced	NN	O	O
hamster	NN	O	O
renal	NN	O	B
carcinomas	NN	O	I
.	NN	O	O

Estrogen	NN	O	O
binding	NN	O	O
sites	NN	O	O
were	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
autoradiography	NN	O	O
in	NN	O	O
one	NN	O	O
transplantable	NN	O	O
and	NN	O	O
five	NN	O	O
primary	NN	O	O
diethylstilbesterol	NN	O	O
induced	NN	O	O
renal	NN	O	B
carcinomas	NN	O	I
in	NN	O	O
three	NN	O	O
hamsters	NN	O	O
.	NN	O	O

Radiolabelling	NN	O	O
,	NN	O	O
following	NN	O	O
the	NN	O	O
in	NN	O	O
vivo	NN	O	O
injection	NN	O	O
of	NN	O	O
3H	NN	O	O
-	NN	O	O
17	NN	O	O
beta	NN	O	O
estradiol	NN	O	O
,	NN	O	O
was	NN	O	O
increased	NN	O	O
only	NN	O	O
over	NN	O	O
the	NN	O	O
nuclei	NN	O	O
of	NN	O	O
tumor	NN	O	B
cells	NN	O	O
;	NN	O	O
stereologic	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
a	NN	O	O
4	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
to	NN	O	O
6	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
times	NN	O	O
higher	NN	O	O
concentration	NN	O	O
of	NN	O	O
reduced	NN	O	O
silver	NN	O	O
grains	NN	O	O
over	NN	O	O
nuclei	NN	O	O
than	NN	O	O
cytoplasm	NN	O	O
of	NN	O	O
these	NN	O	O
cells	NN	O	O
.	NN	O	O

Despite	NN	O	O
rapid	NN	O	O
tubular	NN	O	O
excretion	NN	O	O
of	NN	O	O
estradiol	NN	O	O
which	NN	O	O
peaked	NN	O	O
in	NN	O	O
less	NN	O	O
than	NN	O	O
1	NN	O	O
h	NN	O	O
,	NN	O	O
the	NN	O	O
normal	NN	O	O
cells	NN	O	O
did	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
bind	NN	O	O
the	NN	O	O
ligand	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
published	NN	O	O
report	NN	O	O
documenting	NN	O	O
the	NN	O	O
preferential	NN	O	O
in	NN	O	O
vivo	NN	O	O
binding	NN	O	O
of	NN	O	O
estrogen	NN	O	O
to	NN	O	O
nuclei	NN	O	O
of	NN	O	O
cells	NN	O	O
in	NN	O	O
estrogen	NN	O	O
induced	NN	O	O
hamster	NN	O	O
renal	NN	O	B
carcinomas	NN	O	I
.	NN	O	O

Bradycardia	NN	O	B
due	NN	O	O
to	NN	O	O
biperiden	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
38	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
patient	NN	O	O
suffering	NN	O	O
from	NN	O	O
a	NN	O	O
severe	NN	O	O
postzosteric	NN	O	B
trigeminal	NN	O	B
neuralgia	NN	O	I
,	NN	O	O
intravenous	NN	O	O
application	NN	O	O
of	NN	O	O
10	NN	O	O
mg	NN	O	O
biperiden	NN	O	O
lactate	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
lasting	NN	O	O
paradoxical	NN	O	O
reaction	NN	O	O
characterized	NN	O	O
by	NN	O	O
considerable	NN	O	O
bradycardia	NN	O	B
,	NN	O	O
dysarthria	NN	O	B
,	NN	O	O
and	NN	O	O
dysphagia	NN	O	B
.	NN	O	O

The	NN	O	O
heart	NN	O	O
rate	NN	O	O
was	NN	O	O
back	NN	O	O
to	NN	O	O
normal	NN	O	O
within	NN	O	O
12	NN	O	O
hours	NN	O	O
upon	NN	O	O
administration	NN	O	O
of	NN	O	O
orciprenaline	NN	O	O
under	NN	O	O
cardiac	NN	O	O
monitoring	NN	O	O
in	NN	O	O
an	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
.	NN	O	O

Bradycardia	NN	O	B
induced	NN	O	O
by	NN	O	O
biperiden	NN	O	O
is	NN	O	O
attributed	NN	O	O
to	NN	O	O
the	NN	O	O
speed	NN	O	O
of	NN	O	O
injection	NN	O	O
and	NN	O	O
to	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
related	NN	O	O
dual	NN	O	O
effect	NN	O	O
of	NN	O	O
atropine	NN	O	O
-	NN	O	O
like	NN	O	O
drugs	NN	O	O
on	NN	O	O
muscarine	NN	O	O
receptors	NN	O	O
.	NN	O	O

Deliberate	NN	O	O
hypotension	NN	O	B
induced	NN	O	O
by	NN	O	O
labetalol	NN	O	O
with	NN	O	O
halothane	NN	O	O
,	NN	O	O
enflurane	NN	O	O
or	NN	O	O
isoflurane	NN	O	O
for	NN	O	O
middle	NN	O	O
-	NN	O	O
ear	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
feasibility	NN	O	O
of	NN	O	O
using	NN	O	O
labetalol	NN	O	O
,	NN	O	O
an	NN	O	O
alpha	NN	O	O
-	NN	O	O
and	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
blocking	NN	O	O
agent	NN	O	O
,	NN	O	O
as	NN	O	O
a	NN	O	O
hypotensive	NN	O	B
agent	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
inhalation	NN	O	O
anaesthetics	NN	O	O
(	NN	O	O
halothane	NN	O	O
,	NN	O	O
enflurane	NN	O	O
or	NN	O	O
isoflurane	NN	O	O
)	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
23	NN	O	O
adult	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
middle	NN	O	O
-	NN	O	O
ear	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
was	NN	O	O
decreased	NN	O	O
from	NN	O	O
86	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
(	NN	O	O
s	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
mean	NN	O	O
)	NN	O	O
mmHg	NN	O	O
to	NN	O	O
52	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
mmHg	NN	O	O
(	NN	O	O
11	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
to	NN	O	O
6	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
kPa	NN	O	O
)	NN	O	O
for	NN	O	O
98	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
min	NN	O	O
in	NN	O	O
the	NN	O	O
halothane	NN	O	O
(	NN	O	O
H	NN	O	O
)	NN	O	O
group	NN	O	O
,	NN	O	O
from	NN	O	O
79	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
to	NN	O	O
53	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
mmHg	NN	O	O
(	NN	O	O
10	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
to	NN	O	O
7	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
kPa	NN	O	O
)	NN	O	O
for	NN	O	O
129	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
11	NN	O	O
min	NN	O	O
in	NN	O	O
the	NN	O	O
enflurane	NN	O	O
(	NN	O	O
E	NN	O	O
)	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
from	NN	O	O
80	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
to	NN	O	O
49	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
mmHg	NN	O	O
(	NN	O	O
10	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
to	NN	O	O
6	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
kPa	NN	O	O
)	NN	O	O
for	NN	O	O
135	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
15	NN	O	O
min	NN	O	O
in	NN	O	O
the	NN	O	O
isoflurane	NN	O	O
(	NN	O	O
I	NN	O	O
)	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
H	NN	O	O
concentration	NN	O	O
during	NN	O	O
hypotension	NN	O	B
in	NN	O	O
the	NN	O	O
inspiratory	NN	O	O
gas	NN	O	O
was	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
vol	NN	O	O
%	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
E	NN	O	O
concentration	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
vol	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
mean	NN	O	O
I	NN	O	O
concentration	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
vol	NN	O	O
%	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
patients	NN	O	O
received	NN	O	O
fentanyl	NN	O	O
and	NN	O	O
d	NN	O	O
-	NN	O	O
tubocurarine	NN	O	O
.	NN	O	O

The	NN	O	O
initial	NN	O	O
dose	NN	O	O
of	NN	O	O
labetalol	NN	O	O
for	NN	O	O
lowering	NN	O	O
blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
similar	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
52	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
59	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
in	NN	O	O
all	NN	O	O
the	NN	O	O
groups	NN	O	O
.	NN	O	O

During	NN	O	O
hypotension	NN	O	B
,	NN	O	O
the	NN	O	O
heart	NN	O	O
rate	NN	O	O
was	NN	O	O
stable	NN	O	O
without	NN	O	O
tachy	NN	O	B
-	NN	O	I
or	NN	O	I
bradycardia	NN	O	I
.	NN	O	O

The	NN	O	O
operating	NN	O	O
conditions	NN	O	O
regarding	NN	O	O
bleeding	NN	O	B
were	NN	O	O
estimated	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
manner	NN	O	O
,	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
between	NN	O	O
the	NN	O	O
groups	NN	O	O
.	NN	O	O

During	NN	O	O
hypotension	NN	O	B
,	NN	O	O
the	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
concentration	NN	O	O
rose	NN	O	O
significantly	NN	O	O
in	NN	O	O
all	NN	O	O
groups	NN	O	O
from	NN	O	O
the	NN	O	O
values	NN	O	O
before	NN	O	O
hypotension	NN	O	B
and	NN	O	O
returned	NN	O	O
postoperatively	NN	O	O
to	NN	O	O
the	NN	O	O
initial	NN	O	O
level	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
groups	NN	O	O
,	NN	O	O
except	NN	O	O
the	NN	O	O
isoflurane	NN	O	O
group	NN	O	O
.	NN	O	O

After	NN	O	O
hypotension	NN	O	B
there	NN	O	O
was	NN	O	O
no	NN	O	O
rebound	NN	O	O
phenomenon	NN	O	O
in	NN	O	O
either	NN	O	O
blood	NN	O	O
pressure	NN	O	O
or	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
labetalol	NN	O	O
induces	NN	O	O
easily	NN	O	O
adjustable	NN	O	O
hypotension	NN	O	B
without	NN	O	O
compensatory	NN	O	O
tachycardia	NN	O	B
and	NN	O	O
rebound	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Convulsion	NN	O	B
following	NN	O	O
intravenous	NN	O	O
fluorescein	NN	O	O
angiography	NN	O	O
.	NN	O	O

Tonic	NN	O	B
-	NN	O	I
clonic	NN	O	I
seizures	NN	O	I
followed	NN	O	O
intravenous	NN	O	O
fluorescein	NN	O	O
injection	NN	O	O
for	NN	O	O
fundus	NN	O	O
angiography	NN	O	O
in	NN	O	O
a	NN	O	O
47	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
.	NN	O	O

Despite	NN	O	O
precautions	NN	O	O
this	NN	O	O
adverse	NN	O	O
reaction	NN	O	O
recurred	NN	O	O
on	NN	O	O
re	NN	O	O
-	NN	O	O
exposure	NN	O	O
to	NN	O	O
intravenous	NN	O	O
fluorescein	NN	O	O
.	NN	O	O

Pharmacology	NN	O	O
of	NN	O	O
ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
(	NN	O	O
phenytoin	NN	O	O
prodrug	NN	O	O
)	NN	O	O
.	NN	O	O

ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
,	NN	O	O
the	NN	O	O
disodium	NN	O	O
phosphate	NN	O	O
ester	NN	O	O
of	NN	O	O
3	NN	O	O
-	NN	O	O
hydroxymethyl	NN	O	O
-	NN	O	O
5	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
diphenylhydantoin	NN	O	O
,	NN	O	O
is	NN	O	O
a	NN	O	O
prodrug	NN	O	O
of	NN	O	O
phenytoin	NN	O	O
with	NN	O	O
advantageous	NN	O	O
physicochemical	NN	O	O
properties	NN	O	O
.	NN	O	O

ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
is	NN	O	O
rapidly	NN	O	O
converted	NN	O	O
enzymatically	NN	O	O
to	NN	O	O
phenytoin	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
and	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
have	NN	O	O
equivalent	NN	O	O
anticonvulsant	NN	O	O
activity	NN	O	O
against	NN	O	O
seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
maximal	NN	O	O
electroshock	NN	O	O
(	NN	O	O
MES	NN	O	O
)	NN	O	O
in	NN	O	O
mice	NN	O	O
following	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
,	NN	O	O
oral	NN	O	O
,	NN	O	O
or	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
administration	NN	O	O
.	NN	O	O

The	NN	O	O
ED50	NN	O	O
doses	NN	O	O
were	NN	O	O
16	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
and	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
.	NN	O	O

ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
and	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
have	NN	O	O
similar	NN	O	O
antiarrhythmic	NN	O	O
activity	NN	O	O
against	NN	O	O
ouabain	NN	O	O
-	NN	O	O
induced	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
in	NN	O	O
anesthetized	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
total	NN	O	O
doses	NN	O	O
of	NN	O	O
ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
or	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
necessary	NN	O	O
to	NN	O	O
convert	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B
to	NN	O	O
a	NN	O	O
normal	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
were	NN	O	O
24	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
and	NN	O	O
14	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Only	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
displayed	NN	O	O
in	NN	O	O
vitro	NN	O	O
antiarrhythmic	NN	O	O
activity	NN	O	O
against	NN	O	O
strophanthidin	NN	O	O
-	NN	O	O
induced	NN	O	O
arrhythmias	NN	O	B
in	NN	O	O
guinea	NN	O	O
pig	NN	O	O
right	NN	O	O
atria	NN	O	O
.	NN	O	O

In	NN	O	O
anesthetized	NN	O	O
dogs	NN	O	O
,	NN	O	O
a	NN	O	O
high	NN	O	O
dose	NN	O	O
of	NN	O	O
ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
(	NN	O	O
31	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
infused	NN	O	O
over	NN	O	O
15	NN	O	O
,	NN	O	O
20	NN	O	O
,	NN	O	O
and	NN	O	O
30	NN	O	O
min	NN	O	O
and	NN	O	O
the	NN	O	O
responses	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
an	NN	O	O
equimolar	NN	O	O
dose	NN	O	O
of	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
(	NN	O	O
21	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
and	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
treatments	NN	O	O
produced	NN	O	O
similar	NN	O	O
marked	NN	O	O
reductions	NN	O	O
in	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
contractile	NN	O	O
force	NN	O	O
(	NN	O	O
LVdP	NN	O	O
/	NN	O	O
dt	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
maximum	NN	O	O
effects	NN	O	O
of	NN	O	O
each	NN	O	O
treatment	NN	O	O
occurred	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
maximum	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
levels	NN	O	O
.	NN	O	O

Acute	NN	O	O
toxicity	NN	O	B
studies	NN	O	O
of	NN	O	O
ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
and	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
were	NN	O	O
carried	NN	O	O
out	NN	O	O
in	NN	O	O
mice	NN	O	O
,	NN	O	O
rats	NN	O	O
,	NN	O	O
rabbits	NN	O	O
,	NN	O	O
and	NN	O	O
dogs	NN	O	O
by	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
,	NN	O	O
and	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
routes	NN	O	O
of	NN	O	O
administration	NN	O	O
.	NN	O	O

The	NN	O	O
systemic	NN	O	O
toxic	NN	O	O
signs	NN	O	O
of	NN	O	O
both	NN	O	O
agents	NN	O	O
were	NN	O	O
similar	NN	O	O
and	NN	O	O
occurred	NN	O	O
at	NN	O	O
approximately	NN	O	O
equivalent	NN	O	O
doses	NN	O	O
.	NN	O	O

Importantly	NN	O	O
,	NN	O	O
the	NN	O	O
local	NN	O	O
irritation	NN	O	O
of	NN	O	O
ACC	NN	O	O
-	NN	O	O
9653	NN	O	O
was	NN	O	O
markedly	NN	O	O
less	NN	O	O
than	NN	O	O
phenytoin	NN	O	O
sodium	NN	O	O
following	NN	O	O
i	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
administration	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Tachyphylaxis	NN	O	O
to	NN	O	O
systemic	NN	O	O
but	NN	O	O
not	NN	O	O
to	NN	O	O
airway	NN	O	O
responses	NN	O	O
during	NN	O	O
prolonged	NN	O	O
therapy	NN	O	O
with	NN	O	O
high	NN	O	O
dose	NN	O	O
inhaled	NN	O	O
salbutamol	NN	O	O
in	NN	O	O
asthmatics	NN	O	B
.	NN	O	O

High	NN	O	O
doses	NN	O	O
of	NN	O	O
inhaled	NN	O	O
salbutamol	NN	O	O
produce	NN	O	O
substantial	NN	O	O
improvements	NN	O	O
in	NN	O	O
airway	NN	O	O
response	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
asthma	NN	O	B
,	NN	O	O
and	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
systemic	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
responses	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
tachyphylaxis	NN	O	O
occurs	NN	O	O
during	NN	O	O
prolonged	NN	O	O
treatment	NN	O	O
with	NN	O	O
high	NN	O	O
dose	NN	O	O
inhaled	NN	O	O
salbutamol	NN	O	O
.	NN	O	O

Twelve	NN	O	O
asthmatic	NN	O	B
patients	NN	O	O
(	NN	O	O
FEV1	NN	O	O
,	NN	O	O
81	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
%	NN	O	O
predicted	NN	O	O
)	NN	O	O
,	NN	O	O
requiring	NN	O	O
only	NN	O	O
occasional	NN	O	O
inhaled	NN	O	O
beta	NN	O	O
-	NN	O	O
agonists	NN	O	O
as	NN	O	O
their	NN	O	O
sole	NN	O	O
therapy	NN	O	O
,	NN	O	O
were	NN	O	O
given	NN	O	O
a	NN	O	O
14	NN	O	O
-	NN	O	O
day	NN	O	O
treatment	NN	O	O
with	NN	O	O
high	NN	O	O
dose	NN	O	O
inhaled	NN	O	O
salbutamol	NN	O	O
(	NN	O	O
HDS	NN	O	O
)	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
000	NN	O	O
micrograms	NN	O	O
daily	NN	O	O
,	NN	O	O
low	NN	O	O
dose	NN	O	O
inhaled	NN	O	O
salbutamol	NN	O	O
(	NN	O	O
LDS	NN	O	O
)	NN	O	O
,	NN	O	O
800	NN	O	O
micrograms	NN	O	O
daily	NN	O	O
,	NN	O	O
or	NN	O	O
placebo	NN	O	O
(	NN	O	O
PI	NN	O	O
)	NN	O	O
by	NN	O	O
metered	NN	O	O
-	NN	O	O
dose	NN	O	O
inhaler	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
crossover	NN	O	O
design	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
14	NN	O	O
-	NN	O	O
day	NN	O	O
run	NN	O	O
-	NN	O	O
in	NN	O	O
and	NN	O	O
during	NN	O	O
washout	NN	O	O
periods	NN	O	O
,	NN	O	O
inhaled	NN	O	O
beta	NN	O	O
-	NN	O	O
agonists	NN	O	O
were	NN	O	O
withheld	NN	O	O
and	NN	O	O
ipratropium	NN	O	O
bromide	NN	O	O
was	NN	O	O
substituted	NN	O	O
for	NN	O	O
rescue	NN	O	O
purposes	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
each	NN	O	O
14	NN	O	O
-	NN	O	O
day	NN	O	O
treatment	NN	O	O
,	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
curve	NN	O	O
(	NN	O	O
DRC	NN	O	O
)	NN	O	O
was	NN	O	O
performed	NN	O	O
,	NN	O	O
and	NN	O	O
airway	NN	O	O
(	NN	O	O
FEV1	NN	O	O
,	NN	O	O
FEF25	NN	O	O
-	NN	O	O
75	NN	O	O
)	NN	O	O
chronotropic	NN	O	O
(	NN	O	O
HR	NN	O	O
)	NN	O	O
,	NN	O	O
tremor	NN	O	B
,	NN	O	O
and	NN	O	O
metabolic	NN	O	O
(	NN	O	O
K	NN	O	O
,	NN	O	O
Glu	NN	O	O
)	NN	O	O
responses	NN	O	O
were	NN	O	O
measured	NN	O	O
at	NN	O	O
each	NN	O	O
step	NN	O	O
(	NN	O	O
from	NN	O	O
100	NN	O	O
to	NN	O	O
4	NN	O	O
,	NN	O	O
000	NN	O	O
micrograms	NN	O	O
)	NN	O	O
.	NN	O	O

Treatment	NN	O	O
had	NN	O	O
no	NN	O	O
significant	NN	O	O
effect	NN	O	O
on	NN	O	O
baseline	NN	O	O
values	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
increases	NN	O	O
in	NN	O	O
FEV1	NN	O	O
and	NN	O	O
FEF25	NN	O	O
-	NN	O	O
75	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
HDS	NN	O	O
did	NN	O	O
not	NN	O	O
displace	NN	O	O
the	NN	O	O
DRC	NN	O	O
to	NN	O	O
the	NN	O	O
right	NN	O	O
.	NN	O	O

DRC	NN	O	O
for	NN	O	O
HR	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
K	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
Glu	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
were	NN	O	O
attenuated	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
HDS	NN	O	O
compared	NN	O	O
with	NN	O	O
PI	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
also	NN	O	O
differences	NN	O	O
between	NN	O	O
HDS	NN	O	O
and	NN	O	O
LDS	NN	O	O
for	NN	O	O
HR	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
and	NN	O	O
Glu	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
responses	NN	O	O
.	NN	O	O

Frequency	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
subjective	NN	O	O
adverse	NN	O	O
effects	NN	O	O
were	NN	O	O
also	NN	O	O
reduced	NN	O	O
after	NN	O	O
HDS	NN	O	O
:	NN	O	O
tremor	NN	O	B
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
palpitations	NN	O	B
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Phenytoin	NN	O	O
induced	NN	O	O
fatal	NN	O	O
hepatic	NN	O	B
injury	NN	O	I
.	NN	O	O

A	NN	O	O
61	NN	O	O
year	NN	O	O
old	NN	O	O
female	NN	O	O
developed	NN	O	O
fatal	NN	O	O
hepatic	NN	O	B
failure	NN	O	I
after	NN	O	O
phenytoin	NN	O	O
administration	NN	O	O
.	NN	O	O

A	NN	O	O
typical	NN	O	O
multisystem	NN	O	O
clinical	NN	O	O
pattern	NN	O	O
precedes	NN	O	O
the	NN	O	O
manifestations	NN	O	O
of	NN	O	O
hepatic	NN	O	B
injury	NN	O	I
.	NN	O	O

The	NN	O	O
hematologic	NN	O	O
,	NN	O	O
biochemical	NN	O	O
and	NN	O	O
pathologic	NN	O	O
features	NN	O	O
indicate	NN	O	O
a	NN	O	O
mixed	NN	O	O
hepatocellular	NN	O	B
damage	NN	O	I
due	NN	O	O
to	NN	O	O
drug	NN	O	B
hypersensitivity	NN	O	I
.	NN	O	O

In	NN	O	O
a	NN	O	O
patient	NN	O	O
receiving	NN	O	O
phenytoin	NN	O	O
who	NN	O	O
presents	NN	O	O
a	NN	O	O
viral	NN	O	O
-	NN	O	O
like	NN	O	O
illness	NN	O	O
,	NN	O	O
early	NN	O	O
recognition	NN	O	O
and	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
are	NN	O	O
mandatory	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
lethal	NN	O	O
pertussis	NN	O	O
vaccine	NN	O	O
reaction	NN	O	O
with	NN	O	O
histamine	NN	O	O
H1	NN	O	O
antagonists	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
mortality	NN	O	O
after	NN	O	O
pertussis	NN	O	B
immunization	NN	O	O
in	NN	O	O
the	NN	O	O
mouse	NN	O	O
.	NN	O	O

Without	NN	O	O
treatment	NN	O	O
,	NN	O	O
73	NN	O	O
of	NN	O	O
92	NN	O	O
animals	NN	O	O
(	NN	O	O
80	NN	O	O
%	NN	O	O
)	NN	O	O
died	NN	O	O
after	NN	O	O
injection	NN	O	O
of	NN	O	O
bovine	NN	O	O
serum	NN	O	O
albumin	NN	O	O
(	NN	O	O
BSA	NN	O	O
)	NN	O	O
on	NN	O	O
day	NN	O	O
+	NN	O	O
7	NN	O	O
of	NN	O	O
pertussis	NN	O	B
immunization	NN	O	O
.	NN	O	O

After	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
3	NN	O	O
mg	NN	O	O
of	NN	O	O
cyproheptadine	NN	O	O
,	NN	O	O
2	NN	O	O
mg	NN	O	O
mianserin	NN	O	O
,	NN	O	O
or	NN	O	O
2	NN	O	O
mg	NN	O	O
chlorpheniramine	NN	O	O
,	NN	O	O
only	NN	O	O
5	NN	O	O
of	NN	O	O
105	NN	O	O
animals	NN	O	O
(	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
died	NN	O	O
after	NN	O	O
receiving	NN	O	O
BSA	NN	O	O
on	NN	O	O
day	NN	O	O
+	NN	O	O
7	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Blockade	NN	O	O
of	NN	O	O
histamine	NN	O	O
H1	NN	O	O
receptors	NN	O	O
may	NN	O	O
reduce	NN	O	O
mortality	NN	O	O
in	NN	O	O
pertussis	NN	O	B
immunization	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Support	NN	O	O
for	NN	O	O
adrenaline	NN	O	O
-	NN	O	O
hypertension	NN	O	B
hypothesis	NN	O	O
:	NN	O	O
18	NN	O	O
hour	NN	O	O
pressor	NN	O	O
effect	NN	O	O
after	NN	O	O
6	NN	O	O
hours	NN	O	O
adrenaline	NN	O	O
infusion	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
double	NN	O	O
blind	NN	O	O
,	NN	O	O
crossover	NN	O	O
study	NN	O	O
6	NN	O	O
h	NN	O	O
infusions	NN	O	O
of	NN	O	O
adrenaline	NN	O	O
(	NN	O	O
15	NN	O	O
ng	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
;	NN	O	O
1	NN	O	O
ng	NN	O	O
=	NN	O	O
5	NN	O	O
.	NN	O	O
458	NN	O	O
pmol	NN	O	O
)	NN	O	O
,	NN	O	O
noradrenaline	NN	O	O
(	NN	O	O
30	NN	O	O
ng	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
;	NN	O	O
1	NN	O	O
ng	NN	O	O
=	NN	O	O
5	NN	O	O
.	NN	O	O
911	NN	O	O
pmol	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
5	NN	O	O
%	NN	O	O
dextrose	NN	O	O
solution	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
4	NN	O	O
ml	NN	O	O
/	NN	O	O
h	NN	O	O
)	NN	O	O
,	NN	O	O
were	NN	O	O
given	NN	O	O
to	NN	O	O
ten	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
in	NN	O	O
random	NN	O	O
order	NN	O	O
2	NN	O	O
weeks	NN	O	O
apart	NN	O	O
.	NN	O	O

By	NN	O	O
means	NN	O	O
of	NN	O	O
intra	NN	O	O
-	NN	O	O
arterial	NN	O	O
ambulatory	NN	O	O
monitoring	NN	O	O
the	NN	O	O
haemodynamic	NN	O	O
effects	NN	O	O
were	NN	O	O
followed	NN	O	O
for	NN	O	O
18	NN	O	O
h	NN	O	O
after	NN	O	O
the	NN	O	O
infusions	NN	O	O
were	NN	O	O
stopped	NN	O	O
.	NN	O	O

Adrenaline	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
noradrenaline	NN	O	O
,	NN	O	O
caused	NN	O	O
a	NN	O	O
delayed	NN	O	O
and	NN	O	O
protracted	NN	O	O
pressor	NN	O	O
effect	NN	O	O
.	NN	O	O

Over	NN	O	O
the	NN	O	O
total	NN	O	O
postinfusion	NN	O	O
period	NN	O	O
systolic	NN	O	O
and	NN	O	O
diastolic	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
were	NN	O	O
6	NN	O	O
(	NN	O	O
SEM	NN	O	O
2	NN	O	O
)	NN	O	O
%	NN	O	O
and	NN	O	O
7	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
higher	NN	O	O
than	NN	O	O
after	NN	O	O
dextrose	NN	O	O
infusion	NN	O	O
(	NN	O	O
ANOVA	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
"	NN	O	O
stress	NN	O	O
"	NN	O	O
levels	NN	O	O
of	NN	O	O
adrenaline	NN	O	O
(	NN	O	O
230	NN	O	O
pg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
for	NN	O	O
6	NN	O	O
h	NN	O	O
cause	NN	O	O
a	NN	O	O
delayed	NN	O	O
and	NN	O	O
protracted	NN	O	O
pressor	NN	O	O
effect	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
are	NN	O	O
strong	NN	O	O
support	NN	O	O
for	NN	O	O
the	NN	O	O
adrenaline	NN	O	O
-	NN	O	O
hypertension	NN	O	B
hypothesis	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
alkylxanthines	NN	O	O
on	NN	O	O
gentamicin	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Adenosine	NN	O	O
antagonists	NN	O	O
have	NN	O	O
been	NN	O	O
previously	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
of	NN	O	O
benefit	NN	O	O
in	NN	O	O
some	NN	O	O
ischaemic	NN	O	B
and	NN	O	O
nephrotoxic	NN	O	B
models	NN	O	O
of	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
(	NN	O	O
ARF	NN	O	B
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
three	NN	O	O
alkylxanthines	NN	O	O
with	NN	O	O
different	NN	O	O
potencies	NN	O	O
as	NN	O	O
adenosine	NN	O	O
antagonists	NN	O	O
8	NN	O	O
-	NN	O	O
phenyltheophylline	NN	O	O
,	NN	O	O
theophylline	NN	O	O
and	NN	O	O
enprofylline	NN	O	O
,	NN	O	O
were	NN	O	O
examined	NN	O	O
in	NN	O	O
rats	NN	O	O
developing	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
after	NN	O	O
4	NN	O	O
daily	NN	O	O
injections	NN	O	O
of	NN	O	O
gentamicin	NN	O	O
(	NN	O	O
200	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

Renal	NN	O	O
function	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
biochemical	NN	O	O
(	NN	O	O
plasma	NN	O	O
urea	NN	O	O
and	NN	O	O
creatinine	NN	O	O
)	NN	O	O
,	NN	O	O
functional	NN	O	O
(	NN	O	O
urine	NN	O	O
analysis	NN	O	O
and	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
inulin	NN	O	O
and	NN	O	O
[	NN	O	O
14C	NN	O	O
]	NN	O	O
p	NN	O	O
-	NN	O	O
aminohippuric	NN	O	O
acid	NN	O	O
clearances	NN	O	O
)	NN	O	O
and	NN	O	O
morphological	NN	O	O
(	NN	O	O
degree	NN	O	O
of	NN	O	O
necrosis	NN	O	B
)	NN	O	O
indices	NN	O	O
.	NN	O	O

The	NN	O	O
various	NN	O	O
drug	NN	O	O
treatments	NN	O	O
produced	NN	O	O
improvements	NN	O	O
in	NN	O	O
some	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
all	NN	O	O
,	NN	O	O
measurements	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
any	NN	O	O
improvement	NN	O	O
produced	NN	O	O
by	NN	O	O
drug	NN	O	O
treatment	NN	O	O
was	NN	O	O
largely	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
a	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
exerted	NN	O	O
by	NN	O	O
its	NN	O	O
vehicle	NN	O	O
(	NN	O	O
polyethylene	NN	O	O
glycol	NN	O	O
and	NN	O	O
NaOH	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
lack	NN	O	O
of	NN	O	O
any	NN	O	O
consistent	NN	O	O
protective	NN	O	O
effect	NN	O	O
noted	NN	O	O
with	NN	O	O
the	NN	O	O
alkylxanthines	NN	O	O
tested	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
indicates	NN	O	O
that	NN	O	O
adenosine	NN	O	O
plays	NN	O	O
little	NN	O	O
,	NN	O	O
if	NN	O	O
any	NN	O	O
,	NN	O	O
pathophysiological	NN	O	O
role	NN	O	O
in	NN	O	O
gentamicin	NN	O	O
-	NN	O	O
induced	NN	O	O
ARF	NN	O	B
.	NN	O	O

Adverse	NN	O	O
ocular	NN	O	O
reactions	NN	O	O
possibly	NN	O	O
associated	NN	O	O
with	NN	O	O
isotretinoin	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
261	NN	O	O
adverse	NN	O	O
ocular	NN	O	O
reactions	NN	O	O
occurred	NN	O	O
in	NN	O	O
237	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
isotretinoin	NN	O	O
,	NN	O	O
a	NN	O	O
commonly	NN	O	O
used	NN	O	O
drug	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
severe	NN	O	O
cystic	NN	O	O
acne	NN	O	B
.	NN	O	O

Blepharoconjunctivitis	NN	O	B
,	NN	O	O
subjective	NN	O	O
complaints	NN	O	O
of	NN	O	O
dry	NN	O	B
eyes	NN	O	I
,	NN	O	O
blurred	NN	O	B
vision	NN	O	I
,	NN	O	O
contact	NN	O	O
lens	NN	O	O
intolerance	NN	O	O
,	NN	O	O
and	NN	O	O
photodermatitis	NN	O	B
are	NN	O	O
reversible	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

More	NN	O	O
serious	NN	O	O
ocular	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
include	NN	O	O
papilledema	NN	O	B
,	NN	O	O
pseudotumor	NN	O	B
cerebri	NN	O	I
,	NN	O	O
and	NN	O	O
white	NN	O	O
or	NN	O	O
gray	NN	O	O
subepithelial	NN	O	O
corneal	NN	O	B
opacities	NN	O	I
;	NN	O	O
all	NN	O	O
of	NN	O	O
these	NN	O	O
are	NN	O	O
reversible	NN	O	O
if	NN	O	O
the	NN	O	O
drug	NN	O	O
is	NN	O	O
discontinued	NN	O	O
.	NN	O	O

Reported	NN	O	O
cases	NN	O	O
of	NN	O	O
decreased	NN	O	O
dark	NN	O	O
adaptation	NN	O	O
are	NN	O	O
under	NN	O	O
investigation	NN	O	O
.	NN	O	O

Isotretinoin	NN	O	O
is	NN	O	O
contraindicated	NN	O	O
in	NN	O	O
pregnancy	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
many	NN	O	O
reported	NN	O	O
congenital	NN	O	B
abnormalities	NN	O	I
after	NN	O	O
maternal	NN	O	O
use	NN	O	O
(	NN	O	O
including	NN	O	O
microphthalmos	NN	O	B
,	NN	O	O
orbital	NN	O	O
hypertelorism	NN	O	B
,	NN	O	O
and	NN	O	O
optic	NN	O	B
nerve	NN	O	I
hypoplasia	NN	O	I
)	NN	O	O
.	NN	O	O

Procaterol	NN	O	O
and	NN	O	O
terbutaline	NN	O	O
in	NN	O	O
bronchial	NN	O	B
asthma	NN	O	I
.	NN	O	O

A	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
cross	NN	O	O
-	NN	O	O
over	NN	O	O
study	NN	O	O
.	NN	O	O

Procaterol	NN	O	O
,	NN	O	O
a	NN	O	O
new	NN	O	O
beta	NN	O	O
-	NN	O	O
2	NN	O	O
adrenoceptor	NN	O	O
stimulant	NN	O	O
,	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
cross	NN	O	O
-	NN	O	O
over	NN	O	O
trial	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
bronchial	NN	O	B
asthma	NN	O	I
.	NN	O	O

Oral	NN	O	O
procaterol	NN	O	O
50	NN	O	O
micrograms	NN	O	O
b	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O
,	NN	O	O
procaterol	NN	O	O
100	NN	O	O
micrograms	NN	O	O
b	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O
,	NN	O	O
and	NN	O	O
terbutaline	NN	O	O
5	NN	O	O
mg	NN	O	O
t	NN	O	O
.	NN	O	O
i	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O
,	NN	O	O
were	NN	O	O
compared	NN	O	O
when	NN	O	O
given	NN	O	O
randomly	NN	O	O
in	NN	O	O
1	NN	O	O
-	NN	O	O
week	NN	O	O
treatment	NN	O	O
periods	NN	O	O
.	NN	O	O

The	NN	O	O
best	NN	O	O
clinical	NN	O	O
effect	NN	O	O
was	NN	O	O
found	NN	O	O
with	NN	O	O
terbutaline	NN	O	O
.	NN	O	O

Both	NN	O	O
anti	NN	O	O
-	NN	O	O
asthmatic	NN	O	B
and	NN	O	O
tremorgenic	NN	O	B
effects	NN	O	O
of	NN	O	O
procaterol	NN	O	O
were	NN	O	O
dose	NN	O	O
-	NN	O	O
related	NN	O	O
.	NN	O	O

Procaterol	NN	O	O
appeared	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
doses	NN	O	O
tested	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
twice	NN	O	O
daily	NN	O	O
regimen	NN	O	O
would	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
suitable	NN	O	O
with	NN	O	O
this	NN	O	O
drug	NN	O	O
.	NN	O	O

Subacute	NN	O	O
effects	NN	O	O
of	NN	O	O
propranolol	NN	O	O
and	NN	O	O
B	NN	O	O
24	NN	O	O
/	NN	O	O
76	NN	O	O
on	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
rat	NN	O	O
heart	NN	O	B
hypertrophy	NN	O	I
in	NN	O	O
correlation	NN	O	O
with	NN	O	O
blood	NN	O	O
pressure	NN	O	O
.	NN	O	O

We	NN	O	O
compared	NN	O	O
the	NN	O	O
potential	NN	O	O
beta	NN	O	O
-	NN	O	O
receptor	NN	O	O
blocker	NN	O	O
,	NN	O	O
B	NN	O	O
24	NN	O	O
/	NN	O	O
76	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
(	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dichlorophenoxy	NN	O	O
)	NN	O	O
-	NN	O	O
3	NN	O	O
[	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dimethoxyphenyl	NN	O	O
)	NN	O	O
ethanolamino	NN	O	O
]	NN	O	O
-	NN	O	O
prop	NN	O	O
an	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
ol	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
beta	NN	O	O
1	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
blocking	NN	O	O
and	NN	O	O
beta	NN	O	O
2	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
stimulating	NN	O	O
properties	NN	O	O
with	NN	O	O
propranolol	NN	O	O
.	NN	O	O

The	NN	O	O
studies	NN	O	O
were	NN	O	O
performed	NN	O	O
using	NN	O	O
an	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
heart	NN	O	B
hypertrophy	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

A	NN	O	O
correlation	NN	O	O
of	NN	O	O
the	NN	O	O
blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
neither	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
nor	NN	O	O
in	NN	O	O
the	NN	O	O
attempt	NN	O	O
to	NN	O	O
suppress	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
heart	NN	O	B
hypertrophy	NN	O	I
with	NN	O	O
the	NN	O	O
two	NN	O	O
beta	NN	O	O
-	NN	O	O
receptor	NN	O	O
blockers	NN	O	O
.	NN	O	O

Both	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
influenced	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
hypertrophy	NN	O	B
to	NN	O	O
a	NN	O	O
different	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
reproducible	NN	O	O
extent	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
possible	NN	O	O
to	NN	O	O
suppress	NN	O	O
the	NN	O	O
increased	NN	O	O
ornithine	NN	O	O
decarboxylase	NN	O	O
activity	NN	O	O
with	NN	O	O
both	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
in	NN	O	O
hypertrophied	NN	O	B
hearts	NN	O	I
,	NN	O	O
but	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
heart	NN	O	O
mass	NN	O	O
.	NN	O	O

Neither	NN	O	O
propranolol	NN	O	O
nor	NN	O	O
B	NN	O	O
24	NN	O	O
/	NN	O	O
76	NN	O	O
could	NN	O	O
stop	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
characteristic	NN	O	O
myosin	NN	O	O
isoenzyme	NN	O	O
pattern	NN	O	O
of	NN	O	O
the	NN	O	O
hypertrophied	NN	O	B
rat	NN	O	O
heart	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
investigations	NN	O	O
did	NN	O	O
not	NN	O	O
provide	NN	O	O
any	NN	O	O
evidence	NN	O	O
that	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
receptor	NN	O	O
blockers	NN	O	O
propranolol	NN	O	O
and	NN	O	O
B	NN	O	O
24	NN	O	O
/	NN	O	O
76	NN	O	O
have	NN	O	O
the	NN	O	O
potency	NN	O	O
to	NN	O	O
prevent	NN	O	O
isoproterenol	NN	O	O
from	NN	O	O
producing	NN	O	O
heart	NN	O	B
hypertrophy	NN	O	I
.	NN	O	O

Increased	NN	O	O
anxiogenic	NN	O	O
effects	NN	O	O
of	NN	O	O
caffeine	NN	O	O
in	NN	O	O
panic	NN	O	B
disorders	NN	O	I
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
caffeine	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
on	NN	O	O
behavioral	NN	O	O
ratings	NN	O	O
,	NN	O	O
somatic	NN	O	O
symptoms	NN	O	O
,	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
3	NN	O	O
-	NN	O	O
methoxy	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
hydroxyphenethyleneglycol	NN	O	O
(	NN	O	O
MHPG	NN	O	O
)	NN	O	O
and	NN	O	O
cortisol	NN	O	O
were	NN	O	O
determined	NN	O	O
in	NN	O	O
17	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
and	NN	O	O
21	NN	O	O
patients	NN	O	O
meeting	NN	O	O
DSM	NN	O	O
-	NN	O	O
III	NN	O	O
criteria	NN	O	O
for	NN	O	O
agoraphobia	NN	O	B
with	NN	O	O
panic	NN	O	B
attacks	NN	O	I
or	NN	O	O
panic	NN	O	B
disorder	NN	O	I
.	NN	O	O

Caffeine	NN	O	O
produced	NN	O	O
significantly	NN	O	O
greater	NN	O	O
increases	NN	O	O
in	NN	O	O
subject	NN	O	O
-	NN	O	O
rated	NN	O	O
anxiety	NN	O	B
,	NN	O	O
nervousness	NN	O	O
,	NN	O	O
fear	NN	O	O
,	NN	O	O
nausea	NN	O	B
,	NN	O	O
palpitations	NN	O	B
,	NN	O	O
restlessness	NN	O	B
,	NN	O	O
and	NN	O	O
tremors	NN	O	B
in	NN	O	O
the	NN	O	O
patients	NN	O	O
compared	NN	O	O
with	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
,	NN	O	O
these	NN	O	O
symptoms	NN	O	O
were	NN	O	O
significantly	NN	O	O
correlated	NN	O	O
with	NN	O	O
plasma	NN	O	O
caffeine	NN	O	O
levels	NN	O	O
.	NN	O	O

Seventy	NN	O	O
-	NN	O	O
one	NN	O	O
percent	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
reported	NN	O	O
that	NN	O	O
the	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
caffeine	NN	O	O
were	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
experienced	NN	O	O
during	NN	O	O
panic	NN	O	B
attacks	NN	O	I
.	NN	O	O

Caffeine	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
plasma	NN	O	O
MHPG	NN	O	O
levels	NN	O	O
in	NN	O	O
either	NN	O	O
the	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
or	NN	O	O
patients	NN	O	O
.	NN	O	O

Caffeine	NN	O	O
increased	NN	O	O
plasma	NN	O	O
cortisol	NN	O	O
levels	NN	O	O
equally	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
and	NN	O	O
healthy	NN	O	O
groups	NN	O	O
.	NN	O	O

Because	NN	O	O
caffeine	NN	O	O
is	NN	O	O
an	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
these	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
some	NN	O	O
panic	NN	O	B
disorder	NN	O	I
patients	NN	O	O
may	NN	O	O
have	NN	O	O
abnormalities	NN	O	B
in	NN	O	I
neuronal	NN	O	I
systems	NN	O	I
involving	NN	O	O
adenosine	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
anxiety	NN	O	B
disorders	NN	O	I
may	NN	O	O
benefit	NN	O	O
by	NN	O	O
avoiding	NN	O	O
caffeine	NN	O	O
-	NN	O	O
containing	NN	O	O
foods	NN	O	O
and	NN	O	O
beverages	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
oxitropium	NN	O	O
bromide	NN	O	O
and	NN	O	O
of	NN	O	O
slow	NN	O	O
-	NN	O	O
release	NN	O	O
theophylline	NN	O	O
on	NN	O	O
nocturnal	NN	O	O
asthma	NN	O	B
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
inhaled	NN	O	O
antimuscarinic	NN	O	O
drug	NN	O	O
,	NN	O	O
oxitropium	NN	O	O
bromide	NN	O	O
,	NN	O	O
and	NN	O	O
of	NN	O	O
a	NN	O	O
slow	NN	O	O
-	NN	O	O
release	NN	O	O
theophylline	NN	O	O
preparation	NN	O	O
upon	NN	O	O
nocturnal	NN	O	O
asthma	NN	O	B
were	NN	O	O
compared	NN	O	O
in	NN	O	O
a	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
.	NN	O	O

Two	NN	O	O
samples	NN	O	O
were	NN	O	O
studied	NN	O	O
:	NN	O	O
12	NN	O	O
patients	NN	O	O
received	NN	O	O
oxitropium	NN	O	O
at	NN	O	O
600	NN	O	O
micrograms	NN	O	O
(	NN	O	O
6	NN	O	O
subjects	NN	O	O
)	NN	O	O
or	NN	O	O
at	NN	O	O
400	NN	O	O
micrograms	NN	O	O
t	NN	O	O
.	NN	O	O
i	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O

(	NN	O	O
6	NN	O	O
subjects	NN	O	O
)	NN	O	O
whereas	NN	O	O
11	NN	O	O
received	NN	O	O
theophylline	NN	O	O
at	NN	O	O
300	NN	O	O
mg	NN	O	O
b	NN	O	O
.	NN	O	O
i	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O

Morning	NN	O	O
dipping	NN	O	O
,	NN	O	O
assessed	NN	O	O
by	NN	O	O
the	NN	O	O
fall	NN	O	O
in	NN	O	O
peak	NN	O	O
flow	NN	O	O
overnight	NN	O	O
,	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
in	NN	O	O
the	NN	O	O
periods	NN	O	O
when	NN	O	O
either	NN	O	O
active	NN	O	O
drug	NN	O	O
was	NN	O	O
taken	NN	O	O
,	NN	O	O
whereas	NN	O	O
no	NN	O	O
difference	NN	O	O
was	NN	O	O
noticed	NN	O	O
during	NN	O	O
the	NN	O	O
placebo	NN	O	O
administration	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
difference	NN	O	O
was	NN	O	O
noticed	NN	O	O
between	NN	O	O
results	NN	O	O
obtained	NN	O	O
with	NN	O	O
either	NN	O	O
active	NN	O	O
drug	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
with	NN	O	O
either	NN	O	O
dosage	NN	O	O
of	NN	O	O
oxitropium	NN	O	O
.	NN	O	O

No	NN	O	O
subject	NN	O	O
reported	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
oxitropium	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
three	NN	O	O
subjects	NN	O	O
reporting	NN	O	O
nausea	NN	O	B
,	NN	O	O
vomiting	NN	O	B
and	NN	O	O
tremors	NN	O	B
after	NN	O	O
theophylline	NN	O	O
.	NN	O	O

Oxitropium	NN	O	O
proves	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
valuable	NN	O	O
alternative	NN	O	O
to	NN	O	O
theophylline	NN	O	O
in	NN	O	O
nocturnal	NN	O	O
asthma	NN	O	B
,	NN	O	O
since	NN	O	O
it	NN	O	O
is	NN	O	O
equally	NN	O	O
potent	NN	O	O
,	NN	O	O
safer	NN	O	O
and	NN	O	O
does	NN	O	O
not	NN	O	O
require	NN	O	O
the	NN	O	O
titration	NN	O	O
of	NN	O	O
dosage	NN	O	O
.	NN	O	O

Penicillin	NN	O	O
anaphylaxis	NN	O	B
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
oral	NN	O	O
penicillin	NN	O	O
anaphylaxis	NN	O	B
is	NN	O	O
described	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
terminology	NN	O	O
,	NN	O	O
occurrence	NN	O	O
,	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
,	NN	O	O
pathogenesis	NN	O	O
,	NN	O	O
prevention	NN	O	O
,	NN	O	O
and	NN	O	O
treatment	NN	O	O
of	NN	O	O
anaphylaxis	NN	O	B
are	NN	O	O
reviewed	NN	O	O
.	NN	O	O

Emergency	NN	O	O
physicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
oral	NN	O	O
penicillin	NN	O	O
anaphylaxis	NN	O	B
in	NN	O	O
order	NN	O	O
to	NN	O	O
prevent	NN	O	O
its	NN	O	O
occurrence	NN	O	O
by	NN	O	O
prescribing	NN	O	O
the	NN	O	O
antibiotic	NN	O	O
judiciously	NN	O	O
and	NN	O	O
knowledgeably	NN	O	O
and	NN	O	O
to	NN	O	O
offer	NN	O	O
optimal	NN	O	O
medical	NN	O	O
therapy	NN	O	O
once	NN	O	O
this	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
reaction	NN	O	O
has	NN	O	O
begun	NN	O	O
.	NN	O	O

Reversible	NN	O	O
valproic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
dementia	NN	O	B
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

Reversible	NN	O	O
valproic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
dementia	NN	O	B
was	NN	O	O
documented	NN	O	O
in	NN	O	O
a	NN	O	O
21	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
epilepsy	NN	O	B
who	NN	O	O
had	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
year	NN	O	O
history	NN	O	O
of	NN	O	O
insidious	NN	O	O
progressive	NN	O	O
decline	NN	O	O
in	NN	O	O
global	NN	O	O
cognitive	NN	O	O
abilities	NN	O	O
documented	NN	O	O
by	NN	O	O
serial	NN	O	O
neuropsychological	NN	O	O
studies	NN	O	O
.	NN	O	O

Repeat	NN	O	O
neuropsychological	NN	O	O
testing	NN	O	O
7	NN	O	O
weeks	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
revealed	NN	O	O
dramatic	NN	O	O
improvement	NN	O	O
in	NN	O	O
IQ	NN	O	O
,	NN	O	O
memory	NN	O	O
,	NN	O	O
naming	NN	O	O
,	NN	O	O
and	NN	O	O
other	NN	O	O
tasks	NN	O	O
commensurate	NN	O	O
with	NN	O	O
clinical	NN	O	O
recovery	NN	O	O
in	NN	O	O
his	NN	O	O
intellectual	NN	O	O
capacity	NN	O	O
.	NN	O	O

Possible	NN	O	O
pathophysiological	NN	O	O
mechanisms	NN	O	O
which	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
operative	NN	O	O
in	NN	O	O
this	NN	O	O
case	NN	O	O
include	NN	O	O
:	NN	O	O
a	NN	O	O
direct	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
toxic	NN	O	O
effect	NN	O	O
of	NN	O	O
valproic	NN	O	O
acid	NN	O	O
;	NN	O	O
a	NN	O	O
paradoxical	NN	O	O
epileptogenic	NN	O	O
effect	NN	O	O
secondary	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
;	NN	O	O
and	NN	O	O
an	NN	O	O
indirect	NN	O	O
CNS	NN	O	O
toxic	NN	O	O
effect	NN	O	O
mediated	NN	O	O
through	NN	O	O
valproic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperammonemia	NN	O	B
.	NN	O	O

Reversal	NN	O	O
of	NN	O	O
scopolamine	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B
of	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
by	NN	O	O
pre	NN	O	O
-	NN	O	O
and	NN	O	O
post	NN	O	O
-	NN	O	O
training	NN	O	O
naloxone	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
five	NN	O	O
experiments	NN	O	O
,	NN	O	O
the	NN	O	O
modulating	NN	O	O
role	NN	O	O
of	NN	O	O
naloxone	NN	O	O
on	NN	O	O
a	NN	O	O
scopolamine	NN	O	O
-	NN	O	O
induced	NN	O	O
retention	NN	O	B
deficit	NN	O	I
in	NN	O	O
a	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
paradigm	NN	O	O
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Scopolamine	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
methyl	NN	O	O
scopolamine	NN	O	O
(	NN	O	O
1	NN	O	O
and	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
induced	NN	O	O
an	NN	O	O
amnesia	NN	O	B
as	NN	O	O
measured	NN	O	O
by	NN	O	O
latency	NN	O	O
and	NN	O	O
duration	NN	O	O
parameters	NN	O	O
.	NN	O	O

Naloxone	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
injected	NN	O	O
prior	NN	O	O
to	NN	O	O
training	NN	O	O
attenuated	NN	O	O
the	NN	O	O
retention	NN	O	B
deficit	NN	O	I
with	NN	O	O
a	NN	O	O
peak	NN	O	O
of	NN	O	O
activity	NN	O	O
at	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
naloxone	NN	O	O
could	NN	O	O
be	NN	O	O
antagonized	NN	O	O
with	NN	O	O
morphine	NN	O	O
(	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
demonstrating	NN	O	O
the	NN	O	O
opioid	NN	O	O
specificity	NN	O	O
of	NN	O	O
the	NN	O	O
naloxone	NN	O	O
effect	NN	O	O
.	NN	O	O

Post	NN	O	O
-	NN	O	O
training	NN	O	O
administration	NN	O	O
of	NN	O	O
naloxone	NN	O	O
(	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
as	NN	O	O
a	NN	O	O
single	NN	O	O
or	NN	O	O
as	NN	O	O
a	NN	O	O
split	NN	O	O
dose	NN	O	O
also	NN	O	O
attenuated	NN	O	O
the	NN	O	O
scopolamine	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B
.	NN	O	O

Control	NN	O	O
experiments	NN	O	O
indicated	NN	O	O
that	NN	O	O
neither	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
pain	NN	O	B
sensitivity	NN	O	O
(	NN	O	O
pre	NN	O	O
-	NN	O	O
training	NN	O	O
naloxone	NN	O	O
)	NN	O	O
nor	NN	O	O
an	NN	O	O
induced	NN	O	O
aversive	NN	O	O
state	NN	O	O
(	NN	O	O
post	NN	O	O
-	NN	O	O
training	NN	O	O
naloxone	NN	O	O
)	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
naloxone	NN	O	O
on	NN	O	O
the	NN	O	O
scopolamine	NN	O	O
-	NN	O	O
induced	NN	O	O
retention	NN	O	B
deficit	NN	O	I
.	NN	O	O

These	NN	O	O
results	NN	O	O
extend	NN	O	O
previous	NN	O	O
findings	NN	O	O
implicating	NN	O	O
a	NN	O	O
cholinergic	NN	O	O
-	NN	O	O
opioid	NN	O	O
interaction	NN	O	O
in	NN	O	O
memory	NN	O	O
processes	NN	O	O
.	NN	O	O

A	NN	O	O
possible	NN	O	O
mechanism	NN	O	O
for	NN	O	O
this	NN	O	O
interaction	NN	O	O
involving	NN	O	O
the	NN	O	O
septo	NN	O	O
-	NN	O	O
hippocampal	NN	O	O
cholinergic	NN	O	O
pathway	NN	O	O
is	NN	O	O
discussed	NN	O	O
.	NN	O	O

Electron	NN	O	O
microscopic	NN	O	O
investigations	NN	O	O
of	NN	O	O
the	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
induced	NN	O	O
lesions	NN	O	B
of	NN	O	I
the	NN	O	I
urinary	NN	O	I
bladder	NN	O	I
of	NN	O	O
the	NN	O	O
rat	NN	O	O
and	NN	O	O
their	NN	O	O
prevention	NN	O	O
by	NN	O	O
mesna	NN	O	O
.	NN	O	O

Fully	NN	O	O
developed	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
nearly	NN	O	O
complete	NN	O	O
detachment	NN	O	O
of	NN	O	O
the	NN	O	O
urothelium	NN	O	O
,	NN	O	O
severe	NN	O	O
submucosal	NN	O	O
edema	NN	O	B
owing	NN	O	O
to	NN	O	O
damage	NN	O	O
to	NN	O	O
the	NN	O	O
microvascular	NN	O	O
bed	NN	O	O
and	NN	O	O
focal	NN	O	O
muscle	NN	O	O
necroses	NN	O	B
.	NN	O	O

The	NN	O	O
initial	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
primary	NN	O	O
attack	NN	O	O
by	NN	O	O
the	NN	O	O
cyclophosphamide	NN	O	O
metabolites	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
fragmentation	NN	O	O
of	NN	O	O
the	NN	O	O
luminal	NN	O	O
membrane	NN	O	O
.	NN	O	O

This	NN	O	O
damages	NN	O	O
the	NN	O	O
cellular	NN	O	O
barrier	NN	O	O
against	NN	O	O
the	NN	O	O
hypertonic	NN	O	O
urine	NN	O	O
.	NN	O	O

Subsequent	NN	O	O
breaks	NN	O	O
in	NN	O	O
the	NN	O	O
lateral	NN	O	O
cell	NN	O	O
membranes	NN	O	O
of	NN	O	O
the	NN	O	O
superficial	NN	O	O
cells	NN	O	O
and	NN	O	O
in	NN	O	O
all	NN	O	O
the	NN	O	O
plasma	NN	O	O
membranes	NN	O	O
of	NN	O	O
the	NN	O	O
intermediate	NN	O	O
and	NN	O	O
basal	NN	O	O
cells	NN	O	O
,	NN	O	O
intercellular	NN	O	O
and	NN	O	O
intracellular	NN	O	O
edema	NN	O	B
and	NN	O	O
disintegration	NN	O	O
of	NN	O	O
the	NN	O	O
desmosomes	NN	O	O
and	NN	O	O
hemidesmosomes	NN	O	O
lead	NN	O	O
to	NN	O	O
progressive	NN	O	O
degeneration	NN	O	O
and	NN	O	O
detachment	NN	O	O
of	NN	O	O
the	NN	O	O
epithelial	NN	O	O
cells	NN	O	O
with	NN	O	O
exposure	NN	O	O
and	NN	O	O
splitting	NN	O	O
of	NN	O	O
the	NN	O	O
basal	NN	O	O
membrane	NN	O	O
.	NN	O	O

The	NN	O	O
morphological	NN	O	O
changes	NN	O	O
of	NN	O	O
the	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
,	NN	O	O
which	NN	O	O
become	NN	O	O
more	NN	O	O
pronounced	NN	O	O
in	NN	O	O
the	NN	O	O
later	NN	O	O
stages	NN	O	O
of	NN	O	O
the	NN	O	O
experiment	NN	O	O
,	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
blood	NN	O	O
vessels	NN	O	O
regardless	NN	O	O
of	NN	O	O
their	NN	O	O
diameter	NN	O	O
and	NN	O	O
the	NN	O	O
location	NN	O	O
-	NN	O	O
dependent	NN	O	O
extent	NN	O	O
of	NN	O	O
the	NN	O	O
damage	NN	O	O
indicate	NN	O	O
a	NN	O	O
direct	NN	O	O
type	NN	O	O
of	NN	O	O
damage	NN	O	O
which	NN	O	O
is	NN	O	O
preceded	NN	O	O
by	NN	O	O
a	NN	O	O
mediator	NN	O	O
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
in	NN	O	O
permeability	NN	O	O
,	NN	O	O
the	NN	O	O
morphological	NN	O	O
correlate	NN	O	O
of	NN	O	O
which	NN	O	O
is	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
gaps	NN	O	O
in	NN	O	O
the	NN	O	O
interendothelial	NN	O	O
cell	NN	O	O
connections	NN	O	O
on	NN	O	O
the	NN	O	O
venules	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
can	NN	O	O
be	NN	O	O
effectively	NN	O	O
prevented	NN	O	O
by	NN	O	O
mesna	NN	O	O
.	NN	O	O

The	NN	O	O
only	NN	O	O
sign	NN	O	O
of	NN	O	O
a	NN	O	O
possible	NN	O	O
involvement	NN	O	O
is	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
specific	NN	O	O
granules	NN	O	O
with	NN	O	O
a	NN	O	O
presumed	NN	O	O
lysosomal	NN	O	O
function	NN	O	O
in	NN	O	O
the	NN	O	O
superficial	NN	O	O
cells	NN	O	O
.	NN	O	O

Increase	NN	O	O
in	NN	O	O
intragastric	NN	O	O
pressure	NN	O	O
during	NN	O	O
suxamethonium	NN	O	O
-	NN	O	O
induced	NN	O	O
muscle	NN	O	B
fasciculations	NN	O	I
in	NN	O	O
children	NN	O	O
:	NN	O	O
inhibition	NN	O	O
by	NN	O	O
alfentanil	NN	O	O
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
intragastric	NN	O	O
pressure	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
32	NN	O	O
children	NN	O	O
(	NN	O	O
mean	NN	O	O
age	NN	O	O
6	NN	O	O
.	NN	O	O
9	NN	O	O
yr	NN	O	O
)	NN	O	O
pretreated	NN	O	O
with	NN	O	O
either	NN	O	O
physiological	NN	O	O
saline	NN	O	O
or	NN	O	O
alfentanil	NN	O	O
50	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

Anaesthesia	NN	O	O
was	NN	O	O
induced	NN	O	O
with	NN	O	O
thiopentone	NN	O	O
5	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
and	NN	O	O
intensity	NN	O	O
of	NN	O	O
muscle	NN	O	B
fasciculations	NN	O	I
caused	NN	O	O
by	NN	O	O
suxamethonium	NN	O	O
were	NN	O	O
significantly	NN	O	O
greater	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
alfentanil	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
intragastric	NN	O	O
pressure	NN	O	O
during	NN	O	O
muscle	NN	O	B
fasciculations	NN	O	I
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
16	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
(	NN	O	O
SEM	NN	O	O
)	NN	O	O
cm	NN	O	O
H2O	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
alfentanil	NN	O	O
group	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
(	NN	O	O
SEM	NN	O	O
)	NN	O	O
cm	NN	O	O
H2O	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
increase	NN	O	O
in	NN	O	O
intragastric	NN	O	O
pressure	NN	O	O
was	NN	O	O
directly	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
intensity	NN	O	O
of	NN	O	O
muscle	NN	O	B
fasciculations	NN	O	I
(	NN	O	O
regression	NN	O	O
line	NN	O	O
:	NN	O	O
y	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
4	NN	O	O
.	NN	O	O
78x	NN	O	O
with	NN	O	O
r	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
78	NN	O	O
)	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
intragastric	NN	O	O
pressure	NN	O	O
increases	NN	O	O
significantly	NN	O	O
during	NN	O	O
muscle	NN	O	B
fasciculations	NN	O	I
caused	NN	O	O
by	NN	O	O
suxamethonium	NN	O	O
in	NN	O	O
healthy	NN	O	O
children	NN	O	O
.	NN	O	O

Alfentanil	NN	O	O
50	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
effectively	NN	O	O
inhibits	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
intensity	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
-	NN	O	O
induced	NN	O	O
muscle	NN	O	B
fasciculations	NN	O	I
;	NN	O	O
moreover	NN	O	O
,	NN	O	O
intragastric	NN	O	O
pressure	NN	O	O
remains	NN	O	O
at	NN	O	O
its	NN	O	O
control	NN	O	O
value	NN	O	O
.	NN	O	O

Acute	NN	O	O
insulin	NN	O	O
treatment	NN	O	O
normalizes	NN	O	O
the	NN	O	O
resistance	NN	O	O
to	NN	O	O
the	NN	O	O
cardiotoxic	NN	O	B
effect	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
in	NN	O	O
streptozotocin	NN	O	O
diabetic	NN	O	B
rats	NN	O	O
.	NN	O	O

A	NN	O	O
morphometric	NN	O	O
study	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
induced	NN	O	O
myocardial	NN	O	O
fibrosis	NN	O	B
.	NN	O	O

The	NN	O	O
acute	NN	O	O
effect	NN	O	O
of	NN	O	O
insulin	NN	O	O
treatment	NN	O	O
on	NN	O	O
the	NN	O	O
earlier	NN	O	O
reported	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
streptozotocin	NN	O	O
diabetes	NN	O	B
against	NN	O	O
the	NN	O	O
cardiotoxic	NN	O	B
effect	NN	O	O
of	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
ISO	NN	O	O
)	NN	O	O
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Thirty	NN	O	O
to	NN	O	O
135	NN	O	O
min	NN	O	O
after	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
crystalline	NN	O	O
insulin	NN	O	O
,	NN	O	O
ISO	NN	O	O
was	NN	O	O
given	NN	O	O
subcutaneously	NN	O	O
and	NN	O	O
when	NN	O	O
ISO	NN	O	O
induced	NN	O	O
fibrosis	NN	O	B
in	NN	O	O
the	NN	O	O
myocardium	NN	O	O
was	NN	O	O
morphometrically	NN	O	O
analyzed	NN	O	O
7	NN	O	O
days	NN	O	O
later	NN	O	O
,	NN	O	O
a	NN	O	O
highly	NN	O	O
significant	NN	O	O
correlation	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
83	NN	O	O
,	NN	O	O
2	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
006	NN	O	O
)	NN	O	O
to	NN	O	O
the	NN	O	O
slope	NN	O	O
of	NN	O	O
the	NN	O	O
fall	NN	O	O
in	NN	O	O
blood	NN	O	O
glucose	NN	O	O
after	NN	O	O
insulin	NN	O	O
treatment	NN	O	O
appeared	NN	O	O
.	NN	O	O

The	NN	O	O
myocardial	NN	O	O
content	NN	O	O
of	NN	O	O
catecholamines	NN	O	O
was	NN	O	O
estimated	NN	O	O
in	NN	O	O
these	NN	O	O
8	NN	O	O
day	NN	O	O
diabetic	NN	O	B
rats	NN	O	O
.	NN	O	O

The	NN	O	O
norepinephrine	NN	O	O
content	NN	O	O
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
while	NN	O	O
epinephrine	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
.	NN	O	O

An	NN	O	O
enhanced	NN	O	O
sympathetic	NN	O	O
nervous	NN	O	O
system	NN	O	O
activity	NN	O	O
with	NN	O	O
a	NN	O	O
consequent	NN	O	O
down	NN	O	O
regulation	NN	O	O
of	NN	O	O
the	NN	O	O
myocardial	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
receptors	NN	O	O
could	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
explain	NN	O	O
this	NN	O	O
catecholamine	NN	O	O
resistance	NN	O	O
.	NN	O	O

The	NN	O	O
rapid	NN	O	O
reversion	NN	O	O
after	NN	O	O
insulin	NN	O	O
treatment	NN	O	O
excludes	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
streptozotocin	NN	O	O
in	NN	O	O
itself	NN	O	O
causes	NN	O	O
the	NN	O	O
ISO	NN	O	O
resistance	NN	O	O
and	NN	O	O
points	NN	O	O
towards	NN	O	O
a	NN	O	O
direct	NN	O	O
insulin	NN	O	O
effect	NN	O	O
on	NN	O	O
myocardial	NN	O	O
catecholamine	NN	O	O
sensitivity	NN	O	O
in	NN	O	O
diabetic	NN	O	B
rats	NN	O	O
.	NN	O	O

The	NN	O	O
phenomenon	NN	O	O
described	NN	O	O
might	NN	O	O
elucidate	NN	O	O
pathogenetic	NN	O	O
mechanisms	NN	O	O
behind	NN	O	O
toxic	NN	O	O
myocardial	NN	O	O
cell	NN	O	O
degeneration	NN	O	O
and	NN	O	O
may	NN	O	O
possibly	NN	O	O
have	NN	O	O
relevance	NN	O	O
for	NN	O	O
acute	NN	O	O
cardiovascular	NN	O	O
complications	NN	O	O
in	NN	O	O
diabetic	NN	O	B
patients	NN	O	O
.	NN	O	O

Differential	NN	O	O
effects	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
on	NN	O	O
seizures	NN	O	B
produced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
muscarinic	NN	O	O
cholinergic	NN	O	O
agonist	NN	O	O
pilocarpine	NN	O	O
induces	NN	O	O
in	NN	O	O
rats	NN	O	O
seizures	NN	O	B
and	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
followed	NN	O	O
by	NN	O	O
widespread	NN	O	O
damage	NN	O	O
to	NN	O	O
the	NN	O	O
forebrain	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
5	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
,	NN	O	O
sodium	NN	O	O
salicylate	NN	O	O
,	NN	O	O
phenylbutazone	NN	O	O
,	NN	O	O
indomethacin	NN	O	O
,	NN	O	O
ibuprofen	NN	O	O
and	NN	O	O
mefenamic	NN	O	O
acid	NN	O	O
,	NN	O	O
on	NN	O	O
seizures	NN	O	B
produced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
of	NN	O	O
rats	NN	O	O
with	NN	O	O
sodium	NN	O	O
salicylate	NN	O	O
,	NN	O	O
ED50	NN	O	O
103	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
60	NN	O	O
-	NN	O	O
174	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
phenylbutazone	NN	O	O
,	NN	O	O
59	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
50	NN	O	O
-	NN	O	O
70	NN	O	O
)	NN	O	O
converted	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
convulsant	NN	O	O
dose	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
to	NN	O	O
a	NN	O	O
convulsant	NN	O	O
one	NN	O	O
.	NN	O	O

Indomethacin	NN	O	O
,	NN	O	O
1	NN	O	O
-	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
and	NN	O	O
ibuprofen	NN	O	O
,	NN	O	O
10	NN	O	O
-	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
failed	NN	O	O
to	NN	O	O
modulate	NN	O	O
seizures	NN	O	B
produced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
.	NN	O	O

Mefenamic	NN	O	O
acid	NN	O	O
,	NN	O	O
26	NN	O	O
(	NN	O	O
22	NN	O	O
-	NN	O	O
30	NN	O	O
)	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
prevented	NN	O	O
seizures	NN	O	B
and	NN	O	O
protected	NN	O	O
rats	NN	O	O
from	NN	O	O
seizure	NN	O	B
-	NN	O	O
related	NN	O	O
brain	NN	O	B
damage	NN	O	I
induced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
380	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
differentially	NN	O	O
modulate	NN	O	O
the	NN	O	O
threshold	NN	O	O
for	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
.	NN	O	O

Acute	NN	O	B
neurologic	NN	O	I
dysfunction	NN	O	I
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
etoposide	NN	O	O
therapy	NN	O	O
for	NN	O	O
malignant	NN	O	B
glioma	NN	O	I
.	NN	O	O

Etoposide	NN	O	O
(	NN	O	O
VP	NN	O	O
-	NN	O	O
16	NN	O	O
-	NN	O	O
213	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
many	NN	O	O
solid	NN	O	O
tumors	NN	O	B
and	NN	O	O
hematologic	NN	O	B
malignancies	NN	O	I
.	NN	O	O

When	NN	O	O
used	NN	O	O
in	NN	O	O
high	NN	O	O
doses	NN	O	O
and	NN	O	O
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
autologous	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
,	NN	O	O
this	NN	O	O
agent	NN	O	O
has	NN	O	O
activity	NN	O	O
against	NN	O	O
several	NN	O	O
treatment	NN	O	O
-	NN	O	O
resistant	NN	O	O
cancers	NN	O	B
including	NN	O	O
malignant	NN	O	B
glioma	NN	O	I
.	NN	O	O

In	NN	O	O
six	NN	O	O
of	NN	O	O
eight	NN	O	O
patients	NN	O	O
(	NN	O	O
75	NN	O	O
%	NN	O	O
)	NN	O	O
who	NN	O	O
we	NN	O	O
treated	NN	O	O
for	NN	O	O
recurrent	NN	O	O
or	NN	O	O
resistant	NN	O	O
glioma	NN	O	B
,	NN	O	O
sudden	NN	O	O
severe	NN	O	O
neurologic	NN	O	B
deterioration	NN	O	I
occurred	NN	O	O
.	NN	O	O

This	NN	O	O
developed	NN	O	O
a	NN	O	O
median	NN	O	O
of	NN	O	O
9	NN	O	O
days	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
etoposide	NN	O	O
therapy	NN	O	O
.	NN	O	O

Significant	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
have	NN	O	O
included	NN	O	O
confusion	NN	O	B
,	NN	O	O
papilledema	NN	O	B
,	NN	O	O
somnolence	NN	O	B
,	NN	O	O
exacerbation	NN	O	O
of	NN	O	O
motor	NN	O	B
deficits	NN	O	I
,	NN	O	O
and	NN	O	O
sharp	NN	O	O
increase	NN	O	O
in	NN	O	O
seizure	NN	O	B
activity	NN	O	O
.	NN	O	O

These	NN	O	O
abnormalities	NN	O	O
resolved	NN	O	O
rapidly	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
intravenous	NN	O	O
dexamethasone	NN	O	O
therapy	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
patients	NN	O	O
,	NN	O	O
computerized	NN	O	O
tomographic	NN	O	O
(	NN	O	O
CT	NN	O	O
)	NN	O	O
brain	NN	O	O
scans	NN	O	O
demonstrated	NN	O	O
stability	NN	O	O
in	NN	O	O
tumor	NN	O	B
size	NN	O	O
and	NN	O	O
peritumor	NN	O	O
edema	NN	O	B
when	NN	O	O
compared	NN	O	O
with	NN	O	O
pretransplant	NN	O	O
scans	NN	O	O
.	NN	O	O

This	NN	O	O
complication	NN	O	O
appears	NN	O	O
to	NN	O	O
represent	NN	O	O
a	NN	O	O
significant	NN	O	O
new	NN	O	O
toxicity	NN	O	B
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
etoposide	NN	O	O
therapy	NN	O	O
for	NN	O	O
malignant	NN	O	B
glioma	NN	O	I
.	NN	O	O

Progressive	NN	O	O
bile	NN	O	B
duct	NN	O	I
injury	NN	O	I
after	NN	O	O
thiabendazole	NN	O	O
administration	NN	O	O
.	NN	O	O

A	NN	O	O
27	NN	O	O
-	NN	O	O
yr	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
developed	NN	O	O
jaundice	NN	O	B
2	NN	O	O
wk	NN	O	O
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
thiabendazole	NN	O	O
.	NN	O	O

Cholestasis	NN	O	B
persisted	NN	O	O
for	NN	O	O
3	NN	O	O
yr	NN	O	O
,	NN	O	O
at	NN	O	O
which	NN	O	O
time	NN	O	O
a	NN	O	O
liver	NN	O	O
transplant	NN	O	O
was	NN	O	O
performed	NN	O	O
.	NN	O	O

Two	NN	O	O
liver	NN	O	O
biopsy	NN	O	O
specimens	NN	O	O
and	NN	O	O
the	NN	O	O
hepatectomy	NN	O	O
specimen	NN	O	O
were	NN	O	O
remarkable	NN	O	O
for	NN	O	O
almost	NN	O	O
complete	NN	O	O
disappearance	NN	O	O
of	NN	O	O
interlobular	NN	O	O
bile	NN	O	O
ducts	NN	O	O
.	NN	O	O

Prominent	NN	O	O
fibrosis	NN	O	B
and	NN	O	O
hepatocellular	NN	O	O
regeneration	NN	O	O
were	NN	O	O
also	NN	O	O
present	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
the	NN	O	O
lobular	NN	O	O
architecture	NN	O	O
was	NN	O	O
preserved	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
represents	NN	O	O
an	NN	O	O
example	NN	O	O
of	NN	O	O
"	NN	O	O
idiosyncratic	NN	O	O
"	NN	O	O
drug	NN	O	B
-	NN	O	I
induced	NN	O	I
liver	NN	O	I
damage	NN	O	I
in	NN	O	O
which	NN	O	O
the	NN	O	O
primary	NN	O	O
target	NN	O	O
of	NN	O	O
injury	NN	O	O
is	NN	O	O
the	NN	O	O
bile	NN	O	O
duct	NN	O	O
.	NN	O	O

An	NN	O	O
autoimmune	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
the	NN	O	O
bile	NN	O	B
duct	NN	O	I
destruction	NN	O	I
is	NN	O	O
suggested	NN	O	O
.	NN	O	O

Differential	NN	O	O
effects	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dihydropyridine	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
:	NN	O	O
therapeutic	NN	O	O
implications	NN	O	O
.	NN	O	O

Increasing	NN	O	O
recognition	NN	O	O
of	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
calcium	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
has	NN	O	O
stimulated	NN	O	O
research	NN	O	O
into	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blocking	NN	O	O
agents	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B
diseases	NN	O	I
.	NN	O	O

The	NN	O	O
favorable	NN	O	O
efficacy	NN	O	O
and	NN	O	O
tolerability	NN	O	O
profiles	NN	O	O
of	NN	O	O
these	NN	O	O
agents	NN	O	O
make	NN	O	O
them	NN	O	O
attractive	NN	O	O
therapeutic	NN	O	O
modalities	NN	O	O
.	NN	O	O

Clinical	NN	O	O
applications	NN	O	O
of	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
parallel	NN	O	O
their	NN	O	O
tissue	NN	O	O
selectivity	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
verapamil	NN	O	O
and	NN	O	O
diltiazem	NN	O	O
,	NN	O	O
which	NN	O	O
are	NN	O	O
roughly	NN	O	O
equipotent	NN	O	O
in	NN	O	O
their	NN	O	O
actions	NN	O	O
on	NN	O	O
the	NN	O	O
heart	NN	O	O
and	NN	O	O
vascular	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
,	NN	O	O
the	NN	O	O
dihydropyridine	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
are	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
potent	NN	O	O
peripheral	NN	O	O
vasodilator	NN	O	O
agents	NN	O	O
that	NN	O	O
exert	NN	O	O
minimal	NN	O	O
electrophysiologic	NN	O	O
effects	NN	O	O
on	NN	O	O
cardiac	NN	O	O
nodal	NN	O	O
or	NN	O	O
conduction	NN	O	O
tissue	NN	O	O
.	NN	O	O

As	NN	O	O
the	NN	O	O
first	NN	O	O
dihydropyridine	NN	O	O
available	NN	O	O
for	NN	O	O
use	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
,	NN	O	O
nifedipine	NN	O	O
controls	NN	O	O
angina	NN	O	B
and	NN	O	O
hypertension	NN	O	B
with	NN	O	O
minimal	NN	O	O
depression	NN	O	O
of	NN	O	O
cardiac	NN	O	O
function	NN	O	O
.	NN	O	O

Additional	NN	O	O
members	NN	O	O
of	NN	O	O
this	NN	O	O
group	NN	O	O
of	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
have	NN	O	O
been	NN	O	O
studied	NN	O	O
for	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
indications	NN	O	O
for	NN	O	O
which	NN	O	O
they	NN	O	O
may	NN	O	O
offer	NN	O	O
advantages	NN	O	O
over	NN	O	O
current	NN	O	O
therapy	NN	O	O
.	NN	O	O

Once	NN	O	O
or	NN	O	O
twice	NN	O	O
daily	NN	O	O
dosage	NN	O	O
possible	NN	O	O
with	NN	O	O
nitrendipine	NN	O	O
and	NN	O	O
nisoldipine	NN	O	O
offers	NN	O	O
a	NN	O	O
convenient	NN	O	O
administration	NN	O	O
schedule	NN	O	O
,	NN	O	O
which	NN	O	O
encourages	NN	O	O
patient	NN	O	O
compliance	NN	O	O
in	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
therapy	NN	O	O
of	NN	O	O
hypertension	NN	O	B
.	NN	O	O

The	NN	O	O
coronary	NN	O	O
vasodilating	NN	O	O
properties	NN	O	O
of	NN	O	O
nisoldipine	NN	O	O
have	NN	O	O
led	NN	O	O
to	NN	O	O
the	NN	O	O
investigation	NN	O	O
of	NN	O	O
this	NN	O	O
agent	NN	O	O
for	NN	O	O
use	NN	O	O
in	NN	O	O
angina	NN	O	B
.	NN	O	O

Selectivity	NN	O	O
for	NN	O	O
the	NN	O	O
cerebrovascular	NN	O	O
bed	NN	O	O
makes	NN	O	O
nimodipine	NN	O	O
potentially	NN	O	O
useful	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
subarachnoid	NN	O	B
hemorrhage	NN	O	I
,	NN	O	O
migraine	NN	O	B
headache	NN	O	I
,	NN	O	O
dementia	NN	O	B
,	NN	O	O
and	NN	O	O
stroke	NN	O	B
.	NN	O	O

In	NN	O	O
general	NN	O	O
,	NN	O	O
the	NN	O	O
dihydropyridine	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
are	NN	O	O
usually	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
with	NN	O	O
headache	NN	O	B
,	NN	O	O
facial	NN	O	O
flushing	NN	O	B
,	NN	O	O
palpitations	NN	O	B
,	NN	O	O
edema	NN	O	B
,	NN	O	O
nausea	NN	O	B
,	NN	O	O
anorexia	NN	O	B
,	NN	O	O
and	NN	O	O
dizziness	NN	O	B
being	NN	O	O
the	NN	O	O
more	NN	O	O
common	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
enhancement	NN	O	O
of	NN	O	O
aminonucleoside	NN	O	O
nephrosis	NN	O	B
by	NN	O	O
the	NN	O	O
co	NN	O	O
-	NN	O	O
administration	NN	O	O
of	NN	O	O
protamine	NN	O	O
.	NN	O	O

An	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
focal	NN	O	B
segmental	NN	O	I
glomerular	NN	O	I
sclerosis	NN	O	I
(	NN	O	O
FSGS	NN	O	B
)	NN	O	O
was	NN	O	O
developed	NN	O	O
in	NN	O	O
rats	NN	O	O
by	NN	O	O
the	NN	O	O
combined	NN	O	O
administration	NN	O	O
of	NN	O	O
puromycin	NN	O	O
-	NN	O	O
aminonucleoside	NN	O	O
(	NN	O	O
AMNS	NN	O	O
)	NN	O	O
and	NN	O	O
protamine	NN	O	O
sulfate	NN	O	O
(	NN	O	O
PS	NN	O	O
)	NN	O	O
.	NN	O	O

Male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
,	NN	O	O
uninephrectomized	NN	O	O
three	NN	O	O
weeks	NN	O	O
before	NN	O	O
,	NN	O	O
received	NN	O	O
daily	NN	O	O
injections	NN	O	O
of	NN	O	O
subcutaneous	NN	O	O
AMNS	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
body	NN	O	O
wt	NN	O	O
)	NN	O	O
and	NN	O	O
intravenous	NN	O	O
PS	NN	O	O
(	NN	O	O
2	NN	O	O
separated	NN	O	O
doses	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
body	NN	O	O
wt	NN	O	O
)	NN	O	O
for	NN	O	O
four	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
series	NN	O	O
of	NN	O	O
injections	NN	O	O
were	NN	O	O
repeated	NN	O	O
another	NN	O	O
three	NN	O	O
times	NN	O	O
at	NN	O	O
10	NN	O	O
day	NN	O	O
intervals	NN	O	O
.	NN	O	O

The	NN	O	O
animals	NN	O	O
were	NN	O	O
sacrificed	NN	O	O
on	NN	O	O
days	NN	O	O
24	NN	O	O
,	NN	O	O
52	NN	O	O
,	NN	O	O
and	NN	O	O
80	NN	O	O
.	NN	O	O

They	NN	O	O
developed	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
and	NN	O	O
finally	NN	O	O
renal	NN	O	B
failure	NN	O	I
.	NN	O	O

The	NN	O	O
time	NN	O	O
-	NN	O	O
course	NN	O	O
curve	NN	O	O
of	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
dropped	NN	O	O
and	NN	O	O
showed	NN	O	O
significant	NN	O	O
difference	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
from	NN	O	O
that	NN	O	O
of	NN	O	O
each	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
,	NN	O	O
AMNS	NN	O	O
alone	NN	O	O
,	NN	O	O
PS	NN	O	O
alone	NN	O	O
or	NN	O	O
saline	NN	O	O
injected	NN	O	O
.	NN	O	O

Their	NN	O	O
glomeruli	NN	O	O
showed	NN	O	O
changes	NN	O	O
of	NN	O	O
progressive	NN	O	O
FSGS	NN	O	B
.	NN	O	O

The	NN	O	O
ultrastructural	NN	O	O
studies	NN	O	O
in	NN	O	O
the	NN	O	O
initial	NN	O	O
stage	NN	O	O
revealed	NN	O	O
significant	NN	O	O
lack	NN	O	O
of	NN	O	O
particles	NN	O	O
of	NN	O	O
perfused	NN	O	O
ruthenium	NN	O	O
red	NN	O	O
on	NN	O	O
the	NN	O	O
lamina	NN	O	O
rara	NN	O	O
externa	NN	O	O
and	NN	O	O
marked	NN	O	O
changes	NN	O	O
in	NN	O	O
epithelial	NN	O	O
cell	NN	O	O
cytoplasm	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
PS	NN	O	O
enhances	NN	O	O
the	NN	O	O
toxicity	NN	O	B
of	NN	O	O
AMNS	NN	O	O
on	NN	O	O
the	NN	O	O
glomerulus	NN	O	O
and	NN	O	O
readily	NN	O	O
produces	NN	O	O
progressive	NN	O	O
FSGS	NN	O	B
in	NN	O	O
rats	NN	O	O
resulting	NN	O	O
in	NN	O	O
the	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
renal	NN	O	I
disease	NN	O	I
.	NN	O	O

Theophylline	NN	O	O
neurotoxicity	NN	O	B
in	NN	O	O
pregnant	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
investigation	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
the	NN	O	O
neurotoxicity	NN	O	B
of	NN	O	O
theophylline	NN	O	O
is	NN	O	O
altered	NN	O	O
in	NN	O	O
advanced	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
that	NN	O	O
were	NN	O	O
20	NN	O	O
days	NN	O	O
pregnant	NN	O	O
and	NN	O	O
nonpregnant	NN	O	O
rats	NN	O	O
of	NN	O	O
the	NN	O	O
same	NN	O	O
age	NN	O	O
and	NN	O	O
strain	NN	O	O
received	NN	O	O
infusions	NN	O	O
of	NN	O	O
aminophylline	NN	O	O
until	NN	O	O
onset	NN	O	O
of	NN	O	O
maximal	NN	O	O
seizures	NN	O	B
which	NN	O	O
occurred	NN	O	O
after	NN	O	O
28	NN	O	O
and	NN	O	O
30	NN	O	O
minutes	NN	O	O
respectively	NN	O	O
.	NN	O	O

Theophylline	NN	O	O
concentrations	NN	O	O
at	NN	O	O
this	NN	O	O
endpoint	NN	O	O
in	NN	O	O
serum	NN	O	O
(	NN	O	O
total	NN	O	O
)	NN	O	O
and	NN	O	O
CSF	NN	O	O
were	NN	O	O
similar	NN	O	O
but	NN	O	O
serum	NN	O	O
(	NN	O	O
free	NN	O	O
)	NN	O	O
and	NN	O	O
brain	NN	O	O
concentrations	NN	O	O
were	NN	O	O
slightly	NN	O	O
different	NN	O	O
in	NN	O	O
pregnant	NN	O	O
rats	NN	O	O
.	NN	O	O

Theophylline	NN	O	O
serum	NN	O	O
protein	NN	O	O
binding	NN	O	O
determined	NN	O	O
by	NN	O	O
equilibrium	NN	O	O
dialysis	NN	O	O
was	NN	O	O
lower	NN	O	O
in	NN	O	O
pregnant	NN	O	O
rats	NN	O	O
.	NN	O	O

Fetal	NN	O	O
serum	NN	O	O
concentrations	NN	O	O
at	NN	O	O
onset	NN	O	O
of	NN	O	O
seizures	NN	O	B
in	NN	O	O
the	NN	O	O
mother	NN	O	O
were	NN	O	O
similar	NN	O	O
to	NN	O	O
maternal	NN	O	O
brain	NN	O	O
and	NN	O	O
CSF	NN	O	O
concentrations	NN	O	O
and	NN	O	O
correlated	NN	O	O
significantly	NN	O	O
with	NN	O	O
the	NN	O	O
former	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
advanced	NN	O	O
pregnancy	NN	O	O
has	NN	O	O
a	NN	O	O
negligible	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
neurotoxic	NN	O	B
response	NN	O	O
to	NN	O	O
theophylline	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Hyperkalemia	NN	O	B
induced	NN	O	O
by	NN	O	O
indomethacin	NN	O	O
and	NN	O	O
naproxen	NN	O	O
and	NN	O	O
reversed	NN	O	O
by	NN	O	O
fludrocortisone	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
described	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
severe	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
and	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
mefenamic	NN	O	O
acid	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
whom	NN	O	O
hyperkalemia	NN	O	B
and	NN	O	O
inappropriate	NN	O	O
hypoaldosteronism	NN	O	B
were	NN	O	O
caused	NN	O	O
by	NN	O	O
both	NN	O	O
indomethacin	NN	O	O
and	NN	O	O
naproxen	NN	O	O
,	NN	O	O
without	NN	O	O
major	NN	O	O
decline	NN	O	O
in	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
likely	NN	O	O
that	NN	O	O
preexisting	NN	O	O
renal	NN	O	B
disease	NN	O	I
predisposed	NN	O	O
this	NN	O	O
patient	NN	O	O
to	NN	O	O
type	NN	O	B
IV	NN	O	I
renal	NN	O	I
tubular	NN	O	I
acidosis	NN	O	I
with	NN	O	O
prostaglandin	NN	O	O
synthetase	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

Because	NN	O	O
he	NN	O	O
was	NN	O	O
unable	NN	O	O
to	NN	O	O
discontinue	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drug	NN	O	O
therapy	NN	O	O
,	NN	O	O
fludrocortisone	NN	O	O
was	NN	O	O
added	NN	O	O
,	NN	O	O
correcting	NN	O	O
the	NN	O	O
hyperkalemia	NN	O	B
and	NN	O	O
allowing	NN	O	O
indomethacin	NN	O	O
therapy	NN	O	O
to	NN	O	O
be	NN	O	O
continued	NN	O	O
safely	NN	O	O
.	NN	O	O

Hypotension	NN	O	B
as	NN	O	O
a	NN	O	O
manifestation	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B
in	NN	O	O
three	NN	O	O
patients	NN	O	O
receiving	NN	O	O
cisplatin	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
.	NN	O	O

Cardiac	NN	O	O
symptoms	NN	O	O
,	NN	O	O
including	NN	O	O
hypotension	NN	O	B
,	NN	O	O
developed	NN	O	O
in	NN	O	O
three	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
colorectal	NN	O	B
carcinoma	NN	O	I
while	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
cisplatin	NN	O	O
(	NN	O	O
CDDP	NN	O	O
)	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
two	NN	O	O
patients	NN	O	O
,	NN	O	O
hypotension	NN	O	B
was	NN	O	O
associated	NN	O	O
with	NN	O	O
severe	NN	O	O
left	NN	O	B
ventricular	NN	O	I
dysfunction	NN	O	I
.	NN	O	O

All	NN	O	O
three	NN	O	O
patients	NN	O	O
required	NN	O	O
therapy	NN	O	O
discontinuation	NN	O	O
.	NN	O	O

Cardiac	NN	O	O
enzymes	NN	O	O
remained	NN	O	O
normal	NN	O	O
despite	NN	O	O
transient	NN	O	O
electrocardiographic	NN	O	O
(	NN	O	O
EKG	NN	O	O
)	NN	O	O
changes	NN	O	O
.	NN	O	O

The	NN	O	O
presentation	NN	O	O
and	NN	O	O
cardiac	NN	O	O
evaluation	NN	O	O
(	NN	O	O
hemodynamic	NN	O	O
,	NN	O	O
echocardiographic	NN	O	O
,	NN	O	O
and	NN	O	O
scintigraphic	NN	O	O
)	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
suggest	NN	O	O
new	NN	O	O
manifestations	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
cardiotoxicity	NN	O	B
that	NN	O	O
may	NN	O	O
be	NN	O	O
influenced	NN	O	O
by	NN	O	O
CDDP	NN	O	O
.	NN	O	O

The	NN	O	O
possible	NN	O	O
pathophysiologic	NN	O	O
mechanisms	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Fatal	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
in	NN	O	O
a	NN	O	O
patient	NN	O	O
treated	NN	O	O
with	NN	O	O
carbamazepine	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
fatal	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
due	NN	O	O
to	NN	O	O
carbamazepine	NN	O	O
treatment	NN	O	O
in	NN	O	O
an	NN	O	O
epileptic	NN	O	B
woman	NN	O	O
is	NN	O	O
reported	NN	O	O
.	NN	O	O

Despite	NN	O	O
concerns	NN	O	O
of	NN	O	O
fatal	NN	O	O
bone	NN	O	B
marrow	NN	O	I
toxicity	NN	O	I
due	NN	O	O
to	NN	O	O
carbamazepine	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
only	NN	O	O
the	NN	O	O
fourth	NN	O	O
documented	NN	O	O
and	NN	O	O
published	NN	O	O
report	NN	O	O
.	NN	O	O

Carbamazepine	NN	O	O
is	NN	O	O
a	NN	O	O
safe	NN	O	O
drug	NN	O	O
,	NN	O	O
but	NN	O	O
physicians	NN	O	O
and	NN	O	O
patients	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
exceedingly	NN	O	O
rare	NN	O	O
but	NN	O	O
potentially	NN	O	O
fatal	NN	O	O
side	NN	O	O
effects	NN	O	O
,	NN	O	O
better	NN	O	O
prevented	NN	O	O
by	NN	O	O
clinical	NN	O	O
than	NN	O	O
by	NN	O	O
laboratory	NN	O	O
monitoring	NN	O	O
.	NN	O	O

Participation	NN	O	O
of	NN	O	O
a	NN	O	O
bulbospinal	NN	O	O
serotonergic	NN	O	O
pathway	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
brain	NN	O	O
in	NN	O	O
clonidine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
and	NN	O	O
bradycardia	NN	O	B
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
microinjection	NN	O	O
of	NN	O	O
clonidine	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
10	NN	O	O
micrograms	NN	O	O
in	NN	O	O
1	NN	O	O
microliter	NN	O	O
)	NN	O	O
into	NN	O	O
a	NN	O	O
region	NN	O	O
adjacent	NN	O	O
to	NN	O	O
the	NN	O	O
ventrolateral	NN	O	O
surface	NN	O	O
of	NN	O	O
the	NN	O	O
medulla	NN	O	O
oblongata	NN	O	O
on	NN	O	O
cardiovascular	NN	O	O
function	NN	O	O
were	NN	O	O
assessed	NN	O	O
in	NN	O	O
urethane	NN	O	O
-	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
.	NN	O	O

Intramedullary	NN	O	O
administration	NN	O	O
of	NN	O	O
clonidine	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
saline	NN	O	O
vehicle	NN	O	O
,	NN	O	O
caused	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
decrease	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
and	NN	O	O
the	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

The	NN	O	O
clonidine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
was	NN	O	O
antagonized	NN	O	O
by	NN	O	O
prior	NN	O	O
spinal	NN	O	O
transection	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
bilateral	NN	O	O
vagotomy	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
the	NN	O	O
clonidine	NN	O	O
-	NN	O	O
induced	NN	O	O
bradycardia	NN	O	B
was	NN	O	O
antagonized	NN	O	O
by	NN	O	O
prior	NN	O	O
bilateral	NN	O	O
vagotomy	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
spinal	NN	O	O
transection	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
selective	NN	O	O
destruction	NN	O	O
of	NN	O	O
the	NN	O	O
spinal	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
nerves	NN	O	O
,	NN	O	O
produced	NN	O	O
by	NN	O	O
bilateral	NN	O	O
spinal	NN	O	O
injection	NN	O	O
of	NN	O	O
5	NN	O	O
,	NN	O	O
7	NN	O	O
-	NN	O	O
dihydroxytryptamine	NN	O	O
,	NN	O	O
reduced	NN	O	O
the	NN	O	O
magnitude	NN	O	O
of	NN	O	O
the	NN	O	O
vasodepressor	NN	O	O
or	NN	O	O
the	NN	O	O
bradycardiac	NN	O	B
responses	NN	O	O
to	NN	O	O
clonidine	NN	O	O
microinjected	NN	O	O
into	NN	O	O
the	NN	O	O
area	NN	O	O
near	NN	O	O
the	NN	O	O
ventrolateral	NN	O	O
surface	NN	O	O
of	NN	O	O
the	NN	O	O
medulla	NN	O	O
oblongata	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
a	NN	O	O
bulbospinal	NN	O	O
serotonergic	NN	O	O
pathway	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
development	NN	O	O
of	NN	O	O
clonidine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
and	NN	O	O
bradycardia	NN	O	B
.	NN	O	O

The	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
is	NN	O	O
brought	NN	O	O
about	NN	O	O
by	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
sympathetic	NN	O	O
efferent	NN	O	O
activity	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
induced	NN	O	O
bradycardia	NN	O	B
was	NN	O	O
due	NN	O	O
to	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
vagal	NN	O	O
efferent	NN	O	O
activity	NN	O	O
.	NN	O	O

Hypertension	NN	O	B
in	NN	O	O
neuroblastoma	NN	O	B
induced	NN	O	O
by	NN	O	O
imipramine	NN	O	O
.	NN	O	O

Hypertension	NN	O	B
is	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
known	NN	O	O
finding	NN	O	O
in	NN	O	O
some	NN	O	O
patients	NN	O	O
with	NN	O	O
neuroblastoma	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
it	NN	O	O
has	NN	O	O
not	NN	O	O
previously	NN	O	O
been	NN	O	O
described	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
Imipramine	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
severe	NN	O	O
hypertension	NN	O	B
(	NN	O	O
blood	NN	O	O
pressure	NN	O	O
190	NN	O	O
/	NN	O	O
160	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
4	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
with	NN	O	O
neuroblastoma	NN	O	B
who	NN	O	O
was	NN	O	O
given	NN	O	O
Imipramine	NN	O	O
to	NN	O	O
control	NN	O	O
a	NN	O	O
behavior	NN	O	B
disorder	NN	O	I
.	NN	O	O

It	NN	O	O
was	NN	O	O
determined	NN	O	O
later	NN	O	O
that	NN	O	O
this	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
tumor	NN	O	B
was	NN	O	O
recurring	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
her	NN	O	O
hypertensive	NN	O	B
episode	NN	O	O
.	NN	O	O

Since	NN	O	O
she	NN	O	O
had	NN	O	O
no	NN	O	O
blood	NN	O	O
pressure	NN	O	O
elevation	NN	O	O
at	NN	O	O
initial	NN	O	O
diagnosis	NN	O	O
and	NN	O	O
none	NN	O	O
following	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
Imipramine	NN	O	O
(	NN	O	O
when	NN	O	O
she	NN	O	O
was	NN	O	O
in	NN	O	O
florid	NN	O	O
relapse	NN	O	O
)	NN	O	O
,	NN	O	O
we	NN	O	O
believe	NN	O	O
that	NN	O	O
this	NN	O	O
drug	NN	O	O
rather	NN	O	O
than	NN	O	O
her	NN	O	O
underlying	NN	O	O
disease	NN	O	O
alone	NN	O	O
caused	NN	O	O
her	NN	O	O
hypertension	NN	O	B
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
for	NN	O	O
this	NN	O	O
reaction	NN	O	O
is	NN	O	O
believed	NN	O	O
to	NN	O	O
be	NN	O	O
increased	NN	O	O
levels	NN	O	O
of	NN	O	O
vasoactive	NN	O	O
catecholamines	NN	O	O
due	NN	O	O
to	NN	O	O
interference	NN	O	O
of	NN	O	O
their	NN	O	O
physiologic	NN	O	O
inactivation	NN	O	O
by	NN	O	O
Imipramine	NN	O	O
.	NN	O	O

From	NN	O	O
this	NN	O	O
experience	NN	O	O
,	NN	O	O
we	NN	O	O
urge	NN	O	O
extreme	NN	O	O
caution	NN	O	O
in	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
tricyclic	NN	O	O
antidepressants	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
active	NN	O	O
neuroblastoma	NN	O	B
.	NN	O	O

Rechallenge	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
oral	NN	O	B
candidiasis	NN	O	I
or	NN	O	O
hoarseness	NN	O	B
with	NN	O	O
beclomethasone	NN	O	O
dipropionate	NN	O	O
.	NN	O	O

Of	NN	O	O
158	NN	O	O
asthmatic	NN	O	B
patients	NN	O	O
who	NN	O	O
were	NN	O	O
placed	NN	O	O
on	NN	O	O
inhaled	NN	O	O
beclomethasone	NN	O	O
,	NN	O	O
15	NN	O	O
(	NN	O	O
9	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
either	NN	O	O
hoarseness	NN	O	B
(	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
oral	NN	O	O
thrush	NN	O	B
(	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
both	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

When	NN	O	O
their	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
subsided	NN	O	O
,	NN	O	O
seven	NN	O	O
of	NN	O	O
these	NN	O	O
15	NN	O	O
patients	NN	O	O
were	NN	O	O
rechallenged	NN	O	O
with	NN	O	O
inhaled	NN	O	O
beclomethasone	NN	O	O
.	NN	O	O

These	NN	O	O
included	NN	O	O
five	NN	O	O
cases	NN	O	O
who	NN	O	O
developed	NN	O	O
hoarseness	NN	O	B
and	NN	O	O
three	NN	O	O
who	NN	O	O
developed	NN	O	O
Candidiasis	NN	O	B
.	NN	O	O

One	NN	O	O
patient	NN	O	O
had	NN	O	O
both	NN	O	O
.	NN	O	O

Oral	NN	O	O
thrush	NN	O	B
did	NN	O	O
not	NN	O	O
recur	NN	O	O
,	NN	O	O
but	NN	O	O
60	NN	O	O
%	NN	O	O
(	NN	O	O
3	NN	O	O
/	NN	O	O
5	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
hoarseness	NN	O	B
had	NN	O	O
recurrence	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
patients	NN	O	O
may	NN	O	O
be	NN	O	O
restarted	NN	O	O
on	NN	O	O
inhaled	NN	O	O
beclomethasone	NN	O	O
when	NN	O	O
clinically	NN	O	O
indicated	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
high	NN	O	O
recurrence	NN	O	O
rate	NN	O	O
,	NN	O	O
patients	NN	O	O
who	NN	O	O
develop	NN	O	O
hoarseness	NN	O	B
should	NN	O	O
not	NN	O	O
be	NN	O	O
re	NN	O	O
-	NN	O	O
challenged	NN	O	O
.	NN	O	O

Concomitant	NN	O	O
use	NN	O	O
of	NN	O	O
oral	NN	O	O
prednisone	NN	O	O
and	NN	O	O
topical	NN	O	O
beclomethasone	NN	O	O
may	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
developing	NN	O	O
hoarseness	NN	O	B
or	NN	O	O
candidiasis	NN	O	B
.	NN	O	O

Cyclophosphamide	NN	O	O
cardiotoxicity	NN	O	B
:	NN	O	O
an	NN	O	O
analysis	NN	O	O
of	NN	O	O
dosing	NN	O	O
as	NN	O	O
a	NN	O	O
risk	NN	O	O
factor	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
undergo	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
are	NN	O	O
generally	NN	O	O
immunosuppressed	NN	O	O
with	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	O
(	NN	O	O
CYA	NN	O	O
)	NN	O	O
which	NN	O	O
is	NN	O	O
usually	NN	O	O
calculated	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
weight	NN	O	O
.	NN	O	O

At	NN	O	O
these	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
CYA	NN	O	O
,	NN	O	O
serious	NN	O	O
cardiotoxicity	NN	O	B
may	NN	O	O
occur	NN	O	O
,	NN	O	O
but	NN	O	O
definitive	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
such	NN	O	O
cardiotoxicity	NN	O	B
have	NN	O	O
not	NN	O	O
been	NN	O	O
described	NN	O	O
.	NN	O	O

Since	NN	O	O
chemotherapeutic	NN	O	O
agent	NN	O	O
toxicity	NN	O	B
generally	NN	O	O
correlates	NN	O	O
with	NN	O	O
dose	NN	O	O
per	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
,	NN	O	O
we	NN	O	O
retrospectively	NN	O	O
calculated	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
CYA	NN	O	O
in	NN	O	O
patients	NN	O	O
transplanted	NN	O	O
at	NN	O	O
our	NN	O	O
institution	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
CYA	NN	O	O
cardiotoxicity	NN	O	B
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
dose	NN	O	O
per	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
.	NN	O	O

Eighty	NN	O	O
patients	NN	O	O
who	NN	O	O
were	NN	O	O
to	NN	O	O
receive	NN	O	O
CYA	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
d	NN	O	O
for	NN	O	O
four	NN	O	O
days	NN	O	O
as	NN	O	O
preparation	NN	O	O
for	NN	O	O
marrow	NN	O	O
grafting	NN	O	O
underwent	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
84	NN	O	O
transplants	NN	O	O
for	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
,	NN	O	O
Wiskott	NN	O	B
-	NN	O	I
Aldrich	NN	O	I
syndrome	NN	O	I
,	NN	O	O
or	NN	O	O
severe	NN	O	B
combined	NN	O	I
immunodeficiency	NN	O	I
syndrome	NN	O	I
.	NN	O	O

Fourteen	NN	O	O
of	NN	O	O
84	NN	O	O
(	NN	O	O
17	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
had	NN	O	O
symptoms	NN	O	O
and	NN	O	O
signs	NN	O	O
consistent	NN	O	O
with	NN	O	O
CYA	NN	O	O
cardiotoxicity	NN	O	B
within	NN	O	O
ten	NN	O	O
days	NN	O	O
of	NN	O	O
receiving	NN	O	O
1	NN	O	O
to	NN	O	O
4	NN	O	O
doses	NN	O	O
of	NN	O	O
CYA	NN	O	O
.	NN	O	O

Six	NN	O	O
of	NN	O	O
the	NN	O	O
14	NN	O	O
patients	NN	O	O
died	NN	O	O
with	NN	O	O
congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
.	NN	O	O

The	NN	O	O
dose	NN	O	O
of	NN	O	O
CYA	NN	O	O
per	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
was	NN	O	O
calculated	NN	O	O
for	NN	O	O
all	NN	O	O
patients	NN	O	O
and	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
two	NN	O	O
groups	NN	O	O
based	NN	O	O
on	NN	O	O
daily	NN	O	O
CYA	NN	O	O
dose	NN	O	O
:	NN	O	O
Group	NN	O	O
1	NN	O	O
,	NN	O	O
CYA	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
1	NN	O	O
.	NN	O	O
55	NN	O	O
g	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
;	NN	O	O
Group	NN	O	O
2	NN	O	O
,	NN	O	O
CYA	NN	O	O
greater	NN	O	O
than	NN	O	O
1	NN	O	O
.	NN	O	O
55	NN	O	O
g	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
.	NN	O	O

Cardiotoxicity	NN	O	B
that	NN	O	O
was	NN	O	O
thought	NN	O	O
to	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
CYA	NN	O	O
occurred	NN	O	O
in	NN	O	O
1	NN	O	O
/	NN	O	O
32	NN	O	O
(	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
Group	NN	O	O
1	NN	O	O
and	NN	O	O
in	NN	O	O
13	NN	O	O
/	NN	O	O
52	NN	O	O
(	NN	O	O
25	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
in	NN	O	O
Group	NN	O	O
2	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
025	NN	O	O
)	NN	O	O
.	NN	O	O

Congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
caused	NN	O	O
or	NN	O	O
contributed	NN	O	O
to	NN	O	O
death	NN	O	O
in	NN	O	O
0	NN	O	O
/	NN	O	O
32	NN	O	O
patients	NN	O	O
in	NN	O	O
Group	NN	O	O
1	NN	O	O
v	NN	O	O
6	NN	O	O
/	NN	O	O
52	NN	O	O
(	NN	O	O
12	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
Group	NN	O	O
2	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
engraftment	NN	O	O
of	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
(	NN	O	O
P	NN	O	O
greater	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
CYA	NN	O	O
cardiotoxicity	NN	O	B
correlates	NN	O	O
with	NN	O	O
CYA	NN	O	O
dosage	NN	O	O
as	NN	O	O
calculated	NN	O	O
by	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
patients	NN	O	O
with	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
and	NN	O	O
immunodeficiencies	NN	O	B
can	NN	O	O
be	NN	O	O
effectively	NN	O	O
prepared	NN	O	O
for	NN	O	O
bone	NN	O	O
marrow	NN	O	O
grafting	NN	O	O
at	NN	O	O
a	NN	O	O
CYA	NN	O	O
dose	NN	O	O
of	NN	O	O
1	NN	O	O
.	NN	O	O
55	NN	O	O
g	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
for	NN	O	O
four	NN	O	O
days	NN	O	O
with	NN	O	O
a	NN	O	O
lower	NN	O	O
incidence	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B
than	NN	O	O
patients	NN	O	O
whose	NN	O	O
CYA	NN	O	O
dosage	NN	O	O
is	NN	O	O
calculated	NN	O	O
based	NN	O	O
on	NN	O	O
weight	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
reaffirms	NN	O	O
the	NN	O	O
principle	NN	O	O
that	NN	O	O
drug	NN	O	O
toxicity	NN	O	B
correlates	NN	O	O
with	NN	O	O
dose	NN	O	O
per	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
.	NN	O	O

Studies	NN	O	O
of	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
aminoglycoside	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

The	NN	O	O
epidemiology	NN	O	O
of	NN	O	O
aminoglycoside	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
is	NN	O	O
not	NN	O	O
fully	NN	O	O
understood	NN	O	O
.	NN	O	O

Experimental	NN	O	O
studies	NN	O	O
in	NN	O	O
healthy	NN	O	O
human	NN	O	O
volunteers	NN	O	O
indicate	NN	O	O
aminoglycosides	NN	O	O
cause	NN	O	O
proximal	NN	O	O
tubular	NN	O	O
damage	NN	O	O
in	NN	O	O
most	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
rarely	NN	O	O
,	NN	O	O
if	NN	O	O
ever	NN	O	O
,	NN	O	O
cause	NN	O	O
glomerular	NN	O	B
or	NN	O	I
tubular	NN	O	I
dysfunction	NN	O	I
.	NN	O	O

Clinical	NN	O	O
trials	NN	O	O
of	NN	O	O
aminoglycosides	NN	O	O
in	NN	O	O
seriously	NN	O	O
ill	NN	O	O
patients	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
relative	NN	O	O
risk	NN	O	O
for	NN	O	O
developing	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
during	NN	O	O
therapy	NN	O	O
ranges	NN	O	O
from	NN	O	O
8	NN	O	O
to	NN	O	O
10	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
attributable	NN	O	O
risk	NN	O	O
is	NN	O	O
70	NN	O	O
%	NN	O	O
to	NN	O	O
80	NN	O	O
%	NN	O	O
.	NN	O	O

Further	NN	O	O
analysis	NN	O	O
of	NN	O	O
these	NN	O	O
data	NN	O	O
suggests	NN	O	O
that	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
plasma	NN	O	O
aminoglycoside	NN	O	O
levels	NN	O	O
,	NN	O	O
liver	NN	O	B
disease	NN	O	I
,	NN	O	O
advanced	NN	O	O
age	NN	O	O
,	NN	O	O
high	NN	O	O
initial	NN	O	O
estimated	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
and	NN	O	O
,	NN	O	O
possibly	NN	O	O
,	NN	O	O
female	NN	O	O
gender	NN	O	O
all	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

Other	NN	O	O
causes	NN	O	O
of	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
,	NN	O	O
such	NN	O	O
as	NN	O	O
shock	NN	O	B
,	NN	O	O
appear	NN	O	O
to	NN	O	O
have	NN	O	O
an	NN	O	O
additive	NN	O	O
effect	NN	O	O
.	NN	O	O

Predictive	NN	O	O
models	NN	O	O
have	NN	O	O
been	NN	O	O
developed	NN	O	O
from	NN	O	O
these	NN	O	O
analyses	NN	O	O
that	NN	O	O
should	NN	O	O
be	NN	O	O
useful	NN	O	O
for	NN	O	O
identifying	NN	O	O
patients	NN	O	O
at	NN	O	O
high	NN	O	O
risk	NN	O	O
.	NN	O	O

These	NN	O	O
models	NN	O	O
may	NN	O	O
also	NN	O	O
be	NN	O	O
useful	NN	O	O
in	NN	O	O
developing	NN	O	O
insights	NN	O	O
into	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
aminoglycoside	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

Central	NN	O	O
action	NN	O	O
of	NN	O	O
narcotic	NN	O	O
analgesics	NN	O	O
.	NN	O	O

Part	NN	O	O
IV	NN	O	O
.	NN	O	O

Noradrenergic	NN	O	O
influences	NN	O	O
on	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
analgesics	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
clonidine	NN	O	O
,	NN	O	O
naphazoline	NN	O	O
and	NN	O	O
xylometazoline	NN	O	O
on	NN	O	O
analgesia	NN	O	O
induced	NN	O	O
by	NN	O	O
morphine	NN	O	O
,	NN	O	O
codeine	NN	O	O
,	NN	O	O
fentanyl	NN	O	O
and	NN	O	O
pentazocine	NN	O	O
,	NN	O	O
and	NN	O	O
on	NN	O	O
cataleptic	NN	O	B
effect	NN	O	O
of	NN	O	O
morphine	NN	O	O
,	NN	O	O
codine	NN	O	O
and	NN	O	O
fentanyl	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
biochemical	NN	O	O
assays	NN	O	O
on	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
four	NN	O	O
analgesics	NN	O	O
on	NN	O	O
the	NN	O	O
brain	NN	O	O
concentration	NN	O	O
and	NN	O	O
turnover	NN	O	O
of	NN	O	O
noradrenaline	NN	O	O
(	NN	O	O
NA	NN	O	O
)	NN	O	O
were	NN	O	O
also	NN	O	O
performed	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
found	NN	O	O
that	NN	O	O
three	NN	O	O
drugs	NN	O	O
stimulating	NN	O	O
central	NN	O	O
NA	NN	O	O
receptors	NN	O	O
failed	NN	O	O
to	NN	O	O
affect	NN	O	O
the	NN	O	O
analgesic	NN	O	O
ED50	NN	O	O
of	NN	O	O
all	NN	O	O
antinociceptive	NN	O	O
agents	NN	O	O
and	NN	O	O
they	NN	O	O
enhanced	NN	O	O
catalepsy	NN	O	B
induced	NN	O	O
by	NN	O	O
morphine	NN	O	O
and	NN	O	O
fentanyl	NN	O	O
.	NN	O	O

Codeine	NN	O	O
catalepsy	NN	O	B
was	NN	O	O
increased	NN	O	O
by	NN	O	O
clonidine	NN	O	O
and	NN	O	O
decreased	NN	O	O
by	NN	O	O
naphazoline	NN	O	O
and	NN	O	O
xylometazoline	NN	O	O
.	NN	O	O

The	NN	O	O
brain	NN	O	O
concentration	NN	O	O
of	NN	O	O
NA	NN	O	O
was	NN	O	O
not	NN	O	O
changed	NN	O	O
by	NN	O	O
morphine	NN	O	O
and	NN	O	O
fentanyl	NN	O	O
,	NN	O	O
but	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
doses	NN	O	O
of	NN	O	O
codeine	NN	O	O
(	NN	O	O
45	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
slightly	NN	O	O
enhanced	NN	O	O
it	NN	O	O
.	NN	O	O

Pentazocine	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
decreased	NN	O	O
the	NN	O	O
brain	NN	O	O
level	NN	O	O
of	NN	O	O
NA	NN	O	O
.	NN	O	O

The	NN	O	O
rate	NN	O	O
of	NN	O	O
NA	NN	O	O
turnover	NN	O	O
was	NN	O	O
not	NN	O	O
altered	NN	O	O
by	NN	O	O
analgesics	NN	O	O
except	NN	O	O
for	NN	O	O
the	NN	O	O
higher	NN	O	O
dose	NN	O	O
of	NN	O	O
fentanyl	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
following	NN	O	O
which	NN	O	O
the	NN	O	O
disappearance	NN	O	O
of	NN	O	O
NA	NN	O	O
from	NN	O	O
the	NN	O	O
brain	NN	O	O
was	NN	O	O
diminished	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
are	NN	O	O
discussed	NN	O	O
in	NN	O	O
the	NN	O	O
light	NN	O	O
of	NN	O	O
various	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
uniform	NN	O	O
data	NN	O	O
from	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
in	NN	O	O
rats	NN	O	O
the	NN	O	O
brain	NN	O	O
NA	NN	O	O
plays	NN	O	O
a	NN	O	O
less	NN	O	O
important	NN	O	O
function	NN	O	O
than	NN	O	O
the	NN	O	O
other	NN	O	O
monoamines	NN	O	O
in	NN	O	O
the	NN	O	O
behavioural	NN	O	O
activity	NN	O	O
of	NN	O	O
potent	NN	O	O
analgesics	NN	O	O
.	NN	O	O

Flurothyl	NN	O	O
seizure	NN	O	B
thresholds	NN	O	O
in	NN	O	O
mice	NN	O	O
treated	NN	O	O
neonatally	NN	O	O
with	NN	O	O
a	NN	O	O
single	NN	O	O
injection	NN	O	O
of	NN	O	O
monosodium	NN	O	O
glutamate	NN	O	O
(	NN	O	O
MSG	NN	O	O
)	NN	O	O
:	NN	O	O
evaluation	NN	O	O
of	NN	O	O
experimental	NN	O	O
parameters	NN	O	O
in	NN	O	O
flurothyl	NN	O	O
seizure	NN	O	B
testing	NN	O	O
.	NN	O	O

Monosodium	NN	O	O
glutamate	NN	O	O
(	NN	O	O
MSG	NN	O	O
)	NN	O	O
administration	NN	O	O
to	NN	O	O
neonatal	NN	O	O
rodents	NN	O	O
produces	NN	O	O
convulsions	NN	O	B
and	NN	O	O
results	NN	O	O
in	NN	O	O
numerous	NN	O	O
biochemical	NN	O	O
and	NN	O	O
behavioral	NN	O	O
deficits	NN	O	O
.	NN	O	O

These	NN	O	O
studies	NN	O	O
were	NN	O	O
undertaken	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
neonatal	NN	O	O
administration	NN	O	O
of	NN	O	O
MSG	NN	O	O
produced	NN	O	O
permanent	NN	O	O
alterations	NN	O	O
in	NN	O	O
seizure	NN	O	B
susceptibility	NN	O	O
,	NN	O	O
since	NN	O	O
previous	NN	O	O
investigations	NN	O	O
were	NN	O	O
inconclusive	NN	O	O
.	NN	O	O

A	NN	O	O
flurothyl	NN	O	O
ether	NN	O	O
seizure	NN	O	B
screening	NN	O	O
technique	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
seizure	NN	O	B
susceptibility	NN	O	O
in	NN	O	O
adult	NN	O	O
mice	NN	O	O
that	NN	O	O
received	NN	O	O
neonatal	NN	O	O
injections	NN	O	O
of	NN	O	O
MSG	NN	O	O
(	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
g	NN	O	O
and	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
g	NN	O	O
)	NN	O	O
.	NN	O	O

MSG	NN	O	O
treatment	NN	O	O
resulted	NN	O	O
in	NN	O	O
significant	NN	O	O
reductions	NN	O	O
in	NN	O	O
whole	NN	O	O
brain	NN	O	O
weight	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
seizure	NN	O	B
threshold	NN	O	O
.	NN	O	O

A	NN	O	O
naloxone	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
challenge	NN	O	O
was	NN	O	O
also	NN	O	O
ineffective	NN	O	O
in	NN	O	O
altering	NN	O	O
the	NN	O	O
seizure	NN	O	B
thresholds	NN	O	O
of	NN	O	O
either	NN	O	O
control	NN	O	O
of	NN	O	O
MSG	NN	O	O
-	NN	O	O
treated	NN	O	O
mice	NN	O	O
.	NN	O	O

Flurothyl	NN	O	O
ether	NN	O	O
produced	NN	O	O
hypothermia	NN	O	B
which	NN	O	O
was	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
flurothyl	NN	O	O
exposure	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
the	NN	O	O
relationship	NN	O	O
of	NN	O	O
hypothermia	NN	O	B
to	NN	O	O
seizure	NN	O	B
induction	NN	O	O
was	NN	O	O
unclear	NN	O	O
.	NN	O	O

Flurothyl	NN	O	O
seizure	NN	O	B
testing	NN	O	O
proved	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
rapid	NN	O	O
and	NN	O	O
reliable	NN	O	O
technique	NN	O	O
with	NN	O	O
which	NN	O	O
to	NN	O	O
evaluate	NN	O	O
seizure	NN	O	B
susceptibility	NN	O	O
.	NN	O	O

Susceptibility	NN	O	O
to	NN	O	O
seizures	NN	O	B
produced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
in	NN	O	O
rats	NN	O	O
after	NN	O	O
microinjection	NN	O	O
of	NN	O	O
isoniazid	NN	O	O
or	NN	O	O
gamma	NN	O	O
-	NN	O	O
vinyl	NN	O	O
-	NN	O	O
GABA	NN	O	O
into	NN	O	O
the	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
.	NN	O	O

Pilocarpine	NN	O	O
,	NN	O	O
given	NN	O	O
intraperitoneally	NN	O	O
to	NN	O	O
rats	NN	O	O
,	NN	O	O
reproduces	NN	O	O
the	NN	O	O
neuropathological	NN	O	O
sequelae	NN	O	O
of	NN	O	O
temporal	NN	O	B
lobe	NN	O	I
epilepsy	NN	O	I
and	NN	O	O
provides	NN	O	O
a	NN	O	O
relevant	NN	O	O
animal	NN	O	O
model	NN	O	O
for	NN	O	O
studying	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
buildup	NN	O	O
of	NN	O	O
convulsive	NN	O	B
activity	NN	O	O
and	NN	O	O
pathways	NN	O	O
operative	NN	O	O
in	NN	O	O
the	NN	O	O
generalization	NN	O	O
and	NN	O	O
propagation	NN	O	O
of	NN	O	O
seizures	NN	O	B
within	NN	O	O
the	NN	O	O
forebrain	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
manipulating	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acid	NN	O	O
(	NN	O	O
GABA	NN	O	O
)	NN	O	O
-	NN	O	O
mediated	NN	O	O
synaptic	NN	O	O
inhibition	NN	O	O
within	NN	O	O
the	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
on	NN	O	O
seizures	NN	O	B
produced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
in	NN	O	O
rats	NN	O	O
,	NN	O	O
were	NN	O	O
investigated	NN	O	O
.	NN	O	O

In	NN	O	O
animals	NN	O	O
pretreated	NN	O	O
with	NN	O	O
microinjections	NN	O	O
of	NN	O	O
isoniazid	NN	O	O
,	NN	O	O
150	NN	O	O
micrograms	NN	O	O
,	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
GABA	NN	O	O
-	NN	O	O
synthesizing	NN	O	O
enzyme	NN	O	O
,	NN	O	O
L	NN	O	O
-	NN	O	O
glutamic	NN	O	O
acid	NN	O	O
decarboxylase	NN	O	O
,	NN	O	O
into	NN	O	O
the	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
pars	NN	O	O
reticulata	NN	O	O
(	NN	O	O
SNR	NN	O	O
)	NN	O	O
,	NN	O	O
bilaterally	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
convulsant	NN	O	O
doses	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
100	NN	O	O
and	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
severe	NN	O	O
motor	NN	O	O
limbic	NN	O	O
seizures	NN	O	B
and	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
.	NN	O	O

Electroencephalographic	NN	O	O
and	NN	O	O
behavioral	NN	O	O
monitoring	NN	O	O
revealed	NN	O	O
a	NN	O	O
profound	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
threshold	NN	O	O
for	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
.	NN	O	O

Morphological	NN	O	O
analysis	NN	O	O
of	NN	O	O
frontal	NN	O	O
forebrain	NN	O	O
sections	NN	O	O
with	NN	O	O
light	NN	O	O
microscopy	NN	O	O
revealed	NN	O	O
seizure	NN	O	B
-	NN	O	O
related	NN	O	O
damage	NN	O	O
to	NN	O	O
the	NN	O	O
hippocampal	NN	O	O
formation	NN	O	O
,	NN	O	O
thalamus	NN	O	O
,	NN	O	O
amygdala	NN	O	O
,	NN	O	O
olfactory	NN	O	O
cortex	NN	O	O
,	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
and	NN	O	O
neocortex	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
typically	NN	O	O
observed	NN	O	O
with	NN	O	O
pilocarpine	NN	O	O
in	NN	O	O
doses	NN	O	O
exceeding	NN	O	O
350	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Bilateral	NN	O	O
intrastriatal	NN	O	O
injections	NN	O	O
of	NN	O	O
isoniazid	NN	O	O
did	NN	O	O
not	NN	O	O
augment	NN	O	O
seizures	NN	O	B
produced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Application	NN	O	O
of	NN	O	O
an	NN	O	O
irreversible	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
GABA	NN	O	O
transaminase	NN	O	O
,	NN	O	O
gamma	NN	O	O
-	NN	O	O
vinyl	NN	O	O
-	NN	O	O
GABA	NN	O	O
(	NN	O	O
D	NN	O	O
,	NN	O	O
L	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
amino	NN	O	O
-	NN	O	O
hex	NN	O	O
-	NN	O	O
5	NN	O	O
-	NN	O	O
enoic	NN	O	O
acid	NN	O	O
)	NN	O	O
,	NN	O	O
5	NN	O	O
micrograms	NN	O	O
,	NN	O	O
into	NN	O	O
the	NN	O	O
SNR	NN	O	O
,	NN	O	O
bilaterally	NN	O	O
,	NN	O	O
suppressed	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
electrographic	NN	O	O
and	NN	O	O
behavioral	NN	O	O
seizures	NN	O	B
produced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
380	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

This	NN	O	O
treatment	NN	O	O
was	NN	O	O
also	NN	O	O
sufficient	NN	O	O
to	NN	O	O
protect	NN	O	O
animals	NN	O	O
from	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
brain	NN	O	B
damage	NN	O	I
.	NN	O	O

Microinjections	NN	O	O
of	NN	O	O
gamma	NN	O	O
-	NN	O	O
vinyl	NN	O	O
-	NN	O	O
GABA	NN	O	O
,	NN	O	O
5	NN	O	O
micrograms	NN	O	O
,	NN	O	O
into	NN	O	O
the	NN	O	O
dorsal	NN	O	O
striatum	NN	O	O
,	NN	O	O
bilaterally	NN	O	O
,	NN	O	O
failed	NN	O	O
to	NN	O	O
prevent	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
convulsions	NN	O	B
produced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
380	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
the	NN	O	O
threshold	NN	O	O
for	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
in	NN	O	O
rats	NN	O	O
is	NN	O	O
subjected	NN	O	O
to	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
the	NN	O	O
GABA	NN	O	O
-	NN	O	O
mediated	NN	O	O
synaptic	NN	O	O
inhibition	NN	O	O
within	NN	O	O
the	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
.	NN	O	O

Human	NN	O	O
and	NN	O	O
canine	NN	O	O
ventricular	NN	O	O
vasoactive	NN	O	O
intestinal	NN	O	O
polypeptide	NN	O	O
:	NN	O	O
decrease	NN	O	O
with	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

Vasoactive	NN	O	O
intestinal	NN	O	O
polypeptide	NN	O	O
(	NN	O	O
VIP	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
systemic	NN	O	O
and	NN	O	O
coronary	NN	O	O
vasodilator	NN	O	O
that	NN	O	O
may	NN	O	O
have	NN	O	O
positive	NN	O	O
inotropic	NN	O	O
properties	NN	O	O
.	NN	O	O

Myocardial	NN	O	O
levels	NN	O	O
of	NN	O	O
VIP	NN	O	O
were	NN	O	O
assayed	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
heart	NN	O	B
failure	NN	O	I
in	NN	O	O
two	NN	O	O
canine	NN	O	O
models	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
first	NN	O	O
,	NN	O	O
cobalt	NN	O	O
cardiomyopathy	NN	O	B
was	NN	O	O
induced	NN	O	O
in	NN	O	O
eight	NN	O	O
dogs	NN	O	O
;	NN	O	O
VIP	NN	O	O
(	NN	O	O
by	NN	O	O
radioimmunoassay	NN	O	O
)	NN	O	O
decreased	NN	O	O
from	NN	O	O
35	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
11	NN	O	O
pg	NN	O	O
/	NN	O	O
mg	NN	O	O
protein	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
to	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
pg	NN	O	O
/	NN	O	O
mg	NN	O	O
protein	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
six	NN	O	O
dogs	NN	O	O
with	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
heart	NN	O	B
failure	NN	O	I
,	NN	O	O
VIP	NN	O	O
decreased	NN	O	O
from	NN	O	O
31	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
to	NN	O	O
11	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
pg	NN	O	O
/	NN	O	O
mg	NN	O	O
protein	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
VIP	NN	O	O
content	NN	O	O
of	NN	O	O
left	NN	O	O
ventricular	NN	O	O
muscle	NN	O	O
of	NN	O	O
resected	NN	O	O
failing	NN	O	O
hearts	NN	O	O
in	NN	O	O
10	NN	O	O
patients	NN	O	O
receiving	NN	O	O
a	NN	O	O
heart	NN	O	O
transplant	NN	O	O
was	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
papillary	NN	O	O
muscles	NN	O	O
in	NN	O	O
14	NN	O	O
patients	NN	O	O
(	NN	O	O
five	NN	O	O
with	NN	O	O
rheumatic	NN	O	B
disease	NN	O	I
,	NN	O	O
nine	NN	O	O
with	NN	O	O
myxomatous	NN	O	B
degeneration	NN	O	I
)	NN	O	O
receiving	NN	O	O
mitral	NN	O	O
valve	NN	O	O
prostheses	NN	O	O
.	NN	O	O

The	NN	O	O
lowest	NN	O	O
myocardial	NN	O	O
VIP	NN	O	O
concentration	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
hearts	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B
disease	NN	O	I
(	NN	O	O
one	NN	O	O
patient	NN	O	O
receiving	NN	O	O
a	NN	O	O
transplant	NN	O	O
and	NN	O	O
three	NN	O	O
receiving	NN	O	O
mitral	NN	O	O
prostheses	NN	O	O
)	NN	O	O
(	NN	O	O
6	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
pg	NN	O	O
/	NN	O	O
mg	NN	O	O
protein	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
other	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
transplantation	NN	O	O
had	NN	O	O
an	NN	O	O
average	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
of	NN	O	O
17	NN	O	O
%	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
%	NN	O	O
and	NN	O	O
a	NN	O	O
VIP	NN	O	O
level	NN	O	O
of	NN	O	O
8	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
9	NN	O	O
pg	NN	O	O
/	NN	O	O
mg	NN	O	O
protein	NN	O	O
.	NN	O	O

The	NN	O	O
hearts	NN	O	O
without	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
(	NN	O	O
average	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
of	NN	O	O
this	NN	O	O
group	NN	O	O
62	NN	O	O
%	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
a	NN	O	O
VIP	NN	O	O
concentration	NN	O	O
of	NN	O	O
14	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
.	NN	O	O
9	NN	O	O
pg	NN	O	O
/	NN	O	O
mg	NN	O	O
protein	NN	O	O
,	NN	O	O
and	NN	O	O
this	NN	O	O
was	NN	O	O
greater	NN	O	O
than	NN	O	O
in	NN	O	O
hearts	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B
disease	NN	O	I
and	NN	O	O
the	NN	O	O
hearts	NN	O	O
of	NN	O	O
patients	NN	O	O
receiving	NN	O	O
a	NN	O	O
transplant	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Myocardial	NN	O	O
catecholamines	NN	O	O
were	NN	O	O
also	NN	O	O
determined	NN	O	O
in	NN	O	O
14	NN	O	O
subjects	NN	O	O
;	NN	O	O
a	NN	O	O
weak	NN	O	O
correlation	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
57	NN	O	O
,	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
between	NN	O	O
the	NN	O	O
tissue	NN	O	O
concentrations	NN	O	O
of	NN	O	O
VIP	NN	O	O
and	NN	O	O
norepinephrine	NN	O	O
was	NN	O	O
noted	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Non	NN	O	O
-	NN	O	O
invasive	NN	O	O
detection	NN	O	O
of	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
by	NN	O	O
body	NN	O	O
surface	NN	O	O
electrocardiographic	NN	O	O
mapping	NN	O	O
after	NN	O	O
dipyridamole	NN	O	O
infusion	NN	O	O
.	NN	O	O

Electrocardiographic	NN	O	O
changes	NN	O	O
after	NN	O	O
dipyridamole	NN	O	O
infusion	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
568	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
4	NN	O	O
min	NN	O	O
)	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
41	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
and	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
after	NN	O	O
submaximal	NN	O	O
treadmill	NN	O	O
exercise	NN	O	O
by	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
body	NN	O	O
surface	NN	O	O
mapping	NN	O	O
technique	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
three	NN	O	O
groups	NN	O	O
;	NN	O	O
19	NN	O	O
patients	NN	O	O
without	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
(	NN	O	O
non	NN	O	O
-	NN	O	O
MI	NN	O	B
group	NN	O	O
)	NN	O	O
,	NN	O	O
14	NN	O	O
with	NN	O	O
anterior	NN	O	B
infarction	NN	O	I
(	NN	O	O
ANT	NN	O	B
-	NN	O	I
MI	NN	O	I
)	NN	O	O
and	NN	O	O
eight	NN	O	O
with	NN	O	O
inferior	NN	O	B
infarction	NN	O	I
(	NN	O	O
INF	NN	O	B
-	NN	O	I
MI	NN	O	I
)	NN	O	O
.	NN	O	O

Eighty	NN	O	O
-	NN	O	O
seven	NN	O	O
unipolar	NN	O	O
electrocardiograms	NN	O	O
(	NN	O	O
ECGs	NN	O	O
)	NN	O	O
distributed	NN	O	O
over	NN	O	O
the	NN	O	O
entire	NN	O	O
thoracic	NN	O	O
surface	NN	O	O
were	NN	O	O
simultaneously	NN	O	O
recorded	NN	O	O
.	NN	O	O

After	NN	O	O
dipyridamole	NN	O	O
,	NN	O	O
ischemic	NN	O	B
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
depression	NN	O	B
(	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
mV	NN	O	O
or	NN	O	O
more	NN	O	O
)	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
84	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
MI	NN	O	B
group	NN	O	O
,	NN	O	O
29	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
ANT	NN	O	B
-	NN	O	I
MI	NN	O	I
group	NN	O	O
,	NN	O	O
63	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
INF	NN	O	B
-	NN	O	I
MI	NN	O	I
group	NN	O	O
and	NN	O	O
61	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
total	NN	O	O
population	NN	O	O
.	NN	O	O

Exercise	NN	O	O
-	NN	O	O
induced	NN	O	O
ST	NN	O	O
depression	NN	O	B
was	NN	O	O
observed	NN	O	O
in	NN	O	O
84	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
MI	NN	O	B
group	NN	O	O
,	NN	O	O
43	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
ANT	NN	O	B
-	NN	O	I
MI	NN	O	I
group	NN	O	O
,	NN	O	O
38	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
INF	NN	O	B
-	NN	O	I
MI	NN	O	I
group	NN	O	O
and	NN	O	O
61	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
total	NN	O	O
.	NN	O	O

For	NN	O	O
individual	NN	O	O
patients	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
obvious	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
body	NN	O	O
surface	NN	O	O
distribution	NN	O	O
of	NN	O	O
ST	NN	O	O
depression	NN	O	B
in	NN	O	O
both	NN	O	O
tests	NN	O	O
.	NN	O	O

The	NN	O	O
increase	NN	O	O
in	NN	O	O
pressure	NN	O	O
rate	NN	O	O
product	NN	O	O
after	NN	O	O
dipyridamole	NN	O	O
was	NN	O	O
significantly	NN	O	O
less	NN	O	O
than	NN	O	O
that	NN	O	O
during	NN	O	O
the	NN	O	O
treadmill	NN	O	O
exercise	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
dipyridamole	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
is	NN	O	O
caused	NN	O	O
by	NN	O	O
the	NN	O	O
inhomogenous	NN	O	O
distribution	NN	O	O
of	NN	O	O
myocardial	NN	O	O
blood	NN	O	O
flow	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
dipyridamole	NN	O	O
ECG	NN	O	O
test	NN	O	O
is	NN	O	O
as	NN	O	O
useful	NN	O	O
as	NN	O	O
the	NN	O	O
exercise	NN	O	O
ECG	NN	O	O
test	NN	O	O
for	NN	O	O
the	NN	O	O
assessment	NN	O	O
of	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
.	NN	O	O

Bradycardia	NN	O	B
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
intravenous	NN	O	O
methylprednisolone	NN	O	O
therapy	NN	O	O
.	NN	O	O

In	NN	O	O
5	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
who	NN	O	O
received	NN	O	O
intravenous	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
methylprednisolone	NN	O	O
(	NN	O	O
MP	NN	O	O
)	NN	O	O
therapy	NN	O	O
(	NN	O	O
1	NN	O	O
g	NN	O	O
daily	NN	O	O
for	NN	O	O
2	NN	O	O
or	NN	O	O
3	NN	O	O
consecutive	NN	O	O
days	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
decline	NN	O	O
in	NN	O	O
pulse	NN	O	O
rate	NN	O	O
was	NN	O	O
observed	NN	O	O
,	NN	O	O
most	NN	O	O
pronounced	NN	O	O
on	NN	O	O
day	NN	O	O
4	NN	O	O
.	NN	O	O

In	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
5	NN	O	O
patients	NN	O	O
the	NN	O	O
bradycardia	NN	O	B
was	NN	O	O
associated	NN	O	O
with	NN	O	O
complaints	NN	O	O
of	NN	O	O
substernal	NN	O	O
pressure	NN	O	O
.	NN	O	O

Reversal	NN	O	O
to	NN	O	O
normal	NN	O	O
heart	NN	O	O
rate	NN	O	O
was	NN	O	O
found	NN	O	O
on	NN	O	O
day	NN	O	O
7	NN	O	O
.	NN	O	O

Electrocardiographic	NN	O	O
registrations	NN	O	O
showed	NN	O	O
sinus	NN	O	B
bradycardia	NN	O	I
in	NN	O	O
all	NN	O	O
cases	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
changes	NN	O	O
in	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
electrolytes	NN	O	O
were	NN	O	O
found	NN	O	O
.	NN	O	O

Careful	NN	O	O
observation	NN	O	O
of	NN	O	O
patients	NN	O	O
receiving	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
MP	NN	O	O
is	NN	O	O
recommended	NN	O	O
.	NN	O	O

High	NN	O	O
-	NN	O	O
dose	NN	O	O
MP	NN	O	O
may	NN	O	O
be	NN	O	O
contraindicated	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
known	NN	O	O
heart	NN	O	B
disease	NN	O	I
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
of	NN	O	O
downbeat	NN	O	B
nystagmus	NN	O	I
and	NN	O	O
oscillopsia	NN	O	B
associated	NN	O	O
with	NN	O	O
carbamazepine	NN	O	O
.	NN	O	O

Downbeat	NN	O	B
nystagmus	NN	O	I
is	NN	O	O
often	NN	O	O
associated	NN	O	O
with	NN	O	O
structural	NN	O	O
lesions	NN	O	O
at	NN	O	O
the	NN	O	O
craniocervical	NN	O	O
junction	NN	O	O
,	NN	O	O
but	NN	O	O
has	NN	O	O
occasionally	NN	O	O
been	NN	O	O
reported	NN	O	O
as	NN	O	O
a	NN	O	O
manifestation	NN	O	O
of	NN	O	O
metabolic	NN	O	O
imbalance	NN	O	O
or	NN	O	O
drug	NN	O	O
intoxication	NN	O	O
.	NN	O	O

We	NN	O	O
recorded	NN	O	O
the	NN	O	O
eye	NN	O	O
movements	NN	O	O
of	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
reversible	NN	O	O
downbeat	NN	O	B
nystagmus	NN	O	I
related	NN	O	O
to	NN	O	O
carbamazepine	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
nystagmus	NN	O	B
of	NN	O	O
both	NN	O	O
patients	NN	O	O
resolved	NN	O	O
after	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
serum	NN	O	O
carbamazepine	NN	O	O
levels	NN	O	O
.	NN	O	O

Neuroradiologic	NN	O	O
investigations	NN	O	O
including	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
scans	NN	O	O
in	NN	O	O
both	NN	O	O
patients	NN	O	O
showed	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
intracranial	NN	O	O
abnormality	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
downbeat	NN	O	B
nystagmus	NN	O	I
who	NN	O	O
are	NN	O	O
taking	NN	O	O
anticonvulsant	NN	O	O
medications	NN	O	O
,	NN	O	O
consideration	NN	O	O
should	NN	O	O
be	NN	O	O
given	NN	O	O
to	NN	O	O
reduction	NN	O	O
in	NN	O	O
dose	NN	O	O
before	NN	O	O
further	NN	O	O
investigation	NN	O	O
is	NN	O	O
undertaken	NN	O	O
.	NN	O	O

Improvement	NN	O	O
by	NN	O	O
denopamine	NN	O	O
(	NN	O	O
TA	NN	O	O
-	NN	O	O
064	NN	O	O
)	NN	O	O
of	NN	O	O
pentobarbital	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
failure	NN	O	I
in	NN	O	O
the	NN	O	O
dog	NN	O	O
heart	NN	O	O
-	NN	O	O
lung	NN	O	O
preparation	NN	O	O
.	NN	O	O

The	NN	O	O
efficacy	NN	O	O
of	NN	O	O
denopamine	NN	O	O
,	NN	O	O
an	NN	O	O
orally	NN	O	O
active	NN	O	O
beta	NN	O	O
1	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
agonist	NN	O	O
,	NN	O	O
in	NN	O	O
improving	NN	O	O
cardiac	NN	O	B
failure	NN	O	I
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
dog	NN	O	O
heart	NN	O	O
-	NN	O	O
lung	NN	O	O
preparations	NN	O	O
.	NN	O	O

Cardiac	NN	O	O
functions	NN	O	O
depressed	NN	O	O
by	NN	O	O
pentobarbital	NN	O	O
(	NN	O	O
118	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
28	NN	O	O
mg	NN	O	O
;	NN	O	O
mean	NN	O	O
value	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
such	NN	O	O
that	NN	O	O
cardiac	NN	O	O
output	NN	O	O
and	NN	O	O
maximum	NN	O	O
rate	NN	O	O
of	NN	O	O
rise	NN	O	O
of	NN	O	O
left	NN	O	O
ventricular	NN	O	O
pressure	NN	O	O
(	NN	O	O
LV	NN	O	O
dP	NN	O	O
/	NN	O	O
dt	NN	O	O
max	NN	O	O
)	NN	O	O
had	NN	O	O
been	NN	O	O
reduced	NN	O	O
by	NN	O	O
about	NN	O	O
35	NN	O	O
%	NN	O	O
and	NN	O	O
26	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
respective	NN	O	O
controls	NN	O	O
were	NN	O	O
improved	NN	O	O
by	NN	O	O
denopamine	NN	O	O
(	NN	O	O
10	NN	O	O
-	NN	O	O
300	NN	O	O
micrograms	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

With	NN	O	O
100	NN	O	O
micrograms	NN	O	O
denopamine	NN	O	O
,	NN	O	O
almost	NN	O	O
complete	NN	O	O
restoration	NN	O	O
of	NN	O	O
cardiac	NN	O	O
performance	NN	O	O
was	NN	O	O
attained	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
slight	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

No	NN	O	O
arrhythmias	NN	O	B
were	NN	O	O
induced	NN	O	O
by	NN	O	O
these	NN	O	O
doses	NN	O	O
of	NN	O	O
denopamine	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
warrant	NN	O	O
clinical	NN	O	O
trials	NN	O	O
of	NN	O	O
denopamine	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
cardiac	NN	O	B
failure	NN	O	I
.	NN	O	O

Clonazepam	NN	O	O
monotherapy	NN	O	O
for	NN	O	O
epilepsy	NN	O	B
in	NN	O	O
childhood	NN	O	O
.	NN	O	O

Sixty	NN	O	O
patients	NN	O	O
(	NN	O	O
age	NN	O	O
-	NN	O	O
range	NN	O	O
one	NN	O	O
month	NN	O	O
to	NN	O	O
14	NN	O	O
years	NN	O	O
)	NN	O	O
with	NN	O	O
other	NN	O	O
types	NN	O	O
of	NN	O	O
epilepsy	NN	O	B
than	NN	O	O
infantile	NN	O	B
spasms	NN	O	I
were	NN	O	O
treated	NN	O	O
with	NN	O	O
clonazepam	NN	O	O
.	NN	O	O

Disappearance	NN	O	O
of	NN	O	O
seizures	NN	O	B
and	NN	O	O
normalization	NN	O	O
of	NN	O	O
abnormal	NN	O	O
EEG	NN	O	O
with	NN	O	O
disappearance	NN	O	O
of	NN	O	O
seizures	NN	O	B
were	NN	O	O
recognized	NN	O	O
in	NN	O	O
77	NN	O	O
%	NN	O	O
and	NN	O	O
50	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Seizures	NN	O	B
disappeared	NN	O	O
in	NN	O	O
71	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
generalized	NN	O	O
seizures	NN	O	B
and	NN	O	O
89	NN	O	O
%	NN	O	O
of	NN	O	O
partial	NN	O	O
seizures	NN	O	B
.	NN	O	O

Improvement	NN	O	O
of	NN	O	O
abnormal	NN	O	O
EEG	NN	O	O
was	NN	O	O
noticed	NN	O	O
in	NN	O	O
76	NN	O	O
%	NN	O	O
of	NN	O	O
diffuse	NN	O	O
paroxysms	NN	O	O
and	NN	O	O
in	NN	O	O
67	NN	O	O
%	NN	O	O
of	NN	O	O
focal	NN	O	O
paroxysms	NN	O	O
.	NN	O	O

In	NN	O	O
excellent	NN	O	O
cases	NN	O	O
,	NN	O	O
mean	NN	O	O
effective	NN	O	O
dosages	NN	O	O
were	NN	O	O
0	NN	O	O
.	NN	O	O
086	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
021	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
in	NN	O	O
infants	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
057	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
022	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
in	NN	O	O
schoolchildren	NN	O	O
,	NN	O	O
this	NN	O	O
difference	NN	O	O
was	NN	O	O
statistically	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
side	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
drowsiness	NN	O	B
and	NN	O	O
ataxia	NN	O	B
was	NN	O	O
only	NN	O	O
5	NN	O	O
%	NN	O	O
.	NN	O	O

Postmarketing	NN	O	O
study	NN	O	O
of	NN	O	O
timolol	NN	O	O
-	NN	O	O
hydrochlorothiazide	NN	O	O
antihypertensive	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
postmarketing	NN	O	O
surveillance	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
a	NN	O	O
fixed	NN	O	O
-	NN	O	O
ratio	NN	O	O
combination	NN	O	O
containing	NN	O	O
10	NN	O	O
mg	NN	O	O
of	NN	O	O
timolol	NN	O	O
maleate	NN	O	O
and	NN	O	O
25	NN	O	O
mg	NN	O	O
of	NN	O	O
hydrochlorothiazide	NN	O	O
,	NN	O	O
administered	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
one	NN	O	O
month	NN	O	O
to	NN	O	O
hypertensive	NN	O	B
patients	NN	O	O
.	NN	O	O

Data	NN	O	O
on	NN	O	O
9	NN	O	O
,	NN	O	O
037	NN	O	O
patients	NN	O	O
were	NN	O	O
collected	NN	O	O
by	NN	O	O
1	NN	O	O
,	NN	O	O
455	NN	O	O
participating	NN	O	O
physicians	NN	O	O
.	NN	O	O

Mean	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
decreased	NN	O	O
25	NN	O	O
mmHg	NN	O	O
and	NN	O	O
mean	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
declined	NN	O	O
15	NN	O	O
mmHg	NN	O	O
after	NN	O	O
one	NN	O	O
month	NN	O	O
of	NN	O	O
timolol	NN	O	O
-	NN	O	O
hydrochlorothiazide	NN	O	O
therapy	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
,	NN	O	O
both	NN	O	O
comparisons	NN	O	O
)	NN	O	O
.	NN	O	O

Age	NN	O	O
,	NN	O	O
race	NN	O	O
,	NN	O	O
and	NN	O	O
sex	NN	O	O
appeared	NN	O	O
to	NN	O	O
have	NN	O	O
no	NN	O	O
influence	NN	O	O
on	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
.	NN	O	O

The	NN	O	O
antihypertensive	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
was	NN	O	O
greater	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
more	NN	O	O
severe	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
453	NN	O	O
patients	NN	O	O
experienced	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
2	NN	O	O
,	NN	O	O
658	NN	O	O
adverse	NN	O	O
events	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
being	NN	O	O
fatigue	NN	O	B
,	NN	O	O
dizziness	NN	O	B
,	NN	O	O
and	NN	O	O
weakness	NN	O	B
.	NN	O	O

Treatment	NN	O	O
in	NN	O	O
590	NN	O	O
patients	NN	O	O
was	NN	O	O
discontinued	NN	O	O
because	NN	O	O
of	NN	O	O
adverse	NN	O	O
events	NN	O	O
.	NN	O	O

Salicylate	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
the	NN	O	O
Gunn	NN	O	O
rat	NN	O	O
:	NN	O	O
potential	NN	O	O
role	NN	O	O
of	NN	O	O
prostaglandins	NN	O	O
.	NN	O	O

We	NN	O	O
examined	NN	O	O
the	NN	O	O
potential	NN	O	O
role	NN	O	O
of	NN	O	O
prostaglandins	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
analgesic	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
the	NN	O	O
Gunn	NN	O	O
strain	NN	O	O
of	NN	O	O
rat	NN	O	O
.	NN	O	O

The	NN	O	O
homozygous	NN	O	O
Gunn	NN	O	O
rats	NN	O	O
have	NN	O	O
unconjugated	NN	O	O
hyperbilirubinemia	NN	O	B
due	NN	O	O
to	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
glucuronyl	NN	O	O
transferase	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
marked	NN	O	O
bilirubin	NN	O	O
deposition	NN	O	O
in	NN	O	O
renal	NN	O	O
medulla	NN	O	O
and	NN	O	O
papilla	NN	O	O
.	NN	O	O

These	NN	O	O
rats	NN	O	O
are	NN	O	O
also	NN	O	O
highly	NN	O	O
susceptible	NN	O	O
to	NN	O	O
develop	NN	O	O
papillary	NN	O	B
necrosis	NN	O	I
with	NN	O	O
analgesic	NN	O	O
administration	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
homozygous	NN	O	O
(	NN	O	O
jj	NN	O	O
)	NN	O	O
and	NN	O	O
phenotypically	NN	O	O
normal	NN	O	O
heterozygous	NN	O	O
(	NN	O	O
jJ	NN	O	O
)	NN	O	O
animals	NN	O	O
.	NN	O	O

Four	NN	O	O
groups	NN	O	O
of	NN	O	O
rats	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
were	NN	O	O
studied	NN	O	O
:	NN	O	O
jj	NN	O	O
and	NN	O	O
jJ	NN	O	O
rats	NN	O	O
treated	NN	O	O
either	NN	O	O
with	NN	O	O
aspirin	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
every	NN	O	O
other	NN	O	O
day	NN	O	O
or	NN	O	O
sham	NN	O	O
-	NN	O	O
treated	NN	O	O
.	NN	O	O

After	NN	O	O
one	NN	O	O
week	NN	O	O
,	NN	O	O
slices	NN	O	O
of	NN	O	O
cortex	NN	O	O
,	NN	O	O
outer	NN	O	O
and	NN	O	O
inner	NN	O	O
medulla	NN	O	O
from	NN	O	O
one	NN	O	O
kidney	NN	O	O
were	NN	O	O
incubated	NN	O	O
in	NN	O	O
buffer	NN	O	O
and	NN	O	O
prostaglandin	NN	O	O
synthesis	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
radioimmunoassay	NN	O	O
.	NN	O	O

The	NN	O	O
other	NN	O	O
kidney	NN	O	O
was	NN	O	O
examined	NN	O	O
histologically	NN	O	O
.	NN	O	O

A	NN	O	O
marked	NN	O	O
corticomedullary	NN	O	O
gradient	NN	O	O
of	NN	O	O
prostaglandin	NN	O	O
synthesis	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
all	NN	O	O
groups	NN	O	O
.	NN	O	O

PGE2	NN	O	O
synthesis	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
outer	NN	O	O
medulla	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
cortex	NN	O	O
or	NN	O	O
inner	NN	O	O
medulla	NN	O	O
,	NN	O	O
of	NN	O	O
jj	NN	O	O
(	NN	O	O
38	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
ng	NN	O	O
/	NN	O	O
mg	NN	O	O
prot	NN	O	O
)	NN	O	O
than	NN	O	O
jJ	NN	O	O
rats	NN	O	O
(	NN	O	O
15	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
)	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Aspirin	NN	O	O
treatment	NN	O	O
reduced	NN	O	O
PGE2	NN	O	O
synthesis	NN	O	O
in	NN	O	O
all	NN	O	O
regions	NN	O	O
,	NN	O	O
but	NN	O	O
outer	NN	O	O
medullary	NN	O	O
PGE2	NN	O	O
remained	NN	O	O
higher	NN	O	O
in	NN	O	O
jj	NN	O	O
(	NN	O	O
18	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
)	NN	O	O
than	NN	O	O
jJ	NN	O	O
rats	NN	O	O
(	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
)	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

PGF2	NN	O	O
alpha	NN	O	O
was	NN	O	O
also	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
outer	NN	O	O
medulla	NN	O	O
of	NN	O	O
jj	NN	O	O
rats	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
aspirin	NN	O	O
administration	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
changes	NN	O	O
in	NN	O	O
renal	NN	O	O
prostaglandin	NN	O	O
synthesis	NN	O	O
were	NN	O	O
accompanied	NN	O	O
by	NN	O	O
evidence	NN	O	O
of	NN	O	O
renal	NN	O	B
damage	NN	O	I
in	NN	O	O
aspirin	NN	O	O
-	NN	O	O
treated	NN	O	O
jj	NN	O	O
but	NN	O	O
not	NN	O	O
jJ	NN	O	O
rats	NN	O	O
as	NN	O	O
evidenced	NN	O	O
by	NN	O	O
:	NN	O	O
increased	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
hematuria	NN	O	B
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
;	NN	O	O
increased	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
;	NN	O	O
and	NN	O	O
increase	NN	O	O
in	NN	O	O
outer	NN	O	O
medullary	NN	O	O
histopathologic	NN	O	O
lesions	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
005	NN	O	O
compared	NN	O	O
to	NN	O	O
either	NN	O	O
sham	NN	O	O
-	NN	O	O
treated	NN	O	O
jj	NN	O	O
or	NN	O	O
aspirin	NN	O	O
-	NN	O	O
treated	NN	O	O
jJ	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
enhanced	NN	O	O
prostaglandin	NN	O	O
synthesis	NN	O	O
contributes	NN	O	O
to	NN	O	O
maintenance	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
and	NN	O	O
morphological	NN	O	O
integrity	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
inhibition	NN	O	O
of	NN	O	O
prostaglandin	NN	O	O
synthesis	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
pathological	NN	O	B
renal	NN	O	I
medullary	NN	O	I
lesions	NN	O	I
and	NN	O	O
deterioration	NN	O	B
of	NN	O	I
renal	NN	O	I
function	NN	O	I
.	NN	O	O

Prophylactic	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
phase	NN	O	O
of	NN	O	O
suspected	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

Four	NN	O	O
hundred	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
suspected	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
seen	NN	O	O
within	NN	O	O
6	NN	O	O
hours	NN	O	O
of	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
symptoms	NN	O	O
entered	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
randomized	NN	O	O
trial	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
vs	NN	O	O
placebo	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
1	NN	O	O
hour	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
or	NN	O	O
sustained	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
among	NN	O	O
the	NN	O	O
204	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
was	NN	O	O
low	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
.	NN	O	O

Lidocaine	NN	O	O
,	NN	O	O
given	NN	O	O
in	NN	O	O
a	NN	O	O
300	NN	O	O
mg	NN	O	O
dose	NN	O	O
intramuscularly	NN	O	O
followed	NN	O	O
by	NN	O	O
100	NN	O	O
mg	NN	O	O
intravenously	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
prevent	NN	O	O
sustained	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
,	NN	O	O
although	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
warning	NN	O	O
arrhythmias	NN	O	B
between	NN	O	O
15	NN	O	O
and	NN	O	O
45	NN	O	O
minutes	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
average	NN	O	O
plasma	NN	O	O
lidocaine	NN	O	O
level	NN	O	O
10	NN	O	O
minutes	NN	O	O
after	NN	O	O
administration	NN	O	O
for	NN	O	O
patients	NN	O	O
without	NN	O	O
a	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
that	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
an	NN	O	O
acute	NN	O	O
infarction	NN	O	B
.	NN	O	O

The	NN	O	O
mean	NN	O	O
plasma	NN	O	O
lidocaine	NN	O	O
level	NN	O	O
of	NN	O	O
patients	NN	O	O
on	NN	O	O
beta	NN	O	O
-	NN	O	O
blocking	NN	O	O
agents	NN	O	O
was	NN	O	O
no	NN	O	O
different	NN	O	O
from	NN	O	O
that	NN	O	O
in	NN	O	O
patients	NN	O	O
not	NN	O	O
on	NN	O	O
beta	NN	O	O
blocking	NN	O	O
agents	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
1	NN	O	O
-	NN	O	O
hour	NN	O	O
study	NN	O	O
period	NN	O	O
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
side	NN	O	O
effects	NN	O	O
was	NN	O	O
significantly	NN	O	O
greater	NN	O	O
in	NN	O	O
the	NN	O	O
lidocaine	NN	O	O
group	NN	O	O
,	NN	O	O
hypotension	NN	O	B
occurred	NN	O	O
in	NN	O	O
11	NN	O	O
patients	NN	O	O
,	NN	O	O
nine	NN	O	O
of	NN	O	O
whom	NN	O	O
had	NN	O	O
received	NN	O	O
lidocaine	NN	O	O
,	NN	O	O
and	NN	O	O
four	NN	O	O
patients	NN	O	O
died	NN	O	O
from	NN	O	O
asystole	NN	O	B
,	NN	O	O
three	NN	O	O
of	NN	O	O
whom	NN	O	O
had	NN	O	O
had	NN	O	O
lidocaine	NN	O	O
.	NN	O	O

We	NN	O	O
cannot	NN	O	O
advocate	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
prophylactically	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
hours	NN	O	O
of	NN	O	O
suspected	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

Evidence	NN	O	O
for	NN	O	O
a	NN	O	O
cholinergic	NN	O	O
role	NN	O	O
in	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
.	NN	O	O

Experiments	NN	O	O
in	NN	O	O
mice	NN	O	O
tested	NN	O	O
previous	NN	O	O
evidence	NN	O	O
that	NN	O	O
activation	NN	O	O
of	NN	O	O
cholinergic	NN	O	O
systems	NN	O	O
promotes	NN	O	O
catalepsy	NN	O	B
and	NN	O	O
that	NN	O	O
cholinergic	NN	O	O
mechanisms	NN	O	O
need	NN	O	O
to	NN	O	O
be	NN	O	O
intact	NN	O	O
for	NN	O	O
full	NN	O	O
expression	NN	O	O
of	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
.	NN	O	O

Large	NN	O	O
doses	NN	O	O
of	NN	O	O
the	NN	O	O
cholinomimetic	NN	O	O
,	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
could	NN	O	O
induce	NN	O	O
catalepsy	NN	O	B
when	NN	O	O
peripheral	NN	O	O
cholinergic	NN	O	O
receptors	NN	O	O
were	NN	O	O
blocked	NN	O	O
.	NN	O	O

Low	NN	O	O
doses	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
caused	NN	O	O
a	NN	O	O
pronounced	NN	O	O
enhancement	NN	O	O
of	NN	O	O
the	NN	O	O
catalepsy	NN	O	B
that	NN	O	O
was	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
dopaminergic	NN	O	O
blocker	NN	O	O
,	NN	O	O
haloperidol	NN	O	O
.	NN	O	O

A	NN	O	O
muscarinic	NN	O	O
receptor	NN	O	O
blocker	NN	O	O
,	NN	O	O
atropine	NN	O	O
,	NN	O	O
disrupted	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
.	NN	O	O

Intracranial	NN	O	O
injection	NN	O	O
of	NN	O	O
an	NN	O	O
acetylcholine	NN	O	O
-	NN	O	O
synthesis	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
hemicholinium	NN	O	O
,	NN	O	O
prevented	NN	O	O
the	NN	O	O
catalepsy	NN	O	B
that	NN	O	O
is	NN	O	O
usually	NN	O	O
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
the	NN	O	O
catalepsy	NN	O	B
that	NN	O	O
is	NN	O	O
produced	NN	O	O
by	NN	O	O
neuroleptics	NN	O	O
such	NN	O	O
as	NN	O	O
haloperidol	NN	O	O
is	NN	O	O
actually	NN	O	O
mediated	NN	O	O
by	NN	O	O
intrinsic	NN	O	O
central	NN	O	O
cholinergic	NN	O	O
systems	NN	O	O
.	NN	O	O

Alternatively	NN	O	O
,	NN	O	O
activation	NN	O	O
of	NN	O	O
central	NN	O	O
cholinergic	NN	O	O
systems	NN	O	O
could	NN	O	O
promote	NN	O	O
catalepsy	NN	O	B
by	NN	O	O
suppression	NN	O	O
of	NN	O	O
dopaminergic	NN	O	O
systems	NN	O	O
.	NN	O	O

Cardiovascular	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
hypersensitivity	NN	O	B
to	NN	O	O
sodium	NN	O	O
pentobarbital	NN	O	O
induced	NN	O	O
by	NN	O	O
chronic	NN	O	O
barium	NN	O	O
chloride	NN	O	O
ingestion	NN	O	O
.	NN	O	O

Barium	NN	O	O
-	NN	O	O
supplemented	NN	O	O
Long	NN	O	O
-	NN	O	O
Evans	NN	O	O
hooded	NN	O	O
rats	NN	O	O
were	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
persistent	NN	O	O
hypertension	NN	O	B
that	NN	O	O
was	NN	O	O
evident	NN	O	O
after	NN	O	O
1	NN	O	O
month	NN	O	O
of	NN	O	O
barium	NN	O	O
(	NN	O	O
100	NN	O	O
micrograms	NN	O	O
/	NN	O	O
ml	NN	O	O
mineral	NN	O	O
fortified	NN	O	O
water	NN	O	O
)	NN	O	O
treatment	NN	O	O
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
in	NN	O	O
vivo	NN	O	O
myocardial	NN	O	O
excitability	NN	O	O
,	NN	O	O
contractility	NN	O	O
,	NN	O	O
and	NN	O	O
metabolic	NN	O	O
characteristics	NN	O	O
at	NN	O	O
16	NN	O	O
months	NN	O	O
revealed	NN	O	O
other	NN	O	O
significant	NN	O	O
barium	NN	O	O
-	NN	O	O
induced	NN	O	O
disturbances	NN	O	B
within	NN	O	I
the	NN	O	I
cardiovascular	NN	O	I
system	NN	O	I
.	NN	O	O

The	NN	O	O
most	NN	O	O
distinctive	NN	O	O
aspect	NN	O	O
of	NN	O	O
the	NN	O	O
barium	NN	O	O
effect	NN	O	O
was	NN	O	O
a	NN	O	O
demonstrated	NN	O	O
hypersensitivity	NN	O	B
of	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
system	NN	O	O
to	NN	O	O
sodium	NN	O	O
pentobarbital	NN	O	O
.	NN	O	O

Under	NN	O	O
barbiturate	NN	O	O
anesthesia	NN	O	O
,	NN	O	O
virtually	NN	O	O
all	NN	O	O
of	NN	O	O
the	NN	O	O
myocardial	NN	O	O
contractile	NN	O	O
indices	NN	O	O
were	NN	O	O
depressed	NN	O	O
significantly	NN	O	O
in	NN	O	O
barium	NN	O	O
-	NN	O	O
exposed	NN	O	O
rats	NN	O	O
relative	NN	O	O
to	NN	O	O
the	NN	O	O
corresponding	NN	O	O
control	NN	O	O
-	NN	O	O
fed	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
lack	NN	O	O
of	NN	O	O
a	NN	O	O
similar	NN	O	O
response	NN	O	O
to	NN	O	O
ketamine	NN	O	O
and	NN	O	O
xylazine	NN	O	O
anesthesia	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
actions	NN	O	O
of	NN	O	O
sodium	NN	O	O
pentobarbital	NN	O	O
in	NN	O	O
barium	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
were	NN	O	O
linked	NN	O	O
specifically	NN	O	O
to	NN	O	O
this	NN	O	O
anesthetic	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
not	NN	O	O
representative	NN	O	O
of	NN	O	O
a	NN	O	O
generalized	NN	O	O
anesthetic	NN	O	O
response	NN	O	O
.	NN	O	O

Other	NN	O	O
myocardial	NN	O	O
pathophysiologic	NN	O	O
and	NN	O	O
metabolic	NN	O	O
changes	NN	O	O
induced	NN	O	O
by	NN	O	O
barium	NN	O	O
were	NN	O	O
manifest	NN	O	O
,	NN	O	O
irrespective	NN	O	O
of	NN	O	O
the	NN	O	O
anesthetic	NN	O	O
employed	NN	O	O
.	NN	O	O

The	NN	O	O
contractile	NN	O	O
element	NN	O	O
shortening	NN	O	O
velocity	NN	O	O
of	NN	O	O
the	NN	O	O
cardiac	NN	O	O
muscle	NN	O	O
fibers	NN	O	O
was	NN	O	O
significantly	NN	O	O
slower	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
of	NN	O	O
barium	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
relative	NN	O	O
to	NN	O	O
the	NN	O	O
control	NN	O	O
groups	NN	O	O
,	NN	O	O
irrespective	NN	O	O
of	NN	O	O
the	NN	O	O
anesthetic	NN	O	O
regimen	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
significant	NN	O	O
disturbances	NN	O	O
in	NN	O	O
myocardial	NN	O	O
energy	NN	O	O
metabolism	NN	O	O
were	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
barium	NN	O	O
-	NN	O	O
exposed	NN	O	O
rats	NN	O	O
which	NN	O	O
were	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
reduced	NN	O	O
contractile	NN	O	O
element	NN	O	O
shortening	NN	O	O
velocity	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
excitability	NN	O	O
of	NN	O	O
the	NN	O	O
cardiac	NN	O	O
conduction	NN	O	O
system	NN	O	O
was	NN	O	O
depressed	NN	O	O
preferentially	NN	O	O
in	NN	O	O
the	NN	O	O
atrioventricular	NN	O	O
nodal	NN	O	O
region	NN	O	O
of	NN	O	O
hearts	NN	O	O
from	NN	O	O
barium	NN	O	O
-	NN	O	O
exposed	NN	O	O
rats	NN	O	O
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
the	NN	O	O
altered	NN	O	O
cardiac	NN	O	O
contractility	NN	O	O
and	NN	O	O
excitability	NN	O	O
characteristics	NN	O	O
,	NN	O	O
the	NN	O	O
myocardial	NN	O	O
metabolic	NN	O	B
disturbances	NN	O	I
,	NN	O	O
and	NN	O	O
the	NN	O	O
hypersensitivity	NN	O	B
of	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
system	NN	O	O
to	NN	O	O
sodium	NN	O	O
pentobarbital	NN	O	O
suggest	NN	O	O
the	NN	O	O
existence	NN	O	O
of	NN	O	O
a	NN	O	O
heretofore	NN	O	O
undescribed	NN	O	O
cardiomyopathic	NN	O	B
disorder	NN	O	I
induced	NN	O	O
by	NN	O	O
chronic	NN	O	O
barium	NN	O	O
exposure	NN	O	O
.	NN	O	O

These	NN	O	O
experimental	NN	O	O
findings	NN	O	O
represent	NN	O	O
the	NN	O	O
first	NN	O	O
indication	NN	O	O
that	NN	O	O
life	NN	O	O
-	NN	O	O
long	NN	O	O
barium	NN	O	O
ingestion	NN	O	O
may	NN	O	O
have	NN	O	O
significant	NN	O	O
adverse	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
mammalian	NN	O	O
cardiovascular	NN	O	O
system	NN	O	O
.	NN	O	O

Propranolol	NN	O	O
antagonism	NN	O	O
of	NN	O	O
phenylpropanolamine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Phenylpropanolamine	NN	O	O
(	NN	O	O
PPA	NN	O	O
)	NN	O	O
overdose	NN	O	B
can	NN	O	O
cause	NN	O	O
severe	NN	O	O
hypertension	NN	O	B
,	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
,	NN	O	O
and	NN	O	O
death	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
propranolol	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
PPA	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Subjects	NN	O	O
received	NN	O	O
propranolol	NN	O	O
either	NN	O	O
by	NN	O	O
mouth	NN	O	O
for	NN	O	O
48	NN	O	O
hours	NN	O	O
before	NN	O	O
PPA	NN	O	O
or	NN	O	O
as	NN	O	O
a	NN	O	O
rapid	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
after	NN	O	O
PPA	NN	O	O
.	NN	O	O

PPA	NN	O	O
,	NN	O	O
75	NN	O	O
mg	NN	O	O
alone	NN	O	O
,	NN	O	O
increased	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
31	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
14	NN	O	O
mm	NN	O	O
Hg	NN	O	O
systolic	NN	O	O
,	NN	O	O
20	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
mm	NN	O	O
Hg	NN	O	O
diastolic	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
propranolol	NN	O	O
pretreatment	NN	O	O
antagonized	NN	O	O
this	NN	O	O
increase	NN	O	O
(	NN	O	O
12	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
mm	NN	O	O
Hg	NN	O	O
systolic	NN	O	O
,	NN	O	O
10	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
mm	NN	O	O
Hg	NN	O	O
diastolic	NN	O	O
)	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
propranolol	NN	O	O
after	NN	O	O
PPA	NN	O	O
also	NN	O	O
decreased	NN	O	O
blood	NN	O	O
pressure	NN	O	O
.	NN	O	O

Left	NN	O	O
ventricular	NN	O	O
function	NN	O	O
(	NN	O	O
assessed	NN	O	O
by	NN	O	O
echocardiography	NN	O	O
)	NN	O	O
showed	NN	O	O
that	NN	O	O
PPA	NN	O	O
increased	NN	O	O
the	NN	O	O
stroke	NN	O	B
volume	NN	O	O
30	NN	O	O
%	NN	O	O
(	NN	O	O
from	NN	O	O
62	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
20	NN	O	O
.	NN	O	O
9	NN	O	O
to	NN	O	O
80	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
22	NN	O	O
.	NN	O	O
4	NN	O	O
ml	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
9	NN	O	O
%	NN	O	O
(	NN	O	O
from	NN	O	O
64	NN	O	O
%	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
%	NN	O	O
to	NN	O	O
70	NN	O	O
%	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
cardiac	NN	O	O
output	NN	O	O
14	NN	O	O
%	NN	O	O
(	NN	O	O
from	NN	O	O
3	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
to	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
L	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
propranolol	NN	O	O
reversed	NN	O	O
these	NN	O	O
effects	NN	O	O
.	NN	O	O

Systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
was	NN	O	O
increased	NN	O	O
by	NN	O	O
PPA	NN	O	O
28	NN	O	O
%	NN	O	O
(	NN	O	O
from	NN	O	O
1710	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
200	NN	O	O
to	NN	O	O
2190	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
700	NN	O	O
dyne	NN	O	O
X	NN	O	O
sec	NN	O	O
/	NN	O	O
cm5	NN	O	O
)	NN	O	O
and	NN	O	O
was	NN	O	O
further	NN	O	O
increased	NN	O	O
by	NN	O	O
propranolol	NN	O	O
22	NN	O	O
%	NN	O	O
(	NN	O	O
to	NN	O	O
2660	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1200	NN	O	O
dyne	NN	O	O
X	NN	O	O
sec	NN	O	O
/	NN	O	O
cm5	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
PPA	NN	O	O
increases	NN	O	O
blood	NN	O	O
pressure	NN	O	O
by	NN	O	O
increasing	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
and	NN	O	O
cardiac	NN	O	O
output	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
propranolol	NN	O	O
antagonizes	NN	O	O
this	NN	O	O
increase	NN	O	O
by	NN	O	O
reversing	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
PPA	NN	O	O
on	NN	O	O
cardiac	NN	O	O
output	NN	O	O
.	NN	O	O

That	NN	O	O
propranolol	NN	O	O
antagonizes	NN	O	O
the	NN	O	O
pressor	NN	O	O
effect	NN	O	O
of	NN	O	O
PPA	NN	O	O
is	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
the	NN	O	O
interaction	NN	O	O
in	NN	O	O
which	NN	O	O
propranolol	NN	O	O
enhances	NN	O	O
the	NN	O	O
pressor	NN	O	O
effect	NN	O	O
of	NN	O	O
norepinephrine	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
probably	NN	O	O
because	NN	O	O
PPA	NN	O	O
has	NN	O	O
less	NN	O	O
beta	NN	O	O
2	NN	O	O
activity	NN	O	O
than	NN	O	O
does	NN	O	O
norepinephrine	NN	O	O
.	NN	O	O

Mesangial	NN	O	O
function	NN	O	O
and	NN	O	O
glomerular	NN	O	B
sclerosis	NN	O	I
in	NN	O	O
rats	NN	O	O
with	NN	O	O
aminonucleoside	NN	O	O
nephrosis	NN	O	B
.	NN	O	O

The	NN	O	O
possible	NN	O	O
relationship	NN	O	O
between	NN	O	O
mesangial	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
development	NN	O	O
of	NN	O	O
glomerular	NN	O	B
sclerosis	NN	O	I
was	NN	O	O
studied	NN	O	O
in	NN	O	O
the	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
(	NN	O	O
PAN	NN	O	O
)	NN	O	O
model	NN	O	O
.	NN	O	O

Five	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
received	NN	O	O
repeated	NN	O	O
subcutaneous	NN	O	O
PAN	NN	O	O
injections	NN	O	O
;	NN	O	O
five	NN	O	O
controls	NN	O	O
received	NN	O	O
saline	NN	O	O
only	NN	O	O
.	NN	O	O

After	NN	O	O
4	NN	O	O
weeks	NN	O	O
the	NN	O	O
PAN	NN	O	O
rats	NN	O	O
were	NN	O	O
severely	NN	O	O
proteinuric	NN	O	B
(	NN	O	O
190	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
80	NN	O	O
mg	NN	O	O
/	NN	O	O
24	NN	O	O
hr	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
rats	NN	O	O
were	NN	O	O
given	NN	O	O
colloidal	NN	O	O
carbon	NN	O	O
(	NN	O	O
CC	NN	O	O
)	NN	O	O
intravenously	NN	O	O
.	NN	O	O

At	NN	O	O
5	NN	O	O
months	NN	O	O
glomerular	NN	O	B
sclerosis	NN	O	I
was	NN	O	O
found	NN	O	O
in	NN	O	O
7	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
glomeruli	NN	O	O
of	NN	O	O
PAN	NN	O	O
rats	NN	O	O
;	NN	O	O
glomeruli	NN	O	O
of	NN	O	O
the	NN	O	O
controls	NN	O	O
were	NN	O	O
normal	NN	O	O
.	NN	O	O

Glomeruli	NN	O	O
of	NN	O	O
PAN	NN	O	O
rats	NN	O	O
contained	NN	O	O
significantly	NN	O	O
more	NN	O	O
CC	NN	O	O
than	NN	O	O
glomeruli	NN	O	O
of	NN	O	O
controls	NN	O	O
.	NN	O	O

Glomeruli	NN	O	O
with	NN	O	O
sclerosis	NN	O	B
contained	NN	O	O
significantly	NN	O	O
more	NN	O	O
CC	NN	O	O
than	NN	O	O
non	NN	O	O
-	NN	O	O
sclerotic	NN	O	O
glomeruli	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
kidneys	NN	O	O
.	NN	O	O

CC	NN	O	O
was	NN	O	O
preferentially	NN	O	O
localized	NN	O	O
within	NN	O	O
the	NN	O	O
sclerotic	NN	O	O
areas	NN	O	O
of	NN	O	O
the	NN	O	O
affected	NN	O	O
glomeruli	NN	O	O
.	NN	O	O

Since	NN	O	O
mesangial	NN	O	O
CC	NN	O	O
clearance	NN	O	O
from	NN	O	O
the	NN	O	O
mesangium	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
during	NN	O	O
chronic	NN	O	O
PAN	NN	O	O
treatment	NN	O	O
,	NN	O	O
we	NN	O	O
conclude	NN	O	O
that	NN	O	O
this	NN	O	O
preferential	NN	O	O
CC	NN	O	O
localization	NN	O	O
within	NN	O	O
the	NN	O	O
lesions	NN	O	O
is	NN	O	O
caused	NN	O	O
by	NN	O	O
an	NN	O	O
increased	NN	O	O
CC	NN	O	O
uptake	NN	O	O
shortly	NN	O	O
after	NN	O	O
injection	NN	O	O
in	NN	O	O
apparent	NN	O	O
vulnerable	NN	O	O
areas	NN	O	O
where	NN	O	O
sclerosis	NN	O	B
will	NN	O	O
develop	NN	O	O
subsequently	NN	O	O
.	NN	O	O

Cluster	NN	O	O
analysis	NN	O	O
showed	NN	O	O
a	NN	O	O
random	NN	O	O
distribution	NN	O	O
of	NN	O	O
lesions	NN	O	O
in	NN	O	O
the	NN	O	O
PAN	NN	O	O
glomeruli	NN	O	O
in	NN	O	O
concordance	NN	O	O
with	NN	O	O
the	NN	O	O
random	NN	O	O
localization	NN	O	O
of	NN	O	O
mesangial	NN	O	O
areas	NN	O	O
with	NN	O	O
dysfunction	NN	O	O
in	NN	O	O
this	NN	O	O
model	NN	O	O
.	NN	O	O

Similar	NN	O	O
to	NN	O	O
the	NN	O	O
remnant	NN	O	O
kidney	NN	O	O
model	NN	O	O
in	NN	O	O
PAN	NN	O	O
nephrosis	NN	O	B
the	NN	O	O
development	NN	O	O
of	NN	O	O
glomerular	NN	O	B
sclerosis	NN	O	I
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
"	NN	O	O
mesangial	NN	O	O
overloading	NN	O	O
.	NN	O	O
"	NN	O	O

Relationship	NN	O	O
between	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
hippocampal	NN	O	O
nicotinic	NN	O	O
receptors	NN	O	O
.	NN	O	O

A	NN	O	O
controversy	NN	O	O
has	NN	O	O
existed	NN	O	O
for	NN	O	O
several	NN	O	O
years	NN	O	O
concerning	NN	O	O
the	NN	O	O
physiological	NN	O	O
relevance	NN	O	O
of	NN	O	O
the	NN	O	O
nicotinic	NN	O	O
receptor	NN	O	O
measured	NN	O	O
by	NN	O	O
alpha	NN	O	O
-	NN	O	O
bungarotoxin	NN	O	O
binding	NN	O	O
.	NN	O	O

Using	NN	O	O
mice	NN	O	O
derived	NN	O	O
from	NN	O	O
a	NN	O	O
classical	NN	O	O
F2	NN	O	O
and	NN	O	O
backcross	NN	O	O
genetic	NN	O	O
design	NN	O	O
,	NN	O	O
a	NN	O	O
relationship	NN	O	O
between	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
alpha	NN	O	O
-	NN	O	O
bungarotoxin	NN	O	O
nicotinic	NN	O	O
receptor	NN	O	O
concentration	NN	O	O
was	NN	O	O
found	NN	O	O
.	NN	O	O

Mice	NN	O	O
sensitive	NN	O	O
to	NN	O	O
the	NN	O	O
convulsant	NN	O	O
effects	NN	O	O
of	NN	O	O
nicotine	NN	O	O
had	NN	O	O
greater	NN	O	O
alpha	NN	O	O
-	NN	O	O
bungarotoxin	NN	O	O
binding	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
than	NN	O	O
seizure	NN	O	B
insensitive	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
binding	NN	O	O
sites	NN	O	O
from	NN	O	O
seizure	NN	O	B
sensitive	NN	O	O
and	NN	O	O
resistant	NN	O	O
mice	NN	O	O
were	NN	O	O
equally	NN	O	O
affected	NN	O	O
by	NN	O	O
treatment	NN	O	O
with	NN	O	O
dithiothreitol	NN	O	O
,	NN	O	O
trypsin	NN	O	O
or	NN	O	O
heat	NN	O	O
.	NN	O	O

Thus	NN	O	O
it	NN	O	O
appears	NN	O	O
that	NN	O	O
the	NN	O	O
difference	NN	O	O
between	NN	O	O
seizure	NN	O	B
sensitive	NN	O	O
and	NN	O	O
insensitive	NN	O	O
animals	NN	O	O
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
difference	NN	O	O
in	NN	O	O
hippocampal	NN	O	O
nicotinic	NN	O	O
receptor	NN	O	O
concentration	NN	O	O
as	NN	O	O
measured	NN	O	O
with	NN	O	O
alpha	NN	O	O
-	NN	O	O
bungarotoxin	NN	O	O
binding	NN	O	O
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
p	NN	O	O
-	NN	O	O
aminophenol	NN	O	O
in	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
:	NN	O	O
effect	NN	O	O
of	NN	O	O
bis	NN	O	O
(	NN	O	O
p	NN	O	O
-	NN	O	O
nitrophenyl	NN	O	O
)	NN	O	O
phosphate	NN	O	O
on	NN	O	O
acetaminophen	NN	O	O
and	NN	O	O
p	NN	O	O
-	NN	O	O
aminophenol	NN	O	O
nephrotoxicity	NN	O	B
and	NN	O	O
metabolism	NN	O	O
in	NN	O	O
Fischer	NN	O	O
344	NN	O	O
rats	NN	O	O
.	NN	O	O

Acetaminophen	NN	O	O
(	NN	O	O
APAP	NN	O	O
)	NN	O	O
produces	NN	O	O
proximal	NN	O	O
tubular	NN	O	B
necrosis	NN	O	I
in	NN	O	O
Fischer	NN	O	O
344	NN	O	O
(	NN	O	O
F344	NN	O	O
)	NN	O	O
rats	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
p	NN	O	O
-	NN	O	O
aminophenol	NN	O	O
(	NN	O	O
PAP	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
known	NN	O	O
potent	NN	O	O
nephrotoxicant	NN	O	O
,	NN	O	O
was	NN	O	O
identified	NN	O	O
as	NN	O	O
a	NN	O	O
metabolite	NN	O	O
of	NN	O	O
APAP	NN	O	O
in	NN	O	O
F344	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
PAP	NN	O	O
formation	NN	O	O
is	NN	O	O
a	NN	O	O
requisite	NN	O	O
step	NN	O	O
in	NN	O	O
APAP	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
bis	NN	O	O
(	NN	O	O
p	NN	O	O
-	NN	O	O
nitrophenyl	NN	O	O
)	NN	O	O
phosphate	NN	O	O
(	NN	O	O
BNPP	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
acylamidase	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
on	NN	O	O
APAP	NN	O	O
and	NN	O	O
PAP	NN	O	O
nephrotoxicity	NN	O	B
and	NN	O	O
metabolism	NN	O	O
was	NN	O	O
determined	NN	O	O
.	NN	O	O

BNPP	NN	O	O
(	NN	O	O
1	NN	O	O
to	NN	O	O
8	NN	O	O
mM	NN	O	O
)	NN	O	O
reduced	NN	O	O
APAP	NN	O	O
deacetylation	NN	O	O
and	NN	O	O
covalent	NN	O	O
binding	NN	O	O
in	NN	O	O
F344	NN	O	O
renal	NN	O	O
cortical	NN	O	O
homogenates	NN	O	O
in	NN	O	O
a	NN	O	O
concentration	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
of	NN	O	O
animals	NN	O	O
with	NN	O	O
BNPP	NN	O	O
prior	NN	O	O
to	NN	O	O
APAP	NN	O	O
or	NN	O	O
PAP	NN	O	O
administration	NN	O	O
resulted	NN	O	O
in	NN	O	O
marked	NN	O	O
reduction	NN	O	O
of	NN	O	O
APAP	NN	O	O
(	NN	O	O
900	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
nephrotoxicity	NN	O	B
but	NN	O	O
not	NN	O	O
PAP	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

This	NN	O	O
result	NN	O	O
was	NN	O	O
not	NN	O	O
due	NN	O	O
to	NN	O	O
altered	NN	O	O
disposition	NN	O	O
of	NN	O	O
either	NN	O	O
APAP	NN	O	O
or	NN	O	O
acetylated	NN	O	O
metabolites	NN	O	O
in	NN	O	O
plasma	NN	O	O
or	NN	O	O
renal	NN	O	O
cortical	NN	O	O
and	NN	O	O
hepatic	NN	O	O
tissue	NN	O	O
.	NN	O	O

Rather	NN	O	O
,	NN	O	O
BNPP	NN	O	O
pretreatment	NN	O	O
reduced	NN	O	O
the	NN	O	O
fraction	NN	O	O
of	NN	O	O
APAP	NN	O	O
excreted	NN	O	O
as	NN	O	O
PAP	NN	O	O
by	NN	O	O
64	NN	O	O
and	NN	O	O
75	NN	O	O
%	NN	O	O
after	NN	O	O
APAP	NN	O	O
doses	NN	O	O
of	NN	O	O
750	NN	O	O
and	NN	O	O
900	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

BNPP	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
the	NN	O	O
excretion	NN	O	O
of	NN	O	O
APAP	NN	O	O
or	NN	O	O
any	NN	O	O
of	NN	O	O
its	NN	O	O
non	NN	O	O
-	NN	O	O
deacetylated	NN	O	O
metabolites	NN	O	O
nor	NN	O	O
did	NN	O	O
BNPP	NN	O	O
alter	NN	O	O
excretion	NN	O	O
of	NN	O	O
PAP	NN	O	O
or	NN	O	O
its	NN	O	O
metabolites	NN	O	O
after	NN	O	O
PAP	NN	O	O
doses	NN	O	O
of	NN	O	O
150	NN	O	O
and	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
the	NN	O	O
BNPP	NN	O	O
-	NN	O	O
induced	NN	O	O
reduction	NN	O	O
in	NN	O	O
APAP	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
appears	NN	O	O
to	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
inhibition	NN	O	O
of	NN	O	O
APAP	NN	O	O
deacetylation	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
PAP	NN	O	O
formation	NN	O	O
,	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
accounts	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
for	NN	O	O
APAP	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
tubular	NN	O	I
necrosis	NN	O	I
.	NN	O	O

Morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
in	NN	O	O
newborn	NN	O	O
infants	NN	O	O
.	NN	O	O

Two	NN	O	O
neonates	NN	O	O
suffered	NN	O	O
from	NN	O	O
generalized	NN	O	O
seizures	NN	O	B
during	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
intravenous	NN	O	O
morphine	NN	O	O
sulfate	NN	O	O
for	NN	O	O
post	NN	O	O
-	NN	O	O
operative	NN	O	O
analgesia	NN	O	O
.	NN	O	O

They	NN	O	O
received	NN	O	O
morphine	NN	O	O
in	NN	O	O
doses	NN	O	O
of	NN	O	O
32	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
hr	NN	O	O
and	NN	O	O
40	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
hr	NN	O	O
larger	NN	O	O
than	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
10	NN	O	O
neonates	NN	O	O
who	NN	O	O
received	NN	O	O
6	NN	O	O
-	NN	O	O
24	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
hr	NN	O	O
and	NN	O	O
had	NN	O	O
no	NN	O	O
seizures	NN	O	B
.	NN	O	O

Plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
morphine	NN	O	O
in	NN	O	O
these	NN	O	O
neonates	NN	O	O
was	NN	O	O
excessive	NN	O	O
(	NN	O	O
60	NN	O	O
and	NN	O	O
90	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
.	NN	O	O

Other	NN	O	O
known	NN	O	O
reasons	NN	O	O
for	NN	O	O
seizures	NN	O	B
were	NN	O	O
ruled	NN	O	O
out	NN	O	O
and	NN	O	O
the	NN	O	O
convulsions	NN	O	B
stopped	NN	O	O
a	NN	O	O
few	NN	O	O
hours	NN	O	O
after	NN	O	O
cessation	NN	O	O
of	NN	O	O
morphine	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
reoccur	NN	O	O
in	NN	O	O
the	NN	O	O
subsequent	NN	O	O
8	NN	O	O
months	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
post	NN	O	O
-	NN	O	O
operative	NN	O	O
intravenous	NN	O	O
morphine	NN	O	O
should	NN	O	O
not	NN	O	O
exceed	NN	O	O
20	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
ml	NN	O	O
in	NN	O	O
neonates	NN	O	O
.	NN	O	O

Indomethacin	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
in	NN	O	O
sodium	NN	O	O
and	NN	O	O
volume	NN	O	O
depleted	NN	O	O
rats	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
single	NN	O	O
oral	NN	O	O
dose	NN	O	O
of	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
indomethacin	NN	O	O
(	NN	O	O
IDM	NN	O	O
)	NN	O	O
to	NN	O	O
sodium	NN	O	O
and	NN	O	O
volume	NN	O	O
depleted	NN	O	O
rats	NN	O	O
plasma	NN	O	O
renin	NN	O	O
activity	NN	O	O
(	NN	O	O
PRA	NN	O	O
)	NN	O	O
and	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
fell	NN	O	O
significantly	NN	O	O
within	NN	O	O
four	NN	O	O
hours	NN	O	O
.	NN	O	O

In	NN	O	O
sodium	NN	O	O
repleted	NN	O	O
animals	NN	O	O
indomethacin	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
BP	NN	O	O
)	NN	O	O
although	NN	O	O
plasma	NN	O	O
renin	NN	O	O
activity	NN	O	O
was	NN	O	O
decreased	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
indomethacin	NN	O	O
by	NN	O	O
inhibition	NN	O	O
of	NN	O	O
prostaglandin	NN	O	O
synthesis	NN	O	O
may	NN	O	O
diminish	NN	O	O
the	NN	O	O
blood	NN	O	O
pressure	NN	O	O
maintaining	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
stimulated	NN	O	O
renin	NN	O	O
-	NN	O	O
angiotensin	NN	O	O
system	NN	O	O
in	NN	O	O
sodium	NN	O	O
and	NN	O	O
volume	NN	O	O
depletion	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
antiarrhythmic	NN	O	O
activity	NN	O	O
of	NN	O	O
one	NN	O	O
N	NN	O	O
-	NN	O	O
substituted	NN	O	O
piperazine	NN	O	O
derivative	NN	O	O
of	NN	O	O
trans	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
amino	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
tetrahydroanaphthalene	NN	O	O
.	NN	O	O

The	NN	O	O
antiarrhythmic	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
compound	NN	O	O
N	NN	O	O
-	NN	O	O
(	NN	O	O
trans	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
tetrahydro	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
naphthyl	NN	O	O
)	NN	O	O
-	NN	O	O
N	NN	O	O
-	NN	O	O
(	NN	O	O
3	NN	O	O
-	NN	O	O
oxo	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
phenyl	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
methylpropyl	NN	O	O
)	NN	O	O
-	NN	O	O
piperazine	NN	O	O
hydrochloride	NN	O	O
,	NN	O	O
referred	NN	O	O
to	NN	O	O
as	NN	O	O
P11	NN	O	O
,	NN	O	O
is	NN	O	O
studied	NN	O	O
on	NN	O	O
anaesthesized	NN	O	O
cats	NN	O	O
and	NN	O	O
Wistar	NN	O	O
albino	NN	O	O
rats	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
on	NN	O	O
non	NN	O	O
-	NN	O	O
anaesthesized	NN	O	O
rabbits	NN	O	O
.	NN	O	O

Four	NN	O	O
types	NN	O	O
of	NN	O	O
experimental	NN	O	O
arrhythmia	NN	O	B
are	NN	O	O
used	NN	O	O
-	NN	O	O
-	NN	O	O
with	NN	O	O
BaCl2	NN	O	O
,	NN	O	O
with	NN	O	O
chloroform	NN	O	O
-	NN	O	O
adrenaline	NN	O	O
,	NN	O	O
with	NN	O	O
strophantine	NN	O	O
G	NN	O	O
and	NN	O	O
with	NN	O	O
aconitine	NN	O	O
.	NN	O	O

The	NN	O	O
compound	NN	O	O
P11	NN	O	O
is	NN	O	O
introduced	NN	O	O
in	NN	O	O
doses	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
intravenously	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
orally	NN	O	O
.	NN	O	O

The	NN	O	O
compound	NN	O	O
manifests	NN	O	O
antiarrhythmic	NN	O	O
activity	NN	O	O
in	NN	O	O
all	NN	O	O
models	NN	O	O
of	NN	O	O
experimental	NN	O	O
arrhythmia	NN	O	B
used	NN	O	O
,	NN	O	O
causing	NN	O	O
greatest	NN	O	O
inhibition	NN	O	O
on	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B
induced	NN	O	O
by	NN	O	O
chloroform	NN	O	O
-	NN	O	O
adrenaline	NN	O	O
(	NN	O	O
in	NN	O	O
90	NN	O	O
per	NN	O	O
cent	NN	O	O
)	NN	O	O
and	NN	O	O
with	NN	O	O
BaCl2	NN	O	O
(	NN	O	O
in	NN	O	O
84	NN	O	O
per	NN	O	O
cent	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
obtained	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoblocking	NN	O	O
and	NN	O	O
with	NN	O	O
the	NN	O	O
membrane	NN	O	O
-	NN	O	O
stabilizing	NN	O	O
action	NN	O	O
of	NN	O	O
the	NN	O	O
compound	NN	O	O
.	NN	O	O

Recurrent	NN	O	O
subarachnoid	NN	O	B
hemorrhage	NN	O	I
associated	NN	O	O
with	NN	O	O
aminocaproic	NN	O	O
acid	NN	O	O
therapy	NN	O	O
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
artery	NN	O	I
thrombosis	NN	O	I
.	NN	O	O

Case	NN	O	O
report	NN	O	O
.	NN	O	O

Epsilon	NN	O	O
aminocaproic	NN	O	O
acid	NN	O	O
(	NN	O	O
EACA	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
to	NN	O	O
prevent	NN	O	O
rebleeding	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
subarachnoid	NN	O	B
hemorrhage	NN	O	I
(	NN	O	O
SAH	NN	O	B
)	NN	O	O
.	NN	O	O

Although	NN	O	O
this	NN	O	O
agent	NN	O	O
does	NN	O	O
decrease	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
rebleeding	NN	O	O
,	NN	O	O
several	NN	O	O
reports	NN	O	O
have	NN	O	O
described	NN	O	O
thrombotic	NN	O	B
complications	NN	O	O
of	NN	O	O
EACA	NN	O	O
therapy	NN	O	O
.	NN	O	O

These	NN	O	O
complications	NN	O	O
have	NN	O	O
included	NN	O	O
clinical	NN	O	O
deterioration	NN	O	O
and	NN	O	O
intracranial	NN	O	B
vascular	NN	O	I
thrombosis	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
SAH	NN	O	B
,	NN	O	O
arteriolar	NN	O	O
and	NN	O	O
capillary	NN	O	O
fibrin	NN	O	O
thrombi	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
fibrinolytic	NN	O	O
syndromes	NN	O	O
treated	NN	O	O
with	NN	O	O
EACA	NN	O	O
,	NN	O	O
or	NN	O	O
other	NN	O	O
thromboembolic	NN	O	B
phenomena	NN	O	I
.	NN	O	O

Since	NN	O	O
intravascular	NN	O	O
fibrin	NN	O	O
thrombi	NN	O	B
are	NN	O	O
often	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
fibrinolytic	NN	O	O
disorders	NN	O	O
,	NN	O	O
EACA	NN	O	O
should	NN	O	O
not	NN	O	O
be	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
fibrin	NN	O	O
thrombi	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
disseminated	NN	O	B
intravascular	NN	O	I
coagulation	NN	O	I
or	NN	O	O
other	NN	O	O
"	NN	O	O
consumption	NN	O	B
coagulopathies	NN	O	I
.	NN	O	O
"	NN	O	O
This	NN	O	O
report	NN	O	O
describes	NN	O	O
subtotal	NN	O	O
infarction	NN	O	B
of	NN	O	O
the	NN	O	O
kidney	NN	O	O
due	NN	O	O
to	NN	O	O
thrombosis	NN	O	B
of	NN	O	I
a	NN	O	I
normal	NN	O	I
renal	NN	O	I
artery	NN	O	I
.	NN	O	O

This	NN	O	O
occlusion	NN	O	O
occurred	NN	O	O
after	NN	O	O
EACA	NN	O	O
therapy	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
SAH	NN	O	B
and	NN	O	O
histopathological	NN	O	O
documentation	NN	O	O
of	NN	O	O
recurrent	NN	O	O
SAH	NN	O	B
.	NN	O	O

The	NN	O	O
corresponding	NN	O	O
clinical	NN	O	O
event	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
marked	NN	O	O
hypertension	NN	O	B
and	NN	O	O
abrupt	NN	O	O
neurological	NN	O	O
deterioration	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
vincristine	NN	O	O
sulfate	NN	O	O
on	NN	O	O
Pseudomonas	NN	O	B
infections	NN	O	I
in	NN	O	O
monkeys	NN	O	O
.	NN	O	O

In	NN	O	O
rhesus	NN	O	O
monkeys	NN	O	O
,	NN	O	O
intravenous	NN	O	O
challenge	NN	O	O
with	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
10	NN	O	O
)	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
2	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
10	NN	O	O
)	NN	O	O
Pseudomonas	NN	O	O
aeruginosa	NN	O	O
organisms	NN	O	O
caused	NN	O	O
acute	NN	O	O
illness	NN	O	O
of	NN	O	O
4	NN	O	O
to	NN	O	O
5	NN	O	O
days	NN	O	O
'	NN	O	O
duration	NN	O	O
with	NN	O	O
spontaneous	NN	O	O
recovery	NN	O	O
in	NN	O	O
13	NN	O	O
of	NN	O	O
15	NN	O	O
monkeys	NN	O	O
;	NN	O	O
blood	NN	O	O
cultures	NN	O	O
became	NN	O	O
negative	NN	O	O
3	NN	O	O
to	NN	O	O
17	NN	O	O
days	NN	O	O
after	NN	O	O
challenge	NN	O	O
.	NN	O	O

Leukocytosis	NN	O	B
was	NN	O	O
observed	NN	O	O
in	NN	O	O
all	NN	O	O
monkeys	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
or	NN	O	O
intratracheal	NN	O	O
inoculation	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
of	NN	O	O
vincristine	NN	O	O
sulfate	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
leukopenia	NN	O	B
in	NN	O	O
4	NN	O	O
to	NN	O	O
5	NN	O	O
days	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
inoculation	NN	O	O
of	NN	O	O
4	NN	O	O
.	NN	O	O
2	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
10	NN	O	O
)	NN	O	O
to	NN	O	O
7	NN	O	O
.	NN	O	O
8	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
10	NN	O	O
)	NN	O	O
pyocin	NN	O	O
type	NN	O	O
6	NN	O	O
Pseudomonas	NN	O	O
organisms	NN	O	O
in	NN	O	O
monkeys	NN	O	O
given	NN	O	O
vincristine	NN	O	O
sulfate	NN	O	O
4	NN	O	O
days	NN	O	O
previously	NN	O	O
resulted	NN	O	O
in	NN	O	O
fatal	NN	O	O
infection	NN	O	B
in	NN	O	O
11	NN	O	O
of	NN	O	O
14	NN	O	O
monkeys	NN	O	O
,	NN	O	O
whereas	NN	O	O
none	NN	O	O
of	NN	O	O
four	NN	O	O
receiving	NN	O	O
Pseudomonas	NN	O	O
alone	NN	O	O
died	NN	O	O
.	NN	O	O

These	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
an	NN	O	O
antimetabolite	NN	O	O
-	NN	O	O
induced	NN	O	O
leukopenia	NN	O	B
predisposes	NN	O	O
to	NN	O	O
severe	NN	O	O
Pseudomonas	NN	O	O
sepsis	NN	O	B
and	NN	O	O
that	NN	O	O
such	NN	O	O
monkeys	NN	O	O
may	NN	O	O
serve	NN	O	O
as	NN	O	O
a	NN	O	O
biological	NN	O	O
model	NN	O	O
for	NN	O	O
study	NN	O	O
of	NN	O	O
comparative	NN	O	O
efficacy	NN	O	O
of	NN	O	O
antimicrobial	NN	O	O
agents	NN	O	O
.	NN	O	O

Modification	NN	O	O
by	NN	O	O
propranolol	NN	O	O
of	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
of	NN	O	O
induced	NN	O	O
hypoglycaemia	NN	O	B
.	NN	O	O

The	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
of	NN	O	O
hypoglycaemia	NN	O	B
,	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
beta	NN	O	O
-	NN	O	O
blockade	NN	O	O
,	NN	O	O
were	NN	O	O
compared	NN	O	O
in	NN	O	O
fourteen	NN	O	O
healthy	NN	O	O
men	NN	O	O
.	NN	O	O

Eight	NN	O	O
received	NN	O	O
insulin	NN	O	O
alone	NN	O	O
,	NN	O	O
and	NN	O	O
eight	NN	O	O
,	NN	O	O
including	NN	O	O
two	NN	O	O
of	NN	O	O
the	NN	O	O
original	NN	O	O
insulin	NN	O	O
-	NN	O	O
only	NN	O	O
group	NN	O	O
,	NN	O	O
were	NN	O	O
given	NN	O	O
propranolol	NN	O	O
and	NN	O	O
insulin	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
insulin	NN	O	O
-	NN	O	O
group	NN	O	O
the	NN	O	O
period	NN	O	O
of	NN	O	O
hypoglycaemia	NN	O	B
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
-	NN	O	O
rate	NN	O	O
and	NN	O	O
a	NN	O	O
fall	NN	O	O
in	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
-	NN	O	O
pressure	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
propranolol	NN	O	O
-	NN	O	O
insulin	NN	O	O
group	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
fall	NN	O	O
in	NN	O	O
heart	NN	O	O
-	NN	O	O
rate	NN	O	O
in	NN	O	O
most	NN	O	O
subjects	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
.	NN	O	O

Typical	NN	O	O
S	NN	O	O
-	NN	O	O
T	NN	O	O
/	NN	O	O
T	NN	O	O
changes	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
insulin	NN	O	O
-	NN	O	O
group	NN	O	O
but	NN	O	O
in	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
propranolol	NN	O	O
-	NN	O	O
insulin	NN	O	O
group	NN	O	O
.	NN	O	O

Hypertension	NN	O	B
in	NN	O	O
diabetics	NN	O	B
prone	NN	O	O
to	NN	O	O
hypoglycaemia	NN	O	B
attacks	NN	O	O
should	NN	O	O
not	NN	O	O
be	NN	O	O
treated	NN	O	O
with	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
because	NN	O	O
these	NN	O	O
drugs	NN	O	O
may	NN	O	O
cause	NN	O	O
a	NN	O	O
sharp	NN	O	O
rise	NN	O	O
in	NN	O	O
blood	NN	O	O
-	NN	O	O
pressure	NN	O	O
in	NN	O	O
such	NN	O	O
patients	NN	O	O
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
propranolol	NN	O	O
therapy	NN	O	O
in	NN	O	O
pregnancy	NN	O	O
:	NN	O	O
maternal	NN	O	O
and	NN	O	O
fetal	NN	O	O
outcome	NN	O	O
.	NN	O	O

Propranolol	NN	O	O
,	NN	O	O
a	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
blocking	NN	O	O
agent	NN	O	O
,	NN	O	O
has	NN	O	O
found	NN	O	O
an	NN	O	O
important	NN	O	O
position	NN	O	O
in	NN	O	O
the	NN	O	O
practice	NN	O	O
of	NN	O	O
medicine	NN	O	O
.	NN	O	O

Its	NN	O	O
use	NN	O	O
in	NN	O	O
pregnancy	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
is	NN	O	O
an	NN	O	O
open	NN	O	O
question	NN	O	O
as	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
detrimental	NN	O	O
side	NN	O	O
effects	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
fetus	NN	O	O
and	NN	O	O
neonate	NN	O	O
.	NN	O	O

Ten	NN	O	O
patients	NN	O	O
and	NN	O	O
12	NN	O	O
pregnancies	NN	O	O
are	NN	O	O
reported	NN	O	O
where	NN	O	O
chronic	NN	O	O
propranolol	NN	O	O
has	NN	O	O
been	NN	O	O
administered	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
with	NN	O	O
serial	NN	O	O
pregnancies	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
propranolol	NN	O	O
therapy	NN	O	O
are	NN	O	O
also	NN	O	O
examined	NN	O	O
.	NN	O	O

Maternal	NN	O	O
,	NN	O	O
fetal	NN	O	O
,	NN	O	O
and	NN	O	O
neonatal	NN	O	O
complications	NN	O	O
are	NN	O	O
examined	NN	O	O
.	NN	O	O

An	NN	O	O
attempt	NN	O	O
is	NN	O	O
made	NN	O	O
to	NN	O	O
differentiate	NN	O	O
drug	NN	O	O
-	NN	O	O
related	NN	O	O
complications	NN	O	O
from	NN	O	O
maternal	NN	O	O
disease	NN	O	O
-	NN	O	O
-	NN	O	O
related	NN	O	O
complications	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
previously	NN	O	O
reported	NN	O	O
hypoglycemia	NN	O	B
,	NN	O	O
hyperbilirubinemia	NN	O	B
,	NN	O	O
polycythemia	NN	O	B
,	NN	O	O
neonatal	NN	O	B
apnea	NN	O	I
,	NN	O	O
and	NN	O	O
bradycardia	NN	O	B
are	NN	O	O
not	NN	O	O
invariable	NN	O	O
and	NN	O	O
cannot	NN	O	O
be	NN	O	O
statistically	NN	O	O
correlated	NN	O	O
with	NN	O	O
chronic	NN	O	O
propranolol	NN	O	O
therapy	NN	O	O
.	NN	O	O

Growth	NN	O	B
retardation	NN	O	I
,	NN	O	O
however	NN	O	O
,	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
significant	NN	O	O
in	NN	O	O
both	NN	O	O
of	NN	O	O
our	NN	O	O
series	NN	O	O
.	NN	O	O

Central	NN	O	O
excitatory	NN	O	O
actions	NN	O	O
of	NN	O	O
flurazepam	NN	O	O
.	NN	O	O

Toxic	NN	O	O
actions	NN	O	O
of	NN	O	O
flurazepam	NN	O	O
(	NN	O	O
FZP	NN	O	O
)	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
cats	NN	O	O
,	NN	O	O
mice	NN	O	O
and	NN	O	O
rats	NN	O	O
.	NN	O	O

High	NN	O	O
doses	NN	O	O
caused	NN	O	O
an	NN	O	O
apparent	NN	O	O
central	NN	O	O
excitation	NN	O	O
,	NN	O	O
most	NN	O	O
clearly	NN	O	O
seen	NN	O	O
as	NN	O	O
clonic	NN	O	O
convulsions	NN	O	B
,	NN	O	O
superimposed	NN	O	O
on	NN	O	O
general	NN	O	O
depression	NN	O	B
.	NN	O	O

Following	NN	O	O
a	NN	O	O
lethal	NN	O	O
dose	NN	O	O
,	NN	O	O
death	NN	O	O
was	NN	O	O
always	NN	O	O
associated	NN	O	O
with	NN	O	O
convulsions	NN	O	B
.	NN	O	O

Comparing	NN	O	O
the	NN	O	O
relative	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
central	NN	O	O
depression	NN	O	B
and	NN	O	O
excitation	NN	O	O
revealed	NN	O	O
that	NN	O	O
rats	NN	O	O
were	NN	O	O
least	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
convulsions	NN	O	B
at	NN	O	O
doses	NN	O	O
that	NN	O	O
did	NN	O	O
not	NN	O	O
first	NN	O	O
cause	NN	O	O
loss	NN	O	B
of	NN	O	I
consciousness	NN	O	I
,	NN	O	O
while	NN	O	O
cats	NN	O	O
most	NN	O	O
clearly	NN	O	O
showed	NN	O	O
marked	NN	O	O
central	NN	O	O
excitatory	NN	O	O
actions	NN	O	O
.	NN	O	O

Signs	NN	O	O
of	NN	O	O
FZP	NN	O	O
toxocity	NN	O	B
in	NN	O	O
cats	NN	O	O
included	NN	O	O
excessive	NN	O	O
salivation	NN	O	B
,	NN	O	O
extreme	NN	O	O
apprehensive	NN	O	O
behavior	NN	O	O
,	NN	O	O
retching	NN	O	O
,	NN	O	O
muscle	NN	O	B
tremors	NN	O	I
and	NN	O	O
convulsions	NN	O	B
.	NN	O	O

An	NN	O	O
interaction	NN	O	O
between	NN	O	O
FZP	NN	O	O
and	NN	O	O
pentylenetetrazol	NN	O	O
(	NN	O	O
PTZ	NN	O	O
)	NN	O	O
was	NN	O	O
shown	NN	O	O
by	NN	O	O
pretreating	NN	O	O
mice	NN	O	O
with	NN	O	O
FZP	NN	O	O
before	NN	O	O
PTZ	NN	O	O
challenge	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
function	NN	O	O
of	NN	O	O
dose	NN	O	O
,	NN	O	O
FZP	NN	O	O
first	NN	O	O
protected	NN	O	O
against	NN	O	O
convulsions	NN	O	B
and	NN	O	O
death	NN	O	O
.	NN	O	O

At	NN	O	O
higher	NN	O	O
doses	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
convulsions	NN	O	B
again	NN	O	O
emerged	NN	O	O
.	NN	O	O

These	NN	O	O
doses	NN	O	O
of	NN	O	O
FZP	NN	O	O
were	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
that	NN	O	O
would	NN	O	O
alone	NN	O	O
cause	NN	O	O
convulsions	NN	O	B
.	NN	O	O

These	NN	O	O
results	NN	O	O
may	NN	O	O
be	NN	O	O
relevant	NN	O	O
to	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
FZP	NN	O	O
in	NN	O	O
clinical	NN	O	O
situations	NN	O	O
in	NN	O	O
which	NN	O	O
there	NN	O	O
is	NN	O	O
increased	NN	O	O
neural	NN	O	O
excitability	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
epilepsy	NN	O	B
or	NN	O	O
sedative	NN	O	O
-	NN	O	O
hypnotic	NN	O	O
drug	NN	O	O
withdrawal	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
propranolol	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
idiopathic	NN	O	B
orthostatic	NN	O	I
hypotension	NN	O	I
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
with	NN	O	O
idiopathic	NN	O	B
orthostatic	NN	O	I
hypotension	NN	O	I
who	NN	O	O
had	NN	O	O
physiologic	NN	O	O
and	NN	O	O
biochemical	NN	O	O
evidence	NN	O	O
of	NN	O	O
severe	NN	O	O
autonomic	NN	O	O
dysfunction	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

They	NN	O	O
all	NN	O	O
exhibited	NN	O	O
markedly	NN	O	O
reduced	NN	O	O
plasma	NN	O	O
catecholamines	NN	O	O
and	NN	O	O
plasma	NN	O	O
renin	NN	O	O
activity	NN	O	O
in	NN	O	O
both	NN	O	O
recumbent	NN	O	O
and	NN	O	O
upright	NN	O	O
positions	NN	O	O
and	NN	O	O
had	NN	O	O
marked	NN	O	O
hypersensitivity	NN	O	B
to	NN	O	O
the	NN	O	O
pressor	NN	O	O
effects	NN	O	O
of	NN	O	O
infused	NN	O	O
norepinephrine	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
propanolol	NN	O	O
administered	NN	O	O
intravenously	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
5	NN	O	O
mg	NN	O	O
)	NN	O	O
produced	NN	O	O
increases	NN	O	O
in	NN	O	O
supine	NN	O	O
and	NN	O	O
upright	NN	O	O
blood	NN	O	O
pressure	NN	O	O
in	NN	O	O
4	NN	O	O
of	NN	O	O
the	NN	O	O
5	NN	O	O
individuals	NN	O	O
with	NN	O	O
rises	NN	O	O
ranging	NN	O	O
from	NN	O	O
11	NN	O	O
/	NN	O	O
6	NN	O	O
to	NN	O	O
22	NN	O	O
/	NN	O	O
11	NN	O	O
mmHg	NN	O	O
.	NN	O	O

Chronic	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
propranolol	NN	O	O
(	NN	O	O
40	NN	O	O
-	NN	O	O
160	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
also	NN	O	O
elevated	NN	O	O
the	NN	O	O
blood	NN	O	O
pressures	NN	O	O
of	NN	O	O
these	NN	O	O
individuals	NN	O	O
with	NN	O	O
increases	NN	O	O
in	NN	O	O
the	NN	O	O
order	NN	O	O
of	NN	O	O
20	NN	O	O
-	NN	O	O
35	NN	O	O
/	NN	O	O
15	NN	O	O
-	NN	O	O
25	NN	O	O
mmg	NN	O	O
being	NN	O	O
observed	NN	O	O
.	NN	O	O

In	NN	O	O
1	NN	O	O
patient	NN	O	O
,	NN	O	O
marked	NN	O	O
hypertension	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
propranolol	NN	O	O
and	NN	O	O
the	NN	O	O
drug	NN	O	O
had	NN	O	O
to	NN	O	O
be	NN	O	O
withdrawn	NN	O	O
.	NN	O	O

It	NN	O	O
otherwise	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
and	NN	O	O
no	NN	O	O
important	NN	O	O
side	NN	O	O
effects	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

Treatment	NN	O	O
has	NN	O	O
been	NN	O	O
continued	NN	O	O
in	NN	O	O
3	NN	O	O
individuals	NN	O	O
for	NN	O	O
6	NN	O	O
-	NN	O	O
13	NN	O	O
months	NN	O	O
with	NN	O	O
persistence	NN	O	O
of	NN	O	O
the	NN	O	O
pressor	NN	O	O
effect	NN	O	O
,	NN	O	O
although	NN	O	O
there	NN	O	O
appears	NN	O	O
to	NN	O	O
have	NN	O	O
been	NN	O	O
some	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
response	NN	O	O
with	NN	O	O
time	NN	O	O
.	NN	O	O

Hemodynamic	NN	O	O
measurements	NN	O	O
in	NN	O	O
1	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
demonstrated	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
total	NN	O	O
peripheral	NN	O	O
resistance	NN	O	O
and	NN	O	O
essentially	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
cardiac	NN	O	O
output	NN	O	O
following	NN	O	O
propranolol	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
propranolol	NN	O	O
is	NN	O	O
a	NN	O	O
useful	NN	O	O
drug	NN	O	O
in	NN	O	O
selected	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
idiopathic	NN	O	B
orthostatic	NN	O	I
hypotension	NN	O	I
.	NN	O	O

Total	NN	O	O
intravenous	NN	O	O
anesthesia	NN	O	O
with	NN	O	O
etomidate	NN	O	O
.	NN	O	O

III	NN	O	O
.	NN	O	O

Some	NN	O	O
observations	NN	O	O
in	NN	O	O
adults	NN	O	O
.	NN	O	O

An	NN	O	O
investigation	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
dosage	NN	O	O
of	NN	O	O
etomidate	NN	O	O
required	NN	O	O
to	NN	O	O
maintain	NN	O	O
sleep	NN	O	O
in	NN	O	O
adults	NN	O	O
undergoing	NN	O	O
surgery	NN	O	O
under	NN	O	O
regional	NN	O	O
local	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

Premedication	NN	O	O
of	NN	O	O
diazepam	NN	O	O
10	NN	O	O
mg	NN	O	O
and	NN	O	O
atropine	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
was	NN	O	O
given	NN	O	O
,	NN	O	O
and	NN	O	O
sleep	NN	O	O
was	NN	O	O
induced	NN	O	O
and	NN	O	O
maintained	NN	O	O
by	NN	O	O
intermittent	NN	O	O
intravenous	NN	O	O
injections	NN	O	O
of	NN	O	O
etomidate	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
/	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
given	NN	O	O
whenever	NN	O	O
the	NN	O	O
patient	NN	O	O
would	NN	O	O
open	NN	O	O
his	NN	O	O
eyes	NN	O	O
on	NN	O	O
request	NN	O	O
.	NN	O	O

A	NN	O	O
mean	NN	O	O
overall	NN	O	O
dose	NN	O	O
of	NN	O	O
etomidate	NN	O	O
17	NN	O	O
.	NN	O	O
4	NN	O	O
microgram	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
.	NN	O	O
was	NN	O	O
required	NN	O	O
to	NN	O	O
maintain	NN	O	O
sleep	NN	O	O
,	NN	O	O
but	NN	O	O
great	NN	O	O
individual	NN	O	O
variation	NN	O	O
occurred	NN	O	O
,	NN	O	O
with	NN	O	O
older	NN	O	O
patients	NN	O	O
requiring	NN	O	O
less	NN	O	O
drug	NN	O	O
.	NN	O	O

The	NN	O	O
investigation	NN	O	O
was	NN	O	O
discontinued	NN	O	O
after	NN	O	O
18	NN	O	O
patients	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
frequency	NN	O	O
and	NN	O	O
intensity	NN	O	O
of	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
,	NN	O	O
particularly	NN	O	O
pain	NN	O	B
and	NN	O	O
myoclonia	NN	O	B
,	NN	O	O
which	NN	O	O
caused	NN	O	O
the	NN	O	O
technique	NN	O	O
to	NN	O	O
be	NN	O	O
abandoned	NN	O	O
in	NN	O	O
two	NN	O	O
cases	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
considered	NN	O	O
unlikely	NN	O	O
that	NN	O	O
etomidate	NN	O	O
will	NN	O	O
prove	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
hypnotic	NN	O	O
of	NN	O	O
choice	NN	O	O
for	NN	O	O
a	NN	O	O
totally	NN	O	O
intravenous	NN	O	O
anesthetic	NN	O	O
technique	NN	O	O
in	NN	O	O
adults	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
myoclonia	NN	O	B
after	NN	O	O
prolonged	NN	O	O
administration	NN	O	O
.	NN	O	O

In	NN	O	O
several	NN	O	O
patients	NN	O	O
uncontrollable	NN	O	O
muscle	NN	O	O
movements	NN	O	O
persisted	NN	O	O
for	NN	O	O
many	NN	O	O
minutes	NN	O	O
after	NN	O	O
complete	NN	O	O
recovery	NN	O	O
of	NN	O	O
consciousness	NN	O	O
.	NN	O	O

Evidence	NN	O	O
for	NN	O	O
cardiac	NN	O	O
beta	NN	O	O
2	NN	O	O
-	NN	O	O
adrenoceptors	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

We	NN	O	O
compared	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
single	NN	O	O
doses	NN	O	O
of	NN	O	O
50	NN	O	O
mg	NN	O	O
atenolol	NN	O	O
(	NN	O	O
cardioselective	NN	O	O
)	NN	O	O
,	NN	O	O
40	NN	O	O
mg	NN	O	O
propranolol	NN	O	O
(	NN	O	O
nonselective	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
placebo	NN	O	O
on	NN	O	O
both	NN	O	O
exercise	NN	O	O
-	NN	O	O
and	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
in	NN	O	O
two	NN	O	O
experiments	NN	O	O
involving	NN	O	O
nine	NN	O	O
normal	NN	O	O
subjects	NN	O	O
.	NN	O	O

Maximal	NN	O	O
exercise	NN	O	O
heart	NN	O	O
rate	NN	O	O
was	NN	O	O
reduced	NN	O	O
from	NN	O	O
187	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
(	NN	O	O
SEM	NN	O	O
)	NN	O	O
after	NN	O	O
placebo	NN	O	O
to	NN	O	O
146	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
bpm	NN	O	O
after	NN	O	O
atenolol	NN	O	O
and	NN	O	O
138	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
bpm	NN	O	O
after	NN	O	O
propranolol	NN	O	O
,	NN	O	O
but	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
on	NN	O	O
isoproterenol	NN	O	O
tachycardia	NN	O	B
were	NN	O	O
determined	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
atropine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
04	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
IV	NN	O	O
)	NN	O	O
.	NN	O	O

Isoproterenol	NN	O	O
sensitivity	NN	O	O
was	NN	O	O
determined	NN	O	O
as	NN	O	O
the	NN	O	O
intravenous	NN	O	O
dose	NN	O	O
that	NN	O	O
increased	NN	O	O
heart	NN	O	O
rate	NN	O	O
by	NN	O	O
25	NN	O	O
bpm	NN	O	O
(	NN	O	O
CD25	NN	O	O
)	NN	O	O
and	NN	O	O
this	NN	O	O
was	NN	O	O
increased	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
micrograms	NN	O	O
after	NN	O	O
placebo	NN	O	O
to	NN	O	O
38	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
3	NN	O	O
micrograms	NN	O	O
after	NN	O	O
propranolol	NN	O	O
and	NN	O	O
8	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
micrograms	NN	O	O
after	NN	O	O
atenolol	NN	O	O
.	NN	O	O

The	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
was	NN	O	O
significant	NN	O	O
.	NN	O	O

After	NN	O	O
atropine	NN	O	O
the	NN	O	O
CD25	NN	O	O
was	NN	O	O
unchanged	NN	O	O
after	NN	O	O
placebo	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
micrograms	NN	O	O
)	NN	O	O
and	NN	O	O
atenolol	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
micrograms	NN	O	O
)	NN	O	O
;	NN	O	O
it	NN	O	O
was	NN	O	O
reduced	NN	O	O
after	NN	O	O
propranolol	NN	O	O
(	NN	O	O
24	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
micrograms	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
remained	NN	O	O
different	NN	O	O
from	NN	O	O
atenolol	NN	O	O
.	NN	O	O

This	NN	O	O
change	NN	O	O
with	NN	O	O
propranolol	NN	O	O
sensitivity	NN	O	O
was	NN	O	O
calculated	NN	O	O
as	NN	O	O
the	NN	O	O
apparent	NN	O	O
Ka	NN	O	O
,	NN	O	O
this	NN	O	O
was	NN	O	O
unchanged	NN	O	O
by	NN	O	O
atropine	NN	O	O
(	NN	O	O
11	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
and	NN	O	O
10	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
ml	NN	O	O
/	NN	O	O
ng	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
exercise	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
results	NN	O	O
largely	NN	O	O
from	NN	O	O
beta	NN	O	O
1	NN	O	O
-	NN	O	O
receptor	NN	O	O
activation	NN	O	O
that	NN	O	O
is	NN	O	O
blocked	NN	O	O
by	NN	O	O
both	NN	O	O
cardioselective	NN	O	O
and	NN	O	O
nonselective	NN	O	O
drugs	NN	O	O
,	NN	O	O
whereas	NN	O	O
isoproterenol	NN	O	O
activates	NN	O	O
both	NN	O	O
beta	NN	O	O
1	NN	O	O
-	NN	O	O
and	NN	O	O
beta	NN	O	O
2	NN	O	O
-	NN	O	O
receptors	NN	O	O
so	NN	O	O
that	NN	O	O
after	NN	O	O
cardioselective	NN	O	O
blockade	NN	O	O
there	NN	O	O
remains	NN	O	O
a	NN	O	O
beta	NN	O	O
2	NN	O	O
-	NN	O	O
component	NN	O	O
that	NN	O	O
can	NN	O	O
be	NN	O	O
blocked	NN	O	O
with	NN	O	O
a	NN	O	O
nonselective	NN	O	O
drug	NN	O	O
.	NN	O	O

While	NN	O	O
there	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
beta	NN	O	O
2	NN	O	O
-	NN	O	O
receptors	NN	O	O
in	NN	O	O
the	NN	O	O
human	NN	O	O
heart	NN	O	O
,	NN	O	O
their	NN	O	O
physiologic	NN	O	O
or	NN	O	O
pathologic	NN	O	O
roles	NN	O	O
remain	NN	O	O
to	NN	O	O
be	NN	O	O
defined	NN	O	O
.	NN	O	O

Hormones	NN	O	O
and	NN	O	O
risk	NN	O	O
of	NN	O	O
breast	NN	O	B
cancer	NN	O	I
.	NN	O	O

This	NN	O	O
paper	NN	O	O
reports	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
a	NN	O	O
study	NN	O	O
of	NN	O	O
50	NN	O	O
menopausal	NN	O	O
women	NN	O	O
receiving	NN	O	O
hormonal	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
majority	NN	O	O
(	NN	O	O
29	NN	O	O
)	NN	O	O
had	NN	O	O
surgical	NN	O	O
menopause	NN	O	O
;	NN	O	O
their	NN	O	O
mean	NN	O	O
age	NN	O	O
was	NN	O	O
45	NN	O	O
.	NN	O	O
7	NN	O	O
years	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
progestins	NN	O	O
could	NN	O	O
equilibrate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
estrogenic	NN	O	O
stimulation	NN	O	O
on	NN	O	O
the	NN	O	O
mammary	NN	O	O
and	NN	O	O
endometrial	NN	O	O
target	NN	O	O
tissues	NN	O	O
of	NN	O	O
women	NN	O	O
on	NN	O	O
hormonal	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
treatment	NN	O	O
schedule	NN	O	O
consisted	NN	O	O
of	NN	O	O
conjugated	NN	O	O
estrogens	NN	O	O
(	NN	O	O
Premarin	NN	O	O
)	NN	O	O
1	NN	O	O
.	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
21	NN	O	O
days	NN	O	O
and	NN	O	O
Medroxyprogesterone	NN	O	O
acetate	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
in	NN	O	O
each	NN	O	O
month	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
treatment	NN	O	O
period	NN	O	O
was	NN	O	O
18	NN	O	O
months	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
,	NN	O	O
attention	NN	O	O
was	NN	O	O
paid	NN	O	O
to	NN	O	O
breast	NN	O	O
modifications	NN	O	O
as	NN	O	O
evidenced	NN	O	O
by	NN	O	O
symptomatology	NN	O	O
,	NN	O	O
physical	NN	O	O
examination	NN	O	O
,	NN	O	O
and	NN	O	O
plate	NN	O	O
thermography	NN	O	O
.	NN	O	O

Mastodynia	NN	O	B
was	NN	O	O
reported	NN	O	O
by	NN	O	O
21	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
physical	NN	O	O
examination	NN	O	O
revealed	NN	O	O
a	NN	O	O
light	NN	O	O
increase	NN	O	O
in	NN	O	O
breast	NN	O	O
firmness	NN	O	O
in	NN	O	O
12	NN	O	O
women	NN	O	O
and	NN	O	O
a	NN	O	O
moderate	NN	O	O
increase	NN	O	O
in	NN	O	O
breast	NN	O	O
nodularity	NN	O	O
in	NN	O	O
2	NN	O	O
women	NN	O	O
.	NN	O	O

Themography	NN	O	O
confirmed	NN	O	O
the	NN	O	O
existence	NN	O	O
of	NN	O	O
an	NN	O	O
excessive	NN	O	O
breast	NN	O	O
stimulation	NN	O	O
in	NN	O	O
1	NN	O	O
women	NN	O	O
who	NN	O	O
complained	NN	O	O
of	NN	O	O
moderate	NN	O	O
mastodynia	NN	O	B
and	NN	O	O
in	NN	O	O
5	NN	O	O
of	NN	O	O
the	NN	O	O
7	NN	O	O
women	NN	O	O
who	NN	O	O
complained	NN	O	O
of	NN	O	O
severe	NN	O	O
mastodynia	NN	O	B
.	NN	O	O

Normalization	NN	O	O
was	NN	O	O
obtained	NN	O	O
by	NN	O	O
halving	NN	O	O
the	NN	O	O
estrogen	NN	O	O
dose	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
hormonal	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
can	NN	O	O
be	NN	O	O
safely	NN	O	O
prescribed	NN	O	O
if	NN	O	O
the	NN	O	O
following	NN	O	O
criteria	NN	O	O
are	NN	O	O
satisfied	NN	O	O
:	NN	O	O
1	NN	O	O
)	NN	O	O
preliminary	NN	O	O
evaluation	NN	O	O
of	NN	O	O
patients	NN	O	O
from	NN	O	O
a	NN	O	O
clinical	NN	O	O
,	NN	O	O
metabolic	NN	O	O
,	NN	O	O
cytologic	NN	O	O
,	NN	O	O
and	NN	O	O
mammographic	NN	O	O
perspective	NN	O	O
;	NN	O	O
2	NN	O	O
)	NN	O	O
cyclic	NN	O	O
treatment	NN	O	O
schedule	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
progestative	NN	O	O
phase	NN	O	O
of	NN	O	O
10	NN	O	O
days	NN	O	O
;	NN	O	O
and	NN	O	O
3	NN	O	O
)	NN	O	O
periodic	NN	O	O
complete	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
,	NN	O	O
with	NN	O	O
accurate	NN	O	O
thermographic	NN	O	O
evaluation	NN	O	O
of	NN	O	O
the	NN	O	O
breast	NN	O	O
target	NN	O	O
tissues	NN	O	O
.	NN	O	O

Early	NN	O	O
infections	NN	O	B
in	NN	O	O
kidney	NN	O	O
,	NN	O	O
heart	NN	O	O
,	NN	O	O
and	NN	O	O
liver	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
on	NN	O	O
cyclosporine	NN	O	O
.	NN	O	O

Eighty	NN	O	O
-	NN	O	O
one	NN	O	O
renal	NN	O	O
,	NN	O	O
seventeen	NN	O	O
heart	NN	O	O
,	NN	O	O
and	NN	O	O
twenty	NN	O	O
-	NN	O	O
four	NN	O	O
liver	NN	O	O
transplant	NN	O	O
patients	NN	O	O
were	NN	O	O
followed	NN	O	O
for	NN	O	O
infection	NN	O	B
.	NN	O	O

Seventeen	NN	O	O
renal	NN	O	O
patients	NN	O	O
received	NN	O	O
azathioprine	NN	O	O
(	NN	O	O
Aza	NN	O	O
)	NN	O	O
and	NN	O	O
prednisone	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
a	NN	O	O
randomized	NN	O	O
trial	NN	O	O
of	NN	O	O
immunosuppression	NN	O	O
with	NN	O	O
21	NN	O	O
cyclosporine	NN	O	O
-	NN	O	O
and	NN	O	O
-	NN	O	O
prednisone	NN	O	O
-	NN	O	O
treated	NN	O	O
renal	NN	O	O
transplant	NN	O	O
patients	NN	O	O
.	NN	O	O

All	NN	O	O
others	NN	O	O
received	NN	O	O
cyclosporine	NN	O	O
and	NN	O	O
prednisone	NN	O	O
.	NN	O	O

The	NN	O	O
randomized	NN	O	O
Aza	NN	O	O
patients	NN	O	O
had	NN	O	O
more	NN	O	O
overall	NN	O	O
infections	NN	O	B
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
and	NN	O	O
more	NN	O	O
nonviral	NN	O	O
infections	NN	O	B
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
than	NN	O	O
the	NN	O	O
randomized	NN	O	O
cyclosporine	NN	O	O
patients	NN	O	O
.	NN	O	O

Heart	NN	O	O
and	NN	O	O
liver	NN	O	O
patients	NN	O	O
had	NN	O	O
more	NN	O	O
infections	NN	O	B
than	NN	O	O
cyclosporine	NN	O	O
renal	NN	O	O
patients	NN	O	O
but	NN	O	O
fewer	NN	O	O
infections	NN	O	B
than	NN	O	O
the	NN	O	O
Aza	NN	O	O
renal	NN	O	O
patients	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
infectious	NN	O	O
deaths	NN	O	O
in	NN	O	O
renal	NN	O	O
transplant	NN	O	O
patients	NN	O	O
on	NN	O	O
cyclosporine	NN	O	O
or	NN	O	O
Aza	NN	O	O
,	NN	O	O
but	NN	O	O
infection	NN	O	B
played	NN	O	O
a	NN	O	O
major	NN	O	O
role	NN	O	O
in	NN	O	O
3	NN	O	O
out	NN	O	O
of	NN	O	O
6	NN	O	O
cardiac	NN	O	O
transplant	NN	O	O
deaths	NN	O	O
and	NN	O	O
in	NN	O	O
8	NN	O	O
out	NN	O	O
of	NN	O	O
9	NN	O	O
liver	NN	O	O
transplant	NN	O	O
deaths	NN	O	O
.	NN	O	O

Renal	NN	O	O
patients	NN	O	O
on	NN	O	O
cyclosporine	NN	O	O
had	NN	O	O
the	NN	O	O
fewest	NN	O	O
bacteremias	NN	O	B
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
site	NN	O	O
of	NN	O	O
infection	NN	O	B
showed	NN	O	O
a	NN	O	O
preponderance	NN	O	O
of	NN	O	O
abdominal	NN	O	B
infections	NN	O	I
in	NN	O	O
liver	NN	O	O
patients	NN	O	O
,	NN	O	O
intrathoracic	NN	O	O
infections	NN	O	B
in	NN	O	O
heart	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
urinary	NN	O	B
tract	NN	O	I
infections	NN	O	I
in	NN	O	O
renal	NN	O	O
patients	NN	O	O
.	NN	O	O

Pulmonary	NN	O	O
infections	NN	O	B
were	NN	O	O
less	NN	O	O
common	NN	O	O
in	NN	O	O
cyclosporine	NN	O	O
-	NN	O	O
treated	NN	O	O
renal	NN	O	O
patients	NN	O	O
than	NN	O	O
in	NN	O	O
Aza	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Aza	NN	O	O
patients	NN	O	O
had	NN	O	O
significantly	NN	O	O
more	NN	O	O
staphylococcal	NN	O	B
infections	NN	O	I
than	NN	O	O
all	NN	O	O
other	NN	O	O
transplant	NN	O	O
groups	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
systemic	NN	O	O
fungal	NN	O	B
infections	NN	O	I
occurred	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
transplant	NN	O	O
group	NN	O	O
.	NN	O	O

Cytomegalovirus	NN	O	O
(	NN	O	O
CMV	NN	O	O
)	NN	O	O
shedding	NN	O	O
or	NN	O	O
serological	NN	O	O
rises	NN	O	O
in	NN	O	O
antibody	NN	O	O
titer	NN	O	O
,	NN	O	O
or	NN	O	O
both	NN	O	O
occurred	NN	O	O
in	NN	O	O
78	NN	O	O
%	NN	O	O
of	NN	O	O
cyclosporine	NN	O	O
patients	NN	O	O
and	NN	O	O
76	NN	O	O
%	NN	O	O
of	NN	O	O
Aza	NN	O	O
patients	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
cyclosporine	NN	O	O
patients	NN	O	O
,	NN	O	O
15	NN	O	O
%	NN	O	O
had	NN	O	O
symptoms	NN	O	O
related	NN	O	O
to	NN	O	O
CMV	NN	O	B
infection	NN	O	I
.	NN	O	O

Serological	NN	O	O
evidence	NN	O	O
for	NN	O	O
Epstein	NN	O	B
Barr	NN	O	I
Virus	NN	O	I
infection	NN	O	I
was	NN	O	O
found	NN	O	O
in	NN	O	O
20	NN	O	O
%	NN	O	O
of	NN	O	O
65	NN	O	O
cyclosporine	NN	O	O
patients	NN	O	O
studied	NN	O	O
.	NN	O	O

Three	NN	O	O
had	NN	O	O
associated	NN	O	O
symptoms	NN	O	O
,	NN	O	O
and	NN	O	O
one	NN	O	O
developed	NN	O	O
a	NN	O	O
lymphoma	NN	O	B
.	NN	O	O

Structure	NN	O	O
-	NN	O	O
activity	NN	O	O
and	NN	O	O
dose	NN	O	O
-	NN	O	O
effect	NN	O	O
relationships	NN	O	O
of	NN	O	O
the	NN	O	O
antagonism	NN	O	O
of	NN	O	O
picrotoxin	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
by	NN	O	O
cholecystokinin	NN	O	O
,	NN	O	O
fragments	NN	O	O
and	NN	O	O
analogues	NN	O	O
of	NN	O	O
cholecystokinin	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Intraperitoneal	NN	O	O
administration	NN	O	O
of	NN	O	O
cholecystokinin	NN	O	O
octapeptide	NN	O	O
sulphate	NN	O	O
ester	NN	O	O
(	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
SE	NN	O	O
)	NN	O	O
and	NN	O	O
nonsulphated	NN	O	O
cholecystokinin	NN	O	O
octapeptide	NN	O	O
(	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
NS	NN	O	O
)	NN	O	O
enhanced	NN	O	O
the	NN	O	O
latency	NN	O	O
of	NN	O	O
seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
picrotoxin	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Experiments	NN	O	O
with	NN	O	O
N	NN	O	O
-	NN	O	O
and	NN	O	O
C	NN	O	O
-	NN	O	O
terminal	NN	O	O
fragments	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
C	NN	O	O
-	NN	O	O
terminal	NN	O	O
tetrapeptide	NN	O	O
(	NN	O	O
CCK	NN	O	O
-	NN	O	O
5	NN	O	O
-	NN	O	O
8	NN	O	O
)	NN	O	O
was	NN	O	O
the	NN	O	O
active	NN	O	O
centre	NN	O	O
of	NN	O	O
the	NN	O	O
CCK	NN	O	O
octapeptide	NN	O	O
molecule	NN	O	O
.	NN	O	O

The	NN	O	O
analogues	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
SE	NN	O	O
and	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
NS	NN	O	O
(	NN	O	O
dose	NN	O	O
range	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
4	NN	O	O
mumol	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
caerulein	NN	O	O
dose	NN	O	O
range	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
mumol	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
showed	NN	O	O
bell	NN	O	O
-	NN	O	O
shaped	NN	O	O
dose	NN	O	O
-	NN	O	O
effect	NN	O	O
curves	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
greatest	NN	O	O
maximum	NN	O	O
inhibition	NN	O	O
for	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
NS	NN	O	O
.	NN	O	O

The	NN	O	O
peptide	NN	O	O
CCK	NN	O	O
-	NN	O	O
5	NN	O	O
-	NN	O	O
8	NN	O	O
had	NN	O	O
weak	NN	O	O
anticonvulsant	NN	O	O
activity	NN	O	O
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
the	NN	O	O
octapeptides	NN	O	O
,	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
mumol	NN	O	O
/	NN	O	O
kg	NN	O	O
and	NN	O	O
larger	NN	O	O
doses	NN	O	O
of	NN	O	O
the	NN	O	O
reference	NN	O	O
drug	NN	O	O
,	NN	O	O
diazepam	NN	O	O
,	NN	O	O
totally	NN	O	O
prevented	NN	O	O
picrotoxin	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
mortality	NN	O	O
.	NN	O	O

The	NN	O	O
maximum	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
peptides	NN	O	O
tested	NN	O	O
was	NN	O	O
less	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
diazepam	NN	O	O
.	NN	O	O

Experiments	NN	O	O
with	NN	O	O
analogues	NN	O	O
and	NN	O	O
derivatives	NN	O	O
of	NN	O	O
CCK	NN	O	O
-	NN	O	O
5	NN	O	O
-	NN	O	O
8	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
alanyl	NN	O	O
derivatives	NN	O	O
of	NN	O	O
CCK	NN	O	O
-	NN	O	O
5	NN	O	O
-	NN	O	O
8	NN	O	O
were	NN	O	O
enhanced	NN	O	O
and	NN	O	O
that	NN	O	O
they	NN	O	O
were	NN	O	O
equipotent	NN	O	O
with	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
SE	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
CCK	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
8	NN	O	O
analogues	NN	O	O
,	NN	O	O
Ser	NN	O	O
(	NN	O	O
SO3H	NN	O	O
)	NN	O	O
7	NN	O	O
-	NN	O	O
Ac	NN	O	O
-	NN	O	O
CCK	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
SE	NN	O	O
and	NN	O	O
Thr	NN	O	O
(	NN	O	O
SO3H	NN	O	O
)	NN	O	O
7	NN	O	O
-	NN	O	O
Ac	NN	O	O
-	NN	O	O
CCK	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
SE	NN	O	O
and	NN	O	O
Hyp	NN	O	O
(	NN	O	O
SO3H	NN	O	O
)	NN	O	O
-	NN	O	O
Ac	NN	O	O
-	NN	O	O
CCK	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
SE	NN	O	O
were	NN	O	O
slightly	NN	O	O
more	NN	O	O
active	NN	O	O
than	NN	O	O
CCK	NN	O	O
-	NN	O	O
8	NN	O	O
-	NN	O	O
SE	NN	O	O
.	NN	O	O

Vasopressin	NN	O	O
as	NN	O	O
a	NN	O	O
possible	NN	O	O
contributor	NN	O	O
to	NN	O	O
hypertension	NN	O	B
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
vasopressin	NN	O	O
as	NN	O	O
a	NN	O	O
pressor	NN	O	O
agent	NN	O	O
to	NN	O	O
the	NN	O	O
hypertensive	NN	O	B
process	NN	O	O
was	NN	O	O
examined	NN	O	O
.	NN	O	O

Vasopressin	NN	O	O
plays	NN	O	O
a	NN	O	O
major	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
DOCA	NN	O	O
-	NN	O	O
salt	NN	O	O
hypertension	NN	O	B
,	NN	O	O
since	NN	O	O
the	NN	O	O
elevation	NN	O	O
of	NN	O	O
blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
not	NN	O	O
substantial	NN	O	O
in	NN	O	O
the	NN	O	O
rats	NN	O	O
with	NN	O	O
lithium	NN	O	O
-	NN	O	O
treated	NN	O	O
diabetes	NN	O	B
insipidus	NN	O	I
after	NN	O	O
DOCA	NN	O	O
-	NN	O	O
salt	NN	O	O
treatment	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
DDAVP	NN	O	O
which	NN	O	O
has	NN	O	O
antidiuretic	NN	O	O
action	NN	O	O
but	NN	O	O
minimal	NN	O	O
vasopressor	NN	O	O
effect	NN	O	O
failed	NN	O	O
to	NN	O	O
increase	NN	O	O
blood	NN	O	O
pressure	NN	O	O
to	NN	O	O
the	NN	O	O
levels	NN	O	O
observed	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
AVP	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
pressor	NN	O	O
action	NN	O	O
of	NN	O	O
vasopressin	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
important	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
this	NN	O	O
model	NN	O	O
of	NN	O	O
hypertension	NN	O	B
,	NN	O	O
since	NN	O	O
the	NN	O	O
enhanced	NN	O	O
pressor	NN	O	O
responsiveness	NN	O	O
to	NN	O	O
the	NN	O	O
hormone	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
initial	NN	O	O
stage	NN	O	O
of	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Increased	NN	O	O
secretion	NN	O	O
of	NN	O	O
vasopressin	NN	O	O
from	NN	O	O
neurohypophysis	NN	O	O
also	NN	O	O
promotes	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
the	NN	O	O
hormone	NN	O	O
as	NN	O	O
a	NN	O	O
pathogenetic	NN	O	O
factor	NN	O	O
in	NN	O	O
hypertension	NN	O	B
.	NN	O	O

An	NN	O	O
unproportional	NN	O	O
release	NN	O	O
of	NN	O	O
vasopressin	NN	O	O
compared	NN	O	O
to	NN	O	O
plasma	NN	O	O
osmolality	NN	O	O
may	NN	O	O
be	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
an	NN	O	O
adjusting	NN	O	O
control	NN	O	O
of	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
forming	NN	O	O
and	NN	O	O
receptor	NN	O	O
binding	NN	O	O
capacity	NN	O	O
for	NN	O	O
sodium	NN	O	O
balance	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
vasopressin	NN	O	O
remains	NN	O	O
to	NN	O	O
be	NN	O	O
determined	NN	O	O
in	NN	O	O
human	NN	O	O
essential	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Toxic	NN	O	B
hepatitis	NN	O	I
induced	NN	O	O
by	NN	O	O
disulfiram	NN	O	O
in	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
alcoholic	NN	O	O
.	NN	O	O

A	NN	O	O
reversible	NN	O	O
toxic	NN	O	B
liver	NN	O	I
damage	NN	O	I
was	NN	O	O
observed	NN	O	O
in	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
alcoholic	NN	O	O
woman	NN	O	O
treated	NN	O	O
with	NN	O	O
disulfiram	NN	O	O
.	NN	O	O

The	NN	O	O
causative	NN	O	O
relationship	NN	O	O
was	NN	O	O
proven	NN	O	O
by	NN	O	O
challenge	NN	O	O
.	NN	O	O

Atrial	NN	O	B
thrombosis	NN	O	I
involving	NN	O	O
the	NN	O	O
heart	NN	O	O
of	NN	O	O
F	NN	O	O
-	NN	O	O
344	NN	O	O
rats	NN	O	O
ingesting	NN	O	O
quinacrine	NN	O	O
hydrochloride	NN	O	O
.	NN	O	O

Quinacrine	NN	O	O
hydrochloride	NN	O	O
is	NN	O	O
toxic	NN	O	O
for	NN	O	O
the	NN	O	O
heart	NN	O	O
of	NN	O	O
F	NN	O	O
-	NN	O	O
344	NN	O	O
rats	NN	O	O
.	NN	O	O

Rats	NN	O	O
treated	NN	O	O
with	NN	O	O
500	NN	O	O
ppm	NN	O	O
quinacrine	NN	O	O
hydrochloride	NN	O	O
in	NN	O	O
the	NN	O	O
diet	NN	O	O
all	NN	O	O
developed	NN	O	O
a	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
left	NN	O	O
atrial	NN	O	B
thrombosis	NN	O	I
.	NN	O	O

The	NN	O	O
lesion	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
cardiac	NN	O	B
hypertrophy	NN	O	I
and	NN	O	O
dilatation	NN	O	O
and	NN	O	O
focal	NN	O	O
myocardial	NN	O	B
degeneration	NN	O	I
.	NN	O	O

Rats	NN	O	O
died	NN	O	O
from	NN	O	O
cardiac	NN	O	B
hypertrophy	NN	O	I
with	NN	O	O
severe	NN	O	O
acute	NN	O	O
and	NN	O	O
chronic	NN	O	O
congestion	NN	O	O
of	NN	O	O
the	NN	O	O
lungs	NN	O	O
,	NN	O	O
liver	NN	O	O
,	NN	O	O
and	NN	O	O
other	NN	O	O
organs	NN	O	O
.	NN	O	O

Seventy	NN	O	O
percent	NN	O	O
of	NN	O	O
rats	NN	O	O
given	NN	O	O
250	NN	O	O
ppm	NN	O	O
quinacrine	NN	O	O
hydrochloride	NN	O	O
and	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
ppm	NN	O	O
sodium	NN	O	O
nitrite	NN	O	O
simultaneously	NN	O	O
in	NN	O	O
the	NN	O	O
diet	NN	O	O
had	NN	O	O
thrombosis	NN	O	B
of	NN	O	O
the	NN	O	O
atria	NN	O	O
of	NN	O	O
the	NN	O	O
heart	NN	O	O
,	NN	O	O
while	NN	O	O
untreated	NN	O	O
control	NN	O	O
rats	NN	O	O
in	NN	O	O
this	NN	O	O
laboratory	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
atrial	NN	O	B
thrombosis	NN	O	I
.	NN	O	O

Sodium	NN	O	O
nitrite	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
quinacrine	NN	O	O
hydrochloride	NN	O	O
appeared	NN	O	O
to	NN	O	O
have	NN	O	O
no	NN	O	O
additional	NN	O	O
effect	NN	O	O
.	NN	O	O

Alternating	NN	O	B
sinus	NN	O	I
rhythm	NN	O	I
and	NN	O	O
intermittent	NN	O	O
sinoatrial	NN	O	B
block	NN	O	I
induced	NN	O	O
by	NN	O	O
propranolol	NN	O	O
.	NN	O	O

Alternating	NN	O	B
sinus	NN	O	I
rhythm	NN	O	I
and	NN	O	O
intermittent	NN	O	O
sinoatrial	NN	O	B
(	NN	O	I
S	NN	O	I
-	NN	O	I
A	NN	O	I
)	NN	O	I
block	NN	O	I
was	NN	O	O
observed	NN	O	O
in	NN	O	O
a	NN	O	O
57	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
,	NN	O	O
under	NN	O	O
treatment	NN	O	O
for	NN	O	O
angina	NN	O	B
with	NN	O	O
80	NN	O	O
mg	NN	O	O
propranolol	NN	O	O
daily	NN	O	O
.	NN	O	O

The	NN	O	O
electrocardiogram	NN	O	O
showed	NN	O	O
alternation	NN	O	O
of	NN	O	O
long	NN	O	O
and	NN	O	O
short	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
intervals	NN	O	O
and	NN	O	O
occasional	NN	O	O
pauses	NN	O	O
.	NN	O	O

These	NN	O	O
pauses	NN	O	O
were	NN	O	O
always	NN	O	O
preceded	NN	O	O
by	NN	O	O
the	NN	O	O
short	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
intervals	NN	O	O
and	NN	O	O
were	NN	O	O
usually	NN	O	O
followed	NN	O	O
by	NN	O	O
one	NN	O	O
or	NN	O	O
two	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
intervals	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
92	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
95	NN	O	O
s	NN	O	O
representing	NN	O	O
the	NN	O	O
basic	NN	O	O
sinus	NN	O	O
cycle	NN	O	O
.	NN	O	O

Following	NN	O	O
these	NN	O	O
basic	NN	O	O
sinus	NN	O	O
cycles	NN	O	O
,	NN	O	O
alternating	NN	O	B
rhythm	NN	O	I
started	NN	O	O
with	NN	O	O
the	NN	O	O
longer	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
interval	NN	O	O
.	NN	O	O

The	NN	O	O
long	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
intervals	NN	O	O
ranged	NN	O	O
between	NN	O	O
1	NN	O	O
.	NN	O	O
04	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
12	NN	O	O
s	NN	O	O
and	NN	O	O
the	NN	O	O
short	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
intervals	NN	O	O
between	NN	O	O
0	NN	O	O
.	NN	O	O
80	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
84	NN	O	O
s	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
pauses	NN	O	O
were	NN	O	O
equal	NN	O	O
or	NN	O	O
almost	NN	O	O
equal	NN	O	O
to	NN	O	O
one	NN	O	O
short	NN	O	O
plus	NN	O	O
one	NN	O	O
long	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
interval	NN	O	O
or	NN	O	O
to	NN	O	O
twice	NN	O	O
the	NN	O	O
basic	NN	O	O
sinus	NN	O	O
cycle	NN	O	O
.	NN	O	O

In	NN	O	O
one	NN	O	O
recording	NN	O	O
a	NN	O	O
short	NN	O	O
period	NN	O	O
of	NN	O	O
regular	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
with	NN	O	O
intermittent	NN	O	O
2	NN	O	O
/	NN	O	O
1	NN	O	O
S	NN	O	B
-	NN	O	I
A	NN	O	I
block	NN	O	I
was	NN	O	O
observed	NN	O	O
.	NN	O	O

This	NN	O	O
short	NN	O	O
period	NN	O	O
of	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
was	NN	O	O
interrupted	NN	O	O
by	NN	O	O
sudden	NN	O	O
prolongation	NN	O	O
of	NN	O	O
the	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
interval	NN	O	O
starting	NN	O	O
the	NN	O	O
alternative	NN	O	O
rhythm	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
small	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
shape	NN	O	O
of	NN	O	O
the	NN	O	O
P	NN	O	O
waves	NN	O	O
and	NN	O	O
P	NN	O	O
-	NN	O	O
R	NN	O	O
intervals	NN	O	O
.	NN	O	O

S	NN	O	O
-	NN	O	O
A	NN	O	O
conduction	NN	O	O
through	NN	O	O
two	NN	O	O
pathways	NN	O	O
,	NN	O	O
the	NN	O	O
first	NN	O	O
with	NN	O	O
2	NN	O	O
/	NN	O	O
1	NN	O	O
block	NN	O	O
the	NN	O	O
second	NN	O	O
having	NN	O	O
0	NN	O	O
.	NN	O	O
12	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
14	NN	O	O
s	NN	O	O
longer	NN	O	O
conduction	NN	O	O
time	NN	O	O
and	NN	O	O
with	NN	O	O
occasional	NN	O	O
2	NN	O	O
/	NN	O	O
1	NN	O	O
block	NN	O	O
was	NN	O	O
proposed	NN	O	O
for	NN	O	O
the	NN	O	O
explanation	NN	O	O
of	NN	O	O
the	NN	O	O
alternating	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
interval	NN	O	O
and	NN	O	O
other	NN	O	O
electrocardiographic	NN	O	O
features	NN	O	O
seen	NN	O	O
.	NN	O	O

Atropine	NN	O	O
1	NN	O	O
mg	NN	O	O
given	NN	O	O
intravenously	NN	O	O
resulted	NN	O	O
in	NN	O	O
shortening	NN	O	O
of	NN	O	O
all	NN	O	O
P	NN	O	O
-	NN	O	O
P	NN	O	O
intervals	NN	O	O
without	NN	O	O
changing	NN	O	O
the	NN	O	O
rhythm	NN	O	O
.	NN	O	O

The	NN	O	O
abnormal	NN	O	O
rhythm	NN	O	O
disappeared	NN	O	O
with	NN	O	O
the	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
propranolol	NN	O	O
and	NN	O	O
when	NN	O	O
the	NN	O	O
drug	NN	O	O
was	NN	O	O
restarted	NN	O	O
a	NN	O	O
2	NN	O	O
/	NN	O	O
1	NN	O	O
S	NN	O	B
-	NN	O	I
A	NN	O	I
block	NN	O	I
was	NN	O	O
seen	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
accepted	NN	O	O
as	NN	O	O
evidence	NN	O	O
for	NN	O	O
propranolol	NN	O	O
being	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
this	NN	O	O
conduction	NN	O	B
disorder	NN	O	I
.	NN	O	O

Antitumor	NN	O	O
effect	NN	O	O
,	NN	O	O
cardiotoxicity	NN	O	B
,	NN	O	O
and	NN	O	O
nephrotoxicity	NN	O	B
of	NN	O	O
doxorubicin	NN	O	O
in	NN	O	O
the	NN	O	O
IgM	NN	O	O
solid	NN	O	O
immunocytoma	NN	O	B
-	NN	O	O
bearing	NN	O	O
LOU	NN	O	O
/	NN	O	O
M	NN	O	O
/	NN	O	O
WSL	NN	O	O
rat	NN	O	O
.	NN	O	O

Antitumor	NN	O	O
activity	NN	O	O
,	NN	O	O
cardiotoxicity	NN	O	B
,	NN	O	O
and	NN	O	O
nephrotoxicity	NN	O	B
induced	NN	O	O
by	NN	O	O
doxorubicin	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
LOU	NN	O	O
/	NN	O	O
M	NN	O	O
/	NN	O	O
WSL	NN	O	O
inbred	NN	O	O
rats	NN	O	O
each	NN	O	O
bearing	NN	O	O
a	NN	O	O
transplantable	NN	O	O
solid	NN	O	O
IgM	NN	O	O
immunocytoma	NN	O	B
.	NN	O	O

Animals	NN	O	O
with	NN	O	O
a	NN	O	O
tumor	NN	O	B
(	NN	O	O
diameter	NN	O	O
,	NN	O	O
15	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
3	NN	O	O
mm	NN	O	O
)	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
iv	NN	O	O
injections	NN	O	O
of	NN	O	O
doxorubicin	NN	O	O
on	NN	O	O
5	NN	O	O
consecutive	NN	O	O
days	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
1	NN	O	O
weekly	NN	O	O
injection	NN	O	O
for	NN	O	O
7	NN	O	O
weeks	NN	O	O
(	NN	O	O
dose	NN	O	O
range	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
015	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
wt	NN	O	O
)	NN	O	O
.	NN	O	O

Tumor	NN	O	B
regression	NN	O	O
was	NN	O	O
observed	NN	O	O
with	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
doxorubicin	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Complete	NN	O	O
disappearance	NN	O	O
of	NN	O	O
the	NN	O	O
tumor	NN	O	B
was	NN	O	O
induced	NN	O	O
with	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
doxorubicin	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Histologic	NN	O	O
evidence	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B
scored	NN	O	O
as	NN	O	O
grade	NN	O	O
III	NN	O	O
was	NN	O	O
only	NN	O	O
observed	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
doxorubicin	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Light	NN	O	O
microscopic	NN	O	O
evidence	NN	O	O
of	NN	O	O
renal	NN	O	B
damage	NN	O	I
was	NN	O	O
seen	NN	O	O
above	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
doxorubicin	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
which	NN	O	O
resulted	NN	O	O
in	NN	O	O
albuminuria	NN	O	B
and	NN	O	O
very	NN	O	O
low	NN	O	O
serum	NN	O	O
albumin	NN	O	O
levels	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
group	NN	O	O
that	NN	O	O
received	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
doxorubicin	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
the	NN	O	O
serum	NN	O	O
albumin	NN	O	O
level	NN	O	O
decreased	NN	O	O
from	NN	O	O
33	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
to	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
g	NN	O	O
/	NN	O	O
liter	NN	O	O
.	NN	O	O

Ascites	NN	O	B
and	NN	O	O
hydrothorax	NN	O	B
were	NN	O	O
observed	NN	O	O
simultaneously	NN	O	O
.	NN	O	O

The	NN	O	O
same	NN	O	O
experiments	NN	O	O
were	NN	O	O
performed	NN	O	O
with	NN	O	O
non	NN	O	O
-	NN	O	O
tumor	NN	O	B
-	NN	O	O
bearing	NN	O	O
rats	NN	O	O
,	NN	O	O
in	NN	O	O
which	NN	O	O
no	NN	O	O
major	NN	O	O
differences	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
antitumor	NN	O	O
activity	NN	O	O
,	NN	O	O
cardiotoxicity	NN	O	B
,	NN	O	O
and	NN	O	O
nephrotoxicity	NN	O	B
were	NN	O	O
studied	NN	O	O
simultaneously	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
LOU	NN	O	O
/	NN	O	O
M	NN	O	O
/	NN	O	O
WSL	NN	O	O
rat	NN	O	O
.	NN	O	O

Albuminuria	NN	O	B
due	NN	O	O
to	NN	O	O
renal	NN	O	B
damage	NN	O	I
led	NN	O	O
to	NN	O	O
extremely	NN	O	O
low	NN	O	O
serum	NN	O	O
albumin	NN	O	O
levels	NN	O	O
,	NN	O	O
so	NN	O	O
ascites	NN	O	B
and	NN	O	O
hydrothorax	NN	O	B
were	NN	O	O
not	NN	O	O
necessarily	NN	O	O
a	NN	O	O
consequence	NN	O	O
of	NN	O	O
the	NN	O	O
observed	NN	O	O
cardiomyopathy	NN	O	B
.	NN	O	O

Intraoperative	NN	O	O
bradycardia	NN	O	B
and	NN	O	O
hypotension	NN	O	B
associated	NN	O	O
with	NN	O	O
timolol	NN	O	O
and	NN	O	O
pilocarpine	NN	O	O
eye	NN	O	O
drops	NN	O	O
.	NN	O	O

A	NN	O	O
69	NN	O	O
-	NN	O	O
yr	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
,	NN	O	O
who	NN	O	O
was	NN	O	O
concurrently	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
pilocarpine	NN	O	O
nitrate	NN	O	O
and	NN	O	O
timolol	NN	O	O
maleate	NN	O	O
eye	NN	O	O
drops	NN	O	O
,	NN	O	O
developed	NN	O	O
a	NN	O	O
bradycardia	NN	O	B
and	NN	O	O
became	NN	O	O
hypotensive	NN	O	B
during	NN	O	O
halothane	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

Both	NN	O	O
timolol	NN	O	O
and	NN	O	O
pilocarpine	NN	O	O
were	NN	O	O
subsequently	NN	O	O
identified	NN	O	O
in	NN	O	O
a	NN	O	O
24	NN	O	O
-	NN	O	O
h	NN	O	O
collection	NN	O	O
of	NN	O	O
urine	NN	O	O
.	NN	O	O

Timolol	NN	O	O
(	NN	O	O
but	NN	O	O
not	NN	O	O
pilocarpine	NN	O	O
)	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
a	NN	O	O
sample	NN	O	O
of	NN	O	O
plasma	NN	O	O
removed	NN	O	O
during	NN	O	O
surgery	NN	O	O
;	NN	O	O
the	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
of	NN	O	O
timolol	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
6	NN	O	O
ng	NN	O	O
ml	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
was	NN	O	O
consistent	NN	O	O
with	NN	O	O
partial	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
blockade	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
postulated	NN	O	O
that	NN	O	O
this	NN	O	O
action	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
enhanced	NN	O	O
during	NN	O	O
halothane	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
resultant	NN	O	O
bradycardia	NN	O	B
and	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Pilocarpine	NN	O	O
may	NN	O	O
have	NN	O	O
had	NN	O	O
a	NN	O	O
contributory	NN	O	O
effect	NN	O	O
.	NN	O	O

Succinylcholine	NN	O	O
apnoea	NN	O	B
:	NN	O	O
attempted	NN	O	O
reversal	NN	O	O
with	NN	O	O
anticholinesterases	NN	O	O
.	NN	O	O

Anticholinesterases	NN	O	O
were	NN	O	O
administered	NN	O	O
in	NN	O	O
an	NN	O	O
attempt	NN	O	O
to	NN	O	O
antagonize	NN	O	O
prolonged	NN	O	O
neuromuscular	NN	O	B
blockade	NN	O	I
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
succinylcholine	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
later	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
homozygous	NN	O	O
for	NN	O	O
atypical	NN	O	O
plasma	NN	O	O
cholinesterase	NN	O	O
.	NN	O	O

Edrophonium	NN	O	O
10	NN	O	O
mg	NN	O	O
,	NN	O	O
given	NN	O	O
74	NN	O	O
min	NN	O	O
after	NN	O	O
succinylcholine	NN	O	O
,	NN	O	O
when	NN	O	O
train	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
four	NN	O	O
stimulation	NN	O	O
was	NN	O	O
characteristic	NN	O	O
of	NN	O	O
phase	NN	O	O
II	NN	O	O
block	NN	O	O
,	NN	O	O
produced	NN	O	O
partial	NN	O	O
antagonism	NN	O	O
which	NN	O	O
was	NN	O	O
not	NN	O	O
sustained	NN	O	O
.	NN	O	O

Repeated	NN	O	O
doses	NN	O	O
of	NN	O	O
edrophonium	NN	O	O
to	NN	O	O
70	NN	O	O
mg	NN	O	O
and	NN	O	O
neostigmine	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
did	NN	O	O
not	NN	O	O
antagonize	NN	O	O
or	NN	O	O
augment	NN	O	O
the	NN	O	O
block	NN	O	O
.	NN	O	O

Spontaneous	NN	O	O
respiration	NN	O	O
recommenced	NN	O	O
200	NN	O	O
min	NN	O	O
after	NN	O	O
succinylcholine	NN	O	O
administration	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
anticholinesterases	NN	O	O
are	NN	O	O
only	NN	O	O
partially	NN	O	O
effective	NN	O	O
in	NN	O	O
restoring	NN	O	O
neuromuscular	NN	O	O
function	NN	O	O
in	NN	O	O
succinylcholine	NN	O	O
apnoea	NN	O	B
despite	NN	O	O
muscle	NN	O	O
twitch	NN	O	O
activity	NN	O	O
typical	NN	O	O
of	NN	O	O
phase	NN	O	O
II	NN	O	O
block	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
doxorubicin	NN	O	O
on	NN	O	O
[	NN	O	O
omega	NN	O	O
-	NN	O	O
I	NN	O	O
-	NN	O	O
131	NN	O	O
]	NN	O	O
heptadecanoic	NN	O	O
acid	NN	O	O
myocardial	NN	O	O
scintigraphy	NN	O	O
and	NN	O	O
echocardiography	NN	O	O
in	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
serial	NN	O	O
treatment	NN	O	O
with	NN	O	O
doxorubicin	NN	O	O
on	NN	O	O
dynamic	NN	O	O
myocardial	NN	O	O
scintigraphy	NN	O	O
with	NN	O	O
[	NN	O	O
omega	NN	O	O
-	NN	O	O
I	NN	O	O
-	NN	O	O
131	NN	O	O
]	NN	O	O
heptadecanoic	NN	O	O
acid	NN	O	O
(	NN	O	O
I	NN	O	O
-	NN	O	O
131	NN	O	O
HA	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
on	NN	O	O
global	NN	O	O
left	NN	O	O
-	NN	O	O
ventricular	NN	O	O
function	NN	O	O
determined	NN	O	O
echocardiographically	NN	O	O
,	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
nine	NN	O	O
mongrel	NN	O	O
dogs	NN	O	O
.	NN	O	O

Total	NN	O	O
extractable	NN	O	O
myocardial	NN	O	O
lipid	NN	O	O
was	NN	O	O
compared	NN	O	O
postmortem	NN	O	O
between	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
control	NN	O	O
dogs	NN	O	O
and	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
treated	NN	O	O
dogs	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
and	NN	O	O
then	NN	O	O
progressive	NN	O	O
fall	NN	O	O
in	NN	O	O
global	NN	O	O
LV	NN	O	O
function	NN	O	O
was	NN	O	O
observed	NN	O	O
at	NN	O	O
a	NN	O	O
cumulative	NN	O	O
doxorubicin	NN	O	O
dose	NN	O	O
of	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
myocardial	NN	O	O
t1	NN	O	O
/	NN	O	O
2	NN	O	O
of	NN	O	O
the	NN	O	O
I	NN	O	O
-	NN	O	O
131	NN	O	O
HA	NN	O	O
was	NN	O	O
observed	NN	O	O
only	NN	O	O
at	NN	O	O
a	NN	O	O
higher	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
,	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
alteration	NN	O	O
in	NN	O	O
total	NN	O	O
extractable	NN	O	O
myocardial	NN	O	O
lipids	NN	O	O
was	NN	O	O
observed	NN	O	O
between	NN	O	O
control	NN	O	O
dogs	NN	O	O
and	NN	O	O
those	NN	O	O
treated	NN	O	O
with	NN	O	O
doxorubicin	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
changes	NN	O	O
leading	NN	O	O
to	NN	O	O
an	NN	O	O
alteration	NN	O	O
of	NN	O	O
myocardial	NN	O	O
dynamic	NN	O	O
imaging	NN	O	O
with	NN	O	O
I	NN	O	O
-	NN	O	O
131	NN	O	O
HA	NN	O	O
are	NN	O	O
not	NN	O	O
the	NN	O	O
initiating	NN	O	O
factor	NN	O	O
in	NN	O	O
doxorubicin	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Hemodynamics	NN	O	O
and	NN	O	O
myocardial	NN	O	O
metabolism	NN	O	O
under	NN	O	O
deliberate	NN	O	O
hypotension	NN	O	B
.	NN	O	O

An	NN	O	O
experimental	NN	O	O
study	NN	O	O
in	NN	O	O
dogs	NN	O	O
.	NN	O	O

Coronary	NN	O	O
blood	NN	O	O
flow	NN	O	O
,	NN	O	O
cardiac	NN	O	O
work	NN	O	O
and	NN	O	O
metabolism	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
dogs	NN	O	O
under	NN	O	O
sodium	NN	O	O
nitroprusside	NN	O	O
(	NN	O	O
SNP	NN	O	O
)	NN	O	O
and	NN	O	O
trimetaphan	NN	O	O
(	NN	O	O
TMP	NN	O	O
)	NN	O	O
deliberate	NN	O	O
hypotension	NN	O	B
(	NN	O	O
20	NN	O	O
%	NN	O	O
and	NN	O	O
40	NN	O	O
%	NN	O	O
mean	NN	O	O
pressure	NN	O	O
decrease	NN	O	O
from	NN	O	O
baseline	NN	O	O
)	NN	O	O
.	NN	O	O

Regarding	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
on	NN	O	O
coronary	NN	O	O
blood	NN	O	O
flow	NN	O	O
,	NN	O	O
aortic	NN	O	O
and	NN	O	O
coronary	NN	O	O
sinus	NN	O	O
metabolic	NN	O	O
data	NN	O	O
(	NN	O	O
pH	NN	O	O
,	NN	O	O
pO2	NN	O	O
,	NN	O	O
pCO2	NN	O	O
)	NN	O	O
we	NN	O	O
could	NN	O	O
confirm	NN	O	O
that	NN	O	O
nitroprusside	NN	O	O
hypotension	NN	O	B
could	NN	O	O
be	NN	O	O
safely	NN	O	O
used	NN	O	O
to	NN	O	O
30	NN	O	O
%	NN	O	O
mean	NN	O	O
blood	NN	O	O
pressure	NN	O	O
decrease	NN	O	O
from	NN	O	O
control	NN	O	O
,	NN	O	O
trimetaphan	NN	O	O
hypotension	NN	O	B
to	NN	O	O
20	NN	O	O
%	NN	O	O
mean	NN	O	O
blood	NN	O	O
pressure	NN	O	O
decrease	NN	O	O
.	NN	O	O

Cardiac	NN	O	O
work	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
during	NN	O	O
SNP	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Myocardial	NN	O	O
O2	NN	O	O
consumption	NN	O	O
and	NN	O	O
O2	NN	O	O
availability	NN	O	O
were	NN	O	O
directly	NN	O	O
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
coronary	NN	O	O
perfusion	NN	O	O
.	NN	O	O

Careful	NN	O	O
invasive	NN	O	O
monitoring	NN	O	O
of	NN	O	O
the	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
blood	NN	O	O
gases	NN	O	O
and	NN	O	O
of	NN	O	O
the	NN	O	O
ECG	NN	O	O
ST	NN	O	O
-	NN	O	O
T	NN	O	O
segment	NN	O	O
is	NN	O	O
mandatory	NN	O	O
.	NN	O	O

Evidence	NN	O	O
for	NN	O	O
a	NN	O	O
selective	NN	O	O
brain	NN	O	O
noradrenergic	NN	O	O
involvement	NN	O	O
in	NN	O	O
the	NN	O	O
locomotor	NN	O	O
stimulant	NN	O	O
effects	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Male	NN	O	O
rats	NN	O	O
received	NN	O	O
the	NN	O	O
noradrenaline	NN	O	O
neurotoxin	NN	O	O
DSP4	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
7	NN	O	O
days	NN	O	O
prior	NN	O	O
to	NN	O	O
injection	NN	O	O
of	NN	O	O
D	NN	O	O
-	NN	O	O
amphetamine	NN	O	O
(	NN	O	O
10	NN	O	O
or	NN	O	O
40	NN	O	O
mumol	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
hyperactivity	NN	O	B
induced	NN	O	O
by	NN	O	O
D	NN	O	O
-	NN	O	O
amphetamine	NN	O	O
(	NN	O	O
10	NN	O	O
mumol	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
by	NN	O	O
DSP4	NN	O	O
pretreatment	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
increased	NN	O	O
rearings	NN	O	O
and	NN	O	O
the	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
stereotypies	NN	O	B
were	NN	O	O
not	NN	O	O
blocked	NN	O	O
by	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
DSP4	NN	O	O
.	NN	O	O

The	NN	O	O
reduction	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
hyperactivity	NN	O	B
induced	NN	O	O
by	NN	O	O
DSP4	NN	O	O
was	NN	O	O
blocked	NN	O	O
by	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
the	NN	O	O
noradrenaline	NN	O	O
-	NN	O	O
uptake	NN	O	O
blocking	NN	O	O
agent	NN	O	O
,	NN	O	O
desipramine	NN	O	O
,	NN	O	O
which	NN	O	O
prevents	NN	O	O
the	NN	O	O
neurotoxic	NN	O	B
action	NN	O	O
of	NN	O	O
DSP4	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
results	NN	O	O
suggest	NN	O	O
a	NN	O	O
selective	NN	O	O
involvement	NN	O	O
of	NN	O	O
central	NN	O	O
noradrenergic	NN	O	O
neurones	NN	O	O
in	NN	O	O
the	NN	O	O
locomotor	NN	O	O
stimulant	NN	O	O
effect	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Accelerated	NN	O	B
junctional	NN	O	I
rhythms	NN	O	I
during	NN	O	O
oral	NN	O	O
verapamil	NN	O	O
therapy	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
examined	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
atrioventricular	NN	O	O
(	NN	O	O
AV	NN	O	O
)	NN	O	O
dissociation	NN	O	O
and	NN	O	O
accelerated	NN	O	B
junctional	NN	O	I
rhythms	NN	O	I
in	NN	O	O
59	NN	O	O
patients	NN	O	O
receiving	NN	O	O
oral	NN	O	O
verapamil	NN	O	O
.	NN	O	O

Accelerated	NN	O	B
junctional	NN	O	I
rhythms	NN	O	I
and	NN	O	O
AV	NN	O	O
dissociation	NN	O	O
were	NN	O	O
frequent	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
supraventricular	NN	O	B
tachyarrhythmias	NN	O	I
,	NN	O	O
particularly	NN	O	O
AV	NN	O	O
nodal	NN	O	O
reentry	NN	O	O
.	NN	O	O

Verapamil	NN	O	O
administration	NN	O	O
to	NN	O	O
these	NN	O	O
patients	NN	O	O
led	NN	O	O
to	NN	O	O
an	NN	O	O
asymptomatic	NN	O	O
increase	NN	O	O
in	NN	O	O
activity	NN	O	O
of	NN	O	O
these	NN	O	O
junctional	NN	O	O
pacemakers	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
various	NN	O	O
chest	NN	O	B
pain	NN	O	I
syndromes	NN	O	O
,	NN	O	O
verapamil	NN	O	O
neither	NN	O	O
increased	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
junctional	NN	O	O
rhythms	NN	O	O
nor	NN	O	O
suppressed	NN	O	O
their	NN	O	O
role	NN	O	O
as	NN	O	O
escape	NN	O	O
rhythms	NN	O	O
under	NN	O	O
physiologically	NN	O	O
appropriate	NN	O	O
circumstances	NN	O	O
.	NN	O	O

Interstrain	NN	O	O
variation	NN	O	O
in	NN	O	O
acute	NN	O	O
toxic	NN	O	O
response	NN	O	O
to	NN	O	O
caffeine	NN	O	O
among	NN	O	O
inbred	NN	O	O
mice	NN	O	O
.	NN	O	O

Acute	NN	O	O
toxic	NN	O	O
dosage	NN	O	O
-	NN	O	O
dependent	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
caffeine	NN	O	O
were	NN	O	O
compared	NN	O	O
in	NN	O	O
adult	NN	O	O
males	NN	O	O
from	NN	O	O
seven	NN	O	O
inbred	NN	O	O
mouse	NN	O	O
strains	NN	O	O
(	NN	O	O
A	NN	O	O
/	NN	O	O
J	NN	O	O
,	NN	O	O
BALB	NN	O	O
/	NN	O	O
cJ	NN	O	O
,	NN	O	O
CBA	NN	O	O
/	NN	O	O
J	NN	O	O
,	NN	O	O
C3H	NN	O	O
/	NN	O	O
HeJ	NN	O	O
,	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6J	NN	O	O
,	NN	O	O
DBA	NN	O	O
/	NN	O	O
2J	NN	O	O
,	NN	O	O
SWR	NN	O	O
/	NN	O	O
J	NN	O	O
)	NN	O	O
.	NN	O	O

C57BL	NN	O	O
/	NN	O	O
6J	NN	O	O
,	NN	O	O
chosen	NN	O	O
as	NN	O	O
a	NN	O	O
"	NN	O	O
prototypic	NN	O	O
"	NN	O	O
mouse	NN	O	O
strain	NN	O	O
,	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
determine	NN	O	O
behavioral	NN	O	O
responses	NN	O	O
to	NN	O	O
a	NN	O	O
broad	NN	O	O
range	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
of	NN	O	O
caffeine	NN	O	O
doses	NN	O	O
.	NN	O	O

Five	NN	O	O
phenotypic	NN	O	O
characteristics	NN	O	O
-	NN	O	O
-	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
,	NN	O	O
righting	NN	O	O
ability	NN	O	O
,	NN	O	O
clonic	NN	O	B
seizure	NN	O	I
induction	NN	O	O
,	NN	O	O
stress	NN	O	O
-	NN	O	O
induced	NN	O	O
lethality	NN	O	O
,	NN	O	O
death	NN	O	O
without	NN	O	O
external	NN	O	O
stress	NN	O	O
-	NN	O	O
-	NN	O	O
were	NN	O	O
scored	NN	O	O
at	NN	O	O
various	NN	O	O
caffeine	NN	O	O
doses	NN	O	O
in	NN	O	O
drug	NN	O	O
-	NN	O	O
naive	NN	O	O
animals	NN	O	O
under	NN	O	O
empirically	NN	O	O
optimized	NN	O	O
,	NN	O	O
rigidly	NN	O	O
constant	NN	O	O
experimental	NN	O	O
conditions	NN	O	O
.	NN	O	O

Mice	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
for	NN	O	O
each	NN	O	O
point	NN	O	O
)	NN	O	O
received	NN	O	O
single	NN	O	O
IP	NN	O	O
injections	NN	O	O
of	NN	O	O
a	NN	O	O
fixed	NN	O	O
volume	NN	O	O
/	NN	O	O
g	NN	O	O
body	NN	O	O
weight	NN	O	O
of	NN	O	O
physiological	NN	O	O
saline	NN	O	O
carrier	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
caffeine	NN	O	O
in	NN	O	O
doses	NN	O	O
ranging	NN	O	O
from	NN	O	O
125	NN	O	O
-	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Loss	NN	O	O
of	NN	O	O
righting	NN	O	O
ability	NN	O	O
was	NN	O	O
scored	NN	O	O
at	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
5	NN	O	O
min	NN	O	O
post	NN	O	O
dosing	NN	O	O
and	NN	O	O
at	NN	O	O
5	NN	O	O
min	NN	O	O
intervals	NN	O	O
thereafter	NN	O	O
for	NN	O	O
20	NN	O	O
min	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
same	NN	O	O
animals	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
clonic	NN	O	B
seizures	NN	O	I
was	NN	O	O
scored	NN	O	O
as	NN	O	O
to	NN	O	O
time	NN	O	O
of	NN	O	O
onset	NN	O	O
and	NN	O	O
severity	NN	O	O
for	NN	O	O
20	NN	O	O
min	NN	O	O
after	NN	O	O
drug	NN	O	O
administration	NN	O	O
.	NN	O	O

When	NN	O	O
these	NN	O	O
proceeded	NN	O	O
to	NN	O	O
tonic	NN	O	B
seizures	NN	O	I
,	NN	O	O
death	NN	O	O
occurred	NN	O	O
in	NN	O	O
less	NN	O	O
than	NN	O	O
20	NN	O	O
min	NN	O	O
.	NN	O	O

Animals	NN	O	O
surviving	NN	O	O
for	NN	O	O
20	NN	O	O
min	NN	O	O
were	NN	O	O
immediately	NN	O	O
stressed	NN	O	O
by	NN	O	O
a	NN	O	O
swim	NN	O	O
test	NN	O	O
in	NN	O	O
25	NN	O	O
degrees	NN	O	O
C	NN	O	O
water	NN	O	O
,	NN	O	O
and	NN	O	O
death	NN	O	O
-	NN	O	O
producing	NN	O	O
tonic	NN	O	B
seizures	NN	O	I
were	NN	O	O
scored	NN	O	O
for	NN	O	O
2	NN	O	O
min	NN	O	O
.	NN	O	O

In	NN	O	O
other	NN	O	O
animals	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
was	NN	O	O
measured	NN	O	O
15	NN	O	O
or	NN	O	O
60	NN	O	O
min	NN	O	O
after	NN	O	O
caffeine	NN	O	O
administration	NN	O	O
.	NN	O	O

By	NN	O	O
any	NN	O	O
single	NN	O	O
behavioral	NN	O	O
criterion	NN	O	O
or	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
these	NN	O	O
criteria	NN	O	O
,	NN	O	O
marked	NN	O	O
differences	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
toxic	NN	O	O
caffeine	NN	O	O
doses	NN	O	O
were	NN	O	O
observed	NN	O	O
between	NN	O	O
strains	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
behavioral	NN	O	O
toxicity	NN	O	B
testing	NN	O	O
of	NN	O	O
alkylxanthines	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
mouse	NN	O	O
strain	NN	O	O
may	NN	O	O
be	NN	O	O
misleading	NN	O	O
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
toxic	NN	O	O
responses	NN	O	O
of	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
to	NN	O	O
this	NN	O	O
class	NN	O	O
of	NN	O	O
compounds	NN	O	O
are	NN	O	O
genetically	NN	O	O
influenced	NN	O	O
in	NN	O	O
mammals	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
ovarian	NN	O	B
cancer	NN	O	I
with	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
cis	NN	O	O
-	NN	O	O
platinum	NN	O	O
,	NN	O	O
adriamycin	NN	O	O
,	NN	O	O
cyclophosphamide	NN	O	O
and	NN	O	O
hexamethylmelamine	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
last	NN	O	O
2	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
years	NN	O	O
,	NN	O	O
38	NN	O	O
patients	NN	O	O
with	NN	O	O
ovarian	NN	O	B
cancer	NN	O	I
were	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
cisplatinum	NN	O	O
(	NN	O	O
CPDD	NN	O	O
)	NN	O	O
,	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
,	NN	O	O
adriamycin	NN	O	O
,	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
,	NN	O	O
cyclophosphamide	NN	O	O
,	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
,	NN	O	O
on	NN	O	O
day	NN	O	O
1	NN	O	O
;	NN	O	O
and	NN	O	O
hexamethylmelamine	NN	O	O
(	NN	O	O
HMM	NN	O	O
)	NN	O	O
,	NN	O	O
6	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
daily	NN	O	O
,	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
.	NN	O	O

Each	NN	O	O
course	NN	O	O
was	NN	O	O
repeated	NN	O	O
monthly	NN	O	O
.	NN	O	O

2	NN	O	O
patients	NN	O	O
had	NN	O	O
stage	NN	O	O
II	NN	O	O
,	NN	O	O
14	NN	O	O
stage	NN	O	O
III	NN	O	O
and	NN	O	O
22	NN	O	O
stage	NN	O	O
IV	NN	O	O
disease	NN	O	O
.	NN	O	O

14	NN	O	O
of	NN	O	O
the	NN	O	O
38	NN	O	O
patients	NN	O	O
were	NN	O	O
previously	NN	O	O
treated	NN	O	O
with	NN	O	O
chemotherapy	NN	O	O
,	NN	O	O
1	NN	O	O
with	NN	O	O
radiation	NN	O	O
,	NN	O	O
6	NN	O	O
with	NN	O	O
both	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
radiation	NN	O	O
,	NN	O	O
and	NN	O	O
17	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
any	NN	O	O
treatment	NN	O	O
before	NN	O	O
CPDD	NN	O	O
combination	NN	O	O
.	NN	O	O

31	NN	O	O
of	NN	O	O
the	NN	O	O
38	NN	O	O
cases	NN	O	O
(	NN	O	O
81	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
demonstrated	NN	O	O
objective	NN	O	O
responses	NN	O	O
lasting	NN	O	O
for	NN	O	O
2	NN	O	O
months	NN	O	O
or	NN	O	O
more	NN	O	O
.	NN	O	O

These	NN	O	O
responses	NN	O	O
were	NN	O	O
partial	NN	O	O
in	NN	O	O
19	NN	O	O
and	NN	O	O
complete	NN	O	O
in	NN	O	O
12	NN	O	O
cases	NN	O	O
.	NN	O	O

Hematologic	NN	O	B
toxicity	NN	O	I
was	NN	O	O
moderate	NN	O	O
and	NN	O	O
with	NN	O	O
reversible	NN	O	O
anemia	NN	O	B
developing	NN	O	O
in	NN	O	O
71	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Gastrointestinal	NN	O	O
side	NN	O	O
effects	NN	O	O
from	NN	O	O
CPDD	NN	O	O
were	NN	O	O
universal	NN	O	O
.	NN	O	O

HMM	NN	O	O
gastrointestinal	NN	O	B
toxicity	NN	O	I
necessitated	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
in	NN	O	O
5	NN	O	O
patients	NN	O	O
.	NN	O	O

Severe	NN	O	O
nephrotoxicity	NN	O	B
was	NN	O	O
observed	NN	O	O
in	NN	O	O
2	NN	O	O
patients	NN	O	O
but	NN	O	O
was	NN	O	O
reversible	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
drug	NN	O	O
-	NN	O	O
related	NN	O	O
deaths	NN	O	O
.	NN	O	O

Nontraumatic	NN	O	O
dissecting	NN	O	B
aneurysm	NN	O	I
of	NN	O	O
the	NN	O	O
basilar	NN	O	O
artery	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
nontraumatic	NN	O	O
dissecting	NN	O	B
aneurysm	NN	O	I
of	NN	O	O
the	NN	O	O
basilar	NN	O	O
artery	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
hypertension	NN	O	B
,	NN	O	O
smoke	NN	O	O
,	NN	O	O
and	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
is	NN	O	O
reported	NN	O	O
in	NN	O	O
a	NN	O	O
young	NN	O	O
female	NN	O	O
patient	NN	O	O
with	NN	O	O
a	NN	O	O
locked	NN	O	B
-	NN	O	I
in	NN	O	I
syndrome	NN	O	I
.	NN	O	O

A	NN	O	O
method	NN	O	O
for	NN	O	O
the	NN	O	O
measurement	NN	O	O
of	NN	O	O
tremor	NN	O	B
,	NN	O	O
and	NN	O	O
a	NN	O	O
comparison	NN	O	O
of	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
tocolytic	NN	O	O
beta	NN	O	O
-	NN	O	O
mimetics	NN	O	O
.	NN	O	O

A	NN	O	O
method	NN	O	O
permitting	NN	O	O
measurement	NN	O	O
of	NN	O	O
finger	NN	O	O
tremor	NN	O	B
as	NN	O	O
a	NN	O	O
displacement	NN	O	O
-	NN	O	O
time	NN	O	O
curve	NN	O	O
is	NN	O	O
described	NN	O	O
,	NN	O	O
using	NN	O	O
a	NN	O	O
test	NN	O	O
system	NN	O	O
with	NN	O	O
simple	NN	O	O
amplitude	NN	O	O
calibration	NN	O	O
.	NN	O	O

The	NN	O	O
coordinates	NN	O	O
of	NN	O	O
the	NN	O	O
inversion	NN	O	O
points	NN	O	O
of	NN	O	O
the	NN	O	O
displacement	NN	O	O
-	NN	O	O
time	NN	O	O
curves	NN	O	O
were	NN	O	O
transferred	NN	O	O
through	NN	O	O
graphical	NN	O	O
input	NN	O	O
equipment	NN	O	O
to	NN	O	O
punched	NN	O	O
tape	NN	O	O
.	NN	O	O

By	NN	O	O
means	NN	O	O
of	NN	O	O
a	NN	O	O
computer	NN	O	O
program	NN	O	O
,	NN	O	O
periods	NN	O	O
and	NN	O	O
amplitudes	NN	O	O
of	NN	O	O
tremor	NN	O	B
oscillations	NN	O	O
were	NN	O	O
calculated	NN	O	O
and	NN	O	O
classified	NN	O	O
.	NN	O	O

The	NN	O	O
event	NN	O	O
frequency	NN	O	O
for	NN	O	O
each	NN	O	O
class	NN	O	O
of	NN	O	O
periods	NN	O	O
and	NN	O	O
amplitudes	NN	O	O
was	NN	O	O
determined	NN	O	O
.	NN	O	O

The	NN	O	O
actions	NN	O	O
of	NN	O	O
fenoterol	NN	O	O
-	NN	O	O
hydrobromide	NN	O	O
,	NN	O	O
ritodrin	NN	O	O
-	NN	O	O
HCl	NN	O	O
and	NN	O	O
placebo	NN	O	O
given	NN	O	O
to	NN	O	O
10	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
by	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
crossover	NN	O	O
study	NN	O	O
were	NN	O	O
tested	NN	O	O
by	NN	O	O
this	NN	O	O
method	NN	O	O
.	NN	O	O

At	NN	O	O
therapeutic	NN	O	O
doses	NN	O	O
both	NN	O	O
substances	NN	O	O
raised	NN	O	O
the	NN	O	O
mean	NN	O	O
tremor	NN	O	B
amplitude	NN	O	O
to	NN	O	O
about	NN	O	O
three	NN	O	O
times	NN	O	O
the	NN	O	O
control	NN	O	O
level	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
period	NN	O	O
within	NN	O	O
each	NN	O	O
class	NN	O	O
of	NN	O	O
amplitudes	NN	O	O
shortened	NN	O	O
by	NN	O	O
10	NN	O	O
-	NN	O	O
-	NN	O	O
20	NN	O	O
ms	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
mean	NN	O	O
periods	NN	O	O
calculated	NN	O	O
from	NN	O	O
all	NN	O	O
oscillations	NN	O	O
together	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
significantly	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
fenoterol	NN	O	O
-	NN	O	O
hydrobromide	NN	O	O
infusion	NN	O	O
,	NN	O	O
tremor	NN	O	B
amplitudes	NN	O	O
decreased	NN	O	O
significantly	NN	O	O
faster	NN	O	O
than	NN	O	O
those	NN	O	O
following	NN	O	O
ritodrin	NN	O	O
-	NN	O	O
HCl	NN	O	O
infusion	NN	O	O
.	NN	O	O

Propylthiouracil	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatic	NN	O	B
damage	NN	O	I
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
of	NN	O	O
propylthiouracil	NN	O	O
-	NN	O	O
induced	NN	O	O
liver	NN	O	B
damage	NN	O	I
have	NN	O	O
been	NN	O	O
observed	NN	O	O
.	NN	O	O

The	NN	O	O
first	NN	O	O
case	NN	O	O
is	NN	O	O
of	NN	O	O
an	NN	O	O
acute	NN	O	O
type	NN	O	O
of	NN	O	O
damage	NN	O	O
,	NN	O	O
proven	NN	O	O
by	NN	O	O
rechallenge	NN	O	O
;	NN	O	O
the	NN	O	O
second	NN	O	O
presents	NN	O	O
a	NN	O	O
clinical	NN	O	O
and	NN	O	O
histologic	NN	O	O
picture	NN	O	O
resembling	NN	O	O
chronic	NN	O	B
active	NN	O	I
hepatitis	NN	O	I
,	NN	O	O
with	NN	O	O
spontaneous	NN	O	O
remission	NN	O	O
.	NN	O	O

Studies	NN	O	O
on	NN	O	O
the	NN	O	O
bradycardia	NN	O	B
induced	NN	O	O
by	NN	O	O
bepridil	NN	O	O
.	NN	O	O

Bepridil	NN	O	O
,	NN	O	O
a	NN	O	O
novel	NN	O	O
active	NN	O	O
compound	NN	O	O
for	NN	O	O
prophylactic	NN	O	O
treatment	NN	O	O
of	NN	O	O
anginal	NN	O	B
attacks	NN	O	I
,	NN	O	O
induced	NN	O	O
persistent	NN	O	O
bradycardia	NN	O	B
and	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
specific	NN	O	O
anti	NN	O	O
-	NN	O	O
tachycardial	NN	O	B
effect	NN	O	O
,	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
which	NN	O	O
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

In	NN	O	O
vitro	NN	O	O
perfusion	NN	O	O
of	NN	O	O
bepridil	NN	O	O
in	NN	O	O
the	NN	O	O
life	NN	O	O
-	NN	O	O
support	NN	O	O
medium	NN	O	O
for	NN	O	O
isolated	NN	O	O
sino	NN	O	O
-	NN	O	O
atrial	NN	O	O
tissue	NN	O	O
from	NN	O	O
rabbit	NN	O	O
heart	NN	O	O
,	NN	O	O
caused	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
action	NN	O	O
potential	NN	O	O
(	NN	O	O
AP	NN	O	O
)	NN	O	O
spike	NN	O	O
frequency	NN	O	O
(	NN	O	O
recorded	NN	O	O
by	NN	O	O
KCl	NN	O	O
microelectrodes	NN	O	O
)	NN	O	O
starting	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
5	NN	O	O
X	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
6	NN	O	O
)	NN	O	O
M	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
was	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
up	NN	O	O
to	NN	O	O
concentrations	NN	O	O
of	NN	O	O
5	NN	O	O
X	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
5	NN	O	O
)	NN	O	O
M	NN	O	O
,	NN	O	O
whereupon	NN	O	O
blockade	NN	O	O
of	NN	O	O
sinus	NN	O	O
activity	NN	O	O
set	NN	O	O
in	NN	O	O
.	NN	O	O

Bepridil	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
5	NN	O	O
X	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
6	NN	O	O
)	NN	O	O
M	NN	O	O
,	NN	O	O
induced	NN	O	O
a	NN	O	O
concomitant	NN	O	O
reduction	NN	O	O
in	NN	O	O
AP	NN	O	O
amplitude	NN	O	O
(	NN	O	O
falling	NN	O	O
from	NN	O	O
71	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
mV	NN	O	O
to	NN	O	O
47	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
mV	NN	O	O
)	NN	O	O
,	NN	O	O
maximum	NN	O	O
systolic	NN	O	O
depolarization	NN	O	O
velocity	NN	O	O
(	NN	O	O
phase	NN	O	O
0	NN	O	O
)	NN	O	O
which	NN	O	O
fell	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
85	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
35	NN	O	O
V	NN	O	O
/	NN	O	O
s	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
84	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
28	NN	O	O
V	NN	O	O
/	NN	O	O
s	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
maximum	NN	O	O
diastolic	NN	O	O
depolarization	NN	O	O
velocity	NN	O	O
(	NN	O	O
phase	NN	O	O
4	NN	O	O
)	NN	O	O
which	NN	O	O
fell	NN	O	O
from	NN	O	O
38	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
mV	NN	O	O
/	NN	O	O
s	NN	O	O
to	NN	O	O
24	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
mV	NN	O	O
/	NN	O	O
s	NN	O	O
.	NN	O	O

In	NN	O	O
vivo	NN	O	O
injection	NN	O	O
of	NN	O	O
bepridil	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
into	NN	O	O
6	NN	O	O
anaesthetized	NN	O	O
dogs	NN	O	O
which	NN	O	O
had	NN	O	O
undergone	NN	O	O
ablation	NN	O	O
of	NN	O	O
all	NN	O	O
the	NN	O	O
extrinsic	NN	O	O
cardiac	NN	O	O
afferent	NN	O	O
nerve	NN	O	O
supply	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
a	NN	O	O
bilateral	NN	O	O
medullo	NN	O	O
-	NN	O	O
adrenalectomy	NN	O	O
,	NN	O	O
caused	NN	O	O
a	NN	O	O
marked	NN	O	O
reduction	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
which	NN	O	O
fell	NN	O	O
from	NN	O	O
98	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
2	NN	O	O
beats	NN	O	O
/	NN	O	O
min	NN	O	O
to	NN	O	O
76	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
3	NN	O	O
beats	NN	O	O
/	NN	O	O
min	NN	O	O
sustained	NN	O	O
for	NN	O	O
more	NN	O	O
than	NN	O	O
45	NN	O	O
min	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
bepridil	NN	O	O
reduces	NN	O	O
heart	NN	O	O
rate	NN	O	O
by	NN	O	O
acting	NN	O	O
directly	NN	O	O
on	NN	O	O
the	NN	O	O
sinus	NN	O	O
node	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
,	NN	O	O
which	NN	O	O
results	NN	O	O
in	NN	O	O
a	NN	O	O
flattening	NN	O	O
of	NN	O	O
the	NN	O	O
phase	NN	O	O
0	NN	O	O
and	NN	O	O
phase	NN	O	O
4	NN	O	O
slope	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
a	NN	O	O
longer	NN	O	O
AP	NN	O	O
duration	NN	O	O
,	NN	O	O
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
time	NN	O	O
constants	NN	O	O
of	NN	O	O
slow	NN	O	O
inward	NN	O	O
ionic	NN	O	O
currents	NN	O	O
(	NN	O	O
already	NN	O	O
demonstrated	NN	O	O
elsewhere	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
also	NN	O	O
to	NN	O	O
an	NN	O	O
increased	NN	O	O
time	NN	O	O
constant	NN	O	O
for	NN	O	O
deactivation	NN	O	O
of	NN	O	O
the	NN	O	O
outward	NN	O	O
potassium	NN	O	O
current	NN	O	O
(	NN	O	O
Ip	NN	O	O
)	NN	O	O
.	NN	O	O

Hepatitis	NN	O	B
and	NN	O	O
renal	NN	O	B
tubular	NN	O	I
acidosis	NN	O	I
after	NN	O	O
anesthesia	NN	O	O
with	NN	O	O
methoxyflurane	NN	O	O
.	NN	O	O

A	NN	O	O
69	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
operated	NN	O	O
for	NN	O	O
acute	NN	O	B
cholecystitis	NN	O	I
under	NN	O	O
methoxyflurane	NN	O	O
anesthesia	NN	O	O
developed	NN	O	O
postoperatively	NN	O	O
a	NN	O	O
hepatic	NN	O	B
insufficiency	NN	O	I
syndrome	NN	O	I
and	NN	O	O
renal	NN	O	B
tubular	NN	O	I
acidosis	NN	O	I
.	NN	O	O

Massive	NN	O	O
bleeding	NN	O	B
appeared	NN	O	O
during	NN	O	O
surgery	NN	O	O
which	NN	O	O
lasted	NN	O	O
for	NN	O	O
six	NN	O	O
hours	NN	O	O
.	NN	O	O

Postoperative	NN	O	O
evolution	NN	O	O
under	NN	O	O
supportive	NN	O	O
therapy	NN	O	O
was	NN	O	O
favourable	NN	O	O
.	NN	O	O

Complete	NN	O	O
recovery	NN	O	O
was	NN	O	O
confirmed	NN	O	O
by	NN	O	O
repeated	NN	O	O
controls	NN	O	O
performed	NN	O	O
over	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
one	NN	O	O
year	NN	O	O
after	NN	O	O
surgery	NN	O	O
.	NN	O	O

Pituitary	NN	O	O
response	NN	O	O
to	NN	O	O
luteinizing	NN	O	O
hormone	NN	O	O
-	NN	O	O
releasing	NN	O	O
hormone	NN	O	O
during	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
6	NN	O	O
-	NN	O	O
hour	NN	O	O
infusion	NN	O	O
with	NN	O	O
haloperidol	NN	O	O
on	NN	O	O
serum	NN	O	O
prolactin	NN	O	O
and	NN	O	O
luteinizing	NN	O	O
hormone	NN	O	O
(	NN	O	O
LH	NN	O	O
)	NN	O	O
levels	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
male	NN	O	O
subjects	NN	O	O
.	NN	O	O

Five	NN	O	O
hours	NN	O	O
after	NN	O	O
starting	NN	O	O
the	NN	O	O
infusions	NN	O	O
,	NN	O	O
a	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
pituitary	NN	O	O
responses	NN	O	O
to	NN	O	O
LH	NN	O	O
-	NN	O	O
releasing	NN	O	O
hormone	NN	O	O
(	NN	O	O
LH	NN	O	O
-	NN	O	O
RH	NN	O	O
)	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
.	NN	O	O

Control	NN	O	O
patients	NN	O	O
received	NN	O	O
infusions	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
NaCl	NN	O	O
solution	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
haloperidol	NN	O	O
infusions	NN	O	O
,	NN	O	O
significant	NN	O	O
hyperprolactinemia	NN	O	B
was	NN	O	O
found	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
an	NN	O	O
abolished	NN	O	O
pituitary	NN	O	O
response	NN	O	O
to	NN	O	O
LH	NN	O	O
-	NN	O	O
RH	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
responses	NN	O	O
of	NN	O	O
control	NN	O	O
subjects	NN	O	O
.	NN	O	O

Antirifampicin	NN	O	O
antibodies	NN	O	O
in	NN	O	O
acute	NN	O	O
rifampicin	NN	O	O
-	NN	O	O
associated	NN	O	O
renal	NN	O	B
failure	NN	O	I
.	NN	O	O

5	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
(	NN	O	O
3	NN	O	O
with	NN	O	O
thrombopenia	NN	O	B
and	NN	O	O
hemolysis	NN	O	B
)	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
reintroduction	NN	O	O
of	NN	O	O
rifampicin	NN	O	O
are	NN	O	O
described	NN	O	O
.	NN	O	O

No	NN	O	O
correlation	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
and	NN	O	O
the	NN	O	O
total	NN	O	O
dose	NN	O	O
taken	NN	O	O
by	NN	O	O
the	NN	O	O
patients	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
but	NN	O	O
1	NN	O	O
patient	NN	O	O
,	NN	O	O
antirifampicin	NN	O	O
antibodies	NN	O	O
were	NN	O	O
detected	NN	O	O
.	NN	O	O

Antibodies	NN	O	O
suggested	NN	O	O
to	NN	O	O
be	NN	O	O
of	NN	O	O
the	NN	O	O
IgM	NN	O	O
class	NN	O	O
were	NN	O	O
detected	NN	O	O
in	NN	O	O
all	NN	O	O
3	NN	O	O
patients	NN	O	O
with	NN	O	O
hematological	NN	O	B
disorders	NN	O	I
.	NN	O	O

The	NN	O	O
pattern	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
specific	NN	O	O
acute	NN	O	B
tubular	NN	O	I
necrosis	NN	O	I
found	NN	O	O
in	NN	O	O
the	NN	O	O
2	NN	O	O
biopsied	NN	O	O
patients	NN	O	O
,	NN	O	O
indistinguishable	NN	O	O
from	NN	O	O
that	NN	O	O
of	NN	O	O
ischemic	NN	O	O
origin	NN	O	O
,	NN	O	O
raised	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
a	NN	O	O
vascular	NN	O	O
-	NN	O	O
mediated	NN	O	O
damage	NN	O	O
.	NN	O	O

In	NN	O	O
3	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
a	NN	O	O
triggering	NN	O	O
immunoallergic	NN	O	O
mechanism	NN	O	O
is	NN	O	O
discussed	NN	O	O
.	NN	O	O

Cardiovascular	NN	O	O
effects	NN	O	O
of	NN	O	O
hypotension	NN	O	B
induced	NN	O	O
by	NN	O	O
adenosine	NN	O	O
triphosphate	NN	O	O
and	NN	O	O
sodium	NN	O	O
nitroprusside	NN	O	O
on	NN	O	O
dogs	NN	O	O
with	NN	O	O
denervated	NN	O	O
hearts	NN	O	O
.	NN	O	O

Adenosine	NN	O	O
triphosphate	NN	O	O
(	NN	O	O
ATP	NN	O	O
)	NN	O	O
and	NN	O	O
sodium	NN	O	O
nitroprusside	NN	O	O
(	NN	O	O
SNP	NN	O	O
)	NN	O	O
are	NN	O	O
administered	NN	O	O
to	NN	O	O
patients	NN	O	O
to	NN	O	O
induce	NN	O	O
and	NN	O	O
control	NN	O	O
hypotension	NN	O	B
during	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

SNP	NN	O	O
is	NN	O	O
authorized	NN	O	O
for	NN	O	O
clinical	NN	O	O
use	NN	O	O
in	NN	O	O
USA	NN	O	O
and	NN	O	O
UK	NN	O	O
,	NN	O	O
and	NN	O	O
ATP	NN	O	O
is	NN	O	O
clinically	NN	O	O
used	NN	O	O
in	NN	O	O
other	NN	O	O
countries	NN	O	O
such	NN	O	O
as	NN	O	O
Japan	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
how	NN	O	O
these	NN	O	O
two	NN	O	O
drugs	NN	O	O
act	NN	O	O
on	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
systems	NN	O	O
of	NN	O	O
20	NN	O	O
dogs	NN	O	O
whose	NN	O	O
hearts	NN	O	O
had	NN	O	O
been	NN	O	O
denervated	NN	O	O
by	NN	O	O
a	NN	O	O
procedure	NN	O	O
we	NN	O	O
had	NN	O	O
devised	NN	O	O
.	NN	O	O

ATP	NN	O	O
(	NN	O	O
10	NN	O	O
dogs	NN	O	O
)	NN	O	O
or	NN	O	O
SNP	NN	O	O
(	NN	O	O
10	NN	O	O
dogs	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
reduce	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
by	NN	O	O
30	NN	O	O
%	NN	O	O
to	NN	O	O
70	NN	O	O
%	NN	O	O
of	NN	O	O
control	NN	O	O
.	NN	O	O

Before	NN	O	O
,	NN	O	O
during	NN	O	O
and	NN	O	O
after	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
,	NN	O	O
we	NN	O	O
measured	NN	O	O
major	NN	O	O
cardiovascular	NN	O	O
parameters	NN	O	O
.	NN	O	O

Hypotension	NN	O	B
induced	NN	O	O
by	NN	O	O
ATP	NN	O	O
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
significant	NN	O	O
decreases	NN	O	O
in	NN	O	O
mean	NN	O	O
pulmonary	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
central	NN	O	O
venous	NN	O	O
pressure	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
left	NN	O	O
ventricular	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
total	NN	O	O
peripheral	NN	O	O
resistance	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
rate	NN	O	O
pressure	NN	O	O
product	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
total	NN	O	O
body	NN	O	O
oxygen	NN	O	O
consumption	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
;	NN	O	O
all	NN	O	O
these	NN	O	O
variables	NN	O	O
returned	NN	O	O
normal	NN	O	O
within	NN	O	O
30	NN	O	O
min	NN	O	O
after	NN	O	O
ATP	NN	O	O
was	NN	O	O
stopped	NN	O	O
.	NN	O	O

Cardiac	NN	O	O
output	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
.	NN	O	O

During	NN	O	O
hypotension	NN	O	B
produced	NN	O	O
by	NN	O	O
SNP	NN	O	O
similar	NN	O	O
decreases	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
mean	NN	O	O
pulmonary	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
central	NN	O	O
venous	NN	O	O
pressure	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
left	NN	O	O
ventricular	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
total	NN	O	O
peripheral	NN	O	O
resistance	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
rate	NN	O	O
pressure	NN	O	O
product	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
oxygen	NN	O	O
content	NN	O	O
difference	NN	O	O
between	NN	O	O
arterial	NN	O	O
and	NN	O	O
mixed	NN	O	O
venous	NN	O	O
blood	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
heart	NN	O	O
rate	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
and	NN	O	O
cardiac	NN	O	O
output	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
were	NN	O	O
increased	NN	O	O
.	NN	O	O

Recoveries	NN	O	O
of	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
left	NN	O	O
ventricular	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
were	NN	O	O
not	NN	O	O
shown	NN	O	O
within	NN	O	O
60	NN	O	O
min	NN	O	O
after	NN	O	O
SNP	NN	O	O
had	NN	O	O
been	NN	O	O
stopped	NN	O	O
.	NN	O	O

Both	NN	O	O
ATP	NN	O	O
and	NN	O	O
SNP	NN	O	O
should	NN	O	O
act	NN	O	O
on	NN	O	O
the	NN	O	O
pacemaker	NN	O	O
tissue	NN	O	O
of	NN	O	O
the	NN	O	O
heart	NN	O	O
.	NN	O	O

Comparative	NN	O	O
study	NN	O	O
:	NN	O	O
Endografine	NN	O	O
(	NN	O	O
diatrizoate	NN	O	O
)	NN	O	O
,	NN	O	O
Vasurix	NN	O	O
polyvidone	NN	O	O
(	NN	O	O
acetrizoate	NN	O	O
)	NN	O	O
,	NN	O	O
Dimer	NN	O	O
-	NN	O	O
X	NN	O	O
(	NN	O	O
iocarmate	NN	O	O
)	NN	O	O
and	NN	O	O
Hexabrix	NN	O	O
(	NN	O	O
ioxaglate	NN	O	O
)	NN	O	O
in	NN	O	O
hysterosalpingography	NN	O	O
.	NN	O	O

Side	NN	O	O
effects	NN	O	O
of	NN	O	O
hysterosalpingography	NN	O	O
with	NN	O	O
Dimer	NN	O	O
-	NN	O	O
X	NN	O	O
,	NN	O	O
Hexabrix	NN	O	O
,	NN	O	O
Vasurix	NN	O	O
polyvidone	NN	O	O
and	NN	O	O
Endografine	NN	O	O
in	NN	O	O
142	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
,	NN	O	O
receiving	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
four	NN	O	O
tested	NN	O	O
media	NN	O	O
were	NN	O	O
evaluated	NN	O	O
from	NN	O	O
replies	NN	O	O
to	NN	O	O
postal	NN	O	O
questionnaires	NN	O	O
.	NN	O	O

The	NN	O	O
Dimer	NN	O	O
-	NN	O	O
X	NN	O	O
group	NN	O	O
had	NN	O	O
a	NN	O	O
higher	NN	O	O
incidence	NN	O	O
of	NN	O	O
nausea	NN	O	B
and	NN	O	O
dizziness	NN	O	B
.	NN	O	O

The	NN	O	O
Endografine	NN	O	O
group	NN	O	O
had	NN	O	O
a	NN	O	O
higher	NN	O	O
incidence	NN	O	O
of	NN	O	O
abdominal	NN	O	B
pain	NN	O	I
.	NN	O	O

These	NN	O	O
differences	NN	O	O
occur	NN	O	O
especially	NN	O	O
in	NN	O	O
the	NN	O	O
age	NN	O	O
groups	NN	O	O
under	NN	O	O
30	NN	O	O
years	NN	O	O
.	NN	O	O

Hexabrix	NN	O	O
and	NN	O	O
Vasurix	NN	O	O
polyvidone	NN	O	O
are	NN	O	O
considered	NN	O	O
the	NN	O	O
best	NN	O	O
contrast	NN	O	O
media	NN	O	O
for	NN	O	O
hysterosalpingography	NN	O	O
and	NN	O	O
perhaps	NN	O	O
because	NN	O	O
of	NN	O	O
its	NN	O	O
low	NN	O	O
toxicity	NN	O	B
Hexabrix	NN	O	O
should	NN	O	O
be	NN	O	O
preferred	NN	O	O
.	NN	O	O

Post	NN	O	O
-	NN	O	O
suxamethonium	NN	O	O
pains	NN	O	B
in	NN	O	O
Nigerian	NN	O	O
surgical	NN	O	O
patients	NN	O	O
.	NN	O	O

Contrary	NN	O	O
to	NN	O	O
an	NN	O	O
earlier	NN	O	O
report	NN	O	O
by	NN	O	O
Coxon	NN	O	O
,	NN	O	O
scoline	NN	O	O
pain	NN	O	B
occurs	NN	O	O
in	NN	O	O
African	NN	O	O
negroes	NN	O	O
.	NN	O	O

Its	NN	O	O
incidence	NN	O	O
was	NN	O	O
determined	NN	O	O
in	NN	O	O
a	NN	O	O
prospective	NN	O	O
study	NN	O	O
involving	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
100	NN	O	O
Nigerian	NN	O	O
patients	NN	O	O
(	NN	O	O
50	NN	O	O
out	NN	O	O
-	NN	O	O
patients	NN	O	O
and	NN	O	O
50	NN	O	O
in	NN	O	O
-	NN	O	O
patients	NN	O	O
)	NN	O	O
.	NN	O	O

About	NN	O	O
62	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
out	NN	O	O
-	NN	O	O
patients	NN	O	O
developed	NN	O	O
scoline	NN	O	O
pain	NN	O	B
as	NN	O	O
compared	NN	O	O
with	NN	O	O
about	NN	O	O
26	NN	O	O
%	NN	O	O
among	NN	O	O
the	NN	O	O
in	NN	O	O
-	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
abolition	NN	O	O
of	NN	O	O
muscle	NN	O	O
fasciculations	NN	O	B
(	NN	O	O
by	NN	O	O
0	NN	O	O
.	NN	O	O
075mg	NN	O	O
/	NN	O	O
kg	NN	O	O
dose	NN	O	O
of	NN	O	O
Fazadinium	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
influence	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
scoline	NN	O	O
pain	NN	O	B
.	NN	O	O

Neither	NN	O	O
the	NN	O	O
type	NN	O	O
of	NN	O	O
induction	NN	O	O
agent	NN	O	O
(	NN	O	O
Althesin	NN	O	O
or	NN	O	O
Thiopentone	NN	O	O
)	NN	O	O
nor	NN	O	O
the	NN	O	O
salt	NN	O	O
preparation	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
used	NN	O	O
(	NN	O	O
chloride	NN	O	O
or	NN	O	O
bromide	NN	O	O
)	NN	O	O
,	NN	O	O
affected	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
scoline	NN	O	O
pain	NN	O	B
.	NN	O	O

Invasive	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
renal	NN	O	I
pelvis	NN	O	I
following	NN	O	O
cyclophosphamide	NN	O	O
therapy	NN	O	O
for	NN	O	O
nonmalignant	NN	O	O
disease	NN	O	O
.	NN	O	O

A	NN	O	O
47	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
right	NN	O	O
hydroureteronephrosis	NN	O	B
due	NN	O	O
to	NN	O	O
ureterovesical	NN	O	O
junction	NN	O	O
obstruction	NN	O	O
had	NN	O	O
gross	NN	O	O
hematuria	NN	O	B
after	NN	O	O
being	NN	O	O
treated	NN	O	O
for	NN	O	O
five	NN	O	O
years	NN	O	O
wtih	NN	O	O
cyclophosphamide	NN	O	O
for	NN	O	O
cerebral	NN	O	B
vasculitis	NN	O	I
.	NN	O	O

A	NN	O	O
right	NN	O	O
nephroureterectomy	NN	O	O
was	NN	O	O
required	NN	O	O
for	NN	O	O
control	NN	O	O
of	NN	O	O
bleeding	NN	O	B
.	NN	O	O

The	NN	O	O
pathology	NN	O	O
specimen	NN	O	O
contained	NN	O	O
clinically	NN	O	O
occult	NN	O	O
invasive	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
renal	NN	O	I
pelvis	NN	O	I
.	NN	O	O

Although	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	O
to	NN	O	O
cause	NN	O	O
hemorrhagic	NN	O	B
cystitis	NN	O	I
and	NN	O	O
urine	NN	O	O
cytologic	NN	O	O
abnormalities	NN	O	O
indistinguishable	NN	O	O
from	NN	O	O
high	NN	O	O
grade	NN	O	O
carcinoma	NN	O	B
is	NN	O	O
well	NN	O	O
known	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
less	NN	O	O
widely	NN	O	O
appreciated	NN	O	O
that	NN	O	O
it	NN	O	O
is	NN	O	O
also	NN	O	O
associated	NN	O	O
with	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
urinary	NN	O	I
tract	NN	O	I
.	NN	O	O

Twenty	NN	O	O
carcinomas	NN	O	B
of	NN	O	I
the	NN	O	I
urinary	NN	O	I
bladder	NN	O	I
and	NN	O	O
one	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
prostate	NN	O	I
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
its	NN	O	O
use	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
case	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
renal	NN	O	I
pelvis	NN	O	I
reported	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	O
treatment	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
the	NN	O	O
third	NN	O	O
urinary	NN	O	B
tract	NN	O	I
cancer	NN	O	I
reported	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	O
treatment	NN	O	O
for	NN	O	O
nonmalignant	NN	O	O
disease	NN	O	O
.	NN	O	O

The	NN	O	O
association	NN	O	O
of	NN	O	O
the	NN	O	O
tumor	NN	O	B
with	NN	O	O
preexisting	NN	O	O
hydroureteronephrosis	NN	O	B
suggests	NN	O	O
that	NN	O	O
stasis	NN	O	O
prolonged	NN	O	O
and	NN	O	O
intensified	NN	O	O
exposure	NN	O	O
of	NN	O	O
upper	NN	O	O
urinary	NN	O	O
tract	NN	O	O
epithelium	NN	O	O
to	NN	O	O
cyclophosphamide	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
are	NN	O	O
candidates	NN	O	O
for	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
cyclophosphamide	NN	O	O
treatment	NN	O	O
should	NN	O	O
be	NN	O	O
routinely	NN	O	O
evaluated	NN	O	O
for	NN	O	O
obstructive	NN	O	B
uropathy	NN	O	I
.	NN	O	O

Medial	NN	O	O
changes	NN	O	O
in	NN	O	O
arterial	NN	O	O
spasm	NN	O	B
induced	NN	O	O
by	NN	O	O
L	NN	O	O
-	NN	O	O
norepinephrine	NN	O	O
.	NN	O	O

In	NN	O	O
normal	NN	O	O
rats	NN	O	O
,	NN	O	O
the	NN	O	O
media	NN	O	O
of	NN	O	O
small	NN	O	O
arteries	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
mm	NN	O	O
in	NN	O	O
diameter	NN	O	O
)	NN	O	O
previously	NN	O	O
was	NN	O	O
shown	NN	O	O
to	NN	O	O
contain	NN	O	O
intracellular	NN	O	O
vacuoles	NN	O	O
,	NN	O	O
identified	NN	O	O
ultrastructurally	NN	O	O
as	NN	O	O
herniations	NN	O	O
of	NN	O	O
one	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
cell	NN	O	O
into	NN	O	O
another	NN	O	O
.	NN	O	O

The	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
intense	NN	O	O
vasoconstriction	NN	O	O
would	NN	O	O
increase	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
such	NN	O	O
vacuoles	NN	O	O
has	NN	O	O
been	NN	O	O
tested	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
media	NN	O	O
of	NN	O	O
the	NN	O	O
saphenous	NN	O	O
artery	NN	O	O
and	NN	O	O
its	NN	O	O
distal	NN	O	O
branch	NN	O	O
,	NN	O	O
vasoconstriction	NN	O	O
induced	NN	O	O
by	NN	O	O
L	NN	O	O
-	NN	O	O
norepinephrine	NN	O	O
produced	NN	O	O
many	NN	O	O
cell	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
cell	NN	O	O
hernias	NN	O	B
within	NN	O	O
15	NN	O	O
minutes	NN	O	O
.	NN	O	O

At	NN	O	O
1	NN	O	O
day	NN	O	O
their	NN	O	O
number	NN	O	O
was	NN	O	O
reduced	NN	O	O
to	NN	O	O
about	NN	O	O
1	NN	O	O
/	NN	O	O
10	NN	O	O
of	NN	O	O
the	NN	O	O
original	NN	O	O
number	NN	O	O
.	NN	O	O

By	NN	O	O
7	NN	O	O
days	NN	O	O
the	NN	O	O
vessel	NN	O	O
was	NN	O	O
almost	NN	O	O
restored	NN	O	O
to	NN	O	O
normal	NN	O	O
.	NN	O	O

Triple	NN	O	O
stimulation	NN	O	O
over	NN	O	O
1	NN	O	O
day	NN	O	O
induced	NN	O	O
more	NN	O	O
severe	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
media	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
cells	NN	O	O
are	NN	O	O
susceptible	NN	O	O
to	NN	O	O
damage	NN	O	O
in	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
their	NN	O	O
specific	NN	O	O
function	NN	O	O
.	NN	O	O

The	NN	O	O
experimental	NN	O	O
data	NN	O	O
are	NN	O	O
discussed	NN	O	O
in	NN	O	O
relation	NN	O	O
to	NN	O	O
medial	NN	O	O
changes	NN	O	O
observed	NN	O	O
in	NN	O	O
other	NN	O	O
instances	NN	O	O
of	NN	O	O
arterial	NN	O	O
spasm	NN	O	B
.	NN	O	O

Endothelial	NN	O	O
changes	NN	O	O
that	NN	O	O
developed	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
experimental	NN	O	O
model	NN	O	O
were	NN	O	O
described	NN	O	O
in	NN	O	O
a	NN	O	O
previous	NN	O	O
paper	NN	O	O
.	NN	O	O

Bilateral	NN	O	O
retinal	NN	O	B
artery	NN	O	I
and	NN	O	I
choriocapillaris	NN	O	I
occlusion	NN	O	I
following	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
acting	NN	O	O
corticosteroid	NN	O	O
suspensions	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
other	NN	O	O
drugs	NN	O	O
:	NN	O	O
I	NN	O	O
.	NN	O	O

Clinical	NN	O	O
studies	NN	O	O
.	NN	O	O

Two	NN	O	O
well	NN	O	O
-	NN	O	O
documented	NN	O	O
cases	NN	O	O
of	NN	O	O
bilateral	NN	O	O
retinal	NN	O	B
artery	NN	O	I
and	NN	O	I
choriocapillaris	NN	O	I
occlusions	NN	O	I
with	NN	O	O
blindness	NN	O	B
following	NN	O	O
head	NN	O	O
and	NN	O	O
neck	NN	O	O
soft	NN	O	O
-	NN	O	O
tissue	NN	O	O
injection	NN	O	O
with	NN	O	O
methylprednisolone	NN	O	O
acetate	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
lidocaine	NN	O	O
,	NN	O	O
epinephrine	NN	O	O
,	NN	O	O
or	NN	O	O
penicillin	NN	O	O
are	NN	O	O
reported	NN	O	O
.	NN	O	O

One	NN	O	O
case	NN	O	O
had	NN	O	O
only	NN	O	O
a	NN	O	O
unilateral	NN	O	O
injection	NN	O	O
.	NN	O	O

The	NN	O	O
acute	NN	O	O
observations	NN	O	O
included	NN	O	O
hazy	NN	O	O
sensorium	NN	O	O
,	NN	O	O
superior	NN	O	O
gaze	NN	O	O
palsy	NN	O	B
,	NN	O	O
pupillary	NN	O	B
abnormalities	NN	O	I
,	NN	O	O
and	NN	O	O
conjunctival	NN	O	O
hemorrhages	NN	O	B
with	NN	O	O
edema	NN	O	B
.	NN	O	O

Follow	NN	O	O
-	NN	O	O
up	NN	O	O
changes	NN	O	O
showed	NN	O	O
marked	NN	O	O
visual	NN	O	B
loss	NN	O	I
,	NN	O	O
constricted	NN	O	O
visual	NN	O	O
fields	NN	O	O
,	NN	O	O
optic	NN	O	O
nerve	NN	O	O
pallor	NN	O	O
,	NN	O	O
vascular	NN	O	O
attenuation	NN	O	O
,	NN	O	O
and	NN	O	O
chorioretinal	NN	O	B
atrophy	NN	O	I
.	NN	O	O

The	NN	O	O
literature	NN	O	O
is	NN	O	O
reviewed	NN	O	O
,	NN	O	O
and	NN	O	O
possible	NN	O	O
causes	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Abnormalities	NN	O	O
of	NN	O	O
the	NN	O	O
pupil	NN	O	O
and	NN	O	O
visual	NN	O	O
-	NN	O	O
evoked	NN	O	O
potential	NN	O	O
in	NN	O	O
quinine	NN	O	O
amblyopia	NN	O	B
.	NN	O	O

Total	NN	O	O
blindness	NN	O	B
with	NN	O	O
a	NN	O	O
transient	NN	O	O
tonic	NN	O	B
pupillary	NN	O	I
response	NN	O	O
,	NN	O	O
denervation	NN	O	O
supersensitivity	NN	O	O
,	NN	O	O
and	NN	O	O
abnormal	NN	O	O
visual	NN	O	O
-	NN	O	O
evoked	NN	O	O
potentials	NN	O	O
developed	NN	O	O
in	NN	O	O
a	NN	O	O
54	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
after	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
quinine	NN	O	O
sulfate	NN	O	O
for	NN	O	O
leg	NN	O	B
cramps	NN	O	I
.	NN	O	O

He	NN	O	O
later	NN	O	O
recovered	NN	O	O
normal	NN	O	O
visual	NN	O	O
acuity	NN	O	O
.	NN	O	O

A	NN	O	O
transient	NN	O	O
tonic	NN	O	B
pupillary	NN	O	I
response	NN	O	O
,	NN	O	O
denervation	NN	O	O
supersensitivity	NN	O	O
,	NN	O	O
and	NN	O	O
abnormal	NN	O	O
visual	NN	O	O
-	NN	O	O
evoked	NN	O	O
potentials	NN	O	O
in	NN	O	O
quinine	NN	O	O
toxicity	NN	O	B
,	NN	O	O
to	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
previously	NN	O	O
reported	NN	O	O
.	NN	O	O

Suxamethonium	NN	O	O
-	NN	O	O
induced	NN	O	O
jaw	NN	O	B
stiffness	NN	O	I
and	NN	O	O
myalgia	NN	O	B
associated	NN	O	O
with	NN	O	O
atypical	NN	O	O
cholinesterase	NN	O	O
:	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

An	NN	O	O
11	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
was	NN	O	O
given	NN	O	O
halothane	NN	O	O
,	NN	O	O
nitrous	NN	O	O
oxide	NN	O	O
and	NN	O	O
oxygen	NN	O	O
,	NN	O	O
pancuronium	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
mg	NN	O	O
and	NN	O	O
suxamethonium	NN	O	O
100	NN	O	O
mg	NN	O	O
for	NN	O	O
induction	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

In	NN	O	O
response	NN	O	O
to	NN	O	O
this	NN	O	O
a	NN	O	O
marked	NN	O	O
jaw	NN	O	B
stiffness	NN	O	I
occurred	NN	O	O
which	NN	O	O
lasted	NN	O	O
for	NN	O	O
two	NN	O	O
minutes	NN	O	O
and	NN	O	O
the	NN	O	O
anaesthesia	NN	O	O
were	NN	O	O
terminated	NN	O	O
.	NN	O	O

Four	NN	O	O
hours	NN	O	O
of	NN	O	O
apnoea	NN	O	B
ensued	NN	O	O
and	NN	O	O
he	NN	O	O
suffered	NN	O	O
generalized	NN	O	O
severe	NN	O	O
myalgia	NN	O	B
lasting	NN	O	O
for	NN	O	O
one	NN	O	O
week	NN	O	O
.	NN	O	O

He	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
atypical	NN	O	O
plasma	NN	O	O
cholinesterase	NN	O	O
with	NN	O	O
a	NN	O	O
dibucaine	NN	O	O
number	NN	O	O
of	NN	O	O
12	NN	O	O
,	NN	O	O
indicating	NN	O	O
homozygocity	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
verified	NN	O	O
by	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
family	NN	O	O
.	NN	O	O

The	NN	O	O
case	NN	O	O
shows	NN	O	O
that	NN	O	O
prolonged	NN	O	B
jaw	NN	O	I
rigidity	NN	O	I
and	NN	O	O
myalgia	NN	O	B
may	NN	O	O
occur	NN	O	O
after	NN	O	O
suxamethonium	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
atypical	NN	O	O
cholinesterase	NN	O	O
despite	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
pancuronium	NN	O	O
.	NN	O	O

Indomethacin	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperkalemia	NN	O	B
in	NN	O	O
three	NN	O	O
patients	NN	O	O
with	NN	O	O
gouty	NN	O	B
arthritis	NN	O	I
.	NN	O	O

We	NN	O	O
describe	NN	O	O
three	NN	O	O
patients	NN	O	O
in	NN	O	O
whom	NN	O	O
severe	NN	O	O
,	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
hyperkalemia	NN	O	B
and	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
developed	NN	O	O
after	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	O
gouty	NN	O	B
arthritis	NN	O	I
with	NN	O	O
indomethacin	NN	O	O
.	NN	O	O

This	NN	O	O
complication	NN	O	O
may	NN	O	O
result	NN	O	O
from	NN	O	O
an	NN	O	O
inhibition	NN	O	O
of	NN	O	O
prostaglandin	NN	O	O
synthesis	NN	O	O
and	NN	O	O
consequent	NN	O	O
hyporeninemic	NN	O	B
hypoaidosteronism	NN	O	I
.	NN	O	O

Careful	NN	O	O
attention	NN	O	O
to	NN	O	O
renal	NN	O	O
function	NN	O	O
and	NN	O	O
potassium	NN	O	O
balance	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
indomethacin	NN	O	O
or	NN	O	O
other	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
agents	NN	O	O
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
those	NN	O	O
patients	NN	O	O
with	NN	O	O
diabetes	NN	O	B
mellitus	NN	O	I
or	NN	O	O
preexisting	NN	O	O
renal	NN	O	B
disease	NN	O	I
,	NN	O	O
will	NN	O	O
help	NN	O	O
prevent	NN	O	O
this	NN	O	O
potentially	NN	O	O
serious	NN	O	O
complication	NN	O	O
.	NN	O	O

Etomidate	NN	O	O
:	NN	O	O
a	NN	O	O
foreshortened	NN	O	O
clinical	NN	O	O
trial	NN	O	O
.	NN	O	O

A	NN	O	O
clinical	NN	O	O
evaluation	NN	O	O
of	NN	O	O
etomidate	NN	O	O
for	NN	O	O
outpatient	NN	O	O
cystoscopy	NN	O	O
was	NN	O	O
embarked	NN	O	O
upon	NN	O	O
.	NN	O	O

Unpremedicated	NN	O	O
patients	NN	O	O
were	NN	O	O
given	NN	O	O
fentanyl	NN	O	O
1	NN	O	O
microgram	NN	O	O
/	NN	O	O
kg	NN	O	O
followed	NN	O	O
by	NN	O	O
etomidate	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Anaesthesia	NN	O	O
was	NN	O	O
maintained	NN	O	O
with	NN	O	O
intermittent	NN	O	O
etomidate	NN	O	O
in	NN	O	O
2	NN	O	O
-	NN	O	O
4	NN	O	O
mg	NN	O	O
doses	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
interviewed	NN	O	O
personally	NN	O	O
later	NN	O	O
the	NN	O	O
same	NN	O	O
day	NN	O	O
,	NN	O	O
and	NN	O	O
by	NN	O	O
questionnaire	NN	O	O
three	NN	O	O
to	NN	O	O
four	NN	O	O
weeks	NN	O	O
later	NN	O	O
.	NN	O	O

The	NN	O	O
trial	NN	O	O
was	NN	O	O
discontinued	NN	O	O
after	NN	O	O
20	NN	O	O
cases	NN	O	O
because	NN	O	O
of	NN	O	O
an	NN	O	O
unacceptable	NN	O	O
incidence	NN	O	O
of	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Venous	NN	O	O
pain	NN	O	B
occurred	NN	O	O
in	NN	O	O
68	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
and	NN	O	O
50	NN	O	O
%	NN	O	O
had	NN	O	O
redness	NN	O	O
,	NN	O	O
pain	NN	O	B
or	NN	O	O
swelling	NN	O	B
related	NN	O	O
to	NN	O	O
the	NN	O	O
injection	NN	O	O
site	NN	O	O
,	NN	O	O
in	NN	O	O
some	NN	O	O
cases	NN	O	O
lasting	NN	O	O
up	NN	O	O
to	NN	O	O
three	NN	O	O
weeks	NN	O	O
after	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

Skeletal	NN	O	O
movements	NN	O	O
occurred	NN	O	O
in	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
;	NN	O	O
30	NN	O	O
%	NN	O	O
experienced	NN	O	O
respiratory	NN	O	B
upset	NN	O	I
,	NN	O	O
one	NN	O	O
sufficiently	NN	O	O
severe	NN	O	O
to	NN	O	O
necessitate	NN	O	O
abandoning	NN	O	O
the	NN	O	O
technique	NN	O	O
.	NN	O	O

Nausea	NN	O	B
and	NN	O	O
vomiting	NN	O	B
occurred	NN	O	O
in	NN	O	O
40	NN	O	O
%	NN	O	O
and	NN	O	O
25	NN	O	O
%	NN	O	O
had	NN	O	O
disturbing	NN	O	O
emergence	NN	O	O
psychoses	NN	O	B
.	NN	O	O

Levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
are	NN	O	O
improved	NN	O	O
by	NN	O	O
fluoxetine	NN	O	O
.	NN	O	O

We	NN	O	O
evaluated	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
motor	NN	O	B
disability	NN	O	I
and	NN	O	O
dyskinesias	NN	O	B
in	NN	O	O
seven	NN	O	O
levodopa	NN	O	O
-	NN	O	O
responsive	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
after	NN	O	O
an	NN	O	O
acute	NN	O	O
challenge	NN	O	O
with	NN	O	O
the	NN	O	O
mixed	NN	O	O
dopamine	NN	O	O
agonist	NN	O	O
,	NN	O	O
apomorphine	NN	O	O
,	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
fluoxetine	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
twice	NN	O	O
per	NN	O	O
day	NN	O	O
)	NN	O	O
for	NN	O	O
11	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
days	NN	O	O
.	NN	O	O

After	NN	O	O
fluoxetine	NN	O	O
treatment	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
47	NN	O	O
%	NN	O	O
improvement	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
of	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
without	NN	O	O
modification	NN	O	O
of	NN	O	O
parkinsonian	NN	O	B
motor	NN	O	B
disability	NN	O	I
.	NN	O	O

The	NN	O	O
dyskinesias	NN	O	B
were	NN	O	O
reduced	NN	O	O
predominantly	NN	O	O
in	NN	O	O
the	NN	O	O
lower	NN	O	O
limbs	NN	O	O
during	NN	O	O
the	NN	O	O
onset	NN	O	O
and	NN	O	O
disappearance	NN	O	O
of	NN	O	O
dystonic	NN	O	B
dyskinesias	NN	O	I
(	NN	O	O
onset	NN	O	O
-	NN	O	O
and	NN	O	O
end	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
dose	NN	O	O
dyskinesias	NN	O	B
)	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
upper	NN	O	O
limbs	NN	O	O
during	NN	O	O
choreic	NN	O	B
mid	NN	O	I
-	NN	O	I
dose	NN	O	I
dyskinesias	NN	O	I
.	NN	O	O

The	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
increased	NN	O	O
brain	NN	O	O
serotoninergic	NN	O	O
transmission	NN	O	O
with	NN	O	O
fluoxetine	NN	O	O
may	NN	O	O
reduce	NN	O	O
levodopa	NN	O	O
-	NN	O	O
or	NN	O	O
dopamine	NN	O	O
agonist	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
without	NN	O	O
aggravating	NN	O	O
parkinsonian	NN	O	B
motor	NN	O	B
disability	NN	O	I
.	NN	O	O

A	NN	O	O
large	NN	O	O
population	NN	O	O
-	NN	O	O
based	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
study	NN	O	O
of	NN	O	O
trimethoprim	NN	O	O
-	NN	O	O
sulfamethoxazole	NN	O	O
,	NN	O	O
trimethoprim	NN	O	O
,	NN	O	O
and	NN	O	O
cephalexin	NN	O	O
for	NN	O	O
uncommon	NN	O	O
serious	NN	O	O
drug	NN	O	B
toxicity	NN	O	I
.	NN	O	O

We	NN	O	O
conducted	NN	O	O
a	NN	O	O
population	NN	O	O
-	NN	O	O
based	NN	O	O
45	NN	O	O
-	NN	O	O
day	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
study	NN	O	O
of	NN	O	O
232	NN	O	O
,	NN	O	O
390	NN	O	O
people	NN	O	O
who	NN	O	O
were	NN	O	O
prescribed	NN	O	O
trimethoprim	NN	O	O
-	NN	O	O
sulfamethoxazole	NN	O	O
(	NN	O	O
TMP	NN	O	O
-	NN	O	O
SMZ	NN	O	O
)	NN	O	O
,	NN	O	O
266	NN	O	O
,	NN	O	O
951	NN	O	O
prescribed	NN	O	O
trimethoprim	NN	O	O
alone	NN	O	O
,	NN	O	O
and	NN	O	O
196	NN	O	O
,	NN	O	O
397	NN	O	O
prescribed	NN	O	O
cephalexin	NN	O	O
,	NN	O	O
to	NN	O	O
estimate	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
serious	NN	O	O
liver	NN	O	B
,	NN	O	I
blood	NN	O	I
,	NN	O	I
skin	NN	O	I
,	NN	O	I
and	NN	O	I
renal	NN	O	I
disorders	NN	O	I
resulting	NN	O	O
in	NN	O	O
referral	NN	O	O
or	NN	O	O
hospitalization	NN	O	O
associated	NN	O	O
with	NN	O	O
these	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
were	NN	O	O
based	NN	O	O
on	NN	O	O
information	NN	O	O
recorded	NN	O	O
on	NN	O	O
office	NN	O	O
computers	NN	O	O
by	NN	O	O
selected	NN	O	O
general	NN	O	O
practitioners	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
Kingdom	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
a	NN	O	O
review	NN	O	O
of	NN	O	O
clinical	NN	O	O
records	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
of	NN	O	O
clinically	NN	O	O
important	NN	O	O
idiopathic	NN	O	O
liver	NN	O	B
disease	NN	O	I
was	NN	O	O
similar	NN	O	O
for	NN	O	O
persons	NN	O	O
prescribed	NN	O	O
TMP	NN	O	O
-	NN	O	O
SMZ	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
2	NN	O	O
/	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
)	NN	O	O
and	NN	O	O
those	NN	O	O
prescribed	NN	O	O
trimethoprim	NN	O	O
alone	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
8	NN	O	O
/	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
for	NN	O	O
those	NN	O	O
prescribed	NN	O	O
cephalexin	NN	O	O
was	NN	O	O
somewhat	NN	O	O
lower	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
/	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
)	NN	O	O
.	NN	O	O

Only	NN	O	O
five	NN	O	O
patients	NN	O	O
experienced	NN	O	O
blood	NN	O	O
disorders	NN	O	O
,	NN	O	O
one	NN	O	O
of	NN	O	O
whom	NN	O	O
was	NN	O	O
exposed	NN	O	O
to	NN	O	O
TMP	NN	O	O
-	NN	O	O
SMZ	NN	O	O
;	NN	O	O
of	NN	O	O
seven	NN	O	O
with	NN	O	O
erythema	NN	O	B
multiforme	NN	O	I
and	NN	O	O
Stevens	NN	O	B
-	NN	O	I
Johnson	NN	O	I
syndrome	NN	O	I
,	NN	O	O
four	NN	O	O
were	NN	O	O
exposed	NN	O	O
to	NN	O	O
TMP	NN	O	O
-	NN	O	O
SMZ	NN	O	O
.	NN	O	O

The	NN	O	O
one	NN	O	O
case	NN	O	O
of	NN	O	O
toxic	NN	O	B
epidermal	NN	O	I
necrolysis	NN	O	I
occurred	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
took	NN	O	O
cephalexin	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
only	NN	O	O
five	NN	O	O
cases	NN	O	O
of	NN	O	O
acute	NN	O	O
parenchymal	NN	O	O
renal	NN	O	B
disease	NN	O	I
occurred	NN	O	O
,	NN	O	O
none	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
caused	NN	O	O
by	NN	O	O
a	NN	O	O
study	NN	O	O
drug	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
the	NN	O	O
serious	NN	O	O
diseases	NN	O	O
studied	NN	O	O
is	NN	O	O
small	NN	O	O
for	NN	O	O
the	NN	O	O
three	NN	O	O
agents	NN	O	O
,	NN	O	O
and	NN	O	O
compares	NN	O	O
reasonably	NN	O	O
with	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
many	NN	O	O
other	NN	O	O
antibiotics	NN	O	O
.	NN	O	O

Clinical	NN	O	O
safety	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

STUDY	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
the	NN	O	O
setting	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
(	NN	O	O
MI	NN	O	B
)	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
A	NN	O	O
retrospective	NN	O	O
,	NN	O	O
multicenter	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
nine	NN	O	O
university	NN	O	O
,	NN	O	O
university	NN	O	O
-	NN	O	O
affiliated	NN	O	O
,	NN	O	O
or	NN	O	O
community	NN	O	O
hospitals	NN	O	O
during	NN	O	O
a	NN	O	O
6	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
(	NN	O	O
total	NN	O	O
of	NN	O	O
117	NN	O	O
cumulative	NN	O	O
hospital	NN	O	O
-	NN	O	O
years	NN	O	O
)	NN	O	O
.	NN	O	O

PARTICIPANTS	NN	O	O
:	NN	O	O
Patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
MI	NN	O	B
who	NN	O	O
received	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Of	NN	O	O
29	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
the	NN	O	O
setting	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
MI	NN	O	B
,	NN	O	O
no	NN	O	O
patient	NN	O	O
died	NN	O	O
;	NN	O	O
exhibited	NN	O	O
bradydysrhythmias	NN	O	B
,	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
,	NN	O	O
or	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
;	NN	O	O
or	NN	O	O
experienced	NN	O	O
seizures	NN	O	B
after	NN	O	O
administration	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
0	NN	O	O
%	NN	O	O
to	NN	O	O
11	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Despite	NN	O	O
theoretical	NN	O	O
concerns	NN	O	O
that	NN	O	O
lidocaine	NN	O	O
may	NN	O	O
enhance	NN	O	O
cocaine	NN	O	O
toxicity	NN	O	B
,	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
MI	NN	O	B
was	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
significant	NN	O	O
cardiovascular	NN	O	B
or	NN	O	I
central	NN	O	I
nervous	NN	O	I
system	NN	O	I
toxicity	NN	O	I
.	NN	O	O

Experimental	NN	O	O
progressive	NN	O	O
muscular	NN	O	B
dystrophy	NN	O	I
and	NN	O	O
its	NN	O	O
treatment	NN	O	O
with	NN	O	O
high	NN	O	O
doses	NN	O	O
anabolizing	NN	O	O
agents	NN	O	O
.	NN	O	O

We	NN	O	O
are	NN	O	O
still	NN	O	O
a	NN	O	O
long	NN	O	O
way	NN	O	O
from	NN	O	O
discovering	NN	O	O
an	NN	O	O
unequivocal	NN	O	O
pathogenetic	NN	O	O
interpretation	NN	O	O
of	NN	O	O
progressive	NN	O	O
muscular	NN	O	B
dystrophy	NN	O	I
in	NN	O	O
man	NN	O	O
.	NN	O	O

Noteworthy	NN	O	O
efforts	NN	O	O
have	NN	O	O
been	NN	O	O
made	NN	O	O
in	NN	O	O
the	NN	O	O
experimental	NN	O	O
field	NN	O	O
;	NN	O	O
a	NN	O	O
recessive	NN	O	O
autosomic	NN	O	O
form	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
mouse	NN	O	O
seems	NN	O	O
to	NN	O	O
bear	NN	O	O
the	NN	O	O
closest	NN	O	O
resemblance	NN	O	O
to	NN	O	O
the	NN	O	O
human	NN	O	O
form	NN	O	O
from	NN	O	O
the	NN	O	O
genetic	NN	O	O
point	NN	O	O
of	NN	O	O
view	NN	O	O
.	NN	O	O

Myopathy	NN	O	B
due	NN	O	O
to	NN	O	O
lack	NN	O	O
of	NN	O	O
vitamin	NN	O	O
E	NN	O	O
and	NN	O	O
myopathy	NN	O	B
induced	NN	O	O
by	NN	O	O
certain	NN	O	O
viruses	NN	O	O
have	NN	O	O
much	NN	O	O
in	NN	O	O
common	NN	O	O
anatomically	NN	O	O
and	NN	O	O
pathologically	NN	O	O
with	NN	O	O
the	NN	O	O
human	NN	O	O
form	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
induced	NN	O	O
myodystrophy	NN	O	B
in	NN	O	O
the	NN	O	O
rat	NN	O	O
by	NN	O	O
giving	NN	O	O
it	NN	O	O
a	NN	O	O
diet	NN	O	O
lacking	NN	O	O
in	NN	O	O
vitamin	NN	O	O
E	NN	O	O
.	NN	O	O

The	NN	O	O
pharmacological	NN	O	O
characteristics	NN	O	O
of	NN	O	O
vitamin	NN	O	O
E	NN	O	O
and	NN	O	O
the	NN	O	O
degenerative	NN	O	O
changes	NN	O	O
brought	NN	O	O
about	NN	O	O
by	NN	O	O
its	NN	O	O
deficiency	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
the	NN	O	O
muscles	NN	O	O
,	NN	O	O
are	NN	O	O
illustrated	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
thus	NN	O	O
confirmed	NN	O	O
that	NN	O	O
the	NN	O	O
histological	NN	O	O
characteristics	NN	O	O
of	NN	O	O
myopathic	NN	O	B
rat	NN	O	O
muscle	NN	O	O
induced	NN	O	O
experimentally	NN	O	O
are	NN	O	O
extraordinarily	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
human	NN	O	O
myopathy	NN	O	B
as	NN	O	O
confirmed	NN	O	O
during	NN	O	O
biopsies	NN	O	O
performed	NN	O	O
at	NN	O	O
the	NN	O	O
Orthopaedic	NN	O	O
Traumatological	NN	O	O
Centre	NN	O	O
,	NN	O	O
Florence	NN	O	O
.	NN	O	O

The	NN	O	O
encouraging	NN	O	O
results	NN	O	O
obtained	NN	O	O
in	NN	O	O
various	NN	O	O
authoratative	NN	O	O
departments	NN	O	O
in	NN	O	O
myopathic	NN	O	B
patients	NN	O	O
by	NN	O	O
using	NN	O	O
anabolizing	NN	O	O
steroids	NN	O	O
have	NN	O	O
encouraged	NN	O	O
the	NN	O	O
authors	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
one	NN	O	O
anabolizing	NN	O	O
agent	NN	O	O
(	NN	O	O
Dianabol	NN	O	O
,	NN	O	O
CIBA	NN	O	O
)	NN	O	O
at	NN	O	O
high	NN	O	O
doses	NN	O	O
in	NN	O	O
rats	NN	O	O
rendered	NN	O	O
myopathic	NN	O	B
by	NN	O	O
a	NN	O	O
diet	NN	O	O
deficient	NN	O	O
in	NN	O	O
vitamin	NN	O	O
E	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
way	NN	O	O
they	NN	O	O
obtained	NN	O	O
appreciable	NN	O	O
changes	NN	O	O
in	NN	O	O
body	NN	O	O
weight	NN	O	O
(	NN	O	O
increased	NN	O	O
from	NN	O	O
50	NN	O	O
to	NN	O	O
70	NN	O	O
g	NN	O	O
after	NN	O	O
forty	NN	O	O
days	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
5	NN	O	O
mg	NN	O	O
per	NN	O	O
day	NN	O	O
of	NN	O	O
anabolizing	NN	O	O
agent	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
most	NN	O	O
of	NN	O	O
all	NN	O	O
they	NN	O	O
found	NN	O	O
histological	NN	O	O
changes	NN	O	O
due	NN	O	O
to	NN	O	O
"	NN	O	O
regenerative	NN	O	O
"	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
muscle	NN	O	O
tissue	NN	O	O
,	NN	O	O
which	NN	O	O
however	NN	O	O
maintained	NN	O	O
its	NN	O	O
myopathic	NN	O	B
characteristics	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
animals	NN	O	O
that	NN	O	O
were	NN	O	O
not	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
anabolizing	NN	O	O
agent	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
conclude	NN	O	O
by	NN	O	O
affirming	NN	O	O
the	NN	O	O
undoubted	NN	O	O
efficacy	NN	O	O
of	NN	O	O
the	NN	O	O
anabolizing	NN	O	O
steroids	NN	O	O
in	NN	O	O
experimental	NN	O	O
myopathic	NN	O	B
disease	NN	O	I
,	NN	O	O
but	NN	O	O
they	NN	O	O
have	NN	O	O
reservations	NN	O	O
as	NN	O	O
to	NN	O	O
the	NN	O	O
transfer	NN	O	O
of	NN	O	O
the	NN	O	O
results	NN	O	O
into	NN	O	O
the	NN	O	O
human	NN	O	O
field	NN	O	O
,	NN	O	O
where	NN	O	O
high	NN	O	O
dosage	NN	O	O
cannot	NN	O	O
be	NN	O	O
carried	NN	O	O
out	NN	O	O
continuously	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
on	NN	O	O
virility	NN	O	O
;	NN	O	O
because	NN	O	O
the	NN	O	O
tissue	NN	O	O
injury	NN	O	O
too	NN	O	O
often	NN	O	O
occurs	NN	O	O
at	NN	O	O
an	NN	O	O
irreversible	NN	O	O
stage	NN	O	O
vis	NN	O	O
-	NN	O	O
a	NN	O	O
-	NN	O	O
vis	NN	O	O
the	NN	O	O
"	NN	O	O
regeneration	NN	O	O
"	NN	O	O
of	NN	O	O
the	NN	O	O
muscle	NN	O	O
tissue	NN	O	O
;	NN	O	O
and	NN	O	O
finally	NN	O	O
because	NN	O	O
the	NN	O	O
dystrophic	NN	O	O
injurious	NN	O	O
agent	NN	O	O
is	NN	O	O
certainly	NN	O	O
not	NN	O	O
the	NN	O	O
lack	NN	O	O
of	NN	O	O
vitamin	NN	O	O
E	NN	O	O
but	NN	O	O
something	NN	O	O
as	NN	O	O
yet	NN	O	O
unknown	NN	O	O
.	NN	O	O

Paclitaxel	NN	O	O
3	NN	O	O
-	NN	O	O
hour	NN	O	O
infusion	NN	O	O
given	NN	O	O
alone	NN	O	O
and	NN	O	O
combined	NN	O	O
with	NN	O	O
carboplatin	NN	O	O
:	NN	O	O
preliminary	NN	O	O
results	NN	O	O
of	NN	O	O
dose	NN	O	O
-	NN	O	O
escalation	NN	O	O
trials	NN	O	O
.	NN	O	O

Paclitaxel	NN	O	O
(	NN	O	O
Taxol	NN	O	O
;	NN	O	O
Bristol	NN	O	O
-	NN	O	O
Myers	NN	O	O
Squibb	NN	O	O
Company	NN	O	O
,	NN	O	O
Princeton	NN	O	O
,	NN	O	O
NJ	NN	O	O
)	NN	O	O
by	NN	O	O
3	NN	O	O
-	NN	O	O
hour	NN	O	O
infusion	NN	O	O
was	NN	O	O
combined	NN	O	O
with	NN	O	O
carboplatin	NN	O	O
in	NN	O	O
a	NN	O	O
phase	NN	O	O
I	NN	O	O
/	NN	O	O
II	NN	O	O
study	NN	O	O
directed	NN	O	O
to	NN	O	O
patients	NN	O	O
with	NN	O	O
non	NN	O	B
-	NN	O	I
small	NN	O	I
cell	NN	O	I
lung	NN	O	I
cancer	NN	O	I
.	NN	O	O

Carboplatin	NN	O	O
was	NN	O	O
given	NN	O	O
at	NN	O	O
a	NN	O	O
fixed	NN	O	O
target	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
concentration	NN	O	O
-	NN	O	O
time	NN	O	O
curve	NN	O	O
of	NN	O	O
6	NN	O	O
.	NN	O	O
0	NN	O	O
by	NN	O	O
the	NN	O	O
Calvert	NN	O	O
formula	NN	O	O
,	NN	O	O
whereas	NN	O	O
paclitaxel	NN	O	O
was	NN	O	O
escalated	NN	O	O
in	NN	O	O
patient	NN	O	O
cohorts	NN	O	O
from	NN	O	O
150	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
(	NN	O	O
dose	NN	O	O
level	NN	O	O
I	NN	O	O
)	NN	O	O
to	NN	O	O
175	NN	O	O
,	NN	O	O
200	NN	O	O
,	NN	O	O
225	NN	O	O
,	NN	O	O
and	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
.	NN	O	O

The	NN	O	O
225	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
level	NN	O	O
was	NN	O	O
expanded	NN	O	O
for	NN	O	O
the	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
since	NN	O	O
the	NN	O	O
highest	NN	O	O
level	NN	O	O
achieved	NN	O	O
(	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
)	NN	O	O
required	NN	O	O
modification	NN	O	O
because	NN	O	O
of	NN	O	O
nonhematologic	NN	O	O
toxicities	NN	O	B
(	NN	O	O
arthralgia	NN	O	B
and	NN	O	O
sensory	NN	O	B
neuropathy	NN	O	I
)	NN	O	O
.	NN	O	O

Therapeutic	NN	O	O
effects	NN	O	O
were	NN	O	O
noted	NN	O	O
at	NN	O	O
all	NN	O	O
dose	NN	O	O
levels	NN	O	O
,	NN	O	O
with	NN	O	O
objective	NN	O	O
responses	NN	O	O
in	NN	O	O
17	NN	O	O
(	NN	O	O
two	NN	O	O
complete	NN	O	O
and	NN	O	O
15	NN	O	O
partial	NN	O	O
regressions	NN	O	O
)	NN	O	O
of	NN	O	O
41	NN	O	O
previously	NN	O	O
untreated	NN	O	O
patients	NN	O	O
.	NN	O	O

Toxicities	NN	O	B
were	NN	O	O
compared	NN	O	O
with	NN	O	O
a	NN	O	O
cohort	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
a	NN	O	O
phase	NN	O	O
I	NN	O	O
trial	NN	O	O
of	NN	O	O
paclitaxel	NN	O	O
alone	NN	O	O
at	NN	O	O
identical	NN	O	O
dose	NN	O	O
levels	NN	O	O
.	NN	O	O

Carboplatin	NN	O	O
did	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
add	NN	O	O
to	NN	O	O
the	NN	O	O
hematologic	NN	O	B
toxicities	NN	O	I
observed	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
paclitaxel	NN	O	O
/	NN	O	O
carboplatin	NN	O	O
combination	NN	O	O
could	NN	O	O
be	NN	O	O
dosed	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
effect	NN	O	O
of	NN	O	O
misoprostol	NN	O	O
on	NN	O	O
indomethacin	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
in	NN	O	O
well	NN	O	O
compensated	NN	O	O
cirrhosis	NN	O	B
.	NN	O	O

Misoprostol	NN	O	O
(	NN	O	O
200	NN	O	O
micrograms	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
acutely	NN	O	O
counteract	NN	O	O
the	NN	O	O
indomethacin	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
in	NN	O	O
well	NN	O	O
compensated	NN	O	O
cirrhotic	NN	O	B
patients	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
the	NN	O	O
prophylactic	NN	O	O
value	NN	O	O
of	NN	O	O
misoprostol	NN	O	O
was	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
.	NN	O	O

Parameters	NN	O	O
of	NN	O	O
renal	NN	O	O
hemodynamics	NN	O	O
and	NN	O	O
tubular	NN	O	O
sodium	NN	O	O
and	NN	O	O
water	NN	O	O
handling	NN	O	O
were	NN	O	O
assessed	NN	O	O
by	NN	O	O
clearance	NN	O	O
techniques	NN	O	O
in	NN	O	O
26	NN	O	O
well	NN	O	O
compensated	NN	O	O
cirrhotic	NN	O	B
patients	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
an	NN	O	O
oral	NN	O	O
combination	NN	O	O
of	NN	O	O
50	NN	O	O
mg	NN	O	O
of	NN	O	O
indomethacin	NN	O	O
and	NN	O	O
various	NN	O	O
doses	NN	O	O
of	NN	O	O
misoprostol	NN	O	O
.	NN	O	O

The	NN	O	O
200	NN	O	O
-	NN	O	O
micrograms	NN	O	O
dose	NN	O	O
was	NN	O	O
able	NN	O	O
to	NN	O	O
totally	NN	O	O
abolish	NN	O	O
the	NN	O	O
deleterious	NN	O	O
renal	NN	O	O
effects	NN	O	O
of	NN	O	O
indomethacin	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
800	NN	O	O
-	NN	O	O
micrograms	NN	O	O
dose	NN	O	O
resulted	NN	O	O
in	NN	O	O
significant	NN	O	O
worsening	NN	O	O
of	NN	O	O
renal	NN	O	O
hemodynamics	NN	O	O
and	NN	O	O
sodium	NN	O	O
retention	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
were	NN	O	O
maximal	NN	O	O
in	NN	O	O
the	NN	O	O
hour	NN	O	O
immediately	NN	O	O
after	NN	O	O
medications	NN	O	O
and	NN	O	O
slowly	NN	O	O
returned	NN	O	O
toward	NN	O	O
base	NN	O	O
-	NN	O	O
line	NN	O	O
levels	NN	O	O
thereafter	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
renal	NN	O	O
protective	NN	O	O
effects	NN	O	O
of	NN	O	O
misoprostol	NN	O	O
is	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
until	NN	O	O
this	NN	O	O
apparent	NN	O	O
ability	NN	O	O
of	NN	O	O
200	NN	O	O
micrograms	NN	O	O
of	NN	O	O
misoprostol	NN	O	O
to	NN	O	O
prevent	NN	O	O
the	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
indomethacin	NN	O	O
on	NN	O	O
renal	NN	O	O
function	NN	O	O
is	NN	O	O
confirmed	NN	O	O
with	NN	O	O
chronic	NN	O	O
frequent	NN	O	O
dosing	NN	O	O
,	NN	O	O
it	NN	O	O
would	NN	O	O
be	NN	O	O
prudent	NN	O	O
to	NN	O	O
avoid	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
therapy	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cirrhosis	NN	O	B
.	NN	O	O

Increased	NN	O	O
frequency	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
angio	NN	O	B
-	NN	O	I
oedema	NN	O	I
related	NN	O	O
to	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
therapy	NN	O	O
with	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
.	NN	O	O

Adverse	NN	O	O
reactions	NN	O	O
to	NN	O	O
drugs	NN	O	O
are	NN	O	O
well	NN	O	O
recognized	NN	O	O
as	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
acute	NN	O	O
or	NN	O	O
chronic	NN	O	O
urticaria	NN	O	B
,	NN	O	O
and	NN	O	O
angio	NN	O	B
-	NN	O	I
oedema	NN	O	I
.	NN	O	O

Angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
hypertension	NN	O	B
and	NN	O	O
congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
,	NN	O	O
were	NN	O	O
introduced	NN	O	O
in	NN	O	O
Europe	NN	O	O
in	NN	O	O
the	NN	O	O
middle	NN	O	O
of	NN	O	O
the	NN	O	O
eighties	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
has	NN	O	O
increased	NN	O	O
progressively	NN	O	O
.	NN	O	O

Soon	NN	O	O
after	NN	O	O
the	NN	O	O
introduction	NN	O	O
of	NN	O	O
ACE	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
acute	NN	O	O
bouts	NN	O	O
of	NN	O	O
angio	NN	O	B
-	NN	O	I
oedema	NN	O	I
were	NN	O	O
reported	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
.	NN	O	O

We	NN	O	O
wish	NN	O	O
to	NN	O	O
draw	NN	O	O
attention	NN	O	O
to	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
to	NN	O	O
ACE	NN	O	O
inhibitors	NN	O	O
after	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
and	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
angio	NN	O	B
-	NN	O	I
oedema	NN	O	I
.	NN	O	O

Myoclonus	NN	O	B
associated	NN	O	O
with	NN	O	O
lorazepam	NN	O	O
therapy	NN	O	O
in	NN	O	O
very	NN	O	O
-	NN	O	O
low	NN	O	O
-	NN	O	O
birth	NN	O	O
-	NN	O	O
weight	NN	O	O
infants	NN	O	O
.	NN	O	O

Lorazepam	NN	O	O
is	NN	O	O
being	NN	O	O
used	NN	O	O
with	NN	O	O
increasing	NN	O	O
frequency	NN	O	O
as	NN	O	O
a	NN	O	O
sedative	NN	O	O
in	NN	O	O
the	NN	O	O
newborn	NN	O	O
and	NN	O	O
the	NN	O	O
young	NN	O	O
infant	NN	O	O
.	NN	O	O

Concern	NN	O	O
has	NN	O	O
been	NN	O	O
raised	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
lorazepam	NN	O	O
in	NN	O	O
this	NN	O	O
age	NN	O	O
group	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
very	NN	O	O
-	NN	O	O
low	NN	O	O
-	NN	O	O
birth	NN	O	O
-	NN	O	O
weight	NN	O	O
(	NN	O	O
VLBW	NN	O	O
;	NN	O	O
<	NN	O	O
1	NN	O	O
,	NN	O	O
500	NN	O	O
g	NN	O	O
)	NN	O	O
infants	NN	O	O
.	NN	O	O

Three	NN	O	O
young	NN	O	O
infants	NN	O	O
,	NN	O	O
all	NN	O	O
of	NN	O	O
birth	NN	O	O
weight	NN	O	O
<	NN	O	O
1	NN	O	O
,	NN	O	O
500	NN	O	O
g	NN	O	O
,	NN	O	O
experienced	NN	O	O
myoclonus	NN	O	B
following	NN	O	O
the	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
lorazepam	NN	O	O
.	NN	O	O

The	NN	O	O
potential	NN	O	O
neurotoxic	NN	O	B
effects	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
(	NN	O	O
and	NN	O	O
its	NN	O	O
vehicle	NN	O	O
)	NN	O	O
in	NN	O	O
this	NN	O	O
population	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Injectable	NN	O	O
lorazepam	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
with	NN	O	O
caution	NN	O	O
in	NN	O	O
VLBW	NN	O	O
infants	NN	O	O
.	NN	O	O

Transvenous	NN	O	O
right	NN	O	O
ventricular	NN	O	O
pacing	NN	O	O
during	NN	O	O
cardiopulmonary	NN	O	O
resuscitation	NN	O	O
of	NN	O	O
pediatric	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	O
cardiomyopathy	NN	O	B
.	NN	O	O

We	NN	O	O
describe	NN	O	O
the	NN	O	O
cardiopulmonary	NN	O	O
resuscitation	NN	O	O
efforts	NN	O	O
on	NN	O	O
five	NN	O	O
patients	NN	O	O
who	NN	O	O
presented	NN	O	O
in	NN	O	O
acute	NN	O	O
circulatory	NN	O	B
failure	NN	O	I
from	NN	O	O
myocardial	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
had	NN	O	O
acute	NN	O	O
viral	NN	O	O
myocarditis	NN	O	B
,	NN	O	O
one	NN	O	O
had	NN	O	O
a	NN	O	O
carbamazepine	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
eosinophilic	NN	O	B
myocarditis	NN	O	I
,	NN	O	O
and	NN	O	O
one	NN	O	O
had	NN	O	O
cardiac	NN	O	O
hemosiderosis	NN	O	O
resulting	NN	O	O
in	NN	O	O
acute	NN	O	O
cardiogenic	NN	O	B
shock	NN	O	I
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
continuously	NN	O	O
monitored	NN	O	O
with	NN	O	O
central	NN	O	O
venous	NN	O	O
and	NN	O	O
arterial	NN	O	O
catheters	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
routine	NN	O	O
noninvasive	NN	O	O
monitoring	NN	O	O
.	NN	O	O

An	NN	O	O
introducer	NN	O	O
sheath	NN	O	O
,	NN	O	O
a	NN	O	O
pacemaker	NN	O	O
,	NN	O	O
and	NN	O	O
sterile	NN	O	O
pacing	NN	O	O
wires	NN	O	O
were	NN	O	O
made	NN	O	O
readily	NN	O	O
available	NN	O	O
for	NN	O	O
the	NN	O	O
patients	NN	O	O
,	NN	O	O
should	NN	O	O
the	NN	O	O
need	NN	O	O
arise	NN	O	O
to	NN	O	O
terminate	NN	O	O
resistant	NN	O	O
cardiac	NN	O	O
dysrhythmias	NN	O	B
.	NN	O	O

All	NN	O	O
patients	NN	O	O
developed	NN	O	O
cardiocirculatory	NN	O	O
arrest	NN	O	O
associated	NN	O	O
with	NN	O	O
extreme	NN	O	O
hypotension	NN	O	B
and	NN	O	O
dysrhythmias	NN	O	B
within	NN	O	O
the	NN	O	O
first	NN	O	O
48	NN	O	O
hours	NN	O	O
of	NN	O	O
their	NN	O	O
admission	NN	O	O
to	NN	O	O
the	NN	O	O
pediatric	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
(	NN	O	O
PICU	NN	O	O
)	NN	O	O
.	NN	O	O

Right	NN	O	O
ventricular	NN	O	O
pacemaker	NN	O	O
wires	NN	O	O
were	NN	O	O
inserted	NN	O	O
in	NN	O	O
all	NN	O	O
of	NN	O	O
them	NN	O	O
during	NN	O	O
cardiopulmonary	NN	O	O
resuscitation	NN	O	O
(	NN	O	O
CPR	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
four	NN	O	O
patients	NN	O	O
,	NN	O	O
cardiac	NN	O	O
pacing	NN	O	O
was	NN	O	O
used	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
a	NN	O	O
temporary	NN	O	O
captured	NN	O	O
rhythm	NN	O	O
and	NN	O	O
restoration	NN	O	O
of	NN	O	O
their	NN	O	O
cardiac	NN	O	O
output	NN	O	O
.	NN	O	O

These	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
second	NN	O	O
event	NN	O	O
of	NN	O	O
cardiac	NN	O	B
arrest	NN	O	I
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
death	NN	O	O
,	NN	O	O
within	NN	O	O
10	NN	O	O
to	NN	O	O
60	NN	O	O
minutes	NN	O	O
.	NN	O	O

In	NN	O	O
one	NN	O	O
patient	NN	O	O
,	NN	O	O
cardiac	NN	O	O
pacing	NN	O	O
was	NN	O	O
not	NN	O	O
used	NN	O	O
,	NN	O	O
because	NN	O	O
he	NN	O	O
converted	NN	O	O
to	NN	O	O
normal	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
by	NN	O	O
electrical	NN	O	O
defibrillation	NN	O	O
within	NN	O	O
three	NN	O	O
minutes	NN	O	O
of	NN	O	O
initiating	NN	O	O
CPR	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
cardiac	NN	O	O
pacing	NN	O	O
during	NN	O	O
resuscitative	NN	O	O
efforts	NN	O	O
in	NN	O	O
pediatric	NN	O	O
patients	NN	O	O
suffering	NN	O	O
from	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
dysfunction	NN	O	I
may	NN	O	O
not	NN	O	O
have	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
value	NN	O	O
in	NN	O	O
and	NN	O	O
of	NN	O	O
itself	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
if	NN	O	O
temporary	NN	O	O
hemodynamic	NN	O	O
stability	NN	O	O
is	NN	O	O
achieved	NN	O	O
by	NN	O	O
this	NN	O	O
procedure	NN	O	O
,	NN	O	O
it	NN	O	O
may	NN	O	O
provide	NN	O	O
additional	NN	O	O
time	NN	O	O
needed	NN	O	O
to	NN	O	O
institute	NN	O	O
other	NN	O	O
therapeutic	NN	O	O
modalities	NN	O	O
.	NN	O	O

Efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
granisetron	NN	O	O
,	NN	O	O
a	NN	O	O
selective	NN	O	O
5	NN	O	O
-	NN	O	O
hydroxytryptamine	NN	O	O
-	NN	O	O
3	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
nausea	NN	O	B
and	NN	O	O
vomiting	NN	O	B
induced	NN	O	O
by	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cisplatin	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
the	NN	O	O
antiemetic	NN	O	O
effects	NN	O	O
and	NN	O	O
safety	NN	O	O
profile	NN	O	O
of	NN	O	O
four	NN	O	O
different	NN	O	O
doses	NN	O	O
of	NN	O	O
granisetron	NN	O	O
(	NN	O	O
Kytril	NN	O	O
;	NN	O	O
SmithKline	NN	O	O
Beecham	NN	O	O
Pharmaceuticals	NN	O	O
,	NN	O	O
Philadelphia	NN	O	O
,	NN	O	O
PA	NN	O	O
)	NN	O	O
when	NN	O	O
administered	NN	O	O
as	NN	O	O
a	NN	O	O
single	NN	O	O
intravenous	NN	O	O
(	NN	O	O
IV	NN	O	O
)	NN	O	O
dose	NN	O	O
for	NN	O	O
prophylaxis	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
induced	NN	O	O
nausea	NN	O	B
and	NN	O	O
vomiting	NN	O	B
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
One	NN	O	O
hundred	NN	O	O
eighty	NN	O	O
-	NN	O	O
four	NN	O	O
chemotherapy	NN	O	O
-	NN	O	O
naive	NN	O	O
patients	NN	O	O
receiving	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cisplatin	NN	O	O
(	NN	O	O
81	NN	O	O
to	NN	O	O
120	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
)	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
one	NN	O	O
of	NN	O	O
four	NN	O	O
granisetron	NN	O	O
doses	NN	O	O
(	NN	O	O
5	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
20	NN	O	O
,	NN	O	O
or	NN	O	O
40	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
administered	NN	O	O
before	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
observed	NN	O	O
on	NN	O	O
an	NN	O	O
inpatient	NN	O	O
basis	NN	O	O
for	NN	O	O
18	NN	O	O
to	NN	O	O
24	NN	O	O
hours	NN	O	O
,	NN	O	O
and	NN	O	O
vital	NN	O	O
signs	NN	O	O
,	NN	O	O
nausea	NN	O	B
,	NN	O	O
vomiting	NN	O	B
,	NN	O	O
retching	NN	O	O
,	NN	O	O
and	NN	O	O
appetite	NN	O	O
were	NN	O	O
assessed	NN	O	O
.	NN	O	O

Safety	NN	O	O
analyses	NN	O	O
included	NN	O	O
incidence	NN	O	O
of	NN	O	O
adverse	NN	O	O
experiences	NN	O	O
and	NN	O	O
laboratory	NN	O	O
parameter	NN	O	O
changes	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
After	NN	O	O
granisetron	NN	O	O
doses	NN	O	O
of	NN	O	O
5	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
20	NN	O	O
,	NN	O	O
and	NN	O	O
40	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
a	NN	O	O
major	NN	O	O
response	NN	O	O
(	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
two	NN	O	O
vomiting	NN	O	B
or	NN	O	O
retching	NN	O	O
episodes	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
antiemetic	NN	O	O
rescue	NN	O	O
)	NN	O	O
was	NN	O	O
recorded	NN	O	O
in	NN	O	O
23	NN	O	O
%	NN	O	O
,	NN	O	O
57	NN	O	O
%	NN	O	O
,	NN	O	O
58	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
60	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
complete	NN	O	O
response	NN	O	O
(	NN	O	O
no	NN	O	O
vomiting	NN	O	B
or	NN	O	O
retching	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
antiemetic	NN	O	O
rescue	NN	O	O
)	NN	O	O
in	NN	O	O
18	NN	O	O
%	NN	O	O
,	NN	O	O
41	NN	O	O
%	NN	O	O
,	NN	O	O
40	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
47	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
statistically	NN	O	O
longer	NN	O	O
time	NN	O	O
to	NN	O	O
first	NN	O	O
episode	NN	O	O
of	NN	O	O
nausea	NN	O	B
(	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
0015	NN	O	O
)	NN	O	O
and	NN	O	O
vomiting	NN	O	B
(	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
fewer	NN	O	O
patients	NN	O	O
were	NN	O	O
administered	NN	O	O
additional	NN	O	O
antiemetic	NN	O	O
medication	NN	O	O
in	NN	O	O
the	NN	O	O
10	NN	O	O
-	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
dosing	NN	O	O
groups	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
dosing	NN	O	O
group	NN	O	O
.	NN	O	O

As	NN	O	O
granisetron	NN	O	O
dose	NN	O	O
increased	NN	O	O
,	NN	O	O
appetite	NN	O	O
return	NN	O	O
increased	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
040	NN	O	O
)	NN	O	O
.	NN	O	O

Headache	NN	O	B
was	NN	O	O
the	NN	O	O
most	NN	O	O
frequently	NN	O	O
reported	NN	O	O
adverse	NN	O	O
event	NN	O	O
(	NN	O	O
20	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
A	NN	O	O
single	NN	O	O
10	NN	O	O
-	NN	O	O
,	NN	O	O
20	NN	O	O
-	NN	O	O
,	NN	O	O
or	NN	O	O
40	NN	O	O
-	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
dose	NN	O	O
of	NN	O	O
granisetron	NN	O	O
was	NN	O	O
effective	NN	O	O
in	NN	O	O
controlling	NN	O	O
vomiting	NN	O	B
in	NN	O	O
57	NN	O	O
%	NN	O	O
to	NN	O	O
60	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
cisplatin	NN	O	O
at	NN	O	O
doses	NN	O	O
greater	NN	O	O
than	NN	O	O
81	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
and	NN	O	O
totally	NN	O	O
prevented	NN	O	O
vomiting	NN	O	B
in	NN	O	O
40	NN	O	O
%	NN	O	O
to	NN	O	O
47	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
efficacy	NN	O	O
between	NN	O	O
the	NN	O	O
10	NN	O	O
-	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
dose	NN	O	O
and	NN	O	O
the	NN	O	O
20	NN	O	O
-	NN	O	O
and	NN	O	O
40	NN	O	O
-	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
doses	NN	O	O
.	NN	O	O

Granisetron	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
at	NN	O	O
all	NN	O	O
doses	NN	O	O
.	NN	O	O

Adverse	NN	O	O
interaction	NN	O	O
between	NN	O	O
clonidine	NN	O	O
and	NN	O	O
verapamil	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
a	NN	O	O
possible	NN	O	O
adverse	NN	O	O
interaction	NN	O	O
between	NN	O	O
clonidine	NN	O	O
and	NN	O	O
verapamil	NN	O	O
resulting	NN	O	O
in	NN	O	O
atrioventricular	NN	O	B
(	NN	O	I
AV	NN	O	I
)	NN	O	I
block	NN	O	I
in	NN	O	O
both	NN	O	O
patients	NN	O	O
and	NN	O	O
severe	NN	O	O
hypotension	NN	O	B
in	NN	O	O
one	NN	O	O
patient	NN	O	O
.	NN	O	O

CASE	NN	O	O
SUMMARIES	NN	O	O
:	NN	O	O
A	NN	O	O
54	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
hyperaldosteronism	NN	O	B
was	NN	O	O
treated	NN	O	O
with	NN	O	O
verapamil	NN	O	O
480	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
and	NN	O	O
spironolactone	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
a	NN	O	O
minimal	NN	O	O
dose	NN	O	O
of	NN	O	O
clonidine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
15	NN	O	O
mg	NN	O	O
bid	NN	O	O
)	NN	O	O
,	NN	O	O
she	NN	O	O
developed	NN	O	O
complete	NN	O	O
AV	NN	O	B
block	NN	O	I
and	NN	O	O
severe	NN	O	O
hypotension	NN	O	B
,	NN	O	O
which	NN	O	O
resolved	NN	O	O
upon	NN	O	O
cessation	NN	O	O
of	NN	O	O
all	NN	O	O
medications	NN	O	O
.	NN	O	O

A	NN	O	O
65	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
extended	NN	O	O
-	NN	O	O
release	NN	O	O
verapamil	NN	O	O
240	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
clonidine	NN	O	O
0	NN	O	O
.	NN	O	O
15	NN	O	O
mg	NN	O	O
bid	NN	O	O
she	NN	O	O
developed	NN	O	O
complete	NN	O	O
AV	NN	O	B
block	NN	O	I
,	NN	O	O
which	NN	O	O
resolved	NN	O	O
after	NN	O	O
all	NN	O	O
therapy	NN	O	O
was	NN	O	O
stopped	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
An	NN	O	O
adverse	NN	O	O
interaction	NN	O	O
between	NN	O	O
clonidine	NN	O	O
and	NN	O	O
verapamil	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
reported	NN	O	O
previously	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
two	NN	O	O
such	NN	O	O
cases	NN	O	O
and	NN	O	O
discuss	NN	O	O
the	NN	O	O
various	NN	O	O
mechanisms	NN	O	O
that	NN	O	O
might	NN	O	O
cause	NN	O	O
such	NN	O	O
an	NN	O	O
interaction	NN	O	O
.	NN	O	O

Clinicians	NN	O	O
should	NN	O	O
be	NN	O	O
acquainted	NN	O	O
with	NN	O	O
this	NN	O	O
possibly	NN	O	O
fatal	NN	O	O
interaction	NN	O	O
between	NN	O	O
two	NN	O	O
commonly	NN	O	O
used	NN	O	O
antihypertensive	NN	O	O
drugs	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Caution	NN	O	O
is	NN	O	O
recommended	NN	O	O
in	NN	O	O
combining	NN	O	O
clonidine	NN	O	O
and	NN	O	O
verapamil	NN	O	O
therapy	NN	O	O
,	NN	O	O
even	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
do	NN	O	O
not	NN	O	O
have	NN	O	O
sinus	NN	O	O
or	NN	O	O
AV	NN	O	O
node	NN	O	O
dysfunction	NN	O	O
.	NN	O	O

The	NN	O	O
two	NN	O	O
drugs	NN	O	O
may	NN	O	O
act	NN	O	O
synergistically	NN	O	O
on	NN	O	O
both	NN	O	O
the	NN	O	O
AV	NN	O	O
node	NN	O	O
and	NN	O	O
the	NN	O	O
peripheral	NN	O	O
circulation	NN	O	O
.	NN	O	O

Pharmacological	NN	O	O
studies	NN	O	O
on	NN	O	O
a	NN	O	O
new	NN	O	O
dihydrothienopyridine	NN	O	O
calcium	NN	O	O
antagonist	NN	O	O
,	NN	O	O
S	NN	O	O
-	NN	O	O
312	NN	O	O
-	NN	O	O
d	NN	O	O
.	NN	O	O

5th	NN	O	O
communication	NN	O	O
:	NN	O	O
anticonvulsant	NN	O	O
effects	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

S	NN	O	O
-	NN	O	O
312	NN	O	O
,	NN	O	O
S	NN	O	O
-	NN	O	O
312	NN	O	O
-	NN	O	O
d	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
S	NN	O	O
-	NN	O	O
312	NN	O	O
-	NN	O	O
l	NN	O	O
,	NN	O	O
L	NN	O	O
-	NN	O	O
type	NN	O	O
calcium	NN	O	O
channel	NN	O	O
antagonists	NN	O	O
,	NN	O	O
showed	NN	O	O
anticonvulsant	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
audiogenic	NN	O	B
tonic	NN	O	I
convulsions	NN	O	I
in	NN	O	O
DBA	NN	O	O
/	NN	O	O
2	NN	O	O
mice	NN	O	O
;	NN	O	O
and	NN	O	O
their	NN	O	O
ED50	NN	O	O
values	NN	O	O
were	NN	O	O
18	NN	O	O
.	NN	O	O
4	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
8	NN	O	O
-	NN	O	O
27	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
and	NN	O	O
15	NN	O	O
.	NN	O	O
0	NN	O	O
(	NN	O	O
10	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
23	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
while	NN	O	O
that	NN	O	O
of	NN	O	O
flunarizine	NN	O	O
was	NN	O	O
34	NN	O	O
.	NN	O	O
0	NN	O	O
(	NN	O	O
26	NN	O	O
.	NN	O	O
0	NN	O	O
-	NN	O	O
44	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O

Although	NN	O	O
moderate	NN	O	O
anticonvulsant	NN	O	O
effects	NN	O	O
of	NN	O	O
S	NN	O	O
-	NN	O	O
312	NN	O	O
-	NN	O	O
d	NN	O	O
in	NN	O	O
higher	NN	O	O
doses	NN	O	O
were	NN	O	O
observed	NN	O	O
against	NN	O	O
the	NN	O	O
clonic	NN	O	O
convulsions	NN	O	B
induced	NN	O	O
by	NN	O	O
pentylenetetrazole	NN	O	O
(	NN	O	O
85	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
or	NN	O	O
bemegride	NN	O	O
(	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
,	NN	O	O
no	NN	O	O
effects	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
convulsions	NN	O	B
induced	NN	O	O
by	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartate	NN	O	O
,	NN	O	O
picrotoxin	NN	O	O
,	NN	O	O
or	NN	O	O
electroshock	NN	O	O
in	NN	O	O
Slc	NN	O	O
:	NN	O	O
ddY	NN	O	O
mice	NN	O	O
.	NN	O	O

S	NN	O	O
-	NN	O	O
312	NN	O	O
-	NN	O	O
d	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
in	NN	O	O
the	NN	O	O
therapy	NN	O	O
of	NN	O	O
certain	NN	O	O
types	NN	O	O
of	NN	O	O
human	NN	O	O
epilepsy	NN	O	B
.	NN	O	O

Transmural	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
with	NN	O	O
sumatriptan	NN	O	O
.	NN	O	O

For	NN	O	O
sumatriptan	NN	O	O
,	NN	O	O
tightness	NN	O	O
in	NN	O	O
the	NN	O	O
chest	NN	O	O
caused	NN	O	O
by	NN	O	O
an	NN	O	O
unknown	NN	O	O
mechanism	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
3	NN	O	O
-	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
users	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
47	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
an	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
after	NN	O	O
administration	NN	O	O
of	NN	O	O
sumatriptan	NN	O	O
6	NN	O	O
mg	NN	O	O
subcutaneously	NN	O	O
for	NN	O	O
cluster	NN	O	B
headache	NN	O	I
.	NN	O	O

The	NN	O	O
patient	NN	O	O
had	NN	O	O
no	NN	O	O
history	NN	O	O
of	NN	O	O
underlying	NN	O	O
ischaemic	NN	O	B
heart	NN	O	I
disease	NN	O	I
or	NN	O	O
Prinzmetal	NN	O	B
'	NN	O	I
s	NN	O	I
angina	NN	O	I
.	NN	O	O

She	NN	O	O
recovered	NN	O	O
without	NN	O	O
complications	NN	O	O
.	NN	O	O

Flumazenil	NN	O	O
induces	NN	O	O
seizures	NN	O	B
and	NN	O	O
death	NN	O	O
in	NN	O	O
mixed	NN	O	O
cocaine	NN	O	O
-	NN	O	O
diazepam	NN	O	O
intoxications	NN	O	O
.	NN	O	O

STUDY	NN	O	O
HYPOTHESIS	NN	O	O
:	NN	O	O
Administration	NN	O	O
of	NN	O	O
the	NN	O	O
benzodiazepine	NN	O	O
antagonist	NN	O	O
flumazenil	NN	O	O
may	NN	O	O
unmask	NN	O	O
seizures	NN	O	B
in	NN	O	O
mixed	NN	O	O
cocaine	NN	O	O
-	NN	O	O
benzodiazepine	NN	O	O
intoxication	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
received	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
cocaine	NN	O	O
IP	NN	O	O
alone	NN	O	O
,	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
diazepam	NN	O	O
alone	NN	O	O
,	NN	O	O
or	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
diazepam	NN	O	O
and	NN	O	O
cocaine	NN	O	O
.	NN	O	O

Three	NN	O	O
minutes	NN	O	O
later	NN	O	O
,	NN	O	O
groups	NN	O	O
were	NN	O	O
challenged	NN	O	O
with	NN	O	O
vehicle	NN	O	O
or	NN	O	O
flumazenil	NN	O	O
5	NN	O	O
or	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
IP	NN	O	O
.	NN	O	O

Animal	NN	O	O
behavior	NN	O	O
,	NN	O	O
seizures	NN	O	B
(	NN	O	O
time	NN	O	O
to	NN	O	O
and	NN	O	O
incidence	NN	O	O
)	NN	O	O
,	NN	O	O
death	NN	O	O
(	NN	O	O
time	NN	O	O
to	NN	O	O
and	NN	O	O
incidence	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
cortical	NN	O	O
EEG	NN	O	O
tracings	NN	O	O
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

INTERVENTIONS	NN	O	O
:	NN	O	O
Administration	NN	O	O
of	NN	O	O
flumazenil	NN	O	O
to	NN	O	O
animals	NN	O	O
after	NN	O	O
they	NN	O	O
had	NN	O	O
received	NN	O	O
a	NN	O	O
combination	NN	O	O
dose	NN	O	O
of	NN	O	O
cocaine	NN	O	O
and	NN	O	O
diazepam	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
group	NN	O	O
1	NN	O	O
,	NN	O	O
animals	NN	O	O
received	NN	O	O
cocaine	NN	O	O
followed	NN	O	O
by	NN	O	O
vehicle	NN	O	O
.	NN	O	O

This	NN	O	O
resulted	NN	O	O
in	NN	O	O
100	NN	O	O
%	NN	O	O
developing	NN	O	O
seizures	NN	O	B
and	NN	O	O
death	NN	O	O
.	NN	O	O

Group	NN	O	O
2	NN	O	O
received	NN	O	O
diazepam	NN	O	O
alone	NN	O	O
followed	NN	O	O
by	NN	O	O
vehicle	NN	O	O
.	NN	O	O

Animals	NN	O	O
became	NN	O	O
somnolent	NN	O	O
and	NN	O	O
none	NN	O	O
died	NN	O	O
.	NN	O	O

Group	NN	O	O
3	NN	O	O
received	NN	O	O
diazepam	NN	O	O
followed	NN	O	O
by	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
flumazenil	NN	O	O
.	NN	O	O

Animals	NN	O	O
became	NN	O	O
somnolent	NN	O	O
after	NN	O	O
diazepam	NN	O	O
and	NN	O	O
then	NN	O	O
active	NN	O	O
after	NN	O	O
flumazenil	NN	O	O
administration	NN	O	O
.	NN	O	O

In	NN	O	O
group	NN	O	O
4	NN	O	O
,	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
cocaine	NN	O	O
and	NN	O	O
diazepam	NN	O	O
was	NN	O	O
administered	NN	O	O
simultaneously	NN	O	O
.	NN	O	O

This	NN	O	O
resulted	NN	O	O
in	NN	O	O
no	NN	O	O
overt	NN	O	O
or	NN	O	O
EEG	NN	O	O
-	NN	O	O
detectable	NN	O	O
seizures	NN	O	B
and	NN	O	O
a	NN	O	O
50	NN	O	O
%	NN	O	O
incidence	NN	O	O
of	NN	O	O
death	NN	O	O
.	NN	O	O

Group	NN	O	O
5	NN	O	O
received	NN	O	O
a	NN	O	O
similar	NN	O	O
combination	NN	O	O
of	NN	O	O
cocaine	NN	O	O
and	NN	O	O
diazepam	NN	O	O
,	NN	O	O
followed	NN	O	O
later	NN	O	O
by	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
flumazenil	NN	O	O
.	NN	O	O

This	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
seizures	NN	O	B
,	NN	O	O
90	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
death	NN	O	O
,	NN	O	O
100	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
group	NN	O	O
4	NN	O	O
.	NN	O	O

Group	NN	O	O
6	NN	O	O
received	NN	O	O
cocaine	NN	O	O
and	NN	O	O
diazepam	NN	O	O
followed	NN	O	O
by	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
flumazenil	NN	O	O
.	NN	O	O

This	NN	O	O
also	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
seizures	NN	O	B
,	NN	O	O
90	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
death	NN	O	O
,	NN	O	O
90	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
group	NN	O	O
4	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Flumazenil	NN	O	O
can	NN	O	O
unmask	NN	O	O
seizures	NN	O	B
and	NN	O	O
increase	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
death	NN	O	O
in	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
combined	NN	O	O
cocaine	NN	O	O
-	NN	O	O
diazepam	NN	O	O
intoxications	NN	O	O
.	NN	O	O

Mechanisms	NN	O	O
for	NN	O	O
protective	NN	O	O
effects	NN	O	O
of	NN	O	O
free	NN	O	O
radical	NN	O	O
scavengers	NN	O	O
on	NN	O	O
gentamicin	NN	O	O
-	NN	O	O
mediated	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Studies	NN	O	O
were	NN	O	O
performed	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
for	NN	O	O
the	NN	O	O
protective	NN	O	O
effects	NN	O	O
of	NN	O	O
free	NN	O	O
radical	NN	O	O
scavengers	NN	O	O
on	NN	O	O
gentamicin	NN	O	O
(	NN	O	O
GM	NN	O	O
)	NN	O	O
-	NN	O	O
mediated	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
GM	NN	O	O
at	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
sc	NN	O	O
for	NN	O	O
13	NN	O	O
days	NN	O	O
to	NN	O	O
rats	NN	O	O
induced	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
renal	NN	O	O
blood	NN	O	O
flow	NN	O	O
(	NN	O	O
RBF	NN	O	O
)	NN	O	O
and	NN	O	O
inulin	NN	O	O
clearance	NN	O	O
(	NN	O	O
CIn	NN	O	O
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
marked	NN	O	O
tubular	NN	O	B
damage	NN	O	I
.	NN	O	O

A	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
urinary	NN	O	O
guanosine	NN	O	O
3	NN	O	O
'	NN	O	O
,	NN	O	O
5	NN	O	O
'	NN	O	O
-	NN	O	O
cyclic	NN	O	O
monophosphate	NN	O	O
(	NN	O	O
cGMP	NN	O	O
)	NN	O	O
excretion	NN	O	O
and	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
renal	NN	O	O
cortical	NN	O	O
renin	NN	O	O
and	NN	O	O
endothelin	NN	O	O
-	NN	O	O
1	NN	O	O
contents	NN	O	O
were	NN	O	O
also	NN	O	O
observed	NN	O	O
in	NN	O	O
GM	NN	O	O
-	NN	O	O
mediated	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

Superoxide	NN	O	O
dismutase	NN	O	O
(	NN	O	O
SOD	NN	O	O
)	NN	O	O
or	NN	O	O
dimethylthiourea	NN	O	O
(	NN	O	O
DMTU	NN	O	O
)	NN	O	O
significantly	NN	O	O
lessened	NN	O	O
the	NN	O	O
GM	NN	O	O
-	NN	O	O
induced	NN	O	O
decrement	NN	O	O
in	NN	O	O
CIn	NN	O	O
.	NN	O	O

The	NN	O	O
SOD	NN	O	O
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
in	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
marked	NN	O	O
improvement	NN	O	O
in	NN	O	O
RBF	NN	O	O
,	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
urinary	NN	O	O
cGMP	NN	O	O
excretion	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
renal	NN	O	O
renin	NN	O	O
and	NN	O	O
endothelin	NN	O	O
-	NN	O	O
1	NN	O	O
content	NN	O	O
.	NN	O	O

SOD	NN	O	O
did	NN	O	O
not	NN	O	O
attenuate	NN	O	O
the	NN	O	O
tubular	NN	O	B
damage	NN	O	I
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
DMTU	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
tubular	NN	O	B
damage	NN	O	I
and	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
renal	NN	O	O
hemodynamics	NN	O	O
and	NN	O	O
vasoactive	NN	O	O
substances	NN	O	O
.	NN	O	O

Neither	NN	O	O
SOD	NN	O	O
nor	NN	O	O
DMTU	NN	O	O
affected	NN	O	O
the	NN	O	O
renal	NN	O	O
cortical	NN	O	O
GM	NN	O	O
content	NN	O	O
in	NN	O	O
GM	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
1	NN	O	O
)	NN	O	O
both	NN	O	O
SOD	NN	O	O
and	NN	O	O
DMTU	NN	O	O
have	NN	O	O
protective	NN	O	O
effects	NN	O	O
on	NN	O	O
GM	NN	O	O
-	NN	O	O
mediated	NN	O	O
nephropathy	NN	O	B
,	NN	O	O
2	NN	O	O
)	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
for	NN	O	O
the	NN	O	O
protective	NN	O	O
effects	NN	O	O
differ	NN	O	O
for	NN	O	O
SOD	NN	O	O
and	NN	O	O
DMTU	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
)	NN	O	O
superoxide	NN	O	O
anions	NN	O	O
play	NN	O	O
a	NN	O	O
critical	NN	O	O
role	NN	O	O
in	NN	O	O
GM	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	O
vasoconstriction	NN	O	O
.	NN	O	O

Cephalothin	NN	O	O
-	NN	O	O
induced	NN	O	O
immune	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
.	NN	O	O

A	NN	O	O
patient	NN	O	O
with	NN	O	O
renal	NN	O	B
disease	NN	O	I
developed	NN	O	O
Coombs	NN	O	O
-	NN	O	O
positive	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
while	NN	O	O
receiving	NN	O	O
cephalothin	NN	O	O
therapy	NN	O	O
.	NN	O	O

An	NN	O	O
anti	NN	O	O
-	NN	O	O
cephalothin	NN	O	O
IgG	NN	O	O
antibody	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
serum	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
eluates	NN	O	O
from	NN	O	O
her	NN	O	O
erythrocytes	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
nonimmunologic	NN	O	O
binding	NN	O	O
of	NN	O	O
normal	NN	O	O
and	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
serum	NN	O	O
proteins	NN	O	O
to	NN	O	O
her	NN	O	O
own	NN	O	O
and	NN	O	O
cephalothin	NN	O	O
-	NN	O	O
coated	NN	O	O
normal	NN	O	O
red	NN	O	O
cells	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
.	NN	O	O

Skin	NN	O	O
tests	NN	O	O
and	NN	O	O
in	NN	O	O
vitro	NN	O	O
lymphocyte	NN	O	O
stimulation	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
sensitized	NN	O	O
to	NN	O	O
cephalothin	NN	O	O
and	NN	O	O
also	NN	O	O
to	NN	O	O
ampicillin	NN	O	O
.	NN	O	O

Careful	NN	O	O
investigation	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hemolytic	NN	O	B
anemias	NN	O	I
reveals	NN	O	O
the	NN	O	O
complexity	NN	O	O
of	NN	O	O
the	NN	O	O
immune	NN	O	O
mechanisms	NN	O	O
involved	NN	O	O
.	NN	O	O

Assessment	NN	O	O
of	NN	O	O
cardiomyocyte	NN	O	O
DNA	NN	O	O
synthesis	NN	O	O
during	NN	O	O
hypertrophy	NN	O	B
in	NN	O	O
adult	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
ability	NN	O	O
of	NN	O	O
cardiomyocytes	NN	O	O
to	NN	O	O
synthesize	NN	O	O
DNA	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
experimentally	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
hypertrophy	NN	O	I
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
adult	NN	O	O
mice	NN	O	O
.	NN	O	O

Isoproterenol	NN	O	O
delivered	NN	O	O
by	NN	O	O
osmotic	NN	O	O
minipump	NN	O	O
implantation	NN	O	O
in	NN	O	O
adult	NN	O	O
C3Heb	NN	O	O
/	NN	O	O
FeJ	NN	O	O
mice	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
46	NN	O	O
%	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
weight	NN	O	O
and	NN	O	O
a	NN	O	O
19	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
increase	NN	O	O
in	NN	O	O
cardiomyocyte	NN	O	O
area	NN	O	O
.	NN	O	O

No	NN	O	O
DNA	NN	O	O
synthesis	NN	O	O
,	NN	O	O
as	NN	O	O
assessed	NN	O	O
by	NN	O	O
autoradiographic	NN	O	O
analysis	NN	O	O
of	NN	O	O
isolated	NN	O	O
cardiomyocytes	NN	O	O
,	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
control	NN	O	O
or	NN	O	O
hypertrophic	NN	O	B
hearts	NN	O	I
.	NN	O	O

A	NN	O	O
survey	NN	O	O
of	NN	O	O
15	NN	O	O
independent	NN	O	O
inbred	NN	O	O
strains	NN	O	O
of	NN	O	O
mice	NN	O	O
revealed	NN	O	O
that	NN	O	O
ventricular	NN	O	O
cardiomyocyte	NN	O	O
nuclear	NN	O	O
number	NN	O	O
ranged	NN	O	O
from	NN	O	O
3	NN	O	O
to	NN	O	O
13	NN	O	O
%	NN	O	O
mononucleate	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
cardiomyocyte	NN	O	O
terminal	NN	O	O
differentiation	NN	O	O
is	NN	O	O
influenced	NN	O	O
directly	NN	O	O
or	NN	O	O
indirectly	NN	O	O
by	NN	O	O
genetic	NN	O	O
background	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
whether	NN	O	O
the	NN	O	O
capacity	NN	O	O
for	NN	O	O
reactive	NN	O	O
DNA	NN	O	O
synthesis	NN	O	O
was	NN	O	O
also	NN	O	O
subject	NN	O	O
to	NN	O	O
genetic	NN	O	O
regulation	NN	O	O
,	NN	O	O
cardiac	NN	O	B
hypertrophy	NN	O	I
was	NN	O	O
induced	NN	O	O
in	NN	O	O
the	NN	O	O
strains	NN	O	O
of	NN	O	O
mice	NN	O	O
comprising	NN	O	O
the	NN	O	O
extremes	NN	O	O
of	NN	O	O
the	NN	O	O
nuclear	NN	O	O
number	NN	O	O
survey	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
adult	NN	O	O
mouse	NN	O	O
atrial	NN	O	O
and	NN	O	O
ventricular	NN	O	O
cardiomyocytes	NN	O	O
do	NN	O	O
not	NN	O	O
synthesize	NN	O	O
DNA	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
hypertrophy	NN	O	I
.	NN	O	O

Central	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
of	NN	O	O
AVP	NN	O	O
and	NN	O	O
ANP	NN	O	O
in	NN	O	O
normotensive	NN	O	O
and	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
compare	NN	O	O
influence	NN	O	O
of	NN	O	O
central	NN	O	O
arginine	NN	O	O
vasopressin	NN	O	O
(	NN	O	O
AVP	NN	O	O
)	NN	O	O
and	NN	O	O
of	NN	O	O
atrial	NN	O	O
natriuretic	NN	O	O
peptide	NN	O	O
(	NN	O	O
ANP	NN	O	O
)	NN	O	O
on	NN	O	O
control	NN	O	O
of	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
MAP	NN	O	O
)	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
(	NN	O	O
HR	NN	O	O
)	NN	O	O
in	NN	O	O
normotensive	NN	O	O
(	NN	O	O
WKY	NN	O	O
)	NN	O	O
and	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
(	NN	O	O
SHR	NN	O	O
)	NN	O	O
rats	NN	O	O
.	NN	O	O

Three	NN	O	O
series	NN	O	O
of	NN	O	O
experiments	NN	O	O
were	NN	O	O
performed	NN	O	O
on	NN	O	O
30	NN	O	O
WKY	NN	O	O
and	NN	O	O
30	NN	O	O
SHR	NN	O	O
,	NN	O	O
chronically	NN	O	O
instrumented	NN	O	O
with	NN	O	O
guide	NN	O	O
tubes	NN	O	O
in	NN	O	O
the	NN	O	O
lateral	NN	O	O
ventricle	NN	O	O
(	NN	O	O
LV	NN	O	O
)	NN	O	O
and	NN	O	O
arterial	NN	O	O
and	NN	O	O
venous	NN	O	O
catheters	NN	O	O
.	NN	O	O

MAP	NN	O	O
and	NN	O	O
HR	NN	O	O
were	NN	O	O
monitored	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
injections	NN	O	O
of	NN	O	O
either	NN	O	O
vehicle	NN	O	O
or	NN	O	O
1	NN	O	O
,	NN	O	O
10	NN	O	O
and	NN	O	O
50	NN	O	O
ng	NN	O	O
of	NN	O	O
AVP	NN	O	O
and	NN	O	O
25	NN	O	O
,	NN	O	O
125	NN	O	O
and	NN	O	O
500	NN	O	O
ng	NN	O	O
of	NN	O	O
ANP	NN	O	O
.	NN	O	O

Sensitivity	NN	O	O
of	NN	O	O
cardiac	NN	O	O
component	NN	O	O
of	NN	O	O
baroreflex	NN	O	O
(	NN	O	O
CCB	NN	O	O
)	NN	O	O
,	NN	O	O
expressed	NN	O	O
as	NN	O	O
a	NN	O	O
slope	NN	O	O
of	NN	O	O
the	NN	O	O
regression	NN	O	O
line	NN	O	O
was	NN	O	O
determined	NN	O	O
from	NN	O	O
relationships	NN	O	O
between	NN	O	O
systolic	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
SAP	NN	O	O
)	NN	O	O
and	NN	O	O
HR	NN	O	O
period	NN	O	O
(	NN	O	O
HRp	NN	O	O
)	NN	O	O
during	NN	O	O
phenylephrine	NN	O	O
(	NN	O	O
Phe	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
and	NN	O	O
sodium	NN	O	O
nitroprusside	NN	O	O
(	NN	O	O
SN	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

CCB	NN	O	O
was	NN	O	O
measured	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
either	NN	O	O
vehicle	NN	O	O
,	NN	O	O
AVP	NN	O	O
,	NN	O	O
ANP	NN	O	O
,	NN	O	O
or	NN	O	O
both	NN	O	O
peptides	NN	O	O
together	NN	O	O
.	NN	O	O

Increases	NN	O	O
of	NN	O	O
MAP	NN	O	O
occurred	NN	O	O
after	NN	O	O
LV	NN	O	O
administration	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
10	NN	O	O
and	NN	O	O
50	NN	O	O
ng	NN	O	O
of	NN	O	O
AVP	NN	O	O
in	NN	O	O
WKY	NN	O	O
and	NN	O	O
of	NN	O	O
10	NN	O	O
and	NN	O	O
50	NN	O	O
ng	NN	O	O
in	NN	O	O
SHR	NN	O	O
.	NN	O	O

ANP	NN	O	O
did	NN	O	O
not	NN	O	O
cause	NN	O	O
significant	NN	O	O
changes	NN	O	O
in	NN	O	O
MAP	NN	O	O
in	NN	O	O
both	NN	O	O
strains	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
vehicle	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
abolished	NN	O	O
AVP	NN	O	O
-	NN	O	O
induced	NN	O	O
MAP	NN	O	O
increase	NN	O	O
in	NN	O	O
WKY	NN	O	O
and	NN	O	O
SHR	NN	O	O
.	NN	O	O

CCB	NN	O	O
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
WKY	NN	O	O
and	NN	O	O
SHR	NN	O	O
after	NN	O	O
LV	NN	O	O
administration	NN	O	O
of	NN	O	O
AVP	NN	O	O
during	NN	O	O
SN	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

In	NN	O	O
SHR	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
WKY	NN	O	O
administration	NN	O	O
of	NN	O	O
ANP	NN	O	O
,	NN	O	O
AVP	NN	O	O
and	NN	O	O
ANP	NN	O	O
+	NN	O	O
AVP	NN	O	O
decreased	NN	O	O
CCB	NN	O	O
during	NN	O	O
Phe	NN	O	O
-	NN	O	O
induced	NN	O	O
MAP	NN	O	O
elevation	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
centrally	NN	O	O
applied	NN	O	O
AVP	NN	O	O
and	NN	O	O
ANP	NN	O	O
exert	NN	O	O
differential	NN	O	O
effects	NN	O	O
on	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
baroreflex	NN	O	O
control	NN	O	O
of	NN	O	O
heart	NN	O	O
rate	NN	O	O
in	NN	O	O
WKY	NN	O	O
and	NN	O	O
SHR	NN	O	O
and	NN	O	O
suggest	NN	O	O
interaction	NN	O	O
of	NN	O	O
these	NN	O	O
two	NN	O	O
peptides	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
regulation	NN	O	O
at	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O

Cutaneous	NN	O	O
exposure	NN	O	O
to	NN	O	O
warfarin	NN	O	O
-	NN	O	O
like	NN	O	O
anticoagulant	NN	O	O
causing	NN	O	O
an	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
intercerebral	NN	O	O
hematoma	NN	O	B
due	NN	O	O
to	NN	O	O
warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
coagulopathy	NN	O	B
is	NN	O	O
presented	NN	O	O
.	NN	O	O

The	NN	O	O
39	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
had	NN	O	O
spread	NN	O	O
a	NN	O	O
warfarin	NN	O	O
-	NN	O	O
type	NN	O	O
rat	NN	O	O
poison	NN	O	O
around	NN	O	O
her	NN	O	O
house	NN	O	O
weekly	NN	O	O
using	NN	O	O
her	NN	O	O
bare	NN	O	O
hands	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
washing	NN	O	O
post	NN	O	O
application	NN	O	O
.	NN	O	O

Percutaneous	NN	O	O
absorption	NN	O	O
of	NN	O	O
warfarin	NN	O	O
causing	NN	O	O
coagulopathy	NN	O	B
,	NN	O	O
reported	NN	O	O
three	NN	O	O
times	NN	O	O
in	NN	O	O
the	NN	O	O
past	NN	O	O
,	NN	O	O
is	NN	O	O
a	NN	O	O
significant	NN	O	O
risk	NN	O	O
if	NN	O	O
protective	NN	O	O
measures	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
gloves	NN	O	O
,	NN	O	O
are	NN	O	O
not	NN	O	O
used	NN	O	O
.	NN	O	O

An	NN	O	O
adverse	NN	O	O
drug	NN	O	O
interaction	NN	O	O
with	NN	O	O
piroxicam	NN	O	O
,	NN	O	O
which	NN	O	O
she	NN	O	O
took	NN	O	O
occasionally	NN	O	O
,	NN	O	O
may	NN	O	O
have	NN	O	O
exacerbated	NN	O	O
the	NN	O	O
coagulopathy	NN	O	B
.	NN	O	O

Pediatric	NN	O	O
heart	NN	O	O
transplantation	NN	O	O
without	NN	O	O
chronic	NN	O	O
maintenance	NN	O	O
steroids	NN	O	O
.	NN	O	O

From	NN	O	O
1986	NN	O	O
to	NN	O	O
February	NN	O	O
1993	NN	O	O
,	NN	O	O
40	NN	O	O
children	NN	O	O
aged	NN	O	O
2	NN	O	O
months	NN	O	O
to	NN	O	O
18	NN	O	O
years	NN	O	O
(	NN	O	O
average	NN	O	O
age	NN	O	O
10	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
8	NN	O	O
years	NN	O	O
)	NN	O	O
underwent	NN	O	O
heart	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Indications	NN	O	O
for	NN	O	O
transplantation	NN	O	O
were	NN	O	O
idiopathic	NN	O	B
cardiomyopathy	NN	O	I
(	NN	O	O
52	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
congenital	NN	O	B
heart	NN	O	I
disease	NN	O	I
(	NN	O	O
35	NN	O	O
%	NN	O	O
)	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
prior	NN	O	O
repair	NN	O	O
(	NN	O	O
71	NN	O	O
%	NN	O	O
and	NN	O	O
29	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
,	NN	O	O
hypertrophic	NN	O	B
cardiomyopathy	NN	O	I
(	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
valvular	NN	O	B
heart	NN	O	I
disease	NN	O	I
(	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
doxorubicin	NN	O	O
cardiomyopathy	NN	O	B
(	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
managed	NN	O	O
with	NN	O	O
cyclosporine	NN	O	O
and	NN	O	O
azathioprine	NN	O	O
.	NN	O	O

No	NN	O	O
prophylaxis	NN	O	O
with	NN	O	O
antilymphocyte	NN	O	O
globulin	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

Steroids	NN	O	O
were	NN	O	O
given	NN	O	O
to	NN	O	O
39	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
for	NN	O	O
refractory	NN	O	O
rejection	NN	O	O
,	NN	O	O
but	NN	O	O
weaning	NN	O	O
was	NN	O	O
always	NN	O	O
attempted	NN	O	O
and	NN	O	O
generally	NN	O	O
successful	NN	O	O
(	NN	O	O
64	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
(	NN	O	O
14	NN	O	O
%	NN	O	O
)	NN	O	O
received	NN	O	O
maintenance	NN	O	O
steroids	NN	O	O
.	NN	O	O

Four	NN	O	O
patients	NN	O	O
died	NN	O	O
in	NN	O	O
the	NN	O	O
perioperative	NN	O	O
period	NN	O	O
and	NN	O	O
one	NN	O	O
died	NN	O	O
4	NN	O	O
months	NN	O	O
later	NN	O	O
.	NN	O	O

There	NN	O	O
have	NN	O	O
been	NN	O	O
no	NN	O	O
deaths	NN	O	O
related	NN	O	O
to	NN	O	O
rejection	NN	O	O
or	NN	O	O
infection	NN	O	B
.	NN	O	O

Average	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
was	NN	O	O
36	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
19	NN	O	O
months	NN	O	O
(	NN	O	O
range	NN	O	O
1	NN	O	O
to	NN	O	O
65	NN	O	O
months	NN	O	O
)	NN	O	O
.	NN	O	O

Cumulative	NN	O	O
survival	NN	O	O
is	NN	O	O
88	NN	O	O
%	NN	O	O
at	NN	O	O
5	NN	O	O
years	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
less	NN	O	O
than	NN	O	O
7	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
rejection	NN	O	O
was	NN	O	O
monitored	NN	O	O
noninvasively	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
first	NN	O	O
postoperative	NN	O	O
month	NN	O	O
,	NN	O	O
89	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
for	NN	O	O
rejection	NN	O	O
.	NN	O	O

Freedom	NN	O	O
from	NN	O	O
serious	NN	O	O
infections	NN	O	B
was	NN	O	O
83	NN	O	O
%	NN	O	O
at	NN	O	O
1	NN	O	O
month	NN	O	O
and	NN	O	O
65	NN	O	O
%	NN	O	O
at	NN	O	O
1	NN	O	O
year	NN	O	O
.	NN	O	O

Cytomegalovirus	NN	O	B
infections	NN	O	I
were	NN	O	O
treated	NN	O	O
successfully	NN	O	O
with	NN	O	O
ganciclovir	NN	O	O
in	NN	O	O
11	NN	O	O
patients	NN	O	O
.	NN	O	O

No	NN	O	O
impairment	NN	O	O
of	NN	O	O
growth	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
children	NN	O	O
who	NN	O	O
underwent	NN	O	O
transplantation	NN	O	O
compared	NN	O	O
with	NN	O	O
a	NN	O	O
control	NN	O	O
population	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
one	NN	O	O
patients	NN	O	O
(	NN	O	O
60	NN	O	O
%	NN	O	O
)	NN	O	O
have	NN	O	O
undergone	NN	O	O
annual	NN	O	O
catheterizations	NN	O	O
and	NN	O	O
no	NN	O	O
sign	NN	O	O
of	NN	O	O
graft	NN	O	O
atherosclerosis	NN	O	B
has	NN	O	O
been	NN	O	O
observed	NN	O	O
.	NN	O	O

Seizures	NN	O	B
occurred	NN	O	O
in	NN	O	O
five	NN	O	O
patients	NN	O	O
(	NN	O	O
14	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
hypertension	NN	O	B
was	NN	O	O
treated	NN	O	O
in	NN	O	O
10	NN	O	O
patients	NN	O	O
(	NN	O	O
28	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
patient	NN	O	O
was	NN	O	O
disabled	NN	O	O
and	NN	O	O
no	NN	O	O
lymphoproliferative	NN	O	B
disorder	NN	O	I
was	NN	O	O
observed	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Delirium	NN	O	B
during	NN	O	O
fluoxetine	NN	O	O
treatment	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

The	NN	O	O
correlation	NN	O	O
between	NN	O	O
high	NN	O	O
serum	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
concentrations	NN	O	O
and	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
side	NN	O	O
effects	NN	O	O
has	NN	O	O
been	NN	O	O
well	NN	O	O
established	NN	O	O
.	NN	O	O

Only	NN	O	O
a	NN	O	O
few	NN	O	O
reports	NN	O	O
exist	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
serum	NN	O	O
concentrations	NN	O	O
of	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NN	O	O
(	NN	O	O
SSRIs	NN	O	O
)	NN	O	O
and	NN	O	O
their	NN	O	O
toxic	NN	O	O
effects	NN	O	O
.	NN	O	O

In	NN	O	O
some	NN	O	O
cases	NN	O	O
,	NN	O	O
a	NN	O	O
high	NN	O	O
serum	NN	O	O
concentration	NN	O	O
of	NN	O	O
citalopram	NN	O	O
(	NN	O	O
>	NN	O	O
600	NN	O	O
nmol	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
somnolence	NN	O	B
and	NN	O	O
movement	NN	O	B
difficulties	NN	O	I
.	NN	O	O

Widespread	NN	O	O
cognitive	NN	O	B
disorders	NN	O	I
,	NN	O	O
such	NN	O	O
as	NN	O	O
delirium	NN	O	B
,	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
previously	NN	O	O
linked	NN	O	O
with	NN	O	O
high	NN	O	O
blood	NN	O	O
levels	NN	O	O
of	NN	O	O
SSRIs	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
acute	NN	O	O
hyperkinetic	NN	O	B
delirium	NN	O	B
connected	NN	O	O
with	NN	O	O
a	NN	O	O
high	NN	O	O
serum	NN	O	O
total	NN	O	O
fluoxetine	NN	O	O
(	NN	O	O
fluoxetine	NN	O	O
plus	NN	O	O
desmethylfluoxetine	NN	O	O
)	NN	O	O
concentration	NN	O	O
.	NN	O	O

Pulmonary	NN	O	B
edema	NN	O	I
and	NN	O	O
shock	NN	O	B
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
aracytine	NN	O	O
-	NN	O	O
C	NN	O	O
for	NN	O	O
lymphoma	NN	O	B
;	NN	O	O
possible	NN	O	O
role	NN	O	O
of	NN	O	O
TNF	NN	O	O
-	NN	O	O
alpha	NN	O	O
and	NN	O	O
PAF	NN	O	O
.	NN	O	O

Four	NN	O	O
out	NN	O	O
of	NN	O	O
23	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
Ara	NN	O	O
-	NN	O	O
C	NN	O	O
for	NN	O	O
lymphomas	NN	O	B
in	NN	O	O
our	NN	O	O
institution	NN	O	O
developed	NN	O	O
a	NN	O	O
strikingly	NN	O	O
similar	NN	O	O
syndrome	NN	O	O
during	NN	O	O
the	NN	O	O
perfusion	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
fever	NN	O	B
,	NN	O	O
diarrhea	NN	O	B
,	NN	O	O
shock	NN	O	B
,	NN	O	O
pulmonary	NN	O	B
edema	NN	O	I
,	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
,	NN	O	O
metabolic	NN	O	B
acidosis	NN	O	I
,	NN	O	O
weight	NN	O	B
gain	NN	O	I
and	NN	O	O
leukocytosis	NN	O	B
.	NN	O	O

Thorough	NN	O	O
bacteriological	NN	O	O
screening	NN	O	O
failed	NN	O	O
to	NN	O	O
provide	NN	O	O
evidence	NN	O	O
of	NN	O	O
infection	NN	O	B
.	NN	O	O

Sequential	NN	O	O
biological	NN	O	O
assays	NN	O	O
of	NN	O	O
IL	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
IL	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
TNF	NN	O	O
and	NN	O	O
PAF	NN	O	O
were	NN	O	O
performed	NN	O	O
during	NN	O	O
Ara	NN	O	O
-	NN	O	O
C	NN	O	O
infusion	NN	O	O
to	NN	O	O
ten	NN	O	O
patients	NN	O	O
,	NN	O	O
including	NN	O	O
the	NN	O	O
four	NN	O	O
who	NN	O	O
developed	NN	O	O
the	NN	O	O
syndrome	NN	O	O
.	NN	O	O

TNF	NN	O	O
and	NN	O	O
PAF	NN	O	O
activity	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
of	NN	O	O
respectively	NN	O	O
two	NN	O	O
and	NN	O	O
four	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
six	NN	O	O
controls	NN	O	O
.	NN	O	O

As	NN	O	O
TNF	NN	O	O
and	NN	O	O
PAF	NN	O	O
are	NN	O	O
thought	NN	O	O
to	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
septic	NN	O	O
shock	NN	O	B
and	NN	O	O
adult	NN	O	B
respiratory	NN	O	I
distress	NN	O	I
syndrome	NN	O	I
,	NN	O	O
we	NN	O	O
hypothesize	NN	O	O
that	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
Ara	NN	O	O
-	NN	O	O
C	NN	O	O
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
cytokine	NN	O	O
release	NN	O	O
.	NN	O	O

Protective	NN	O	O
effect	NN	O	O
of	NN	O	O
clentiazem	NN	O	O
against	NN	O	O
epinephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
injury	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
clentiazem	NN	O	O
,	NN	O	O
a	NN	O	O
1	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
benzothiazepine	NN	O	O
calcium	NN	O	O
antagonist	NN	O	O
,	NN	O	O
on	NN	O	O
epinephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

With	NN	O	O
2	NN	O	O
-	NN	O	O
week	NN	O	O
chronic	NN	O	O
epinephrine	NN	O	O
infusion	NN	O	O
,	NN	O	O
16	NN	O	O
of	NN	O	O
30	NN	O	O
rats	NN	O	O
died	NN	O	O
within	NN	O	O
4	NN	O	O
days	NN	O	O
,	NN	O	O
and	NN	O	O
severe	NN	O	O
ischemic	NN	O	B
lesions	NN	O	I
and	NN	O	O
fibrosis	NN	O	B
of	NN	O	O
the	NN	O	O
left	NN	O	O
ventricles	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

In	NN	O	O
epinephrine	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
left	NN	O	O
atrial	NN	O	O
and	NN	O	O
left	NN	O	O
ventricular	NN	O	O
papillary	NN	O	O
muscle	NN	O	O
contractile	NN	O	O
responses	NN	O	O
to	NN	O	O
isoproterenol	NN	O	O
were	NN	O	O
reduced	NN	O	O
,	NN	O	O
but	NN	O	O
responses	NN	O	O
to	NN	O	O
calcium	NN	O	O
were	NN	O	O
normal	NN	O	O
or	NN	O	O
enhanced	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
.	NN	O	O

Left	NN	O	O
ventricular	NN	O	O
alpha	NN	O	O
and	NN	O	O
beta	NN	O	O
adrenoceptor	NN	O	O
densities	NN	O	O
were	NN	O	O
also	NN	O	O
reduced	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
clentiazem	NN	O	O
prevented	NN	O	O
epinephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
death	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
attenuated	NN	O	O
the	NN	O	O
ventricular	NN	O	O
ischemic	NN	O	B
lesions	NN	O	I
and	NN	O	O
fibrosis	NN	O	B
,	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

Left	NN	O	O
atrial	NN	O	O
and	NN	O	O
left	NN	O	O
ventricular	NN	O	O
papillary	NN	O	O
muscle	NN	O	O
contractile	NN	O	O
responses	NN	O	O
to	NN	O	O
isoproterenol	NN	O	O
were	NN	O	O
reduced	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
in	NN	O	O
groups	NN	O	O
treated	NN	O	O
with	NN	O	O
clentiazem	NN	O	O
alone	NN	O	O
,	NN	O	O
but	NN	O	O
combined	NN	O	O
with	NN	O	O
epinephrine	NN	O	O
,	NN	O	O
clentiazem	NN	O	O
restored	NN	O	O
left	NN	O	O
atrial	NN	O	O
responses	NN	O	O
and	NN	O	O
enhanced	NN	O	O
left	NN	O	O
ventricular	NN	O	O
papillary	NN	O	O
responses	NN	O	O
to	NN	O	O
isoproterenol	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
clentiazem	NN	O	O
did	NN	O	O
not	NN	O	O
prevent	NN	O	O
epinephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
down	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
alpha	NN	O	O
and	NN	O	O
beta	NN	O	O
adrenoceptors	NN	O	O
.	NN	O	O

Interestingly	NN	O	O
,	NN	O	O
clentiazem	NN	O	O
,	NN	O	O
infused	NN	O	O
alone	NN	O	O
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
decreased	NN	O	O
adrenergic	NN	O	O
receptor	NN	O	O
densities	NN	O	O
in	NN	O	O
the	NN	O	O
left	NN	O	O
ventricle	NN	O	O
.	NN	O	O

Clentiazem	NN	O	O
also	NN	O	O
did	NN	O	O
not	NN	O	O
prevent	NN	O	O
the	NN	O	O
enhanced	NN	O	O
responses	NN	O	O
to	NN	O	O
calcium	NN	O	O
seen	NN	O	O
in	NN	O	O
the	NN	O	O
epinephrine	NN	O	O
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
,	NN	O	O
although	NN	O	O
the	NN	O	O
high	NN	O	O
dose	NN	O	O
of	NN	O	O
clentiazem	NN	O	O
partially	NN	O	O
attenuated	NN	O	O
the	NN	O	O
maximal	NN	O	O
response	NN	O	O
to	NN	O	O
calcium	NN	O	O
compared	NN	O	O
to	NN	O	O
epinephrine	NN	O	O
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
clentiazem	NN	O	O
attenuated	NN	O	O
epinephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
injury	NN	O	I
,	NN	O	O
possibly	NN	O	O
through	NN	O	O
its	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
adrenergic	NN	O	O
pathway	NN	O	O
.	NN	O	O

Kaliuretic	NN	O	O
effect	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
treatment	NN	O	O
in	NN	O	O
parkinsonian	NN	O	B
patients	NN	O	O
.	NN	O	O

Hypokalemia	NN	O	B
,	NN	O	O
sometimes	NN	O	O
severe	NN	O	O
,	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
some	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
-	NN	O	O
treated	NN	O	O
parkinsonian	NN	O	B
patients	NN	O	O
.	NN	O	O

The	NN	O	O
influence	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
on	NN	O	O
the	NN	O	O
renal	NN	O	O
excretion	NN	O	O
of	NN	O	O
potassium	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
3	NN	O	O
patients	NN	O	O
with	NN	O	O
hypokalemia	NN	O	B
and	NN	O	O
in	NN	O	O
5	NN	O	O
normokalemic	NN	O	O
patients	NN	O	O
by	NN	O	O
determination	NN	O	O
of	NN	O	O
renal	NN	O	O
plasma	NN	O	O
flow	NN	O	O
,	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
,	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
of	NN	O	O
potassium	NN	O	O
and	NN	O	O
sodium	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
urinary	NN	O	O
excretion	NN	O	O
of	NN	O	O
potassium	NN	O	O
,	NN	O	O
sodium	NN	O	O
and	NN	O	O
aldosterone	NN	O	O
.	NN	O	O

L	NN	O	O
-	NN	O	O
Dopa	NN	O	O
intake	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
cause	NN	O	O
an	NN	O	O
increased	NN	O	O
excretion	NN	O	O
of	NN	O	O
potassium	NN	O	O
,	NN	O	O
and	NN	O	O
sometimes	NN	O	O
also	NN	O	O
of	NN	O	O
sodium	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
hypokalemic	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
normokalemic	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
renal	NN	O	O
function	NN	O	O
could	NN	O	O
be	NN	O	O
prohibited	NN	O	O
by	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
peripheral	NN	O	O
dopa	NN	O	O
decarbodylase	NN	O	O
inhibitor	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
why	NN	O	O
this	NN	O	O
effect	NN	O	O
occurred	NN	O	O
in	NN	O	O
some	NN	O	O
individuals	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
others	NN	O	O
,	NN	O	O
but	NN	O	O
our	NN	O	O
results	NN	O	O
indicate	NN	O	O
a	NN	O	O
correlation	NN	O	O
between	NN	O	O
aldosterone	NN	O	O
production	NN	O	O
and	NN	O	O
this	NN	O	O
renal	NN	O	O
effect	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
induced	NN	O	O
by	NN	O	O
cocaine	NN	O	O
.	NN	O	O

The	NN	O	O
ischemia	NN	O	B
probably	NN	O	O
induced	NN	O	O
by	NN	O	O
coronary	NN	O	B
artery	NN	O	I
spasm	NN	O	I
was	NN	O	O
reversed	NN	O	O
by	NN	O	O
nitroglycerin	NN	O	O
and	NN	O	O
calcium	NN	O	O
blocking	NN	O	O
agents	NN	O	O
.	NN	O	O

Doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
monitored	NN	O	O
by	NN	O	O
ECG	NN	O	O
in	NN	O	O
freely	NN	O	O
moving	NN	O	O
mice	NN	O	O
.	NN	O	O

A	NN	O	O
new	NN	O	O
model	NN	O	O
to	NN	O	O
test	NN	O	O
potential	NN	O	O
protectors	NN	O	O
.	NN	O	O

In	NN	O	O
laboratory	NN	O	O
animals	NN	O	O
,	NN	O	O
histology	NN	O	O
is	NN	O	O
most	NN	O	O
commonly	NN	O	O
used	NN	O	O
to	NN	O	O
study	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
for	NN	O	O
monitoring	NN	O	O
during	NN	O	O
treatment	NN	O	O
,	NN	O	O
large	NN	O	O
numbers	NN	O	O
of	NN	O	O
animals	NN	O	O
are	NN	O	O
needed	NN	O	O
.	NN	O	O

Recently	NN	O	O
we	NN	O	O
developed	NN	O	O
a	NN	O	O
new	NN	O	O
method	NN	O	O
to	NN	O	O
measure	NN	O	O
ECG	NN	O	O
values	NN	O	O
in	NN	O	O
freely	NN	O	O
moving	NN	O	O
mice	NN	O	O
by	NN	O	O
telemetry	NN	O	O
.	NN	O	O

With	NN	O	O
this	NN	O	O
model	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
chronic	NN	O	O
doxorubicin	NN	O	O
administration	NN	O	O
on	NN	O	O
the	NN	O	O
ECG	NN	O	O
of	NN	O	O
freely	NN	O	O
moving	NN	O	O
BALB	NN	O	O
/	NN	O	O
c	NN	O	O
mice	NN	O	O
and	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
ICRF	NN	O	O
-	NN	O	O
187	NN	O	O
as	NN	O	O
a	NN	O	O
protective	NN	O	O
agent	NN	O	O
.	NN	O	O

The	NN	O	O
ST	NN	O	O
interval	NN	O	O
significantly	NN	O	O
widened	NN	O	O
from	NN	O	O
15	NN	O	O
.	NN	O	O
0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
to	NN	O	O
56	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
11	NN	O	O
.	NN	O	O
8	NN	O	O
ms	NN	O	O
in	NN	O	O
week	NN	O	O
10	NN	O	O
(	NN	O	O
7	NN	O	O
weekly	NN	O	O
doses	NN	O	O
of	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
doxorubicin	NN	O	O
given	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
plus	NN	O	O
3	NN	O	O
weeks	NN	O	O
of	NN	O	O
observation	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
ECG	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
animals	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
during	NN	O	O
the	NN	O	O
entire	NN	O	O
study	NN	O	O
.	NN	O	O

After	NN	O	O
sacrifice	NN	O	O
the	NN	O	O
hearts	NN	O	O
of	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
were	NN	O	O
enlarged	NN	O	O
and	NN	O	O
the	NN	O	O
atria	NN	O	O
were	NN	O	O
hypertrophic	NN	O	B
.	NN	O	O

As	NN	O	O
this	NN	O	O
schedule	NN	O	O
exerted	NN	O	O
more	NN	O	O
toxicity	NN	O	B
than	NN	O	O
needed	NN	O	O
to	NN	O	O
investigate	NN	O	O
protective	NN	O	O
agents	NN	O	O
,	NN	O	O
the	NN	O	O
protection	NN	O	O
of	NN	O	O
ICRF	NN	O	O
-	NN	O	O
187	NN	O	O
was	NN	O	O
determined	NN	O	O
using	NN	O	O
a	NN	O	O
dose	NN	O	O
schedule	NN	O	O
with	NN	O	O
lower	NN	O	O
general	NN	O	O
toxicity	NN	O	B
(	NN	O	O
6	NN	O	O
weekly	NN	O	O
doses	NN	O	O
of	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
doxorubicin	NN	O	O
given	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
plus	NN	O	O
2	NN	O	O
weeks	NN	O	O
of	NN	O	O
observation	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
this	NN	O	O
schedule	NN	O	O
,	NN	O	O
the	NN	O	O
animals	NN	O	O
'	NN	O	O
hearts	NN	O	O
appeared	NN	O	O
normal	NN	O	O
after	NN	O	O
sacrifice	NN	O	O
and	NN	O	O
ICRF	NN	O	O
-	NN	O	O
187	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
given	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
1	NN	O	O
h	NN	O	O
before	NN	O	O
doxorubicin	NN	O	O
)	NN	O	O
provided	NN	O	O
almost	NN	O	O
full	NN	O	O
protection	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
were	NN	O	O
confirmed	NN	O	O
by	NN	O	O
histology	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
this	NN	O	O
new	NN	O	O
model	NN	O	O
is	NN	O	O
very	NN	O	O
sensitive	NN	O	O
and	NN	O	O
enables	NN	O	O
monitoring	NN	O	O
of	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B
with	NN	O	O
time	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
result	NN	O	O
in	NN	O	O
a	NN	O	O
model	NN	O	O
that	NN	O	O
allows	NN	O	O
the	NN	O	O
testing	NN	O	O
of	NN	O	O
protectors	NN	O	O
against	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
as	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
the	NN	O	O
protection	NN	O	O
provided	NN	O	O
by	NN	O	O
ICRF	NN	O	O
-	NN	O	O
187	NN	O	O
.	NN	O	O

Epinephrine	NN	O	O
dysrhythmogenicity	NN	O	O
is	NN	O	O
not	NN	O	O
enhanced	NN	O	O
by	NN	O	O
subtoxic	NN	O	O
bupivacaine	NN	O	O
in	NN	O	O
dogs	NN	O	O
.	NN	O	O

Since	NN	O	O
bupivacaine	NN	O	O
and	NN	O	O
epinephrine	NN	O	O
may	NN	O	O
both	NN	O	O
precipitate	NN	O	O
dysrhythmias	NN	O	B
,	NN	O	O
circulating	NN	O	O
bupivacaine	NN	O	O
during	NN	O	O
regional	NN	O	O
anesthesia	NN	O	O
could	NN	O	O
potentiate	NN	O	O
dysrhythmogenic	NN	O	O
effects	NN	O	O
of	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
examined	NN	O	O
whether	NN	O	O
bupivacaine	NN	O	O
alters	NN	O	O
the	NN	O	O
dysrhythmogenicity	NN	O	O
of	NN	O	O
subsequent	NN	O	O
administration	NN	O	O
of	NN	O	O
epinephrine	NN	O	O
in	NN	O	O
conscious	NN	O	O
,	NN	O	O
healthy	NN	O	O
dogs	NN	O	O
and	NN	O	O
in	NN	O	O
anesthetized	NN	O	O
dogs	NN	O	O
with	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
one	NN	O	O
conscious	NN	O	O
dogs	NN	O	O
received	NN	O	O
10	NN	O	O
micrograms	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

Seventeen	NN	O	O
animals	NN	O	O
responded	NN	O	O
with	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
(	NN	O	O
VT	NN	O	B
)	NN	O	O
within	NN	O	O
3	NN	O	O
min	NN	O	O
.	NN	O	O

After	NN	O	O
3	NN	O	O
h	NN	O	O
,	NN	O	O
these	NN	O	O
responders	NN	O	O
randomly	NN	O	O
received	NN	O	O
1	NN	O	O
or	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
bupivacaine	NN	O	O
or	NN	O	O
saline	NN	O	O
over	NN	O	O
5	NN	O	O
min	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
10	NN	O	O
micrograms	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
bupivacaine	NN	O	O
groups	NN	O	O
,	NN	O	O
epinephrine	NN	O	O
caused	NN	O	O
fewer	NN	O	O
prodysrhythmic	NN	O	O
effects	NN	O	O
than	NN	O	O
without	NN	O	O
bupivacaine	NN	O	O
.	NN	O	O

VT	NN	O	B
appeared	NN	O	O
in	NN	O	O
fewer	NN	O	O
dogs	NN	O	O
and	NN	O	O
at	NN	O	O
a	NN	O	O
later	NN	O	O
time	NN	O	O
,	NN	O	O
and	NN	O	O
there	NN	O	O
were	NN	O	O
more	NN	O	O
sinoatrial	NN	O	O
beats	NN	O	O
and	NN	O	O
less	NN	O	O
ectopies	NN	O	O
.	NN	O	O

Epinephrine	NN	O	O
shortened	NN	O	O
QT	NN	O	O
less	NN	O	O
after	NN	O	O
bupivacaine	NN	O	O
than	NN	O	O
in	NN	O	O
control	NN	O	O
animals	NN	O	O
.	NN	O	O

One	NN	O	O
day	NN	O	O
after	NN	O	O
experimental	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
,	NN	O	O
six	NN	O	O
additional	NN	O	O
halothane	NN	O	O
-	NN	O	O
anesthetized	NN	O	O
dogs	NN	O	O
received	NN	O	O
4	NN	O	O
micrograms	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
epinephrine	NN	O	O
until	NN	O	O
VT	NN	O	B
appeared	NN	O	O
.	NN	O	O

After	NN	O	O
45	NN	O	O
min	NN	O	O
,	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
bupivacaine	NN	O	O
was	NN	O	O
injected	NN	O	O
over	NN	O	O
5	NN	O	O
min	NN	O	O
,	NN	O	O
again	NN	O	O
followed	NN	O	O
by	NN	O	O
4	NN	O	O
micrograms	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

In	NN	O	O
these	NN	O	O
dogs	NN	O	O
,	NN	O	O
the	NN	O	O
prodysrhythmic	NN	O	O
response	NN	O	O
to	NN	O	O
epinephrine	NN	O	O
was	NN	O	O
also	NN	O	O
mitigated	NN	O	O
by	NN	O	O
preceding	NN	O	O
bupivacaine	NN	O	O
.	NN	O	O

Bupivacaine	NN	O	O
antagonizes	NN	O	O
epinephrine	NN	O	O
dysrhythmogenicity	NN	O	O
in	NN	O	O
conscious	NN	O	O
dogs	NN	O	O
susceptible	NN	O	O
to	NN	O	O
VT	NN	O	B
and	NN	O	O
in	NN	O	O
anesthetized	NN	O	O
dogs	NN	O	O
with	NN	O	O
spontaneous	NN	O	O
postinfarct	NN	O	O
dysrhythmias	NN	O	B
.	NN	O	O

There	NN	O	O
is	NN	O	O
no	NN	O	O
evidence	NN	O	O
that	NN	O	O
systemic	NN	O	O
subtoxic	NN	O	O
bupivacaine	NN	O	O
administration	NN	O	O
enhances	NN	O	O
the	NN	O	O
dysrhythmogenicity	NN	O	O
of	NN	O	O
subsequent	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

Milk	NN	O	B
-	NN	O	I
alkali	NN	O	I
syndrome	NN	O	I
induced	NN	O	O
by	NN	O	O
1	NN	O	O
,	NN	O	O
25	NN	O	O
(	NN	O	O
OH	NN	O	O
)	NN	O	O
2D	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
hypoparathyroidism	NN	O	B
.	NN	O	O

Milk	NN	O	B
-	NN	O	I
alkali	NN	O	I
syndrome	NN	O	I
was	NN	O	O
first	NN	O	O
described	NN	O	O
70	NN	O	O
years	NN	O	O
ago	NN	O	O
in	NN	O	O
the	NN	O	O
context	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
peptic	NN	O	B
ulcer	NN	O	I
disease	NN	O	I
with	NN	O	O
large	NN	O	O
amounts	NN	O	O
of	NN	O	O
calcium	NN	O	O
and	NN	O	O
alkali	NN	O	O
.	NN	O	O

Although	NN	O	O
with	NN	O	O
current	NN	O	O
ulcer	NN	O	B
therapy	NN	O	O
(	NN	O	O
H	NN	O	O
-	NN	O	O
2	NN	O	O
blockers	NN	O	O
,	NN	O	O
omeprazole	NN	O	O
,	NN	O	O
and	NN	O	O
sucralfate	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
milk	NN	O	B
-	NN	O	I
alkali	NN	O	I
syndrome	NN	O	I
has	NN	O	O
decreased	NN	O	O
significantly	NN	O	O
,	NN	O	O
the	NN	O	O
classic	NN	O	O
triad	NN	O	O
of	NN	O	O
hypercalcemia	NN	O	B
,	NN	O	O
alkalosis	NN	O	B
,	NN	O	O
and	NN	O	O
renal	NN	O	B
impairment	NN	O	I
remains	NN	O	O
the	NN	O	O
hallmark	NN	O	O
of	NN	O	O
the	NN	O	O
syndrome	NN	O	O
.	NN	O	O

Milk	NN	O	B
-	NN	O	I
alkali	NN	O	I
syndrome	NN	O	I
can	NN	O	O
present	NN	O	O
serious	NN	O	O
and	NN	O	O
occasionally	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
illness	NN	O	O
unless	NN	O	O
diagnosed	NN	O	O
and	NN	O	O
treated	NN	O	O
appropriately	NN	O	O
.	NN	O	O

This	NN	O	O
article	NN	O	O
presents	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
hypoparathyroidism	NN	O	B
who	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
calcium	NN	O	O
carbonate	NN	O	O
and	NN	O	O
calcitriol	NN	O	O
resulting	NN	O	O
in	NN	O	O
two	NN	O	O
admissions	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
for	NN	O	O
milk	NN	O	B
-	NN	O	I
alkali	NN	O	I
syndrome	NN	O	I
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
successfully	NN	O	O
treated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
pamidronate	NN	O	O
on	NN	O	O
his	NN	O	O
first	NN	O	O
admission	NN	O	O
and	NN	O	O
with	NN	O	O
hydrocortisone	NN	O	O
on	NN	O	O
the	NN	O	O
second	NN	O	O
.	NN	O	O

This	NN	O	O
illustrates	NN	O	O
intravenous	NN	O	O
pamidronate	NN	O	O
as	NN	O	O
a	NN	O	O
valuable	NN	O	O
therapeutic	NN	O	O
tool	NN	O	O
when	NN	O	O
milk	NN	O	B
-	NN	O	I
alkali	NN	O	I
syndrome	NN	O	I
presents	NN	O	O
as	NN	O	O
hypercalcemic	NN	O	B
emergency	NN	O	I
.	NN	O	O

Famotidine	NN	O	O
-	NN	O	O
associated	NN	O	O
delirium	NN	O	B
.	NN	O	O

A	NN	O	O
series	NN	O	O
of	NN	O	O
six	NN	O	O
cases	NN	O	O
.	NN	O	O

Famotidine	NN	O	O
is	NN	O	O
a	NN	O	O
histamine	NN	O	O
H2	NN	O	O
-	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
used	NN	O	O
in	NN	O	O
inpatient	NN	O	O
settings	NN	O	O
for	NN	O	O
prevention	NN	O	O
of	NN	O	O
stress	NN	O	O
ulcers	NN	O	B
and	NN	O	O
is	NN	O	O
showing	NN	O	O
increasing	NN	O	O
popularity	NN	O	O
because	NN	O	O
of	NN	O	O
its	NN	O	O
low	NN	O	O
cost	NN	O	O
.	NN	O	O

Although	NN	O	O
all	NN	O	O
of	NN	O	O
the	NN	O	O
currently	NN	O	O
available	NN	O	O
H2	NN	O	O
-	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
have	NN	O	O
shown	NN	O	O
the	NN	O	O
propensity	NN	O	O
to	NN	O	O
cause	NN	O	O
delirium	NN	O	B
,	NN	O	O
only	NN	O	O
two	NN	O	O
previously	NN	O	O
reported	NN	O	O
cases	NN	O	O
have	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
famotidine	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
report	NN	O	O
on	NN	O	O
six	NN	O	O
cases	NN	O	O
of	NN	O	O
famotidine	NN	O	O
-	NN	O	O
associated	NN	O	O
delirium	NN	O	B
in	NN	O	O
hospitalized	NN	O	O
patients	NN	O	O
who	NN	O	O
cleared	NN	O	O
completely	NN	O	O
upon	NN	O	O
removal	NN	O	O
of	NN	O	O
famotidine	NN	O	O
.	NN	O	O

The	NN	O	O
pharmacokinetics	NN	O	O
of	NN	O	O
famotidine	NN	O	O
are	NN	O	O
reviewed	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
its	NN	O	O
metabolism	NN	O	O
in	NN	O	O
the	NN	O	O
elderly	NN	O	O
population	NN	O	O
seen	NN	O	O
.	NN	O	O

The	NN	O	O
implications	NN	O	O
of	NN	O	O
using	NN	O	O
famotidine	NN	O	O
in	NN	O	O
elderly	NN	O	O
persons	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Encephalopathy	NN	O	B
during	NN	O	O
amitriptyline	NN	O	O
therapy	NN	O	O
:	NN	O	O
are	NN	O	O
neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
and	NN	O	O
serotonin	NN	O	B
syndrome	NN	O	I
spectrum	NN	O	O
disorders	NN	O	O
?	NN	O	O

This	NN	O	O
report	NN	O	O
describes	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
encephalopathy	NN	O	B
developed	NN	O	O
in	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
amitriptyline	NN	O	O
therapy	NN	O	O
,	NN	O	O
during	NN	O	O
a	NN	O	O
remission	NN	O	O
of	NN	O	O
unipolar	NN	O	B
depression	NN	O	I
.	NN	O	O

This	NN	O	O
patient	NN	O	O
could	NN	O	O
have	NN	O	O
been	NN	O	O
diagnosed	NN	O	O
as	NN	O	O
having	NN	O	O
either	NN	O	O
neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
(	NN	O	O
NMS	NN	O	B
)	NN	O	O
or	NN	O	O
serotonin	NN	O	B
syndrome	NN	O	I
(	NN	O	O
SS	NN	O	B
)	NN	O	O
.	NN	O	O

The	NN	O	O
major	NN	O	O
determinant	NN	O	O
of	NN	O	O
the	NN	O	O
symptoms	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
dopamine	NN	O	O
/	NN	O	O
serotonin	NN	O	O
imbalance	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O

The	NN	O	O
NMS	NN	O	B
-	NN	O	O
like	NN	O	O
encephalopathy	NN	O	B
that	NN	O	O
develops	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
antidepressants	NN	O	O
indicates	NN	O	O
that	NN	O	O
NMS	NN	O	B
and	NN	O	O
SS	NN	O	B
are	NN	O	O
spectrum	NN	O	O
disorders	NN	O	O
induced	NN	O	O
by	NN	O	O
drugs	NN	O	O
with	NN	O	O
both	NN	O	O
antidopaminergic	NN	O	O
and	NN	O	O
serotonergic	NN	O	O
effects	NN	O	O
.	NN	O	O

Genetic	NN	O	O
separation	NN	O	O
of	NN	O	O
tumor	NN	O	B
growth	NN	O	O
and	NN	O	O
hemorrhagic	NN	O	B
phenotypes	NN	O	O
in	NN	O	O
an	NN	O	O
estrogen	NN	O	O
-	NN	O	O
induced	NN	O	O
tumor	NN	O	B
.	NN	O	O

Chronic	NN	O	O
administration	NN	O	O
of	NN	O	O
estrogen	NN	O	O
to	NN	O	O
the	NN	O	O
Fischer	NN	O	O
344	NN	O	O
(	NN	O	O
F344	NN	O	O
)	NN	O	O
rat	NN	O	O
induces	NN	O	O
growth	NN	O	O
of	NN	O	O
large	NN	O	O
,	NN	O	O
hemorrhagic	NN	O	B
pituitary	NN	O	B
tumors	NN	O	I
.	NN	O	O

Ten	NN	O	O
weeks	NN	O	O
of	NN	O	O
diethylstilbestrol	NN	O	O
(	NN	O	O
DES	NN	O	O
)	NN	O	O
treatment	NN	O	O
caused	NN	O	O
female	NN	O	O
F344	NN	O	O
rat	NN	O	O
pituitaries	NN	O	O
to	NN	O	O
grow	NN	O	O
to	NN	O	O
an	NN	O	O
average	NN	O	O
of	NN	O	O
109	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
3	NN	O	O
mg	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SE	NN	O	O
)	NN	O	O
versus	NN	O	O
11	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
4	NN	O	O
mg	NN	O	O
for	NN	O	O
untreated	NN	O	O
rats	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
become	NN	O	O
highly	NN	O	O
hemorrhagic	NN	O	B
.	NN	O	O

The	NN	O	O
same	NN	O	O
DES	NN	O	O
treatment	NN	O	O
produced	NN	O	O
no	NN	O	O
significant	NN	O	O
growth	NN	O	O
(	NN	O	O
8	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
for	NN	O	O
treated	NN	O	O
females	NN	O	O
versus	NN	O	O
8	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
for	NN	O	O
untreated	NN	O	O
females	NN	O	O
)	NN	O	O
or	NN	O	O
morphological	NN	O	O
changes	NN	O	O
in	NN	O	O
Brown	NN	O	O
Norway	NN	O	O
(	NN	O	O
BN	NN	O	O
)	NN	O	O
rat	NN	O	O
pituitaries	NN	O	O
.	NN	O	O

An	NN	O	O
F1	NN	O	O
hybrid	NN	O	O
of	NN	O	O
F344	NN	O	O
and	NN	O	O
BN	NN	O	O
exhibited	NN	O	O
significant	NN	O	O
pituitary	NN	O	O
growth	NN	O	O
after	NN	O	O
10	NN	O	O
weeks	NN	O	O
of	NN	O	O
DES	NN	O	O
treatment	NN	O	O
with	NN	O	O
an	NN	O	O
average	NN	O	O
mass	NN	O	O
of	NN	O	O
26	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
mg	NN	O	O
compared	NN	O	O
with	NN	O	O
8	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
for	NN	O	O
untreated	NN	O	O
rats	NN	O	O
.	NN	O	O

Surprisingly	NN	O	O
,	NN	O	O
the	NN	O	O
F1	NN	O	O
hybrid	NN	O	O
tumors	NN	O	B
were	NN	O	O
not	NN	O	O
hemorrhagic	NN	O	B
and	NN	O	O
had	NN	O	O
hemoglobin	NN	O	O
content	NN	O	O
and	NN	O	O
outward	NN	O	O
appearance	NN	O	O
identical	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
BN	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
both	NN	O	O
growth	NN	O	O
and	NN	O	O
morphological	NN	O	O
changes	NN	O	O
is	NN	O	O
due	NN	O	O
to	NN	O	O
multiple	NN	O	O
genes	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
while	NN	O	O
DES	NN	O	O
-	NN	O	O
induced	NN	O	O
pituitary	NN	O	O
growth	NN	O	O
exhibited	NN	O	O
quantitative	NN	O	O
,	NN	O	O
additive	NN	O	O
inheritance	NN	O	O
,	NN	O	O
the	NN	O	O
hemorrhagic	NN	O	B
phenotype	NN	O	O
exhibited	NN	O	O
recessive	NN	O	O
,	NN	O	O
epistatic	NN	O	O
inheritance	NN	O	O
.	NN	O	O

Only	NN	O	O
5	NN	O	O
of	NN	O	O
the	NN	O	O
160	NN	O	O
F2	NN	O	O
pituitaries	NN	O	O
exhibited	NN	O	O
the	NN	O	O
hemorrhagic	NN	O	B
phenotype	NN	O	O
;	NN	O	O
36	NN	O	O
of	NN	O	O
the	NN	O	O
160	NN	O	O
F2	NN	O	O
pituitaries	NN	O	O
were	NN	O	O
in	NN	O	O
the	NN	O	O
F344	NN	O	O
range	NN	O	O
of	NN	O	O
mass	NN	O	O
,	NN	O	O
but	NN	O	O
31	NN	O	O
of	NN	O	O
these	NN	O	O
were	NN	O	O
not	NN	O	O
hemorrhagic	NN	O	B
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
hemorrhagic	NN	O	B
phenotype	NN	O	O
is	NN	O	O
not	NN	O	O
merely	NN	O	O
a	NN	O	O
consequence	NN	O	O
of	NN	O	O
extensive	NN	O	O
growth	NN	O	O
.	NN	O	O

The	NN	O	O
hemorrhagic	NN	O	B
F2	NN	O	O
pituitaries	NN	O	O
were	NN	O	O
all	NN	O	O
among	NN	O	O
the	NN	O	O
most	NN	O	O
massive	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
genes	NN	O	O
regulate	NN	O	O
both	NN	O	O
phenotypes	NN	O	O
.	NN	O	O

Increased	NN	O	O
expression	NN	O	O
of	NN	O	O
neuronal	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
synthase	NN	O	O
in	NN	O	O
bladder	NN	O	O
afferent	NN	O	O
pathways	NN	O	O
following	NN	O	O
chronic	NN	O	O
bladder	NN	O	B
irritation	NN	O	I
.	NN	O	O

Immunocytochemical	NN	O	O
techniques	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
examine	NN	O	O
alterations	NN	O	O
in	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
neuronal	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
synthase	NN	O	O
(	NN	O	O
NOS	NN	O	O
)	NN	O	O
in	NN	O	O
bladder	NN	O	O
pathways	NN	O	O
following	NN	O	O
acute	NN	O	O
and	NN	O	O
chronic	NN	O	O
irritation	NN	O	B
of	NN	O	I
the	NN	O	I
urinary	NN	O	I
tract	NN	O	I
of	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Chemical	NN	O	O
cystitis	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
cyclophosphamide	NN	O	O
(	NN	O	O
CYP	NN	O	O
)	NN	O	O
which	NN	O	O
is	NN	O	O
metabolized	NN	O	O
to	NN	O	O
acrolein	NN	O	O
,	NN	O	O
an	NN	O	O
irritant	NN	O	O
eliminated	NN	O	O
in	NN	O	O
the	NN	O	O
urine	NN	O	O
.	NN	O	O

Injection	NN	O	O
of	NN	O	O
CYP	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
,	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
2	NN	O	O
hours	NN	O	O
prior	NN	O	O
to	NN	O	O
perfusion	NN	O	O
(	NN	O	O
acute	NN	O	O
treatment	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
increased	NN	O	O
Fos	NN	O	O
-	NN	O	O
immunoreactivity	NN	O	O
(	NN	O	O
IR	NN	O	O
)	NN	O	O
in	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
dorsal	NN	O	O
commissure	NN	O	O
,	NN	O	O
dorsal	NN	O	O
horn	NN	O	O
,	NN	O	O
and	NN	O	O
autonomic	NN	O	O
regions	NN	O	O
of	NN	O	O
spinal	NN	O	O
segments	NN	O	O
(	NN	O	O
L1	NN	O	O
-	NN	O	O
L2	NN	O	O
and	NN	O	O
L6	NN	O	O
-	NN	O	O
S1	NN	O	O
)	NN	O	O
which	NN	O	O
receive	NN	O	O
afferent	NN	O	O
inputs	NN	O	O
from	NN	O	O
the	NN	O	O
bladder	NN	O	O
,	NN	O	O
urethra	NN	O	O
,	NN	O	O
and	NN	O	O
ureter	NN	O	O
.	NN	O	O

Fos	NN	O	O
-	NN	O	O
IR	NN	O	O
in	NN	O	O
the	NN	O	O
spinal	NN	O	O
cord	NN	O	O
was	NN	O	O
not	NN	O	O
changed	NN	O	O
in	NN	O	O
rats	NN	O	O
receiving	NN	O	O
chronic	NN	O	O
CYP	NN	O	O
treatment	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
15	NN	O	O
,	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
,	NN	O	O
every	NN	O	O
3rd	NN	O	O
day	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
control	NN	O	O
animals	NN	O	O
and	NN	O	O
in	NN	O	O
animals	NN	O	O
treated	NN	O	O
acutely	NN	O	O
with	NN	O	O
CYP	NN	O	O
,	NN	O	O
only	NN	O	O
small	NN	O	O
numbers	NN	O	O
of	NN	O	O
NOS	NN	O	O
-	NN	O	O
IR	NN	O	O
cells	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
cell	NN	O	O
profiles	NN	O	O
/	NN	O	O
sections	NN	O	O
)	NN	O	O
were	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
L6	NN	O	O
-	NN	O	O
S1	NN	O	O
dorsal	NN	O	O
root	NN	O	O
ganglia	NN	O	O
(	NN	O	O
DRG	NN	O	O
)	NN	O	O
.	NN	O	O

Chronic	NN	O	O
CYP	NN	O	O
administration	NN	O	O
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
.	NN	O	O
002	NN	O	O
)	NN	O	O
increased	NN	O	O
bladder	NN	O	O
weight	NN	O	O
by	NN	O	O
60	NN	O	O
%	NN	O	O
and	NN	O	O
increased	NN	O	O
(	NN	O	O
7	NN	O	O
-	NN	O	O
to	NN	O	O
11	NN	O	O
-	NN	O	O
fold	NN	O	O
)	NN	O	O
the	NN	O	O
numbers	NN	O	O
of	NN	O	O
NOS	NN	O	O
-	NN	O	O
immunoreactive	NN	O	O
(	NN	O	O
IR	NN	O	O
)	NN	O	O
afferent	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
L6	NN	O	O
-	NN	O	O
S1	NN	O	O
DRG	NN	O	O
.	NN	O	O

A	NN	O	O
small	NN	O	O
increase	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
fold	NN	O	O
)	NN	O	O
also	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
L1	NN	O	O
DRG	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
change	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
L2	NN	O	O
and	NN	O	O
L5	NN	O	O
DRG	NN	O	O
.	NN	O	O

Bladder	NN	O	O
afferent	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
L6	NN	O	O
-	NN	O	O
S1	NN	O	O
DRG	NN	O	O
labeled	NN	O	O
by	NN	O	O
Fluorogold	NN	O	O
(	NN	O	O
40	NN	O	O
microliters	NN	O	O
)	NN	O	O
injected	NN	O	O
into	NN	O	O
the	NN	O	O
bladder	NN	O	O
wall	NN	O	O
did	NN	O	O
not	NN	O	O
exhibit	NN	O	O
NOS	NN	O	O
-	NN	O	O
IR	NN	O	O
in	NN	O	O
control	NN	O	O
animals	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
following	NN	O	O
chronic	NN	O	O
CYP	NN	O	O
administration	NN	O	O
,	NN	O	O
a	NN	O	O
significant	NN	O	O
percentage	NN	O	O
of	NN	O	O
bladder	NN	O	O
afferent	NN	O	O
neurons	NN	O	O
were	NN	O	O
NOS	NN	O	O
-	NN	O	O
IR	NN	O	O
:	NN	O	O
L6	NN	O	O
(	NN	O	O
19	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
S1	NN	O	O
(	NN	O	O
25	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
neuronal	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
visceral	NN	O	O
sensory	NN	O	O
pathways	NN	O	O
can	NN	O	O
be	NN	O	O
upregulated	NN	O	O
by	NN	O	O
chemical	NN	O	O
irritation	NN	O	O
of	NN	O	O
afferent	NN	O	O
receptors	NN	O	O
in	NN	O	O
the	NN	O	O
urinary	NN	O	O
tract	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
that	NN	O	O
pathological	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
urinary	NN	O	O
tract	NN	O	O
can	NN	O	O
initiate	NN	O	O
chemical	NN	O	O
signals	NN	O	O
that	NN	O	O
alter	NN	O	O
the	NN	O	O
chemical	NN	O	O
properties	NN	O	O
of	NN	O	O
visceral	NN	O	O
afferent	NN	O	O
neurons	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
calcium	NN	O	O
antagonist	NN	O	O
,	NN	O	O
CD	NN	O	O
-	NN	O	O
832	NN	O	O
,	NN	O	O
on	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
in	NN	O	O
dogs	NN	O	O
with	NN	O	O
partial	NN	O	O
coronary	NN	O	B
stenosis	NN	O	I
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
CD	NN	O	O
-	NN	O	O
832	NN	O	O
on	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
ISO	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
were	NN	O	O
studied	NN	O	O
in	NN	O	O
dogs	NN	O	O
with	NN	O	O
partial	NN	O	O
coronary	NN	O	B
stenosis	NN	O	I
of	NN	O	O
the	NN	O	O
left	NN	O	O
circumflex	NN	O	O
coronary	NN	O	O
artery	NN	O	O
and	NN	O	O
findings	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
for	NN	O	O
nifedipine	NN	O	O
or	NN	O	O
diltiazem	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
coronary	NN	O	B
artery	NN	O	I
stenosis	NN	O	I
,	NN	O	O
3	NN	O	O
-	NN	O	O
min	NN	O	O
periods	NN	O	O
of	NN	O	O
intracoronary	NN	O	O
ISO	NN	O	O
infusion	NN	O	O
(	NN	O	O
10	NN	O	O
ng	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
increased	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
maximal	NN	O	O
rate	NN	O	O
of	NN	O	O
left	NN	O	O
ventricular	NN	O	O
pressure	NN	O	O
rise	NN	O	O
,	NN	O	O
which	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
percentage	NN	O	O
segmental	NN	O	O
shortening	NN	O	O
and	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
elevation	NN	O	O
of	NN	O	O
the	NN	O	O
epicardial	NN	O	O
electrocardiogram	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
control	NN	O	O
ISO	NN	O	O
infusion	NN	O	O
with	NN	O	O
stenosis	NN	O	B
was	NN	O	O
performed	NN	O	O
,	NN	O	O
equihypotensive	NN	O	O
doses	NN	O	O
of	NN	O	O
CD	NN	O	O
-	NN	O	O
832	NN	O	O
(	NN	O	O
3	NN	O	O
and	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
,	NN	O	O
nifedipine	NN	O	O
(	NN	O	O
1	NN	O	O
and	NN	O	O
3	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
9	NN	O	O
)	NN	O	O
or	NN	O	O
diltiazem	NN	O	O
(	NN	O	O
10	NN	O	O
and	NN	O	O
30	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
were	NN	O	O
infused	NN	O	O
5	NN	O	O
min	NN	O	O
before	NN	O	O
and	NN	O	O
during	NN	O	O
the	NN	O	O
second	NN	O	O
and	NN	O	O
third	NN	O	O
ISO	NN	O	O
infusion	NN	O	O
.	NN	O	O

Both	NN	O	O
CD	NN	O	O
-	NN	O	O
832	NN	O	O
and	NN	O	O
diltiazem	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
nifedipine	NN	O	O
,	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
induced	NN	O	O
by	NN	O	O
ISO	NN	O	O
infusion	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
nifedipine	NN	O	O
,	NN	O	O
CD	NN	O	O
-	NN	O	O
832	NN	O	O
(	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
prevented	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
percentage	NN	O	O
segmental	NN	O	O
shortening	NN	O	O
from	NN	O	O
32	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
%	NN	O	O
to	NN	O	O
115	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
26	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
value	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
and	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
elevation	NN	O	O
from	NN	O	O
5	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mV	NN	O	O
to	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
mV	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
at	NN	O	O
3	NN	O	O
min	NN	O	O
after	NN	O	O
ISO	NN	O	O
infusion	NN	O	O
with	NN	O	O
stenosis	NN	O	B
.	NN	O	O

Diltiazem	NN	O	O
(	NN	O	O
30	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
also	NN	O	O
prevented	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
percentage	NN	O	O
segmental	NN	O	O
shortening	NN	O	O
from	NN	O	O
34	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
14	NN	O	O
%	NN	O	O
to	NN	O	O
63	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
18	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
value	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
and	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
elevation	NN	O	O
from	NN	O	O
4	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
mV	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
mV	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
at	NN	O	O
3	NN	O	O
min	NN	O	O
after	NN	O	O
ISO	NN	O	O
infusion	NN	O	O
with	NN	O	O
stenosis	NN	O	B
.	NN	O	O

These	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
CD	NN	O	O
-	NN	O	O
832	NN	O	O
improves	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
during	NN	O	O
ISO	NN	O	O
infusion	NN	O	O
with	NN	O	O
stenosis	NN	O	B
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
negative	NN	O	O
chronotropic	NN	O	O
property	NN	O	O
of	NN	O	O
CD	NN	O	O
-	NN	O	O
832	NN	O	O
plays	NN	O	O
a	NN	O	O
major	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
CD	NN	O	O
-	NN	O	O
832	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
recombinant	NN	O	O
human	NN	O	O
insulin	NN	O	O
-	NN	O	O
like	NN	O	O
growth	NN	O	O
factor	NN	O	O
-	NN	O	O
I	NN	O	O
on	NN	O	O
chronic	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

We	NN	O	O
recently	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
recombinant	NN	O	O
hGH	NN	O	O
exacerbates	NN	O	O
renal	NN	O	O
functional	NN	O	O
and	NN	O	O
structural	NN	O	O
injury	NN	O	O
in	NN	O	O
chronic	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
(	NN	O	O
PAN	NN	O	O
)	NN	O	O
nephropathy	NN	O	B
,	NN	O	O
an	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
glomerular	NN	O	B
disease	NN	O	I
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
we	NN	O	O
examined	NN	O	O
whether	NN	O	O
recombinant	NN	O	O
human	NN	O	O
(	NN	O	O
rh	NN	O	O
)	NN	O	O
IGF	NN	O	O
-	NN	O	O
I	NN	O	O
is	NN	O	O
a	NN	O	O
safer	NN	O	O
alternative	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
growth	NN	O	B
failure	NN	O	I
in	NN	O	O
rats	NN	O	O
with	NN	O	O
chronic	NN	O	O
PAN	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

The	NN	O	O
glomerulopathy	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
seven	NN	O	O
serial	NN	O	O
injections	NN	O	O
of	NN	O	O
PAN	NN	O	O
over	NN	O	O
12	NN	O	O
wk	NN	O	O
.	NN	O	O

Experimental	NN	O	O
animals	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
received	NN	O	O
rhIGF	NN	O	O
-	NN	O	O
I	NN	O	O
,	NN	O	O
400	NN	O	O
micrograms	NN	O	O
/	NN	O	O
d	NN	O	O
,	NN	O	O
whereas	NN	O	O
control	NN	O	O
rats	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
received	NN	O	O
the	NN	O	O
vehicle	NN	O	O
.	NN	O	O

rhIGF	NN	O	O
-	NN	O	O
I	NN	O	O
improved	NN	O	O
weight	NN	O	O
gain	NN	O	O
by	NN	O	O
14	NN	O	O
%	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
without	NN	O	O
altering	NN	O	O
hematocrit	NN	O	O
or	NN	O	O
blood	NN	O	O
pressure	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
renal	NN	O	B
disease	NN	O	I
.	NN	O	O

Urinary	NN	O	O
protein	NN	O	O
excretion	NN	O	O
was	NN	O	O
unaltered	NN	O	O
by	NN	O	O
rhIGF	NN	O	O
-	NN	O	O
I	NN	O	O
treatment	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
chronic	NN	O	O
PAN	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

After	NN	O	O
12	NN	O	O
wk	NN	O	O
,	NN	O	O
the	NN	O	O
inulin	NN	O	O
clearance	NN	O	O
was	NN	O	O
higher	NN	O	O
in	NN	O	O
rhIGF	NN	O	O
-	NN	O	O
I	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
48	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
08	NN	O	O
versus	NN	O	O
0	NN	O	O
.	NN	O	O
24	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
06	NN	O	O
mL	NN	O	O
/	NN	O	O
min	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
of	NN	O	O
body	NN	O	O
weight	NN	O	O
in	NN	O	O
untreated	NN	O	O
PAN	NN	O	O
nephropathy	NN	O	B
animals	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
.	NN	O	O

The	NN	O	O
improvement	NN	O	O
in	NN	O	O
GFR	NN	O	O
was	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
enhanced	NN	O	O
glomerular	NN	O	B
hypertrophy	NN	O	I
or	NN	O	O
increased	NN	O	O
segmental	NN	O	O
glomerulosclerosis	NN	O	B
,	NN	O	O
tubulointerstitial	NN	O	B
injury	NN	O	I
,	NN	O	O
or	NN	O	O
renal	NN	O	O
cortical	NN	O	O
malondialdehyde	NN	O	O
content	NN	O	O
.	NN	O	O

In	NN	O	O
rats	NN	O	O
with	NN	O	O
PAN	NN	O	O
nephropathy	NN	O	B
,	NN	O	O
administration	NN	O	O
of	NN	O	O
rhIGF	NN	O	O
-	NN	O	O
I	NN	O	O
increased	NN	O	O
IGF	NN	O	O
-	NN	O	O
I	NN	O	O
and	NN	O	O
GH	NN	O	O
receptor	NN	O	O
gene	NN	O	O
expression	NN	O	O
,	NN	O	O
without	NN	O	O
altering	NN	O	O
the	NN	O	O
steady	NN	O	O
state	NN	O	O
level	NN	O	O
of	NN	O	O
IGF	NN	O	O
-	NN	O	O
I	NN	O	O
receptor	NN	O	O
mRNA	NN	O	O
.	NN	O	O

In	NN	O	O
normal	NN	O	O
rats	NN	O	O
with	NN	O	O
intact	NN	O	O
kidneys	NN	O	O
,	NN	O	O
rhIGF	NN	O	O
-	NN	O	O
I	NN	O	O
administration	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
weight	NN	O	O
gain	NN	O	O
,	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
proteinuria	NN	O	B
,	NN	O	O
GFR	NN	O	O
,	NN	O	O
glomerular	NN	O	O
planar	NN	O	O
area	NN	O	O
,	NN	O	O
renal	NN	O	O
cortical	NN	O	O
malondialdehyde	NN	O	O
content	NN	O	O
,	NN	O	O
or	NN	O	O
glomerular	NN	O	O
or	NN	O	O
tubulointerstitial	NN	O	B
damage	NN	O	I
,	NN	O	O
compared	NN	O	O
with	NN	O	O
untreated	NN	O	O
animals	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
.	NN	O	O

rhIGF	NN	O	O
-	NN	O	O
I	NN	O	O
treatment	NN	O	O
reduced	NN	O	O
the	NN	O	O
steady	NN	O	O
state	NN	O	O
renal	NN	O	O
IGF	NN	O	O
-	NN	O	O
I	NN	O	O
mRNA	NN	O	O
level	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
modify	NN	O	O
gene	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
IGF	NN	O	O
-	NN	O	O
I	NN	O	O
or	NN	O	O
GH	NN	O	O
receptors	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
:	NN	O	O
1	NN	O	O
)	NN	O	O
administration	NN	O	O
of	NN	O	O
rhIGF	NN	O	O
-	NN	O	O
I	NN	O	O
improves	NN	O	O
growth	NN	O	O
and	NN	O	O
GFR	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
chronic	NN	O	O
PAN	NN	O	O
nephropathy	NN	O	B
and	NN	O	O
2	NN	O	O
)	NN	O	O
unlike	NN	O	O
rhGH	NN	O	O
,	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
rhIGF	NN	O	O
-	NN	O	O
I	NN	O	O
does	NN	O	O
not	NN	O	O
worsen	NN	O	O
renal	NN	O	O
functional	NN	O	O
and	NN	O	O
structural	NN	O	O
injury	NN	O	O
in	NN	O	O
this	NN	O	O
disease	NN	O	O
model	NN	O	O
.	NN	O	O

Nefiracetam	NN	O	O
(	NN	O	O
DM	NN	O	O
-	NN	O	O
9384	NN	O	O
)	NN	O	O
reverses	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B
of	NN	O	O
a	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
response	NN	O	O
:	NN	O	O
delayed	NN	O	O
emergence	NN	O	O
of	NN	O	O
the	NN	O	O
memory	NN	O	O
retention	NN	O	O
effects	NN	O	O
.	NN	O	O

Nefiracetam	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
pyrrolidone	NN	O	O
derivative	NN	O	O
which	NN	O	O
attenuates	NN	O	O
scopolamine	NN	O	O
-	NN	O	O
induced	NN	O	O
learning	NN	O	B
and	NN	O	I
post	NN	O	I
-	NN	O	I
training	NN	O	I
consolidation	NN	O	I
deficits	NN	O	I
.	NN	O	O

Given	NN	O	O
that	NN	O	O
apomorphine	NN	O	O
inhibits	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
retention	NN	O	O
when	NN	O	O
given	NN	O	O
during	NN	O	O
training	NN	O	O
or	NN	O	O
in	NN	O	O
a	NN	O	O
defined	NN	O	O
10	NN	O	O
-	NN	O	O
12h	NN	O	O
post	NN	O	O
-	NN	O	O
training	NN	O	O
period	NN	O	O
,	NN	O	O
we	NN	O	O
evaluated	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
nefiracetam	NN	O	O
to	NN	O	O
attenuate	NN	O	O
amnesia	NN	O	B
induced	NN	O	O
by	NN	O	O
dopaminergic	NN	O	O
agonism	NN	O	O
.	NN	O	O

A	NN	O	O
step	NN	O	O
-	NN	O	O
down	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
paradigm	NN	O	O
was	NN	O	O
employed	NN	O	O
and	NN	O	O
nefiracetam	NN	O	O
(	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
apomorphine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
were	NN	O	O
given	NN	O	O
alone	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
during	NN	O	O
training	NN	O	O
and	NN	O	O
at	NN	O	O
the	NN	O	O
10	NN	O	O
-	NN	O	O
12h	NN	O	O
post	NN	O	O
-	NN	O	O
training	NN	O	O
period	NN	O	O
of	NN	O	O
consolidation	NN	O	O
.	NN	O	O

Co	NN	O	O
-	NN	O	O
administration	NN	O	O
of	NN	O	O
nefiracetam	NN	O	O
and	NN	O	O
apomorphine	NN	O	O
during	NN	O	O
training	NN	O	O
or	NN	O	O
10h	NN	O	O
thereafter	NN	O	O
produced	NN	O	O
no	NN	O	O
significant	NN	O	O
anti	NN	O	O
-	NN	O	O
amnesic	NN	O	O
effect	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
administration	NN	O	O
of	NN	O	O
nefiracetam	NN	O	O
during	NN	O	O
training	NN	O	O
completely	NN	O	O
reversed	NN	O	O
the	NN	O	O
amnesia	NN	O	B
induced	NN	O	O
by	NN	O	O
apomorphine	NN	O	O
at	NN	O	O
the	NN	O	O
10h	NN	O	O
post	NN	O	O
-	NN	O	O
training	NN	O	O
time	NN	O	O
and	NN	O	O
the	NN	O	O
converse	NN	O	O
was	NN	O	O
also	NN	O	O
true	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
were	NN	O	O
not	NN	O	O
mediated	NN	O	O
by	NN	O	O
a	NN	O	O
dopaminergic	NN	O	O
mechanism	NN	O	O
as	NN	O	O
nefiracetam	NN	O	O
,	NN	O	O
at	NN	O	O
millimolar	NN	O	O
concentrations	NN	O	O
,	NN	O	O
failed	NN	O	O
to	NN	O	O
displace	NN	O	O
either	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
SCH	NN	O	O
23390	NN	O	O
or	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
spiperone	NN	O	O
binding	NN	O	O
from	NN	O	O
D1	NN	O	O
or	NN	O	O
D2	NN	O	O
dopamine	NN	O	O
receptor	NN	O	O
subtypes	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
nefiracetam	NN	O	O
augments	NN	O	O
molecular	NN	O	O
processes	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
stages	NN	O	O
of	NN	O	O
events	NN	O	O
which	NN	O	O
ultimately	NN	O	O
lead	NN	O	O
to	NN	O	O
consolidation	NN	O	O
of	NN	O	O
memory	NN	O	O
.	NN	O	O

Phenytoin	NN	O	O
encephalopathy	NN	O	B
as	NN	O	O
probable	NN	O	O
idiosyncratic	NN	O	O
reaction	NN	O	O
:	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
phenytoin	NN	O	O
(	NN	O	O
DPH	NN	O	O
)	NN	O	O
encephalopathy	NN	O	B
with	NN	O	O
increasing	NN	O	O
seizures	NN	O	B
and	NN	O	O
EEG	NN	O	O
and	NN	O	O
mental	NN	O	O
changes	NN	O	O
is	NN	O	O
described	NN	O	O
.	NN	O	O

Despite	NN	O	O
adequate	NN	O	O
oral	NN	O	O
dosage	NN	O	O
of	NN	O	O
DPH	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
daily	NN	O	O
)	NN	O	O
the	NN	O	O
plasma	NN	O	O
level	NN	O	O
was	NN	O	O
very	NN	O	O
low	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
8	NN	O	O
microgramg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
encephalopathy	NN	O	B
was	NN	O	O
probably	NN	O	O
an	NN	O	O
idiosyncratic	NN	O	O
and	NN	O	O
not	NN	O	O
toxic	NN	O	O
or	NN	O	O
allergic	NN	O	O
reaction	NN	O	O
.	NN	O	O

In	NN	O	O
fact	NN	O	O
the	NN	O	O
concentration	NN	O	O
of	NN	O	O
free	NN	O	O
DPH	NN	O	O
was	NN	O	O
normal	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
presented	NN	O	O
a	NN	O	O
retarded	NN	O	O
morbilliform	NN	O	O
rash	NN	O	B
during	NN	O	O
DPH	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
protidogram	NN	O	O
was	NN	O	O
normal	NN	O	O
,	NN	O	O
and	NN	O	O
an	NN	O	O
intradermic	NN	O	O
DPH	NN	O	O
injection	NN	O	O
had	NN	O	O
no	NN	O	O
local	NN	O	O
effect	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
conclude	NN	O	O
that	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
starting	NN	O	O
DPH	NN	O	O
treatment	NN	O	O
an	NN	O	O
unexpected	NN	O	O
increase	NN	O	O
in	NN	O	O
seizures	NN	O	B
,	NN	O	O
with	NN	O	O
EEG	NN	O	O
and	NN	O	O
mental	NN	O	O
changes	NN	O	O
occurring	NN	O	O
simultaneously	NN	O	O
,	NN	O	O
should	NN	O	O
alert	NN	O	O
the	NN	O	O
physician	NN	O	O
to	NN	O	O
the	NN	O	O
possible	NN	O	O
need	NN	O	O
for	NN	O	O
eliminating	NN	O	O
DPH	NN	O	O
from	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
regimen	NN	O	O
,	NN	O	O
even	NN	O	O
if	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
are	NN	O	O
low	NN	O	O
.	NN	O	O

Prevention	NN	O	O
and	NN	O	O
treatment	NN	O	O
of	NN	O	O
endometrial	NN	O	B
disease	NN	O	I
in	NN	O	O
climacteric	NN	O	O
women	NN	O	O
receiving	NN	O	O
oestrogen	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
treatment	NN	O	O
regimens	NN	O	O
are	NN	O	O
described	NN	O	O
in	NN	O	O
74	NN	O	O
patients	NN	O	O
with	NN	O	O
endometrial	NN	O	B
disease	NN	O	I
among	NN	O	O
850	NN	O	O
climacteric	NN	O	O
women	NN	O	O
receiving	NN	O	O
oestrogen	NN	O	O
therapy	NN	O	O
.	NN	O	O

Cystic	NN	O	O
hyperplasia	NN	O	B
was	NN	O	O
associated	NN	O	O
with	NN	O	O
unopposed	NN	O	O
oestrogen	NN	O	O
therapy	NN	O	O
without	NN	O	O
progestagen	NN	O	O
.	NN	O	O

Two	NN	O	O
courses	NN	O	O
of	NN	O	O
21	NN	O	O
days	NN	O	O
of	NN	O	O
5	NN	O	O
mg	NN	O	O
norethisterone	NN	O	O
daily	NN	O	O
caused	NN	O	O
reversion	NN	O	O
to	NN	O	O
normal	NN	O	O
in	NN	O	O
all	NN	O	O
57	NN	O	O
cases	NN	O	O
of	NN	O	O
cystic	NN	O	O
hyperplasia	NN	O	B
and	NN	O	O
6	NN	O	O
of	NN	O	O
the	NN	O	O
8	NN	O	O
cases	NN	O	O
of	NN	O	O
atypical	NN	O	O
hyperplasia	NN	O	B
.	NN	O	O

4	NN	O	O
cases	NN	O	O
of	NN	O	O
endometrial	NN	O	B
carcinoma	NN	O	I
referred	NN	O	O
from	NN	O	O
elsewhere	NN	O	O
demonstrated	NN	O	O
the	NN	O	O
problems	NN	O	O
of	NN	O	O
inappropriate	NN	O	O
and	NN	O	O
unsupervised	NN	O	O
unopposed	NN	O	O
oestrogen	NN	O	O
therapy	NN	O	O
and	NN	O	O
the	NN	O	O
difficulty	NN	O	O
in	NN	O	O
distinguishing	NN	O	O
severe	NN	O	O
hyperplasia	NN	O	B
from	NN	O	O
malignancy	NN	O	B
.	NN	O	O

Cyclical	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
oestrogen	NN	O	O
therapy	NN	O	O
with	NN	O	O
7	NN	O	O
-	NN	O	O
-	NN	O	O
13	NN	O	O
days	NN	O	O
of	NN	O	O
progestagen	NN	O	O
does	NN	O	O
not	NN	O	O
seem	NN	O	O
to	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
endometrial	NN	O	B
hyperplasia	NN	O	I
or	NN	O	O
carcinoma	NN	O	B
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
exercise	NN	O	O
on	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
exercise	NN	O	O
on	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
was	NN	O	O
studied	NN	O	O
in	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

Ninety	NN	O	O
-	NN	O	O
three	NN	O	O
rats	NN	O	O
were	NN	O	O
randomly	NN	O	O
divided	NN	O	O
into	NN	O	O
three	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
exercise	NN	O	O
-	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
E	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
and	NN	O	O
exercise	NN	O	O
control	NN	O	O
(	NN	O	O
EC	NN	O	O
)	NN	O	O
groups	NN	O	O
exercised	NN	O	O
daily	NN	O	O
for	NN	O	O
thirty	NN	O	O
days	NN	O	O
on	NN	O	O
a	NN	O	O
treadmill	NN	O	O
at	NN	O	O
1	NN	O	O
mph	NN	O	O
,	NN	O	O
2	NN	O	O
%	NN	O	O
grade	NN	O	O
while	NN	O	O
animals	NN	O	O
of	NN	O	O
the	NN	O	O
sedentary	NN	O	O
-	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
S	NN	O	O
-	NN	O	O
I	NN	O	O
)	NN	O	O
group	NN	O	O
remained	NN	O	O
sedentary	NN	O	O
.	NN	O	O

Eight	NN	O	O
animals	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
the	NN	O	O
sedentary	NN	O	O
control	NN	O	O
(	NN	O	O
SC	NN	O	O
)	NN	O	O
group	NN	O	O
which	NN	O	O
remained	NN	O	O
sedentary	NN	O	O
throughout	NN	O	O
the	NN	O	O
experimental	NN	O	O
period	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
eight	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
final	NN	O	O
exercise	NN	O	O
period	NN	O	O
,	NN	O	O
S	NN	O	O
-	NN	O	O
I	NN	O	O
and	NN	O	O
E	NN	O	O
-	NN	O	O
I	NN	O	O
animals	NN	O	O
received	NN	O	O
a	NN	O	O
single	NN	O	O
subcutaneous	NN	O	O
injection	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
.	NN	O	O

Animals	NN	O	O
of	NN	O	O
the	NN	O	O
S	NN	O	O
-	NN	O	O
I	NN	O	O
group	NN	O	O
exhibited	NN	O	O
significantly	NN	O	O
(	NN	O	O
Pp	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
greater	NN	O	O
mortality	NN	O	O
from	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
than	NN	O	O
animals	NN	O	O
of	NN	O	O
the	NN	O	O
E	NN	O	O
-	NN	O	O
I	NN	O	O
group	NN	O	O
.	NN	O	O

Serum	NN	O	O
CPK	NN	O	O
activity	NN	O	O
for	NN	O	O
E	NN	O	O
-	NN	O	O
I	NN	O	O
animals	NN	O	O
was	NN	O	O
significantly	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
greater	NN	O	O
than	NN	O	O
for	NN	O	O
animals	NN	O	O
in	NN	O	O
the	NN	O	O
S	NN	O	O
-	NN	O	O
I	NN	O	O
and	NN	O	O
EC	NN	O	O
groups	NN	O	O
twenty	NN	O	O
hours	NN	O	O
following	NN	O	O
isoproterenol	NN	O	O
injection	NN	O	O
.	NN	O	O

No	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
observed	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
isoproterenol	NN	O	O
treated	NN	O	O
groups	NN	O	O
for	NN	O	O
severity	NN	O	O
of	NN	O	O
the	NN	O	O
induced	NN	O	O
lesions	NN	O	O
,	NN	O	O
changes	NN	O	O
in	NN	O	O
heart	NN	O	O
weight	NN	O	O
,	NN	O	O
or	NN	O	O
heart	NN	O	O
weight	NN	O	O
to	NN	O	O
body	NN	O	O
weight	NN	O	O
ratios	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicated	NN	O	O
that	NN	O	O
exercise	NN	O	O
reduced	NN	O	O
the	NN	O	O
mortality	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
large	NN	O	O
dosages	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
but	NN	O	O
had	NN	O	O
little	NN	O	O
on	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
the	NN	O	O
infarction	NN	O	B
.	NN	O	O

Human	NN	O	O
corticotropin	NN	O	O
-	NN	O	O
releasing	NN	O	O
hormone	NN	O	O
and	NN	O	O
thyrotropin	NN	O	O
-	NN	O	O
releasing	NN	O	O
hormone	NN	O	O
modulate	NN	O	O
the	NN	O	O
hypercapnic	NN	O	B
ventilatory	NN	O	O
response	NN	O	O
in	NN	O	O
humans	NN	O	O
.	NN	O	O

Human	NN	O	O
corticotropin	NN	O	O
-	NN	O	O
releasing	NN	O	O
hormone	NN	O	O
(	NN	O	O
hCRH	NN	O	O
)	NN	O	O
and	NN	O	O
thyrotropin	NN	O	O
-	NN	O	O
releasing	NN	O	O
hormone	NN	O	O
(	NN	O	O
TRH	NN	O	O
)	NN	O	O
are	NN	O	O
known	NN	O	O
to	NN	O	O
stimulate	NN	O	O
ventilation	NN	O	O
after	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
administration	NN	O	O
in	NN	O	O
humans	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
single	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
we	NN	O	O
aimed	NN	O	O
to	NN	O	O
clarify	NN	O	O
if	NN	O	O
both	NN	O	O
peptides	NN	O	O
act	NN	O	O
by	NN	O	O
altering	NN	O	O
central	NN	O	O
chemosensitivity	NN	O	O
.	NN	O	O

Two	NN	O	O
subsequent	NN	O	O
CO2	NN	O	O
-	NN	O	O
rebreathing	NN	O	O
tests	NN	O	O
were	NN	O	O
performed	NN	O	O
in	NN	O	O
healthy	NN	O	O
young	NN	O	O
volunteers	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
first	NN	O	O
test	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
NaCl	NN	O	O
was	NN	O	O
given	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
;	NN	O	O
during	NN	O	O
the	NN	O	O
second	NN	O	O
test	NN	O	O
200	NN	O	O
micrograms	NN	O	O
of	NN	O	O
hCRH	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
)	NN	O	O
or	NN	O	O
400	NN	O	O
micrograms	NN	O	O
of	NN	O	O
TRH	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
Nine	NN	O	O
subjects	NN	O	O
received	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
NaCl	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
during	NN	O	O
both	NN	O	O
rebreathing	NN	O	O
manoeuvres	NN	O	O
.	NN	O	O

The	NN	O	O
CO2	NN	O	O
-	NN	O	O
response	NN	O	O
curves	NN	O	O
for	NN	O	O
the	NN	O	O
two	NN	O	O
tests	NN	O	O
were	NN	O	O
compared	NN	O	O
within	NN	O	O
the	NN	O	O
same	NN	O	O
subject	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
hCRH	NN	O	O
group	NN	O	O
a	NN	O	O
marked	NN	O	O
parallel	NN	O	O
shift	NN	O	O
of	NN	O	O
the	NN	O	O
CO2	NN	O	O
-	NN	O	O
response	NN	O	O
curve	NN	O	O
to	NN	O	O
the	NN	O	O
left	NN	O	O
was	NN	O	O
observed	NN	O	O
after	NN	O	O
hCRH	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
same	NN	O	O
effect	NN	O	O
occurred	NN	O	O
following	NN	O	O
TRH	NN	O	O
but	NN	O	O
was	NN	O	O
less	NN	O	O
striking	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

hCRH	NN	O	O
and	NN	O	O
TRH	NN	O	O
caused	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
CO2	NN	O	O
threshold	NN	O	O
.	NN	O	O

The	NN	O	O
CO2	NN	O	O
-	NN	O	O
response	NN	O	O
curves	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
were	NN	O	O
nearly	NN	O	O
identical	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
an	NN	O	O
additive	NN	O	O
effect	NN	O	O
of	NN	O	O
both	NN	O	O
releasing	NN	O	O
hormones	NN	O	O
on	NN	O	O
the	NN	O	O
hypercapnic	NN	O	B
ventilatory	NN	O	O
response	NN	O	O
in	NN	O	O
humans	NN	O	O
,	NN	O	O
presumably	NN	O	O
independent	NN	O	O
of	NN	O	O
central	NN	O	O
chemosensitivity	NN	O	O
.	NN	O	O

Lamivudine	NN	O	O
is	NN	O	O
effective	NN	O	O
in	NN	O	O
suppressing	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
DNA	NN	O	O
in	NN	O	O
Chinese	NN	O	O
hepatitis	NN	O	O
B	NN	O	O
surface	NN	O	O
antigen	NN	O	O
carriers	NN	O	O
:	NN	O	O
a	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

Lamivudine	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
2	NN	O	O
'	NN	O	O
,	NN	O	O
3	NN	O	O
'	NN	O	O
-	NN	O	O
dideoxy	NN	O	O
cytosine	NN	O	O
analogue	NN	O	O
that	NN	O	O
has	NN	O	O
potent	NN	O	O
inhibitory	NN	O	O
effects	NN	O	O
on	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
replication	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

We	NN	O	O
performed	NN	O	O
a	NN	O	O
single	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
study	NN	O	O
to	NN	O	O
assess	NN	O	O
its	NN	O	O
effectiveness	NN	O	O
and	NN	O	O
safety	NN	O	O
in	NN	O	O
Chinese	NN	O	O
hepatitis	NN	O	O
B	NN	O	O
surface	NN	O	O
antigen	NN	O	O
(	NN	O	O
HBsAg	NN	O	O
)	NN	O	O
carriers	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
two	NN	O	O
Chinese	NN	O	O
HBsAg	NN	O	O
carriers	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
placebo	NN	O	O
(	NN	O	O
6	NN	O	O
patients	NN	O	O
)	NN	O	O
or	NN	O	O
lamivudine	NN	O	O
orally	NN	O	O
in	NN	O	O
dosages	NN	O	O
of	NN	O	O
25	NN	O	O
mg	NN	O	O
,	NN	O	O
100	NN	O	O
mg	NN	O	O
,	NN	O	O
or	NN	O	O
300	NN	O	O
mg	NN	O	O
daily	NN	O	O
(	NN	O	O
12	NN	O	O
patients	NN	O	O
for	NN	O	O
each	NN	O	O
dosage	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
drug	NN	O	O
was	NN	O	O
given	NN	O	O
for	NN	O	O
4	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
were	NN	O	O
closely	NN	O	O
monitored	NN	O	O
clinically	NN	O	O
,	NN	O	O
biochemically	NN	O	O
,	NN	O	O
and	NN	O	O
serologically	NN	O	O
up	NN	O	O
to	NN	O	O
4	NN	O	O
weeks	NN	O	O
after	NN	O	O
drug	NN	O	O
treatment	NN	O	O
.	NN	O	O

All	NN	O	O
36	NN	O	O
patients	NN	O	O
receiving	NN	O	O
lamivudine	NN	O	O
had	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
(	NN	O	O
HBV	NN	O	O
)	NN	O	O
DNA	NN	O	O
values	NN	O	O
of	NN	O	O
>	NN	O	O
90	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
001	NN	O	O
compared	NN	O	O
with	NN	O	O
placebo	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
25	NN	O	O
mg	NN	O	O
of	NN	O	O
lamivudine	NN	O	O
was	NN	O	O
slightly	NN	O	O
less	NN	O	O
effective	NN	O	O
than	NN	O	O
100	NN	O	O
mg	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
011	NN	O	O
)	NN	O	O
and	NN	O	O
300	NN	O	O
mg	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
,	NN	O	O
it	NN	O	O
still	NN	O	O
induced	NN	O	O
94	NN	O	O
%	NN	O	O
suppression	NN	O	O
of	NN	O	O
HBV	NN	O	O
DNA	NN	O	O
after	NN	O	O
the	NN	O	O
fourth	NN	O	O
week	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

HBV	NN	O	O
DNA	NN	O	O
values	NN	O	O
returned	NN	O	O
to	NN	O	O
pretreatment	NN	O	O
levels	NN	O	O
within	NN	O	O
4	NN	O	O
weeks	NN	O	O
of	NN	O	O
cessation	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
e	NN	O	O
antigen	NN	O	O
status	NN	O	O
or	NN	O	O
in	NN	O	O
aminotransferase	NN	O	O
levels	NN	O	O
.	NN	O	O

No	NN	O	O
serious	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
a	NN	O	O
4	NN	O	O
-	NN	O	O
week	NN	O	O
course	NN	O	O
of	NN	O	O
lamivudine	NN	O	O
was	NN	O	O
safe	NN	O	O
and	NN	O	O
effective	NN	O	O
in	NN	O	O
suppression	NN	O	O
of	NN	O	O
HBV	NN	O	O
DNA	NN	O	O
in	NN	O	O
Chinese	NN	O	O
HBsAg	NN	O	O
carriers	NN	O	O
.	NN	O	O

The	NN	O	O
suppression	NN	O	O
was	NN	O	O
>	NN	O	O
90	NN	O	O
%	NN	O	O
but	NN	O	O
reversible	NN	O	O
.	NN	O	O

Studies	NN	O	O
with	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
lamivudine	NN	O	O
administration	NN	O	O
should	NN	O	O
be	NN	O	O
performed	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
prolonged	NN	O	O
suppression	NN	O	O
of	NN	O	O
HBV	NN	O	O
DNA	NN	O	O
can	NN	O	O
be	NN	O	O
achieved	NN	O	O
.	NN	O	O

Population	NN	O	O
-	NN	O	O
based	NN	O	O
study	NN	O	O
of	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
associated	NN	O	O
with	NN	O	O
various	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Four	NN	O	O
studies	NN	O	O
published	NN	O	O
since	NN	O	O
December	NN	O	O
,	NN	O	O
1995	NN	O	O
,	NN	O	O
reported	NN	O	O
that	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
(	NN	O	O
VTE	NN	O	B
)	NN	O	O
was	NN	O	O
higher	NN	O	O
in	NN	O	O
women	NN	O	O
who	NN	O	O
used	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
(	NN	O	O
OCs	NN	O	O
)	NN	O	O
containing	NN	O	O
the	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
progestagens	NN	O	O
gestodene	NN	O	O
or	NN	O	O
desogestrel	NN	O	O
than	NN	O	O
in	NN	O	O
users	NN	O	O
of	NN	O	O
OCs	NN	O	O
containing	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
progestagens	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
confounding	NN	O	O
and	NN	O	O
bias	NN	O	O
in	NN	O	O
the	NN	O	O
design	NN	O	O
of	NN	O	O
these	NN	O	O
studies	NN	O	O
may	NN	O	O
have	NN	O	O
affected	NN	O	O
the	NN	O	O
findings	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
our	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
re	NN	O	O
-	NN	O	O
examine	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
risk	NN	O	O
of	NN	O	O
VTE	NN	O	B
and	NN	O	O
OC	NN	O	O
use	NN	O	O
with	NN	O	O
a	NN	O	O
different	NN	O	O
study	NN	O	O
design	NN	O	O
and	NN	O	O
analysis	NN	O	O
to	NN	O	O
avoid	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
bias	NN	O	O
and	NN	O	O
confounding	NN	O	O
of	NN	O	O
the	NN	O	O
earlier	NN	O	O
studies	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
used	NN	O	O
computer	NN	O	O
records	NN	O	O
of	NN	O	O
patients	NN	O	O
from	NN	O	O
143	NN	O	O
general	NN	O	O
practices	NN	O	O
in	NN	O	O
the	NN	O	O
UK	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
was	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
medical	NN	O	O
records	NN	O	O
of	NN	O	O
about	NN	O	O
540	NN	O	O
,	NN	O	O
000	NN	O	O
women	NN	O	O
born	NN	O	O
between	NN	O	O
1941	NN	O	O
and	NN	O	O
1981	NN	O	O
.	NN	O	O

All	NN	O	O
women	NN	O	O
who	NN	O	O
had	NN	O	O
a	NN	O	O
recorded	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
deep	NN	O	B
-	NN	O	I
vein	NN	O	I
thrombosis	NN	O	I
,	NN	O	O
venous	NN	O	B
thrombosis	NN	O	I
not	NN	O	O
otherwise	NN	O	O
specified	NN	O	O
,	NN	O	O
or	NN	O	O
pulmonary	NN	O	O
embolus	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
period	NN	O	O
,	NN	O	O
and	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
treated	NN	O	O
with	NN	O	O
an	NN	O	O
anticoagulant	NN	O	O
were	NN	O	O
identified	NN	O	O
as	NN	O	O
potential	NN	O	O
cases	NN	O	O
of	NN	O	O
VTE	NN	O	B
.	NN	O	O

We	NN	O	O
did	NN	O	O
a	NN	O	O
cohort	NN	O	O
analysis	NN	O	O
to	NN	O	O
estimate	NN	O	O
and	NN	O	O
compare	NN	O	O
incidence	NN	O	O
of	NN	O	O
VTE	NN	O	B
in	NN	O	O
users	NN	O	O
of	NN	O	O
the	NN	O	O
main	NN	O	O
OC	NN	O	O
preparations	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
nested	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
to	NN	O	O
calculate	NN	O	O
the	NN	O	O
odds	NN	O	O
ratios	NN	O	O
of	NN	O	O
VTE	NN	O	B
associated	NN	O	O
with	NN	O	O
use	NN	O	O
of	NN	O	O
different	NN	O	O
types	NN	O	O
of	NN	O	O
OC	NN	O	O
,	NN	O	O
after	NN	O	O
adjustment	NN	O	O
for	NN	O	O
potential	NN	O	O
confounding	NN	O	O
factors	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
matched	NN	O	O
cases	NN	O	O
to	NN	O	O
controls	NN	O	O
by	NN	O	O
exact	NN	O	O
year	NN	O	O
of	NN	O	O
birth	NN	O	O
,	NN	O	O
practice	NN	O	O
,	NN	O	O
and	NN	O	O
current	NN	O	O
use	NN	O	O
of	NN	O	O
OCs	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
a	NN	O	O
multiple	NN	O	O
logistic	NN	O	O
regression	NN	O	O
model	NN	O	O
that	NN	O	O
included	NN	O	O
body	NN	O	O
-	NN	O	O
mass	NN	O	O
index	NN	O	O
,	NN	O	O
number	NN	O	O
of	NN	O	O
cycles	NN	O	O
,	NN	O	O
change	NN	O	O
in	NN	O	O
type	NN	O	O
of	NN	O	O
OC	NN	O	O
prescribed	NN	O	O
within	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
the	NN	O	O
event	NN	O	O
,	NN	O	O
previous	NN	O	O
pregnancy	NN	O	O
,	NN	O	O
and	NN	O	O
concurrent	NN	O	O
disease	NN	O	O
.	NN	O	O

FINDINGS	NN	O	O
:	NN	O	O
85	NN	O	O
women	NN	O	O
met	NN	O	O
the	NN	O	O
inclusion	NN	O	O
criteria	NN	O	O
for	NN	O	O
VTE	NN	O	B
,	NN	O	O
two	NN	O	O
of	NN	O	O
whom	NN	O	O
were	NN	O	O
users	NN	O	O
of	NN	O	O
progestagen	NN	O	O
-	NN	O	O
only	NN	O	O
OCs	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
83	NN	O	O
cases	NN	O	O
of	NN	O	O
VTE	NN	O	B
associated	NN	O	O
with	NN	O	O
use	NN	O	O
of	NN	O	O
combined	NN	O	O
OCs	NN	O	O
,	NN	O	O
43	NN	O	O
were	NN	O	O
recorded	NN	O	O
as	NN	O	O
deep	NN	O	B
-	NN	O	I
vein	NN	O	I
thrombosis	NN	O	I
,	NN	O	O
35	NN	O	O
as	NN	O	O
pulmonary	NN	O	O
thrombosis	NN	O	B
,	NN	O	O
and	NN	O	O
five	NN	O	O
as	NN	O	O
venous	NN	O	B
thrombosis	NN	O	I
not	NN	O	O
otherwise	NN	O	O
specified	NN	O	O
.	NN	O	O

The	NN	O	O
crude	NN	O	O
rate	NN	O	O
of	NN	O	O
VTE	NN	O	B
per	NN	O	O
10	NN	O	O
,	NN	O	O
000	NN	O	O
woman	NN	O	O
-	NN	O	O
years	NN	O	O
was	NN	O	O
4	NN	O	O
.	NN	O	O
10	NN	O	O
in	NN	O	O
current	NN	O	O
users	NN	O	O
of	NN	O	O
any	NN	O	O
OC	NN	O	O
,	NN	O	O
3	NN	O	O
.	NN	O	O
10	NN	O	O
in	NN	O	O
users	NN	O	O
of	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
OCs	NN	O	O
,	NN	O	O
and	NN	O	O
4	NN	O	O
.	NN	O	O
96	NN	O	O
in	NN	O	O
users	NN	O	O
of	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
preparations	NN	O	O
.	NN	O	O

After	NN	O	O
adjustment	NN	O	O
for	NN	O	O
age	NN	O	O
,	NN	O	O
the	NN	O	O
rate	NN	O	O
ratio	NN	O	O
of	NN	O	O
VTE	NN	O	B
in	NN	O	O
users	NN	O	O
of	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
relative	NN	O	O
to	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
OCs	NN	O	O
was	NN	O	O
1	NN	O	O
.	NN	O	O
68	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1	NN	O	O
.	NN	O	O
04	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
75	NN	O	O
)	NN	O	O
.	NN	O	O

Logistic	NN	O	O
regression	NN	O	O
showed	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
VTE	NN	O	B
between	NN	O	O
users	NN	O	O
of	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
and	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
OCs	NN	O	O
.	NN	O	O

Among	NN	O	O
users	NN	O	O
of	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
progestagens	NN	O	O
,	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
VTE	NN	O	B
was	NN	O	O
higher	NN	O	O
in	NN	O	O
users	NN	O	O
of	NN	O	O
desogestrel	NN	O	O
with	NN	O	O
20	NN	O	O
g	NN	O	O
ethinyloestradiol	NN	O	O
than	NN	O	O
in	NN	O	O
users	NN	O	O
of	NN	O	O
gestodene	NN	O	O
or	NN	O	O
desogestrel	NN	O	O
with	NN	O	O
30	NN	O	O
g	NN	O	O
ethinyloestradiol	NN	O	O
.	NN	O	O

With	NN	O	O
all	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
OCs	NN	O	O
as	NN	O	O
the	NN	O	O
reference	NN	O	O
,	NN	O	O
the	NN	O	O
odds	NN	O	O
ratios	NN	O	O
for	NN	O	O
VTE	NN	O	B
were	NN	O	O
3	NN	O	O
.	NN	O	O
49	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
21	NN	O	O
-	NN	O	O
10	NN	O	O
.	NN	O	O
12	NN	O	O
)	NN	O	O
for	NN	O	O
desogestrel	NN	O	O
plus	NN	O	O
20	NN	O	O
g	NN	O	O
ethinyloestradiol	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
18	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
66	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
17	NN	O	O
)	NN	O	O
for	NN	O	O
the	NN	O	O
other	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
progestagens	NN	O	O
.	NN	O	O

INTERPRETATION	NN	O	O
:	NN	O	O
The	NN	O	O
previously	NN	O	O
reported	NN	O	O
increase	NN	O	O
in	NN	O	O
odds	NN	O	O
ratio	NN	O	O
associated	NN	O	O
with	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
OCs	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
products	NN	O	O
is	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
been	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
residual	NN	O	O
confounding	NN	O	O
by	NN	O	O
age	NN	O	O
.	NN	O	O

The	NN	O	O
increased	NN	O	O
odds	NN	O	O
ratio	NN	O	O
associated	NN	O	O
with	NN	O	O
products	NN	O	O
containing	NN	O	O
20	NN	O	O
micrograms	NN	O	O
ethinyloestradiol	NN	O	O
and	NN	O	O
desogestrel	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
30	NN	O	O
micrograms	NN	O	O
product	NN	O	O
is	NN	O	O
biologically	NN	O	O
implausible	NN	O	O
,	NN	O	O
and	NN	O	O
is	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
preferential	NN	O	O
prescribing	NN	O	O
and	NN	O	O
,	NN	O	O
thus	NN	O	O
,	NN	O	O
confounding	NN	O	O
.	NN	O	O

MK	NN	O	O
-	NN	O	O
801	NN	O	O
augments	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
electrographic	NN	O	O
seizure	NN	O	B
but	NN	O	O
protects	NN	O	O
against	NN	O	O
brain	NN	O	B
damage	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

1	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
examined	NN	O	O
the	NN	O	O
anticonvulsant	NN	O	O
effects	NN	O	O
of	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
on	NN	O	O
the	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizure	NN	O	B
model	NN	O	O
.	NN	O	O

Intraperitoneal	NN	O	O
injection	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
(	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
induced	NN	O	O
tonic	NN	O	B
and	NN	O	I
clonic	NN	O	I
seizure	NN	O	I
.	NN	O	O

Scopolamine	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
pentobarbital	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
prevented	NN	O	O
development	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
behavioral	NN	O	O
seizure	NN	O	B
but	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
.	NN	O	O

2	NN	O	O
.	NN	O	O

An	NN	O	O
electrical	NN	O	O
seizure	NN	O	B
measured	NN	O	O
with	NN	O	O
hippocampal	NN	O	O
EEG	NN	O	O
appeared	NN	O	O
in	NN	O	O
the	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
.	NN	O	O

Scopolamine	NN	O	O
and	NN	O	O
pentobarbital	NN	O	O
blocked	NN	O	O
the	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
electrographic	NN	O	O
seizure	NN	O	B
,	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
treatment	NN	O	O
augmented	NN	O	O
the	NN	O	O
electrographic	NN	O	O
seizure	NN	O	B
induced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
.	NN	O	O

3	NN	O	O
.	NN	O	O

Brain	NN	O	B
damage	NN	O	I
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
examining	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
microscopically	NN	O	O
.	NN	O	O

Pilocarpine	NN	O	O
produced	NN	O	O
neuronal	NN	O	B
death	NN	O	I
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
,	NN	O	O
which	NN	O	O
showed	NN	O	O
pyknotic	NN	O	O
changes	NN	O	O
.	NN	O	O

Pentobarbital	NN	O	O
,	NN	O	O
scopolamine	NN	O	O
and	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
protected	NN	O	O
the	NN	O	O
brain	NN	O	B
damage	NN	O	I
by	NN	O	O
pilocarpine	NN	O	O
,	NN	O	O
though	NN	O	O
in	NN	O	O
the	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
pyramidal	NN	O	O
cells	NN	O	O
of	NN	O	O
hippocampus	NN	O	O
appeared	NN	O	O
darker	NN	O	O
than	NN	O	O
normal	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
treatments	NN	O	O
,	NN	O	O
granule	NN	O	O
cells	NN	O	O
of	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
were	NN	O	O
not	NN	O	O
affected	NN	O	O
.	NN	O	O

4	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
induced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
is	NN	O	O
initiated	NN	O	O
by	NN	O	O
cholinergic	NN	O	O
overstimulation	NN	O	O
and	NN	O	O
propagated	NN	O	O
by	NN	O	O
glutamatergic	NN	O	O
transmission	NN	O	O
,	NN	O	O
the	NN	O	O
elevation	NN	O	O
of	NN	O	O
which	NN	O	O
may	NN	O	O
cause	NN	O	O
brain	NN	O	B
damage	NN	O	I
through	NN	O	O
an	NN	O	O
excitatory	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
-	NN	O	O
mediated	NN	O	O
mechanism	NN	O	O
.	NN	O	O

Paclitaxel	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
,	NN	O	O
and	NN	O	O
folinic	NN	O	O
acid	NN	O	O
in	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
cancer	NN	O	I
:	NN	O	O
BRE	NN	O	O
-	NN	O	O
26	NN	O	O
,	NN	O	O
a	NN	O	O
phase	NN	O	O
II	NN	O	O
trial	NN	O	O
.	NN	O	O

5	NN	O	O
-	NN	O	O
Fluorouracil	NN	O	O
plus	NN	O	O
folinic	NN	O	O
acid	NN	O	O
and	NN	O	O
paclitaxel	NN	O	O
(	NN	O	O
Taxol	NN	O	O
;	NN	O	O
Bristol	NN	O	O
-	NN	O	O
Myers	NN	O	O
Squibb	NN	O	O
Company	NN	O	O
,	NN	O	O
Princeton	NN	O	O
,	NN	O	O
NJ	NN	O	O
)	NN	O	O
are	NN	O	O
effective	NN	O	O
salvage	NN	O	O
therapies	NN	O	O
for	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
cancer	NN	O	I
patients	NN	O	O
.	NN	O	O

Paclitaxel	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
have	NN	O	O
additive	NN	O	O
cytotoxicity	NN	O	B
in	NN	O	O
MCF	NN	O	O
-	NN	O	O
7	NN	O	O
cell	NN	O	O
lines	NN	O	O
.	NN	O	O

We	NN	O	O
performed	NN	O	O
a	NN	O	O
phase	NN	O	O
II	NN	O	O
trial	NN	O	O
of	NN	O	O
paclitaxel	NN	O	O
175	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
over	NN	O	O
3	NN	O	O
hours	NN	O	O
on	NN	O	O
day	NN	O	O
I	NN	O	O
followed	NN	O	O
by	NN	O	O
folinic	NN	O	O
acid	NN	O	O
300	NN	O	O
mg	NN	O	O
over	NN	O	O
1	NN	O	O
hour	NN	O	O
before	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
350	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
to	NN	O	O
3	NN	O	O
every	NN	O	O
28	NN	O	O
days	NN	O	O
(	NN	O	O
TFL	NN	O	O
)	NN	O	O
in	NN	O	O
women	NN	O	O
with	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
cancer	NN	O	I
.	NN	O	O

Analysis	NN	O	O
is	NN	O	O
reported	NN	O	O
on	NN	O	O
37	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
minimum	NN	O	O
of	NN	O	O
6	NN	O	O
months	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
who	NN	O	O
received	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
192	NN	O	O
cycles	NN	O	O
of	NN	O	O
TFL	NN	O	O
:	NN	O	O
nine	NN	O	O
cycles	NN	O	O
(	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
grade	NN	O	O
3	NN	O	O
/	NN	O	O
4	NN	O	O
neutropenia	NN	O	B
requiring	NN	O	O
hospitalization	NN	O	O
;	NN	O	O
seven	NN	O	O
(	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
cycles	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
required	NN	O	O
granulocyte	NN	O	O
colony	NN	O	O
-	NN	O	O
stimulating	NN	O	O
factor	NN	O	O
due	NN	O	O
to	NN	O	O
neutropenia	NN	O	B
;	NN	O	O
no	NN	O	O
patient	NN	O	O
required	NN	O	O
platelet	NN	O	O
transfusions	NN	O	O
.	NN	O	O

Grade	NN	O	O
3	NN	O	O
/	NN	O	O
4	NN	O	O
nonhematologic	NN	O	O
toxicities	NN	O	B
were	NN	O	O
uncommon	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
34	NN	O	O
patients	NN	O	O
evaluable	NN	O	O
for	NN	O	O
response	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
three	NN	O	O
complete	NN	O	O
responses	NN	O	O
(	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
18	NN	O	O
partial	NN	O	O
responses	NN	O	O
(	NN	O	O
53	NN	O	O
%	NN	O	O
)	NN	O	O
for	NN	O	O
an	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
of	NN	O	O
62	NN	O	O
%	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
19	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
with	NN	O	O
prior	NN	O	O
doxorubicin	NN	O	O
exposure	NN	O	O
,	NN	O	O
11	NN	O	O
(	NN	O	O
58	NN	O	O
%	NN	O	O
)	NN	O	O
responded	NN	O	O
compared	NN	O	O
with	NN	O	O
nine	NN	O	O
of	NN	O	O
15	NN	O	O
(	NN	O	O
60	NN	O	O
%	NN	O	O
)	NN	O	O
without	NN	O	O
prior	NN	O	O
doxorubicin	NN	O	O
.	NN	O	O

Plasma	NN	O	O
paclitaxel	NN	O	O
concentrations	NN	O	O
were	NN	O	O
measured	NN	O	O
at	NN	O	O
the	NN	O	O
completion	NN	O	O
of	NN	O	O
paclitaxel	NN	O	O
infusion	NN	O	O
and	NN	O	O
at	NN	O	O
24	NN	O	O
hours	NN	O	O
in	NN	O	O
19	NN	O	O
patients	NN	O	O
.	NN	O	O

TFL	NN	O	O
is	NN	O	O
an	NN	O	O
active	NN	O	O
,	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
regimen	NN	O	O
in	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
cancer	NN	O	I
.	NN	O	O

Efficacy	NN	O	O
and	NN	O	O
proarrhythmia	NN	O	B
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
for	NN	O	O
sustained	NN	O	O
ventricular	NN	O	B
tachyarrhythmias	NN	O	I
.	NN	O	O

This	NN	O	O
study	NN	O	O
prospectively	NN	O	O
evaluated	NN	O	O
the	NN	O	O
clinical	NN	O	O
efficacy	NN	O	O
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
,	NN	O	O
and	NN	O	O
the	NN	O	O
presumable	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
for	NN	O	O
sustained	NN	O	O
ventricular	NN	O	B
tachyarrhythmias	NN	O	I
.	NN	O	O

Eighty	NN	O	O
-	NN	O	O
one	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
(	NN	O	O
54	NN	O	O
with	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
,	NN	O	O
and	NN	O	O
20	NN	O	O
with	NN	O	O
dilated	NN	O	B
cardiomyopathy	NN	O	I
)	NN	O	O
with	NN	O	O
inducible	NN	O	O
sustained	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
or	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
received	NN	O	O
oral	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
to	NN	O	O
prevent	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
ventricular	NN	O	B
tachyarrhythmia	NN	O	I
.	NN	O	O

During	NN	O	O
oral	NN	O	O
loading	NN	O	O
with	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
,	NN	O	O
continuous	NN	O	O
electrocardiographic	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
monitoring	NN	O	O
was	NN	O	O
performed	NN	O	O
.	NN	O	O

Those	NN	O	O
patients	NN	O	O
in	NN	O	O
whom	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
prevented	NN	O	O
induction	NN	O	O
of	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
or	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
were	NN	O	O
discharged	NN	O	O
with	NN	O	O
the	NN	O	O
drug	NN	O	O
and	NN	O	O
followed	NN	O	O
up	NN	O	O
on	NN	O	O
an	NN	O	O
outpatient	NN	O	O
basis	NN	O	O
for	NN	O	O
21	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
18	NN	O	O
months	NN	O	O
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
the	NN	O	O
ventricular	NN	O	B
tachyarrhythmia	NN	O	I
was	NN	O	O
prevented	NN	O	O
by	NN	O	O
oral	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
in	NN	O	O
35	NN	O	O
(	NN	O	O
43	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
;	NN	O	O
the	NN	O	O
ventricular	NN	O	B
tachyarrhythmia	NN	O	I
remained	NN	O	O
inducible	NN	O	O
in	NN	O	O
40	NN	O	O
(	NN	O	O
49	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
;	NN	O	O
and	NN	O	O
two	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
did	NN	O	O
not	NN	O	O
tolerate	NN	O	O
even	NN	O	O
40	NN	O	O
mg	NN	O	O
of	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
once	NN	O	O
daily	NN	O	O
.	NN	O	O

Four	NN	O	O
(	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
had	NN	O	O
from	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
during	NN	O	O
the	NN	O	O
initial	NN	O	O
oral	NN	O	O
treatment	NN	O	O
with	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
.	NN	O	O

Neither	NN	O	O
ECG	NN	O	O
[	NN	O	O
sinus	NN	O	O
-	NN	O	O
cycle	NN	O	O
length	NN	O	O
(	NN	O	O
SCL	NN	O	O
)	NN	O	O
,	NN	O	O
QT	NN	O	O
or	NN	O	O
QTc	NN	O	O
interval	NN	O	O
,	NN	O	O
or	NN	O	O
U	NN	O	O
wave	NN	O	O
]	NN	O	O
nor	NN	O	O
clinical	NN	O	O
parameters	NN	O	O
identified	NN	O	O
patients	NN	O	O
at	NN	O	O
risk	NN	O	O
for	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
oral	NN	O	O
dose	NN	O	O
of	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
(	NN	O	O
200	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
46	NN	O	O
vs	NN	O	O
.	NN	O	O
328	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
53	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0017	NN	O	O
)	NN	O	O
.	NN	O	O

Risk	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
were	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
an	NN	O	O
U	NN	O	O
wave	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
049	NN	O	O
)	NN	O	O
,	NN	O	O
female	NN	O	O
gender	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
015	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
significant	NN	O	O
dose	NN	O	O
-	NN	O	O
corrected	NN	O	O
changes	NN	O	O
of	NN	O	O
SCL	NN	O	O
,	NN	O	O
QT	NN	O	O
interval	NN	O	O
,	NN	O	O
and	NN	O	O
QTc	NN	O	O
interval	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
,	NN	O	O
seven	NN	O	O
(	NN	O	O
20	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
nonfatal	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
recurrence	NN	O	O
,	NN	O	O
and	NN	O	O
two	NN	O	O
(	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
died	NN	O	O
suddenly	NN	O	O
.	NN	O	O

One	NN	O	O
female	NN	O	O
patient	NN	O	O
with	NN	O	O
stable	NN	O	O
cardiac	NN	O	B
disease	NN	O	I
had	NN	O	O
recurrent	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
after	NN	O	O
2	NN	O	O
years	NN	O	O
of	NN	O	O
successful	NN	O	O
treatment	NN	O	O
with	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
.	NN	O	O

Torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
occurred	NN	O	O
early	NN	O	O
during	NN	O	O
treatment	NN	O	O
even	NN	O	O
with	NN	O	O
low	NN	O	O
doses	NN	O	O
of	NN	O	O
oral	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
.	NN	O	O

Pronounced	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
surface	NN	O	O
ECG	NN	O	O
(	NN	O	O
cycle	NN	O	O
length	NN	O	O
,	NN	O	O
QT	NN	O	O
,	NN	O	O
and	NN	O	O
QTc	NN	O	O
)	NN	O	O
in	NN	O	O
relation	NN	O	O
to	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
oral	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
might	NN	O	O
identify	NN	O	O
a	NN	O	O
subgroup	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
.	NN	O	O

Other	NN	O	O
ECG	NN	O	O
parameters	NN	O	O
before	NN	O	O
the	NN	O	O
application	NN	O	O
of	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
did	NN	O	O
not	NN	O	O
identify	NN	O	O
patients	NN	O	O
at	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
.	NN	O	O

Recurrence	NN	O	O
rates	NN	O	O
of	NN	O	O
ventricular	NN	O	B
tachyarrhythmias	NN	O	I
are	NN	O	O
high	NN	O	O
despite	NN	O	O
complete	NN	O	O
suppression	NN	O	O
of	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B
during	NN	O	O
programmed	NN	O	O
stimulation	NN	O	O
.	NN	O	O

Therefore	NN	O	O
programmed	NN	O	O
electrical	NN	O	O
stimulation	NN	O	O
in	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
d	NN	O	O
,	NN	O	O
l	NN	O	O
-	NN	O	O
sotalol	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
of	NN	O	O
limited	NN	O	O
prognostic	NN	O	O
value	NN	O	O
.	NN	O	O

Chronic	NN	O	O
hyperprolactinemia	NN	O	B
and	NN	O	O
changes	NN	O	O
in	NN	O	O
dopamine	NN	O	O
neurons	NN	O	O
.	NN	O	O

The	NN	O	O
tuberoinfundibular	NN	O	O
dopaminergic	NN	O	O
(	NN	O	O
TIDA	NN	O	O
)	NN	O	O
system	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
inhibit	NN	O	O
prolactin	NN	O	O
(	NN	O	O
PRL	NN	O	O
)	NN	O	O
secretion	NN	O	O
.	NN	O	O

In	NN	O	O
young	NN	O	O
animals	NN	O	O
this	NN	O	O
system	NN	O	O
responds	NN	O	O
to	NN	O	O
acute	NN	O	O
elevations	NN	O	O
in	NN	O	O
serum	NN	O	O
PRL	NN	O	O
by	NN	O	O
increasing	NN	O	O
its	NN	O	O
activity	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
this	NN	O	O
responsiveness	NN	O	O
is	NN	O	O
lost	NN	O	O
in	NN	O	O
aging	NN	O	O
rats	NN	O	O
with	NN	O	O
chronically	NN	O	O
high	NN	O	O
serum	NN	O	O
PRL	NN	O	O
levels	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
induce	NN	O	O
hyperprolactinemia	NN	O	B
in	NN	O	O
rats	NN	O	O
for	NN	O	O
extended	NN	O	O
periods	NN	O	O
of	NN	O	O
time	NN	O	O
and	NN	O	O
examine	NN	O	O
its	NN	O	O
effects	NN	O	O
on	NN	O	O
dopaminergic	NN	O	O
systems	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

Hyperprolactinemia	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
treatment	NN	O	O
with	NN	O	O
haloperidol	NN	O	O
,	NN	O	O
a	NN	O	O
dopamine	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
and	NN	O	O
Palkovits	NN	O	O
'	NN	O	O
microdissection	NN	O	O
technique	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
performance	NN	O	O
liquid	NN	O	O
chromatography	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
measure	NN	O	O
neurotransmitter	NN	O	O
concentrations	NN	O	O
in	NN	O	O
several	NN	O	O
areas	NN	O	O
of	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

After	NN	O	O
6	NN	O	O
months	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B
,	NN	O	O
dopamine	NN	O	O
(	NN	O	O
DA	NN	O	O
)	NN	O	O
concentrations	NN	O	O
in	NN	O	O
the	NN	O	O
median	NN	O	O
eminence	NN	O	O
(	NN	O	O
ME	NN	O	O
)	NN	O	O
increased	NN	O	O
by	NN	O	O
84	NN	O	O
%	NN	O	O
over	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

Nine	NN	O	O
months	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B
produced	NN	O	O
a	NN	O	O
50	NN	O	O
%	NN	O	O
increase	NN	O	O
in	NN	O	O
DA	NN	O	O
concentrations	NN	O	O
in	NN	O	O
the	NN	O	O
ME	NN	O	O
over	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
DA	NN	O	O
response	NN	O	O
was	NN	O	O
lost	NN	O	O
if	NN	O	O
a	NN	O	O
9	NN	O	O
-	NN	O	O
month	NN	O	O
long	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B
was	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
1	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
month	NN	O	O
-	NN	O	O
long	NN	O	O
extremely	NN	O	O
high	NN	O	O
increase	NN	O	O
in	NN	O	O
serum	NN	O	O
PRL	NN	O	O
levels	NN	O	O
produced	NN	O	O
by	NN	O	O
implantation	NN	O	O
of	NN	O	O
MMQ	NN	O	O
cells	NN	O	O
under	NN	O	O
the	NN	O	O
kidney	NN	O	O
capsule	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
DA	NN	O	O
,	NN	O	O
norepinephrine	NN	O	O
(	NN	O	O
NE	NN	O	O
)	NN	O	O
,	NN	O	O
serotonin	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
their	NN	O	O
metabolites	NN	O	O
in	NN	O	O
the	NN	O	O
arcuate	NN	O	O
nucleus	NN	O	O
(	NN	O	O
AN	NN	O	O
)	NN	O	O
,	NN	O	O
medial	NN	O	O
preoptic	NN	O	O
area	NN	O	O
(	NN	O	O
MPA	NN	O	O
)	NN	O	O
,	NN	O	O
caudate	NN	O	O
putamen	NN	O	O
(	NN	O	O
CP	NN	O	O
)	NN	O	O
,	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
(	NN	O	O
SN	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
zona	NN	O	O
incerta	NN	O	O
(	NN	O	O
ZI	NN	O	O
)	NN	O	O
,	NN	O	O
except	NN	O	O
for	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
5	NN	O	O
-	NN	O	O
hydroxyindoleacetic	NN	O	O
acid	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
HIAA	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
AN	NN	O	O
after	NN	O	O
6	NN	O	O
-	NN	O	O
months	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
DA	NN	O	O
concentrations	NN	O	O
in	NN	O	O
the	NN	O	O
AN	NN	O	O
after	NN	O	O
9	NN	O	O
-	NN	O	O
months	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B
.	NN	O	O

These	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
hyperprolactinemia	NN	O	B
specifically	NN	O	O
affects	NN	O	O
TIDA	NN	O	O
neurons	NN	O	O
and	NN	O	O
these	NN	O	O
effects	NN	O	O
vary	NN	O	O
,	NN	O	O
depending	NN	O	O
on	NN	O	O
the	NN	O	O
duration	NN	O	O
and	NN	O	O
intensity	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B
.	NN	O	O

The	NN	O	O
age	NN	O	O
-	NN	O	O
related	NN	O	O
decrease	NN	O	O
in	NN	O	O
hypothalamic	NN	O	O
dopamine	NN	O	O
function	NN	O	O
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
increases	NN	O	O
in	NN	O	O
PRL	NN	O	O
secretion	NN	O	O
.	NN	O	O

Treatment	NN	O	O
-	NN	O	O
related	NN	O	O
disseminated	NN	O	O
necrotizing	NN	O	O
leukoencephalopathy	NN	O	B
with	NN	O	O
characteristic	NN	O	O
contrast	NN	O	O
enhancement	NN	O	O
of	NN	O	O
the	NN	O	O
white	NN	O	O
matter	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
describes	NN	O	O
unique	NN	O	O
contrast	NN	O	O
enhancement	NN	O	O
of	NN	O	O
the	NN	O	O
white	NN	O	O
matter	NN	O	O
on	NN	O	O
T1	NN	O	O
-	NN	O	O
weighted	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
images	NN	O	O
of	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
disseminated	NN	O	O
necrotizing	NN	O	O
leukoencephalopathy	NN	O	B
,	NN	O	O
which	NN	O	O
developed	NN	O	O
from	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
treated	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
methotrexate	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
enhancement	NN	O	O
was	NN	O	O
more	NN	O	O
pronounced	NN	O	O
near	NN	O	O
the	NN	O	O
base	NN	O	O
of	NN	O	O
the	NN	O	O
brain	NN	O	O
than	NN	O	O
at	NN	O	O
the	NN	O	O
vertex	NN	O	O
.	NN	O	O

Necropsy	NN	O	O
of	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
revealed	NN	O	O
loss	NN	O	B
of	NN	O	I
myelination	NN	O	I
and	NN	O	O
necrosis	NN	O	B
of	NN	O	O
the	NN	O	O
white	NN	O	O
matter	NN	O	O
.	NN	O	O

Possible	NN	O	O
mechanisms	NN	O	O
causing	NN	O	O
such	NN	O	O
a	NN	O	O
leukoencephalopathy	NN	O	B
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Thrombotic	NN	O	B
complications	NN	O	O
in	NN	O	O
acute	NN	O	B
promyelocytic	NN	O	I
leukemia	NN	O	I
during	NN	O	O
all	NN	O	O
-	NN	O	O
trans	NN	O	O
-	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
,	NN	O	O
due	NN	O	O
to	NN	O	O
occlusion	NN	O	B
of	NN	O	I
renal	NN	O	I
vessels	NN	O	I
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
acute	NN	O	B
promyelocytic	NN	O	I
leukemia	NN	O	I
(	NN	O	O
APL	NN	O	B
)	NN	O	O
treated	NN	O	O
with	NN	O	O
all	NN	O	O
-	NN	O	O
trans	NN	O	O
-	NN	O	O
retinoic	NN	O	O
acid	NN	O	O
(	NN	O	O
ATRA	NN	O	O
)	NN	O	O
and	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
has	NN	O	O
been	NN	O	O
described	NN	O	O
recently	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
in	NN	O	O
an	NN	O	O
APL	NN	O	B
patient	NN	O	O
treated	NN	O	O
with	NN	O	O
ATRA	NN	O	O
alone	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
further	NN	O	O
supports	NN	O	O
the	NN	O	O
concern	NN	O	O
about	NN	O	O
thromboembolic	NN	O	B
complications	NN	O	O
associated	NN	O	O
with	NN	O	O
ATRA	NN	O	O
therapy	NN	O	O
in	NN	O	O
APL	NN	O	B
patients	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
,	NN	O	O
a	NN	O	O
43	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
,	NN	O	O
presented	NN	O	O
all	NN	O	O
the	NN	O	O
signs	NN	O	O
and	NN	O	O
symptoms	NN	O	O
of	NN	O	O
APL	NN	O	B
and	NN	O	O
was	NN	O	O
included	NN	O	O
in	NN	O	O
a	NN	O	O
treatment	NN	O	O
protocol	NN	O	O
with	NN	O	O
ATRA	NN	O	O
.	NN	O	O

After	NN	O	O
10	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
he	NN	O	O
developed	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
that	NN	O	O
was	NN	O	O
completely	NN	O	O
reversible	NN	O	O
after	NN	O	O
complete	NN	O	O
remission	NN	O	O
of	NN	O	O
APL	NN	O	B
was	NN	O	O
achieved	NN	O	O
and	NN	O	O
therapy	NN	O	O
discontinued	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
ATRA	NN	O	O
is	NN	O	O
a	NN	O	O
valid	NN	O	O
therapeutic	NN	O	O
choice	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
APL	NN	O	B
,	NN	O	O
although	NN	O	O
the	NN	O	O
procoagulant	NN	O	O
tendency	NN	O	O
is	NN	O	O
not	NN	O	O
completely	NN	O	O
corrected	NN	O	O
.	NN	O	O

Thrombotic	NN	O	B
events	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
could	NN	O	O
be	NN	O	O
avoided	NN	O	O
by	NN	O	O
using	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
heparin	NN	O	O
.	NN	O	O

Pupillary	NN	O	O
changes	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
stimulant	NN	O	O
-	NN	O	O
induced	NN	O	O
mania	NN	O	B
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

A	NN	O	O
30	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
cocaine	NN	O	O
-	NN	O	O
dependent	NN	O	O
man	NN	O	O
who	NN	O	O
was	NN	O	O
a	NN	O	O
subject	NN	O	O
in	NN	O	O
a	NN	O	O
study	NN	O	O
evaluating	NN	O	O
the	NN	O	O
anticraving	NN	O	O
efficacy	NN	O	O
of	NN	O	O
the	NN	O	O
stimulant	NN	O	O
medication	NN	O	O
diethylpropion	NN	O	O
(	NN	O	O
DEP	NN	O	O
)	NN	O	O
became	NN	O	O
manic	NN	O	B
during	NN	O	O
his	NN	O	O
second	NN	O	O
week	NN	O	O
on	NN	O	O
the	NN	O	O
study	NN	O	O
drug	NN	O	O
.	NN	O	O

Pupillometric	NN	O	O
changes	NN	O	O
while	NN	O	O
on	NN	O	O
DEP	NN	O	O
,	NN	O	O
especially	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
total	NN	O	O
power	NN	O	O
of	NN	O	O
pupillary	NN	O	B
oscillation	NN	O	I
,	NN	O	O
were	NN	O	O
dramatically	NN	O	O
different	NN	O	O
than	NN	O	O
those	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
eight	NN	O	O
other	NN	O	O
study	NN	O	O
subjects	NN	O	O
who	NN	O	O
did	NN	O	O
not	NN	O	O
become	NN	O	O
manic	NN	O	B
.	NN	O	O

The	NN	O	O
large	NN	O	O
changes	NN	O	O
in	NN	O	O
total	NN	O	O
power	NN	O	O
of	NN	O	O
pupillary	NN	O	B
oscillation	NN	O	I
occurred	NN	O	O
a	NN	O	O
few	NN	O	O
days	NN	O	O
before	NN	O	O
the	NN	O	O
patient	NN	O	O
became	NN	O	O
fully	NN	O	O
manic	NN	O	B
.	NN	O	O

Such	NN	O	O
medication	NN	O	O
-	NN	O	O
associated	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
total	NN	O	O
power	NN	O	O
of	NN	O	O
pupillary	NN	O	B
oscillation	NN	O	I
might	NN	O	O
be	NN	O	O
of	NN	O	O
utility	NN	O	O
in	NN	O	O
identifying	NN	O	O
persons	NN	O	O
at	NN	O	O
risk	NN	O	O
for	NN	O	O
manic	NN	O	B
-	NN	O	O
like	NN	O	O
adverse	NN	O	O
effects	NN	O	O
during	NN	O	O
the	NN	O	O
medical	NN	O	O
use	NN	O	O
of	NN	O	O
psychomotor	NN	O	O
stimulants	NN	O	O
or	NN	O	O
sympathomimetic	NN	O	O
agents	NN	O	O
.	NN	O	O

Fetal	NN	O	O
risks	NN	O	O
due	NN	O	O
to	NN	O	O
warfarin	NN	O	O
therapy	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

Two	NN	O	O
mothers	NN	O	O
with	NN	O	O
heart	NN	O	O
valve	NN	O	O
prosthesis	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
warfarin	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
a	NN	O	O
caesarean	NN	O	O
section	NN	O	O
was	NN	O	O
done	NN	O	O
one	NN	O	O
week	NN	O	O
after	NN	O	O
replacement	NN	O	O
of	NN	O	O
warfarin	NN	O	O
with	NN	O	O
heparin	NN	O	O
.	NN	O	O

The	NN	O	O
baby	NN	O	O
died	NN	O	O
of	NN	O	O
cerebral	NN	O	B
and	NN	O	I
pulmonary	NN	O	I
hemorrhage	NN	O	I
.	NN	O	O

The	NN	O	O
second	NN	O	O
mother	NN	O	O
had	NN	O	O
a	NN	O	O
male	NN	O	O
infant	NN	O	O
by	NN	O	O
caesarean	NN	O	O
section	NN	O	O
.	NN	O	O

The	NN	O	O
baby	NN	O	O
showed	NN	O	O
warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
embryopathy	NN	O	B
with	NN	O	O
nasal	NN	O	B
hypoplasia	NN	O	I
and	NN	O	O
stippled	NN	O	B
epiphyses	NN	O	I
(	NN	O	O
chondrodysplasia	NN	O	B
punctata	NN	O	I
)	NN	O	O
.	NN	O	O

Nasal	NN	O	B
hypoplasia	NN	O	I
with	NN	O	O
or	NN	O	O
without	NN	O	O
stippled	NN	O	B
epiphyses	NN	O	I
has	NN	O	O
now	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
11	NN	O	O
infants	NN	O	O
born	NN	O	O
to	NN	O	O
mothers	NN	O	O
treated	NN	O	O
with	NN	O	O
warfarin	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
trimester	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
causal	NN	O	O
association	NN	O	O
is	NN	O	O
probable	NN	O	O
.	NN	O	O

In	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
risks	NN	O	O
to	NN	O	O
both	NN	O	O
mother	NN	O	O
and	NN	O	O
fetus	NN	O	O
in	NN	O	O
women	NN	O	O
with	NN	O	O
prosthetic	NN	O	O
cardiac	NN	O	O
valves	NN	O	O
it	NN	O	O
is	NN	O	O
recommended	NN	O	O
that	NN	O	O
therapeutic	NN	O	O
abortion	NN	O	O
be	NN	O	O
advised	NN	O	O
as	NN	O	O
the	NN	O	O
first	NN	O	O
alternative	NN	O	O
.	NN	O	O

The	NN	O	O
negative	NN	O	O
mucosal	NN	O	O
potential	NN	O	O
:	NN	O	O
separating	NN	O	O
central	NN	O	O
and	NN	O	O
peripheral	NN	O	O
effects	NN	O	O
of	NN	O	O
NSAIDs	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
We	NN	O	O
wanted	NN	O	O
to	NN	O	O
test	NN	O	O
whether	NN	O	O
assessment	NN	O	O
of	NN	O	O
both	NN	O	O
a	NN	O	O
central	NN	O	O
pain	NN	O	B
-	NN	O	O
related	NN	O	O
signal	NN	O	O
(	NN	O	O
chemo	NN	O	O
-	NN	O	O
somatosensory	NN	O	O
evoked	NN	O	O
potential	NN	O	O
,	NN	O	O
CSSEP	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
concomitantly	NN	O	O
recorded	NN	O	O
peripheral	NN	O	O
signal	NN	O	O
(	NN	O	O
negative	NN	O	O
mucosal	NN	O	O
potential	NN	O	O
,	NN	O	O
NMP	NN	O	O
)	NN	O	O
allows	NN	O	O
for	NN	O	O
separation	NN	O	O
of	NN	O	O
central	NN	O	O
and	NN	O	O
peripheral	NN	O	O
effects	NN	O	O
of	NN	O	O
NSAIDs	NN	O	O
.	NN	O	O

For	NN	O	O
this	NN	O	O
purpose	NN	O	O
,	NN	O	O
experimental	NN	O	O
conditions	NN	O	O
were	NN	O	O
created	NN	O	O
in	NN	O	O
which	NN	O	O
NSAIDs	NN	O	O
had	NN	O	O
previously	NN	O	O
been	NN	O	O
observed	NN	O	O
to	NN	O	O
produce	NN	O	O
effects	NN	O	O
on	NN	O	O
phasic	NN	O	O
and	NN	O	O
tonic	NN	O	O
pain	NN	O	B
by	NN	O	O
either	NN	O	O
central	NN	O	O
or	NN	O	O
peripheral	NN	O	O
mechanisms	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
According	NN	O	O
to	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
randomised	NN	O	O
,	NN	O	O
controlled	NN	O	O
,	NN	O	O
threefold	NN	O	O
cross	NN	O	O
-	NN	O	O
over	NN	O	O
design	NN	O	O
,	NN	O	O
18	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
(	NN	O	O
11	NN	O	O
males	NN	O	O
,	NN	O	O
7	NN	O	O
females	NN	O	O
;	NN	O	O
mean	NN	O	O
age	NN	O	O
26	NN	O	O
years	NN	O	O
)	NN	O	O
received	NN	O	O
either	NN	O	O
placebo	NN	O	O
,	NN	O	O
400	NN	O	O
mg	NN	O	O
ibuprofen	NN	O	O
,	NN	O	O
or	NN	O	O
800	NN	O	O
mg	NN	O	O
ibuprofen	NN	O	O
.	NN	O	O

Phasic	NN	O	O
pain	NN	O	B
was	NN	O	O
applied	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
short	NN	O	O
pulses	NN	O	O
of	NN	O	O
CO2	NN	O	O
to	NN	O	O
the	NN	O	O
nasal	NN	O	O
mucosa	NN	O	O
(	NN	O	O
stimulus	NN	O	O
duration	NN	O	O
500	NN	O	O
ms	NN	O	O
,	NN	O	O
interval	NN	O	O
approximately	NN	O	O
60	NN	O	O
s	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
tonic	NN	O	O
pain	NN	O	B
was	NN	O	O
induced	NN	O	O
in	NN	O	O
the	NN	O	O
nasal	NN	O	O
cavity	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
dry	NN	O	O
air	NN	O	O
of	NN	O	O
controlled	NN	O	O
temperature	NN	O	O
,	NN	O	O
humidity	NN	O	O
and	NN	O	O
flow	NN	O	O
rate	NN	O	O
(	NN	O	O
22	NN	O	O
degrees	NN	O	O
C	NN	O	O
,	NN	O	O
0	NN	O	O
%	NN	O	O
relative	NN	O	O
humidity	NN	O	O
,	NN	O	O
145	NN	O	O
ml	NN	O	O
.	NN	O	O
s	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

Both	NN	O	O
CSSEPs	NN	O	O
as	NN	O	O
central	NN	O	O
and	NN	O	O
NMPs	NN	O	O
as	NN	O	O
peripheral	NN	O	O
correlates	NN	O	O
of	NN	O	O
pain	NN	O	B
were	NN	O	O
obtained	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
CO2	NN	O	O
stimuli	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
the	NN	O	O
subjects	NN	O	O
rated	NN	O	O
the	NN	O	O
intensity	NN	O	O
of	NN	O	O
both	NN	O	O
phasic	NN	O	O
and	NN	O	O
tonic	NN	O	O
pain	NN	O	B
by	NN	O	O
means	NN	O	O
of	NN	O	O
visual	NN	O	O
analogue	NN	O	O
scales	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
As	NN	O	O
described	NN	O	O
earlier	NN	O	O
,	NN	O	O
administration	NN	O	O
of	NN	O	O
ibuprofen	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
tonic	NN	O	O
pain	NN	O	B
but	NN	O	O
-	NN	O	O
relative	NN	O	O
to	NN	O	O
placebo	NN	O	O
-	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
correlates	NN	O	O
of	NN	O	O
phasic	NN	O	O
pain	NN	O	B
,	NN	O	O
indicating	NN	O	O
a	NN	O	O
specific	NN	O	O
effect	NN	O	O
of	NN	O	O
ibuprofen	NN	O	O
on	NN	O	O
the	NN	O	O
interaction	NN	O	O
between	NN	O	O
the	NN	O	O
pain	NN	O	B
stimuli	NN	O	O
under	NN	O	O
these	NN	O	O
special	NN	O	O
experimental	NN	O	O
conditions	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
the	NN	O	O
similar	NN	O	O
behaviour	NN	O	O
of	NN	O	O
CSSEP	NN	O	O
and	NN	O	O
NMP	NN	O	O
,	NN	O	O
it	NN	O	O
was	NN	O	O
concluded	NN	O	O
that	NN	O	O
the	NN	O	O
pharmacological	NN	O	O
process	NN	O	O
underlying	NN	O	O
this	NN	O	O
phenomenon	NN	O	O
was	NN	O	O
localised	NN	O	O
in	NN	O	O
the	NN	O	O
periphery	NN	O	O
.	NN	O	O

By	NN	O	O
means	NN	O	O
of	NN	O	O
the	NN	O	O
simultaneous	NN	O	O
recording	NN	O	O
of	NN	O	O
interrelated	NN	O	O
peripheral	NN	O	O
and	NN	O	O
central	NN	O	O
electrophysiologic	NN	O	O
correlates	NN	O	O
of	NN	O	O
nociception	NN	O	O
,	NN	O	O
it	NN	O	O
was	NN	O	O
possible	NN	O	O
to	NN	O	O
separate	NN	O	O
central	NN	O	O
and	NN	O	O
peripheral	NN	O	O
effects	NN	O	O
of	NN	O	O
an	NN	O	O
NSAID	NN	O	O
.	NN	O	O

The	NN	O	O
major	NN	O	O
advantage	NN	O	O
of	NN	O	O
this	NN	O	O
pain	NN	O	B
model	NN	O	O
is	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
obtaining	NN	O	O
peripheral	NN	O	O
pain	NN	O	B
-	NN	O	O
related	NN	O	O
activity	NN	O	O
directly	NN	O	O
using	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
invasive	NN	O	O
technique	NN	O	O
in	NN	O	O
humans	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
D	NN	O	O
-	NN	O	O
Glucarates	NN	O	O
on	NN	O	O
basic	NN	O	O
antibiotic	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
damage	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Dehydrated	NN	O	B
rats	NN	O	O
regularly	NN	O	O
develop	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
following	NN	O	O
single	NN	O	O
injection	NN	O	O
of	NN	O	O
aminoglycoside	NN	O	O
antibiotics	NN	O	O
combined	NN	O	O
with	NN	O	O
dextran	NN	O	O
or	NN	O	O
of	NN	O	O
antibiotics	NN	O	O
only	NN	O	O
.	NN	O	O

Oral	NN	O	O
administration	NN	O	O
of	NN	O	O
2	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
di	NN	O	O
-	NN	O	O
O	NN	O	O
-	NN	O	O
acetyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
glucaro	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
6	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
dilactone	NN	O	O
protected	NN	O	O
rats	NN	O	O
against	NN	O	O
renal	NN	O	B
failure	NN	O	I
induced	NN	O	O
by	NN	O	O
kanamycin	NN	O	O
-	NN	O	O
dextran	NN	O	O
.	NN	O	O

The	NN	O	O
protective	NN	O	O
effect	NN	O	O
was	NN	O	O
prevalent	NN	O	O
among	NN	O	O
D	NN	O	O
-	NN	O	O
glucarates	NN	O	O
,	NN	O	O
and	NN	O	O
also	NN	O	O
to	NN	O	O
other	NN	O	O
saccharic	NN	O	O
acid	NN	O	O
,	NN	O	O
hexauronic	NN	O	O
acids	NN	O	O
and	NN	O	O
hexaaldonic	NN	O	O
acids	NN	O	O
,	NN	O	O
although	NN	O	O
to	NN	O	O
a	NN	O	O
lesser	NN	O	O
degree	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
to	NN	O	O
a	NN	O	O
hexaaldose	NN	O	O
,	NN	O	O
sugar	NN	O	O
alcohols	NN	O	O
,	NN	O	O
substances	NN	O	O
inthe	NN	O	O
TCA	NN	O	O
cycle	NN	O	O
and	NN	O	O
other	NN	O	O
acidic	NN	O	O
compounds	NN	O	O
.	NN	O	O

D	NN	O	O
-	NN	O	O
Glucarates	NN	O	O
were	NN	O	O
effective	NN	O	O
against	NN	O	O
renal	NN	O	B
damage	NN	O	I
induced	NN	O	O
by	NN	O	O
peptide	NN	O	O
antibiotics	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
various	NN	O	O
aminoglycoside	NN	O	O
antibitocis	NN	O	O
.	NN	O	O

Dose	NN	O	O
-	NN	O	O
responses	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
D	NN	O	O
-	NN	O	O
Glucarates	NN	O	O
.	NN	O	O

With	NN	O	O
a	NN	O	O
D	NN	O	O
-	NN	O	O
glucarate	NN	O	O
of	NN	O	O
a	NN	O	O
fixed	NN	O	O
size	NN	O	O
of	NN	O	O
dose	NN	O	O
,	NN	O	O
approximately	NN	O	O
the	NN	O	O
same	NN	O	O
degree	NN	O	O
of	NN	O	O
protection	NN	O	O
was	NN	O	O
obtained	NN	O	O
against	NN	O	O
renal	NN	O	B
damages	NN	O	I
induced	NN	O	O
by	NN	O	O
different	NN	O	O
basic	NN	O	O
antibiotics	NN	O	O
despite	NN	O	O
large	NN	O	O
disparities	NN	O	O
in	NN	O	O
administration	NN	O	O
doses	NN	O	O
of	NN	O	O
different	NN	O	O
antibiotics	NN	O	O
.	NN	O	O

D	NN	O	O
-	NN	O	O
Glucarates	NN	O	O
had	NN	O	O
the	NN	O	O
ability	NN	O	O
to	NN	O	O
prevent	NN	O	O
renal	NN	O	B
damage	NN	O	I
but	NN	O	O
not	NN	O	O
to	NN	O	O
cure	NN	O	O
it	NN	O	O
.	NN	O	O

Rats	NN	O	O
excreted	NN	O	O
acidic	NN	O	O
urine	NN	O	O
when	NN	O	O
they	NN	O	O
were	NN	O	O
spared	NN	O	O
from	NN	O	O
renal	NN	O	B
lesions	NN	O	I
by	NN	O	O
monosaccharides	NN	O	O
.	NN	O	O

The	NN	O	O
reduction	NN	O	O
effect	NN	O	O
of	NN	O	O
D	NN	O	O
-	NN	O	O
glucarates	NN	O	O
against	NN	O	O
nephrotoxicity	NN	O	B
of	NN	O	O
basic	NN	O	O
antibiotics	NN	O	O
was	NN	O	O
discussed	NN	O	O
.	NN	O	O

Acute	NN	O	O
severe	NN	O	O
depression	NN	O	B
following	NN	O	O
peri	NN	O	O
-	NN	O	O
operative	NN	O	O
ondansetron	NN	O	O
.	NN	O	O

A	NN	O	O
41	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
a	NN	O	O
strong	NN	O	O
history	NN	O	O
of	NN	O	O
postoperative	NN	O	B
nausea	NN	O	I
and	NN	O	I
vomiting	NN	O	I
presented	NN	O	O
for	NN	O	O
abdominal	NN	O	O
hysterectomy	NN	O	O
3	NN	O	O
months	NN	O	O
after	NN	O	O
a	NN	O	O
previous	NN	O	O
anaesthetic	NN	O	O
where	NN	O	O
ondansetron	NN	O	O
prophylaxis	NN	O	O
had	NN	O	O
been	NN	O	O
used	NN	O	O
.	NN	O	O

She	NN	O	O
had	NN	O	O
developed	NN	O	O
a	NN	O	O
severe	NN	O	O
acute	NN	O	O
major	NN	O	B
depression	NN	O	I
disorder	NN	O	I
almost	NN	O	O
immediately	NN	O	O
thereafter	NN	O	O
,	NN	O	O
possibly	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
a	NN	O	O
serotonin	NN	O	O
antagonist	NN	O	O
.	NN	O	O

Nine	NN	O	O
years	NN	O	O
before	NN	O	O
she	NN	O	O
had	NN	O	O
experienced	NN	O	O
a	NN	O	O
self	NN	O	O
-	NN	O	O
limited	NN	O	O
puerperal	NN	O	O
depressive	NN	O	B
episode	NN	O	I
.	NN	O	O

Anaesthesia	NN	O	O
with	NN	O	O
a	NN	O	O
propofol	NN	O	O
infusion	NN	O	O
and	NN	O	O
avoidance	NN	O	O
of	NN	O	O
serotonin	NN	O	O
antagonists	NN	O	O
provided	NN	O	O
a	NN	O	O
nausea	NN	O	B
-	NN	O	O
free	NN	O	O
postoperative	NN	O	O
course	NN	O	O
without	NN	O	O
exacerbation	NN	O	O
of	NN	O	O
the	NN	O	O
depression	NN	O	B
disorder	NN	O	I
.	NN	O	O

Hypertensive	NN	O	B
response	NN	O	O
during	NN	O	O
dobutamine	NN	O	O
stress	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Among	NN	O	O
3	NN	O	O
,	NN	O	O
129	NN	O	O
dobutamine	NN	O	O
stress	NN	O	O
echocardiographic	NN	O	O
studies	NN	O	O
,	NN	O	O
a	NN	O	O
hypertensive	NN	O	B
response	NN	O	O
,	NN	O	O
defined	NN	O	O
as	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
BP	NN	O	O
)	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
220	NN	O	O
mm	NN	O	O
Hg	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
diastolic	NN	O	O
BP	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
110	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
occurred	NN	O	O
in	NN	O	O
30	NN	O	O
patients	NN	O	O
(	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
this	NN	O	O
response	NN	O	O
more	NN	O	O
often	NN	O	O
had	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
hypertension	NN	O	B
and	NN	O	O
had	NN	O	O
higher	NN	O	O
resting	NN	O	O
systolic	NN	O	O
and	NN	O	O
diastolic	NN	O	O
BP	NN	O	O
before	NN	O	O
dobutamine	NN	O	O
infusion	NN	O	O
.	NN	O	O

Continuously	NN	O	O
nebulized	NN	O	O
albuterol	NN	O	O
in	NN	O	O
severe	NN	O	O
exacerbations	NN	O	O
of	NN	O	O
asthma	NN	O	B
in	NN	O	O
adults	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
-	NN	O	O
controlled	NN	O	O
study	NN	O	O
.	NN	O	O

A	NN	O	O
retrospective	NN	O	O
,	NN	O	O
case	NN	O	O
-	NN	O	O
controlled	NN	O	O
analysis	NN	O	O
comparing	NN	O	O
patients	NN	O	O
admitted	NN	O	O
to	NN	O	O
a	NN	O	O
medical	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
with	NN	O	O
severe	NN	O	O
exacerbations	NN	O	O
of	NN	O	O
asthma	NN	O	B
who	NN	O	O
received	NN	O	O
continuously	NN	O	O
nebulized	NN	O	O
albuterol	NN	O	O
(	NN	O	O
CNA	NN	O	O
)	NN	O	O
versus	NN	O	O
intermittent	NN	O	O
albuterol	NN	O	O
(	NN	O	O
INA	NN	O	O
)	NN	O	O
treatments	NN	O	O
is	NN	O	O
reported	NN	O	O
.	NN	O	O

Forty	NN	O	O
matched	NN	O	O
pairs	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
asthma	NN	O	B
are	NN	O	O
compared	NN	O	O
.	NN	O	O

CNA	NN	O	O
was	NN	O	O
administered	NN	O	O
for	NN	O	O
a	NN	O	O
mean	NN	O	O
of	NN	O	O
11	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
hr	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
cardiac	NN	O	B
dysrhythmias	NN	O	I
was	NN	O	O
similar	NN	O	O
between	NN	O	O
groups	NN	O	O
.	NN	O	O

Symptomatic	NN	O	O
hypokalemia	NN	O	B
did	NN	O	O
not	NN	O	O
occur	NN	O	O
.	NN	O	O

CNA	NN	O	O
patients	NN	O	O
had	NN	O	O
higher	NN	O	O
heart	NN	O	O
rates	NN	O	O
during	NN	O	O
treatment	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
reflect	NN	O	O
severity	NN	O	O
of	NN	O	O
illness	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
intubation	NN	O	O
was	NN	O	O
similar	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
CNA	NN	O	O
and	NN	O	O
INA	NN	O	O
demonstrated	NN	O	O
similar	NN	O	O
profiles	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
safety	NN	O	O
,	NN	O	O
morbidity	NN	O	O
,	NN	O	O
and	NN	O	O
mortality	NN	O	O
.	NN	O	O

Paraplegia	NN	O	B
following	NN	O	O
intrathecal	NN	O	O
methotrexate	NN	O	O
:	NN	O	O
report	NN	O	O
of	NN	O	O
a	NN	O	O
case	NN	O	O
and	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
paraplegia	NN	O	B
following	NN	O	O
the	NN	O	O
intrathecal	NN	O	O
instillation	NN	O	O
of	NN	O	O
methotrexate	NN	O	O
is	NN	O	O
discribed	NN	O	O
.	NN	O	O

The	NN	O	O
ten	NN	O	O
previously	NN	O	O
reported	NN	O	O
cases	NN	O	O
of	NN	O	O
this	NN	O	O
unusual	NN	O	O
complication	NN	O	O
are	NN	O	O
reviewed	NN	O	O
.	NN	O	O

The	NN	O	O
following	NN	O	O
factors	NN	O	O
appear	NN	O	O
to	NN	O	O
predispose	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
this	NN	O	O
complication	NN	O	O
:	NN	O	O
abnormal	NN	O	O
cerebrospinal	NN	O	O
dynamics	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
central	NN	O	B
nervous	NN	O	I
system	NN	O	I
leukemia	NN	O	I
,	NN	O	O
and	NN	O	O
epidural	NN	O	O
cerebrospinal	NN	O	O
leakage	NN	O	O
;	NN	O	O
elevated	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
methothexate	NN	O	O
concentration	NN	O	O
related	NN	O	O
to	NN	O	O
abnormal	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
dynamics	NN	O	O
and	NN	O	O
to	NN	O	O
inappropriately	NN	O	O
high	NN	O	O
methotrexate	NN	O	O
doses	NN	O	O
based	NN	O	O
on	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
calculations	NN	O	O
in	NN	O	O
older	NN	O	O
children	NN	O	O
and	NN	O	O
adults	NN	O	O
;	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
neurotoxic	NN	O	B
preservatives	NN	O	O
in	NN	O	O
commercially	NN	O	O
available	NN	O	O
methotrexate	NN	O	O
preparations	NN	O	O
and	NN	O	O
diluents	NN	O	O
;	NN	O	O
and	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
methotrexate	NN	O	O
diluents	NN	O	O
of	NN	O	O
unphysiologic	NN	O	O
pH	NN	O	O
,	NN	O	O
ionic	NN	O	O
content	NN	O	O
and	NN	O	O
osmolarity	NN	O	O
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
methotrexate	NN	O	O
contaminants	NN	O	O
,	NN	O	O
local	NN	O	O
folate	NN	O	B
deficiency	NN	O	I
,	NN	O	O
and	NN	O	O
cranial	NN	O	O
irradiation	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
intrathecal	NN	O	O
methotrexate	NN	O	O
toxicity	NN	O	B
is	NN	O	O
unclear	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
neurotoxicity	NN	O	B
may	NN	O	O
be	NN	O	O
reduced	NN	O	O
by	NN	O	O
employing	NN	O	O
lower	NN	O	O
doses	NN	O	O
of	NN	O	O
methotrexate	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
central	NN	O	B
nervous	NN	O	I
system	NN	O	I
leukemia	NN	O	I
,	NN	O	O
in	NN	O	O
older	NN	O	O
children	NN	O	O
and	NN	O	O
adults	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
epidural	NN	O	O
leakage	NN	O	O
.	NN	O	O

Only	NN	O	O
preservative	NN	O	O
-	NN	O	O
free	NN	O	O
methotrexate	NN	O	O
in	NN	O	O
Elliott	NN	O	O
'	NN	O	O
s	NN	O	O
B	NN	O	O
Solution	NN	O	O
at	NN	O	O
a	NN	O	O
concentration	NN	O	O
of	NN	O	O
not	NN	O	O
more	NN	O	O
than	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
for	NN	O	O
intrathecal	NN	O	O
administration	NN	O	O
.	NN	O	O

Periodic	NN	O	O
monitoring	NN	O	O
of	NN	O	O
cerebruspinal	NN	O	O
fluid	NN	O	O
methotrexate	NN	O	O
levels	NN	O	O
may	NN	O	O
be	NN	O	O
predictive	NN	O	O
of	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
serious	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

Hyperosmolar	NN	O	B
nonketotic	NN	O	I
coma	NN	O	I
precipitated	NN	O	O
by	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrogenic	NN	O	B
diabetes	NN	O	I
insipidus	NN	O	I
.	NN	O	O

A	NN	O	O
45	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
10	NN	O	O
-	NN	O	O
year	NN	O	O
history	NN	O	O
of	NN	O	O
manic	NN	O	B
depression	NN	O	I
treated	NN	O	O
with	NN	O	O
lithium	NN	O	O
,	NN	O	O
was	NN	O	O
admitted	NN	O	O
with	NN	O	O
hyperosmolar	NN	O	B
,	NN	O	I
nonketotic	NN	O	I
coma	NN	O	I
.	NN	O	O

He	NN	O	O
gave	NN	O	O
a	NN	O	O
five	NN	O	O
-	NN	O	O
year	NN	O	O
history	NN	O	O
of	NN	O	O
polyuria	NN	O	B
and	NN	O	O
polydipsia	NN	O	B
,	NN	O	O
during	NN	O	O
which	NN	O	O
time	NN	O	O
urinalysis	NN	O	O
had	NN	O	O
been	NN	O	O
negative	NN	O	O
for	NN	O	O
glucose	NN	O	O
.	NN	O	O

After	NN	O	O
recovery	NN	O	O
from	NN	O	O
hyperglycaemia	NN	O	B
,	NN	O	O
he	NN	O	O
remained	NN	O	O
polyuric	NN	O	B
despite	NN	O	O
normal	NN	O	O
blood	NN	O	O
glucose	NN	O	O
concentrations	NN	O	O
;	NN	O	O
water	NN	O	O
deprivation	NN	O	O
testing	NN	O	O
indicated	NN	O	O
nephrogenic	NN	O	B
diabetes	NN	O	I
insipidus	NN	O	I
,	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
.	NN	O	O

We	NN	O	O
hypothesize	NN	O	O
that	NN	O	O
when	NN	O	O
this	NN	O	O
man	NN	O	O
developed	NN	O	O
type	NN	O	B
2	NN	O	I
diabetes	NN	O	I
,	NN	O	O
chronic	NN	O	O
polyuria	NN	O	B
due	NN	O	O
to	NN	O	O
nephrogenic	NN	O	B
diabetes	NN	O	I
insipidus	NN	O	I
was	NN	O	O
sufficient	NN	O	O
to	NN	O	O
precipitate	NN	O	O
hyperosmolar	NN	O	O
dehydration	NN	O	B
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
the	NN	O	O
intracoronary	NN	O	O
infusion	NN	O	O
of	NN	O	O
cocaine	NN	O	O
on	NN	O	O
left	NN	O	O
ventricular	NN	O	O
systolic	NN	O	O
and	NN	O	O
diastolic	NN	O	O
function	NN	O	O
in	NN	O	O
humans	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
In	NN	O	O
dogs	NN	O	O
,	NN	O	O
a	NN	O	O
large	NN	O	O
amount	NN	O	O
of	NN	O	O
intravenous	NN	O	O
cocaine	NN	O	O
causes	NN	O	O
a	NN	O	O
profound	NN	O	O
deterioration	NN	O	B
of	NN	O	I
left	NN	O	I
ventricular	NN	O	I
(	NN	O	I
LV	NN	O	I
)	NN	O	I
systolic	NN	O	I
function	NN	O	I
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
LV	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
done	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
a	NN	O	O
high	NN	O	O
intracoronary	NN	O	O
cocaine	NN	O	O
concentration	NN	O	O
on	NN	O	O
LV	NN	O	O
systolic	NN	O	O
and	NN	O	O
diastolic	NN	O	O
function	NN	O	O
in	NN	O	O
humans	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
20	NN	O	O
patients	NN	O	O
(	NN	O	O
14	NN	O	O
men	NN	O	O
and	NN	O	O
6	NN	O	O
women	NN	O	O
aged	NN	O	O
39	NN	O	O
to	NN	O	O
72	NN	O	O
years	NN	O	O
)	NN	O	O
referred	NN	O	O
for	NN	O	O
cardiac	NN	O	O
catheterization	NN	O	O
for	NN	O	O
the	NN	O	O
evaluation	NN	O	O
of	NN	O	O
chest	NN	O	B
pain	NN	O	I
,	NN	O	O
we	NN	O	O
measured	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
systemic	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
,	NN	O	O
LV	NN	O	O
pressure	NN	O	O
and	NN	O	O
its	NN	O	O
first	NN	O	O
derivative	NN	O	O
(	NN	O	O
dP	NN	O	O
/	NN	O	O
dt	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
LV	NN	O	O
volumes	NN	O	O
and	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
before	NN	O	O
and	NN	O	O
during	NN	O	O
the	NN	O	O
final	NN	O	O
2	NN	O	O
to	NN	O	O
3	NN	O	O
minutes	NN	O	O
of	NN	O	O
a	NN	O	O
15	NN	O	O
-	NN	O	O
minute	NN	O	O
intracoronary	NN	O	O
infusion	NN	O	O
of	NN	O	O
saline	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
,	NN	O	O
control	NN	O	O
subjects	NN	O	O
)	NN	O	O
or	NN	O	O
cocaine	NN	O	O
hydrochloride	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
min	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
variable	NN	O	O
changed	NN	O	O
with	NN	O	O
saline	NN	O	O
.	NN	O	O

With	NN	O	O
cocaine	NN	O	O
,	NN	O	O
the	NN	O	O
drug	NN	O	O
concentration	NN	O	O
in	NN	O	O
blood	NN	O	O
obtained	NN	O	O
from	NN	O	O
the	NN	O	O
coronary	NN	O	O
sinus	NN	O	O
was	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
mg	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
similar	NN	O	O
in	NN	O	O
magnitude	NN	O	O
to	NN	O	O
the	NN	O	O
blood	NN	O	O
cocaine	NN	O	O
concentration	NN	O	O
reported	NN	O	O
in	NN	O	O
abusers	NN	O	O
dying	NN	O	O
of	NN	O	O
cocaine	NN	O	O
intoxication	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
induced	NN	O	O
no	NN	O	O
significant	NN	O	O
change	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
LV	NN	O	O
dP	NN	O	O
/	NN	O	O
dt	NN	O	O
(	NN	O	O
positive	NN	O	O
or	NN	O	O
negative	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
LV	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
volume	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
caused	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
systolic	NN	O	O
and	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressures	NN	O	O
,	NN	O	O
LV	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
,	NN	O	O
and	NN	O	O
LV	NN	O	O
end	NN	O	O
-	NN	O	O
systolic	NN	O	O
volume	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
LV	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
humans	NN	O	O
,	NN	O	O
the	NN	O	O
intracoronary	NN	O	O
infusion	NN	O	O
of	NN	O	O
cocaine	NN	O	O
sufficient	NN	O	O
in	NN	O	O
amount	NN	O	O
to	NN	O	O
achieve	NN	O	O
a	NN	O	O
high	NN	O	O
drug	NN	O	O
concentration	NN	O	O
in	NN	O	O
coronary	NN	O	O
sinus	NN	O	O
blood	NN	O	O
causes	NN	O	O
a	NN	O	O
deterioration	NN	O	B
of	NN	O	I
LV	NN	O	I
systolic	NN	O	I
and	NN	O	I
diastolic	NN	O	I
performance	NN	O	I
.	NN	O	O

Ascending	NN	O	O
dose	NN	O	O
tolerance	NN	O	O
study	NN	O	O
of	NN	O	O
intramuscular	NN	O	O
carbetocin	NN	O	O
administered	NN	O	O
after	NN	O	O
normal	NN	O	O
vaginal	NN	O	O
birth	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
maximum	NN	O	O
tolerated	NN	O	O
dose	NN	O	O
(	NN	O	O
MTD	NN	O	O
)	NN	O	O
of	NN	O	O
carbetocin	NN	O	O
(	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
acting	NN	O	O
synthetic	NN	O	O
analogue	NN	O	O
of	NN	O	O
oxytocin	NN	O	O
)	NN	O	O
,	NN	O	O
when	NN	O	O
administered	NN	O	O
immediately	NN	O	O
after	NN	O	O
vaginal	NN	O	O
delivery	NN	O	O
at	NN	O	O
term	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Carbetocin	NN	O	O
was	NN	O	O
given	NN	O	O
as	NN	O	O
an	NN	O	O
intramuscular	NN	O	O
injection	NN	O	O
immediately	NN	O	O
after	NN	O	O
the	NN	O	O
birth	NN	O	O
of	NN	O	O
the	NN	O	O
infant	NN	O	O
in	NN	O	O
45	NN	O	O
healthy	NN	O	O
women	NN	O	O
with	NN	O	O
normal	NN	O	O
singleton	NN	O	O
pregnancies	NN	O	O
who	NN	O	O
delivered	NN	O	O
vaginally	NN	O	O
at	NN	O	O
term	NN	O	O
.	NN	O	O

Dosage	NN	O	O
groups	NN	O	O
of	NN	O	O
15	NN	O	O
,	NN	O	O
30	NN	O	O
,	NN	O	O
50	NN	O	O
,	NN	O	O
75	NN	O	O
,	NN	O	O
100	NN	O	O
,	NN	O	O
125	NN	O	O
,	NN	O	O
150	NN	O	O
,	NN	O	O
175	NN	O	O
or	NN	O	O
200	NN	O	O
microg	NN	O	O
carbetocin	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
blocks	NN	O	O
of	NN	O	O
three	NN	O	O
women	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
continual	NN	O	O
reassessment	NN	O	O
method	NN	O	O
(	NN	O	O
CRM	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
All	NN	O	O
dosage	NN	O	O
groups	NN	O	O
consisted	NN	O	O
of	NN	O	O
three	NN	O	O
women	NN	O	O
,	NN	O	O
except	NN	O	O
those	NN	O	O
with	NN	O	O
100	NN	O	O
microg	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
and	NN	O	O
200	NN	O	O
microg	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
18	NN	O	O
)	NN	O	O
.	NN	O	O

Recorded	NN	O	O
were	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
adverse	NN	O	O
events	NN	O	O
:	NN	O	O
hyper	NN	O	B
-	NN	O	I
or	NN	O	I
hypotension	NN	O	I
(	NN	O	O
three	NN	O	O
)	NN	O	O
,	NN	O	O
severe	NN	O	O
abdominal	NN	O	B
pain	NN	O	I
(	NN	O	O
0	NN	O	O
)	NN	O	O
,	NN	O	O
vomiting	NN	O	B
(	NN	O	O
0	NN	O	O
)	NN	O	O
and	NN	O	O
retained	NN	O	B
placenta	NN	O	I
(	NN	O	O
four	NN	O	O
)	NN	O	O
.	NN	O	O

Serious	NN	O	O
adverse	NN	O	O
events	NN	O	O
occurred	NN	O	O
in	NN	O	O
seven	NN	O	O
women	NN	O	O
:	NN	O	O
six	NN	O	O
cases	NN	O	O
with	NN	O	O
blood	NN	O	B
loss	NN	O	I
>	NN	O	O
or	NN	O	O
=	NN	O	O
1000	NN	O	O
ml	NN	O	O
,	NN	O	O
four	NN	O	O
cases	NN	O	O
of	NN	O	O
manual	NN	O	O
placenta	NN	O	O
removal	NN	O	O
,	NN	O	O
five	NN	O	O
cases	NN	O	O
of	NN	O	O
additional	NN	O	O
oxytocics	NN	O	O
administration	NN	O	O
and	NN	O	O
five	NN	O	O
cases	NN	O	O
of	NN	O	O
blood	NN	O	O
transfusion	NN	O	O
.	NN	O	O

Maximum	NN	O	O
blood	NN	O	B
loss	NN	O	I
was	NN	O	O
greatest	NN	O	O
at	NN	O	O
the	NN	O	O
upper	NN	O	O
and	NN	O	O
lower	NN	O	O
dose	NN	O	O
levels	NN	O	O
,	NN	O	O
and	NN	O	O
lowest	NN	O	O
in	NN	O	O
the	NN	O	O
70	NN	O	O
-	NN	O	O
125	NN	O	O
microg	NN	O	O
dose	NN	O	O
range	NN	O	O
.	NN	O	O

Four	NN	O	O
out	NN	O	O
of	NN	O	O
six	NN	O	O
cases	NN	O	O
with	NN	O	O
blood	NN	O	B
loss	NN	O	I
>	NN	O	O
or	NN	O	O
=	NN	O	O
1000	NN	O	O
ml	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
200	NN	O	O
microg	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
majority	NN	O	O
of	NN	O	O
additional	NN	O	O
administration	NN	O	O
of	NN	O	O
oxytocics	NN	O	O
(	NN	O	O
4	NN	O	O
/	NN	O	O
5	NN	O	O
)	NN	O	O
and	NN	O	O
blood	NN	O	O
transfusion	NN	O	O
(	NN	O	O
3	NN	O	O
/	NN	O	O
5	NN	O	O
)	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
dose	NN	O	O
groups	NN	O	O
of	NN	O	O
200	NN	O	O
microg	NN	O	O
.	NN	O	O

All	NN	O	O
retained	NN	O	O
placentae	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
of	NN	O	O
200	NN	O	O
microg	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
MTD	NN	O	O
was	NN	O	O
calculated	NN	O	O
to	NN	O	O
be	NN	O	O
at	NN	O	O
200	NN	O	O
microg	NN	O	O
carbetocin	NN	O	O
.	NN	O	O

Heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
,	NN	O	O
paradoxical	NN	O	O
thromboembolism	NN	O	B
,	NN	O	O
and	NN	O	O
other	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
heparin	NN	O	O
therapy	NN	O	O
.	NN	O	O

Although	NN	O	O
several	NN	O	O
new	NN	O	O
anticoagulant	NN	O	O
drugs	NN	O	O
are	NN	O	O
in	NN	O	O
development	NN	O	O
,	NN	O	O
heparin	NN	O	O
remains	NN	O	O
the	NN	O	O
drug	NN	O	O
of	NN	O	O
choice	NN	O	O
for	NN	O	O
most	NN	O	O
anticoagulation	NN	O	O
needs	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
effects	NN	O	O
of	NN	O	O
heparin	NN	O	O
are	NN	O	O
meritorious	NN	O	O
,	NN	O	O
but	NN	O	O
side	NN	O	O
effects	NN	O	O
do	NN	O	O
exist	NN	O	O
.	NN	O	O

Important	NN	O	O
untoward	NN	O	O
effects	NN	O	O
of	NN	O	O
heparin	NN	O	O
therapy	NN	O	O
including	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
,	NN	O	O
heparin	NN	O	O
-	NN	O	O
associated	NN	O	O
osteoporosis	NN	O	B
,	NN	O	O
eosinophilia	NN	O	B
,	NN	O	O
skin	NN	O	B
reactions	NN	O	I
,	NN	O	O
allergic	NN	O	B
reactions	NN	O	I
other	NN	O	O
than	NN	O	O
thrombocytopenia	NN	O	B
and	NN	O	O
alopecia	NN	O	B
will	NN	O	O
be	NN	O	O
discussed	NN	O	O
in	NN	O	O
this	NN	O	O
article	NN	O	O
.	NN	O	O

Nonopaque	NN	O	O
crystal	NN	O	O
deposition	NN	O	O
causing	NN	O	O
ureteric	NN	O	B
obstruction	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
HIV	NN	O	O
undergoing	NN	O	O
indinavir	NN	O	O
therapy	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
We	NN	O	O
describe	NN	O	O
the	NN	O	O
unique	NN	O	O
CT	NN	O	O
features	NN	O	O
of	NN	O	O
ureteric	NN	O	B
calculi	NN	O	I
in	NN	O	O
six	NN	O	O
HIV	NN	O	B
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
receiving	NN	O	O
indinavir	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
commonly	NN	O	O
used	NN	O	O
HIV	NN	O	O
protease	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
urolithiasis	NN	O	B
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Ureteric	NN	O	B
obstruction	NN	O	I
caused	NN	O	O
by	NN	O	O
precipitated	NN	O	O
indinavir	NN	O	O
crystals	NN	O	O
may	NN	O	O
be	NN	O	O
difficult	NN	O	O
to	NN	O	O
diagnose	NN	O	O
with	NN	O	O
unenhanced	NN	O	O
CT	NN	O	O
.	NN	O	O

The	NN	O	O
calculi	NN	O	O
are	NN	O	O
not	NN	O	O
opaque	NN	O	O
,	NN	O	O
and	NN	O	O
secondary	NN	O	O
signs	NN	O	O
of	NN	O	O
obstruction	NN	O	O
may	NN	O	O
be	NN	O	O
absent	NN	O	O
or	NN	O	O
minimal	NN	O	O
and	NN	O	O
should	NN	O	O
be	NN	O	O
sought	NN	O	O
carefully	NN	O	O
.	NN	O	O

Images	NN	O	O
may	NN	O	O
need	NN	O	O
to	NN	O	O
be	NN	O	O
obtained	NN	O	O
using	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
contrast	NN	O	O
material	NN	O	O
to	NN	O	O
enable	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
ureteric	NN	O	B
stones	NN	O	I
or	NN	O	I
obstruction	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
HIV	NN	O	B
infection	NN	O	I
who	NN	O	O
receive	NN	O	O
indinavir	NN	O	O
therapy	NN	O	O
.	NN	O	O

Ischemic	NN	O	B
colitis	NN	O	I
and	NN	O	O
sumatriptan	NN	O	O
use	NN	O	O
.	NN	O	O

Sumatriptan	NN	O	O
succinate	NN	O	O
,	NN	O	O
a	NN	O	O
serotonin	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
hydroxytryptamine	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
,	NN	O	O
is	NN	O	O
an	NN	O	O
antimigraine	NN	O	O
drug	NN	O	O
that	NN	O	O
is	NN	O	O
reported	NN	O	O
to	NN	O	O
act	NN	O	O
by	NN	O	O
selectively	NN	O	O
constricting	NN	O	O
intracranial	NN	O	O
arteries	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
vasopressor	NN	O	O
responses	NN	O	O
that	NN	O	O
are	NN	O	O
distinct	NN	O	O
from	NN	O	O
the	NN	O	O
cranial	NN	O	O
circulation	NN	O	O
have	NN	O	O
been	NN	O	O
demonstrated	NN	O	O
to	NN	O	O
occur	NN	O	O
in	NN	O	O
the	NN	O	O
systemic	NN	O	O
,	NN	O	O
pulmonary	NN	O	O
,	NN	O	O
and	NN	O	O
coronary	NN	O	O
circulations	NN	O	O
.	NN	O	O

Cases	NN	O	O
have	NN	O	O
been	NN	O	O
published	NN	O	O
of	NN	O	O
coronary	NN	O	B
vasospasm	NN	O	I
,	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
,	NN	O	O
and	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
occurring	NN	O	O
after	NN	O	O
sumatriptan	NN	O	O
use	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
8	NN	O	O
serious	NN	O	O
cases	NN	O	O
of	NN	O	O
ischemic	NN	O	B
colitis	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
migraine	NN	O	B
treated	NN	O	O
with	NN	O	O
sumatriptan	NN	O	O
.	NN	O	O

Pallidotomy	NN	O	O
with	NN	O	O
the	NN	O	O
gamma	NN	O	O
knife	NN	O	O
:	NN	O	O
a	NN	O	O
positive	NN	O	O
experience	NN	O	O
.	NN	O	O

51	NN	O	O
patients	NN	O	O
with	NN	O	O
medically	NN	O	O
refractory	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
underwent	NN	O	O
stereotactic	NN	O	O
posteromedial	NN	O	O
pallidotomy	NN	O	O
between	NN	O	O
August	NN	O	O
1993	NN	O	O
and	NN	O	O
February	NN	O	O
1997	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
bradykinesia	NN	O	B
,	NN	O	O
rigidity	NN	O	B
,	NN	O	O
and	NN	O	O
L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
.	NN	O	O

In	NN	O	O
29	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
pallidotomies	NN	O	O
were	NN	O	O
performed	NN	O	O
with	NN	O	O
the	NN	O	O
Leksell	NN	O	O
Gamma	NN	O	O
Knife	NN	O	O
and	NN	O	O
in	NN	O	O
22	NN	O	O
they	NN	O	O
were	NN	O	O
performed	NN	O	O
with	NN	O	O
the	NN	O	O
standard	NN	O	O
radiofrequency	NN	O	O
(	NN	O	O
RF	NN	O	O
)	NN	O	O
method	NN	O	O
.	NN	O	O

Clinical	NN	O	O
assessment	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
blinded	NN	O	O
ratings	NN	O	O
of	NN	O	O
Unified	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
Disease	NN	O	I
Rating	NN	O	O
Scale	NN	O	O
(	NN	O	O
UPDRS	NN	O	O
)	NN	O	O
scores	NN	O	O
were	NN	O	O
carried	NN	O	O
out	NN	O	O
pre	NN	O	O
-	NN	O	O
and	NN	O	O
postoperatively	NN	O	O
.	NN	O	O

Mean	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
time	NN	O	O
is	NN	O	O
20	NN	O	O
.	NN	O	O
6	NN	O	O
months	NN	O	O
(	NN	O	O
range	NN	O	O
6	NN	O	O
-	NN	O	O
48	NN	O	O
)	NN	O	O
and	NN	O	O
all	NN	O	O
except	NN	O	O
4	NN	O	O
patients	NN	O	O
have	NN	O	O
been	NN	O	O
followed	NN	O	O
more	NN	O	O
than	NN	O	O
one	NN	O	O
year	NN	O	O
.	NN	O	O

85	NN	O	O
percent	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
dyskinesias	NN	O	B
were	NN	O	O
relieved	NN	O	O
of	NN	O	O
symptoms	NN	O	O
,	NN	O	O
regardless	NN	O	O
of	NN	O	O
whether	NN	O	O
the	NN	O	O
pallidotomies	NN	O	O
were	NN	O	O
performed	NN	O	O
with	NN	O	O
the	NN	O	O
Gamma	NN	O	O
Knife	NN	O	O
or	NN	O	O
radiofrequency	NN	O	O
methods	NN	O	O
.	NN	O	O

About	NN	O	O
2	NN	O	O
/	NN	O	O
3	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
in	NN	O	O
both	NN	O	O
Gamma	NN	O	O
Knife	NN	O	O
and	NN	O	O
radiofrequency	NN	O	O
groups	NN	O	O
showed	NN	O	O
improvements	NN	O	O
in	NN	O	O
bradykinesia	NN	O	B
and	NN	O	O
rigidity	NN	O	B
,	NN	O	O
although	NN	O	O
when	NN	O	O
considered	NN	O	O
as	NN	O	O
a	NN	O	O
group	NN	O	O
neither	NN	O	O
the	NN	O	O
Gamma	NN	O	O
Knife	NN	O	O
nor	NN	O	O
the	NN	O	O
radiofrequency	NN	O	O
group	NN	O	O
showed	NN	O	O
statistically	NN	O	O
significant	NN	O	O
improvements	NN	O	O
in	NN	O	O
UPDRS	NN	O	O
scores	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
in	NN	O	O
the	NN	O	O
Gamma	NN	O	O
Knife	NN	O	O
group	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
a	NN	O	O
homonymous	NN	O	B
hemianopsia	NN	O	I
9	NN	O	O
months	NN	O	O
following	NN	O	O
treatment	NN	O	O
and	NN	O	O
5	NN	O	O
patients	NN	O	O
(	NN	O	O
27	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
radiofrequency	NN	O	O
group	NN	O	O
became	NN	O	O
transiently	NN	O	O
confused	NN	O	O
postoperatively	NN	O	O
.	NN	O	O

No	NN	O	O
other	NN	O	O
complications	NN	O	O
were	NN	O	O
seen	NN	O	O
.	NN	O	O

Gamma	NN	O	O
Knife	NN	O	O
pallidotomy	NN	O	O
is	NN	O	O
as	NN	O	O
effective	NN	O	O
as	NN	O	O
radiofrequency	NN	O	O
pallidotomy	NN	O	O
in	NN	O	O
controlling	NN	O	O
certain	NN	O	O
of	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

It	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
only	NN	O	O
practical	NN	O	O
technique	NN	O	O
available	NN	O	O
in	NN	O	O
certain	NN	O	O
patients	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
those	NN	O	O
who	NN	O	O
take	NN	O	O
anticoagulants	NN	O	O
,	NN	O	O
have	NN	O	O
bleeding	NN	O	B
diatheses	NN	O	O
or	NN	O	O
serious	NN	O	O
systemic	NN	O	O
medical	NN	O	O
illnesses	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
a	NN	O	O
viable	NN	O	O
option	NN	O	O
for	NN	O	O
other	NN	O	O
patients	NN	O	O
as	NN	O	O
well	NN	O	O
.	NN	O	O

Centrally	NN	O	O
mediated	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
of	NN	O	O
intracisternal	NN	O	O
application	NN	O	O
of	NN	O	O
carbachol	NN	O	O
in	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
pressor	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
intracisternal	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
injection	NN	O	O
of	NN	O	O
carbachol	NN	O	O
(	NN	O	O
1	NN	O	O
mug	NN	O	O
)	NN	O	O
in	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
was	NN	O	O
analyzed	NN	O	O
.	NN	O	O

This	NN	O	O
response	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
by	NN	O	O
the	NN	O	O
intravenous	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
injection	NN	O	O
of	NN	O	O
guanethidine	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
)	NN	O	O
,	NN	O	O
hexamethonium	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
)	NN	O	O
or	NN	O	O
phentolamine	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
conversely	NN	O	O
,	NN	O	O
potentiated	NN	O	O
by	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
desmethylimipramine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
mg	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
propranolol	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
)	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
selectively	NN	O	O
inhibited	NN	O	O
the	NN	O	O
enlargement	NN	O	B
of	NN	O	I
pulse	NN	O	I
pressure	NN	O	I
and	NN	O	O
the	NN	O	O
tachycardia	NN	O	B
following	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
carbachol	NN	O	O
(	NN	O	O
1	NN	O	O
mug	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
the	NN	O	O
pressor	NN	O	O
response	NN	O	O
to	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
carbachol	NN	O	O
(	NN	O	O
1	NN	O	O
mug	NN	O	O
)	NN	O	O
was	NN	O	O
almost	NN	O	O
completely	NN	O	O
blocked	NN	O	O
by	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
atropine	NN	O	O
(	NN	O	O
3	NN	O	O
mug	NN	O	O
)	NN	O	O
or	NN	O	O
hexamethonium	NN	O	O
(	NN	O	O
500	NN	O	O
mug	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
by	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
chlorpromazine	NN	O	O
(	NN	O	O
50	NN	O	O
mug	NN	O	O
)	NN	O	O
but	NN	O	O
significantly	NN	O	O
potentiated	NN	O	O
by	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
desmethylimipramine	NN	O	O
(	NN	O	O
30	NN	O	O
mug	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
pressor	NN	O	O
response	NN	O	O
to	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
carbachol	NN	O	O
(	NN	O	O
1	NN	O	O
mug	NN	O	O
)	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
after	NN	O	O
sectioning	NN	O	O
of	NN	O	O
the	NN	O	O
bilateral	NN	O	O
cervical	NN	O	O
vagal	NN	O	O
nerves	NN	O	O
but	NN	O	O
disappeared	NN	O	O
after	NN	O	O
sectioning	NN	O	O
of	NN	O	O
the	NN	O	O
spinal	NN	O	O
cord	NN	O	O
(	NN	O	O
C7	NN	O	O
-	NN	O	O
C8	NN	O	O
)	NN	O	O
.	NN	O	O

From	NN	O	O
the	NN	O	O
above	NN	O	O
result	NN	O	O
it	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
pressor	NN	O	O
response	NN	O	O
to	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
carbachol	NN	O	O
ortral	NN	O	O
and	NN	O	O
peripheral	NN	O	O
adrenergic	NN	O	O
mechanisms	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
sympathetic	NN	O	O
trunk	NN	O	O
is	NN	O	O
the	NN	O	O
main	NN	O	O
pathway	NN	O	O
.	NN	O	O

Neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
and	NN	O	O
methylphenidate	NN	O	O
.	NN	O	O

A	NN	O	O
1	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
presented	NN	O	O
with	NN	O	O
neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
probably	NN	O	O
caused	NN	O	O
by	NN	O	O
methylphenidate	NN	O	O
.	NN	O	O

She	NN	O	O
had	NN	O	O
defects	NN	O	O
in	NN	O	O
the	NN	O	O
supratentorial	NN	O	O
brain	NN	O	O
including	NN	O	O
the	NN	O	O
basal	NN	O	O
ganglia	NN	O	O
and	NN	O	O
the	NN	O	O
striatum	NN	O	O
(	NN	O	O
multicystic	NN	O	B
encephalomalacia	NN	O	I
)	NN	O	O
due	NN	O	O
to	NN	O	O
severe	NN	O	O
perinatal	NN	O	O
hypoxic	NN	O	B
-	NN	O	I
ischemic	NN	O	I
encephalopathy	NN	O	I
,	NN	O	O
which	NN	O	O
was	NN	O	O
considered	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
possible	NN	O	O
predisposing	NN	O	O
factor	NN	O	O
causing	NN	O	O
neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
.	NN	O	O

A	NN	O	O
dopaminergic	NN	O	O
blockade	NN	O	O
mechanism	NN	O	O
generally	NN	O	O
is	NN	O	O
accepted	NN	O	O
as	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
this	NN	O	O
syndrome	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
methylphenidate	NN	O	O
is	NN	O	O
a	NN	O	O
dopamine	NN	O	O
agonist	NN	O	O
via	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
uptake	NN	O	O
of	NN	O	O
dopamine	NN	O	O
,	NN	O	O
and	NN	O	O
therefore	NN	O	O
dopaminergic	NN	O	O
systems	NN	O	O
in	NN	O	O
the	NN	O	O
brainstem	NN	O	O
(	NN	O	O
mainly	NN	O	O
the	NN	O	O
midbrain	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
spinal	NN	O	O
cord	NN	O	O
were	NN	O	O
unlikely	NN	O	O
to	NN	O	O
participate	NN	O	O
in	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
this	NN	O	O
syndrome	NN	O	O
.	NN	O	O

A	NN	O	O
relative	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acid	NN	O	O
-	NN	O	O
ergic	NN	O	O
deficiency	NN	O	O
might	NN	O	O
occur	NN	O	O
because	NN	O	O
diazepam	NN	O	O
,	NN	O	O
a	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acid	NN	O	O
-	NN	O	O
mimetic	NN	O	O
agent	NN	O	O
,	NN	O	O
was	NN	O	O
strikingly	NN	O	O
effective	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
patient	NN	O	O
with	NN	O	O
neuroleptic	NN	O	B
malignant	NN	O	I
syndrome	NN	O	I
probably	NN	O	O
caused	NN	O	O
by	NN	O	O
methylphenidate	NN	O	O
.	NN	O	O

Differential	NN	O	O
effects	NN	O	O
of	NN	O	O
17alpha	NN	O	O
-	NN	O	O
ethinylestradiol	NN	O	O
on	NN	O	O
the	NN	O	O
neutral	NN	O	O
and	NN	O	O
acidic	NN	O	O
pathways	NN	O	O
of	NN	O	O
bile	NN	O	O
salt	NN	O	O
synthesis	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
17alpha	NN	O	O
-	NN	O	O
ethinylestradiol	NN	O	O
(	NN	O	O
EE	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
neutral	NN	O	O
and	NN	O	O
acidic	NN	O	O
biosynthetic	NN	O	O
pathways	NN	O	O
of	NN	O	O
bile	NN	O	O
salt	NN	O	O
(	NN	O	O
BS	NN	O	O
)	NN	O	O
synthesis	NN	O	O
were	NN	O	O
evaluated	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
an	NN	O	O
intact	NN	O	O
enterohepatic	NN	O	O
circulation	NN	O	O
and	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
bile	NN	O	O
diversion	NN	O	O
to	NN	O	O
induce	NN	O	O
BS	NN	O	O
synthesis	NN	O	O
.	NN	O	O

For	NN	O	O
this	NN	O	O
purpose	NN	O	O
,	NN	O	O
bile	NN	O	O
salt	NN	O	O
pool	NN	O	O
composition	NN	O	O
,	NN	O	O
synthesis	NN	O	O
of	NN	O	O
individual	NN	O	O
BS	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
hepatic	NN	O	O
activities	NN	O	O
,	NN	O	O
and	NN	O	O
expression	NN	O	O
levels	NN	O	O
of	NN	O	O
cholesterol	NN	O	O
7alpha	NN	O	O
-	NN	O	O
hydroxylase	NN	O	O
(	NN	O	O
CYP7A	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
sterol	NN	O	O
27	NN	O	O
-	NN	O	O
hydroxylase	NN	O	O
(	NN	O	O
CYP27	NN	O	O
)	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
of	NN	O	O
other	NN	O	O
enzymes	NN	O	O
involved	NN	O	O
in	NN	O	O
BS	NN	O	O
synthesis	NN	O	O
,	NN	O	O
were	NN	O	O
analyzed	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
EE	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
3	NN	O	O
days	NN	O	O
)	NN	O	O
or	NN	O	O
its	NN	O	O
vehicle	NN	O	O
.	NN	O	O

BS	NN	O	O
pool	NN	O	O
size	NN	O	O
was	NN	O	O
decreased	NN	O	O
by	NN	O	O
27	NN	O	O
%	NN	O	O
but	NN	O	O
total	NN	O	O
BS	NN	O	O
synthesis	NN	O	O
was	NN	O	O
not	NN	O	O
affected	NN	O	O
by	NN	O	O
EE	NN	O	O
in	NN	O	O
intact	NN	O	O
rats	NN	O	O
.	NN	O	O

Synthesis	NN	O	O
of	NN	O	O
cholate	NN	O	O
was	NN	O	O
reduced	NN	O	O
by	NN	O	O
68	NN	O	O
%	NN	O	O
in	NN	O	O
EE	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
while	NN	O	O
that	NN	O	O
of	NN	O	O
chenodeoxycholate	NN	O	O
was	NN	O	O
increased	NN	O	O
by	NN	O	O
60	NN	O	O
%	NN	O	O
.	NN	O	O

The	NN	O	O
recently	NN	O	O
identified	NN	O	O
Delta22	NN	O	O
-	NN	O	O
isomer	NN	O	O
of	NN	O	O
beta	NN	O	O
-	NN	O	O
muricholate	NN	O	O
contributed	NN	O	O
for	NN	O	O
5	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
and	NN	O	O
18	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
to	NN	O	O
the	NN	O	O
pool	NN	O	O
in	NN	O	O
control	NN	O	O
and	NN	O	O
EE	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
but	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
detected	NN	O	O
in	NN	O	O
bile	NN	O	O
after	NN	O	O
exhaustion	NN	O	O
of	NN	O	O
the	NN	O	O
pool	NN	O	O
.	NN	O	O

A	NN	O	O
clear	NN	O	O
reduction	NN	O	O
of	NN	O	O
BS	NN	O	O
synthesis	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
bile	NN	O	O
-	NN	O	O
diverted	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
EE	NN	O	O
,	NN	O	O
yet	NN	O	O
biliary	NN	O	O
BS	NN	O	O
composition	NN	O	O
was	NN	O	O
only	NN	O	O
minimally	NN	O	O
affected	NN	O	O
.	NN	O	O

Activity	NN	O	O
of	NN	O	O
CYP7A	NN	O	O
was	NN	O	O
decreased	NN	O	O
by	NN	O	O
EE	NN	O	O
in	NN	O	O
both	NN	O	O
intact	NN	O	O
and	NN	O	O
bile	NN	O	O
-	NN	O	O
diverted	NN	O	O
rats	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
CYP27	NN	O	O
was	NN	O	O
not	NN	O	O
affected	NN	O	O
.	NN	O	O

Hepatic	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
of	NN	O	O
CYP7A	NN	O	O
were	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
by	NN	O	O
EE	NN	O	O
in	NN	O	O
bile	NN	O	O
-	NN	O	O
diverted	NN	O	O
rats	NN	O	O
only	NN	O	O
;	NN	O	O
CYP27	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
were	NN	O	O
not	NN	O	O
affected	NN	O	O
by	NN	O	O
EE	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
of	NN	O	O
sterol	NN	O	O
12alpha	NN	O	O
-	NN	O	O
hydroxylase	NN	O	O
and	NN	O	O
lithocholate	NN	O	O
6beta	NN	O	O
-	NN	O	O
hydroxylase	NN	O	O
were	NN	O	O
increased	NN	O	O
by	NN	O	O
bile	NN	O	O
diversion	NN	O	O
and	NN	O	O
suppressed	NN	O	O
by	NN	O	O
EE	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
shows	NN	O	O
that	NN	O	O
17alpha	NN	O	O
-	NN	O	O
ethinylestradiol	NN	O	O
(	NN	O	O
EE	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
intrahepatic	NN	O	B
cholestasis	NN	O	I
in	NN	O	O
rats	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
selective	NN	O	O
inhibition	NN	O	O
of	NN	O	O
the	NN	O	O
neutral	NN	O	O
pathway	NN	O	O
of	NN	O	O
bile	NN	O	O
salt	NN	O	O
(	NN	O	O
BS	NN	O	O
)	NN	O	O
synthesis	NN	O	O
.	NN	O	O

Simultaneous	NN	O	O
impairment	NN	O	O
of	NN	O	O
other	NN	O	O
enzymes	NN	O	O
in	NN	O	O
the	NN	O	O
BS	NN	O	O
biosynthetic	NN	O	O
pathways	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
overall	NN	O	O
effects	NN	O	O
of	NN	O	O
EE	NN	O	O
on	NN	O	O
BS	NN	O	O
synthesis	NN	O	O
.	NN	O	O

Glibenclamide	NN	O	O
-	NN	O	O
sensitive	NN	O	O
hypotension	NN	O	B
produced	NN	O	O
by	NN	O	O
helodermin	NN	O	O
assessed	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
helodermin	NN	O	O
,	NN	O	O
a	NN	O	O
basic	NN	O	O
35	NN	O	O
-	NN	O	O
amino	NN	O	O
acid	NN	O	O
peptide	NN	O	O
isolated	NN	O	O
from	NN	O	O
the	NN	O	O
venom	NN	O	O
of	NN	O	O
a	NN	O	O
lizard	NN	O	O
salivary	NN	O	O
gland	NN	O	O
,	NN	O	O
on	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
were	NN	O	O
examined	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
,	NN	O	O
focusing	NN	O	O
on	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
activation	NN	O	O
of	NN	O	O
ATP	NN	O	O
sensitive	NN	O	O
K	NN	O	O
+	NN	O	O
(	NN	O	O
K	NN	O	O
(	NN	O	O
ATP	NN	O	O
)	NN	O	O
)	NN	O	O
channels	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
responses	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
were	NN	O	O
also	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
vasoactive	NN	O	O
intestinal	NN	O	O
polypeptide	NN	O	O
(	NN	O	O
VIP	NN	O	O
)	NN	O	O
.	NN	O	O

Helodermin	NN	O	O
produced	NN	O	O
hypotension	NN	O	B
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
with	NN	O	O
approximately	NN	O	O
similar	NN	O	O
potency	NN	O	O
and	NN	O	O
duration	NN	O	O
to	NN	O	O
VIP	NN	O	O
.	NN	O	O

Hypotension	NN	O	B
induced	NN	O	O
by	NN	O	O
both	NN	O	O
peptides	NN	O	O
was	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
by	NN	O	O
glibenclamide	NN	O	O
,	NN	O	O
which	NN	O	O
abolished	NN	O	O
a	NN	O	O
levcromakalim	NN	O	O
-	NN	O	O
produced	NN	O	O
decrease	NN	O	O
in	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
.	NN	O	O

Oxyhemoglobin	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
helodermin	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
,	NN	O	O
whereas	NN	O	O
it	NN	O	O
shortened	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
acetylcholine	NN	O	O
(	NN	O	O
ACh	NN	O	O
)	NN	O	O
-	NN	O	O
produced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
helodermin	NN	O	O
-	NN	O	O
produced	NN	O	O
hypotension	NN	O	B
is	NN	O	O
partly	NN	O	O
attributable	NN	O	O
to	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
glibenclamide	NN	O	O
-	NN	O	O
sensitive	NN	O	O
K	NN	O	O
+	NN	O	O
channels	NN	O	O
(	NN	O	O
K	NN	O	O
(	NN	O	O
ATP	NN	O	O
)	NN	O	O
channels	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
presumably	NN	O	O
exist	NN	O	O
on	NN	O	O
arterial	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
cells	NN	O	O
.	NN	O	O

EDRF	NN	O	O
(	NN	O	O
endothelium	NN	O	O
-	NN	O	O
derived	NN	O	O
relaxing	NN	O	O
factor	NN	O	O
)	NN	O	O
/	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
does	NN	O	O
not	NN	O	O
seem	NN	O	O
to	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
peptide	NN	O	O
-	NN	O	O
produced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
efficacy	NN	O	O
and	NN	O	O
adverse	NN	O	O
event	NN	O	O
of	NN	O	O
nifedipine	NN	O	O
sustained	NN	O	O
-	NN	O	O
release	NN	O	O
tablets	NN	O	O
for	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
psoriasis	NN	O	B
.	NN	O	O

Thirteen	NN	O	O
psoriatic	NN	O	B
patients	NN	O	O
with	NN	O	O
hypertension	NN	O	B
during	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
therapy	NN	O	O
were	NN	O	O
treated	NN	O	O
for	NN	O	O
25	NN	O	O
months	NN	O	O
with	NN	O	O
a	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blocker	NN	O	O
,	NN	O	O
sustained	NN	O	O
-	NN	O	O
release	NN	O	O
nifedipine	NN	O	O
,	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
clinical	NN	O	O
antihypertensive	NN	O	O
effects	NN	O	O
and	NN	O	O
adverse	NN	O	O
events	NN	O	O
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
both	NN	O	O
drugs	NN	O	O
.	NN	O	O

Seven	NN	O	O
of	NN	O	O
the	NN	O	O
13	NN	O	O
patients	NN	O	O
had	NN	O	O
exhibited	NN	O	O
a	NN	O	O
subclinical	NN	O	O
hypertensive	NN	O	B
state	NN	O	O
before	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
therapy	NN	O	O
.	NN	O	O

Both	NN	O	O
systolic	NN	O	O
and	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
pressures	NN	O	O
of	NN	O	O
these	NN	O	O
13	NN	O	O
patients	NN	O	O
were	NN	O	O
decreased	NN	O	O
significantly	NN	O	O
after	NN	O	O
4	NN	O	O
weeks	NN	O	O
of	NN	O	O
nifedipine	NN	O	O
therapy	NN	O	O
,	NN	O	O
and	NN	O	O
blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
maintained	NN	O	O
within	NN	O	O
the	NN	O	O
normal	NN	O	O
range	NN	O	O
thereafter	NN	O	O
for	NN	O	O
25	NN	O	O
months	NN	O	O
.	NN	O	O

The	NN	O	O
adverse	NN	O	O
events	NN	O	O
during	NN	O	O
combined	NN	O	O
therapy	NN	O	O
with	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
and	NN	O	O
nifedipine	NN	O	O
included	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
blood	NN	O	O
urea	NN	O	O
nitrogen	NN	O	O
levels	NN	O	O
in	NN	O	O
9	NN	O	O
of	NN	O	O
the	NN	O	O
13	NN	O	O
patients	NN	O	O
and	NN	O	O
development	NN	O	O
of	NN	O	O
gingival	NN	O	B
hyperplasia	NN	O	I
in	NN	O	O
2	NN	O	O
of	NN	O	O
the	NN	O	O
13	NN	O	O
patients	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
sustained	NN	O	O
-	NN	O	O
release	NN	O	O
nifedipine	NN	O	O
is	NN	O	O
useful	NN	O	O
for	NN	O	O
hypertensive	NN	O	B
psoriatic	NN	O	B
patients	NN	O	O
under	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
treatment	NN	O	O
with	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
,	NN	O	O
but	NN	O	O
that	NN	O	O
these	NN	O	O
patients	NN	O	O
should	NN	O	O
be	NN	O	O
monitored	NN	O	O
for	NN	O	O
gingival	NN	O	B
hyperplasia	NN	O	I
.	NN	O	O

